PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Fouladpour, N				Fouladpour, Nickolas			Poppy's Final Lesson	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Fouladpour, Nickolas] Ohio State Univ, Dept Internal Med, Div Palliat Med, Columbus, OH 43210 USA	Ohio State University	Fouladpour, N (corresponding author), Ohio State Univ, McCampbell Hall,Fifth Floor,1581 Dodd Dr, Columbus, OH 43210 USA.	fouladpour@osumc.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2022	327	4					325	326						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV9PW	35076662				2023-01-03	WOS:000753055700007
J	Willett, LL; Bromberg, GK; Chung, R; Leaf, RK; Goldman, RH; Dickey, AK				Willett, Lisa L.; Bromberg, Gabrielle K.; Chung, Ryan; Leaf, Rebecca K.; Goldman, Rose H.; Dickey, Amy K.			Case 38-2021: A 76-Year-Old Woman with Abdominal Pain, Weight Loss, and Memory Impairment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEAD; RECOMMENDATIONS; PORPHYRIAS; DIAGNOSIS		[Willett, Lisa L.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA; [Bromberg, Gabrielle K.; Leaf, Rebecca K.; Dickey, Amy K.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Chung, Ryan] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA; [Bromberg, Gabrielle K.; Leaf, Rebecca K.; Goldman, Rose H.; Dickey, Amy K.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Chung, Ryan] Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA; [Goldman, Rose H.] Cambridge Hlth Alliance, Dept Med, Cambridge, MA USA	University of Alabama System; University of Alabama Birmingham; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Cambridge Health Alliance	Willett, LL (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA.			Bromberg, Gabrielle/0000-0002-2140-7702				Akagi R, 2006, MOL GENET METAB, V87, P329, DOI 10.1016/j.ymgme.2005.10.011; Anderson KE, 2005, ANN INTERN MED, V142, P439, DOI 10.7326/0003-4819-142-6-200503150-00010; Apostoli P, 2002, AM J IND MED, V42, P180, DOI 10.1002/ajim.10123; Austin DW, 2008, J TOXICOL ENV HEAL A, V71, P1349, DOI 10.1080/15287390802271723; Balwani M, 2017, HEPATOLOGY, V66, P1314, DOI 10.1002/hep.29313; Bissell DM, 2017, NEW ENGL J MED, V377, P862, DOI 10.1056/NEJMra1608634; Bonkovsky HL, 2014, AM J MED, V127, P1233, DOI 10.1016/j.amjmed.2014.06.036; Bradberry S, 2009, CLIN TOXICOL, V47, P617, DOI 10.1080/15563650903174828; Centers for Disease Control and Prevention, 2021, CHILDH LEAD POIS PRE; Chen B, 2016, HUM MUTAT, V37, P1215, DOI 10.1002/humu.23067; Chinsky Jeffrey M, 2017, Genet Med, V19, DOI 10.1038/gim.2017.101; Di Pierro E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103462; Flora SJS, 2010, INT J ENV RES PUB HE, V7, P2745, DOI 10.3390/ijerph7072745; Glassy EF, 1998, COLOR ATLAS HEMATOLO; Kosnett MJ, 2007, ENVIRON HEALTH PERSP, V115, P463, DOI 10.1289/ehp.9784; LAMOLA AA, 1974, SCIENCE, V186, P936, DOI 10.1126/science.186.4167.936; National Institutes of Health, 2021, CLIN TRIALS GOV KET; Puy H, 2010, LANCET, V375, P924, DOI 10.1016/S0140-6736(09)61925-5; Saper RB, 2008, JAMA-J AM MED ASSOC, V300, P915, DOI 10.1001/jama.300.8.915; Siegert SWK, 2008, ADV THER, V25, P842, DOI 10.1007/s12325-008-0094-y; Solomon CG, 2019, NEW ENGL J MED, V381, P466, DOI 10.1056/NEJMcps1900774; Stolzel U, 2019, GASTROENTEROLOGY, V157, P365, DOI 10.1053/j.gastro.2019.04.050; US CDC, 2017, MMWR SURVEILL SUMM, DOI DOI 10.15585/MINVIRR.SS6603A1.; WATSON CJ, 1947, PHYSIOL REV, V27, P478, DOI 10.1152/physrev.1947.27.3.478; WEISSBERG JB, 1971, NEW ENGL J MED, V284, P565, DOI 10.1056/NEJM197103182841101; WILSON AT, 1966, BMJ-BRIT MED J, V1, P921, DOI 10.1136/bmj.1.5492.921; Wong J, 2020, INTERN MED J, V50, P239, DOI 10.1111/imj.14729	27	2	2	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 16	2021	385	25					2378	2388		10.1056/NEJMcpc2107354	http://dx.doi.org/10.1056/NEJMcpc2107354			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE4WZ	34910867				2023-01-03	WOS:000741129200017
J	Li, Y; Zhang, CR; Huang, ZX; Liu, H; Ren, M; Xi, TY; Ma, J; Wang, JX				Li, Yue; Zhang, Chengrui; Huang, Zexian; Liu, Huan; Ren, Meng; Xi, Tongyuan; Ma, Jian; Wang, Jianxin			Pastoral subsistence and mounted fighting in the Eastern Tianshan Mountain region: New insights from the Shirenzigou worked bone assemblage	PLOS ONE			English	Article							BALIKUN COUNTY; CEMETERY; EXCHANGE; HORSE	Situated at a geographic crossroads, the eastern Tianshan Mountain region in northwest China is crucial to understanding various economic, social, and cultural developments on the Eurasian Steppes. One promising way to gain a better knowledge of ancient subsistence economy, craft production, and social change in the eastern Tianshan Mountain region is to study the artifact assemblages from archaeological contexts. Here, we present an analysis of 488 worked animal bones from the large site of Shirenzigou (ca. 1300-1 BCE), to date the largest assemblage of this kind uncovered in the eastern Tianshan Mountain region. We classified these worked bones into six categories, including "ritual objects", "ornaments", "tools", "worked astragali", "warfare and mobility", and "indeterminate". The identification of animal species and skeletal elements indicates that worked bones from Shirenzigou are characterized by a predominance of caprine products, particularly worked astragali, which is consistent with the large proportion of caprine fragments found in animal remains associated with food consumption. This demonstrates the contribution of caprine pastoralism to bone working activities at Shirenzigou. The making of most worked bones does not appear to have required advanced or specialized skills. Considering the absence of dedicated bone working space, alongside the variability in raw material selection and in dimensions of certain types of artifacts, we infer that worked bone production at Shirenzigou was not standardized. In terms of raw material selection and mode of production, Shirenzigou differed from their settled, farming counterparts in the Yellow River valley of northern China. In addition, along with the evidence for violence and horseback riding, the increasing use of bone artifacts associated with warfare and mobility during the late occupation phase of Shirenzigou reflects growing social instability and implies the likely emergence of single mounted horsemen, equipped with light armors, in the region during the late first millennium BCE. Our results provide new insights into animal resource exploitation and changing lifeways of early pastoral societies in the eastern Tianshan Mountain region, expanding our knowledge of the economic, social, and political milieu of late Bronze Age and early Iron Age eastern Eurasia.	[Li, Yue; Huang, Zexian; Ren, Meng; Xi, Tongyuan; Ma, Jian; Wang, Jianxin] Northwest Univ, Sch Cultural Heritage, Xian, Peoples R China; [Li, Yue; Huang, Zexian; Ren, Meng; Xi, Tongyuan; Ma, Jian; Wang, Jianxin] Northwest Univ, Collaborat Res Ctr Silk Rd Archaeol, Xian, Peoples R China; [Li, Yue; Huang, Zexian; Ren, Meng; Xi, Tongyuan; Ma, Jian; Wang, Jianxin] Northwest Univ, Minist Sci & Technol One Belt, One Rd Joint Lab Human & Environm China & Cent As, Xian, Peoples R China; [Zhang, Chengrui] Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA; [Liu, Huan] Xianyang Normal Univ, Sch Resource Environm & Hist Culture, Xianyang, Peoples R China	Northwest University Xi'an; Northwest University Xi'an; Northwest University Xi'an; Harvard University; Xianyang Normal University	Li, Y; Wang, JX (corresponding author), Northwest Univ, Sch Cultural Heritage, Xian, Peoples R China.; Li, Y; Wang, JX (corresponding author), Northwest Univ, Collaborat Res Ctr Silk Rd Archaeol, Xian, Peoples R China.; Li, Y; Wang, JX (corresponding author), Northwest Univ, Minist Sci & Technol One Belt, One Rd Joint Lab Human & Environm China & Cent As, Xian, Peoples R China.	liyue@nwu.edu.cn; 13319185059@163.com		Li, Yue/0000-0002-2941-1490; Zhang, Chengrui/0000-0003-3133-6319	National Social Science Fund of China [18CKG024, 14ZDB052]; Young Scholar Professional Support Program of Northwest University; University Youth Innovation Team of Shaanxi	National Social Science Fund of China; Young Scholar Professional Support Program of Northwest University; University Youth Innovation Team of Shaanxi	This study was funded by the National Social Science Fund of China (http://www.nopss. gov.cn/) through a grant awarded to YL (Grant No. 18CKG024) and a grant awarded to JW (Grant No. 14ZDB052). YL was also supported by the Young Scholar Professional Support Program of Northwest University (https://rsc.nwu.edu.cn/). The University Youth Innovation Team of Shaanxi (http://jyt.shaanxi.gov.cn/news/jiaoyutingwenjian/) also supported this study through a grant awarded to JM (No Grant No.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anthony DW, 2007, HORSE, THE WHEEL, AND LANGUAGE: HOW BRONZE-AGE RIDERS FROM THE EURASIAN STEPPES SHAPED THE MODERN WORLD, P1; Anthony DW, 2011, J WORLD PREHIST, V24, P131, DOI 10.1007/s10963-011-9051-9; Barfield T., 1989, PERILOUS FRONTIER NO; Barnes G.L., 2015, ARCHAEOLOGY E ASIA R; Beckwith CI, 2009, EMPIRES OF THE SILK ROAD: A HISTORY OF CENTRAL EURASIA FROM THE BRONZE AGE TO THE PRESENT, P1; BEHRENSMEYER AK, 1978, PALEOBIOLOGY, V4, P150, DOI 10.1017/S0094837300005820; Bejenaru L, 2018, QUATERN INT, V472, P1, DOI 10.1016/j.quaint.2018.04.007; Boyle K., 2002, ANCIENT INTERACTIONS; Brunson K, 2016, INT J OSTEOARCHAEOL, V26, P460, DOI 10.1002/oa.2436; Campana DV., 1989, BAR INT SERIES; Campbell RB, 2011, ANTIQUITY, V85, P1279, DOI 10.1017/S0003598X00062050; Chen G., 2016, KAOGU, V5, P59; Chen J., 2013, WENWU, V10, P77; Choyke A.M., 2013, THESE BARE BONESRAW, P1; Clutton-Brock J., 1992, HORSE POWER HIST HOR; Costin C.L., 2005, HDB ARCHAEOLOGICAL M, P1034; CREEL HG, 1965, AM HIST REV, V70, P647, DOI 10.2307/1845936; Dai L, 2014, KAOGU, V1, P94; Dandoy J.R., 2006, INTEGRATING ZOOARCHA, P131; dErrico F., 2005, TOOLS SYMBOLS EARLY, P238, DOI DOI 10.18772/22005064174.22; Di Cosmo N, 1999, J WORLD HIST, V10, P1, DOI 10.1353/jwh.2005.0008; Di Cosmo Nicola, 2004, ANCIENT CHINA ITS EN; DICOSMO N, 1994, J ASIAN STUD, V53, P1092, DOI 10.2307/2059235; Dong GH, 2018, HOLOCENE, V28, P621, DOI 10.1177/0959683617735585; Dou H., 2019, KAOGU, V10, P15; Drews R., 2004, EARLY RIDERS BEGINNI; Flad RK, 2008, CURR ANTHROPOL, V49, P403, DOI 10.1086/588495; Gates St Pierre C., 2007, BONES TOOLS CURRENT, P1; Gilmour G.H., 1997, OXFORD J ARCHAEOL, V16, P167, DOI 10.1111/1468-0092.00032; Guo J, 1997, KAOGU, V9, P33; HAN JIANYE, 2007, XINJIANG QINGTONG SH; Hanks B. K., 2009, SOCIAL COMPLEXITY PR; Hanks B, 2010, ANNU REV ANTHROPOL, V39, P469, DOI 10.1146/annurev.anthro.012809.105110; Hou YF, 2018, ASIAN PERSPECT, V57, P281, DOI 10.1353/asi.2018.0018; Kelekna Pita, 2009, HORSE HUMAN HIST; Khudjakov J. S., 2005, ACTA ORIENT ACAD SCI, V58, P117; Kohl PL, 2007, CAMB WOR ARCHAEOL, P1, DOI 10.1017/CBO9780511618468; Kuzmina EE, 2008, ENCOUNTERS ASIA, P1; Li S, 1999, XINJIANG WENWU, V1, P53; Li X., 2020, NANFANG WENWU, V4, P187; Li Y, 2020, P NATL ACAD SCI USA, V117, P29569, DOI 10.1073/pnas.2004360117; Li Z, 2011, KAOGU, V7, P76; Lin Y, 2009, XIYU YANJIU, V3, P34, DOI DOI 10.1073/PNAS.2004360117; Linduff K.M., 2004, METALLURGY ANCIENT E; Ling X., 2018, GUISUANYAN XUEBAO, V37, P918; Liu X., 2016, J BR ACAD, V4, P73, DOI DOI 10.5871/JBA/004.073; Liu XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187405; LK Liulihe kaogudui, 1990, KAOGU, V1, P20; Lyman RL, 2008, CAMB MAN ARCHAEOL, P1, DOI 10.1017/CBO9780511813863; Ma J., 2009, KAOGU YU WENWU 2014, V5, P25; Ma J, 2008, WENWU, V7, P17; Ma J., 2016, WENWU, V5, P15; Ma J., 2014, EURASIAN STUDIES, P29; Ma J., 2016, KAOGU YU WENWU, V1, P17; Ma J, 2017, ZHONGGUO SHEHUI KEXU; Ma X, 2018, ZHONGYUAN WENWU, V2, P53; Ma X., 2010, HUAXIA KAOGU, V2, P138; Ma X., 2015, WENWU, V6, P39; [马志坤 Ma Zhikun], 2021, [第四纪研究, Quaternary Sciences], V41, P214; Meserve RI, 1998, Z DEUT MORGENLAND G, V148, P277; Mo Z, 2010, KAOGU YU WENWU, V5, P51; Ning C, 2019, CURR BIOL, V29, P2526, DOI 10.1016/j.cub.2019.06.044; Olsen S., 2007, BONES TOOLS CURRENT, P175; Orton DC, 2012, INT J OSTEOARCHAEOL, V22, P320, DOI 10.1002/oa.1212; Qu T., 2005, KAOGU, V12, P99; Ramsey CB, 2009, RADIOCARBON, V51, P337, DOI 10.1017/S0033822200033865; Reimer PJ, 2020, RADIOCARBON, V62, P725, DOI 10.1017/RDC.2020.41; REN MENG, 2011, XIBU KAOGU, V5, P252; Rogers J, 2012, J ARCHAEOL RES, V20, P205, DOI 10.1007/s10814-011-9053-2; Savchenko EI, 2006, ROSS ARKHEOL, V1, P88; Schmid E., 1992, DONGWU GUGE TUPU; SHAO HUIQIU, 2018, XINJIANG SHIQIAN SHI; Shelach-Lavi G, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024835118; Tan P., 2016, WENWU, V5, P85; Taylor WTT, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57735-y; Tian D, 2021, ZHONGGUO NONGSHI, V3, P44; Tian D., 2017, ENVIRON ARCHAEOL, V12, P1; Unterlander M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14615; Usmanova ER, 2018, ARCHAEOL ETHNOL ANTH, V46, P106, DOI [10.17746/1563-0110.2018.46.2.106-113, 10.17746/1563-0102.2018.46.2.106-113]; von den Driesch A, 1976, GUIDE MEASUREMENT AN; Wang J., 2009, KAOGU, V1, P28; Wang J, 2008, XIBEI DAXUE XUEBAO Z, V38, P86; Wang J., 2009, KAOGU, V1, P3; Wang J., 2006, KAOGU YU WENWU, V5, P16; Wang Y, 2020, XIYU YANJIU, V3, P106; Wei D., 2012, RENLEIXUE XUEBAO, V21, P176; WEI DONG, 2017, QINGTONG SHIDAI ZHI; Wen R., 2016, WENWU, V5, P92; Wen R, 2016, SPECTROSC SPECT ANAL, V36, P2961, DOI 10.3964/j.issn.1000-0593(2016)09-2961-05; Xi T, 2009, KAOGU YU WENWU 2014, V4, P24; XICRA (Xinjiang Institute of Cultural Relics and Archaeology), 2020, XINJIANG BAIQIER MUD; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Xu W., 2019, KAOGU YU WENWU, V3, P50; You Y., 2016, KAOGU, V12, P104; You Y., 2016, NANFANG WENWU, V2, P116; Yu T., 2003, ZHONGZHOU GUJI CHUBA; Yuan J., 2015, ZHONGGUO DONGWU KAOG; Yuan J., 2019, ZHONGGUO XINSHIQI SH; Zhang J., 2017, ZHONGGUO GUOJIA BOWU, V1, P6; Zhang P, 1989, KAOGU XUEBAO, V3, P325; Zhou J., 2002, KAOGU, V6, P30; Zhu JS, 2021, HOLOCENE, V31, P217, DOI 10.1177/0959683620970260; 安成邦, 2020, [中国科学. 地球科学, Scientia Sinica Terrae], V50, P295	103	1	1	26	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2021	16	12							e0259985	10.1371/journal.pone.0259985	http://dx.doi.org/10.1371/journal.pone.0259985			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY2HZ	34905540	gold, Green Published			2023-01-03	WOS:000754615500003
J	Weiss, A; Touret, F; Baronti, C; Gilles, M; Hoen, B; Nougairede, A; de Lamballerie, X; Sommer, MOA				Weiss, Anne; Touret, Franck; Baronti, Cecile; Gilles, Magali; Hoen, Bruno; Nougairede, Antoine; de Lamballerie, Xavier; Sommer, Morten O. A.			Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)	PLOS ONE			English	Article								SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.	[Weiss, Anne] UNION Therapeut Res Serv, Hellerup, Denmark; [Weiss, Anne; Sommer, Morten O. A.] Tech Univ Denmark, Novo Nordisk Ctr Biosustainabil, Lyngby, Denmark; [Touret, Franck; Baronti, Cecile; Gilles, Magali; Nougairede, Antoine; de Lamballerie, Xavier] Aix Marseille Univ, Unite Virus Emergents UVE, IHU Mediterranee Infect, Inserm 1207,IRD 190, Marseille, France; [Hoen, Bruno] Inst Pasteur, Paris, France; [Sommer, Morten O. A.] UNION Therapeut, Hellerup, Denmark	Technical University of Denmark; Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Sommer, MOA (corresponding author), Tech Univ Denmark, Novo Nordisk Ctr Biosustainabil, Lyngby, Denmark.; de Lamballerie, X (corresponding author), Aix Marseille Univ, Unite Virus Emergents UVE, IHU Mediterranee Infect, Inserm 1207,IRD 190, Marseille, France.; Sommer, MOA (corresponding author), UNION Therapeut, Hellerup, Denmark.	xavier.de-lamballerie@univ-amu.fr; morten.sommer@uniontherapeutics.com	Touret, Franck/ABD-3236-2020	Touret, Franck/0000-0002-4734-2249; Sommer, Morten Otto Alexander/0000-0003-4005-5674; baronti, cecile/0000-0002-2319-9484; Weiss, Anne/0000-0002-1738-0519	Innovationsfonden Denmark [0208-00081, 0153-00209]; Novo Nordisk Foundation under NFF [NNF20CC0035580]	Innovationsfonden Denmark; Novo Nordisk Foundation under NFF	We are thankful for the support of Innovationsfonden Denmark under the grant number: 0208-00081 and 0153-00209 (receiver: AW, MOAS; https://innovationsfonden.dk) and The Novo Nordisk Foundation under NFF grant number: NNF20CC0035580 (receiver: MOAS; https://novonordiskfonden.dk).The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.	[Anonymous], JOHNSON JOHNSON ANNO; Backer V, 2021, LANCET REG HEALTH-EU, V4, DOI 10.1016/j.lanepe.2021.100084; Boda B, 2018, ANTIVIR RES, V156, P72, DOI 10.1016/j.antiviral.2018.06.007; Braga L, 2021, NATURE, V594, P88, DOI 10.1038/s41586-021-03491-6; Brunaugh AD., 2020, BROAD SPECTRUM PATIE; Campbell F, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.24.2100509; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Davies N.G., 2020, MEDRXIV, DOI [10.1126/science.abg3055, 10.1101/2020.12.24.20248822.]; Delang L, 2016, SCI REP-UK, V6, DOI 10.1038/srep31819; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Essaidi-Laziosi M, 2018, J ALLERGY CLIN IMMUN, V141, P2074, DOI 10.1016/j.jaci.2017.07.018; Gassen NC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24007-w; Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20; Jurgeit A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002976; Lamers M. M., 2021, HUMAN ORGANOID SYSTE, DOI [10.1101/2021.05.03.441080, DOI 10.1101/2021.05.03.441080]; Lee J., 2021, 438540 BIORXIV, DOI [10.1101/2021.04.06.438540, DOI 10.1101/2021.04.06.438540]; Lee S, 2020, EMERG MICROBES INFEC, V9, P2169, DOI 10.1080/22221751.2020.1827985; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n296; Pearson CA, ESTIMATES SEVERITY T, DOI DOI 10.1038/s41423-021-00641-8; Pizzorno A, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100059; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Touret F, 2021, ANTIVIR RES, V193, DOI 10.1016/j.antiviral.2021.105137; Touret F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70143-6; Wang P, 2021, NATURE, DOI [10. 1101/2021.01.25.428137, DOI 10.1038/S41586-021-03398-2, 10.1101/2021.01.25.428137]; Shi Pei-Yong, 2021, Res Sq, DOI [10.1101/2021.01.07.425740, 10.21203/rs.3.rs-143532/v1]; Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052	27	9	9	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2021	16	12							e0260958	10.1371/journal.pone.0260958	http://dx.doi.org/10.1371/journal.pone.0260958			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW0CT	34855904	gold, Green Published			2023-01-03	WOS:000735299000156
J	Shafiq, S; Akram, NA; Ashraf, M; AL-Harbi, MS; Samra, BN				Shafiq, Sidra; Akram, Nudrat Aisha; Ashraf, Muhammad; AL-Harbi, Mohammad S.; Samra, Bassem N.			Sugar beet extract rich in glycine betaine modulates oxidative defense system and key physiological characteristics of maize under water-deficit stress	PLOS ONE			English	Article							DIFFERENT GROWTH-STAGES; DROUGHT TOLERANCE; BIOCHEMICAL ATTRIBUTES; LIPID-PEROXIDATION; OSMOTIC ADJUSTMENT; ASCORBIC-ACID; L.; PLANTS; ROLES; COMPONENTS	Now-a-days, plant-based extracts, as a cheap source of growth activators, are being widely used to treat plants grown under extreme climatic conditions. So, a trial was conducted to assess the response of two maize (Zea mays L.) varieties, Sadaf (drought tolerant) and Sultan (drought sensitive) to foliar-applied sugar beet extract (SBE) under varying water-deficit conditions. Different SBE (control, 1%, 2%, 3% & 4%) levels were used in this study, and plants were exposed to water-deficit [(75% and 60% of field capacity (FC)] and control (100% FC) conditions. It was observed that root and shoot dry weights (growth), total soluble proteins, RWC-relative water contents, total phenolics, chlorophyll pigments and leaf area per plant decreased under different water stress regimes. While, proline, malondialdehyde (MDA), RMP-relative membrane permeability, H2O2-hydrogen peroxide and the activities of antioxidant enzymes [CAT-catalase, POD-peroxidase and SOD-superoxide dismutase] were found to be improved in water stress affected maize plants. Exogenous application of varying levels of SBE ameliorated the negative effects of water-deficit stress by enhancing the growth attributes, photosynthetic pigments, RWC, proline, glycinebetaine (GB), activities of POD and CAT enzymes and levels of total phenolics, whereas it reduced the lipid peroxidation in both maize varieties under varying water stress levels. It was noted that 3% and 4% levels of SBE were more effective than the other levels used in enhancing the growth as well as other characteristics of the maize varieties. Overall, the sugar beet extract proved to be beneficial for improving growth and metabolism of maize plants exposed to water stress.	[Shafiq, Sidra; Akram, Nudrat Aisha] Govt Coll Univ, Dept Bot, Faisalabad, Pakistan; [Ashraf, Muhammad] Univ Agr Faisalabad, Faisalabad, Pakistan; [AL-Harbi, Mohammad S.; Samra, Bassem N.] Taif Univ, Coll Sci, Dept Biol, At Taif, Saudi Arabia	Government College University Faisalabad; University of Agriculture Faisalabad; Taif University	Akram, NA (corresponding author), Govt Coll Univ, Dept Bot, Faisalabad, Pakistan.	nudrataauaf@yahoo.com	Akram, Nudrat Aisha/F-6882-2010; Ashraf, Muhammad/F-6294-2010	Akram, Nudrat Aisha/0000-0001-9140-8252; Samra, Bassem/0000-0002-1345-1172	Deanship of Scientific Research at Taif University, Taif University, Taif, Saudi Arabia [TURSP-2020/64]; Higher Education Commission Pakistan, HEC project [NRPU-5599]	Deanship of Scientific Research at Taif University, Taif University, Taif, Saudi Arabia; Higher Education Commission Pakistan, HEC project	The authors would like to thank the Deanship of Scientific Research at Taif University for supporting this work through Researchers Supporting Project number (TURSP-2020/64), Taif University, Taif, Saudi Arabia. Additionally, this manuscript is part of research work conducted by SS and was funded by Higher Education Commission Pakistan through the project Number, HEC project #. NRPU-5599.	Abdellatif YMR., 2018, INT J BOT; Ahmad P, 2019, ENVIRON EXP BOT, V161, P1, DOI 10.1016/j.envexpbot.2019.02.017; Ahmad P, 2010, CRIT REV BIOTECHNOL, V30, P161, DOI 10.3109/07388550903524243; Akram NA, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.00613; Akram NA, 2018, PROTOPLASMA, V255, P163, DOI 10.1007/s00709-017-1140-x; Ali Z, 2015, PAK J BOT, V47, P845; Anjum SA, 2011, PLANT SOIL ENVIRON, V57, P326, DOI 10.17221/41/2011-PSE; Annunziata MG, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00230; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Ashraf M, 2007, ENVIRON EXP BOT, V59, P206, DOI 10.1016/j.envexpbot.2005.12.006; Ashraf M, 2013, PHOTOSYNTHETICA, V51, P163, DOI 10.1007/s11099-013-0021-6; Ashraf MA, 2010, PAK J BOT, V42, P559; Avramova V, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.00084; BARRS HD, 1962, AUST J BIOL SCI, V15, P413, DOI 10.1071/BI9620413; Basu Supratim, 2016, F1000Res, V5, DOI 10.12688/f1000research.7678.1; BATES LS, 1973, PLANT SOIL, V39, P205, DOI 10.1007/BF00018060; Bayoumi TY, 2008, AFR J BIOTECHNOL, V7, P2341; Begum N, 2019, PLANTS-BASEL, V8, DOI 10.3390/plants8120579; Bolat I, 2014, SCI WORLD J, DOI 10.1155/2014/769732; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAKMAK I, 1991, PHYSIOL PLANTARUM, V83, P463, DOI 10.1111/j.1399-3054.1991.tb00121.x; Caverzan A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051086; Caverzan A, 2016, ABIOTIC AND BIOTIC STRESS IN PLANTS - RECENT ADVANCES AND FUTURE PERSPECTIVES, P463, DOI 10.5772/61368; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; du Jardin P, 2015, SCI HORTIC-AMSTERDAM, V196, P3, DOI 10.1016/j.scienta.2015.09.021; Fahad S, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.01147; FARIDUDDIN Q, 2013, PLANT STRESS, V7, P8, DOI DOI 10.1080/17429145.2012.716455; Farooq A, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9010104; Fathi A., 2016, International Journal of Life Sciences, V10, P1, DOI 10.3126/ijls.v10i1.14509; Fayez K. A., 2014, Journal of the Saudi Society of Agricultural Sciences, V13, P45, DOI 10.1016/j.jssas.2013.01.001; Ghorbanli M., 2013, IRAN J PLANT PHYSL, V3, P651, DOI DOI 10.22034/IJPP.2013.540675; GIANNOPOLITIS CN, 1977, PLANT PHYSIOL, V59, P309, DOI 10.1104/pp.59.2.309; GRIEVE CM, 1983, PLANT SOIL, V70, P303, DOI 10.1007/BF02374789; Gunes A, 2008, RUSS J PLANT PHYSL+, V55, P59, DOI 10.1134/S102144370801007X; Gupta D.K., 2015, REACTIVE OXYGEN SPEC; Gupta N, 2014, PLANT GROWTH REGUL, V72, P221, DOI 10.1007/s10725-013-9853-0; Habib N, 2012, S AFR J BOT, V83, P151, DOI 10.1016/j.sajb.2012.08.005; Habibi G., 2018, Acta Agriculturae Slovenica, V111, P463, DOI 10.14720/aas.2018.111.2.19; Iqbal N, 2008, S AFR J BOT, V74, P274, DOI 10.1016/j.sajb.2007.11.016; Jamil S, 2015, BRAZ J BOT, V38, P527, DOI 10.1007/s40415-015-0174-6; JULKUNENTIITTO R, 1985, J AGR FOOD CHEM, V33, P213, DOI 10.1021/jf00062a013; Kaya C, 2019, PLANT PHYSIOL BIOCH, V143, P119, DOI 10.1016/j.plaphy.2019.08.024; Keyvan S., 2010, Journal of Animal and Plant Sciences (JAPS), V8, P1051; Koester RP, 2014, J EXP BOT, V65, P3311, DOI 10.1093/jxb/eru187; Kohli SK, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8120641; Kosar F, 2015, S AFR J BOT, V96, P71, DOI 10.1016/j.sajb.2014.10.015; Kosar F, 2021, PHYSIOL PLANTARUM, V172, P317, DOI 10.1111/ppl.13155; Kumar V., 2017, STRESS SIGNALING PLA, V2, P111, DOI 10.1007/978-3-319-42183-4_5; Kusaka M, 2005, PHYSIOL PLANTARUM, V125, P474, DOI 10.1111/j.1399-3054.2005.00578.x; Latif M, 2016, J HORTIC SCI BIOTECH, V91, P129, DOI 10.1080/14620316.2015.1117226; Lehtimaki N, 2011, J PLANT PHYSIOL, V168, P594, DOI 10.1016/j.jplph.2010.09.013; Li DX, 2019, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01995; Lisko KA., 2014, PHYTOCHEMICALS BIOSY, P109; Mahmood T, 2009, PAK J BOT, V41, P1291; Maluventhen Viji, 2012, African Journal of Biotechnology, V11, P10340, DOI 10.5897/AJB12.368; Meher, 2018, SAUDI J BIOL SCI, V25, P285, DOI 10.1016/j.sjbs.2017.04.008; Mitsuya S, 2013, PLANT PROD SCI, V16, P117, DOI 10.1626/pps.16.117; Moller IM, 2007, ANNU REV PLANT BIOL, V58, P459, DOI 10.1146/annurev.arplant.58.032806.103946; Mosfeq-Ul Hasan M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092636; MUKHERJEE SP, 1983, PHYSIOL PLANTARUM, V58, P166, DOI 10.1111/j.1399-3054.1983.tb04162.x; Naz H, 2016, PAK J BOT, V48, P877; Quan NT, 2016, AGRICULTURE-BASEL, V6, DOI 10.3390/agriculture6020023; Noman A, 2018, ACTA PHYSIOL PLANT, V40, DOI 10.1007/s11738-018-2681-0; Noreen Z, 2009, J PLANT PHYSIOL, V166, P1764, DOI 10.1016/j.jplph.2009.05.005; Osman H. S., 2015, Annals of Agricultural Science (Cairo), V60, P389, DOI 10.1016/j.aoas.2015.10.004; Osmolovskaya N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124089; Raja V, 2020, 3 BIOTECH, V10, DOI 10.1007/s13205-020-02206-4; Reddy K. R., 2013, American Journal of Experimental Agriculture, V3, P1; Shafei S., 2005, STUDY WATER SHORTAGE; Shafiq S, 2019, PAK J BOT, V51, P1241, DOI [10.30848/PJB2019-4(21), 10.30848/pjb2019-4(21)]; Shafiq S, 2015, SCI HORTIC-AMSTERDAM, V185, P68, DOI 10.1016/j.scienta.2015.01.010; Shahid MA, 2015, TURK J BOT, V39, P408, DOI 10.3906/bot-1406-84; Sharma A, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9070285; Sharma P., 2012, J BOT, V2012, DOI [10.1155/2012/217037, DOI 10.1155/2012/217037]; Singh M, 2015, REV ENVIRON SCI BIO, V14, P407, DOI 10.1007/s11157-015-9372-8; SNEDECOR G W, 1980; Srivastava N., 2014, UNIQUE J PHARM BIOOG, V2, P15; Sultana S, 2013, BANGL J PHARMACOL, V8, P214, DOI 10.3329/bjp.v8i2.14708; Tatrai ZA, 2016, INT J AGRON, V2016, DOI 10.1155/2016/4165750; Velikova V, 2000, PLANT SCI, V151, P59, DOI 10.1016/S0168-9452(99)00197-1; Wang GP, 2010, PHOTOSYNTHETICA, V48, P30, DOI 10.1007/s11099-010-0006-7; Weraduwagel SM, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00167; Xie XL, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9732325; Yadav S. K., 2005, Indian Journal of Plant Physiology, V10, P20; Yang GP, 1996, AUST J PLANT PHYSIOL, V23, P437, DOI 10.1071/PP9960437; Yuan S, 2005, PHYSIOL PLANTARUM, V125, P464, DOI 10.1111/j.1399-3054.2005.00577.x	86	3	3	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2021	16	11							e0254906	10.1371/journal.pone.0254906	http://dx.doi.org/10.1371/journal.pone.0254906			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU5IH	34843496	gold, Green Published			2023-01-03	WOS:000752076100003
J	Meltzer, PS; Helman, LJ				Meltzer, Paul S.; Helman, Lee J.			New Horizons in the Treatment of Osteosarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PEDIATRIC-ONCOLOGY-GROUP; HIGH-GRADE OSTEOSARCOMA; PHASE-II; PREOPERATIVE CHEMOTHERAPY; METASTATIC OSTEOSARCOMA; ADJUVANT CHEMOTHERAPY; HISTOLOGIC RESPONSE; MURAMYL TRIPEPTIDE; OSTEOGENIC-SARCOMA; CANCER GENOME	Osteosarcoma Osteosarcoma, which is most common in people 10 to 30 years of age, is generally treated with resection and adjuvant chemotherapy. Detection of gene rearrangements, copy-number variations, and targeted disruption of tumor suppressors by whole-genome sequencing has not yet led to improved treatment.	[Meltzer, Paul S.] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Helman, Lee J.] Osteo Sarcoma Inst, 100 Crescent Ct, Dallas, TX 75205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Helman, LJ (corresponding author), Osteo Sarcoma Inst, 100 Crescent Ct, Dallas, TX 75205 USA.	lhelman@osinst.org		Meltzer, Paul/0000-0003-0963-1768				Ahmed N, 2015, J CLIN ONCOL, V33, P1688, DOI 10.1200/JCO.2014.58.0225; Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Bacci G, 2003, CANCER, V97, P3068, DOI 10.1002/cncr.11456; Behjati S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15936; Ben-Ami E, 2020, CANCERS, V12, DOI 10.3390/cancers12030757; Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776; Bielack SS, 2015, J CLIN ONCOL, V33, P2279, DOI 10.1200/JCO.2014.60.0734; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Coley W B, 1891, Ann Surg, V14, P199, DOI 10.1097/00000658-189112000-00015; Davis LE, 2019, J CLIN ONCOL, V37, P1424, DOI 10.1200/JCO.18.02374; Disel U, 2020, ONCOLOGIST, V25, pE39, DOI 10.1634/theoncologist.2018-0528; Donehower LA, 2019, CELL REP, V28, P1370, DOI 10.1016/j.celrep.2019.07.001; Duffaud F, 2019, LANCET ONCOL, V20, P120, DOI 10.1016/S1470-2045(18)30742-3; Ebb D, 2012, J CLIN ONCOL, V30, P2545, DOI 10.1200/JCO.2011.37.4546; Ekhtiari S, 2020, LANCET ONCOL, V21, P1021, DOI 10.1016/S1470-2045(20)30171-6; ENNEKING WF, 1980, CLIN ORTHOP RELAT R, P106; Feng WL, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920922055; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fujiwara T, 2021, MOL CANCER THER, V20, P1388, DOI 10.1158/1535-7163.MCT-20-0591; Fujiwara T, 2021, CANCERS, V13, DOI 10.3390/cancers13051086; Gomez-Brouchet A, 2019, ORTHOP TRAUMATOL-SUR, V105, P773, DOI 10.1016/j.otsr.2018.12.015; Goorin AM, 2003, J CLIN ONCOL, V21, P1574, DOI 10.1200/JCO.2003.08.165; Gorlick R, 2013, PEDIATR BLOOD CANCER, V60, P1009, DOI 10.1002/pbc.24429; Guenther LM, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26896; Hong AL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11987; Italiano A, 2020, LANCET ONCOL, V21, P446, DOI [10.1016/51470-2045(19)30825-3, 10.1016/S1470-2045(19)30825-3]; Jacobs JFM, 2007, INT J CANCER, V120, P67, DOI 10.1002/ijc.22118; Joseph CG, 2014, GENE CHROMOSOME CANC, V53, P15, DOI 10.1002/gcc.22114; Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132; Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940; Krishnadas DK, 2015, CANCER IMMUNOL IMMUN, V64, P1251, DOI 10.1007/s00262-015-1731-3; Lagmay JP, 2016, J CLIN ONCOL, V34, P3031, DOI 10.1200/JCO.2015.65.5381; Le Cesne A, 2019, EUR J CANCER, V119, P151, DOI 10.1016/j.ejca.2019.07.018; Lim G, 2005, GENE CHROMOSOME CANC, V42, P392, DOI 10.1002/gcc.20157; LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502; Lu LC, 2020, ADV EXP MED BIOL, V1258, P37, DOI 10.1007/978-3-030-43085-6_3; Lu YC, 2017, J CLIN ONCOL, V35, P3322, DOI 10.1200/JCO.2017.74.5463; Ma XT, 2018, NATURE, V555, P371, DOI 10.1038/nature25795; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARCOVE RC, 1970, J BONE JOINT SURG AM, VA 52, P411, DOI 10.2106/00004623-197052030-00001; Meyers P A, 1993, Cancer Treat Res, V62, P309; Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031; Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Mirabello L, 2020, JAMA ONCOL, V6, P724, DOI 10.1001/jamaoncol.2020.0197; Mross K, 2012, CLIN CANCER RES, V18, P2658, DOI 10.1158/1078-0432.CCR-11-1900; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Odes EJ, 2016, S AFR J SCI, V112, P100, DOI 10.17159/sajs.2016/20150471; Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111; Purcell JW, 2018, CANCER RES, V78, P4059, DOI 10.1158/0008-5472.CAN-18-0327; ROSEN G, 1979, CANCER-AM CANCER SOC, V43, P2163, DOI 10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S; Roth M, 2014, CANCER-AM CANCER SOC, V120, P548, DOI 10.1002/cncr.28461; Sayles LC, 2019, CANCER DISCOV, V9, P46, DOI 10.1158/2159-8290.CD-17-1152; Selvarajah S, 2006, CHROMOSOMA, V115, P459, DOI 10.1007/s00412-006-0074-4; Slemmons KK, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28771; Smeland S, 2019, EUR J CANCER, V109, P36, DOI 10.1016/j.ejca.2018.11.027; Sorenson L, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1629779; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Tanaka H, 2005, NAT GENET, V37, P320, DOI 10.1038/ng1515; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; Taylor BJM, 2013, ELIFE, V2, DOI 10.7554/eLife.00534; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vlachos A, 2012, BLOOD, V119, P3815, DOI 10.1182/blood-2011-08-375972; Vollger MR, 2020, ANN HUM GENET, V84, P125, DOI 10.1111/ahg.12364; Wang LL, 2003, J NATL CANCER I, V95, P669, DOI 10.1093/jnci/95.9.669; WIEMANN B, 1994, PHARMACOL THERAPEUT, V64, P529, DOI 10.1016/0163-7258(94)90023-X; Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864	67	48	48	19	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2021	385	22					2066	2076		10.1056/NEJMra2103423	http://dx.doi.org/10.1056/NEJMra2103423			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC3KG	34818481				2023-01-03	WOS:000721915400011
J	Hailemariam, D; Kumie, A; Wakuma, S; Tefera, Y; Abegaz, T; Tefera, W; Ayele, W; Tamire, M; Yirsaw, S				Hailemariam, Damen; Kumie, Abera; Wakuma, Samson; Tefera, Yifoker; Abegaz, Teferi; Tefera, Worku; Ayele, Wondimu; Tamire, Mulugeta; Yirsaw, Shibabaw			Trends in non-pharmaceutical intervention (NPI) related community practice for the prevention of COVID-19 in Addis Ababa, Ethiopia	PLOS ONE			English	Article							TRANSMISSION	Background The COVID-19 pandemic has affected Ethiopia since March 13, 2020, when the first case was detected in Addis Ababa. Since then, the incidence of cases has continued to increase day by day. As a result, the health sector has recommended universal preventive measures to be practiced by the public. However, studies on adherence to these preventive measures are limited. Objective To monitor the status of preventive practices of the population related to hand washing, physical distancing, and respiratory hygiene practices at selected sites within the city of Addis Ababa. Methods Weekly cross-sectional non-participatory observations were done during the period of April-June, 2020. Data was collected using the Open Data Kit (ODK) tool in ten public sites involving eight public facilities targeted for individual observations. Ten individuals were randomly observed at each facility over two days a week at peak hours of public services. WHO operational definitions of the preventive behaviors were adopted for this study. Observations were conducted anonymously at gates or entrances of public facilities and places. Results A total of 12,056 individual observations with 53% males and 82% in an estimated age range of 18-50 years age group were involved in this study. There was an increase in the practice of respiratory hygiene from 14% in week one to 77% in week 10, while those of hand hygiene and physical distancing changed little over the weeks from their baseline of 24% and 34%, respectively. Overall, respiratory hygiene demonstrated an increased rate of 6% per week, while hand hygiene and physical distancing had less than a 1% change per week, Females and the estimated age group of 18-50 years had practice changes in respiratory hygiene with no difference in hand hygiene and physical distancing practices. Respiratory hygiene took about six weeks to reach a level of 77% from its baseline of 24%, making an increment of about 9% per week. Conclusion The public practice of respiratory hygiene improved threefold whereas hand hygiene and physical distancing revealed no change. Regularly sustained public mobilization and mass education are required to sustain the achievements gained in respiratory hygiene and further hand hygiene and physical distancing.	[Hailemariam, Damen; Kumie, Abera; Wakuma, Samson; Tefera, Yifoker; Abegaz, Teferi; Tefera, Worku; Ayele, Wondimu; Tamire, Mulugeta; Yirsaw, Shibabaw] Addis Ababa Univ, Coll Hlth Sci, Sch Publ Hlth, Addis Ababa, Ethiopia	Addis Ababa University	Kumie, A (corresponding author), Addis Ababa Univ, Coll Hlth Sci, Sch Publ Hlth, Addis Ababa, Ethiopia.	aberakumie2@yahoo.com			College of Health Sciences	College of Health Sciences	The authors are grateful to the College of Health Sciences and the School of Public Health of Addis Ababa University for allowing this study to happen. The leadership of Dr Dawit Wendimagegn, who is the Chief Executive Director of the College of Health Sciences is greatly thanked for his support to undertake this study.	Alexander D, NMA CONDEMNS NONADHE; Badillo-Goicoechea E, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-12175-9; Beattie RM, 2020, FRONTLINE GASTROENTE, V11, P290, DOI 10.1136/flgastro-2020-101507; Bo YC, 2021, INT J INFECT DIS, V102, P247, DOI 10.1016/j.ijid.2020.10.066; Centers for Diseases Control and Prevention, IMPL MIT STRAT COMM; Chen XG, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00137-4; Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9; Dalton CB, 2020, MED J AUSTRALIA, V212, P443, DOI 10.5694/mja2.50602; Dudley JP, 2020, CLIN INFECT DIS, V71, P863, DOI 10.1093/cid/ciaa354; European Centre for Disease Prevention and Control, INF PREV CONTR PREP; Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4; Jefferson T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3675; Koh WC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240205; Lai SJ, 2020, NATURE, V585, P410, DOI [10.1038/s41586-020-2293-x, 10.1101/2020.03.03.20029843]; Lau JTF, 2004, J EPIDEMIOL COMMUN H, V58, P988, DOI 10.1136/jech.2003.017483; Liu JY, 2020, EMERG INFECT DIS, V26, P1320, DOI 10.3201/eid2606.200239; Matusiak L, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13909; Missoni E, 2021, DISASTER MED PUBLIC, V15, pE29, DOI 10.1017/dmp.2020.207; Muller O, 2020, DEUT MED WOCHENSCHR, V145, P670, DOI 10.1055/a-1162-1987; Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262; Pei S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd6370; Qian GQ, 2020, CLIN INFECT DIS, V71, P861, DOI 10.1093/cid/ciaa316; Qiu XT, 2021, CLIN MICROBIOL INFEC, V27, P511, DOI 10.1016/j.cmi.2021.01.011; Rea E, 2007, EPIDEMIOL INFECT, V135, P914, DOI 10.1017/S0950268806007771; Shahnazi H, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00776-2; Stutt ROJH, 2020, P ROY SOC A-MATH PHY, V476, DOI 10.1098/rspa.2020.0376; Taylor S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246317; UN. United Nations, WORLD POPULATION PRO; Van den Broucke S, 2020, HEALTH PROMOT INT, V35, P181, DOI 10.1093/heapro/daaa042; Wold Health Organization, MOD TRANSM VIR CAUS; World Health Organization, 2019, COR DIS COVID 19 ADV; World Health Organization, CONS IMPL ADJ PUBL H; World Health Organization, 2014, INF PREV CONTR EP PA; Worldometers, ETH COR VIR CAS 2020; Yu XX, 2020, INFLUENZA OTHER RESP, V14, P474, DOI 10.1111/irv.12743; Zhang LJ, 2013, EMERG INFECT DIS, V19, P1403, DOI 10.3201/eid1909.121765	36	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2021	16	11							e0259229	10.1371/journal.pone.0259229	http://dx.doi.org/10.1371/journal.pone.0259229			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ8YK	34813617	Green Published, gold			2023-01-03	WOS:000755756800010
J	Nguyen, HTT; Dinh, DX; Nguyen, TD; Nguyen, VM				Huong Thi Thanh Nguyen; Dai Xuan Dinh; Trung Duc Nguyen; Van Minh Nguyen			Availability, prices and affordability of essential medicines: A cross-sectional survey in Hanam province, Vietnam	PLOS ONE			English	Article							COUNTRIES; CHINA	Objective To measure medicines' prices, availability, and affordability in Hanam, Vietnam. Methods The standardized methodology developed by the World Health Organization (WHO) and Health Action International was used to survey 30 essential medicines (EMs) in 30 public health facilities and 35 private medicine outlets in 2020. The availability of medicine was computed as the percentage of health facilities in which this medicine was found on the data-collection day. International reference prices (IRPs) from Management Sciences for Health (2015) were used to compute Median Price Ratio (MPR). The affordability of treatments for common diseases was computed as the number of days' wages of the lowest-paid unskilled government worker needed to purchase medicines prescribed at a standard dose. Statistic analysis was done using R software version 4.1.1. Results The mean availability of originator brands (OBs) and lowest-priced generics (LPGs) was 0.7%, 63.2% in the public sector, and 13.7%, 47.9% in the private sector, respectively. In private medicine outlets, the mean availability of both OBs and LPGs in urban areas was significantly higher than that in rural areas (p = 0.0013 and 0.0306, respectively). In the public sector, LPGs' prices were nearly equal to their IRPs (median MPRs = 0.95). In the private medicine outlets, OBs were generally sold at 6.24 times their IRPs while this figure for LPGs was 1.65. The affordability of LPGs in both sectors was good for all conditions, with standard treatments costing a day's wage or less. Conclusion In both sectors, generic medicines were the predominant product type available. The availability of EMs was fairly high but still lower than WHO's benchmark. A national-scale study should be conducted to provide a comprehensive picture of the availability, prices, and affordability of EMs, thereby helping the government to identify the urgent priorities and improving access to EMs in Vietnam.	[Huong Thi Thanh Nguyen; Dai Xuan Dinh] Hanoi Univ Pharm, Dept Pharmaceut Management & PharmacoEcon, Hanoi, Vietnam; [Trung Duc Nguyen] 108 Mil Ctr Hosp, Pharm Dept, Hanoi, Vietnam; [Van Minh Nguyen] Hanoi Univ Publ Hlth, Ctr Populat Hlth Sci, Hanoi, Vietnam	Hanoi University of Pharmacy; Hanoi University of Public Health	Dinh, DX (corresponding author), Hanoi Univ Pharm, Dept Pharmaceut Management & PharmacoEcon, Hanoi, Vietnam.	dinhxuandai.224@gmail.com	Dinh, Dai Xuan/ADC-5116-2022	Dinh, Dai Xuan/0000-0001-6387-2496; Nguyen, Huong/0000-0003-2191-6408				Abrha S, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2109-2; Alefan Q, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3593-9; Anh Tuan Nguyen, 2009, Southern Med Review, V2, P2; Bizimana T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236411; Chan M., 2017, 10 YEARS PUBLIC HLTH; Dong ZJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241761; Dorj G, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1123-x; Gelders S., 2006, PRICE AVAILABILITY A; General Statitics Office of Vietnam, 2021, STAT YB 2020; Hagen S., 2019, INT J MOL SCI; Hailu AD, 2020, BMC MED INFORM DECIS, V20, DOI 10.1186/s12911-020-01247-2; Hanam Department of Health, 2019, DEC GRANT MED FAC CO; Hanam Department of Health, 2021, REP RES IMPL 2020 OR; Health Action International, COLL EV MED PRIC AV; Health Action International, SURV REL REP; Heidari E, 2019, E MEDITERR HEALTH J, V25, P473, DOI 10.26719/emhj.18.068; Jiang MH, 2015, INT J CLIN PHARM-NET, V37, P12, DOI 10.1007/s11096-014-0037-4; Kaiser AH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226169; Kasonde L, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4221-z; Khanal S, 2019, INQUIRY-J HEALTH CAR, V56, DOI 10.1177/0046958019887572; Khuluza F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212125; Krakauer EL, 2015, J PAIN SYMPTOM MANAG, V49, P916, DOI 10.1016/j.jpainsymman.2014.10.012; Le Duc-Cuong., 2010, ASIAN PACIFIC J DIS, V4, P23, DOI DOI 10.7223/apjdm.4.23; Management Sciences for Health World Health Organization, 2015, INT MED PROD PRIC GU; Ministry of Health, 2018, HLTH STAT YB; Ongarora D, 2019, PHARMACY-BASEL, V7, DOI 10.3390/pharmacy7020040; Party Committee of Hanam Province, INTR HAN ADM UN; Saeed A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216122; Schafermann S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227515; Sun XL, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023646; Tadesse T, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10745-5; Nguyen TA, 2017, HEALTH POLICY PLANN, V32, P647, DOI 10.1093/heapol/czw174; Vietnam Ministry of Health, 2018, NAT ESS MED LIST; Vietnam Ministry of Health, 2018, CIRCULAR NO 302018TT; Wang HP, 2017, ASIA-PAC J PUBLIC HE, V29, P268, DOI 10.1177/1010539517700472; WHO, 2020, TESTING SURVEY QUEST; WHO, 2017, ACC MED MAK MARK FOR; Wong SL, 2019, APPL HEALTH ECON HEA, V17, P641, DOI 10.1007/s40258-019-00480-9; World Health Organization, 2020, DIG VERS ESS MED LIS; World Health Organization, WHO MOD LISTS ESS ME; World Health Organization, 2020, CHILDR IMPR SURV WEL; World Health Organization, 2018, MED VACC HLTH PROD A; World Health Organization, SIGNP WHO ESS MED; World Health Organization  Health Action International, 2008, MEAS MED PRIC AV AFF, V2nd edition; World Health Organization Rotary International Centers for Disease Control and Prevention and UNICEF, 2013, GLOB ACT PLAN PREV C; Xu RX, 2020, INT J HEALTH PLAN M, V35, P545, DOI 10.1002/hpm.2963; Yang CJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.602421	47	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2021	16	11							e0260142	10.1371/journal.pone.0260142	http://dx.doi.org/10.1371/journal.pone.0260142			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2NY	34793554	gold, Green Published			2023-01-03	WOS:000755319200110
J	Taylor, C; McHugh, C; Mockler, D; Minogue, C; Reilly, RB; Fleming, N				Taylor, Clare; McHugh, Conor; Mockler, David; Minogue, Conor; Reilly, Richard B.; Fleming, Neil			Transcutaneous spinal cord stimulation and motor responses in individuals with spinal cord injury: A methodological review	PLOS ONE			English	Review							ELECTRICAL-STIMULATION; LEG MUSCLES; MODULATION; QUALITY; INTERVENTIONS; MOVEMENTS; RECOVERY; POSITION; WALKING; HUMANS	Background Transcutaneous spinal cord stimulation (tSCS) is a non-invasive modality in which electrodes can stimulate spinal circuitries and facilitate a motor response. This review aimed to evaluate the methodology of studies using tSCS to generate motor activity in persons with spinal cord injury (SCI) and to appraise the quality of included trials. Methods A systematic search for studies published until May 2021 was made of the following databases: EMBASE, Medline (Ovid) and Web of Science. Two reviewers independently screened the studies, extracted the data, and evaluated the quality of included trials. The electrical characteristics of stimulation were summarised to allow for comparison across studies. In addition, the surface electromyography (EMG) recording methods were evaluated. Results A total of 3753 articles were initially screened, of which 25 met the criteria for inclusion. Studies were divided into those using tSCS for neurophysiological investigations of reflex responses (n = 9) and therapeutic investigations of motor recovery (n = 16). The overall quality of evidence was deemed to be poor-to-fair (10.5 4.9) based on the Downs and Black Quality Checklist criteria. The electrical characteristics were collated to establish the dosage range across stimulation trials. The methods employed by included studies relating to stimulation parameters and outcome measurement varied extensively, although some trends are beginning to appear in relation to electrode configuration and EMG outcomes. Conclusion This review outlines the parameters currently employed for tSCS of the cervicothoracic and thoracolumbar regions to produce motor responses. However, to establish standardised procedures for neurophysiological assessments and therapeutic investigations of tSCS, further high-quality investigations are required, ideally utilizing consistent electrophysiological recording methods, and reporting common characteristics of the electrical stimulation administered.	[Taylor, Clare; McHugh, Conor; Minogue, Conor; Fleming, Neil] Univ Dublin, Trinity Coll, Sch Med, Dept Anat, Dublin, Ireland; [Mockler, David] St James Hosp, Sch Med, John Stearne Med Lib, Trinity Ctr Hlth Sci, Dublin, Ireland; [Reilly, Richard B.] Univ Dublin, Trinity Coll, Trinity Ctr Biomed Engn, Dublin, Ireland; [Reilly, Richard B.] Univ Dublin, Trinity Coll, Sch Engn, Dublin, Ireland; [Reilly, Richard B.] Univ Dublin, Trinity Coll, Sch Med, Dublin, Ireland	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin	Taylor, C (corresponding author), Univ Dublin, Trinity Coll, Sch Med, Dept Anat, Dublin, Ireland.	taylorc1@tcd.ie	; Reilly, Richard/F-7034-2011	Mockler, David/0000-0001-6171-8751; Taylor, Clare/0000-0001-6765-1789; Reilly, Richard/0000-0001-8578-1245	Disruptive Technology Innovation Fund [DT -2018-0128]	Disruptive Technology Innovation Fund	This study was supported by the Disruptive Technology Innovation Fund, grant number DT -2018-0128 (RR, NF, CM) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Administation UFaD, GUID DOC POW MUSCL S; Al'joboori Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092765; Alam M, 2020, ANN CLIN TRANSL NEUR, V7, P829, DOI 10.1002/acn3.51051; Andrews JC, 2015, NEUROSCI LETT, V589, P144, DOI 10.1016/j.neulet.2015.01.041; Angeli CA, 2014, BRAIN, V137, P1394, DOI 10.1093/brain/awu038; Atkinson DA, 2020, CLIN NEUROPHYSIOL, V131, P1519, DOI 10.1016/j.clinph.2020.03.021; Barss TS, 2020, J NEUROPHYSIOL, V123, P158, DOI 10.1152/jn.00433.2019; Bedi PK, 2016, J EXER SCI PHYSIOTHE, V12, P69; Belanger A-Y., 2010, THERAPEUTIC ELECTROP, V2nd ed; Benavides FD, 2020, J NEUROSCI, V40, P2633, DOI 10.1523/JNEUROSCI.2374-19.2020; Besomi M, 2020, J ELECTROMYOGR KINES, V53, DOI 10.1016/j.jelekin.2020.102438; Calvert JS, 2019, J NEUROPHYSIOL, V122, P2111, DOI 10.1152/jn.00454.2019; Courtine GG, 2007, J PHYSIOL-LONDON, V582, P1125, DOI 10.1113/jphysiol.2007.128447; Currier DP, 1999, CLIN ELECT; Danner SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147479; Danner SM, 2011, ARTIF ORGANS, V35, P257, DOI 10.1111/j.1525-1594.2011.01213.x; De Luca CJ, 1997, J APPL BIOMECH, V13, P135, DOI 10.1123/jab.13.2.135; Deeks J J, 2003, Health Technol Assess, V7, piii; Dietz V, 2001, EUR J NEUROSCI, V14, P1906, DOI 10.1046/j.0953-816x.2001.01813.x; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Duffell LD, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00607; Dy CJ, 2010, J NEUROPHYSIOL, V103, P2808, DOI 10.1152/jn.00316.2009; EblenZajjur AA, 1997, NEUROSCIENCE, V76, P39; Einhorn J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076940; Emeliannikov D V, 2016, Fiziol Cheloveka, V42, P32; Eng Janice J, 2007, Top Spinal Cord Inj Rehabil, V13, P1, DOI 10.1310/sci1301-1; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Freyvert Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33123-5; Gad P, 2018, J NEUROTRAUM, V35, P2145, DOI 10.1089/neu.2017.5461; Gad P, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00333; Gerasimenko Y, 2015, ANN PHYS REHABIL MED, V58, P225, DOI 10.1016/j.rehab.2015.05.003; Gerasimenko YP, 2015, J NEUROTRAUM, V32, P1968, DOI 10.1089/neu.2015.4008; Gill ML, 2018, NAT MED, V24, P1677, DOI 10.1038/s41591-018-0175-7; Ginis KAM, 2005, EXERC SPORT SCI REV, V33, P49; Hamdan Puteri Nur Farhana, 2022, J Sport Health Sci, V11, P671, DOI 10.1016/j.jshs.2020.10.002; Hermens HJ, 2000, J ELECTROMYOGR KINES, V10, P361, DOI 10.1016/S1050-6411(00)00027-4; Hofmann Lorenz, 2011, Front Neuroeng, V4, P9, DOI 10.3389/fneng.2011.00009; Hofstoetter US, 2008, ARTIF ORGANS, V32, P644, DOI 10.1111/j.1525-1594.2008.00616.x; Hofstoetter US, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0227057; Hofstoetter US, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192013; Hofstoetter US, 2017, CURR PHARM DESIGN, V23, P1805, DOI 10.2174/1381612822666161214144655; Hofstoetter US, 2015, ARTIF ORGANS, V39, pE176, DOI 10.1111/aor.12615; Hofstoetter US, 2013, BIOMED TECH BERL, V58; Huang H, 2006, IEEE T NEUR SYS REH, V14, P14, DOI 10.1109/TNSRE.2005.862694; Ibitoye MO, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149024; Inanici F, 2021, IEEE T NEUR SYS REH, V29, P310, DOI 10.1109/TNSRE.2021.3049133; Inanici F, 2018, IEEE T NEUR SYS REH, V26, P1272, DOI 10.1109/TNSRE.2018.2834339; Islam MA, 2021, FRONT HUM NEUROSCI, V15, DOI 10.3389/fnhum.2021.620414; Islam MA, 2020, NEUROSCI LETT, V732, DOI 10.1016/j.neulet.2020.135052; Kaneko N, 2019, BRAIN SCI, V9, DOI 10.3390/brainsci9120333; Kim M, 2021, FRONT HUM NEUROSCI, V15, DOI 10.3389/fnhum.2021.660583; Kitano K, 2009, J NEUROSCI METH, V180, P111, DOI 10.1016/j.jneumeth.2009.03.006; Knikou M, 2013, BIOELECTROMAGNETICS, V34, P630, DOI 10.1002/bem.21808; Krenn M, 2013, BIOMED ENG-BIOMED TE, V58, DOI 10.1515/bmt-2013-4010; Krenn M, 2015, ARTIF ORGANS, V39, P834, DOI 10.1111/aor.12616; Ladenbauer J, 2010, IEEE T NEUR SYS REH, V18, P637, DOI 10.1109/TNSRE.2010.2054112; Laliberte AM, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00512; Lam Tania, 2007, Top Spinal Cord Inj Rehabil, V13, P32, DOI 10.1310/sci1301-32; Manson GA, 2020, PHYSIOL REP, V8, DOI 10.14814/phy2.14397; Masugi Y, 2017, IEEE ENG MED BIO, P1114, DOI 10.1109/EMBC.2017.8037024; Masugi Y, 2016, NEUROSCI LETT, V627, P100, DOI 10.1016/j.neulet.2016.05.047; McHugh C, 2021, NEUROREHABILITATION, V49, P1, DOI 10.3233/NRE-210093; McKay WB, 2011, SPINAL CORD, V49, P87, DOI 10.1038/sc.2010.73; Garcia AM, 2020, NEUROREHAB NEURAL RE, V34, P3, DOI 10.1177/1545968319893298; Meyer C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113541; Militskova A, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00552; Milosevic M, 2019, J NEUROPHYSIOL, V121, P1672, DOI 10.1152/jn.00802.2018; Minassian K, 2007, HUM MOVEMENT SCI, V26, P275, DOI 10.1016/j.humov.2007.01.005; Minassian K, 2007, MUSCLE NERVE, V35, P327, DOI 10.1002/mus.20700; Minassian K, 2017, NEUROSCIENTIST, V23, P649, DOI 10.1177/1073858417699790; Minassian K, 2016, NEUROREHAB NEURAL RE, V30, P233, DOI 10.1177/1545968315591706; Murray LM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213696; Pilkar R, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.578559; Ranger MRB, 2008, BRIT J ANAESTH, V101, P804, DOI 10.1093/bja/aen295; Rath M, 2018, J NEUROTRAUM, V35, P2540, DOI 10.1089/neu.2017.5584; Roy RR, 2012, ARCH PHYS MED REHAB, V93, P1487, DOI 10.1016/j.apmr.2012.04.034; Sabbahi MA, 2012, SPINAL CORD, V50, P432, DOI 10.1038/sc.2011.166; Sabbahi MA, 2014, J SPINAL CORD MED, V37, P401, DOI 10.1179/2045772313Y.0000000157; Saifuddin A, 1998, SPINE, V23, P1452, DOI 10.1097/00007632-199807010-00005; Saunders LD, 2003, WESTERN J NURS RES, V25, P223, DOI 10.1177/0193945902250039; Sayenko DG, 2019, J NEUROTRAUM, V36, P1435, DOI 10.1089/neu.2018.5956; Sayenko DG, 2015, J APPL PHYSIOL, V118, P1364, DOI 10.1152/japplphysiol.01128.2014; Sayenko DG, 2014, J NEUROPHYSIOL, V111, P1088, DOI 10.1152/jn.00489.2013; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647; Shapkova EY, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00416; Sherwood AM, 1996, MUSCLE NERVE, V19, P966, DOI 10.1002/(SICI)1097-4598(199608)19:8<966::AID-MUS5>3.3.CO;2-N; Silverman SR, 2012, SPINAL CORD, V50, P718, DOI 10.1038/sc.2012.78; Taccola G, 2018, PROG NEUROBIOL, V160, P64, DOI 10.1016/j.pneurobio.2017.10.004; Taccola G, 2020, BRAIN STIMUL, V13, P20, DOI 10.1016/j.brs.2019.09.013; Troni W, 2011, CLIN NEUROPHYSIOL, V122, P2071, DOI 10.1016/j.clinph.2011.03.002; van den Brand R, 2015, ANN PHYS REHABIL MED, V58, P232, DOI 10.1016/j.rehab.2015.04.003; Luna JLV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125609; Wagner FB, 2018, NATURE, V563, P65, DOI 10.1038/s41586-018-0649-2; Ward AR, 2002, ARCH PHYS MED REHAB, V83, P1024, DOI 10.1053/apmr.2002.33116; Wu YK, 2020, CLIN NEUROPHYSIOL, V131, P451, DOI 10.1016/j.clinph.2019.11.056; Young W, 2015, CELL TRANSPLANT, V24, P429, DOI 10.3727/096368915X686904; Zhang F, 2020, IEEE T NEUR SYS REH, V28, P3167, DOI 10.1109/TNSRE.2020.3048592; Zheng Y, 2020, J NEURAL ENG, V17, DOI 10.1088/1741-2552/ab5e09	98	6	6	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2021	16	11							e0260166	10.1371/journal.pone.0260166	http://dx.doi.org/10.1371/journal.pone.0260166			33	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ2NY	34793572	gold, Green Published			2023-01-03	WOS:000755319200115
J	Alketbi, A; Basit, S; Hamza, N; Walton, LM; Moustafa, IM				Alketbi, Azza; Basit, Salah; Hamza, Nouran; Walton, Lori M.; Moustafa, Ibrahim M.			The added value of cognition-targeted exercise versus symptom-targeted exercise for multiple sclerosis fatigue: A randomized controlled pilot trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; BEHAVIOR THERAPY; GRADED-EXERCISE; SCALE; MECHANISMS; OUTCOMES; REDUCE; IMPACT; WORK	Background Fatigue is considered one of the most common symptoms of multiple sclerosis (MS) and lacks a current standardized treatment. Therefore, the aim of this study was to examine the feasibility and effectiveness of a cognition-targeted exercise versus symptom-targeted exercise for MS fatigue. Methods In this Pilot, parallel-group, randomized controlled trial, sixty participants with multiple sclerosis, were randomly assigned to either a Cognition-Targeted Exercise (CTE) (N = 30, mean age 41) or a Symptom-Targeted Exercise (STE) (N = 30, mean age 42). The participants in the experimental group received eight, 50-minute sessions of weekly Cognitive Behavior Therapy (CBT) in addition to a CTE Program; whereas, participants in the control group received eight, 50-minute sessions of weekly CBT in addition to the standardized physiotherapy program (STE Program). Feasibility was assessed through recruitment rate, participant retention, adherence and safety, in addition to clinical outcome measures, including: (1) Modified Fatigue Impact Scale (MFIS), (2) Work and Social Adjustment Scale (WSAS), (3) Hospital Anxiety and Depression Scale (HADS), and Perceived Stress Scale (PSS). All outcome measures were assessed at baseline (pretreatment), following completion of the eight visit intervention protocol, and at 3-months follow-up. Results The recruitment rate was 60% and 93% of participants completed the entire study. The recruited participants complied with 98% of the required visits. No adverse events were recorded. A Generalized Estimation Equation Model revealed a significant difference over time as an interaction term during the post and follow up visit for all clinical outcome measures (p < .001). Conclusion The addition of CTE to CBT exhibited positive and more lasting influence on MS fatigue outcomes compared to Symptom-Targeted Exercise (STE). Feasibility and efficacy data from this pilot study provide support for a full-scale RCT of CTE as an integral component of Multiple Sclerosis fatigue management.	[Alketbi, Azza; Moustafa, Ibrahim M.] Univ Sharjah, Coll Hlth Sci, Dept Physiotherapy, Sharjah, U Arab Emirates; [Basit, Salah; Moustafa, Ibrahim M.] Cairo Univ, Fac Phys Therapy, Giza, Egypt; [Hamza, Nouran] Med Agcy Res & Stat MARS, Giza, Egypt; [Walton, Lori M.] Univ Scranton, Dept Phys Therapy, Scranton, PA 18510 USA	University of Sharjah; Egyptian Knowledge Bank (EKB); Cairo University; University of Scranton	Moustafa, IM (corresponding author), Univ Sharjah, Coll Hlth Sci, Dept Physiotherapy, Sharjah, U Arab Emirates.; Moustafa, IM (corresponding author), Cairo Univ, Fac Phys Therapy, Giza, Egypt.	labuamr@sharjah.ac.ae		Moustafa, Ibrahim/0000-0002-4859-1490; Hamza, Nouran/0000-0001-8008-4598				Al Aseri ZA, 2015, BMC EMERG MED, V15, DOI 10.1186/s12873-015-0051-4; Andreasen AK., EFFECT EXERCISE THER; [Anonymous], 2003, COCHRANE DB SYST REV; Asano M, 2014, MULT SCLER INT, V2014, DOI 10.1155/2014/798285; Baik SH, 2019, J HEALTH PSYCHOL, V24, P628, DOI 10.1177/1359105316684938; Blikman LJ, 2013, ARCH PHYS MED REHAB, V94, P1360, DOI 10.1016/j.apmr.2013.01.025; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Chetta A, 2004, RESP MED, V98, P522, DOI 10.1016/j.rmed.2003.11.011; Cohen S., 1994, PERCEIVED STRESS SCA; Deale A, 1998, J PSYCHOSOM RES, V45, P77, DOI 10.1016/S0022-3999(98)00021-X; Friedman EH, 1995, CAN J NEUROL SCI, P75, DOI [10.1017/s0317167100040555, DOI 10.1017/S0317167100040555]; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; Goodin DS, 2008, NEUROLOGY, V71, pS8, DOI 10.1212/WNL.0b013e31818f3d8b; Gutierrez GM, 2005, ARCH PHYS MED REHAB, V86, P1824, DOI 10.1016/j.apmr.2005.04.008; Hartung TJ, 2017, CANCER-AM CANCER SOC, V123, P4236, DOI 10.1002/cncr.30846; Julian LJ, 2008, J NEUROL, V255, P1354, DOI 10.1007/s00415-008-0910-y; Malouff JA, 2008, CLIN PSYCHOL REV, V28, P736, DOI 10.1016/j.cpr.2007.10.004; McCullagh R, 2008, CLIN REHABIL, V22, P206, DOI 10.1177/0269215507082283; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; McGuinness SD, 1999, REHABILITATION NURSI, P30; Michel P, 2006, J NEUROL NEUROSUR PS, V77, P1, DOI 10.1136/jnnp.2005.078287; Moss-Morris R, 2005, J HEALTH PSYCHOL, V10, P245, DOI 10.1177/1359105305049774; Mucke M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006788.pub3; Mundt JC, 2002, BRIT J PSYCHIAT, V180, P461, DOI 10.1192/bjp.180.5.461; Nazarboland N., 2017, INT J BEHAV SCI; Newman MA, 2007, MULT SCLER, V13, P113, DOI 10.1177/1352458506071169; Pilutti LA, 2013, PSYCHOSOM MED, V75, P575, DOI 10.1097/PSY.0b013e31829b4525; Price JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001027.pub2; Quarmby L, 2007, BEHAV RES THER, V45, P1085, DOI 10.1016/j.brat.2006.08.019; Rolak Loren A, 2003, Clin Med Res, V1, P57; Rooney S, 2019, MULT SCLER RELAT DIS, V35, P158, DOI 10.1016/j.msard.2019.07.028; Runia TF, 2012, CNS NEUROL DISORD-DR, V11, P497; Schulz KH, 2004, J NEUROL SCI, V225, P11, DOI 10.1016/j.jns.2004.06.009; Sharpe M, 1998, VERHALTENSTHERAPIE, V8, P118, DOI 10.1159/000030637; Tellez N, 2005, MULT SCLER J, V11, P198, DOI 10.1191/1352458505ms1148oa; van den Berg M, 2006, J NEUROL NEUROSUR PS, V77, P531, DOI 10.1136/jnnp.2005.064410; van Kessel K, 2008, PSYCHOSOM MED, V70, P205, DOI 10.1097/PSY.0b013e3181643065; Wearden AJ, 1998, BRIT J PSYCHIAT, V172, P485, DOI 10.1192/bjp.172.6.485; Wiborg JF, 2010, PSYCHOL MED, V40, P1281, DOI 10.1017/S0033291709992212; Wiborg JF, 2011, J PSYCHOSOM RES, V70, P306, DOI 10.1016/j.jpsychores.2010.12.011	41	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2021	16	11							e0258752	10.1371/journal.pone.0258752	http://dx.doi.org/10.1371/journal.pone.0258752			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ4ST	34748549	Green Published, gold			2023-01-03	WOS:000755468000014
J	Barclay, R; Leclair, L; Webber, SC				Barclay, Ruth; Leclair, Leanne; Webber, Sandra C.			Experiences of stroke survivors and measurement of post stroke participation and activity across seasons-A mixed methods approach	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; SEDENTARY BEHAVIOR; OLDER-ADULTS; COMMUNITY AMBULATION; BALANCE CONFIDENCE; ACTIVITY MONITORS; WALKING ACTIVITY; PEOPLE; RELIABILITY; VALIDITY	Participation and activity post stroke can be limited due to adverse weather conditions. This study aimed to: Quantify and compare summer and winter participation and activity, and explore how community dwelling people with stroke describe their feelings about their level of participation and activity by season. This embedded mixed-methods observational study took place in a city with weather extremes. Community dwelling individuals at least one year post-stroke, able to walk >= 50 metres +/- a walking aide were included. Evaluations and interviews occurred at participants' homes in two seasons: Reintegration to Normal living Index (RNL), Activities-specific Balance Confidence (ABC) and descriptive outcomes. Participants wore activity monitors for one week each season. Analysis included descriptive statistics, non-parametric tests and an inductive approach to content analysis. Thirteen individuals participated in quantitative evaluation with eight interviewed. Mean age 61.5 years, 62% female and mean 6.2 years post-stroke. No differences between winter-summer values of RNL, ABC, or activity monitor outcomes. However, participants felt they could do more and were more independent in summer. The winter conditions such as ice, snow, cold and wind restricted participation and limited activities. Nonetheless, many participants were active and participated despite the winter challenges by finding other ways to be active, and relying on social supports and personal motivation. The qualitative findings explained unexpected quantitative results. Participants described many challenges with winter weather, but also ways they had discovered to participate and be active despite these challenges. Changes to future studies into seasonal differences are suggested.	[Barclay, Ruth; Webber, Sandra C.] Univ Manitoba, Coll Rehabil Sci, Rady Fac Hlth Sci, Dept Phys Therapy, Winnipeg, MB, Canada; [Leclair, Leanne] Univ Manitoba, Coll Rehabil Sci, Rady Fac Hlth Sci, Dept Occupat Therapy, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba	Barclay, R (corresponding author), Univ Manitoba, Coll Rehabil Sci, Rady Fac Hlth Sci, Dept Phys Therapy, Winnipeg, MB, Canada.	ruth.barclay@umanitoba.ca	Webber, Sandra/GRN-7933-2022	Barclay, Ruth/0000-0002-2961-5821; Leclair, Leanne/0000-0003-2215-2788	University of Manitoba, College Of Rehabilitation Sciences Catalyst Research Grant	University of Manitoba, College Of Rehabilitation Sciences Catalyst Research Grant	RB, LL, SW received funding for this project from the University of Manitoba, College Of Rehabilitation Sciences Catalyst Research Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akinrolie O, 2021, J AGING PHYS ACTIV, V29, P843, DOI 10.1123/japa.2020-0350; Allen L, 2016, CAN J NEUROL SCI, V43, P98, DOI 10.1017/cjn.2015.324; Andersson AG, 2006, J REHABIL MED, V38, P186, DOI 10.1080/16501970500478023; Barclay R, 2018, INT J STROKE, V13, P63; Barclay R, 2016, PHYSIOTHER CAN, V68, P216, DOI 10.3138/ptc.2015-44; Barclay R, 2015, CLIN REHABIL, V29, P509, DOI 10.1177/0269215514546769; BERG K, 1995, SCAND J REHABIL MED, V27, P27; Bertapelli F, 2019, J INTELL DISABIL RES, V63, P21, DOI 10.1111/jir.12550; Botner EM, 2005, DISABIL REHABIL, V27, P156, DOI 10.1080/09638280400008982; Clarke PJ, 2015, AM J PUBLIC HEALTH, V105, P1489, DOI 10.2105/AJPH.2015.302582; Creswell J.W., 2003, RES DESIGN, Vsecond; De Winter JC, 2013, PRACT ASSESS RES EVA, V18, P1; Duncan PW, 1999, STROKE, V30, P2131, DOI 10.1161/01.STR.30.10.2131; Egan M, 2014, ARCH PHYS MED REHAB, V95, P262, DOI 10.1016/j.apmr.2013.08.013; Environment Canada, 2016, ENV CAN HIST CLIM DA; Feito Y, 2012, MED SCI SPORT EXER, V44, P733, DOI 10.1249/MSS.0b013e3182351913; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; Foley EL, 2019, BEHAV NEUROL, V2019, DOI 10.1155/2019/2606039; Fulk George D, 2008, J Neurol Phys Ther, V32, P8, DOI 10.1097/NPT0b013e31816593c0; Fulk GD, 2010, ARCH PHYS MED REHAB, V91, P1582, DOI 10.1016/j.apmr.2010.07.005; Fusch PI, 2015, QUAL REP, V20, P1408; Goto Y, 2019, GERIATR GERONTOL INT, V19, P240, DOI 10.1111/ggi.13594; Gu YY, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1944-z; Hammel J, 2006, TOP STROKE REHABIL, V13, P43, DOI 10.1310/5X2G-V1Y1-TBK7-Q27E; Hassard TH, 1991, UNDERSTANDING BIOSTA; Heinemann AW, 2016, QUAL LIFE RES, V25, P2775, DOI 10.1007/s11136-016-1314-6; Janssen SL, 2014, OCCUP THER INT, V21, P53, DOI 10.1002/oti.1361; Kimura T, 2015, J PHYSIOL ANTHROPOL, V34, DOI 10.1186/s40101-015-0071-5; King L, 2013, PHYS THER, V93, P571, DOI 10.2522/ptj.2013.93.4.571; Korpan SM, 2015, J AGING PHYS ACTIV, V23, P377, DOI 10.1123/japa.2014-0033; Law M., 2008, EVIDENCE BASED REHAB, V2008; Logan PA, 2004, CLIN REHABIL, V18, P703, DOI 10.1191/0269215504cr742oa; Malinowsky C, 2020, SCAND J OCCUP THER, V27, P204, DOI 10.1080/11038128.2019.1668958; Mayo NE, 2015, CLIN REHABIL, V29, P1198, DOI 10.1177/0269215514565396; Mayo NE, 2014, QUAL LIFE RES, V23, P39, DOI 10.1007/s11136-013-0441-6; Mayo NE, 2002, ARCH PHYS MED REHAB, V83, P1035, DOI 10.1053/apmr.2002.33984; Mayo NE, 1999, DISABIL REHABIL, V21, P258; McCormack GR, 2010, J EPIDEMIOL COMMUN H, V64, DOI 10.1136/jech.2009.092841; Merchant AT, 2007, CAN J PUBLIC HEALTH, V98, P203, DOI 10.1007/BF03403713; Paul L, 2016, DISABIL REHABIL, V38, P362, DOI 10.3109/09638288.2015.1041615; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Public Health Agency of Canada, 2017, STROK CAN HIGHL CAN; Rabinovich RA, 2013, EUR RESPIR J, V42, P1205, DOI 10.1183/09031936.00134312; ROCCAFORTE WH, 1992, J AM GERIATR SOC, V40, P697, DOI 10.1111/j.1532-5415.1992.tb01962.x; Roos MA, 2012, PHYS THER, V92, P1141, DOI 10.2522/ptj.20120034; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Santos-Lozano A, 2012, MED ENG PHYS, V34, P787, DOI 10.1016/j.medengphy.2012.02.005; Schneidert M, 2003, DISABIL REHABIL, V25, P588, DOI 10.1080/0963828031000137090; Schuch F, 2017, J AFFECT DISORDERS, V210, P139, DOI 10.1016/j.jad.2016.10.050; Semanik PA, 2015, AM J PUBLIC HEALTH, V105, P560, DOI 10.2105/AJPH.2014.302270; Shenton A. K., 2004, ED INFORM, V22, P63, DOI DOI 10.3233/EFI-2004-22201; Spinney JEL, 2011, INT J BIOMETEOROL, V55, P133, DOI 10.1007/s00484-010-0319-z; Stewart AL, 2001, MED SCI SPORT EXER, V33, P1126, DOI 10.1097/00005768-200107000-00010; Stewart AL, 2001, J GERONTOL A-BIOL, V56, pM465, DOI 10.1093/gerona/56.8.M465; Tooth LR, 2003, DISABIL REHABIL, V25, P433, DOI 10.1080/0963828031000069726; Tudor-Locke C, 2012, J PHYS ACT HEALTH, V9, P1125, DOI 10.1123/jpah.9.8.1125; van de Port IGL, 2006, STROKE, V37, P167, DOI 10.1161/01.STR.0000195180.69904.f2; Webber SC, 2020, J AGING PHYS ACTIV, V28, P782, DOI 10.1123/japa.2019-0235; Webber SC, 2016, J AGING PHYS ACTIV, V24, P451, DOI 10.1123/japa.2015-0234; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; World Health Organization, 2001, ICF INT CLASFUNCT; World Stroke Organization, 2020, GLOB STROK FACT SHEE; Yiu J, 2012, NEUROREHAB NEURAL RE, V26, P999, DOI 10.1177/1545968312437941	63	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2021	16	10							e0259307	10.1371/journal.pone.0259307	http://dx.doi.org/10.1371/journal.pone.0259307			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY8NO	34714877	gold, Green Published			2023-01-03	WOS:000755042500048
J	Fillmore, N; Bell, S; Shen, CY; Nguyen, V; La, J; Dubreuil, M; Strymish, J; Brophy, M; Mehta, G; Wu, H; Lieberman, J; Do, N; Sander, C				Fillmore, Nathanael; Bell, Steven; Shen, Ciyue; Nguyen, Vinh; La, Jennifer; Dubreuil, Maureen; Strymish, Judith; Brophy, Mary; Mehta, Gautam; Wu, Hao; Lieberman, Judy; Do, Nhan; Sander, Chris			Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study	PLOS ONE			English	Article								Effective, low-cost therapeutics are needed to prevent and treat COVID-19. Severe COVID-19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases. We investigated the potential effects of disulfiram on SARS-CoV-2 infection and disease severity in an observational study using a large database of clinical records from the national US Veterans Affairs healthcare system. A multivariable Cox regression adjusted for demographic information and diagnosis of alcohol use disorder revealed a reduced risk of SARS-CoV-2 infection with disulfiram use at a hazard ratio of 0.66 (34% lower risk, 95% confidence interval 24-43%). There were no COVID-19 related deaths among the 188 SARS-CoV-2 positive patients treated with disulfiram, in contrast to 5-6 statistically expected deaths based on the untreated population (P = 0.03). Our epidemiological results suggest that disulfiram may contribute to the reduced incidence and severity of COVID-19. These results support carefully planned clinical trials to assess the potential therapeutic effects of disulfiram in COVID-19.	[Fillmore, Nathanael; Nguyen, Vinh; La, Jennifer; Brophy, Mary; Do, Nhan] VA Boston Healthcare Syst, Boston VA Cooperat Studies Program CSP Ctr, Boston, MA 02130 USA; [Fillmore, Nathanael; Strymish, Judith] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Bell, Steven] Univ Cambridge, Dept Clin Neurosci, Cambridge, England; [Shen, Ciyue; Sander, Chris] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA; [Shen, Ciyue; Sander, Chris] Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02115 USA; [Shen, Ciyue; Sander, Chris] Broad Inst Harvard & MIT, Boston, MA 02115 USA; [Dubreuil, Maureen] Boston Univ, Sch Med, Sect Rheumatol, Boston, MA 02118 USA; [Dubreuil, Maureen] VA Boston Healthcare Syst, Rheumatol, Boston, MA USA; [Strymish, Judith] VA Boston Healthcare Syst, Infect Dis, Boston, MA USA; [Brophy, Mary] Boston Univ, Sch Med, Sect Hematol & Med Oncol, Boston, MA 02118 USA; [Mehta, Gautam] UCL, Inst Liver & Digest Hlth, London, England; [Mehta, Gautam] Fdn Liver Res, Inst Hepatol, London, England; [Wu, Hao] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Wu, Hao; Lieberman, Judy] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA; [Lieberman, Judy] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Do, Nhan] Boston Univ, Sch Med, Sect Gen Internal Med, Boston, MA 02118 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Harvard Medical School; University of Cambridge; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Boston University; University of London; University College London; University of London; University College London; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; Boston University	Do, N (corresponding author), VA Boston Healthcare Syst, Boston VA Cooperat Studies Program CSP Ctr, Boston, MA 02130 USA.; Sander, C (corresponding author), Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA.; Sander, C (corresponding author), Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02115 USA.; Sander, C (corresponding author), Broad Inst Harvard & MIT, Boston, MA 02115 USA.; Do, N (corresponding author), Boston Univ, Sch Med, Sect Gen Internal Med, Boston, MA 02118 USA.	Nhan.Do@va.gov; sander.research@gmail.com		, Hao/0000-0002-7281-8579; Shen, Ciyue/0000-0002-5416-2481; Mehta, Gautam/0000-0002-5696-359X; Bell, Steven/0000-0001-6774-3149	British Heart Foundation [RG/4/32218]; VA Cooperative Studies Program; VA Boston Healthcare System; National Institute of Arthritis and Musculoskeletal and Skin Disease (NIH/NIAMS) [K23AR069127]; Dana-Farber Cancer Institute; Harvard Medical School; National Institutes of Health	British Heart Foundation(British Heart Foundation); VA Cooperative Studies Program; VA Boston Healthcare System(US Department of Veterans Affairs); National Institute of Arthritis and Musculoskeletal and Skin Disease (NIH/NIAMS); Dana-Farber Cancer Institute; Harvard Medical School; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The work was supported by the British Heart Foundation RG/4/32218 (S. Bell), the VA Cooperative Studies Program (N. Fillmore, V. Nguyen, J. La, M. Brophy, N. Do), the VA Boston Healthcare System (all VA authors), the National Institute of Arthritis and Musculoskeletal and Skin Disease (NIH/NIAMS) K23AR069127 (M. Dubreuil), Dana-Farber Cancer Institute and Harvard Medical School (C. Shen, C. Sander), and the National Institutes of Health (H. Wu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Batalha PN, 2021, BIOORG CHEM, V106, DOI 10.1016/j.bioorg.2020.104488; Chen T, 2021, ACS PHARMACOL TRANSL, V4, P898, DOI 10.1021/acsptsci.1c00022; Cihlova B, 2021, MOLECULES, V26, DOI 10.3390/molecules26133792; Fillmore NR, 2021, JNCI-J NATL CANCER I, V113, P1084, DOI 10.1093/jnci/djab007; Fillmore NR, 2021, JNCI-J NATL CANCER I, V113, P691, DOI 10.1093/jnci/djaa159; Gasparini A, 2018, J OPEN SOURCE SOFTW, V3, P648, DOI DOI 10.21105/JOSS.00648; Hu JJ, 2020, NAT IMMUNOL, V21, P736, DOI 10.1038/s41590-020-0669-6; Israel A, 2021, ELIFE, V10, DOI 10.7554/eLife.68165; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Kuo CJ, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.02577-20; Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015; Lobo-Galo N, 2021, J BIOMOL STRUCT DYN, V39, P3419, DOI 10.1080/07391102.2020.1764393; Ma CL, 2020, ACS PHARMACOL TRANSL, V3, P1265, DOI 10.1021/acsptsci.0c00130; Maynard C, 2017, DATABASE METHODS CYB; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Sargsyan K, 2020, CHEM SCI, V11, P9904, DOI 10.1039/d0sc02646h; Smith E, 2020, SLAS DISCOV, V25, P1152, DOI 10.1177/2472555220963667; Suh JJ, 2006, J CLIN PSYCHOPHARM, V26, P290, DOI 10.1097/01.jcp.0000222512.25649.08; Tamburin S, 2021, INTERN EMERG MED, V16, P1729, DOI 10.1007/s11739-021-02633-y	19	18	19	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2021	16	10							0259061	10.1371/journal.pone.0259061	http://dx.doi.org/10.1371/journal.pone.0259061			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ6CS	34710137	Green Published, Green Submitted			2023-01-03	WOS:000755563200061
J	Coletta, AM; Playdon, MC; Baron, KG; Wei, M; Kelley, K; Vaklavas, C; Beck, A; Buys, SS; Chipman, J; Ulrich, CM; Walker, D; White, S; Oza, S; Zingg, RW; Hansen, PA				Coletta, Adriana M.; Playdon, Mary C.; Baron, Kelly G.; Wei, Mei; Kelley, Kristen; Vaklavas, Christos; Beck, Anna; Buys, Saundra S.; Chipman, Jonathan; Ulrich, Cornelia M.; Walker, Darren; White, Shelley; Oza, Sonal; Zingg, Rebecca W.; Hansen, Pamela A.			The association between time-of-day of habitual exercise training and changes in relevant cancer health outcomes among cancer survivors	PLOS ONE			English	Article							BODY-COMPOSITION; CARDIORESPIRATORY FITNESS; PHYSICAL-ACTIVITY; PROSTATE-CANCER; OBESITY PARADOX; GO TEST; PREVENTION; THERAPY; FATIGUE	Objective To assess the relationship between time-of-day of exercise training and changes in relevant cancer health outcomes among cancer survivors. Methods Retrospective analysis of data collected from 2016-2019 from a hospital-based exercise oncology program. Descriptive statistics were calculated for demographic, clinical, and exercise timing characteristics (e.g. AM, PM, or mix) among survivors with available data for exercise training time (n = 233). For the total sample and a breast cancer sub-analysis, univariate analysis of covariance, adjusted for age, was carried out by exercise training time, for change in the following outcomes collected during the program's assessment sessions: cardiorespiratory fitness and muscular endurance (human performance variables), physical function, anthropometrics, self-reported fatigue, and quality of life (QoL). Change in body mass index (BMI) and body weight was included in the breast cancer analysis. Results Overall, 37.3% of survivors habitually engaged in AM exercise (e.g. >= 75% AM training), 34.3% in PM exercise, and 28.3% in a mix of AM and PM exercise training throughout the program. Median time in the program was 17 weeks. Significant improvements in most human performance and physical function variables were observed in the total sample regardless of exercise training time-of-day. Among breast cancer survivors, PM but not AM or mixed was associated with improvements in fitness, and lower-body muscular endurance and function. Mixed exercise timing was linked with greater increase in waist circumference (total sample: 3.02cm, 95%CI 1.55, 4.49; breast cancer: 3.57cm 95%CI 0.96, 6.18), body weight (breast cancer: 1.6kg, 95%CI 0.3, 2.8) and BMI (breast cancer: 0.6kg/m(2), 95%CI 0.1, 1.0). AM and PM exercise, but not mixed, was associated with improvements in fatigue and QoL. Conclusion Time-of-day of exercise training may differentially impact changes in human performance and physical function variables. Mixed exercise training time may result in less favorable outcomes related of weight management variables among cancer survivors.	[Coletta, Adriana M.] Univ Utah, Dept Hlth & Kinesiol, Salt Lake City, UT 84112 USA; [Coletta, Adriana M.; Playdon, Mary C.; Wei, Mei; Kelley, Kristen; Vaklavas, Christos; Beck, Anna; Buys, Saundra S.; Chipman, Jonathan; Ulrich, Cornelia M.; Walker, Darren; White, Shelley; Oza, Sonal; Zingg, Rebecca W.; Hansen, Pamela A.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Playdon, Mary C.] Univ Utah, Dept Nutr & Integrat Physiol, Salt Lake City, UT USA; [Baron, Kelly G.] Univ Utah, Dept Family & Prevent Med, Salt Lake City, UT USA; [Wei, Mei; Kelley, Kristen; Vaklavas, Christos; Beck, Anna; Buys, Saundra S.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; [Chipman, Jonathan; Ulrich, Cornelia M.] Univ Utah, Dept Populat Hlth Sci, Salt Lake City, UT USA; [Oza, Sonal; Zingg, Rebecca W.; Hansen, Pamela A.] Univ Utah, Div Phys Med & Rehabil, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Coletta, AM (corresponding author), Univ Utah, Dept Hlth & Kinesiol, Salt Lake City, UT 84112 USA.; Coletta, AM (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.	adriana.coletta@hci.utah.edu		Vaklavas, Christos/0000-0002-9919-2748; Coletta, Adriana/0000-0002-2503-2792; White, Shelley/0000-0003-2315-9498	Huntsman Cancer Institute at the University of Utah; National Cancer Institute of the National Institutes of Health [P30CA042014]	Huntsman Cancer Institute at the University of Utah; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by the Huntsman Cancer Institute at the University of Utah, which is supported by the National Cancer Institute of the National Institutes of Health under award number P30CA042014.	Alghadir A, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0637-8; Alizadeh Z, 2017, CLIN OBES, V7, P157, DOI 10.1111/cob.12187; Ancoli-Israel S, 2014, SUPPORT CARE CANCER, V22, P2535, DOI 10.1007/s00520-014-2204-5; Berger AM, 2010, SUPPORT CARE CANCER, V18, P105, DOI 10.1007/s00520-009-0636-0; Blackwell JEM, 2020, PROSTATE CANCER P D, V23, P696, DOI 10.1038/s41391-020-0219-1; Bohannon Richard W, 2019, J Phys Ther Sci, V31, P75, DOI 10.1589/jpts.31.75; Brown JC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204875; Brown JC, 2018, PSYCHO-ONCOLOGY, V27, P1221, DOI 10.1002/pon.4655; Caan BJ, 2017, CANCER EPIDEM BIOMAR, V26, P1008, DOI [10.1158/1055-9965.EPI-17-0200, 10.1158/1055-9965.epi-17-0200]; Campbell KL, 2019, MED SCI SPORT EXER, V51, P2375, DOI 10.1249/MSS.0000000000002116; Celik E, 2021, J OBSTET GYNAECOL RE, V47, P560, DOI 10.1111/jog.14560; Cella D, 2002, J PAIN SYMPTOM MANAG, V24, P547, DOI 10.1016/S0885-3924(02)00529-8; Chtourou H, 2012, J STRENGTH COND RES, V26, P1984, DOI 10.1519/JSC.0b013e31825770a7; Coletta AM, 2021, SUPPORT CARE CANCER, V29, P4663, DOI 10.1007/s00520-021-06010-5; Cushen SJ, 2016, CLIN NUTR ESPEN, V13, pE39, DOI 10.1016/j.clnesp.2016.04.001; Devin JL, 2018, CLIN COLORECTAL CANC, V17, pE269, DOI 10.1016/j.clcc.2018.01.004; Devin JL, 2016, J CANCER SURVIV, V10, P467, DOI 10.1007/s11764-015-0490-7; Duglan D, 2019, TRENDS ENDOCRIN MET, V30, P347, DOI 10.1016/j.tem.2019.04.003; Gabriel BM, 2019, NAT REV ENDOCRINOL, V15, P197, DOI 10.1038/s41574-018-0150-x; Godinho-Mota JCM, 2021, CLIN NUTR, V40, P3421, DOI 10.1016/j.clnu.2020.11.020; Gonzalez MC, 2014, AM J CLIN NUTR, V99, P999, DOI 10.3945/ajcn.113.071399; Hanson ED, 2021, PROSTATE CANCER P D, V24, P725, DOI 10.1038/s41391-020-00317-w; Iwase T, 2021, BREAST CANCER RES TR, V186, P273, DOI 10.1007/s10549-020-06092-5; Iwase T, 2020, BREAST CANCER RES TR, V179, P435, DOI 10.1007/s10549-019-05467-7; Kashiwagi E, 2020, PROSTATE INT, V8, P22, DOI 10.1016/j.prnil.2019.11.002; Lakoski SG, 2015, JAMA ONCOL, V1, P231, DOI 10.1001/jamaoncol.2015.0226; Maury E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071597; McTiernan A, 2019, MED SCI SPORT EXER, V51, P1252, DOI 10.1249/MSS.0000000000001937; Mesquita R, 2016, CHRON RESP DIS, V13, P344, DOI 10.1177/1479972316647178; Mesquita R, 2013, ARCH PHYS MED REHAB, V94, P2131, DOI 10.1016/j.apmr.2013.03.024; Mitsuzuka K, 2018, INT J UROL, V25, P45, DOI 10.1111/iju.13473; dos Santos WDN, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00918; Pahk K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57937-4; Patel AV, 2019, MED SCI SPORT EXER, V51, P2391, DOI 10.1249/MSS.0000000000002117; Pati AK, 2007, CHRONOBIOL INT, V24, P1179, DOI 10.1080/07420520701800868; Pierobon ES, 2021, J CLIN MED, V10, DOI 10.3390/jcm10143033; Playdon MC, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv275; Stout NL, 2017, PM&R, V9, pS347, DOI 10.1016/j.pmrj.2017.07.074; Teo SYM, 2020, MED SCI SPORT EXER, V52, P323, DOI 10.1249/MSS.0000000000002139; van der Kruk SR, 2021, SUPPORT CARE CANCER, V29, P4711, DOI 10.1007/s00520-021-06015-0; Wang XS, 2021, GYNECOL ONCOL, V161, P83, DOI 10.1016/j.ygyno.2021.01.021; Willis EA, 2020, INT J OBESITY, V44, P114, DOI 10.1038/s41366-019-0409-x; Wright AA, 2011, J ORTHOP SPORT PHYS, V41, P319, DOI 10.2519/jospt.2011.3515; Xiao J, 2018, EUR J CANCER CARE, V27, DOI 10.1111/ecc.12611; Zhang Y, 2018, INT J GYNECOL CANCER, V28, P285, DOI 10.1097/IGC.0000000000001165	45	1	1	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2021	16	10							e0258135	10.1371/journal.pone.0258135	http://dx.doi.org/10.1371/journal.pone.0258135			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7ZF	34637457	gold, Green Published			2023-01-03	WOS:000755690100013
J	O'Connor, E; Kerrigan, V; Aitken, R; Castillon, C; Mithen, V; Madrill, G; Roman, C; Ralph, AP				O'Connor, Elise; Kerrigan, Vicki; Aitken, Robyn; Castillon, Craig; Mithen, Vincent; Madrill, Gail; Roman, Curtis; Ralph, Anna P.			Does improved interpreter uptake reduce self-discharge rates in hospitalised patients? A successful hospital intervention explained	PLOS ONE			English	Article							HEALTH-CARE	Background Aboriginal language interpreters are under-utilised in healthcare in northern Australia. Self-discharge from hospital is an adverse outcome occurring at high rates among Aboriginal people, with poor communication thought to be a contributor. We previously reported increased Aboriginal interpreter uptake and decreased rates of self-discharge during implementation of a 12-month hospital-based intervention. Interrupted time-series analysis showed sudden increase and up-trending improvement in interpreter use, and a corresponding decrease in self-discharge rates, during a 12-month intervention period (April 2018-March 2019) compared with a 24-month baseline period (April 2016 -March 2018). This paper aims to investigate reasons for these outcomes and explore a potential causal association between study activities and outcomes. Methods The study was implemented at the tertiary referral hospital in northern Australia. We used the Template for Intervention Description and Replication (TIDieR) as a framework to describe intervention components according to what, how, where, when, how much, tailoring, modifications and reach. Components of the study intervention were: employment of an Aboriginal Interpreter Coordinator, 'Working with Interpreters' training for healthcare providers, and championing of interpreter use by doctors. We evaluated the relative importance of intervention components according to TIDieR descriptors in relation to outcomes. Activities independent of the study that may have affected study findings were reviewed. The relationship between proportion of hospital separations among Aboriginal people ending in self-discharge and numbers of Aboriginal interpreter bookings made during April 2016-March 2019 was tested using linear regression. 'Working with Interpreters' training sessions were undertaken at a regional hospital as well as the tertiary hospital. Training evaluation comprised an anonymous online survey before the training, immediately after and then at six to eight months. Survey data from the sites were pooled for analysis. Results Employment of the Aboriginal Interpreter Coordinator was deemed the most important component of the intervention, based on reach compared to the other components, and timing of the changes in outcomes in relation to the employment period of the coordinator. There was an inverse association between interpreter bookings and self-discharge rate among Aboriginal inpatients throughout the baseline and intervention period (p = 0.02). This association, the timing of changes and assessment of intercurrent activities at the hospital indicated that the study intervention was likely to be casually related to the measured outcomes. Conclusions Communication in healthcare can be improved through targeted strategies, with associated improvements in patient outcomes. Health services with high interpreter needs would benefit from employing an interpreter coordinator.	[O'Connor, Elise; Castillon, Craig; Madrill, Gail; Ralph, Anna P.] Royal Darwin Hosp, Dept Hlth, Top End Hlth Serv, Darwin, NT, Australia; [Kerrigan, Vicki; Aitken, Robyn; Mithen, Vincent; Ralph, Anna P.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia; [Aitken, Robyn] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia; [Madrill, Gail] Top End Hlth Serv, Dept Hlth, Darwin, NT, Australia; [Roman, Curtis] Aboriginal Interpreter Serv, Darwin, NT, Australia	Charles Darwin University; Menzies School of Health Research; Flinders University South Australia	Ralph, AP (corresponding author), Royal Darwin Hosp, Dept Hlth, Top End Hlth Serv, Darwin, NT, Australia.; Ralph, AP (corresponding author), Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia.	anna.ralph@menzies.edu.au		Kerrigan, Vicki/0000-0001-6863-1528	Improving Health Outcomes in the Tropical North: A Multidisciplinary Collaboration (HOT NORTH), National Health and Medical Research Council [GNT1131932]; National Health and Medical Research Council fellowship [1142011]; Menzies School of Health Research Grants Scheme	Improving Health Outcomes in the Tropical North: A Multidisciplinary Collaboration (HOT NORTH), National Health and Medical Research Council; National Health and Medical Research Council fellowship(National Health and Medical Research Council (NHMRC) of Australia); Menzies School of Health Research Grants Scheme	This study was supported by the Menzies School of Health Research Grants Scheme, and Improving Health Outcomes in the Tropical North: A Multidisciplinary Collaboration (HOT NORTH), National Health and Medical Research Council GNT1131932. APR is supported by a National Health and Medical Research Council fellowship (1142011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allam L, 2018, DARWIN HOSP LEFT ABO; Australian Broadcasting Corporation, 2019, ABC NEWS 0720; Australian Bureau of Statistics, 2020, MAIN LANG SPOK HOM E; Australian Commission on Safety and Quality in Health Care, 2017, NAT SAF QUAL HLTH SE; Australian Institute of Health and Welfare, 2017, ABORIGINAL TORRES ST; Australian Institute of Health and Welfare, 2020, AUSTR I HLTH WELF 20; Communicate Study Grp, 2020, MED J AUSTRALIA, V213, P180, DOI 10.5694/mja2.50700; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Einsiedel LJ, 2013, AUST HEALTH REV, V37, P239, DOI 10.1071/AH11087; Flores G, 2005, MED CARE RES REV, V62, P255, DOI 10.1177/1077558705275416; Henry B, 2007, PREVALENCE RATES EXP; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Jandoc R, 2015, J CLIN EPIDEMIOL, V68, P950, DOI 10.1016/j.jclinepi.2014.12.018; Johnson MJ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008592; Karliner LS, 2007, HEALTH SERV RES, V42, P727, DOI 10.1111/j.1475-6773.2006.00629.x; Kerrigan V, 2020, ASK SPECIALIST LARRA; Kerrigan V, 2020, BMC MED EDUC, V20, DOI 10.1186/s12909-020-02086-5; Lavallee JF, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0670-0; Menzies School of Health Research, 2020, ASK SPEC CULT ED POD; Mithen V, 2021, HEALTH PROMOT J AUST, V32, P155, DOI 10.1002/hpja.415; National Collaborating Centre for Indigenous Health C, 2020, CULT SAF MET INTR HL; Northern Territory Government, 2020, AB LANG NT; Northern Territory Health, 2016, ABORIGINAL CULTURAL; Ralph AP, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2689-y; Stata Software StataCorp, 2017, STATA STAT SOFTWARE; Williams J., 2019, LIGHTHOUSE HOSP PROJ	26	1	1	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2021	16	10							e0257825	10.1371/journal.pone.0257825	http://dx.doi.org/10.1371/journal.pone.0257825			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7ZF	34637434	Green Published, gold			2023-01-03	WOS:000755690100006
J	Caballero-Hernandez, CI; Gonzalez-Chavez, SA; Urenda-Quezada, A; Reyes-Cordero, GC; Pelaez-Ballestas, I; Alvarez-Hernandez, E; Pacheco-Tena, C				Isabel Caballero-Hernandez, Claudia; Aidee Gonzalez-Chavez, Susana; Urenda-Quezada, Adelfia; Cristina Reyes-Cordero, Greta; Pelaez-Ballestas, Ingris; Alvarez-Hernandez, Everardo; Pacheco-Tena, Cesar			Prevalence of complementary and alternative medicine despite limited perceived efficacy in patients with rheumatic diseases in Mexico: Cross-sectional study	PLOS ONE			English	Article							HEALTH BELIEFS; ARTHRITIS; THERAPIES; MANAGEMENT; OSTEOARTHRITIS; BEHAVIORS; ORTHODOX; TRENDS; CAM	Introduction Complementary and alternative medicine (CAM) is frequently used by patients with rheumatic diseases (RD) to improve their symptoms; however, its diversity and availability have increased notably while scientific support for its effectiveness and adverse effects is still scarce. Objective To describe the prevalence and diversity of CAM in patients with RD in Chihuahua, Mexico. Methods A cross-sectional study was conducted in 500 patients with RD who were interviewed about the use of CAM to treat their disease. The interview included sociodemographic aspects, characteristics of the disease, as well as a description of CAM use, including type, frequency of use, perception of the benefit, communication with the rheumatologist, among others. Results The prevalence of CAM use was reported by 59.2% of patients, which informed a total of 155 different therapies. The herbal CAM group was the most used (31.4%) and included more than 50 different therapies. The use of menthol-based and arnica ointments was highly prevalent (35%). Most patients (62.3%) reported very little or no improvement in their symptoms. Only a fourth of the patients informed the rheumatologist of the use of CAM. The use of CAM was influenced by female sex, university degree, diagnosis delay, lack adherence to the rheumatologist's treatment, family history of RD, and orthopedic devices. Conclusion The use of CAM in our population is highly prevalent and similar to reports in different populations suggesting a widespread use in many different societies. We found high use of herbal remedies; however, there were many different types suggesting a lack of significant effect. Patients continue using CAM despite a perception of no-effectiveness. Recurrent use of CAM is explained by factors other than its efficacy.	[Isabel Caballero-Hernandez, Claudia; Aidee Gonzalez-Chavez, Susana; Pacheco-Tena, Cesar] Univ Autonoma Chihuahua, Fac Med & Ciencias Biomed, Lab PABIOM, Chihuahua, Mexico; [Urenda-Quezada, Adelfia; Cristina Reyes-Cordero, Greta] Univ Autonoma Chihuahua, Fac Med & Ciencias Biomed, Chihuahua, Mexico; [Pelaez-Ballestas, Ingris; Alvarez-Hernandez, Everardo] Hosp Gen Mexico Dr Eduardo Liceaga, Serv Reumatol, Mexico City, DF, Mexico		Pacheco-Tena, C (corresponding author), Univ Autonoma Chihuahua, Fac Med & Ciencias Biomed, Lab PABIOM, Chihuahua, Mexico.	dr.cesarpacheco@gmail.com		REYES-CORDERO, GRETA/0000-0001-6313-133X; Pacheco-Tena, Cesar/0000-0002-0793-8988; Alvarez-Hernandez, Everardo/0000-0003-2557-5866; Gonzalez-Chavez, Susana Aidee/0000-0002-1779-296X				Almuhareb AM, 2019, SAUDI PHARM J, V27, P939, DOI 10.1016/j.jsps.2019.07.002; Alvarez-Hernandez E, 2006, REUMATOL CLIN, V2, P183, DOI 10.1016/S1699-258X(06)73044-3; Alvarez-Nemegyei J, 2009, CLIN RHEUMATOL, V28, P547, DOI 10.1007/s10067-008-1082-y; Annapureddy N, 2018, LUPUS, V27, P982, DOI 10.1177/0961203318758503; Astin JA, 1998, ARCH INTERN MED, V158, P2303, DOI 10.1001/archinte.158.21.2303; Avila C, 2020, COMPLEMENT THER MED, V49, DOI 10.1016/j.ctim.2020.102317; Baig S, 2020, CURR RHEUMATOL REP, V22, DOI 10.1007/s11926-020-00938-z; Bishop FL, 2010, J ALTERN COMPLEM MED, V16, P175, DOI 10.1089/acm.2009.0292; Bishop FL, 2005, COMPLEMENT THER MED, V13, P144, DOI 10.1016/j.ctim.2005.01.005; Boon H, 2000, J CLIN ONCOL, V18, P2515, DOI 10.1200/JCO.2000.18.13.2515; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Contreras-Yanez I, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237504; Danve A, 2018, CURR OPIN RHEUMATOL, V30, P310, DOI 10.1097/BOR.0000000000000513; Del Rio Najera D, 2016, JCR-J CLIN RHEUMATOL, V22, P188, DOI 10.1097/RHU.0000000000000380; Eibensteiner F, 2021, J MED INTERNET RES, V23, DOI 10.2196/28973; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2011, CURR PAIN HEADACHE R, V15, P431, DOI 10.1007/s11916-011-0227-x; Fernandez-Llanio Comella N, 2016, REUMATOL CLIN, V12, P151, DOI 10.1016/j.reuma.2015.10.011; Fletcher A, 2020, INT J RHEUMATOL, V2020, DOI 10.1155/2020/6542965; Fuggle NR, 2020, AGING CLIN EXP RES, V32, P547, DOI 10.1007/s40520-020-01515-1; Furnham A, 1996, BRIT J CLIN PSYCHOL, V35, P49, DOI 10.1111/j.2044-8260.1996.tb01161.x; FURNHAM A, 1993, BRIT J CLIN PSYCHOL, V32, P237, DOI 10.1111/j.2044-8260.1993.tb01051.x; Garza-Ocanas L, 2013, SALUD PUBLICA MEXICO, V55, P498; Germani F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247642; Goldberg RJ, 2007, PAIN, V129, P210, DOI 10.1016/j.pain.2007.01.020; Grainger R, 2014, CLIN RHEUMATOL, V33, P3, DOI 10.1007/s10067-013-2379-z; Han M, 2015, J RHEUMATOL, V42, P2075, DOI 10.3899/jrheum.141447; Hernan MF, 2011, REV ARGENT REUMATOL, V22, P31; Hsiao AF, 2003, JAIDS-J ACQ IMM DEF, V33, P157, DOI 10.1097/00126334-200306010-00007; Hubner J, 2013, FORSCH KOMPLEMENTMED, V20, P120, DOI 10.1159/000350049; Institute of Medicine, 2005, COMPL ALT MED US; Jarvis A, 2015, PRIM HEALTH CARE RES, V16, P246, DOI 10.1017/S146342361400022X; Kajiyama Hiroshi, 2006, Mod Rheumatol, V16, P355, DOI 10.1007/s10165-006-0521-3; Kaminski M, 2021, CYBERPSYCH BEH SOC N, V24, P123, DOI 10.1089/cyber.2020.0336; Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003-4819-135-4-200108210-00011; Lahiri M, 2017, INT J RHEUM DIS, V20, P567, DOI 10.1111/1756-185X.13091; Macfarlane GJ, 2011, RHEUMATOLOGY, V50, P1672, DOI 10.1093/rheumatology/ker119; Michalsen A, 2013, J RHEUMATOL, V40, P547, DOI 10.3899/jrheum.130107; Monchablon C, 2020, CLIN RHEUMATOL, V39, P207, DOI 10.1007/s10067-019-04837-2; Moore AD, 2000, ARTHRITIS RHEUM-US, V43, P1410, DOI 10.1002/1529-0131(200006)43:6<1410::AID-ANR27>3.0.CO;2-U; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Mueller SM, 2020, J MED INTERNET RES, V22, DOI 10.2196/15599; Orozco María Celeste, 2016, Rev. argent. reumatolg., V27, P11; Phang JK, 2018, COMPLEMENT THER MED, V37, P143, DOI 10.1016/j.ctim.2018.03.003; Pincus T, 2007, BEST PRACT RES CL RH, V21, P789, DOI 10.1016/j.berh.2007.02.009; Posadzki P, 2012, CLIN MED, V12, P505, DOI 10.7861/clinmedicine.12-6-505; Pratt M, 2020, SYST REV-LONDON, V9, DOI 10.1186/s13643-020-01328-3; Ramos-Remus C, 1998, ARTHRIT CARE RES, V11, P411, DOI 10.1002/art.1790110513; Ramos-Remus C, 1999, RHEUM DIS CLIN N AM, V25, P789, DOI 10.1016/S0889-857X(05)70100-9; Roberts JA, 2020, CURR RHEUMATOL REP, V22, DOI 10.1007/s11926-020-00956-x; Rodruiguez Chamorro M.A., 2009, PHARM CARE ESPANA, V11, P183; Sanitarios CF para la P contra R. COFEPRIS ALERTA SOBRE COMERCIALIZACIO N ILEGAL DEL PRODUCTO, CUAL NO CUENTA CONRE; Sanvisens N, 2020, COMPLEMENT THER CLIN, V39, DOI 10.1016/j.ctcp.2020.101164; Skiba MB, 2020, J NUTR, V150, P2451, DOI 10.1093/jn/nxaa197; Sleigh J, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10851-4; Topf JM, 2021, BLOOD PURIFICAT, V50, P595, DOI 10.1159/000512707; Westhoff G, 2007, Z RHEUMATOL, V66, P121, DOI 10.1007/s00393-007-0153-9; WHO, 2013, WHO TRADITIONAL MED; WHO (World Health Organization), 2019, WHO GLOB REP TRAD CO; Zhao SZ, 2017, DRUG AGING, V34, P255, DOI 10.1007/s40266-017-0443-0	60	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2021	16	9							e0257319	10.1371/journal.pone.0257319	http://dx.doi.org/10.1371/journal.pone.0257319			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2D4JQ	34582473	Green Published, gold			2023-01-03	WOS:000811515800009
J	Xu, C; Liu, SJ; Yang, F; Zhang, KY; Li, Y; Zhao, XL; Zhang, JY; Lu, T; Lu, SQ; Jiang, Y; Qin, WJ; Shi, CH; Zhang, R; Yang, AG; Zhao, AZ; Han, DH; Wen, WH				Xu, Chao; Liu, Shaojie; Yang, Fa; Zhang, Keying; Li, Yu; Zhao, Xiaolong; Zhang, Jiayu; Lu, Tong; Lu, Shiqi; Jiang, Yao; Qin, Weijun; Shi, Changhong; Zhang, Rui; Yang, An-Gang; Zhao, Aizhi; Han, Donghui; Wen, Weihong			Antibody-drug conjugates targeting CD248(+) myofibroblasts effectively alleviate renal fibrosis in mice	FASEB JOURNAL			English	Article						antibody-drug conjugate (ADC); CD248; myofibroblasts; renal fibrosis; specific killing	INTERSTITIAL MYOFIBROBLASTS; ENDOSIALIN; CELL; FIBROBLASTS; MECHANISMS; MARKER; APOPTOSIS; DELIVERY; PROTEINS; PROTECTS	Myofibroblasts, or activated fibroblasts, play a critical role in the process of renal fibrosis. Targeting myofibroblasts to inhibit their activation or induce specific cell death has been considered to be an effective strategy to attenuate renal fibrosis. However, specific biomarkers for myofibroblasts are needed to ensure the efficacy of these strategies. Here, we verified that CD248 was mainly expressed in myofibroblasts in patients with chronic kidney disease, which was inversely correlated with renal function. The same result was also confirmed in renal fibrotic mice induced by unilateral ureteral obstruction and aristolochic acid nephropathy. By using an antibody-drug conjugate (ADC) named IgG78-DM1, in which maytansinoid (DM1) was linked to a fully human antibody IgG78 through an uncleavable SMCC linker, we demonstrated that it could effectively bind with and kill CD248(+) fibroblasts in vitro and alleviate renal fibrosis in mice models. Besides, we confirmed that IgG78-DM1 had qualified biosafety in vivo. Our results confirmed that CD248 can be used as a specific marker for myofibroblasts, and specific killing of CD248(+) myofibroblasts by IgG78-DM1 has excellent anti-fibrotic effect in renal fibrotic mice. Our study expanded the application of ADC and provided a novel strategy for the treatment of renal fibrosis.	[Xu, Chao; Liu, Shaojie; Yang, Fa; Zhang, Keying; Li, Yu; Zhao, Xiaolong; Zhang, Jiayu; Lu, Tong; Jiang, Yao; Qin, Weijun; Han, Donghui] Air Force Mil Med Univ, Xijing Hosp, Dept Urol, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Lu, Shiqi; Wen, Weihong] Northwestern Polytech Univ, Inst Med Res, 127 West Youyi Rd, Xian 710072, Shaanxi, Peoples R China; [Shi, Changhong] Air Force Mil Med Univ, Lab Anim Ctr, Xian, Peoples R China; [Zhang, Rui; Yang, An-Gang] Air Force Mil Med Univ, Dept Immunol, State Key Lab Canc Biol, Xian, Peoples R China; [Zhao, Aizhi] OriMAbs Ltd, Newark, DE USA	Air Force Military Medical University; Northwestern Polytechnical University; Air Force Military Medical University	Han, DH (corresponding author), Air Force Mil Med Univ, Xijing Hosp, Dept Urol, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.; Wen, WH (corresponding author), Northwestern Polytech Univ, Inst Med Res, 127 West Youyi Rd, Xian 710072, Shaanxi, Peoples R China.	906812205@qq.com; weihongwen@nwpu.edu.cn	温, 家琦/GYV-3177-2022	Xu, Chao/0000-0001-8462-8337	National Natural Science Foundation of China [81772734]; Innovation Capability Support Program of Shaanxi [2020PT-021]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Capability Support Program of Shaanxi	This work was partly supported by grants from the National Natural Science Foundation of China (No. 81772734), and the Innovation Capability Support Program of Shaanxi (Program No. 2020PT-021)	Aghajanian H, 2019, NATURE, V573, P430, DOI 10.1038/s41586-019-1546-z; Ashley SL, 2016, AM J RESP CELL MOL, V54, P482, DOI 10.1165/rcmb.2015-0148OC; Bagley RG, 2008, MICROVASC RES, V76, P180, DOI 10.1016/j.mvr.2008.07.008; Boor P, 2010, NAT REV NEPHROL, V6, P643, DOI 10.1038/nrneph.2010.120; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Castello-Cros Remedios, 2009, V522, P275, DOI 10.1007/978-1-59745-413-1_19; Chau CH, 2019, LANCET, V394, P793, DOI 10.1016/S0140-6736(19)31774-X; Chevalier RL, 2009, KIDNEY INT, V75, P1145, DOI 10.1038/ki.2009.86; Christian S, 2001, J BIOL CHEM, V276, P7408, DOI 10.1074/jbc.M009604200; Darby IA, 2016, CELL MOL LIFE SCI, V73, P1145, DOI 10.1007/s00018-015-2110-0; Hinz B, 2020, NAT REV RHEUMATOL, V16, P11, DOI 10.1038/s41584-019-0324-5; Humphreys BD, 2018, ANNU REV PHYSIOL, V80, P309, DOI 10.1146/annurev-physiol-022516-034227; Kuppe C, 2021, NATURE, V589, P281, DOI 10.1038/s41586-020-2941-1; Lax S, 2007, FEBS LETT, V581, P3550, DOI 10.1016/j.febslet.2007.06.063; LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218; Levey AS, 2015, JAMA-J AM MED ASSOC, V313, P837, DOI 10.1001/jama.2015.0602; Li QH, 2019, J CELL MOL MED, V23, P1951, DOI 10.1111/jcmm.14097; Li R, 2020, J CONTROL RELEASE, V320, P32, DOI 10.1016/j.jconrel.2020.01.017; Li R, 2020, APOPTOSIS, V25, P105, DOI 10.1007/s10495-019-01583-3; Luo JW, 2019, ACS NANO, V13, P3910, DOI 10.1021/acsnano.8b06924; Luyckx VA, 2021, NAT REV NEPHROL, V17, P15, DOI 10.1038/s41581-020-00363-6; MacFadyen JR, 2005, FEBS LETT, V579, P2569, DOI 10.1016/j.febslet.2005.03.071; Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48; Modi S, 2020, NEW ENGL J MED, V382, P610, DOI 10.1056/NEJMoa1914510; Morton RL, 2021, NAT REV NEPHROL, V17, P5, DOI 10.1038/s41581-020-00376-1; Munoz-Felix JM, 2015, PHARMACOL THERAPEUT, V156, P44, DOI 10.1016/j.pharmthera.2015.10.003; O'Shannessy Daniel J., 2016, Sarcoma, V2016, P5213628, DOI 10.1155/2016/5213628; Pai CH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73194-x; Poosti F, 2016, ONCOTARGET, V7, P54240, DOI 10.18632/oncotarget.11095; Poosti F, 2015, FASEB J, V29, P1029, DOI 10.1096/fj.14-258459; Rouleau C, 2008, CLIN CANCER RES, V14, P7223, DOI 10.1158/1078-0432.CCR-08-0499; Safiri S, 2019, ANN RHEUM DIS, V78, P1463, DOI 10.1136/annrheumdis-2019-215920; Shitara K, 2020, NEW ENGL J MED, V382, P2419, DOI 10.1056/NEJMoa2004413; Smith SW, 2011, KIDNEY INT, V80, P200, DOI 10.1038/ki.2011.103; Smith SW, 2015, NEPHRON, V131, P265, DOI 10.1159/000438754; Strutz F, 2006, J AM SOC NEPHROL, V17, P2992, DOI 10.1681/ASN.2006050420; Teicher Beverly A, 2019, Oncotarget, V10, P993, DOI 10.18632/oncotarget.26590; Thomas A, 2016, LANCET ONCOL, V17, pE254, DOI 10.1016/S1470-2045(16)30030-4; von Minckwitz G, 2019, NEW ENGL J MED, V380, P617, DOI 10.1056/NEJMoa1814017; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Yang F, 2020, CANCER RES, V80, P3892, DOI 10.1158/0008-5472.CAN-19-2691; Zhao H, 2020, FASEB J, V34, P12599, DOI 10.1096/fj.202000949R; Zhou J, 2021, MOL PHARMACEUT, V18, P1373, DOI 10.1021/acs.molpharmaceut.0c01182	43	1	1	3	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2022	36	2							e22102	10.1096/fj.202101441R	http://dx.doi.org/10.1096/fj.202101441R			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YO5NJ	34972243				2023-01-03	WOS:000747987800004
J	Smalling, RV; Bechard, ME; Duryea, J; Kingsley, PJ; Roberts, ER; Marnett, LJ; Bilbao, D; Stauffer, SR; McDonald, OG				Smalling, Rana, V; Bechard, Matthew E.; Duryea, Jeff; Kingsley, Philip J.; Roberts, Evan R.; Marnett, Lawrence J.; Bilbao, Daniel; Stauffer, Shaun R.; McDonald, Oliver G.			Aminopyridine analogs selectively target metastatic pancreatic cancer	ONCOGENE			English	Article							DISTANT METASTASIS; 6-AMINONICOTINAMIDE; HETEROGENEITY; ADENOCARCINOMA; METABOLISM; CELLS	Metastatic outgrowth is supported by metabolic adaptations that may differ from the primary tumor of origin. However, it is unknown if such adaptations are therapeutically actionable. Here we report a novel aminopyridine compound that targets a unique Phosphogluconate Dehydrogenase (PGD)-dependent metabolic adaptation in distant metastases from pancreatic cancer patients. Compared to structurally similar analogs, 6-aminopicolamine (6AP) potently and selectively reversed PGD-dependent metastatic properties, including intrinsic tumorigenic capacity, excess glucose consumption, and global histone hyperacetylation. 6AP acted as a water-soluble prodrug that was converted into intracellular bioactive metabolites that inhibited PGD in vitro, and 6AP monotherapy demonstrated anti-metastatic efficacy with minimal toxicity in vivo. Collectively, these studies identify 6AP and possibly other 6-aminopyridines as well-tolerated prodrugs with selectivity for metastatic pancreatic cancers. If unique metabolic adaptations are a common feature of metastatic or otherwise aggressive human malignancies, then such dependencies could provide a largely untapped pool of druggable targets for patients with advanced cancers.	[Smalling, Rana, V; Bechard, Matthew E.; McDonald, Oliver G.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; [Duryea, Jeff; Roberts, Evan R.; Bilbao, Daniel; McDonald, Oliver G.] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol & Lab Med, Miller Sch Med, Miami, FL 33136 USA; [Kingsley, Philip J.; Marnett, Lawrence J.] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN USA; [Stauffer, Shaun R.] Vanderbilt Univ, Dept Pharmacol, Med Ctr, Nashville, TN USA; [Stauffer, Shaun R.] Cleveland Clin, Ctr Therapeut Discovery, Cleveland, OH USA	Vanderbilt University; University of Miami; Vanderbilt University; Vanderbilt University; Cleveland Clinic Foundation	McDonald, OG (corresponding author), Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA.; McDonald, OG (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol & Lab Med, Miller Sch Med, Miami, FL 33136 USA.	ogm443@miami.edu		McDonald, Oliver/0000-0002-6602-7535; Kingsley, Philip/0000-0002-5470-4340	National Institutes of Health [R01 CA222594, 5P30 DK058404]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institutes of Health grants R01 CA222594 (OGM) and 5P30 DK058404 (OGM).	Balachandran VP, 2019, GASTROENTEROLOGY, V156, P2056, DOI 10.1053/j.gastro.2018.12.038; Bechard ME, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17839-5; Bechard ME, 2018, ONCOGENE, V37, P5248, DOI 10.1038/s41388-018-0346-5; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Daneshmandi S, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108831; DIETRICH LS, 1958, J BIOL CHEM, V233, P964; Embuscado EE, 2005, CANCER BIOL THER, V4, P548, DOI 10.4161/cbt.4.5.1663; Fendt SM, 2020, CANCER DISCOV, V10, P1797, DOI 10.1158/2159-8290.CD-20-0844; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Hayashi A, 2021, NAT REV GASTRO HEPAT, V18, P469, DOI 10.1038/s41575-021-00463-z; HERKEN H, 1976, N-S ARCH PHARMACOL, V293, P245, DOI 10.1007/BF00507347; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Iacobuzio-Donahue CA, 2020, NAT CANCER, V1, P3, DOI 10.1038/s43018-019-0002-1; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; JOHNSON WJ, 1955, SCIENCE, V122, P834, DOI 10.1126/science.122.3174.834; Ju HQ, 2016, CANCER LETT, V379, P1, DOI 10.1016/j.canlet.2016.05.024; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; KOHLER E, 1970, FEBS LETT, V6, P225, DOI 10.1016/0014-5793(70)80063-1; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McDonald OG, 2020, MOL CELL ONCOL, V7, DOI 10.1080/23723556.2020.1825910; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Recouvreux MV, 2020, J EXP MED, V217, DOI 10.1084/jem.20200388; Reiter JG, 2018, SCIENCE, V361, P1033, DOI 10.1126/science.aat7171; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Roe JS, 2017, CELL, V170, P875, DOI 10.1016/j.cell.2017.07.007; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Soares Kevin C, 2014, J Vis Exp, P51677, DOI 10.3791/51677; Storz P, 2020, GASTROENTEROLOGY, V158, P2072, DOI 10.1053/j.gastro.2020.02.059; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Walker DL, 1999, BIOCHEM PHARMACOL, V58, P1057, DOI 10.1016/S0006-2952(99)00179-3; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yoshida T, 2020, BIOCHEM BIOPH RES CO, V522, P633, DOI 10.1016/j.bbrc.2019.11.130	40	1	1	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1518	1525		10.1038/s41388-022-02183-3	http://dx.doi.org/10.1038/s41388-022-02183-3		JAN 2022	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35031771	Green Accepted			2023-01-03	WOS:000742613600002
J	Jorga, SD; Dessie, YL; Kedir, MR; Donacho, DO				Jorga, Sime Daba; Dessie, Yohannes Lulu; Kedir, Mohammed Reshad; Donacho, Dereje Oljira			Prevalence of Tungiasis and its risk factors of among children of Mettu woreda, southwest Ethiopia, 2020	PLOS ONE			English	Article							TUNGA-PENETRANS; COMMUNITIES	Tungiasis is caused by the flea tunga penetrans and results in painful skin lesions, skin infections, and permanent disability. However, limited information is available that shows the magnitude of the problem and its risk factors that help for intervention in Ethiopia. The goal of this study was to determine the prevalence and risk factors of tungiasis in children aged 5 to 14 in Mettu woreda in 2020. A community based cross sectional study was conducted among randomly selected kebeles of Mettu woreda, in Southwest Ethiopia. To select study participants, multistage sampling was used. The data were collected through physical examination of the children, interview of parents/guardians of the children, and observation of the home environment using checklists and questionnaires. The descriptive analysis was done for socio-demographic characteristics, prevalence of tungiasis, and housing conditions. A logistic regression analysis was performed, and variables in multivariable regression reported odds ratios and their 95% confidence intervals once the variables were identified using a p-value of 0.05 as a risk factor of statistical significance. The prevalence of tungiasis among children 5-14 years of age in Mettu rural woreda was 52 percent (n = 821). As a risk factor, large family size (AOR: 2.9, 95% CI: 2.13, 4.40); school attendance (AOR: 1.5, 95% CI: 1.02, 2.18), floor inside the house (AOR: 3.8, 95% CI: 1.76, 8.43); having sleeping bed (AOR: 0.16, 95% CI: 0.03, 0.82); access to protected water sources (AOR: 0.24, 95% CI: 0.15, 0.39); access to improved toilet facilities(AOR: 0.63: 95% CI: 0.44, 0.89); access to electric services (AOR: 0.30, 95% CI: 0.15, 0.62); and lack of own farmland (AOR: 0.36, 95% CI: 0.26, 0.50) were found. Therefore, planning and implementation of interventions focus on those risk factors that are particularly important. Water, sanitation and hygiene interventions, and livelihood improvement interventions are required to solve the problem in the setting.	[Jorga, Sime Daba; Kedir, Mohammed Reshad] Mettu Univ, Coll Hlth Sci, Dept Publ Hlth, Metu, Ethiopia; [Dessie, Yohannes Lulu] Mettu Univ, Coll Hlth Sci, Dept Nursing, Metu, Ethiopia; [Donacho, Dereje Oljira] Mettu Univ, Coll Hlth Sci, Dept Hlth Informat, Jimma, Ethiopia; [Donacho, Dereje Oljira] Jimma Univ, Dept Environm Hlth Sci & Technol, Jimma, Ethiopia	Jimma University	Donacho, DO (corresponding author), Mettu Univ, Coll Hlth Sci, Dept Hlth Informat, Jimma, Ethiopia.; Donacho, DO (corresponding author), Jimma Univ, Dept Environm Hlth Sci & Technol, Jimma, Ethiopia.	dodbau3687@gmail.com	Donacho, Dereje Oljira/AAS-7401-2021	Donacho, Dereje Oljira/0000-0001-6145-2914				[Anonymous], JIGGERS REMOVAL PROG; CSA Ethiopia, 2013, POPULATION PROJECTIO, P118; Feldmeier H, 2013, EUR J CLIN MICROBIOL, V32, P19, DOI 10.1007/s10096-012-1725-4; Feldmeier H, 2003, EMERG INFECT DIS, V9, P949; Feldmeier H, 2013, TRAVEL MED INFECT DI, V11, P357, DOI 10.1016/j.tmaid.2013.10.001; Feldmeier H, 2009, B WORLD HEALTH ORGAN, V87, P152, DOI 10.2471/BLT.07.047308; Franck Sabine, 2003, Travel Med Infect Dis, V1, P159, DOI 10.1016/j.tmaid.2003.09.005; Girma M, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3373-5; Heukelbach J, 2004, B WORLD HEALTH ORGAN, V82, P563; Heukelbach J, 2007, J INFECT DEV COUNTR, V1; IBM Corp, 2011, IBM SPSS STAT WINDOW; Karunamoorthi K, 2013, PARASITOL RES, V112, P3635, DOI 10.1007/s00436-013-3551-8; Lauritsen JM., 2004, EPIDATA VERSION 3 1; Lwanga S.K., 1991, SAMPLE SIZE DETERMIN; Mazengia AL, 2018, J NUTR METAB, V2018, DOI 10.1155/2018/7521751; Muehlen M, 2006, T ROY SOC TROP MED H, V100, P371, DOI 10.1016/j.trstmh.2005.06.033; Mutebi F, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004126; Obebe OO, 2020, PATHOG GLOB HEALTH, V114, P360, DOI 10.1080/20477724.2020.1813489; Pilger D, 2008, PARASITOL RES, V102, P875, DOI 10.1007/s00436-007-0840-0; Ramaswamy V., 2016, INT J INTEGR MED SCI, V3, P211, DOI DOI 10.16965/IJIMS; Sachse MM, 2007, J EUR ACAD DERMATOL, V21, P11, DOI 10.1111/j.1468-3083.2006.01888.x; Ugbomoiko US, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000087; Ugbomoiko US, 2007, INT J DERMATOL, V46, P475, DOI 10.1111/j.1365-4632.2007.03245.x; Wafula ST, 2016, PAN AFR MED J, V24, DOI 10.11604/pamj.2016.24.77.8916; Walker SL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005808; Winter B, 2009, J INFECT DEV COUNTR, V3, P458, DOI 10.3855/jidc.418	26	0	0	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2022	17	1							e0262168	10.1371/journal.pone.0262168	http://dx.doi.org/10.1371/journal.pone.0262168			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZO8DB	34986188	Green Published, gold			2023-01-03	WOS:000765956200020
J	Bernal, AJ; da Silva, MMG; Musungaie, DB; Kovalchuk, E; Gonzalez, A; Delos Reyes, V; Martin-Quiros, A; Caraco, Y; Williams-Diaz, A; Brown, ML; Du, J; Pedley, A; Assaid, C; Strizki, J; Grobler, JA; Shamsuddin, HH; Tipping, R; Wan, H; Paschke, A; Butterton, JR; Johnson, MG; De Anda, C				Bernal, A. Jayk; da Silva, M. M. Gomes; Musungaie, D. B.; Kovalchuk, E.; Gonzalez, A.; Delos Reyes, V; Martin-Quiros, A.; Caraco, Y.; Williams-Diaz, A.; Brown, M. L.; Du, J.; Pedley, A.; Assaid, C.; Strizki, J.; Grobler, J. A.; Shamsuddin, H. H.; Tipping, R.; Wan, H.; Paschke, A.; Butterton, J. R.; Johnson, M. G.; De Anda, C.		MOVe-OUT Study Grp	Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; HOSPITALIZATION; SARS-COV-2	BACKGROUND New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS We conducted a phase 3, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of treatment with molnupiravir started within 5 days after the onset of signs or symptoms in nonhospitalized, unvaccinated adults with mild-to-moderate, laboratory-confirmed Covid-19 and at least one risk factor for severe Covid-19 illness. Participants in the trial were randomly assigned to receive 800 mg of molnupiravir or placebo twice daily for 5 days. The primary efficacy end point was the incidence hospitalization or death at day 29; the incidence of adverse events was the primary safety end point. A planned interim analysis was performed when 50% of 1550 participants (target enrollment) had been followed through day 29. RESULTS A total of 1433 participants underwent randomization; 716 were assigned to receive molnupiravir and 717 to receive placebo. With the exception of an imbalance in sex, baseline characteristics were similar in the two groups. The superiority of molnupiravir was demonstrated at the interim analysis; the risk of hospitalization for any cause or death through day 29 was lower with molnupiravir (28 of 385 participants [7.3%]) than with placebo (53 of 377 (14.1%)) (difference, -6.8 percentage points; 95% confidence interval, -11.3 to -2.4; P=0.001). In the analysis of all participants who had undergone randomization, the percentage of participants who were hospitalized or died through day 29 was lower in the molnupiravir group than in the placebo group (6.8% [48 of 709) vs. 9.7% [68 of 699); difference, -3.0 percentage points; 95% confidence interval, -5.9 to -0.1). Results of subgroup analyses were largely consistent with these overall results; in some subgroups, such as patients with evidence of previous SARS-CoV-2 infection, those with low baseline viral load, and those with diabetes, the point estimate for the difference favored placebo. One death was reported in the molnupiravir group and 9 were reported in the placebo group through day 29. Adverse events were reported in 216 of 710 participants (30.4%) in the molnupiravir group and 231 of 701 (33.0%) in the placebo group. CONCLUSIONS Early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.	[Bernal, A. Jayk] IMAT Oncomed, Monteria, Colombia; [da Silva, M. M. Gomes] Univ Fed Parana, Hosp Clin, Dept Publ Hlth, Curitiba, Parana, Brazil; [Musungaie, D. B.] Jongaie Res, Pretoria, South Africa; [Kovalchuk, E.] Med Res Inst, St Petersburg, Russia; [Gonzalez, A.] Adv Res Hlth Improvement, Immokalee, FL USA; [Delos Reyes, V] Lung Ctr Philippines, Quezon City, Philippines; [Martin-Quiros, A.] Hosp Univ La Paz, IdiPAZ, Madrid, Spain; [Caraco, Y.] Hadassah Hebrew Univ Med Ctr, Clin Pharmacol Unit, Jerusalem, Israel; [Williams-Diaz, A.; Brown, M. L.; Du, J.; Pedley, A.; Assaid, C.; Strizki, J.; Grobler, J. A.; Shamsuddin, H. H.; Tipping, R.; Wan, H.; Paschke, A.; Butterton, J. R.; Johnson, M. G.; De Anda, C.] Merck, Kenilworth, NJ USA	Universidade Federal do Parana; Lung Center of the Philippines; Hospital Universitario La Paz; Hebrew University of Jerusalem; Merck & Company	Bernal, AJ (corresponding author), IMAT Oncomed, Monteria, Colombia.			Mateu, Lourdes/0000-0001-7223-7611; Martin-Quiros, Alejandro/0000-0003-4630-7668	Merck Sharp and Dohme	Merck Sharp and Dohme(Merck & Company)	Supported by Merck Sharp and Dohme, a subsidiary of Merck, Kenilworth, NJ.	Abdelnabi R, 2021, J INFECT DIS, V224, P749, DOI 10.1093/infdis/jiab361; Agostini ML, 2019, J VIROL, V93, DOI 10.1128/JVI.01348-19; [Anonymous], 2020, WHO COVID 19 CAS DEF; [Anonymous], 2020, COVID 19 DEV DRUGS B; [Anonymous], 2021, WHO COR COVID 19 DAS; Arribas JR, 2022, NEJM EVID, V2022, P1, DOI 10.1056/EVIDoa2100044; Bajema KL, 2021, MMWR-MORBID MORTAL W, V70, P1294, DOI 10.15585/mmwr.mm7037e3; Caraco Y, 2022, NEJM EVID, P1, DOI [10.1056/EVIDoa2100043, DOI 10.1056/EVIDOA2100043]; Chawla A., 2021, P ABSTR 31 ANN M EUR; Cohen Myron S, 2021, Clin Infect Dis, V73, P1717, DOI 10.1093/cid/ciab494; Cowman K., 2021, OPEN FORUM INFECT DI, V8, pofab313, DOI DOI 10.1093/ofid/ofab313; Cox RM, 2021, NAT MICROBIOL, V6, P11, DOI 10.1038/s41564-020-00835-2; Fischer W., 2021, MOLNUPIRAVIR ORAL AN, DOI [10.1101/2021.06.17.21258639v1, DOI 10.1101/2021.06.17.21258639V1]; Gordon CJ, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100770; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Grobler J., 2021, P ABSTR IDWEEK 2021; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Hurt AC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040628; HWANG IK, 1990, STAT MED, V9, P1439, DOI 10.1002/sim.4780091207; Kabinger F, 2021, NAT STRUCT MOL BIOL, V28, P740, DOI 10.1038/s41594-021-00651-0; Khoo SH, 2021, J ANTIMICROB CHEMOTH, V76, P3286, DOI 10.1093/jac/dkab318; Ko JY, 2021, CLIN INFECT DIS, V72, pE695, DOI 10.1093/cid/ciaa1419; Kompaniyets L, 2021, MMWR-MORBID MORTAL W, V70, P355, DOI 10.15585/mmwr.mm7010e4; Malone B, 2021, NAT STRUCT MOL BIOL, V28, P706, DOI 10.1038/s41594-021-00657-8; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; Nguyen KH, 2021, ANN MED, V53, P1419, DOI 10.1080/07853890.2021.1957998; Painter WP, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.02428-20; Pogue JM, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab268; RECOVERY Collaborative group, 2021, LANCET, DOI [10.1101/2021.06.15.21258542, DOI 10.1101/2021.06.15.21258542V1]; Rosenberg ES, 2021, MMWR-MORBID MORTAL W, V70, P1306, DOI 10.15585/mmwr.mm7037a7; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P1156, DOI 10.15585/mmwr.mm7034e2; Tenforde MW, 2020, MMWR-MORBID MORTAL W, V69, P993, DOI 10.15585/mmwr.mm6930e1externalicon; Urakova N, 2018, J VIROL, V92, DOI 10.1128/JVI.01965-17; Wagner CE, 2021, SCIENCE, V373, P1488, DOI 10.1126/science.abj7364; Wahl A, 2021, NATURE, V591, P451, DOI 10.1038/s41586-021-03312-w; Yoon Jeong-Joong, 2018, Antimicrob Agents Chemother, V62, DOI [10.1128/AAC.00766-18, 10.1128/aac.00766-18]	38	396	396	31	75	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2022	386	6					509	520		10.1056/NEJMoa2116044	http://dx.doi.org/10.1056/NEJMoa2116044		DEC 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW0GW	34914868	Bronze, Green Published			2023-01-03	WOS:000730795400001
J	Stavroulaki, EM; Suchodolski, JS; Pilla, R; Fosgate, GT; Sung, CH; Lidbury, JA; Steiner, JM; Xenoulis, PG				Stavroulaki, Evangelia M.; Suchodolski, Jan S.; Pilla, Rachel; Fosgate, Geoffrey T.; Sung, Chi-Hsuan; Lidbury, Jonathan A.; Steiner, Jorg M.; Xenoulis, Panagiotis G.			Short- and long-term effects of amoxicillin/clavulanic acid or doxycycline on the gastrointestinal microbiome of growing cats	PLOS ONE			English	Article							GUT MICROBIOTA; FECAL MICROBIOTA; ANTIBIOTIC EXPOSURE; WEIGHT-GAIN; DOGS; DISEASE; HEALTHY; DYSBIOSIS; IMMUNITY; RNA	Antibiotic treatment in early life influences gastrointestinal (GI) microbial composition and function. In humans, the resultant intestinal dysbiosis is associated with an increased risk for certain diseases later in life. The objective of this study was to determine the temporal effects of antibiotic treatment on the GI microbiome of young cats. Fecal samples were collected from cats randomly allocated to receive either amoxicillin/clavulanic acid (20 mg/kg q12h) for 20 days (AMC group; 15 cats) or doxycycline (10 mg/kg q24h) for 28 days (DOX group;15 cats) as part of the standard treatment of upper respiratory tract infection. In addition, feces were collected from healthy control cats (CON group;15 cats). All cats were approximately two months of age at enrolment. Samples were collected on days 0 (baseline), 20 or 28 (AMC and DOX, respectively; last day of treatment), 60, 120, and 300. DNA was extracted and sequencing of the 16S rRNA gene and qPCR assays were performed. Fecal microbial composition was different on the last day of treatment for AMC cats, and 1 month after the end of antibiotic treatment for DOX cats, compared to CON cats. Species richness was significantly greater in DOX cats compared to CON cats on the last day of treatment. Abundance of Enterobacteriales was increased, and that of Erysipelotrichi was decreased in cats of the AMC group on the last day of treatment compared to CON cats. The abundance of the phylum Proteobacteria was increased in cats of the DOX group on days 60 and 120 compared to cats of the CON group. Only minor differences in abundances between the treatment groups and the control group were present on day 300. Both antibiotics appear to delay the developmental progression of the microbiome, and this effect is more profound during treatment with amoxicillin/clavulanic acid and one month after treatment with doxycycline. Future studies are required to determine if these changes influence microbiome function and whether they have possible effects on disease susceptibility in cats.	[Stavroulaki, Evangelia M.; Xenoulis, Panagiotis G.] Univ Thessaly, Fac Vet Sci, Clin Med, Kardhitsa, Greece; [Suchodolski, Jan S.; Pilla, Rachel; Sung, Chi-Hsuan; Lidbury, Jonathan A.; Steiner, Jorg M.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Gastrointestinal Lab, College Stn, TX USA; [Fosgate, Geoffrey T.] Univ Pretoria, Dept Prod Anim Studies, Onderstepoort, South Africa	University of Thessaly; Texas A&M University System; Texas A&M University College Station; University of Pretoria	Stavroulaki, EM (corresponding author), Univ Thessaly, Fac Vet Sci, Clin Med, Kardhitsa, Greece.	evangelia.stavroulaki@gmail.com	Fosgate, Geoffrey T/N-8700-2014	Fosgate, Geoffrey T/0000-0002-9432-0042	Miller Trust Award of the Winn Feline Foundation [MT18- 003]	Miller Trust Award of the Winn Feline Foundation	The study was funded by the Miller Trust Award of the Winn Feline Foundation (MT18- 003; JSS, PGX, JMS, EMS). The URL of the funder's website is https://everycat.org/. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abeles SR, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0187-9; Abu-Sbeih H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0714-x; Agyepong N, 2018, ANTIMICROB RESIST IN, V7, DOI 10.1186/s13756-018-0324-2; Alessandri G, 2020, APPL ENVIRON MICROB, V86, DOI 10.1128/AEM.02875-19; AlShawaqfeh MK, 2017, FEMS MICROBIOL ECOL, V93, DOI 10.1093/femsec/fix136; Angelakis E, 2017, MICROB PATHOGENESIS, V106, P162, DOI 10.1016/j.micpath.2016.11.002; Angelakis E, 2014, ANTIMICROB AGENTS CH, V58, P3342, DOI 10.1128/AAC.02437-14; [Anonymous], 2020, J FELINE MED SURG, V22, P813, DOI 10.1177/1098612X20941784; Apprill A, 2015, AQUAT MICROB ECOL, V75, P129, DOI 10.3354/ame01753; Aversa Z, 2021, MAYO CLIN PROC, V96, P66, DOI 10.1016/j.mayocp.2020.07.019; Baars Annemarie, 2015, Microorganisms, V3, P641, DOI 10.3390/microorganisms3040641; Becker E, 2017, INT J ANTIMICROB AG, V50, P342, DOI 10.1016/j.ijantimicag.2017.03.017; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bermingham EN, 2013, MICROBIOLOGYOPEN, V2, P173, DOI 10.1002/mbo3.60; Blake AB, 2020, J VET INTERN MED, V34, P2345, DOI 10.1111/jvim.15928; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Boynton Felicia D Duke, 2017, BMC Res Notes, V10, P644, DOI 10.1186/s13104-017-2960-7; Bresciani F, 2018, J VET INTERN MED, V32, P1903, DOI 10.1111/jvim.15227; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Candon S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125448; Costantini L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122645; Deusch O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144881; Deusch O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101021; Di Caprio R, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/329418; Dogra S, 2015, MBIO, V6, DOI 10.1128/mBio.02419-14; Elvers KT, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035677; Ferrer M, 2017, BIOCHEM PHARMACOL, V134, P114, DOI 10.1016/j.bcp.2016.09.007; Galla S, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014373; Gasparrini AJ, 2019, NAT MICROBIOL, V4, P2285, DOI 10.1038/s41564-019-0550-2; Gendrin M, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw074; Graversen KB, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00496; Gronvold AMR, 2010, FEMS MICROBIOL ECOL, V71, P313, DOI 10.1111/j.1574-6941.2009.00808.x; Guard BC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175718; Hoehne SN, 2017, VET PATHOL, V54, P234, DOI 10.1177/0300985816664792; Hooda S, 2013, BRIT J NUTR, V109, P1637, DOI 10.1017/S0007114512003479; Hornef MW, 2020, IMMUNOLOGY, V159, P15, DOI 10.1111/imm.13149; Igarashi H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107909; Inness VL, 2007, J ANIM PHYSIOL AN N, V91, P48, DOI 10.1111/j.1439-0396.2006.00640.x; Janeczko S, 2008, VET MICROBIOL, V128, P178, DOI 10.1016/j.vetmic.2007.10.014; Jess T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48065-9; Jung JY, 2018, ANAEROBE, V49, P85, DOI 10.1016/j.anaerobe.2017.12.011; Kaakoush NO, 2015, FRONT CELL INFECT MI, V5, DOI [10.3389/fcimb.2015.00084, 10.3309/fcimb.2015.00004]; Kabbani TA, 2017, GUT MICROBES, V8, P17, DOI 10.1080/19490976.2016.1267890; Kalenyak K, 2018, FEMS MICROBIOL ECOL, V94, DOI 10.1093/femsec/fix173; Kaur H, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01365; Koo H, 2019, NPJ BIOFILMS MICROBI, V5, DOI 10.1038/s41522-019-0103-8; Korpela K, 2020, PEDIATR RES, V88, P438, DOI 10.1038/s41390-020-0761-5; Laflamme D, 1997, FELINE PRACT, V25, P13; Laflamme DP, 2012, J FELINE MED SURG, V14, P669, DOI 10.1177/1098612X12446906; Langdon A, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0294-z; Lange K, 2016, DIGEST DIS, V34, P260, DOI 10.1159/000443360; Lappin MR, 2017, J VET INTERN MED, V31, P279, DOI 10.1111/jvim.14627; Levy M, 2017, NAT REV IMMUNOL, V17, P219, DOI 10.1038/nri.2017.7; Li QH, 2021, MSYSTEMS, V6, DOI 10.1128/mSystems.00111-21; Liu L, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01213; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Lyu Y, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01661; MacPherson CW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29229-5; Manchester AC, 2019, J VET INTERN MED, V33, P2605, DOI 10.1111/jvim.15635; Milani C, 2017, MICROBIOL MOL BIOL R, V81, DOI 10.1128/MMBR.00036-17; Minamoto Y, 2015, GUT MICROBES, V6, P33, DOI 10.1080/19490976.2014.997612; Modi SR, 2014, J CLIN INVEST, V124, P4212, DOI 10.1172/JCI72333; Mohr KI, 2016, CURR TOP MICROBIOL, V398, P237, DOI 10.1007/82_2016_499; Moon CD, 2018, MICROBIOLOGYOPEN, V7, DOI 10.1002/mbo3.677; Mueller NT, 2015, TRENDS MOL MED, V21, P109, DOI 10.1016/j.molmed.2014.12.002; Mulder M, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1791677; Neuman H, 2018, FEMS MICROBIOL REV, V42, P489, DOI 10.1093/femsre/fuy018; Nobel YR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8486; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; Oliphant K, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0704-8; Ortqvist AK, 2019, GUT, V68, P218, DOI 10.1136/gutjnl-2017-314352; Parada AE, 2016, ENVIRON MICROBIOL, V18, P1403, DOI 10.1111/1462-2920.13023; Venegas DP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00277; Patrick DM, 2020, LANCET RESP MED, V8, P1094, DOI 10.1016/S2213-2600(20)30052-7; Pilla R, 2020, J VET INTERN MED, V34, P1853, DOI 10.1111/jvim.15871; Pilla R, 2020, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00498; Ramadan Z, 2014, J VET INTERN MED, V28, P59, DOI 10.1111/jvim.12261; Ritchie LE, 2010, VET MICROBIOL, V144, P140, DOI 10.1016/j.vetmic.2009.12.045; Schmidt M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201279; Shao XQ, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00170; Soontararak S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220522; Stinson LF, 2020, J DEV ORIG HLTH DIS, V11, P201, DOI 10.1017/S2040174419000588; Subramanian S, 2014, NATURE, V510, P417, DOI 10.1038/nature13421; Suchodolski JS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127378; Suchodolski JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039333; Suchodolski JS, 2010, VET MICROBIOL, V142, P394, DOI 10.1016/j.vetmic.2009.11.002; Suchodolski JS, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-210; Sykes JE, 2014, VET CLIN N AM-SMALL, V44, P331, DOI 10.1016/j.cvsm.2013.10.005; Tanaka S, 2009, FEMS IMMUNOL MED MIC, V56, P80, DOI 10.1111/j.1574-695X.2009.00553.x; Tauchi H, 2019, BENEF MICROBES, V10, P641, DOI 10.3920/BM2019.0003; Tierney BT, 2019, CELL HOST MICROBE, V26, P283, DOI 10.1016/j.chom.2019.07.008; Tizard IR, 2018, VET CLIN N AM-SMALL, V48, P307, DOI 10.1016/j.cvsm.2017.10.008; Torres-Henderson C, 2017, TOP COMPANION ANIM M, V32, P104, DOI 10.1053/j.tcam.2017.11.002; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Ungaro R, 2014, AM J GASTROENTEROL, V109, P1728, DOI 10.1038/ajg.2014.246; Vangay P, 2015, CELL HOST MICROBE, V17, P553, DOI 10.1016/j.chom.2015.04.006; Watson VE, 2019, VET MICROBIOL, V231, P197, DOI 10.1016/j.vetmic.2019.03.020; WHITE AR, 1985, J ANTIMICROB CHEMOTH, V15, P227, DOI 10.1093/jac/15.suppl_A.227; Whittemore JC, 2019, GUT MICROBES, V10, P521, DOI 10.1080/19490976.2018.1560754; Whittemore JC, 2018, PEERJ, V6, DOI 10.7717/peerj.5130; Xenoulis PG, 2008, FEMS MICROBIOL ECOL, V66, P579, DOI 10.1111/j.1574-6941.2008.00556.x; Yang YT, 2021, POL J MICROBIOL, V70, P33, DOI 10.33073/pjm-2021-001; Young WN, 2016, SCI REP-UK, V6, DOI 10.1038/srep34668; Zaura E, 2015, MBIO, V6, DOI 10.1128/mBio.01693-15; Zhang JH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52632-5	105	4	4	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2021	16	12							e0253031	10.1371/journal.pone.0253031	http://dx.doi.org/10.1371/journal.pone.0253031			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY5KW	34910719	gold, Green Submitted, Green Published			2023-01-03	WOS:000754828900004
J	Park, MS; Lee, S; Ahn, T; Kim, D; Jung, MH; Choi, JH; Han, S; Ryu, KH; Kim, EJ				Park, Myung Soo; Lee, Sunki; Ahn, Taehoon; Kim, Doyoung; Jung, Mi-Hyang; Choi, Jae Hyuk; Han, Seongwoo; Ryu, Kyu Hyung; Kim, Eung Ju			Current status of cardiac rehabilitation among representative hospitals treating acute myocardial infarction in South Korea	PLOS ONE			English	Article							HEART-DISEASE; UPDATE; PARTICIPATION; SERVICES; FAILURE	Cardiac rehabilitation services are mostly underutilized despite the documentation of substantial morbidity and mortality benefits of cardiac rehabilitation post-acute myocardial infarction. To assess the implementation rate and barriers to cardiac rehabilitation in hospitals dealing with acute myocardial infarction in South Korea, between May and July 2016, questionnaires were emailed to cardiology directors of 93 hospitals in South Korea; all hospitals were certified institutes for coronary interventions. The questionnaires included 16 questions on the hospital type, cardiology practice, and implementation of cardiac rehabilitation. The obtained data were categorized into two groups based on the type of the hospital (secondary or tertiary) and statistically analysed. Of the 72 hospitals that responded (response rate of 77%), 39 (54%) were tertiary medical centers and 33 (46%) were secondary medical centers. All hospitals treated acute myocardial infarction patients and performed emergency percutaneous coronary intervention; 79% (57/72) of the hospitals performed coronary artery bypass grafting. However, the rate of implementation of cardiac rehabilitation was low overall (28%, 20/72 hospitals) and even lower in secondary medical centers (12%, 4/33 hospitals) than in tertiary centers (41%, 16/39 hospitals, p = 0.002). The major barriers to cardiac rehabilitation included the lack of staff (59%) and lack of space (33%). In contrast to the wide availability of acute-phase invasive treatment for AMI, the overall implementation of cardiac rehabilitation is extremely poor in South Korea. Considering the established benefits of cardiac rehabilitation in patients with acute myocardial infarction, more administrative support, such as increasing the fee for cardiac rehabilitation services by an appropriate level of health insurance coverage should be warranted.	[Park, Myung Soo; Lee, Sunki; Kim, Doyoung; Jung, Mi-Hyang; Choi, Jae Hyuk; Han, Seongwoo; Ryu, Kyu Hyung] Hallym Univ, Dept Cardiol, Dongtan Sacred Hosp, Hwaseong, South Korea; [Ahn, Taehoon] Korea Univ, Dept Cardiol, Anam Hosp, Seoul, South Korea; [Kim, Eung Ju] Korea Univ, Dept Cardiol, Guro Hosp, Seoul, South Korea	Hallym University; Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine)	Kim, EJ (corresponding author), Korea Univ, Dept Cardiol, Guro Hosp, Seoul, South Korea.	withnoel@empal.com	안, 태훈/GON-9067-2022	안, 태훈/0000-0003-1544-1784; Kim, Eung Ju/0000-0003-2322-6267; Park, Myung Soo/0000-0002-8352-5069; Jung, Mi-Hyang/0000-0003-0224-5178				ADES PA, 1992, ARCH INTERN MED, V152, P1033, DOI 10.1001/archinte.152.5.1033; Ding RJ, 2017, ADV EXP MED BIOL, V1000, P31, DOI 10.1007/978-981-10-4304-8_3; Europa WRf, 1992, NEEDS ACT PRI CARD R; Francis T, 2019, CAN J CARDIOL, V35, P352, DOI 10.1016/j.cjca.2018.11.013; Giannuzzi P, 2003, Eur J Cardiovasc Prev Rehabil, V10, P319, DOI 10.1097/01.hjr.0000086303.28200.50; Go AS, 2013, CIRCULATION, V127, P143, DOI 10.1161/CIR.0b013e318282ab8f; Goto Y, 2007, CIRC J, V71, P173, DOI 10.1253/circj.71.173; Goto Y, 2014, PROG CARDIOVASC DIS, V56, P557, DOI 10.1016/j.pcad.2013.12.001; Jeon B, 2013, HEALTH POLICY, V113, P69, DOI 10.1016/j.healthpol.2013.05.007; Kim C, 2010, ANN REHABIL MED-ARM, V34, P491; Kim Chul LJW., PUBL HLTH WEEKL REP, V13; Kim H, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7439-0; Kim SH, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e262; Korenfeld Y, 2009, AM HEART J, V158, P480, DOI 10.1016/j.ahj.2009.06.020; Lavin D, 2005, IRISH J MED SCI, V174, P33, DOI 10.1007/BF03168979; Lee SW, 2015, KOREAN CIRC J, V45, P202, DOI 10.4070/kcj.2015.45.3.202; McMahon SR, 2017, TRENDS CARDIOVAS MED, V27, P420, DOI 10.1016/j.tcm.2017.02.005; Olsen SJS, 2018, EUR J CARDIOVASC NUR, V17, P273, DOI 10.1177/1474515117737766; Pesah E, 2019, HEART, V105, P1806, DOI 10.1136/heartjnl-2018-314486; Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106; Reiss N., 2019, THORAC CARDIOV SURG; Ribeiro F, 2020, ARQ BRAS CARDIOL, V114, P708, DOI 10.36660/abc.20200157; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Servey JT, 2016, AM FAM PHYSICIAN, V94, P37; Suaya JA, 2009, J AM COLL CARDIOL, V54, P25, DOI 10.1016/j.jacc.2009.01.078; Sukul D, 2019, J AM COLL CARDIOL, V73, P3148, DOI 10.1016/j.jacc.2019.03.515; Thomas RJ, 2010, CIRCULATION, V122, P1342, DOI 10.1161/CIR.0b013e3181f5185b; Turk-Adawi K, 2014, NAT REV CARDIOL, V11, P586, DOI 10.1038/nrcardio.2014.98; Turk-Adawi KI, 2015, HEART LUNG CIRC, V24, P510, DOI 10.1016/j.hlc.2014.11.013; van Engen-Verheul M, 2013, EUR J PREV CARDIOL, V20, P349, DOI 10.1177/2047487312439497	30	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2021	16	12							e0261072	10.1371/journal.pone.0261072	http://dx.doi.org/10.1371/journal.pone.0261072			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY2LS	34879117	Green Published, gold			2023-01-03	WOS:000754625200048
J	Howe, K; Bourke, S; Sansom, L				Howe, Katrina; Bourke, Siobhan; Sansom, Lloyd			The extent to which off-patent registered prescription medicines are used for off-label indications in Australia: A scoping review	PLOS ONE			English	Review							DRUG-USE; PALLIATIVE CARE; RITUXIMAB; ONCOLOGY	Aim The aim of this scoping review was to determine the extent of off-patent prescription medicine use beyond registered indications in various Australian clinical settings. Method The review followed the Joanna Briggs Institute approach and reported using PRISMA Extension for Scoping Reviews. Online databases were used to identify published literature about off-patent registered prescription medicines used for off-label indications in Australian public hospital, community and primary healthcare settings. In addition, empirical data from the Queensland and the South Australian state-wide medicine formularies were screened for the same medication/off-label indication dyads identified in the literature, and other locally approved uses. Results Overall, fourteen studies were included, conducted in public hospitals (n = 11), palliative care units (n = 2) and the community setting (n = 1). There were 213 reports extracted from the literature describing off-patent registered prescription medicines used for off-label indications, representing 128 unique medication/off-label indication dyads and 32 different medicines. Of these, just five medication/off-label indication dyads were approved for use on both the Queensland and South Australian state-wide medicine formularies, with 12 others only approved for use in Queensland and 16 others only approved for use in South Australia. Further examination of these state-wide formularies demonstrated that the use of off-patent registered prescription medicines beyond registered indications is more extensive than has been reported to date in the literature. There were 28 additional medication/off-label indication dyads approved on the Queensland state-wide medicine formulary and 14 such examples approved for use in South Australia. Of these, just two medication/off-label indication dyads were approved for use on both formularies. Conclusion The extent to which off-patent registered prescription medicines have been repurposed in clinical settings for off-label indications in Australia is greater than previously reported in the literature. Usage and funded availability of certain medication/off-label indication dyads, varies across Australia. These results further expose the two tiered system of medicines regulation in Australia, and its impact on equity of access to medicines. Further research is required to support policy change to encourage submission of registration updates for off-patent prescription medicines.	[Howe, Katrina; Bourke, Siobhan] Australian Natl Univ, Res Sch Populat Hlth, Dept Hlth Serv Res & Policy, Coll Hlth & Med, Canberra, ACT, Australia; [Sansom, Lloyd] Univ South Australia, Clin & Hlth Sci Unit, Adelaide, SA, Australia	Australian National University; University of South Australia	Howe, K (corresponding author), Australian Natl Univ, Res Sch Populat Hlth, Dept Hlth Serv Res & Policy, Coll Hlth & Med, Canberra, ACT, Australia.	katrina.howe@anu.edu.au		Howe, Katrina/0000-0001-6850-6524	Australian Government Research Training Program (RTP) Scholarship; Sir Roland Wilson Foundation Scholarship; The Australian Government Department of Health	Australian Government Research Training Program (RTP) Scholarship(Australian GovernmentDepartment of Industry, Innovation and Science); Sir Roland Wilson Foundation Scholarship; The Australian Government Department of Health	The authors received no specific funding for this work. KH is supported by an Australian Government Research Training Program (RTP) Scholarship and a Sir Roland Wilson Foundation Scholarship (https://srwfoundation.anu.edu.au/). The Australian Government Department of Health provided funding support in the form of salaries for authors [KH, LS] but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	[Anonymous], COVIDENCE SYSTEMATIC; Aromaratis E., 2020, JOANNA BRIGGS I, DOI [10.46658/JBIMES-20-01, DOI 10.46658/JBIMES-20-01]; Australian Government Department of Health, PRESCR MED INF PBS P; Australian Government Department of Health, AUSTR REG PRESCR MED; Australian Government Department of Health, TGA BUS PLAN 2019 20; Australian Government Department of Health, CONS REP PRESCR MED; Australian Healthcare Associates. Department of Health,, PBS PHARM HOSP REV R; Ballard CDJ, 2013, J PAEDIATR CHILD H, V49, P38, DOI 10.1111/jpc.12065; Bicknell ME., 1995, AUSTR J HOSP PHARM, V25, P527; Brunero S, 2016, INT PSYCHOGERIATR, V28, P967, DOI 10.1017/S104161021500232X; Butterly SJ, 2010, INTERN MED J, V40, P443, DOI 10.1111/j.1445-5994.2009.01988.x; Chay J, 2013, INTERN MED J, V43, P871, DOI 10.1111/imj.12207; Colvin L, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/909860; Council of Australian Therapeutic Advisory Groups, 2013, RETH MED DEC MAK AUS; Gazarian M, 2006, MED J AUSTRALIA, V185, P544, DOI 10.5694/j.1326-5377.2006.tb00689.x; Hagemann V, 2019, PALLIATIVE MED, V33, P650, DOI 10.1177/0269216319840602; Inglis JM, 2019, INT J CLIN PHARM-NET, V41, P920, DOI 10.1007/s11096-019-00853-z; Langedijk J, 2015, DRUG DISCOV TODAY, V20, P1027, DOI 10.1016/j.drudis.2015.05.001; Magalhaes J, 2015, EUR J CLIN PHARMACOL, V71, P1, DOI 10.1007/s00228-014-1768-9; McD Taylor David, 2015, Emerg Med Australas, V27, P440, DOI 10.1111/1742-6723.12431; McLachlan AJ, 2020, AUST PRESCR, V43, P24, DOI 10.18773/austprescr.2020.007; Mellor JD, 2009, ASIA-PAC J CLIN ONCO, V5, P242, DOI 10.1111/j.1743-7563.2009.01239.x; Murteira Susana, 2013, J Mark Access Health Policy, V1, DOI 10.3402/jmahp.v1i0.21131; Newton PJ, 2012, BMC PALLIAT CARE, V11, DOI 10.1186/1472-684X-11-6; O'Connor K, 2013, INTERN MED J, V43, P863, DOI 10.1111/imj.12206; O'Donnell CPF, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e52; Ong N, 2017, AUSTRALAS J DERMATOL, V58, P30, DOI 10.1111/ajd.12392; Parliament of Australia, INQ APPR PROC NEW DR; Poole SG, 2004, SUPPORT CARE CANCER, V12, P302, DOI 10.1007/s00520-004-0593-6; Queensland Government, 2020, LIST APPR MED LAM; Queensland Health, FORM NOT LIST APPR M; Queensland Health, GUID REQ CHANG QUEEN; Richard D., 2013, AUST PRESCR, V26, P182, DOI DOI 10.18773/AUSTPRESCR.2013.075; Saiyed MM, 2017, J CLIN PHARM THER, V42, P251, DOI 10.1111/jcpt.12507; Santos J, 2020, BRIT J CLIN PHARMACO, V86, P533, DOI 10.1111/bcp.14127; Seale JP, 2014, MED J AUSTRALIA, V200, P65, DOI 10.5694/mja13.00184; Sharma R, 2007, INTERN MED J, V37, P569, DOI 10.1111/j.1445-5994.2007.01406.x; South Australian Health, S AUSTR MED FORM 202; The EndNote Team, 2013, ENDNOTE ENDNOTE X9; To THM, 2013, PALLIATIVE MED, V27, P320, DOI 10.1177/0269216312464263; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Turner Sean, 1999, Australian Journal of Hospital Pharmacy, V29, P265; Wongseelashote S, 2018, INTERN MED J, V48, P165, DOI 10.1111/imj.13554; Zarkali A, 2014, CURR MED RES OPIN, V30, P471, DOI 10.1185/03007995.2013.855186	44	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2021	16	12							e0261022	10.1371/journal.pone.0261022	http://dx.doi.org/10.1371/journal.pone.0261022			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY3JJ	34860857	Green Accepted, gold, Green Published			2023-01-03	WOS:000754686900024
J	Mollerup, A; Henriksen, M; Larsen, SC; Bennetzen, AS; Simonsen, MK; Kofod, LM; Knudsen, JD; Nielsen, XC; Weis, N; Heitmann, BL				Mollerup, Annette; Henriksen, Marius; Larsen, Sofus Christian; Bennetzen, Anita Selmer; Simonsen, Mette Kildevaeld; Kofod, Linette Marie; Knudsen, Jenny Dahl; Nielsen, Xiaohui Chen; Weis, Nina; Heitmann, Berit Lilienthal			Effect of PEP flute self-care versus usual care in early covid-19: non-drug, open label, randomised controlled trial in a Danish community setting	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSITIVE EXPIRATORY PRESSURE	OBJECTIVE To determine whether positive expiratory pressure (PEP) by PEP flute self-care is effective in reducing respiratory symptoms among community dwelling adults with SARS-CoV-2 infection and early stage covid-19. DESIGN Non-drug, open label, randomised controlled trial. SETTING Capital Region and Region Zealand in Denmark from 6 October 2020 to 26 February 2021. PARTICIPANTS Community dwelling adults, able to perform self-care, with a new SARS-CoV-2 infection (verified by reverse transcription polymerase chain reaction tests) and symptoms of covid-19. INTERVENTION Participants were randomised to use PEP flute selfcare in addition to usual care or have usual care only. Randomisation was based on permuted random blocks in a 1:1 ratio, stratified for sex and age (<60 or >= 60 years). The PEP self-care group was instructed to use a PEP flute three times per day during the 30 day intervention. MAIN OUTCOME MEASURES Primary outcome was a change in symptom severity from baseline to day 30, as assessed by the self-reported COPD (chronic obstructive pulmonary disease) assessment test (CAT), which was adjusted for baseline values and stratification factors. Participants completed the CAT test questionnaire every day online. Secondary outcomes were selfreported urgent care visits due to covid-19, number of covid-19 related symptoms, and change in self-rated health, all within 30-days' follow-up. RESULTS 378 participants were assigned to the PEP flute selfcare intervention (n=190) or usual care only (n=188). In the PEP self-care group, the median number of days with PEP flute use was 21 days (interquartile range 13-25). For the intention-to-treat population, a group difference was observed in changes from baseline in CAT scores of -1.2 points (95% confidence interval -2.1 to -0.2; P=0.017) in favour of the PEP flute selfcare group. At day 30, the PEP flute self-care group also reported less chest tightness, less dyspnoea, more vigour, and higher level of daily activities, but these differences were small, and no consistent effects were seen on the secondary outcomes. No serious adverse events were reported. CONCLUSIONS In community dwelling adults with early covid-19, PEP flute self-care had a significant, yet marginal and uncertain clinical effect on respiratory symptom severity, as measured by CAT scores.	[Mollerup, Annette; Henriksen, Marius; Larsen, Sofus Christian; Bennetzen, Anita Selmer; Simonsen, Mette Kildevaeld; Heitmann, Berit Lilienthal] Copenhagen Univ Hosp Bispebjerg Frederiksberg, Parker Inst, Frederiksberg, Denmark; [Mollerup, Annette] Univ Coll Diakonissestiftelsen, Bachelor Sci Nursing Programme, Danish Deaconess Community, Frederiksberg, Denmark; [Simonsen, Mette Kildevaeld] Copenhagen Univ Hosp Bispebjerg Frederiksberg, Dept Neurol, Frederiksberg, Denmark; [Kofod, Linette Marie] Copenhagen Univ Hosp Hvidovre, Dept Physio & Occupat Therapy, Hvidovre, Denmark; [Kofod, Linette Marie] Copenhagen Univ Hosp Hvidovre, PMR C, Hvidovre, Denmark; [Knudsen, Jenny Dahl] Copenhagen Univ Hosp, Rigshosp, Dept Clin Microbiol, Copenhagen, Denmark; [Nielsen, Xiaohui Chen] Zealand Univ Hosp, Dept Clin Microbiol, Slagelse, Denmark; [Weis, Nina] Copenhagen Univ Hosp Hvidovre, Dept Infect Dis, Hvidovre, Denmark; [Henriksen, Marius; Weis, Nina] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark; [Heitmann, Berit Lilienthal] Univ Sydney, Boden Inst Obes Nutr Exercise & Eating Disorders, Sydney, NSW, Australia; [Heitmann, Berit Lilienthal] Univ Copenhagen, Dept Publ Hlth, Sect Gen Practice, Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Sydney; University of Copenhagen	Mollerup, A (corresponding author), Copenhagen Univ Hosp Bispebjerg Frederiksberg, Parker Inst, Frederiksberg, Denmark.; Mollerup, A (corresponding author), Univ Coll Diakonissestiftelsen, Bachelor Sci Nursing Programme, Danish Deaconess Community, Frederiksberg, Denmark.	amol@ucdiakonissen.dk	Larsen, Sofus Christian/AAO-5894-2020; Mollerup, Annette/GQQ-6381-2022	Larsen, Sofus Christian/0000-0002-0838-9378; Kofod, Linette Marie/0000-0002-1184-9451; Heitmann, Berit Lilienthal/0000-0002-6809-4504	Innovation Fund Denmark [0211-00023B]; Danish Nursing Council; Oak Foundation [OCAY-18-774]	Innovation Fund Denmark; Danish Nursing Council; Oak Foundation	The study was supported by Innovation Fund Denmark (grant 0211-00023B) and a grant (unnumbered) from the Danish Nursing Council. The Parker Institute, Bispebjerg-Frederiksberg hospital, is supported by a core grant from the Oak Foundation (grant OCAY-18-774). The funders had no role in the study design, conduct of the trial, data analysis and interpretation, writing of the manuscript, or the decision to publish the study.	Bo A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1095; Butler CC, 2021, LANCET, V397, P1063, DOI 10.1016/S0140-6736(21)00461-X; Clarke JM, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1239; Daynes E, 2021, THORAX, V76, P185, DOI 10.1136/thoraxjnl-2020-215916; Detry MA, 2016, JAMA-J AM MED ASSOC, V315, P407, DOI 10.1001/jama.2015.19394; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Ellis-Petersen H, 2021, GUARDIAN; GlaxoSmithKline, COPD ASS TEST CAT HE; Haase N, 2021, ACTA ANAESTH SCAND, V65, P68, DOI 10.1111/aas.13701; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Jones P, 2018, HEALTHCARE PROFESSIO, P1; Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509; Kofod LM, 2021, EUR CLIN RESPIR J, V8, DOI 10.1080/20018525.2021.1910191; Lenze EJ, 2020, JAMA-J AM MED ASSOC, V324, P2292, DOI 10.1001/jama.2020.22760; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Moller T, 2016, AM J HEMATOL, V91, P271, DOI 10.1002/ajh.24262; Mollerup A, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-050582; Ni YM, 2018, EXP THER MED, V16, P3241, DOI 10.3892/etm.2018.6552; Olsen MF, 2015, RESP MED, V109, P297, DOI 10.1016/j.rmed.2014.11.003; Osadnik CR, 2014, THORAX, V69, P137, DOI 10.1136/thoraxjnl-2013-203425; Osadnik CR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008328.pub2; Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2; Radovanovic D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041191; Ramakrishnan S, 2021, LANCET RESP MED, V9, P763, DOI 10.1016/S2213-2600(21)00160-0; Smith JA, 2012, J PHYSIOL-LONDON, V590, P563, DOI 10.1113/jphysiol.2011.213157; Statens Serum Institut, COVIDMETER; Sudre CH, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01292-y; The Lancet Infectious Diseases, LANCET INFEC DIS, V21, P1471, DOI [10.1016/S1473-3099(21)00633-2, DOI 10.1016/S1473-3099(21)00633-2]; Thomas S, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0369	29	1	1	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 24	2021	375								e066952	10.1136/bmj-2021-066952	http://dx.doi.org/10.1136/bmj-2021-066952			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE1ME	34819329	hybrid			2023-01-03	WOS:000740893700014
J	Horve, PF; Dietz, L; Northcutt, D; Stenson, J; Van den Wymelenberg, K				Horve, Patrick Finn; Dietz, Leslie; Northcutt, Dale; Stenson, Jason; Van den Wymelenberg, Kevin			Evaluation of a bioaerosol sampler for indoor environmental surveillance of Severe Acute Respiratory Syndrome Coronavirus 2	PLOS ONE			English	Article							AIRBORNE TRANSMISSION; RELATIVE-HUMIDITY; FLOCKED SWABS; VIRAL-RNA; SARS-COV-2; COLLECTION; AIR; TEMPERATURE; DIAGNOSIS; VIRUSES	The worldwide spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has ubiquitously impacted many aspects of life. As vaccines continue to be manufactured and administered, limiting the spread of SARS-CoV-2 will rely more heavily on the early identification of contagious individuals occupying reopened and increasingly populated indoor environments. In this study, we investigated the utility of an impaction-based bioaerosol sampling system with multiple nucleic acid collection media. Heat-inactivated SARS-CoV-2 was utilized to perform bench-scale, short-range aerosol, and room-scale aerosol experiments. Through bench-scale experiments, AerosolSense Capture Media (ACM) and nylon flocked swabs were identified as the highest utility media. In room-scale aerosol experiments, consistent detection of aerosol SARS-CoV-2 was achieved at an estimated aerosol concentration equal to or greater than 0.089 genome copies per liter of room air (gc/L) when air was sampled for eight hours or more at less than one air change per hour (ACH). Shorter sampling periods (75 minutes) yielded consistent detection at similar to 31.8 gc/L of room air and intermittent detection down to similar to 0.318 gc/L at (at both 1 and 6 ACH). These results support further exploration in real-world testing scenarios and suggest the utility of indoor aerosol surveillance as an effective risk mitigation strategy in occupied buildings.	[Horve, Patrick Finn; Dietz, Leslie; Northcutt, Dale; Stenson, Jason; Van den Wymelenberg, Kevin] Univ Oregon, Biol & Built Environm Ctr, Eugene, OR 97403 USA; [Northcutt, Dale; Stenson, Jason; Van den Wymelenberg, Kevin] Univ Oregon, Energy Studies Bldg Lab, Eugene, OR 97403 USA; [Van den Wymelenberg, Kevin] Univ Oregon, Inst Hlth & Built Environm, Portland, OR 97403 USA	University of Oregon; University of Oregon; University of Oregon	Van den Wymelenberg, K (corresponding author), Univ Oregon, Biol & Built Environm Ctr, Eugene, OR 97403 USA.; Van den Wymelenberg, K (corresponding author), Univ Oregon, Energy Studies Bldg Lab, Eugene, OR 97403 USA.; Van den Wymelenberg, K (corresponding author), Univ Oregon, Inst Hlth & Built Environm, Portland, OR 97403 USA.	kevinvdw@uoregon.edu	Horve, Patrick/AAJ-2608-2020; Dietz, Leslie G/AAJ-1915-2020	Horve, Patrick/0000-0002-9318-9249; Van Den Wymelenberg, Kevin/0000-0002-0336-5537	Thermo Fisher Scientific [4133V1]	Thermo Fisher Scientific	Van Den Wymelenberg serves as a scientific advisor to EnviralTech, a company that conducts viral environmental surveillance, including in senior care facilities. EnviralTech did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This research was funded by Thermo Fisher Scientific under award number 4133V1. The funder provided the university with support in the form of salaries for all authors, equipment, and reagents but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. However, per contractual obligations, the funder had the right to review the final manuscript for confidential information prior to submission. The specific roles of these authors are articulated in the `author contributions' section.	Abdelwhab EM, 2011, J VIROL METHODS, V174, P120, DOI 10.1016/j.jviromet.2011.03.017; Ahlawat A, 2020, AEROSOL AIR QUAL RES, V20, P1856, DOI 10.4209/aaqr.2020.06.0302; Alsved M, 2020, AEROSOL SCI TECH, V54, P1245, DOI 10.1080/02786826.2020.1812502; Apparatus HSE-H, 2004, OP INSTR PARI JET NE; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bouzenada S, 2016, PROCEDIA COMPUT SCI, V83, P718, DOI 10.1016/j.procs.2016.04.159; Callaway E, 2021, NATURE, V589, P177, DOI 10.1038/d41586-021-00031-0; Cardona-Ospina JA, 2019, PREV VET MED, V172, DOI 10.1016/j.prevetmed.2019.104772; Casanova LM, 2010, APPL ENVIRON MICROB, V76, P2712, DOI 10.1128/AEM.02291-09; Chan KH, 2008, J CLIN VIROL, V42, P65, DOI 10.1016/j.jcv.2007.12.003; Chan K, 2011, ADV OPTOELECTRON, V2011, DOI [10.1155/2011/734690, 10.1155/2011/196707]; Chia PY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16670-2; Colaneri M, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.05.009; Coleman KK, 2022, CLIN INFECT DIS, V74, P1722, DOI 10.1093/cid/ciab691; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Correia G, 2020, MED HYPOTHESES, V141, DOI 10.1016/j.mehy.2020.109781; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Crits-Christoph A, 2021, MBIO, V12, DOI 10.1128/mBio.02703-20; Dauner AL, 2015, AM J TROP MED HYG, V93, P46, DOI 10.4269/ajtmh.15-0110; Dietz L, 2020, MSYSTEMS, V5, DOI [10.1128/mSystems.00245-20., 10.1128/mSystems.00245-20]; Dreier J, 2005, J CLIN MICROBIOL, V43, P4551, DOI 10.1128/JCM.43.9.4551-4557.2005; Faria NR., 2021, GENOMIC CHARACTERISA, V12; Garnett L, 2020, J VIROL METHODS, V285, DOI 10.1016/j.jviromet.2020.113947; Gonzalez R, 2020, WATER RES, V186, DOI 10.1016/j.watres.2020.116296; Gregson FKA, 2021, AEROSOL SCI TECH, V55, P681, DOI 10.1080/02786826.2021.1883544; Hall-Mendelin S, 2017, AM J TROP MED HYG, V96, P1241, DOI 10.4269/ajtmh.16-0981; Hamner L, 2020, MMWR-MORBID MORTAL W, V69, P606, DOI 10.15585/mmwr.mm6919e6; Hata A, 2015, FOOD ENVIRON VIROL, V7, P7, DOI 10.1007/s12560-014-9169-x; Hermesch AC, 2020, OBSTET GYNECOL, V136, P827, DOI 10.1097/AOG.0000000000004112; Hinds W.C, 1999, AEROSOL TECHNOLOGY P, DOI 10.1016/0021-8502(83)90049-6; Hinds W.C., 2011, AEROSOL MEASUREMENT, P31; Horve PF, 2020, J EXPO SCI ENV EPID, V30, P219, DOI 10.1038/s41370-019-0157-y; Iker BC, 2013, J VIROL METHODS, V191, P24, DOI 10.1016/j.jviromet.2013.03.011; Jayamohan H, 2021, ANAL BIOANAL CHEM, V413, P49, DOI 10.1007/s00216-020-02958-1; Jones SL, 2020, FOOD ENVIRON VIROL, V12, P158, DOI 10.1007/s12560-020-09421-5; Kim SW, 2007, AEROBIOLOGIA, V23, P239, DOI 10.1007/s10453-007-9068-9; Kline A, 2021, DIAGN MICR INFEC DIS, V99, DOI 10.1016/j.diagmicrobio.2020.115209; Lednicky JA, 2020, AEROSOL AIR QUAL RES, V20, P1167, DOI [10.4209/aaqr.2020.05.0202, 10.4209/aaqr.2020.02.0202]; Lednickya JA, 2020, INT J INFECT DIS, V100, P476, DOI [10.1016/j.ijid.2020.09.025, 10.1101/2020.08.03.20167395]; Likert R., 1932, ARCH PSYCHOL, V140, P1; Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3; Lobel L., 2015, BIOPROTOC, P5, DOI [10.21769/bioprotoc.1660, DOI 10.21769/BIOPROTOC.1660]; Loveday EK., 2020, VIRUSES-BASEL, P2020, DOI [10.1101/2020.11.14.383026, DOI 10.1101/2020.11.14.383026]; Lu JY, 2020, EMERG INFECT DIS, V26, P1628, DOI 10.3201/eid2607.200764; MacIntyre CR, 2020, ANTIMICROB RESIST IN, V9, DOI 10.1186/s13756-020-00868-6; Miller SL, 2021, INDOOR AIR, V31, P314, DOI 10.1111/ina.12751; Milton DK, 2020, J PEDIAT INF DIS SOC, V9, P413, DOI 10.1093/jpids/piaa079; Moore C, 2008, J VIROL METHODS, V153, P84, DOI 10.1016/j.jviromet.2008.08.001; Moore JP, 2021, JAMA-J AM MED ASSOC, V325, P821, DOI 10.1001/jama.2021.1114; Morawska L, 2020, ENVIRON INT, V142, DOI 10.1016/j.envint.2020.105832; Moriarty LF, 2020, MMWR-MORBID MORTAL W, V69, P347, DOI 10.15585/mmwr.mm6912e3; Nilsson AC, 2010, SCAND J INFECT DIS, V42, P679, DOI 10.3109/00365548.2010.486001; Nissen K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76442-2; Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227; Perchetti GA, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01094-20; Pere H, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00721-20; Pernice S, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05490-w; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; R Core Team, 2021, R LANG ENV STAT COMP; Ronnqvist M, 2013, J FOOD PROTECT, V76, P1421, DOI 10.4315/0362-028X.JFP-12-371; Runcharoen C, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0397-1; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Samet JM, 2021, CLIN INFECT DIS, V73, P1924, DOI 10.1093/cid/ciab039; Santarpia JL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69286-3; Scansen KA, 2010, J CLIN MICROBIOL, V48, P852, DOI 10.1128/JCM.01897-09; Scientific TF, IN AIR PATHOGEN SURV; Sharma A, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00512; Somsen GA, 2020, LANCET RESP MED, V8, P658, DOI 10.1016/S2213-2600(20)30245-9; Tang JW, 2021, J HOSP INFECT, V110, P89, DOI 10.1016/j.jhin.2020.12.022; Torii S, 2021, SCI TOTAL ENVIRON, V756, DOI 10.1016/j.scitotenv.2020.143067; Waris M, 2013, J CLIN VIROL, V58, P200, DOI 10.1016/j.jcv.2013.06.002; Williams TC, 2021, LANCET RESP MED, V9, P333, DOI 10.1016/S2213-2600(21)00075-8	72	2	2	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2021	16	11							e0257689	10.1371/journal.pone.0257689	http://dx.doi.org/10.1371/journal.pone.0257689			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2IU	34780482	gold, Green Published			2023-01-03	WOS:000755305800009
J	Connors, JM; Brooks, MM; Sciurba, FC; Krishnan, JA; Bledsoe, JR; Kindzelski, A; Baucom, AL; Kirwan, BA; Eng, H; Martin, D; Zaharris, E; Everett, B; Castro, L; Shapiro, NL; Lin, JY; Hou, PC; Pepine, CJ; Handberg, E; Haight, DO; Wilson, JW; Majercik, S; Fu, ZX; Zhong, YQ; Venugopal, V; Beach, S; Wisniewski, S; Ridker, PM				Connors, Jean M.; Brooks, Maria M.; Sciurba, Frank C.; Krishnan, Jerry A.; Bledsoe, Joseph R.; Kindzelski, Andrei; Baucom, Amanda L.; Kirwan, Bridget-Anne; Eng, Heather; Martin, Deborah; Zaharris, Elaine; Everett, Brendan; Castro, Lauren; Shapiro, Nancy L.; Lin, Janet Y.; Hou, Peter C.; Pepine, Carl J.; Handberg, Eileen; Haight, Daniel O.; Wilson, Jason W.; Majercik, Sarah; Fu, Zhuxuan; Zhong, Yongqi; Venugopal, Vidya; Beach, Scott; Wisniewski, Steve; Ridker, Paul M.		ACTIV-4B Investigators	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19 The ACTIV-4B Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RIVAROXABAN; APIXABAN	IMPORTANCE Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy, although the risks and benefits of this intervention among outpatients with COVID-19 have not been established. OBJECTIVE To assess whether anticoagulant or antiplatelet therapy can safely reduce major adverse cardiopulmonary outcomes among symptomatic but clinically stable outpatients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS The ACTIV-4B Outpatient Thrombosis Prevention Trial was designed as a minimal-contact, adaptive, randomized, double-blind, placebo-controlled trial to compare anticoagulant and antiplatelet therapy among 7000 symptomatic but clinically stable outpatients with COVID-19. The trial was conducted at 52 US sites between September 2020 and June 2021; final follow-up was August 5, 2021. Prior to initiating treatment, participants were required to have platelet count greater than 100 000/mm(3) and estimated glomerular filtration rate greater than 30 mL/min/1.73 m(2). INTERVENTIONS Random allocation in a 1:1:1:1 ratio to aspirin (81 mg orally once daily; n = 164), prophylactic-dose apixaban (2.5 mg orally twice daily; n = 165), therapeutic-dose apixaban (5 mg orally twice daily; n = 164), or placebo (n = 164) for 45 days. MAIN OUTCOMES AND MEASURES The primary end point was a composite of all-cause mortality, symptomatic venous or arterial thromboembolism, myocardial infarction, stroke, or hospitalization for cardiovascular or pulmonary cause. The primary analyses for efficacy and bleeding events were limited to participants who took at least 1 dose of trial medication. RESULTS On June 18, 2021, the trial data and safety monitoring board recommended early termination because of lower than anticipated event rates; at that time, 657 symptomatic outpatients with COVID-19 had been randomized (median age, 54 years [IQR, 46-59]; 59% women). The median times from diagnosis to randomization and from randomization to initiation of study treatment were 7 days and 3 days, respectively. Twenty-two randomized participants (3.3%) were hospitalized for COVID-19 prior to initiating treatment. Among the 558 patients who initiated treatment, the adjudicated primary composite end point occurred in 1 patient (0.7%) in the aspirin group, 1 patient (0.7%) in the 2.5-mg apixaban group, 2 patients (1.4%) in the 5-mg apixaban group, and 1 patient (0.7%) in the placebo group. The risk differences compared with placebo for the primary end point were 0.0% (95% CI not calculable) in the aspirin group, 0.7% (95% CI, -2.1% to 4.1%) in the 2.5-mg apixaban group, and 1.4% (95% CI, -1.5% to 5.0%) in the 5-mg apixaban group. Risk differences compared with placebo for bleeding events were 2.0% (95% CI, -2.7% to 6.8%), 4.5% (95% CI, -0.7% to 10.2%), and 6.9% (95% CI, 1.4% to 12.9%) among participants who initiated therapy in the aspirin, prophylactic apixaban, and therapeutic apixaban groups, respectively, although none were major. Findings inclusive of all randomized patients were similar. CONCLUSIONS AND RELEVANCE Among symptomatic clinically stable outpatients with COVID-19, treatment with aspirin or apixaban compared with placebo did not reduce the rate of a composite clinical outcome. However, the study was terminated after enrollment of 9% of participants because of an event rate lower than anticipated.	[Connors, Jean M.; Zaharris, Elaine; Everett, Brendan; Hou, Peter C.; Ridker, Paul M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Brooks, Maria M.; Sciurba, Frank C.; Baucom, Amanda L.; Eng, Heather; Martin, Deborah; Fu, Zhuxuan; Zhong, Yongqi; Venugopal, Vidya; Beach, Scott; Wisniewski, Steve] Univ Pittsburgh, Pittsburgh, PA USA; [Krishnan, Jerry A.; Castro, Lauren; Shapiro, Nancy L.; Lin, Janet Y.] Univ Illinois, Chicago, IL USA; [Bledsoe, Joseph R.; Majercik, Sarah] Intermt Healthcare, Murray, UT USA; [Kindzelski, Andrei] NHLBI, Bldg 10, Bethesda, MD 20892 USA; [Kirwan, Bridget-Anne] SOCAR Res SA, Nyon, Switzerland; [Pepine, Carl J.; Handberg, Eileen] Univ Florida, Gainesville, FL USA; [Haight, Daniel O.] Univ S Florida, Lakeland Reg Hlth, Lakeland, FL USA; [Wilson, Jason W.] Tampa Gen Hosp, Tampa, FL 33606 USA	Harvard University; Brigham & Women's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Intermountain Healthcare; Intermountain Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University System of Florida; University of Florida; State University System of Florida; University of South Florida; Tampa General Hospital	Ridker, PM (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Div Prevent Med, 900 Commonwealth Ave, Boston, MA 02215 USA.; Ridker, PM (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, 900 Commonwealth Ave, Boston, MA 02215 USA.	pridker@bwh.harvard.edu	Bledsoe, Joseph/GLS-8543-2022; fu, zhuxuan/ABB-2107-2021; Zhong, Yongqi/J-1670-2017; Maggioni, Aldo Pietro/AAL-5334-2020; Wilson, Jason/C-8939-2017	Bledsoe, Joseph/0000-0002-3005-2878; fu, zhuxuan/0000-0002-9190-195X; Zhong, Yongqi/0000-0002-4042-7450; Maggioni, Aldo Pietro/0000-0003-2764-6779; sciurba, frank/0000-0001-7468-2225; Adler, David/0000-0002-8797-1621; Wilson, Jason/0000-0002-4291-5802; Pepine, Carl/0000-0002-6011-681X; Yadav, Kabir/0000-0002-1092-9935; Beiser, David/0000-0001-9676-087X	National Institutes of Health (NIH) [1OT2HL156812-01]; National Heart, Lung, and Blood Institute (NHLBI)	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was, in part, funded by National Institutes of Health (NIH) Agreement 1OT2HL156812-01. Specifically, the ACTIV-4B trial was supported by Other Transition Authorities from the National Heart, Lung, and Blood Institute (NHLBI). Grantee institutions included the University of Pittsburgh; the University of Illinois Chicago; and the Brigham andWomen's Hospital. The trial drugs and matching placebo were donated by the Bristol Myers Squibb-Pfizer Alliance.	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Agnelli G, 2013, NEW ENGL J MED, V369, P799, DOI 10.1056/NEJMoa1302507; Agnelli G, 2013, NEW ENGL J MED, V368, P699, DOI 10.1056/NEJMoa1207541; [Anonymous], WHO COR COVID 19 DAS; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096; Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Kaatz S, 2015, J THROMB HAEMOST, V13, P2119, DOI 10.1111/jth.13140; Lawler PR, 2021, NEW ENGL J MED, V385, P790, DOI 10.1056/NEJMoa2105911; Lopes RD, 2021, LANCET, V397, P2253, DOI 10.1016/S0140-6736(21)01203-4; Nopp S, 2020, RES PRACT THROMB HAE, V4, P1178, DOI 10.1002/rth2.12439; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sadeghipour P, 2021, JAMA-J AM MED ASSOC, V325, P1620, DOI 10.1001/jama.2021.4152; Spyropoulos AC, 2020, J AM COLL CARDIOL, V75, P3140, DOI 10.1016/j.jacc.2020.04.071; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163	19	76	76	7	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2021	326	17					1703	1712		10.1001/jama.2021.17272	http://dx.doi.org/10.1001/jama.2021.17272		OCT 2021	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW8DB	34633405	Bronze, Green Published			2023-01-03	WOS:000707427200001
J	Pedrotti, CHS; Accorsi, TAD; Lima, KD; Silva, JRD; Morbeck, RA; Cordioli, E				Pedrotti, Carlos H. S.; Accorsi, Tarso A. D.; Lima, Karine De Amicis; Silva Filho, Jose R. de O.; Morbeck, Renata A.; Cordioli, Eduardo			Cross-sectional study of the ambulance transport between healthcare facilities with medical support via telemedicine: Easy, effective, and safe tool	PLOS ONE			English	Article							EMERGENCY; GUIDELINES	Background Feasibility and safety of ambulance transport between healthcare facilities with medical support exclusively via telemedicine are unknown. Methods This was a retrospective study with a single telemedicine center reference for satellite emergency departments of the same hospital. The study population was all critically ill patients admitted to one of the peripheral units from November 2016 to May 2020 and who needed to be transferred to the main building. Telemedicine-assisted transportation was performed by an emergency specialist. The inclusion criteria included patients above the age of 15 and initial stabilization performed at the emergency department. Unstable, intubated, ST-elevation myocardial infarction and acute stroke patients were excluded. There was a double-check of safety conditions by the nurse and the remote doctor before the ambulance departure. The primary endpoint was the number of telemedicine-guided interventions during transport. Results 2840 patients were enrolled. The population was predominantly male (53.2%) with a median age of 60 years. Sepsis was the most prevalent diagnosis in 28% of patients, followed by acute coronary syndromes (8.5%), arrhythmia (6.7%), venous thromboembolism (6.1%), stroke (6.1%), acute abdomen (3.6%), respiratory distress (3.3%), and heart failure (2.5%). Only 22 (0.8%) patients required telemedicine-assisted support during transport. Administration of oxygen therapy and analgesics were the most common recommendations made by telemedicine emergency physicians. There were no communication problems in the telemedicine-assisted group. Conclusions Telemedicine-assisted ambulance transportation between healthcare facilities of stabilized critically ill patients may be an option instead of an onboard physician. The frequency of clinical support requests by telemedicine is minimal, and most evaluations are of low complexity and easily and safely performed by trained nurses.	[Pedrotti, Carlos H. S.; Accorsi, Tarso A. D.; Lima, Karine De Amicis; Silva Filho, Jose R. de O.; Morbeck, Renata A.; Cordioli, Eduardo] Hosp Israelita Albert Einstein, Telemed Dept, Sao Paulo, Brazil	Hospital Israelita Albert Einstein	Pedrotti, CHS (corresponding author), Hosp Israelita Albert Einstein, Telemed Dept, Sao Paulo, Brazil.	carlos.pedrotti@einstein.br		Pedrotti, Carlos/0000-0002-0634-7086				Abimbola S, 2019, HEALTH POLICY PLANN, V34, P605, DOI 10.1093/heapol/czz055; Black JJM, 2005, RESUSCITATION, V64, P21, DOI 10.1016/j.resuscitation.2004.10.004; Champagne-Langabeer T, 2019, PREHOSP EMERG CARE, V23, P712, DOI 10.1080/10903127.2019.1568650; Dwyer R, 2014, AGE AGEING, V43, P759, DOI 10.1093/ageing/afu117; Ekeland AG, 2010, INT J MED INFORM, V79, P736, DOI 10.1016/j.ijmedinf.2010.08.006; Fromm RE, 2000, CRIT CARE CLIN, V16, P695, DOI 10.1016/S0749-0704(05)70141-X; Fugok K, 2018, TELEMED E-HEALTH, V24, P367, DOI 10.1089/tmj.2017.0095; Gray JT, 2007, EMERG MED J, V24, P727, DOI 10.1136/emj.2007.048850; Hanchate AD, 2017, ANN EMERG MED, V70, P533, DOI 10.1016/j.annemergmed.2017.03.029; Hauswald Mark, 2002, Prehosp Emerg Care, V6, P383, DOI 10.1080/10903120290937978; Hemphill RR, 2009, ACAD EMERG MED, V16, P1019, DOI 10.1111/j.1553-2712.2009.00529.x; Hjalte L, 2007, EUR J EMERG MED, V14, P151; Hoot NR, 2008, ANN EMERG MED, V52, P126, DOI 10.1016/j.annemergmed.2008.03.014; Langabeer JR, 2016, WEST J EMERG MED, V17, P713, DOI 10.5811/westjem.2016.8.30660; Neumar RW, 2015, CIRCULATION, V132, pS315, DOI 10.1161/CIR.0000000000000252; Pavlopoulos S, 1998, IEEE Trans Inf Technol Biomed, V2, P261, DOI 10.1109/4233.737581; Rogers H, 2017, TELEMED E-HEALTH, V23, P707, DOI 10.1089/tmj.2016.0248; Silvestri Salvatore, 2002, Prehosp Emerg Care, V6, P387, DOI 10.1080/10903120290937987; Siriwardena AN, 2019, PROGRAMME GRANTS APP; Slattery DE, 2009, PREHOSP EMERG CARE, V13, P388, DOI 10.1080/10903120802706104; Thrall JH, 1998, SEMIN NUCL MED, V28, P145, DOI 10.1016/S0001-2998(98)80004-4; Valenzuela Espinoza Alexis, 2016, Interact J Med Res, V5, pe9, DOI 10.2196/ijmr.5015; Versel Neil, 2009, Hosp Health Netw, V83, P12; Wallace PGM, 1999, BRIT MED J, V319, P368, DOI 10.1136/bmj.319.7206.368; Winburn AS, 2018, J TELEMED TELECARE, V24, P473, DOI 10.1177/1357633X17713140	25	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2021	16	9							e0257801	10.1371/journal.pone.0257801	http://dx.doi.org/10.1371/journal.pone.0257801			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YI5QV	34591876	Green Published, gold			2023-01-03	WOS:000743903000035
J	Saldanha, LL; Delgado, AQ; Marcourt, L; Camaforte, NAD; Vareda, PMP; Ebrahimi, SN; Vilegas, W; Dokkedal, AL; Queiroz, EF; Wolfender, JL; Bosqueiro, JR				Saldanha, Luiz Leonardo; Delgado, Aislan Quintiliano; Marcourt, Laurence; de Paula Camaforte, Nathalia Aparecida; Ponce Vareda, Priscilla Maria; Ebrahimi, Samad Nejad; Vilegas, Wagner; Dokkedal, Anne Ligia; Queiroz, Emerson Ferreira; Wolfender, Jean-Luc; Bosqueiro, Jose Roberto			Hypoglycemic active principles from the leaves of Bauhinia holophylla: Comprehensive phytochemical characterization and in vivo activity profile	PLOS ONE			English	Article							PREPARATIVE ISOLATION; FLAVONOIDS; LITHOSPERMOSIDE; ANTIOXIDANT; GLYCOSIDES; QUERCETIN; PINITOL	Bauhinia holophylla leaves, also known as "pata-de-vaca", are traditionally used in Brazil to treat diabetes. Although the hypoglycemic activity of this medicinal plant has already been described, the active compounds responsible for the hypoglycemic activity have not yet been identified. To rapidly obtain two fractions in large amounts compatible with further in vivo assay, the hydroalcoholic extract of B. holophylla leaves was fractionated by Vacuum Liquid Chromatography and then purified by medium pressure liquid chromatography combined with an in vivo Glucose Tolerance Test in diabetic mice. This approach resulted in the identification of eleven compounds (1-11), including an original non-cyanogenic cyanoglucoside derivative. The structures of the isolated compounds were elucidated by nuclear magnetic resonance and high-resolution mass spectrometry. One of the major compounds of the leaves, lithospermoside (3), exhibited strong hypoglycemic activity in diabetic mice at the doses of 10 and 20 mg/kg b.w. and prevents body weight loss. The proton nuclear magnetic resonance (H-1 NMR) quantification revealed that the hydroalcoholic leaves extract contained 1.7% of lithospermoside (3) and 3.1% of flavonoids. The NMR analysis also revealed the presence of a high amount of pinitol (4) (9.5%), a known compound possessing in vivo hypoglycemic activity. The hypoglycemic properties of the hydroalcoholic leaves extract and the traditional water infusion extracts of the leaves of B. holophylla seem thus to be the result of the activity of three unrelated classes of compounds. Such results support to some extent the traditional use of Bauhinia holophylla to treat diabetes.	[Saldanha, Luiz Leonardo; Delgado, Aislan Quintiliano; de Paula Camaforte, Nathalia Aparecida; Ponce Vareda, Priscilla Maria; Dokkedal, Anne Ligia; Bosqueiro, Jose Roberto] Sao Paulo State Univ UNESP, Fac Sci, Bauru, SP, Brazil; [Saldanha, Luiz Leonardo; Marcourt, Laurence; Queiroz, Emerson Ferreira; Wolfender, Jean-Luc] Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland; [Saldanha, Luiz Leonardo; Marcourt, Laurence; Queiroz, Emerson Ferreira; Wolfender, Jean-Luc] Univ Geneva, Inst Pharmaceut Sci Western Switzerland ISPSO, Geneva, Switzerland; [Ebrahimi, Samad Nejad] Shahid Beheshti Univ, Med Plants & Drugs Res Inst, Dept Phytochem, GC, Tehran, Iran; [Vilegas, Wagner] Sao Paulo State Univ UNESP, Inst Biociences, Sao Vicente, SP, Brazil	Universidade Estadual Paulista; University of Geneva; University of Geneva; Shahid Beheshti University; Universidade Estadual Paulista	Bosqueiro, JR (corresponding author), Sao Paulo State Univ UNESP, Fac Sci, Bauru, SP, Brazil.; Queiroz, EF; Wolfender, JL (corresponding author), Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland.; Queiroz, EF; Wolfender, JL (corresponding author), Univ Geneva, Inst Pharmaceut Sci Western Switzerland ISPSO, Geneva, Switzerland.	emerson.ferreira@unige.ch; jean-Luc.wolfender@unige.ch; jose.bosqueiro@unesp.br	Bosqueiro, José Roberto/N-3864-2019; Saldanha, Luiz Leonardo/F-7040-2012; Ebrahimi, Samad Nejad/G-1574-2016; Nejad Ebrahimi, Samad/F-2477-2017	Bosqueiro, José Roberto/0000-0001-5367-7427; Saldanha, Luiz Leonardo/0000-0003-2454-067X; Nejad Ebrahimi, Samad/0000-0003-2167-8032	Sao Paulo Research Foundation (FAPESP) [09/52237-9, 16/18628-4]; Swiss National Science Foundation (SNF R'Equip grant) [316030_164095]	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Swiss National Science Foundation (SNF R'Equip grant)(Swiss National Science Foundation (SNSF))	WV and JRB were funded by Sao Paulo Research Foundation (FAPESP) grants 09/52237-9 and 16/18628-4, respectively. JLW is thankful to the Swiss National Science Foundation for the support in the acquisition of the NMR 600 MHz (SNF R'Equip grant 316030_164095). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AL-Ishaq RK, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090430; Andrikopoulos S, 2008, AM J PHYSIOL-ENDOC M, V295, pE1323, DOI 10.1152/ajpendo.90617.2008; Antonowski T, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102314; Bates SH, 2000, BRIT J PHARMACOL, V130, P1944, DOI 10.1038/sj.bjp.0703523; Bruhn T, 2013, CHIRALITY, V25, P243, DOI 10.1002/chir.22138; Cechinel V, 2009, PHYTOTHER RES, V23, P1347, DOI 10.1002/ptr.2756; Cermak R, 2004, BRIT J NUTR, V91, P849, DOI 10.1079/BJN20041128; Challal S, 2015, PLANTA MED, V81, P1636, DOI 10.1055/s-0035-1545912; Chen S, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9340637; Camaforte NAD, 2019, PHARM BIOL, V57, P269, DOI 10.1080/13880209.2019.1599962; Farag MA, 2015, PHYTOCHEMISTRY, V119, P41, DOI 10.1016/j.phytochem.2015.09.004; Fort DM, 2001, BIOCHEM SYST ECOL, V29, P439, DOI 10.1016/S0305-1978(00)00057-0; Frisch M.J., 2009, GAUSSIAN 09 REVISION; Gao YF, 2015, J AGR FOOD CHEM, V63, P6019, DOI 10.1021/acs.jafc.5b01238; Gindro K, 2017, J NAT PROD, V80, P887, DOI 10.1021/acs.jnatprod.6b00760; Gleadow RM, 2014, ANNU REV PLANT BIOL, V65, P155, DOI 10.1146/annurev-arplant-050213-040027; Holzgrabe U, 2010, PROG NUCL MAG RES SP, V57, P229, DOI 10.1016/j.pnmrs.2010.05.001; Hostettmann K., 2013, PREPARATIVE CHROMATO, V2; Jung MJ, 2004, ARCH PHARM RES, V27, P593, DOI 10.1007/BF02980155; Kang SJ, 2015, FOOD SCI BIOTECHNOL, V24, P1897, DOI 10.1007/s10068-015-0249-y; Kunert O, 2000, MONATSH CHEM, V131, P195; Mahmoud MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063784; Mukhopadhyay P, 2015, RSC ADV, V5, P97547, DOI 10.1039/c5ra18896b; NARAYANAN CR, 1987, CURR SCI INDIA, V56, P139; NICOLLIER G, 1983, J NAT PROD, V46, P112, DOI 10.1021/np50025a011; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Oliveira F, 1989, REV BRAS FARMACOGN, V2, P170; Pauli GF, 2014, J MED CHEM, V57, P9220, DOI 10.1021/jm500734a; Pinafo MS, 2019, TOXICOL REP, V6, P244, DOI 10.1016/j.toxrep.2019.03.001; Pinheiro MS, 2017, AN ACAD BRAS CIENC, V89, P263, DOI 10.1590/0001-3765201720160050; Vareda PMP, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/543606; Salatino Antonio, 1999, Revista Brasileira de Botanica, V22, P17, DOI 10.1590/S0100-84041999000100003; Silva TMS, 2013, CHEM NAT COMPD+, V49, P685, DOI 10.1007/s10600-013-0707-9; WENKERT E, 1977, PHYTOCHEMISTRY, V16, P1811, DOI 10.1016/0031-9422(71)85095-1; WU J, 1979, J NAT PROD, V42, P688; Yang NY, 2010, NAT PROD RES, V24, P1843, DOI 10.1080/14786419.2010.482057; Zhang H, 2004, CHINESE J CHEM, V22, P1200; Zhu YD, 2013, MOLECULES, V18, P15648, DOI 10.3390/molecules181215648	38	4	4	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2021	16	9							e0258016	10.1371/journal.pone.0258016	http://dx.doi.org/10.1371/journal.pone.0258016			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY2YF	34559860	Green Published, gold			2023-01-03	WOS:000754657900058
J	Franz, M; Schmidt, B; Hecht, H; Naumann, E; Miltner, WHR				Franz, Marcel; Schmidt, Barbara; Hecht, Holger; Naumann, Ewald; Miltner, Wolfgang H. R.			Suggested visual blockade during hypnosis: Top-down modulation of stimulus processing in a visual oddball task	PLOS ONE			English	Article							EVOKED POTENTIALS; INTRACEREBRAL POTENTIALS; RARE TARGET; SOURCE LOCALIZATION; HYPNOTIC ANALGESIA; NEURAL MECHANISMS; BRAIN; P300; EEG; ATTENTION	Several theories of hypnosis assume that responses to hypnotic suggestions are implemented through top-down modulations via a frontoparietal network that is involved in monitoring and cognitive control. The current study addressed this issue re-analyzing previously published event-related-potentials (ERP) (N1, P2, and P3b amplitudes) and combined it with source reconstruction and connectivity analysis methods. ERP data were obtained from participants engaged in a visual oddball paradigm composed of target, standard, and distractor stimuli during a hypnosis (HYP) and a control (CON) condition. In both conditions, participants were asked to count the rare targets presented on a video screen. During HYP participants received suggestions that a wooden board in front of their eyes would obstruct their view of the screen. The results showed that participants' counting accuracy was significantly impaired during HYP compared to CON. ERP components in the N1 and P2 window revealed no amplitude differences between CON and HYP at sensor-level. In contrast, P3b amplitudes in response to target stimuli were significantly reduced during HYP compared to CON. Source analysis of the P3b amplitudes in response to targets indicated that HYP was associated with reduced source activities in occipital and parietal brain areas related to stimulus categorization and attention. We further explored how these brain sources interacted by computing time-frequency effective connectivity between electrodes that best represented frontal, parietal, and occipital sources. This analysis revealed reduced directed information flow from parietal attentional to frontal executive sources during processing of target stimuli. These results provide preliminary evidence that hypnotic suggestions of a visual blockade are associated with a disruption of the coupling within the frontoparietal network implicated in top-down control.	[Franz, Marcel; Schmidt, Barbara; Hecht, Holger; Miltner, Wolfgang H. R.] Friedrich Schiller Univ Jena, Inst Psychol, Jena, Germany; [Naumann, Ewald] Univ Trier, Inst Psychol, Trier, Germany	Friedrich Schiller University of Jena; Universitat Trier	Miltner, WHR (corresponding author), Friedrich Schiller Univ Jena, Inst Psychol, Jena, Germany.	wolfgang.miltner@uni-jena.de	Schmidt, Barbara/AAH-4517-2020	Schmidt, Barbara/0000-0002-6828-5546	Deutsche Forschungsgemeinschaft [NA 482/5-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	Deutsche Forschungsgemeinschaft (Award number: MI 265/15-1 | recipient: W.H.R. Miltner); Deutsche Forschungsgemeinschaft (Award number: NA 482/5-1 | recipient: Ewald Naumann).	[Anonymous], 2011, RHYTHMS BRAIN; Babiloni C, 2006, CEREB CORTEX, V16, P37, DOI 10.1093/cercor/bhi082; Babiloni C, 2009, HUM BRAIN MAPP, V30, P998, DOI 10.1002/hbm.20567; Baccala LA, 2001, BIOL CYBERN, V84, P463, DOI 10.1007/PL00007990; BARABASZ AF, 1983, J ABNORM PSYCHOL, V92, P520, DOI 10.1037/0021-843X.92.4.520; BAUDENA P, 1995, ELECTROEN CLIN NEURO, V94, P251, DOI 10.1016/0013-4694(95)98476-O; Bigdely-Shamlo N, 2013, IEEE ENG MED BIO, P5845, DOI 10.1109/EMBC.2013.6610881; Bledowski C, 2004, J NEUROSCI, V24, P9353, DOI 10.1523/JNEUROSCI.1897-04.2004; Bocquillon P, 2011, CLIN NEUROPHYSIOL, V122, P1991, DOI 10.1016/j.clinph.2011.03.014; BOWERS KS, 1992, CONSCIOUS COGN, V1, P32, DOI 10.1016/1053-8100(92)90042-9; Braboszcz C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10310-4; Buzsaki G, 2013, NEURON, V80, P751, DOI 10.1016/j.neuron.2013.10.002; Cavina-Pratesi C, 2006, J NEUROSCI, V26, P2704, DOI 10.1523/JNEUROSCI.3176-05.2006; Clarke JM, 1999, CLIN NEUROPHYSIOL, V110, P1210, DOI 10.1016/S1388-2457(99)00063-2; Cojan Y, 2009, NEURON, V62, P862, DOI 10.1016/j.neuron.2009.05.021; Connors MH, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00361; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; CRAWFORD HJ, 1994, INT J CLIN EXP HYP, V42, P204, DOI 10.1080/00207149408409352; Crawford HJ, 1998, INT J CLIN EXP HYP, V46, P92, DOI 10.1080/00207149808409992; DAVISON GC, 1967, INT J CLIN EXP HYP, V15, P57, DOI 10.1080/00207146708407509; De Pascalis V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128474; DEHAENE S, 1992, COGNITION, V44, P1, DOI 10.1016/0010-0277(92)90049-N; DEHAENE S, 1994, J EXP PSYCHOL HUMAN, V20, P958, DOI 10.1037/0096-1523.20.5.958; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Delorme A, 2007, NEUROIMAGE, V34, P1443, DOI 10.1016/j.neuroimage.2006.11.004; Delorme A, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/130714; Dienes Z., 2007, HYPNOSIS CONSCIOUS S, P293; DiMaio V, 1995, PERCEPT MOTOR SKILL, V81, P1315, DOI 10.2466/pms.1995.81.3f.1315; Eger E, 2009, CURR BIOL, V19, P1608, DOI 10.1016/j.cub.2009.08.047; Egner T, 2005, NEUROIMAGE, V27, P969, DOI 10.1016/j.neuroimage.2005.05.002; Florin E, 2010, NEUROIMAGE, V50, P577, DOI 10.1016/j.neuroimage.2009.12.050; Friederich M, 2001, PSYCHOPHYSIOLOGY, V38, P768, DOI 10.1017/S0048577201000221; Friedrich J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61025-y; Gazzaley A, 2012, TRENDS COGN SCI, V16, P129, DOI 10.1016/j.tics.2011.11.014; Gmaj B, 2016, ACTA NEUROBIOL EXP, V76, P75, DOI 10.21307/ane-2017-007; Goebel R, 2004, HUMAN NERVOUS SYSTEM, VSecond, P1280; Gruzelier J.H., 2006, CONT HYPN, V23, P15, DOI DOI 10.1002/CH.35; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P191, DOI 10.1016/0013-4694(94)00259-N; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P229, DOI 10.1016/0013-4694(95)98475-N; Herrmann MJ, 2004, J PSYCHOPHYSIOL, V18, P1, DOI 10.1027/0269-8803.18.1.1; Hilgard E. R., 1991, THEORIES HYPNOSIS CU, P83; Hilgard E.R., 1977, DIVIDED CONSCIOUSNES; Hopfinger JB, 2000, NAT NEUROSCI, V3, P284, DOI 10.1038/72999; Jasiukaitis P, 1996, NEUROPSYCHOLOGIA, V34, P661, DOI 10.1016/0028-3932(95)00149-2; JOHNSON R, 1986, PSYCHOPHYSIOLOGY, V23, P367, DOI 10.1111/j.1469-8986.1986.tb00649.x; Jung TP, 2000, PSYCHOPHYSIOLOGY, V37, P163, DOI 10.1111/1469-8986.3720163; Kallio S, 2016, INT J CLIN EXP HYP, V64, P261, DOI 10.1080/00207144.2016.1171088; Kilner JM, 2010, ANN APPL STAT, V4, P1272, DOI 10.1214/10-AOAS337; Kirenskaya AV, 2019, INT J CLIN EXP HYP, V67, P81, DOI 10.1080/00207144.2019.1553764; Kirino E, 2000, J NEUROSCI, V20, P6612, DOI 10.1523/JNEUROSCI.20-17-06612.2000; Knight RT, 1998, J CLIN NEUROPHYSIOL, V15, P3, DOI 10.1097/00004691-199801000-00003; Kok A, 2001, PSYCHOPHYSIOLOGY, V38, P557, DOI 10.1017/S0048577201990559; Kosslyn SM, 2000, AM J PSYCHIAT, V157, P1279, DOI 10.1176/appi.ajp.157.8.1279; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Leistritz L, 2013, PHILOS T R SOC A, V371, DOI 10.1098/rsta.2011.0616; Litvak V, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/852961; LUCK SJ, 1994, PSYCHOPHYSIOLOGY, V31, P291, DOI 10.1111/j.1469-8986.1994.tb02218.x; Luck SJ, 2011, OXFORD HDB EVENT REL, P329, DOI DOI 10.1093/0XF0RDHB/9780195374148.013.0161; Mallard D, 2001, INT J CLIN EXP HYP, V49, P330, DOI 10.1080/00207140108410082; Matsumoto E, 2004, EXP BRAIN RES, V158, P9, DOI 10.1007/s00221-004-1872-7; McGeown WJ, 2012, CONSCIOUS COGN, V21, P100, DOI 10.1016/j.concog.2011.10.015; Miller B. L., 2018, HUMAN FRONTAL LOBES; Miltner WHR., 1993, HYPNOSE KOGNITION, V10, P22; Oakley DA, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01924; Oakley DA, 2013, NAT REV NEUROSCI, V14, P565, DOI 10.1038/nrn3538; Oakley DA, 2009, TRENDS COGN SCI, V13, P264, DOI 10.1016/j.tics.2009.03.004; Omoto S, 2010, CLIN NEUROPHYSIOL, V121, P386, DOI 10.1016/j.clinph.2009.12.005; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; Piazza M, 2003, P ROY SOC B-BIOL SCI, V270, P1237, DOI 10.1098/rspb.2003.2356; Piazza M, 2016, NEUROPSYCHOLOGIA, V83, P257, DOI 10.1016/j.neuropsychologia.2015.09.025; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Scharmuller W, 2011, BRAIN RES, V1397, P10, DOI 10.1016/j.brainres.2011.04.018; Scherg Michael, 1992, Brain Topography, V5, P103, DOI 10.1007/BF01129037; Schmidt B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05195-2; Schuler G, 1996, HYPN KOGN, V13, P79; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Shomstein S, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00038; Spiegel D, 2013, DEPRESS ANXIETY, V30, P342, DOI 10.1002/da.22046; Terhune DB, 2017, NEUROSCI BIOBEHAV R, V81, P59, DOI 10.1016/j.neubiorev.2017.02.002; Terhune DB, 2011, PSYCHOPHYSIOLOGY, V48, P1444, DOI 10.1111/j.1469-8986.2011.01211.x; Trippe RH, 2004, ANASTH INTENSIVMED, V45, P642; VERLEGER R, 1994, COGNITIVE BRAIN RES, V2, P103, DOI 10.1016/0926-6410(94)90007-8; Verleger R, 2020, PSYCHOPHYSIOLOGY, V57, DOI 10.1111/psyp.13542; Woody EZ, 2008, DISSOCIATION THEORIE	86	2	2	4	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2021	16	9							e0257380	10.1371/journal.pone.0257380	http://dx.doi.org/10.1371/journal.pone.0257380			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG6DR	34525129	Green Published, gold			2023-01-03	WOS:000707084400033
J	Adeyemi, OO; Alabi, AS; Adeyemi, OA; Talabi, OT; Abidakun, OM; Joel, IY; Stonehouse, NJ				Adeyemi, Oluwapelumi Olufemi; Alabi, Ade Stephen; Adeyemi, Oluwasanmi Anuoluwapo; Talabi, Olaoluwa Temitope; Abidakun, Oreoluwa M.; Joel, Ireoluwa Yinka; Stonehouse, Nicola J.			Acute gastroenteritis and the usage pattern of antibiotics and traditional herbal medications for its management in a Nigerian community	PLOS ONE			English	Article							ANTIDIARRHEAL ACTIVITY; OCIMUM-GRATISSIMUM; AQUEOUS EXTRACT; LEAVES	Acute gastroenteritis (AGE) is the highest cause of mortality worldwide in children under the age of 5 years, with the highest mortalities occurring in low-to-middle income countries. Treatment can involve use of unregulated herbal medication and antibiotics. A cross sectional study was carried out to investigate the use of antibiotics and traditional herbal medications in the management of AGE among Yoruba-speaking communities in Kwara State, Nigeria. Our findings suggest habitual use of antibiotics (54.6%) and herbal medication (42.5%) in the management of AGE with high levels of self-prescription of antibiotics (21.7%) and herbal medications (36.2%) within the community. Ethanolic extracts of selected herbal plants reported (i.e. Aristolochia ringens, Azadirachta indica, Chromolaena odorata, Etanda Africana, Ficus capensis, Ficus vogelii, Mangifera indica, Momordica charantia, Ocimum gratisimum, Senna alata, Sorghum bicolor and Vernonia amygdalina) were investigated for antibacterial properties, using bacteria known to be causative agents of AGE. Our findings showed that, with exception of Ficus vogelii, which enhanced bacterial growth, the plant extracts reported all showed some antibacterial activity. We further discuss our findings within a regulatory context, with the aim to guide the use of traditional and herbal medication in low-to medium income countries (LMICs) and reduce the potential risks associated with the development of antimicrobial resistance.	[Adeyemi, Oluwapelumi Olufemi] Univ Ilorin, Coll Hlth Sci, Fac Basic Clin Sci, Dept Med Microbiol & Parasitol, Ilorin, Nigeria; [Adeyemi, Oluwapelumi Olufemi; Stonehouse, Nicola J.] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Garstang Bldg, Leeds, W Yorkshire, England; [Adeyemi, Oluwapelumi Olufemi; Stonehouse, Nicola J.] Univ Leeds, Fac Biol Sci, Astbury Ctr Struct Mol Biol, Garstang Bldg, Leeds, W Yorkshire, England; [Alabi, Ade Stephen] Univ Ilorin, Coll Hlth Sci, Fac Basic Med Sci, Dept Anat, Ilorin, Nigeria; [Adeyemi, Oluwasanmi Anuoluwapo] Ajayi Crowther Univ, Fac Life Sci, Dept Microbiol, Oyo, Nigeria; [Talabi, Olaoluwa Temitope] Univ Lagos, Coll Med, Fac Basic Med Sci, Dept Biochem, Lagos, Nigeria; [Abidakun, Oreoluwa M.; Joel, Ireoluwa Yinka] Univ Ilorin, Cent Res Lab, Ilorin, Nigeria	University of Ilorin; University of Leeds; University of Leeds; University of Ilorin; University of Lagos; University of Ilorin	Adeyemi, OO (corresponding author), Univ Ilorin, Coll Hlth Sci, Fac Basic Clin Sci, Dept Med Microbiol & Parasitol, Ilorin, Nigeria.; Adeyemi, OO; Stonehouse, NJ (corresponding author), Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Garstang Bldg, Leeds, W Yorkshire, England.; Adeyemi, OO; Stonehouse, NJ (corresponding author), Univ Leeds, Fac Biol Sci, Astbury Ctr Struct Mol Biol, Garstang Bldg, Leeds, W Yorkshire, England.	adeyemi.oo@unilorin.edu.ng; n.j.stonehouse@leeds.ac.uk	Adeyemi, Oluwapelumi Olufemi/W-4095-2018; Adeyemi, Oluwasanmi/ACI-9024-2022	Adeyemi, Oluwapelumi Olufemi/0000-0002-0848-5917; Daniel, Oreoluwa/0000-0003-2439-5142; Joel, Ireoluwa/0000-0002-7160-8270; Talabi, Ola.T/0000-0003-0741-5770	Global Challenge Research Fund, UK (QR allocation to University of Leeds)	Global Challenge Research Fund, UK (QR allocation to University of Leeds)	This work was supported by funding from the Global Challenge Research Fund, UK (QR allocation to University of Leeds) allocated to NJS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aba Patrick Emeka, 2015, J Complement Integr Med, V12, P301, DOI 10.1515/jcim-2014-0033; Abdullahi AL, 2001, PHYTOTHER RES, V15, P431, DOI 10.1002/ptr.860; Adeyemi O O, 2012, Nig Q J Hosp Med, V22, P29; Akindele Abidemi James, 2015, J Tradit Complement Med, V5, P35, DOI 10.1016/j.jtcme.2014.05.001; Atanda JA, 1996, YORUBA HIST CULT LAN, V7; Ayisi NK, 2003, ANTIVIR RES, V58, P25, DOI 10.1016/S0166-3542(02)00166-3; Badam Lalita, 1999, Journal of Communicable Diseases, V31, P79; Bakare RI, 2011, J PHARMACOGN PHYTHER, V3, P1; Bamisaye F. A., 2018, Fountain Journal of Natural and Applied Sciences, V7, P20; Bedu OO, 2015, S AM J CLIN RES, V2; Brinkhoff T, 2016, CITY POPULATION; Ciapponi A, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011083.pub2; Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564, DOI 10.1128/CMR.12.4.564; Cudmore SL, 2004, CLIN MICROBIOL REV, V17, P783, DOI 10.1128/CMR.17.4.783-793.2004; Cupp MJ, 1999, AM FAM PHYSICIAN, V59, P1239; Davies J, 2010, MICROBIOL MOL BIOL R, V74, P417, DOI 10.1128/MMBR.00016-10; Dharmalingam SR, 2014, AFR J TRADIT COMPLEM, V11, P292, DOI 10.4314/ajtcam.v11i2.11; Dyar OJ, 2016, EXPERT REV ANTI-INFE, V14, P403, DOI 10.1586/14787210.2016.1151353; Efurosibina A., 1994, MULTILINGUA J CROSS, V13, P253, DOI [10.1515/mult.1994.13.3.253, DOI 10.1515/MULT.1994.13.3.253]; Ekor M, 2014, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00177; Elfil M, 2017, EMERGENCY, V5; Elliott EJ, 2007, BMJ-BRIT MED J, V334, P35, DOI 10.1136/bmj.39036.406169.80; Fair RJ, 2014, PERSPECT MED CHEM, V6, P25, DOI 10.4137/PMC.S14459; Fletcher SM, 2011, J PUBLIC HEALTH AFR, V2, P127, DOI 10.4081/jphia.2011.e30; Francino MP, 2016, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01543; Harrison RD, 2005, BIOSCIENCE, V55, P1053, DOI 10.1641/0006-3568(2005)055[1053:FATDOT]2.0.CO;2; HOGERZEIL HV, 1993, LANCET, V342, P1408, DOI 10.1016/0140-6736(93)92760-Q; Hunegnaw Z., 2016, DISCOV PHYTOMEDICINE, V3, P22, DOI [10.15562/phytomedicine.2016.36, DOI 10.15562/PHYTOMEDICINE.2016.36]; Izzo AA, 2012, MED PRIN PRACT, V21, P404, DOI 10.1159/000334488; Jagai JS, 2012, INT J ENV RES PUB HE, V9, P1771, DOI 10.3390/ijerph9051771; Kundra TS, 2015, J CLIN DIAGN RES, V9, pUD1, DOI 10.7860/JCDR/2015/15503.6274; Kwara State Government, 2020, STAT HARM; Leekha S, 2011, MAYO CLIN PROC, V86, P156, DOI 10.4065/mcp.2010.0639; Li N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01551; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Mathew S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37162-w; Mosisa Gudeta Biruk, 2020, J Exp Pharmacol, V12, P455, DOI 10.2147/JEP.S282669; Motayo BO, 2018, J PATHOG, V2018, DOI 10.1155/2018/6513682; Negi PS, 2001, EUR FOOD RES TECHNOL, V213, P484, DOI 10.1007/s002170100394; Nnamdi OD, 2018, INT INVENT SCI J, V2; Offiah VN, 1999, J ETHNOPHARMACOL, V68, P327, DOI 10.1016/S0378-8741(99)00100-2; Oreagba IA, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-117; Owolabi OJ, 2013, NIGER J PHARM SCI, V12; Panigrahi A, EXTRACT AZADIRACHTA; Parida MM, 2002, J ETHNOPHARMACOL, V79, P273, DOI 10.1016/S0378-8741(01)00395-6; Patel MM, 2008, EMERG INFECT DIS, V14, P1224, DOI 10.3201/eid1408.071114; Sharma Sharad, 2011, International Journal of Research in Ayurveda and Pharmacy (IJRAP), V2, P103; Smith A, 2018, BRIT DENT J, V224, DOI 10.1038/sj.bdj.2018.221; Sofowora A, 1996, J Altern Complement Med, V2, P365, DOI 10.1089/acm.1996.2.365; STRANZ MH, 1981, DRUG INTEL CLIN PHAR, V15, P838; Thielman NM, 2004, NEW ENGL J MED, V350, P38, DOI 10.1056/NEJMcp031534; UPTON GJG, 1992, J ROY STAT SOC A STA, V155, P395, DOI 10.2307/2982890; Verhoef J, 2003, ADV EXP MED BIOL, V531, P301; Wachtel-Galor S., 2011, HERBAL MED BIOMOLECU, P1, DOI DOI 10.1201/B10787; WHO WHO, 1976, AFRICAN TRADITIONAL, V1, P8; Yakubu MT, 2015, J ETHNOPHARMACOL, V163, P135, DOI 10.1016/j.jep.2014.12.060	56	2	2	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	10							e0257837	10.1371/journal.pone.0257837	http://dx.doi.org/10.1371/journal.pone.0257837			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB1WH	34607333	Green Published, gold			2023-01-03	WOS:000703369200007
J	Huberty, J; Puzia, ME; Larkey, L; Vranceanu, AM; Irwin, MR; Useche, SA; Useche, SA; Useche, SA				Huberty, Jennifer; Puzia, Megan E.; Larkey, Linda; Vranceanu, Ana-Maria; Irwin, Michael R.; Useche, Sergio A.; Useche, Sergio A.; Useche, Sergio A.			Can a meditation app help my sleep? A cross-sectional survey of Calm users	PLOS ONE			English	Article							QUALITY INDEX; OLDER-ADULTS; RISK-FACTORS; MINDFULNESS; INSOMNIA; HEALTH; EPIDEMIOLOGY; PREVALENCE; MECHANISMS	Use of mindfulness mobile apps has become popular, however, there is little information about subscribers' perceptions of app content and its impact on sleep and mental health. The purpose of this study was to survey subscribers to Calm, a popular mindfulness meditation app, to explore perceived improvements in sleep and mental health, evaluate what components of the app were associated with improvements in sleep and mental health, and determine whether improvements differed based on sleep quality. Calm subscribers who had used a sleep-related component in the last 90 days completed a Web-based investigator-developed survey and the Pittsburgh Sleep Quality Index. The survey included questions about using Calm for sleep, sleep disturbances, mental health diagnoses (i.e., anxiety, depression, PTSD) and perceived impacts of the app. Participants reported on the extent to which they felt that using Calm had improved their sleep and mental health. Most participants reported sleep disturbance, and almost half reported a mental health diagnosis. The majority of participants reported that using Calm helped them fall asleep, stay asleep, and get restful sleep. All sleep components were associated with perceived improvements in sleep disturbance. Severity of sleep disturbance moderated relationships between using Calm components and reporting improved sleep. Among subscribers with mental health diagnoses, most reported that Calm helped improve symptoms. Perceived improvement in anxiety and depression was associated with using Calm's meditation components but not Sleep Stories or music/soundscapes. Severity of sleep disturbance did not moderate relationships between using Calm components and reporting mental health improvements. Given the accessibility of app-based meditation, research is needed to evaluate the efficacy of meditation apps to improve sleep disturbance. While some sleep content may be helpful for sleep, more research is needed to test what specific content affects mental health.	[Huberty, Jennifer] Arizona State Univ, Coll Hlth Solut, Phoenix, AZ 85004 USA; [Puzia, Megan E.] Behav Res & Analyt LLC, Salt Lake City, UT USA; [Larkey, Linda] Arizona State Univ, Edson Coll Nursing & Hlth Innovat, Ctr Hlth Promot & Dis Prevent, Phoenix, AZ USA; [Vranceanu, Ana-Maria] Harvard Med Sch, Dept Psychiat, Integrated Brain Hlth Clin & Res Program, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Irwin, Michael R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci,Jane & Terry Semel I, Cousins Ctr Psychoneuroimmunol,Mindful Awareness, Los Angeles, CA 90095 USA	Arizona State University; Arizona State University-Downtown Phoenix; Arizona State University; Arizona State University-Downtown Phoenix; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Huberty, J (corresponding author), Arizona State Univ, Coll Hlth Solut, Phoenix, AZ 85004 USA.	JHuberty@asu.edu	Useche, Sergio A./O-7552-2014; Irwin, Michael/H-4870-2013	Useche, Sergio A./0000-0002-5099-4627; Irwin, Michael/0000-0002-1502-8431				Anderson KN, 2013, NAT SCI SLEEP, V5, P61, DOI 10.2147/NSS.S34842; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Bennett-Levy J., 2010, OXFORD GUIDE LOW INT, P3, DOI DOI 10.1093/MED:PSYCH/9780199590117.003.0001; Black DS, 2015, JAMA INTERN MED, V175, P494, DOI 10.1001/jamainternmed.2014.8081; Bower P, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f540; Britton WB, 2014, ANN NY ACAD SCI, V1307, P64, DOI 10.1111/nyas.12279; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chattu VK, 2018, HEALTHCARE-BASEL, V7, DOI 10.3390/healthcare7010001; Cole JC, 2006, SLEEP, V29, P112, DOI 10.1093/sleep/29.1.112; Cormier RE, 1990, NEUROPSYCHIATRIC COG, V3rd edition, P192; Espie CA, 2002, ANNU REV PSYCHOL, V53, P215, DOI 10.1146/annurev.psych.53.100901.135243; Espie CA, 2009, SLEEP, V32, P1549, DOI 10.1093/sleep/32.12.1549; Flett JAM, 2019, MINDFULNESS, V10, P863, DOI 10.1007/s12671-018-1050-9; Gagne A., 2001, J CLIN GEROPSYCHOLOG, V7, P131, DOI DOI 10.1023/A:1009537722740; Garland EL, 2016, ANN NY ACAD SCI, V1373, P25, DOI 10.1111/nyas.13034; Greeson JM, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/4505191; Harvard Medical School, 2007, DAT TABL 1 LIF PREV; Hayashino Y, 2010, SLEEP MED, V11, P366, DOI 10.1016/j.sleep.2009.05.021; Howells A, 2016, J HAPPINESS STUD, V17, P163, DOI 10.1007/s10902-014-9589-1; Huberty J., 2020, JMIR FORM RES, V3; Huberty J, 2020, JMIR FORM RES, V4, DOI 10.2196/19508; Huberty J, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/15648; Irwin MR, 2015, ANNU REV PSYCHOL, V66, P143, DOI 10.1146/annurev-psych-010213-115205; Irwin MR, 2006, HEALTH PSYCHOL, V25, P3, DOI 10.1037/0278-6133.25.1.3; Jean-Louis G., 2006, SLEEP DISORD, V202, P19; Kabat-Zinn J., 2013, FULL CATASTROPHE LIV; Lau WKW, 2018, MINDFULNESS, V9, P547, DOI 10.1007/s12671-017-0796-9; Liu Y, 2016, MMWR-MORBID MORTAL W, V65, P137, DOI 10.15585/mmwr.mm6506a1; McCallum SM, 2019, J PSYCHOSOM RES, V123, DOI 10.1016/j.jpsychores.2019.05.005; Morin CM, 2013, SLEEP MED CLIN, V8, P281, DOI 10.1016/j.jsmc.2013.05.002; Ong Jason C, 2017, Curr Sleep Med Rep, V3, P57, DOI 10.1007/s40675-017-0068-1; Parry DA, 2021, NAT HUM BEHAV, V5, P1535, DOI 10.1038/s41562-021-01117-5; Perlis ML, 2008, J CLIN SLEEP MED, V4, P11; Rusch HL, 2019, ANN NY ACAD SCI, V1445, P5, DOI 10.1111/nyas.13996; Shallcross AJ, 2019, CURR OPIN PSYCHOL, V28, P37, DOI 10.1016/j.copsyc.2018.10.005; Sharma A, 2014, J THEOR BIOL, V357, P143, DOI 10.1016/j.jtbi.2014.05.019; Singareddy R, 2012, SLEEP MED, V13, P346, DOI 10.1016/j.sleep.2011.10.033; Vieten C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205740; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013	39	2	2	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	10							e0257518	10.1371/journal.pone.0257518	http://dx.doi.org/10.1371/journal.pone.0257518			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XT1ZB	34679078	gold, Green Published			2023-01-03	WOS:000733392900007
J	Park, H; Byun, JM; Yoon, SS; Koh, Y; Yoon, SW; Shin, DY; Hong, J; Kim, I				Park, Hyunkyung; Byun, Ja Min; Yoon, Sung-Soo; Koh, Youngil; Yoon, Sock-Won; Shin, Dong-Yeop; Hong, Junshik; Kim, Inho			Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM	PLOS ONE			English	Article							LOW-DOSE DEXAMETHASONE; REFRACTORY MULTIPLE-MYELOMA; RENAL IMPAIRMENT; POMALIDOMIDE; LENALIDOMIDE	In the backdrop of rapidly changing relapsed/refractory (RR) multiple myeloma (MM) treatment schema that mainly evolves around immunotherapies, it is easy to disregard more traditional drugs. Finding the best partner for pomalidomide, a potent third-generation immunomodulatory drug, is an important agenda we face as a community and cyclophosphamide addition has been used for outcomes augmentation. We carried out this real-world study to identify patients who will show durable response to pomalidomide and those who will benefit from cyclophosphamide addition. A total of 103 patients (57 in pomalidomide-dexamethasone [Pd] group versus 46 in pomalidomide-cyclophosphamide-dexamethasone [PCd]) were studied. They were previously treated with bortezomib (98.1%) or lenalidomide (100%) and previous lines of therapy were median 3 lines. Significantly better overall response rate (ORR) was seen in the PCd (75.6%) than Pd (41.7%) group (p = 0.001), but no differences in survival outcomes. Subgroup analysis revealed that high-risk myeloma features, poor response to lenalidomide or bortezomib had superior ORRs when cyclophosphamide was added. Also, long-term responders for pomalidomide were associated with excellent response to previous IMiD treatments. Pomalidomide-based therapy was discontinued in five patients due to intolerance or adverse events, but there was no mortality during treatment. In conclusion, we showed that pomalidomide-based treatment is still relevant and can ensure durable response in RRMM setting, especially for patients who responded well to previous lenalidomide. Addition of cyclophosphamide to Pd is associated with better ORR, and can be positively considered in fit patients with high-risk MM, extramedullary disease, and less-than-satisfactory response to previous lenalidomide treatment.	[Park, Hyunkyung] Seoul Natl Univ, Dept Internal Med, Boramae Med Ctr, Seoul, South Korea; [Byun, Ja Min; Yoon, Sung-Soo; Koh, Youngil; Yoon, Sock-Won; Shin, Dong-Yeop; Hong, Junshik; Kim, Inho] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea; [Byun, Ja Min; Yoon, Sung-Soo; Koh, Youngil; Shin, Dong-Yeop; Hong, Junshik] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea; [Yoon, Sung-Soo; Hong, Junshik] Seoul Natl Univ Hosp, Ctr Med Innovat, Biomed Res Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Yoon, SS; Koh, Y (corresponding author), Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea.; Yoon, SS; Koh, Y (corresponding author), Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea.; Yoon, SS (corresponding author), Seoul Natl Univ Hosp, Ctr Med Innovat, Biomed Res Inst, Seoul, South Korea.	ssysmc@snu.ac.kr; go01@snu.ac.kr		Byun, Ja Min/0000-0003-1780-5553; Yoon, Sung-Soo/0000-0003-2591-7459	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI14C1277]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This study was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C1277).	Baz RC, 2016, BLOOD, V127, P2561, DOI 10.1182/blood-2015-11-682518; Chanan-Khan AA, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.38; Dimopoulos M, 2018, J CLIN ONCOL, V36, P2035, DOI 10.1200/JCO.2017.76.1742; Dimopoulos MA, 2021, HEMASPHERE, V5, DOI 10.1097/HS9.0000000000000528; Dimopoulos MA, 2016, BLOOD, V128, P497, DOI 10.1182/blood-2016-02-700872; Garderet L, 2018, BLOOD, V132, P2555, DOI 10.1182/blood-2018-07-863829; Kastritis E, 2019, BLOOD ADV, V3, P4095, DOI 10.1182/bloodadvances.2019000539; Kim DS, 2010, SOC WORK PUBLIC HLTH, V25, P127, DOI 10.1080/19371910903070333; Lakshman A, 2018, AM J HEMATOL, V93, P179, DOI 10.1002/ajh.24954; Lonial S, 2016, LEUKEMIA, V30, P526, DOI 10.1038/leu.2015.223; Lonial S, 2015, BLOOD, V126, P1536, DOI 10.1182/blood-2015-06-653261; Lu J, 2017, BRIT J HAEMATOL, V176, P743, DOI 10.1111/bjh.14465; Maciocia N, 2017, BRIT J HAEMATOL, V176, P908, DOI 10.1111/bjh.14547; Mikkilineni L, 2021, NAT REV CLIN ONCOL, V18, P71, DOI 10.1038/s41571-020-0427-6; Moreau P, 2017, ANN ONCOL, V28, P52, DOI 10.1093/annonc/mdx096; Network NCC, 2021, ANTIEMESIS; O'Donnell PH, 2009, CLIN CANCER RES, V15, P4806, DOI 10.1158/1078-0432.CCR-09-0344; Park S, 2014, ANN HEMATOL, V93, P99, DOI 10.1007/s00277-013-1952-5; Pinto V, 2020, CANCERS, V12, DOI 10.3390/cancers12020407; Quach H, 2010, LEUKEMIA, V24, P22, DOI 10.1038/leu.2009.236; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; Miguel JS, 2013, LANCET ONCOL, V14, P1055, DOI 10.1016/S1470-2045(13)70380-2; Shah N, 2020, LEUKEMIA, V34, P985, DOI 10.1038/s41375-020-0734-z; Soekojo CY, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0245-1; Trudel S, 2019, ANN HEMATOL, V98, P1441, DOI 10.1007/s00277-019-03649-3; Yu B, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00962-7	26	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0260113	10.1371/journal.pone.0260113	http://dx.doi.org/10.1371/journal.pone.0260113			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085238	Green Published, gold			2023-01-03	WOS:000779379600011
J	Tomasi, E; de Assis, TM; Muller, PG; da Silveira, DS; Neves, RG; Fantinel, E; Thume, E; Facchini, LA				Tomasi, Elaine; de Assis, Thales Moura; Muller, Paulo Guilherme; da Silveira, Denise Silva; Neves, Rosalia Garcia; Fantinel, Everton; Thume, Elaine; Facchini, Luiz Augusto			Evolution of the quality of prenatal care in the primary network of Brazil from 2012 to 2018: What can (and should) improve?	PLOS ONE			English	Article							HEALTH; PROGRAM; POVERTY	The article describes the temporal evolution of prenatal quality indicators in the primary health care network in Brazil and investigates regional differences. This study used data from the external evaluation of Brazil's National Program for Improving Primary Care Access and Quality (PMAQ) with health teams participating in Cycles I, II and III of the Program, carried out respectively in 2012, 2013/14 and 2017/18. The number of visits, physical examination procedures, guidelines and request for laboratory tests were investigated. There was a positive evolution for tests-HIV, syphilis, blood glucose and ultrasound, and for all tests, guidance on feeding and weight gain of the baby and examination of the oral cavity. The indicators that performed the worst were: performance of tetanus vaccine, six or more visits, receiving guidance on exclusive breastfeeding and care for the newborn, and the procedures-all, measurement of uterine height, gynecological exam and cervix cancer prevention. These changes had a varied behavior between the regions of the country.	[Tomasi, Elaine; da Silveira, Denise Silva; Fantinel, Everton; Facchini, Luiz Augusto] Univ Fed Pelotas, Dept Social Med, Pelotas, RS, Brazil; [Tomasi, Elaine; Facchini, Luiz Augusto] Univ Fed Pelotas, Postgrad Programme Epidemiol, Pelotas, RS, Brazil; [Tomasi, Elaine; da Silveira, Denise Silva; Thume, Elaine; Facchini, Luiz Augusto] Univ Fed Pelotas, Postgrad Programme Family Hlth PROFSAUDE, Pelotas, RS, Brazil; [de Assis, Thales Moura; Muller, Paulo Guilherme] Univ Fed Pelotas, Fac Med, Pelotas, RS, Brazil; [Neves, Rosalia Garcia] State Dept Hlth, Porto Alegre, RS, Brazil; [Fantinel, Everton; Thume, Elaine; Facchini, Luiz Augusto] Univ Fed Pelotas, Postgrad Programme Nursing, Pelotas, RS, Brazil	Universidade Federal de Pelotas; Universidade Federal de Pelotas; Universidade Federal de Pelotas; Universidade Federal de Pelotas; Universidade Federal de Pelotas	Tomasi, E (corresponding author), Univ Fed Pelotas, Dept Social Med, Pelotas, RS, Brazil.; Tomasi, E (corresponding author), Univ Fed Pelotas, Postgrad Programme Epidemiol, Pelotas, RS, Brazil.; Tomasi, E (corresponding author), Univ Fed Pelotas, Postgrad Programme Family Hlth PROFSAUDE, Pelotas, RS, Brazil.	tomasiet@gmail.com	Thume, Elaine/A-8252-2011	Thume, Elaine/0000-0002-1169-8884	Ministry of Health [2013/2014, 2017/2018]	Ministry of Health	The data from this study were produced within the scope of an external evaluation process of the Program for Improving Access and Quality of Primary Care (PMAQ-AB). This program was fully funded by the Ministry of Health, which transferred resources to several federal universities for them to conduct fieldwork in 2012, 2013/2014 and 2017/2018. Resources were decentralized to Universities and managed by supporting foundations. In our case, the Federal University of Pelotas and the Delfim Mendes da Silveira Foundation (FDMS) and the University Support Foundation (FAU). The resources were mainly applied in tickets and daily rates for interviewers, acquisition of tablets and accessories, and research grants. Research grants were not a salary, they were a temporary incentive for researchers to dedicate themselves to the project's activities. Data are available in open access to the entire population. Our research group -and others across the country -has been producing several scientific articles, published in Brazil and abroad, since 2013. In total, the amount transferred to our institution, responsible for 20% of data collection throughout Brazil, was $3,386,415.The Ministry of Health only guided the development and standardization of data collection instruments, so that the information collected by the universities could also be used in the teams' certification process. This certification defined the values of transfers to municipalities. Funders did not participate in data analysis, decision to publish or preparation of the manuscript.	Araujo CD, 2017, INTERFACE-BOTUCATU, V21, P1217, DOI 10.1590/1807-57622016.0607; Barcelos MRB, 2017, REV SAUDE PUBL, V51, DOI [10.1590/s1518-8787.2017051006802, 10.1590/S1518-8787.2017051006802]; Bonin JE., 2011, REV APS, V14; Brasil, 2012, MAN GEST PROGR ESC T; BRASIL, 2019, PRES REP GAB SEG I P; Brasil. Constituicao 1988, 1988, CONSTITUICAO REPUBLI; Brasil. Ministerio da Saude, 2017, PORTARIA N 2436 21 S, V183, P67; Brasil. Ministerio da Saude, 2012, CADERNOS ATENCAO BAS, P318; Brasil. Ministerio da Saude. Secretaria de Atencao Primaria (SAPS). Programa Nacional de Melhoria do Acesso e da Qualidade-PMAQ, 2021, INF 3 CICL PROGR NAC; Caccia Bava MCG, 2020, ATENCAO BASICA CAMIN, P125; Cesare N, 2020, INT J INFECT DIS, V98, P275, DOI 10.1016/j.ijid.2020.06.092; Conill Eleonor Minho, 2004, Cad. Saúde Pública, V20, P1417, DOI 10.1590/S0102-311X2004000500038; Cruz RdSBLC., 2014, REV BRAS CIENC SAUDE, P87; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Duarte G, 2008, REV BRAS GINECOL OBS, V30, P93, DOI 10.1590/S0100-72032008000200008; Facchini L, 2020, ATENCAO BASICA CAMIN, P486; Facchini Luiz Augusto, 2018, Saúde debate, V42, P208, DOI 10.1590/0103-11042018s114; Fischmann A., 2000, DOENCAS INFECCIOSAS, V2, DOI [10.1007/s004010000180, DOI 10.1007/S004010000180]; Fonseca SC, 2014, CIENC SAUDE COLETIVA, V19, P1991, DOI 10.1590/1413-81232014197.04212013; Giovanella L, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311x00029818, 10.1590/0102-311X00029818]; Guimaraes WSG, 2018, CAD SAUDE PUBLICA, V34, DOI 10.1590/0102-311X00110417; Gostin LO, 2020, LANCET INFECT DIS, V20, pE11, DOI 10.1016/S1473-3099(19)30558-4; Guanais F, 2009, J AMBUL CARE MANAG, V32, P115, DOI 10.1097/JAC.0b013e31819942e51; Iinstituto Brasileiro de Geografia e Estatistica, 2020, PESQ NAC SAUD 2019 I, P85; Instituto Brasileiro de Geografia e Estatistica, 2020, CONH BRAS POP RAC PN; Instituto Brasileiro de Geografia e Estatistica (IBGE), 2020, COORD TRAB REND PESQ; Leal MD, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00078816, 10.1590/0102-311x00078816]; Luz Leandro Alves da, 2018, Saúde debate, V42, P111, DOI 10.1590/0103-11042018s208; Macinko J, 2017, J AMBUL CARE MANAG, V40, pS4, DOI 10.1097/JAC.0000000000000189; Martinelli KG, 2014, REV BRAS GINECOL OBS, V36, P56, DOI 10.1590/S0100-72032014000200003; Massuda A, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000829; Melo EAA P.F., 2019, SAUDE DEBATE, V43, P137; Miranda FFS., 2019, CADERNOS MEDICINA UN, V2; Morosini Márcia Valéria, 2018, Saúde debate, V42, P261, DOI 10.1590/0103-11042018s117; Neves RG, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.5123/s1679-49742020000100008, 10.5123/S1679-49742020000100008]; Organizacao Das Nacoes Unidas, 2015, TRANSF NOSS MUND AG; Pacheco FC, 2019, VACCINE, V37, P2651, DOI 10.1016/j.vaccine.2019.04.019; Paim JS., 2010, B INSTITUTO SA DE, V12, P109; Ferrari RAP, 2014, REV BRAS ENFERM, V67, P354, DOI 10.5935/0034-7167.20140046; Pinheiro FJ, 2020, OBSERVATORIO DESIGUA; Rodrigues NCP, 2016, J PEDIAT-BRAZIL, V92, P567, DOI 10.1016/j.jped.2016.03.004; PINTO H. A., 2014, REV DIVULGACAO SAUDE, V51, P105; Pitombeira DF, 2020, CIENC SAUDE COLETIVA, V25, P1699, DOI 10.1590/1413-81232020255.33972019; Prudencio PS., 2018, REV GAUCH ENFERM, P39; Rasella D, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002570; Rezende J, 2014, REZENDE OBSTETRICIA, V13; Varela PLR, 2017, REV LAT-AM ENFERM, V25, DOI 10.1590/1518-8345.2156.2949; Sato APS, 2018, REV SAUDE PUBL, V52, DOI [10.11606/s1518-8787.2018052001199, 10.11606/S1518-8787.2018052001199]; Silveira MF, 2020, VACCINE, V38, P482, DOI 10.1016/j.vaccine.2019.10.070; STARFIELD B, 1992, B NEW YORK ACAD MED, V68, P17; Tomasi E, 2017, CAD SAUDE PUBLICA, V33, DOI 10.1590/0102-311X00195815; Molina RT, 2019, REV MED CHILE, V147, P190, DOI 10.4067/s0034-98872019000200190; Tuncalp O, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003375; Victora CG, 2011, LANCET, V377, P1863, DOI 10.1016/S0140-6736(11)60138-4; Vieira FS., 2016, I PESQUI EC APL, V4, P9; Santos LAV, 2018, CIENC SAUDE COLETIVA, V23, P617, DOI 10.1590/1413-81232018232.10962016; Viellas EF, 2014, CAD SAUDE PUBLICA, V30, DOI 10.1590/0102-311X00126013	57	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2022	17	1							e0262217	10.1371/journal.pone.0262217	http://dx.doi.org/10.1371/journal.pone.0262217			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2G1LZ	35041716	gold, Green Published			2023-01-03	WOS:000813361200027
J	Adedini, SA; Abatan, SM; Ogunsakin, AD; Alex-Ojei, CA; Babalola, BI; Shittu, SB; Odusina, EK; Ntoimo, LFC				Adedini, Sunday A.; Abatan, Sunday Matthew; Ogunsakin, Adesoji Dunsin; Alex-Ojei, Christiana Alake; Babalola, Blessing Iretioluwa; Shittu, Sarafa Babatunde; Odusina, Emmanuel Kolawole; Ntoimo, Lorretta Favour C.			Comparing the timeliness and adequacy of antenatal care uptake between women who married as child brides and adult brides in 20 sub-Saharan African countries	PLOS ONE			English	Article							TEENAGE PREGNANCY; FAMILY-STRUCTURE; HEALTH; MORTALITY; DETERMINANTS; INFANT; ASSOCIATION; SERVICES; CONTEXT	Context Considering the persistent poor maternal and child health outcomes in sub-Saharan Africa (SSA), this study undertook a comparative analysis of the timing and adequacy of antenatal care uptake between women (aged 20-24 years) who married before age 18 and those who married at age 18 or above. Method Data came from Demographic and Health Surveys of 20 SSA countries. We performed binary logistic regression analysis on pooled data of women aged 20-24 (n = 33,630). Results Overall, the percentage of child brides in selected countries was 57.1%, with the lowest prevalence found in Rwanda (19.1%) and the highest rate in Chad (80.9%). Central and West African countries had the highest prevalence of child marriage compared to other sub-regions. Bivariate results indicate that a lower proportion of child brides (50.0%) had 4+ ANC visits compared to the adult brides (60.9%) and a lower percentage of them (34.0%) initiated ANC visits early compared to the adult brides (37.5%). After controlling for country of residence and selected socio-economic and demographic characteristics, multivariable results established significantly lower odds of having an adequate/prescribed number of ANC visits among women who married before age 15 (OR: 0.63, CI: 0.57-0.67, p<0.001), and women who married at ages 15-17 (OR: 0.81, CI: 0.75-0.84, p<0.001) compared to those who married at age 18+. Similar results were established between age at first marriage and timing of first ANC visit. Other interesting results emerged that young women who married earlier than age 18 and those who married at age 18+ differ significantly by several socio-economic and demographic characteristics. Conclusion Efforts to improve maternal and child health outcomes in SSA must give attention to address the underutilization and late start of antenatal care uptake among child brides.	[Adedini, Sunday A.; Abatan, Sunday Matthew; Ogunsakin, Adesoji Dunsin; Alex-Ojei, Christiana Alake; Babalola, Blessing Iretioluwa; Shittu, Sarafa Babatunde; Odusina, Emmanuel Kolawole; Ntoimo, Lorretta Favour C.] Fed Univ Oye Ekiti, Demog & Social Stat Dept, Fac Social Sci, Oye Ekiti, Nigeria; [Adedini, Sunday A.] Univ Witwatersrand, Sch Publ Hlth, Programme Demog & Populat Studies, Johannesburg, South Africa; [Adedini, Sunday A.] Univ Witwatersrand, Schools Social Sci, Programme Demog & Populat Studies, Johannesburg, South Africa	University of Witwatersrand; University of Witwatersrand	Adedini, SA (corresponding author), Fed Univ Oye Ekiti, Demog & Social Stat Dept, Fac Social Sci, Oye Ekiti, Nigeria.; Adedini, SA (corresponding author), Univ Witwatersrand, Sch Publ Hlth, Programme Demog & Populat Studies, Johannesburg, South Africa.; Adedini, SA (corresponding author), Univ Witwatersrand, Schools Social Sci, Programme Demog & Populat Studies, Johannesburg, South Africa.	sunday.adedini@fuoye.edu.ng	Adedini, Sunday/GZM-8362-2022; Adedini, Sunday/AAM-6790-2021	Adedini, Sunday/0000-0003-0378-1941				Adedini, 2016, MATERNAL HLTH NIGERI; Adedini SA., 2014, GENDER BEHAV, V12, P6050; Adedini SA, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.23499; Adedini SA, 2015, J BIOSOC SCI, V47, P165, DOI 10.1017/S0021932013000734; Adhikari R., 2018, J HLTH PROMOTION, V6, P49; Akinyemi JO, 2016, TROP MED INT HEALTH, V21, P1572, DOI 10.1111/tmi.12779; Al-Eisawi Z, 2021, PUBLIC UNDERST SCI, V30, P319, DOI 10.1177/0963662520968468; Alex-Ojei CA, 2020, MIDWIFERY, V82, DOI 10.1016/j.midw.2019.102619; [Anonymous], 2019, TRENDS MATERNAL MORT; Awasthi MS, 2018, J PREGNANCY, V2018, DOI 10.1155/2018/3467308; Ayoade MA., 2020, GEOJOURNAL, P1; Babalola S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-43; Banke-Thomas OE, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1246-3; Bwana VM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214807; Chung HW, 2018, J ADOLESCENCE, V69, P180, DOI 10.1016/j.adolescence.2018.10.007; de Groot R, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5166-6; Delprato M, 2017, ANN GLOB HEALTH, V83, P557, DOI 10.1016/j.aogh.2017.10.005; Dey A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204810; Efendi F, 2017, WOMEN HEALTH, V57, P614, DOI 10.1080/03630242.2016.1181136; Godha D, 2013, J ADOLESCENT HEALTH, V52, P552, DOI 10.1016/j.jadohealth.2013.01.021; Jarnkvist K, 2019, MARRIAGE FAM REV, V55, P38, DOI 10.1080/01494929.2018.1458002; Kaphagawani NC, 2017, GLOB PUBLIC HEALTH, V12, P694, DOI 10.1080/17441692.2016.1229354; Kidman R, 2017, INT J EPIDEMIOL, V46, P662, DOI 10.1093/ije/dyw225; Koski A, 2017, POPUL DEV REV, V43, P7, DOI 10.1111/padr.12035; Mobolaji JW, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08714-5; Muldoon KA, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-42; Nour NM, 2006, EMERG INFECT DIS, V12, P1644, DOI 10.3201/eid1211.060510; Odimegwu C., 2014, GENDER BEHAV, V12, P5843; Odimegwu C, 2018, J PSYCHOL AFR, V28, P479, DOI 10.1080/14330237.2018.1544390; Okedo-Alex IN, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031890; Omariba DWR, 2007, POPUL RES POLICY REV, V26, P299, DOI 10.1007/s11113-007-9031-z; Omariba DWR, 2007, J MARRIAGE FAM, V69, P528, DOI 10.1111/j.1741-3737.2007.00381.x; Raj A, 2010, ARCH DIS CHILD, V95, P931, DOI 10.1136/adc.2009.178707; Schaffnit SB, 2021, GLOB PUBLIC HEALTH, V16, P1820, DOI 10.1080/17441692.2020.1837911; Schaffnit SB, 2019, SEX REPROD HLTH MATT, V27, P93, DOI 10.1080/09688080.2019.1571304; Sekine K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222643; Shimamoto K, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1499-x; Shimamoto K, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0591-3; Singh P, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-03607-w; Spagnoletti BRM, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1991-y; Stanton K, 2013, WORLD J PREV MED, V1, P22; Tarekegn SM, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-161; Tekelab T., 2014, SCI TECHNOL ARTS RES, V3, P108, DOI [10.4314/star.v3i1.17, DOI 10.4314/STAR.V3I1.17]; Thapa DK, 2013, SOC SCI MED, V93, P1, DOI 10.1016/j.socscimed.2013.06.003; Trhas TB., 2020, ADV PUBLIC HLTH, V2020; Uthman OA, 2009, J TROP PEDIATRICS, V55, P109, DOI 10.1093/tropej/fmn093; Wahhaj Z., 2015, SCH EC DISCUSSION PA; Wall LL, 1998, STUD FAMILY PLANN, V29, P341, DOI 10.2307/172248; Westoff C. F., 2003, DHS COMP REPORT; WHO, CHILD MARR 39 000 EV; WHO, 2014, TRENDS MAT MORT 1990; Yaya S, 2019, BMC INT HEALTH HUM R, V19, DOI 10.1186/s12914-019-0219-1	52	1	1	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2022	17	1							e0262688	10.1371/journal.pone.0262688	http://dx.doi.org/10.1371/journal.pone.0262688			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H0VF	35025949	gold, Green Published			2023-01-03	WOS:000796264200095
J	Kanguya, T; Koyuncu, A; Sharma, A; Kusanathan, T; Mubanga, M; Chi, BH; Vinikoor, MJ; Mubiana-Mbewe, M				Kanguya, Tukiya; Koyuncu, Aybueke; Sharma, Anjali; Kusanathan, Thankian; Mubanga, Martha; Chi, Benjamin H.; Vinikoor, Michael J.; Mubiana-Mbewe, Mwangelwa			Identifying barriers to ART initiation and adherence: An exploratory qualitative study on PMTCT in Zambia	PLOS ONE			English	Article							TO-CHILD TRANSMISSION; MALE INVOLVEMENT; ANTIRETROVIRAL THERAPY; HIV CARE; PREVENTION; PREGNANCY; WOMEN; RETENTION; PROGRAMS	Background Though antiretroviral therapy (ART) is widely available, HIV positive pregnant women in Zambia are less likely to start and remain on therapy throughout pregnancy and after delivery. This study sought to understand readiness to start ART among HIV pregnant women from the perspectives of both women and men in order to suggest more holistic programs to support women to continue life-long ART after delivery. Methods We conducted a qualitative study with HIV positive pregnant women before and after ART initiation, and men with female partners, to understand readiness to start lifelong ART. We conducted 28 in-depth interviews among women and 2 focus group discussions among male partners. Data were transcribed verbatim and analyzed in NVivo 12 using thematic analysis. Emerging themes from the data were organized using the social ecological framework. Results Men thought of their female partners as young and needing their supervision to initiate and stay on ART. Women agreed that disclosure and partner support were necessary preconditions to ART initiation and adherence and, expressed fear of divorce as a prominent barrier to disclosure. Maternal love and desire to look after one's children instilled a sense of responsibility among women which motivated them to overcome individual, interpersonal and health system level barriers to initiation and adherence. Women preferred adherence strategies that were discrete, the effectiveness of which, depended on women's intrinsic motivation. Conclusion The results support current policies in Zambia to encourage male engagement in ART care. To appeal to male partners, messaging on ART should be centered on emphasizing the importance of male involvement to ensure women remain engaged in ART care. Programs aimed at supporting postpartum ART adherence should design messages that appeal to both men's role in couples' joint decision-making and women's maternal love as motivators for adherence.	[Kanguya, Tukiya; Koyuncu, Aybueke; Sharma, Anjali; Mubanga, Martha; Mubiana-Mbewe, Mwangelwa] Ctr Infect Dis Res Zambia, Lusaka, Zambia; [Kusanathan, Thankian] Univ Zambia, Dept Gender Studies, Lusaka, Zambia; [Chi, Benjamin H.] Univ N Carolina, Chapel Hill, NC 27515 USA; [Vinikoor, Michael J.] Univ Alabama Birmingham, Birmingham, AL USA	University of Zambia; University of North Carolina; University of North Carolina Chapel Hill; University of Alabama System; University of Alabama Birmingham	Kanguya, T; Koyuncu, A (corresponding author), Ctr Infect Dis Res Zambia, Lusaka, Zambia.	Tukiya.Kanguya@cidrz.org; akoyuncu@berkeley.edu			President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Centers for Disease Control andPrevention (CDC) [U01GH000530]	President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Centers for Disease Control andPrevention (CDC)	This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR; https://www.state.gov/pepfar/) through the United States Centers for Disease Control andPrevention (CDC) under the terms of cooperative agreement number U01GH000530 (Funding recipient MMM). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggleton P., 2001, CURR SOCIOL, V49, P23, DOI [DOI 10.1177/0011392101496005, 10.1177/0011392101496005]; Auvinen J, 2010, PSYCHOL HEALTH MED, V15, P288, DOI 10.1080/13548501003615290; Buregyeya E, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1276-x; Chadambuka A, 2017, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-4611-2; Clouse K, 2014, JAIDS-J ACQ IMM DEF, V67, pE12, DOI 10.1097/QAI.0000000000000263; Elwell K, 2016, AIDS CARE, V28, P971, DOI 10.1080/09540121.2016.1153586; Fernandez MI, 2011, AIDS CARE, V23, P1492, DOI 10.1080/09540121.2011.565020; Gill MM, 2017, AIDS PATIENT CARE ST, V31, P153, DOI 10.1089/apc.2016.0234; Golden SD, 2012, HEALTH EDUC BEHAV, V39, P364, DOI 10.1177/1090198111418634; Hampanda K, 2021, SOC SCI MED, V283, DOI 10.1016/j.socscimed.2021.114029; Harvey SM, 2002, J SEX RES, V39, P284, DOI 10.1080/00224490209552152; Hershow RB, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25293; Hodgson I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111421; Hommann K., 2019, WHICH WAY LIVABLE PR, DOI [10.1596/978-1-4648-1405-1, DOI 10.1596/978-1-4648-1405-1]; Katirayi L, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20919; Kim MH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149527; Knettel BA, 2018, JAIDS-J ACQ IMM DEF, V77, P427, DOI 10.1097/QAI.0000000000001616; Krueger RA, 2009, FOCUS GROUPS PRACTIC; Kululanga LI, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-36; LeCompte M, 2010, DESIGNING CONDUCTING, V2nd; Loomba Foundation, 2015, GLOB WID REP 2015 GL; Lusaka (Province Zambia), POPULATION STAT CHAR; Masters SH, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002166; Millennium Development Goals United Nations General Assembly Special Session World Health Organization, 2010, PMTCT STRAT VIS 2010; Ministry of Health Zambia, 2019, ZAMB POP BAS HIV IMP; Morfaw Frederick, 2013, Syst Rev, V2, P5, DOI 10.1186/2046-4053-2-5; Mubiana-Mbewe M, 2021, AIDS BEHAV, V25, P992, DOI 10.1007/s10461-020-03060-4; Musheke M, 2013, AIDS PATIENT CARE ST, V27, P231, DOI 10.1089/apc.2012.0341; Naigino R, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0367-5; Nowell LS, 2017, INT J QUAL METH, V16, DOI 10.1177/1609406917733847; Orne-Gliemann J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-197; Patel RC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168057; Peacock D., 2008, MEN CARE CONTEXT HIV; Simuyemba MC, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-019-2700-1; Takah NF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207060; The Republic of Zambia Ministry of Health, ELIMINATION MOTHER T; The World Bank, 2018, 124032ZM WORLD BANK; Theuring S, 2009, AIDS BEHAV, V13, pS92, DOI 10.1007/s10461-009-9543-0; Vermeulen E, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0853-8	39	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2022	17	1							e0262392	10.1371/journal.pone.0262392	http://dx.doi.org/10.1371/journal.pone.0262392			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H0VF	35025923	Green Published, gold			2023-01-03	WOS:000796264200065
J	Venkatesh, AK; Janke, AT; Kinsman, J; Rothenberg, C; Goyal, P; Malicki, C; D'Onofrio, G; Taylor, A; Hawk, K				Venkatesh, Arjun K.; Janke, Alexander T.; Kinsman, Jeremy; Rothenberg, Craig; Goyal, Pawan; Malicki, Caitlin; D'Onofrio, Gail; Taylor, Andrew; Hawk, Kathryn			Emergency department utilization for substance use disorders and mental health conditions during COVID-19	PLOS ONE			English	Article							MEDICAL-SERVICES; UNITED-STATES; VISITS	Background As the emergency department (ED) has evolved into the de-facto site of care for a variety of substance use disorder (SUD) presentations, trends in ED utilization are an essential public health surveillance tool. Changes in ED visit patterns during the COVID-19 pandemic may reflect changes in access to outpatient treatment, changes in SUD incidence, or the unintended effects of public policy to mitigate COVID-19. We use a national emergency medicine registry to describe and characterize trends in ED visitation for SUDs since 2019. Methods We included all ED visits identified in a national emergency medicine clinical quality registry, which included 174 sites across 33 states with data from January 2019 through June 2021. We defined SUD using ED visit diagnosis codes including: opioid overdose and opioid use disorder (OUD), alcohol use disorders (AUD), and other SUD. To characterize changes in ED utilization, we plotted the 3-week moving average ratio of visit counts in 2020 and 2021 as compared to visit counts in 2019. Findings While overall ED visits declined in the early pandemic period and had not returned to 2019 baseline by June 2021, ED visit counts for SUD demonstrated smaller declines in March and April of 2020, so that the proportion of overall ED visits that were for SUD increased. Furthermore, in the second half of 2020, ED visits for SUD returned to baseline, and increased above baseline for OUD ever since May 2020. Conclusions We observe distinct patterns in ED visitation for SUDs over the course of the COVID-19 pandemic, particularly for OUD for which ED visitation barely declined and now exceeds previous baselines. These trends likely demonstrate the essential role of hospital-based EDs in providing 24/7/365 care for people with SUDs and mental health conditions. Allocation of resources must be directed towards the ED as a de-facto safety net for populations in crisis.	[Venkatesh, Arjun K.; Janke, Alexander T.; Kinsman, Jeremy; Rothenberg, Craig; Malicki, Caitlin; D'Onofrio, Gail; Taylor, Andrew; Hawk, Kathryn] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT 06510 USA; [Venkatesh, Arjun K.] Yale Univ, Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT 06510 USA; [Goyal, Pawan] Amer Coll Emergency Phys, Irving, TX USA; [Hawk, Kathryn] Yale Sch Publ Hlth, New Haven, CT USA	Yale University; Yale University; Yale University	Venkatesh, AK; Janke, AT (corresponding author), Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT 06510 USA.; Venkatesh, AK (corresponding author), Yale Univ, Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT 06510 USA.	arjun.venkatesh@yale.edu; alexander.janke@yale.edu	Hawk, Kathryn/GPW-9108-2022; Hawk, Kathryn/AAS-7613-2021	Hawk, Kathryn/0000-0001-7435-5945; /0000-0002-9082-6644; Kinsman, Jeremiah/0000-0002-2794-2917; GOYAL, GoyalP/0000-0002-3863-6501	HHS Office of the Secretary Patient Centered Outcomes Research Trust Fund (PCORTF) under IDDA [ASPE-2018-001]; NIDA [UG1DA015831-18S2]; National Center for Advancing Translational Sciences of the NIH [KL2 TR000140]; American Board of Emergency Medicine -National Academy of Medicine Anniversary Fellowship	HHS Office of the Secretary Patient Centered Outcomes Research Trust Fund (PCORTF) under IDDA; NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Center for Advancing Translational Sciences of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); American Board of Emergency Medicine -National Academy of Medicine Anniversary Fellowship	This work was supported by the HHS Office of the Secretary Patient Centered Outcomes Research Trust Fund (PCORTF) under IDDA#ASPE-2018-001 and NIDA UG1DA015831-18S2. In addition, AKV was supported by KL2 TR000140 from the National Center for Advancing Translational Sciences of the NIH and the American Board of Emergency Medicine -National Academy of Medicine Anniversary Fellowship. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official view of NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad FB, 2021, PS PROVISIONAL DRUG; ahrq, 2021, ALC DRUG DEP VAL SET; Alter A., 2020, COVID 19 IMPACT US N; Annual Survey: American Hospital Association, 2018, AHA ANN SURV DAT REP; [Anonymous], COVID 19 IMPACT ANAL; [Anonymous], ZIP Code RUCA Approximation; [Anonymous], RURAL URBAN COMMUTIN; [Anonymous], 2021, SPIK DRUG OV DEATHS; Bernstein SL, 2017, ADDICT SCI CLIN PRAC, V12, DOI 10.1186/s13722-017-0083-z; Census Regions and Divisions of the United States: U.S. Department of Commerce Economics and Statistics Administration U.S. Census Bureau, US; Clark SA, 2021, J SUBST ABUSE TREAT, V124, DOI 10.1016/j.jsat.2021.108283; Cone DC, 2020, J ADDICT MED, V14, pE369, DOI 10.1097/ADM.0000000000000746; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Friedman J, 2021, JAMA PSYCHIAT, V78, P562, DOI 10.1001/jamapsychiatry.2020.4218; Haley DF, 2020, JAMA-J AM MED ASSOC, V324, P1615, DOI 10.1001/jama.2020.18543; Han B, 2017, HEALTH AFFAIR, V36, P1739, DOI 10.1377/hlthaff.2017.0584; Hartnett KP, 2020, MMWR-MORBID MORTAL W, V69, P699, DOI 10.15585/mmwr.mm6923e1; Healthcare Cost and Utilization Project (HCUP), CLIN CLASSIFICATIONS; Holland KM, 2021, JAMA PSYCHIAT, V78, P372, DOI 10.1001/jamapsychiatry.2020.4402; Hopkins RS, 2018, PUBLIC HEALTH REP, V133, P523, DOI 10.1177/0033354918784913; Jeffery MM, 2020, JAMA INTERN MED, V180, P1328, DOI 10.1001/jamainternmed.2020.3288; Khatri UG, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.34878; Knapp EA, 2019, AM J EPIDEMIOL, V188, P2131, DOI 10.1093/aje/kwz103; Koob GF, 2020, AM J PSYCHIAT, V177, P1031, DOI 10.1176/appi.ajp.2020.20091375; Lord K, 2021, AM J EMERG MED, V45, P548, DOI 10.1016/j.ajem.2020.07.040; Lucero AD, 2020, WEST J EMERG MED, V21, P15, DOI 10.5811/westjem.2020.8.48632; Muggeo VMR, 2003, STAT MED, V22, P3055, DOI 10.1002/sim.1545; Ochalek TA, 2020, JAMA-J AM MED ASSOC, V324, P1673, DOI 10.1001/jama.2020.17477; Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017; Pines JM, 2021, J SUBST ABUSE TREAT, V129, DOI 10.1016/j.jsat.2021.108391; Satty T, 2021, AM J EMERG MED, V42, P1, DOI 10.1016/j.ajem.2020.12.078; Savioli G, 2022, INTERN EMERG MED, V17, P503, DOI 10.1007/s11739-021-02732-w; Slavova S, 2020, DRUG ALCOHOL DEPEN, V214, DOI 10.1016/j.drugalcdep.2020.108176; Wang QQ, 2021, MOL PSYCHIATR, V26, P30, DOI 10.1038/s41380-020-00880-7; Woolf SH, 2019, JAMA-J AM MED ASSOC, V322, P1996, DOI 10.1001/jama.2019.16932	35	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2022	17	1							e0262136	10.1371/journal.pone.0262136	http://dx.doi.org/10.1371/journal.pone.0262136			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H0VF	35025921	gold, Green Published			2023-01-03	WOS:000796264200050
J	Daniels, JP				Daniels, Joe Parkin			Colombia euthanasia cases prompt regional debate	LANCET			English	Editorial Material																			0	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN	2022	399	10322					348	348						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YL7CQ	35065775				2023-01-03	WOS:000746046100009
J	Zhang, XQ; Li, LX; Yu, C; Nath, KA; Zhuang, SG; Li, XG				Zhang, Xiaoqin; Li, Linda Xiaoyan; Yu, Chen; Nath, Karl A.; Zhuang, Shougang; Li, Xiaogang			Targeting lysine-specific demethylase 1A inhibits renal epithelial-mesenchymal transition and attenuates renal fibrosis	FASEB JOURNAL			English	Article						EMT; epigenetic regulation; LSD1; renal fibrosis	TRANSCRIPTION FACTOR SNAIL; CELL-CYCLE ARREST; FIBROBLAST ACTIVATION; ANDROGEN RECEPTOR; MECHANISMS; EXPRESSION; GROWTH	Lysine-specific histone demethylase 1 (LSD1) as the first identified histone/lysine demethylase regulates gene expression and protein functions in diverse diseases. In this study, we show that the expression of LSD1 is increased in mouse kidneys with unilateral ureteral obstruction (UUO) and in cultured NRK-52E cells undergoing TGF-beta 1-induced epithelial-mesenchymal transition (EMT). Inhibition of LSD1 with its specific inhibitor ORY1001 attenuated renal EMT and fibrosis, which was associated with decreased the deposition of extracellular matrix proteins and the expression of fibrotic markers, including alpha-smooth muscle actin (alpha-SMA) and fibronectin, and the recovery of E-cadherin expression and decrease of N-cadherin expression in UUO kidneys and in NRK-52E cells induced with TGF-beta 1. Targeting LSD1 also decreased the expression of Snail family transcriptional repressor 1 (Snail-1) and its interaction with LSD1 in UUO kidneys and in NRK-52E cells treated with TGF-beta 1. In addition, we identified a novel LSD1-14-3-3 zeta-PKC alpha axis in the regulation of the activation of AKT and Stat3 and then the activation of fibroblasts. This study suggests that LSD1 plays a critical role in regulation of renal EMT and fibrosis through activation of diverse signaling pathways and places an emphasis that LSD1 has potential as a therapeutic target for the treatment of renal fibrosis.	[Zhang, Xiaoqin; Li, Linda Xiaoyan; Nath, Karl A.; Li, Xiaogang] Mayo Clin, Dept Internal Med, 200 1st St SW, Rochester, MN 55905 USA; [Zhang, Xiaoqin; Yu, Chen] Tongji Univ, Tongji Hosp, Sch Med, Dept Nephrol, Shanghai, Peoples R China; [Li, Linda Xiaoyan; Li, Xiaogang] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Zhuang, Shougang] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Med, Providence, RI 02903 USA	Mayo Clinic; Tongji University; Mayo Clinic; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Li, XG (corresponding author), Mayo Clin, Dept Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	li.xiaogang@mayo.edu			Foundation for the National Institutes of Health (FNIH) [R01 DK129241, R01 DK126662, R01 DK119167]; PKD Foundation research [231G18a]	Foundation for the National Institutes of Health (FNIH); PKD Foundation research	Foundation for the National Institutes of Health (FNIH), Grant/Award Number: ROl DK129241; Foundation for the National Institutes of Health (FNIH), Grant/Award Number: RO1 DK126662; Foundation for the National Institutes of Health (FNI11), Grant/Award Number: RO1 DK119167; PKD Foundation research, Grant/Award Number: 231G18a	Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bechtel W, 2010, NAT MED, V16, P544, DOI 10.1038/nm.2135; Bilyk O, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00145; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cai CM, 2014, CELL REP, V9, P1618, DOI 10.1016/j.celrep.2014.11.008; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carew RM, 2012, CELL TISSUE RES, V347, P103, DOI 10.1007/s00441-011-1227-1; Carmichael CL, 2020, BLOOD, V136, P957, DOI 10.1182/blood.2019002548; Efstratiadis G, 2009, HIPPOKRATIA, V13, P224; Fang Y, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0811-9; Garg Minal, 2013, World J Stem Cells, V5, P188, DOI 10.4252/wjsc.v5.i4.188; Hino S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1755; Huo JL, 2021, CIRC RES, V129, P400, DOI 10.1161/CIRCRESAHA.120.318149; Kang Moon-Il, 2012, Genes Cancer, V3, P37, DOI 10.1177/1947601912448820; Kim DH, 2018, J CLIN MED, V7, DOI 10.3390/jcm7010001; Kittirat Y, 2018, ONCOL LETT, V15, P347, DOI 10.3892/ol.2017.7326; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lan AP, 2015, NEPHROL DIAL TRANSPL, V30, P385, DOI 10.1093/ndt/gfu196; Lee JJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.501; Li Y, 2012, ONCOGENE, V31, P5007, DOI 10.1038/onc.2012.8; Liu LR, 2021, FASEB J, V35, DOI 10.1096/fj.202000554RRR; Lovisa S, 2016, TRENDS ENDOCRIN MET, V27, P681, DOI 10.1016/j.tem.2016.06.004; Lovisa S, 2015, NAT MED, V21, P998, DOI 10.1038/nm.3902; Lv SA, 2010, EUR J CELL BIOL, V89, P557, DOI 10.1016/j.ejcb.2010.01.004; Maes T, 2018, CANCER CELL, V33, P495, DOI 10.1016/j.ccell.2018.02.002; Majello B, 2019, CANCERS, V11, DOI 10.3390/cancers11030324; MattoYelin M, 1997, MOL BIOL CELL, V8, P1889, DOI 10.1091/mbc.8.10.1889; Meran S, 2011, INT J EXP PATHOL, V92, P158, DOI 10.1111/j.1365-2613.2011.00764.x; Pang MY, 2010, KIDNEY INT, V78, P257, DOI 10.1038/ki.2010.154; Partovian C, 2008, MOL CELL, V32, P140, DOI 10.1016/j.molcel.2008.09.010; Pennington KL, 2018, ONCOGENE, V37, P5587, DOI 10.1038/s41388-018-0348-3; Rivero S, 2015, ONCOGENE, V34, P5264, DOI 10.1038/onc.2014.446; Salamero O, 2020, J CLIN ONCOL, V38, P4260, DOI 10.1200/JCO.19.03250; Sheng LL, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.569322; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sun GD, 2010, J AM SOC NEPHROL, V21, P2069, DOI 10.1681/ASN.2010060633; Sureshbabu A, 2016, AM J PHYSIOL-RENAL, V310, pF596, DOI 10.1152/ajprenal.00365.2015; Takayama K, 2013, INT J UROL, V20, P756, DOI 10.1111/iju.12146; Tampe B, 2014, NEPHROL DIAL TRANSPL, V29, pI1, DOI 10.1093/ndt/gft361; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang YD, 2017, AM J PHYSIOL-RENAL, V313, pF1, DOI 10.1152/ajprenal.00588.2016; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; Wu CF, 2013, AM J PATHOL, V182, P118, DOI 10.1016/j.ajpath.2012.09.009; Yang GJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23123194; Yang L, 2010, NAT MED, V16, P535, DOI 10.1038/nm.2144; Yang SJ, 2017, EMBO J, V36, P1011, DOI 10.15252/embj.201694408; Zhou XX, 2018, FASEB J, V32, P5976, DOI 10.1096/fj.201800237R; Zhu LS, 2019, ACTA PHARM SIN B, V9, P324, DOI 10.1016/j.apsb.2018.10.006	49	2	2	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2022	36	1							e22122	10.1096/fj.202101566R	http://dx.doi.org/10.1096/fj.202101566R			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XV5OR	34958158	Green Accepted			2023-01-03	WOS:000734992000020
J	Ruggenenti, P; Di Marco, F; Cortinovis, M; Lorini, L; Sala, S; Novelli, L; Raimondi, F; Gastoldi, S; Galbusera, M; Donadelli, R; Mele, C; Piras, R; Noris, M; Portalupi, V; Cappelletti, L; Carrara, C; Tomatis, F; Bernardi, S; Perna, A; Peracchi, T; Diadei, O; Benigni, A; Remuzzi, G				Ruggenenti, Piero; Di Marco, Fabiano; Cortinovis, Monica; Lorini, Luca; Sala, Silvia; Novelli, Luca; Raimondi, Federico; Gastoldi, Sara; Galbusera, Miriam; Donadelli, Roberta; Mele, Caterina; Piras, Rossella; Noris, Marina; Portalupi, Valentina; Cappelletti, Laura; Carrara, Camillo; Tomatis, Federica; Bernardi, Silvia; Perna, Annalisa; Peracchi, Tobia; Diadei, Olimpia; Benigni, Ariela; Remuzzi, Giuseppe			Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study	PLOS ONE			English	Article							COMPLEMENT ACTIVATION; AHUS	Background Complement activation contributes to lung dysfunction in coronavirus disease 2019 (COVID-19). We assessed whether C5 blockade with eculizumab could improve disease outcome. Methods In this single-centre, academic, unblinded study two 900 mg eculizumab doses were added-on standard therapy in ten COVID-19 patients admitted from February 2020 to April 2020 and receiving Continuous-Positive-Airway-Pressure (CPAP) ventilator support from <= 24 hours. We compared their outcomes with those of 65 contemporary similar controls. Primary outcome was respiratory rate at one week of ventilator support. Secondary outcomes included the combined endpoint of mortality and discharge with chronic complications. Results Baseline characteristics of eculizumab-treated patients and controls were similar. At baseline, sC5b-9 levels, ex vivo C5b-9 and thrombi deposition were increased. Ex vivo tests normalised in eculizumab-treated patients, but not in controls. In eculizumab-treated patients respiratory rate decreased from 26.8 +/- 7.3 breaths/min at baseline to 20.3 +/- 3.8 and 18.0 +/- 4.8 breaths/min at one and two weeks, respectively (p<0.05 for both), but did not change in controls. Between-group changes differed significantly at both time-points (p<0.01). Changes in respiratory rate correlated with concomitant changes in ex vivo C5b-9 deposits at one (rs = 0.706, p = 0.010) and two (rs = 0.751, p = 0.032) weeks. Over a median (IQR) period of 47.0 (14.0-121.0) days, four eculizumab-treated patients died or had chronic complications versus 52 controls [HRCrude (95% CI): 0.26 (0.09-0.72), p = 0.010]. Between-group difference was significant even after adjustment for age, sex and baseline serum creatinine [HRAdjusted (95% CI): 0.30 (0.10-0.84), p = 0.023]. Six patients and 13 controls were discharged without complications [HRCrude (95% CI): 2.88 (1.08-7.70), p = 0.035]. Eculizumab was tolerated well. The main study limitations were the relatively small sample size and the non-randomised design. Conclusions In patients with severe COVID-19, eculizumab safely improved respiratory dysfunction and decreased the combined endpoint of mortality and discharge with chronic complications. Findings need confirmation in randomised controlled trials.	[Ruggenenti, Piero; Cortinovis, Monica; Gastoldi, Sara; Galbusera, Miriam; Donadelli, Roberta; Mele, Caterina; Piras, Rossella; Noris, Marina; Perna, Annalisa; Peracchi, Tobia; Diadei, Olimpia; Benigni, Ariela; Remuzzi, Giuseppe] Ist Ric Farmacol Mario Negri IRCCS, Bergamo, Italy; [Ruggenenti, Piero; Portalupi, Valentina; Cappelletti, Laura; Carrara, Camillo; Tomatis, Federica; Bernardi, Silvia] Azienda Sociosanit Terr ASST Papa Giovanni XXIII, Unit Nephrol & Dialysis, Bergamo, Italy; [Di Marco, Fabiano; Novelli, Luca; Raimondi, Federico] Azienda Sociosanit Terr ASST Papa Giovanni XXIII, Unit Pulm Med, Bergamo, Italy; [Di Marco, Fabiano; Raimondi, Federico] Univ Milan, Dept Hlth Sci, Milan, Italy; [Lorini, Luca; Sala, Silvia] Azienda Sociosanit Terr ASST Papa Giovanni XXIII, Intens Care Unit, Bergamo, Italy; [Tomatis, Federica; Bernardi, Silvia] Univ Milan, Sch Nephrol, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; ASST Papa Giovanni XXIII; ASST Papa Giovanni XXIII; University of Milan; ASST Papa Giovanni XXIII; University of Milan	Remuzzi, G (corresponding author), Ist Ric Farmacol Mario Negri IRCCS, Bergamo, Italy.	giuseppe.remuzzi@marionegri.it	Novelli, Luca/AFT-6501-2022	Novelli, Luca/0000-0002-2705-248X; Raimondi, Federico/0000-0001-9599-6864; di marco, fabiano/0000-0002-1743-0504	ASST Papa Giovanni XXIII in Bergamo (Italy); initiative "Progetto TrexUno"	ASST Papa Giovanni XXIII in Bergamo (Italy); initiative "Progetto TrexUno"	The ASST Papa Giovanni XXIII in Bergamo (Italy) sponsored the trial, Brembo SpA (Curno, Bergamo, Italy) partially covered study costs by a liberal grant under the initiative "Progetto TrexUno" and Alexion Pharma Italy S.R.L. (Milan, Italy) freely supplied the study drug. Neither the sponsor nor the companies had any role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. All authors had full access to all the data in the study and accept responsibility to submit for publication. There was no additional funding received for this study. The funder provided support in the form of salaries for authors PR, FDM, LL, SS, LN, VP, LC and CC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Amara U, 2010, J IMMUNOL, V185, P5628, DOI 10.4049/jimmunol.0903678; Annane D, 2020, ECLINICALMEDICINE, V28, DOI 10.1016/j.eclinm.2020.100590; Barkoff CM, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9010011; Bettoni S, 2017, J IMMUNOL, V199, P1021, DOI 10.4049/jimmunol.1601121; Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419; de Bont CM, 2019, CELL MOL IMMUNOL, V16, P19, DOI 10.1038/s41423-018-0024-0; Diao B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22781-1; Effah CY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.597907; Galbusera M, 2019, AM J KIDNEY DIS, V74, P56, DOI 10.1053/j.ajkd.2018.11.012; Giudice V, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00857; Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Gruppo RA, 2009, NEW ENGL J MED, V360, P544, DOI 10.1056/NEJMc0809959; Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jhaveri KD, 2020, KIDNEY INT, V98, P509, DOI 10.1016/j.kint.2020.05.025; Jiang YT, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0063-8; Keenswijk W, 2018, EUR J PEDIATR, V177, P311, DOI 10.1007/s00431-017-3077-7; Lee MMY, 2022, EUR HEART J-CARD PHA, V8, P165, DOI 10.1093/ehjcvp/pvaa138; Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Noris M, 2020, KIDNEY INT, V98, P314, DOI 10.1016/j.kint.2020.05.013; Noris M, 2014, BLOOD, V124, P1715, DOI 10.1182/blood-2014-02-558296; Noris M, 2010, CLIN J AM SOC NEPHRO, V5, P1844, DOI 10.2215/CJN.02210310; Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814; Polycarpou A, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012642; Porzionato A, 2020, FEBS J, V287, P3681, DOI 10.1111/febs.15481; Risitano AM, 2020, NAT REV IMMUNOL, V20, P343, DOI 10.1038/s41577-020-0320-7; Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9; Valoti E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00853; Wang RX, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.28; World Health Organization, COR DIS COVID 19 OUT; Yu J, 2020, BLOOD, V136, P2080, DOI 10.1182/blood.2020008248; Zelek WM, 2020, AM J RESP CRIT CARE, V202, P1304, DOI 10.1164/rccm.202007-2778LE; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	35	6	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2021	16	12							e0261113	10.1371/journal.pone.0261113	http://dx.doi.org/10.1371/journal.pone.0261113			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ0QU	34928990	Green Published, gold			2023-01-03	WOS:000755188900022
J	Lanza, G; Fisicaro, F; D'Agate, CC; Ferri, R; Cantone, M; Falzone, L; Pennisi, G; Bella, R; Hadjivassiliou, M; Pennisi, M				Lanza, Giuseppe; Fisicaro, Francesco; D'Agate, Carmela Cinzia; Ferri, Raffaele; Cantone, Mariagiovanna; Falzone, Luca; Pennisi, Giovanni; Bella, Rita; Hadjivassiliou, Marios; Pennisi, Manuela			Preserved central cholinergic functioning to transcranial magnetic stimulation in de novo patients with celiac disease	PLOS ONE			English	Article							LATENCY AFFERENT INHIBITION; MOTOR CORTEX EXCITABILITY; COGNITIVE IMPAIRMENT; CORTICAL EXCITABILITY; GLUTEN SENSITIVITY; ALZHEIMERS-DISEASE; BRAIN FOG; CIRCUITS; TMS; FACILITATION	Background Celiac disease (CD) is now viewed as a systemic disease with multifaceted clinical manifestations. Among the extra-intestinal features, neurological and neuropsychiatric symptoms are still a diagnostic challenge, since they can precede or follow the diagnosis of CD. In particular, it is well known that some adults with CD may complain of cognitive symptoms, that improve when the gluten-free diet (GFD) is started, although they may re-appear after incidental gluten intake. Among the neurophysiological techniques, motor evoked potentials (MEPs) to transcranial magnetic stimulation (TMS) can non-invasively probe in vivo the excitation state of cortical areas and cortico-spinal conductivity, being also able to unveil preclinical impairment in several neurological and psychiatric disorders, as well as in some systemic diseases affecting the central nervous system (CNS), such as CD. We previously demonstrated an intracortical disinhibition and hyperfacilitation of MEP responses to TMS in newly diagnosed patients. However, no data are available on the central cholinergic functioning indexed by specific TMS measures, such as the short-latency afferent inhibition (SAI), which might represent the neurophysiological correlate of cognitive changes in CD patients, also at the preclinical level. Methods Cognitive and depressive symptoms were screened by means of the Montreal Cognitive Assessment (MoCA) and the 17-item Hamilton Depression Rating Scale (HDRS), respectively, in 15 consecutive de novo CD patients and 15 healthy controls. All patients were on normal diet at the time of the enrolment. Brain computed tomography (CT) was performed in all patients. SAI, recorded at two interstimulus intervals (2 and 8 ms), was assessed as the percentage amplitude ratio between the conditioned and the unconditioned MEP response. Resting motor threshold, MEP amplitude and latency, and central motor conduction time were also measured. Results The two groups were comparable for age, sex, anthropometric features, and educational level. Brain CT ruled out intracranial calcifications and clear radiological abnormalities in all patients. Scores at MoCA and HDRS were significantly worse in patients than in controls. The comparison of TMS data between the two groups revealed no statistically significant difference for all measures, including SAI at both interstimulus intervals. Conclusions Central cholinergic functioning explored by the SAI of the motor cortex resulted to be not affected in these de novo CD patients compared to age-matched healthy controls. Although the statistically significant difference in MoCA, an overt cognitive impairment was not clinically evident in CD patients. Coherently, to date, no study based on TMS or other diagnostic techniques has shown any involvement of the central acetylcholine or the cholinergic fibers within the CNS in CD. This finding might add support to the vascular inflammation hypothesis underlying the so-called "gluten encephalopathy", which seems to be due to an aetiology different from that of the cholinergic dysfunction. Longitudinal studies correlating clinical, TMS, and neuroimaging data, both before and after GFD, are needed.	[Lanza, Giuseppe; Pennisi, Giovanni] Univ Catania, Dept Surg & Med Surg Specialties, Catania, Italy; [Lanza, Giuseppe; Ferri, Raffaele] IRCCS, Oasi Res Inst, Clin Neurophysiol Res Unit, Troina, Italy; [Fisicaro, Francesco; Pennisi, Manuela] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy; [D'Agate, Carmela Cinzia] Univ Hosp Policlin G Rodolico San Marco, Gastroenterol & Endoscopy Unit, Catania, Italy; [Cantone, Mariagiovanna] ASP Caltanissetta, St Elia Hosp, Dept Neurol, Caltanissetta, Italy; [Falzone, Luca] IRCCS Fdn G Pascale, Inst Nazl Tumori, Epidemiol & Biostat Unit, Naples, Italy; [Bella, Rita] Univ Catania, Dept Med & Surg Sci & Adv Technol, Catania, Italy; [Hadjivassiliou, Marios] Royal Hallamshire Hosp, Sheffield Teaching Hosp NHS Fdn Trust, Acad Dept Neurosci, Sheffield, S Yorkshire, England	University of Catania; University of Catania; IRCCS Fondazione Pascale; University of Catania; University of Sheffield	Lanza, G (corresponding author), Univ Catania, Dept Surg & Med Surg Specialties, Catania, Italy.; Lanza, G (corresponding author), IRCCS, Oasi Res Inst, Clin Neurophysiol Res Unit, Troina, Italy.	giuseppe.lanza1@unict.it	Cantone, Mariagiovanna/C-9392-2017; Falzone, Luca/AAC-2085-2019; Lanza, Giuseppe/R-3065-2017; Fisicaro, Francesco/AAN-3552-2020; Ferri, Raffaele/B-5439-2013	Cantone, Mariagiovanna/0000-0002-9072-4971; Falzone, Luca/0000-0001-7349-6826; Lanza, Giuseppe/0000-0002-5659-662X; Fisicaro, Francesco/0000-0002-1579-8807; Ferri, Raffaele/0000-0001-6937-3065				Asmussen MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060496; Bailey AZ, 2016, J NEUROPHYSIOL, V116, P637, DOI 10.1152/jn.00276.2016; Bekdash RA, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122995; Bella R, 2016, BRAIN STIMUL, V9, P225, DOI 10.1016/j.brs.2015.09.013; Bella R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129218; Bernini P, 2011, J PROTEOME RES, V10, P714, DOI 10.1021/pr100896s; Bertini I, 2009, J PROTEOME RES, V8, P170, DOI 10.1021/pr800548z; Bhandari A, 2016, CLIN NEUROPHYSIOL, V127, P2834, DOI 10.1016/j.clinph.2016.05.363; Briani C, 2008, J NEUROIMMUNOL, V195, P171, DOI 10.1016/j.jneuroim.2008.01.008; Brown KE, 2017, BRAIN STIMUL, V10, P1102, DOI 10.1016/j.brs.2017.07.011; Cantone M, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.721906; Cantone M, 2019, FRONT HUM NEUROSCI, V13, DOI 10.3389/fnhum.2019.00185; Casella S, 2012, DIGEST LIVER DIS, V44, P729, DOI 10.1016/j.dld.2012.03.008; Chen R, 1999, EXP BRAIN RES, V129, P77, DOI 10.1007/s002210050938; COLLIN P, 1991, NEUROLOGY, V41, P372, DOI 10.1212/WNL.41.3.372; Concerto C, 2018, COMPLEMENT THER MED, V41, P141, DOI 10.1016/j.ctim.2018.09.013; Concerto C, 2017, PHYSIOL BEHAV, V179, P361, DOI 10.1016/j.physbeh.2017.07.013; Concerto C, 2015, SOMATOSENS MOT RES, V32, P207, DOI 10.3109/08990220.2015.1048329; Crupi R, 2010, BIOL PSYCHIAT, V67, P558, DOI 10.1016/j.biopsych.2009.12.008; Currie S, 2012, J NEUROL NEUROSUR PS, V83, P1216, DOI 10.1136/jnnp-2012-303281; Devanne H, 2009, EUR J NEUROSCI, V30, P439, DOI 10.1111/j.1460-9568.2009.06815.x; Di Cagno R, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-219; Di Lazzaro V, 2008, CLIN NEUROPHYSIOL, V119, P2494, DOI 10.1016/j.clinph.2008.08.010; Di Lazzaro V, 2000, EXP BRAIN RES, V135, P455, DOI 10.1007/s002210000543; Di Lazzaro V, 2021, CLIN NEUROPHYSIOL, V132, P2568, DOI 10.1016/j.clinph.2021.05.035; Faro A., 2010, 12 MEDITERRANEAN C M, P200, DOI [DOI 10.1007/978-3-642-13039-7_50, 10.1007/978-3-642-13039-7_50]; Ferreri F, 2013, REV NEUROSCIENCE, V24, P431, DOI 10.1515/revneuro-2013-0019; Fisicaro F, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051530; Fisicaro F, 2020, J PERS MED, V10, DOI 10.3390/jpm10040274; Fisicaro F, 2020, J CLIN NEUROL, V16, P158, DOI 10.3988/jcn.2020.16.1.158; Giordano D, 2012, COMPUT METH PROG BIO, V107, P4, DOI 10.1016/j.cmpb.2011.10.008; Green PHR, 2005, BEST PRACT RES CL GA, V19, P389, DOI 10.1016/j.bpg.2005.02.006; Gunther C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168870; Hadjivassiliou M, 2002, J NEUROL NEUROSUR PS, V72, P560, DOI 10.1136/jnnp.72.5.560; Hadjivassiliou M, 2019, CLIN GASTROENTEROL H, V17, P2678, DOI 10.1016/j.cgh.2019.03.014; Hadjivassiliou Marios, 2014, Handb Clin Neurol, V120, P607, DOI 10.1016/B978-0-7020-4087-0.00041-3; Hadjivassiliou M, 2010, LANCET NEUROL, V9, P318, DOI 10.1016/S1474-4422(09)70290-X; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hopper AD, 2007, BRIT MED J, V335, P558, DOI 10.1136/bmj.39316.442338.AD; Hu WT, 2006, ARCH NEUROL-CHICAGO, V63, P1440, DOI 10.1001/archneur.63.10.1440; Husby S, 2020, J PEDIATR GASTR NUTR, V70, P141, DOI 10.1097/MPG.0000000000002497; Kammer T, 2001, CLIN NEUROPHYSIOL, V112, P250, DOI 10.1016/S1388-2457(00)00513-7; Kirchberg FF, 2016, J AUTOIMMUN, V72, P95, DOI 10.1016/j.jaut.2016.05.006; Lanza G, 2019, ADV PHARMACOL, V84, P101, DOI 10.1016/bs.apha.2018.12.002; Lanza G, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082243; Lanza G, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/351680; Lebwohl B, 2016, J ALZHEIMERS DIS, V49, P179, DOI 10.3233/JAD-150388; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Lichtwark IT, 2014, ALIMENT PHARM THER, V40, P566, DOI 10.1111/apt.12867; Lurie Y, 2008, J CLIN GASTROENTEROL, V42, P59, DOI 10.1097/01.mcg.0000247995.12087.7b; Maffiuletti NA, 2001, J APPL PHYSIOL, V90, P3, DOI 10.1152/jappl.2001.90.1.3; Martin-Masot R, 2020, NUTRIENTS, V12, DOI 10.3390/nu12123723; Mimura Y, 2021, NEUROSCI BIOBEHAV R, V121, P47, DOI 10.1016/j.neubiorev.2020.12.003; Muhammad H, 2019, P NUTR SOC, V78, P418, DOI 10.1017/S002966511800277X; Nardone R, 2008, J NEURAL TRANSM, V115, P1557, DOI 10.1007/s00702-008-0129-1; Nardone R, 2012, J NEURAL TRANSM, V119, P463, DOI 10.1007/s00702-011-0725-3; Nardone R, 2011, DEMENT GERIATR COGN, V32, P18, DOI 10.1159/000330016; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Obrenovich MEM, 2018, MICROORGANISMS, V6, DOI 10.3390/microorganisms6040107; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Paulus W, 2008, BRAIN STIMUL, V1, P151, DOI 10.1016/j.brs.2008.06.002; Pennisi G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102790; Pennisi M, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00498; Pennisi M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177560; Reis J, 2008, J PHYSIOL-LONDON, V586, P325, DOI 10.1113/jphysiol.2007.144824; Rizzo V, 2001, NEUROL SCI, V22, P229, DOI 10.1007/s100720100002; Rossi S, 2021, CLIN NEUROPHYSIOL, V132, P269, DOI 10.1016/j.clinph.2020.10.003; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Sellitto M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033387; Sen P, 2019, CLIN TRANSL GASTROEN, V10, DOI 10.14309/ctg.0000000000000044; Slim M, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070875; Tokimura H, 2000, J PHYSIOL-LONDON, V523, P503, DOI 10.1111/j.1469-7793.2000.t01-1-00503.x; Turco CV, 2021, CLIN NEUROPHYSIOL, V132, P1462, DOI 10.1016/j.clinph.2021.02.402; Turco CV, 2019, BRAIN RES, V1723, DOI 10.1016/j.brainres.2019.146394; Turco CV, 2018, J PHYSIOL-LONDON, V596, P5267, DOI 10.1113/JP276710; Turco CV, 2017, J NEUROPHYSIOL, V118, P610, DOI 10.1152/jn.00118.2017; Vinciguerra L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082977; WENDT HW, 1972, EUR J SOC PSYCHOL, V2, P463, DOI 10.1002/ejsp.2420020412; Yelland GW, 2017, J GASTROEN HEPATOL, V32, P90, DOI 10.1111/jgh.13706; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006; Ziemann U, 2015, CLIN NEUROPHYSIOL, V126, P1847, DOI 10.1016/j.clinph.2014.08.028; Ziemann Ulf, 2013, Handb Clin Neurol, V116, P387, DOI 10.1016/B978-0-444-53497-2.00032-2	82	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2021	16	12							e0261373	10.1371/journal.pone.0261373	http://dx.doi.org/10.1371/journal.pone.0261373			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY9FU	34914787	Green Accepted, Green Published, gold			2023-01-03	WOS:000755091500088
J	Green, MJ; Callender, B				Green, Michael J.; Callender, Brian			Graphic Medicine-The Best of 2021	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Green, Michael J.] Penn State Coll Med, Dept Humanities, 500 Univ Dr, Hershey, PA 17033 USA; [Green, Michael J.] Penn State Coll Med, Dept Med, Hershey, PA USA; [Callender, Brian] Univ Chicago, Med, Chicago, IL 60637 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Chicago	Green, MJ (corresponding author), Penn State Coll Med, Dept Humanities, 500 Univ Dr, Hershey, PA 17033 USA.	mjg15@psu.edu						Czerwiec, 2020, MENOPAUSE COMIC TREA, DOI [10.1515/9780271089096, DOI 10.1515/9780271089096]; Durand E, 2021, PARENTHESIS; Esp?, 2021, PARAKEET; Feder T., 2020, DANCING PITY PARTY D; Johnson R., 2021, COVID CHRONICLES COM, DOI [10.1515/9780271091723, DOI 10.1515/9780271091723]; Slattery, 2021, COMA	6	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	2021	326	24					2453	2455		10.1001/jama.2021.21248	http://dx.doi.org/10.1001/jama.2021.21248		DEC 2021	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC6FM	34889958				2023-01-03	WOS:000728825300002
J	Yessoufou, K; Ambani, AE; Elansary, HO; Gaoue, OG				Yessoufou, Kowiyou; Ambani, Annie Estelle; Elansary, Hosam O.; Gaoue, Orou G.			Alien woody plants are more versatile than native, but both share similar therapeutic redundancy in South Africa	PLOS ONE			English	Article							MEDICINAL-PLANTS; ETHNOBOTANICAL SURVEY; STATISTICAL-ANALYSIS; SPECIES RICHNESS; FORESTS; FLORA; HYPOTHESES; FAMILIES; DISTRICT	Understanding why alien plant species are incorporated into the medicinal flora in several local communities is central to invasion biology and ethnobiology. Theories suggest that alien plants are incorporated in local pharmacopoeias because they are more versatile or contribute unique secondary chemistry which make them less therapeutically redundant, or simply because they are locally more abundant than native species. However, a lack of a comprehensive test of these hypotheses limits our understanding of the dynamics of plants knowledge, use and potential implications for invasion. Here, we tested the predictions of several of these hypotheses using a unique dataset on the woody medicinal flora of southern Africa. We found that the size of a plant family predicts the number of medicinal plants in that family, a support for the non-random hypothesis of medicinal plant selection. However, we found no support for the diversification hypothesis: i) both alien and native plants were used in the treatment of similar diseases; ii) significantly more native species than alien contribute to disease treatments particularly of parasitic infections and obstetric-gynecological diseases, and iii) alien and native species share similar therapeutic redundancy. However, we found support for the versatility hypothesis, i.e., alien plants were more versatile than natives. These findings imply that, although alien plant species are not therapeutically unique, they do provide more uses than native plants (versatility), thus suggesting that they may not have been introduced primarily for therapeutic reasons. We call for similar studies to be carried out on alien herbaceous plants for a broader understanding of the integration of alien plants into the pharmacopoeias of the receiving communities.	[Yessoufou, Kowiyou; Ambani, Annie Estelle; Gaoue, Orou G.] Univ Johannesburg, Dept Geog Environm Management & Energy Studies, Johannesburg, South Africa; [Elansary, Hosam O.] King Saud Univ, Coll Food & Agr Sci, Plant Prod Dept, Riyadh, Saudi Arabia; [Gaoue, Orou G.] Univ Tennessee, Dept Ecol & Evolutionary Biol, Knoxville, TN USA; [Gaoue, Orou G.] Univ Parakou, Fac Agron, Parakou, Benin	University of Johannesburg; King Saud University; University of Tennessee System; University of Tennessee Knoxville	Yessoufou, K (corresponding author), Univ Johannesburg, Dept Geog Environm Management & Energy Studies, Johannesburg, South Africa.	kowiyouy@uj.ac.za	Elansary, Hosam O./E-3684-2019	Elansary, Hosam O./0000-0002-4476-2408; Yessoufou, Prof. Kowiyou/0000-0002-4789-1723; Ambani, Annie Estelle/0000-0003-2040-681X	King Saud University [RSP-2020/118]; National Research Foundation, South Africa [112113]; South Africa's National Research Foundation (NRF) -Research Development Grants for Y-Rated Researchers [112113]; Carnegie African Diaspora Fellowship; University of Tennessee Knoxville; University of Johannesburg	King Saud University(King Saud University); National Research Foundation, South Africa(National Research Foundation - South Africa); South Africa's National Research Foundation (NRF) -Research Development Grants for Y-Rated Researchers; Carnegie African Diaspora Fellowship; University of Tennessee Knoxville; University of Johannesburg	This research was funded by King Saud University (Grant RSP-2020/118) and the National Research Foundation, South Africa (Grant 112113). KY is grateful to the South Africa's National Research Foundation (NRF) -Research Development Grants for Y-Rated Researchers (Grant No: 112113); OGG was supported by the Carnegie African Diaspora Fellowship and start-up funds from the University of Tennessee Knoxville. KY also received support from the University of Johannesburg in the form of a salary.	Albuquerque UP, 2012, J ETHNOPHARMACOL, V140, P197, DOI 10.1016/j.jep.2011.12.042; Alencar NL, 2014, REV BRAS FARMACOGN, V24, P506, DOI 10.1016/j.bjp.2014.09.003; Alencar NL, 2010, ECON BOT, V64, P68, DOI 10.1007/s12231-009-9104-5; Amiguet VT, 2006, ECON BOT, V60, P24, DOI 10.1663/0013-0001(2006)60[24:ARAOQM]2.0.CO;2; APG IV, 2016, BOT J LINN SOC, V181, P1; Arnold T. H., 2002, STRELITZIA, V13; Bennett BC, 2000, ECON BOT, V54, P90, DOI 10.1007/BF02866603; Bennett BC, 2008, J ETHNOPHARMACOL, V116, P422, DOI 10.1016/j.jep.2007.12.006; Bennett BM, 2010, INT REV SOC HIST, V55, P27, DOI 10.1017/S0020859010000489; Bezeng SB, 2015, J ECOL, V103, P871, DOI 10.1111/1365-2745.12410; Bletter N., 2010, P 2010 SE AS GEOGR A, P1; Boon R., 2010, POOLEYS TREES E S AF; Chintamunnee V, 2012, J HERB MED, V2, P113, DOI 10.1016/j.hermed.2012.06.001; Coates-Palgrave M., 2002, TREES SO AFRICA, V3rd ed.; Coe MA, 2021, PEOPLE NAT, V3, P770, DOI 10.1002/pan3.10216; Curtis B., 2005, TREE ATLAS NAMIBIA; da Silva TC, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/2519212; Das D., 2015, INDIAN J OBSTET GYNA, V2, P16; Albuquerque UP, 2007, J ETHNOPHARMACOL, V113, P156, DOI 10.1016/j.jep.2007.05.025; de Albuquerque UP, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-30; de Boer HJ, 2005, J ETHNOPHARMACOL, V96, P461, DOI 10.1016/j.jep.2004.09.035; de Medeiros PM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185358; de Medeiros PM, 2013, J ETHNOPHARMACOL, V150, P729, DOI 10.1016/j.jep.2013.09.026; Douwes E, 2008, J ETHNOPHARMACOL, V119, P356, DOI 10.1016/j.jep.2008.07.040; El-Shemy H.A, 2017, ACTIVE INGREDIENTS A, DOI [10.5772/65725, DOI 10.5772/65725]; Ferreira FS, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/126938; Flint A, 2015, INT J ENV RES PUB HE, V12, P4321, DOI 10.3390/ijerph120404321; Ford J, 2017, ECON BOT, V71, P123, DOI 10.1007/s12231-017-9380-4; Gaoue OG, 2021, PLANTS PEOPLE PLANET, V3, P710, DOI 10.1002/ppp3.10202; Gaoue O, 2017, ECON BOT, V71, P269, DOI 10.1007/s12231-017-9389-8; Germishuizen G., 2003, STRELITZIA; Glen H., 2016, GUIDE TREES INTRO SO, DOI DOI 10.1111/j.1466-8238.2011.00666.x; Global Biodiversity Information Facility, SEARCH OCC; Hart G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184369; Henderson L, 2007, BOTHALIA, V37, P215, DOI 10.4102/abc.v37i2.322; Hyde MA, 2002, FLORA ZIMBABWE; Hyde MA., FLORA BOTSWANA; Hyde MA., 2002, FLORA MOZAMBIQUE; IPNI, 2018, INT PLANT NAMES INDE; Jama B, 2000, AGROFOREST SYST, V49, P201, DOI 10.1023/A:1006339025728; Jernigan K, 2012, ECON BOT, V66, P46, DOI 10.1007/s12231-011-9184-x; KAPUR SK, 1992, J ETHNOPHARMACOL, V36, P87, DOI 10.1016/0378-8741(92)90064-X; Kindscher Kelly, 2013, Transactions of the Kansas Academy of Science, V116, P149, DOI 10.1660/062.116.0308; Kose LS, 2015, J ETHNOPHARMACOL, V170, P184, DOI 10.1016/j.jep.2015.04.047; Mankga LT, 2017, AOB PLANTS, V9, DOI 10.1093/aobpla/plx022; Maroyi A, 2011, J ETHNOPHARMACOL, V136, P347, DOI 10.1016/j.jep.2011.05.003; Maurin O, 2014, NEW PHYTOL, V204, P201, DOI 10.1111/nph.12936; Moerman Daniel E., 1999, Journal of Ethnobiology, V19, P49; MOERMAN DE, 1979, J ETHNOPHARMACOL, V1, P111, DOI 10.1016/0378-8741(79)90002-3; MOERMAN DE, 1991, J ETHNOPHARMACOL, V31, P1, DOI 10.1016/0378-8741(91)90141-Y; Moerman DE, 2003, J ETHNOPHARMACOL, V87, P51, DOI 10.1016/S0378-8741(03)00105-3; Moerman DE, 1996, J ETHNOPHARMACOL, V52, P1, DOI 10.1016/0378-8741(96)01393-1; Muleba I, 2021, ENVIRON DEV SUSTAIN, V23, P4162, DOI 10.1007/s10668-020-00763-5; Nascimento A.L.B., 2015, EVOLUTIONARY ETHNOBI, P121, DOI DOI 10.1007/978-3-319-19917-7; Ngarivhume T, 2015, J ETHNOPHARMACOL, V159, P224, DOI 10.1016/j.jep.2014.11.011; O'Hara RB, 2010, METHODS ECOL EVOL, V1, P118, DOI 10.1111/j.2041-210X.2010.00021.x; OBRIEN EM, 1993, J BIOGEOGR, V20, P181, DOI 10.2307/2845670; PHILLIPS O, 1993, ECON BOT, V47, P33, DOI 10.1007/BF02862204; Poynton RJ., 2009, TREE PLANTING SO AFR, V3; RBGKew, 2017, STATE WORLDS PLANTS; Royal Museum for Central Africa, 2018, PREL DAT MED PLANTS; SANBI, FLORA SO AFRICA; Saslis-Lagoudakis CH, 2011, J ETHNOPHARMACOL, V135, P476, DOI 10.1016/j.jep.2011.03.044; Savo V, 2015, J ETHNOBIOL ETHNOMED, V11, DOI 10.1186/s13002-015-0038-y; Schmidt E., 2007, TREES SHRUBS MPUMALA; Shikalepo R, 2018, J HERB MED, V12, P73, DOI 10.1016/j.hermed.2017.09.007; Tabassum Nahida, 2011, Pharmacogn Rev, V5, P30, DOI 10.4103/0973-7847.79097; Terblanche C, 2016, BOTHALIA, V46, DOI 10.4102/abc.v46i1.2053; van Wilgen BW, 2012, BIOL CONSERV, V148, P28, DOI 10.1016/j.biocon.2011.12.035; van Wyk B., 2013, FIELD GUIDE TREES SO; van Wyk BE, 2008, J ETHNOPHARMACOL, V119, P342, DOI 10.1016/j.jep.2008.05.029; Van Wyk BE, 2011, S AFR J BOT, V77, P812, DOI 10.1016/j.sajb.2011.08.011; Van Wyk B.-E., 2000, PEOPLES PLANTS GUIDE; van Wyk BE, 2002, S AFR J BOT, V68, P1, DOI 10.1016/S0254-6299(15)30433-6; Voeks RA, 2004, ANN ASSOC AM GEOGR, V94, P868; von Staden L., 2009, V25, P1; Williams VL, 2013, S AFR J BOT, V86, P23, DOI 10.1016/j.sajb.2013.01.006; Yessoufou K, 2015, MOL ECOL RESOUR, V15, P405, DOI 10.1111/1755-0998.12310; Ziyyat A, 1997, J ETHNOPHARMACOL, V58, P45, DOI 10.1016/S0378-8741(97)00077-9	79	1	1	5	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2021	16	11							e0260390	10.1371/journal.pone.0260390	http://dx.doi.org/10.1371/journal.pone.0260390			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW9KP	34847163	Green Published, gold			2023-01-03	WOS:000735928900030
J	Dusetzina, SB				Dusetzina, Stacie B.			Relief in Sight - Estimated Savings under Medicare Part D Redesign	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Relief in Sight Relief may be in sight for Medicare Part D beneficiaries who currently face high out-of-pocket spending. Redesign of the program is expected to be part of the fiscal year 2022 budget reconciliation currently moving through Congress.	[Dusetzina, Stacie B.] Vanderbilt Univ, Dept Hlth Policy, Sch Med, 221 Kirkland Hall, Nashville, TN 37235 USA; [Dusetzina, Stacie B.] Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University	Dusetzina, SB (corresponding author), Vanderbilt Univ, Dept Hlth Policy, Sch Med, 221 Kirkland Hall, Nashville, TN 37235 USA.; Dusetzina, SB (corresponding author), Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37235 USA.							Brodie, 2021, PUBLIC WEIGHS MEDICA; Cubanski J., 2021, KEY FACTS MEDICARE D; Cubanski Juliette., 2019, OUT OF POCKET COST D; Dusetzina SB, 2020, NEW ENGL J MED, V382, P1878, DOI 10.1056/NEJMp2001649; Medicare Payment Advisory Commission, 2021, MED PRESCR DRUG PROG	5	4	3	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	2021	385	26					E93	E93		10.1056/NEJMp2116586	http://dx.doi.org/10.1056/NEJMp2116586		NOV 2021	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XS4FC	34758246				2023-01-03	WOS:000716662100001
J	Miller, M; Hanna, N				Miller, Meagan; Hanna, Nasser			Advances in systemic therapy for non-small cell lung cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Review							VINORELBINE PLUS CISPLATIN; OPEN-LABEL; PHASE-III; 1ST-LINE TREATMENT; PALLIATIVE CARE; PREOPERATIVE CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; SURVIVAL-DATA; J-ALEX	Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. Trimodality treatment with surgical resection has been a subject of debate for decades. For patients with unresectable or inoperable locally advanced disease, the incorporation of immunotherapy consolidation after chemoradiation has defined a new standard of care. For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduction of targeted therapies and immunotherapy, the landscape of treatment has rapidly evolved. This review discusses the integration of these innovative therapies in the management of patients with newly diagnosed NSCLC.	[Miller, Meagan; Hanna, Nasser] Indiana Univ Sch Med, Indianapolis, IN 46208 USA	Indiana University System; Indiana University Bloomington	Miller, M (corresponding author), Indiana Univ Sch Med, Indianapolis, IN 46208 USA.	meaemill@iu.edu						Adderley H, 2021, CANCER IMMUNOL IMMUN, V70, P589, DOI 10.1007/s00262-020-02714-5; Akamatsu H, 2021, JAMA ONCOL, V7, P386, DOI 10.1001/jamaoncol.2020.6758; Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140-6736(09)60737-6; Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561; Ambroggi M, 2018, SUPPORT CARE CANCER, V26, P2945, DOI 10.1007/s00520-018-4184-3; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burdett S, 2014, LANCET, V383, P1561, DOI 10.1016/S0140-6736(13)62159-5; Camidge DR, 2018, NEW ENGL J MED, V379, P2027, DOI 10.1056/NEJMoa1810171; Camidge DR, 2020, J CLIN ONCOL, V38, P3592, DOI 10.1200/JCO.20.00505; Camidge DR, 2019, J THORAC ONCOL, V14, P1233, DOI 10.1016/j.jtho.2019.03.007; Charalambous H, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-59; Dong HD, 1999, NAT MED, V5, P1365; Douillard JY, 2006, LANCET ONCOL, V7, P719, DOI 10.1016/S1470-2045(06)70804-X; Drilon A, 2020, NEW ENGL J MED, V383, P813, DOI 10.1056/NEJMoa2005653; Drilon A, 2020, LANCET ONCOL, V21, P261, DOI 10.1016/S1470-2045(19)30690-4; Durm GA, 2020, CANCER-AM CANCER SOC, V126, P4353, DOI 10.1002/cncr.33083; Enguidanos S, 2021, AM J HOSP PALLIAT ME, V38, P1112, DOI 10.1177/1049909120973200; Faivre-Finn C, 2021, J THORAC ONCOL, V16, P860, DOI 10.1016/j.jtho.2020.12.015; Falchook GS, 2016, J CLIN ONCOL, V34, pE141, DOI 10.1200/JCO.2013.50.5016; Felip E, 2010, J CLIN ONCOL, V28, P3138, DOI 10.1200/JCO.2009.27.6204; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Gadgeel S, 2020, J CLIN ONCOL, V38, P1505, DOI 10.1200/JCO.19.03136; Gainor JF, 2020, J CLIN ONCOL, V38; Gainor JF, 2013, CLIN CANCER RES, V19, P4273, DOI 10.1158/1078-0432.CCR-13-0318; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gray JE, 2019, J CLIN ONCOL, V37; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Hida T, 2017, LANCET, V390, P29, DOI 10.1016/S0140-6736(17)30565-2; Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239; Horn L., 2020, J CLIN ONCOL, V38, P9580, DOI [10.1200/JCO.2020.38.15_suppl.9580, DOI 10.1200/JCO.2020.38.15_SUPPL.9580]; Hosomi Y, 2020, J CLIN ONCOL, V38, P115, DOI 10.1200/JCO.19.01488; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Jassem J, 2017, ANN ONCOL, V28; King JD, 2016, J PAIN SYMPTOM MANAG, V51, P1027, DOI 10.1016/j.jpainsymman.2016.01.003; Kruser TJ, 2020, ANN PALLIAT MED, V9, P2800, DOI 10.21037/apm-20-270; Lally BE, 2006, J CLIN ONCOL, V24, P2998, DOI 10.1200/JCO.2005.04.6110; Laskin J, 2020, ANN ONCOL, V31, P1693, DOI 10.1016/j.annonc.2020.08.2335; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Le Pechoux C, 2020, ANN ONCOL, V31, pS1178, DOI 10.1016/j.annonc.2020.08.2280; Le XN, 2020, J CLIN ONCOL, V38; Lee JMCJ., 2020 WORLD C LUNG CA; Lee K, 2020, CANCER RES TREAT, V52, P292, DOI 10.4143/crt.2019.186; Li BT, 2018, J CLIN ONCOL, V36, P2532, DOI 10.1200/JCO.2018.77.9777; Lim SM, 2017, J CLIN ONCOL, V35, P2613, DOI 10.1200/JCO.2016.71.3701; Lisberg A, 2018, J THORAC ONCOL, V13, P1138, DOI 10.1016/j.jtho.2018.03.035; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mazieres J, 2020, ANN ONCOL, V31, P289, DOI 10.1016/j.annonc.2019.10.022; Mazieres J, 2016, ANN ONCOL, V27, P281, DOI 10.1093/annonc/mdv573; Mok T, 2020, ANN ONCOL, V31, P1056, DOI 10.1016/j.annonc.2020.04.478; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Nakagawa K, 2019, LANCET ONCOL, V20, P1655, DOI 10.1016/S1470-2045(19)30634-5; National Comprehensive Cancer Network, 2021, NCCN GUID NONSM CELL; Nipp RD, 2018, PALLIATIVE MED, V32, P757, DOI 10.1177/0269216317751893; NORONHA V, 2019, J CLIN ONCOL, DOI DOI 10.1200/JCO.2019.37.15_SUPPL.9001; Noronha V, 2020, J CLIN ONCOL, V38, P124, DOI 10.1200/JCO.19.01154; Paik PK, 2020, NEW ENGL J MED, V383, P931, DOI 10.1056/NEJMoa2004407; Park K, 2020, J CLIN ONCOL, V38; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Piotrowska Z, 2020, J CLIN ONCOL, V38; Planchard D, 2017, LANCET ONCOL, V18, P1307, DOI 10.1016/S1470-2045(17)30679-4; Pless M, 2015, LANCET, V386, P1049, DOI 10.1016/S0140-6736(15)60294-X; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Ramalingam SS, 2020, J CLIN ONCOL, V38; Reck M, 2020, J CLIN ONCOL, V38; Reck M, 2019, J CLIN ONCOL, V37, P537, DOI 10.1200/JCO.18.00149; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ridge CA, 2013, SEMIN INTERVENT RAD, V30, P93, DOI 10.1055/s-0033-1342949; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Rodig SJ, 2009, CLIN CANCER RES, V15, P5216, DOI 10.1158/1078-0432.CCR-09-0802; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Sabari JK, 2018, ANN ONCOL, V29, P2085, DOI 10.1093/annonc/mdy334; Saito H, 2019, LANCET ONCOL, V20, P625, DOI 10.1016/S1470-2045(19)30035-X; Sands J, 2020, J CLIN ONCOL, V38; Scagliotti GV, 2012, J CLIN ONCOL, V30, P172, DOI 10.1200/JCO.2010.33.7089; Schaake EE, 2012, J CLIN ONCOL, V30, P2731, DOI 10.1200/JCO.2011.39.4882; Schoenfeld AJ, 2019, ANN ONCOL, V30, P839, DOI 10.1093/annonc/mdz077; Seto T, 2019, J CLIN ONCOL, V37; Seto T, 2014, LANCET ONCOL, V15, P1236, DOI 10.1016/S1470-2045(14)70381-X; Sezer A, 2021, LANCET, V397, P592, DOI 10.1016/S0140-6736(21)00228-2; Shaw AT, 2019, ANN ONCOL, V30, P1121, DOI 10.1093/annonc/mdz131; Shaw AT, 2020, NEW ENGL J MED, V383, P2018, DOI 10.1056/NEJMoa2027187; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Shen L, 2020, CANCER MED-US, V9, P3310, DOI 10.1002/cam4.2972; Shi YK, 2017, ANN ONCOL, V28, P2443, DOI 10.1093/annonc/mdx359; Slotman BJ, 2011, J RADIOSURGERY SBRT, V1, P63; Smit EF, 2020, J CLIN ONCOL, V38; Smith CB, 2012, ANN ONCOL, V23, P382, DOI 10.1093/annonc/mdr345; Socinski MA, 2020, ANN ONCOL, V31, pS1188, DOI 10.1016/j.annonc.2020.08.2293; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Spiro SG, 2005, AM J RESP CRIT CARE, V172, P523, DOI 10.1164/rccm.200504-531OE; Steffen L, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.34_suppl.36; Takahashi Masahide, 2020, JMA J, V3, P175, DOI 10.31662/jmaj.2020-0021; Temel JS, 2006, CLIN LUNG CANCER, V7, P241, DOI 10.3816/CLC.2006.n.001; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Wang Y, 2019, ANN ONCOL, V30, P447, DOI 10.1093/annonc/mdy542; Waterhouse DM, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.00131; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Wolf J., 2018, ANN ONCOL, V29, P741; Wolf J, 2020, J CLIN ONCOL, V38; World Health Organization International Agency for Research on Cancer, 2018, CA CANC J CLIN, V68, P394; Wu YL, 2015, ANN ONCOL, V26, P1883, DOI 10.1093/annonc/mdv270; Wu YL, 2020, NEW ENGL J MED, V383, P1711, DOI 10.1056/NEJMoa2027071; Wu YL, 2018, J CLIN ONCOL, V36, P3101, DOI 10.1200/JCO.2018.77.7326; Wu YL, 2017, LANCET ONCOL, V18, P1454, DOI 10.1016/S1470-2045(17)30608-3; Yamamoto N, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9007; Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8; Yoshizawa A, 2014, LUNG CANCER, V85, P373, DOI 10.1016/j.lungcan.2014.06.007; Zhao J, 2020, JCO PRECIS ONCOL, V4, P411, DOI 10.1200/PO.19.00333; Zhou C, 2015, ANN ONCOL, V26, P1877, DOI 10.1093/annonc/mdv276; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X	117	25	25	14	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2021	375								n2363	10.1136/bmj.n2363	http://dx.doi.org/10.1136/bmj.n2363			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW9ZF	34753715				2023-01-03	WOS:000718264400012
J	Yan, TT; Luo, YH; Xia, YL; Hamada, K; Wang, Q; Yan, NN; Krausz, KW; Ward, JM; Hao, HP; Wang, P; Gonzalez, FJ				Yan, Tingting; Luo, Yuhong; Xia, Yangliu; Hamada, Keisuke; Wang, Qiong; Yan, Nana; Krausz, Kristopher W.; Ward, Jerrold M.; Hao, Haiping; Wang, Ping; Gonzalez, Frank J.			St. John's Wort alleviates dextran sodium sulfate-induced colitis through pregnane X receptor-dependent NF kappa B antagonism	FASEB JOURNAL			English	Article						DSS; IBD; natural products; NF kappa B; PXR; small intestine	INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; TNF-ALPHA; MOUSE MODELS; HUMAN PXR; METABOLISM; ACTIVATION; PHARMACOLOGY; INDUCTION; RIFAXIMIN	St. John's wort (SJW), from traditional herbs, activates the pregnane X receptor (PXR), a potential drug target for treating inflammatory bowel disease (IBD). However, how SJW alleviates dextran sodium sulfate (DSS)-induced experimental IBD by activating PXR is unknown. To test this, PXR-humanized, wild-type (WT) and Pxr-null mice, primary intestinal organoids cultures, and the luciferase reporter gene assays were employed. In vivo, a diet supplemented with SJW was found to activate intestinal PXR both in WT and PXR-humanized mice, but not in Pxr-null mice. SJW prevented DSS-induced IBD in PXR-humanized and WT mice, but not in Pxr-null mice. In vitro, hyperforin, a major component of SJW, activated PXR and suppressed tumor necrosis factor (TNF)alpha-induced nuclear factor (NF) kappa B translocation in primary intestinal organoids from PXR-humanized mice, but not Pxr-null mice. Luciferase reporter gene assays showed that hyperforin dose-dependently alleviated TNF alpha-induced NF kappa B transactivation by activating human PXR in Caco2 cells. Furthermore, SJW therapeutically attenuated DSS-induced IBD in PXR-humanized mice. These data indicate the therapeutic potential of SJW in alleviating DSS-induced IBD in vivo, and TNF alpha-induced NF kappa B activation in vitro, dependent on PXR activation, which may have clinical implications for using SJW as a herbal drug anti-IBD treatment.	[Yan, Tingting; Luo, Yuhong; Xia, Yangliu; Hamada, Keisuke; Wang, Qiong; Yan, Nana; Krausz, Kristopher W.; Ward, Jerrold M.; Wang, Ping; Gonzalez, Frank J.] NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Yan, Nana; Hao, Haiping] China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, State Key Lab Nat Med, Nanjing, Peoples R China; [Wang, Ping] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); China Pharmaceutical University; Shanghai University of Traditional Chinese Medicine	Wang, P; Gonzalez, FJ (corresponding author), NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	pwang@shutcm.edu.cn; gonzalef@mail.nih.gov	LUO, YUHONG/GPW-8361-2022; yan, na/HDM-3747-2022	Hamada, Keisuke/0000-0002-7774-0790	HHS | NIH | National Cancer Institute (NCI); Office of Dietary Supplements (ODS); Chinese Scholarship Council [201806065070]; National Science Foundation of Shanghai [18ZR1436500]	HHS | NIH | National Cancer Institute (NCI); Office of Dietary Supplements (ODS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chinese Scholarship Council(China Scholarship Council); National Science Foundation of Shanghai	HHS | NIH | National Cancer Institute (NCI); Office of Dietary Supplements (ODS); Chinese Scholarship Council, Grant/Award Number: 201806065070; National Science Foundation of Shanghai, Grant/Award Number: 18ZR1436500	Ananthakrishnan AN, 2015, NAT REV GASTRO HEPAT, V12, P205, DOI 10.1038/nrgastro.2015.34; Barberio B, 2021, LANCET GASTROENTEROL, V6, P359, DOI 10.1016/S2468-1253(21)00014-5; Barnes J, 2001, J PHARM PHARMACOL, V53, P583, DOI 10.1211/0022357011775910; Beelen EMJ, 2020, GUT, V69, P1708, DOI 10.1136/gutjnl-2019-319321; Chang TKH, 2009, AAPS J, V11, P590, DOI 10.1208/s12248-009-9135-y; Cheng J, 2012, TRENDS PHARMACOL SCI, V33, P323, DOI 10.1016/j.tips.2012.03.003; Cheng J, 2010, J PHARMACOL EXP THER, V335, P32, DOI 10.1124/jpet.110.170225; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Cohen LJ, 2019, GASTROENTEROLOGY, V156, P2174, DOI 10.1053/j.gastro.2019.03.017; Deuring JJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221924; Dost T, 2009, DIGEST DIS SCI, V54, P1214, DOI 10.1007/s10620-008-0477-6; Dou W, 2014, INT IMMUNOPHARMACOL, V23, P170, DOI 10.1016/j.intimp.2014.08.025; Dou W, 2014, J NUTR BIOCHEM, V25, P923, DOI 10.1016/j.jnutbio.2014.04.006; Dou W, 2013, J PHARMACOL EXP THER, V345, P473, DOI 10.1124/jpet.112.201863; DuPont HL, 2011, EXPERT OPIN PHARMACO, V12, P293, DOI 10.1517/14656566.2011.546347; El Mourabet M, 2010, CURR DRUG TARGETS, V11, P234; Erickson SL, 2020, FASEB J, V34, P2198, DOI 10.1096/fj.201902083RR; Ferrari D, 2016, TOXICOL LETT, V264, P51, DOI 10.1016/j.toxlet.2016.10.014; Geier MS, 2009, DIGEST DIS SCI, V54, P1222, DOI 10.1007/s10620-008-0495-4; Goyal N, 2014, INFLAMMOPHARMACOLOGY, V22, P219, DOI 10.1007/s10787-014-0207-y; Ikpa PT, 2020, CELL MOL GASTROENTER, V9, P47, DOI 10.1016/j.jcmgh.2019.08.006; Ikpa PT, 2020, GENOMICS, V112, P1139, DOI 10.1016/j.ygeno.2019.06.028; Kim AH, 2018, J CROHNS COLITIS, V12, P408, DOI 10.1093/ecco-jcc/jjx161; Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125; Lang A, 2004, CLIN NUTR, V23, P1199, DOI 10.1016/j.clnu.2004.03.011; LeCluyse EL, 2001, CHEM-BIOL INTERACT, V134, P283, DOI 10.1016/S0009-2797(01)00163-6; Li F, 2013, NAT MED, V19, P418, DOI 10.1038/nm.3104; Liu YM, 2017, EXP CELL RES, V358, P335, DOI 10.1016/j.yexcr.2017.07.008; Liu YF, 2017, P NATL ACAD SCI USA, V114, pE3796, DOI 10.1073/pnas.1700909114; Ma X, 2007, DRUG METAB DISPOS, V35, P194, DOI 10.1124/dmd.106.012831; Manna SK, 2015, CANCER PREV RES, V8, P786, DOI 10.1158/1940-6207.CAPR-14-0113; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moreels TG, 2001, EUR J PHARMACOL, V423, P211, DOI 10.1016/S0014-2999(01)01088-3; Mueller C, 2002, IMMUNOLOGY, V105, P1, DOI 10.1046/j.1365-2567.2002.01329.x; Nunes NS, 2019, EBIOMEDICINE, V45, P495, DOI 10.1016/j.ebiom.2019.06.033; Oh SY, 2014, INT J MOL MED, V33, P333, DOI 10.3892/ijmm.2013.1569; Ohtsuka Y, 2003, PEDIATR RES, V53, P143, DOI 10.1203/01.PDR.0000041519.16507.06; Ojetti V, 2009, EXPERT OPIN DRUG MET, V5, P675, DOI 10.1517/17425250902973695; Pacyniak EK, 2007, TOXICOL SCI, V97, P94, DOI 10.1093/toxsci/kfm025; Pizarro TT, 2003, TRENDS MOL MED, V9, P218, DOI 10.1016/S1471-4914(03)00052-2; Randhawa PK, 2014, KOREAN J PHYSIOL PHA, V18, P279, DOI 10.4196/kjpp.2014.18.4.279; Ren YJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53305-z; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Sehirli AO, 2015, J PHYSIOL PHARMACOL, V66, P203; Shah YM, 2007, AM J PHYSIOL-GASTR L, V292, pG1114, DOI 10.1152/ajpgi.00528.2006; Shehu AI, 2019, J CLIN INVEST, V129, P2898, DOI 10.1172/JCI128274; Su LP, 2013, GASTROENTEROLOGY, V145, P407, DOI 10.1053/j.gastro.2013.04.011; Sun AN, 2016, J FUNCT FOODS, V21, P418, DOI 10.1016/j.jff.2015.12.029; Sun H, 2008, EXPERT OPIN DRUG MET, V4, P395, DOI [10.1517/17425255.4.4.395, 10.1517/17425255.4.4.395 ]; Sun RB, 2017, MOL PHARMACOL, V91, P110, DOI 10.1124/mol.116.106617; Trigo-Salado C, 2018, REV ESP ENFERM DIG, V110, P836, DOI 10.17235/reed.2018.5725/2018; Watkins RE, 2003, BIOCHEMISTRY-US, V42, P1430, DOI 10.1021/bi0268753; West NR, 2017, NAT MED, V23, P579, DOI 10.1038/nm.4307; Xiao YT, 2016, CYTOKINE, V83, P189, DOI 10.1016/j.cyto.2016.04.012; Yan TT, 2020, ACTA PHARM SIN B, V10, P3, DOI 10.1016/j.apsb.2019.11.017; Zhang GH, 2020, J ETHNOPHARMACOL, V248, DOI 10.1016/j.jep.2019.112302; Zhang JJ, 2015, J PHARMACOL EXP THER, V352, P315, DOI 10.1124/jpet.114.218750; Zhang YB, 2020, FREE RADICAL BIO MED, V148, P33, DOI 10.1016/j.freeradbiomed.2019.12.012; Zhou C, 2006, J CLIN INVEST, V116, P2280, DOI 10.1172/JCI26283	60	3	3	9	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2021	35	11							e21968	10.1096/fj.202001098R	http://dx.doi.org/10.1096/fj.202001098R			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WN8IK	34644426				2023-01-03	WOS:000712009200059
J	Ueda, Y; Ookawara, S; Ito, K; Sasabuchi, Y; Hayasaka, H; Kofuji, M; Uchida, T; Imai, S; Kiryu, S; Minato, S; Miyazawa, H; Sanayama, H; Hirai, K; Tabei, K; Morishita, Y				Ueda, Yuichiro; Ookawara, Susumu; Ito, Kiyonori; Sasabuchi, Yusuke; Hayasaka, Hideyuki; Kofuji, Masaya; Uchida, Takayuki; Imai, Sojiro; Kiryu, Satoshi; Minato, Saori; Miyazawa, Haruhisa; Sanayama, Hidenori; Hirai, Keiji; Tabei, Kaoru; Morishita, Yoshiyuki			Association between hepatic oxygenation on near-infrared spectroscopy and clinical factors in patients undergoing hemodialysis	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CEREBRAL OXYGENATION; MANAGEMENT; LIVER; HEMODYNAMICS; HYPOTENSION; MECHANISM; ALBUMIN; OBESITY; ANEMIA	The hepato-splanchnic circulation directly influences oxygenation of the abdominal organs and plays an important role in compensating for the blood volume reduction that occurs in the central circulation during hemodialysis (HD) with ultrafiltration. However, the hepato-splanchnic circulation and oxygenation cannot be easily evaluated in the clinical setting of HD therapy. We included 185 HD patients and 15 healthy volunteers as the control group in this study. Before HD, hepatic regional oxygen saturation (rSO(2)), a marker of hepatic oxygenation reflecting the hepato-splanchnic circulation and oxygenation, was monitored using an INVOS 5100c oxygen saturation monitor. Hepatic rSO(2) was significantly lower in patients undergoing HD than in healthy controls (56.4 +/- 14.9% vs. 76.2 +/- 9.6%, p < 0.001). Multivariable regression analysis showed that hepatic rSO(2) was independently associated with body mass index (BMI; standardized coefficient: 0.294), hemoglobin (Hb) level (standardized coefficient: 0.294), a history of cardiovascular disease (standardized coefficient: -0.157), mean blood pressure (BP; standardized coefficient: 0.154), and serum albumin concentration (standardized coefficient: 0.150) in Model 1 via a simple linear regression analysis. In Model 2 using the colloid osmotic pressure (COP) in place of serum albumin concentration, the COP (standardized coefficient: 0.134) was also identified as affecting hepatic rSO(2). Basal hepatic oxygenation before HD might be affected by BMI, Hb levels, a history of cardiovascular disease, mean BP, serum albumin concentration, and the COP. Further prospective studies are needed to clarify whether changes in these parameters, including during HD, affect the hepato-splanchnic circulation and oxygenation in HD patients.	[Ueda, Yuichiro; Ookawara, Susumu; Ito, Kiyonori; Minato, Saori; Miyazawa, Haruhisa; Hirai, Keiji; Morishita, Yoshiyuki] Jichi Med Univ, Saitama Med Ctr, Dept Integrated Med, Div Nephrol, Saitama, Japan; [Sasabuchi, Yusuke] Jichi Med Univ, Data Sci Ctr, Shimotsuke, Tochigi, Japan; [Hayasaka, Hideyuki; Kofuji, Masaya; Uchida, Takayuki] Jichi Med Univ, Saitama Med Ctr, Dept Clin Engn, Saitama, Japan; [Imai, Sojiro; Kiryu, Satoshi; Tabei, Kaoru] Minami Uonuma City Hosp, Dept Dialysis, Niigata, Japan; [Sanayama, Hidenori] Jichi Med Univ, Saitama Med Ctr, Dept Integrated Med, Div Neurol, Saitama, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University; Jichi Medical University	Ookawara, S (corresponding author), Jichi Med Univ, Saitama Med Ctr, Dept Integrated Med, Div Nephrol, Saitama, Japan.	su-ooka@hb.tp1.jp			Japanese Association of Dialysis Physicians (JADP) [2018-10]; JSPS KAKENHI [JP20K11534]	Japanese Association of Dialysis Physicians (JADP); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a grant from the Japanese Association of Dialysis Physicians (JADP Grant 2018-10, www.touseki-ikai.or.jp/htm/03_research/) and JSPS KAKENHI (no. JP20K11534, https://www-shinsei.jsps.go.jp/kaken/english/index.html) to SO. The funders of this study had no role in the study design; data collection, analysis, and interpretation; writing; or decision to submit the manuscript for publication.	Bernardi M, 2014, J CLIN EXP HEPATOL, V4, P302, DOI 10.1016/j.jceh.2014.08.007; Carvalho JR, 2018, ANN HEPATOL, V17, P547, DOI 10.5604/01.3001.0012.0916; Cozzolino M, 2021, CLIN KIDNEY J, V14, P382, DOI 10.1093/ckj/sfz155; Daugirdas JT, 2019, SEMIN DIALYSIS, V32, P243, DOI 10.1111/sdi.12781; Daugirdas JT, 2001, AM J KIDNEY DIS, V38, pS11, DOI 10.1053/ajkd.2001.28090; Dervisevic Amela, 2015, Mater Sociomed, V27, P99, DOI 10.5455/msm.2015.27.99-103; Ferrari M, 2004, CAN J APPL PHYSIOL, V29, P463, DOI 10.1139/h04-031; Guyon PW, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.563483; Harper D, 2016, BJA EDUC, V16, P66, DOI 10.1093/bjaceaccp/mkv017; Hogas S, 2017, ARCH MED SCI, V13, P897, DOI 10.5114/aoms.2016.58664; HONGO K, 1995, NEUROL RES, V17, P89, DOI 10.1080/01616412.1995.11740293; Hoshino T, 2014, NEPHRON CLIN PRACT, V126, P57, DOI 10.1159/000358432; Imai S, 2018, BLOOD PURIFICAT, V45, P345, DOI 10.1159/000486232; Ito K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117474; Jakob SM, 2002, CRIT CARE, V6, P306, DOI 10.1186/cc1515; Jakob SM, 2001, AM J PHYSIOL-GASTR L, V280, pG819, DOI 10.1152/ajpgi.2001.280.5.G819; Kalantar-Zadeh K, 2005, AM J KIDNEY DIS, V46, P489, DOI 10.1053/j.ajkd.2005.05.020; Kitano T, 2020, J ARTIF ORGANS, V23, P187, DOI 10.1007/s10047-019-01147-x; Ko YT, 2020, HEMODIAL INT, V24, P221, DOI 10.1111/hdi.12806; LAUTT WW, 1985, AM J PHYSIOL, V249, pG549, DOI 10.1152/ajpgi.1985.249.5.G549; Lemes HP, 2011, CLIN EXP NEPHROL, V15, P554, DOI 10.1007/s10157-011-0427-z; Locatelli F, 2013, NEPHROL DIAL TRANSPL, V28, P1346, DOI 10.1093/ndt/gft033; Maduell F, 2019, ARTIF ORGANS, V43, P1014, DOI 10.1111/aor.13480; Maslehaty Homajoun, 2012, ISRN Neurol, V2012, P907187, DOI 10.5402/2012/907187; Minato S, 2019, J ARTIF ORGANS, V22, P316, DOI 10.1007/s10047-019-01118-2; Moist LM, 2013, AM J KIDNEY DIS, V62, P860, DOI 10.1053/j.ajkd.2013.08.001; Nasri H, 2006, Minerva Urol Nefrol, V58, P189; Nitta K, 2020, RENAL REPLACE THER, V6, DOI 10.1186/s41100-020-00286-9; Ookawara S, 2018, J ARTIF ORGANS, V21, P86, DOI 10.1007/s10047-017-0978-1; Ookawara S, 2014, THER APHER DIAL, V18, P202, DOI 10.1111/1744-9987.12070; Park J, 2014, PROG CARDIOVASC DIS, V56, P415, DOI 10.1016/j.pcad.2013.10.005; Prohovnik I, 2007, J CEREBR BLOOD F MET, V27, P1861, DOI 10.1038/sj.jcbfm.9600478; Rastegari Ebrahim, 2012, J Nephropharmacol, V1, P19; Scholze A, 2007, OBESITY, V15, P1617, DOI 10.1038/oby.2007.191; Tobias JD, 2006, EXPERT REV MED DEVIC, V3, P235, DOI 10.1586/17434440.3.2.235; Vincent JL, 2016, J CRIT CARE, V35, P161, DOI 10.1016/j.jcrc.2016.04.019; Yamamoto H., 2017, RENAL REPLACE THER, V3, P36, DOI [10.1186/s41100-017-0114-y, DOI 10.1186/S41100-017-0114-Y]; Yu AW, 1997, KIDNEY INT, V51, P1986, DOI 10.1038/ki.1997.270	39	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2021	16	10							e0259064	10.1371/journal.pone.0259064	http://dx.doi.org/10.1371/journal.pone.0259064			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7VP	34673824	Green Published, gold			2023-01-03	WOS:000755680200060
J	Jacobs, J; Johnson, AK; Boshara, A; Hunt, B; Khouri, C; Cruz, J; Glick, N				Jacobs, Jacquelyn; Johnson, Amy K.; Boshara, Arianna; Hunt, Bijou; Khouri, Christina; Cruz, Javier; Glick, Nancy			COVID-19 health inequities and association with mechanical ventilation and prolonged length of stay at an urban safety-net health system in Chicago	PLOS ONE			English	Article							ETHNIC DISPARITIES; UNITED-STATES; RACE	Millions of Americans have been infected with COVID-19 and communities of color have been disproportionately burdened. We investigated the relationship between demographic characteristics and COVID-19 positivity, and comorbidities and severe COVID-19 illness (use of mechanical ventilation and length of stay) within a racial/ethnic minority population. Patients tested for COVID-19 between March 2020 and January 2021 (N = 14171) were 49.9% (n = 7072) female; 50.1% (n = 7104) non-Hispanic Black; 33.2% (n = 4698) Hispanic; and 23.6% (n = 3348) aged 65+. Overall COVID-19 positivity was 16.1% (n = 2286). Compared to females, males were 1.1 times more likely to test positive (p = 0.014). Compared to non-Hispanic Whites, non-Hispanic Black and Hispanic persons were 1.4 (p = 0.003) and 2.4 (p<0.001) times more likely, respectively, to test positive. Compared to persons ages 18-24, the odds of testing positive were statistically significantly higher for every age group except 25-34, and those aged 65+ were 2.8 times more likely to test positive (p<0.001). Adjusted for race, sex, and age, COVID-positive patients with chronic obstructive pulmonary disease were 1.9 times more likely to require a ventilator compared to those without chronic obstructive pulmonary disease (p = 0.001). Length of stay was not statistically significantly associated with any of the comorbidity variables. Our findings emphasize the importance of documenting COVID-19 disparities in marginalized populations.	[Jacobs, Jacquelyn; Boshara, Arianna; Hunt, Bijou] Sinai Hlth Syst, Sinai Urban Hlth Inst, Chicago, IL USA; [Johnson, Amy K.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Hunt, Bijou; Glick, Nancy] Sinai Infect Dis Ctr, Chicago, IL USA; [Khouri, Christina; Cruz, Javier] Rosalind Franklin Univ, Chicago Med Sch, N Chicago, IL USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Chicago Medical School; Rosalind Franklin University Medical & Science	Jacobs, J (corresponding author), Sinai Hlth Syst, Sinai Urban Hlth Inst, Chicago, IL USA.	Jackie.Jacobs@sinai.org		Cruz, Javier/0000-0002-1268-0985; Jacobs, Jacquelyn/0000-0003-1584-3521				Ahmad K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241327; Anderson MR, 2021, PHARMACOECON-OPEN, V5, P129, DOI 10.1007/s41669-020-00243-6; Anesi GL, 2020, UPTODATE, P1; Azar KMJ, 2020, HEALTH AFFAIR, V39, P1253, DOI 10.1377/hlthaff.2020.00598; Bhargava A, 2020, CLIN INFECT DIS, V71, P1962, DOI 10.1093/cid/ciaa674; Bode Bruce, 2020, J Diabetes Sci Technol, V14, P813, DOI 10.1177/1932296820924469; CDC, 2020, COVID DAT TRACK; Center for Disease Control and Prevention, 2020, PEOPL CERT MED COND; Centers for Disease Control and Prevention, 2020, RISK COVID 19 INF HO; Centers for Disease Control and Prevention, 2020, EV US UPD LIST UND M; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; Chicago Department of Public Health, 2021, VACC DAT GLANC; Chicago Department of Public Health, 2020, COVID DASHB; Corona G, 2021, REV ENDOCR METAB DIS, V22, P275, DOI 10.1007/s11154-021-09630-8; Fang XY, 2020, AGING-US, V12, P12493, DOI 10.18632/aging.103579; Jaiswal J, 2019, BEHAV MED, V45, P79, DOI 10.1080/08964289.2019.1619511; Kaufman HW, 2021, POPUL HEALTH MANAG, V24, P20, DOI 10.1089/pop.2020.0163; Kim C., 2021, RACE HISPANIC ORIGIN; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Rentsch Christopher T, 2020, medRxiv, DOI [10.1101/2020.04.09.20059964, 10.1101/2020.05.12.20099135]; Rho HJ., 2020, BASIC DEMOGRAPHIC PR, V2020; Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623; Romano SD, 2021, MMWR-MORBID MORTAL W, V70, P560, DOI [10.15585/mmwr.mm7015e2, 10.15585/mmwr.mm7015e2externalicon]; Rossen LM, 2020, MMWR-MORBID MORTAL W, V69, P1522, DOI [10.1101/2020.06.06.20120857v1.full.pdf, 10.15585/mmwr.mm6942e2]; Rubin-Miller L, 2020, COVID 19 RACIAL DISP; Sinai Health System, 2013, MOUNT SIN HOSP COMM; Williams DR, 2010, J HEALTH SOC BEHAV, V51, pS15, DOI 10.1177/0022146510383838; Word DL., 1996, BUILDING SPANISH SUR; Wu Renyi, 2020, Curr Pharmacol Rep, V6, P56, DOI 10.1007/s40495-020-00216-7; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	31	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2021	16	10							e0258243	10.1371/journal.pone.0258243	http://dx.doi.org/10.1371/journal.pone.0258243			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR9CY	34644327	Green Published, gold			2023-01-03	WOS:000732519500030
J	Dolenc, E; Slabe, D; Kovacic, U				Dolenc, Eva; Slabe, Damjan; Kovacic, Uros			The needs and opportunities of older laypeople to acquire first aid skills	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION; CARDIAC-ARREST; EUROPEAN RESUSCITATION; COUNCIL GUIDELINES; BYSTANDER CPR; COMMUNITY; FALLS; FACILITATORS; POPULATION; MANAGEMENT	We aimed to determine the needs and opportunities of older lay people to obtain first aid skills. We determined the level of theoretical knowledge of performing first aid with a structured questionnaire, performed on the sample of 842 adult inhabitants of Slovenia. The method of sampling was balanced by using a system of sampling weights in order to correct deviations in the structure of the sample to the level of the population structure. We also checked their attitude regarding the renewal of first aid knowledge. The level of self-assessment of first aid knowledge and actual theoretical knowledge of proper first aid measures typically decreased with age. The percentage of those who had attended first aid courses at any time was statistically significantly lower among respondents over the age of 60; 38% of elderly respondents thought they needed to renew their first aid knowledge, and 44% would attend a suitable first aid course. None of the 29 European Red Cross and Red Crescent Societies member states that responded have a developed a formally adopted first aid program to train the elderly. A tailored first aid training program for the elderly could be one of the many steps that should be taken to ensure adequate health care for the elderly population.	[Dolenc, Eva; Slabe, Damjan] Univ Ljubljana, Fac Hlth Sci, Sanit Engn Dept, Publ Hlth Div, Ljubljana, Slovenia; [Kovacic, Uros] Univ Ljubljana, Fac Med, Inst Pathophysiol, Ljubljana, Slovenia	University of Ljubljana; University of Ljubljana	Dolenc, E (corresponding author), Univ Ljubljana, Fac Hlth Sci, Sanit Engn Dept, Publ Hlth Div, Ljubljana, Slovenia.	eva.dolenc@zf.uni-lj.si		Dolenc Sparovec, Eva/0000-0002-8740-1186				Al-Aama T, 2011, CAN FAM PHYSICIAN, V57, P771; [Anonymous], 2018, HLTH GLANCE EUROPE 2; Bakke HK, 2017, BMC EMERG MED, V17, DOI 10.1186/s12873-017-0116-7; Bell BA, 2012, AM J PUBLIC HEALTH, V102, P1399, DOI 10.2105/AJPH.2011.300398; Birkenes TS, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-40; Brinkrolf P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178938; Burton J, 2017, B C MED J, V59, P189; Cesuroglu T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010243; Chair SY, 2014, HONG KONG MED J, V20, P126, DOI 10.12809/hkmj134076; Ciol MA, 2006, ARCH PHYS MED REHAB, V87, P299, DOI 10.1016/j.apmr.2005.09.021; Dobbie F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193391; Dolenc E., 2014, ATTITUDE MOTOR VEHIC; Esteves M, 2019, AGING-US, V11, P4779, DOI 10.18632/aging.102127; Evangelatos N, 2018, INT J PUBLIC HEALTH, V63, P433, DOI 10.1007/s00038-017-1055-5; Barbosa KTF, 2019, REV BRAS ENFERM, V72, P337, DOI 10.1590/0034-7167-2018-0728; First Aid Education European Network, 2013, 1 AID TRAINING OLDER; Geda YE, 2011, J NEUROPSYCH CLIN N, V23, P149, DOI 10.1176/appi.neuropsych.23.2.149; Greif R, 2015, RESUSCITATION, V95, P288, DOI 10.1016/j.resuscitation.2015.07.032; International Federation of Red Cross and Red Crescent Societies, 2018, WE WORK; International Federation of Red Cross and Red Crescent Societies, 2015, WORLD 1 AID DAY 12 S; Jonker AAGC, 2009, EUR J AGEING, V6, P303, DOI 10.1007/s10433-009-0131-y; Kampfen F, 2018, INT J PUBLIC HEALTH, V63, P1011, DOI 10.1007/s00038-018-1137-z; Kojima G, 2018, AGE AGEING, V47, P193, DOI 10.1093/ageing/afx162; Kuramoto N, 2008, RESUSCITATION, V79, P475, DOI 10.1016/j.resuscitation.2008.07.005; Lai PH, 2020, JAMA CARDIOL, V5, P1154, DOI 10.1001/jamacardio.2020.2488; Laukaityte I, 2018, COMMUN STAT-THEOR M, V47, P4991, DOI 10.1080/03610926.2017.1383429; Lynch DM, 2006, AUST NZ J PUBL HEAL, V30, P147, DOI 10.1111/j.1467-842X.2006.tb00108.x; Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003; Moller TP, 2014, RESUSCITATION, V85, P1504, DOI 10.1016/j.resuscitation.2014.08.006; Monette M, 2012, CAN MED ASSOC J, V184, pE785, DOI 10.1503/cmaj.109-4278; Neset A, 2010, RESUSCITATION, V81, P887, DOI 10.1016/j.resuscitation.2010.03.028; Nielsen AM, 2014, RESUSCITATION, V85, P1450, DOI 10.1016/j.resuscitation.2014.08.019; Nunez DE, 2009, WORLDV EVID-BASED NU, V6, P130, DOI 10.1111/j.1741-6787.2009.00157.x; Office of the Surgeon General (the US, 2004, BON HLTH OST REP SUR; Panday SB, 2019, AGING-US, V11, P5276, DOI 10.18632/aging.102126; Park HJ, 2020, EMERG MED INT, V2020, DOI 10.1155/2020/8356201; Peeters Geeske M E E, 2007, BMC Geriatr, V7, P15, DOI 10.1186/1471-2318-7-15; Richman PB, 2007, J EMERG MED, V33, P395, DOI 10.1016/j.jemermed.2007.02.020; Robnett HR., 2020, GERONTOLOGY HLTH CAR, V4th, DOI [10.1187/cbe.20-05-0085, DOI 10.1187/CBE.20-05-0085]; Rosen Tony, 2013, J Inj Violence Res, V5, P61, DOI 10.5249/jivr.v5i1.177; Rubenstein LZ, 2006, AGE AGEING, V35, P37, DOI 10.1093/ageing/afl084; Sasson C, 2013, CIRC-CARDIOVASC QUAL, V6, P550, DOI 10.1161/CIRCOUTCOMES.111.000097; Schick S, 2018, INT J LEGAL MED, V132, P1699, DOI 10.1007/s00414-018-1876-7; Sheikhbardsiri H, 2017, WORLD J EMERG MED, V8, P253, DOI 10.5847/wjem.j.1920-8642.2017.04.002; Smith AB., 2016, DIVERSITY INCLUSION, P161, DOI [10.1007/978-3-319-22840-2_15, DOI 10.1007/978-3-319-22840-2_15]; Soar J, 2015, RESUSCITATION, V95, P100, DOI 10.1016/j.resuscitation.2015.07.016; Swor R, 2006, ACAD EMERG MED, V13, P596, DOI 10.1197/j.aem.2005.12.021; Takei Y, 2014, RESUSCITATION, V85, P492, DOI 10.1016/j.resuscitation.2013.12.019; Vaillancourt C, 2013, RESUSCITATION, V84, P1747, DOI 10.1016/j.resuscitation.2013.08.001; Veninsek G, 2018, ZDRAV VARST, V57, P106, DOI 10.2478/sjph-2018-0014; World Health Organization, 2015, AG HLTH; Wu ZX, 2018, RESUSCITATION, V122, P135, DOI 10.1016/j.resuscitation.2017.07.016; Young L, 2008, PHYSIOTHER CAN, P96, DOI [10.3138/physio/60/1/96, DOI 10.3138/PHYSIO/60/1/96]	53	1	1	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2021	16	10							e0255964	10.1371/journal.pone.0255964	http://dx.doi.org/10.1371/journal.pone.0255964			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7ZF	34637443	Green Published, gold			2023-01-03	WOS:000755690100003
J	[Anonymous]				[Anonymous]			Update to living WHO guideline on drugs for covid-19	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	5	5	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	2021	374								n2219	10.1136/bmj.n2219	http://dx.doi.org/10.1136/bmj.n2219			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ1JE	34556469				2023-01-03	WOS:000701967300004
J	Tugin, S; Souza, VH; Nazarova, MA; Novikov, PA; Tervo, AE; Nieminen, JO; Lioumis, P; Ziemann, U; Nikulin, VV; Ilmoniemi, RJ				Tugin, Sergei; Souza, Victor H.; Nazarova, Maria A.; Novikov, Pavel A.; Tervo, Aino E.; Nieminen, Jaakko O.; Lioumis, Pantelis; Ziemann, Ulf; Nikulin, Vadim V.; Ilmoniemi, Risto J.			Effect of stimulus orientation and intensity on short-interval intracortical inhibition (SICI) and facilitation (SICF): A multi-channel transcranial magnetic stimulation study	PLOS ONE			English	Article							PRIMARY MOTOR CORTEX; COIL ORIENTATION; TMS; MECHANISMS; HAND; EXCITABILITY; AXONS	Besides stimulus intensities and interstimulus intervals (ISI), the electric field (E-field) orientation is known to affect both short-interval intracortical inhibition (SICI) and facilitation (SICF) in paired-pulse transcranial magnetic stimulation (TMS). However, it has yet to be established how distinct orientations of the conditioning (CS) and test stimuli (TS) affect the SICI and SICF generation. With the use of a multi-channel TMS transducer that provides electronic control of the stimulus orientation and intensity, we aimed to investigate how changes in the CS and TS orientation affect the strength of SICI and SICF. We hypothesized that the CS orientation would play a major role for SICF than for SICI, whereas the CS intensity would be more critical for SICI than for SICF. In eight healthy subjects, we tested two ISIs (1.5 and 2.7 ms), two CS and TS orientations (anteromedial (AM) and posteromedial (PM)), and four CS intensities (50, 70, 90, and 110% of the resting motor threshold (RMT)). The TS intensity was fixed at 110% RMT. The intensities were adjusted to the corresponding RMT in the AM and PM orientations. SICI and SICF were observed in all tested CS and TS orientations. SICI depended on the CS intensity in a U-shaped manner in any combination of the CS and TS orientations. With 70% and 90% RMT CS intensities, stronger PM-oriented CS induced stronger inhibition than weaker AM-oriented CS. Similar SICF was observed for any CS orientation. Neither SICI nor SICF depended on the TS orientation. We demonstrated that SICI and SICF could be elicited by the CS perpendicular to the TS, which indicates that these stimuli affected either overlapping or strongly connected neuronal populations. We concluded that SICI is primarily sensitive to the CS intensity and that CS intensity adjustment resulted in similar SICF for different CS orientations.	[Tugin, Sergei; Souza, Victor H.; Tervo, Aino E.; Nieminen, Jaakko O.; Lioumis, Pantelis; Ilmoniemi, Risto J.] Aalto Univ, Dept Neurosci & Biomed Engn, Sch Sci, Espoo, Finland; [Tugin, Sergei; Souza, Victor H.; Tervo, Aino E.; Nieminen, Jaakko O.; Lioumis, Pantelis; Ilmoniemi, Risto J.] Univ Helsinki, BioMag Lab, Helsinki, Finland; [Tugin, Sergei; Souza, Victor H.; Tervo, Aino E.; Nieminen, Jaakko O.; Lioumis, Pantelis; Ilmoniemi, Risto J.] Helsinki Univ Hosp, HUS Med Imaging Ctr, Helsinki, Finland; [Souza, Victor H.] Univ Fed Juiz de Fora, Sch Physiotherapy, Juiz De Fora, MG, Brazil; [Nazarova, Maria A.; Novikov, Pavel A.; Nikulin, Vadim V.] Natl Res Univ Higher Sch Econ, Ctr Cognit & Decis Making, Inst Cognit Neurosci, Moscow, Russia; [Nazarova, Maria A.] Fed Med Biol Agcy, Fed State Budgetary Inst, Fed Ctr Brain Res & Neurotechnol, Moscow, Russia; [Ziemann, Ulf] Eberhard Karls Univ Tubingen, Dept Neurol & Stroke, Tubingen, Germany; [Ziemann, Ulf] Eberhard Karls Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany; [Nikulin, Vadim V.] Max Planck Inst Human Cognit & Brain Sci, Dept Neurol, Leipzig, Germany	Aalto University; University of Helsinki; Hyvinkaan Sairaala; University of Helsinki; Helsinki University Central Hospital; Universidade Federal de Juiz de Fora; HSE University (National Research University Higher School of Economics); Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Max Planck Society	Tugin, S (corresponding author), Aalto Univ, Dept Neurosci & Biomed Engn, Sch Sci, Espoo, Finland.; Tugin, S (corresponding author), Univ Helsinki, BioMag Lab, Helsinki, Finland.	sergei.tugin@aalto.fi	Ilmoniemi, Risto/E-9704-2012; Nieminen, Jaakko O./E-7311-2012; Souza, Victor Hugo/D-1611-2012; Tugin, Sergei/GQY-8574-2022; Nazarova, Maria/D-8810-2012	Ilmoniemi, Risto/0000-0002-3340-2618; Nieminen, Jaakko O./0000-0002-7826-3519; Souza, Victor Hugo/0000-0002-0254-4322; Tugin, Sergei/0000-0002-1274-8863; Nazarova, Maria/0000-0001-5347-5948; Nieminen, Aino/0000-0002-6841-7043; Ziemann, Ulf/0000-0001-8372-3615; Novikov, Pavel/0000-0003-4102-1580	European Research Council (ERC) under the European Union [810377]; Jane and Aatos Erkko Foundation; Academy of Finland [294625, 306845, 327326]; Finnish Cultural Foundation; Aalto AScI Visiting Researcher Programme; RFBR [20-315-70048]	European Research Council (ERC) under the European Union(European Research Council (ERC)); Jane and Aatos Erkko Foundation; Academy of Finland(Academy of Finland); Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Aalto AScI Visiting Researcher Programme; RFBR(Russian Foundation for Basic Research (RFBR))	This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 810377), the Jane and Aatos Erkko Foundation, the Academy of Finland (Decisions No. 294625, 306845, and 327326) and the Finnish Cultural Foundation. Pavel A. Novikov was funded by Aalto AScI Visiting Researcher Programme and by RFBR, project number 20-315-70048. Maria A. Nazarova was funded by RFBR, project number 20-315-70048.	Alle H, 2009, J PHYSIOL-LONDON, V587, P5163, DOI 10.1113/jphysiol.2009.179820; Awiszus F, 2003, SUPPL CLIN NEUROPHYS, V56, P13; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Cash RFH, 2009, EXP BRAIN RES, V193, P1, DOI 10.1007/s00221-008-1590-7; Chan JHL, 2002, J PHYSIOL-LONDON, V542, P951, DOI 10.1113/jphysiol.2002.018937; Chen M, 2018, NEUROMODULATION, V21, P368, DOI 10.1111/ner.12773; Chen R, 2004, EXP BRAIN RES, V154, P1, DOI 10.1007/s00221-003-1684-1; Cirillo J, 2018, BRAIN STIMUL, V11, P1296, DOI 10.1016/j.brs.2018.07.047; Cirillo J, 2016, EUR J NEUROSCI, V44, P2614, DOI 10.1111/ejn.13369; D'Ostilio K, 2016, CLIN NEUROPHYSIOL, V127, P675, DOI 10.1016/j.clinph.2015.05.017; Davila-Perez P, 2018, NEUROSCIENCE, V393, P97, DOI 10.1016/j.neuroscience.2018.09.044; Delvendahl I, 2014, BRAIN STIMUL, V7, P49, DOI 10.1016/j.brs.2013.08.002; Esser SK, 2005, J NEUROPHYSIOL, V94, P622, DOI 10.1152/jn.01230.2004; Fisher RJ, 2002, EXP BRAIN RES, V143, P240, DOI 10.1007/s00221-001-0988-2; Furuya S, 2018, J PHYSIOL-LONDON, V596, P2397, DOI 10.1113/JP275813; Hanajima R, 2008, CLIN NEUROPHYSIOL, V119, P1400, DOI 10.1016/j.clinph.2008.02.009; Hanajima R, 2002, J PHYSIOL-LONDON, V538, P253, DOI 10.1113/jphysiol.2001.013094; Hanajima R, 1998, J PHYSIOL-LONDON, V509, P607, DOI 10.1111/j.1469-7793.1998.607bn.x; Hanajima R, 2003, EXP BRAIN RES, V151, P427, DOI 10.1007/s00221-003-1455-z; Hashemirad F, 2017, BASIC CLIN NEUROSCI, V8, P43, DOI 10.15412/J.BCN.03080106; Ilic TV, 2002, J PHYSIOL-LONDON, V545, P153, DOI 10.1113/jphysiol.2002.030122; Janssen AM, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0036-2; Kallioniemi E, 2018, BRAIN STIMUL, V11, P322, DOI 10.1016/j.brs.2017.10.014; Koponen LM, 2018, HUM BRAIN MAPP, V39, P2405, DOI 10.1002/hbm.24010; Koponen LM, 2018, BRAIN STIMUL, V11, P849, DOI 10.1016/j.brs.2018.03.014; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Laakso I, 2014, PHYS MED BIOL, V59, P203, DOI 10.1088/0031-9155/59/1/203; Ljubisavljevic M, 2006, EXP BRAIN RES, V173, P215, DOI 10.1007/s00221-006-0538-z; Miranda PC, 2003, IEEE T BIO-MED ENG, V50, P1074, DOI 10.1109/TBME.2003.816079; Nieminen JO, 2019, NEUROIMAGE, V203, DOI 10.1016/j.neuroimage.2019.116194; Nieminen JO, 2015, BRAIN STIMUL, V8, P582, DOI 10.1016/j.brs.2015.01.004; Orth M, 2003, CLIN NEUROPHYSIOL, V114, P2362, DOI 10.1016/S1388-2457(03)00243-8; Peterchev AV, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/5/056023; Peurala SH, 2008, CLIN NEUROPHYSIOL, V119, P2291, DOI 10.1016/j.clinph.2008.05.031; Porter LL, 2000, SOMATOSENS MOT RES, V17, P67; Rosenkranz K, 2008, NEUROLOGY, V70, P304, DOI 10.1212/01.wnl.0000296829.66406.14; Rossi S, 2021, CLIN NEUROPHYSIOL, V132, P269, DOI 10.1016/j.clinph.2020.10.003; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Roth Y, 2020, BRAIN STIMUL, V13, P900, DOI 10.1016/j.brs.2020.03.010; Sale MV, 2016, CLIN NEUROPHYSIOL, V127, P635, DOI 10.1016/j.clinph.2015.04.062; Shirota Y, 2016, BRAIN STIMUL, V9, P755, DOI 10.1016/j.brs.2016.04.019; Sommer M, 2018, BRAIN STIMUL, V11, P558, DOI 10.1016/j.brs.2018.01.001; Souza VH, FINE MULTICOIL ELECT, V2021, DOI [10.1101/2021.08.20.457096, DOI 10.1101/2021.08.20.457096]; Souza VH, PROBING ORIENTATION, V2021, DOI [10.1101/2021.08.20.457101, DOI 10.1101/2021.08.20.457101]; ter Braack EM, 2019, BRAIN TOPOGR, V32, P17, DOI 10.1007/s10548-018-0662-7; Tervo AE, 2020, NEUROIMAGE, V220, DOI 10.1016/j.neuroimage.2020.117082; Thielscher A, 2011, NEUROIMAGE, V54, P234, DOI 10.1016/j.neuroimage.2010.07.061; Van den Bos MAJ, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00240; Vucic S, 2011, CEREB CORTEX, V21, P1639, DOI 10.1093/cercor/bhq235; Wagle-Shukla A, 2009, J PHYSIOL-LONDON, V587, P5665, DOI 10.1113/jphysiol.2009.181446; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734; Ziemann U, 2020, EXP BRAIN RES, V238, P1601, DOI 10.1007/s00221-020-05764-4; Ziemann U, 2015, CLIN NEUROPHYSIOL, V126, P1847, DOI 10.1016/j.clinph.2014.08.028	53	2	2	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2021	16	9							e0257554	10.1371/journal.pone.0257554	http://dx.doi.org/10.1371/journal.pone.0257554			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YS4WS	34550997	Green Published, gold			2023-01-03	WOS:000750679800023
J	Fan, C; Huang, SY; Xiang, CH; An, TH; Song, Y				Fan, Cheng; Huang, Shiyuan; Xiang, Chunhua; An, Tianhui; Song, Yi			Identification of key genes and immune infiltration modulated by CPAP in obstructive sleep apnea by integrated bioinformatics analysis	PLOS ONE			English	Article							EXPRESSION	Patients with obstructive sleep apnea (OSA) experience partial or complete upper airway collapses during sleep resulting in nocturnal hypoxia-normoxia cycling, and continuous positive airway pressure (CPAP) is the golden treatment for OSA. Nevertheless, the exact mechanisms of action, especially the transcriptome effect of CPAP on OSA patients, remain elusive. The goal of this study was to evaluate the longitudinal alterations in peripheral blood mononuclear cells transcriptome profiles of OSA patients in order to identify the hub gene and immune response. GSE133601 was downloaded from Gene Expression Omnibus (GEO). We identified black module via weighted gene co-expression network analysis (WGCNA), the genes in which were correlated significantly with the clinical trait of CPAP treatment. Finally, eleven hub genes (TRAV10, SNORA36A, RPL10, OBP2B, IGLV1-40, H2BC8, ESAM, DNASE1L3, CD22, ANK3, ACP3) were traced and used to construct a random forest model to predict therapeutic efficacy of CPAP in OSA with a good performance with AUC of 0.92. We further studied the immune cells infiltration in OSA patients with CIBERSORT, and monocytes were found to be related with the remission of OSA and partially correlated with the hub genes identified. In conclusion, these key genes and immune infiltration may be of great importance in the remission of OSA and related research of these genes may provide a new therapeutic target for OSA in the future.	[Fan, Cheng; Huang, Shiyuan; Xiang, Chunhua; An, Tianhui; Song, Yi] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Geriatr, Wuhan, Peoples R China	Huazhong University of Science & Technology	Song, Y (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Geriatr, Wuhan, Peoples R China.	yisong@hust.edu.cn	Fan, Cheng/GXW-3204-2022	Song, Yi/0000-0003-2334-4896				Almendros I, 2022, J SLEEP RES, V31, DOI 10.1111/jsr.13418; Behzadi P, 2019, ACTA MICROBIOL IMM H, V66, P19, DOI 10.1556/030.65.2018.028; Bonsignore MR, 2013, EUR RESPIR REV, V22, P353, DOI 10.1183/09059180.00003413; Brozyna-Tkaczyk K, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57040310; Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055; Chan BKC, 2018, ADV EXP MED BIOL, V1082, P47, DOI 10.1007/978-3-319-93791-5_2; Charkoftaki G, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0191-9; Chen H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-35; Degenhardt F, 2019, BRIEF BIOINFORM, V20, P492, DOI 10.1093/bib/bbx124; Di Luca M, 2020, INT J MED ROBOT COMP, V16, DOI 10.1002/rcs.2106; DOWDY SF, 1991, NUCLEIC ACIDS RES, V19, P5763, DOI 10.1093/nar/19.20.5763; Dyugovskaya L, 2002, AM J RESP CRIT CARE, V165, P934, DOI 10.1164/ajrccm.165.7.2104126; Gharib SA, 2020, SLEEP, V43, DOI 10.1093/sleep/zsz314; Hernandez-Jimenez E, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02456-2016; Hoffmann MS, 2013, ATHEROSCLEROSIS, V231, P378, DOI 10.1016/j.atherosclerosis.2013.09.033; Jellusova J, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00096; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Lacazette E, 2000, HUM MOL GENET, V9, P289, DOI 10.1093/hmg/9.2.289; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lefranc MP, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00022; Loftus TM, 1997, BIOCHEMISTRY-US, V36, P8224, DOI 10.1021/bi970288d; Maher LLM, 2022, J AM ASSOC NURSE PRA, V34, P389, DOI 10.1097/JXX.0000000000000632; Maniaci A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020277; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nilsson RH, 2019, NAT REV MICROBIOL, V17, P95, DOI 10.1038/s41579-018-0116-y; Parsons C, 2017, FUTUR CARDIOL, V13, P397, DOI 10.2217/fca-2017-0004; Rigatti Steven J, 2017, J Insur Med, V47, P31, DOI 10.17849/insm-47-01-31-39.1; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Speiser JL, 2015, STAT MED, V34, P887, DOI 10.1002/sim.6351; Tserenpil G, 2020, CUREUS, V12, DOI 10.7759/cureus.9905; Wang HZ, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-0900-5; Wang XT, 2019, CURR MED SCI, V39, P52, DOI 10.1007/s11596-019-1999-1; Zhang H, 2021, ONCOTARGETS THER, V14, P1021, DOI 10.2147/OTT.S294500	34	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2021	16	9							e0255708	10.1371/journal.pone.0255708	http://dx.doi.org/10.1371/journal.pone.0255708			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5YY	34529670	gold, Green Published, Green Submitted			2023-01-03	WOS:000707071500010
J	Schilberg, L; Ten Oever, S; Schuhmann, T; Sack, AT				Schilberg, Lukas; Ten Oever, Sanne; Schuhmann, Teresa; Sack, Alexander T.			Phase and power modulations on the amplitude of TMS-induced motor evoked potentials	PLOS ONE			English	Article							BRAIN-STIMULATION; EEG; VARIABILITY; EXCITABILITY; SYSTEM; CORTEX; SYNCHRONIZATION; OSCILLATIONS; PLASTICITY; RESPONSES	The evaluation of transcranial magnetic stimulation (TMS)-induced motor evoked potentials (MEPs) promises valuable information about fundamental brain related mechanisms and may serve as a diagnostic tool for clinical monitoring of therapeutic progress or surgery procedures. However, reports about spontaneous fluctuations of MEP amplitudes causing high intra-individual variability have led to increased concerns about the reliability of this measure. One possible cause for high variability of MEPs could be neuronal oscillatory activity, which reflects fluctuations of membrane potentials that systematically increase and decrease the excitability of neuronal networks. Here, we investigate the dependence of MEP amplitude on oscillation power and phase by combining the application of single pulse TMS over the primary motor cortex with concurrent recordings of electromyography and electroencephalography. Our results show that MEP amplitude is correlated to alpha phase, alpha power as well as beta phase. These findings may help explain corticospinal excitability fluctuations by highlighting the modulatory effect of alpha and beta phase on MEPs. In the future, controlling for such a causal relationship may allow for the development of new protocols, improve this method as a (diagnostic) tool and increase the specificity and efficacy of general TMS applications.	[Schilberg, Lukas; Ten Oever, Sanne; Schuhmann, Teresa; Sack, Alexander T.] Maastricht Univ, Fac Psychol & Neurosci, Dept Cognit Neurosci, Sect Brain Stimulat & Cognit, Maastricht, Netherlands; [Ten Oever, Sanne] Max Planck Inst Psycholinguist, Language & Computat Neural Syst Grp, Nijmegen, Netherlands; [Ten Oever, Sanne] Radboud Univ Nijmegen, Donders Inst Neuroimaging, Nijmegen, Netherlands; [Schuhmann, Teresa; Sack, Alexander T.] Maastricht Univ, Maastricht Brain Imaging Ctr MBIC, Maastricht, Netherlands; [Schuhmann, Teresa; Sack, Alexander T.] Maastricht Univ, Fac Psychol & Neurosci, Fac Hlth Med & Life Sci, Ctr Integrat Neurosci, Maastricht, Netherlands; [Sack, Alexander T.] Maastricht Univ, Fac Hlth Med & Life Sci, Sch Mental Hlth & Neurosci MHeNS, Dept Psychiat & Neuropsychol,Med Ctr, Maastricht, Netherlands	Maastricht University; Max Planck Society; Radboud University Nijmegen; Maastricht University; Maastricht University; Maastricht University	Sack, AT (corresponding author), Maastricht Univ, Fac Psychol & Neurosci, Dept Cognit Neurosci, Sect Brain Stimulat & Cognit, Maastricht, Netherlands.; Sack, AT (corresponding author), Maastricht Univ, Maastricht Brain Imaging Ctr MBIC, Maastricht, Netherlands.; Sack, AT (corresponding author), Maastricht Univ, Fac Psychol & Neurosci, Fac Hlth Med & Life Sci, Ctr Integrat Neurosci, Maastricht, Netherlands.; Sack, AT (corresponding author), Maastricht Univ, Fac Hlth Med & Life Sci, Sch Mental Hlth & Neurosci MHeNS, Dept Psychiat & Neuropsychol,Med Ctr, Maastricht, Netherlands.	a.sack@maastrichtuniversity.nl		ten Oever, Sanne/0000-0001-7547-5842; Sack, Alexander/0000-0002-1471-0885	Netherlands Organization for Scientific Research (NWO) [453-15008]	Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	This work was funded by the research program NWO VICI "The rhythms of cognition: Using simultaneous TMS-fMRI-EEG to integrate brain-wide network and oscillatory communication mechanisms for enhancing human cognition" (awarded to ATS) with project number 453-15008, which is financed by the Netherlands Organization for Scientific Research (NWO).	Berens P, 2009, J STAT SOFTW, V31, P1, DOI 10.18637/jss.v031.i10; Berger B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/936096; Bergmann TO, 2019, J NEUROSCI, V39, P10034, DOI 10.1523/JNEUROSCI.1730-19.2019; Bergmann TO, 2016, NEUROIMAGE, V140, P4, DOI 10.1016/j.neuroimage.2016.02.012; BURKE D, 1995, ELECTROMYOGR MOTOR C, V97, P231, DOI 10.1016/0924-980X(95)00005-4; Devanne H, 1997, EXP BRAIN RES, V114, P329, DOI 10.1007/PL00005641; Feurra M, 2011, J NEUROSCI, V31, P12165, DOI 10.1523/JNEUROSCI.0978-11.2011; GASSER T, 1982, ELECTROEN CLIN NEURO, V53, P119, DOI 10.1016/0013-4694(82)90112-2; Goetz SM, 2014, BRAIN STIMUL, V7, P541, DOI 10.1016/j.brs.2014.03.002; Gomez-Herrero G, 2006, 2006 7TH NORDIC SIGNAL PROCESSING SYMPOSIUM, P130; Guerrero APC, 2016, CONTRADICCIONES DE LOS SISTEMAS DE GESTION DE CALIDAD: ENTRE LA ESTANDARIZACION Y LA INNOVACION PEDAGOGICA, P1, DOI 10.1093/cercor/bhw245; Haegens S, 2014, NEUROIMAGE, V92, P46, DOI 10.1016/j.neuroimage.2014.01.049; Hussain SJ, 2019, CEREB CORTEX, V29, P3766, DOI 10.1093/cercor/bhy255; Jackson AF, 2014, PSYCHOPHYSIOLOGY, V51, P1061, DOI 10.1111/psyp.12283; Jones PR, 2019, ATTEN PERCEPT PSYCHO, V81, P1189, DOI 10.3758/s13414-019-01726-3; Kayser J, 2006, CLIN NEUROPHYSIOL, V117, P348, DOI 10.1016/j.clinph.2005.08.034; Keil J, 2014, J NEUROPHYSIOL, V111, P513, DOI 10.1152/jn.00387.2013; Khademi F, 2019, BRAIN STIMUL, V12, P296, DOI 10.1016/j.brs.2018.10.015; KIERS L, 1993, ELECTROEN CLIN NEURO, V89, P415, DOI 10.1016/0168-5597(93)90115-6; Kilavik BE, 2013, EXP NEUROL, V245, P15, DOI 10.1016/j.expneurol.2012.09.014; KUHLMAN WN, 1978, ELECTROEN CLIN NEURO, V44, P83, DOI 10.1016/0013-4694(78)90107-4; Lepage JF, 2008, J NEUROSCI METH, V175, P17, DOI 10.1016/j.jneumeth.2008.07.021; Maki H, 2010, CLIN NEUROPHYSIOL, V121, P492, DOI 10.1016/j.clinph.2009.11.078; Mathewson KE, 2009, J NEUROSCI, V29, P2725, DOI 10.1523/JNEUROSCI.3963-08.2009; Mitchell WK, 2007, J PHYSIOL-LONDON, V583, P567, DOI 10.1113/jphysiol.2007.134031; Muellbacher W, 2000, CLIN NEUROPHYSIOL, V111, P344, DOI 10.1016/S1388-2457(99)00243-6; NICHOLSON C, 1975, J NEUROPHYSIOL, V38, P356, DOI 10.1152/jn.1975.38.2.356; Niedermeyer E., 2005, ELECTROEN CLIN NEURO; Ogata K, 2019, BRAIN STIMUL, V12, P1508, DOI 10.1016/j.brs.2019.06.013; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Pellegrini M, 2021, NEUROSCI RES, V166, P12, DOI 10.1016/j.neures.2020.06.002; Pellegrini M, 2018, BRAIN RES, V1700, P190, DOI 10.1016/j.brainres.2018.09.002; Peters JC, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0764-0; PFURTSCHELLER G, 1994, NEUROSCI LETT, V174, P93, DOI 10.1016/0304-3940(94)90127-9; Raco V, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00143; Rossi S, 2004, TRENDS COGN SCI, V8, P273, DOI 10.1016/j.tics.2004.04.012; Sauseng P, 2009, NEUROPSYCHOLOGIA, V47, P284, DOI 10.1016/j.neuropsychologia.2008.07.021; Schaworonkow N, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00954; Schaworonkow N, 2019, BRAIN STIMUL, V12, P110, DOI 10.1016/j.brs.2018.09.009; Schilberg L, 2018, CORTEX, V103, P142, DOI 10.1016/j.cortex.2018.03.001; Schilberg L, 2017, J COGNITIVE NEUROSCI, V29, P1022, DOI 10.1162/jocn_a_01100; Schulz H, 2014, CEREB CORTEX, V24, P1708, DOI 10.1093/cercor/bht024; Smulders FTY, 2018, EUR J NEUROSCI, V48, P2585, DOI 10.1111/ejn.13854; Sohn Young H, 2004, Phys Med Rehabil Clin N Am, V15, P117, DOI 10.1016/S1047-9651(03)00105-0; Stefanou MI, 2019, JOVE-J VIS EXP, DOI 10.3791/59711; ten Oever S, 2015, P NATL ACAD SCI USA, V112, P15833, DOI 10.1073/pnas.1517519112; Thies M, 2018, BRAIN STIMUL, V11, P1119, DOI 10.1016/j.brs.2018.06.006; Torrecillos F, 2020, J NEUROSCI, V40, P369, DOI 10.1523/JNEUROSCI.1953-19.2019; Wassermann EM, 1996, EXP BRAIN RES, V109, P158; Wassermann EM, 2002, CLIN NEUROPHYSIOL, V113, P1165, DOI 10.1016/S1388-2457(02)00144-X; Zarkowski P, 2006, CLIN EEG NEUROSCI, V37, P247, DOI 10.1177/155005940603700316; Zrenner C, 2018, BRAIN STIMUL, V11, P374, DOI 10.1016/j.brs.2017.11.016	52	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2021	16	9							e0255815	10.1371/journal.pone.0255815	http://dx.doi.org/10.1371/journal.pone.0255815			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5YY	34529682	gold, Green Published			2023-01-03	WOS:000707071500011
J	Ijdi, RE; Tumlinson, K; Curtis, SL				Ijdi, Rashida-E; Tumlinson, Katherine; Curtis, Sian L.			Exploring association between place of delivery and newborn care with early-neonatal mortality in Bangladesh	PLOS ONE			English	Article							MIDDLE-INCOME COUNTRIES; INFANT-MORTALITY; DEATHS; STILLBIRTHS; HEALTH; QUALITY; INDIA; RISK	Objective Bangladesh achieved the fourth Millennium Development Goal well ahead of schedule, with a significant reduction in under-5 mortality between 1990 and 2015. However, the reduction in neonatal mortality has been stagnant in recent years. The purpose of this study is to explore the association between place of delivery and newborn care with early neonatal mortality (ENNM), which represents more than 80% of total neonatal mortality in Bangladesh. Methods In this study, 2014 Bangladesh Demographic and Health Survey data were used to assess early neonatal survival in children born in the three years preceding the survey. The roles of place of the delivery and newborn care in ENNM were examined using multivariable logistic regression models adjusted for clustering and relevant socio-economic, pregnancy, and newborn characteristics. Results Between 2012 and 2014, there were 4,624 deliveries in 17,863 sampled households, 39% of which were delivered at health facilities. The estimated early neonatal mortality rate during this period was 15 deaths per 1,000 live births. We found that newborns who had received at least 3 components of essential newborn care (ENC) were 56% less likely to die during the first seven days of their lives compared to their counterparts who received 0-2 components of ENC (aOR: 0.44; 95% CI: 0.24-0.81). In addition, newborns who had received any postnatal care (PNC) were 68% less likely to die in the early neonatal period than those who had not received any PNC (aOR: 0.32; 95% CI: 0.16-0.64). Facility delivery was not significantly associated with the risk of early newborn death in any of the models. Conclusion Our study findings highlight the importance of newborn and postnatal care in preventing early neonatal deaths. Further, findings suggest that increasing the proportion of women who give birth in a healthcare facility is not sufficient to reduce ENNM by itself; to realize the theoretical potential of facility delivery to avert neonatal deaths, we must also ensure quality of care during delivery, guarantee all components of ENC, and provide high-quality early PNC. Therefore, sustained efforts to expand access to high-quality ENC and PNC are needed in health facilities, particularly in facilities serving low-income populations.	[Ijdi, Rashida-E; Tumlinson, Katherine; Curtis, Sian L.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA; [Ijdi, Rashida-E; Tumlinson, Katherine; Curtis, Sian L.] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ijdi, RE (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA.; Ijdi, RE (corresponding author), Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27515 USA.	rashida.ijdi@gmail.com	Tumlinson, Katherine/E-6975-2013	Tumlinson, Katherine/0000-0001-8314-8219				Abir T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187090; Akter T, 2016, J PERINATOL, V36, P225, DOI 10.1038/jp.2015.181; Al Kibria GM, 2018, GLOBALIZATION HEALTH, V14, DOI 10.1186/s12992-018-0363-8; Alam N, 2007, TROP MED INT HEALTH, V12, P1506, DOI 10.1111/j.1365-3156.2007.01959.x; Baqui AH, 2006, Bull World Health Organ, V84, P706, DOI 10.2471/BLT.05.026443; Belizan JM, 2012, AM J PERINAT, V29, P649, DOI 10.1055/s-0032-1314885; Bhutta ZA, 2008, B WORLD HEALTH ORGAN, V86, P452, DOI 10.2471/BLT.07.045849; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Blanc AK, 2016, J GLOB HEALTH, V6, DOI 10.7189/jogh.06.010405; Brocklehurst P, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7400; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Fikree Fariyal F., 2006, JPMA Journal of the Pakistan Medical Association, V56, P156; Fottrell E, 2015, ARCH DIS CHILD-FETAL, V100, pF439, DOI 10.1136/archdischild-2014-307636; Government of the People's Republic of Bangladesh, 2016, MILLENNIUM DEV GOALS; Greenland S., 2012, MODERN EPIDEMIOLOGY, V2nd; Halim A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159388; Hossain MB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221503; Kamal S. M. M., 2012, Journal of Nepal Paediatric Society, V32, P37, DOI 10.3126/jnps.v32i1.4845; Kim E, 2017, MATERN CHILD HLTH J, V21, P2078, DOI 10.1007/s10995-017-2319-7; Kumar V, 2008, LANCET, V372, P1151, DOI 10.1016/S0140-6736(08)61483-X; Kunkel M, 2019, SEMIN PERINATOL, V43, P252, DOI 10.1053/j.semperi.2019.03.014; Lawn J, 2005, B WORLD HEALTH ORGAN, V83, P409; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Lawn JE, 2009, INT J GYNECOL OBSTET, V107, pS5, DOI 10.1016/j.ijgo.2009.07.016; Lehtonen L, 2017, SEMIN FETAL NEONAT M, V22, P153, DOI 10.1016/j.siny.2017.02.006; Lohela TJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45148-5; Luke B, 2006, PEDIATRICS, V118, P2488, DOI 10.1542/peds.2006-1824; Malqvist M, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-762; National Institute of Population Research and Training (NIPORT) Association for Community and Population Research (ACPR) and ICF International, 2016, 2014 BANGL HLTH FAC; National Institute of Population Research and Training (NIPORT) Mitra and Associates and ICF International, 2016, BANGL DEM HLTH SURV; Ngoc NTN, 2006, B WORLD HEALTH ORGAN, V84, P699, DOI 10.2471/BLT.05.027300; NIPORT. & ICF, 2019, BANGL HLTH FAC SURV; Pullum TW, 2014, DHS METHODOLOGICAL R, V11; Richiardi L, 2013, INT J EPIDEMIOL, V42, P1511, DOI 10.1093/ije/dyt127; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Ronsmans C, 2010, B WORLD HEALTH ORGAN, V88, P289, DOI 10.2471/BLT.09.069385; StataCorp, 2017, STATA STAT SOFTWARE, DOI DOI 10.2307/2234838; Sven K., 2010, EPIDEMIOLOGY, V21, P159, DOI [10.1097/EDE.0b013e3181c307ce, DOI 10.1097/EDE.0B013E3181C307CE]; Titaley CR, 2012, HEALTH POLICY PLANN, V27, P405, DOI 10.1093/heapol/czr053; United Nations Population Division, LEV TRENDS CHILD MOR; van den Broek NR, 2009, BJOG-INT J OBSTET GY, V116, P18, DOI 10.1111/j.1471-0528.2009.02333.x; World Health Organization, 2013, SERVICE AVAILABILITY; World Health Organization, 2006, NEONATAL PERINATAL M; World Health Organization (WHO), 2017, WORLD HLTH ORG WHO R; World Health Organization (WHO) The United Nations Children's Fund (UNICEF), 2014, EV NEWB ACT END PREV	45	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0262408	10.1371/journal.pone.0262408	http://dx.doi.org/10.1371/journal.pone.0262408			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085299	Green Published, gold			2023-01-03	WOS:000779379600052
J	Crowley, C; Murphy, B; McCaul, C; Cahill, R; Nolan, KP				Crowley, Caroline; Murphy, Brian; McCaul, Conan; Cahill, Ronan; Nolan, Kevin Patrick			Airborne particle dispersion by high flow nasal oxygen: An experimental and CFD analysis	PLOS ONE			English	Article								High Flow Nasal Oxygen (HFNO) therapy offers a proven means of delivering respiratory support to critically ill patients suffering from viral illness such as COVID-19. However, the therapy has the potential to modify aerosol generation and dispersion patterns during exhalation and thereby put healthcare workers at increased risk of disease transmission. Fundamentally, a gap exists in the literature with regards to the effect of the therapy on the fluid dynamics of the exhalation jet which is essential in understanding the dispersion of aerosols and hence quantifying the disease transmission risk posed by the therapy. In this paper, a multi-faceted approach was taken to studying the aerosol-laden exhalation jet. Schlieren imaging was used to visualise the flow field for a range of expiratory activities for three healthy human volunteers receiving HFNO therapy at flow rates of 0-60 L/min. A RANS turbulence model was implemented using the CFD software OpenFOAM and used to perform a parametric study on the influence of exhalation velocity and duration on the dispersion patterns of non-evaporating droplets in a room environment. A dramatic increase in the turbulence of the exhalation jet was observed when HFNO was applied. Quantitative analysis indicated that the mean exhalation velocity was increased by 2.2-3.9 and 2.3-3 times that for unassisted breathing and coughing, respectively. A 1-2 second increase was found in the exhalation duration. The CFD model showed that small droplets (10-40 mu m) were most greatly affected, where a 1 m/s increase in velocity and 1 s increase in duration caused an 80% increase in axial travel distance.	[Crowley, Caroline; Nolan, Kevin Patrick] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland; [Murphy, Brian; McCaul, Conan] Rotunda Hosp, Dept Anaesthesia, Dublin, Ireland; [Murphy, Brian; McCaul, Conan] Mater Misericordiae Univ Hosp, Dept Anaesthesia, Dublin, Ireland; [McCaul, Conan; Cahill, Ronan] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland; [Cahill, Ronan] Univ Coll Dublin, Sch Med, Sect Surg & Surg Special, Ctr Precis Surg, Dublin, Ireland	University College Dublin; Mater Misericordiae University Hospital; University College Dublin; University College Dublin; University College Dublin	Nolan, KP (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland.	kevin.nolan@ucd.ie		Cahill, Ronan/0000-0002-1270-4000; Nolan, Kevin/0000-0001-7042-3162	Irish Centre for High-End Computing (ICHEC); ResearchIT Sonic cluster	Irish Centre for High-End Computing (ICHEC); ResearchIT Sonic cluster	The authors wish to acknowledge the Irish Centre for High-End Computing (ICHEC) and the ResearchIT Sonic cluster for the provision of computational facilities and support. The authors also wish to thank the Mater Misericordiae University Hospital for facilitating the schlieren experiments.	Alhazzani Waleed, 2020, Crit Care Med, V48, pe440, DOI [10.1007/s00134-020-06022-5, 10.1097/CCM.0000000000004363]; [Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; Asadi S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38808-z; Bourouiba L, 2014, J FLUID MECH, V745, P537, DOI 10.1017/jfm.2014.88; Calligaro GL, 2020, ECLINICALMEDICINE, V28, DOI 10.1016/j.eclinm.2020.100570; Celik IB, 2008, J FLUID ENG-T ASME, V130, DOI 10.1115/1.2960953; Chao CYH, 2009, J AEROSOL SCI, V40, P122, DOI 10.1016/j.jaerosci.2008.10.003; Dbouk T, 2021, PHYS FLUIDS, V33, DOI 10.1063/5.0038180; Dbouk T, 2020, PHYS FLUIDS, V32, DOI 10.1063/5.0024272; Dbouk T, 2020, PHYS FLUIDS, V32, DOI 10.1063/5.0015044; Dbouk T, 2020, PHYS FLUIDS, V32, DOI 10.1063/5.0011960; Evgeniy Romenski, 2009, J SCI COMPUTING, V42, P1; Farneback G, 2003, LECT NOTES COMPUT SC, V2749, P363, DOI 10.1007/3-540-45103-x_50; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Gaeckle NT, 2020, AM J RESP CRIT CARE, V202, P1115, DOI 10.1164/rccm.202006-2309OC; Gupta JK, 2009, INDOOR AIR, V19, P517, DOI 10.1111/j.1600-0668.2009.00619.x; Guy T, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01154-2020; HAIDER A, 1989, POWDER TECHNOL, V58, P63, DOI 10.1016/0032-5910(89)80008-7; Hardy N, 2021, BRIT J SURG, V108, P1022, DOI 10.1093/bjs/znab114; Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018; Jackson T, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000730; Johnson GR, 2011, J AEROSOL SCI, V42, P839, DOI 10.1016/j.jaerosci.2011.07.009; Leonard S, 2020, JACEP OPEN, V1, P578, DOI 10.1002/emp2.12158; Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007; Lindsley WG, 2012, J OCCUP ENVIRON HYG, V9, P443, DOI 10.1080/15459624.2012.684582; Lyons C, 2020, ANAESTHESIA, V75, P843, DOI 10.1111/anae.15073; Menter FR, 2014, HEAT MASS TRANSFER, V4, P625; Mittal R, 2020, J FLUID MECH, V894, DOI 10.1017/jfm.2020.330; Pendar MR, 2020, PHYS FLUIDS, V32, DOI 10.1063/5.0018432; Shelton J, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253615; Simha PP, 2020, PHYS FLUIDS, V32, DOI 10.1063/5.0021666; Tang JLW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059970; Tang JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034818; VanSciver M, 2011, AEROSOL SCI TECH, V45, P415, DOI 10.1080/02786826.2010.542785; Verma S, 2020, PHYS FLUIDS, V32, DOI 10.1063/5.0016018; Vuorinen V, 2020, SAFETY SCI, V130, DOI 10.1016/j.ssci.2020.104866; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Xie X, 2007, INDOOR AIR, V17, P211, DOI 10.1111/j.1600-0668.2007.00469.x; Xie X, 2009, J ROYAL SOC INTER S6, V6, DOI [10.1098/rsif.2009.0388.focus, DOI 10.1098/RSIF.2009.0388.F0CUS]; Xu CW, 2017, BUILD ENVIRON, V112, P190, DOI 10.1016/j.buildenv.2016.11.032; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	41	0	0	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0262547	10.1371/journal.pone.0262547	http://dx.doi.org/10.1371/journal.pone.0262547			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061806	gold, Green Published			2023-01-03	WOS:000791072800140
J	Gandhi, RT; Malani, PN; del Rio, C				Gandhi, Rajesh T.; Malani, Preeti N.; del Rio, Carlos			COVID-19 Therapeutics for Nonhospitalized Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Gandhi, Rajesh T.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Malani, Preeti N.] Univ Michigan Hlth Syst, Dept Internal Med, Div Infect Dis, Ann Arbor, MI USA; [del Rio, Carlos] Emory Univ, Sch Med, Dept Med, Georgia Grady Hlth Syst,Div Infect Dis, Atlanta, GA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Michigan System; University of Michigan; Emory University	Gandhi, RT (corresponding author), Massachusetts Gen Hosp, Cox 548, Boston, MA 02114 USA.	rgandhi@mgh.harvard.edu	del Rio, Carlos/B-3763-2012	del Rio, Carlos/0000-0002-0153-3517	Harvard University Center for AIDS Research [NIAID 5P30AI060354]; AIDS Clinical Trials Group (NIH/NIAID) [UM1 AI069412-09]	Harvard University Center for AIDS Research; AIDS Clinical Trials Group (NIH/NIAID)	Dr Gandhi receives funding from the Harvard University Center for AIDS Research (NIAID 5P30AI060354) and AIDS Clinical Trials Group (NIH/NIAID UM1 AI069412-09).	Bernal AJ, 2022, NEW ENGL J MED, V386, P509, DOI 10.1056/NEJMoa2116044; Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249; Gottlieb RL, 2022, NEW ENGL J MED, V386, P305, DOI 10.1056/NEJMoa2116846; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Infectious Disease Society of America, IDSA GUID TREATM MAN; National Institutes of Health, COR DIS 2019 COVID 1; Owen DR, 2021, SCIENCE, V374, P1586, DOI 10.1126/science.abl4784; Planas D, 2021, CONSIDERABLE ESCAPE, DOI [10.1101/2021.12.14.472630, DOI 10.1101/2021.12.14.472630]; US Food and Drug Administration, FACT SHEET HEALTHC P; Zhou ST, 2021, J INFECT DIS, V224, P415, DOI 10.1093/infdis/jiab247	10	23	24	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2022	327	7					617	618		10.1001/jama.2022.0335	http://dx.doi.org/10.1001/jama.2022.0335		JAN 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD5SM	35029659				2023-01-03	WOS:000742417400001
J	Powles, T; Yuen, KC; Gillessen, S; Kadel, EE; Rathkopf, D; Matsubara, N; Drake, CG; Fizazi, K; Piulats, JM; Wysocki, PJ; Jr, GLB; Alekseev, B; Mellado, B; Karaszewska, B; Doss, JF; Rasuo, G; Datye, A; Mariathasan, S; Williams, P; Sweeney, CJ				Powles, Thomas; Yuen, Kobe C.; Gillessen, Silke; Kadel, Edward E.; Rathkopf, Dana; Matsubara, Nobuaki; Drake, Charles G.; Fizazi, Karim; Piulats, Josep M.; Wysocki, Piotr J.; Jr, Gary L. Buchschacher; Alekseev, Boris; Mellado, Begona; Karaszewska, Boguslawa; Doss, Jennifer F.; Rasuo, Grozdana; Datye, Asim; Mariathasan, Sanjeev; Williams, Patrick; Sweeney, Christopher J.			Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial	NATURE MEDICINE			English	Article							CLINICAL-IMPLICATIONS; DOUBLE-BLIND; OPEN-LABEL; III TRIAL; CHEMOTHERAPY; IPILIMUMAB; PLACEBO; MULTICENTER; ABIRATERONE; RADIOTHERAPY	Early clinical data indicate that some patients with castration-resistant prostate cancer may benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide. The IMbassador250 trial (no. NCT03016312) enrolled 759 men with metastatic castration-resistant prostate cancer whose disease progressed on abiraterone. The addition of atezolizumab to enzalutamide in an open-label randomized trial did not meet the primary endpoint of improved overall survival in unselected patients (stratified hazard ratio 1.12, 95% confidence interval (0.91, 1.37), P = 0.28), despite an acceptable safety profile. In archival tumor samples, prostate tumors showed comparatively low expression of key immune biomarkers. DNA damage-response alterations, phosphatase and tensin homolog status and PD-L1 expression levels were similar between hormone-sensitive and castration-resistant prostate cancers. In planned biomarker analysis, longer progression-free survival was seen with atezolizumab in patients with high PD-L1 IC2/3, CD8 expression and established immune gene signatures. Exploratory analysis linked progression-free survival in the atezolizumab arm with immune genes such as CXCL9 and TAP1, together with other potentially relevant biomarkers including phosphatase and tensin homolog alterations. Together these data indicate that the expected biology associated with response to immune checkpoint inhibitors is present in prostate cancer, albeit in fewer patients. Careful patient selection may be required for immune checkpoint inhibitors to identify subgroups of patients who may benefit from this treatment approach. In the phase 3 IMbassador250 clinical trial, a checkpoint immunotherapy combination with enzalutamide did not improve survival over enzalutamide alone in patients with metastatic castration-resistant prostate cancer whose disease progressed on abiraterone. The study uncovered genomic and immune biomarkers that may identify patients deriving benefit.	[Powles, Thomas] Queen Mary Univ London, Barts Canc Inst, London, England; [Yuen, Kobe C.; Kadel, Edward E.; Doss, Jennifer F.; Mariathasan, Sanjeev; Williams, Patrick] Genentech Inc, San Francisco, CA 94080 USA; [Gillessen, Silke] EOC, Oncol Inst Southern Switzerland, Bellinzona, Switzerland; [Gillessen, Silke] Univ Svizzera Italiana, Fac Biomed Sci, Lugano, Switzerland; [Rathkopf, Dana] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Matsubara, Nobuaki] Natl Canc Ctr Hosp East, Chiba, Japan; [Drake, Charles G.] Columbia Univ, Irving Med Ctr, New York, NY USA; [Fizazi, Karim] Univ Paris Saclay, Gustave Roussy, Villejuif, France; [Piulats, Josep M.] Inst Catala Oncol IDIBELL CIBERONC, Barcelona, Spain; [Wysocki, Piotr J.] Jagiellonian Univ Med Coll, Krakow, Poland; [Jr, Gary L. Buchschacher] Los Angeles Med Ctr, Kaiser Permanente Southern Calif, Los Angeles, CA USA; [Alekseev, Boris] Res Oncol Inst, Tomsk, Russia; [Mellado, Begona] Univ Barcelona, Hosp Clin & Prov, Inst Invest Biomed August Pi & Sunyer, Med Oncol Dept, Barcelona, Spain; [Karaszewska, Boguslawa] Przychodnia Lekarska KOMED, Konin, Poland; [Rasuo, Grozdana; Datye, Asim] F Hoffmann La Roche Ltd, Basel, Switzerland; [Sweeney, Christopher J.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA; [Doss, Jennifer F.] Global Blood Therapeut Inc, San Francisco, CA USA	University of London; Queen Mary University London; Roche Holding; Genentech; Institute of Oncology Research (IOR); Universita della Svizzera Italiana; Memorial Sloan Kettering Cancer Center; National Cancer Center - Japan; Columbia University; NewYork-Presbyterian Hospital; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Jagiellonian University; Collegium Medicum Jagiellonian University; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Roche Holding; Harvard University; Dana-Farber Cancer Institute	Powles, T (corresponding author), Queen Mary Univ London, Barts Canc Inst, London, England.; Sweeney, CJ (corresponding author), Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.	thomas.powles1@nhs.net; Christopher_Sweeney@dfci.harvard.edu	; Alekseev, Boris/O-1008-2017	Wysocki, Piotr/0000-0003-4003-5278; Alekseev, Boris/0000-0002-3398-4128	F. Hoffmann-La Roche Ltd./Genentech, Inc., a member of the Roche Group; Kaiser Permanente NCI National Community Oncology Research Program [SUG1CA189821-08]; F. Hoffmann-La Roche Ltd.	F. Hoffmann-La Roche Ltd./Genentech, Inc., a member of the Roche Group; Kaiser Permanente NCI National Community Oncology Research Program; F. Hoffmann-La Roche Ltd.(Hoffmann-La Roche)	The study was supported by F. Hoffmann-La Roche Ltd./Genentech, Inc., a member of the Roche Group. Disclosure forms, Methods and a data-sharing statement provided by the authors are available within the full text of this article at nature.com/nm. G.L.B. is partially funded by the Kaiser Permanente NCI National Community Oncology Research Program (grant no. SUG1CA189821-08). We thank the patients who participated in the trial and the clinical site investigators. Medical writing assistance for this manuscript was provided by P. Hong of Health Interactions, Inc. and was funded by F. Hoffmann-La Roche Ltd.	Abida W, 2019, JAMA ONCOL, V5, P471, DOI 10.1001/jamaoncol.2018.5801; Antonarakis ES, 2016, PROSTATE CANCER P D, V19, P231, DOI 10.1038/pcan.2016.17; Antonarakis ES, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01638; Basch E, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju244; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Beer TM, 2017, J CLIN ONCOL, V35, P40, DOI 10.1200/JCO.2016.69.1584; Bishop JL, 2015, ONCOTARGET, V6, P234, DOI 10.18632/oncotarget.2703; Bou-Dargham MJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07058-y; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Danaher P, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0367-1; Donahue RN, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-4901; Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782; Feng Q, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00858; Fernandez-Poma SM, 2017, CANCER RES, V77, P3672, DOI 10.1158/0008-5472.CAN-17-0236; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Fizazi K, 2020, EUR UROL, V78, P822, DOI 10.1016/j.eururo.2020.07.032; Fizazi K, 2014, LANCET ONCOL, V15, P1147, DOI 10.1016/S1470-2045(14)70303-1; Graff JN, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000642; Graff JN, 2016, ONCOTARGET, V7, P52810, DOI 10.18632/oncotarget.10547; Haffner MC, 2018, AM J PATHOL, V188, P1478, DOI 10.1016/j.ajpath.2018.02.014; Hansen AR, 2018, ANN ONCOL, V29, P1807, DOI 10.1093/annonc/mdy232; Hegde PS, 2016, CLIN CANCER RES, V22, P1865, DOI 10.1158/1078-0432.CCR-15-1507; Hellmann Matthew D, 2018, N Engl J Med, V378, P2093, DOI 10.1056/NEJMoa1801946; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Konstantinopoulos PA, 2019, J CLIN ONCOL, V37, P2786, DOI 10.1200/JCO.19.01021; Kowanetz M, 2018, P NATL ACAD SCI USA, V115, pE10119, DOI 10.1073/pnas.1802166115; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Logothetis CJ, 2012, LANCET ONCOL, V13, P1210, DOI 10.1016/S1470-2045(12)70473-4; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mateo J, 2020, J CLIN INVEST, V130, P1743, DOI [10.1172/JCl132031, 10.1172/JCI132031]; Mateo J, 2020, LANCET ONCOL, V21, P162, DOI 10.1016/S1470-2045(19)30684-9; McDermott DF, 2018, NAT MED, V24, P749, DOI 10.1038/s41591-018-0053-3; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Petrylak DP, 2021, CLIN CANCER RES, V27, P3360, DOI 10.1158/1078-0432.CCR-20-1981; Powles T, 2021, NAT MED, V27, P793, DOI 10.1038/s41591-021-01317-6; Powles T, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.6_suppl.409; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Qi ZH, 2019, J MOL DIAGN, V21, P796, DOI 10.1016/j.jmoldx.2019.04.011; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schlomm T, 2016, EUR UROL, V69, P1157, DOI 10.1016/j.eururo.2016.02.024; Sharma M, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017257; Sharma P, 2020, CANCER CELL, V38, P489, DOI 10.1016/j.ccell.2020.08.007; Sokol ES, 2019, ONCOLOGIST, V24, P1526, DOI 10.1634/theoncologist.2019-0214; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; TECENTRIQ (atezolizumab), 2020, PRESCRIBING INFORM; Trabucco SE, 2019, J MOL DIAGN, V21, P1053, DOI 10.1016/j.jmoldx.2019.06.011; Vericiguat, 2021, SUMMARY PRODUCT CHAR; Vidotto T, 2020, BRIT J CANCER, V122, P1732, DOI 10.1038/s41416-020-0834-6; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034	61	20	20	8	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					144	+		10.1038/s41591-021-01600-6	http://dx.doi.org/10.1038/s41591-021-01600-6		JAN 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35013615				2023-01-03	WOS:000741630800003
J	Owen, DR; Allerton, CMN; Anderson, AS; Aschenbrenner, L; Avery, M; Berritt, S; Boras, B; Cardin, RD; Carlo, A; Coffman, KJ; Dantonio, A; Di, L; Eng, H; Ferre, R; Gajiwala, KS; Gibson, SA; Greasley, SE; Hurst, BL; Kadar, EP; Kalgutkar, AS; Lee, JC; Lee, J; Liu, W; Mason, SW; Noell, S; Novak, JJ; Obach, RS; Ogilvie, K; Patel, NC; Pettersson, M; Rai, DK; Reese, MR; Sammons, MF; Sathish, JG; Singh, RSP; Steppan, CM; Stewart, A; Tuttle, JB; Updyke, L; Verhoest, PR; Wei, LQ; Yang, QY; Zhu, YA				Owen, Dafydd R.; Allerton, Charlotte M. N.; Anderson, Annaliesa S.; Aschenbrenner, Lisa; Avery, Melissa; Berritt, Simon; Boras, Britton; Cardin, Rhonda D.; Carlo, Anthony; Coffman, Karen J.; Dantonio, Alyssa; Di, Li; Eng, Heather; Ferre, RoseAnn; Gajiwala, Ketan S.; Gibson, Scott A.; Greasley, Samantha E.; Hurst, Brett L.; Kadar, Eugene P.; Kalgutkar, Amit S.; Lee, Jack C.; Lee, Jisun; Liu, Wei; Mason, Stephen W.; Noell, Stephen; Novak, Jonathan J.; Obach, R. Scott; Ogilvie, Kevin; Patel, Nandini C.; Pettersson, Martin; Rai, Devendra K.; Reese, Matthew R.; Sammons, Matthew F.; Sathish, Jean G.; Singh, Ravi Shankar P.; Steppan, Claire M.; Stewart, Al E.; Tuttle, Jamison B.; Updyke, Lawrence; Verhoest, Patrick R.; Wei, Liuqing; Yang, Qingyi; Zhu, Yuao			An oral SARS-CoV-2 M-pro inhibitor clinical candidate for the treatment of COVID-19	SCIENCE			English	Article							3CL PROTEASE INHIBITORS; MICRONUCLEUS ASSAY; DESIGN; CORONAVIRUS; VALIDATION; PARAMETERS; MANAGEMENT; PROTOCOL	The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency in a phase 1 clinical trial in healthy human participants.	[Owen, Dafydd R.; Allerton, Charlotte M. N.; Kalgutkar, Amit S.; Patel, Nandini C.; Pettersson, Martin; Sammons, Matthew F.; Singh, Ravi Shankar P.; Tuttle, Jamison B.; Updyke, Lawrence; Verhoest, Patrick R.; Yang, Qingyi] Pfizer Worldwide Res, Dev & Med, Cambridge, MA 02139 USA; [Anderson, Annaliesa S.; Cardin, Rhonda D.; Mason, Stephen W.; Rai, Devendra K.; Sathish, Jean G.; Zhu, Yuao] Pfizer Worldwide Res, Dev & Med, Pearl River, NY 10965 USA; [Aschenbrenner, Lisa; Avery, Melissa; Berritt, Simon; Carlo, Anthony; Coffman, Karen J.; Dantonio, Alyssa; Di, Li; Eng, Heather; Kadar, Eugene P.; Lee, Jack C.; Lee, Jisun; Noell, Stephen; Novak, Jonathan J.; Obach, R. Scott; Ogilvie, Kevin; Reese, Matthew R.; Steppan, Claire M.; Wei, Liuqing] Pfizer Worldwide Res, Dev & Med Groton, Groton, CT 06340 USA; [Boras, Britton; Ferre, RoseAnn; Gajiwala, Ketan S.; Greasley, Samantha E.; Liu, Wei; Stewart, Al E.] Pfizer Worldwide Res, Dev & Med, La Jolla, CA 92121 USA; [Gibson, Scott A.; Hurst, Brett L.] Utah State Univ, Inst Antiviral Res, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA; [Mason, Stephen W.] Janssen Biopharma, San Francisco, CA 94080 USA; [Novak, Jonathan J.] Praxis Precis Med, Cambridge, MA 02142 USA; [Pettersson, Martin] GRT Therapeut, Cambridge, MA 02142 USA	Pfizer; Pfizer; Pfizer; Pfizer; Utah System of Higher Education; Utah State University	Owen, DR (corresponding author), Pfizer Worldwide Res, Dev & Med, Cambridge, MA 02139 USA.	Dafydd.owen@pfizer.com	Patel, Nandini/GZH-2007-2022; SINGH, RAVI SHANKAR PRASAD/L-9408-2014	Mason, Stephen/0000-0002-6662-9624; SINGH, RAVI SHANKAR PRASAD/0000-0001-6298-8219; Berritt, Simon/0000-0001-5572-6771; Dantonio, Alyssa/0000-0001-9067-3660; Eng, Heather/0000-0002-2914-3967	Pfizer, Inc.	Pfizer, Inc.(Pfizer)	This study was sponsored by Pfizer, Inc.	Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Banker MJ, 2003, J PHARM SCI-US, V92, P967, DOI 10.1002/jps.10332; Barilli A, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050127; Boras B., 2020, BIORXIV293498PREPRIN, DOI [10.1101/2020.09.12.293498v2, DOI 10.1101/2020.09.12.293498V2]; Boras Britton, 2021, bioRxiv, DOI 10.1101/2020.09.12.293498; Bricogne G., 2016, BUSTER VERSION 2 11; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Cannalire R, 2016, J MED CHEM, V59, P16, DOI 10.1021/acs.jmedchem.5b00825; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chuck CP, 2013, EUR J MED CHEM, V59, P1, DOI [10.1016/j.ejmech.2013.06.026, 10.1016/j.ejmech.2012.10.053]; Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001; Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9; Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004; DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122; de Vries M, 2021, J VIROL, V95, DOI 10.1128/JVI.01819-20; Di L, 2011, J PHARM SCI-US, V100, P4974, DOI 10.1002/jps.22674; Dragovich PS, 2000, BIOORG MED CHEM LETT, V10, P45, DOI 10.1016/S0960-894X(99)00587-9; Dugdale RC, 1998, NATURE, V391, P270, DOI 10.1038/34630; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Ghosh AK, 2016, J MED CHEM, V59, P5172, DOI 10.1021/acs.jmedchem.5b01697; Good SS, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.02479-20; GREEN MHL, 1976, MUTAT RES, V38, P3, DOI 10.1016/0165-1161(76)90076-5; Grum-Tokars V, 2008, VIRUS RES, V133, P63, DOI 10.1016/j.virusres.2007.02.015; Hamada S, 2001, ENVIRON MOL MUTAGEN, V37, P93, DOI 10.1002/em.1017; Hattori S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-20900-6; Hayashi M, 2000, ENVIRON MOL MUTAGEN, V35, P234, DOI 10.1002/(SICI)1098-2280(2000)35:3<234::AID-EM10>3.0.CO;2-L; Hoffman RL, 2020, J MED CHEM, V63, P12725, DOI 10.1021/acs.jmedchem.0c01063; International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, 2011, GUID GEN TEST DAT IN; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.1218231, 10.1126/science.121823]; Kato M., DRUG METAB PHARMACOK, V18, P365; Kato Motohiro, 2003, Drug Metab Pharmacokinet, V18, P365, DOI 10.2133/dmpk.18.365; Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12; Kirsch-Volders M, 2000, ENVIRON MOL MUTAGEN, V35, P167, DOI 10.1002/(SICI)1098-2280(2000)35:3<167::AID-EM3>3.0.CO;2-G; Konno S, 2013, BIOORGAN MED CHEM, V21, P412, DOI 10.1016/j.bmc.2012.11.017; Leist SR, 2020, CELL, V183, P1070, DOI 10.1016/j.cell.2020.09.050; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McKeage K, 2009, DRUGS, V69, P477, DOI 10.2165/00003495-200969040-00007; MOON JB, 1986, J AM CHEM SOC, V108, P1350, DOI 10.1021/ja00266a066; Obach RS, 1997, J PHARMACOL EXP THER, V283, P46; OpenEye Scientific, 2021, AFITT 2 4 1 2 OPENEY; Organisation for Economic Co-operation and Development, 2016, TEST NO 474 MAMM ERY; Organisation for Economic Co-operation and Development, 2016, TEST NO 487 IN VITR; Organisation for Economic Co-operation and Development, 2020, TEST NO 471 BACT REV; PARRY JM, 1993, MUTAT RES, V287, P3, DOI 10.1016/0027-5107(93)90140-B; Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461; Prior AM, 2013, BIOORG MED CHEM LETT, V23, P6317, DOI 10.1016/j.bmcl.2013.09.070; Qiao JX, 2021, SCIENCE, V371, P1374, DOI 10.1126/science.abf1611; Reddy MB, 2012, ANTIMICROB AGENTS CH, V56, P3144, DOI 10.1128/AAC.06283-11; REED L. J., 1938, AMER JOUR HYG, V27, P493; Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1; Rut W, 2021, NAT CHEM BIOL, V17, P222, DOI 10.1038/s41589-020-00689-z; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Thanigaimalai P, 2013, EUR J MED CHEM, V68, P372, DOI 10.1016/j.ejmech.2013.07.037; Tickle I. J., 2018, STARANISO; Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589; Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n; Vonrhein C, 2011, ACTA CRYSTALLOGR D, V67, P293, DOI 10.1107/S0907444911007773; Wahl A, 2021, NATURE, V591, P451, DOI 10.1038/s41586-021-03312-w; Walsky RL, 2004, DRUG METAB DISPOS, V32, P647, DOI 10.1124/dmd.32.6.647; Weiss MS, 1997, J APPL CRYSTALLOGR, V30, P203, DOI 10.1107/S0021889897003907; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Wlodek S, 2006, ACTA CRYSTALLOGR D, V62, P741, DOI 10.1107/S0907444906016076; Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405; Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	70	382	386	76	220	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	2021	374	6575					1586	+		10.1126/science.abl4784	http://dx.doi.org/10.1126/science.abl4784			114	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX9EL	34726479	Green Submitted			2023-01-03	WOS:000736589300028
J	Li, ML; Li, Y; Meng, QT; Li, YY; Tian, XM; Liu, RX; Fang, JB				Li, Minlu; Li, Yuan; Meng, Qingtong; Li, Yinyin; Tian, Xiaomeng; Liu, Ruixia; Fang, Jinbo			Effects of nurse-led transitional care interventions for patients with heart failure on healthcare utilization: A meta-analysis of randomized controlled trials	PLOS ONE			English	Article							DISEASE MANAGEMENT PROGRAM; CLINICAL-OUTCOMES; READMISSION; MORBIDITY; MORTALITY; DISCHARGE; QUALITY; RATES	Background Heart failure (HF) imposes a substantial burden on patients and healthcare systems. Hospital-to-home transitional care, involving time-limited interventions delivered predominantly by nurses, was introduced to lighten this burden. This study aimed to examine the effectiveness and dose-response of nurse-led transitional care interventions (TCIs) on healthcare utilization among patients with HF. Methods Health-related databases were systematically searched for articles published from January 2000 to June 2020. We included randomized controlled trials (RCTs) that compared nurse-led TCIs with usual care for adults hospitalized with HF and reported the following healthcare utilization outcomes: all-cause readmissions, HF-specific readmissions, emergency department visits, or length of hospital stay. Random-effects meta-analysis, meta-regression analysis, and dose-response analysis were performed to estimate the treatment effects and explain the heterogeneity. Results Twenty-five RCTs including 8422 patients with HF were included. Nurse-led TCIs for patients with HF resulted in a mean 9% (RR = 0.91; 95% CI = 0.82 to 0.99; p = 0.04; I-2 = 46%) and 29% (RR = 0.71; 95% CI = 0.60 to 0.84; p < 0.0001; I-2 = 0%) reduction in all-cause and HF-specific readmission risks respectively compared to usual care. The interventions were also effective in shortening the length of hospital stay (MD = -2.37; 95% CI = -3.16 to -1.58; p < 0.0001; I-2 = 14%). However, no significant reduction was found for emergency department visits (RR = 0.96; 95% CI = 0.84 to 1.10; p = 0.58; I-2 = 0%). The effect of meta-regression coefficients on all-cause and HF-specific readmissions was not statistically significant for any prespecified trial-level characteristic. Dose-response analysis revealed that the HF-specific readmission risk decreased in a dose-dependent manner with the complexity and intensity of nurse-led TCIs. Conclusions Nurse-led TCIs were effective in decreasing all-cause and HF-specific readmission risks, as well as in reducing the length of hospital stay; however, the interventions were not effective in reducing the frequency of emergency department visits.	[Li, Minlu; Li, Yuan; Meng, Qingtong; Li, Yinyin; Liu, Ruixia; Fang, Jinbo] Sichuan Univ, West China Sch Nursing, Chengdu, Sichuan, Peoples R China; [Li, Minlu] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Sichuan, Peoples R China; [Tian, Xiaomeng] Sichuan Univ, West China Hosp, Dept Cardiol, Chengdu, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Fang, JB (corresponding author), Sichuan Univ, West China Sch Nursing, Chengdu, Sichuan, Peoples R China.	fangjinbo1107@163.com	Li, Yuan/AEV-2196-2022	Li, Yuan/0000-0002-5550-0307				Angermann CE, 2012, CIRC-HEART FAIL, V5, P25, DOI 10.1161/CIRCHEARTFAILURE.111.962969; [Anonymous], 2020, GRADEPRO GDT GRADEPR; Barth V., 2016, PRACTICE, V13, P436, DOI [10.1177/108482230101300604, DOI 10.1177/108482230101300604]; Blum MR, 2020, ANN INTERN MED, V172, P248, DOI 10.7326/M19-1980; Boult Chad, 2008, Perm J, V12, P50; Coleman EA, 2003, J AM GERIATR SOC, V51, P556, DOI 10.1046/j.1532-5415.2003.51186.x; Daliri S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213593; de Souza EN, 2014, EUR J HEART FAIL, V16, P1002, DOI 10.1002/ejhf.125; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Domingues FB, 2011, ARQ BRAS CARDIOL, V96, P233, DOI 10.1590/S0066-782X2011005000014; Ducharme A, 2005, CAN MED ASSOC J, V173, P40, DOI 10.1503/cmaj.1041137; Dunagan WC, 2005, J CARD FAIL, V11, P358, DOI 10.1016/j.cardfail.2004.12.004; Feltner C, 2014, ANN INTERN MED, V160, P774, DOI 10.7326/M14-0083; Fergenbaum Jennifer, 2015, J Cardiovasc Nurs, V30, pS44, DOI 10.1097/JCN.0000000000000235; Grange J, 2005, HEART, V91, P39, DOI 10.1136/hrt.2005.062117; Gupta A, 2018, JAMA CARDIOL, V3, P44, DOI 10.1001/jamacardio.2017.4265; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Irabrgui BAE, 2007, REV ESP CARDIOL, V60, P914, DOI 10.1157/13109644; Kasper EK, 2002, J AM COLL CARDIOL, V39, P471, DOI 10.1016/S0735-1097(01)01761-2; Kwok CS, 2019, AM J CARDIOL, V124, P736, DOI 10.1016/j.amjcard.2019.05.053; Kwok T, 2008, J CLIN NURS, V17, P109, DOI 10.1111/j.1365-2702.2007.01978.x; Laramee AS, 2003, ARCH INTERN MED, V163, P809, DOI 10.1001/archinte.163.7.809; Li Y, 2021, J AM MED DIR ASSOC, V22, P621, DOI 10.1016/j.jamda.2020.09.019; Linne Agneta Bjorck, 2006, BMC Cardiovasc Disord, V6, P30, DOI 10.1186/1471-2261-6-30; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Naylor MD, 2017, J AM GERIATR SOC, V65, P1119, DOI 10.1111/jgs.14782; Naylor MD, 2011, HEALTH AFFAIR, V30, P746, DOI 10.1377/hlthaff.2011.0041; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Negarandeh R, 2019, APPL CLIN INFORM, V10, P261, DOI 10.1055/s-0039-1685167; Nucifora G, 2006, J CARDIOVASC MED, V7, P614, DOI 10.2459/01.JCM.0000237910.34000.58; Ong MK, 2016, JAMA INTERN MED, V176, P310, DOI 10.1001/jamainternmed.2015.7712; Pekmezaris R, 2018, HEALTH AFFAIR, V37, P1983, DOI 10.1377/hlthaff.2018.05087; Ponikowski P, 2016, EUR J HEART FAIL, V18, P891, DOI 10.1002/ejhf.592; Pugh LC., 2001, MEDSURG NURS, V10, P71; Qaddoura A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129282; Riegel B, 2006, J CARD FAIL, V12, P211, DOI 10.1016/j.cardfail.2006.01.005; Riegel B, 2002, ARCH INTERN MED, V162, P705, DOI 10.1001/archinte.162.6.705; Riegel B, 2010, CIRC-CARDIOVASC QUAL, V3, P324, DOI 10.1161/CIRCOUTCOMES.109.877324; Ritchie CS, 2016, TRANSL BEHAV MED, V6, P428, DOI 10.1007/s13142-016-0422-8; Schunemann H, HDB GRADING QUALITY; Schwarz Karen A, 2008, Prog Cardiovasc Nurs, V23, P18, DOI 10.1111/j.1751-7117.2008.tb00527.x; Sethares KA, 2004, HEART LUNG, V33, P249, DOI 10.1016/j.hrtlng.2004.03.005; Shafie AA, 2018, HEART FAIL REV, V23, P131, DOI 10.1007/s10741-017-9661-0; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Stromberg A, 2003, EUR HEART J, V24, P1014, DOI 10.1016/S0195-668X(03)00112-X; Thompson DR, 2005, EUR J HEART FAIL, V7, P377, DOI 10.1016/j.ejheart.2004.10.008; Van Spall HGC, 2017, EUR J HEART FAIL, V19, P1427, DOI 10.1002/ejhf.765; Van Spall HGC, 2019, JAMA-J AM MED ASSOC, V321, P753, DOI 10.1001/jama.2019.0710; Vedel I, 2015, ANN FAM MED, V13, P562, DOI 10.1370/afm.1844; Xu C, 2018, INT J EVID-BASED HEA, V16, P138, DOI 10.1097/XEB.0000000000000132	52	3	3	5	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2021	16	12							e0261300	10.1371/journal.pone.0261300	http://dx.doi.org/10.1371/journal.pone.0261300			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY9FU	34914810	gold, Green Published			2023-01-03	WOS:000755091500077
J	Roura, S; Alvarez, G; Sola, I; Cerritelli, F				Roura, Sonia; Alvarez, Gerard; Sola, Ivan; Cerritelli, Francesco			Do manual therapies have a specific autonomic effect? An overview of systematic reviews	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; OSTEOPATHIC MANIPULATIVE TREATMENT; LOW-BACK-PAIN; SYMPATHETIC-NERVOUS-SYSTEM; PHYSIOLOGICAL CONDITION; SPINAL MOBILIZATIONS; HIGH-VELOCITY; PLACEBO; ORGANIZATION; TRIALS	Background The impact of manual therapy interventions on the autonomic nervous system have been largely assessed, but with heterogeneous findings regarding the direction of these effects. We conducted an overview of systematic reviews to describe if there is a specific autonomic effect elicited by manual therapy interventions, its relation with the type of technique used and the body region where the intervention was applied. Methods We conducted an overview according to a publicly registered protocol. We searched the Cochrane Database of Systematic Reviews, MEDLINE, EPISTEMONIKOS and SCOPUS, from their inception to march 2021. We included systematic reviews for which the primary aim of the intervention was to assess the autonomic effect elicited by a manual therapy intervention in either healthy or symptomatic individuals. Two authors independently applied the selection criteria, assessed risk of bias from the included reviews and extracted data. An established model of generalisation guided the data analysis and interpretation. Results We included 12 reviews (5 rated as low risk of bias according the ROBIS tool). The findings showed that manual therapies may have an effect on both sympathetic and parasympathetic systems. However, the results from included reviews were inconsistent due to differences in their methodological rigour and how the effects were measured. The reviews with a lower risk of bias could not discriminate the effects depending on the body region to which the technique was applied. Conclusion The magnitude of the specific autonomic effect elicited by manual therapies and its clinical relevance is uncertain. We point out some specific recommendations in order to improve the quality and relevance of future research in this field.	[Roura, Sonia; Alvarez, Gerard] Fdn COME Collaborat, Spain Natl Ctr, Barcelona, Spain; [Alvarez, Gerard; Sola, Ivan] IIB St Pau, Beroamer Cochrane Ctr, Biomed Res Inst St Pau, Barcelona, Spain; [Cerritelli, Francesco] Fdn COME Collaborat, Italian Natl Ctr, Pescara, Italy		Roura, S (corresponding author), Fdn COME Collaborat, Spain Natl Ctr, Barcelona, Spain.	soniaroura6@gmail.com	Alvarez, Gerard/AAT-5342-2021	Alvarez, Gerard/0000-0002-2680-6331; Sola, Ivan/0000-0003-0078-3706; Roura Carvajal, Sonia/0000-0002-3822-4814	Registro de Osteopatas de Espana (ROE)	Registro de Osteopatas de Espana (ROE)	Funding for the publication of this article was provided by Registro de Osteopatas de Espana (ROE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez G, 2021, J CLIN EPIDEMIOL, V130, P96, DOI 10.1016/j.jclinepi.2020.10.018; Alvarez G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234713; Alvarez G, 2020, J CLIN EPIDEMIOL, V121, P32, DOI 10.1016/j.jclinepi.2020.01.006; Alvarez G, 2016, MANUAL THER, V24, P85, DOI 10.1016/j.math.2016.03.004; American Association of Colleges of Osteopathic Medicine, 2017, GLOSSARY OSTEOPATHIC, Vthird; Borges BLA, 2018, J BODYW MOV THER, V22, P203, DOI 10.1016/j.jbmt.2017.09.025; Andrianome S, 2017, J APPL PHYSIOL, V123, P1055, DOI 10.1152/japplphysiol.00229.2017; Araujo FX, 2019, J MANIP PHYSIOL THER, V42, P623, DOI 10.1016/j.jmpt.2018.12.005; Bandeira PM, 2021, SCAND J PAIN, V21, P426, DOI 10.1515/sjpain-2021-0006; Banzi R, 2018, J CLIN EPIDEMIOL, V99, P24, DOI 10.1016/j.jclinepi.2018.02.024; Bayo-Tallon V, 2019, COMPLEMENT THER CLIN, V36, P125, DOI 10.1016/j.ctcp.2019.06.008; Benedetti F., 2013, PATIENTS BRAIN NEURO, DOI [10.1093/med/9780199579518.003.0006, DOI 10.1093/MED/9780199579518.003.0006]; Benedetti F, 2014, NEURON, V84, P623, DOI 10.1016/j.neuron.2014.10.023; Benedetti F, 2013, PHYSIOL REV, V93, P1207, DOI 10.1152/physrev.00043.2012; Bertizzolo L, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028382; Bialosky JE, 2018, J ORTHOP SPORT PHYS, V48, P8, DOI 10.2519/jospt.2018.7476; Bialosky JE, 2017, J ORTHOP SPORT PHYS, V47, P301, DOI 10.2519/jospt.2017.0604; Bialosky JE, 2014, J PAIN, V15, P136, DOI 10.1016/j.jpain.2013.10.005; Bialosky JE, 2009, MANUAL THER, V14, P531, DOI 10.1016/j.math.2008.09.001; Billman GE, 2013, FRONT PHYSIOL, V4, DOI [10.3389/fphys.2013.00222, 10.3389/fphys.2013.00026]; Bishop MD, 2015, PAIN MANAG, V5, P455, DOI 10.2217/pmt.15.39; Bokarius AV, 2010, PAIN PRACT, V10, P451, DOI 10.1111/j.1533-2500.2010.00377.x; Bronfort Gert, 2010, Chiropr Osteopat, V18, P3, DOI 10.1186/1746-1340-18-3; Buijs Ruud M, 2013, Handb Clin Neurol, V117, P1, DOI 10.1016/B978-0-444-53491-0.00001-8; Camm AJ, 1996, EUR HEART J, V17, P354; Cannon WB, 1929, PHYSIOL REV, V9, P399, DOI 10.1152/physrev.1929.9.3.399; Carnevali L, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.579365; Carney KBM, 2020, BIOL RES NURS, V22, P205, DOI 10.1177/1099800420907964; Cerritelli F, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83893-8; Cerritelli F, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00887; Cerritelli F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235539; Cerritelli F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60253-6; Cerritelli F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211353; Cerritelli F, 2017, J PAIN RES, V10, P601, DOI 10.2147/JPR.S130501; Cerritelli F, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004728; Cerritelli F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127370; Curi ACC, 2018, J BODYW MOV THER, V22, P666, DOI 10.1016/j.jbmt.2017.11.013; Cheshire WP, 2021, CLIN NEUROPHYSIOL, V132, P666, DOI 10.1016/j.clinph.2020.11.024; Chiera M, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.561186; Chu J, 2014, J MAN MANIP THER, V22, P220, DOI 10.1179/2042618613Y.0000000062; Clar C, 2014, CHIROPR MAN THER, V22, DOI 10.1186/2045-709X-22-12; Colloca L, 2014, Z PSYCHOL, V222, P124, DOI 10.1027/2151-2604/a000177; Cook C, 2011, J MAN MANIP THER, V19, P3, DOI 10.1179/106698110X12804993427009; Corazza I, 2014, COMPUT METH PROG BIO, V117, P267, DOI 10.1016/j.cmpb.2014.08.002; Cowen R, 2015, ANAESTHESIA, V70, P828, DOI 10.1111/anae.13018; Craig AD, 2013, BEHAV BRAIN SCI, V36, P685, DOI 10.1017/S0140525X13001489; Craig AD, 2003, CURR OPIN NEUROBIOL, V13, P500, DOI 10.1016/S0959-4388(03)00090-4; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; D'Alessandro G, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00100; Dal Farra F, 2021, COMPLEMENT THER MED, V56, DOI 10.1016/j.ctim.2020.102616; Degenhardt BF., 2007, J AM OSTEOPATH ASSOC, V107, P387; Dobrek L., 2015, J PRECLIN CLIN RES, V9, P63, DOI [10.5604/18982395.1157579, DOI 10.5604/18982395.1157579]; Engel RM, 2016, J MAN MANIP THER, V24, DOI 10.1179/2042618614Y.0000000074; Fawkes CA, 2014, MANUAL THER, V19, P125, DOI 10.1016/j.math.2013.09.001; Franke H, 2017, J BODYW MOV THER, V21, P752, DOI 10.1016/j.jbmt.2017.05.014; Franke H, 2015, INT J OSTEOPATH MED, V18, P255, DOI 10.1016/j.ijosm.2015.05.003; Freeman R, 2013, HAND CLINIC, V115, P115, DOI 10.1016/B978-0-444-52902-2.00007-2; Galindez-Ibarbengoetxea X, 2017, J ALTERN COMPLEM MED, V23, P667, DOI 10.1089/acm.2017.0002; Gates M, 2020, SYST REV-LONDON, V9, DOI 10.1186/s13643-020-01509-0; Ghiasi S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62225-2; Gibbins I, 2013, ORGANOGENESIS, V9, P169, DOI 10.4161/org.25126; Goldstein David S, 2013, Handb Clin Neurol, V117, P13, DOI 10.1016/B978-0-444-53491-0.00002-X; Goldstein DS, 2011, EXP PHYSIOL, V96, P1255, DOI 10.1113/expphysiol.2010.056259; Gonzalez GZ, 2018, ARCH PHYS MED REHAB, V99, P129, DOI 10.1016/j.apmr.2017.08.485; Goossen K, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-00983-3; Greenhalgh T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3725; Gyer G, 2019, J INTEGR MED-JIM, V17, P328, DOI 10.1016/j.joim.2019.05.004; Hegedus EJ, 2011, J MAN MANIP THER, V19, P143, DOI 10.1179/2042618611Y.0000000003; Iellamo F, 2018, CURR SPORT MED REP, V17, P473, DOI 10.1249/JSR.0000000000000544; Janig W, 2000, PROG BRAIN RES, V122, P351; Kaptchuk TJ, 2015, NEW ENGL J MED, V373, P8, DOI 10.1056/NEJMp1504023; King HH., 2010, SCI CLIN APPL MANUAL, V1st, DOI [10.1016/j.math.2009.12.001, DOI 10.1016/J.MATH.2009.12.001]; Kingston L, 2014, MANUAL THER, V19, P281, DOI 10.1016/j.math.2014.04.004; Martinic MK, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0855-0; Laborde S, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00213; Langley JN, 1903, BRAIN, V26, P1, DOI 10.1093/brain/26.1.1; Lascurain-Aguirrebena I, 2019, MUSCULOSKEL SCI PRAC, V42, P90, DOI 10.1016/j.msksp.2019.05.001; Lascurain-Aguirrebena I, 2016, SPINE, V41, P159, DOI 10.1097/BRS.0000000000001151; Licciardone JC, 2016, J AM OSTEOPATH ASSOC, V116, P144, DOI 10.7556/jaoa.2016.031; Linson A, 2018, FRONT ROBOT AI, V5, DOI 10.3389/frobt.2018.00021; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; McGlone F, 2017, NEUROSCI BIOBEHAV R, V72, P1, DOI 10.1016/j.neubiorev.2016.11.009; McGlone F, 2014, NEURON, V82, P737, DOI 10.1016/j.neuron.2014.05.001; Meyer AL, 2019, CHIROPR MAN THER, V27, DOI 10.1186/s12998-019-0265-8; Minary L, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0736-6; Moseley AM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222770; Moyer CA, 2011, J BODYW MOV THER, V15, P3, DOI 10.1016/j.jbmt.2010.06.001; Navarro-Santana MJ, 2020, PHYSIOTHERAPY, V107, P118, DOI 10.1016/j.physio.2019.07.001; Oliveira-Campelo NM, 2013, J MANIP PHYSIOL THER, V36, P300, DOI 10.1016/j.jmpt.2013.04.008; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Petrofsky J.S., 2017, TXB AGING SKIN, P1091; Picchiottino M, 2019, CHIROPR MAN THER, V27, DOI 10.1186/s12998-019-0235-1; Pieper D, 2019, J CLIN EPIDEMIOL, V108, P26, DOI 10.1016/j.jclinepi.2018.12.004; Pieper D, 2014, J CLIN EPIDEMIOL, V67, P1302, DOI 10.1016/j.jclinepi.2014.08.008; Rechberger V, 2019, EUR J MED RES, V24, DOI 10.1186/s40001-019-0394-5; Riley SP, 2016, J MAN MANIP THER, V24, P241, DOI 10.1080/10669817.2015.1119372; Rossettini G, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-1943-8; Sacristan JA, 2018, J CLIN EPIDEMIOL, V99, P164, DOI 10.1016/j.jclinepi.2018.02.003; Savoie I, 2003, INT J TECHNOL ASSESS, V19, P168, DOI 10.1017/S0266462303000163; Schloemer T, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0751-8; Schmid A, 2008, MANUAL THER, V13, P387, DOI 10.1016/j.math.2007.12.007; Seravalle G, 2013, CURR CLIN PHARMACOL, V8, P182, DOI 10.2174/1574884711308030003; Sgoifo A, 2015, STRESS, V18, P343, DOI 10.3109/10253890.2015.1045868; Shaffer F, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00258; Sullivan Stephanie Gb, 2020, Acta Biomed, V91, pe2020017, DOI 10.23750/abm.v91i13-S.10524; Teodorczyk-Injeyan JA, 2006, J MANIP PHYSIOL THER, V29, P14, DOI 10.1016/j.jmpt.2005.10.002; Treweek S, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-37; Valenzuela PL, 2019, SPINE, V44, P609, DOI 10.1097/BRS.0000000000002908; van Dun PLS, 2016, INT J OSTEOPATH MED, V20, P3, DOI 10.1016/j.ijosm.2016.01.003; Voogt L, 2015, MANUAL THER, V20, P250, DOI 10.1016/j.math.2014.09.001; Weimer LH, 2010, NEUROLOGIST, V16, P215, DOI 10.1097/NRL.0b013e3181cf86ab; Whiting P, 2016, J CLIN EPIDEMIOL, V69, P225, DOI 10.1016/j.jclinepi.2015.06.005; Wirth B, 2019, SPINE, V44, pE914, DOI 10.1097/BRS.0000000000003013; Zegarra-Parodi R, 2015, MANUAL THER, V20, P228, DOI 10.1016/j.math.2014.08.011; Zygmunt A, 2010, ARCH MED SCI, V6, P11, DOI 10.5114/aoms.2010.13500	117	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2021	16	12							e0260642	10.1371/journal.pone.0260642	http://dx.doi.org/10.1371/journal.pone.0260642			36	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW0CT	34855830	Green Published, gold			2023-01-03	WOS:000735299000082
J	Ceruti, S; Glotta, A; Biggiogero, M; Maida, PA; Marzano, M; Urso, P; Bona, G; Garzoni, C; Molnar, Z				Ceruti, Samuele; Glotta, Andrea; Biggiogero, Maira; Maida, Pier Andrea; Marzano, Martino; Urso, Patrizia; Bona, Giovanni; Garzoni, Christian; Molnar, Zsolt			Admission criteria in critically ill COVID-19 patients: A physiology-based approach	PLOS ONE			English	Article							EPIDEMIC	Introduction The COVID-19 pandemic required careful management of intensive care unit (ICU) admissions, to reduce ICU overload while facing limitations in resources. We implemented a standardized, physiology-based, ICU admission criteria and analyzed the mortality rate of patients refused from the ICU. Materials and methods In this retrospective observational study, COVID-19 patients proposed for ICU admission were consecutively analyzed; Do-Not-Resuscitate patients were excluded. Patients presenting an oxygen peripheral saturation (SpO(2)) lower than 85% and/or dyspnea and/or mental confusion resulted eligible for ICU admission; patients not presenting these criteria remained in the ward with an intensive monitoring protocol. Primary outcome was both groups' survival rate. Secondary outcome was a sub analysis correlating SpO(2) cutoff with ICU admission. Results From March 2020 to January 2021, 1623 patients were admitted to our Center; 208 DNR patients were excluded; 97 patients were evaluated. The ICU-admitted group (n = 63) mortality rate resulted 15.9% at 28 days and 27% at 40 days; the ICU-refused group (n = 34) mortality rate resulted 0% at both intervals (p < 0.001). With a SpO(2) cut-off of 85%, a significant correlation was found (p = 0.009), but with a 92% a cut-off there was no correlation with ICU admission (p = 0.26). A similar correlation was also found with dyspnea (p = 0.0002). Conclusion In COVID-19 patients, standardized ICU admission criteria appeared to safely reduce ICU overload. In the absence of dyspnea and/or confusion, a SpO(2) cutoff up to 85% for ICU admission was not burdened by negative outcomes. In a pandemic context, the SpO(2) cutoff of 92%, as a threshold for ICU admission, needs critical re-evaluation.	[Ceruti, Samuele; Glotta, Andrea] Clin Luganese Moncucco, Dept Crit Care, Lugano, Switzerland; [Biggiogero, Maira; Maida, Pier Andrea; Bona, Giovanni] Clin Luganese Moncucco, Clin Res Unit, Lugano, Switzerland; [Marzano, Martino; Garzoni, Christian] Clin Luganese Moncucco, Internal Med Serv, Lugano, Switzerland; [Urso, Patrizia] Clin Luganese Moncucco, Radiotherapy Serv, Lugano, Switzerland; [Molnar, Zsolt] Semmelweis Univ, Dept Anaesthesiol & Intens Therapy, Budapest, Hungary; [Molnar, Zsolt] Poznan Univ Med Sci, Dept Anaesthesiol & Intens Therapy, Poznan, Poland	Semmelweis University; Poznan University of Medical Sciences	Ceruti, S (corresponding author), Clin Luganese Moncucco, Dept Crit Care, Lugano, Switzerland.	samuele.ceruti@moncucco.ch	Glotta, Andrea/CAG-8159-2022; Glotta, Andrea/CAF-5354-2022; Ceruti, Samuele/N-8404-2019	Glotta, Andrea/0000-0001-7953-1231; Glotta, Andrea/0000-0001-7953-1231; Ceruti, Samuele/0000-0003-4146-3434; Bona, Giovanni/0000-0003-0771-5431				Alhazzani Waleed, 2020, Crit Care Med, V48, pe440, DOI [10.1007/s00134-020-06022-5, 10.1097/CCM.0000000000004363]; [Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; Bendjelid K, 2020, ANAESTH CRIT CARE PA, V39, P389, DOI 10.1016/j.accpm.2020.04.003; Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x; Chuang CH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005629; Foti G, 2020, MINERVA ANESTESIOL, V86, P1234, DOI 10.23736/S0375-9393.20.14762-X; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Fumagalli J, 2019, ANESTHESIOLOGY, V130, P791, DOI 10.1097/ALN.0000000000002638; Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z; Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE; Gattinoni L, 2020, INTENS CARE MED, V46, P780, DOI 10.1007/s00134-020-05981-z; Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539; Harutyunyan G, 2020, BRIT J HAEMATOL, V190, P725, DOI 10.1111/bjh.17051; Izcovich A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241955; Liao XL, 2020, INTENS CARE MED, V46, P357, DOI 10.1007/s00134-020-05954-2; Nates JL, 2016, CRIT CARE MED, V44, P1553, DOI 10.1097/CCM.0000000000001856; Nous M, 2020, NOUVELLES RECOMMANDA, P60; Packham V, 2015, CLIN MED, V15, P388, DOI 10.7861/clinmedicine.15-4-388; Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262; Pastores SM, 2019, CRIT CARE MED, V47, P550, DOI 10.1097/CCM.0000000000003637; Peigne V, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0107-y; Peter MS, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20230; Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914; Scheidegger D, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20229; Societe Suisse de Medecine Intensive,, 2013, DIR MED ETHIQUES MES; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; Tadic M, 2020, J CLIN HYPERTENS, V22, P1120, DOI 10.1111/jch.13925; Williams N, 2017, OCCUP MED-OXFORD, V67, P496, DOI 10.1093/occmed/kqx086; Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7	29	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2021	16	11							e0260318	10.1371/journal.pone.0260318	http://dx.doi.org/10.1371/journal.pone.0260318			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU5IH	34843531	Green Submitted, Green Published, gold			2023-01-03	WOS:000752076100062
J	Pattnaik, A; Mohan, D; Tsui, A; Chipokosa, S; Katengeza, H; Ndawala, J; Marx, MA				Pattnaik, Anooj; Mohan, Diwakar; Tsui, Amy; Chipokosa, Sam; Katengeza, Hans; Ndawala, Jameson; Marx, Melissa A.			The aggregate effect of implementation strength of family planning programs on modern contraceptive use at the health systems level in rural Malawi	PLOS ONE			English	Article							DEVELOPING-COUNTRIES; DESIRED FERTILITY; ACCESS; SERVICES; QUALITY; WORKERS; DEMAND; WOMEN; CARE	To explore the association between the strength of implementation of family planning (FP) programs on the use of modern contraceptives. Specifically, how strongly these programs are being implemented across a health facility's catchment area in Malawi and the odds of a woman in that catchment area is using modern contraceptives. This information can be used to assess whether the combined impact of multiple large-scale FP programs is leading to change in the health outcomes they aim to improve. We used data from the 2017 Implementation Strength Assessment (ISA) that quantified how much of family planning programs at the health facility and community health worker levels were being implemented across every district of Malawi. We used a summary measure developed in a previous study that employs quantitative methods to combine data across FP domains and health system levels. We tested the association of this summary measure for implementation strength with household data from the 2015 Malawi Demographic Health Survey (DHS). We found that areas with stronger implementation of FP programs had higher odds of women using modern contraceptives compared with areas with weaker implementation. The association of ISA with use of modern contraception was different by education, marital status, and geography. After controlling for these factors, we found that the adjusted odds of using a modern contraceptive was three times higher in catchment areas with high implementation strength compared to those with lower strength. Metrics that summarize how strongly FP programs are being implemented were used to show a statistically significantly positive relationship between increasing implementation strength and higher rates of modern contraceptive use. Decisionmakers at the various levels of health authority can use this type of summary measure to better understand the combined impact of their diverse FP programming and inform future programmatic and policy decisions. The findings also reinforce the idea that having a well-supported and supplied cadre of community health workers supplementing FP provision at the health facility can be an important health systems mechanism, especially in rural settings and to target youth populations.	[Pattnaik, Anooj; Mohan, Diwakar; Marx, Melissa A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [Tsui, Amy] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA; [Chipokosa, Sam; Ndawala, Jameson] Natl Stat Off, Zomba, Malawi; [Katengeza, Hans] Minist Hlth, Reprod Hlth Directorate, Lilongwe, Malawi	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Pattnaik, A (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	ajpattnaik@gmail.com			Global Affairs of Canada [7059904, 7061914]	Global Affairs of Canada	MM received funding from Global Affairs of Canada on two grants: 1) Real Accountability: Data Analysis for Results (RADAR) and the National Evaluation Program (NEP) projects. The grant number for RADAR was 7061914 and 7059904 for NEP. The URL for the funder, Global Affairs of Canada, is: https://www.international.gc.ca/gac-amc/index.aspx?lang=eng The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anand S, 2007, LANCET, V369, P1277, DOI 10.1016/S0140-6736(07)60599-6; Behrman JA, 2015, DEMOGRAPHY, V52, P787, DOI 10.1007/s13524-015-0392-3; Bongaarts J, 2017, INT PERSPECT SEX R H, V43, P41, DOI 10.1363/43e3917; Bongaarts J, 2017, POPUL DEV REV, V43, P39, DOI 10.1111/j.1728-4457.2016.00164.x; Burgert CR, 2014, DHS SPATIAL ANAL REP; Chansa C., 2018, Expanding health care provision in a low-income country: the experience of Malawi; Child D., 2006, ESSENTIALS FACTOR AN; Chipokosa S, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020901; Cleland J, 2014, STUD FAMILY PLANN, V45, P105, DOI 10.1111/j.1728-4465.2014.00380.x; Digitale J, 2017, ANN AM ACAD POLIT SS, V669, P93, DOI 10.1177/0002716216678591; FRANKLIN SB, 1995, J VEG SCI, V6, P99, DOI 10.2307/3236261; Goodkind D, 2018, GLOBAL HEALTH ACTION, V11, DOI 10.1080/16549716.2018.1423861; Government of Malawi, 2015, MAL COST IMPL PLAN F; International Monetary Fund, 2017, 17184 IMF; Jain AK, 2012, INT PERSPECT SEX R H, V38, P15, DOI 10.1363/3801512; Jain Aparna., 2014, INCONSISTENCIES TOTA; Jayachandran V, 2016, MALAWI MED J, V28, P48, DOI 10.4314/mmj.v28i2.4; Kidayi PL., 2015, ADV SEX MED, V05, P43, DOI DOI 10.4236/ASM.2015.53006; Kuang B, 2016, INT PERSPECT SEX R H, V42, P33, DOI 10.1363/42e0316; Leslie HH, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002464; Lutz W, 2014, POPUL DEV REV, V40, P527, DOI 10.1111/j.1728-4457.2014.00696.x; May JF, 2017, POPUL DEV REV, V43, P308, DOI 10.1111/j.1728-4457.2016.00165.x; Ministry of Development Planning and Cooperation, 2010, RAP POP DEV MAL; Ministry of Health [Malawi], 2011, MAL HLTH SECT STRAT; National Statistical Office, 2015, MAL MDG ENDL SURV 20; National Statistical Office and ICF, 2017, MAL DEM HLTH SURV 20; National Statistics Office, 2008 MAL POP HOUS CE; Pattnaik A., RAW DATA SCORE COMP, V2021; Perry HB, 2014, ANNU REV PUBL HEALTH, V35, P399, DOI 10.1146/annurev-publhealth-032013-182354; Peters MA, 2020, POPUL HEALTH METR, V18, DOI 10.1186/s12963-020-00242-z; PRITCHETT LH, 1994, POPUL DEV REV, V20, P1, DOI 10.2307/2137629; RamaRao S, 2003, INT FAM PLAN PERSPEC, V29, P76, DOI 10.2307/3181061; Ross J, 2017, DYNAMICS FAMILY PLAN; Ross J, 2013, J BIOSOC SCI, V45, P761, DOI 10.1017/S0021932012000715; Sedgh G., 2016, UNMET NEED CONTRACEP; Shiferaw S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187311; Skiles MP, 2015, INT PERSPECT SEX R H, V41, P20, DOI 10.1363/4102015; Skiles MP, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-14; Starrs AM, 2018, LANCET, V391, P2642, DOI 10.1016/S0140-6736(18)30293-9; Team RC, R LANG ENV STAT COMP; Tessema GA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165627; Tsui AO., 2002, MEASURE EVALUATION; Wang W., 2012, DHS ANAL STUD; White JS, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-143; Yao J, 2013, SOC SCI MED, V96, P60, DOI [10.1016/j.socscimed.2013.07.025, 10.1016/j.socscimed.2012.11.005]	45	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2021	16	11							e0232504	10.1371/journal.pone.0232504	http://dx.doi.org/10.1371/journal.pone.0232504			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ2IU	34780507	Green Published, gold, Green Submitted			2023-01-03	WOS:000755305800001
J	Ng, JKY; Guduru, K; Huxtable, J				Ng, Jonathan K. Y.; Guduru, Kalyan; Huxtable, James			Sudden loss of vision at the gym	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							LASER TREATMENT; HEMORRHAGE		[Ng, Jonathan K. Y.; Guduru, Kalyan; Huxtable, James] Bolton NHS Fdn Trust, Dept Ophthalmol, Bolton, England		Huxtable, J (corresponding author), Bolton NHS Fdn Trust, Dept Ophthalmol, Bolton, England.	james.huxtable@boltonft.nhs.uk		Ng, Jonathan Kuang Yin/0000-0002-6848-5740				Bagheri N, 2015, PRIMARY CARE, V42, P347, DOI 10.1016/j.pop.2015.05.010; Beran David I, 2009, J La State Med Soc, V161, P214; Bourne RA, 1999, EYE, V13, P791, DOI 10.1038/eye.1999.232; De Maeyer K, 2007, BRIT J OPHTHALMOL, V91, P869, DOI 10.1136/bjo.2006.109132; Durukan AH, 2008, EYE, V22, P214, DOI 10.1038/sj.eye.6702574; Garcia Fernandez Miriam, 2012, J Med Case Rep, V6, P346, DOI 10.1186/1752-1947-6-346; Sabella P, 2010, GRAEF ARCH CLIN EXP, V248, P599, DOI 10.1007/s00417-009-1252-x	7	0	0	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	2021	375								e067964	10.1136/bmj-2021-067964	http://dx.doi.org/10.1136/bmj-2021-067964			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY1KD	34764193				2023-01-03	WOS:000719043000008
J	Khan, SU; Ullah, F; Mehmood, S; Fahad, S; Rahi, AA; Althobaiti, F; Dessoky, ES; Saud, S; Danish, S; Datta, R				Khan, Safi Ullah; Ullah, Faizan; Mehmood, Sultan; Fahad, Shah; Rahi, Arsalan Ahmad; Althobaiti, Fayez; Dessoky, Eldessoky S.; Saud, Shah; Danish, Subhan; Datta, Rahul			RETRACTED: Antimicrobial, antioxidant and cytotoxic properties of Chenopodium glaucum L. (Retracted article. See vol. 17, 2022)	PLOS ONE			English	Article; Retracted Publication							ESSENTIAL OIL; GRAPE SEED; EXTRACTS; INFECTIONS; PHENOLICS; HERBS	We evaluated phytochemical composition, antibacterial, antifungal, anti-oxidant and cytotoxic properties of aqueous (water) and organic extracts (methanol, ethyl acetate and n-hexane) of Chenopodium glaucum. Highest phenolic content 45 mg gallic acid equivalents (GAE)/g d.w was found in aqueous extract followed by ethyl acetate (41mg GAE/g d.w) and methanol extract (34.46 mg GAE/g d.w). Antibacterial potential of aqueous and organic extracts of C. glaucum was examined against Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli and Staphylococcus epidermidis. The aqueous, methanolic, ethyl acetate, and n-hexane extract showed antibacterial activity against A. baumannii, K. pneumoniae, E. coli and S. epidermidis. However, against A. baumannii significantly higher inhibition zone (19 mm and 18.96 mm respectively) was shown by ethyl acetate and methanol extracts. Aqueous extract possessed highest growth inhibition (11 mm) against E. coli. Aqueous, ethyl acetate and methanol extracts showed 9 mm, 10 mm, and 10.33 mm zone of inhibition against the K. pneumoniae. For antifungal activity, the extracts were less effective against Aspergillus niger but showed strong antifungal activity against Aspergillus flavus (A. flavus). The antioxidant activity was measured as DPPH (2, 2-diphenyl-1-picrylhydrazyl), H2O2 and ABTS (2, 2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) scavenging activity of free radicals. All the organic extracts of C. glaucum possessed ABTS, DPPH and H2O2 scavenging properties. The highest cytotoxic activity measured as half maximal inhibitory concentration (IC50) against human lungs carcinoma cells was recorded for methanolic (IC50 = 16 mu g/mL) and n-hexane (IC50 = 25 mu g/mL) extracts, respectively. The Gas chromatography-mass spectrometry (GC-MS) analysis showed 4 major and 26 minor compounds in n-hexane extract and 4 major and 7 minor compounds in methanol extract of the C. glaucum. It is concluded that aqueous and organic extracts of C. glaucum would be potential therapeutic agents and could be exploited on a pilot scale to treat human pathogenic diseases.	[Khan, Safi Ullah; Ullah, Faizan; Mehmood, Sultan] Univ Sci & Technol Bannu, Dept Bot, Bannu, KP, Pakistan; [Fahad, Shah] Hainan Univ, Coll Trop Crops, Hainan Key Lab Sustainable Utilizat Trop Bioresou, Haikou, Hainan, Peoples R China; [Fahad, Shah] Univ Haripur, Dept Agron, Haripur, Pakistan; [Rahi, Arsalan Ahmad] Univ Hertfordshire, Fac Artificial Intelligence & Machine Learning, Dept Engn, Hatfield, Herts, England; [Althobaiti, Fayez] Taif Univ, Coll Sci, Dept Biotechnol, At Taif, Saudi Arabia; [Dessoky, Eldessoky S.] Taif Univ, Coll Sci, Dept Biol, At Taif, Saudi Arabia; [Saud, Shah] Northeast Agr Univ, Dept Hort, Harbin, Peoples R China; [Danish, Subhan] Bahauddin Zakariya Univ, Fac Agr Sci & Technol, Dept Soil Sci, Multan, Punjab, Pakistan; [Datta, Rahul] Mendel Univ Brno, Fac Forestry & Wood Technol, Dept Geol & Pedol, Brno, Czech Republic	University of Science & Technology Bannu; Hainan University; University of Hertfordshire; Taif University; Taif University; Northeast Agricultural University - China; Bahauddin Zakariya University; Mendel University in Brno	Ullah, F (corresponding author), Univ Sci & Technol Bannu, Dept Bot, Bannu, KP, Pakistan.; Fahad, S (corresponding author), Hainan Univ, Coll Trop Crops, Hainan Key Lab Sustainable Utilizat Trop Bioresou, Haikou, Hainan, Peoples R China.; Fahad, S (corresponding author), Univ Haripur, Dept Agron, Haripur, Pakistan.; Danish, S (corresponding author), Bahauddin Zakariya Univ, Fac Agr Sci & Technol, Dept Soil Sci, Multan, Punjab, Pakistan.; Datta, R (corresponding author), Mendel Univ Brno, Fac Forestry & Wood Technol, Dept Geol & Pedol, Brno, Czech Republic.	drfaizanwazir@gmail.com; shah_fahad80@yahoo.com; sd96850@gmail.com; rahulmedcure@gmail.com	Hassan, Mohamed/AEY-5600-2022; Salem, Mohamed Zidan Mohamed/B-2981-2013; Datta, Rahul/J-9495-2014; Fahad, Shah/J-7265-2019; Saud, Shah/AEA-9474-2022; Danish, Subhan/Q-1414-2018; Hassan, Mohamed M./GQH-8348-2022; Fahad, Shah/GZM-2604-2022	Hassan, Mohamed/0000-0003-1612-107X; Salem, Mohamed Zidan Mohamed/0000-0002-3961-7935; Datta, Rahul/0000-0001-9001-2555; Fahad, Shah/0000-0002-7525-0296; Saud, Shah/0000-0002-3761-2858; Danish, Subhan/0000-0002-6182-6207; Hassan, Mohamed M./0000-0003-1612-107X; Rahi, Arsalan/0000-0002-1674-179X	Taif University Researchers Supporting Project, Saudi Arabia [TURSP - 2020/222]	Taif University Researchers Supporting Project, Saudi Arabia	The authors are also very highly grateful to Taif University Researchers Supporting Project number (TURSP - 2020/222), Saudi Arabia.	Agarwal G, 2020, BIOTECHNOL ADV, V38, DOI 10.1016/j.biotechadv.2019.01.004; Ajaib M, 2016, J CHEM-NY, V2016, DOI 10.1155/2016/4827157; Ajaib Muhammad, 2014, International Journal of Biology and Biotechnology, V11, P71; Ali-Shtayeh MS, 1999, MYCOSES, V42, P665, DOI 10.1046/j.1439-0507.1999.00499.x; Araiza J, 2006, Rev Laryngol Otol Rhinol (Bord), V127, P251; Aziz MA, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-017-0204-5; Bashir Ahmad, 2003, Asian Journal of Plant Sciences, V2, P1072; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Chanda S., 2013, J PHARMACOGN PHYTOCH, V2; Cheesman Matthew J, 2017, Pharmacogn Rev, V11, P57, DOI 10.4103/phrev.phrev_21_17; CHOUDHARY MI, 1995, PHYTOCHEMISTRY, V40, P1243, DOI 10.1016/0031-9422(95)00429-B; Dubreuil JD, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03410; Effah CY, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-019-0343-8; Gaganpreet Kaur, 2018, Journal of Applied and Natural Science, V10, P1149, DOI 10.31018/jans.v10i4.1856; Gupta PD, 2017, J AYURVEDA INTEGR ME, V8, P266, DOI 10.1016/j.jaim.2017.05.004; Hajji M, 2010, PROCESS BIOCHEM, V45, P1486, DOI 10.1016/j.procbio.2010.05.027; Jayaprakasha GK, 2001, FOOD CHEM, V73, P285, DOI 10.1016/S0308-8146(00)00298-3; Kareem S. O., 2008, African Journal of Biomedical Research, V11, P105; Khan AM, 2011, J MED PLANTS RES, V5, P6017, DOI 10.5897/JMPR11.869; Klich MA, 2007, MOL PLANT PATHOL, V8, P713, DOI 10.1111/J.1364-3703.2007.00436.X; Laghari AH, 2011, FOOD CHEM, V126, P1850, DOI 10.1016/j.foodchem.2010.11.165; Lee YL, 2007, LWT-FOOD SCI TECHNOL, V40, P823, DOI 10.1016/j.lwt.2006.04.002; Loudon KW, 1996, J HOSP INFECT, V32, P191, DOI 10.1016/S0195-6701(96)90145-0; Mbata TI., 2008, AFRICAN J BIOTECHNOL, P7; Mulyaningsih, 2011, PHARM BIOL, V49, P893, DOI 10.3109/13880209.2011.553625; Naz R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236319; Nejad BS, 2009, JUNDISHAPUR J MICROB, V2, P25; Nelson L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14551-2; Nguyen TMH, 2020, J ETHNOPHARMACOL, V263, DOI 10.1016/j.jep.2020.113136; Ogunlesi M, 2019, KEM IND, V68, P7, DOI 10.15255/KUI.2018.027; Ogunlesi M, 2009, AFR J BIOTECHNOL, V8, P7042; Ozsoy N, 2008, FOOD CHEM, V110, P571, DOI 10.1016/j.foodchem.2008.02.037; Paudel P, 2012, J ESSENT OIL BEAR PL, V15, P854, DOI 10.1080/0972060X.2012.10644131; Pavithra PS, 2018, LIFE SCI, V197, P19, DOI 10.1016/j.lfs.2018.01.029; Pervez K, 2017, KUWAIT J SCI, V44, P110; Preethi R., 2010, ADV BIOL RES, V4, P122; Pu ZH, 2010, AGR SCI CHINA, V9, P1236, DOI 10.1016/S1671-2927(09)60212-1; Rababah TM, 2004, J AGR FOOD CHEM, V52, P5183, DOI 10.1021/jf049645z; Rahuman A. Abdul, 2000, Fitoterapia, V71, P553, DOI 10.1016/S0367-326X(00)00164-7; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Refaat J, 2013, PHARM BIOL, V51, P100, DOI 10.3109/13880209.2012.698286; RICEEVANS CA, 1995, FREE RADICAL RES, V22, P375, DOI 10.3109/10715769509145649; RUCH RJ, 1989, CARCINOGENESIS, V10, P1003, DOI 10.1093/carcin/10.6.1003; Russo TA, 2003, MICROBES INFECT, V5, P449, DOI 10.1016/S1286-4579(03)00049-2; Saeed Z, 2020, KUWAIT J SCI, V47; Sahreen S, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0736-y; Sahreen S, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-40; Sak A, 2012, INT J RADIAT ONCOL, V84, P492, DOI 10.1016/j.ijrobp.2011.12.021; Steel R. G. D., 1980, Principles and procedures of statistics, a biometrical approach.; SWAIN T., 1959, Journal of the Science of Food and Agriculture, V10, P63, DOI 10.1002/jsfa.2740100110; Triantaphyllou K, 2001, INT J FOOD SCI NUTR, V52, P313, DOI 10.1080/09637480120057512; Venugopala KN, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/963248; Villers D, 1998, ANN INTERN MED, V129, P182, DOI 10.7326/0003-4819-129-3-199808010-00003; Vuong C, 2002, MICROBES INFECT, V4, P481, DOI 10.1016/S1286-4579(02)01563-0	54	2	2	5	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2021	16	10							e0255502	10.1371/journal.pone.0255502	http://dx.doi.org/10.1371/journal.pone.0255502			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8NO	34714855	Green Published, gold			2023-01-03	WOS:000755042500002
J	Hanley, GE; Bickford, C; Ip, A; Lanphear, N; Lanphear, B; Weikum, W; Zwaigenbaum, L; Oberlander, TF				Hanley, Gillian E.; Bickford, Celeste; Ip, Angie; Lanphear, Nancy; Lanphear, Bruce; Weikum, Whitney; Zwaigenbaum, Lonnie; Oberlander, Tim F.			Association of Epidural Analgesia During Labor and Delivery With Autism Spectrum Disorder in Offspring	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Question Does use of epidural analgesia during labor and delivery increase the risk for autism spectrum disorder in offspring? Findings In this population-based retrospective cohort study that included 388 254 term singleton children born via vaginal delivery, the use of epidural analgesia during labor and delivery was significantly associated with a small increase in risk of autism spectrum disorder in offspring (1.53% in exposed children vs 1.26% in unexposed children; adjusted hazard ratio, 1.09). Meaning Maternal epidural analgesia use during labor and delivery was associated with a small increase in the risk of autism spectrum disorder in offspring that met the threshold for statistical significance; however, given the likelihood of residual confounding that may account for the results, these findings do not provide strong supporting evidence for this association. This cohort study assesses the association of maternal use of epidural analgesia during labor and delivery with autism spectrum disorder in offspring using a large population-based data set of term singleton children born in British Columbia, Canada, between April 1, 2000, and December 31, 2014. Importance Evidence from studies investigating the association of epidural analgesia use during labor and delivery with risk of autism spectrum disorder (ASD) in offspring is conflicting. Objective To assess the association of maternal use of epidural analgesia during labor and delivery with ASD in offspring using a large population-based data set with clinical data on ASD case status. Design, Setting, and Participants This population-based retrospective cohort study included term singleton children born in British Columbia, Canada, between April 1, 2000, and December 31, 2014. Stillbirths and cesarean deliveries were excluded. Clinical ASD diagnostic data were obtained from the British Columbia Autism Assessment Network and the British Columbia Ministry of Education. All children were followed up until clinical diagnosis of ASD, death, or the study end date of December 31, 2016. Exposures Use of epidural analgesia during labor and delivery. Main Outcomes and Measures A clinical diagnosis of ASD made by pediatricians, psychiatrists, and psychologists with specialty training to assess ASD. Cox proportional hazards models were used to estimate the hazard ratio of epidural analgesia use and ASD. Models were adjusted for maternal sociodemographics; maternal conditions during pregnancy; labor, delivery, and antenatal care characteristics; infant sex; gestational age; and status of small or large for gestational age. A conditional logistic regression model matching women with 2 births or more and discordance in ASD status of the offspring also was performed. Results Of the 388 254 children included in the cohort (49.8% female; mean gestational age, 39.2 [SD, 1.2] weeks; mean follow-up, 9.05 [SD, 4.3] years), 5192 were diagnosed with ASD (1.34%) and 111 480 (28.7%) were exposed to epidural analgesia. A diagnosis of ASD was made for 1710 children (1.53%) among the 111 480 deliveries exposed to epidural analgesia (94 157 women) vs a diagnosis of ASD in 3482 children (1.26%) among the 276 774 deliveries not exposed to epidural analgesia (192 510 women) (absolute risk difference, 0.28% [95% CI, 0.19%-0.36%]). The unadjusted hazard ratio was 1.32 (95% CI, 1.24-1.40) and the fully adjusted hazard ratio was 1.09 (95% CI, 1.00-1.15). There was no statistically significant association of epidural analgesia use during labor and delivery with ASD in the within-woman matched conditional logistic regression (839/1659 [50.6%] in the exposed group vs 1905/4587 [41.5%] in the unexposed group; fully adjusted hazard ratio, 1.07 [95% CI, 0.87-1.30]). Conclusions and Relevance In this population-based study, maternal epidural analgesia use during labor and delivery was associated with a small increase in the risk of autism spectrum disorder in offspring that met the threshold for statistical significance. However, given the likelihood of residual confounding that may account for the results, these findings do not provide strong supporting evidence for this association.	[Hanley, Gillian E.] Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC, Canada; [Hanley, Gillian E.; Lanphear, Nancy; Lanphear, Bruce; Weikum, Whitney; Oberlander, Tim F.] Univ British Columbia, British Columbia Childrens Hosp, Res Inst, Vancouver, BC, Canada; [Ip, Angie; Lanphear, Nancy; Weikum, Whitney; Oberlander, Tim F.] Univ British Columbia, Div Dev Pediat, Dept Pediat, Vancouver, BC, Canada; [Bickford, Celeste; Oberlander, Tim F.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Lanphear, Bruce] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada; [Zwaigenbaum, Lonnie] Univ Alberta, Dept Pediat, Edmonton, AB, Canada	University of British Columbia; BC Childrens Hospital; University of British Columbia; University of British Columbia; University of British Columbia; Simon Fraser University; University of Alberta	Hanley, GE (corresponding author), Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC, Canada.; Hanley, GE (corresponding author), Univ British Columbia, British Columbia Childrens Hosp, Res Inst, Vancouver, BC, Canada.	gillian.hanley@vch.ca		Oberlander, Tim/0000-0003-4781-6579; Hanley, Gillian/0000-0001-9594-0545; Ip, Angie/0000-0001-7592-4521				Anim-Somuah M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub4; Autism and Developmental Disabilities Monitoring Network, DAT STAT; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; Bickford CD, 2020, AUTISM RES, V13, P456, DOI 10.1002/aur.2252; Butwick AJ, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.6567; Frosst G, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0563-7; Kierans WJ., NEW BIRTH WEIGHT GES; Klauck SM, 2006, EUR J HUM GENET, V14, P714, DOI 10.1038/sj.ejhg.5201610; Kolevzon A, 2007, ARCH PEDIAT ADOL MED, V161, P326, DOI 10.1001/archpedi.161.4.326; Maher GM, 2018, JAMA PSYCHIAT, V75, P809, DOI 10.1001/jamapsychiatry.2018.0854; Perinatal Services BC, BRIT COL PER DAT REG; Population Data British Columbia, AUT DAT; Population Data British Columbia, VIT STAT DEATH; Population Data British Columbia, CONS FIL MSP REG PRE; Public Health Agency of Canada, LAB BIRTH CAN INF; Qiu CY, 2020, JAMA PEDIATR, V174, P1168, DOI 10.1001/jamapediatrics.2020.3231; Rowland J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84573-3; Stuart EA, 2013, J CLIN EPIDEMIOL, V66, pS84, DOI 10.1016/j.jclinepi.2013.01.013; Wall-Wieler E, 2021, JAMA PEDIATR, V175, P698, DOI 10.1001/jamapediatrics.2021.0376; Wang CZ, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006696, 10.1097/md.0000000000006696]	20	13	13	2	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2021	326	12					1178	1185		10.1001/jama.2021.14986	http://dx.doi.org/10.1001/jama.2021.14986			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC5VU	34581736	Bronze, Green Published			2023-01-03	WOS:000704326300020
J	Liu, WQ; Yang, QF; Xu, ZE; Hu, Y; Wang, YM; Liu, ZQ; Zhao, QQ; Wang, ZC; Wei, H; Hua, ZY				Liu, Weiqin; Yang, Qifen; Xu, Zhen-e; Hu, Ya; Wang, Yongming; Liu, Zhenqiu; Zhao, Qianqian; Wang, Zhuangcheng; Wei, Hong; Hua, Ziyu			Impact of the COVID-19 pandemic on neonatal admissions in a tertiary children's hospital in southwest China: An interrupted time-series study	PLOS ONE			English	Article								Background The unprecedented coronavirus disease 2019 (COVID-19) pandemic has caused millions of infections worldwide and represents a significant challenge facing modern health care systems. This study was conducted to investigate the impact of lockdown measures in a tertiary Children's Hospital in southwest China, which might be used to predict long-term effects related to health-seeking behavior of parents/caregivers. Methods This study included newborns enrolled over a span of 86 weeks between January 4, 2019, and August 27, 2020. We designated two time periods for analysis purposes: a stable pre-COVID period(55 weeks between January 4, 2019, and January 23, 2020) and a COVID-impacted period (31 weeks between January 24, 2020, and August 27, 2020). An interrupted time-series analysis was employed to compare changes and trends in hospital admissions and disease spectra before and after the period of nonpharmaceutical interventions (NPIs). Furthermore, this study was conducted to evaluate whether the health-seeking behavior of parents/caregivers was influenced by pandemic factors. Results Overall, 16,640 infants were admitted to the neonatology department during the pre-COVID period (n = 12,082) and the COVID-impacted period (n = 4,558). The per week neonatal admissions consistently decreased following the first days of NPIs (January 24, 2020). The average weekly admission rates of 220/week pre-COVID period and 147/week COVID-impacted period. There was an evident decrease in the volume of admissions for all disease spectra after the intervention, whereas the decrease of patients complaining about pathological jaundice-related conditions was statistically significant (p<0.05). In the COVID-impacted period, the percentage of patients who suffered from respiratory system diseases, neonatal encephalopathy, and infectious diseases decreased, while the percentage of pathological jaundice-related conditions and gastrointestinal system diseases increased. The neonatal mortality rates (NMRs) increased by 8.7% during the COVID-impacted period compared with the pre-COVID period. Conclusions In summary, there was a significant decline in neonatal admissions in a tertiary care hospital during the COVID-19 Pandemic and the associated NPIs. Additionally, this situation had a remarkable impact on disease spectra and health-seeking behavior of parents/caregivers. We, therefore, advise continuing follow-ups and monitoring the main health indicators in vulnerable populations affected by this Pandemic over time.	[Liu, Weiqin; Xu, Zhen-e; Hu, Ya; Wang, Yongming; Liu, Zhenqiu; Zhao, Qianqian; Wei, Hong; Hua, Ziyu] Chongqing Med Univ, Key Lab Child Dev & Disorders, Natl Clin Res Ctr Child Hlth & Disorders, Childrens Hosp,Minist Educ,Dept Neonatol, Chongqing, Peoples R China; [Liu, Weiqin; Xu, Zhen-e; Hu, Ya; Wang, Yongming; Liu, Zhenqiu; Zhao, Qianqian; Wei, Hong; Hua, Ziyu] Chongqing Med Univ, Childrens Hosp, Chongqing Key Lab Pediat, Chongqing, Peoples R China; [Yang, Qifen] Southwest Univ, Sch Life Sci, Chongqing, Peoples R China; [Wang, Zhuangcheng] Chongqing Univ, Engn Res Ctr, Childrens Med Big Data Intelligent Applicat, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University; Southwest University - China; Chongqing University	Hua, ZY (corresponding author), Chongqing Med Univ, Key Lab Child Dev & Disorders, Natl Clin Res Ctr Child Hlth & Disorders, Childrens Hosp,Minist Educ,Dept Neonatol, Chongqing, Peoples R China.; Hua, ZY (corresponding author), Chongqing Med Univ, Childrens Hosp, Chongqing Key Lab Pediat, Chongqing, Peoples R China.	h_ziyu@126.com			Clinical Research Project of Children's Hospital of Chongqing Medical University [YBXM 2019007]	Clinical Research Project of Children's Hospital of Chongqing Medical University	this study was supported by grants from the Clinical Research Project of Children's Hospital of Chongqing Medical University (YBXM 2019007), the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angoulvant F, 2021, CLIN INFECT DIS, V72, P319, DOI 10.1093/cid/ciaa710; Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467; Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Ezeh OK, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013350; Gazzin S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010299; Hartnett KP, 2020, MMWR-MORBID MORTAL W, V69, P699, DOI 10.15585/mmwr.mm6923e1; Hegyi T, 2019, J MATERN-FETAL NEO M, V32, P2721, DOI 10.1080/14767058.2018.1448380; Lei L, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.924609; Li M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237420; Li Q., 2020, NEW ENGL J MED, V382, P1199, DOI [10.1056/NEJMoa2001316, DOI 10.1056/NEJMOA2001316]; Liang XH, 2020, WORLD J CLIN CASES, V8, P2959, DOI 10.12998/wjcc.v8.i14.2959; Liguoro I, 2020, EUR J PEDIATR, V179, P1029, DOI 10.1007/s00431-020-03684-7; Liu TC, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000102; Melnick ER, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1924; Mengistu BA, 2020, BMC PEDIATR, V20, DOI 10.1186/s12887-020-02031-x; Mwansa-Kambafwile J, 2010, INT J EPIDEMIOL, V39, P122, DOI 10.1093/ije/dyq029; Oestergaard MZ, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001080; Piroozi Bakhtiar, 2018, Med J Islam Repub Iran, V32, P121, DOI 10.14196/mjiri.32.121; Riordan SM, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00376; TEAM, 2014, LANG ENV STAT COMP; Tsioufis K, 2020, CLIN RES CARDIOL, V109, P1483, DOI 10.1007/s00392-020-01682-1; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Yang LL, 2020, CELL STEM CELL, V27, P125, DOI 10.1016/j.stem.2020.06.015	25	1	1	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2022	17	1							e0262202	10.1371/journal.pone.0262202	http://dx.doi.org/10.1371/journal.pone.0262202			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H0VF	35025931	Green Published, gold			2023-01-03	WOS:000796264200054
J	Alatinga, KA; Affah, J; Abiiro, GA				Alatinga, Kennedy A.; Affah, Jennifer; Abiiro, Gilbert Abotisem			Why do women attend antenatal care but give birth at home? a qualitative study in a rural Ghanaian District	PLOS ONE			English	Article							MEDICAL-CARE	Background The Sustainable Development Goal Three has prioritised reducing maternal, under-5 and neonatal mortalities as core global health policy objectives. The place, where expectant mothers choose to deliver their babies has a direct effect on maternal health outcomes. In sub-Saharan Africa, existing literature has shown that some women attend antenatal care during pregnancy but choose to deliver their babies at home. Using the Andersen and Newman Behavioural Model, this study explored the institutional and socio-cultural factors motivating women to deliver at home after attending antenatal care. Methods A qualitative, exploratory, cross-sectional design was deployed. Data were collected from a purposive sample of 23 women, who attended antenatal care during pregnancy but delivered their babies at home, 10 health workers and 17 other community-level stakeholders. The data were collected through semi-structured interviews, which were audio-recorded, transcribed and thematically analysed. Results In line with the Andersen and Newman Model, the study discovered that traditional and religious belief systems about marital fidelity and the role of the gods in childbirth, myths about consequences of facility-based delivery, illiteracy, and weak women's autonomy in healthcare decision-making, predisposed women to home delivery. Home delivery was also enabled by inadequate midwives at health facilities, the unfriendly attitude of health workers, hidden charges for facility-based delivery, and long distances to healthcare facilities. The fear of caesarean section, also created the need for women who attended antenatal care to deliver at home. Conclusion The study has established that socio-cultural and institutional level factors influenced women's decisions to deliver at home. We recommend a general improvement in the service delivery capacity of health facilities, and the implementation of collaborative educational and women empowerment programmes by stakeholders, to strengthen women's autonomy and reshape existing traditional and religious beliefs facilitating home delivery.	[Alatinga, Kennedy A.] SD Dombo Univ Business & Integrated Dev Studies, Fac Planning & Land Management, Dept Community Dev, Wa, Ghana; [Affah, Jennifer] Wa Tech Inst, Dept Social Studies, Wa, Ghana; [Abiiro, Gilbert Abotisem] Univ Dev Studies, Sch Publ Hlth, Dept Populat & Reprod Hlth, Tamale, Ghana; [Abiiro, Gilbert Abotisem] Univ Dev Studies, Sch Publ Hlth, Dept Hlth Serv Policy Planning Management & Econ, Tamale, Ghana	University for Development Studies; University for Development Studies	Alatinga, KA (corresponding author), SD Dombo Univ Business & Integrated Dev Studies, Fac Planning & Land Management, Dept Community Dev, Wa, Ghana.	kalatinga@gmail.com		Abiiro, Gilbert Abotisem/0000-0002-3809-2671				Adatara P, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03198-y; Afulani PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117996; Agha S, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-31; Ameyaw Edward Kwabena, 2016, Int J Reprod Med, V2016, P6569514, DOI 10.1155/2016/6569514; Amoro VA, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913-021-06573-3; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P749; Barbi L, 2021, GLOB PUBLIC HEALTH, V16, P532, DOI 10.1080/17441692.2020.1839926; Boah M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230341; Bulto GA, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03135-z; Dalinjong Philip Ayizem, 2018, BMC Res Notes, V11, P341, DOI 10.1186/s13104-018-3452-0; Dalinjong PA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0184830; Dapaah J. M., 2019, Advances in Public Health, V2019, DOI 10.1155/2019/5487293; Dotse-Gborgbortsi W, 2020, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-002020; Dugle G, 2021, WOMEN BIRTH, V34, P187, DOI 10.1016/j.wombi.2020.02.015; Gabrysch S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-34; Ghana Health Service. Upper West Regional Health Services, 2013, UPP W REG HLTH SERV; Ghana Statistical Service, 2013, 2010 POP HOUS CENS; Ghana Statistical Service (GSS) Ghana Health Service (GHS) ICF, 2018, GHAN MAT HLTH SURV 2; Hajizadeh K, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03118-0; Heath G, 2012, HEALTH PLACE, V18, P1068, DOI 10.1016/j.healthplace.2012.05.003; Jirapa Municipality Health Directorate, 2019, 2018 ANN REP; Jirapa Municipality Health Directorate, 2018, 2017 ANN REP; Kifle MM, 2018, J HEALTH POPUL NUTR, V37, DOI 10.1186/s41043-018-0153-1; Kimani M., 2008, AFRICA RENEWAL; Lowe M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163653; Ministry of Health, 2018, DISTR HLTH INF MAN S; Moyer CA, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-40; Paudel M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194328; Raymondville M, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002526; Sarker BK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146161; Shah R, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0454-y; Tebekaw Y, 2015, OBSTET GYNECOL INT, V2015, DOI 10.1155/2015/439748; Tesfaye G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208729; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Titaley CR, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-43; UN, 2015, ARES701 UN, DOI 10.1163/157180910X12665776638740; University of Ghana School of Public Health, 2018, STAT NAT HLTH REP; Vasileiou K, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0594-7; Yaya S, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001341	41	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2021	16	12							e0261316	10.1371/journal.pone.0261316	http://dx.doi.org/10.1371/journal.pone.0261316			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY9FU	34914793	Green Published, gold			2023-01-03	WOS:000755091500079
J	O'Connor, D; Lynch, H; Boyle, B				O'Connor, Deirdre; Lynch, Helen; Boyle, Bryan			A qualitative study of child participation in decision-making: Exploring rights-based approaches in pediatric occupational therapy	PLOS ONE			English	Article							UNITED-NATIONS CONVENTION; FAMILY-CENTERED CARE; DISABILITIES; PARENTS; REHABILITATION; CONSULTATIONS	Background According to Article 12 of the United Nations Convention on the Rights of the Child, therapists are duty-bound to include children in decisions that impact them. Although occupational therapists champion client-centred, collaborative practice, there remains a paucity of studies detailing children's rights and experiences of decision-making in pediatric occupational therapy. Purpose This qualitative study described the decision-making experiences of children, parents and therapists in occupational therapy. Methods Semi-structured interviews were conducted with 17 participants (six children, five parents and six occupational therapists), and data analysed using thematic analysis. Findings Three themes emerged: 1) Goal-setting experiences; 2) Adults: child-rights gatekeepers or defenders? and 3) Decision-making in context. Findings suggest that decision-making is mostly adult directed, and children's voices are subsumed by adult-led services, priorities, and agendas. Implications Children's rights need to be embedded as an aspect of best practice in providing services that are child-centred in occupational therapy practices and education.	[O'Connor, Deirdre; Lynch, Helen; Boyle, Bryan] Univ Coll Cork, Dept Occupat Sci & Occupat Therapy, Cork, Ireland	University College Cork	O'Connor, D (corresponding author), Univ Coll Cork, Dept Occupat Sci & Occupat Therapy, Cork, Ireland.	doconnor@ucc.ie		Boyle, Bryan/0000-0002-9630-7415; O'Connor, Deirdre/0000-0003-1842-076X; Lynch, Helen/0000-0002-3534-9144				An M, 2014, DISABIL REHABIL, V36, P434, DOI 10.3109/09638288.2013.797510; Andersen CS, 2015, PHYS OCCUP THER PEDI, V35, P218, DOI 10.3109/01942638.2014.918075; Angeli JM, 2019, PEDIATR QUAL SAF, V4, DOI 10.1097/pq9.0000000000000199; Archard D, 2009, INT J CHILD RIGHTS, V17, P1, DOI 10.1163/157181808X358276; Birt L, 2016, QUAL HEALTH RES, V26, P1802, DOI 10.1177/1049732316654870; Bland D, 2018, INT J RES METHOD EDU, V41, P342, DOI 10.1080/1743727X.2017.1307957; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Carpenter C, 2008, QUALITATIVE RES OCCU; Clark A, 2004, WHY WE LISTEN CHILDR; Committee on the Rights of the Child, 2009, 12 COMM RIGHTS CHILD; Council of Europe, 2018, GUID COMM MIN COUNC; Coyne I, 2006, J CLIN NURS, V15, P61, DOI 10.1111/j.1365-2702.2005.01247.x; Coyne I, 2016, J CHILD HEALTH CARE, V20, P494, DOI 10.1177/1367493516642744; Coyne I, 2014, EUR J ONCOL NURS, V18, P273, DOI 10.1016/j.ejon.2014.01.006; Coyne I, 2011, J CHILD HEALTH CARE, V15, P312, DOI 10.1177/1367493511406570; Coyne I, 2008, INT J NURS STUD, V45, P1682, DOI 10.1016/j.ijnurstu.2008.05.002; D'Arrigo RG, 2020, AUST OCCUP THER J, V67, P537, DOI 10.1111/1440-1630.12670; Darrah J, 2012, CHILD CARE HLTH DEV, V38, P41, DOI 10.1111/j.1365-2214.2010.01160.x; Delany C, 2014, DEV NEUROREHABIL, V17, P347, DOI 10.3109/17518423.2013.784816; Department of Children and Youth Affairs, 2012, GUID DEV ETH RES PRO; Dixon-Woods M, 1999, BRIT MED J, V319, P778, DOI 10.1136/bmj.319.7212.778; Epstein I., 2006, INT J QUAL METH, V5, P1, DOI [DOI 10.1177/160940690600500301, 10.1177/]; Faux S A, 1988, West J Nurs Res, V10, P180, DOI 10.1177/019394598801000206; Franklin A, 2006, BRIT J SOC WORK, V36, P723, DOI 10.1093/bjsw/bch306; Gardner H, 2012, NURSE RES, V19; Goldhagen J, 2020, BMJ PAEDIATR OPEN, V4, DOI 10.1136/bmjpo-2019-000589; Hammell KRW, 2012, SCAND J OCCUP THER, V19, P385, DOI 10.3109/11038128.2011.611821; Hayes N., 2009, RIGHT CHILDREN CHILD; Kelly M, 2012, J CHILD HEALTH CARE, V16, P190, DOI 10.1177/1367493511426421; Kennan D, 2018, BRIT J SOC WORK, V48, P1985, DOI 10.1093/bjsw/bcx142; Kilkelly U., 2006, CHILDS RIGHT BE HEAR; Kolehmainen N, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-76; Kramer J, 2012, OTJR-OCCUP PART HEAL, V32, pS48, DOI 10.3928/15394492-20110906-02; Kyler PL, 2008, OCCUP THER MENT HEAL, V24, P100, DOI 10.1080/01642120802055150; Law M, 1995, Can J Occup Ther, V62, P250; Le Borgne C, 2017, SOC INCL, V5, P122, DOI 10.17645/si.v5i3.986; Lewis S, 2015, HEALTH PROMOT PRACT, V16, P473, DOI 10.1177/1524839915580941; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; London L., 2008, HLTH HUMAN RIGHTS, V10, P65; Lundy L, 2007, BRIT EDUC RES J, V33, P927, DOI 10.1080/01411920701657033; Lynch R., LYNCHLYNCH2013CHILDR; Missiuna C, 2006, AM J OCCUP THER, V60, P204, DOI 10.5014/ajot.60.2.204; Missiuna C, 2000, Can J Occup Ther, V67, P101; Neergaard MA, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-52; Nordstrom B, 2020, INT J DISABIL DEV ED, DOI 10.1080/1034912X.2020.1846689; O'Dea AE, 2021, BRIT J OCCUP THER, V84, P307, DOI 10.1177/0308022620944100; Okeeffe B., 2017, WORKING TOGETHER SUP; Percy-Smith B., 2010, HDB CHILDREN YOUNG P; Pilnick A, 2011, SOCIOL REV, V59, P303, DOI 10.1111/j.1467-954X.2011.02006.x; Playford ED., 2017, REHABILITATION GOAL, V1st, P89; Pritchard L, 2022, DISABIL REHABIL, V44, P1042, DOI 10.1080/09638288.2020.1788178; Pritchard-Wiart L, 2019, CLIN REHABIL, V33, P1515, DOI 10.1177/0269215519846220; Pritchard-Wiart L, 2018, CLIN REHABIL, V32, P954, DOI 10.1177/0269215518758484; Rodger, 2010, OCCUPATION CENTRED P; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Savage E, 2007, SOC SCI MED, V64, P363, DOI 10.1016/j.socscimed.2006.09.003; Schwartz SP, 2020, CAN J OCCUP THER, V87, P278, DOI 10.1177/0008417420941980; Shier H., 2001, CHILD SOC, V15, P107, DOI 10.1002/CHI.617; Sinclair R., 2004, CHILD SOC, V18, P106; Sullivan-Bolyai S, 2005, NURS OUTLOOK, V53, P127, DOI 10.1016/j.outlook.2005.03.005; Sullivan-Bolyai S, 2005, NURSING RES CANADA M, P247; Teachman G, 2013, QUAL HEALTH RES, V23, P264, DOI 10.1177/1049732312468063; United Nations, 2006, CONVENTION RIGHTS PE; UNITED NATIONS, 1989, CONV RIGHTS CHILD; Vroland-Nordstrand K, 2016, DEV MED CHILD NEUROL, V58, P589, DOI 10.1111/dmcn.12925; Wood EA, 2014, INT J EARLY YEARS ED, V22, P4, DOI 10.1080/09669760.2013.830562; World Federation of Occupational Therapists, 2019, POSITION STATEMENT O; World Federation of Occupational Therapists, 2016, MIN STAND ED OCC THE; World Federation of Occupational Therapists, 2010, POSITION STATEMENT C; Zoe Slade, 2009, DEP CHILDREN SCH FAM, V28	70	1	1	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2021	16	12							e0260975	10.1371/journal.pone.0260975	http://dx.doi.org/10.1371/journal.pone.0260975			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY9FU	34914778	Green Published, gold			2023-01-03	WOS:000755091500046
J	DeClercq, V; Nearing, JT; Langille, MGI				DeClercq, Vanessa; Nearing, Jacob T.; Langille, Morgan G., I			Investigation of the impact of commonly used medications on the oral microbiome of individuals living without major chronic conditions	PLOS ONE			English	Article							PROTON PUMP INHIBITORS; GUT MICROBIOTA; DISEASE; ASSOCIATION; PARTNERSHIP; DYSBIOSIS; PROJECT; COHORT	Background Commonly used medications produce changes in the gut microbiota, however, the impact of these medications on the composition of the oral microbiota is understudied. Methods Saliva samples were obtained from 846 females and 368 males aged 35-69 years from a Canadian population cohort, the Atlantic Partnership for Tomorrow's Health (PATH). Samples were analyzed by 16S rRNA gene sequencing and differences in microbial community compositions between nonusers, single-, and multi-drug users as well as the 3 most commonly used medications (thyroid hormones, statins, and proton pump inhibitors (PPI)) were examined. Results Twenty-six percent of participants were taking 1 medication and 21% were reported taking 2 or more medications. Alpha diversity indices of Shannon diversity, Evenness, Richness, and Faith's phylogenetic diversity were similar among groups, likewise beta diversity as measured by Bray-Curtis dissimilarity (R-2 = 0.0029, P = 0.053) and weighted UniFrac distances (R-2 = 0.0028, P = 0.161) were non-significant although close to our alpha value threshold (P = 0.05). After controlling for covariates (sex, age, BMI), six genera (Saprospiraceae uncultured, Bacillus, Johnsonella, Actinobacillus, Stenotrophomonas, and Mycoplasma) were significantly different from non-medication users. Thyroid hormones, HMG-CoA reductase inhibitors (statins) and PPI were the most reported medications. Shannon diversity differed significantly among those taking no medication and those taking only thyroid hormones, however, there were no significant difference in other measures of alpha- or beta diversity with single thyroid hormone, statin, or PPI use. Compared to participants taking no medications, the relative abundance of eight genera differed significantly in participants taking thyroid hormones, six genera differed in participants taking statins, and no significant differences were observed with participants taking PPI. Conclusion The results from this study show negligible effect of commonly used medications on microbial diversity and small differences in the relative abundance of specific taxa, suggesting a minimal influence of commonly used medication on the salivary microbiome of individuals living without major chronic conditions.	[DeClercq, Vanessa; Langille, Morgan G., I] Dalhousie Univ, Dept Pharmacol, Halifax, NS, Canada; [DeClercq, Vanessa] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada; [Nearing, Jacob T.; Langille, Morgan G., I] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada	Dalhousie University; Dalhousie University; Dalhousie University	DeClercq, V (corresponding author), Dalhousie Univ, Dept Pharmacol, Halifax, NS, Canada.; DeClercq, V (corresponding author), Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada.	vanessa.de.clercq@dal.ca			Canadian Partnership Against Cancer and Health Canada; Nova Scotia Graduate Scholarship; ResearchNS Scotia Scholars award	Canadian Partnership Against Cancer and Health Canada; Nova Scotia Graduate Scholarship; ResearchNS Scotia Scholars award	Thank you to all participants of the Atlantic PATH project for donating their time, personal health information and biological samples to this project, and to Atlantic PATH team members for data collection and management. The data used in this research were made available by the Atlantic Partnership for Tomorrow's Health (Atlantic PATH) study, which is the Atlantic Canada regional component of the Canadian Partnership for Tomorrow Project funded by the Canadian Partnership Against Cancer and Health Canada. The views expressed herein represent the views of the authors and do not necessarily represent the views of Health Canada. JTN is funded by both a Nova Scotia Graduate Scholarship and a ResearchNS Scotia Scholars award.	Al-Zyoud W, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010256; Amir A, 2017, MSYSTEMS, V2, DOI 10.1128/mSystems.00191-16; Amir I, 2014, ENVIRON MICROBIOL, V16, P2905, DOI 10.1111/1462-2920.12285; Belstrom D, 2020, J ORAL MICROBIOL, V12, DOI 10.1080/20002297.2020.1723975; Bokulich NA, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0470-z; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Buckley JP, 2013, INFLAMM BOWEL DIS, V19, P2725, DOI 10.1097/01.MIB.0000435442.07237.a4; Chhibber-Goel J, 2016, NPJ BIOFILMS MICROBI, V2, DOI 10.1038/s41522-016-0009-7; Dethlefsen L, 2011, P NATL ACAD SCI USA, V108, P4554, DOI 10.1073/pnas.1000087107; Doestzada M, 2018, PROTEIN CELL, V9, P432, DOI 10.1007/s13238-018-0547-2; Dummer TJB, 2018, CAN MED ASSOC J, V190, pE710, DOI 10.1503/cmaj.170292; Fernandes AD, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-15; Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766; Gnjidic D, 2017, PUBLIC HEALTH RES PR, V27, DOI 10.17061/phrp27341702; Hsiao WWL, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-345; Human Microbiome Project Consortium, 2012, Nature, V486, P207, DOI 10.1038/nature11234; Imhann F, 2017, GUT MICROBES, V8, P351, DOI 10.1080/19490976.2017.1284732; Imhann F, 2016, GUT, V65, P740, DOI 10.1136/gutjnl-2015-310376; Jackson MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05184-7; Jackson MA, 2016, GUT, V65, P749, DOI 10.1136/gutjnl-2015-310861; Jia YJ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.658203; Kaul A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02114; Kawar N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80170-y; Keats MR, 2021, SUPPORT CARE CANCER, V29, P713, DOI 10.1007/s00520-020-05529-3; Khan TJ, 2018, OMICS, V22, P154, DOI 10.1089/omi.2017.0130; Long J, 2017, J PERIODONTAL RES, V52, P636, DOI 10.1111/jre.12432; Mallick H, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1009442; Martin BD, 2020, ANN APPL STAT, V14, P94, DOI [10.1214/19-AOAS1283, 10.1214/19-aoas1283]; Mishiro T, 2018, J GASTROEN HEPATOL, V33, P1059, DOI 10.1111/jgh.14040; Moura CS, 2022, CHRONIC ILLN, V18, P729, DOI 10.1177/1742395320985913; Nearing JT, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00451-20; Nearing JT, 2021, BIOINFORMATICS, V2021, DOI [10.1101/2021.05.10.443486, DOI 10.1101/2021.05.10.443486]; Pedersen E, 2021, J CLIN EPIDEMIOL, V135, P115, DOI 10.1016/j.jclinepi.2021.02.015; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Rademacher WMH, 2020, ORAL DIS, V26, P213, DOI 10.1111/odi.13199; Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584; Said HS, 2014, DNA RES, V21, P15, DOI 10.1093/dnares/dst037; Segata N, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r42; Seidel CL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218218; Shi YC, 2019, GENOM PROTEOM BIOINF, V17, P52, DOI 10.1016/j.gpb.2018.12.004; Sweeney E, 2017, INT J EPIDEMIOL, V46, P1762, DOI 10.1093/ije/dyx124; Vieira-Silva S, 2020, NATURE, V581, P310, DOI 10.1038/s41586-020-2269-x; Vila AV, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14177-z; Wallace BD, 2010, SCIENCE, V330, P831, DOI 10.1126/science.1191175; Wang JZ, 2019, INTEST RES, V17, P496, DOI 10.5217/ir.2019.00050; WHO, 2018, GUIDELINES ATC CLASS; Yamashita Y, 2017, J ORAL SCI, V59, P201, DOI 10.2334/josnusd.16-0856; Yang Y, 2020, AGING-US, V12, P13090, DOI 10.18632/aging.103399; Yao ZY, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00495; Yuan A, 2015, OR SURG OR MED OR PA, V119, P35, DOI 10.1016/j.oooo.2014.09.009; Zaura E, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-259; Zimmermann M, 2019, NATURE, V570, P462, DOI 10.1038/s41586-019-1291-3	53	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2021	16	12							e0261032	10.1371/journal.pone.0261032	http://dx.doi.org/10.1371/journal.pone.0261032			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8LQ	34882708	Green Published, gold			2023-01-03	WOS:000755037200054
J	McCartney, G; Douglas, M; Taulbut, M; Katikireddi, SV; McKee, M				McCartney, Gerry; Douglas, Margaret; Taulbut, Martin; Katikireddi, S. Vittal; McKee, Martin			Tackling population health challenges as we build back from the pandemic	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ECONOMY; IMPACT		[McCartney, Gerry] Univ Glasgow, Coll Social Sci, Glasgow, Lanark, Scotland; [Douglas, Margaret] Univ Edinburgh, Coll Med & Vet Med, Usher Inst, Edinburgh, Midlothian, Scotland; [McCartney, Gerry; Douglas, Margaret; Taulbut, Martin; Katikireddi, S. Vittal] Publ Hlth Scotland, Glasgow, Lanark, Scotland; [Katikireddi, S. Vittal] Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland; [McKee, Martin] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England	University of Glasgow; University of Edinburgh; MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; University of London; London School of Hygiene & Tropical Medicine	McCartney, G (corresponding author), Univ Glasgow, Coll Social Sci, Glasgow, Lanark, Scotland.; McCartney, G (corresponding author), Publ Hlth Scotland, Glasgow, Lanark, Scotland.	Gerard.McCartney@glasgow.ac.uk		Katikireddi, Srinivasa/0000-0001-6593-9092; Douglas, Margaret/0000-0003-1560-5451; McCartney, Gerry/0000-0001-6341-3521	NRS senior clinical fellowship [SCAF/15/02]; Medical Research Council [MC_UU_00022/2]; Scottish Government Chief Scientist Office [SPHSU17]	NRS senior clinical fellowship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Scottish Government Chief Scientist Office	SVK acknowledges funding from a NRS senior clinical fellowship (SCAF/15/02), the Medical Research Council (MC_UU_00022/2), and Scottish Government Chief Scientist Office (SPHSU17).	[Anonymous], 2010, WHO ADELAIDE STATEME; [Anonymous], 2006, SECURING GOOD CARE O; [Anonymous], 2021, COVID 19 WID IMP HLT; Baker MG, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4907; Bambra C, 2020, J EPIDEMIOL COMMUN H, V74, P964, DOI 10.1136/jech-2020-214401; Burnett D, 2020, PROTECTING HLTH WORK; Calvert J, FAILURES STATE INSID, P2021; Cameron EE., 2019, GLOBAL HLTH SECURITY; Chrysopoulou A, 2021, FAILURE DEMAND COUNT; Commission on Race and Ethnic Disparities, REPORT, P2021; Cooper K, 2021, CONSERVATIVE GOVERNM; Di Gessa G, MEDRXIV2021202104012, V2021; Douglas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1557; Fenton L, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029936; Glei DA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0226732; Green F., 2018, WORK INTENSITY BRITA; Green L, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18189468; Hiam L, 2020, BRIT MED BULL, V133, P4, DOI 10.1093/bmb/ldz041; House of Commons Committee of Public Accounts, 2021, TEST TRAC UPD; Intergovernmental Panel on Climate Change, 2021, SYNTH REP 6 ASS REP; Islam N, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj-2021-066768; Joyce R, 2013, OXFORD REV ECON POL, V29, P178, DOI 10.1093/oxrep/grt008; Katikireddi SV, 2021, J ROY COLL PHYS EDIN, V51, pS40, DOI 10.4997/JRCPE.2021.240; Marmot M., 2020, PANDEMIC SOCIOECONOM; McCartney Gerry, 2020, Public Health Pract (Oxf), V1, P100003, DOI 10.1016/j.puhip.2020.100003; McCartney G, 2019, AM J PUBLIC HEALTH, V109, pE1, DOI 10.2105/AJPH.2019.305001; Mercer SW, 2021, LANCET, V397, P775, DOI 10.1016/S0140-6736(21)00317-2; Minton J, 2020, J EPIDEMIOL COMMUN H, V74, P741, DOI 10.1136/jech-2020-213870; ONS, INT COMP GDP COR COV, P2021; Parolin Z, 2021, POTENTIAL POVERTY RE; Rajan S., 2020, J LONG TERM CARE, V2020, P185, DOI [10.31389/jltc.53, DOI 10.31389/JLTC.53]; Scottish Government, 2011, CHRIST COMM FUT DEL; Sheikh A, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010370; Shipton D, 2021, J EPIDEMIOL COMMUN H, V75, P1129, DOI 10.1136/jech-2020-216070; Smith LE, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n608; Suleman M., 2021, UNEQUAL PANDEMIC FAI; Teuton J, 2020, RAPID REV EVIDENCE S; UK Health and Social Care, 2021, SCI TECHN COMM COR L; Walsh D, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-038135; Wellbeing Economy Alliance, 2021, WELLB EC GOV	40	12	12	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 7	2021	375								e066232	10.1136/bmj-2021-066232	http://dx.doi.org/10.1136/bmj-2021-066232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XP4DA	34876411	hybrid, Green Accepted, Green Submitted, Green Published			2023-01-03	WOS:000730815800011
J	Cilloniz, C; Torres, A; Niederman, MS				Cilloniz, Catia; Torres, Antoni; Niederman, Michael S.			Management of pneumonia in critically ill patients	BMJ-BRITISH MEDICAL JOURNAL			English	Review							COMMUNITY-ACQUIRED PNEUMONIA; VENTILATOR-ASSOCIATED PNEUMONIA; INFECTIOUS-DISEASES-SOCIETY; DRUG-RESISTANT PATHOGENS; COMBINATION ANTIBIOTIC-THERAPY; SUBGLOTTIC SECRETION DRAINAGE; CARE-UNIT ADMISSION; RECEIVING MECHANICAL VENTILATION; C-REACTIVE PROTEIN; INTENSIVE-CARE	Severe pneumonia is associated with high mortality (short and long term), as well as pulmonary and extrapulmonary complications. Appropriate diagnosis and early initiation of adequate antimicrobial treatment for severe pneumonia are crucial in improving survival among critically ill patients. Identifying the underlying causative pathogen is also critical for antimicrobial stewardship. However, establishing an etiological diagnosis is challenging in most patients, especially in those with chronic underlying disease; those who received previous antibiotic treatment; and those treated with mechanical ventilation. Furthermore, as antimicrobial therapy must be empiric, national and international guidelines recommend initial antimicrobial treatment according to the location's epidemiology; for patients admitted to the intensive care unit, specific recommendations on disease management are available. Adherence to pneumonia guidelines is associated with better outcomes in severe pneumonia. Yet, the continuing and necessary research on severe pneumonia is expansive, inviting different perspectives on host immunological responses, assessment of illness severity, microbial causes, risk factors for multidrug resistant pathogens, diagnostic tests, and therapeutic options.	[Cilloniz, Catia; Torres, Antoni] Hosp Clin Barcelona, Dept Pneumol, Barcelona, Spain; [Cilloniz, Catia; Torres, Antoni] August Pi & Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain; [Cilloniz, Catia; Torres, Antoni] Univ Barcelona, Barcelona, Spain; [Cilloniz, Catia; Torres, Antoni] Biomed Res Networking Centers Resp Dis CIBERES, Barcelona, Spain; [Niederman, Michael S.] Weill Cornell Med Coll, Dept Pulm Crit Care Med, New York, NY 10065 USA	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Cornell University	Niederman, MS (corresponding author), Weill Cornell Med Coll, Dept Pulm Crit Care Med, New York, NY 10065 USA.	msn9004@med.cornell.edu	Cillóniz, Catia/Y-1898-2018	cilloniz, catia/0000-0002-4646-9838				Aarts MAW, 2008, CRIT CARE MED, V36, P108, DOI 10.1097/01.CCM.0000297956.27474.9D; Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9; Abelenda-Alonso G, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa066; Aguilera ER, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00105; Akagi T, 2019, AM J MED SCI, V358, P33, DOI 10.1016/j.amjms.2019.04.005; Aldas I, 2020, ARCH BRONCONEUMOL, V56, P551, DOI 10.1016/j.arbres.2019.10.009; Aliberti S, 2014, CURR OPIN INFECT DIS, V27, P295, DOI [10.1097/QCO.0000000000000060, 10.1097/QCO.0000000000000055]; Aliberti S, 2013, THORAX, V68, P997, DOI 10.1136/thoraxjnl-2013-203384; Aliberti S, 2012, CLIN INFECT DIS, V54, P470, DOI 10.1093/cid/cir840; Alimi Y, 2017, J CLIN VIROL, V95, P26, DOI 10.1016/j.jcv.2017.07.019; Almeida ST, 2021, J INFECT DIS, V223, P1590, DOI 10.1093/infdis/jiaa558; Lerma FA, 2014, MED INTENSIVA, V38, P226, DOI 10.1016/j.medin.2013.12.007; Alvarez-Lerma F, 2018, CRIT CARE MED, V46, P181, DOI 10.1097/CCM.0000000000002736; Anderson R, 2007, J ANTIMICROB CHEMOTH, V60, P1155, DOI 10.1093/jac/dkm338; Anderson R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041147; Annane D, 2018, NEW ENGL J MED, V378, P809, DOI 10.1056/NEJMoa1705716; [Anonymous], 2017, HEALTHCARE ASS INFEC; Antoni Torres CC, 2015, CLIN MANAGEMENT BACT, DOI [10.1007/978-3- 319-22062-8, DOI 10.1007/978-3-319-22062-8]; Arthur LE, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004267.pub4; Baby N, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02432-16, 10.1128/aac.02432-16]; Baddour LM, 2004, AM J RESP CRIT CARE, V170, P440, DOI 10.1164/rccm.200311-1578OC; Bassetti M, 2021, LANCET INFECT DIS, V21, P226, DOI 10.1016/S1473-3099(20)30796-9; Bassetti M, 2018, CURR OPIN CRIT CARE, V24, P385, DOI 10.1097/MCC.0000000000000534; Bassi GL, 2017, INTENS CARE MED, V43, P1572, DOI 10.1007/s00134-017-4858-1; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bein T, 2018, CURR OPIN CRIT CARE, V24, P35, DOI 10.1097/MCC.0000000000000476; Beno SM, 2020, J INFECT DIS, V222, P1882, DOI 10.1093/infdis/jiaa295; Bermejo-Martin JF, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110400; Bermejo-Martin JF, 2017, LANCET RESP MED, V5, pE35, DOI 10.1016/S2213-2600(17)30444-7; Bermejo-Martin JF, 2017, EBIOMEDICINE, V24, P231, DOI 10.1016/j.ebiom.2017.09.023; Bhalodi AA, 2019, J ANTIMICROB CHEMOTH, V74, P6, DOI 10.1093/jac/dky530; Black AD, 2016, PNEUMONIA, V8, DOI 10.1186/s41479-016-0002-1; Blackburn R, 2018, CLIN INFECT DIS, V67, P8, DOI 10.1093/cid/cix1144; Blot S, 2014, CRIT CARE MED, V42, P601, DOI 10.1097/01.ccm.0000435665.07446.50; Bonneau E, 2019, EJIFCC, V30, P114; Bouza E, 2008, CHEST, V134, P938, DOI 10.1378/chest.08-0103; Briel M, 2018, CLIN INFECT DIS, V66, P346, DOI 10.1093/cid/cix801; Brown AO, 2015, AM J RESP CRIT CARE, V191, P739, DOI 10.1164/rccm.201411-1951PP; Brown SM, 2009, CRIT CARE MED, V37, P3010, DOI 10.1097/CCM.0b013e3181b030d9; Buelow E, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0309-z; Burja S, 2018, BOSNIAN J BASIC MED, V18, P105, DOI 10.17305/bjbms.2017.2278; Burk M, 2016, EUR RESPIR REV, V25, P178, DOI 10.1183/16000617.0076-2015; Burns KEA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004127.pub3; Burrell A, 2018, NEW ENGL J MED, V378, P2138, DOI 10.1056/NEJMc1717178; Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616; Caroff DA, 2016, CRIT CARE MED, V44, P830, DOI 10.1097/CCM.0000000000001414; Cavallazzi R, 2020, CHEST, V158, P1008, DOI 10.1016/j.chest.2020.03.051; Cavallazzi R, 2018, CLIN CHEST MED, V39, P703, DOI 10.1016/j.ccm.2018.07.005; Ceccato A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060843; Cerceo E, 2016, MICROB DRUG RESIST, V22, P412, DOI 10.1089/mdr.2015.0220; Chalmers JD, 2008, AM J MED, V121, P219, DOI 10.1016/j.amjmed.2007.10.033; Chalmers JD, 2011, CLIN INFECT DIS, V53, P503, DOI 10.1093/cid/cir463; Chamot E, 2003, ANTIMICROB AGENTS CH, V47, P2756, DOI 10.1128/AAC.47.9.2756-2764.2003; Chastre J, 2016, INTENS CARE MED, V42, P1159, DOI 10.1007/s00134-016-4239-1; Chen JL, 2021, J MED MICROBIOL, V70, DOI 10.1099/jmm.0.001259; Chen YX, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1351-0; Chiewchalermsri C, 2020, J ASTHMA ALLERGY, V13, P127, DOI 10.2147/JAA.S207980; Chiu CY, 2019, NAT REV GENET, V20, P341, DOI 10.1038/s41576-019-0113-7; Christ-Crain M, 2006, AM J RESP CRIT CARE, V174, P84, DOI 10.1164/rccm.200512-1922OC; Cilloniz C, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00773-2020; Cilloniz C, 2019, CURR OPIN INFECT DIS, V32, P656, DOI 10.1097/QCO.0000000000000596; Cilloniz C, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070961; Cilloniz C, 2019, J INFECT DIS, V220, P1166, DOI 10.1093/infdis/jiz257; Cilloniz C, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7020049; Cilloniz C, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02215-2017; Cilloniz C, 2016, EXPERT REV RESP MED, V10, P1211, DOI 10.1080/17476348.2016.1240037; Cilloniz C, 2016, RESPIROLOGY, V21, P65, DOI 10.1111/resp.12663; Cilloniz C, 2013, CHEST, V144, P999, DOI 10.1378/chest.13-0062; Ciofu O, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00913; Claessens YE, 2015, AM J RESP CRIT CARE, V192, P974, DOI 10.1164/rccm.201501-0017OC; Colombo SM, 2020, INTENS CARE MED, V46, P368, DOI 10.1007/s00134-019-05882-w; Corrales-Medina VF, 2015, AM HEART J, V170, P306, DOI 10.1016/j.ahj.2015.04.028; Corrales-Medina VF, 2013, LANCET, V381, P496, DOI 10.1016/S0140-6736(12)61266-5; Corrales-Medina VF, 2012, CIRCULATION, V125, P773, DOI 10.1161/CIRCULATIONAHA.111.040766; Danin PE, 2015, RESP CARE, V60, P21, DOI 10.4187/respcare.02722; De Gonzalo-Calvo D, 2021, TRANSL RES, V236, P147, DOI 10.1016/j.trsl.2021.05.004; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; de la Torre MC, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2016-000152; de la Torre MC, 2016, J CRIT CARE, V35, P115, DOI 10.1016/j.jcrc.2016.05.005; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; Deschepper M, 2018, INTENS CARE MED, V44, P1017, DOI 10.1007/s00134-018-5171-3; Dezfulian C, 2005, AM J MED, V118, P11, DOI 10.1016/j.amjmed.2004.07.051; Ding CY, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2566-7; Souza LCD, 2017, BRAZ ORAL RES, V31, DOI [10.1590/1807-3107bor-2017.vol31.0038, 10.1590/1807-3107BOR-2017.vol31.0038]; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; Drewett GP, 2022, INFECT CONT HOSP EP, V43, P542, DOI 10.1017/ice.2021.28; Dudeck MA, 2015, AM J INFECT CONTROL, V43, P206, DOI 10.1016/j.ajic.2014.11.014; Esperatti M, 2013, CRIT CARE MED, V41, P2151, DOI 10.1097/CCM.0b013e31828a674a; Eurich DT, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j413; Ewig S, 2019, CLIN MICROBIOL INFEC, V25, P1173, DOI 10.1016/j.cmi.2019.02.022; Feldman C, 1999, EUR RESPIR J, V13, P546, DOI 10.1183/09031936.99.13354699; Feldman C, 2021, PNEUMONIA, V13, DOI 10.1186/s41479-021-00083-w; Fernandez-Barat L, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2523-5; Fernandez-Barat L, 2016, FUTURE MICROBIOL, V11, P1599, DOI 10.2217/fmb-2016-0040; Fernando SM, 2020, INTENS CARE MED, V46, P1170, DOI 10.1007/s00134-020-06036-z; Ferreira-Coimbra J, 2020, EUR J CLIN MICROBIOL, V39, P281, DOI 10.1007/s10096-019-03720-x; Flannery AH, 2020, CRIT CARE MED, V48, P912, DOI 10.1097/CCM.0000000000004326; Forel JM, 2012, CRIT CARE, V16, DOI 10.1186/cc11312; Frank RC, 2019, NEW ENGL J MED, V380, DOI 10.1056/NEJMc1901647; Franquet T, 2018, J THORAC IMAG, V33, P282, DOI 10.1097/RTI.0000000000000347; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Frost SA, 2013, AUST CRIT CARE, V26, P180, DOI 10.1016/j.aucc.2013.03.003; Fukuyama H, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-534; Garnacho-Montero J, 2007, CRIT CARE MED, V35, P1888, DOI 10.1097/01.CCM.0000275389.31974.22; Gilbert DN, 2017, INFECT DIS CLIN N AM, V31, P435, DOI 10.1016/j.idc.2017.05.003; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Giuliano KK, 2018, AM J INFECT CONTROL, V46, P322, DOI 10.1016/j.ajic.2017.09.005; Han J, 2020, CLIN MED, V20, pE47, DOI 10.7861/clinmed.Let.20.3.3; Hao JJ, 2016, INT J ANTIMICROB AG, V47, P28, DOI 10.1016/j.ijantimicag.2015.10.019; He HY, 2020, SEMIN RESP CRIT CARE, V41, P470, DOI 10.1055/s-0040-1709992; Herkel T, 2016, BIOMED PAP, V160, P448, DOI 10.5507/bp.2016.014; Heyland DK, 2008, CRIT CARE MED, V36, P737, DOI 10.1097/01.CCM.0B013E31816203D6; Hirata K, 2002, VET HUM TOXICOL, V44, P89; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hua Fang, 2016, Cochrane Database Syst Rev, V10, pCD008367; Huang XA, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011223, 10.1097/md.0000000000011223]; Ibn Saied W, 2019, CRIT CARE MED, V47, P345, DOI 10.1097/CCM.0000000000003553; Iizuka Y, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1764-4; Ishida T, 2017, J INFECT CHEMOTHER, V23, P23, DOI 10.1016/j.jiac.2016.09.002; Ito A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54922-4; Ito A, 2017, J INFECT CHEMOTHER, V23, P142, DOI 10.1016/j.jiac.2016.11.006; Jaillette E, 2017, INTENS CARE MED, V43, P1562, DOI 10.1007/s00134-017-4736-x; Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870; Julian-Jimenez A, 2017, MED CLIN-BARCELONA, V148, P501, DOI 10.1016/j.medcli.2017.02.024; Justel M, 2013, J CLIN VIROL, V58, P564, DOI 10.1016/j.jcv.2013.09.006; Kalil AC, 2016, CLIN INFECT DIS, V63, P575, DOI 10.1093/cid/ciw504; Karhu J, 2014, CLIN INFECT DIS, V59, P62, DOI 10.1093/cid/ciu237; Kelly BJ, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0151-8; Keramat F, 2018, INT J GEN MED, V11, P217, DOI 10.2147/IJGM.S165190; Khan F, 2017, EXPERT REV CLIN PHAR, V10, P201, DOI 10.1080/17512433.2017.1268051; Kim MW, 2017, SCAND J CLIN LAB INV, V77, P486, DOI 10.1080/00365513.2017.1344298; Klompas M, 2007, JAMA-J AM MED ASSOC, V297, P1583, DOI 10.1001/jama.297.14.1583; Klompas M, 2017, SEMIN RESP CRIT CARE, V38, P381, DOI 10.1055/s-0037-1602584; Klompas M, 2016, JAMA INTERN MED, V176, P1277, DOI 10.1001/jamainternmed.2016.2427; Klompas M, 2015, AM J RESP CRIT CARE, V192, P1420, DOI 10.1164/rccm.201506-1161CI; Klompas M, 2014, JAMA INTERN MED, V174, P751, DOI 10.1001/jamainternmed.2014.359; Kobayashi D, 2018, INFECT DRUG RESIST, V11, P1703, DOI 10.2147/IDR.S165669; Kolditz M, 2016, INTENS CARE MED, V42, P2108, DOI 10.1007/s00134-016-4517-y; Kollef MH, 2019, LANCET INFECT DIS, V19, P1299, DOI 10.1016/S1473-3099(19)30403-7; Kollef MH, 2017, CHEST, V151, P1239, DOI 10.1016/j.chest.2016.11.026; Kontou P, 2009, AM J EMERG MED, V27, P968, DOI 10.1016/j.ajem.2008.07.037; Ekren PK, 2018, AM J RESP CRIT CARE, V197, P826, DOI 10.1164/rccm.201708-1717LE; Krein SL, 2017, CLIN INFECT DIS, V64, pS105, DOI 10.1093/cid/cix073; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kumar A, 2010, CRIT CARE MED, V38, P1651, DOI 10.1097/CCM.0b013e3181e96b91; Kuypers J, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.01890-18; Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090; Kyriazopoulou E, 2021, INFECT DIS THER, V10, P1437, DOI 10.1007/s40121-021-00459-x; La Combe B, 2018, INTENS CARE MED, V44, P531, DOI 10.1007/s00134-018-5061-8; Labeau SO, 2011, LANCET INFECT DIS, V11, P845, DOI 10.1016/S1473-3099(11)70127-X; Lan SH, 2020, J GLOB ANTIMICROB RE, V23, P94, DOI 10.1016/j.jgar.2020.08.005; Laporte L, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0430-6; Laursen CB., 2013, SCAND J TRAUMA RESUS, V21, pA21, DOI [DOI 10.1186/1757-7241-21-S2-A21, 10.1186/1757 -7241 -21 -S2 -A21]; Legramante JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187702; Leone M, 2018, ANAESTH CRIT CARE PA, V37, P83, DOI 10.1016/j.accpm.2017.11.006; Liapikou A, 2009, CLIN INFECT DIS, V48, P377, DOI 10.1086/596307; Liu YT, 2017, FRONT MED-PRC, V11, P239, DOI 10.1007/s11684-017-0509-8; Lodise TP, 2007, ANTIMICROB AGENTS CH, V51, P3977, DOI 10.1128/AAC.00006-07; Long L, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005713; Luo QZ, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-1943-y; Maertens B, 2018, CRIT CARE MED, V46, P316, DOI 10.1097/CCM.0000000000002889; Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801; Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x; Man WH, 2017, NAT REV MICROBIOL, V15, P259, DOI 10.1038/nrmicro.2017.14; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Mao Z, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1527-7; Martin-Loeches I, 2010, INTENS CARE MED, V36, P612, DOI 10.1007/s00134-009-1730-y; Martin-Loeches I, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03219-4; Martinez JA, 2010, ANTIMICROB AGENTS CH, V54, P3590, DOI 10.1128/AAC.00115-10; Maruyama T, 2019, CLIN INFECT DIS, V68, P1080, DOI 10.1093/cid/ciy631; McCluskey SM, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofw238; Melsen WG, 2013, LANCET INFECT DIS, V13, P665, DOI 10.1016/S1473-3099(13)70081-1; Mendez R, 2018, AM J RESP CRIT CARE, V198, P370, DOI 10.1164/rccm.201709-1908OC; Menendez R, 2008, THORAX, V63, P447, DOI 10.1136/thx.2007.086785; Menendez R, 2019, CHEST, V156, P1080, DOI 10.1016/j.chest.2019.06.040; Metersky ML, 2016, JAMA-J AM MED ASSOC, V316, P2427, DOI 10.1001/jama.2016.16226; Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST; Micek ST, 2016, CHEST, V150, P1008, DOI 10.1016/j.chest.2016.04.009; Micek ST, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0926-5; Micek ST, 2010, ANTIMICROB AGENTS CH, V54, P1742, DOI 10.1128/AAC.01365-09; Monro-Somerville T, 2017, CRIT CARE MED, V45, pE449, DOI 10.1097/CCM.0000000000002091; Moreno G, 2018, INTENS CARE MED, V44, P1470, DOI 10.1007/s00134-018-5332-4; Muller M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188913; Muscedere J, 2011, CRIT CARE MED, V39, P1985, DOI 10.1097/CCM.0b013e318218a4d9; Musher DM, 2007, CLIN INFECT DIS, V45, P158, DOI 10.1086/518849; Musher DM, 2004, CLIN INFECT DIS, V39, P165, DOI 10.1086/421497; Musuuza JS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251170; Naghavi M, 2003, CIRCULATION, V107, P762, DOI 10.1161/01.CIR.0000048190.68071.2B; National Institutes of Health, INF COV 19 TREATM PR; Niederman MS, 2020, LANCET INFECT DIS, V20, P330, DOI 10.1016/S1473-3099(19)30574-2; Niederman MS, 2012, INTENS CARE MED, V38, P263, DOI 10.1007/s00134-011-2420-0; Odedra KM, 2014, POSTGRAD MED J, V90, P709, DOI 10.1136/postgradmedj-2013-132291; Palacios G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008540; Paonessa JR, 2019, CHEST, V155, P999, DOI 10.1016/j.chest.2019.02.007; Park SC, 2013, INT J TUBERC LUNG D, V17, P704, DOI 10.5588/ijtld.12.0723; Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191; Philippart F, 2015, AM J RESP CRIT CARE, V191, P637, DOI 10.1164/rccm.201408-1398OC; Phua J, 2010, EUR RESPIR J, V36, P826, DOI 10.1183/09031936.00154209; Phua J, 2009, THORAX, V64, P598, DOI 10.1136/thx.2009.113795; Pileggi C, 2018, CRIT CARE MED, V46, P1167, DOI 10.1097/CCM.0000000000003136; Piralla A, 2017, J CLIN VIROL, V92, P48, DOI 10.1016/j.jcv.2017.05.004; Plantinga NL, 2018, CLIN MICROBIOL INFEC, V24, P505, DOI 10.1016/j.cmi.2017.08.019; Plantinga NL, 2016, INTENS CARE MED, V42, P620, DOI 10.1007/s00134-016-4217-7; Pogue M., 2007, Morbidity and Mortality Weekly Report, V56, P325; Postma DF, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-018-3630-7; Pozuelo-Carrascosa DP, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0107-2019; Price R, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2197; Prina E, 2015, LANCET, V386, P1097, DOI 10.1016/S0140-6736(15)60733-4; Prina E, 2015, ANN AM THORAC SOC, V12, P153, DOI 10.1513/AnnalsATS.201407-305OC; Ranzani OT, 2017, AM J RESP CRIT CARE, V196, P1287, DOI [10.1164/rccm.201611-2262OC, 10.1164/rccm.201611-2262oc]; Renaud B, 2009, CRIT CARE MED, V37, P2867, DOI 10.1097/CCM.0b013e3181b02dbb; Restrepo MI, 2016, SEMIN RESP CRIT CARE, V37, P897, DOI 10.1055/s-0036-1593754; Restrepo MI, 2010, CHEST, V137, P552, DOI 10.1378/chest.09-1547; Righy C, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0291-4; Rodrigo C, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub2; Roquilly A, 2019, LANCET RESP MED, V7, P710, DOI 10.1016/S2213-2600(19)30140-7; Said MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060273; Saito M, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000024906; Sangla F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243762; Schuetz P, 2018, LANCET INFECT DIS, V18, P95, DOI [10.1016/S1473-3099(17)30592-3, 10.1016/s1473-3099(17)30592-3]; Schuetz P, 2009, JAMA-J AM MED ASSOC, V302, P1059, DOI 10.1001/jama.2009.1297; Segal LN, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.31, 10.1038/nmicrobiol.2016.31]; Self WH, 2017, CLIN INFECT DIS, V65, P183, DOI 10.1093/cid/cix317; Sellers SA, 2017, INFLUENZA OTHER RESP, V11, P372, DOI 10.1111/irv.12470; Sharma A, 2019, J ALLERGY CLIN IMMUN, V144, P1214, DOI 10.1016/j.jaci.2019.06.025; Shenoy AT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204032; Shi SJ, 2017, CLIN RESPIR J, V11, P352, DOI 10.1111/crj.12346; Shindo Y, 2013, AM J RESP CRIT CARE, V188, P985, DOI 10.1164/rccm.201301-0079OC; Shorr AF, 2008, ARCH INTERN MED, V168, P2205, DOI 10.1001/archinte.168.20.2205; Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X; Siddiqui A.H., 2021, METHICILLIN RESISTAN; Siegel SJ, 2014, CELL HOST MICROBE, V16, P55, DOI 10.1016/j.chom.2014.06.005; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sligl WI, 2014, CRIT CARE MED, V42, P420, DOI 10.1097/CCM.0b013e3182a66b9b; Sommerstein R, 2019, ANTIMICROB RESIST IN, V8, DOI 10.1186/s13756-019-0530-6; Soraluce A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12010054; Spoorenberg SMC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190575; Staub LJ, 2021, J INTENSIVE CARE MED, V36, P304, DOI 10.1177/0885066619894279; Stokker J, 2020, INTENS CARE MED, V46, P546, DOI 10.1007/s00134-019-05914-5; Su KC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182252; Sweeney DA, 2019, CLIN MICROBIOL INFEC, V25, P1195, DOI 10.1016/j.cmi.2019.04.018; Tagami T, 2015, J INFECTION, V71, P158, DOI 10.1016/j.jinf.2015.04.003; Talbot GH, 2019, J INFECT DIS, V219, P1536, DOI 10.1093/infdis/jiy578; Tansarli GS, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/aac.00635-18, 10.1128/AAC.00635-18]; Taubert M, 2016, ANTIMICROB AGENTS CH, V60, P5254, DOI 10.1128/AAC.00356-16; Thorarinsdottir HR, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03092-1; Titov Ivan, 2021, Clin Infect Dis, V73, pe4539, DOI 10.1093/cid/ciaa803; Tokioka F, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0307-7; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; Torres A, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz149; Torres A, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00259-0; Torres A, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00582-2017; Torres A, 2016, EUR RESPIR J, V48, P1764, DOI 10.1183/13993003.01144-2016; Torres A, 2015, JAMA-J AM MED ASSOC, V313, P677, DOI 10.1001/jama.2015.88; Tralhao A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020414; Valles J, 2016, MED INTENSIVA, V40, P238, DOI [10.1016/j.medin.2015.07.005, 10.1016/j.medine.2016.04.004]; Vardakas KZ, 2009, EUR RESPIR J, V34, P1148, DOI 10.1183/09031936.00041009; Vaschetto R, 2019, INTENS CARE MED, V45, P62, DOI 10.1007/s00134-018-5478-0; Vaughn VM, 2019, BMJ QUAL SAF, V28, P74, DOI 10.1136/bmjqs-2017-007573; Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835; Viasus D, 2013, J INFECTION, V66, P27, DOI 10.1016/j.jinf.2012.09.003; Vincent JL, 2020, JAMA-J AM MED ASSOC, V323, P1478, DOI 10.1001/jama.2020.2717; Violi F, 2017, CLIN INFECT DIS, V64, P1486, DOI 10.1093/cid/cix164; Walden AP, 2014, CRIT CARE, V18, DOI 10.1186/cc13812; Wang L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009946.pub2; Wang Z, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1085-z; Waterer Grant W, 2005, Curr Opin Infect Dis, V18, P157, DOI 10.1097/01.qco.0000160906.02308.3c; Watkins Richard R, 2019, F1000Res, V8, DOI 10.12688/f1000research.16517.2; Webb BJ, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00057-2019; Welte T, 2018, INTENS CARE MED, V44, P438, DOI 10.1007/s00134-018-5143-7; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wilden JJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115486; Wittekamp BH, 2018, JAMA-J AM MED ASSOC, V320, P2087, DOI 10.1001/jama.2018.13765; Woo TE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42862-y; Woodhead M, 2006, CRIT CARE, V10, DOI 10.1186/cc4927; Woolever Nathan L, 2020, Mayo Clin Proc Innov Qual Outcomes, V4, P550, DOI 10.1016/j.mayocpiqo.2020.05.002; Wu BG, 2018, CLIN CHEST MED, V39, P677, DOI 10.1016/j.ccm.2018.07.003; Wunderink RG, 2021, LANCET INFECT DIS, V21, P213, DOI 10.1016/S1473-3099(20)30731-3; Wunderink RG, 2018, INFECT DIS THER, V7, P439, DOI 10.1007/s40121-018-0214-1; Xie F, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06039-1; Zakharkina T, 2017, THORAX, V72, P803, DOI 10.1136/thoraxjnl-2016-209158; Zand F, 2017, J CRIT CARE, V40, P318, DOI 10.1016/j.jcrc.2017.02.029; Zhao TT, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008367.pub4; Zhou F, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.02406-2018; Zhou HJ, 2020, EMERG MED INT, V2020, DOI 10.1155/2020/7979353; Zhou HJ, 2018, AM J EMERG MED, V36, P2155, DOI 10.1016/j.ajem.2018.03.050	286	4	4	2	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 6	2021	375								e065871	10.1136/bmj-2021-065871	http://dx.doi.org/10.1136/bmj-2021-065871			24	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP4CS	34872910	Bronze			2023-01-03	WOS:000730815000007
J	Ali, S; Li, YZ; Ul Haq, I; Abbas, W; Shabbir, MZ; Khan, MM; Mamay, M; Niaz, Y; Farooq, T; Skalicky, M; Zuan, ATK; Nasif, O; Ansari, MJ				Ali, Shahbaz; Li, Yunzhou; Ul Haq, Inzamam; Abbas, Waseem; Shabbir, Muhammad Zeeshan; Khan, Muhammad Musa; Mamay, Mehmet; Niaz, Yasir; Farooq, Tahir; Skalicky, Milan; Zuan, Ali Tan Kee; Nasif, Omaima; Ansari, Mohamad Javed			RETRACTED: The impact of different plant extracts on population suppression of Helicoverpa armigera (Hub.) and tomato (Lycopersicon esculentum Mill) yield under field conditions (Retracted article. See vol. 17, 2022)	PLOS ONE			English	Article; Retracted Publication							FRUIT-QUALITY; EFFICACY; GROWTH	Helicoverpa armigera (Hub.) is a destructive pest of the tomato (Lycopersicon esculentum Mill) crop in Pakistan. Although insecticides are the primary management strategy used to control H. armigera, most of them are not effective due to considerable toxic residual effects on the fruits. Nonetheless, H. armigera is rapidly evolving resistance against the available pesticides for its management. This situation calls upon the need of alternative management options against the pest. Different plant extracts have been suggested as a viable, environment-friendly option for plant protection with minimal side effects. Furthermore, the plant extracts could also manage the insect species evolving resistance against pesticides. This study evaluated the efficacy of different plant extracts (i.e., Neem seed, turmeric, garlic and marsh pepper) against H. armigera. Furthermore, the impact of the plant extracts on growth and yield of tomato crop was also tested under field conditions. The results revealed that all plant extracts resulted in higher mortality of H. armigera compared to control. Similarly, the highest plant height was observed for the plants treated with the plant extracts compared to untreated plants. Moreover, the highest tomato yield was observed in plants treated with plant extracts, especially with neem seed (21.013 kg/plot) followed by pepper extract (19.25 kg/plot), and garlic extract 18.4 kg/plot) compared to the untreated plants (8.9 kg/plot). It is concluded that plant extracts can be used as eco-friendly approaches for improving tomato yield and resistance management of H. armigera.	[Ali, Shahbaz; Li, Yunzhou] Guizhou Univ, Coll Agr, Dept Plant Pathol, Guiyang, Guizhou, Peoples R China; [Ali, Shahbaz; Niaz, Yasir] Khawaja Fareed Univ Engn & Informat Technol, Dept Agr Engn, Rahim Yar Khan, Punjab, Pakistan; [Ul Haq, Inzamam] Gansu Agr Univ, Coll Crop Protect, Dept Plant Protect, Lanzhou, Peoples R China; [Abbas, Waseem] Univ Agr Faisalabad, Dept Entomol, Faisalabad, Pakistan; [Shabbir, Muhammad Zeeshan; Farooq, Tahir] Guangdong Acad Agr Sci, Plant Protect Res Inst, Guangzhou, Guangdong, Peoples R China; [Khan, Muhammad Musa] South China Agr Univ, Engn Res Ctr Biol Control, Key Lab Bio Pesticide Innovat & Applicat, Guangzhou, Peoples R China; [Mamay, Mehmet] Harran Univ, Fac Agr, Dept Plant Protect, Sanliurfa, Turkey; [Skalicky, Milan] Czech Univ Life Sci, Fac Agrobiol Food & Nat Resources, Dept Bot & Plant Physiol, Prague, Czech Republic; [Zuan, Ali Tan Kee] Univ Putra Malaysia, Fac Agr, Dept Land Management, Seri Kembangan, Selangor, Malaysia; [Nasif, Omaima] King Saud Univ, Coll Med, Dept Physiol, Riyadh, Saudi Arabia; [Nasif, Omaima] King Saud Univ, King Khalid Univ Hosp, Riyadh, Saudi Arabia; [Ansari, Mohamad Javed] Mahatma Jyotiba Phule Rohilkhand Univ Bareilly, Hindu Coll Moradabad, Dept Bot, Bareilly, Uttar Pradesh, India	Guizhou University; Gansu Agricultural University; University of Agriculture Faisalabad; Guangdong Academy of Agricultural Sciences; South China Agricultural University; Harran University; Czech University of Life Sciences Prague; Universiti Putra Malaysia; King Saud University; King Saud University; King Khalid University Hospital	Ali, S; Li, YZ (corresponding author), Guizhou Univ, Coll Agr, Dept Plant Pathol, Guiyang, Guizhou, Peoples R China.; Ali, S (corresponding author), Khawaja Fareed Univ Engn & Informat Technol, Dept Agr Engn, Rahim Yar Khan, Punjab, Pakistan.; Zuan, ATK (corresponding author), Univ Putra Malaysia, Fac Agr, Dept Land Management, Seri Kembangan, Selangor, Malaysia.	shahbaz@kfueit.edu.pk; liyunzhou2007@126.com; tkz@upm.edu.my	Farooq, Tahir/ABE-9638-2020; Skalicky, Milan/B-2449-2009; LI, Yunzhou/AHD-2500-2022; MAMAY, Mehmet/I-9814-2014	Farooq, Tahir/0000-0001-7738-7993; Skalicky, Milan/0000-0002-4114-6909; MAMAY, Mehmet/0000-0003-3723-5228; Ul Haq, Inzamam/0000-0001-5707-3612	National Nature Science Foundation [32060679]; Guizhou University [GuidapeiYU[2019]52, [2017]50]; King Saud University, Riyadh, Saudi Arabia [RSP-2021/257]	National Nature Science Foundation(National Natural Science Foundation of China (NSFC)); Guizhou University; King Saud University, Riyadh, Saudi Arabia(King Saud University)	This work was supported by projects of the National Nature Science Foundation (No. 32060679) and projects of Guizhou University (No. GuidapeiYU[2019]52 and No. [2017]50). This project was supported by Researchers Supporting Project number (RSP-2021/257), King Saud University, Riyadh, Saudi Arabia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali N, 2016, J APPL PHYCOL, V28, P1353, DOI 10.1007/s10811-015-0608-3; Amjad Usman, 2018, Pure and Applied Biology, V7, P1014; Arshad U, 2020, INT J AGRIC BIOL, V24, P961, DOI 10.17957/IJAB/15.1522; Balasubramanian R., 2008, Journal of Biopesticides, V1, P201; Binay Kumar, 2002, Indian Journal of Entomology, V64, P411; Chohan T. Z., 2008, Pakistan Journal of Life and Social Sciences, V6, P96; Ciniviz G., 2020, AGR FORESTRYPOLJOPRI, V66; Colla G, 2017, HORTSCIENCE, V52, P1214, DOI 10.21273/HORTSCI12200-17; Desai S., 2000, J PESTOLOGY, V24, P62; Dubey NK, 2011, NATURAL PRODUCTS IN PLANT PEST MANAGEMENT, P1, DOI 10.1079/9781845936716.0001; Hegde KK, 2004, ECOFRIENDLY APPROACH; Hussain B., 2007, Journal of Entomology, V4, P64; Kumar M., 2013, BIOSCAN, V8, P727; Mallapur C. P., 2010, International Journal of Plant Protection, V3, P194; Matharu KS., 2016, BIOSCAN, V11, P155; Mehta P, 2010, NAT S PERSP CHALL IN; Miller GT, 2004, SUSTAINING THE EARTH, V9, P211; Mordue (Luntz) A. Jennifer, 2000, Anais da Sociedade Entomologica do Brasil, V29, P615, DOI 10.1590/S0301-80592000000400001; Morgan ED, 2009, BIOORGAN MED CHEM, V17, P4096, DOI 10.1016/j.bmc.2008.11.081; Mustafiz SSB., 2015, ACAD J ENTOMOL, V8, P140, DOI DOI 10.5829/idosi.aje.2015.8.3.95246; Mutlu C, 2020, PHYTOPARASITICA, V48, P191, DOI 10.1007/s12600-020-00785-9; Nongmaithem D, 2013, BIOSCAN, V8, P1207; Pakistan Government, 2011, AGR STAT PAKISTAN, P84; Patil D., 2010, BIOSCAN, V5, P653; Raja N, 2005, CURR SCI INDIA, V88, P220; Rastogi R., 2003, J INDIAN, V53, P59; Sahare KN, 2008, INDIAN J EXP BIOL, V46, P128; Sahayaraj K., 2006, Journal of Applied Bioscience, V32, P59; Sahayaraj K., 2001, J ADV ZOOL, V22, P8; Shah J. A., 2013, Sarhad Journal of Agriculture, V29, P93; Sharma HC, 2010, CLIMATE CHANGE AND MANAGEMENT OF COOL SEASON GRAIN LEGUME CROPS, P115, DOI 10.1007/978-90-481-3709-1_7; Singh I., 2001, J BIOVED, V12, P41; Subiyakto, 2011, SJJPDPP, V30, P81; SUBIYAKTO SJP., 2015, STRATEGI PENGEMBANGA, V8, P108; Sujak, 2020, ADV BIO SCI RES, V8, P177; Sunarto DA., 2009, J ENTOMOL INDONES, V6, P42, DOI DOI 10.5994/JEI.6.1.42; Sundararajan G., 2002, Journal of Ecotoxicology & Environmental Monitoring, V12, P305; Teke MA, 2021, J PLANT DIS PROTECT, V128, P109, DOI 10.1007/s41348-020-00377-z; Usman A, 2013, PAK J ZOOL, V45, P113; Yankanchi S. R., 2009, Journal of Biopesticides, V2, P32	40	4	4	6	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2021	16	12							e0260470	10.1371/journal.pone.0260470	http://dx.doi.org/10.1371/journal.pone.0260470			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ9AQ	34852006	Green Published, gold			2023-01-03	WOS:000755762900037
J	Tanaka, M; Tanaka, T; Takamatsu, M; Shibue, C; Imao, Y; Ando, T; Baba, H; Kamiya, Y				Tanaka, Moegi; Tanaka, Tsunehiko; Takamatsu, Misako; Shibue, Chieko; Imao, Yuriko; Ando, Takako; Baba, Hiroshi; Kamiya, Yoshinori			Effects of the Kampo medicine Yokukansan for perioperative anxiety and postoperative pain in women undergoing breast surgery: A randomized, controlled trial	PLOS ONE			English	Article							PREOPERATIVE ANXIETY; CANCER-PATIENTS; RECOVERY SCORE; ALPHA-AMYLASE; RISK-FACTORS; RECEPTORS; ANESTHESIA; PREVENTION; SEROTONIN; ANALGESIA	Yokukansan (YKS) is a traditional Japanese herbal (Kampo) medicine prescribed for anxiety. In this randomized controlled trial, we compared the subjective assessment of anxiety using questionnaires and its objective assessment using salivary alpha-amylase concentrations in YKS and control (CNT) groups of women undergoing breast surgery. The trial was registered at the University Hospital Medical Information Network Clinical Trials Registry (registration number: UMIN000028998), and the investigators were blinded to drug administration. One hundred patients who underwent breast cancer surgery were allocated to either the YKS or the CNT group. Finally, 35 and 42 patients in the YKS and CNT groups were analyzed, respectively. The YKS group received two 2.5 g doses of the medication before sleeping on the night before surgery and 2 h before inducing anesthesia, while the CNT group did not receive medication preoperatively. Patients answered two questionnaires, the Hospital Anxiety and Depression Scale and the State-Trait Anxiety Inventory, pre-and postoperatively as subjective anxiety assessments. As an objective anxiety indicator, salivary alpha-amylase levels were measured the day before, directly before, and the day after surgery (T3). In the YKS group, salivary alpha-amylase scores directly before operation were significantly lower than those on the day before surgery and at one day postoperatively (F [2,150] = 3.76, p = 0.03). Moreover, the Hospital Anxiety and Depression Scale-Anxiety and State-Trait Anxiety Inventory-Trait scores were significantly more improved postoperatively in the YKS group than in the CNT group (difference in Hospital Anxiety and Depression Scale-Anxiety: YKS, mean -2.77, 95% confidence interval [-1.48 --4.06], p <0.001, and CNT, -1.43 [-0.25--2.61], p = 0.011; and difference in State-Trait Anxiety Inventory: YKS group, -4.23 [-6.95--1.51], p = 0.0004; and CNT group, 0.12 [-2.36-2.60], p = 0.92). No side effects were associated with YKS. YKS may reduce perioperative anxiety in patients undergoing surface surgery.	[Tanaka, Moegi; Baba, Hiroshi; Kamiya, Yoshinori] Niigata Univ, Div Anesthesiol, Grad Sch Med & Dent Sci, Niigata, Japan; [Tanaka, Tsunehiko] Niigata Univ, Educ Psychol Course, Fac Educ, Niigata, Japan; [Takamatsu, Misako; Shibue, Chieko; Ando, Takako] Niigata Canc Ctr Hosp, Dept Anesthesiol, Niigata, Japan; [Imao, Yuriko; Ando, Takako] Niigata Univ Med & Dent Hosp, Dept Anesthesiol, Niigata, Japan	Niigata University; Niigata University; Niigata University	Kamiya, Y (corresponding author), Niigata Univ, Div Anesthesiol, Grad Sch Med & Dent Sci, Niigata, Japan.	y-kamiya@med.niigata-u.ac.jp		Kamiya, Yoshinori/0000-0001-9790-9867	Japan Society for the Promotion of Science, Tokyo, Japan [19K18288]	Japan Society for the Promotion of Science, Tokyo, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by the Japan Society for the Promotion of Science, Tokyo, Japan (URL: https://kaken.nii.ac.jp/en/) [grant numbers 19K18288 to MT] The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aigner CJ, 2014, SUPPORT CARE CANCER, V22, P2323, DOI 10.1007/s00520-014-2219-y; Akiyama H, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017000; Ali A, 2014, J ANESTH, V28, P222, DOI 10.1007/s00540-013-1712-7; Arai YC, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/965045; Aston-Jones G, 1998, Adv Pharmacol, V42, P755; Bardin L, 2011, BEHAV PHARMACOL, V22, P390, DOI 10.1097/FBP.0b013e328349aae4; Bilotta F, 2013, MINERVA ANESTESIOL, V79, P1066; Caumo W, 2002, ANAESTHESIA, V57, P740, DOI 10.1046/j.1365-2044.2002.02690.x; Clarke H, 2015, DRUGS, V75, P339, DOI 10.1007/s40265-015-0365-2; Edwards MA, 2007, NEUROTOXICOLOGY, V28, P876, DOI 10.1016/j.neuro.2007.04.006; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Folkman S., 1984, STRESS APPRAISAL COP; GROZA P, 1971, Revue Roumaine de Physiologie, V8, P307; Hintze JL, 1998, AM STAT, V52, P181, DOI 10.2307/2685478; Ikarashi Y, 2016, PHARMACOL THERAPEUT, V166, P84, DOI 10.1016/j.pharmthera.2016.06.018; Iwasaki K, 2005, J CLIN PSYCHIAT, V66, P1612, DOI 10.4088/JCP.v66n1219a; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Knuppel L, 2004, J CLIN PSYCHIAT, V65, P1470; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; MILLAR K, 1995, BRIT J ANAESTH, V74, P180, DOI 10.1093/bja/74.2.180; Myles PS, 1999, ANESTH ANALG, V88, P83, DOI 10.1097/00000539-199901000-00016; Nabi H, 2013, J CLIN PSYCHOPHARM, V33, P371, DOI 10.1097/JCP.0b013e31828b26c2; Nakamura Yoshitaka, 2009, Masui, V58, P1248; Nater UM, 2009, PSYCHONEUROENDOCRINO, V34, P486, DOI 10.1016/j.psyneuen.2009.01.014; Nelson FV, 1998, J PAIN SYMPTOM MANAG, V15, P102, DOI 10.1016/S0885-3924(98)80007-9; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; R Core Team, 2021, R LANG ENV STAT COMP; Schug SA, 2019, PAIN, V160, P45, DOI 10.1097/j.pain.0000000000001413; Spielberger C., 1983, MANUAL STATE TRAIT A; Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b; Suzuki Y, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/953459; TESHIMA S, 1985, CLIN CHIM ACTA, V150, P165, DOI 10.1016/0009-8981(85)90241-4; Ueki T, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/6804017; Wada S, 2021, J PAIN SYMPTOM MANAG, V61, P71, DOI 10.1016/j.jpainsymman.2020.07.009; Wada S, 2019, WORLD J SURG, V43, P134, DOI 10.1007/s00268-018-4761-0; Walker KJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002192.pub2; White PF, 2009, ANESTH ANALG, V108, P1140, DOI 10.1213/ane.0b013e31818d40ce; Yamaguchi M, 2006, BIOSENS BIOELECTRON, V21, P1007, DOI 10.1016/j.bios.2005.03.014; Yamaguchi T, 2012, J ETHNOPHARMACOL, V143, P533, DOI 10.1016/j.jep.2012.07.007; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	40	3	3	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2021	16	11							e0260524	10.1371/journal.pone.0260524	http://dx.doi.org/10.1371/journal.pone.0260524			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YN4MP	34818363	gold, Green Published			2023-01-03	WOS:000747234800048
J	Liu, Q; Tan, CQ; Yi, LD; Wan, XM; Peng, LB; Li, JH; Luo, X; Zeng, XH				Liu, Qiao; Tan, Chongqing; Yi, Lidan; Wan, Xiaomin; Peng, Liubao; Li, Jianhe; Luo, Xia; Zeng, Xiaohui			Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer	PLOS ONE			English	Article								Background The phase III KEYNOTE-604 study confirmed the benefit of pembrolizumab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). Taken into account the clinical benefits of pembrolizumab and its high cost, this study aimed to assess the cost-effectiveness of adding pembrolizumab to standard first-line etoposide-platinum (EP) for patients with ES-SCLC from the US payer perspective. Methods A Markov model was developed to compare the cost and quality-adjusted life-year (QALY) of pembrolizumab plus EP and placebo plus EP over a 10-year time horizon. Clinical efficacy and safety data were pooled from the KEYNOTE-604 trial. Utilities were obtained from published resources. Costs were mainly collected from Medicare in 2020. Sensitivity analyses were performed to examine the robustness of our model. Results Adding pembrolizumab to standard first-line EP resulted in the better effectiveness than EP chemotherapy alone for ES-SCLC by 0.22 QALYs. Pembrolizumab plus EP was dominated economically by placebo plus EP, leading to an incremental cost-effectiveness ratio (ICER) of $334,373/ QALY. Deterministic sensitivity analyses indicated that the uncertainty in model parameters exerted no substantial effect on our results. Probability sensitivity analysis indicated that probabilities for pembrolizumab plus EP being cost-effective within a wide range of willingness to pay were modest. Conclusion From the US payer perspective, the first-line treatment for ES-SCLC with pembrolizumab plus EP was not cost-effective compared with placebo plus EP. Although pembrolizumab combination chemotherapy was beneficial to the survival of ES-SCLC, price reduction may be the necessary to improve its cost-effectiveness.	[Liu, Qiao; Tan, Chongqing; Yi, Lidan; Wan, Xiaomin; Peng, Liubao; Li, Jianhe; Luo, Xia] Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha, Hunan, Peoples R China; [Zeng, Xiaohui] Cent South Univ, Xiangya Hosp 2, PET Image Ctr, Dept Nucl Med, Changsha, Hunan, Peoples R China	Central South University; Central South University	Luo, X (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha, Hunan, Peoples R China.; Zeng, XH (corresponding author), Cent South Univ, Xiangya Hosp 2, PET Image Ctr, Dept Nucl Med, Changsha, Hunan, Peoples R China.	luoxia@csu.edu.cn; zengxiaohui2008@csu.edu.cn	Wan, Xiaomin/GPX-4388-2022	/0000-0001-5315-8141	Hunan Provincial Natural Science Foundation [2019JJ50864]; Scientific research project of Hunan Health Commission [B2019156]	Hunan Provincial Natural Science Foundation(Natural Science Foundation of Hunan Province); Scientific research project of Hunan Health Commission	This work was supported by the Hunan Provincial Natural Science Foundation [grant numbers 2019JJ50864]; Scientific research project of Hunan Health Commission in 2019[grant numbers B2019156]. Qiao Liu received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akamatsu H, 2019, INT J CLIN ONCOL, V24, P731, DOI 10.1007/s10147-019-01431-z; [Anonymous], 2020, PHYS FEE SCHED SEARC; Briggs AH, 2012, VALUE HEALTH, V15, P835, DOI 10.1016/j.jval.2012.04.014; Centers for Medicare and Medicaid Services, ASP DRUG PRIC FIL; Chung HC, 2020, J THORAC ONCOL, V15, P618, DOI 10.1016/j.jtho.2019.12.109; Criss SD, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.11952; Farago AF, 2018, TRANSL LUNG CANCER R, V7, P69, DOI 10.21037/tlcr.2018.01.16; Fruh M, 2013, ANN ONCOL, V24, P99, DOI 10.1093/annonc/mdt178; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Healthcare Cost and Utilization Project, HEALTHC COST UT PROJ; Hellmann MD, 2016, JAMA ONCOL, V2, P167, DOI 10.1001/jamaoncol.2015.4345; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Insinga RP, 2018, J MED ECON, V21, P1191, DOI 10.1080/13696998.2018.1521416; Jones GS, 2020, LUNG CANCER, V141, P44, DOI 10.1016/j.lungcan.2019.12.015; Monk BJ, 2009, J CLIN ONCOL, V27, P1069, DOI 10.1200/JCO.2008.18.9043; National Comprehensive Cancer Network, 2020, NAT NCCN CLIN PRACT; Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158; Paz-Ares L, 2019, LANCET, V394, P1929, DOI 10.1016/S0140-6736(19)32222-6; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Rudin CM, 2020, J CLIN ONCOL, V38, P2369, DOI 10.1200/JCO.20.00793; Rudin CM, 2015, J CLIN ONCOL, V33, P4106, DOI 10.1200/JCO.2015.63.7918; Siegel Rebecca L, 2019, CA Cancer J Clin, V69, P7, DOI 10.3322/caac.21551; US Food and Drug Administration, PEMBR KEYTRUDA CHECK; US Food and Drug Administration, FDA GRANTS REG APPR; Wang SC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01571-0; Waqar SN, 2017, PHARMACOL THERAPEUT, V180, P16, DOI 10.1016/j.pharmthera.2017.06.002; Zhang LF, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.602185; Zhou KX, 2019, LUNG CANCER, V130, P1, DOI 10.1016/j.lungcan.2019.01.019	28	1	1	6	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2021	16	11							e0258605	10.1371/journal.pone.0258605	http://dx.doi.org/10.1371/journal.pone.0258605			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2IU	34780478	Green Published, gold			2023-01-03	WOS:000755305800014
J	Karapetyan, S; Schneider, A; Linde, K; Donnachie, E; Hapfelmeier, A				Karapetyan, Siranush; Schneider, Antonius; Linde, Klaus; Donnachie, Ewan; Hapfelmeier, Alexander			SARS-CoV-2 infection and cardiovascular or pulmonary complications in ambulatory care: A risk assessment based on routine data	PLOS ONE			English	Article								Background Risk factors of severe COVID-19 have mainly been investigated in the hospital setting. We investigated pre-defined risk factors for testing positive for SARS-CoV-2 infection and cardiovascular or pulmonary complications in the outpatient setting. Methods The present cohort study makes use of ambulatory claims data of statutory health insurance physicians in Bavaria, Germany, with polymerase chain reaction (PCR) test confirmed or excluded SARS-CoV-2 infection in first three quarters of 2020. Statistical modelling and machine learning were used for effect estimation and for hypothesis testing of risk factors, and for prognostic modelling of cardiovascular or pulmonary complications. Results A cohort of 99 811 participants with PCR test was identified. In a fully adjusted multivariable regression model, dementia (odds ratio (OR) = 1.36), type 2 diabetes (OR = 1.14) and obesity (OR = 1.08) were identified as significantly associated with a positive PCR test result. Significant risk factors for cardiovascular or pulmonary complications were coronary heart disease (CHD) (OR = 2.58), hypertension (OR = 1.65), tobacco consumption (OR = 1.56), chronic obstructive pulmonary disease (COPD) (OR = 1.53), previous pneumonia (OR = 1.53), chronic kidney disease (CKD) (OR = 1.25) and type 2 diabetes (OR = 1.23). Three simple decision rules derived from prognostic modelling based on age, hypertension, CKD, COPD and CHD were able to identify high risk patients with a sensitivity of 74.8% and a specificity of 80.0%. Conclusions The decision rules achieved a high prognostic accuracy non-inferior to complex machine learning methods. They might help to identify patients at risk, who should receive special attention and intensified protection in ambulatory care.	[Karapetyan, Siranush; Schneider, Antonius; Linde, Klaus; Hapfelmeier, Alexander] Tech Univ Munich, Sch Med, Inst Gen Practice & Hlth Serv Res, Munich, Bavaria, Germany; [Donnachie, Ewan] Bavarian Assoc Statutory Hlth Insurance Phys, Munich, Bavaria, Germany; [Hapfelmeier, Alexander] Tech Univ Munich, Sch Med, Inst Med Informat Stat & Epidemiol, Munich, Bavaria, Germany	Technical University of Munich; Technical University of Munich	Karapetyan, S (corresponding author), Tech Univ Munich, Sch Med, Inst Gen Practice & Hlth Serv Res, Munich, Bavaria, Germany.	siranush.karapetyan@mri.tum.de	Donnachie, Ewan/E-3912-2019	Donnachie, Ewan/0000-0002-0668-0049	Bavarian State Ministry of Science and the Arts (Bayerische Staatsministerium fur Wissenschaft und Kunst) [H.40001.1.7(DMS)-TUM-1]	Bavarian State Ministry of Science and the Arts (Bayerische Staatsministerium fur Wissenschaft und Kunst)	This work was supported by the Bavarian State Ministry of Science and the Arts (Bayerische Staatsministerium fur Wissenschaft und Kunst) (grant No H.40001.1.7(DMS)-TUM-1)	Altschul DJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73962-9; Atkins JL, 2020, J GERONTOL A-BIOL, V75, P2224, DOI 10.1093/gerona/glaa183; Barron E, 2020, LANCET DIABETES ENDO, V8, P813, DOI 10.1016/S2213-8587(20)30272-2; BBSR, 2010, LAUF RAUMB RAUM SIED; Chadeau-Hyam M, 2020, INT J EPIDEMIOL, V49, P1454, DOI 10.1093/ije/dyaa134; Chang S, 2021, NATURE, V589, P82, DOI 10.1038/s41586-020-2923-3; Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010; Clift AK, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3731; Deutsches Institut fur Medizinische Dokumentation und Information, 2020, INT STAT CLASS DIS R, V10th; Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8; Fang XY, 2020, AGING-US, V12, P12493, DOI 10.18632/aging.103579; Gale SA, 2018, AM J MED, V131, P1161, DOI 10.1016/j.amjmed.2018.01.022; Hapfelmeier A, 2018, J APPL STAT, V45, P2864, DOI 10.1080/02664763.2018.1444152; Hastie CE, 2021, EUR J NUTR, V60, P545, DOI 10.1007/s00394-020-02372-4; Hosmer DW, 2013, WILEY SER PROBAB ST, P89; Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425; Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8; Ioannidis JPA, 2021, B WORLD HEALTH ORGAN, V99, P19, DOI 10.2471/BLT.20.265892; Levin AT, 2020, EUR J EPIDEMIOL, V35, P1123, DOI 10.1007/s10654-020-00698-1; Molnar C., 2020, LULU COM; Olm M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035575; Popkin BM, 2020, OBES REV, V21, DOI 10.1111/obr.13128; Ro&beta;ler M., 2021, EPID B, V19, P3; Rozenfeld Y, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01242-z; Swart E, 2015, GESUNDHEITSWESEN, V77, DOI [10.1055/s-0034-1396815, 10.1055/s-0035-1562981]; Vandenbroucke JP, 2020, EPIDEMIOLOGY, V31, P836, DOI 10.1097/EDE.0000000000001251; Williams RD., 2020, MEDRXIV2020052620112; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; World Health Organization, 2020, INT GUID CERT CLASS; Yang J, 2020, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268820003027; Yanover C, 2020, JMIR PUBLIC HLTH SUR, V6, P349, DOI 10.2196/20872; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021	32	1	1	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2021	16	10							e0258914	10.1371/journal.pone.0258914	http://dx.doi.org/10.1371/journal.pone.0258914			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7VP	34673818	Green Published, gold			2023-01-03	WOS:000755680200049
J	Wortham, JM; Meador, SA; Hadler, JL; Yousey-Hindes, K; See, I; Whitaker, M; O'Halloran, A; Milucky, J; Chai, SJ; Reingold, A; Alden, NB; Kawasaki, B; Anderson, EJ; Openo, KP; Weigel, A; Monroe, ML; Ryan, PA; Kim, S; Reeg, L; Lynfield, R; McMahon, M; Sosin, DM; Eisenberg, N; Rowe, A; Barney, G; Bennett, NM; Bushey, S; Billing, LM; Shiltz, J; Sutton, M; West, N; Talbot, HK; Schaffner, W; McCaffrey, K; Spencer, M; Kambhampati, AK; Anglin, O; Piasecki, AM; Holstein, R; Hall, AJ; Fry, AM; Garg, S; Kim, L				Wortham, Jonathan M.; Meador, Seth A.; Hadler, James L.; Yousey-Hindes, Kimberly; See, Isaac; Whitaker, Michael; O'Halloran, Alissa; Milucky, Jennifer; Chai, Shua J.; Reingold, Arthur; Alden, Nisha B.; Kawasaki, Breanna; Anderson, Evan J.; Openo, Kyle P.; Weigel, Andrew; Monroe, Maya L.; Ryan, Patricia A.; Kim, Sue; Reeg, Libby; Lynfield, Ruth; McMahon, Melissa; Sosin, Daniel M.; Eisenberg, Nancy; Rowe, Adam; Barney, Grant; Bennett, Nancy M.; Bushey, Sophrena; Billing, Laurie M.; Shiltz, Jess; Sutton, Melissa; West, Nicole; Talbot, H. Keipp; Schaffner, William; McCaffrey, Keegan; Spencer, Melanie; Kambhampati, Anita K.; Anglin, Onika; Piasecki, Alexandra M.; Holstein, Rachel; Hall, Aron J.; Fry, Alicia M.; Garg, Shikha; Kim, Lindsay			Census tract socioeconomic indicators and COVID-19-associated hospitalization rates-COVID-NET surveillance areas in 14 states, March 1-April 30, 2020	PLOS ONE			English	Article							NEW-HAVEN COUNTY; UNITED-STATES; RACIAL DISPARITIES; CONNECTICUT; POVERTY	Objectives Some studies suggested more COVID-19-associated hospitalizations among racial and ethnic minorities. To inform public health practice, the COVID-19-associated Hospitalization Surveillance Network (COVID-NET) quantified associations between race/ethnicity, census tract socioeconomic indicators, and COVID-19-associated hospitalization rates. Methods Using data from COVID-NET population-based surveillance reported during March 1-April 30, 2020 along with socioeconomic and denominator data from the US Census Bureau, we calculated COVID-19-associated hospitalization rates by racial/ethnic and census tract-level socioeconomic strata. Results Among 16,000 COVID-19-associated hospitalizations, 34.8% occurred among non-Hispanic White (White) persons, 36.3% among non-Hispanic Black (Black) persons, and 18.2% among Hispanic or Latino (Hispanic) persons. Age-adjusted COVID-19-associated hospitalization rate were 151.6 (95% Confidence Interval (CI): 147.1-156.1) in census tracts with >15.2%-83.2% of persons living below the federal poverty level (high-poverty census tracts) and 75.5 (95% CI: 72.9-78.1) in census tracts with 0%-4.9% of persons living below the federal poverty level (low-poverty census tracts). Among White, Black, and Hispanic persons living in high-poverty census tracts, age-adjusted hospitalization rates were 120.3 (95% CI: 112.3-128.2), 252.2 (95% CI: 241.4-263.0), and 341.1 (95% CI: 317.3-365.0), respectively, compared with 58.2 (95% CI: 55.4-61.1), 304.0 (95%: 282.4-325.6), and 540.3 (95% CI: 477.0-603.6), respectively, in low-poverty census tracts. Conclusions Overall, COVID-19-associated hospitalization rates were highest in high-poverty census tracts, but rates among Black and Hispanic persons were high regardless of poverty level. Public health practitioners must ensure mitigation measures and vaccination campaigns address needs of racial/ethnic minority groups and people living in high-poverty census tracts.	[Wortham, Jonathan M.; Meador, Seth A.; See, Isaac; Whitaker, Michael; O'Halloran, Alissa; Milucky, Jennifer; Kambhampati, Anita K.; Anglin, Onika; Piasecki, Alexandra M.; Holstein, Rachel; Hall, Aron J.; Fry, Alicia M.; Garg, Shikha; Kim, Lindsay] CDC COVID NET Team, Atlanta, GA USA; [Wortham, Jonathan M.; See, Isaac; Fry, Alicia M.; Garg, Shikha; Kim, Lindsay] US PHS, Bethesda, MD 20892 USA; [Hadler, James L.; Yousey-Hindes, Kimberly] Yale Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA; [Chai, Shua J.; Reingold, Arthur] Calif Emerging Infect Program, Oakland, CA USA; [Chai, Shua J.] CDC Career Epidemiol Field Off, Oakland, CA USA; [Alden, Nisha B.; Kawasaki, Breanna] Colorado Dept Publ Hlth & Environm, Denver, CO USA; [Anderson, Evan J.; Openo, Kyle P.] Georgia Dept Publ Hlth, Emerging Infect Program, Atlanta, GA USA; [Anderson, Evan J.; Openo, Kyle P.] Vet Affairs Med Ctr, Atlanta, GA 30033 USA; [Anderson, Evan J.; Openo, Kyle P.] Emory Univ, Div Infect Dis, Sch Med, Atlanta, GA 30322 USA; [Weigel, Andrew] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA; [Monroe, Maya L.; Ryan, Patricia A.] Maryland Dept Hlth, Baltimore, MD USA; [Kim, Sue; Reeg, Libby] Michigan Dept Hlth & Human Serv, Lansing, MI USA; [Lynfield, Ruth; McMahon, Melissa] Minnesota Dept Hlth, St Paul, MN USA; [Sosin, Daniel M.] New Mexico Dept Hlth, Santa Fe, NM USA; [Eisenberg, Nancy] Univ New Mexico, Emerging Infect Program, Albuquerque, NM 87131 USA; [Rowe, Adam; Barney, Grant] New York State Dept Hlth, Albany, NY USA; [Bennett, Nancy M.; Bushey, Sophrena] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Billing, Laurie M.; Shiltz, Jess] Ohio Dept Hlth, Columbus, OH 43266 USA; [Sutton, Melissa; West, Nicole] Oregon Hlth Author, Publ Hlth Div, Portland, OR USA; [Talbot, H. Keipp; Schaffner, William] Vanderbilt Univ, Med Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA; [McCaffrey, Keegan] Utah Dept Hlth, Salt Lake City, UT 84116 USA; [Spencer, Melanie] Salt Lake Cty Hlth Dept, Salt Lake City, UT USA	United States Public Health Service; Yale University; California Emerging Infections Program; Colorado Department of Public Health & Environment; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University; MDHHS - Michigan Department of Health & Human Services; Minnesota Department of Health (MHD); New Mexico Department of Health; University of New Mexico; State University of New York (SUNY) System; University of Rochester; Vanderbilt University	Wortham, JM (corresponding author), CDC COVID NET Team, Atlanta, GA USA.; Wortham, JM (corresponding author), US PHS, Bethesda, MD 20892 USA.	vij5@cdc.gov	Sutton, Melissa/ABH-9659-2020	Sutton, Melissa/0000-0001-8817-8724; , Andy/0000-0002-8775-0466	CDC through an Emerging Infections Program cooperative agreement [CK17-1701]; CDC through a Council of State and Territorial Epidemiologists cooperative agreement [NU38OT000297-02-00]	CDC through an Emerging Infections Program cooperative agreement(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); CDC through a Council of State and Territorial Epidemiologists cooperative agreement(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This work was supported by the CDC through an Emerging Infections Program cooperative agreement (number CK17-1701) and through a Council of State and Territorial Epidemiologists cooperative agreement (number NU38OT000297-02-00). Role of Funder/Sponsor: CDC designed and conducted the study; collected, managed, analyzed, and interpreted the data; prepared, reviewed, and approved the manuscript; and had a role in the decision to submit the manuscript for publication and journal choice, and had the right to veto publication. Disclaimer: The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).	Ahmad K, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012422; Berchick ER., 2019, HLTH INSURANCE COVER; C. J.Patel, 2020, medRxiv, DOI 10.1101/2020.09.30.20201830; Chandrasekhar R, 2017, INFLUENZA OTHER RESP, V11, P479, DOI 10.1111/irv.12483; Cunningham TJ, 2017, MMWR-MORBID MORTAL W, V66, P444, DOI 10.15585/mmwr.mm6617e1; Finney N, 2015, ARE POVERTY ETHNICIT; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Gaskin DJ, 2014, AM J PUBLIC HEALTH, V104, P2147, DOI 10.2105/AJPH.2013.301420; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hadler JL, 2016, MMWR-MORBID MORTAL W, V65, P101, DOI 10.15585/mmwr.mm6505a1; Hawkins D, 2020, AM J IND MED, V63, P817, DOI 10.1002/ajim.23145; Johns Hopkins Coronavirus Resource Center, 2021, COVID 19 DASHB CTR S, DOI DOI 10.36072/DB; Killerby ME, 2020, MMWR-MORBID MORTAL W, V69, P790, DOI 10.15585/mmwr.mm6925e1; Kim L, 2021, CLIN INFECT DIS, V72, pE206, DOI 10.1093/cid/ciaa1012; Ko JY, 2021, CLIN INFECT DIS, V72, pE695, DOI 10.1093/cid/ciaa1419; Krieger N, PUBLIC HLTH DISPARIT; Liu LY, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242476; Mervosh S., 2020, NEW YORK TIMES; Noel RA, 2018, RACE EC SOCIAL STATU; Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141; Reese H, 2021, CLIN INFECT DIS, V72, pE1010, DOI 10.1093/cid/ciaa1780; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rubin-Miller L, 2020, COVID 19 RACIAL DISP; See I, 2017, CLIN INFECT DIS, V64, P597, DOI 10.1093/cid/ciw808; Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2; Tam K, 2014, INFLUENZA OTHER RESP, V8, P274, DOI 10.1111/irv.12231; U.S. Census Bureau, AM COMMUNITY SURVEY; US Department of Health and Human Services, HLTH PEOPL 2020 2020; Wadhera RK, 2020, JAMA-J AM MED ASSOC, V323, P2192, DOI 10.1001/jama.2020.7197; Weaver C., 2020, WALL STR J; Wortham JM, 2020, MMWR-MORBID MORTAL W, V69, P923, DOI 10.15585/mmwr.mm6928e1; Xu Jiaquan, 2020, NCHS Data Brief, P1; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Yousey-Hindes KM, 2011, AM J PUBLIC HEALTH, V101, P1785, DOI 10.2105/AJPH.2011.300224	34	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2021	16	9							e0257622	10.1371/journal.pone.0257622	http://dx.doi.org/10.1371/journal.pone.0257622			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY2YF	34559838	gold, Green Published			2023-01-03	WOS:000754657900036
J	Jacobs, M; Ellis, C				Jacobs, Molly; Ellis, Charles			Estimating the cost and value of functional changes in communication ability following telepractice treatment for aphasia	PLOS ONE			English	Article								Context Aphasia is a post-stroke condition that can dramatically impact a person with aphasia's (PWA) communication abilities. To date, few if any studies have considered the cost and cost-effectiveness of functional change in aphasia nor considered measures of patient's value for aphasia treatment. Objective To assess the cost, cost-effectiveness, and perceived value associated with improved functional communication in individuals receiving telerehabilitation treatment for aphasia. Design Twenty PWA completed between 5 and 12 telehealth rehabilitation sessions of 45-60 minutes within a 6-week time frame using a Language-Oriented Treatment (LOT) designed to address a range of language issues among individuals with aphasia. National Outcomes Measures (NOMS) comprehension and verbal expression and the ASHA Quality of Communication Life (QCL) were completed prior to and at the completion of rehabilitation to obtain baseline and treatment measures. Results Age, education, and race are significantly correlated with improvement in the NOMS verbal expression. African Americans (OR = 2.0917) are twice as likely as Whites to experience improvement after treatment. The likelihood of improvement also increases with each additional year of education (OR = 1.002) but decrease with age (OR = 0.9463). A total of 15 PWA showed improvement in NOMS comprehension and nine patients showed improvement in NOMS verbal expression. Improving patients attended between five and 12 treatment sessions. The average cost of improvement in NOMS comprehension was $1,152 per patient and NOMS verbal expression was $1,128 per patient with individual treatment costs varying between $540 and $1,296. However, on average, the monetary equivalent in patient's improved QCL was between $1,790.39 to $3,912,54-far exceeding the financial cost of treatment. Conclusions When measuring the functional improvement of patients with aphasia, patient's quality of communication life received from treatment exceeded financial cost of services provided.	[Jacobs, Molly] Univ Florida, Dept Hlth Serv Res Management & Policy, Gainesville, FL 32611 USA; [Ellis, Charles] Univ Florida, Dept Speech Language & Hearing Sci, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Jacobs, M (corresponding author), Univ Florida, Dept Hlth Serv Res Management & Policy, Gainesville, FL 32611 USA.	mollyjacobs@ufl.edu			Agency for Healthcare Research and Quality [1 R03 HS025043-01A1]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This study was funded by the Agency for Healthcare Research and Quality https://www.ahrq.gov/Grant #: 1 R03 HS025043-01A1 awarded to CE. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Speech-Language Hearing Association, 2020, APH OV; American Speech-Language-Hearing Association, 2021, ASHAS NAT OUTCC MEAS; Armstrong E, 2013, AM J SPEECH-LANG PAT, V22, pS268, DOI 10.1044/1058-0360(2012/12-0084); Bandur DL., 2008, LANGUAGE INTERVENTIO, P756; Bettger JP, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.115.002391; Butzer JF, 2019, ARCH PHYS MED REHAB, V100, P990, DOI 10.1016/j.apmr.2018.11.008; Dalemans RJP, 2010, DISABIL REHABIL, V32, P1678, DOI 10.3109/09638281003649938; Doedens WJ, 2020, APHASIOLOGY, V34, P492, DOI 10.1080/02687038.2019.1702848; Ellis C, 2018, APHASIOLOGY, V32, P1075, DOI 10.1080/02687038.2017.1385052; Ellis C, 2012, STROKE, V43, P1429, DOI 10.1161/STROKEAHA.111.647339; Fucetola R, 2015, AM J SPEECH-LANG PAT, V24, pS790, DOI 10.1044/2015_AJSLP-14-0135; Guyomard V, 2009, J AM GERIATR SOC, V57, P2101, DOI 10.1111/j.1532-5415.2009.02526.x; Jacobs M, 2021, J TELEMED TELECARE, DOI 10.1177/1357633X20982773; Jebahi F., 2021, CURRENT TRENDS NEURO, P1; Kertesz A, 2007, W APHASIA BATTERY; Mazaux JM, 2013, J REHABIL MED, V45, P341, DOI 10.2340/16501977-1122; MULLEN R., 2016, ASHA LEADER, V21, P38, DOI [10.1044/leader.OTP.21102016.38, DOI 10.1044/LEADER.OTP.21102016.38]; Oakes AH, 2021, JAMA-J AM MED ASSOC, V325, P1715, DOI 10.1001/jama.2021.3308; Palmer R, 2012, STROKE, V43, P1904, DOI 10.1161/STROKEAHA.112.650671; Patient Protection and Affordable Care Act, 2010, PUBLIC LAW, V111, P759; Paul D., 2005, QUALITY COMMUNICATIO; Porter ME, 2010, NEW ENGL J MED, V363, P2477, DOI 10.1056/NEJMp1011024; Roth EJ., 2021, ARCH PHYS MED REHAB; Schumacher R, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa118; Shewan CM., 1986, TREATMENT APHASIA LA; Simmons-Mackie N., 2018, APHASIA N AM STATE A; Wegner Steven E, 2016, N C Med J, V77, P276, DOI 10.18043/ncm.77.4.276; Wenke R, 2014, INT J SPEECH-LANG PA, V16, P250, DOI 10.3109/17549507.2014.887777	28	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2021	16	9							e0257462	10.1371/journal.pone.0257462	http://dx.doi.org/10.1371/journal.pone.0257462			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5ZQ	34534254	Green Published, gold			2023-01-03	WOS:000707073300031
J	Afshari, K; Ozturk, ED; Yates, B; Picard, G; Taylor, JA				Afshari, Khashayar; Ozturk, Erin D.; Yates, Brandon; Picard, Glen; Taylor, J. Andrew			Effect of hybrid FES exercise on body composition during the sub-acute phase of spinal cord injury	PLOS ONE			English	Article							FUNCTIONAL ELECTRICAL-STIMULATION; VISCERAL ADIPOSE-TISSUE; BONE-MINERAL CONTENT; MASS INDEX; CARDIOVASCULAR FITNESS; METABOLIC PROFILE; ROWING EXERCISE; INDIVIDUALS; INTENSITY; STRENGTH	Objectives To determine the Effect of Hybrid functional electrically stimulated (FES) Exercise on Body Composition during the Sub-acute Phase of Spinal Cord Injury (SCI). Design Randomized Clinical Trial. Setting Rehabilitation Hospital. Participants Patients within sub-acute phase (3-24 months) of SCI. Interventions We investigated if high-intensity exercise training via the addition of functional electrically stimulated (FES) leg muscles, provides sufficient stimulus to mitigate against body composition changes in the sub-acute phase after SCI. Main outcome measures We explored potential effects of FES row training (FESRT) on body fat gain, lean mass loss, and cardiometabolic parameters and compared the effects of 6-month of FESRT (n = 18) to standard of care (SOC, n = 13). Those in SOC were crossed over to FESRT. Results FESRT resulted in greater exercise capacity and a tendency for lesser total body fat accumulation with a significant increase in total and leg lean mass (p<0.05). In addition pelvis and total bone mineral density declines were significantly less (p<0.05). Compared to SOC, FESRT did not lead to any significant difference in insulin sensitivity or serum lipids. However, HbA1C levels were significantly decreased in SOC participants who crossed over to 6-month FESRT. Conclusion FESRT early after SCI provides a sufficient stimulus to mitigate against detrimental body composition changes. This may lead to prevention of losses in lean mass, including bone.	[Afshari, Khashayar; Yates, Brandon; Taylor, J. Andrew] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Afshari, Khashayar; Ozturk, Erin D.; Yates, Brandon; Picard, Glen; Taylor, J. Andrew] Spaulding Hosp Cambridge, Cardiovasc Res Lab, Cambridge, MA 02138 USA; [Afshari, Khashayar; Yates, Brandon; Taylor, J. Andrew] Spaulding Res Inst, Charlestown, MA 02129 USA	Harvard University; Harvard Medical School	Taylor, JA (corresponding author), Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA.; Taylor, JA (corresponding author), Spaulding Hosp Cambridge, Cardiovasc Res Lab, Cambridge, MA 02138 USA.; Taylor, JA (corresponding author), Spaulding Res Inst, Charlestown, MA 02129 USA.	jandrew_taylor@hms.harvard.edu	Afshari, Khashayar/I-6373-2019	Afshari, Khashayar/0000-0001-9099-7948	NIH [R01HL117037]; ACL [90SI5021-01]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACL	Support provided by NIH Grant R01HL117037 and ACL Grant 90SI5021-01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Apstein MD, 1998, METABOLISM, V47, P367, DOI 10.1016/S0026-0495(98)90044-0; BIERINGSORENSEN F, 1990, EUR J CLIN INVEST, V20, P330, DOI 10.1111/j.1365-2362.1990.tb01865.x; Bresnahan JJ, 2019, J SPINAL CORD MED, V42, P272, DOI 10.1080/10790268.2017.1412562; Brurok B, 2011, AM J PHYS MED REHAB, V90, P407, DOI 10.1097/PHM.0b013e31820f960f; Castro MJ, 1999, EUR J APPL PHYSIOL, V80, P373, DOI 10.1007/s004210050606; Chou RC, 2020, SPINAL CORD, V58, P914, DOI 10.1038/s41393-020-0445-3; de Paleville DGLT, 2019, J SPINAL CORD MED, V42, P32, DOI 10.1080/10790268.2018.1449373; Dolbow DR, 2021, J SPINAL CORD MED, V44, P533, DOI 10.1080/10790268.2019.1710939; Dolbow DR, 2018, J SPINAL CORD MED, V41, P248, DOI 10.1080/10790268.2017.1367358; Draghici AE, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10200; Dudley-Javoroski S, 2012, OSTEOPOROSIS INT, V23, P2335, DOI 10.1007/s00198-011-1879-4; Edwards LA, 2008, AM J CLIN NUTR, V87, P600, DOI 10.1093/ajcn/87.3.600; Fang Y, 2017, J BIOMECH, V55, P11, DOI 10.1016/j.jbiomech.2017.01.036; Fisher JA, 2015, AGING DIS, V6, P271, DOI 10.14336/AD.2014.0912; Ginis KAM, 2018, SPINAL CORD, V56, P308, DOI 10.1038/s41393-017-0017-3; Gorgey AS, 2018, SPINAL CORD, V56, P987, DOI 10.1038/s41393-018-0079-x; Gorgey AS, 2016, J SPINAL CORD MED, V39, P699, DOI 10.1080/10790268.2016.1157970; Gorgey AS, 2014, J SPINAL CORD MED, V37, P693, DOI 10.1179/2045772314Y.0000000245; Gorgey AS, 2012, MED SCI SPORT EXER, V44, P165, DOI 10.1249/MSS.0b013e31822672aa; Gorgey AS, 2011, METABOLISM, V60, P843, DOI 10.1016/j.metabol.2010.08.002; Gutin B, 2002, AM J CLIN NUTR, V75, P818, DOI 10.1093/ajcn/75.5.818; Hicks AL, 2011, SPINAL CORD, V49, P1103, DOI 10.1038/sc.2011.62; Irving BA, 2008, MED SCI SPORT EXER, V40, P1863, DOI 10.1249/MSS.0b013e3181801d40; Jacobs PL, 2004, SPORTS MED, V34, P727, DOI 10.2165/00007256-200434110-00003; Jeon JY, 2010, ARCH PHYS MED REHAB, V91, P1957, DOI 10.1016/j.apmr.2010.08.024; Kim DI, 2014, SPINAL CORD, V52, P621, DOI 10.1038/sc.2014.76; LASKIN JJ, 1993, PARAPLEGIA, V31, P534, DOI 10.1038/sc.1993.87; Laughton GE, 2009, SPINAL CORD, V47, P757, DOI 10.1038/sc.2009.33; Liusuwan A, 2004, J SPINAL CORD MED, V27, pS24, DOI 10.1080/10790268.2004.11753781; Maruyama Y, 2008, SPINAL CORD, V46, P494, DOI 10.1038/sj.sc.3102171; McCauley LS, 2020, J CLIN DENSITOM, V23, P63, DOI 10.1016/j.jocd.2018.12.003; McDonald CM, 2007, J SPINAL CORD MED, V30, pS97, DOI 10.1080/10790268.2007.11754612; Medicine ACoS, 2013, ACSMS GUIDELINES EXE, V9th ed.; Mercier HW, 2021, SPINAL CORD, V59, P74, DOI 10.1038/s41393-020-0527-2; Mogharnasi M, 2019, DISABIL HEALTH J, V12, P29, DOI 10.1016/j.dhjo.2018.07.003; Nash MS, 2007, ARCH PHYS MED REHAB, V88, P70, DOI 10.1016/j.apmr.2006.10.003; Nightingale TE, 2018, MED SCI SPORT EXER, V50, P1305, DOI 10.1249/MSS.0000000000001548; Ozturk ED., 2020, MED SCI SPORT EXER; Panisset MG, 2016, SPINAL CORD, V54, P84, DOI 10.1038/sc.2015.150; Peckham PH, 2005, ANNU REV BIOMED ENG, V7, P327, DOI 10.1146/annurev.bioeng.6.040803.140103; Pelletier CA, 2018, APPL PHYSIOL NUTR ME, V43, P139, DOI 10.1139/apnm-2017-0304; Scott JM, 2011, SPINAL CORD, V49, P4, DOI 10.1038/sc.2010.53; Serra-Ano P, 2012, SPINAL CORD, V50, P827, DOI 10.1038/sc.2012.32; Singh R, 2014, INDIAN J ORTHOP, V48, P168, DOI 10.4103/0019-5413.128760; Slentz CA, 2004, ARCH INTERN MED, V164, P31, DOI 10.1001/archinte.164.1.31; Solinsky R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247576; Solinsky R, 2021, PM&R, V13, P937, DOI 10.1002/pmrj.12507; Solinsky R, 2021, CLIN AUTON RES, V31, P293, DOI 10.1007/s10286-020-00677-2; Wheeler GD, 2002, ARCH PHYS MED REHAB, V83, P1093, DOI 10.1053/apmr.2002.33656; WILMET E, 1995, PARAPLEGIA, V33, P674, DOI 10.1038/sc.1995.141	50	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2022	17	1							e0262864	10.1371/journal.pone.0262864	http://dx.doi.org/10.1371/journal.pone.0262864			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ4EH	35073366	gold, Green Published			2023-01-03	WOS:000773223800046
J	Sabuj, MZR; Dargaville, TR; Nissen, L; Islam, N				Sabuj, Mohammad Zaidur Rahman; Dargaville, Tim R.; Nissen, Lisa; Islam, Nazrul			Inhaled ciprofloxacin-loaded poly(2-ethyl-2-oxazoline) nanoparticles from dry powder inhaler formulation for the potential treatment of lower respiratory tract infections	PLOS ONE			English	Article							SOLID LIPID NANOPARTICLES; IN-VITRO; CHITOSAN NANOPARTICLES; DRUG-DELIVERY; CONTROLLED-RELEASE; ALGINATE/CHITOSAN; SURFACE; PH; REDUCTION; PARTICLES	Lower respiratory tract infections (LRTIs) are one of the fatal diseases of the lungs that have severe impacts on public health and the global economy. The currently available antibiotics administered orally for the treatment of LRTIs need high doses with frequent administration and cause dose-related adverse effects. To overcome this problem, we investigated the development of ciprofloxacin (CIP) loaded poly(2-ethyl-2-oxazoline) (PEtOx) nanoparticles (NPs) for potential pulmonary delivery from dry powder inhaler (DPI) formulations against LRTIs. NPs were prepared using a straightforward co-assembly reaction carried out by the intermolecular hydrogen bonding among PEtOx, tannic acid (TA), and CIP. The prepared NPs were characterized by scanning electron microscopy (SEM), dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), powder X-ray diffraction analysis (PXRD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA). The CIP was determined by validated HPLC and UV spectrophotometry methods. The CIP loading into the PEtOx was between 21-67% and increased loading was observed with the increasing concentration of CIP. The NP sizes of PEtOx with or without drug loading were between 196-350 nm and increased with increasing drug loading. The in vitro CIP release showed the maximum cumulative release of about 78% in 168 h with a burst release of 50% in the first 12 h. The kinetics of CIP release from NPs followed non-Fickian or anomalous transport thus suggesting the drug release was regulated by both diffusion and polymer degradation. The in vitro aerosolization study carried out using a Twin Stage Impinger (TSI) at 60 L/min air flow showed the fine particle fraction (FPF) between 34.4% and 40.8%. The FPF was increased with increased drug loading. The outcome of this study revealed the potential of the polymer PEtOx as a carrier for developing CIP-loaded PEtOx NPs as DPI formulation for pulmonary delivery against LRTIs.	[Sabuj, Mohammad Zaidur Rahman; Nissen, Lisa; Islam, Nazrul] Queensland Univ Technol, Fac Hlth, Sch Clin Sci, Pharm Discipline, Brisbane, Qld, Australia; [Dargaville, Tim R.] Queensland Univ Technol, Fac Sci, Sch Chem & Phys, Brisbane, Qld, Australia; [Islam, Nazrul] Queensland Univ Technol, Ctr Immunol & Infect Control CIIC, Brisbane, Qld, Australia	Queensland University of Technology (QUT); Queensland University of Technology (QUT); Queensland University of Technology (QUT)	Islam, N (corresponding author), Queensland Univ Technol, Fac Hlth, Sch Clin Sci, Pharm Discipline, Brisbane, Qld, Australia.; Islam, N (corresponding author), Queensland Univ Technol, Ctr Immunol & Infect Control CIIC, Brisbane, Qld, Australia.	nazrul.islam@qut.edu.au	; Nissen, Lisa/C-3403-2008	Dargaville, Tim/0000-0003-4665-9508; Nissen, Lisa/0000-0001-5826-4605; Sabuj, Mohammad Zaidur Rahman/0000-0001-5167-7669; Islam, Nazrul/0000-0001-6751-6915				Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017; Al-Omar Mohammed A, 2005, Profiles Drug Subst Excip Relat Methodol, V31, P163, DOI 10.1016/S0099-5428(04)31004-X; Asada M, 2004, INT J PHARMACEUT, V270, P167, DOI 10.1016/j.ijpharm.2003.11.001; Bag PP, 2014, CRYSTENGCOMM, V16, P7393, DOI 10.1039/c4ce00631c; Bu LR, 2019, DRUG DELIV, V26, P300, DOI 10.1080/10717544.2019.1580323; Celebi O., 2014, SYNTHESIS CHARACTERI; Christiansen K., 1996, AUSTR PRESCRIBERS, P48; Cox PJ, 1999, INT J PHARMACEUT, V193, P73, DOI 10.1016/S0378-5173(99)00320-8; Fan HL, 2017, MACROMOLECULES, V50, P666, DOI 10.1021/acs.macromol.6b02106; Gao NS, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00270; Gazori T, 2009, CARBOHYD POLYM, V77, P599, DOI 10.1016/j.carbpol.2009.02.019; Ghaffari S, 2012, J DISPER SCI TECHNOL, V33, P685, DOI 10.1080/01932691.2011.579831; Gomathi T, 2014, INT J PHARMACEUT, V468, P214, DOI 10.1016/j.ijpharm.2014.04.026; Gowda R, 2010, ADV MECH ENG, DOI 10.1155/2010/807610; Gulyuz S, 2018, EXPRESS POLYM LETT, V12, P146, DOI 10.3144/expresspolymlett.2018.13; HADDOW A, 1989, AM J MED, V87, pS113, DOI 10.1016/0002-9343(89)90036-3; Hadinoto K, 2007, INT J PHARM, V341, P195, DOI 10.1016/j.ijpharm.2007.03.035; Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1; HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210; Hixson AW, 1931, IND ENG CHEM, V23, P923, DOI 10.1021/ie50260a018; Isa T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050713; Islam N, 2008, INT J PHARMACEUT, V360, P1, DOI 10.1016/j.ijpharm.2008.04.044; Islam N, 2008, DRUG DISCOV THER, V2, P264; Jeong YI, 2008, INT J PHARMACEUT, V352, P317, DOI 10.1016/j.ijpharm.2007.11.001; Kamberi M, 1999, ANTIMICROB AGENTS CH, V43, P525, DOI 10.1128/AAC.43.3.525; Khoo XJ, 2013, BIOMATERIALS, V34, P1281, DOI 10.1016/j.biomaterials.2012.10.025; KORSMEYER RW, 1983, INT J PHARM, V15, P25, DOI 10.1016/0378-5173(83)90064-9; Koshkina O, 2016, MACROMOL BIOSCI, V16, P1287, DOI 10.1002/mabi.201600074; Kostova B, 2014, AAPS PHARMSCITECH, V15, P939, DOI 10.1208/s12249-014-0120-0; Kyziol A, 2017, J BIOMATER APPL, V32, P162, DOI 10.1177/0885328217714352; Liu JJ, 2019, J PHOTOCH PHOTOBIO B, V197, DOI 10.1016/j.jphotobiol.2019.05.007; Liu L, 2020, CHINESE CHEM LETT, V31, P501, DOI 10.1016/j.cclet.2019.04.041; Mahashur A, 2018, LUNG INDIA, V35, P143, DOI 10.4103/lungindia.lungindia_262_17; Marinho R, 2018, BRAZ J CHEM ENG, V35, P631, DOI 10.1590/0104-6632.20180352s20160453; Muchohi SN, 2011, J CHROMATOGR B, V879, P146, DOI 10.1016/j.jchromb.2010.11.032; Muhsin MDA, 2016, MOL PHARMACEUT, V13, P1455, DOI 10.1021/acs.molpharmaceut.5b00859; Pharmacopoeia B., 2012, APPENDIX 12 C CONSIS; Pilcer G, 2009, INT J PHARMACEUT, V365, P162, DOI 10.1016/j.ijpharm.2008.08.014; Sabuj MZR, 2021, NANOSCALE ADV, V3, P4005, DOI 10.1039/d1na00205h; Sadeek SA, 2011, SPECTROCHIM ACTA A, V78, P854, DOI 10.1016/j.saa.2010.12.048; Seyfoddin A, 2010, DRUG DELIV, V17, P467, DOI 10.3109/10717544.2010.483257; Siepmann J, 2011, INT J PHARMACEUT, V418, P6, DOI 10.1016/j.ijpharm.2011.03.051; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Telko Martin J, 2005, Respir Care, V50, P1209; Tewes F, 2016, MOL PHARMACEUT, V13, P100, DOI 10.1021/acs.molpharmaceut.5b00543; Trucchi C, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4412-7; Tureli NG, 2017, EUR J PHARM BIOPHARM, V117, P363, DOI 10.1016/j.ejpb.2017.04.032; Ulbricht J, 2014, BIOMATERIALS, V35, P4848, DOI 10.1016/j.biomaterials.2014.02.029; Varshosaz J, 2015, J APPL POLYM SCI, V132, DOI 10.1002/app.41799; Vlassi E, 2017, EUR POLYM J, V88, P516, DOI 10.1016/j.eurpolymj.2016.10.034; Wan A, 2009, CARBOHYD POLYM, V75, P566, DOI 10.1016/j.carbpol.2008.08.019; Wang CY, 2018, J POLYM SCI POL CHEM, V56, P1520, DOI 10.1002/pola.29033; Wang H, 2018, ADV POWDER TECHNOL, V29, P3079, DOI 10.1016/j.apt.2018.08.011; Wang H, 2017, EUR J PHARM BIOPHARM, V113, P118, DOI 10.1016/j.ejpb.2016.12.023; Yuan JY, 2019, J MICROBIOL IMMUNOL, V52, P35, DOI 10.1016/j.jmii.2017.07.011; Zhang HN, 2020, RSC ADV, V10, P25435, DOI 10.1039/d0ra02779k	56	3	3	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2021	16	12							e0261720	10.1371/journal.pone.0261720	http://dx.doi.org/10.1371/journal.pone.0261720			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ1OP	34941946	Green Published, gold			2023-01-03	WOS:000755252200072
J	Du, B; Wang, CT; Singer, M				Du, Bin; Wang, Chunting; Singer, Mervyn			Learning for the next pandemic: the Wuhan experience of managing critically ill people	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Du, Bin] Peking Union Med Coll Hosp, Med Intens Care Unit, State Key Lab Rare Complex & Crit Dis, Beijing 100730, Peoples R China; [Wang, Chunting] Shandong First Med Univ, Dept Crit Care Med, Shandong Prov Hosp, Jinan, Shandong, Peoples R China; [Singer, Mervyn] UCL, Div Med, Bloomsbury Inst Intens Care Med, London, England	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Shandong First Medical University & Shandong Academy of Medical Sciences; University of London; University College London	Du, B (corresponding author), Peking Union Med Coll Hosp, Med Intens Care Unit, State Key Lab Rare Complex & Crit Dis, Beijing 100730, Peoples R China.	dubin98@gmail.com			Ministry of Science and Technology of the People's Republic of China [2021YFC0863100]	Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China)	This work was supported, in part, by funds from Ministry of Science and Technology of the People's Republic of China (2021YFC0863100).	Burki T, 2020, LANCET INFECT DIS, V20, P292, DOI 10.1016/S1473-3099(20)30076-1; Cao B, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2008043; Chen SM, 2020, LANCET, V395, P1305, DOI 10.1016/S0140-6736(20)30744-3; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575	9	3	3	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 2	2021	375								e066090	10.1136/bmj-2021-066090	http://dx.doi.org/10.1136/bmj-2021-066090			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XS2XZ	34852995	Green Published, hybrid			2023-01-03	WOS:000732779300024
J	Mallach, G; Kasloff, SB; Kovesi, T; Kumar, A; Kulka, R; Krishnan, J; Robert, B; McGuinty, M; den Otter-Moore, S; Yazji, B; Cutts, T				Mallach, Gary; Kasloff, Samantha B.; Kovesi, Tom; Kumar, Anand; Kulka, Ryan; Krishnan, Jay; Robert, Benoit; McGuinty, Michaeline; den Otter-Moore, Sophia; Yazji, Bashour; Cutts, Todd			Aerosol SARS-CoV-2 in hospitals and long-term care homes during the COVID-19 pandemic	PLOS ONE			English	Article							INFECTION	Background Few studies have quantified aerosol concentrations of SARS-CoV-2 in hospitals and longterm care homes, and fewer still have examined samples for viability. This information is needed to clarify transmission risks beyond close contact. Methods We deployed particulate air samplers in rooms with COVID-19 positive patients in hospital ward and ICU rooms, rooms in long-term care homes experiencing outbreaks, and a correctional facility experiencing an outbreak. Samplers were placed between 2 and 3 meters from the patient. Aerosol (small liquid particles suspended in air) samples were collected onto gelatin filters by Ultrasonic Personal Air Samplers (UPAS) fitted with <2.5 mu m (micrometer) and < 10 mu m size-selective inlets operated for 16 hours (total 1.92m(3)), and with a Coriolis Biosampler over 10 minutes (total 1.5m(3)). Samples were assayed for viable SARS-CoV-2 virus and for the viral genome by multiplex PCR using the E and N protein target sequences. We validated the sampling methods by inoculating gelatin filters with viable vesicular stomatitis virus (VSV), and with three concentrations of viable SARS-CoV-2, operating personal samplers for 16hrs, and quantifying viable virus recovery by TCID50 assay. Results In total, 138 samples were collected from 99 rooms. RNA samples were positive in 9.1% (6/66) of samples obtained with the UPAS 2.5 mu m samplers, 13.5% (7/52) with the UPAS 10 mu m samplers, and 10.0% (2/20) samples obtained with the Coriolis samplers. Culturable virus was not recovered in any samples. Viral RNA was detected in 15.1% of the rooms sampled. There was no significant difference in viral RNA recovery between the different room locations or samplers. Method development experiments indicated minimal loss of SARS-CoV-2 viability via the personal air sampler operation.	[Mallach, Gary; Kulka, Ryan] Hlth Canada, Water & Air Qual Bur, Ottawa, ON, Canada; [Kasloff, Samantha B.; Krishnan, Jay; Cutts, Todd] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada; [Kovesi, Tom] Univ Ottawa, Childrens Hosp Eastern Ontario, Ottawa, ON, Canada; [Kumar, Anand] Univ Manitoba, Dept Med, Sect Crit Care Med, Winnipeg, MB, Canada; [Kumar, Anand] Univ Manitoba, Dept Med, Sect Infect Dis, Winnipeg, MB, Canada; [Kumar, Anand] Univ Manitoba, Dept Med Microbiol, Sect Crit Care Med, Winnipeg, MB, Canada; [Kumar, Anand] Univ Manitoba, Dept Med Microbiol, Sect Infect Dis, Winnipeg, MB, Canada; [Kumar, Anand] Univ Manitoba, Dept Pharmacol, Sect Crit Care Med, Winnipeg, MB, Canada; [Kumar, Anand] Univ Manitoba, Dept Pharmacol, Sect Infect Dis, Winnipeg, MB, Canada; [Robert, Benoit] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [McGuinty, Michaeline; Yazji, Bashour] Univ Ottawa, Ottawa Hosp, Dept Med, Ottawa, ON, Canada; [den Otter-Moore, Sophia] Queens Univ, Fac Med, Kingston, ON, Canada	Health Canada; Public Health Agency of Canada; University of Ottawa; Children's Hospital of Eastern Ontario; University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Queens University - Canada	Mallach, G (corresponding author), Hlth Canada, Water & Air Qual Bur, Ottawa, ON, Canada.	gary.mallach@canada.ca		Mallach, Gary/0000-0002-0927-592X; Kovesi, Thomas/0000-0002-0521-8936				American Society for Testing and Materials, 2002, STAND QUANT DISK CAR; American Society of Heating Refrigeration and Air Conditioning Engineers, 2020, ASHRAE POSITION DOCU; Anderson EL, 2020, RISK ANAL, V40, P902, DOI 10.1111/risa.13500; Asadi S, 2020, AEROSOL SCI TECH, V54, P635, DOI 10.1080/02786826.2020.1749229; Binder RA, 2020, J INFECT DIS, V222, P1798, DOI 10.1093/infdis/jiaa575; Birgand G, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.33232; Bixler SL, AEROSOL EXPOSURE CYN, V2021; Bullard J, 2021, CAN MED ASSOC J, V193, pE601, DOI 10.1503/cmaj.210263; Bullard J, 2020, CLIN INFECT DIS, V71, P2663, DOI 10.1093/cid/ciaa638; Calistri P, 2021, INT J INFECT DIS, V105, P753, DOI 10.1016/j.ijid.2021.03.005; CDC, 2020, RES US ONL 2019 NOV; Cheng VCC, 2020, INFECT CONT HOSP EP, V41, P1258, DOI 10.1017/ice.2020.282; Chia PY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16670-2; Chin AWH, 2020, LANCET MICROBE, V1, pE10, DOI [10.1016/S2666-5247(20)30003-3, 10.1016/S2666-5247(20)30095-1]; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Dabisch P, 2021, AEROSOL SCI TECH, V55, P142, DOI 10.1080/02786826.2020.1829536; Dumont-Leblond N, 2020, EMERG MICROBES INFEC, V9, P2597, DOI 10.1080/22221751.2020.1850184; Engelmann I, 2021, ACS OMEGA, V6, P6528, DOI 10.1021/acsomega.1c00166; Fang FC, 2021, CLIN INFECT DIS, V72, P2225, DOI 10.1093/cid/ciaa1654; Fennelly KP, 2020, LANCET RESP MED, V8, P914, DOI 10.1016/S2213-2600(20)30323-4; Fisman DN, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.15957; Gao CX, 2021, SCI TOTAL ENVIRON, V752, DOI 10.1016/j.scitotenv.2020.141856; Greenhalgh T, 2021, LANCET, V397, P1603, DOI 10.1016/S0140-6736(21)00869-2; Heneghan C., 2021, F1000RESEARCH, V10, DOI [DOI 10.12688/F1000RESEARCH.52091.1, 10.12688/f1000research.52091.1]; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Kasloff SB, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80098-3; Kenarkoohi A, 2020, SCI TOTAL ENVIRON, V748, DOI 10.1016/j.scitotenv.2020.141324; Kissler S.M., 2021, DENSELY SAMPLED VIRA, DOI 10.1101/2021.02.16.21251535; Lednicky JA, 2021, INT J INFECT DIS, V108, P212, DOI 10.1016/j.ijid.2021.04.063; Lednickya JA, 2020, INT J INFECT DIS, V100, P476, DOI [10.1016/j.ijid.2020.09.025, 10.1101/2020.08.03.20167395]; Lee K, 2009, GLOB INST, P1; Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3; MacIntyre CR, 2020, ANTIMICROB RESIST IN, V9, DOI 10.1186/s13756-020-00868-6; Miller SL, 2021, INDOOR AIR, V31, P314, DOI 10.1111/ina.12751; Morawska L, 2020, ENVIRON INT, V142, DOI 10.1016/j.envint.2020.105832; Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730; Noorimotlagh Z, 2021, ENVIRON RES, V193, DOI 10.1016/j.envres.2020.110612; Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227; Prather KA, 2020, SCIENCE, V368, P1422, DOI 10.1126/science.abc6197; Razzini K, 2020, SCI TOTAL ENVIRON, V742, DOI 10.1016/j.scitotenv.2020.140540; REED L. J., 1938, AMER JOUR HYG, V27, P493; Riddell S, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01418-7; Rogers AA, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00708-20; Santarpia JL, 2020, 2020071320041632 MED, DOI 10.1101/2020.07.13.20041632; Santarpia JL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69286-3; Singanayagam A, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.32.2001483; Tang S, 2020, ENVIRON INT, V144, DOI 10.1016/j.envint.2020.106039; Tellier R, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3707-y; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1101/2020.03.09.20033217, 10.1056/NEJMc2004973]; Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097; WHO, 2010, WORLD MALARIA REPORT 2010, P1; Wilson NM, 2020, ANAESTHESIA, V75, P1086, DOI 10.1111/anae.15093; Worldometers, COVID 19 COR PAND, P2021; Wu ZL, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2171; Yang Q, 2021, P NATL ACAD SCI USA, V118, DOI [10.1073/pnas.2104547118, 10.1101/2021.03.01.21252250]	55	8	8	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2021	16	9								10.1371/journal.pone.0258151	http://dx.doi.org/10.1371/journal.pone.0258151			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YI5QV	34591919	Green Published, gold, Green Submitted			2023-01-03	WOS:000743903000087
J	Suran, M				Suran, Melissa			Preparing Hospitals' Medical Oxygen Delivery Systems for a Respiratory "Twindemic"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item; Early Access								This Medical News feature examines the challenges that hospitals face as they prepare for a spike in severe cases of COVID-19 and other respiratory illnesses that require supplemental oxygen.											0	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2021.23392	http://dx.doi.org/10.1001/jama.2021.23392		JAN 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG3TV	35019960	Bronze			2023-01-03	WOS:000742416400002
J	van Ruitenbeek, RE; Slik, JS; Bhulai, S				van Ruitenbeek, Robin Enrico; Slik, Jesper Siem; Bhulai, Sandjai			On the relation between COVID-19, mobility, and the stock market	PLOS ONE			English	Article								The Covid-19 pandemic has brought forth a major landscape shock in the mobility sector. Due to its recentness, researchers have just started studying and understanding the implications of this crisis on mobility. We contribute by combining mobility data from various sources to bring a novel angle to understanding mobility patterns during Covid-19. The goal is to expose relations between mobility and Covid-19 variables and understand them by using our data. This is crucial information for governments to understand and address the underlying root causes of the impact.	[van Ruitenbeek, Robin Enrico; Slik, Jesper Siem] Pon, Amsterdam, Netherlands; [Bhulai, Sandjai] Vrije Univ Amsterdam, Amsterdam, Netherlands	Vrije Universiteit Amsterdam	van Ruitenbeek, RE; Slik, JS (corresponding author), Pon, Amsterdam, Netherlands.; Bhulai, S (corresponding author), Vrije Univ Amsterdam, Amsterdam, Netherlands.	r.e.van.ruitenbeek@vu.nl; j.s.slik@vu.nl; s.bhulai@vu.nl		van Ruitenbeek, Robin, Enrico/0000-0003-4774-1511; Bhulai, Sandjai/0000-0003-1124-8821				Abdullah Muhammad, 2020, Transp Res Interdiscip Perspect, V8, P100255, DOI 10.1016/j.trip.2020.100255; AeroDataBox, 2019, AERODATABOX API; Agarwal M, 2020, WHAT IS SPEED SHIP S; AIS Hub Exchange, 2021, AIS DAT SHAR VESS TR; Aroussi R., 2020, YFINANCE; Barbieri DM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245886; Clark DE, 2009, IMPACT OF 9/11 ON BUSINESS AND ECONOMICS: THE BUSINESS OF TERROR - THE DAY THAT CHANGED EVERYTHING, P75; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; FlightRadar, 2020, FLIGHTRADAR24; Giorgino T, 2009, J STAT SOFTW, V31, P1, DOI 10.18637/jss.v031.i07; Google, 2020, GOOGL TRENDS EXPL WH; Hacker J, 2020, EUR J INFORM SYST, V29, P563, DOI 10.1080/0960085X.2020.1814680; Hegele ArdenAlexandra., 2020, COLUMBIA NEWS; Humanitarian Data Exchange, 2020, HDX GLOB PORTS; International Energy Agency, 2020, CHANG TRANSP BEH COV; Keogh E, 2005, KNOWL INF SYST, V7, P358, DOI 10.1007/s10115-004-0154-9; Nouvellet P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21358-2; Rijksoverheid, 2020, PERSC COR EENV TAAL; Schweizer AM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249268; Suzumura T, 2020, IEEE INT CONF BIG DA, P2443, DOI 10.1109/BigData50022.2020.9378218; Tirachini A, 2020, J PUBLIC TRANSPORT, V22, P1, DOI [10.5038/2375-091.22.1.1, 10.5038/2375-0901.22.1.1]; van Ruitenbeek RE, 2021, DATA REPOSITORYON RE; Wang KY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089405; Wikipedia, 2020, BUS AIRP CONT; WR Richards KO., 2010, NEW AIR TRAFFIC SURV; YahooFinance, 2020, MAJ WORLD IND	26	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2021	16	12							e0261381	10.1371/journal.pone.0261381	http://dx.doi.org/10.1371/journal.pone.0261381			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW9UF	34962952	gold, Green Published			2023-01-03	WOS:000771548500016
J	Wilcock, AD; Joshi, S; Escarce, J; Huckfeldt, PJ; Nuckols, T; Popescu, I; Sood, N				Wilcock, Andrew D.; Joshi, Sushant; Escarce, Jose; Huckfeldt, Peter J.; Nuckols, Teryl; Popescu, Ioana; Sood, Neeraj			Luck of the draw: Role of chance in the assignment of medicare readmissions penalties	PLOS ONE			English	Article							REDUCTION PROGRAM; HEART-FAILURE; HOSPITALS; RISK; RELIABILITY; MORTALITY; PATIENT	Pay-for-performance programs are one strategy used by health plans to improve the efficiency and quality of care delivered to beneficiaries. Under such programs, providers are often compared against their peers in order to win bonuses or face penalties in payment. Yet luck has the potential to affect performance assessment through randomness in the sorting of patients among providers or through random events during the evaluation period. To investigate the impact luck can have on the assessment of performance, we investigated its role in assigning penalties under Medicare's Hospital Readmissions Reduction Policy (HRRP), a program that penalizes hospitals with excess readmissions. We performed simulations that estimated program hospitals' 2015 readmission penalties in 1,000 different hypothetical fiscal years. These hypothetical fiscal years were created by: (a) randomly varying which patients were admitted to each hospital and (b) randomly varying the readmission status of discharged patients. We found significant differences in penalty sizes and probability of penalty across hypothetical fiscal years, signifying the importance of luck in readmission performance under the HRRP. Nearly all of the impact from luck arose from events occurring after hospital discharge. Luck played a smaller role in determining penalties for hospitals with more beds, teaching hospitals, and safety-net hospitals.	[Wilcock, Andrew D.] Univ Vermont, Coll Med, Burlington, VT 05405 USA; [Joshi, Sushant; Sood, Neeraj] Univ Southern Calif, Sol Price Sch Publ Policy, Dept Hlth Policy & Management, Los Angeles, CA 90007 USA; [Joshi, Sushant; Sood, Neeraj] Univ Southern Calif, Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90007 USA; [Escarce, Jose; Popescu, Ioana] Univ Calif Los Angeles, Dept Gen Internal Med, Los Angeles, CA USA; [Huckfeldt, Peter J.] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA; [Nuckols, Teryl] Cedars Sinai Med Ctr, Div Gen Internal Med, Dept Med, Los Angeles, CA 90048 USA	University of Vermont; University of Southern California; University of Southern California; University of California System; University of California Los Angeles; University of Minnesota System; University of Minnesota Twin Cities; Cedars Sinai Medical Center	Wilcock, AD (corresponding author), Univ Vermont, Coll Med, Burlington, VT 05405 USA.	andrew.wilcock@med.uvm.edu	Joshi, Sushant/AAO-3906-2020	Joshi, Sushant/0000-0002-4724-6847	Agency for Healthcare Research and Quality [R01 HS024284]; National Institute of Aging [R01AG046838]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants from The Agency for Healthcare Research and Quality (R01 HS024284) and National Institute of Aging (R01AG046838) (all authors). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams JL, 2010, NEW ENGL J MED, V362, P1014, DOI 10.1056/NEJMsa0906323; Barnett ML, 2015, JAMA INTERN MED, V175, P1803, DOI 10.1001/jamainternmed.2015.4660; Calvillo-King L, 2013, J GEN INTERN MED, V28, P269, DOI 10.1007/s11606-012-2235-x; Centers for Medicare and Medicaid Services, 2019, HOSP READM RED PROGR; Centers for Medicare and Medicaid Services, 2015, 2015 PROC SPEC READM; Centers for Medicare and Medicaid Services, 2015, 2015 COND SPEC MEAS; Colquitt JA, 2001, J APPL PSYCHOL, V86, P425, DOI 10.1037//0021-9010.86.3.425; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Figueroa JF, 2016, BMJ QUAL SAF, V25, P898, DOI 10.1136/bmjqs-2015-005040; Gilman M, 2015, ANN INTERN MED, V163, P427, DOI 10.7326/M14-2813; Gu Q, 2014, HEALTH SERV RES, V49, P818, DOI 10.1111/1475-6773.12150; Gupta A, 2018, JAMA CARDIOL, V3, P44, DOI 10.1001/jamacardio.2017.4265; Hesterberg TC, 2015, AM STAT, V69, P371, DOI 10.1080/00031305.2015.1089789; Joshi S, 2019, JAMA INTERN MED, V179, P1167, DOI 10.1001/jamainternmed.2019.1004; Joynt KE, 2016, AM J MANAG CARE, V22, pE287; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Kind AJH, 2014, ANN INTERN MED, V161, P765, DOI 10.7326/M13-2946; Roberts ET, 2018, JAMA INTERN MED, V178, P1498, DOI 10.1001/jamainternmed.2018.4481; Singh S, 2014, J GEN INTERN MED, V29, P572, DOI 10.1007/s11606-013-2723-7; Tak HJ, 2019, J GEN INTERN MED, V34, P1766, DOI 10.1007/s11606-019-05115-2; Thompson MP, 2017, HEALTH AFFAIR, V36, P893, DOI 10.1377/hlthaff.2016.1204; Thompson MP, 2016, HEALTH SERV RES, V51, P2095, DOI 10.1111/1475-6773.12587	22	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2021	16	12							e0261363	10.1371/journal.pone.0261363	http://dx.doi.org/10.1371/journal.pone.0261363			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0X1HA	34932592	gold, Green Published			2023-01-03	WOS:000789464700030
J	Bijwaard, GE; Alessie, R; Angelini, V; Lumey, LH				Bijwaard, Govert E.; Alessie, Rob; Angelini, Viola; Lumey, L. H.			Physical and psychological health at adolescence and home care use later in life	PLOS ONE			English	Article							CHILDHOOD SOCIOECONOMIC-STATUS; PRENATAL FAMINE EXPOSURE; ADULT MORTALITY; EDUCATION; ORIGINS; DISEASE; MODELS	Objectives To examine the relation between physical and psychological health indicators at adolescence (age 18) and household, personal, and nursing home care use later in life at ages 57-69 years. Methods Using medical examinations on men born in 1944-1947 who were evaluated for military service at age 18 in the Netherlands, we link physical and psychological health assessments to national administrative microdata on the use of home care services at ages 57-69 years. We postulate a panel probit model for home care use over these years. In the analyses, we account for selective survival through correlated panel probit models. Results Poor mental health and being overweight at age 18 are important predictors of later life home care use. Home care use at ages 57-69 years is also highly related to and interacts with father's socioeconomic status and recruits' education at age 18. Discussion Specific health characteristics identified at age 18 are highly related to the later utilization of home-care at age 57-69 years. Some characteristics may be amenable to early life health interventions to decrease the future costs of long-term home care.	[Bijwaard, Govert E.] Univ Groningen, Netherlands Interdisciplinary Demog Inst, NIDI KNAW, Groningen, Netherlands; [Alessie, Rob; Angelini, Viola] Univ Groningen, Dept Econ Econometr & Finance, Groningen, Netherlands; [Lumey, L. H.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA	Royal Netherlands Academy of Arts & Sciences; Netherlands Interdisciplinary Demographic Institute (NIDI-KNAW); University of Groningen; University of Groningen; Columbia University	Bijwaard, GE (corresponding author), Univ Groningen, Netherlands Interdisciplinary Demog Inst, NIDI KNAW, Groningen, Netherlands.	Bijwaard@nidi.nl		Bijwaard, Govert/0000-0002-6458-1647; Alessie, Rob/0000-0002-5128-6753				Alessie RJM, 2019, SOC SCI MED, V224, P77, DOI 10.1016/j.socscimed.2019.02.006; Almond D, 2018, J ECON LIT, V56, P1360, DOI 10.1257/jel.20171164; Almond D, 2011, J ECON PERSPECT, V25, P153, DOI 10.1257/jep.25.3.153; Batty GD, 2007, ANN EPIDEMIOL, V17, P278, DOI 10.1016/j.annepidem.2006.07.010; Batty GD, 2004, BMJ-BRIT MED J, V329, P585, DOI 10.1136/bmj.329.7466.585; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; Bijwaard GE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141200; Case A, 2005, J HEALTH ECON, V24, P365, DOI 10.1016/j.jhealeco.2004.09.008; Case A, 2010, DEMOGRAPHY, V47, pS65, DOI 10.1353/dem.2010.0007; Clark D, 2013, AM ECON REV, V103, P2087, DOI 10.1257/aer.103.6.2087; Cohen S, 2010, ANN NY ACAD SCI, V1186, P37, DOI 10.1111/j.1749-6632.2009.05334.x; Conti G, 2010, PERSPECT PSYCHOL SCI, V5, P585, DOI 10.1177/1745691610383502; Currie J, 2009, J ECON LIT, V47, P87, DOI 10.1257/jel.47.1.87; Deary I, 2008, NATURE, V456, P175, DOI 10.1038/456175a; Doblhammer G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074915; Ekamper P, 2014, SOC SCI MED, V119, P232, DOI 10.1016/j.socscimed.2013.10.027; Ekamper P, 2015, AM J EPIDEMIOL, V181, P271, DOI 10.1093/aje/kwu288; Galama TJ, 2019, ECON J, V129, P338, DOI 10.1111/ecoj.12577; Portrait F, 2000, HEALTH ECON, V9, P513, DOI 10.1002/1099-1050(200009)9:6<513::AID-HEC534>3.0.CO;2-R; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Roodman D, 2011, STATA J, V11, P159, DOI 10.1177/1536867X1101100202; Stein Z., 1975, Famine and human development. The Dutch hunger winter of 1944-1945.; Swinkels JC, 2016, AGEING SOC, V36, P1870, DOI 10.1017/S0144686X1500077X; van den Berg G, 2011, DEMOGRAPHY, V48, P507, DOI 10.1007/s13524-011-0021-8; Van Den Berg GJ, 2006, AM ECON REV, V96, P290, DOI 10.1257/000282806776157740; Vasunilashorn S, 2013, J AGING HEALTH, V25, P758, DOI 10.1177/0898264313491426; Zimmer Z, 2016, DEMOGR RES, V34, P285, DOI 10.4054/DemRes.2016.34.10	27	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2021	16	12							e0261078	10.1371/journal.pone.0261078	http://dx.doi.org/10.1371/journal.pone.0261078			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY2LS	34879115	Green Published, gold			2023-01-03	WOS:000754625200049
J	Bennett, S; Tiollier, E; Brocherie, F; Owens, DJ; Morton, JP; Louis, J				Bennett, Samuel; Tiollier, Eve; Brocherie, Franck; Owens, Daniel J.; Morton, James P.; Louis, Julien			Three weeks of a home-based "sleep low-train low" intervention improves functional threshold power in trained cyclists: A feasibility study	PLOS ONE			English	Article							REDUCED CARBOHYDRATE AVAILABILITY; SKELETAL-MUSCLE ADAPTATION; FAT ADAPTATION; TRANSCRIPTIONAL REGULATION; MITOCHONDRIAL BIOGENESIS; GLYCOGEN AVAILABILITY; ATHLETIC PERFORMANCE; SIGNALING RESPONSES; EXERCISE INTENSITY; ADAPTIVE RESPONSE	Background "Sleep Low-Train Low" is a training-nutrition strategy intended to purposefully reduce muscle glycogen availability around specific exercise sessions, potentially amplifying the training stimulus via augmented cell signalling. The aim of this study was to assess the feasibility of a 3-week home-based "sleep low-train low" programme and its effects on cycling performance in trained athletes. Methods Fifty-five trained athletes (Functional Threshold Power [FTP]: 258 52W) completed a home-based cycling training program consisting of evening high-intensity training (6 x 5 min at 105% FTP), followed by low-intensity training (1 hr at 75% FTP) the next morning, three times weekly for three consecutive weeks. Participant's daily carbohydrate (CHO) intake (6 g.kg(-1).d(-1)) was matched but timed differently to manipulate CHO availability around exercise: no CHO consumption post- HIT until post-LIT sessions [Sleep Low (SL), n = 28] or CHO consumption evenly distributed throughout the day [Control (CON), n = 27]. Sessions were monitored remotely via power data uploaded to an online training platform, with performance tests conducted pre-, post-intervention. Results LIT exercise intensity reduced by 3% across week 1, 3 and 2% in week 2 (P < 0.01) with elevated RPE in SL vs. CON (P < 0.01). SL enhanced FTP by +5.5% vs. +1.2% in CON (P < 0.01). Comparable increases in 5-min peak power output (PPO) were observed between groups (P < 0.01) with +2.3% and +2.7% in SL and CON, respectively (P = 0.77). SL 1-min PPO was unchanged (+0.8%) whilst CON improved by +3.9% (P = 0.0144). Conclusion Despite reduced relative training intensity, our data demonstrate short-term "sleep low-train low" intervention improves FTP compared with typically "normal" CHO availability during exercise. Importantly, training was completed unsupervised at home (during the COVID-19 pandemic), thus demonstrating the feasibility of completing a "sleep low-train low" protocol under non-laboratory conditions.	[Bennett, Samuel; Owens, Daniel J.; Morton, James P.; Louis, Julien] Liverpool John Moores Univ, Res Inst Sport & Exercise Sci RISES, Liverpool, Merseyside, England; [Bennett, Samuel; Tiollier, Eve; Brocherie, Franck] French Inst Sport, Lab Sport Expertise & Performance EA 7370, Paris, France	Liverpool John Moores University	Louis, J (corresponding author), Liverpool John Moores Univ, Res Inst Sport & Exercise Sci RISES, Liverpool, Merseyside, England.	J.B.Louis@ljmu.ed.uk		Owens, Daniel/0000-0002-1908-8677; Bennett, Samuel/0000-0002-3588-1819; Brocherie, Franck/0000-0002-0808-7986				Allen H., 2019, TRAINING RACING POWE; Andrade-Souza VA, 2020, FASEB J, V34, P1602, DOI 10.1096/fj.201901207RR; Areta JL, 2018, SPORTS MED, V48, P2091, DOI 10.1007/s40279-018-0941-1; Bartlett JD, 2013, AM J PHYSIOL-REG I, V304, pR450, DOI 10.1152/ajpregu.00498.2012; Borg G, 2001, INT J SPORT PSYCHOL, V32, P110; Borszcz FK, 2020, INT J SPORTS MED, V41, P175, DOI 10.1055/a-1018-1965; Borszcz FK, 2018, INT J SPORTS MED, V39, P737, DOI 10.1055/s-0044-101546; Bouillod A, 2017, INT J SPORT PHYSIOL, V12, P1023, DOI 10.1123/ijspp.2016-0436; Burke LM, 2006, J APPL PHYSIOL, V100, P7, DOI 10.1152/japplphysiol.01238.2005; Burke LM, 2001, SPORTS MED, V31, P267, DOI 10.2165/00007256-200131040-00003; Burke LM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234027; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Cochran AJR, 2015, INT J SPORT NUTR EXE, V25, P463, DOI 10.1123/ijsnem.2014-0263; Cohen J., 2013, STAT POWER ANAL BEHA; Costa VP, 2019, ISOKINET EXERC SCI, V27, P55, DOI 10.3233/IES-181198; Czajkowski M., 2016, SRM DEVICE J SCI CYC, P5; De Pauw K, 2013, INT J SPORT PHYSIOL, V8, P111, DOI 10.1123/ijspp.8.2.111; Decroix L, 2016, INT J SPORT PHYSIOL, V11, P204, DOI 10.1123/ijspp.2015-0153; Denham J, 2020, J STRENGTH COND RES, V34, P3489, DOI 10.1519/JSC.0000000000002253; Duhamel TA, 2006, AM J PHYSIOL-REG I, V291, pR1100, DOI 10.1152/ajpregu.00858.2005; Fell JM, 2021, J PHYSIOL-LONDON, V599, P2823, DOI 10.1113/JP281127; Gejl KD, 2017, MED SCI SPORT EXER, V49, P2486, DOI 10.1249/MSS.0000000000001377; Gejl KD, 2014, MED SCI SPORT EXER, V46, P496, DOI 10.1249/MSS.0000000000000132; Ghiarone T, 2019, J APPL PHYSIOL, V127, P713, DOI 10.1152/japplphysiol.00060.2019; Halson SL, 2013, INT J SPORT PHYSIOL, V8, P597, DOI 10.1123/ijspp.8.6.597; Hansen AK, 2005, J APPL PHYSIOL, V98, P93, DOI 10.1152/japplphysiol.00163.2004; Hargreaves M, 1997, Exerc Sport Sci Rev, V25, P21; Havemann L, 2006, J APPL PHYSIOL, V100, P194, DOI 10.1152/japplphysiol.00813.2005; HAWLEY JA, 1992, EUR J APPL PHYSIOL, V65, P79, DOI 10.1007/BF01466278; Hawley JA, 2013, NESTLE NUTR WORKS SE, V75, P1, DOI 10.1159/000345813; Hearris MA, 2019, J APPL PHYSIOL, V126, P1587, DOI 10.1152/japplphysiol.00913.2018; Hearris MA, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030298; HOLLOSZY JO, 1970, BIOCHEM BIOPH RES CO, V40, P1368, DOI 10.1016/0006-291X(70)90017-3; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Hoon M., 2016, J SCI CYCLING, V5, P11; Hopkins WG., 2015, SPORTSCIENCE, V19, P36; Howlett RA, 1998, AM J PHYSIOL-REG I, V275, pR418, DOI 10.1152/ajpregu.1998.275.2.R418; Hulston CJ, 2010, MED SCI SPORT EXER, V42, P2046, DOI 10.1249/MSS.0b013e3181dd5070; Hurst HT., 2015, J SCI CYCLING, V4, P21; Impey SG, 2018, SPORTS MED, V48, P1031, DOI 10.1007/s40279-018-0867-7; Impey SG, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12803; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jeukendrup A E, 2000, J Sci Med Sport, V3, P414, DOI 10.1016/S1440-2440(00)80008-0; Kim J, 2014, CLIN ORTHOP SURG, V6, P103, DOI 10.4055/cios.2014.6.1.103; Lane SC, 2015, J APPL PHYSIOL, V119, P643, DOI 10.1152/japplphysiol.00857.2014; Lillo-Bevia JR, 2022, J STRENGTH COND RES, V36, P167, DOI 10.1519/JSC.0000000000003403; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lindsay FH, 1996, MED SCI SPORT EXER, V28, P1427, DOI 10.1097/00005768-199611000-00013; MacInnis MJ, 2019, INT J SPORT PHYSIOL, V14, P38, DOI 10.1123/ijspp.2018-0100; Maier T, 2017, INT J SPORTS MED, V38, P456, DOI 10.1055/s-0043-102945; Marquet LA, 2016, NUTRIENTS, V8, DOI 10.3390/nu8120755; Marquet LA, 2016, MED SCI SPORT EXER, V48, P663, DOI 10.1249/MSS.0000000000000823; McBride A, 2009, CELL METAB, V9, P23, DOI 10.1016/j.cmet.2008.11.008; McGRATH Eanna, 2019, Int J Exerc Sci, V12, P1334; Montalvo-Perez A, 2021, SENSORS-BASEL, V21, DOI 10.3390/s21072277; Morton JP, 2009, J APPL PHYSIOL, V106, P1513, DOI 10.1152/japplphysiol.00003.2009; Novak AR, 2016, MEAS PHYS EDUC EXERC, V20, P167, DOI 10.1080/1091367X.2016.1191496; Ortenblad N, 2011, J PHYSIOL-LONDON, V589, P711, DOI 10.1113/jphysiol.2010.195982; Pallares JG, 2018, J SPORT SCI MED, V17, P305; Philp A, 2012, AM J PHYSIOL-ENDOC M, V302, pE1343, DOI 10.1152/ajpendo.00004.2012; Philp A, 2011, J BIOL CHEM, V286, P30561, DOI 10.1074/jbc.M111.261685; Pilegaard H, 2005, METABOLISM, V54, P1048, DOI 10.1016/j.metabol.2005.03.008; Pilegaard H, 2004, P NUTR SOC, V63, P221, DOI 10.1079/PNS2004345; Pilegaard H, 2002, J PHYSIOL-LONDON, V541, P261, DOI 10.1113/jphysiol.2002.016832; Podlogar T, 2021, EUR J SPORT SCI, V21, P213, DOI 10.1080/17461391.2020.1730447; Polekhina G, 2005, STRUCTURE, V13, P1453, DOI 10.1016/j.str.2005.07.008; Psilander N, 2013, EUR J APPL PHYSIOL, V113, P951, DOI 10.1007/s00421-012-2504-8; Riis S, 2019, SCAND J MED SCI SPOR, V29, P1866, DOI 10.1111/sms.13541; ROMIJN JA, 1993, AM J PHYSIOL, V265, pE380, DOI 10.1152/ajpendo.1993.265.3.E380; Schneeweiss P., 2018, THE J, V7, P3, DOI DOI 10.28985/180130.JSC.02; Sorensen A, 2019, SPORTS, V7, DOI 10.3390/sports7100217; Stannard S.R., 2015, SPORTS TECHNOLOGY, V8, P44, DOI [10.1080/19346182.2015.1108979, DOI 10.1080/19346182.2015.1108979]; Starritt EC, 1999, J APPL PHYSIOL, V86, P450, DOI 10.1152/jappl.1999.86.2.450; Steinberg GR, 2006, APPL PHYSIOL NUTR ME, V31, P302, DOI 10.1139/H06-003; Stellingwerff T, 2006, AM J PHYSIOL-ENDOC M, V290, pE380, DOI 10.1152/ajpendo.00268.2005; Stellingwerff T, 2007, PFLUG ARCH EUR J PHY, V454, P635, DOI 10.1007/s00424-007-0236-0; Stellingwerff T, 2019, INT J SPORT NUTR EXE, V29, P141, DOI 10.1123/ijsnem.2018-0305; Stellingwerff T, 2012, INT J SPORT NUTR EXE, V22, P392, DOI 10.1123/ijsnem.22.5.392; Stepto NK, 2001, MED SCI SPORT EXER, V33, P303; Stocks B, 2019, AM J PHYSIOL-ENDOC M, V316, pE230, DOI 10.1152/ajpendo.00311.2018; Tanaka H, 2001, J AM COLL CARDIOL, V37, P153, DOI 10.1016/S0735-1097(00)01054-8; Teixeira V, 2018, NUTR DIET, V75, P219, DOI 10.1111/1747-0080.12401; van Loon LJC, 2001, J PHYSIOL-LONDON, V536, P295, DOI 10.1111/j.1469-7793.2001.00295.x; Wainwright B, 2017, J SPORT SCI, V35, P1451, DOI 10.1080/02640414.2016.1215495; Waterworth SP, 2020, INT J SPORT NUTR EXE, V30, P105, DOI 10.1123/ijsnem.2019-0275; Wojtaszewski JFP, 2003, AM J PHYSIOL-ENDOC M, V284, pE813, DOI 10.1152/ajpendo.00436.2002; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yeo WK, 2008, J APPL PHYSIOL, V105, P1519, DOI 10.1152/japplphysiol.90540.2008; Yeo WK, 2008, J APPL PHYSIOL, V105, P1462, DOI 10.1152/japplphysiol.90882.2008; Yeo WK, 2010, EXP PHYSIOL, V95, P351, DOI 10.1113/expphysiol.2009.049353; Zamuner AR, 2011, J SPORT SCI MED, V10, P130	93	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2021	16	12							e0260959	10.1371/journal.pone.0260959	http://dx.doi.org/10.1371/journal.pone.0260959			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW0CT	34855913	gold, Green Accepted, Green Published			2023-01-03	WOS:000735299000157
J	Berlin, I; Berlin, N; Malecot, M; Breton, M; Jusot, F; Goldzahl, L				Berlin, Ivan; Berlin, Noemi; Malecot, Marie; Breton, Martine; Jusot, Florence; Goldzahl, Leontine			Financial incentives for smoking cessation in pregnancy: multicentre randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VOUCHER-BASED INCENTIVES; CONTINGENCY MANAGEMENT; CIGARETTE-SMOKING; ABSTINENCE	OBJECTIVE To evaluate the efficacy of financial incentives dependent on continuous smoking abstinence on smoking cessation and birth outcomes among pregnant smokers. DESIGN Single blind, randomised controlled trial. SETTING Financial Incentive for Smoking Cessation in Pregnancy (FISCP) trial in 18 maternity wards in France. PARTICIPANTS 460 pregnant smokers aged at least 18 years who smoked <= 5 cigarettes/day or <= 3 roll-your-own cigarettes/day and had a pregnancy gestation of <18 weeks were randomised to a financial incentives group (n=231) or a control group (n=229). INTERVENTIONS Participants in the financial incentives group received a voucher equivalent to euro 20 (17; pound $23), and further progressively increasing vouchers at each study visit if they remained abstinent. Participants in the control group received no financial incentive for abstinence. All participants received a euro 20 show-up fee at each of six visits. MAIN OUTCOME MEASURES The main outcome measure was continuous smoking abstinence from the first post-quit date visit to visit 6, before delivery. Secondary outcomes in the mothers were point prevalence abstinence, time to smoking relapse, withdrawal symptoms, blood pressure, and alcohol and cannabis use in past 30 days. Secondary outcomes in the babies were gestational age at birth, birth characteristics (birth weight, length, head circumference, Apgar score), and a poor neonatal outcome-a composite measure of transfer to the neonatal unit, congenital malformation, convulsions, or perinatal death. RESULTS Mean age was 29 years. In the financial incentives and control groups, respectively, 137 (59%) and 148 (65%) were employed, 163 (71%) and 171 (75%) were in a relationship, and 41 (18%) and 31 (13%) were married. The participants had smoked a median of 60 cigarettes in the past seven days. The continuous abstinence rate was significantly higher in the financial incentives group (16%, 38/231) than control group (7%, 17/229): odds ratio 2.45 (95% confidence interval 1.34 to 4.49), P=0.004). The point prevalence abstinence rate was higher (4.61, 1.41 to 15.01, P=0.011), the median time to relapse was longer (visit 5 (interquartile range 3-6) and visit 4 (3-6), P<0.001)), and craving for tobacco was lower (beta=-1.81, 95% confidence interval -3.55 to -0.08, P=0.04) in the financial incentives group than control group. Financial incentives were associated with a 7% reduction in the risk of a poor neonatal outcome: 4 babies (2%) in the financial incentives group and 18 babies (9%) in the control group: mean difference 14 (95% confidence interval 5 to 23), P=0.003. Post hoc analyses suggested that more babies in the financial incentives group had birth weights >= 2500 g than in the control group: unadjusted odds ratio 1.95 (95% confidence interval 0.99 to 3.85), P=0.055; sex adjusted odds ratio 2.05 (1.03 to 4.10), P=0.041; and sex and prematurity adjusted odds ratio 2.06 (0.90 to 4.71), P=0.086. As these are post hoc analyses, the results should be interpreted with caution. CONCLUSIONS Financial incentives to reward smoking abstinence compared with no financial incentives were associated with an increased abstinence rate in pregnant smokers. Financial incentives dependent on smoking abstinence could be implemented as a safe and effective intervention to help pregnant smokers quit smoking. TRIAL REGISTRATION ClinicalTrials.gov NCT02606227.	[Berlin, Ivan] Sorbonne Univ, Hop Pitie Salpetriere, Dept Pharmacol, F-75013 Paris, France; [Berlin, Noemi] Univ Paris Nanterre, CNRS, EconomiX, Nanterre, France; [Malecot, Marie] Ctr Hosp St Joseph St Luc, Unite Addictol, Lyon, France; [Breton, Martine] CHU Morvan, Brest, France; [Jusot, Florence] PSL Res Univ, Univ Paris Dauphine, LEDa, Paris, France; [Goldzahl, Leontine] EDHEC Business Sch, Roubaix, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CHU Brest; Universite de Bretagne Occidentale; UDICE-French Research Universities; PSL Research University Paris; Universite Paris-Dauphine; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Laboratoire dEconomie de Dauphine LEDa; Universite Catholique de Lille; EDHEC Business School	Berlin, I (corresponding author), Sorbonne Univ, Hop Pitie Salpetriere, Dept Pharmacol, F-75013 Paris, France.	berlin.ivan@gmail.com		Berlin, Ivan/0000-0002-5928-5616	French National Cancer Institute (INCa) Recherche en Prevention Primaire [2014-100]	French National Cancer Institute (INCa) Recherche en Prevention Primaire	This research was funded by the French National Cancer Institute (INCa) Recherche en Prevention Primaire (grant No 2014-100). Logistic support was provided by Assistance Publique-Hopitaux de Paris, Direction a la Recherche Clinique et Innovation, Paris, France. The present paper represents the opinions of the authors and does not necessarily reflect the position of their employers. Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/and declare: no support from the French National Cancer Institute (INCa); no support from any organisation for the submitted work with the exception of LG who was supported by the study's grant and by a grant from the health chair-a joint initiative between Paris Sciences et Lettres (PSL), Universite Paris-Dauphine, l'Ecole nationale de la statistique et de l'administration economique (ENSAE), Mutuelle generale de l'Education nationale (MGEN), Universite Paris-Dauphine, and ISTYA Collectives under the aegis of the Fondation du Risque as a postdoctoral fellow. All authors declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.	[Anonymous], 2012, BORN TOO SOON GLOBAL; Berlin I, 2010, NICOTINE TOB RES, V12, P500, DOI 10.1093/ntr/ntq039; Berlin N, 2018, EUR J HEALTH ECON, V19, P697, DOI 10.1007/s10198-017-0914-6; Berlin N, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011669; Claire R, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010078.pub3; Conference de consensus, 2005, PROF SAGE FEMME, P19; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fagerstrom K, 2012, NICOTINE TOB RES, V14, P75, DOI 10.1093/ntr/ntr137; Grange G, 2020, J GYNECOL OBSTET HUM, V49, DOI 10.1016/j.jogoh.2020.101847; Heil SH, 2008, ADDICTION, V103, P1009, DOI 10.1111/j.1360-0443.2008.02237.x; Higgins ST, 2004, NICOTINE TOB RES, V6, P1015, DOI 10.1080/14622200412331324910; Higgins ST, 2014, PREV MED, V68, P51, DOI 10.1016/j.ypmed.2014.03.024; Higgins ST, 2012, PREV MED, V55, pS33, DOI 10.1016/j.ypmed.2011.12.016; Higgins ST, 2010, ADDICTION, V105, P2023, DOI 10.1111/j.1360-0443.2010.03073.x; HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289; Krist AH, 2021, JAMA-J AM MED ASSOC, V325, P265, DOI 10.1001/jama.2020.25019; National Centre for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health, 2014, HLTH CONS SMOK; Notley C, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004307.pub6; Ondersma SJ, 2012, NICOTINE TOB RES, V14, P351, DOI 10.1093/ntr/ntr221; SRNT Subcommittee on Biochemical Verification, 2002, Nicotine Tob Res, V4, P149, DOI 10.1080/14622200210123581; Tappin D, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h134; Taylor L, 2021, ADDICTION, V116, P239, DOI 10.1111/add.15185; US Centres for Disease Control and Prevention U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; Valent AM, 2020, OBSTET GYNECOL, V135, pE221, DOI 10.1097/AOG.0000000000003822; Weise A., 2012, GLOBAL NUTR TARGETS, P1	25	7	7	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 1	2021	375								065217	10.1136/bmj-2021-065217	http://dx.doi.org/10.1136/bmj-2021-065217			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ3JK	34853024	Green Published, hybrid			2023-01-03	WOS:000726688600010
J	Yarmarkovich, M; Marshall, QF; Warrington, JM; Premaratne, R; Farrel, A; Groff, D; Li, W; di Marco, M; Runbeck, E; Truong, H; Toor, JS; Tripathi, S; Nguyen, S; Shen, HA; Noel, T; Church, NL; Weiner, A; Kendsersky, N; Martinez, D; Weisberg, R; Christie, M; Eisenlohr, L; Bosse, KR; Dimitrov, DS; Stevanovic, S; Sgourakis, NG; Kiefel, BR; Maris, JM				Yarmarkovich, Mark; Marshall, Quinlen F.; Warrington, John M.; Premaratne, Rasika; Farrel, Alvin; Groff, David; Li, Wei; di Marco, Moreno; Runbeck, Erin; Truong, Hau; Toor, Jugmohit S.; Tripathi, Sarvind; Nguyen, Son; Shen, Helena; Noel, Tiffany; Church, Nicole L.; Weiner, Amber; Kendsersky, Nathan; Martinez, Dan; Weisberg, Rebecca; Christie, Molly; Eisenlohr, Laurence; Bosse, Kristopher R.; Dimitrov, Dimiter S.; Stevanovic, Stefan; Sgourakis, Nikolaos G.; Kiefel, Ben R.; Maris, John M.			Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs	NATURE			English	Article							CLINICAL-SIGNIFICANCE; PHOX2B; TOXICITY; DECONVOLUTION; EXPRESSION; PREDICTION; PROTEINS; CELLS	The majority of oncogenic drivers are intracellular proteins, thus constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes(1). However, most cancers have a modest mutational burden that is insufficient to generate responses using neoantigen-based therapies2,3. Neuroblastoma is a paediatric cancer that harbours few mutations and is instead driven by epigenetically deregulated transcriptional networks4. Here we show that the neuroblastoma immunopeptidome is enriched with peptides derived from proteins that are essential for tumourigenesis and focus on targeting the unmutated peptide QYNPIRTTF, discovered on HLA-A*24:02, which is derived from the neuroblastoma dependency gene and master transcriptional regulator PHOX2B. To target QYNPIRTTF, we developed peptide-centric chimeric antigen receptors (CARs) using a counter-panning strategy with predicted potentially cross-reactive peptides. We further hypothesized that peptide-centric CARs could recognize peptides on additional HLA allotypes when presented in a similar manner. Informed by computational modelling, we showed that PHOX2B peptide-centric CARs also recognize QYNPIRTTF presented by HLA-A*23:01 and the highly divergent HLA-B*14:02. Finally, we demonstrated potent and specific killing of neuroblastoma cells expressing these HLAs in vitro and complete tumour regression in mice. These data suggest that peptide-centric CARs have the potential to vastly expand the pool of immunotherapeutic targets to include non-immunogenic intracellular oncoproteins and widen the population of patients who would benefit from such therapy by breaking conventional HLA restriction.	[Yarmarkovich, Mark; Marshall, Quinlen F.; Warrington, John M.; Farrel, Alvin; Groff, David; Runbeck, Erin; Truong, Hau; Shen, Helena; Noel, Tiffany; Weiner, Amber; Kendsersky, Nathan; Weisberg, Rebecca; Christie, Molly; Bosse, Kristopher R.; Sgourakis, Nikolaos G.; Maris, John M.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Yarmarkovich, Mark; Marshall, Quinlen F.; Warrington, John M.; Premaratne, Rasika; Farrel, Alvin; Groff, David; Runbeck, Erin; Truong, Hau; Shen, Helena; Noel, Tiffany; Church, Nicole L.; Weiner, Amber; Kendsersky, Nathan; Weisberg, Rebecca; Christie, Molly; Bosse, Kristopher R.; Sgourakis, Nikolaos G.; Kiefel, Ben R.; Maris, John M.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA; [Premaratne, Rasika; Church, Nicole L.; Kiefel, Ben R.] Myrio Tx, Melbourne, Vic, Australia; [Farrel, Alvin] Childrens Hosp Philadelphia, Dept Biomed & Hlth Informat, Philadelphia, PA 19104 USA; [Li, Wei; Dimitrov, Dimiter S.] Univ Pittsburgh, Pittsburgh, PA USA; [di Marco, Moreno; Stevanovic, Stefan] Univ Tubingen, Tubingen, Germany; [Toor, Jugmohit S.; Tripathi, Sarvind] Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; [Nguyen, Son] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Kendsersky, Nathan; Eisenlohr, Laurence] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Bosse, Kristopher R.; Maris, John M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Eberhard Karls University of Tubingen; University of California System; University of California Santa Cruz; Massachusetts Institute of Technology (MIT); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Maris, JM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.; Maris, JM (corresponding author), Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA.; Maris, JM (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.	maris@chop.edu	Nguyen, Son/AAA-6827-2020; Tripathi, Sarvind/F-6959-2015	Nguyen, Son/0000-0002-0475-5158; Toor, Jugmohit/0000-0002-8796-8799; Tripathi, Sarvind/0000-0002-6959-0577; Marshall, Quinlen/0000-0002-4736-9716; Warrington, John/0000-0001-6066-5491	St Baldrick's Foundation-Stand Up to Cancer Dream Team Translational Research Grant [SU2C-AACR-DT-27-17]; NIH, Beau Biden Cancer Moonshot Program [U54 CA232568]; NIH [R35 CA220500, R01 AI143997, R35 GM125034]; Science Center Quod Erat Demonstrandum (QED) program at the Philadelphia Science Center; Children's Hospital of Philadelphia Cell and Gene Therapy Collaborative; Giulio D'Angio Endowed Chair; Office of Science, Office of Basic Energy Sciences [DE-AC02-05CH11231]; U.S. Department of Energy [DE-AC02-05CH11231]	St Baldrick's Foundation-Stand Up to Cancer Dream Team Translational Research Grant; NIH, Beau Biden Cancer Moonshot Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Science Center Quod Erat Demonstrandum (QED) program at the Philadelphia Science Center; Children's Hospital of Philadelphia Cell and Gene Therapy Collaborative; Giulio D'Angio Endowed Chair; Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); U.S. Department of Energy(United States Department of Energy (DOE))	This work was supported by a St Baldrick's Foundation-Stand Up to Cancer Dream Team Translational Research Grant (SU2C-AACR-DT-27-17). The St. Baldrick's Foundation collaborates with Stand Up To Cancer. Research Grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research (J.M.M.). This work was also supported by NIH grants U54 CA232568 as part of the Beau Biden Cancer Moonshot Program (J.M.M.) and NIH R35 CA220500 (J.M.M.), R01 AI143997 (N.G.S.), R35 GM125034 (N.G.S), the Science Center Quod Erat Demonstrandum (QED) program at the Philadelphia Science Center (J.M.M. and M.Y.), the Children's Hospital of Philadelphia Cell and Gene Therapy Collaborative (J.M.M. and M.Y.), and the Giulio D'Angio Endowed Chair (J.M.M.). Diffraction data for protein crystallography were collected at the Advanced Light Source, which is supported by the Director, Office of Science, Office of Basic Energy Sciences, and U.S. Department of Energy, under contract DE-AC02-05CH11231. We thank D. Canaday, A. Wolpaw, E. Hooijberg and H. Goldstein for providing reagents. BioRender.com was used in generating figures.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alvarez B, 2019, MOL CELL PROTEOMICS, V18, P2459, DOI 10.1074/mcp.TIR119.001658; Andreatta M, 2013, BIOINFORMATICS, V29, P8, DOI 10.1093/bioinformatics/bts621; Asgharzadeh S, 2012, J CLIN ONCOL, V30, P3525, DOI 10.1200/JCO.2011.40.9169; Bassani-Sternberg M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13404; Beasley MD, 2015, BIOTECHNOL J, V10, P783, DOI 10.1002/biot.201400560; Burr ML, 2019, CANCER CELL, V36, P385, DOI 10.1016/j.ccell.2019.08.008; Canaday David H, 2013, Methods Mol Biol, V960, P297, DOI 10.1007/978-1-62703-218-6_22; Cardoso-Moreira M, 2019, NATURE, V571, P505, DOI 10.1038/s41586-019-1338-5; Chen WZ, 2010, ANTIVIR RES, V88, P107, DOI 10.1016/j.antiviral.2010.08.004; Cole DK, 2016, J CLIN INVEST, V126, P2191, DOI 10.1172/JCI85679; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Dharia NV, 2021, NAT GENET, V53, P529, DOI 10.1038/s41588-021-00819-w; Dolton G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01378; Douglass J, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abd5515; Durbin AD, 2018, NAT GENET, V50, P1240, DOI 10.1038/s41588-018-0191-z; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Freudenmann LK, 2018, IMMUNOLOGY, V154, P331, DOI 10.1111/imm.12936; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Hata JL, 2015, ARCH PATHOL LAB MED, V139, P543, DOI 10.5858/arpa.2014-0255-OA; HSIUE EHC, 2021, SCIENCE; Kowalewski Daniel J, 2013, Methods Mol Biol, V960, P145, DOI 10.1007/978-1-62703-218-6_12; Kunert A, 2017, CLIN CANCER RES, V23, P6012, DOI 10.1158/1078-0432.CCR-17-1012; Lee NH, 2016, CANCER RES TREAT, V48, P1399, DOI 10.4143/crt.2015.481; Leko V, 2020, CANCER CELL, V38, P454, DOI 10.1016/j.ccell.2020.07.013; Linette GP, 2013, BLOOD, V122, P863, DOI 10.1182/blood-2013-03-490565; Ma XT, 2018, NATURE, V555, P371, DOI 10.1038/nature25795; Maccari G, 2017, NUCLEIC ACIDS RES, V45, pD860, DOI 10.1093/nar/gkw1050; Majzner RG, 2019, NAT MED, V25, P1341, DOI 10.1038/s41591-019-0564-6; Marachelian A, 2017, CLIN CANCER RES, V23, P5374, DOI 10.1158/1078-0432.CCR-16-2647; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Maus MV, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.23; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038; Morgan RA, 2013, J IMMUNOTHER, V36, P133, DOI 10.1097/CJI.0b013e3182829903; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Nerli Santrupti, 2020, Front Med Technol, V2, P553478, DOI 10.3389/fmedt.2020.553478; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Overall SA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15710-1; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Pearlman AH, 2021, NAT CANCER, V2, P487, DOI 10.1038/s43018-021-00210-y; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Raabe EH, 2008, ONCOGENE, V27, P469, DOI 10.1038/sj.onc.1210659; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Rokita JL, 2019, CELL REP, V29, P1675, DOI 10.1016/j.celrep.2019.09.071; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Shao WG, 2020, METHODS MOL BIOL, V2120, P173, DOI 10.1007/978-1-0716-0327-7_12; Shao WG, 2018, NUCLEIC ACIDS RES, V46, pD1237, DOI 10.1093/nar/gkx664; Shimizu A, 2013, SCI REP-UK, V3, DOI 10.1038/srep03097; Studier FW, 2014, METHODS MOL BIOL, V1091, P17, DOI 10.1007/978-1-62703-691-7_2; Toor JS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00099; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Wang L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13515-5; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Yang S, 2008, GENE THER, V15, P1411, DOI 10.1038/gt.2008.90; Yarmarkovich M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00069; Yossef R, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122467; Zhang MY, 2009, METHODS MOL BIOL, V562, P143, DOI 10.1007/978-1-60327-302-2_11; Zhu Zhongyu, 2009, V525, P129, DOI 10.1007/978-1-59745-554-1_6	64	30	30	11	44	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 18	2021	599	7885					477	+		10.1038/s41586-021-04061-6	http://dx.doi.org/10.1038/s41586-021-04061-6		NOV 2021	37	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ6DP	34732890	hybrid, Green Published, Green Submitted			2023-01-03	WOS:000714340500010
J	Kelly, BJ; Williams, BR; Gravely, AA; Schwanz, K; Sechriest, VF				Kelly, Brandon J.; Williams, Benjamin R.; Gravely, Amy A.; Schwanz, Kersten; Sechriest, V. Franklin, II			Femoral head collapse after hip intra-articular corticosteroid injection: An institutional response to improve practice and increase patient safety	PLOS ONE			English	Article							SUBCHONDRAL INSUFFICIENCY FRACTURE; ONSET	Introduction Femoral head collapse (FHC) is a rarely reported complication of hip intra-articular corticosteroid injection (IACSI). Upon observing a high rate of FHC after hip IACSI, we sought to (1) describe how we addressed the problem through a systematic evaluation of clinical data and institutional care practices followed by process improvement efforts; and (2) report our results. Methods Patients receiving hip IACSI during a 27-month period underwent retrospective review to determine the rate of FHC and to identify associated patient factors or practice shortfalls. Findings led to institution-wide interventions: (1) to improve patient/provider awareness of this association; and (2) to develop/implement practice guidelines. Rates of FHC after hip IACSI and practice patterns among providers before and after intervention were compared. Results Initial FHC rate after hip IACSI was 20.4%. Patient-related factors included body mass index (p = 0.025), history of cancer therapy (p = 0.012), Vitamin D level (p = 0.030), and multiple injections (p = 0.004). Volume/dose of injectate and post-injection surveillance methods varied widely. Quality improvement (QI) intervention resulted in fewer treatment referrals (from 851 to 436), fewer repeat injections (mean = 1.61 to 1.37; p = 0.0006), and a 5% lower FHC rate (p = 0.1292). Variation in practice patterns persisted, so a systems-based Clinical Pathway was established. Discussion When a high rate of FHC after hip IACSI was found to be associated with certain patient and practice factors, introduction of education materials and treatment guidelines decreased number of referrals, number of injections per patient, and FHC rate. In the absence of the systems-based Pathway, the type, dose, and volume of injectate and post-procedure follow-up remained variable.	[Kelly, Brandon J.; Williams, Benjamin R.; Sechriest, V. Franklin, II] Univ Minnesota, Dept Orthoped Surg, Minneapolis, MN 55455 USA; [Gravely, Amy A.] Vet Affairs Med Ctr, Dept Res Serv, Minneapolis, MN USA; [Schwanz, Kersten] Univ Minnesota, Dept Phys Med Rehabil, Minneapolis, MN USA; [Sechriest, V. Franklin, II] Vet Affairs Med Ctr, Dept Orthopaed Surg, Minneapolis, MN 55417 USA	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Sechriest, VF (corresponding author), Univ Minnesota, Dept Orthoped Surg, Minneapolis, MN 55455 USA.; Sechriest, VF (corresponding author), Vet Affairs Med Ctr, Dept Orthopaed Surg, Minneapolis, MN 55417 USA.	Vernon.Sechriest@va.gov						Al-Omari AA, 2020, EUR J ORTHOP SURG TR, V30, P193, DOI 10.1007/s00590-019-02555-8; Anderson PA, 2019, J BONE JOINT SURG AM, V101, P1413, DOI 10.2106/JBJS.18.01229; Beck M, 2004, CLIN ORTHOP RELAT R, P149, DOI 10.1097/01.blo.0000128296.28666.35; Braun HJ, 2012, KNEE SURG SPORT TR A, V20, P1689, DOI 10.1007/s00167-011-1728-1; Dragoo JL, 2012, KNEE SURG SPORT TR A, V20, P1809, DOI 10.1007/s00167-011-1820-6; Farkas B, 2010, CLIN ORTHOP RELAT R, V468, P3112, DOI 10.1007/s11999-010-1443-0; Kassam AM., 2010, BMJ CASE REP, P1; Kompel AJ, 2019, RADIOLOGY, V293, P656, DOI 10.1148/radiol.2019190341; Kreuz PC, 2018, KNEE SURG SPORT TR A, V26, P819, DOI 10.1007/s00167-017-4470-5; MacMahon PJ, 2009, RADIOLOGY, V252, P647, DOI 10.1148/radiol.2523081929; McCabe PS, 2016, OSTEOARTHR CARTILAGE, V24, P1509, DOI 10.1016/j.joca.2016.04.018; Ottanelli S, 2015, CLIN CASES MINER BON, V12, P116, DOI 10.11138/ccmbm/2015.12.2.116; Quinn RH, 2018, J AM ACAD ORTHOP SUR, V26, pE434, DOI 10.5435/JAAOS-D-18-00351; Schairer WW, 2016, J ARTHROPLASTY, V31, pS166, DOI 10.1016/j.arth.2016.04.008; Simeone FJ, 2019, SKELETAL RADIOL, V48, P1417, DOI 10.1007/s00256-019-03189-x; Syed HM, 2011, CLIN ORTHOP RELAT R, V469, P2941, DOI 10.1007/s11999-011-1834-x; Thompson AR, 2020, AM J PHYS MED REHAB, V99, pE54, DOI 10.1097/PHM.0000000000001202; Tran EY, 2017, JBJS REV, V5, DOI 10.2106/JBJS.RVW.16.00084; Wernecke C, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115581163; Wissing MD, 2015, CURR OSTEOPOROS REP, V13, P140, DOI 10.1007/s11914-015-0266-z; Yamamoto T, 2000, SKELETAL RADIOL, V29, P40, DOI 10.1007/s002560050007; Yamamoto T, 1999, ARTHRITIS RHEUM-US, V42, P2719, DOI 10.1002/1529-0131(199912)42:12<2719::AID-ANR31>3.0.CO;2-X; Yamamoto T, 2006, J RHEUMATOL, V33, P1701; Yamamoto T, 2014, ARCH ORTHOP TRAUM SU, V134, P1199, DOI 10.1007/s00402-014-2044-2; Yen Chi-Hung, 2009, J Orthop Surg Res, V4, P8, DOI 10.1186/1749-799X-4-8	25	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2021	16	11							e0259242	10.1371/journal.pone.0259242	http://dx.doi.org/10.1371/journal.pone.0259242			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8OO	34727125	gold, Green Published			2023-01-03	WOS:000755045200017
J	Cavanaugh, SM; Cavanaugh, RP; Gilbert, GE; Leavitt, EL; Ketzis, JK; Vieira, AB				Cavanaugh, Sarah M.; Cavanaugh, Ryan P.; Gilbert, Gregory E.; Leavitt, Elena L.; Ketzis, Jennifer K.; Vieira, Aline B.			Short-term amino acid, clinicopathologic, and echocardiographic findings in healthy dogs fed a commercial plant-based diet	PLOS ONE			English	Article							WHOLE-BLOOD TAURINE; DILATED CARDIOMYOPATHY; FECAL CHARACTERISTICS; DIGESTIBILITY; DEFICIENCY; DECREASES; PLASMA; VEGETABLES; RISK	Consumer demand for commercially prepared plant-based (PB) dog food is increasing, but studies evaluating the short- or long-term effects of PB diets on canine health are lacking. The objective of this study was to assess the short-term amino acid (AA), clinicopathologic, and echocardiographic findings in 34 client-owned dogs fed a commercial extruded plant-based diet (PBD) in which pea protein was the primary protein source and 4 control dogs fed a commercial extruded traditional diet (TD). Plasma AA and whole blood taurine concentrations were measured in dogs at baseline and after 4 weeks on the PBD or the TD. Hematologic, serum biochemical, and echocardiographic testing were performed at baseline and after 12 weeks on the PBD or the TD. Four dogs in the PBD group did not complete the study. All essential AAs, except methionine, were higher in dogs after 4 weeks on the PBD compared to baseline. Taurine (plasma and whole blood) was also higher after 4 weeks on the PBD compared to baseline. A meaningful difference was detected in whole blood taurine between the PBD group and the control group at 4 weeks (P =.026) with the PBD group being higher. Median hematologic and biochemical results for the PBD group were within normal limits at baseline and at 12 weeks. In the PBD group, left ventricular internal diastolic dimension (LVIDd, P = <.001) and normalized LVIDd (P =.031) were higher 12 weeks post-PBD compared to baseline. There were no meaningful differences in left ventricular internal systolic dimension (LVIDs), normalized LVIDs, or fractional shortening 12 weeks post-PBD. There was no statistical evidence of difference between the 2 groups of dogs for any of the echocardiographic parameters at baseline or at 12 weeks. Essential AA or taurine deficiency was not observed in this cohort of dogs fed a commercial extruded PBD. Additionally, clinically relevant hematologic, serum biochemical and echocardiographic alterations were not detected. Further research is required to determine if longterm static feeding of PB diets can meet and maintain AA and other nutrient targets in dogs.	[Cavanaugh, Sarah M.; Cavanaugh, Ryan P.; Leavitt, Elena L.] Ross Univ, Sch Vet Med, Dept Clin Sci, West Farm, Basseterre, St Kitts & Nevi; [Gilbert, Gregory E.] Adtalem Global Educ, Downers Grove, IL USA; [Gilbert, Gregory E.] Ross Univ, Ctr Teaching & Learning, Sch Med, Roseau, Dominica; [Ketzis, Jennifer K.; Vieira, Aline B.] Ross Univ, Sch Vet Med, Dept Biomed Sci, West Farm, Basseterre, St Kitts & Nevi; [Gilbert, Gregory E.] Igma Tats Consulting LLC, Charleston, SC USA; [Gilbert, Gregory E.] ICON Plc, N Wales, PA USA; [Leavitt, Elena L.] Univ Missouri, Vet Hlth Ctr, Columbia, MO USA	ICON plc; University of Missouri System; University of Missouri Columbia	Cavanaugh, SM (corresponding author), Ross Univ, Sch Vet Med, Dept Clin Sci, West Farm, Basseterre, St Kitts & Nevi.	sacvanaugh@rossvet.edu.kn	Cavanaugh, Ryan Patrick/E-1202-2018	Cavanaugh, Ryan Patrick/0000-0002-1064-3785; Cavanaugh, Sarah/0000-0003-0406-2631	Ross University School of Veterinary Medicine (RUSVM) [42001-2019]	Ross University School of Veterinary Medicine (RUSVM)	This study was funded by an intramural grant (42001-2019) from Ross University School of Veterinary Medicine (RUSVM) (https://veterinary.rossu.edu).SC, RC, JK, and AV are employed by RUSVM. EL was a student at RUSVM from 2017 to 2020. GG was employed by Adtalem Global Education and Ross University School of Medicine at the time this study was performed (2018). GG is currently employed by ICON plc and SigmaStats Consulting, LLC. Funders provided support in the form of salaries for authors (SC, RC, JK, AV, GG), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section. The plant-based dog food used in this study was donated by the manufacturer at the request of the first author (SC). The traditional dog food used in this study was purchased by the dog owners. The pet food manufacturers had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adin D, 2021, J VET INTERN MED, V35, P771, DOI 10.1111/jvim.16075; Adin D, 2019, J VET CARDIOL, V21, P1, DOI 10.1016/j.jvc.2018.11.002; Association of American Feed Control Officials (AAFCO), 2019, AAFCO DOG CAT FOOD F; Backus RC, 2003, J AM VET MED ASSOC, V223, P1130, DOI 10.2460/javma.2003.223.1130; Beloshapka AN, 2016, J ANIM SCI, V94, P3826, DOI 10.2527/jas.2016-0449; Cargo-Froom CL, 2019, J ANIM SCI, V97, P1010, DOI 10.1093/jas/skz001; Clapper GM, 2001, J ANIM SCI, V79, P1523; Cornell CC, 2004, J VET INTERN MED, V18, P311, DOI 10.1892/0891-6640(2004)18&lt;311:ASOMCM&gt;2.0.CO;2; Craddock JC, 2019, ADV NUTR, V10, P433, DOI 10.1093/advances/nmy103; de Godoy MRC, 2014, J NUTR SCI, V3, DOI 10.1017/jns.2014.46; Delaney SJ, 2003, J ANIM PHYSIOL AN N, V87, P236, DOI 10.1046/j.1439-0396.2003.00433.x; Dinu M, 2017, CRIT REV FOOD SCI, V57, P3640, DOI 10.1080/10408398.2016.1138447; Dodd SAS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210806; Dodd SAS, 2018, JAVMA-J AM VET MED A, V253, P1425, DOI 10.2460/javma.253.11.1425; Donadelli RA, 2019, POULTRY SCI, V98, P1371, DOI 10.3382/ps/pey462; Dukes-McEwan J, 2002, VET RADIOL ULTRASOUN, V43, P144, DOI 10.1111/j.1740-8261.2002.tb01662.x; Eichelmann F, 2016, OBES REV, V17, P1067, DOI 10.1111/obr.12439; Fascetti AJ, 2003, J AM VET MED ASSOC, V223, P1137, DOI 10.2460/javma.2003.223.1137; Fascetti AJ., 2012, APPL VET CLIN NUTR, P681; Fernstrom JD., 1979, AM J CLIN NUTR, P1012; Freeman LM, 2018, JAVMA-J AM VET MED A, V253, P1390, DOI 10.2460/javma.253.11.1390; Gallagher A., 2017, TXB VET INTERNAL MED, V8, P158; Golder C, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10030541; Graham PA., 2017, TXB VET INTERNAL MED, V8th ed., P283; Gray K, 2016, J ANIM PHYSIOL AN N, V100, P532, DOI 10.1111/jpn.12378; Heilberg IP, 2013, ADV CHRONIC KIDNEY D, V20, P165, DOI 10.1053/j.ackd.2012.12.001; Kaplan JL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209112; Kempe R, 2004, AGR FOOD SCI, V13, P5, DOI 10.2137/1239099041838067; Knight A, 2016, ANIMALS, V6, DOI 10.3390/ani6090057; Ko Kwang Suk, 2016, Journal of Animal Science and Technology, V58, P29, DOI 10.1186/s40781-016-0112-6; Mansilla WD, 2020, J ANIM SCI, V98, DOI 10.1093/jas/skaa324; Maria APJ, 2017, J ANIM SCI, V95, P2452, DOI 10.2527/jas.2016.1302; Meschi T, 2004, KIDNEY INT, V66, P2402, DOI 10.1111/j.1523-1755.2004.66029.x; Nizami HL, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201900109; Qian F, 2019, JAMA INTERN MED, V179, P1335, DOI 10.1001/jamainternmed.2019.2195; Reilly LM, 2020, TRANSL ANIM SCI, V4, DOI 10.1093/tas/txaa133; Reilly LM, 2020, J ANIM SCI, V98, DOI 10.1093/jas/skaa149; Sorensen MD, 2014, J UROLOGY, V192, P1694, DOI 10.1016/j.juro.2014.05.086; Stratton-Phelps M, 2002, J NUTR, V132, p1745S, DOI 10.1093/jn/132.6.1745S; Thatcher CD., 2010, SMALL ANIMAL CLIN NU, V5th ed., P3; Thompson DK, 2012, METABOLOMICS, V8, P556, DOI 10.1007/s11306-011-0345-9; Torres CL, 2004, VET CLIN PATH, V33, P228, DOI 10.1111/j.1939-165X.2004.tb00378.x; Torres CL, 2003, J ANIM PHYSIOL AN N, V87, P359, DOI 10.1046/j.1439-0396.2003.00446.x; United States Food and Drug Administration, 2019, FDA INV POT LINK CER; Wakefield LA, 2006, JAVMA-J AM VET MED A, V229, P70, DOI 10.2460/javma.229.1.70; Walker AL, 2022, J VET CARDIOL, V40, P99, DOI 10.1016/j.jvc.2021.02.001; Willard MD., 2017, TXB VET INTERNAL MED, V8, P164; Zurbau A, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017728	48	0	0	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2021	16	10							e0258044	10.1371/journal.pone.0258044	http://dx.doi.org/10.1371/journal.pone.0258044			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7ZF	34637461	gold, Green Published			2023-01-03	WOS:000755690100010
J	Thomas, NE; Feng, W; Henzler-Wildman, KA				Thomas, Nathan E.; Feng, Wei; Henzler-Wildman, Katherine A.			A solid-supported membrane electrophysiology assay for efficient characterization of ion-coupled transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; PHOSPHOLIPID-BILAYERS; STOICHIOMETRY; BINDING; PERMEATION; EXCHANGER; KINETICS; HOMOLOG	Transport stoichiometry determination can provide great insight into the mechanism and function of ion-coupled transporters. Traditional reversal potential assays are a reliable, general method for determining the transport stoichiometry of ion-coupled transporters, but the time and material costs of this technique hinder investigations of transporter behavior under multiple experimental conditions. Solid supported membrane electrophysiology (SSME) allows multiple recordings of liposomal or membrane samples adsorbed onto a sensor and is sensitive enough to detect transport currents from moderate -flux transporters that are inaccessible to traditional electrophysiology techniques. Here, we use SSME to develop a new method for measuring transport stoichiometry with greatly improved throughput. Using this technique, we were able to verify the recent report of a fixed 2:1 stoichiometry for the proton:guanidinium antiporter Gdx, reproduce the 1H(+):2Cl(-) antiport stoichiometry of CLC-ec1, and confirm loose proton:nitrate coupling for CLC-ec1. Furthermore, we were able to demonstrate quantitative exchange of internal contents of liposomes adsorbed onto SSME sensors to allow multiple experimental conditions to be tested on a single sample. Our SSME method provides a fast, easy, general method for measuring transport stoichiometry, which will facilitate future mechanistic and functional studies of ion-coupled transporters.	[Thomas, Nathan E.; Henzler-Wildman, Katherine A.] Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53705 USA; [Feng, Wei] Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	University of Wisconsin System; University of Wisconsin Madison; Stanford University	Henzler-Wildman, KA (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53705 USA.	henzlerwildm@wisc.edu			National Institutes of Health [1R01GM095839]; NIH National Research Service Award [T32 GM007215]; Stanford Bridge Funding	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stanford Bridge Funding	Funding was provided by National Institutes of Health Grant 1R01GM095839 (N. E. T. and K. A. H.-W.) , NIH National Research Service Award T32 GM007215 (N. E. T.) , and Stanford Bridge Funding (W. F.) . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Accardi A, 2006, J MOL BIOL, V362, P691, DOI 10.1016/j.jmb.2006.07.081; Bazzone A, 2017, BIOPHYS J, V113, P2736, DOI 10.1016/j.bpj.2017.09.038; Bazzone A, 2017, METHOD ENZYMOL, V594, P31, DOI 10.1016/bs.mie.2017.05.008; Bazzone A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156392; Bozzi AT, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2021.166991; Bozzi AT, 2019, J GEN PHYSIOL, V151, P1413, DOI 10.1085/jgp.201912428; Bozzi AT, 2019, ELIFE, V8, DOI 10.7554/eLife.41124; Burtscher V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215365; Calinescu O, 2016, J BIOL CHEM, V291, P26786, DOI 10.1074/jbc.M116.761080; Calinescu O, 2014, J BIOL CHEM, V289, P13168, DOI 10.1074/jbc.M113.542993; Chavan TS, 2020, ELIFE, V9, DOI 10.7554/eLife.53479; Coady MJ, 1996, J MEMBRANE BIOL, V149, P1, DOI 10.1007/s002329900001; Fitzgerald GA, 2017, ELIFE, V6, DOI 10.7554/eLife.21016.001; FUKUHARA Y, 1984, BIOCHIM BIOPHYS ACTA, V770, P73, DOI 10.1016/0005-2736(84)90075-0; Garcia-Celma J, 2013, J GEN PHYSIOL, V141, P479, DOI 10.1085/jgp.201210927; Garcia-Celma JJ, 2009, P NATL ACAD SCI USA, V106, P7373, DOI 10.1073/pnas.0902471106; Garibsingh RAA, 2019, TRENDS PHARMACOL SCI, V40, P790, DOI 10.1016/j.tips.2019.08.006; Grabe M, 2020, J GEN PHYSIOL, V152, DOI 10.1085/jgp.201912467; Groeneveld M, 2010, BIOCHEMISTRY-US, V49, P3511, DOI 10.1021/bi100430s; Guskov A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13420; Henderson RK, 2019, CURR OPIN BIOTECH, V58, P62, DOI 10.1016/j.copbio.2018.11.005; Hill TL, 1989, FREE ENERGY TRANSDUC; Hille B., 2001, ION CHANNELS EXCITAB, DOI 10.1007/978-94-009-7755-6_30; Hussey GA, 2020, J GEN PHYSIOL, V152, DOI 10.1085/jgp.201912437; Jiang T, 2016, J AM CHEM SOC, V138, P3066, DOI 10.1021/jacs.5b12062; Kang TM, 2004, NATURE, V427, P544, DOI 10.1038/nature02271; Kermani AA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19820-8; Kermani AA, 2018, P NATL ACAD SCI USA, V115, P3060, DOI 10.1073/pnas.1719187115; LAPOINTE JY, 1986, J MEMBRANE BIOL, V93, P205, DOI 10.1007/BF01871175; Li Z, 2015, J BIOL CHEM, V290, P127, DOI 10.1074/jbc.M114.584383; Lin L, 2015, NAT REV DRUG DISCOV, V14, P543, DOI 10.1038/nrd4626; Mulligan C, 2014, J GEN PHYSIOL, V143, P745, DOI 10.1085/jgp.201311141; Nguitragool W, 2006, J MOL BIOL, V362, P682, DOI 10.1016/j.jmb.2006.07.006; Parker JL, 2014, ELIFE, V3, DOI 10.7554/eLife.04273; Paula S, 1996, BIOPHYS J, V70, P339, DOI 10.1016/S0006-3495(96)79575-9; Paula S, 1998, BIOPHYS J, V74, P319, DOI 10.1016/S0006-3495(98)77789-6; Piscitelli CL, 2010, NATURE, V468, P1129, DOI 10.1038/nature09581; Quick M, 2018, P NATL ACAD SCI USA, V115, pE7924, DOI 10.1073/pnas.1717444115; Ravera S, 2007, AM J PHYSIOL-CELL PH, V293, pC606, DOI 10.1152/ajpcell.00064.2007; Robinson AE, 2017, P NATL ACAD SCI USA, V114, pE10083, DOI 10.1073/pnas.1708671114; Sacher A, 2001, J EXP BIOL, V204, P1053; Schulz P, 2009, BIOPHYS J, V97, P388, DOI 10.1016/j.bpj.2009.04.022; Schulz P, 2008, METHODS, V46, P97, DOI 10.1016/j.ymeth.2008.07.002; Schwartz JW, 2005, J BIOL CHEM, V280, P19177, DOI 10.1074/jbc.M412923200; Shao XM, 2014, BMC BIOPHYS, V7, DOI 10.1186/s13628-014-0014-2; TURNER RJ, 1982, J MEMBRANE BIOL, V67, P73, DOI 10.1007/BF01868649; Walden M, 2007, J GEN PHYSIOL, V129, P317, DOI 10.1085/jgp.200709756; Wang Z, 2018, J AM CHEM SOC, V140, P16535, DOI 10.1021/jacs.8b07614; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	51	0	0	3	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT	2021	297	4							101220	10.1016/j.jbc.2021.101220	http://dx.doi.org/10.1016/j.jbc.2021.101220			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP4JL	34562455	gold, Green Published			2023-01-03	WOS:000713100100009
J	Meng, J; Lv, ZY; Guo, MM; Sun, CX; Li, XP; Jiang, ZG; Zhang, WC; Chen, C				Meng, Jiao; Lv, Zhenyu; Guo, Miaomiao; Sun, Chuanxin; Li, Xiaopeng; Jiang, Zhenguo; Zhang, Wanchang; Chen, Chang			A Lycium barbarum extract inhibits beta-amyloid toxicity by activating the antioxidant system and mtUPR in a Caenorhabditis elegans model of Alzheimer's disease	FASEB JOURNAL			English	Article						Alzheimer's disease; antioxidant activity; A beta; Lycium barbarum extract; mtUPR	UNFOLDED PROTEIN RESPONSE; A-BETA; PEPTIDE; PROTEOSTASIS; CAPACITY; STRESS; GENES	Lycium barbarum, a traditional Chinese medicine, has been shown to have antioxidant properties and has a protective effect in many diseases related to oxidative stress, such as neurodegenerative diseases, cardiovascular diseases, and cancer. Although the neuroprotective effects of L. barbarum extract (LBE) have been reported in several studies, the underlying molecular mechanisms are still unclear. In this study, the transgenic Caenorhabditis elegans strain CL2006 was used to investigate the function and molecular mechanism of an LBE in Alzheimer's disease (AD). LBE had high antioxidant potential and effectively delayed A beta-induced paralysis in the CL2006 strain. LBE inhibited the production of excessive reactive oxygen species by inducing the SKN-1-mediated antioxidant system, thereby inhibiting the generation of A beta and inhibiting mitochondrial damage. Importantly, LBE reduced A beta levels by inducing FSHR-1-mediated activation of the mtUPR. Therefore, our study not only reveals a new mechanism of LBE in the treatment of AD but also identifies a novel strategy for the treatment of AD by enhancing the mtUPR.	[Meng, Jiao; Lv, Zhenyu; Guo, Miaomiao; Sun, Chuanxin; Li, Xiaopeng; Chen, Chang] Chinese Acad Sci, CAS Ctr Excellence Biomacromol, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; [Lv, Zhenyu; Guo, Miaomiao; Chen, Chang] Univ Chinese Acad Sci, Beijing, Peoples R China; [Jiang, Zhenguo; Zhang, Wanchang] Hosp Tradit Chinese Med Zhongning Cty, Yinchuan, Ningxia, Peoples R China; [Chen, Chang] Capital Med Univ, Beijing Inst Brain Disorders, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Capital Medical University	Chen, C (corresponding author), Chinese Acad Sci, CAS Ctr Excellence Biomacromol, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.	changchen@moon.ibp.ac.cn		Meng, Jiao/0000-0001-9645-758X	National Key R&D Program of China [2017YFA0504000]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB39000000]; Ningxia Key Research and Development Program Grant [2016BZ05]; Regional key projects of science and technology service network plan (STS plan) of Chinese Academy of Sciences [KFJ-STS-QYZD-181]; National Natural Science Foundation of China-Key program project [91849203]	National Key R&D Program of China; Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); Ningxia Key Research and Development Program Grant; Regional key projects of science and technology service network plan (STS plan) of Chinese Academy of Sciences; National Natural Science Foundation of China-Key program project	This research was financially supported by National Key R&D Program of China (Grant No. 2017YFA0504000), Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDB39000000), Ningxia Key Research and Development Program Grant (Grant No. 2016BZ05), Regional key projects of science and technology service network plan (STS plan) of Chinese Academy of Sciences (Grant No. KFJ-STS-QYZD-181), National Natural Science Foundation of China-Key program project (Grant No. 91849203)	Beck JS, 2016, CURR ALZHEIMER RES, V13, P610, DOI 10.2174/1567205013666151221145445; Benzie IFF, 1999, METHOD ENZYMOL, V299, P15; Bull K, 2007, INT J PARASITOL, V37, P627, DOI 10.1016/j.ijpara.2006.10.013; Cai ZY, 2011, NEUROMOL MED, V13, P223, DOI 10.1007/s12017-011-8155-9; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen WW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088076; Cheng J, 2015, DRUG DES DEV THER, V9, P33, DOI [10.2147/DDDT.572892, 10.2147/DDDT.S72892]; Ewald CY, 2010, BRAIN STRUCT FUNCT, V214, P263, DOI 10.1007/s00429-009-0235-3; Gao K, 2015, MOLECULES, V20, P293, DOI 10.3390/molecules20010293; GRAY EG, 1987, NEUROPATH APPL NEURO, V13, P91, DOI 10.1111/j.1365-2990.1987.tb00174.x; Haque R, 2018, ADV BIOTECHNOL MICRO, V11; Hu XY, 2018, MOL MED REP, V17, P3599, DOI 10.3892/mmr.2017.8310; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kim HY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9997; Kim S, 2020, GENETICS, V214, P409, DOI 10.1534/genetics.119.302947; LINK CD, 1995, P NATL ACAD SCI USA, V92, P9368, DOI 10.1073/pnas.92.20.9368; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066; Meng J, 2021, ANTIOXID REDOX SIGN, V34, P1069, DOI 10.1089/ars.2020.8212; Meng J, 2020, FASEB J, V34, P11460, DOI 10.1096/fj.202000136R; [孟姣 Meng Jiao], 2018, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V29, P2489; Meng J, 2017, REDOX BIOL, V11, P365, DOI 10.1016/j.redox.2016.12.026; Price DL, 1998, NAT GENET, V19, P314, DOI 10.1038/1196; Rebolledo DL, 2011, J NEUROSCI, V31, P10149, DOI 10.1523/JNEUROSCI.0336-11.2011; Scheper W, 2011, AUTOPHAGY, V7, P910, DOI 10.4161/auto.7.8.15761; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shen Y, 2020, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00568; Singh SK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7361613; Skovronsky DM, 2006, ANNU REV PATHOL-MECH, V1, P151, DOI 10.1146/annurev.pathol.1.110304.100113; Sorrentino V, 2017, NATURE, V552, P187, DOI 10.1038/nature25143; van Marum RJ, 2008, FUND CLIN PHARMACOL, V22, P265, DOI 10.1111/j.1472-8206.2008.00578.x; Wang HB, 2013, EUR REV MED PHARMACO, V17, P2760; Yoneda T, 2004, J CELL SCI, V117, P4055, DOI 10.1242/jcs.01275; Yu MS, 2007, INT J MOL MED, V20, P261; Yu MS, 2005, EXP GERONTOL, V40, P716, DOI 10.1016/j.exger.2005.06.010; Zhang QL, 2013, EXP THER MED, V5, P1528, DOI 10.3892/etm.2013.1006; Zhou XL, 2014, NUCLEIC ACIDS RES, V42, P13873, DOI 10.1093/nar/gku1218; Zhou Y, 2020, INT J BIOL MACROMOL, V144, P1004, DOI 10.1016/j.ijbiomac.2019.09.177	38	5	5	7	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2022	36	2							e22156	10.1096/fj.202101116RR	http://dx.doi.org/10.1096/fj.202101116RR			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YO5NJ	35044707				2023-01-03	WOS:000747987800020
J	Lunsmann, BJ; Polotzek, K; Kleber, C; Gebler, R; Bierbaum, V; Walther, F; Baum, F; Juncken, K; Forkert, C; Lange, T; Held, HC; Mogwitz, A; Weidemann, RR; Sedlmayr, M; Lakowa, N; Stehr, SN; Albrecht, M; Karschau, J; Schmitt, J				Luensmann, Benedict J.; Polotzek, Katja; Kleber, Christian; Gebler, Richard; Bierbaum, Veronika; Walther, Felix; Baum, Fabian; Juncken, Kathleen; Forkert, Christoph; Lange, Toni; Held, Hanns-Christoph; Mogwitz, Andreas; Weidemann, Robin R.; Sedlmayr, Martin; Lakowa, Nicole; Stehr, Sebastian N.; Albrecht, Michael; Karschau, Jens; Schmitt, Jochen			Regional responsibility and coordination of appropriate inpatient care capacities for patients with COVID-19-the German DISPENSE model	PLOS ONE			English	Article								As of late 2019, the COVID-19 pandemic has been a challenge to health care systems worldwide. Rapidly rising local COVID-19 incidence rates, result in demand for high hospital and intensive care bed capacities on short notice. A detailed up-to-date regional surveillance of the dynamics of the pandemic, precise prediction of required inpatient capacities of care as well as a centralized coordination of the distribution of regional patient fluxes is needed to ensure optimal patient care. In March 2020, the German federal state of Saxony established three COVID-19 coordination centers located at each of its maximum care hospitals, namely the University Hospitals Dresden and Leipzig and the hospital Chemnitz. Each center has coordinated inpatient care facilities for the three regions East, Northwest and Southwest Saxony with 36, 18 and 29 hospital sites, respectively. Fed by daily data flows from local public health authorities capturing the dynamics of the pandemic as well as daily reports on regional inpatient care capacities, we established the information and prognosis tool DISPENSE. It provides a regional overview of the current pandemic situation combined with daily prognoses for up to seven days as well as outlooks for up to 14 days of bed requirements. The prognosis precision varies from 21% and 38% to 12% and 15% relative errors in normal ward and ICU bed demand, respectively, depending on the considered time period. The deployment of DISPENSE has had a major positive impact to stay alert for the second wave of the COVID-19 pandemic and to allocate resources as needed. The application of a mathematical model to forecast required bed capacities enabled concerted actions for patient allocation and strategic planning. The ad-hoc implementation of these tools substantiates the need of a detailed data basis that enables appropriate responses, both on regional scales in terms of clinic resource planning and on larger scales concerning political reactions to pandemic situations.	[Luensmann, Benedict J.; Polotzek, Katja; Bierbaum, Veronika; Walther, Felix; Baum, Fabian; Forkert, Christoph; Lange, Toni; Karschau, Jens; Schmitt, Jochen] Tech Univ Dresden, Ctr Evidence Based Healthcare, Univ Hosp Dresden, Dresden, Germany; [Luensmann, Benedict J.; Polotzek, Katja; Gebler, Richard; Bierbaum, Veronika; Walther, Felix; Baum, Fabian; Forkert, Christoph; Lange, Toni; Sedlmayr, Martin; Karschau, Jens; Schmitt, Jochen] Tech Univ Dresden, Med Fac Carl Gustav Carus, Dresden, Germany; [Kleber, Christian] Univ Hosp Carl Gustav Carus, Univ Ctr Orthopaed Trauma & Plast Surg, Dresden, Germany; [Gebler, Richard; Sedlmayr, Martin] Tech Univ Dresden, Inst Med Informat & Biometry, Univ Hosp Dresden, Dresden, Germany; [Walther, Felix] Univ Hosp Carl Gustav Carus Dresden, Qual & Med Risk Management, Dresden, Germany; [Juncken, Kathleen; Lakowa, Nicole] Klinikum Chemnitz, Clin Infect Dis & Trop Med, Chemnitz, Germany; [Held, Hanns-Christoph; Stehr, Sebastian N.] Leipzig Univ Hosp, Dept Anesthesia & Crit Care Med, Leipzig, Germany; [Mogwitz, Andreas; Weidemann, Robin R.; Albrecht, Michael] Univ Hosp Carl Gustav Carus Dresden, Dresden, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Chemnitz Clinic; Leipzig University; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Lunsmann, BJ (corresponding author), Tech Univ Dresden, Ctr Evidence Based Healthcare, Univ Hosp Dresden, Dresden, Germany.; Lunsmann, BJ (corresponding author), Tech Univ Dresden, Med Fac Carl Gustav Carus, Dresden, Germany.	benedict.luensmann@tu-dresden.de	Walther, Felix/AAZ-8545-2020	Walther, Felix/0000-0002-5259-124X; Polotzek, Katja/0000-0002-4023-6654	Saxon Ministry for Social Affairs; TU Dresden	Saxon Ministry for Social Affairs; TU Dresden(European Commission)	The study was funded by the Saxon Ministry for Social Affairs. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Open Access Funding by the Publication Fund of the TU Dresden.	Bandyopadhyay A., 2020, COVID 19 ITALY TARGE, DOI [10.1101/2020.10.12.20211169, DOI 10.1101/2020.10.12.20211169]; Barabasi A-L., 2016, NETW SCI, DOI [10.1017/nws.2016.2, DOI 10.1017/NWS.2016.2]; Bicher M., 2021, EVALUATION CONTACT T, DOI [10.1101/2020.05.12.20098970, DOI 10.1101/2020.05.12.20098970]; Dichter JR, 2014, CHEST, V146, pE87S, DOI 10.1378/chest.14-0738; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Dreher M, 2020, DTSCH ARZTEBL INT, V117, P271, DOI 10.3238/arztebl.2020.0271; Duncan A., 2020, GEOTEMPORAL SURVEY H, DOI [10.1101/2020.06.24.20139048, DOI 10.1101/2020.06.24.20139048]; Grasner J-T., 2020, DEUT ARZTEBLATT, V117; Hale T, 2021, NAT HUM BEHAV, V5, P529, DOI 10.1038/s41562-021-01079-8; Kontis V, 2021, NAT MED, V27, P562, DOI 10.1038/s41591-021-01254-4; Kontopantelis E, 2021, J EPIDEMIOL COMMUN H, V75, P213, DOI 10.1136/jech-2020-214764; Kuhlen R, 2020, DTSCH ARZTEBL INT, V117, P488, DOI [10.3238/arztebl.2020.0489, 10.3238/arztebl.2020.0488]; Kuhn M.J., 2020, ASSESSMENT EFFECTIVE, DOI [10.1101/2020.12.18.20248509, DOI 10.1101/2020.12.18.20248509]; Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538; Neher, 2020, COVID 19 SCENARIOS I, DOI [https://doi.org/10.1101/2020.05.05.20091363, 10.1101/2020.05.05.20091363]; Porter ME, 2010, NEW ENGL J MED, V363, P2477, DOI 10.1056/NEJMp1011024; Qin J, 2020, SCI ADV, V6, DOI [10.1126/sciadv.abc1202, 10.1101/2020.03.06.20032417]; Robert Koch Institute,, 2020, MOD BEISP SARS COV 2; Rommele C, 2020, ANAESTHESIST, V69, P717, DOI 10.1007/s00101-020-00830-6; Rommel A, 2021, DTSCH ARZTEBL INT, V118, P145, DOI 10.3238/arztebl.m2021.0147; Rudan I, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010335; Wei Y, 2020, SYSTEMATIC REV METAA; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Yang L, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001338; Zangrillo A, 2020, INTENS CARE MED, V46, P1622, DOI 10.1007/s00134-020-06137-9	25	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0262491	10.1371/journal.pone.0262491	http://dx.doi.org/10.1371/journal.pone.0262491			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085297	Green Published, gold			2023-01-03	WOS:000779379600060
J	Mihretie, GN; Getie, SA; Shiferaw, S; Ayele, AD; Liyeh, TM; Kassa, BG; Asferie, WN				Mihretie, Gedefaye Nibret; Getie, Simegnew Asmer; Shiferaw, Shumye; Ayele, Alemu Degu; Liyeh, Tewachew Muche; Kassa, Bekalu Getnet; Asferie, Worku Necho			Interbirth interval practices among reproductive age women in rural and Urban kebeles in Farta Woreda: Case-control study	PLOS ONE			English	Article							PRETERM BIRTH; DETERMINANTS; COUNTRIES	Background Closely spaced births have been reported all over the world especially in developing countries, and they have been correlated with poor maternal and infant health. Enhancing optimal birth interval is one of the key strategies to promote the health status of mothers and their children. However, factors affecting short birth intervals have not been identified in the study area and region. This study was aimed to assess determinants of short birth interval practice among reproductive women in Farta woreda, Ethiopia, 2019. Methods Community based unmatched case-control study design was conducted from February to March 2019. The sample size of 303 (101 case and 202 controls) was included by using multistage sampling and then study participants were selected by simple random sampling technique. The data was collected by structured and pre-tested face-to-face interviewer-administered questionnaires from the selected respondents. The collected data were entered with Epi-Data version 4.2 and analyzed by using SPSS version 23 software. Bivariate and multivariate analyses were used to examine the association. Odds ratios, 95% CI, and P-value <0.05 were used to determine the statistical association. Results Women who had no formal education (AOR = 2.15, 95% CI (1.19, 3.88), had not a history of antenatal care follow up (AOR = 2.66, 95% CI (1.55, 4.56)), did not use modern contraceptives before getting the latest pregnancy (AOR = 3.48, 95% CI (1.74, 6.95)) and duration of breastfeeding less than 24 months (AOR = 3.59, 95% CI (2.06, 6.24)) were significantly associated with short birth interval. Conclusions and recommendation Maternal education, duration of breastfeeding, contraceptive utilization, and antenatal follow-up were identified as the predictor variables of short birth interval practice. Therefore, providing health information for reproductive-age women about the benefit of contraceptive utilization, breastfeeding practice and antenatal care follow up to minimize problems resulting from the short birth intervals.	[Mihretie, Gedefaye Nibret; Ayele, Alemu Degu; Liyeh, Tewachew Muche; Kassa, Bekalu Getnet] Debre Tabor Univ, Coll Hlth Sci, Dept Midwifery, Debre Tabor Town, Ethiopia; [Getie, Simegnew Asmer; Shiferaw, Shumye] Bahir Dar Univ, Coll Hlth Sci, Dept Midwifery, Bahir Dar City, Ethiopia; [Asferie, Worku Necho] Debre Tabor Univ, Coll Hlth Sci, Dept Neonatal Nursing & Child Hlth, Debre Tabor Town, Ethiopia	Bahir Dar University	Mihretie, GN (corresponding author), Debre Tabor Univ, Coll Hlth Sci, Dept Midwifery, Debre Tabor Town, Ethiopia.	gedefayen@gmail.com	Mihretie, Gedefaye Nibret/AAD-5787-2022; Kassa, Bekalu Getnet/ADQ-8258-2022	Mihretie, Gedefaye Nibret/0000-0003-1223-7980; Kassa, Bekalu Getnet/0000-0003-2837-922X				Abdel-Tawab NG, 2008, REPROD HEALTH, DOI [DOI 10.31899/RH4.1136, 10.31899/rh4.1136]; Alemu A, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-189; Amare M., 2018, J MED SCI TECHNOLOGY, V7, P6; Amare Mebrhit., 2018, DETERMINANTS SHORT I, V7, P2; Asifa P, 2012, J STAT, V19, P54; Begum K., 2018, J BANGLADESH COLL PH, V36, P1; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; CSA I., 2016, ETH DEM HLTH SURV 20, V2017; De Bruijn B.J., 2006, FERTILITY THEORIES F; de Jonge HCC, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0427-6; Eyowas FA, 2016, PEDIATR HEALTH MED T, V7, P65, DOI 10.2147/PHMT.S102619; Fallahzadeh H, 2013, IRAN J REPROD MED, V11, P379; Gebremedhin Samson, 2009, Afr J Reprod Health, V13, P93; Gebreyesus SH, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6422-0; Government of Ethiopia, 2016, DAHS; Hailu Desta, 2016, Int J Reprod Med, V2016, P6072437, DOI 10.1155/2016/6072437; Human Services, 2010, HLTH PEOPL; Kamal A., 2012, J STAT, V19, P54; Kombo S.A., 2018, DUJOPAS, V4, P236; Lilungulu Athanase, 2015, Matern Health Neonatol Perinatol, V1, P1, DOI 10.1186/s40748-014-0002-1; Mamo H, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255613; McClure EM, 2009, J MATERN-FETAL NEO M, V22, P183, DOI 10.1080/14767050802559129; Mourad-Youssif M, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-24; Negussie A.A., 2000, PROXIMATE DETERMINAN; Odu K., 2011, INT J CROSS DISCIPLI, V2, P414; Organization W.H., 2005, REP WHO TECHN CONS B; Orji E O, 2004, East Afr Med J, V81, P388; Rockville M., 2016, US CSA ICF ETHIOPIA; Samuel Yohannes M.W, 2010, MULUMEBET ABERA2 DAG; Sebayang SK, 2012, TROP MED INT HEALTH, V17, P938, DOI 10.1111/j.1365-3156.2012.03039.x; Setty-Venugopal V, 2002, BIRTH SPACING 3 5 SA; Shifti DM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227798; Singh S.N., 2010, ONLINE J HLTH ALLIED; Tehranian N., 2016, J MIDWIFERY REPROD H, V4, P600; Teklehaimanot N., 2014, INT J NUTR FOOD SCI, V3, P560; United Nations, 2011, MILLENNIUM DEV GOALS; Yohannis Fitaw, 2003, Ethiopian Journal of Health Development, V17, P17	37	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0256193	10.1371/journal.pone.0256193	http://dx.doi.org/10.1371/journal.pone.0256193			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085250	gold, Green Published			2023-01-03	WOS:000779379600003
J	Casadio, M; David, DJV; Wang, J; Wang, Z				Casadio, Melina; David, Daryl J., V; Wang, Jie; Wang, Zhe			Enhancing T cell therapy	NATURE CELL BIOLOGY			English	Editorial Material																			0	0	0	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2022	24	1					1	1		10.1038/s41556-021-00831-6	http://dx.doi.org/10.1038/s41556-021-00831-6		JAN 2022	1	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	YG8PK	35027737				2023-01-03	WOS:000742323100002
J	Bilska, A				Bilska, Agnieszka			Effect of Morus alba leaf extract dose on lipid oxidation, microbiological stability, and sensory evaluation of functional liver pates during refrigerated storage	PLOS ONE			English	Article							ANTIOXIDANT PROPERTIES; INHIBITORY-ACTIVITY; CONVERTING-ENZYME; MULBERRY; ACETYLCHOLINESTERASE; LEAVES; RICH	Mulberry (Morus alba L.), and above all the extract from the leaves of this plant, is a natural medicine that has been used in traditional medicine for hundreds of years. Mulberry leaves contains polyphenol compounds: flavonoids, coumarins, numerous phenolic acids, as well as terpenes and steroids. The antioxidant effect of these compounds may be beneficial to the fat fraction of meat products, thereby increasing their functional qualities. The aim of the study was to evaluate the effectiveness of the use of mulberry water leaf extract, as an additive limiting adverse fat changes and affecting the functionality in model liver pates. Pork pates were prepared by replacing 20% of animal fat with rapeseed oil (RO), and water extract of mulberry leaves was added in the proportion of 0.2%, 0.6% and 1.0%. It has been shown that the addition of mulberry leaf extract delayed the appearance of primary and secondary fat oxidation products. The most effective antioxidant effect during 15-day storage was observed in the sample with the addition of 0.6% and 1.0% water mulberry leaf extract. These samples also showed inhibiting activity against angiotensin-converting enzymes and cholinesterase's. During storage, the tested pates had a high sensory quality with unchanged microbiological quality. Mulberry leaf extract can be an interesting addition to the production of fat meat products, delaying adverse changes in the lipid fraction and increasing the functionality of products.	[Bilska, Agnieszka] Poznan Univ Life Sci, Dept Meat Technol, Poznan, Poland	Poznan University of Life Sciences	Bilska, A (corresponding author), Poznan Univ Life Sci, Dept Meat Technol, Poznan, Poland.	agnieszka.bilska@up.poznan.pl			Polish Ministry of Science and Higher Education [005 / RID / 2018/19]	Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	This study was funded by the Polish Ministry of Science and Higher Education's program:" Regional Initiative Excellence "in the years 2019-2022 (No. 005 / RID / 2018/19). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, 3960 ISO, V5th ed.; [Anonymous], 2008, 54922008 ISO, P1; [Anonymous], 1999, 29171999EN ISO, P1; [Anonymous], 2010, 137202010 ISO, P1; [Anonymous], 1997, PNA8205571997, P1; [Anonymous], 2016, 132992016 ISO, V2nd, P1; Bilska A, 2019, ELECTRON J BIOTECHN, V40, P22, DOI 10.1016/j.ejbt.2019.03.007; Bilska A, 2018, J SCI FOOD AGR, V98, P4112, DOI 10.1002/jsfa.8928; Carillon J, 2012, FOOD CHEM, V135, P1298, DOI 10.1016/j.foodchem.2012.05.064; Cukon N., 2012, MESO, V14, P271; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Estevez M, 2006, MEAT SCI, V72, P348, DOI 10.1016/j.meatsci.2005.08.005; Fan WJ, 2014, MEAT SCI, V96, P1, DOI 10.1016/j.meatsci.2013.06.025; Ferlemi AV, 2015, CHEM-BIOL INTERACT, V237, P47, DOI 10.1016/j.cbi.2015.04.013; FOLCH J, 1957, J BIOL CHEM, V226, P497; ISO, 2013, 483312013 ISO; Kang TH, 2006, BIOL PHARM BULL, V29, P270, DOI 10.1248/bpb.29.270; Khyade VB., 2016, J MED PLANTS STUD, V4, P4; Kobus-Cisowska J, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061377; Kobus-Cisowska J, 2019, ELECTRON J BIOTECHN, V37, P1, DOI 10.1016/j.ejbt.2018.10.002; Kobus-Cisowska J, 2014, MEAT SCI, V97, P174, DOI 10.1016/j.meatsci.2014.01.011; Kojima Y, 2010, J CLIN BIOCHEM NUTR, V47, P155, DOI 10.3164/jcbn.10-53; Korczak J., 2013, AGR SCI, V4, P130, DOI [10.4236/as.2013.45B024, DOI 10.4236/AS.2013.45B024, 10.4236/as.2013.45b024]; Lorenzo JM, 2014, FOOD CHEM, V155, P57, DOI 10.1016/j.foodchem.2014.01.038; Niidome T, 2007, NEUROREPORT, V18, P813, DOI 10.1097/WNR.0b013e3280dce5af; Ozarowski M, 2013, FITOTERAPIA, V91, P261, DOI 10.1016/j.fitote.2013.09.012; PIKUL J, 1989, J AGR FOOD CHEM, V37, P1309, DOI 10.1021/jf00089a022; Przeor M, 2016, INDIAN J TRADIT KNOW, V15, P237; Shahidi F, 2015, J FUNCT FOODS, V18, P820, DOI 10.1016/j.jff.2015.06.018; TARLADGIS BG, 1960, J AM OIL CHEM SOC, V37, P44, DOI 10.1007/BF02630824; Yuan QX, 2017, J AGR FOOD CHEM, V65, P10383, DOI 10.1021/acs.jafc.7b03614; Zhang HX, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7050069	33	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2021	16	12							e0260030	10.1371/journal.pone.0260030	http://dx.doi.org/10.1371/journal.pone.0260030			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ1OP	34941877	gold, Green Published			2023-01-03	WOS:000755252200009
J	Zhou, ZJ; Li, JX; Wang, H; Luan, Z; Li, Y; Peng, X				Zhou, Zijun; Li, Jiaxin; Wang, He; Luan, Ze; Li, Yuan; Peng, Xin			Upper limb rehabilitation system based on virtual reality for breast cancer patients: Development and usability study	PLOS ONE			English	Article							LYMPHEDEMA; TECHNOLOGY; SICKNESS; OUTCOMES; THERAPY	Background Functional exercise is crucial for breast cancer patients after surgery, and the use of virtual reality technology to assist patients with postoperative upper limb functional rehabilitation has gradually attracted the attention of researchers. However, the usability of the developed rehabilitation system is still unknown to a large extent. The purpose of this study was to develop a virtual reality upper limb rehabilitation system for patients after breast cancer surgery and to explore its usability. Methods We built a multidisciplinary team based on virtual reality and human-computer interaction technology and designed and developed an upper limb function rehabilitation system for breast cancer patients after surgery. Breast cancer patients were recruited from a grade III-a general hospital in Changchun city for the experiment. We used the System Usability Scale to evaluate the system availability, the Presence Questionnaire scale to measure the immersive virtual reality scene, and the Simulator Sickness Questionnaire subjective measurement scale for simulator sickness symptoms. Results This upper limb rehabilitation system hardware consisted of Head-mounted Display, a control handle and notebook computers. The software consisted of rehabilitation exercises and game modules. A total of 15 patients were tested on this system, all of whom were female. The mean age was 54.737.78 years, and no patients were excluded from the experiment because of adverse reactions such as dizziness and vomiting. The System Usability Scale score was 90.50 +/- 5.69, the Presence Questionnaire score was 113.40 +/- 9.58, the Simulator Sickness Questionnaire-nausea score was 0.93 +/- 1.16, the Simulator Sickness Questionnaire-oculomotor score was 0.80 +/- 1.27, the Simulator Sickness Questionnaire-disorientation score was 0.80 +/- 1.27, and the Simulator Sickness Questionnaire total score was 2.53 +/- 3.40. Conclusions This study fills in the blanks regarding the upper limb rehabilitation of breast cancer patients based on virtual reality technology system usability research. As the starting point of research in the future, we will improve the system's function and design strictly randomized controlled trials, using larger samples in the promotion, to evaluate its application in breast cancer patients with upper limbs and other physiological functions and the feasibility and effects of rehabilitation.	[Zhou, Zijun; Wang, He] Jilin Prov Tumor Hosp, Breast Surg, Jilin, Jilin, Peoples R China; [Li, Jiaxin; Luan, Ze; Li, Yuan; Peng, Xin] Jilin Univ, Sch Nursing, Jilin, Jilin, Peoples R China	Jilin University	Peng, X (corresponding author), Jilin Univ, Sch Nursing, Jilin, Jilin, Peoples R China.	pengxin2016@163.com		Li, Yuan/0000-0003-1506-3082	Jilin University [2020B38]	Jilin University(Jilin University)	This study is funded by Jilin University. The project name is: Jilin University Bethune Plan Project (2020B38), and author Xin Peng is the main leader of the project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmadpour N, 2020, JMIR SERIOUS GAMES, V8, DOI 10.2196/14565; Albert W, MEASURING USER EXPER; [Anonymous], 2019, 9241 ISO; Axenie C, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01419; Ayed I, 2019, INT J MED INFORM, V131, DOI 10.1016/j.ijmedinf.2019.06.016; Bangor A, 2008, INT J HUM-COMPUT INT, V24, P574, DOI 10.1080/10447310802205776; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brooke J., 1996, USABILITY EVALUATION, P189, DOI 10.1201/9781498710411; Buche H, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.631186; Campbell KL, 2019, MED SCI SPORT EXER, V51, P2375, DOI 10.1249/MSS.0000000000002116; Casella D, 2018, BREAST, V39, P8, DOI 10.1016/j.breast.2018.02.001; Chirico A, 2020, J CELL PHYSIOL, V235, P5353, DOI 10.1002/jcp.29422; Chirico A, 2016, J CELL PHYSIOL, V231, P275, DOI 10.1002/jcp.25117; Ciudad P, 2016, MICROSURG, V36, P359, DOI 10.1002/micr.22459; Cohen SR, 2001, CANCER-AM CANCER SOC, V92, P980, DOI 10.1002/1097-0142(20010815)92:4+<980::AID-CNCR1410>3.0.CO;2-E; Zapata BC, 2015, J MED SYST, V39, DOI 10.1007/s10916-014-0182-2; Cummings JJ, 2016, MEDIA PSYCHOL, V19, P272, DOI 10.1080/15213269.2015.1015740; De Sire A, 2020, EUR REV MED PHARMACO, V24, P4476, DOI 10.26355/eurrev_202004_21030; Duzmanska N, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02132; Engel J, 2003, BREAST CANCER RES TR, V79, P47, DOI 10.1023/A:1023330206021; Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6; Feyzioglu O, 2020, SUPPORT CARE CANCER, V28, P4295, DOI 10.1007/s00520-019-05287-x; Meneses-Echavez JF, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1069-4; Hayes SC, 2012, CANCER-AM CANCER SOC, V118, P2237, DOI 10.1002/cncr.27467; He X, 2020, J BIOMED INFORM, V110, DOI 10.1016/j.jbi.2020.103571; House G, 2016, BRIT J PAIN, V10, P186, DOI 10.1177/2049463716664370; Hussain R, 2021, SENSORS-BASEL, V21, DOI 10.3390/s21124006; Invernizzi M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.556718; Invernizzi M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00422; Invernizzi M, 2020, JOVE-J VIS EXP, DOI 10.3791/60093; Invernizzi M, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4851-2; Johnson T, 2020, J PALLIAT MED, V23, P1233, DOI 10.1089/jpm.2019.0411; Kaciulyte J, 2019, EUR REV MED PHARMACO, V23, P4448, DOI 10.26355/eurrev_201905_17955; Karamians R, 2020, ARCH PHYS MED REHAB, V101, P885, DOI 10.1016/j.apmr.2019.10.195; Kennedy R. S., 1993, INT J AVIAT PSYCHOL, V3, P203, DOI [10.1207/s15327108ijap0303_3, DOI 10.1207/S15327108IJAP0303_3]; Keshavarz B, 2018, TRANSPORT RES F-TRAF, V54, P47, DOI 10.1016/j.trf.2018.01.007; Kim WS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103369; Klein I, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89908-8; Lee N, 2021, BMC GERIATR, V21, DOI 10.1186/s12877-021-02263-1; Li L, 2017, AM J TRANSL RES, V9, P3867; Maramba I, 2019, INT J MED INFORM, V126, P95, DOI 10.1016/j.ijmedinf.2019.03.018; McCredie MRE, 2001, BREAST, V10, P515, DOI 10.1054/brst.2000.0291; McNeely ML, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005211.pub2; Michelotti A, 2019, BREAST, V44, P15, DOI 10.1016/j.breast.2018.12.009; Mijwel S, 2018, BREAST CANCER RES TR, V168, P79, DOI 10.1007/s10549-017-4571-3; Mohammad EB, 2019, PALLIAT SUPPORT CARE, V17, P29, DOI 10.1017/S1478951518000639; Mortenson MM, 2004, ARCH SURG-CHICAGO, V139, P988, DOI 10.1001/archsurg.139.9.988; Niki K, 2019, J PALLIAT MED, V22, P702, DOI 10.1089/jpm.2018.0527; OMAN CM, 1990, CAN J PHYSIOL PHARM, V68, P294, DOI 10.1139/y90-044; Park HY, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05535-8; Perez-Marcos D, 2018, J NEUROENG REHABIL, V15, DOI 10.1186/s12984-018-0461-0; REGAN EC, 1994, AVIAT SPACE ENVIR MD, V65, P527; Ribeiro IL, 2019, CLIN REHABIL, V33, P1876, DOI 10.1177/0269215519873026; Ryans K, 2021, J CANCER SURVIV, DOI 10.1007/s11764-021-00991-2; Sharifpour S, 2021, COUNS PSYCHOTHER RES, V21, P218, DOI 10.1002/capr.12311; Lacomba MT, 2009, BREAST CANCER RES TR, V117, P625, DOI 10.1007/s10549-009-0371-8; VIRZI RA, 1992, HUM FACTORS, V34, P457, DOI 10.1177/001872089203400407; Wang RZ, 2020, CANCERS, V12, DOI 10.3390/cancers12010194; Witlox L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215517; Witmer BG, 1998, PRESENCE-TELEOP VIRT, V7, P225, DOI 10.1162/105474698565686; Yang SNY, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030281; Zeng YC, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419871108; Zhang T, 2020, JMIR SERIOUS GAMES, V8, DOI 10.2196/18153	63	1	1	12	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2021	16	12							e0261220	10.1371/journal.pone.0261220	http://dx.doi.org/10.1371/journal.pone.0261220			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY5KW	34910786	gold, Green Published			2023-01-03	WOS:000754828900043
J	Bergin, M; Tucker, K; Vicenzino, B; Hodges, PW				Bergin, Michael; Tucker, Kylie; Vicenzino, Bill; Hodges, Paul W.			"Taking action" to reduce pain-Has interpretation of the motor adaptation to pain been too simplistic?	PLOS ONE			English	Article							CHRONIC MUSCULOSKELETAL PAIN; MUSCLE PAIN; BACK-PAIN; VARIABILITY; TASK; MECHANISMS; MOVEMENT; INCREASE; FORCES	Movement adapts during acute pain. This is assumed to reduce nociceptive input, but the interpretation may not be straightforward. We investigated whether movement adaptation during pain reflects a purposeful search for a less painful solution. Three groups of participants performed two blocks (Baseline, Experimental) of wrist movements in the radial-ulnar direction. For the Control group (n = 10) both blocks were painfree. In two groups, painful electrical stimulation was applied at the elbow in Experimental conditions when the wrist crossed radial-ulnar neutral. Different stimulus intensities were given for specific wrist angles in a secondary direction (flexion-extension) as the wrist passed radial-ulnar neutral (Pain 5-1 group:painful stimulation at similar to 5 or similar to 1/10-n = 21; Pain 5-0 group:similar to 5 or 0(no stimulation)/10-n = 6)). Participants were not informed about the less painful alternative and could use any strategy. We recorded the percentage of movements using the wrist flexion/extension alignment that evoked the lower intensity noxious stimulus, movement variability, and change in wrist/forearm alignment during pain. Participants adapted their strategy of wrist movement during pain provocation and reported less pain over time. Three adaptations of wrist movement were observed; (i) greater use of the wrist alignment with no/less noxious input (Pain 5-1, n = 8/21; Pain 5-0, n = 2/6); (ii) small (n = 9/21; n = 3/6) or (iii) large (n = 4/21; n = 1/6) change of wrist/forearm alignment to a region that was not allocated to provide an actual reduction in noxious stimulus. Pain reduction was achieved with "taking action" to relieve pain and did not depend on reduced noxious stimulus.	[Bergin, Michael; Tucker, Kylie; Vicenzino, Bill; Hodges, Paul W.] Univ Queensland, Sch Hlth & Rehabil Sci, NHMRC Ctr Clin Res Excellence Spinal Pain Injury, St Lucia, Qld, Australia; [Bergin, Michael] Spaulding Rehabil Hosp, Neurorehabil Lab, Charlestown, MA USA; [Vicenzino, Bill] Univ Queensland, Sch Biomed Sci, St Lucia, Qld, Australia	University of Queensland; Harvard University; Spaulding Rehabilitation Hospital; University of Queensland	Hodges, PW (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, NHMRC Ctr Clin Res Excellence Spinal Pain Injury, St Lucia, Qld, Australia.	p.hodges@uq.edu.au	Hodges, Paul/B-6578-2008	Hodges, Paul/0000-0002-1206-9107				Anderson FC, 2001, J BIOMECH ENG-T ASME, V123, P381, DOI 10.1115/1.1392310; Bergin MJG, 2014, EUR J APPL PHYSIOL, V114, P385, DOI 10.1007/s00421-013-2777-6; Boudreau S, 2007, PAIN, V132, P169, DOI 10.1016/j.pain.2007.07.019; Clarke RW, 2004, BRAIN RES REV, V46, P163, DOI 10.1016/j.brainresrev.2004.07.005; Conley KE, 2002, J EXP BIOL, V205, P2175; Crombez G, 1997, PAIN, V70, P149, DOI 10.1016/S0304-3959(96)03304-0; Gasser HS, 1929, AM J PHYSIOL, V88, P581, DOI 10.1152/ajplegacy.1929.88.4.581; Harris CM, 1998, NATURE, V394, P780, DOI 10.1038/29528; Hodges PW, 2011, PAIN, V152, pS90, DOI 10.1016/j.pain.2010.10.020; Hu XG, 2011, NEUROSCI LETT, V490, P121, DOI 10.1016/j.neulet.2010.12.040; Hug F., 2014, J NEUROPHYSIOL; Hug F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154524; Hug F, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2015.1908; Hug F, 2014, J NEUROPHYSIOL, V111, P2298, DOI 10.1152/jn.00911.2013; Hug F, 2013, J ELECTROMYOGR KINES, V23, P1413, DOI 10.1016/j.jelekin.2013.08.014; Ingham D, 2011, EUR J PAIN, V15, P1028, DOI 10.1016/j.ejpain.2011.04.006; Jonas R, 2018, ANN NEUROL, V83, P945, DOI 10.1002/ana.25231; Kording KP, 2004, NATURE, V427, P244, DOI 10.1038/nature02169; Kurniawan IT, 2010, PSYCHOL SCI, V21, P840, DOI 10.1177/0956797610370160; LUND JP, 1991, CAN J PHYSIOL PHARM, V69, P683, DOI 10.1139/y91-102; Madeleine P, 2008, EXP BRAIN RES, V185, P689, DOI 10.1007/s00221-007-1199-2; Moseley GL, 2006, BEHAV NEUROSCI, V120, P474, DOI 10.1037/0735-7044.120.2.474; Murray GM, 2007, J OROFAC PAIN, V21, P263; PANDY MG, 1995, J BIOMECH ENG-T ASME, V117, P15, DOI 10.1115/1.2792265; ROLAND MO, 1986, CLIN BIOMECH, V1, P102, DOI 10.1016/0268-0033(86)90085-9; Salomoni SE, 2013, EUR J APPL PHYSIOL, V113, P567, DOI 10.1007/s00421-012-2461-2; Salomoni SE, 2012, EUR J APPL PHYSIOL, V112, P3607, DOI 10.1007/s00421-012-2343-7; SCHAIBLE HG, 1993, PAIN, V55, P5, DOI 10.1016/0304-3959(93)90183-P; Svensson P, 1996, PAIN, V64, P241, DOI 10.1016/0304-3959(95)00133-6; Todorov E, 2002, NAT NEUROSCI, V5, P1226, DOI 10.1038/nn963; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Tucker KJ, 2010, EUR J PAIN, V14, P932, DOI 10.1016/j.ejpain.2010.03.006; Van Dillen LR, 2009, MANUAL THER, V14, P52, DOI 10.1016/j.math.2007.09.012; Van Ryckeghem DML, 2012, PAIN, V153, P2345, DOI 10.1016/j.pain.2012.07.032; Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0; Wall Patrick David, 2000, PAIN SCI SUFFERING; Wiech K, 2008, TRENDS COGN SCI, V12, P306, DOI 10.1016/j.tics.2008.05.005; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030	38	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2021	16	12							e0260715	10.1371/journal.pone.0260715	http://dx.doi.org/10.1371/journal.pone.0260715			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY2LS	34879091	gold, Green Published			2023-01-03	WOS:000754625200026
J	Virata, MD; Shenoi, SV; Ladines-Lim, J; Villanueva, MS; Barakat, LA				Virata, Michael D.; Shenoi, Sheela, V; Ladines-Lim, Joseph; Villanueva, Merceditas S.; Barakat, Lydia A.			Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study	PLOS ONE			English	Article							CORONAVIRUS; DEATH	There continue to be conflicting data regarding the outcomes of people with HIV (PWH) who have COVID-19 infection with most studies describing the early epidemic. We present a single site experience spanning a later timeframe from the first report on January 21, 2020 to January 20, 2021 and describe clinical outcomes and predictors of hospitalization among a cohort of PWH in an urban center in Connecticut, USA. Among 103 PWH with controlled HIV disease, hospitalization occurred in 33% and overall mortality was 1%. HIV associated factors (CD4 count, HIV viral suppression) were not associated with hospitalization. Chronic lung disease (OR: 3.35, 95% CI:1.28-8.72), and cardiovascular disease (OR: 3.4, 95% CI:1.27-9.12) were independently associated with hospitalization. An increasing number of non-communicable comorbidities increased the likelihood of hospitalization (OR: 1.61, 95% CI:1.22-2.13).	[Virata, Michael D.; Shenoi, Sheela, V; Villanueva, Merceditas S.; Barakat, Lydia A.] Yale Sch Med, Dept Internal Med, Sect Infect Dis, New Haven, CT 06510 USA; [Ladines-Lim, Joseph] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Ladines-Lim, Joseph] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA	Yale University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Virata, MD (corresponding author), Yale Sch Med, Dept Internal Med, Sect Infect Dis, New Haven, CT 06510 USA.	michael.virata@yale.edu	Shenoi, Sheela/Z-2641-2019; Shenoi, Sheela/GRY-6103-2022	Shenoi, Sheela/0000-0001-7654-4344; Villanueva, Merceditas/0000-0003-1022-7746; Virata, Michael/0000-0003-3636-9283; Ladines-Lim, Joseph/0000-0002-2461-2752	Doris Duke Charitable Foundation [201516]	Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF))	Sheela Shenoi received support from the Doris Duke Charitable Foundation (#201516). The funder did not play any role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. All other authors received no specific funding for this work.	Bhaskaran K, 2021, LANCET HIV, V8, pe24, DOI 10.1016/S2352-3018(20)30305-2; Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9; Boulle A, 2021, CLIN INFECT DIS, V73, pE2005, DOI 10.1093/cid/ciaa1198; Cooper TJ, 2020, HIV MED, V21, P567, DOI 10.1111/hiv.12911; del Amo J, 2021, ANN INTERN MED, V174, P581, DOI 10.7326/L20-1399; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Durstenfeld Matthew S, 2021, medRxiv, DOI 10.1101/2021.04.05.21254938; Gallant J, 2017, J INFECT DIS, V216, P1525, DOI 10.1093/infdis/jix518; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Geretti AM, 2021, CLIN INFECT DIS, V73, pE2095, DOI 10.1093/cid/ciaa1605; Gervasoni C, 2020, CLIN INFECT DIS, V71, P2276, DOI 10.1093/cid/ciaa579; Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Karmen-Tuohy S, 2020, JAIDS-J ACQ IMM DEF, V85, P6, DOI 10.1097/QAI.0000000000002423; Mehraeen E, 2020, EUR J INTEGR MED, V40, DOI 10.1016/j.eujim.2020.101226; Mirzaei H, 2021, AIDS BEHAV, V25, P85, DOI 10.1007/s10461-020-02983-2; Moran C.A., 2021, C RETR OPP INF VIRT; SeyedAlinaghi S, 2021, EUR J MED RES, V26, DOI 10.1186/s40001-021-00524-8; Sigel K, 2020, CLIN INFECT DIS, V71, P2933, DOI 10.1093/cid/ciaa880; Sun J., 2021, C RETR OPP INF VIRT; Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Yendewa G.A., 2021, C RETR OPP INF VIRT; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2233, DOI 10.1093/cid/ciaa408; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	26	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2021	16	12							e0260251	10.1371/journal.pone.0260251	http://dx.doi.org/10.1371/journal.pone.0260251			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ9AQ	34851963	Green Published, gold			2023-01-03	WOS:000755762900028
J	Schor, J; Koscal, N; Knoper, K				Schor, Joshua; Koscal, Natalie; Knoper, Kim			Revival	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Revival In this Graphic Perspective, a physician traveler responding to a medical crisis on the train he's taking is moved and inspired by the conductor whose quick action, dedication, and compassion save the day.	[Schor, Joshua] OptumHealth, Eden Prairie, MN 55344 USA; Daughters Israel, Med, W Orange, NJ USA	Optum	Schor, J (corresponding author), OptumHealth, Eden Prairie, MN 55344 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2021	385	21					1925	1927		10.1056/NEJMp2108154	http://dx.doi.org/10.1056/NEJMp2108154		NOV 2021	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WY8NB	34767319				2023-01-03	WOS:000718032000001
J	Ruiz-Lopez, MF				Ruiz-Lopez, Manuel F.			Midair transformations of aerosols Spontaneous reactions play an important role in shaping the chemistry of aerosols	SCIENCE			English	Editorial Material							ATMOSPHERIC AEROSOLS; WATER; REACTIVITY		[Ruiz-Lopez, Manuel F.] Univ Lorraine, CNRS BP 70239, UMR CNRS 7019, Lab Phys & Chim Theor, BP 70239, F-54506 Vandoeuvre Les Nancy, France	Universite de Lorraine	Ruiz-Lopez, MF (corresponding author), Univ Lorraine, CNRS BP 70239, UMR CNRS 7019, Lab Phys & Chim Theor, BP 70239, F-54506 Vandoeuvre Les Nancy, France.							Abbatt JPD, 2006, SCIENCE, V313, P1770, DOI 10.1126/science.1129726; Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; Anglada JM, 2020, J AM CHEM SOC, V142, P16140, DOI 10.1021/jacs.0c06858; Dobson CM, 2000, P NATL ACAD SCI USA, V97, P11864, DOI 10.1073/pnas.200366897; George C, 2015, CHEM REV, V115, P4218, DOI 10.1021/cr500648z; Knipping EM, 2000, SCIENCE, V288, P301, DOI 10.1126/science.288.5464.301; Kong XR, 2021, SCIENCE, V374, P747, DOI 10.1126/science.abc5311; Lee JK, 2019, P NATL ACAD SCI USA, V116, P19294, DOI 10.1073/pnas.1911883116; Martins-Costa MTC, 2012, ANGEW CHEM INT EDIT, V51, P5413, DOI 10.1002/anie.201200656; Mishra H, 2012, P NATL ACAD SCI USA, V109, P18679, DOI 10.1073/pnas.1209307109; Narayan S, 2005, ANGEW CHEM INT EDIT, V44, P3275, DOI 10.1002/anie.200462883; Ravishankara AR, 1997, SCIENCE, V276, P1058, DOI 10.1126/science.276.5315.1058; Ruiz-Lopez MF, 2020, NAT REV CHEM, V4, P459, DOI 10.1038/s41570-020-0203-2; Serrano-Luginbuhl S, 2018, NAT REV CHEM, V2, P306, DOI 10.1038/s41570-018-0042-6; Yan X, 2016, ANGEW CHEM INT EDIT, V55, P12960, DOI 10.1002/anie.201602270	15	1	1	8	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2021	374	6568					686	687		10.1126/science.abl8914	http://dx.doi.org/10.1126/science.abl8914			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WS1MC	34735224	Green Submitted			2023-01-03	WOS:000714952000015
J	Kiptanui, Z; Ghosh, S; Ali, S; Desai, K; Harris, I				Kiptanui, Zippora; Ghosh, Sanchari; Ali, Sabeen; Desai, Karishma; Harris, Ilene			Transparency, health equity, and strategies in state-based protocols for remdesivir allocation and use	PLOS ONE			English	Article								Background The Emergency Use Authorization (EUA) of remdesivir for coronavirus disease 2019 raised questions on transparency of applied strategy, and how to equitably allocate and prioritize eligible patients given limited supply of the medication. The absence of federal oversight highlighted the critical role by states in health policymaking during a pandemic. Objective To identify public state-based protocols for remdesivir allocation and clinical guidance for prioritizing remdesivir use and assess approaches and inclusion of language promoting equitable access or mitigating health disparities. Methods We identified remdesivir allocation strategies and clinical use guidelines for all 50 states in the U.S. and the District of Columbia accessible on state health department websites or via internet searches. Public protocols dated between May 1, 2020 and September 30, 2020 were included in the study. We reviewed strategies for allocation and clinical use, including whether protocols contained explicit language on equitable access to remdesivir or mitigating health disparities. Results A total of 38 states had a remdesivir allocation strategy, with 33 states (87%) making these public. States used diverse allocation strategies, and only 10 (30%) of the 33 states included language on equitable allocation. A total of 30 states had remdesivir clinical use guidelines, where all were publicly accessible. All guidelines referenced recommendations by federal agencies but varied in their presentation format. Of the 30 states, 12 (40%) had guidelines that included language on equitable use. Neither an allocation strategy or clinical use guideline were identified (public or non-public) for 10 states and the District of Columbia during the study period. Conclusions The experience with the remdesivir EUA presents an opportunity for federal and state governments to develop transparent protocols promoting fair and equal access to treatments for future pandemics.	[Kiptanui, Zippora] Index Analyt LLC, Catonsville, MD USA; [Ghosh, Sanchari; Ali, Sabeen; Desai, Karishma; Harris, Ilene] IMPAQ Int LLC, Columbia, MD USA	American Institutes for Research	Kiptanui, Z (corresponding author), Index Analyt LLC, Catonsville, MD USA.	zkiptanui@index-analytics.com		Kiptanui, Zippora/0000-0003-1212-7642				Abutaleb Yasmeen., 2020, WASH POST; Akl EA, 2017, J CLIN EPIDEMIOL, V90, P68, DOI 10.1016/j.jclinepi.2017.01.017; [Anonymous], 2020, ETH COVID 19 RES ALL; [Anonymous], 2020, REMD EM US AUTH; [Anonymous], 2020, PROV DEATH COUNTS CO; [Anonymous], 2020, REMD COMM MARK FAQS; [Anonymous], 2020, COVID NET WEEKL SUMM; [Anonymous], 2020, COVID 19 CRIS STAND; [Anonymous], 2012, HHS RETR 2009 H1N1 I; Benavidez G, 2019, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20190730.874541/full/, DOI 10.1377/HBLOG20190730.874541/FULL]; Birnkrant D, 2009, NEW ENGL J MED, V361, P2204, DOI 10.1056/NEJMp0910479; Boodman E., 2020, STATNEWS; Browne AJ, 2012, INT J EQUITY HEALTH, V11, DOI 10.1186/1475-9276-11-59; Buckwalter W, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240651; DeJong C, 2020, JAMA-J AM MED ASSOC, V323, P2367, DOI 10.1001/jama.2020.8914; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Facher L., 2020, STATNEWS; IDSA, 2020, HIVMA CALL TRANSP EQ; Ison MG, 2020, JAMA-J AM MED ASSOC, V323, P2365, DOI 10.1001/jama.2020.8863; Lim S, 2020, MAYO CLIN PROC, V95, P1946, DOI 10.1016/j.mayocp.2020.06.016; Lopez L, 2021, JAMA-J AM MED ASSOC, V325, P719, DOI 10.1001/jama.2020.26443; Mun F, 2021, AM J HEALTH-SYST PH, V78, P235, DOI 10.1093/ajhp/zxaa391; Office of the Commissioner, 2020, COVID 19 UPD FDA BRO; Rosenfeld RM, 2013, OTOLARYNG HEAD NECK, V148, pS1, DOI 10.1177/0194599812467004; Sarpatwari A, 2020, JAMA-J AM MED ASSOC, V324, P331, DOI 10.1001/jama.2020.11932; Schwartz JL, 2020, NEW ENGL J MED, V383, P1703, DOI 10.1056/NEJMp2026393; Welch VA, 2017, J CLIN EPIDEMIOL, V90, P59, DOI 10.1016/j.jclinepi.2017.01.014; Wen LS., 2020, HLTH AFF BLOG, DOI [10.1377/hblog20200716.620294, DOI 10.1377/HBLOG20200716.620294]; White DB, 2020, ALLOCATION SCARCE CR; White DB, 2020, JAMA-J AM MED ASSOC, V324, P329, DOI 10.1001/jama.2020.11464	30	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2021	16	10							e0257648	10.1371/journal.pone.0257648	http://dx.doi.org/10.1371/journal.pone.0257648			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU0SG	34662359	gold, Green Published			2023-01-03	WOS:000733985600003
J	Sheather, J; Slattery, D				Sheather, Julian; Slattery, Dubhfeasa			The great resignation-how do we support and retain staff already stretched to their limit?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PHYSICIANS		[Sheather, Julian] British Med Assoc, London, England		Sheather, J (corresponding author), British Med Assoc, London, England.	JSheather@bma.org.uk						Hu YY, 2012, ARCH SURG-CHICAGO, V147, P212, DOI 10.1001/archsurg.2011.312; Marsh S, 2021, GUARDIAN 0727; Plews-Ogan M, 2016, ACAD MED, V91, P233, DOI 10.1097/ACM.0000000000000886; Shanafelt TD, 2010, ANN SURG, V251, P995, DOI 10.1097/SLA.0b013e3181bfdab3; Sinsky CA, 2017, MAYO CLIN PROC, V92, P1625, DOI 10.1016/j.mayocp.2017.08.017	5	19	19	11	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2021	375								n2533	10.1136/bmj.n2533	http://dx.doi.org/10.1136/bmj.n2533			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WI7KT	34663568	Bronze			2023-01-03	WOS:000708537000006
J	Siegrist, V; Mata, R; Langewitz, W; Gerger, H; Furger, S; Hertwig, R; Bingisser, R				Siegrist, Victoria; Mata, Rui; Langewitz, Wolf; Gerger, Heike; Furger, Stephan; Hertwig, Ralph; Bingisser, Roland			Does information structuring improve recall of discharge information? A cluster randomized clinical trial	PLOS ONE			English	Article							PATIENT RECALL; WRITTEN INFORMATION; EMERGENCY-DEPARTMENT; PHYSICIAN EMPATHY; INFORMED-CONSENT; COMMUNICATION; INTERVENTIONS; SATISFACTION; LITERACY; CANCER	Objectives The impact of the quality of discharge communication between physicians and their patients is critical on patients' health outcomes. Nevertheless, low recall of information given to patients at discharge from emergency departments (EDs) is a well-documented problem. Therefore, we investigated the outcomes and related benefits of two different communication strategies: Physicians were instructed to either use empathy (E) or information structuring (S) skills hypothesizing superior recall by patients in the S group. Methods For the direct comparison of two communication strategies at discharge, physicians were cluster-randomized to an E or a S skills training. Feasibility was measured by training completion rates. Outcomes were measured in patients immediately after discharge, after 7, and 30 days. Primary outcome was patients' immediate recall of discharge information. Secondary outcomes were feasibility of training implementation, patients' adherence to recommendations and satisfaction, as well as the patient-physician relationship. Results Of 117 eligible physicians, 80 (68.4%) completed the training. Out of 256 patients randomized to one of the two training groups (E: 146 and S: 119) 196 completed the post-discharge assessment. Patients' immediate recall of discharge information was superior in patients in the S-group vs. E-group. Patients in the S-group adhered to more recommendations within 30 days (p = .002), and were more likely to recommend the physician to family and friends (p = .021). No differences were found on other assessed outcome domains. Conclusions and practice Implications Immediate recall and subsequent adherence to recommendations were higher in the S group. Feasibility was shown by a 69.6% completion rate of trainings. Thus, trainings of discharge information structuring are feasible and improve patients' recall, and may therefore improve quality of care in the ED.	[Siegrist, Victoria; Bingisser, Roland] Univ Hosp Basel, Emergency Dept, Basel, Switzerland; [Siegrist, Victoria; Mata, Rui] Univ Basel, Ctr Cognit & Decis Sci, Basel, Switzerland; [Langewitz, Wolf] Univ Hosp Basel, Dept Psychosomat Med Commun Med, Basel, Switzerland; [Gerger, Heike] Univ Basel, Fac Psychol, Clin Psychol & Psychotherapy, Basel, Switzerland; [Gerger, Heike] Erasmus MC Univ Med Ctr, Dept Gen Practice, Rotterdam, Netherlands; [Furger, Stephan] Univ Bern, Univ Hosp Psychiat, Translat Res Ctr, Bern, Switzerland; [Hertwig, Ralph] Max Planck Inst Human Dev, Ctr Adapt Rational, Berlin, Germany	University of Basel; University of Basel; University of Basel; University of Basel; Erasmus University Rotterdam; Erasmus MC; University of Bern; University Hospital of Bern; Max Planck Society	Bingisser, R (corresponding author), Univ Hosp Basel, Emergency Dept, Basel, Switzerland.	roland.bingisser@usb.ch	Hertwig, Ralph/B-3468-2015; Gerger, Heike/Q-6862-2017	Hertwig, Ralph/0000-0002-9908-9556; Furger, Stephan/0000-0001-7467-2510; Siegrist, Victoria/0000-0002-8661-1632; Gerger, Heike/0000-0002-7077-658X				Ackermann S, 2017, PSYCHOL HEALTH MED, V22, P646, DOI 10.1080/13548506.2016.1198816; Ackermann S, 2016, HEALTH COMMUN, V31, P557, DOI 10.1080/10410236.2014.979115; AUGUST DA, 1985, CANCER-AM CANCER SOC, V55, P1490, DOI 10.1002/1097-0142(19850401)55:7<1490::AID-CNCR2820550712>3.0.CO;2-N; Barth J, 2011, ANN ONCOL, V22, P1030, DOI 10.1093/annonc/mdq441; Bates D., 2014, J STAT SOFTW, DOI [10.18637/jss.v067.i01, DOI 10.18637/JSS.V067.I01]; Bingisser R, 2017, EUR J INTERN MED, V45, P8, DOI 10.1016/j.ejim.2017.09.013; Byrne G., 1996, JOUNRAL CLIN NURS, V39, P289; Christensen RHB, 2015, ORDINAL REGRESSION M, P28; Cordell WH, 2002, AM J EMERG MED, V20, P165, DOI 10.1053/ajem.2002.32643; Derksen F, 2013, BRIT J GEN PRACT, V63, DOI [10.3399/bjgp13X660814, 10.3399/bjgpbjgp13X660814]; Dong L, 2017, J BEHAV THER EXP PSY, V54, P219, DOI 10.1016/j.jbtep.2016.08.017; Eisenberg EM, 2005, COMMUN MONOGR, V72, P390, DOI 10.1080/03637750500322602; Ekwall A, 2013, J EMERG NURS, V39, P534, DOI 10.1016/j.jen.2010.10.003; Engel KG., 2010, J CLIN OUTCOMES MANA, V17, P449; Funder DC, 2019, ADV METH PRACT PSYCH, V2, DOI 10.1177/2515245919847202; Gabrijel S, 2008, J CLIN ONCOL, V26, P297, DOI 10.1200/JCO.2007.13.0609; Galassi J. P., 1992, PSYCHOL ASSESSMENT, V4, P346, DOI DOI 10.1037/1040-3590.4.3.346; Gensichen J., 2016, Z ALLG MED, V92, P103, DOI [10.5167/uzh-132556, DOI 10.5167/UZH-132556]; Hojat M, 2011, ACAD MED, V86, P359, DOI 10.1097/ACM.0b013e3182086fe1; Jadin SMM, 2017, J ANESTH CLIN RES, V8, P767; Jansen J, 2008, J CLIN ONCOL, V26, P5450, DOI 10.1200/JCO.2007.15.2322; Kessels RPC, 2003, J ROY SOC MED, V96, P219, DOI 10.1258/jrsm.96.5.219; Kiessling C., 2013, GMS Z MED AUSBILD, V30, P1; Kim SS, 2004, EVAL HEALTH PROF, V27, P237, DOI 10.1177/0163278704267037; Langdon IJ, 2002, ANN ROY COLL SURG, V84, P404, DOI 10.1308/003588402760978201; Langewitz W, 2015, PATIENT EDUC COUNS, V98, P716, DOI 10.1016/j.pec.2015.02.003; Laws MB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191940; Lehmann V, 2020, PATIENT EDUC COUNS, V103, P55, DOI 10.1016/j.pec.2019.07.011; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Lienard A, 2010, BRIT J CANCER, V103, P171, DOI 10.1038/sj.bjc.6605749; Linn Annemiek J, 2013, J Crohns Colitis, V7, pe543, DOI 10.1016/j.crohns.2013.04.001; Mauffrey C, 2008, INT ORTHOP, V32, P425, DOI 10.1007/s00264-007-0361-6; Menendez ME, 2015, J HAND SURG-AM, V40, P1860, DOI 10.1016/j.jhsa.2015.06.105; Petermann F, 2011, Z PSYCHIATR PSYCH PS, V59, P251, DOI 10.1024/1661-4747/a000077; POWERS RD, 1988, ANN EMERG MED, V17, P124, DOI 10.1016/S0196-0644(88)80295-6; Siegrist V, 2018, PATIENT EDUC COUNS, V101, P2090, DOI 10.1016/j.pec.2018.08.008; Smith HK, 2012, INJURY, V43, P1534, DOI 10.1016/j.injury.2011.06.419; Street RL, 2009, PATIENT EDUC COUNS, V74, P295, DOI 10.1016/j.pec.2008.11.015; Sustersic M, 2017, HEALTH EXPECT, V20, P531, DOI 10.1111/hex.12487; van der Meulen N, 2008, PSYCHO-ONCOLOGY, V17, P857, DOI 10.1002/pon.1290; Vashi A, 2011, ANN EMERG MED, V57, P315, DOI 10.1016/j.annemergmed.2010.08.024; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Watson PWB, 2009, J ROY SOC MED, V102, P235, DOI 10.1258/jrsm.2009.090013; Williams DM, 1996, AM J EMERG MED, V14, P19, DOI 10.1016/S0735-6757(96)90006-6	44	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2021	16	10							e0257656	10.1371/journal.pone.0257656	http://dx.doi.org/10.1371/journal.pone.0257656			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XU0SG	34662341	Green Accepted, Green Published, gold			2023-01-03	WOS:000733985600004
J	Liu, SB; Wang, ZF; Su, YS; Qi, L; Yang, W; Fu, MZ; Jing, XH; Wang, YQ; Ma, QF				Liu, Shenbin; Wang, Zhifu; Su, Yangshuai; Qi, Lu; Yang, Wei; Fu, Mingzhou; Jing, Xianghong; Wang, Yanqing; Ma, Qiufu			A neuroanatomical basis for electroacupuncture to drive the vagal-adrenal axis	NATURE			English	Article							ACUPUNCTURE; STIMULATION; NOCICEPTORS; MODULATION; MECHANISMS; SEPSIS; PAIN	Somatosensory autonomic reflexes allow electroacupuncture stimulation (ES) to modulate body physiology at distant sites(1-6) (for example, suppressing severe systemic inflammation(6-9)). Since the 1970s, an emerging organizational rule about these reflexes has been the presence of body-region specificity(1-6). For example, ES at the hindlimb ST36 acupoint but not the abdominal ST25 acupoint can drive the vagal-adrenal anti-inflammatory axis in mice(10,11). The neuroanatomical basis of this somatotopic organization is, however, unknown. Here we show that PROKR2(Cre)-marked sensory neurons, which innervate the deep hindlimb fascia (for example, the periosteum) but not abdominal fascia (for example, the peritoneum), are crucial for driving the vagal-adrenal axis. Low-intensity ES at the ST36 site in mice with ablated PROKR2(Cre)-marked sensory neurons failed to activate hindbrain vagal efferent neurons or to drive catecholamine release from adrenal glands. As a result, ES no longer suppressed systemic inflammation induced by bacterial endotoxins. By contrast, spinal sympathetic reflexes evoked by high-intensity ES at both ST25 and ST36 sites were unaffected. We also show that optogenetic stimulation of PROKR2(Cre)-marked nerve terminals through the ST36 site is sufficient to drive the vagal-adrenal axis but not sympathetic reflexes. Furthermore, the distribution patterns of PROKR2(Cre) nerve fibres can retrospectively predict body regions at which low-intensity ES will or will not effectively produce anti-inflammatory effects. Our studies provide a neuroanatomical basis for the selectivity and specificity of acupoints in driving specific autonomic pathways.	[Liu, Shenbin; Wang, Zhifu; Su, Yangshuai; Qi, Lu; Yang, Wei; Fu, Mingzhou; Ma, Qiufu] Dana Farber Canc Inst, Boston, MA 02115 USA; [Liu, Shenbin; Wang, Zhifu; Su, Yangshuai; Qi, Lu; Yang, Wei; Fu, Mingzhou; Ma, Qiufu] Harvard Med Sch, Dept Neurobiol, Boston, MA 02115 USA; [Liu, Shenbin; Wang, Yanqing] Fudan Univ, Inst Acupuncture & Moxibust, Fudan Inst Integrat Med, Shanghai, Peoples R China; [Liu, Shenbin; Wang, Yanqing] Fudan Univ, Sch Basic Med Sci, Dept Integrat Med & Neurobiol, Shanghai, Peoples R China; [Liu, Shenbin; Wang, Yanqing] Fudan Univ, Inst Brain Sci, Shanghai, Peoples R China; [Su, Yangshuai; Jing, Xianghong] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Meridians Res Ctr, Beijing, Peoples R China	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Fudan University; Fudan University; Fudan University; China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS	Ma, QF (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.; Ma, QF (corresponding author), Harvard Med Sch, Dept Neurobiol, Boston, MA 02115 USA.	Qiufu_Ma@dfci.harvard.edu	Jing, Xianghong/HHS-4003-2022	Fu, Mingzhou/0000-0001-5506-259X; Ma, Qiufu/0000-0001-7896-7914	NIH [R01AT010629]; Harvard/MIT Joint Research Program in Basic Neuroscience; Wellcome Trust [200183/Z/15/Z]; China Postdoctoral Science Foundation [KLF101846]; Development Project of Shanghai Peak Disciplines-Integrated Medicine [20150407]; China Scholarship Council (CSC) [201609110039, 20190600178]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard/MIT Joint Research Program in Basic Neuroscience; Wellcome Trust(Wellcome TrustEuropean Commission); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Development Project of Shanghai Peak Disciplines-Integrated Medicine; China Scholarship Council (CSC)(China Scholarship Council)	We thank D. D. Ginty for critical comments, and W. Lu and B. Zhao for helpful discussions; D. D. Ginty, M. Goulding, S. M. Dymecki, staff at GENSAT/MMRRC at the University of Davis, and the Allen Brain Institute/the Jackson Laboratory for genetically modified mice; and S. Celine for her assistance in histochemical analyses. All experimental data were generated at the Dana-Farber Cancer Institute, and the work was supported primarily by a NIH grant (R01AT010629) and partially by the Harvard/MIT Joint Research Program in Basic Neuroscience and a Wellcome Trust grant (200183/Z/15/Z) to Q.M. S.L.'s salary was supported primarily by a NIH grant (R01AT010629) and partly by the China Postdoctoral Science Foundation (KLF101846) and by the Development Project of Shanghai Peak Disciplines-Integrated Medicine (20150407) during an early period before the NIH grant (R01AT010629) was funded. Y.S.'s and W.Y.'s salary was supported by the China Scholarship Council (CSC no. 201609110039 and CSC no. 20190600178, respectively). Z.W.'s salary was supported by Fujian University of Traditional Chinese Medicine and by the Harvard/MIT Joint Research Program in Basic Neuroscience. Histochemical imaging was supported by Boston Children's Hospital IDDRC (1U54HD090255).	Bourane S, 2015, CELL, V160, P503, DOI 10.1016/j.cell.2015.01.011; Chavan SS, 2017, IMMUNITY, V46, P927, DOI 10.1016/j.immuni.2017.06.008; Choi EM, 2012, CHIN MED-UK, V7, DOI 10.1186/1749-8546-7-4; Choi S, 2020, NATURE, V587, P258, DOI 10.1038/s41586-020-2860-1; Damarey B, 2013, EUR J RADIOL, V82, P27, DOI 10.1016/j.ejrad.2011.04.035; Gerfen CR, 2013, NEURON, V80, P1368, DOI 10.1016/j.neuron.2013.10.016; Ghitani N, 2017, NEURON, V95, P944, DOI 10.1016/j.neuron.2017.07.024; KAMETANI H, 1979, J PHYSIOL-LONDON, V294, P407, DOI 10.1113/jphysiol.1979.sp012937; Kleinlogel S, 2011, NAT NEUROSCI, V14, P513, DOI 10.1038/nn.2776; KUCERA J, 1995, ANAT EMBRYOL, V192, P137; Kupari J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21725-z; Langevin HM, 2018, J ALTERN COMPLEM MED, V24, P200, DOI 10.1089/acm.2017.0366; Li YQ, 2007, WORLD J GASTROENTERO, V13, P709, DOI 10.3748/wjg.v13.i5.709; Lima D., 2008, SCI PAIN, P477; Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015; Liu Y, 2010, NEURON, V68, P543, DOI 10.1016/j.neuron.2010.09.008; Longhurst JC, 2010, J ACUPUNCT MERIDIAN, V3, P67, DOI 10.1016/S2005-2901(10)60014-3; Ma QF, 2020, MED ACUPUNCT, V32, P362, DOI 10.1089/acu.2020.1488; Pan WX, 2021, AUTON NEUROSCI-BASIC, V232, DOI 10.1016/j.autneu.2021.102793; Peng ZF, 2016, WORLD J ACUPUNCT-MOX, V26, P1; Quiroz-Gonzalz S, 2014, J ACUPUNCT MERIDIAN, V7, P25, DOI 10.1016/j.jams.2013.06.013; Remick DG, 2000, SHOCK, V13, P110, DOI 10.1097/00024382-200013020-00004; SATO A, 1987, JPN J PHYSIOL, V37, P1, DOI 10.2170/jjphysiol.37.1; Sato A, 1997, Neurosci Behav Physiol, V27, P610, DOI 10.1007/BF02463910; Sharma N, 2020, NATURE, V577, P392, DOI 10.1038/s41586-019-1900-1; Takahashi T, 2013, INT REV NEUROBIOL, V111, P273, DOI 10.1016/B978-0-12-411545-3.00014-6; Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479; Travagli RA, 2016, NAT REV GASTRO HEPAT, V13, P389, DOI 10.1038/nrgastro.2016.76; Ulloa L, 2017, TRENDS MOL MED, V23, P1103, DOI 10.1016/j.molmed.2017.10.006; van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36; Xing JJ, 2013, INT REV NEUROBIOL, V111, P49, DOI 10.1016/B978-0-12-411545-3.00003-1; Yang FC, 2013, CELL REP, V5, P1353, DOI 10.1016/j.celrep.2013.11.005; Zylka MJ, 2005, NEURON, V45, P17, DOI 10.1016/j.neuron.2004.12.015	33	81	94	66	291	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 28	2021	598	7882					641	+		10.1038/s41586-021-04001-4	http://dx.doi.org/10.1038/s41586-021-04001-4		OCT 2021	31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WO4NQ	34646018	Green Accepted			2023-01-03	WOS:000706973200009
J	Suolang, D; Chen, BDJ; Wang, NY; Gottesman, RF; Faigle, R				Suolang, Deji; Chen, Bridget J.; Wang, Nae-Yuh; Gottesman, Rebecca F.; Faigle, Roland			Temporal Trends in Stroke Thrombolysis in the US by Race and Ethnicity, 2009-2018	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CARE	This study investigates the temporal trend in racial and ethnic differences in use of intravenous thrombolysis for stroke treatment between 2009 and 2018 in a representative sample of US adults.	[Suolang, Deji; Chen, Bridget J.; Gottesman, Rebecca F.; Faigle, Roland] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Wang, Nae-Yuh] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Gottesman, Rebecca F.] Natl Inst Neurol Disorders, Stroke Branch, Bethesda, MD USA; [Gottesman, Rebecca F.] Stroke Intramural Res Program, Bethesda, MD USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Faigle, R (corresponding author), Johns Hopkins Univ, Sch Med, 600 N Wolfe St,Phipps 484, Baltimore, MD 21287 USA.	rfaigle1@jhmi.edu		Wang, Nae-Yuh/0000-0001-6513-9730; Chen, Bridget/0000-0001-6167-8315	National Center for Advancing Translational Sciences [UL1 TR003098]; National Institute on Aging [K24 AG052573]; National Institute of Neurological Disorders and Stroke [K23 NS101124]	National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was in part supported by awards from the National Center for Advancing Translational Sciences (UL1 TR003098), the National Institute on Aging (K24 AG052573), and the National Institute of Neurological Disorders and Stroke (K23 NS101124).	Aparicio HJ, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001877; Faigle R, 2016, JAMA NEUROL, V73, P1151, DOI 10.1001/jamaneurol.2016.1914; Hsia AW, 2011, STROKE, V42, P2217, DOI 10.1161/STROKEAHA.111.613828; Kimball MM, 2014, J STROKE CEREBROVASC, V23, P17, DOI 10.1016/j.jstrokecerebrovasdis.2012.06.004; Sacco RL, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004073; Schwamm LH, 2010, CIRCULATION, V121, P1492, DOI 10.1161/CIRCULATIONAHA.109.881490	6	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2021	326	17					1741	1743		10.1001/jama.2021.12966	http://dx.doi.org/10.1001/jama.2021.12966		OCT 2021	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW8DB	34633406	Bronze, Green Published			2023-01-03	WOS:000707427200004
J	Choi, GJ; Ahn, EJ; Lee, OH; Kang, H; Hrncic, D; Hrncic, D; Hrncic, D				Choi, Geun Joo; Ahn, Eun Jin; Lee, Oh Haeng; Kang, Hyun; Hrncic, Dragan; Hrncic, Dragan; Hrncic, Dragan			Effects of a BMI1008 mixture on postoperative pain in a rat model of incisional pain	PLOS ONE			English	Article							METHYLENE-BLUE; LOCAL-ANESTHETICS; DOUBLE-BLIND; LIDOCAINE; DEXAMETHASONE; VITAMINS	Background The purpose of this study was to evaluate the analgesic effect of BMI1008 (a new drug containing lidocaine, methylene blue, dexamethasone and vitamin B complex) and to investigate the analgesic effect of lidocaine and BMI-L (other components of BMI1008 except lidocaine) at different concentrations in a rat model of incisional pain. Methods Male Sprague-Dawley rats (250-300 g) were used for the incisional pain model simulating postoperative pain. After the operation, normal saline, various concentrations of BMI1008, lidocaine with a fixed concentration of BMI-L, and BMI-L with a fixed concentration of lidocaine were injected at the incision site. The preventive analgesic effect was evaluated using BMI1008 administered 30 min before and immediately after the operation. In addition, BMI1008 was compared with positive controls using intraperitoneal ketorolac 30 mg/kg and fentanyl 0.5 mu g/kg. The mechanical withdrawal threshold was measured with a von Frey filament. Results The analgesic effect according to the concentration of BMI1008, lidocaine with a fixed concentration of BMI-L, and BMI-L with a fixed concentration of lidocaine showed a concentration-dependent response and statistically significant difference among the groups (P <0.001, P <0.001, and P <0.001, respectively). The analgesic effect according to the time point of administration (before and after the operation) showed no evidence of a statistically significant difference between the groups (P = 0.170). Compared with the positive control groups, the results showed a statistically significant difference between the groups (P = 0.024). Conclusion BMI1008 showed its analgesic effect in a rat model of incisional pain in a concentration-dependent manner. Moreover, BMI-L showed an additive effect on the analgesic effect of lidocaine.	[Choi, Geun Joo; Ahn, Eun Jin; Lee, Oh Haeng; Kang, Hyun] Chung Ang Univ, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea	Chung Ang University; Chung Ang University Hospital	Kang, H (corresponding author), Chung Ang Univ, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea.	roman00@naver.com	Choi, Geun Joo/AAF-5102-2021	Kang, Hyun/0000-0003-2844-5880				Abacioglu N, 2000, LIFE SCI, V67, P1127, DOI 10.1016/S0024-3205(00)00711-6; Ang CD, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004573.pub3; Aronov Stela, 2005, Drug Metabolism and Drug Interactions, V21, P41; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; BADER AM, 1988, ANESTHESIOLOGY, V69, P409, DOI 10.1097/00000542-198809000-00022; Berrocal M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143521; Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1; BRUGGEMANN G, 1990, KLIN WOCHENSCHR, V68, P116, DOI 10.1007/BF01646858; Choi GJ, 2016, J SURG RES, V206, P223, DOI 10.1016/j.jss.2016.08.005; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Farrokhi MR, 2016, CLIN NEUROL NEUROSUR, V150, P6, DOI 10.1016/j.clineuro.2016.08.018; Flanders CA, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2690-4; Fransiska Dewi, 2017, Adv Med, V2017, P3968278, DOI 10.1155/2017/3968278; FUJINAGA M, 1986, ANESTHESIOLOGY, V65, P626, DOI 10.1097/00000542-198612000-00010; Gillman PK, 2008, CAN J ANAESTH, V55, P311, DOI 10.1007/BF03017212; Gordh T, 2010, ANESTHESIOLOGY, V113, P1433, DOI 10.1097/ALN.0b013e3181fcef48; Greca FH, 2008, ACTA CIR BRAS, V23, P149, DOI 10.1590/S0102-86502008000200007; Holte K, 2002, J AM COLL SURGEONS, V195, P694, DOI 10.1016/S1072-7515(02)01491-6; Horner DL, 2012, BJA EDUC, V12, P199, DOI 10.1093/bjaceaccp/mks021; Hurley RW, 2008, ANESTH ANALG, V107, P309, DOI 10.1213/01.ane.0b013e31816ba437; Kallewaard JW, 2019, PAIN, V160, P945, DOI 10.1097/j.pain.0000000000001475; Khezri MB, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006545; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kjetil H, 2007, ANESTH ANALG, V105, P481, DOI 10.1213/01.ane.0000267261.61444.69; Kopacz DJ, 2003, ANESTH ANALG, V96, P576, DOI 10.1097/00000539-200302000-00050; Mentes B B, 2004, Tech Coloproctol, V8, P11, DOI 10.1007/s10151-004-0043-y; Mohammad HR, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0485-8; Moiniche S, 1998, BRIT J ANAESTH, V81, P377, DOI 10.1093/bja/81.3.377; OSullivan BT, 1997, BIOL PSYCHIAT, V41, P574, DOI 10.1016/S0006-3223(96)00094-7; Parham SM, 1996, CAN J SURG, V39, P31; Peng BG, 2010, PAIN, V149, P124, DOI 10.1016/j.pain.2010.01.021; Ponce-Monter HA, 2012, PAIN RES TREAT, V2012, DOI 10.1155/2012/104782; RAYMOND SA, 1989, ANESTH ANALG, V68, P563; Reyes-Garcia G, 2002, P W PHARMACOL SOC, V45, P144; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sluka KA, 2001, MUSCLE NERVE, V24, P37, DOI 10.1002/1097-4598(200101)24:1<37::AID-MUS4>3.0.CO;2-8; Staff Nathan P, 2014, Continuum (Minneap Minn), V20, P1293, DOI 10.1212/01.CON.0000455880.06675.5a; Swain A, 2017, WORLD J CLIN CASES, V5, P307, DOI 10.12998/wjcc.v5.i8.307; Thomas S, 2006, CAN J ANAESTH, V53, P899, DOI 10.1007/BF03022833; Vaccaro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042117; van den Berg JP, 2017, BRIT J ANAESTH, V118, P44, DOI 10.1093/bja/aew312; Wu CL, 2011, LANCET, V377, P2215, DOI 10.1016/S0140-6736(11)60245-6; Zhang YG, 2010, NEUROTOXICOLOGY, V31, P724, DOI 10.1016/j.neuro.2010.07.001	43	0	0	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257267	10.1371/journal.pone.0257267	http://dx.doi.org/10.1371/journal.pone.0257267			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM7DR	34570780	Green Published, gold			2023-01-03	WOS:000728983400028
J	Mafi, JN; Craff, M; Vangala, S; Pu, T; Skinner, D; Tabatabai-Yazdi, C; Nelson, A; Reid, R; Agniel, D; Tseng, CH; Sarkisian, C; Damberg, CL; Kahn, KL				Mafi, John N.; Craff, Melody; Vangala, Sitaram; Pu, Thomas; Skinner, Dale; Tabatabai-Yazdi, Cyrus; Nelson, Anikia; Reid, Rachel; Agniel, Denis; Tseng, Chi-Hong; Sarkisian, Catherine; Damberg, Cheryl L.; Kahn, Katherine L.			Trends in US Ambulatory Care Patterns During the COVID-19 Pandemic, 2019-2021	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; VISITS; DISPARITIES; IMPACT	IMPORTANCE Following reductions in US ambulatory care early in the pandemic, it remains unclear whether care consistently returned to expected rates across insurance types and services. OBJECTIVE To assess whether patients with Medicaid or Medicare-Medicaid dual eligibility had significantly lower than expected return to use of ambulatory care rates than patients with commercial, Medicare Advantage, or Medicare fee-for-service insurance. DESIGN, SETTING, AND PARTICIPANTS In this retrospective cohort study examining ambulatory care service patterns from January 1, 2019, through February 28, 2021, claims data from multiple US payers were combined using the Milliman Medlnsight research database. Using a difference-in-differences design, the extent to which utilization during the pandemic differed from expected rates had the pandemic not occurred was estimated. Changes in utilization rates between January and February 2020 and each subsequent 2-month time frame during the pandemic were compared with the changes in the corresponding months from the year prior. Age- and sex-adjusted Poisson regression models of monthly utilization counts were used, offsetting for total patient-months and stratifying by service and insurance type. EXPOSURES Patients with Medicaid or Medicare-Medicaid dual eligibility compared with patients with commercial, Medicare Advantage, or Medicare fee-for-service insurance, respectively. MAIN OUTCOMES AND MEASURES Utilization rates per 100 people for 6 services: emergency department, office and urgent care, behavioral health, screening colonoscopies, screening mammograms, and contraception counseling or HIV screening. RESULTS More than 14.5 million US adults were induded (mean age, 52.7 years; 54.9% women). In the March-April 2020 time frame, the combined use of 6 ambulatory services declined to 67.0% (95% CI, 66.9%-67.1%) of expected rates, but returned to 96.7% (95% CI, 96.6%-96.8%) of expected rates by the November-December 2020 time frame. During the second COVID-19 wave in the January-February 2021 time frame, overall utilization again declined to 86.2% (95% CI, 86.1%-86.3%) of expected rates, with colonoscopy remaining at 65.0% (95% CI, 64.1%-65.9%) and mammography at 79.2% (95% CI, 78.5%-79.8%) of expected rates. By the January-February 2021 time frame, overall utilization returned to expected rates as follows: patients with Medicaid at 78.4% (95% CI. 78.2%-78.7%), Medicare-Medicaid dual eligibility at 73.3% (95% CI. 72.8%-73.8%). commercial at 90.7% (95% CI. 90.5%-90.9%), Medicare Advantage at 83.2% (95% CI. 81.7%-82.2%), and Medicare fee-for-service at 82.0% (95% CI, 81.7%-82.2%; P < .001; comparing return to expected utilization rates among patients with Medicaid and Medicare-Medicaid dual eligibility, respectively, with each of the other insurance types). CONCLUSIONS AND RELEVANCE Between March 2020 and February 2021, aggregate use of 6 ambulatory care services increased after the preceding decrease in utilization that followed the onset of the COVID-19 pandemic. However, the rate of increase in use of these ambulatory care services was significantly lower for participants with Medicaid or Medicare-Medicaid dual eligibility than for those insured by commercial, Medicare Advantage, or Medicare fee-for-service.	[Mafi, John N.; Vangala, Sitaram; Tseng, Chi-Hong; Sarkisian, Catherine; Kahn, Katherine L.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, 1100 Glendon Ave,908, Los Angeles, CA 90024 USA; [Mafi, John N.; Reid, Rachel; Agniel, Denis; Damberg, Cheryl L.; Kahn, Katherine L.] RAND Corp, RAND Hlth, Santa Monica, CA USA; [Craff, Melody; Pu, Thomas; Skinner, Dale; Nelson, Anikia] Milliman MedInsight, Seattle, WA USA; [Tabatabai-Yazdi, Cyrus] Univ Calif Los Angeles, Sch Comp Sci, Los Angeles, CA USA; [Reid, Rachel] Harvard Med Sch, Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation; University of California System; University of California Los Angeles; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mafi, JN (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, 1100 Glendon Ave,908, Los Angeles, CA 90024 USA.	jmafi@mednet.ucla.edu			National Institute on Aging K76 Career Development Award	National Institute on Aging K76 Career Development Award	This work was supported by the National Institute on Aging K76 Career Development Award. UCLA paid Milliman to provide the data and perform descriptive cohort analyses provided by Drs Craff and Nelson and Messrs Pu and Skinner. UCLA also paid Mr Tabatabai-Yazdi to perform data analysis and data visualization. All statistical analyses were completed at UCLA.	[Anonymous], MILLIMAN MEDINSIGHT; [Anonymous], Overview of Medicare and Medicaid state telehealth policies; [Anonymous], MEDICARE TELEMEDICIN; [Anonymous], 2006, WHO WHAT WHY NPI; [Anonymous], Coding scenario: coding for telehealth visits; [Anonymous], NEW YORK TIMES; Becker NV, 2021, JAMA-HEALTH FORUM, V2, DOI 10.1001/jamahealthforum.2021.1408; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bray MJC, 2021, JAMA PSYCHIAT, V78, P444, DOI 10.1001/jamapsychiatry.2020.3938; Cox C., HAVE HLTH SPENDING U; Czeisler ME, 2020, MMWR-MORBID MORTAL W, V69, P1250, DOI 10.15585/mmwr.mm6936a4; Findling Mary G, 2020, JAMA Health Forum, V1, pe201463, DOI 10.1001/jamahealthforum.2020.1463; Fronstin P, MANY AM HAVE LOST J; Godwin J, 2021, INQUIRY-J HEALTH CAR, V58, DOI 10.1177/0046958021991276; Hartnett KP, 2020, MMWR-MORBID MORTAL W, V69, P699, DOI 10.15585/mmwr.mm6923e1; Health Resources & Services Administration, WOM PREV SERV GUID; Khorrami P, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.9463; Maddox KEJ, 2019, JAMA INTERN MED, V179, P769, DOI 10.1001/jamainternmed.2019.0117; Maringe C, 2020, LANCET ONCOL, V21, P1023, DOI 10.1016/S1470-2045(20)30388-0; Martin K, IMPACT COVID 19 USE; Mehrotra A, WHAT IMPACT HAS COVI; Mehrotra A, TELEMEDICINE WHAT SH; Nolen LST, HEALTH AFFAIR, DOI [10.1377/forefront.20200828.661111/full, DOI 10.1377/FOREFRONT.20200828.661111/FULL]; Parikh-Patel A, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009125; Patel SY, 2021, JAMA INTERN MED, V181, P388, DOI 10.1001/jamainternmed.2020.5928; Rodriguez JA, 2021, AM J MANAG CARE, V27, P21, DOI 10.37765/ajmc.2021.88573; Saloner B, 2014, NEW ENGL J MED, V370, P1177, DOI 10.1056/NEJMp1316370; Schmidt AL, 2020, CANCER CELL, V38, P769, DOI 10.1016/j.ccell.2020.10.023; Telemedicine, MED; US Preventive Services Task Force, GRADE B REC SERV; Uscher-Pines L, 2021, JAMA-J AM MED ASSOC, V325, P1106, DOI 10.1001/jama.2021.0282; Whaley CM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.24984; Woolf SH, 2021, JAMA-J AM MED ASSOC, V325, P1786, DOI 10.1001/jama.2021.5199; Woolf SH, 2020, JAMA-J AM MED ASSOC, V324, P510, DOI 10.1001/jama.2020.11787; Yabroff KR, 2020, JNCI-J NATL CANCER I, V112, P671, DOI 10.1093/jnci/djaa048; Yang J, 2020, GEN HOSP PSYCHIAT, V67, P100, DOI 10.1016/j.genhosppsych.2020.09.004	36	10	10	5	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2022	327	3					237	247		10.1001/jama.2021.24294	http://dx.doi.org/10.1001/jama.2021.24294			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV9PQ	35040886	Bronze, Green Published			2023-01-03	WOS:000753055100018
J	Humphries, H; Upfold, M; Mahlase, G; Mdladla, M; Gengiah, TN; Karim, QA				Humphries, Hilton; Upfold, Michele; Mahlase, Gethwana; Mdladla, Makhosazana; Gengiah, Tanuja N.; Karim, Quarraisha Abdool			Implants for HIV prevention in young women: Provider perceptions and lessons learned from contraceptive implant provision	PLOS ONE			English	Article							ACTING REVERSIBLE CONTRACEPTION; HEALTH-CARE PROVIDERS; SOUTH-AFRICA; PREEXPOSURE PROPHYLAXIS; MISCONCEPTIONS; PERSPECTIVES; MYTHS; RISK; GAPS	Preventing new HIV infections, especially amongst young women, is key to ending the HIV epidemic especially in sub-Saharan Africa. Potent antiretroviral (ARV) drugs used as pre-exposure prophylaxis (PrEP) are currently being formulated as long-acting implantable devices, or nanosuspension injectables that release drug at a sustained rate providing protection from acquiring HIV. PrEP as implants (PrEP Implants) offers an innovative and novel approach, expanding the HIV prevention toolbox. Feedback from providers and future users in the early clinical product development stages may identify modifiable characteristics which can improve acceptability and uptake of new technologies. Healthcare workers (HCWs) perspectives and lessons learned during the rollout of contraceptive implants will allow us to understand what factors may impact the roll-out of PrEP implants. We conducted eighteen interviews with HCWs (9 Nurses and 9 Community Healthcare Workers) in rural KwaZulu-Natal, South Africa. HCWs listed the long-acting nature of the contraceptive implant as a key benefit, helping to overcome healthcare system barriers like heavy workloads and understaffing. However, challenges like side effects, migration of the implant, stakeholder buy-in and inconsistent training on insertion and removal hampered the roll-out of the contraceptive implant. For PrEP implants, HCWs preferred long-acting products that were palpable and biodegradable. Our findings highlighted that the characteristics of PrEP implants that are perceived to be beneficial by HCWs may not align with that of potential users, potentially impacting the acceptability and uptake of PrEP implants. Further our data highlight the need for sustained and multi-pronged approaches to training HCWs and introducing new health technologies into communities. Finding a balance between the needs of HCWs that accommodate their heavy workloads, limited resources at points of delivery of care and the needs and preferences of potential users need to be carefully considered in the development of PrEP implants.	[Humphries, Hilton; Upfold, Michele; Mahlase, Gethwana; Mdladla, Makhosazana; Gengiah, Tanuja N.; Karim, Quarraisha Abdool] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa	University of Kwazulu Natal	Humphries, H (corresponding author), Univ KwaZulu Natal, Nelson R Mandela Sch Med, Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa.	Hilton.humphries@caprisa.org	Abdool Karim, Quarraisha/GVS-1160-2022	Abdool Karim, Quarraisha/0000-0002-0985-477X; Humphries, Hilton/0000-0001-8503-4127; Gengiah, Tanuja/0000-0002-3405-5128	South African Medical Research Council Special initiative grant [00251]; Department of Science and Innovation-National Research Foundation Centre of Excellence in HIV Prevention	South African Medical Research Council Special initiative grant; Department of Science and Innovation-National Research Foundation Centre of Excellence in HIV Prevention	Funding: Funding for the study was provided by South African Medical Research Council Special initiative grant (00251), and partial support from the Department of Science and Innovation-National Research Foundation Centre of Excellence in HIV Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baeten JM, 2016, NEW ENGL J MED, V375, P2121, DOI 10.1056/NEJMoa1506110; Beesham I, 2021, AFR J REPROD HEALTH, V25, P41, DOI 10.29063/ajrh2021/v25i1.5; Bekker LG, 2018, LANCET HIV, V5, pE68, DOI 10.1016/S2352-3018(17)30156-X; Blackstone SR, 2017, INT Q COMMUNITY HEAL, V37, P79, DOI 10.1177/0272684X16685254; Boyatzis Richard E., 1998, TRANSFORMING QUALITA, DOI 10.1191/1478088706qp063oa; Brown A, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7312-1; Bukenya D, 2019, AIDS RES THER, V16, DOI 10.1186/s12981-018-0214-y; Dunbar MS, 2018, SEX HEALTH, V15, P513, DOI 10.1071/SH18061; Garrett CC, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0227-9; IAVI, 2021, EV ACC PATHW LONG AC; Ismail H, 2006, J FAM PLAN REPROD H, V32, P157, DOI 10.1783/147118906777888413; Karim SSAA, 2019, CAPRISA 018 PHASE 3; Kerrigan D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190487; Kharsany ABM, 2018, LANCET HIV, V5, pE427, DOI 10.1016/S2352-3018(18)30104-8; Kharsany ABM, 2015, JAIDS-J ACQ IMM DEF, V70, P289, DOI 10.1097/QAI.0000000000000761; Kriel Y, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0749-y; Krogstad EA, 2019, AIDS PATIENT CARE ST, V33, P157, DOI 10.1089/apc.2018.0177; Mansoor LE, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25381; Montgomery ET, 2019, JAIDS-J ACQ IMM DEF, V80, P542, DOI 10.1097/QAI.0000000000001960; Morrison CS, 2007, AIDS, V21, P85, DOI 10.1097/QAD.0b013e3280117c8b; Mullick S, 2017, SAMJ S AFR MED J, V107, P812, DOI [10.7196/SAMJ.2017.v107i10.12849, 10.7196/samj.2017.v107i10.12849]; Mwaisaka J, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09849-1; Nanda K, 2015, WOMENS HEALTH, V11, P729, DOI 10.2217/whe.15.84; Nel A, 2016, NEW ENGL J MED, V375, P2133, DOI 10.1056/NEJMoa1602046; Ontiri S, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091543; Patel RC, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21396; Pillay D, 2017, SAMJ S AFR MED J, V107, P827, DOI [10.7196/SAMJ.2017.v107i10.12822, 10.7196/samj.2017.v107i10.12822]; Pleaner M, 2017, SAMJ S AFR MED J, V107, P933, DOI [10.7196/SAMJ.2017.v107i11.12805, 10.7196/samj.2017.v107i11.12805]; Ralph LJ, 2015, LANCET INFECT DIS, V15, P181, DOI 10.1016/S1473-3099(14)71052-7; Rees H, 2017, SAMJ S AFR MED J, V107, P939, DOI [10.7196/SAMJ.2017.v107i11.12903, 10.7196/samj.2017.v107i11.12903]; Roberts K, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0707-y; Russo JA, 2013, J ADOLESCENT HEALTH, V52, pS14, DOI 10.1016/j.jadohealth.2013.02.003; Schneider H, 2008, HEALTH POLICY PLANN, V23, P179, DOI 10.1093/heapol/czn006; Staveteig S, 2015, DHS ANAL STUDIES, V54; Strauss A., 1994, HDB QUALITATIVE RES, DOI DOI 10.1007/BF00988593; Thomson KA, 2016, CURR OPIN HIV AIDS, V11, P18, DOI 10.1097/COH.0000000000000207; UNAIDS, 2019, WOM HIV SPOTL AD GIR, P120	37	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2022	17	1							e0262043	10.1371/journal.pone.0262043	http://dx.doi.org/10.1371/journal.pone.0262043			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H0VF	35025908	Green Published, gold			2023-01-03	WOS:000796264200041
J	Teal, S; Edelman, A				Teal, Stephanie; Edelman, Alison			Contraception Selection, Effectiveness, and Adverse Effects A Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LEVONORGESTREL INTRAUTERINE SYSTEM; HUMAN CHORIONIC-GONADOTROPIN; FAMILY-PLANNING CLIENTS; ORAL-CONTRACEPTIVES; EMERGENCY CONTRACEPTION; ULIPRISTAL ACETATE; BLEEDING PATTERNS; DRUG-INTERACTIONS; QUICK START; VENOUS THROMBOEMBOLISM	IMPORTANCE Many women spend a substantial proportion of their lives preventing or planning for pregnancy, and approximately 87% of US women use contraception during their lifetime. OBSERVATIONS Contraceptive effectiveness is determined by a combination of drug or device efficacy, individual fecundability, coital frequency, and user adherence and continuation. In the US, oral contraceptive pills are the most commonly used reversible method of contraception and comprise 21.9% of all contraception in current use. Pregnancy rates of women using oral contraceptives are 4% to 7% per year. Use of long-acting methods, such as intrauterine devices and subdermal implants, has increased substantially, from 6% of all contraceptive users in 2008 to 17.8% in 2016; these methods have failure rates of less than 1% per year. Estrogen-containing methods, such as combined oral contraceptive pills, increase the risk of venous thrombosis from 2 to 10 venous thrombotic events per 10 000 women-years to 7 to 10 venous thrombotic events per 10 000 women-years, whereas progestin-only and nonhormonal methods, such as implants and condoms, are associated with rare serious risks. Hormonal contraceptives can improve medical conditions associated with hormonal changes related to the menstrual cycle, such as acne, endometriosis, and premenstrual dysphoric disorder. Optimal contraceptive selection requires patient and clinician discussion of the patient's tolerance for risk of pregnancy, menstrual bleeding changes, other risks, and personal values and preferences. CONCLUSIONS AND RELEVANCE Oral contraceptive pills are the most commonly used reversible contraceptives, intrauterine devices and subdermal implants have the highest effectiveness, and progestin-only and nonhormonal methods have the lowest risks. Optimal contraceptive selection incorporates patient values and preferences.	[Teal, Stephanie] Univ Hosp Med Ctr, Dept OB GYN, Portland, ME USA; [Teal, Stephanie] Case Western Reserve Univ, Cleveland, OH USA; [Edelman, Alison] Oregon Hlth & Sci Univ, Dept OB GYN, Portland, ME USA	Case Western Reserve University; Oregon Health & Science University	Teal, S (corresponding author), Univ Hosp Med Ctr, Dept OB GYN, 11100 Euclid Ave,MAC-5304, Cleveland, OH 44106 USA.; Teal, S (corresponding author), Case Western Reserve Univ, 11100 Euclid Ave,MAC-5304, Cleveland, OH 44106 USA.	Stephanie.Teal@uhhospitals.org						Abou-Setta AM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005072.pub3; Ali M, 2016, HUM REPROD, V31, P2491, DOI 10.1093/humrep/dew222; Arowojolu AO, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004425.pub5, 10.1002/14651858.CD004425.pub6]; Barnhart K, 2004, OBSTET GYNECOL, V104, P975, DOI 10.1097/01.AOG.0000142712.80407.fd; Bellanca HK, 2013, CONTRACEPTION, V88, P3, DOI 10.1016/j.contraception.2013.05.003; BELSEY EM, 1988, CONTRACEPTION, V38, P181, DOI 10.1016/0010-7824(88)90038-8; Birtch RL, 2006, CONTRACEPTION, V73, P235, DOI 10.1016/j.contraception.2005.09.009; Brache V, 2013, CONTRACEPTION, V88, P611, DOI 10.1016/j.contraception.2013.05.010; BRACKEN MB, 1978, INT J EPIDEMIOL, V7, P309, DOI 10.1093/ije/7.4.309; Centers for Disease Control and Prevention, US MED EL CRIT CONTR; Centers for Disease Control and Prevention, NAT AMB MED CAR SURV; Centre for Disease Control and Prevention, 2014, US SEL PRACT REC CON; Christensen J, 2007, EPILEPSIA, V48, P484, DOI 10.1111/j.1528-1167.2007.00997.x; Contraceptive Technology, 2018, TABL 26 1 PERC WOM E; Creinin MD, 2020, CONTRACEPTION, V102, P143, DOI 10.1016/j.contraception.2020.05.017; Critchley HOD, 1998, HUM REPROD, V13, P1218, DOI 10.1093/humrep/13.5.1218; Daniels Kimberly, 2013, Natl Health Stat Report, P1; DERICKSTAN JSE, 1983, OBSTET GYNECOL, V62, P687; Dinger J, 2011, OBSTET GYNECOL, V117, P33, DOI 10.1097/AOG.0b013e31820095a2; Dinger JC, 2007, CONTRACEPTION, V75, P344, DOI 10.1016/j.contraception.2006.12.019; Dinger JC, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-77; Duijkers IJM, 2016, CONTRACEPTION, V93, P303, DOI 10.1016/j.contraception.2015.12.007; Edelman A, 2007, CONTRACEPTION, V75, P450, DOI 10.1016/j.contraception.2007.02.005; Edelman A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004695.pub3; Edelman AB, 2006, OBSTET GYNECOL, V107, P657, DOI 10.1097/01.AOG.0000199950.64545.16; Edelman AB, 2014, CONTRACEPTION, V90, P550, DOI 10.1016/j.contraception.2014.06.033; Endrikat J, 2011, CONTRACEPTION, V84, P549, DOI 10.1016/j.contraception.2011.04.009; ESHRE Capri Workshop Grp, 2013, HUM REPROD UPDATE, V19, P471, DOI 10.1093/humupd/dmt028; Fedele L, 1997, FERTIL STERIL, V68, P426, DOI 10.1016/S0015-0282(97)00245-8; Food and Drug Administration, 2020, CLIN DRUG INT STUD C; Gaffield ME, 2011, CONTRACEPTION, V83, P16, DOI 10.1016/j.contraception.2010.06.013; Gallo MF, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003989.pub4; GARDNER JM, 1970, FERTIL STERIL, V21, P286; Geist C, 2019, CONTRACEPTION, V99, P22, DOI 10.1016/j.contraception.2018.08.014; Glasier A, 2013, OBSTET GYNECOL SURV, V68, P208, DOI 10.1097/OGX.0b013e318285bc06; Glasier AF, 2010, LANCET, V375, P555, DOI 10.1016/S0140-6736(10)60101-8; Grentzer JM, 2015, CONTRACEPTION, V92, P313, DOI 10.1016/j.contraception.2015.06.012; Grimes DA, 2005, CONTRACEPTION, V72, P85, DOI 10.1016/j.contraception.2005.03.010; Grimes DA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007541.pub3; Heinemann LAJ, 2007, CONTRACEPTION, V75, P328, DOI 10.1016/j.contraception.2006.12.018; Hubacher D, 2001, NEW ENGL J MED, V345, P561, DOI 10.1056/NEJMoa010438; Hubacher D, 2009, CONTRACEPTION, V80, P113, DOI 10.1016/j.contraception.2009.02.008; Hurskainen R, 2004, ACTA OBSTET GYN SCAN, V83, P401, DOI 10.1111/j.0001-6349.2004.00440.x; Istre O, 2001, FERTIL STERIL, V76, P304, DOI 10.1016/S0015-0282(01)01909-4; Jackson E, 2011, OBSTET GYNECOL, V117, P691, DOI 10.1097/AOG.0b013e31820ce2db; Kavanaugh Megan L, 2020, F S Rep, V1, P83, DOI 10.1016/j.xfre.2020.06.006; KESSERU E, 1975, FERTIL STERIL, V26, P57; Lethaby A, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000154.pub3; Lowe RF, 2013, CONTRACEPTION, V87, P486, DOI 10.1016/j.contraception.2012.09.025; Mahmood T, 1998, HUM REPROD, V13, P2991, DOI 10.1093/humrep/13.11.2991; Mansour D, 2008, EUR J CONTRACEP REPR, V13, P13, DOI 10.1080/13625180801959931; Mantha S, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4944; Matteson KA, 2013, OBSTET GYNECOL, V121, P632, DOI 10.1097/AOG.0b013e3182839e0e; Mohllajee AP, 2006, CONTRACEPTION, V73, P145, DOI 10.1016/j.contraception.2005.08.007; Nanda K, 2017, AIDS, V31, P917, DOI 10.1097/QAD.0000000000001392; National Center for Health Statistics Centers for Disease Control and Prevention, KEY STAT NAT SURV FA; Nelson AL, 2019, EXPERT REV CLIN PHAR, V12, P953, DOI 10.1080/17512433.2019.1669448; Ortiz ME, 2007, CONTRACEPTION, V75, pS16, DOI 10.1016/j.contraception.2007.01.020; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; Polis CB, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005497.pub2; Raymond EG, 2011, OBSTET GYNECOL, V117, P673, DOI 10.1097/AOG.0b013e318209dc25; Reid PC, 2005, BJOG-INT J OBSTET GY, V112, P1121, DOI 10.1111/j.1471-0528.2005.00642.x; Richards M, 2017, CONTRACEPTION, V95, P364, DOI 10.1016/j.contraception.2017.01.010; Ruchhoft EA, 1996, FERTIL STERIL, V66, P54, DOI 10.1016/S0015-0282(16)58387-3; Schafer JE, 2006, CONTRACEPTION, V73, P488, DOI 10.1016/j.contraception.2005.11.003; Schindler AE, 2003, MATURITAS, V46, pS7, DOI 10.1016/j.maturitas.2003.09.014; Schreiber CA, 2018, EUR J CONTRACEP REPR, V23, P116, DOI 10.1080/13625187.2018.1449825; Simmons KB, 2018, BJOG-INT J OBSTET GY, V125, P804, DOI 10.1111/1471-0528.15027; Simmons KB, 2018, AM J OBSTET GYNECOL, V218, P88, DOI 10.1016/j.ajog.2017.07.003; SIVIN I, 1990, CONTRACEPTION, V42, P361, DOI 10.1016/0010-7824(90)90046-X; Soysal S, 2005, GYNECOL OBSTET INVES, V59, P29, DOI 10.1159/000080932; Stanback J, 1999, LANCET, V354, P566, DOI 10.1016/S0140-6736(99)01578-0; Stanback J, 2006, J FAM PLAN REPROD H, V32, P27, DOI 10.1783/147118906775275370; Stanback J, 2008, REV PANAM SALUD PUBL, V23, P116, DOI 10.1590/S1020-49892008000200007; Stanczyk FZ, 2003, STEROIDS, V68, P879, DOI 10.1016/j.steroids.2003.08.003; STEIER JA, 1984, OBSTET GYNECOL, V64, P391; Sufrin CB, 2012, OBSTET GYNECOL, V120, P1314, DOI [10.1097/AOG.0b013e318273364c, http://10.1097/AOG.0b013e318273364c]; Suhonen S, 2004, CONTRACEPTION, V69, P407, DOI 10.1016/j.contraception.2003.11.008; Sulak PJ, 2000, OBSTET GYNECOL, V95, P261, DOI 10.1016/S0029-7844(99)00524-4; Sundaram A, 2017, PERSPECT SEX REPRO H, V49, P7, DOI 10.1363/psrh.12017; Tepper NK, 2016, CONTRACEPTION, V94, P678, DOI 10.1016/j.contraception.2016.04.014; TOIVONEN J, 1991, OBSTET GYNECOL, V77, P261, DOI 10.1097/00006250-199102000-00019; TRUSSELL J, 1991, AM J OBSTET GYNECOL, V165, P2054, DOI 10.1016/S0002-9378(11)90581-X; Tsuchiya Y, 2005, CANCER LETT, V227, P115, DOI 10.1016/j.canlet.2004.10.007; Turok DK, 2021, NEW ENGL J MED, V384, P335, DOI 10.1056/NEJMoa2022141; Turok DK, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.05.017; Turok DK, 2016, CONTRACEPTION, V93, P526, DOI 10.1016/j.contraception.2016.01.009; van Zuuren EJ, 2016, BRIT J DERMATOL, V175, P45, DOI 10.1111/bjd.14486; VESSEY M, 1987, BRIT MED J, V294, P1518, DOI 10.1136/bmj.294.6586.1518; VESSEY MP, 1968, BMJ-BRIT MED J, V2, P199, DOI 10.1136/bmj.2.5599.199; von Hertzen H, 2002, LANCET, V360, P1803, DOI 10.1016/S0140-6736(02)11767-3; Westhoff C, 2000, AM J EPIDEMIOL, V152, P242, DOI 10.1093/aje/152.3.242; Westhoff C, 2002, CONTRACEPTION, V66, P141, DOI 10.1016/S0010-7824(02)00351-7; Westhoff C, 2007, OBSTET GYNECOL, V109, P1270, DOI 10.1097/01.AOG.0000264550.41242.f2; Wilcox AJ, 2001, JAMA-J AM MED ASSOC, V286, P1759, DOI 10.1001/jama.286.14.1759; Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855; Wong CL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002120.pub3	97	18	18	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	2021	326	24					2507	2518		10.1001/jama.2021.21392	http://dx.doi.org/10.1001/jama.2021.21392			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC6FM	34962522	Bronze			2023-01-03	WOS:000739785000023
J	Gurram, S; Preetam, VC; Lakshmi, KV; Raju, MVLN; Venkateshwarlu, M; Bora, S				Gurram, Srinivas; Preetam, Chinni, V; Lakshmi, Vijaya K.; Raju, M. V. L. N.; Venkateshwarlu, M.; Bora, Swathi			Supplementation of chicory root powder as an alternative to antibiotic growth promoter on gut pH, gut microflora and gut histomorphometery of male broilers	PLOS ONE			English	Article							INTESTINAL MICROFLORA; PERFORMANCE; INULIN; MORPHOLOGY; CHICKENS	The experiment was conducted to study the effect of chicory root powder on the gut performance of broilers. For this purpose, two hundred commercial male broiler chicks were randomly divided into 5 treatment groups with 8 replications of 5 birds each and reared in battery brooders up to 42 days of age. The experimental design consisted of; T1 basal diet (BD) without antibiotic, T2: BD + antibiotic (BMD at 500 gm/ton), T3: BD + chicory root powder (0.5%), T4: BD + chicory root powder (1.0%), T5: BD + chicory root powder (1.5%). The results revealed that supplementation of 1.0% chicory root powder recorded significantly (P<0.05) higher body weight gain, feed intake and better feed conversion ratio (FCR) compared to antibiotic, control and 0.5 & 1.5% chicory powder at 42 days of age. Supplementation of various levels of chicory root powder significantly (P<0.05) lowered (P<0.05) the pH in duodenum, jejunum, ileum and caecum compared to control. Supplementation of chicory root powder (0.5, 1.0 & 1.5%) significantly (P<0.05) decreased the E. coli and Salmonella counts and (P<0.05) increased the Lactobacilli counts in ileum when compared to control and antibiotic groups. Supplementation of chicory (1.0% and 1.5%) groups significantly (P<0.05) increased the villus height (VH), crypt depth (CD), VH:CD ratio and villus width (VW) in the duodenum, ileum and jejunum at 42 d of age. Supplementation of chicory 1.0% and 1.5% groups significantly (P<0.05) increased the goblet cell number in duodenum, jejunum and ileum of broilers. Therefore, chicory root powder (1.0 and 1.5%) can be used as an alternative to antibiotic for improving gut performance of broiler chicken.	[Gurram, Srinivas; Preetam, Chinni, V] PV Narsimha Rao Telangana Vet Univ, Coll Vet Sci, Dept Poultry Sci, Hyderabad, India; [Lakshmi, Vijaya K.] PV Narsimha Rao Telangana Vet Univ, Coll Vet Sci, Dept Livestock Farm Complex, Warangal, Andhra Pradesh, India; [Raju, M. V. L. N.] ICAR Res Complex, Poultry Nutr, Poultry Res, Hyderabad, India; [Venkateshwarlu, M.] PV Narsimha Rao Telangana Vet Univ, Dept Anim Nutr, Hyderabad, India; [Bora, Swathi] PV Narsimha Rao Telangana Vet Univ, Coll Vet Sci, Dept Vet Pathol, Hyderabad, India		Gurram, S (corresponding author), PV Narsimha Rao Telangana Vet Univ, Coll Vet Sci, Dept Poultry Sci, Hyderabad, India.	gurramsrinivas4@gmail.com		Bora, Dr. Swathi/0000-0003-4141-4026; srinivas, gurram/0000-0003-0745-8834; RAJU, M.V.L.N./0000-0001-5175-8784				Biswas A, 2019, INDIAN J ANIM RES, V53, P785, DOI 10.18805/ijar.B-3579; CORRIER DE, 1990, AVIAN DIS, V34, P617, DOI 10.2307/1591254; Dibner JJ, 2005, POULTRY SCI, V84, P634, DOI 10.1093/ps/84.4.634; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; Gunal M., 2006, International Journal of Poultry Science, V5, P149; Huyghebaert G, 2011, VET J, V187, P182, DOI 10.1016/j.tvjl.2010.03.003; Izadi Homan, 2013, Vet Res Forum, V4, P169; Kareem KY, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0790-9; Kirkpinar F, 2018, J ANIMAL PRODUCTION, V59, P1, DOI DOI 10.29185/HAYURETIM.469862; Liu HY, 2011, POULTRY SCI, V90, P815, DOI 10.3382/ps.2010-01181; Nabizadeh A, 2012, J ANIM FEED SCI, V21, P725, DOI 10.22358/jafs/66144/2012; Ortiz LT, 2009, BRIT POULTRY SCI, V50, P325, DOI 10.1080/00071660902806962; Osfar S, 2019, INT J FOOD SCI AGR, V3, P292; Praveen T, 2017, INT J CURRENT MICROB, V6, P1470; Rebole A, 2010, POULTRY SCI, V89, P276, DOI 10.3382/ps.2009-00336; Roberfroid MB, 1998, BRIT J NUTR, V80, pS197, DOI 10.1017/S0007114500006024; Saeed M, 2017, INT J PHARMACOL, V13, P351, DOI 10.3923/ijp.2017.351.360; Schmidt BM, 2007, FOOD CHEM TOXICOL, V45, P1131, DOI 10.1016/j.fct.2006.12.019; Shang HM, 2010, BRIT POULTRY SCI, V51, P791, DOI 10.1080/00071668.2010.531005; Snedecor G.W., 1983, AMES IOWA STATE U PR, V6th; Wang Y, 2018, FOOD AGR IMMUNOL, P1; Xu ZR, 2003, POULTRY SCI, V82, P1030, DOI 10.1093/ps/82.6.1030; Yousfi Z, 2017, IRANIAN J ANIMAL SCI, V2, P185; Yusrizal ChenTC, 2003, INT J POULT SCI, V2, P188	24	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2021	16	12							e0260923	10.1371/journal.pone.0260923	http://dx.doi.org/10.1371/journal.pone.0260923			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY9FU	34914731	Green Published, gold			2023-01-03	WOS:000755091500044
J	Tilly, H; Morschhauser, F; Sehn, LH; Friedberg, JW; Trneny, M; Sharman, JP; Herbaux, C; Burke, JM; Matasar, M; Rai, S; Izutsu, K; Mehta-Shah, N; Oberic, L; Chauchet, A; Jurczak, W; Song, YQ; Greil, R; Mykhalska, L; Bergua-Burgues, JM; Cheung, MC; Pinto, A; Shin, HJ; Hapgood, G; Munhoz, E; Abrisqueta, P; Gau, JP; Hirata, J; Jiang, YW; Yan, M; Lee, C; Flowers, CR; Salles, G				Tilly, Herve; Morschhauser, Franck; Sehn, Laurie H.; Friedberg, Jonathan W.; Trneny, M.; Sharman, Jeff P.; Herbaux, Charles; Burke, John M.; Matasar, Matthew; Rai, Shinya; Izutsu, Koji; Mehta-Shah, Neha; Oberic, Lucie; Chauchet, Adrien; Jurczak, Wojciech; Song, Yuqin; Greil, Richard; Mykhalska, Larysa; Bergua-Burgues, Juan M.; Cheung, Matthew C.; Pinto, Antonio; Shin, Ho-Jin; Hapgood, Greg; Munhoz, Eduardo; Abrisqueta, Pau; Gau, Jyh-Pyng; Hirata, Jamie; Jiang, Yanwen; Yan, Mark; Lee, Calvin; Flowers, Christopher R.; Salles, Gilles			Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RITUXIMAB PLUS CYCLOPHOSPHAMIDE; NON-HODGKIN-LYMPHOMA; ANTIBODY-DRUG CONJUGATE; ELDERLY-PATIENTS; PHASE-III; R-CHOP; VINCRISTINE; DOXORUBICIN; TRIAL; CHEMOTHERAPY	BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured with R-CHOP. Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, which is ubiquitously expressed on the surface of malignant B cells. METHODS We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab vedotin, as compared with standard R-CHOP, in patients with previously untreated intermediate-risk or high-risk DLBCL. Patients 18 to 80 years of age were randomly assigned in a 1:1 ratio to receive six cycles of either pola-R-CHP or R-CHOP, plus two cycles of rituximab alone. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival and safety. RESULTS Overall, 879 patients underwent randomization: 440 were assigned to the pola-R-CHP group and 439 to the R-CHOP group. After a median follow-up of 28.2 months, the percentage of patients surviving without progression was significantly higher in the pola-R-CHP group than in the R-CHOP group (76.7% [95% confidence interval (CI), 72.7 to 80.8] vs. 70.2% [95% CI, 65.8 to 74.6] at 2 years; stratified hazard ratio for progression, relapse, or death, 0.73 by Cox regression; 95% CI, 0.57 to 0.95; P=0.02). Overall survival at 2 years did not differ significantly between the groups (88.7% [95% CI, 85.7 to 91.6] in the pola-R-CHP group and 88.6% [95% CI, 85.6 to 91.6] in the R-CHOP group; hazard ratio for death, 0.94; 95% CI, 0.65 to 1.37; P=0.75). The safety profile was similar in the two groups. CONCLUSIONS Among patients with previously untreated intermediate-risk or high-risk DLBCL, the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those who received R-CHOP.	[Tilly, Herve] Ctr Henri Becquerel, Dept Hematol, Rouen, France; [Tilly, Herve] Ctr Henri Becquerel, INSERM Unit 1245, Rouen, France; [Tilly, Herve] Univ Rouen, Rouen, France; [Morschhauser, Franck] Univ Lille, Ctr Hosp Univ CHU Lille, ULR 7365 GRITA Grp Rech Sur Formes Injectables &, Lille, France; [Herbaux, Charles] CHU Montpellier, Montpellier, France; [Oberic, Lucie] Inst Univ Canc, Dept Hematol, Toulouse Oncopole, Toulouse, France; [Chauchet, Adrien] Ctr Hosp Reg Univ Besancon, Dept Hematol, Besancon, France; [Sehn, Laurie H.] BC Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada; [Sehn, Laurie H.] Univ British Columbia, Vancouver, BC, Canada; [Cheung, Matthew C.] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Yan, Mark] F Hoffmann La Roche, Mississauga, ON, Canada; [Friedberg, Jonathan W.] Univ Rochester, Wilmot Canc Inst, Rochester, NY USA; [Matasar, Matthew; Salles, Gilles] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Trneny, M.] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Trneny, M.] Gen Univ Hosp, Prague, Czech Republic; [Sharman, Jeff P.] US Oncol Network, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA; [Burke, John M.] Rocky Mt Canc Ctr, Aurora, CO USA; [Matasar, Matthew] Mem Sloan Kettering Canc Ctr, Montvale, NJ USA; [Rai, Shinya] Kindai Univ, Fac Med, Dept Hematol & Rheumatol, Osaka, Japan; [Izutsu, Koji] Natl Canc Ctr, Tokyo, Japan; [Mehta-Shah, Neha] Washington Univ, St Louis, MO 63110 USA; [Jurczak, Wojciech] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland; [Song, Yuqin] Peking Univ Canc Hosp, Beijing, Peoples R China; [Greil, Richard] Paracelsus Med Univ, Salzburg Canc Res Inst, Med Dept 3, Ctr Clin Canc & Immunol Trials, Salzburg, Austria; [Greil, Richard] Canc Cluster Salzburg, Salzburg, Austria; [Mykhalska, Larysa] Feofaniya Clin Hosp, Kiev, Ukraine; [Bergua-Burgues, Juan M.] Hosp San Pedro de Alcantara, Caceres, Spain; [Abrisqueta, Pau] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Hematol, Barcelona, Spain; [Pinto, Antonio] IRCCS, Hematol Oncol & Stem Cell Transplantat Unit, Ist Nazl Tumori, Fdn G Pascale, Naples, Italy; [Shin, Ho-Jin] Pusan Natl Univ, Pusan Natl Univ Hosp, Res Inst Med Sci, Dept Internal Med,Div Hematol Oncol,Sch Med, Busan, South Korea; [Hapgood, Greg] Princess Alexandra Hosp, Brisbane, Qld, Australia; [Munhoz, Eduardo] Hosp Erasto Gaertner, Curitiba, Parana, Brazil; [Gau, Jyh-Pyng] Taipei Vet Gen Hosp, Taipei, Taiwan; [Hirata, Jamie; Jiang, Yanwen; Lee, Calvin] Genentech Inc, San Francisco, CA 94080 USA; [Flowers, Christopher R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	UNICANCER; Centre Henri Becquerel; UNICANCER; Centre Henri Becquerel; Universite de Rouen Normandie; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Montpellier; CHU de Montpellier; Universite de Franche-Comte; CHU Besancon; University of British Columbia; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Roche Holding; University of Rochester; Memorial Sloan Kettering Cancer Center; Charles University Prague; General University Hospital Prague; Rocky Mountain Cancer Centers; Memorial Sloan Kettering Cancer Center; Kindai University (Kinki University); National Cancer Center - Japan; Washington University (WUSTL); Peking University; Paracelsus Private Medical University; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Fondazione Pascale; Pusan National University; Pusan National University Hospital; Taipei Veterans General Hospital; Roche Holding; Genentech; University of Texas System; UTMD Anderson Cancer Center	Tilly, H (corresponding author), Ctr Henri Becquerel, Rue Amiens,CS 11516, F-76038 Rouen 1, France.	herve.tilly@chb.unicancer.fr	Jurczak, Wojciech/ABB-2136-2020	Jurczak, Wojciech/0000-0003-1879-8084; BERGUA BURGUES, JUAN MIGUEL/0000-0001-8229-1208; Rai, Shinya/0000-0003-3929-9751	F. Hoffmann-La Roche/Genentech	F. Hoffmann-La Roche/Genentech(Hoffmann-La RocheRoche HoldingGenentech)	Supported by F. Hoffmann-La Roche/Genentech.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bartlett NL, 2019, J CLIN ONCOL, V37, P1790, DOI 10.1200/JCO.18.01994; Bretz F, 2009, STAT MED, V28, P586, DOI 10.1002/sim.3495; Chapuy B, 2018, NAT MED, V24, P679, DOI 10.1038/s41591-018-0016-8; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Crump M, 2017, BLOOD, V130, P1800, DOI 10.1182/blood-2017-03-769620; Cunningham D, 2013, LANCET, V381, P1817, DOI 10.1016/S0140-6736(13)60313-X; Delarue R, 2013, LANCET ONCOL, V14, P525, DOI 10.1016/S1470-2045(13)70122-0; Dornan D, 2009, BLOOD, V114, P2721, DOI 10.1182/blood-2009-02-205500; Ennishi D, 2019, J CLIN ONCOL, V37, P190, DOI 10.1200/JCO.18.01583; Goy A, 2017, J CLIN ONCOL, V35, P3519, DOI 10.1200/JCO.2017.74.7360; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Horwitz S, 2019, LANCET, V393, P229, DOI 10.1016/S0140-6736(18)32984-2; Jaeger U, 2015, HAEMATOLOGICA, V100, P955, DOI 10.3324/haematol.2015.125344; Lugtenburg PJ, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.03418; Maurer MJ, 2018, ANN ONCOL, V29, P1822, DOI 10.1093/annonc/mdy203; Maurer MJ, 2014, J CLIN ONCOL, V32, P1066, DOI 10.1200/JCO.2013.51.5866; Morschhauser F, 2019, LANCET HAEMATOL, V6, pE254, DOI 10.1016/S2352-3026(19)30026-2; Nowakowski GS, 2021, J CLIN ONCOL, V39, P1317, DOI 10.1200/JCO.20.01366; OKAZAKI M, 1993, BLOOD, V81, P84; Palanca-Wessels MCA, 2015, LANCET ONCOL, V16, P704, DOI 10.1016/S1470-2045(15)70128-2; Pfeifer M, 2015, LEUKEMIA, V29, P1578, DOI 10.1038/leu.2015.48; Pfreundschuh M, 2011, LANCET ONCOL, V12, P1013, DOI 10.1016/S1470-2045(11)70235-2; Polson AG, 2007, BLOOD, V110, P616, DOI 10.1182/blood-2007-01-066704; Schmitz R, 2018, NEW ENGL J MED, V378, P1396, DOI 10.1056/NEJMoa1801445; Sehn LH, 2021, NEW ENGL J MED, V384, P842, DOI 10.1056/NEJMra2027612; Sehn LH, 2020, J CLIN ONCOL, V38, P155, DOI 10.1200/JCO.19.00172; Shi Q, 2018, J CLIN ONCOL, V36, P2593, DOI 10.1200/JCO.2018.77.9124; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Teras LR, 2016, CA-CANCER J CLIN, V66, P443, DOI 10.3322/caac.21357; Thieblemont C, 2017, J CLIN ONCOL, V35, P2473, DOI 10.1200/JCO.2017.72.6984; Tilly H, 2019, LANCET ONCOL, V20, P998, DOI 10.1016/S1470-2045(19)30091-9; Vitolo U, 2017, J CLIN ONCOL, V35, P3529, DOI 10.1200/JCO.2017.73.3402; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Younes A, 2019, J CLIN ONCOL, V37, P1285, DOI 10.1200/JCO.18.02403	37	43	44	2	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2022	386	4					351	363		10.1056/NEJMoa2115304	http://dx.doi.org/10.1056/NEJMoa2115304		DEC 2021	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW6UB	34904799	Green Published, Bronze			2023-01-03	WOS:000729947300001
J	Crovetto, F; Crispi, F; Casas, R; Martin-Asuero, A; Borras, R; Vieta, E; Estruch, R; Gratacos, E				Crovetto, Francesca; Crispi, Fatima; Casas, Rosa; Martin-Asuero, Andres; Borras, Roger; Vieta, Eduard; Estruch, Ramon; Gratacos, Eduard		IMPACT BCN Trial Investigators	Effects of Mediterranean Diet or Mindfulness-Based Stress Reduction on Prevention of Small-for-Gestational Age Birth Weights in Newborns Born to At-Risk Pregnant Individuals The IMPACT BCN Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FETAL-GROWTH RESTRICTION; PREDICTION; OUTCOMES; TERM	IMPORTANCE Being born small for gestational age (SGA) is a leading cause of perinatal morbidity and mortality with no effective prevention or therapy. Maternal suboptimal nutrition and high stress levels have been associated with poor fetal growth and adverse pregnancy outcomes. OBJECTIVE To investigate whether structured interventions based on a Mediterranean diet or mindfulness-based stress reduction (stress reduction) in high-risk pregnancies can reduce the percentage of newborns who were born SGA and other adverse pregnancy outcomes. DESIGN, SETTING, AND PARTICIPANTS Parallel-group randomized clinical trial conducted at a university hospital in Barcelona, Spain, including 1221 individuals with singleton pregnancies (19-23 weeks' gestation) at high risk for SGA. Enrollment took place from February 1, 2017, to October 10, 2019, with follow-up until delivery (final follow-up on March 1, 2020). INTERVENTIONS Participants in the Mediterranean diet group (n = 407) received 2 hours monthly of individual and group educational sessions and free provision of extra-virgin olive oil and walnuts. Individuals in the stress reduction group (n = 407) underwent an 8-week stress reduction program adapted for pregnancy, consisting of weekly 2.5-hour sessions and 1 full-day session. Individuals in the usual care group (n = 407) received pregnancy care per institutional protocols. MAIN OUTCOMES AND MEASURES The primary end point was the percentage of newborns who were SGA at delivery, defined as birth weight below the 10th percentile. The secondary end point was a composite adverse perinatal outcome (at least 1 of the following: preterm birth, preeclampsia, perinatal mortality, severe SGA, neonatal acidosis, low Apgar score, or presence of any major neonatal morbidity). RESULTS Among the 1221 randomized individuals (median [IQR] age, 37 [34-40] years), 1184 (97%) completed the trial (392 individuals assigned to the Mediterranean diet group, 391 to the stress reduction group, and 401 to the usual care group). SGA occurred in 88 newborns (21.9%) in the control group, 55 (14.0%) in the Mediterranean diet group (odds ratio [OR], 0.58 [95% CI, 0.40-0.84]; risk difference [RD], -7.9 [95% CI, -13.6 to -2.6]; P = .004), and 61 (15.6%) in the stress reduction group (OR, 0.66 [95% CI, 0.46-0.94]; RD, -6.3 [95% CI, -11.8 to -0.9]; P = .02). The composite adverse perinatal outcome occurred in 105 newborns (26.2%) in the control group, 73 (18.6%) in the Mediterranean diet group (OR, 0.64 [95% CI, 0.46-0.90]; RD, -7.6 [95% CI, -13.4 to -1.8]; P = .01), and 76 (19.5%) in the stress reduction group (OR, 0.68 [95% CI, 0.49-0.95]; RD, -6.8 [95% CI, -12.6 to -0.3]; P = .02). CONCLUSIONS AND RELEVANCE In this randomized trial conducted at a single institution in Spain, treating pregnant individuals at high risk for SGA with a structured Mediterranean diet or with mindfulness-based stress reduction, compared with usual care, significantly reduced the percentage of newborns with birth weight below the 10th percentile. Due to important study limitations, these findings should be considered preliminary and require replication, as well as assessment in additional patient populations, before concluding that these treatments should be recommended to patients.	[Crovetto, Francesca; Crispi, Fatima; Gratacos, Eduard] Hosp Clin Barcelona, BCNatal Fetal Med Res Ctr, Barcelona, Spain; [Crovetto, Francesca; Crispi, Fatima; Gratacos, Eduard] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp St Joan de Deu, Barcelona, Spain; [Crovetto, Francesca; Crispi, Fatima; Gratacos, Eduard] Ctr Biomed Res Rare Dis CIBER ER, Madrid, Spain; [Casas, Rosa; Estruch, Ramon] Inst Salud Carlos III, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Madrid, Spain; [Casas, Rosa; Estruch, Ramon] Univ Barcelona, Dept Internal Med Hosp Clin, IDIBAPS, Barcelona, Spain; [Martin-Asuero, Andres] Inst EsMindfulness, Barcelona, Spain; [Borras, Roger] Univ Autonoma Barcelona, Hosp Clin, Cardiovasc Inst, IDIBAPS, Barcelona, Spain; [Borras, Roger; Vieta, Eduard] Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain; [Vieta, Eduard] Univ Barcelona, Hosp Clin, Neurosci Inst, IDIBAPS,Dept Psychiat & Psychol, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Autonomous University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Instituto de Salud Carlos III; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Gratacos, E (corresponding author), Univ Barcelona, BCNatal Hosp St Joan de Diu, Sabino de Arana 1, Barcelona 08036, Spain.; Gratacos, E (corresponding author), Univ Barcelona, Hosp Clin, Sabino de Arana 1, Barcelona 08036, Spain.	egratacos@ub.edu	COLLADO, MARIA CARMEN/H-4924-2012; Casas, Rosa/ABD-1915-2020; Vieta, Eduard/I-6330-2013	COLLADO, MARIA CARMEN/0000-0002-6204-4864; Casas, Rosa/0000-0002-0211-9166; Nakaki, Ayako/0000-0002-4395-3878; Gratacos, Eduard/0000-0002-7405-7224; Vellve, Kilian/0000-0002-2376-7664; Domenech, Monica/0000-0001-5447-6686; Vieta, Eduard/0000-0002-0548-0053	"La Caixa" Foundation [LCF/PR/GN18/10310003]; Cerebra Foundation for the Brain Injured Child (Carmarthen, Wales, UK); AGAUR under grant 2017 SGR [1531]; Centro de Investigaciones Biomedicas en Red sobre Enfermedades Raras (CIBERER); "La Caixa" Foundation, Doctoral INPhINIT Retaining fellowship [LCF/BQ/DR19/11740018]	"La Caixa" Foundation(La Caixa Foundation); Cerebra Foundation for the Brain Injured Child (Carmarthen, Wales, UK); AGAUR under grant 2017 SGR; Centro de Investigaciones Biomedicas en Red sobre Enfermedades Raras (CIBERER); "La Caixa" Foundation, Doctoral INPhINIT Retaining fellowship	The project was partially funded by a grant from "La Caixa" Foundation (LCF/PR/GN18/10310003); Cerebra Foundation for the Brain Injured Child (Carmarthen, Wales, UK); AGAUR under grant 2017 SGR No. 1531. Dr Crovetto has received support from Centro de Investigaciones Biomedicas en Red sobre Enfermedades Raras (CIBERER). Dr Nakaki has received support from a fellowship from "La Caixa" Foundation, Doctoral INPhINIT Retaining fellowship (LCF/BQ/DR19/11740018).	Al Wattar BH, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002857; American College of Obstetricians and Gynecologists' Committee on Practice BulletinsObstetrics and the Society forMaternal-FetalMedicin, 2019, Obstet Gynecol, V133, pe97, DOI 10.1097/AOG.0000000000003070; [Anonymous], INVESTIGATION MANAGE; Assaf-Balut C, 2019, ANN NUTR METAB, V74, P69, DOI 10.1159/000495793; Assaf-Balut C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185873; Bakalis S, 2015, ULTRASOUND OBST GYN, V45, P409, DOI 10.1002/uog.14822; Brosens I, 2011, AM J OBSTET GYNECOL, V204, P193, DOI 10.1016/j.ajog.2010.08.009; Burton GJ, 2018, AM J OBSTET GYNECOL, V218, pS745, DOI 10.1016/j.ajog.2017.11.577; Bussieres EL, 2015, DEV REV, V36, P179, DOI 10.1016/j.dr.2015.04.001; Crispi F, 2018, AM J OBSTET GYNECOL, V218, pS869, DOI 10.1016/j.ajog.2017.12.012; Crovetto F, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05309-2; Dhillon A, 2017, MINDFULNESS, V8, P1421, DOI 10.1007/s12671-017-0726-x; Dossett ML, 2020, NEW ENGL J MED, V382, P1390, DOI 10.1056/NEJMp1917461; Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]; Figueras F, 2008, EUR J OBSTET GYN R B, V136, P20, DOI 10.1016/j.ejogrb.2006.12.015; Figueras F, 2009, PEDIATRICS, V124, pE934, DOI 10.1542/peds.2008-3346; Galante J, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003481; Gardosi J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f108; Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018; Guo PP, 2021, J ADV NURS, V77, P125, DOI 10.1111/jan.14588; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Juton C, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051629; Katanoda K, 2017, J EPIDEMIOL, V27, P428, DOI 10.1016/j.je.2016.08.016; Khoury J, 2005, AM J OBSTET GYNECOL, V193, P1292, DOI 10.1016/j.ajog.2005.05.016; Koncz A, 2021, HEALTH PSYCHOL REV, V15, P56, DOI 10.1080/17437199.2020.1760727; Lindsay KL, 2017, ANN NUTR METAB, V70, P191, DOI 10.1159/000457136; Ludwig DS, 2008, JAMA-J AM MED ASSOC, V300, P1350, DOI 10.1001/jama.300.11.1350; Middleton P, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003402.pub3; Miranda J, 2017, ULTRASOUND OBST GYN, V50, P353, DOI 10.1002/uog.17317; Pilliod RA, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.06.039; Poston L, 2015, LANCET DIABETES ENDO, V3, P767, DOI 10.1016/S2213-8587(15)00227-2; Raghavan R, 2019, AM J CLIN NUTR, V109, p729S, DOI 10.1093/ajcn/nqy353; Ros E, 2014, ADV NUTR, V5, p330S, DOI 10.3945/an.113.005389; Ross S, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-31; Sacchi C, 2020, JAMA PEDIATR, V174, P772, DOI 10.1001/jamapediatrics.2020.1097; Schwingshackl L, 2020, BRIT J PHARMACOL, V177, P1241, DOI 10.1111/bph.14778; Traylor CS, 2020, AM J OBST GYNEC MFM, V2, DOI 10.1016/j.ajogmf.2020.100229; Valls-Pedret C, 2015, JAMA INTERN MED, V175, P1094, DOI 10.1001/jamainternmed.2015.1668	38	15	14	11	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	2021	326	21					2150	2160		10.1001/jama.2021.20178	http://dx.doi.org/10.1001/jama.2021.20178			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XO3GR	34874420	Green Published, Bronze			2023-01-03	WOS:000730077500018
J	Bennell, KL; Paterson, KL; Metcalf, BR; Duong, V; Eyles, J; Kasza, J; Wang, YY; Cicuttini, F; Buchbinder, R; Forbes, A; Harris, A; Yu, SP; Connell, D; Linklater, J; Wang, BH; Oo, WM; Hunter, DJ				Bennell, Kim L.; Paterson, Kade L.; Metcalf, Ben R.; Duong, Vicky; Eyles, Jillian; Kasza, Jessica; Wang, Yuanyuan; Cicuttini, Flavia; Buchbinder, Rachelle; Forbes, Andrew; Harris, Anthony; Yu, Shirley P.; Connell, David; Linklater, James; Wang, Bing Hui; Oo, Win Min; Hunter, David J.			Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis The RESTORE Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Question Does intra-articular injection of platelet-rich plasma (PRP), compared with placebo saline injection, improve symptoms and joint structure in patients with knee osteoarthritis? Findings In this randomized clinical trial that included 288 adults aged 50 years or older with mild to moderate radiographic knee osteoarthritis, treatment with PRP vs placebo injection resulted in a mean change in knee pain scores of -2.1 vs -1.8 on an 11-point scale (range, 0-10) and a mean change in medial tibial cartilage volume of -1.4% vs -1.2% at 12 months. Neither comparison was statistically significant. Meaning Among adults with mild to moderate knee osteoarthritis, treatment with PRP vs saline injection did not significantly improve knee pain or slow disease progression. Importance Most clinical guidelines do not recommend platelet-rich plasma (PRP) for knee osteoarthritis (OA) because of lack of high-quality evidence on efficacy for symptoms and joint structure, but the guidelines emphasize the need for rigorous studies. Despite this, use of PRP in knee OA is increasing. Objective To evaluate the effects of intra-articular PRP injections on symptoms and joint structure in patients with symptomatic mild to moderate radiographic medial knee OA. Design, Setting, and Participants This randomized, 2-group, placebo-controlled, participant-, injector-, and assessor-blinded clinical trial enrolled community-based participants (n = 288) aged 50 years or older with symptomatic medial knee OA (Kellgren and Lawrence grade 2 or 3) in Sydney and Melbourne, Australia, from August 24, 2017, to July 5, 2019. The 12-month follow-up was completed on July 22, 2020. Interventions Interventions involved 3 intra-articular injections at weekly intervals of either leukocyte-poor PRP using a commercially available product (n = 144 participants) or saline placebo (n = 144 participants). Main Outcomes and Measures The 2 primary outcomes were 12-month change in overall average knee pain scores (11-point scale; range, 0-10, with higher scores indicating worse pain; minimum clinically important difference of 1.8) and percentage change in medial tibial cartilage volume as assessed by magnetic resonance imaging (MRI). Thirty-one secondary outcomes (25 symptom related and 6 MRI assessed; minimum clinically important difference not known) evaluated pain, function, quality of life, global change, and joint structures at 2-month and/or 12-month follow-up. Results Among 288 patients who were randomized (mean age, 61.9 [SD, 6.5] years; 169 [59%] women), 269 (93%) completed the trial. In both groups, 140 participants (97%) received all 3 injections. After 12 months, treatment with PRP vs placebo injection resulted in a mean change in knee pain scores of -2.1 vs -1.8 points, respectively (difference, -0.4 [95% CI, -0.9 to 0.2] points; P = .17). The mean change in medial tibial cartilage volume was -1.4% vs -1.2%, respectively (difference, -0.2% [95% CI, -1.9% to 1.5%]; P = .81). Of 31 prespecified secondary outcomes, 29 showed no significant between-group differences. Conclusions and Relevance Among patients with symptomatic mild to moderate radiographic knee OA, intra-articular injection of PRP, compared with injection of saline placebo, did not result in a significant difference in symptoms or joint structure at 12 months. These findings do not support use of PRP for the management of knee OA. This randomized trial assesses the effect of injections of platelet-rich plasma vs saline placebo on 12-month changes in knee pain scores and medial tibial cartilage volume among patients with symptomatic mild to moderate knee osteoarthritis.	[Bennell, Kim L.; Paterson, Kade L.; Metcalf, Ben R.] Univ Melbourne, Fac Med Dent & Hlth Sci, Ctr Hlth Exercise & Sports Med, Sch Hlth Sci,Dept Physiotherapy, Melbourne, Vic, Australia; [Duong, Vicky; Eyles, Jillian; Yu, Shirley P.; Oo, Win Min; Hunter, David J.] Univ Sydney, Royal North Shore Hosp, Inst Bone & Joint Res, Kolling Inst,Rheumatol Dept, Sydney, NSW, Australia; [Kasza, Jessica; Wang, Yuanyuan; Cicuttini, Flavia; Forbes, Andrew] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Cicuttini, Flavia] Alfred Hosp, Rheumatol Dept, Melbourne, Vic, Australia; [Buchbinder, Rachelle] Cabrini Inst, Monash Dept Clin Epidemiol, Melbourne, Vic, Australia; [Harris, Anthony] Monash Univ, Ctr Hlth Econ, Melbourne, Vic, Australia; [Connell, David] Imaging Olymp Pk, Melbourne, Vic, Australia; [Linklater, James] Castlereagh Imaging, Sydney, NSW, Australia; [Wang, Bing Hui] Monash Univ, Monash Ctr Cardiovasc Res & Educ Therapeut, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Wang, Bing Hui] Baker Heart & Diabet Inst, Biomarker Discovery Lab, Melbourne, Vic, Australia; [Oo, Win Min] Univ Med Mandalay, Dept Phys Med & Rehabil, Mandalay, Myanmar	University of Melbourne; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Monash University; Florey Institute of Neuroscience & Mental Health; Cabrini Health; Monash University; Monash University; Monash University	Bennell, KL (corresponding author), Univ Melbourne, Dept Physiotherapy, Ctr Hlth Exercise Arid Sports Med, 161 Barry St, Carlton, Vic 3010, Australia.	k.bennell@unimelb.edu.au	Oo, Win Min/D-9508-2015; Duong, Vicky/K-2012-2019; Paterson, Kade/G-4715-2012	Duong, Vicky/0000-0002-4450-8194; Oo, Win Min/0000-0002-4065-7395; Paterson, Kade/0000-0002-0323-6129				Ahmad HS, 2018, INT J RHEUM DIS, V21, P960, DOI 10.1111/1756-185X.13315; Altman RD, 2007, OSTEOARTHR CARTILAGE, V15, pA1, DOI 10.1016/j.joca.2006.11.009; [Anonymous], 2015, REGENBCT TUBE PERFOR; Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011; Belk JW, 2021, AM J SPORT MED, V49, P249, DOI 10.1177/0363546520909397; BELLAMY N, 1992, J RHEUMATOL, V19, P444; Bennell KL, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0652-x; Bennell KL, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2912; Buendia-Lopez D, 2018, J ORTHOP TRAUMATOL, V19, DOI 10.1186/s10195-018-0501-3; Carpenter JA, 2013, STUD WORLD CHR SER, P1; Cicuttini FM, 2004, ANN RHEUM DIS, V63, P1124, DOI 10.1136/ard.2004.021253; Elik H, 2020, J BACK MUSCULOSKELET, V33, P127, DOI 10.3233/BMR-181374; Fice MP, 2019, ARTHROSCOPY, V35, P961, DOI 10.1016/j.arthro.2018.10.125; Hawker GA, 2008, OSTEOARTHR CARTILAGE, V16, P409, DOI 10.1016/j.joca.2007.12.015; Hay SI, 2017, LANCET, V389, pE1; Hohmann E, 2020, EUR J ORTHOP SURG TR, V30, P955, DOI 10.1007/s00590-020-02623-4; Hong M, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/2191926; Hunter DJ, 2015, OSTEOARTHR CARTILAGE, V23, P698, DOI 10.1016/j.joca.2015.03.012; Hunter DJ, 2011, OSTEOARTHR CARTILAGE, V19, P990, DOI 10.1016/j.joca.2011.05.004; James KE, 1996, STAT MED, V15, P1421; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI [10.1002/art.41142, 10.1002/acr.24131]; Kon E, 2020, EXPERT OPIN BIOL TH, V20, P1447, DOI 10.1080/14712598.2020.1798925; McAlindon TE, 2015, OSTEOARTHR CARTILAGE, V23, P747, DOI 10.1016/j.joca.2015.03.005; Murray IR, 2017, J BONE JOINT SURG AM, V99, P809, DOI 10.2106/JBJS.16.00793; Patel S, 2013, AM J SPORT MED, V41, P356, DOI 10.1177/0363546512471299; Paterson KL, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2205-5; Richardson J, 2014, PATIENT, V7, P85, DOI 10.1007/s40271-013-0036-x; Roos EM, 1998, J ORTHOP SPORT PHYS, V28, P88, DOI 10.2519/jospt.1998.28.2.88; Royston P, 2004, STAT MED, V23, P2509, DOI 10.1002/sim.1815; Shen LX, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018-017-0521-3; ten Klooster PM, 2006, PAIN, V121, P151, DOI 10.1016/j.pain.2005.12.021; Werner BC, 2020, ORTHOP J SPORTS MED, V8, DOI 10.1177/2325967119900811	33	43	43	14	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	2021	326	20					2021	2030		10.1001/jama.2021.19415	http://dx.doi.org/10.1001/jama.2021.19415			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF3VI	34812863	Bronze, Green Published			2023-01-03	WOS:000724001500022
J	Incze, MA; Kelley, AT; Singer, PM				Incze, Michael A.; Kelley, A. Taylor; Singer, Phillip M.			Heterogeneous State Cannabis Policies Potential Implications for Patients and Health Care Professionals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint discusses how the varied and fragmented policies and sources of information about cannabis use in the US can lead to confusion among patients and clinicians.	[Incze, Michael A.; Kelley, A. Taylor] Univ Utah, Sch Med, Program Addict Res Clin Care Knowledge & Advocacy, Div Epidemiol,Dept Internal Med, Salt Lake City, UT USA; [Kelley, A. Taylor] VA Salt Lake City Hlth Care Syst, Vulnerable Vet Innovat Patient Aligned Care Team, Initiat Informat Decis Enhancement & Analyt Sci I, Salt Lake City, UT USA; [Singer, Phillip M.] Univ Utah, Dept Polit Sci, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Utah System of Higher Education; University of Utah	Incze, MA (corresponding author), Univ Utah, Div Gen Internal Med, 30 N 1900 E,Room 5R218, Salt Lake City, UT 84132 USA.	michael.incze@hsc.utah.edu						[Anonymous], DEA CONT PRIOR EFF E; Boatwright KD, 2020, J PHARM PRACT, V33, P457, DOI 10.1177/0897190018818907; Han BJH, 2020, JAMA INTERN MED, V180, P609, DOI 10.1001/jamainternmed.2019.7517; Natl Acad Sci Engn Med, 2017, HEALTH EFFECTS OF CANNABIS AND CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH, P1, DOI 10.17226/24625; Philpot LM, 2019, BMC FAM PRACT, V20, DOI 10.1186/s12875-019-0906-y; Rehman Y, 2021, AIMS NEUROSCI, V8, P414, DOI 10.3934/Neuroscience.2021022; SAMHSA, 2019, PEP195068 HHS; Schauer GL, 2016, AM J PREV MED, V50, P1, DOI 10.1016/j.amepre.2015.05.027; Stacey D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001431.pub5; Williams AR, 2020, ANN INTERN MED, V173, pITC65, DOI 10.7326/AITC202011030	10	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	2021	326	23					2363	2364		10.1001/jama.2021.21182	http://dx.doi.org/10.1001/jama.2021.21182		NOV 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC5RI	34797377				2023-01-03	WOS:000720515700002
J	Higaki, Y; Yamato, Y; Fujie, S; Inoue, K; Shimomura, M; Kato, S; Horii, N; Ogoh, S; Iemitsu, M				Higaki, Yuya; Yamato, Yosuke; Fujie, Shumpei; Inoue, Kenichiro; Shimomura, Mio; Kato, Shosaku; Horii, Naoki; Ogoh, Shigehiko; Iemitsu, Motoyuki			Acute effects of the different relaxation periods during passive intermittent static stretching on arterial stiffness	PLOS ONE			English	Article							FLOW-MEDIATED DILATION; ENDOTHELIAL FUNCTION; BRACHIAL-ARTERY; NITRIC-OXIDE; EXERCISE; SHEAR; OXYGENATION; STRESS; HUMANS	To clarify whether the relaxation period during stretching affects the degree of elevated shear rate and the degree of reduction of arterial stiffness, we examined relaxation duration to build an adequate stretching protocol. In Experiment 1, the changes in cardiac output, the shear rate in the posterior tibial artery, and blood volume in the calf muscle were measured during recovery (0-60 s) from a single bout of one-legged passive calf stretching in 12 healthy young men. In Experiment 2, the effects of different relaxation periods (5-, 10-, 20-, and 60-s) of passive one-legged intermittent calf stretching (30-s x 6 sets) on the femoral-ankle pulse wave velocity (faPWV) as an index of peripheral arterial stiffness were identified in 17 healthy young men. As a result, the stretched leg's shear rate significantly increased from 0 to 10(th) s after stretching. The muscle blood volume in the stretched leg significantly reduced during stretching, and then significantly increased during the recovery period after stretching; however, cardiac output remained unchanged during stretching and recovery. Additionally, the reduction in faPWV from the pre-stretching value in the stretched leg was significantly larger in the protocol with 10-s and 20-s relaxation periods than that in the non-stretched leg, but this did not differ in the 5-s and 60-s relaxation periods. These findings suggest that the relaxation periods of intermittent static stretching that cause a high transient increase in shear rate (via reperfusion after microvascular compression by the stretched calf muscles) are effective to reduce arterial stiffness.	[Higaki, Yuya; Yamato, Yosuke; Fujie, Shumpei; Inoue, Kenichiro; Shimomura, Mio; Kato, Shosaku; Horii, Naoki; Iemitsu, Motoyuki] Ritsumeikan Univ, Fac Sport & Hlth Sci, Kusatsu, Shiga, Japan; [Yamato, Yosuke] Aino Univ, Dept Phys Therapy, Osaka, Japan; [Inoue, Kenichiro; Horii, Naoki] Japan Soc Promot Sci, Tokyo, Japan; [Ogoh, Shigehiko] Toyo Univ, Dept Biomed Engn, Saitama, Japan	Ritsumeikan University; Japan Society for the Promotion of Science; Toyo University	Iemitsu, M (corresponding author), Ritsumeikan Univ, Fac Sport & Hlth Sci, Kusatsu, Shiga, Japan.	iemitsu@fc.ritsumei.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [KAKENHI: 19K22828]	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (KAKENHI: 19K22828 for M. Iemitsu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agewall S, 2001, CLIN PHYSIOL, V21, P9, DOI 10.1046/j.1365-2281.2001.00302.x; Bisconti AV, 2020, J PHYSIOL-LONDON, V598, P3645, DOI 10.1113/JP279866; Carter HH, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13285; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Evanoff NG, 2016, J CLIN ULTRASOUND, V44, P182, DOI 10.1002/jcu.22324; Green DJ, 2017, PHYSIOL REV, V97, P495, DOI 10.1152/physrev.00014.2016; Higashi Y, 2004, PHARMACOL THERAPEUT, V102, P87, DOI 10.1016/j.pharmthera.2004.02.003; Kingwell Bronwyn A., 1997, American Journal of Physiology, V273, pH2186; Kobayashi K, 2004, ATHEROSCLEROSIS, V173, P13, DOI 10.1016/j.atherosclerosis.2003.10.013; Kruse NT, 2016, AM J PHYSIOL-HEART C, V310, pH1210, DOI 10.1152/ajpheart.00732.2015; Kruse NT, 2016, CLIN PHYSIOL FUNCT I, V36, P126, DOI 10.1111/cpf.12205; Laurent S, 2001, HYPERTENSION, V37, P1236, DOI 10.1161/01.HYP.37.5.1236; LEWIS JF, 1984, CIRCULATION, V70, P425, DOI 10.1161/01.CIR.70.3.425; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nishiwaki M, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1337-4; Schmitt M, 2005, HYPERTENSION, V46, P227, DOI 10.1161/01.HYP.0000164581.39811.bd; Shinno H, 2017, EUR J SPORT SCI, V17, P586, DOI 10.1080/17461391.2017.1284267; Thijssen DHJ, 2011, AM J PHYSIOL-HEART C, V300, pH2, DOI 10.1152/ajpheart.00471.2010; Venturelli M, 2019, J APPL PHYSIOL, V127, P376, DOI 10.1152/japplphysiol.00823.2018; Wray DW, 2006, MED SCI SPORT EXER, V38, P1804, DOI 10.1249/01.mss.0000230342.86870.94; Yamamoto K, 2009, AM J PHYSIOL-HEART C, V297, pH1314, DOI 10.1152/ajpheart.00061.2009; Yamato Y, 2021, EUR J APPL PHYSIOL, V121, P331, DOI 10.1007/s00421-020-04524-0; Yamato Y, 2017, EUR J APPL PHYSIOL, V117, P1227, DOI 10.1007/s00421-017-3609-x; Yamato Y, 2016, AM J PHYS MED REHAB, V95, P764, DOI 10.1097/PHM.0000000000000498; Zhou J, 2014, ARTERIOSCL THROM VAS, V34, P2191, DOI 10.1161/ATVBAHA.114.303422	26	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2021	16	11							e0259444	10.1371/journal.pone.0259444	http://dx.doi.org/10.1371/journal.pone.0259444			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2IU	34780500	Green Published, gold			2023-01-03	WOS:000755305800030
J	Miron, VD; Banica, L; Sandulescu, O; Paraschiv, S; Surleac, M; Florea, D; Vlaicu, O; Milu, P; Streinu-Cercel, A; Bilasco, A; Otelea, D; Pitigoi, D; Streinu-Cercel, A; Draganescu, AC				Miron, Victor Daniel; Banica, Leontina; Sandulescu, Oana; Paraschiv, Simona; Surleac, Marius; Florea, Dragos; Vlaicu, Ovidiu; Milu, Petre; Streinu-Cercel, Anca; Bilasco, Anuta; Otelea, Dan; Pitigoi, Daniela; Streinu-Cercel, Adrian; Draganescu, Anca Cristina			Clinical and molecular epidemiology of influenza viruses from Romanian patients hospitalized during the 2019/20 season	PLOS ONE			English	Article								Two main mechanisms contribute to the continuous evolution of influenza viruses: accumulation of mutations in the hemagglutinin and neuraminidase genes (antigenic drift) and genetic re-assortments (antigenic shift). Epidemiological surveillance is important in identifying new genetic variants of influenza viruses with potentially increased pathogenicity and transmissibility. In order to characterize the 2019/20 influenza epidemic in Romania, 1042 respiratory samples were collected from consecutive patients hospitalized with acute respiratory infections in the National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest Romania and tested for influenza A virus, influenza B virus and respiratory syncytial virus (RSV) by real-time PCR. Out of them, 516 cases were positive for influenza, with relatively equal distribution of influenza A and B. Two patients had influenza A and B coinfection and 8 patients had influenza-RSV co-infection. The most severe cases, requiring supplemental oxygen administration or intensive care, and the most deaths were reported in patients aged 65 years and over. Subtyping showed the predominance of A(H3N2) compared to A(H1N1)pdm09 pdm09 (60.4% and 39.6% of all subtyped influenza A isolates, respectively), and the circulation of Victoria B lineage only. Influenza B started to circulate first (week 47/2019), with influenza A appearing slightly later (week 50/2019), followed by continued co-circulation of A and B viruses throughout the season. Sixty-eight samples, selected to cover the entire influenza season and all circulating viral types, were analysed by next generation sequencing (NGS). All A(H1N1)pdm09 sequences identified during this season in Romania were clustered in the 6b1.A clade (sub-clades: 6b1.A.183P -5a and 6b1. A.187A). For most A(H1N1)pdm09 sequences, the dominant epitope was Sb (p(epitope) = 0.25), reducing the vaccine efficacy by approximately 60%. According to phylogenetic analysis, influenza A(H3N2) strains circulating in this season belonged predominantly to clade 3C.3A, with only few sequences in clade 3C.2A1b. These 3C.2A1b sequences, two of which belonged to vaccinated patients, harbored mutations in antigenic sites leading to potential reduction of vaccine efficacy. Phylogenetic analysis of influenza B, lineage Victoria, sequences showed that the circulating strains belonged to clade V1A3. As compared to the other viral types, fewer mutations were observed in B/Victoria strains, with limited impact on vaccine efficiency based on estimations.	[Miron, Victor Daniel; Sandulescu, Oana; Paraschiv, Simona; Florea, Dragos; Milu, Petre; Streinu-Cercel, Anca; Pitigoi, Daniela; Streinu-Cercel, Adrian] Carol Davila Univ Med & Pharm, Bucharest, Romania; [Banica, Leontina; Sandulescu, Oana; Paraschiv, Simona; Surleac, Marius; Florea, Dragos; Vlaicu, Ovidiu; Milu, Petre; Streinu-Cercel, Anca; Bilasco, Anuta; Otelea, Dan; Pitigoi, Daniela; Streinu-Cercel, Adrian; Draganescu, Anca Cristina] Prof Dr Matei Bals Natl Inst Infect Dis, Bucharest, Romania; [Surleac, Marius] Univ Bucharest ICUB, Res Inst, Bucharest, Romania	Carol Davila University of Medicine & Pharmacy; National Institute for Infectious Diseases "Matei Bals"	Paraschiv, S (corresponding author), Carol Davila Univ Med & Pharm, Bucharest, Romania.; Paraschiv, S (corresponding author), Prof Dr Matei Bals Natl Inst Infect Dis, Bucharest, Romania.	simona.paraschiv@umfcd.ro	Miron, Victor Daniel/Q-1288-2019; Draganescu, Anca Cristina/AAH-6671-2021; Sandulescu, Oana/M-6242-2017; Streinu-Cercel, Adrian/M-5835-2017; Streinu-Cercel, Anca/AAE-4742-2019	Sandulescu, Oana/0000-0002-2586-4070; Streinu-Cercel, Adrian/0000-0001-6382-5067; Otelea, Dan/0000-0002-0821-6346	Global Influenza Hospital Surveillance Network (GIHSN) project; Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project; Foundation for Influenza Epidemiology; EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE) [777363]; National Institute for Infectious Diseases, Bucharest, Romania; GIHSN project; Research Institute of the University of Bucharest (ICUB) [20964/30.10.2020]; ICUB	Global Influenza Hospital Surveillance Network (GIHSN) project; Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project; Foundation for Influenza Epidemiology; EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE); National Institute for Infectious Diseases, Bucharest, Romania; GIHSN project; Research Institute of the University of Bucharest (ICUB); ICUB	The study received funding from the Global Influenza Hospital Surveillance Network (GIHSN) project and the Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project, as follows: GIHSN project was co-funded by the Foundation for Influenza Epidemiology; the DRIVE study has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant n degrees 777363). Both studies were co-funded by the National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania. GIHSN and DRIVE contributed to study design but had no role in data collection and analysis, decision to publish, or preparation of the manuscript. The National Institute for Infectious Diseases,Prof. Dr. Matei Bals" contributed to study design, data collection and analysis, but had no role in the decision to publish, or preparation of the manuscript. The authors VDM, LB, OS, SP, MS, DF, OV, Anca S-C, AB, DO, DP, Adrian S-C and ACD were supported by GIHSN project. MS was supported by Research Institute of the University of Bucharest (ICUB) grant no. 20964/30.10.2020. The funder ICUB provided support in the form of fellowship for the author MS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen RB, 2008, J MOL EVOL, V66, P655, DOI 10.1007/s00239-008-9119-z; Cheng AC, 2019, COMMUN DIS INTELL, V43, DOI 10.33321/cdi.2019.43.48; Draganescu A, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4613-z; Draganescu A, 2018, BRAZ J INFECT DIS, V22, P377, DOI 10.1016/j.bjid.2018.10.275; ECDC, SEAS INFL 2019 2020; Gouma S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16183-y; Gupta Ramneek, 2002, Pac Symp Biocomput, P310; Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019; Matsuzaki Y, 2014, J VIROL, V88, P12364, DOI 10.1128/JVI.01381-14; Miron VD, 2018, REV CHIM-BUCHAREST, V69, P2749; Mohebbi A, 2019, VIRUS RES, V259, P38, DOI 10.1016/j.virusres.2018.10.001; Pitigoi D, 2020, INFLUENZA OTHER RESP, V14, P530, DOI 10.1111/irv.12752; Pitigoi D, 2019, GERMS, V9, P142, DOI 10.18683/germs.2019.1169; Plotkin JB, 2003, P NATL ACAD SCI USA, V100, P7152, DOI 10.1073/pnas.1132114100; Popova L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041895; Prachanronarong KL, 2019, J VIROL, V93, DOI 10.1128/JVI.01639-18; Puig-Barbera J, 2015, INFLUENZA OTHER RESP, V9, P277, DOI 10.1111/irv.12335; Stuurman AL, 2020, VACCINE, V38, P6455, DOI 10.1016/j.vaccine.2020.07.063; Suntronwong N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80895-w; Surleac M, 2020, LIFE-BASEL, V10, DOI 10.3390/life10080152; Wang WJ, 2010, J VIROL, V84, P6570, DOI 10.1128/JVI.00221-10; World Health Organization,, REC COMP INFL VIR VA; Wu NC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15102-5; Zhou B, 2014, J CLIN MICROBIOL, V52, P1330, DOI 10.1128/JCM.03265-13; Zhou B, 2009, J VIROL, V83, P10309, DOI 10.1128/JVI.01109-09	25	3	3	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2021	16	11							e0258798	10.1371/journal.pone.0258798	http://dx.doi.org/10.1371/journal.pone.0258798			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ1NM	34767579	Green Published, gold			2023-01-03	WOS:000755249300014
J	Dickinson, S; Chong, HY; Leslie, T; Rowland, M; Hansen, KS; Boyers, D				Dickinson, Simon; Chong, Huey Yi; Leslie, Toby; Rowland, Mark; Hansen, Kristian Schultz; Boyers, Dwayne			Cost-effectiveness of point-of-care C-Reactive Protein test compared to current clinical practice as an intervention to improve antibiotic prescription in malaria-negative patients in Afghanistan	PLOS ONE			English	Article							RESPIRATORY-TRACT INFECTIONS; FEBRILE ILLNESS; RESISTANCE; ETIOLOGY	Background Antimicrobial resistance (AMR) is a global health problem requiring a reduction in inappropriate antibiotic prescribing. Point-of-Care C-Reactive Protein (POCCRP) tests could distinguish between bacterial and non-bacterial causes of fever in malaria-negative patients and thus reduce inappropriate antibiotic prescribing. However, the cost-effectiveness of POCCRP testing is unclear in low-income settings. Methods A decision tree model was used to estimate cost-effectiveness of POCCRP versus current clinical practice at primary healthcare facilities in Afghanistan. Data were analysed from healthcare delivery and societal perspectives. Costs were reported in 2019 USD. Effectiveness was measured as correctly treated febrile malaria-negative patient. Cost, effectiveness and diagnostic accuracy parameters were obtained from primary data from a cost-effectiveness study on malaria rapid diagnostic tests in Afghanistan and supplemented with POCCRP-specific data sourced from the literature. Incremental cost-effectiveness ratios (ICERs) reported the additional cost per additional correctly treated febrile malaria-negative patient over a 28-day time horizon. Univariate and probabilistic sensitivity analyses examined the impact of uncertainty of parameter inputs. Scenario analysis included economic cost of AMR per antibiotic prescription. Results The model predicts that POCCRP intervention would result in 137 fewer antibiotic prescriptions (6%) with a 12% reduction (279 prescriptions) in inappropriate prescriptions compared to current clinical practice. ICERs were $14.33 (healthcare delivery), $11.40 (societal), and $9.78 (scenario analysis) per additional correctly treated case. Conclusions POCCRP tests could improve antibiotic prescribing among malaria-negative patients in Afghanistan. Cost-effectiveness depends in part on willingness to pay for reductions in inappropriate antibiotic prescribing that will only have modest impact on immediate clinical outcomes but may have long-term benefits in reducing overuse of antibiotics. A reduction in the overuse of antibiotics is needed and POCCRP tests may add to other interventions in achieving this aim. Assessment of willingness to pay among policy makers and donors and undertaking operational trials will help determine cost-effectiveness and assist decision making.	[Dickinson, Simon; Leslie, Toby] Mott MacDonald Ltd, London, England; [Dickinson, Simon; Chong, Huey Yi; Boyers, Dwayne] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland; [Rowland, Mark] London Sch Hyg & Trop Med, Dept Dis Control, London, Scotland; [Hansen, Kristian Schultz] Univ Copenhagen, Dept Publ Hlth, Copenhagen, Denmark	The Mott MacDonald Group; University of Aberdeen; University of London; London School of Hygiene & Tropical Medicine; University of Copenhagen	Dickinson, S (corresponding author), Mott MacDonald Ltd, London, England.; Dickinson, S (corresponding author), Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland.	simon.dickinson85@gmail.com		Hansen, Kristian Schultz/0000-0003-2976-4947	Chief Scientist's office of the Scottish government health directorates; Bill and Melinda Gates Foundation; UK Defence Science and Technology Laboratory	Chief Scientist's office of the Scottish government health directorates; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); UK Defence Science and Technology Laboratory	Publication fees for the article are paid by Mott MacDonald Ltd. The authors received no additional funding for this article. Two of the authors (SD and TL) are affiliated to a commercial organisation (Mott MacDonald Ltd). We confirm there is no commercial affiliation between Mott MacDonald and this article. Aside from publication fees, no funding was provided for the production of the article. Three of the authors (SD, HYU and DB) are affiliated to the Health Economics Research Unit at the University of Aberdeen, which is funded by the Chief Scientist's office of the Scottish government health directorates. The primary data collection (2009-2012) for the malaria RDT IRT (Ref: 30) and CEA (Ref: 41) in Afghanistan was funded by the Bill and Melinda Gates Foundation through a grant to the London School of Hygiene and Tropical Medicine. Data on aetiological agents of disease (Ref: 14) was collected with funding from the UK Defence Science and Technology Laboratory. These funding organisations did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials.	Althaus T, 2019, LANCET GLOB HEALTH, V7, pE119, DOI 10.1016/S2214-109X(18)30444-3; Aslam B, 2018, INFECT DRUG RESIST, V11, P1645, DOI 10.2147/IDR.S173867; Aslam Sadaf, 2010, Indian J Sex Transm Dis AIDS, V31, P47, DOI 10.4103/0253-7184.69003; Bebell LM, 2014, GLOB HEART, V9, P347, DOI 10.1016/j.gheart.2014.08.009; Bhatia R, 2018, NATL MED J INDIA, V31, P133, DOI 10.4103/0970-258X.255752; Briggs A, 2006, DECISION MODELLING H; Cals JWL, 2011, J EVAL CLIN PRACT, V17, P1059, DOI 10.1111/j.1365-2753.2010.01472.x; Crump JA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002324; Elfving K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146054; Gregory S., 2013, AGENCY HEALTHCARE RE; Hansen KS, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0696-1; Hildenwall H, 2016, TROP MED INT HEALTH, V21, P149, DOI 10.1111/tmi.12635; Holmes EAF, 2018, ANTIBIOTICS-BASEL, V7, DOI 10.3390/antibiotics7040106; Hopkins H, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j1054; Hsu J, 2018, PEDIATRICS, V141, DOI 10.1542/peds.141.1_MeetingAbstract.463; Huang YF, 2013, BRIT J GEN PRACT, V63, pE787, DOI 10.3399/bjgp13X674477; Hughes A., 2016, CLIN PHARMACIST; Hughes A., 2016, CLIN PHARMACIST, V8; Hunter R, 2015, ADV THER, V32, P69, DOI 10.1007/s12325-015-0180-x; International Monetary Fund, WORLD EC OUTLOOK APR; Jonas OB, 2017, REPORT NO 114679, V2; Leslie T., 2012, CAUSES NONMALARIAL C; Leslie T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3730; Leslie T, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e4389; Llor C, 2014, THER ADV DRUG SAF, V5, P229, DOI 10.1177/2042098614554919; Lubell Y, 2018, ANTIMICROB RESIST IN, V7, DOI 10.1186/s13756-018-0414-1; Lubell Y, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1272-6; Mayxay M, 2013, LANCET GLOB HEALTH, V1, pE46, DOI 10.1016/S2214-109X(13)70008-1; Michaelidis CI, 2014, J GEN INTERN MED, V29, P579, DOI 10.1007/s11606-013-2679-7; Ministry of Public Health GD of PA, 2013, NATL STANDARD TREATM; O'Neill J., 2016, Tackling drug-resistant infections globally: final report and recommendations; Oanda, CURRENCY CONVERTER F; ONeill J, 2014, REV ANTIMICROBIAL RE; Oppong R, 2013, BRIT J GEN PRACT, V63, pE465, DOI 10.3399/bjgp13X669185; Petel D, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022133; Phommasone K, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1360-2; Prasad N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127962; Shrestha P, 2018, ANTIMICROB RESIST IN, V7, DOI 10.1186/s13756-018-0384-3; Tam PYI, 2016, J PEDIAT INF DIS SOC, V5, P190, DOI 10.1093/jpids/piw016; The World Bank, INFLATION CONSUMER P; van Stralen KJ, 2009, KIDNEY INT, V75, P1257, DOI 10.1038/ki.2009.92; Ward Caroline, 2018, BMJ Open Qual, V7, pe000391, DOI 10.1136/bmjoq-2018-000391; Who, 2015, GUID START ANT THER; World Health Organization, 2018, REG DISS WORKSH GUID; World Health Organization, 2016, ROLE RDTS MALARIA CO; World Health Organization, 2018, WHO REPORT SURVEILLA; Zecca E, 2009, CLIN CHEM LAB MED, V47, P1081, DOI 10.1515/CCLM.2009.246	47	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2021	16	11							e0258299	10.1371/journal.pone.0258299	http://dx.doi.org/10.1371/journal.pone.0258299			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ4ST	34748558	gold, Green Published			2023-01-03	WOS:000755468000006
J	Kaur, M; Black, D; Fine, J; Wise, BL				Kaur, Manmeet; Black, Daniel; Fine, Jeffrey; Wise, Barton L.			Referrals for physical therapy for osteoarthritis during the COVID-19 pandemic: A retrospective analysis	PLOS ONE			English	Article							MANAGEMENT	Background Osteoarthritis (OA) is a leading cause of musculoskeletal pain and disability among Americans. Physical therapy (PT) is recommended per the 2019 ACR /Arthritis Foundation Guideline for Treatment of OA of the Hand, Hip, and Knee. During COVID-19, access to healthcare has been altered in a variety of clinical settings, with the pandemic creating delays in healthcare, with an unknown impact on access to PT care for OA. Objectives We sought to determine whether referrals to PT for OA were reduced in 2020 during the COVID-19 pandemic compared to 2019. Methods A retrospective analysis was done of 3586 PT referrals placed by the University of California, Davis for 206 OA ICD-10 codes from January to November 2019 and from January to November 2020. The numbers of PT referrals per month of each year were compared using both descriptive statistics and Poisson Regression analysis. Results A total of 1972 PT referrals for OA were placed from January to November 2019. Only 1614 referrals for OA were placed from January to November 2020, representing a significant decrease (p = 0.001). Month-by-month analysis of 2020 compared to 2019 revealed statistically significant drops in PT referrals for OA in April (p = 0.001), May (p = 0.001), and August (p = 0.001). Conclusions These findings reveal a significant reduction in the number of referrals for PT for OA placed in 2020 during the first year of the COVID-19 pandemic. These reductions were particularly evident in the months following state-mandated actions and closures. Factors associated with this outcome may include decreased access to primary care providers, perceptions of PT availability by health care providers, decreased mobility limiting access to both clinic and PT appointments, and/or willingness to engage in PT by patients during the pandemic.	[Kaur, Manmeet] Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA; [Black, Daniel] Univ Calif Davis, Dept Med, Div Clin Affairs Div Qual & Safety, Sacramento, CA 95817 USA; [Fine, Jeffrey] Univ Calif Davis, Dept Publ Hlth Sci, Sacramento, CA 95817 USA; [Wise, Barton L.] Univ Calif Davis, Dept Orthopaed Surg, Dept Med, Div Rheumatol, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Kaur, M (corresponding author), Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA.	mmkaur@ucdavis.edu		Wise, Barton/0000-0002-6540-6031				[Anonymous], 2020, GOVERNOR NEWSOM PROV; Bambra C, 2020, J EPIDEMIOL COMMUN H, V74, P964, DOI 10.1136/jech-2020-214401; Brakke R, 2012, PM&R, V4, pS53, DOI 10.1016/j.pmrj.2012.02.017; California S of, COVID 19 RESTR; Deyle GD, 2020, NEW ENGL J MED, V382, P1420, DOI 10.1056/NEJMoa1905877; Kolasinski SL, 2020, ARTHRIT CARE RES, V72, P149, DOI 10.1002/acr.24131; Miller MJ, 2021, PHYS THER, V101, DOI 10.1093/ptj/pzaa193; Osteoarthritis, BMUS BURD MUSC DIS U; Poitras S, 2010, JOINT BONE SPINE, V77, P458, DOI 10.1016/j.jbspin.2010.08.001; Wosik J, 2020, J AM MED INFORM ASSN, V27, P957, DOI 10.1093/jamia/ocaa067	10	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2021	16	11							e0259679	10.1371/journal.pone.0259679	http://dx.doi.org/10.1371/journal.pone.0259679			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY7XS	34739521	Green Published, gold			2023-01-03	WOS:000755000800050
J	Frede, J; Anand, P; Sotudeh, N; Pinto, RA; Nair, MS; Stuart, H; Yee, AJ; Vijaykumar, T; Waldschmidt, JM; Potdar, S; Kloeber, JA; Kokkalis, A; Dimitrova, V; Mann, M; Laubach, JP; Richardson, PG; Anderson, KC; Raje, NS; Knoechel, B; Lohr, JG				Frede, Julia; Anand, Praveen; Sotudeh, Noori; Pinto, Ricardo A.; Nair, Monica S.; Stuart, Hannah; Yee, Andrew J.; Vijaykumar, Tushara; Waldschmidt, Johannes M.; Potdar, Sayalee; Kloeber, Jake A.; Kokkalis, Antonis; Dimitrova, Valeriya; Mann, Mason; Laubach, Jacob P.; Richardson, Paul G.; Anderson, Kenneth C.; Raje, Noopur S.; Knoechel, Birgit; Lohr, Jens G.			Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma	NATURE CELL BIOLOGY			English	Article							DIFFERENTIAL EXPRESSION ANALYSIS; RNA-SEQ; PROGRAMS; CELLS; HETEROGENEITY; ACTIVATION; SOFTWARE; HALLMARK; PROMOTER; STATES	Frede et al. perform single-cell transcriptome and chromatin accessibility profiling of immune cells isolated from patients with refractory multiple myeloma before or during the course of chemotherapy. While there is extensive evidence for genetic variation as a basis for treatment resistance, other sources of variation result from cellular plasticity. Using multiple myeloma as an example of an incurable lymphoid malignancy, we show how cancer cells modulate lineage restriction, adapt their enhancer usage and employ cell-intrinsic diversity for survival and treatment escape. By using single-cell transcriptome and chromatin accessibility profiling, we show that distinct transcriptional states co-exist in individual cancer cells and that differential transcriptional regulon usage and enhancer rewiring underlie these alternative transcriptional states. We demonstrate that exposure to standard treatment further promotes transcriptional reprogramming and differential enhancer recruitment while simultaneously reducing developmental potential. Importantly, treatment generates a distinct complement of actionable immunotherapy targets, such as CXCR4, which can be exploited to overcome treatment resistance. Our studies therefore delineate how to transform the cellular plasticity that underlies drug resistance into immuno-oncologic therapeutic opportunities.	[Frede, Julia; Anand, Praveen; Sotudeh, Noori; Nair, Monica S.; Stuart, Hannah; Vijaykumar, Tushara; Waldschmidt, Johannes M.; Kloeber, Jake A.; Kokkalis, Antonis; Laubach, Jacob P.; Richardson, Paul G.; Anderson, Kenneth C.; Lohr, Jens G.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA; [Frede, Julia; Anand, Praveen; Sotudeh, Noori; Yee, Andrew J.; Waldschmidt, Johannes M.; Kokkalis, Antonis; Dimitrova, Valeriya; Laubach, Jacob P.; Richardson, Paul G.; Anderson, Kenneth C.; Raje, Noopur S.; Knoechel, Birgit; Lohr, Jens G.] Harvard Med Sch, Boston, MA 02115 USA; [Frede, Julia; Anand, Praveen; Sotudeh, Noori; Pinto, Ricardo A.; Waldschmidt, Johannes M.; Kokkalis, Antonis; Dimitrova, Valeriya; Knoechel, Birgit; Lohr, Jens G.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Pinto, Ricardo A.] Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02115 USA; [Pinto, Ricardo A.] Harvard Med Sch, Dept Data Sci, Boston, MA 02115 USA; [Yee, Andrew J.; Mann, Mason; Raje, Noopur S.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Potdar, Sayalee; Dimitrova, Valeriya; Knoechel, Birgit] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute	Lohr, JG (corresponding author), Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA.; Knoechel, B; Lohr, JG (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Knoechel, B; Lohr, JG (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Knoechel, B (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.	birgit_knoechel@dfci.harvard.edu; jensg_lohr@dfci.harvard.edu		Frede, Julia/0000-0002-4380-9673; Anand, Praveen/0000-0002-2478-7042	National Cancer Institute [K08CA191026, K08CA191091]; Anna Fuller Fund; V Foundation for Cancer Research; German Research Foundation (DFG); American Association for Cancer Research (AACR)	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Anna Fuller Fund; V Foundation for Cancer Research; German Research Foundation (DFG)(German Research Foundation (DFG)); American Association for Cancer Research (AACR)	The authors would like to thank A. Letai for discussion and critical comments on the manuscript. This project was supported by grants from the National Cancer Institute (K08CA191026 to J.G.L.), (K08CA191091 to B.K.), the Anna Fuller Fund (to J.G.L.) and a Scholar Award by the V Foundation for Cancer Research (to J.G.L.). K.C.A. is an American Cancer Society Clinical Research Professor. J.F. acknowledges support from the German Research Foundation (DFG) and the American Association for Cancer Research (AACR).	Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/nmeth.4463, 10.1038/NMETH.4463]; Anand P, 2021, BLOOD, V137, P2463, DOI 10.1182/blood.2019004547; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590-018-0276-y; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Barwick BG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01121; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Boutros, 2019, LINEAGE SPECIFIC COR, DOI [10.1101/609552, DOI 10.1101/609552]; Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood-2009-12-261032; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Campbell KS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02551; Chen WY, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0554-8; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; Cuitino MC, 2019, CELL REP, V27, P3547, DOI 10.1016/j.celrep.2019.05.004; DiPersio JF, 2009, BLOOD, V113, P5720, DOI 10.1182/blood-2008-08-174946; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Ewels PA, 2020, NAT BIOTECHNOL, V38, P276, DOI 10.1038/s41587-020-0439-x; Fan J, 2016, NAT METHODS, V13, P241, DOI [10.1038/nmeth.3734, 10.1038/NMETH.3734]; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Fulciniti M, 2018, CELL REP, V25, P3693, DOI 10.1016/j.celrep.2018.12.016; Fulco CP, 2019, NAT GENET, V51, P1664, DOI 10.1038/s41588-019-0538-0; Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367; Ghobrial IM, 2020, CLIN CANCER RES, V26, P344, DOI 10.1158/1078-0432.CCR-19-0647; Goenawan IH, 2016, BIOINFORMATICS, V32, P2713, DOI 10.1093/bioinformatics/btw187; Granja JM, 2021, NAT GENET, V53, P403, DOI 10.1038/s41588-021-00790-6; Gulati GS, 2020, SCIENCE, V367, P405, DOI 10.1126/science.aax0249; Hangauer MJ, 2017, NATURE, V551, P247, DOI 10.1038/nature24297; Hay SB, 2018, EXP HEMATOL, V68, P51, DOI 10.1016/j.exphem.2018.09.004; Huang YH, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02461-5; Jia YL, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00421-7; Jin Y, 2018, BLOOD, V131, P2138, DOI 10.1182/blood-2017-09-808063; Joseph D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206368; Joshi S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006600; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Katz Y, 2010, NAT METHODS, V7, P1009, DOI 10.1038/NMETH.1528; Kaya-Okur HS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09982-5; Kinker GS, 2020, NAT GENET, V52, P1208, DOI 10.1038/s41588-020-00726-6; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; LaFave LM, 2020, CANCER CELL, V38, P212, DOI 10.1016/j.ccell.2020.06.006; Ledergor G, 2018, NAT MED, V24, P1867, DOI 10.1038/s41591-018-0269-2; Lee JH, 2013, BIOCHEM BIOPH RES CO, V439, P327, DOI 10.1016/j.bbrc.2013.08.087; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lun Aaron T L, 2016, F1000Res, V5, P2122; Mandal M, 2019, NAT IMMUNOL, V20, P1393, DOI 10.1038/s41590-019-0468-0; Fernandez JM, 2016, CELL SYST, V3, P491, DOI 10.1016/j.cels.2016.10.021; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Muller S, 2018, BIOINFORMATICS, V34, P3217, DOI 10.1093/bioinformatics/bty316; Ordonez R, 2020, GENOME RES, V30, P1217, DOI 10.1101/gr.265520.120; Paiva B, 2017, LEUKEMIA, V31, P382, DOI 10.1038/leu.2016.211; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Pliner HA, 2018, MOL CELL, V71, P858, DOI 10.1016/j.molcel.2018.06.044; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Risom T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05729-w; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roccaro AM, 2015, CELL REP, V12, P622, DOI 10.1016/j.celrep.2015.06.059; Salomonis N, 2010, P NATL ACAD SCI USA, V107, P10514, DOI 10.1073/pnas.0912260107; Schep AN, 2017, NAT METHODS, V14, P975, DOI [10.1038/nmeth.4401, 10.1038/NMETH.4401]; Schubert M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02391-6; Setz CS, 2018, CELL REP, V24, P391, DOI 10.1016/j.celrep.2018.06.035; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Teschendorff AE, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15599; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0; Wouters J, 2020, NAT CELL BIOL, V22, P986, DOI 10.1038/s41556-020-0547-3	74	7	7	9	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2021	23	11					1199	+		10.1038/s41556-021-00766-y	http://dx.doi.org/10.1038/s41556-021-00766-y		OCT 2021	36	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	WS6SF	34675390	Green Accepted			2023-01-03	WOS:000709708800001
J	Bundo, M; de Schrijver, E; Federspiel, A; Toreti, A; Xoplaki, E; Luterbacher, J; Franco, OH; Muller, T; Vicedo-Cabrera, AM				Bundo, Marvin; de Schrijver, Evan; Federspiel, Andrea; Toreti, Andrea; Xoplaki, Elena; Luterbacher, Juerg; Franco, Oscar H.; Mueller, Thomas; Vicedo-Cabrera, Ana M.			Ambient temperature and mental health hospitalizations in Bern, Switzerland: A 45-year time-series study	PLOS ONE			English	Article							HEAT-WAVE; SCHIZOPHRENIA; DISORDERS; GENE; ASSOCIATION; ADMISSIONS; SUICIDE; DEATHS; IMPACT; RISK	Background Psychiatric disorders constitute a major public health concern that are associated with substantial health and socioeconomic burden. Psychiatric patients may be more vulnerable to high temperatures, which under current climate change projections will most likely increase the burden of this public health concern. Objective This study investigated the short-term association between ambient temperature and mental health hospitalizations in Bern, Switzerland. Methods Daily hospitalizations for mental disorders between 1973 and 2017 were collected from the University Hospital of Psychiatry and Psychotherapy in Bern. Population-weighted daily mean ambient temperatures were derived for the catchment area of the hospital from 2.3-km gridded weather maps. Conditional quasi-Poisson regression with distributed lag linear models were applied to assess the association up to three days after the exposure. Stratified analyses were conducted by age, sex, and subdiagnosis, and by subperiods (1973-1989 and 1990-2017). Additional subanalyses were performed to assess whether larger risks were found during the warm season or were due to heatwaves. Results The study included a total number of 88,996 hospitalizations. Overall, the hospitalization risk increased linearly by 4.0% (95% CI 2.0%, 7.0%) for every 10 degrees C increase in mean daily temperature. No evidence of a nonlinear association or larger risks during the warm season or heatwaves was found. Similar estimates were found across for all sex and age categories, and larger risks were found for hospitalizations related to developmental disorders (29.0%; 95% CI 9.0%, 54.0%), schizophrenia (10.0%; 95% CI 4.0%, 15.0%), and for the later rather than the earlier period (5.0%; 95% CI 2.0%, 8.0% vs. 2.0%; 95% CI -3.0%, 8.0%). Conclusions Our findings suggest that increasing temperatures could negatively affect mental status in psychiatric patients. Specific public health policies are urgently needed to protect this vulnerable population from the effects of climate change.	[Bundo, Marvin; de Schrijver, Evan; Franco, Oscar H.; Vicedo-Cabrera, Ana M.] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [Bundo, Marvin; de Schrijver, Evan; Vicedo-Cabrera, Ana M.] Univ Bern, Oeschger Ctr Climate Change Res, Bern, Switzerland; [Bundo, Marvin; de Schrijver, Evan] Univ Bern, Grad Sch Hlth Sci, Bern, Switzerland; [Federspiel, Andrea; Mueller, Thomas] Univ Bern, Translat Res Ctr TRC, Univ Hosp Psychiat & Psychotherapy, Bern, Switzerland; [Toreti, Andrea] European Commiss, Joint Res Ctr, Ispra, Italy; [Xoplaki, Elena] Justus Liebig Univ Giessen, Dept Geog Climatol Climate Dynam & Climate Change, Giessen, Germany; [Xoplaki, Elena] Justus Liebig Univ Giessen, Ctr Int Dev & Environm Res ZEU, Giessen, Germany; [Luterbacher, Juerg] World Meteorol Org WMO, Sci & Innovat Dept, Geneva, Switzerland; [Mueller, Thomas] Privatclin Meiringen, Meiringen, Switzerland	University of Bern; University of Bern; University of Bern; University of Bern; University Hospital of Bern; European Commission Joint Research Centre; EC JRC ISPRA Site; Justus Liebig University Giessen; Justus Liebig University Giessen	Vicedo-Cabrera, AM (corresponding author), Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.; Vicedo-Cabrera, AM (corresponding author), Univ Bern, Oeschger Ctr Climate Change Res, Bern, Switzerland.; Muller, T (corresponding author), Univ Bern, Translat Res Ctr TRC, Univ Hosp Psychiat & Psychotherapy, Bern, Switzerland.; Muller, T (corresponding author), Privatclin Meiringen, Meiringen, Switzerland.	thomas.mueller@upd.unibe.ch; anamaria.vicedo@ispm.unibe.ch	Müller, Thomas/D-1212-2010	Müller, Thomas/0000-0001-9315-8138; de Schrijver, Evan/0000-0002-2679-0464; Vicedo Cabrera, Ana Maria/0000-0001-6982-8867	European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant through the SSPH+ Global PhD Fellowship Programme in Public Health Sciences (GlobalP3HS) of the Swiss School of Public Health [801076]; Academy of Athens and the Greek "National Research Network on Climate Change and its Impact" [200/937]; German Federal Ministry of Education and Research (BMBF) [01LR2002F, 01LP1903C]	European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant through the SSPH+ Global PhD Fellowship Programme in Public Health Sciences (GlobalP3HS) of the Swiss School of Public Health; Academy of Athens and the Greek "National Research Network on Climate Change and its Impact"; German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	This project has received funding in the form of salaries for the authors MB and EDV from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 801076, through the SSPH+ Global PhD Fellowship Programme in Public Health Sciences (GlobalP3HS) of the Swiss School of Public Health. The author EX acknowledges support by the Academy of Athens and the Greek "National Research Network on Climate Change and its Impact" (project code 200/937) and the German Federal Ministry of Education and Research (BMBF) (01LR2002F) projects NUKLEUS and ClimXtreme (01LP1903C). Privatclinic Meiringen (Switzerland) provided support in the form of salaries for the author TM. None of the funding sources mentioned here have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	[Anonymous], 2003, Saudi Med J, V24, P1154; Armstrong BG, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-122; Bark N, 1998, PSYCHIATR SERV, V49, P1088, DOI 10.1176/ps.49.8.1088; Basu R, 2002, EPIDEMIOL REV, V24, P190, DOI 10.1093/epirev/mxf007; Batscha C L, 1997, J Psychosoc Nurs Ment Health Serv, V35, P12; Bolker B., 2014, COMPARE, V1; Bolton M., 2020, INITIAL EVIDENCE INC, V12; Bouchama A, 2007, ARCH INTERN MED, V167, P2170, DOI 10.1001/archinte.167.20.ira70009; Butler Rhonda, 2007, J AHIMA, V78, P84; Chan EYY, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040754; Chen JY, 2020, AGING-US, V12, P8434, DOI 10.18632/aging.103150; Chong TW, 2004, SCHIZOPHR RES, V69, P149, DOI 10.1016/S0920-9964(03)00222-6; Cianconi P, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00074; Dai DJ, 2014, BIOMED REP, V2, P886, DOI 10.3892/br.2014.324; Davido A, 2006, EMERG MED J, V23, P515, DOI 10.1136/emj.2005.028290; Dunn W, 1997, INFANT YOUNG CHILD, V9, P23, DOI 10.1097/00001163-199704000-00005; Dunn W, 2001, AM J OCCUP THER, V55, P608, DOI 10.5014/ajot.55.6.608; Federal Office of Meteorology and Climatology MeteoSwiss, 2020, SPAT CLIM AN; Fonseca-Rodriguez O, 2020, INT J BIOMETEOROL, V64, P1435, DOI 10.1007/s00484-020-01921-0; Funk M., 2016, GLOBAL BURDEN MENTAL; Gao JJ, 2019, SCI TOTAL ENVIRON, V646, P1021, DOI 10.1016/j.scitotenv.2018.07.098; Gasparrini A, 2010, STAT MED, V29, P2224, DOI 10.1002/sim.3940; Gasparrini A, 2015, LANCET, V386, P369, DOI 10.1016/S0140-6736(14)62114-0; Gasparrini A, 2011, EPIDEMIOLOGY, V22, P68, DOI 10.1097/EDE.0b013e3181fdcd99; Guo YM, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP1026; Guo YM, 2011, ENVIRON HEALTH PERSP, V119, P1719, DOI 10.1289/ehp.1103598; GUPTA S, 1992, BRIT J PSYCHIAT, V160, P788, DOI 10.1192/bjp.160.6.788; Haber G, 2021, BIOSTATISTICS, V22, P858, DOI 10.1093/biostatistics/kxaa002; Hansen A, 2008, ENVIRON HEALTH PERSP, V116, P1369, DOI 10.1289/ehp.11339; Hayes K, 2018, INT J MENT HEALTH SY, V12, DOI 10.1186/s13033-018-0210-6; Hermesh H, 2000, AM J PSYCHIAT, V157, P1327, DOI 10.1176/appi.ajp.157.8.1327; Ji HH, 2015, EXP THER MED, V9, P1831, DOI 10.3892/etm.2015.2327; Jiang L, 2019, J CLIN ENDOCR METAB, V104, P4539, DOI 10.1210/jc.2019-00495; Kessler RC, 2009, EPIDEMIOL PSICHIAT S, V18, P23, DOI 10.1017/S1121189X00001421; Kim Y, 2019, ENVIRON HEALTH PERSP, V127, DOI 10.1289/EHP4898; Kim Y, 2016, ENVIRON HEALTH PERSP, V124, P75, DOI 10.1289/ehp.1409392; Lee S, 2018, SCI TOTAL ENVIRON, V616, P688, DOI 10.1016/j.scitotenv.2017.10.260; Liubicic D, 2007, J PHOTOCH PHOTOBIO B, V89, P63, DOI 10.1016/j.jphotobiol.2007.09.002; Lohmus M, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071515; MAES M, 1995, ARCH GEN PSYCHIAT, V52, P937; Martin-Latry K, 2007, EUR PSYCHIAT, V22, P335, DOI 10.1016/j.eurpsy.2007.03.007; Masson-Delmotte V., 2021, CONTRIBUTION WORKING; Miller LJ, 2007, AM J OCCUP THER, V61, P135, DOI 10.5014/ajot.61.2.135; National Autistic Society, 2018, ENV SORR; Nitschke M, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-42; Park RJ, 2020, AM ECON J-ECON POLIC, V12, P306, DOI 10.1257/pol.20180612; Peng ZX, 2017, SCI TOTAL ENVIRON, V590, P281, DOI 10.1016/j.scitotenv.2017.02.237; Pervilhac C, 2020, NERVENARZT, V91, P227, DOI 10.1007/s00115-019-00795-x; Trang PM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155609; Ragettli M., 2019, BUNDESGESUNDHEITSBLA, V62; Ragettli MS, 2019, BUNDESGESUNDHEITSBLA, V62, P605, DOI 10.1007/s00103-019-02928-8; Rivara FP, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.12502; SARRIAS MJ, 1989, BIOL PSYCHIAT, V26, P695, DOI 10.1016/0006-3223(89)90104-2; Scahill L, 2001, PERCEPT MOTOR SKILL, V92, P419, DOI 10.2466/PMS.92.2.419-432; Schmeltz MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186509; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; Shiloh R, 2005, EUR PSYCHIAT, V20, P61, DOI 10.1016/j.eurpsy.2004.09.020; Shiloh R, 2007, EUR NEUROPSYCHOPHARM, V17, P478, DOI 10.1016/j.euroneuro.2006.12.001; Simister J, 2005, STRESS HEALTH, V21, P3, DOI 10.1002/smi.1029; Spangler KR, 2019, J EXPO SCI ENV EPID, V29, P777, DOI 10.1038/s41370-018-0105-2; TADA K, 1984, EUR J PEDIATR, V142, P204, DOI 10.1007/BF00442450; Taylor L, 2016, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00372; Thompson R, 2018, PUBLIC HEALTH, V161, P171, DOI 10.1016/j.puhe.2018.06.008; Tong SL, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003579; Trautmann S, 2016, EMBO REP, V17, P1245, DOI 10.15252/embr.201642951; Turner LR, 2012, EPIDEMIOLOGY, V23, P594, DOI 10.1097/EDE.0b013e3182572795; Wang X, 2014, J AFFECT DISORDERS, V155, P154, DOI 10.1016/j.jad.2013.10.042; Wang XH, 2021, J CLIN ENDOCR METAB, V106, pE4641, DOI 10.1210/clinem/dgab454; Watts N, 2021, LANCET, V397, P129, DOI 10.1016/S0140-6736(20)32290-X; Watts N, 2019, LANCET, V394, P1836, DOI 10.1016/S0140-6736(19)32596-6; WHO, 2001, WORLD HLTH REP MENT; Williams ZJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49103-2; World Health Organization, 2013, GUIDELINES MANAGEMEN; Wu YL, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-00902-6; Xu MQ, 2007, SCHIZOPHR RES, V91, P6, DOI 10.1016/j.schres.2006.12.008; Xu MQ, 2011, PROG NEURO-PSYCHOPH, V35, P1255, DOI 10.1016/j.pnpbp.2010.11.001; Xu MQ, 2010, ATHEROSCLEROSIS, V213, P191, DOI 10.1016/j.atherosclerosis.2010.07.046; Xu MQ, 2010, AM J MED GENET B, V153B, P1266, DOI 10.1002/ajmg.b.31096; Xu MQ, 2010, SCHIZOPHR RES, V120, P131, DOI 10.1016/j.schres.2010.02.1031; Yan XT, 2018, PROG NEURO-PSYCHOPH, V83, P64, DOI 10.1016/j.pnpbp.2017.12.016; Zhang FQ, 2021, HUM GENET, V140, P1267, DOI 10.1007/s00439-021-02288-x; Zhang FQ, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI145942; Zheng SY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02415	83	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2021	16	10							e0258302	10.1371/journal.pone.0258302	http://dx.doi.org/10.1371/journal.pone.0258302			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ7ZF	34637463	Green Published, Green Submitted, gold			2023-01-03	WOS:000755690100017
J	Morrison, RS; Meier, DE; Arnold, RM				Morrison, R. Sean; Meier, Diane E.; Arnold, Robert M.			What's Wrong With Advance Care Planning?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Morrison, R. Sean; Meier, Diane E.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA; [Morrison, R. Sean] James J Peters VA Med Ctr, Bronx, NY USA; [Arnold, Robert M.] Univ Pittsburgh, Med Ctr, Sect Palliat Care & Med Eth, Pittsburgh, PA USA	Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Morrison, RS (corresponding author), Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA.	sean.morrison@mssm.edu			National Institute on Aging [P01AG066605, P30AG028741, R33AG065726]; National Palliative Care Research Center; Center to Advance Palliative Care	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Palliative Care Research Center; Center to Advance Palliative Care	Drs Morrison and Meier were supported by grants P01AG066605 and P30AG028741 from the National Institute on Aging. Dr Morrison was additionally supported by the National Palliative Care Research Center and grant R33AG065726 from the National Institute on Aging. Dr Meier was supported by the Center to Advance Palliative Care.	Center for Health Equity Research and Promotion, 2018, BER FAM SURV INP; Fischer GS, 1998, J GEN INTERN MED, V13, P447, DOI 10.1046/j.1525-1497.1998.00133.x; Gabbard J, 2021, JAMA INTERN MED, V181, P361, DOI 10.1001/jamainternmed.2020.5950; Halpern SD, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.1742; Jimenez G, 2018, J PAIN SYMPTOM MANAG, V56, P436, DOI 10.1016/j.jpainsymman.2018.05.016; Korfage IJ, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003422; Malhotra C, 2020, J CARD FAIL, V26, P594, DOI 10.1016/j.cardfail.2020.01.015; McMahan RD, 2021, J AM GERIATR SOC, V69, P234, DOI 10.1111/jgs.16801; Mitchell SL, 2020, JAMA INTERN MED, V180, P1070, DOI 10.1001/jamainternmed.2020.2366	9	70	70	3	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2021	326	16					1575	1576		10.1001/jama.2021.16430	http://dx.doi.org/10.1001/jama.2021.16430		OCT 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YI2LG	34623373	Green Accepted			2023-01-03	WOS:000704806500002
J	Ishikawa, M; Takashima, A; Nagata, Y; Sawada, R; Aoki, M; Imazeki, H; Hirano, H; Shoji, H; Honma, Y; Iwasa, S; Okita, N; Kato, K; Saruta, M; Boku, N				Ishikawa, Masashi; Takashima, Atsuo; Nagata, Yusuke; Sawada, Ryoichi; Aoki, Masahiko; Imazeki, Hiroshi; Hirano, Hidekazu; Shoji, Hirokazu; Honma, Yoshitaka; Iwasa, Satoru; Okita, Natsuko; Kato, Ken; Saruta, Masayuki; Boku, Narikazu			Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study	PLOS ONE			English	Article							RANDOMIZED PHASE-III; 1ST-LINE TREATMENT; CARCINOMA PATIENTS; OXALIPLATIN; CETUXIMAB; BEVACIZUMAB; MONOTHERAPY; GUIDELINES; IRINOTECAN; EVALUATE	Background In clinical practice, the same chemotherapeutic agents are occasionally reused (re-challenge) after failure of all available standard chemotherapy options for metastatic colorectal cancer (mCRC). However, the benefits of re-challenge chemotherapy (Re-Cx) are unclear. This retrospective study evaluated the efficacy of Re-Cx, focusing on the tumor growth rate (TGR). Methods The study included mCRC patients with measurable lesions who received Re-Cx from November 2011 to October 2018 at National Cancer Center Hospital. Re-Cx was defined as re-administration of agents which had been used in prior lines of chemotherapy and discontinued due to disease progression. We compared the TGR immediately after initiating Re-Cx regimens with that observed at the time of disease progression during prior chemotherapy (Prior-Cx) immediately before Re-Cx. Results Of the 25 patients who received Re-Cx, five patients received two Re-Cx regimens. Therefore, a total of 30 cases of Re-Cx were analyzed in this study. The regimens of Re-Cx were oxaliplatin based (19 cases), irinotecan based (8 cases), and others (3 cases). Although the objective response rate to Re-Cx was 0%, the disease control rate was 60% (18 cases), and 40% (12 cases) showed some tumor shrinkage. We compared the effects of Re-Cx and Prior-Cx by the TGR and found that the TGR of Re-Cx was slower than that recorded in Prior-Cx in 26 of 30 cases (87%). In particular, the ratio of% TGR <0, which indicates tumor shrinkage, was obtained in 13 of 30 cases (43.3%). The median progression-free survival and overall survival after Re-Cx were 3.8 and 6.57 months, respectively. Conclusion We found that Re-Cx may have some anti-tumor efficacy as salvage treatment for mCRC and these results also suggested the clinical benefits of Re-Cx.	[Ishikawa, Masashi; Takashima, Atsuo; Aoki, Masahiko; Imazeki, Hiroshi; Hirano, Hidekazu; Shoji, Hirokazu; Honma, Yoshitaka; Iwasa, Satoru; Okita, Natsuko; Kato, Ken; Boku, Narikazu] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Chuo Ku, Tokyo, Japan; [Nagata, Yusuke; Sawada, Ryoichi; Saruta, Masayuki] Jikei Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Minato Ku,Sch Med, Tokyo, Japan	National Cancer Center - Japan; Jikei University	Takashima, A (corresponding author), Natl Canc Ctr, Gastrointestinal Med Oncol Div, Chuo Ku, Tokyo, Japan.	atakashi@ncc.go.jp	Saruta, Masayuki/ABL-4991-2022	Saruta, Masayuki/0000-0001-8172-3240; Takashima, Atuso/0000-0002-8456-1248				Becouarn Y, 1998, SEMIN ONCOL, V25, P23; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cassidy J, 2008, J CLIN ONCOL, V26, P2006, DOI 10.1200/JCO.2007.14.9898; Chibaudel B, 2013, EUR J CANCER, V49, P3813, DOI 10.1016/j.ejca.2013.07.150; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Diaz-Rubio E, 1998, ANN ONCOL, V9, P105, DOI 10.1023/A:1008200825886; Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ferte C, 2014, EUR UROL, V65, P713, DOI 10.1016/j.eururo.2013.08.010; Ferte C, 2014, CLIN CANCER RES, V20, P246, DOI 10.1158/1078-0432.CCR-13-2098; Gomez-Roca C, 2011, EUR J CANCER, V47, P2512, DOI 10.1016/j.ejca.2011.06.012; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Hashiguchi Y, 2020, INT J CLIN ONCOL, V25, P1, DOI 10.1007/s10147-019-01485-z; Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4; Kato S, 2017, CLIN CANCER RES, V23, P4242, DOI 10.1158/1078-0432.CCR-16-3133; Kim JJ, 2018, MED ONCOL, V35, DOI 10.1007/s12032-018-1124-5; Kubicka S, 2013, ANN ONCOL, V24, P2342, DOI 10.1093/annonc/mdt231; Maindrault-Goebel F, 2004, ANN ONCOL, V15, P1210, DOI 10.1093/annonc/mdh305; Mansoori B, 2017, ADV PHARM BULL, V7, P339, DOI 10.15171/apb.2017.041; Mauri G, 2019, CANCER TREAT REV, V73, P41, DOI 10.1016/j.ctrv.2018.12.006; Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325; National Comprehensive Cancer Network (NCCN), 2018, NCCN CLIN PRACT GUID; Santini D, 2012, ANN ONCOL, V23, P2313, DOI 10.1093/annonc/mdr623; Suenaga M., J CLIN ONCOL, V33, P758; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Venook AP., 2017, J CLIN ONCOL, V32; Zhang W, 2010, ANTICANCER RES, V30, P4209	28	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2021	16	9							e0257551	10.1371/journal.pone.0257551	http://dx.doi.org/10.1371/journal.pone.0257551			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY2YF	34559818	Green Published, gold			2023-01-03	WOS:000754657900029
J	Cyr, MP; Dostie, R; Camden, C; Dumoulin, C; Bessette, P; Pina, A; Gotlieb, WH; Lapointe-Milot, K; Mayrand, MH; Morin, M				Cyr, Marie-Pierre; Dostie, Rosalie; Camden, Chantal; Dumoulin, Chantale; Bessette, Paul; Pina, Annick; Gotlieb, Walter Henry; Lapointe-Milot, Korine; Mayrand, Marie-Helene; Morin, Melanie			Improvements following multimodal pelvic floor physical therapy in gynecological cancer survivors suffering from pain during sexual intercourse: Results from a one-year follow- up mixed-method study	PLOS ONE			English	Article							CERVICAL-CANCER; ENDOMETRIAL CANCER; FEAR-AVOIDANCE; PROVOKED VESTIBULODYNIA; PSYCHOSEXUAL OUTCOMES; CLINICAL IMPORTANCE; BEHAVIORAL-THERAPY; FUNCTION INDEX; SINGLE-ARM; WOMEN	Background A large proportion of gynecological cancer survivors suffer from pain during sexual intercourse, also known as dyspareunia. Following a multimodal pelvic floor physical therapy (PFPT) treatment, a reduction in pain and improvement in psychosexual outcomes were found in the short term, but no study thus far has examined whether these changes are sustained over time. Purpose To examine the improvements in pain, sexual functioning, sexual distress, body image concerns, pain anxiety, pain catastrophizing, painful intercourse self-efficacy, depressive symptoms and pelvic floor disorder symptoms in gynecological cancer survivors with dyspareunia after PFPT, and to explore women's perceptions of treatment effects at one-year follow-up. Methods This mixed-method study included 31 gynecological cancer survivors affected by dyspareunia. The women completed a 12-week PFPT treatment comprising education, manual therapy and pelvic floor muscle exercises. Quantitative data were collected using validated questionnaires at baseline, post-treatment and one-year follow-up. As for qualitative data, semi-structured interviews were conducted at one-year follow-up to better understand women's perception and experience of treatment effects. Results Significant improvements were found from baseline to one-year follow-up on all quantitative outcomes (P <= 0.028). Moreover, no changes were found from post-treatment to one-year follow-up, supporting that the improvements were sustained at follow-up. Qualitative data highlighted that reduction in pain, improvement in sexual functioning and reduction in urinary symptoms were the most meaningful effects perceived by participants. Women expressed that these effects resulted from positive biological, psychological and social changes attributable to multimodal PFPT. Adherence was also perceived to influence treatment outcomes. Conclusions Findings suggest that the short-term improvements following multimodal PFPT are sustained and meaningful for gynecological cancer survivors with dyspareunia one year after treatment.	[Cyr, Marie-Pierre; Dostie, Rosalie; Camden, Chantal; Morin, Melanie] Univ Sherbrooke, Fac Med & Hlth Sci, Sch Rehabil, Sherbrooke, PQ, Canada; [Cyr, Marie-Pierre; Dostie, Rosalie; Camden, Chantal; Bessette, Paul; Lapointe-Milot, Korine; Morin, Melanie] Ctr Hosp Univ Sherbrooke, Res Ctr, Sherbrooke, PQ, Canada; [Dumoulin, Chantale] Univ Montreal, Fac Med, Sch Rehabil, Montreal, PQ, Canada; [Dumoulin, Chantale] Inst Univ Geriatrie Montreal, Res Ctr, Montreal, PQ, Canada; [Bessette, Paul; Lapointe-Milot, Korine] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Obstet & Gynecol, Div Gynecol Oncol, Sherbrooke, PQ, Canada; [Pina, Annick] Univ Montreal, Fac Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Montreal, PQ, Canada; [Pina, Annick; Mayrand, Marie-Helene] Ctr Hosp Univ Montreal, Res Ctr, Montreal, PQ, Canada; [Gotlieb, Walter Henry] McGill Univ, Fac Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Montreal, PQ, Canada; [Gotlieb, Walter Henry] Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ, Canada; [Mayrand, Marie-Helene] Univ Montreal, Fac Med, Dept Obstet, Montreal, PQ, Canada; [Mayrand, Marie-Helene] Univ Montreal, Dept Gynecol, Montreal, PQ, Canada; [Mayrand, Marie-Helene] Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, Canada	University of Sherbrooke; University of Sherbrooke; Universite de Montreal; Universite de Montreal; University of Sherbrooke; Universite de Montreal; Universite de Montreal; McGill University; Lady Davis Institute; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal	Morin, M (corresponding author), Univ Sherbrooke, Fac Med & Hlth Sci, Sch Rehabil, Sherbrooke, PQ, Canada.; Morin, M (corresponding author), Ctr Hosp Univ Sherbrooke, Res Ctr, Sherbrooke, PQ, Canada.	melanie.m.morin@usherbrooke.ca		dumoulin, chantale/0000-0002-4594-5775; dostie, rosalie/0000-0003-0276-8083; gotlieb, walter/0000-0001-6227-6369				Abbott-Anderson K, 2012, GYNECOL ONCOL, V124, P477, DOI 10.1016/j.ygyno.2011.11.030; Abildgaard JS, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01380; Andersen BL, 1997, J CONSULT CLIN PSYCH, V65, P221, DOI 10.1037/0022-006X.65.2.221; Ashbeck EL, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0144-0; Avery K, 2004, NEUROUROL URODYNAM, V23, P322, DOI 10.1002/nau.20041; Bahng AY, 2012, INT J RADIAT ONCOL, V82, P667, DOI 10.1016/j.ijrobp.2010.10.071; Bakker RM, 2017, PSYCHO-ONCOLOGY, V26, P1470, DOI 10.1002/pon.4317; Bakker RM, 2017, SUPPORT CARE CANCER, V25, P729, DOI 10.1007/s00520-016-3453-2; Bergeron S., 2015, CURR SEX HLTH REP, V7, P159, DOI [https://doi.org/10.1007/s11930-015-0053-y, DOI 10.1007/S11930-015-0053-Y]; Blackman T, 2013, EVALUATION-US, V19, P126, DOI 10.1177/1356389013484203; Bober SL, 2018, CANCER-AM CANCER SOC, V124, P176, DOI 10.1002/cncr.30976; Bowes H, 2014, EUR J ONCOL NURS, V18, P211, DOI 10.1016/j.ejon.2013.10.007; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brennen R, 2020, PHYS THER, V100, P1357, DOI 10.1093/ptj/pzaa081; Carpenter KM, 2009, ARCH SEX BEHAV, V38, P828, DOI 10.1007/s10508-008-9349-6; Carter J, 2020, GYNECOL ONCOL, V158, P366, DOI 10.1016/j.ygyno.2020.05.025; Carter J, 2018, J CLIN ONCOL, V36, P492, DOI 10.1200/JCO.2017.75.8995; Carter J, 2017, J CANCER SURVIV, V11, P274, DOI 10.1007/s11764-016-0585-9; Cleary V, 2011, EUR J ONCOL NURS, V15, P38, DOI 10.1016/j.ejon.2010.05.008; Coady D, 2016, OBSTET GYNECOL, V128, P775, DOI 10.1097/AOG.0000000000001621; Corsini-Munt S, 2017, J PAIN RES, V10, P2425, DOI 10.2147/JPR.S126259; Crean-Tate KK, 2020, AM J OBSTET GYNECOL, V222, P103, DOI 10.1016/j.ajog.2019.08.043; Cyr MP, 2021, J SEX MED, V18, P946, DOI 10.1016/j.jsxm.2021.02.014; Cyr MP, 2021, PHYS THER, V101, DOI 10.1093/ptj/pzab042; Cyr MP, 2020, GYNECOL ONCOL, V159, P778, DOI 10.1016/j.ygyno.2020.09.001; Cyr MP., 2021, PHYSIOTHERAPY; Damast S, 2019, PRACT RADIAT ONCOL, V9, P479, DOI 10.1016/j.prro.2019.07.001; DeRogatis L, 2008, J SEX MED, V5, P357, DOI 10.1111/j.1743-6109.2007.00672.x; DeSimone M, 2014, AM J CLIN ONCOL-CANC, V37, P101, DOI 10.1097/COC.0b013e318248d89d; Desrochers G, 2009, CLIN J PAIN, V25, P520, DOI 10.1097/AJP.0b013e31819976e3; Dumoulin C, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005654.pub4; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Dworkin RH, 2010, PAIN, V149, P177, DOI 10.1016/j.pain.2010.02.018; Edmunds K, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3450-x; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Fitzpatrick T, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.6019; Frawley HC, 2017, PHYS THER, V97, P425, DOI 10.1093/ptj/pzx006; Gentilcore-Saulnier E, 2010, J SEX MED, V7, P1003, DOI 10.1111/j.1743-6109.2009.01642.x; Goldfinger C, 2016, J SEX MED, V13, P88, DOI 10.1016/j.jsxm.2015.12.003; Goldfinger C, 2009, J SEX MED, V6, P1955, DOI 10.1111/j.1743-6109.2009.01304.x; Gondi V, 2012, INT J RADIAT ONCOL, V84, P973, DOI 10.1016/j.ijrobp.2012.01.064; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Hartmann D, 2007, J REPROD MED, V52, P48; Hlatky MA, 2006, CLIN TRIALS, V3, P543, DOI 10.1177/1740774506073105; Hopwood P, 2001, EUR J CANCER, V37, P189, DOI 10.1016/S0959-8049(00)00353-1; Howlader NR, 2020, BREAST CANCER RES TR, V182, P739, DOI 10.1007/s10549-020-05738-8; Huffman LB, 2016, GYNECOL ONCOL, V140, P359, DOI 10.1016/j.ygyno.2015.11.010; Irvine FE, 2020, J ADV NURS, V76, P2798, DOI 10.1111/jan.14479; Izycki D, 2016, MENOPAUSE REV, V15, P112, DOI 10.5114/pm.2016.61194; Juraskova I, 2003, PSYCHO-ONCOLOGY, V12, P267, DOI 10.1002/pon.639; Kollberg KS, 2015, ACTA ONCOL, V54, P772, DOI 10.3109/0284186X.2014.1001036; Lemieux AJ, 2013, J SEX MED, V10, P2274, DOI 10.1111/jsm.12252; Li J, 2016, EUR J ONCOL NURS, V21, P174, DOI 10.1016/j.ejon.2015.09.009; Mackenzie N., 2009, J ASS CHARTERED PHYS, V105, P24; McCracken Lance M, 2002, Pain Res Manag, V7, P45; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Mercier J, 2020, CLIMACTERIC, V23, P468, DOI 10.1080/13697137.2020.1724942; Meyer-Bahlburg HFL, 2007, J SEX MARITAL THER, V33, P217, DOI 10.1080/00926230701267852; Morin M, 2021, AM J OBSTET GYNECOL, V224, DOI 10.1016/j.ajog.2020.08.038; Morin M, 2017, SEX MED REV, V5, P375, DOI 10.1016/j.sxmr.2017.02.003; O'Cathain A, 2008, J HEALTH SERV RES PO, V13, P92, DOI 10.1258/jhsrp.2007.007074; Pieterse QD, 2013, INT J GYNECOL CANCER, V23, P1717, DOI 10.1097/IGC.0b013e3182a80a65; Price N, 2006, BJOG-INT J OBSTET GY, V113, P700, DOI 10.1111/j.1471-0528.2006.00938.x; Reis N, 2010, EUR J ONCOL NURS, V14, P137, DOI 10.1016/j.ejon.2009.09.004; Rutledge TL, 2014, GYNECOL ONCOL, V132, P154, DOI 10.1016/j.ygyno.2013.10.024; Rutledge TL, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.08.004; Santos-Iglesias P, 2018, J SEX MED, V15, P625, DOI 10.1016/j.jsxm.2018.02.020; Schielzeth H, 2020, METHODS ECOL EVOL, V11, P1141, DOI 10.1111/2041-210X.13434; Schoonenboom J, 2017, KOLNER Z SOZIOL SOZ, V69, P107, DOI 10.1007/s11577-017-0454-1; Sekse RJT, 2010, SCAND J CARING SCI, V24, P799, DOI 10.1111/j.1471-6712.2010.00778.x; Stabile C, 2015, TRANSL ANDROL UROL, V4, P169, DOI 10.3978/j.issn.2223-4683.2015.04.03; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Thomten J, 2014, WOMENS HEALTH, V10, P571, DOI [10.2217/WHE.14.51, 10.2217/whe.14.51]; Thomten O, 2013, WOMENS HEALTH, V9, P251, DOI [10.2217/whe.13.19, 10.2217/WHE.13.19]; Torre LA, 2017, CANCER EPIDEM BIOMAR, V26, P444, DOI 10.1158/1055-9965.EPI-16-0858; Turner JA, 2004, PAIN, V112, P307, DOI 10.1016/j.pain.2004.09.010; Venegas M, 2018, NEUROUROL URODYNAM, V37, P1120, DOI 10.1002/nau.23432; Vermeer WM, 2016, SUPPORT CARE CANCER, V24, P1679, DOI 10.1007/s00520-015-2925-0; Wiegel M, 2005, J SEX MARITAL THER, V31, P1, DOI 10.1080/00926230590475206; Wijma AJ, 2016, PHYSIOTHER THEOR PR, V32, P368, DOI 10.1080/09593985.2016.1194651; Yang EJ, 2012, GYNECOL ONCOL, V125, P705, DOI 10.1016/j.ygyno.2012.03.045; Zhu G., 2016, EFFECT POSTOPERATIVE, V28, P819	83	2	2	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2022	17	1							e0262844	10.1371/journal.pone.0262844	http://dx.doi.org/10.1371/journal.pone.0262844			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	1B8ZK	35077479	gold, Green Published			2023-01-03	WOS:000792720400039
J	Finfer, S; Micallef, S; Hammond, N; Navarra, L; Bellomo, R; Billot, L; Delaney, A; Gallagher, M; Gattas, D; Li, Q; Biostat, M; Mackie, D; Mysore, J; Saxena, M; Taylor, C; Young, P; Myburgh, J				Finfer, Simon; Micallef, Sharon; Hammond, Naomi; Navarra, Leanlove; Bellomo, Rinaldo; Billot, Laurent; Delaney, Anthony; Gallagher, Martin; Gattas, David; Li, Qiang; Biostat, M.; Mackie, Diane; Mysore, Jayanthi; Saxena, Manoj; Taylor, Colman; Young, Paul; Myburgh, John		PLUS Study Investigators; Australian New Zealand Intensive C	Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA-LYTE 148; RANDOMIZED CONTROLLED-TRIAL; CARE FLUID THERAPY; HYDROXYETHYL STARCH; KIDNEY INJURY; RESUSCITATION; PROTOCOL; ALBUMIN; PLUS; DEFINITIONS	BACKGROUND Whether the use of balanced multielectrolyte solution (BMES) in preference to 0.9% sodium chloride solution (saline) in critically ill patients reduces the risk of acute kidney injury or death is uncertain. METHODS In a double-blind, randomized, controlled trial, we assigned critically ill patients to receive BMES (Plasma-Lyte 148) or saline as fluid therapy in the intensive care unit (ICU) for 90 days. The primary outcome was death from any cause within 90 days after randomization. Secondary outcomes were receipt of new renal-replacement therapy and the maximum increase in the creatinine level during ICU stay. RESULTS A total of 5037 patients were recruited from 53 ICUs in Australia and New Zealand - 2515 patients were assigned to the BMES group and 2522 to the saline group. Death within 90 days after randomization occurred in 530 of 2433 patients (21.8%) in the BMES group and in 530 of 2413 patients (22.0%) in the saline group, for a difference of -0.15 percentage points (95% confidence interval [CI], -3.60 to 3.30; P=0.90). New renal-replacement therapy was initiated in 306 of 2403 patients (12.7%) in the BMES group and in 310 of 2394 patients (12.9%) in the saline group, for a difference of -0.20 percentage points (95% CI, -2.96 to 2.56). The mean (+/- SD) maximum increase in serum creatinine level was 36.6 +/- 94.0 mu mol per liter (0.41 +/- 1.06 mg per deciliter) in the BMES group and 36.1 +/- 90.2 mu mol per liter (0.41 +/- 1.02 mg per deciliter) in the saline group, for a difference of 0.5 mu mol per liter (95% CI, -4.7 to 5.3) (0.01 mg per deciliter [95% CI, -0.05 to 0.06]). The number of adverse and serious adverse events did not differ meaningfully between the groups. CONCLUSIONS We found no evidence that the risk of death or acute kidney injury among critically ill adults in the ICU was lower with the use of BMES than with saline.	[Finfer, Simon; Micallef, Sharon; Hammond, Naomi; Billot, Laurent; Delaney, Anthony; Gallagher, Martin; Li, Qiang; Mysore, Jayanthi; Saxena, Manoj; Taylor, Colman; Myburgh, John] George Inst Global Hlth, Sydney, NSW, Australia; [Finfer, Simon; Micallef, Sharon; Hammond, Naomi; Billot, Laurent; Delaney, Anthony; Gallagher, Martin; Li, Qiang; Mysore, Jayanthi; Saxena, Manoj; Taylor, Colman; Myburgh, John] Univ New South Wales, Sydney, NSW, Australia; [Hammond, Naomi; Delaney, Anthony] Royal North Shore Hosp, Malcolm Fisher Dept Intens Care, St Leonards, NSW, Australia; [Delaney, Anthony] Northern Clin Sch, Camperdown, NSW, Australia; [Gattas, David] Cent Clin Sch, Camperdown, NSW, Australia; [Gattas, David] Univ Sydney, Royal Prince Alfred Hosp, Intens Care Unit, Camperdown, NSW, Australia; [Biostat, M.; Myburgh, John] St George Hosp, Dept Intens Care, Kogarah, NSW, Australia; [Saxena, Manoj] Bankstown Hosp, Intens Care Unit, Sydney, NSW, Australia; [Bellomo, Rinaldo] Austin Hosp, Intens Care Unit, Heidelberg, Vic, Australia; [Bellomo, Rinaldo] Royal Melbourne Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Bellomo, Rinaldo; Young, Paul] Univ Melbourne, Dept Crit Care, Melbourne, Vic, Australia; [Bellomo, Rinaldo; Young, Paul] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Finfer, Simon] Imperial Coll London, Sch Publ Hlth, London, England; [Navarra, Leanlove; Mackie, Diane; Young, Paul] Med Res Inst New Zealand, Wellington, New Zealand; [Navarra, Leanlove; Young, Paul] Wellington Reg Hosp, Dept Intens Care, Wellington, New Zealand	George Institute for Global Health; University of Sydney; University of New South Wales Sydney; Royal North Shore Hospital; University of Sydney; St George Hospital; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Royal Melbourne Hospital; University of Melbourne; Monash University; Imperial College London; Medical Research Institute Of New Zealand	Finfer, S (corresponding author), George Inst Global Hlth, 1 King St, Newtown, NSW 2042, Australia.	sfinfer@georgeinstitute.org.au	Presneill, Jeffrey/B-4894-2012	Presneill, Jeffrey/0000-0001-7177-7667; Finfer, Simon/0000-0002-2785-5864; Micallef, Sharon/0000-0002-8496-2324; Myburgh, John/0000-0003-4088-7016; Delaney, Anthony/0000-0002-1015-7146; Saxena, Manoj/0000-0002-0385-6731; Young, Paul/0000-0002-3428-3083; Billot, Laurent/0000-0002-4975-9793; Thompson, Kelly/0000-0003-2304-8931; Bellomo, Rinaldo/0000-0002-1650-8939; Gallagher, Martin/0000-0001-9187-6187; Hammond, Naomi/0000-0002-6559-7747; Venkatesh, Bala/0000-0002-3234-5244	National Health and Medical Research Council of Australia [177267]; Health Research Council of New Zealand [16/009]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Health Research Council of New Zealand(Health Research Council of New Zealand)	Supported by project grants from the National Health and Medical Research Council of Australia (177267) and the Health Research Council of New Zealand (16/009); by Practitioner Fellowships from the National Health and Medical Research Council of Australia (to Drs. Finfer and Bellomo); by a National Health and Medical Research Council of Australia Leadership Fellowship (to Dr. Myburgh); by a National Health and Medical Research Council of Australia Emerging Leader Investigator Grant (to Dr. Hammond); and by a Health Research Council of New Zealand Clinical Practitioner Research Fellowship (to Dr. Young). The Medical Research Institute of New Zealand received Independent Research Organization funding from the Health Research Council of New Zealand. Baxter Healthcare and its subsidiary manufactured, supplied, and distributed the concealed trial fluids. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.	Billot L, 2021, CRIT CARE RESUSC, V23, P24; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brown RM, 2019, AM J RESP CRIT CARE, V200, P1487, DOI 10.1164/rccm.201903-0557OC; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Hammond NE, 2015, INTENS CARE MED, V41, P1611, DOI 10.1007/s00134-015-3878-y; Hammond NE, 2019, CRIT CARE RESUSC, V21, P284; Hammond NE, 2017, CRIT CARE RESUSC, V19, P239; Hammond NE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176292; Hammond NE., 2022, NEJM EVID, V1, DOI [10.1056/EVIDoa2100010, DOI 10.1056/EVIDOA2100010]; Hernan MA, 2017, NEW ENGL J MED, V377, P1391, DOI 10.1056/NEJMsm1605385; Iguchi N, 2018, CRIT CARE RESUSC, V20, P48; Kellum JA, 2004, CHEST, V125, P243, DOI 10.1378/chest.125.1.243; Kellum JA, 2018, NAT REV NEPHROL, V14, P358, DOI 10.1038/s41581-018-0008-4; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Liu C, 2019, AM J EMERG MED, V37, P2072, DOI 10.1016/j.ajem.2019.02.045; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Myburgh J, 2018, NEW ENGL J MED, V378, P862, DOI 10.1056/NEJMe1800449; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Raghunathan K, 2014, CRIT CARE MED, V42, P1585, DOI 10.1097/CCM.0000000000000305; Ramanan M, 2021, INTENS CARE MED, V47, P1248, DOI 10.1007/s00134-021-06480-5; Reeve R, 2018, STAT METHODS MED RES, V27, P451, DOI 10.1177/0962280216631583; Roquilly A, 2013, CRIT CARE, V17, DOI 10.1186/cc12686; Self WH, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.24596; Semler MW, 2018, NEW ENGL J MED, V378, P829, DOI 10.1056/NEJMoa1711584; Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Young P, 2015, JAMA-J AM MED ASSOC, V314, P1701, DOI 10.1001/jama.2015.12334; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Yunos NM, 2011, CRIT CARE MED, V39, P2419, DOI 10.1097/CCM.0b013e31822571e5; Yunos NM, 2010, CRIT CARE, V14, DOI 10.1186/cc9052; Zampieri FG, 2021, JAMA-J AM MED ASSOC, V326, P818, DOI 10.1001/jama.2021.11684	34	32	32	3	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 3	2022	386	9					815	826		10.1056/NEJMoa2114464	http://dx.doi.org/10.1056/NEJMoa2114464		JAN 2022	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK5CH	35041780	Bronze			2023-01-03	WOS:000743650000001
J	Chua, KP; Conti, RM; Becker, NV				Chua, Kao-Ping; Conti, Rena M.; Becker, Nora V.			US Insurer Spending on Ivermectin Prescriptions for COVID-19	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Chua, Kao-Ping] Univ Michigan, Sch Med, Susan B Meister Child Hlth Evaluat & Res Ctr, 300 N Ingalls St,SPC 5456,Room 6E18, Ann Arbor, MI 48109 USA; [Conti, Rena M.] Boston Univ, Questrom Sch Business, Dept Markets Publ Policy & Law, Boston, MA USA; [Becker, Nora V.] Univ Michigan, Sch Med, Div Gen Med, Ann Arbor, MI USA	University of Michigan System; University of Michigan; Boston University; University of Michigan System; University of Michigan	Chua, KP (corresponding author), Univ Michigan, Sch Med, Susan B Meister Child Hlth Evaluat & Res Ctr, 300 N Ingalls St,SPC 5456,Room 6E18, Ann Arbor, MI 48109 USA.	chuak@med.umich.edu						Centers for Disease Control and Prevention, 2021, RAP INCR IV PRESCR R; Chernew ME, 2007, HEALTH AFFAIR, V26, pW195, DOI 10.1377/hlthaff.26.2.w195; Lopez-Medina E, 2021, JAMA-J AM MED ASSOC, V325, P1426, DOI 10.1001/jama.2021.3071; Schwartz AL, 2014, JAMA INTERN MED, V174, P1067, DOI 10.1001/jamainternmed.2014.1541; The IQVIA Institute, 2021, US MED US	5	5	5	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2022	327	6					584	587		10.1001/jama.2021.24352	http://dx.doi.org/10.1001/jama.2021.24352		JAN 2022	5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD5RT	35024763	Bronze, Green Published			2023-01-03	WOS:000742416300002
J	Namasivayam, P; Bui, DT; Low, C; Barnett, T; Bridgman, H; Marsh, P; Lee, S				Namasivayam, Pathmavathy; Bui, Dung T.; Low, Christine; Barnett, Tony; Bridgman, Heather; Marsh, Pauline; Lee, Simone			Use of telehealth in the provision of after-hours palliative care services in rural and remote Australia: A scoping review protocol	PLOS ONE			English	Review							CAREGIVERS; SUPPORT; TOOLS	Introduction After-hours services are essential in ensuring patients with life limiting illness and their caregivers are supported to enable continuity of care. Telehealth is a valuable approach to meeting after-hours support needs of people living with life-limiting illness, their families, and caregivers in rural and remote communities. It is important to explore the provision of after-hours palliative care services using telehealth to understand the reach of these services in rural and remote Australia. A preliminary search of databases failed to reveal any scoping or systematic reviews of telehealth in after-hours palliative care services in rural or remote Australia. Aim To review and map the available evidence about the use of telehealth in providing after-hours palliative care services in Australian rural and remote communities. Methods The proposed scoping review will be conducted using the Arksey and O'Malley methodological framework and in accordance with the Joanna Briggs Institute methodology for scoping reviews. The reporting of the scoping review will be guided by the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). This review will consider research and evaluation of after-hours services using telehealth for palliative care stakeholders in rural and remote Australia. Peer reviewed studies and grey literature published in English from 2000 to May 2021 will be included. Scopus, Web of Science, CINAHL Complete, Embase via Ovid, PsycINFO via Ovid, Emcare via Ovid, Medline via Ovid, and grey literature will be searched for relevant articles. Titles and abstracts will be screened by two independent reviewers for assessment against the inclusion criteria. Data will be extracted and analysed by two reviewers using an adapted data extraction tool and thematic analysis techniques. Diagrams, tables, and summary narratives will be used to map, summarise and thematically group the characteristics of palliative care telehealth services in rural and remote Australia, including stakeholders' perceptions and benefits and challenges of the services.	[Namasivayam, Pathmavathy; Bui, Dung T.] Univ Tasmania, Sch Nursing, Hobart, Tas, Australia; [Bui, Dung T.; Low, Christine; Barnett, Tony; Bridgman, Heather; Marsh, Pauline; Lee, Simone] Univ Tasmania, Sch Hlth Sci, Ctr Rural Hlth, Newnham, Tas, Australia	University of Tasmania; University of Tasmania	Bui, DT (corresponding author), Univ Tasmania, Sch Hlth Sci, Ctr Rural Hlth, Newnham, Tas, Australia.	dungtrung.bui@utas.edu.au		Namasivayam, Pathmavathy/0000-0003-0761-223X; Bui, Trung Dung/0000-0002-9907-8240; Low, Christine/0000-0002-4247-6467				Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [10.1080/1364557032000119616, https://doi.org/10.1080/1364557032000119616, DOI 10.1080/1364557032000119616]; Armstrong K., 2016, HLTH FUTURE AUSTR; Australian Bureau of Statistics, 2017, AUSTR DEM STAT; Australian Bureau of Statistics, 2014, AUSTR HIST POP STAT; Australian Department of Health, TEL PIL PROGR; Australian Department of Health, MOD MON MOD INT; Australian Department of Health and Human Services, TASM MOD SERV DEL PA; Australian Institute of Health and Welfare, 2018, OLD AUSTR GLANC; Australian Institute of Health and Welfare, RURAL REMOTE HEALTH; Australian Institute of Health and Welfare, PALL CAR SERV AUSTR; Baird-Bower D, 2016, INT J PALLIAT NURS, V22, P286, DOI 10.12968/ijpn.2016.22.6.286; Bradford NK, 2016, RURAL REMOTE HEALTH, V16; Bradford N, 2012, J PEDIATR ONCOL NURS, V29, P141, DOI 10.1177/1043454212446023; CareSearch, RUR REM SPEC POP INT; Chi NC, 2015, J TELEMED TELECARE, V21, P37, DOI 10.1177/1357633X14562734; Chiang LC, 2012, INT J NURS STUD, V49, P1230, DOI 10.1016/j.ijnurstu.2012.04.013; Chih MY, 2013, PALLIATIVE MED, V27, P533, DOI 10.1177/0269216312457213; Ciechomski L, 2009, ASIA-PAC J HEALTH MA, V4, P57; CRANA plus, 2015, CRANA PLUS POS PAP P; Crawford M., 2017, GEN REPORT PERFORMAN; Cromwell D., 2003, CAN NATL PALLIATIVE; Demiris G, 2012, J PALLIAT MED, V15, P653, DOI 10.1089/jpm.2011.0488; Demiris G, 2007, CLIN GERONTOLOGIST, V31, P43, DOI 10.1300/J018v31n01_04; Dionne-Odom JN, 2018, J PAIN SYMPTOM MANAG, V55, P1519, DOI 10.1016/j.jpainsymman.2018.02.009; Disalvo D, 2021, PALLIATIVE MED, V35, P1385, DOI 10.1177/02692163211024451; Grindrod A, 2018, ANN PALLIAT MED, V7, pS73, DOI 10.21037/apm.2018.04.01; Johnston Bridget M, 2020, HRB Open Res, V3, P9, DOI 10.12688/hrbopenres.13006.1; McGowan J, 2016, J CLIN EPIDEMIOL, V75, P40, DOI 10.1016/j.jclinepi.2016.01.021; National Rural Health Alliance, 2012, PALL CAR RUR REM ARE; Oliver DP, 2010, AM J HOSP PALLIAT ME, V27, P465, DOI 10.1177/1049909110362402; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Palliative Care Australia, 2018, PALL CAR SERV DEV GU; Palliative Care Australia, 2017, PALL CAR AUSTR SUBM; Palliative Care Australia, 2020, CALLS PALL CAR REF P; Palliative Care Tasmania, PALL CAR; Palliative Care team, 2012, AFT HOURS PALL CAR F; Peters M. D. J., 2020, JBI MANUAL EVIDENCE, DOI [DOI 10.46658/JBIMES-20-01, 10.46658/JBIMES-20-12]; Phillips JL, 2008, J PAIN SYMPTOM MANAG, V36, P11, DOI 10.1016/j.jpainsymman.2007.08.017; Royal Australian Coffege of General Practitioners, 2016, GP LED PALL CAR RUR; Snoswell CL, 2020, AUST HEALTH REV, V44, P737, DOI 10.1071/AH20183; The Australian Department of Health, 2015, TEL; Thomas J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-45; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Victoria Department of Health Human Services, 2013, HOURS PALL CAR PIL P; Wadhwa A, 2006, MED EDUC, V40, P759, DOI 10.1111/j.1365-2929.2006.02534.x; Wenham S, 2020, PUBLIC HEALTH RES PR, V30, DOI 10.17061/phrp3012001; WHO, 2019, TEL WHO; Wilkes Lesley, 2004, Aust J Rural Health, V12, P95, DOI 10.1111/j.1440-1854.2004.00568.x; World Health Organization, PALL CAR; Zheng YQ, 2016, TELEMED E-HEALTH, V22, P288, DOI 10.1089/tmj.2015.0090	50	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2022	17	1							e0261962	10.1371/journal.pone.0261962	http://dx.doi.org/10.1371/journal.pone.0261962			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H0VF	35025895	Green Published, Green Accepted, gold			2023-01-03	WOS:000796264200037
J	Attard, G; Murphy, L; Clarke, NW; Cross, W; Jones, RJ; Parker, CC; Gillessen, S; Cook, A; Brawley, C; Amos, CL; Atako, N; Pugh, C; Buckner, M; Chowdhury, S; Malik, Z; Russell, JM; Gilson, C; Rush, H; Bowen, J; Lydon, A; Pedley, I; O'Sullivan, JM; Birtle, A; Gale, J; Srihari, N; Thomas, C; Tanguay, J; Wagstaff, J; Das, P; Gray, E; Alzoueb, M; Parikh, O; Robinson, A; Syndikus, I; Wylie, J; Zarkar, A; Thalmann, G; de Bono, JS; Dearnaley, DP; Mason, MD; Gilbert, D; Langley, RE; Millman, R; Matheson, D; Sydes, MR; Brown, LC; Parmar, MKB; James, ND				Attard, Gerhardt; Murphy, Laura; Clarke, Noel W.; Cross, William; Jones, Robert J.; Parker, Christopher C.; Gillessen, Silke; Cook, Adrian; Brawley, Chris; Amos, Claire L.; Atako, Nafisah; Pugh, Cheryl; Buckner, Michelle; Chowdhury, Simon; Malik, Zafar; Russell, J. Martin; Gilson, Clare; Rush, Hannah; Bowen, Jo; Lydon, Anna; Pedley, Ian; O'Sullivan, Joe M.; Birtle, Alison; Gale, Joanna; Srihari, Narayanan; Thomas, Carys; Tanguay, Jacob; Wagstaff, John; Das, Prantik; Gray, Emma; Alzoueb, Mymoona; Parikh, Omi; Robinson, Angus; Syndikus, Isabel; Wylie, James; Zarkar, Anjali; Thalmann, George; de Bono, Johann S.; Dearnaley, David P.; Mason, Malcolm D.; Gilbert, Duncan; Langley, Ruth E.; Millman, Robin; Matheson, David; Sydes, Matthew R.; Brown, Louise C.; Parmar, Mahesh K. B.; James, Nicholas D.		Systemic Therapy Advancing Metasta	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol	LANCET			English	Article							ANDROGEN DEPRIVATION THERAPY; SURVIVAL; RADIOTHERAPY	Background Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to ADT in this patient population. Methods These open-label, phase 3 trials were done at 113 sites in the UK and Switzerland. Eligible patients (no age restrictions) had high-risk (defined as node positive or, if node negative, having at least two of the following: tumour stage T3 or T4, Gleason sum score of 8-10, and prostate-specific antigen [PSA] concentration >= 40 ng/mL) or relapsing with high-risk features (<= 12 months of total ADT with an interval of >= 12 months without treatment and PSA concentration >= 4 ng/mL with a doubling time of <6 months, or a PSA concentration >= 20 ng/mL, or nodal relapse) non-metastatic prostate cancer, and a WHO performance status of 0-2. Local radiotherapy (as per local guidelines, 74 Gy in 37 fractions to the prostate and seminal vesicles or the equivalent using hypofractionated schedules) was mandated for node negative and encouraged for node positive disease. In both trials, patients were randomly assigned (1:1), by use of a computerised algorithm, to ADT alone (control group), which could include surgery and luteinising-hormone-releasing hormone agonists and antagonists, or with oral abiraterone acetate (1000 mg daily) and oral prednisolone (5 mg daily; combination-therapy group). In the second trial with no overlapping controls, the combination-therapy group also received enzalutamide (160 mg daily orally). ADT was given for 3 years and combination therapy for 2 years, except if local radiotherapy was omitted when treatment could be delivered until progression. In this primary analysis, we used meta-analysis methods to pool events from both trials. The primary endpoint of this meta-analysis was metastasis-free survival. Secondary endpoints were overall survival, prostate cancer-specific survival, biochemical failure-free survival, progression-free survival, and toxicity and adverse events. For 90% power and a one-sided type 1 error rate set to 1.25% to detect a target hazard ratio for improvement in metastasis-free survival of 0.75, approximately 315 metastasis-free survival events in the control groups was required. Efficacy was assessed in the intention-to-treat population and safety according to the treatment started within randomised allocation. STAMPEDE is registered with ClinicalTrials.gov, NCT00268476, and with the ISRCTN registry, ISRCTN78818544. Findings Between Nov 15, 2011, and March 31, 2016, 1974 patients were randomly assigned to treatment. The first trial allocated 455 to the control group and 459 to combination therapy, and the second trial, which included enzalutamide, allocated 533 to the control group and 527 to combination therapy. Median age across all groups was 68 years (IQR 63-73) and median PSA 34 ng/ml (14.7-47); 774 (39%) of 1974 patients were node positive, and 1684 (85%) were planned to receive radiotherapy. With median follow-up of 72 months (60-84), there were 180 metastasis-free survival events in the combination-therapy groups and 306 in the control groups. Metastasis-free survival was significantly longer in the combination-therapy groups (median not reached, IQR not evaluable [NE]-NE) than in the control groups (not reached, 97-NE; hazard ratio [HR] 0.53, 95% CI 0.44-0.64, p<0.0001). 6-year metastasis-free survival was 82% (95% CI 79-85) in the combination-therapy group and 69% (66-72) in the control group. There was no evidence of a difference in metatasis-free survival when enzalutamide and abiraterone acetate were administered concurrently compared with abiraterone acetate alone (interaction HR 1.02, 0.70-1.50, p=0.91) and no evidence of between-trial heterogeneity (I-2 p=0.90). Overall survival (median not reached [IQR NE-NE] in the combination-therapy groups vs not reached [103-NE] in the control groups; HR 0.60, 95% CI 0.48-0.73, p<0.0001), prostate cancer-specific survival (not reached [NE-NE] vs not reached [NE-NE]; 0.49, 0.37-0.65, p<0.0001), biochemical failure-free-survival (not reached [NE-NE] vs 86 months [83-NE]; 0.39, 0.33-0.47, p<0.0001), and progression-free-survival (not reached [NE-NE] vs not reached [103-NE]; 0.44, 0.36-0.54, p<0.0001) were also significantly longer in the combination-therapy groups than in the control groups. Adverse events grade 3 or higher during the first 24 months were, respectively, reported in 169 (37%) of 451 patients and 130 (29%) of 455 patients in the combination-therapy and control groups of the abiraterone trial, respectively, and 298 (58%) of 513 patients and 172 (32%) of 533 patients of the combination-therapy and control groups of the abiraterone and enzalutamide trial, respectively. The two most common events more frequent in the combination-therapy groups were hypertension (abiraterone trial: 23 (5%) in the combination-therapy group and six (1%) in control group; abiraterone and enzalutamide trial: 73 (14%) and eight (2%), respectively) and alanine transaminitis (abiraterone trial: 25 (6%) in the combination-therapy group and one (<1%) in control group; abiraterone and enzalutamide trial: 69 (13%) and four (1%), respectively). Seven grade 5 adverse events were reported: none in the control groups, three in the abiraterone acetate and prednisolone group (one event each of rectal adenocarcinoma, pulmonary haemorrhage, and a respiratory disorder), and four in the abiraterone acetate and prednisolone with enzalutamide group (two events each of septic shock and sudden death). Interpretation Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone. Abiraterone acetate with prednisolone should be considered a new standard treatment for this population.	[Attard, Gerhardt] UCL, Canc Inst, London WC1E 6DD, England; [Attard, Gerhardt] Univ Coll London Hosp, London, England; [Murphy, Laura; Cook, Adrian; Brawley, Chris; Amos, Claire L.; Atako, Nafisah; Pugh, Cheryl; Buckner, Michelle; Gilson, Clare; Rush, Hannah; Gilbert, Duncan; Langley, Ruth E.; Millman, Robin; Sydes, Matthew R.; Brown, Louise C.; Parmar, Mahesh K. B.] UCL, MRC Clin Trials Unit, London, England; [Clarke, Noel W.; Wylie, James] Christie & Salford Royal NHS Fdn Trusts, Manchester, Lancs, England; [Cross, William] St James Univ Hosp, Leeds, W Yorkshire, England; [Jones, Robert J.] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Parker, Christopher C.; de Bono, Johann S.; Dearnaley, David P.; James, Nicholas D.] Royal Marsden NHS Fdn Trust, London, England; [Parker, Christopher C.; de Bono, Johann S.; Dearnaley, David P.; James, Nicholas D.] Inst Canc Res, London, England; [Gillessen, Silke] Oncol Inst Southern Switzerland, Bellinzona, Switzerland; [Gillessen, Silke] Univ Svizzera Italiana, Lugano, Switzerland; [Chowdhury, Simon] Guys & St Thomas NHS Fdn Trust, London, England; [Malik, Zafar; Syndikus, Isabel] Clatterbridge Canc Ctr NHS Fdn Trust, Wirral, Merseyside, England; [Russell, J. Martin] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Bowen, Jo] Cheltenham Gen Hosp, Cheltenham, Glos, England; [Lydon, Anna] Torbay & South Devon NHS Fdn Trust, Torquay, England; [Pedley, Ian] Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England; [O'Sullivan, Joe M.] Queens Univ Belfast, Belfast, Antrim, North Ireland; [Birtle, Alison] Royal Preston Hosp, Preston, Lancs, England; [Gale, Joanna] Queen Alexandra Hosp, Portsmouth, Hants, England; [Srihari, Narayanan] Shrewsbury & Telford Hosp NHS Trust, Shrewsbury, Salop, England; [Thomas, Carys] Kent Oncol Ctr, Maidstone, Kent, England; [Tanguay, Jacob] Velindre Hosp, Cardiff, Wales; [Wagstaff, John] Singleton Hosp, Swansea, W Glam, Wales; [Das, Prantik] Royal Derby Hosp, Derby, England; [Gray, Emma] Yeovil Dist Hosp NHS Fdn Trust, Yeovil, England; [Gray, Emma] Musgrove Pk Hosp, Taunton, Somerset, England; [Alzoueb, Mymoona] Weston Pk Hosp, Sheffield, S Yorkshire, England; [Parikh, Omi] Lancashire Teaching Hosp NHS Fdn Trust, Preston, Lancs, England; [Robinson, Angus] Royal Sussex Cty Hosp, Brighton, E Sussex, England; [Zarkar, Anjali] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Thalmann, George] Univ Spital Bern, Inselspital, Bern, Switzerland; [Mason, Malcolm D.] Cardiff Univ, Cardiff, Wales; [Matheson, David] Univ Wolverhampton, Fac Educ Hlth & Wellbeing, Walsall, W Midlands, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Medical Research Council Clinical Trials Unit; University of London; University College London; Christie NHS Foundation Trust; Saint James's University Hospital; Beatson Oncology Centre; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Institute of Oncology Research (IOR); Universita della Svizzera Italiana; Guy's & St Thomas' NHS Foundation Trust; University of Glasgow; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; Queens University Belfast; Royal Preston Hospital; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Velindre Hospital; Singleton Hospital; University of Nottingham; Musgrove Park Hospital; Weston Park Hospital; University of Brighton; University of Birmingham; University of Bern; University Hospital of Bern; Cardiff University; University of Wolverhampton	Attard, G (corresponding author), UCL, Canc Inst, London WC1E 6DD, England.	g.attard@ucl.ac.uk	; Sydes, Matthew/C-3373-2008	Attard, Gerhardt/0000-0002-4811-7983; O'Sullivan, Joe/0000-0001-6999-2739; , Prantik/0000-0003-2976-4410; Rogers, Paul/0000-0003-2593-2595; Brawley, Christopher/0000-0003-3641-278X; Rush, Hannah/0000-0001-9550-8808; Gilbert, Duncan/0000-0003-1859-7012; de Bono, Johann S/0000-0002-2034-595X; Sydes, Matthew/0000-0002-9323-1371; James, Nicholas/0000-0002-7314-8204; Boussios, Stergios/0000-0002-2512-6131; Paisey, Sangeeta/0000-0002-4304-1940	Cancer Research UK; UK Medical Research Council; Swiss Group for Clinical Cancer Research; Janssen; Astellas	Cancer Research UK(Cancer Research UK); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Swiss Group for Clinical Cancer Research; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Astellas(Astellas Pharmaceuticals)	Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas.	Armstrong AJ, 2019, J CLIN ONCOL, V37, P2974, DOI 10.1200/JCO.19.00799; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Attard G, 2021, EUR UROL, V80, P522, DOI 10.1016/j.eururo.2021.06.023; Attard G, 2019, JAMA ONCOL, V5, P1159, DOI 10.1001/jamaoncol.2019.1011; Attard G, 2018, J CLIN ONCOL, V36, P2639, DOI 10.1200/JCO.2018.77.9827; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; Bolla M, 2009, NEW ENGL J MED, V360, P2516, DOI 10.1056/NEJMoa0810095; Chi KN, 2019, NEW ENGL J MED, V381, P13, DOI 10.1056/NEJMoa1903307; Clarke NW, 2019, ANN ONCOL, V30, P1992, DOI 10.1093/annonc/mdz396; Davis ID, 2019, NEW ENGL J MED, V381, P121, DOI 10.1056/NEJMoa1903835; Efstathiou E, 2020, J CLIN ONCOL, V38; Fizazi K, 2018, ANN ONCOL, V29; Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174; Helgstrand JT, 2017, EUR J CANCER, V84, P18, DOI 10.1016/j.ejca.2017.07.007; Hoyle AP, 2019, EUR UROL, V76, P719, DOI 10.1016/j.eururo.2019.08.006; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; James ND, 2019, ANN ONCOL, V30, pv331, DOI [10.1093/annonc/mdz248.008a, DOI 10.1093/ANNONC/MDZ248.008A]; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; Mason MD, 2017, J CLIN ONCOL, V35, P1530, DOI 10.1200/JCO.2016.69.0677; McKay RR, 2019, J CLIN ONCOL, V37, P923, DOI 10.1200/JCO.18.01777; Morris MJ, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.5008; Park JJH, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3664-1; Parker CC, 2018, LANCET, V392, P2353, DOI 10.1016/S0140-6736(18)32486-3; Roy S, 2019, CLIN ONCOL-UK, V31, P630, DOI 10.1016/j.clon.2019.04.012; Saad F, 2021, LANCET ONCOL, V22, P1541, DOI [10.1016/S1470-2045(21)00402-2, 10.1016/S1470-2045(21)00402]; Sandler HM, 2020, J CLIN ONCOL, V38; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140-6736(10)60172-9; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Warde P, 2011, LANCET, V378, P2104, DOI 10.1016/S0140-6736(11)61095-7; Widmark A, 2009, LANCET, V373, P301, DOI 10.1016/S0140-6736(08)61815-2; Xie WL, 2017, J CLIN ONCOL, V35, P3097, DOI 10.1200/JCO.2017.73.9987	31	51	51	13	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2022	399	10323					447	460		10.1016/S0140-6736(21)02437-5	http://dx.doi.org/10.1016/S0140-6736(21)02437-5			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY9YU	34953525	Green Accepted, Green Published			2023-01-03	WOS:000755141600025
J	Kitagawa, Y; Kawamura, I; Suzuki, K; Okada, H; Ishihara, T; Tomita, H; Suzuki, K; Takada, C; Sampei, S; Kano, S; Kondo, K; Asano, H; Wakayama, Y; Kamidani, R; Kawasaki, Y; Fukuda, H; Nishio, A; Miyake, T; Fukuta, T; Yasuda, R; Oiwa, H; Kakino, Y; Miyazaki, N; Watanabe, T; Yoshida, T; Doi, T; Suzuki, A; Yoshida, S; Matsuo, H; Ogura, S				Kitagawa, Yuichiro; Kawamura, Itta; Suzuki, Keiko; Okada, Hideshi; Ishihara, Takuma; Tomita, Hiroyuki; Suzuki, Kodai; Takada, Chihiro; Sampei, So; Kano, Soichiro; Kondo, Kohei; Asano, Hirotaka; Wakayama, Yugo; Kamidani, Ryo; Kawasaki, Yuki; Fukuda, Hirotsugu; Nishio, Ayane; Miyake, Takahito; Fukuta, Tetsuya; Yasuda, Ryu; Oiwa, Hideaki; Kakino, Yoshinori; Miyazaki, Nagisa; Watanabe, Takatomo; Yoshida, Takahiro; Doi, Tomoaki; Suzuki, Akio; Yoshida, Shozo; Matsuo, Hitoshi; Ogura, Shinji			Serum syndecan-1 concentration in hospitalized patients with heart failure may predict readmission-free survival	PLOS ONE			English	Article							BRAIN NATRIURETIC PEPTIDE; LEFT-VENTRICULAR MASS; ENDOTHELIAL GLYCOCALYX; BIOMARKERS; DISEASE; SEPSIS; MODEL; RISK; EXTRAVASATION; HYPERTROPHY	Syndecan-1 is found in the endothelial glycocalyx and is released into the bloodstream during stressed conditions, including severe diseases such as acute kidney injury, chronic kidney disease, and cardiovascular disease. This study investigated the prognostic value of serum syndecan-1 concentration in patients with heart failure upon admission. Serum syndecan-1 concentration was analyzed in 152 patients who were hospitalized for worsening heart failure from September 2017 to June 2018. The primary outcome of the study was readmission-free survival, defined as the time from the first admission to readmission for worsened heart failure or death from any cause, which was assessed at 30 months after discharge from the hospital. The secondary outcome of the study was survival time. Blood samples and echocardiogram data were analyzed. Univariate and multivariable time-dependent Cox regression analyses adjusted for age, creatinine levels, and use of antibiotics were conducted. The serum syndecan-1 concentration was significantly associated with readmission-free survival. Subsequently, the syndecan-1 concentration may have gradually decreased with treatment. The administration of human atrial natriuretic peptide and antibiotics may have modified the relationship between readmission-free survival and serum syndecan-1 concentration (p = 0.01 and 0.008, respectively). Serum syndecan-1 concentrations, which may indicate injury to the endothelial glycocalyx, predict readmission-free survival in patients with heart failure.	[Kitagawa, Yuichiro; Okada, Hideshi; Suzuki, Kodai; Takada, Chihiro; Sampei, So; Kano, Soichiro; Kondo, Kohei; Asano, Hirotaka; Wakayama, Yugo; Kamidani, Ryo; Kawasaki, Yuki; Fukuda, Hirotsugu; Nishio, Ayane; Miyake, Takahito; Fukuta, Tetsuya; Oiwa, Hideaki; Kakino, Yoshinori; Watanabe, Takatomo; Yoshida, Takahiro; Ogura, Shinji] Gifu Univ, Dept Emergency & Disaster Med, Grad Sch Med, Gifu, Japan; [Kawamura, Itta; Matsuo, Hitoshi] Gifu Heart Ctr, Gifu, Japan; [Suzuki, Keiko; Suzuki, Akio] Gifu Univ Hosp, Dept Pharm, Gifu, Japan; [Ishihara, Takuma] Gifu Univ Hosp, Innovat & Clin Res Promot Ctr, Gifu, Japan; [Tomita, Hiroyuki] Gifu Univ, Dept Tumor Pathol, Grad Sch Med, Gifu, Japan; [Yasuda, Ryu] Gifu Univ, Dept Abuse Prevent Emergency Med, Grad Sch Med, Gifu, Japan; [Miyazaki, Nagisa] Asahi Univ, Sch Dent, Dept Internal Med, Mizuho, Japan; [Watanabe, Takatomo] Gifu Univ Hosp, Dept Clin Lab, Gifu, Japan	Gifu University; Gifu University; Gifu University; Gifu University; Gifu University; Asahi University; Gifu University	Okada, H (corresponding author), Gifu Univ, Dept Emergency & Disaster Med, Grad Sch Med, Gifu, Japan.	hideshi@gifu-u.ac.jp	Kamidani, Ryo/GXZ-6859-2022	Kamidani, Ryo/0000-0002-8478-9197; Okada, Hideshi/0000-0002-7775-4308				Ando Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35976-2; Anker SD, 2014, J CACHEXIA SARCOPENI, V5, P1, DOI 10.1007/s13539-014-0135-0; Becker BF, 2010, BASIC RES CARDIOL, V105, P687, DOI 10.1007/s00395-010-0118-z; Berg S, 2002, ACTA ANAESTH SCAND, V46, P166, DOI 10.1034/j.1399-6576.2002.460207.x; Bettencourt P, 2004, CIRCULATION, V110, P2168, DOI 10.1161/01.CIR.0000144310.04433.BE; Burke-Gaffney A, 2012, CRIT CARE, V16, DOI 10.1186/cc11239; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chelazzi C, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0741-z; Couchman JR, 2010, ANNU REV CELL DEV BI, V26, P89, DOI 10.1146/annurev-cellbio-100109-104126; Fisher LD, 1999, ANNU REV PUBL HEALTH, V20, P145, DOI 10.1146/annurev.publhealth.20.1.145; Frati-Munari Alberto C., 2013, Arch. Cardiol. Méx., V83, P303, DOI 10.1016/j.acmx.2013.04.015; Haider AW, 1998, J AM COLL CARDIOL, V32, P1454, DOI 10.1016/S0735-1097(98)00407-0; Henrich M, 2010, THESCIENTIFICWORLDJO, V10, P917, DOI 10.1100/tsw.2010.88; Huo YL, 2009, J APPL PHYSIOL, V107, P500, DOI 10.1152/japplphysiol.91013.2008; Inagawa R, 2018, CHEST, V154, P317, DOI 10.1016/j.chest.2018.03.003; Joseph SM, 2009, TEX HEART I J, V36, P510; Kalogeropoulos AP, 2012, PROG CARDIOVASC DIS, V55, P3, DOI 10.1016/j.pcad.2012.05.004; Lambaerts K, 2009, CURR OPIN CELL BIOL, V21, P662, DOI 10.1016/j.ceb.2009.05.002; Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320; Leong DP, 2015, LANCET, V386, P266, DOI 10.1016/S0140-6736(14)62000-6; Li LY, 2012, MOL BIOSYST, V8, P1613, DOI 10.1039/c2mb25021g; Liborio AB, 2015, AM J TROP MED HYG, V92, P611, DOI 10.4269/ajtmh.14-0232; LUFT JH, 1966, FED PROC, V25, P1773; Machin DR, 2018, AM J PHYSIOL-HEART C, V315, pH531, DOI 10.1152/ajpheart.00104.2018; Maeda K, 2000, J AM COLL CARDIOL, V36, P1587, DOI 10.1016/S0735-1097(00)00912-8; Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233; Mangini S, 2013, EINSTEIN-SAO PAULO, V11, P383, DOI 10.1590/S1679-45082013000300022; Manon-Jensen T, 2010, FEBS J, V277, P3876, DOI 10.1111/j.1742-4658.2010.07798.x; Mitic VT, 2020, TOHOKU J EXP MED, V250, P233, DOI 10.1620/tjem.250.233; Motiwala SR, 2013, CARDIOL REV, V21, P127, DOI 10.1097/CRD.0b013e3182769073; Nakada Y, 2019, CIRC J, V83, P395, DOI 10.1253/circj.CJ-18-0523; Nakada Y, 2016, AM J PHYSIOL-HEART C, V310, pH813, DOI 10.1152/ajpheart.00602.2015; Oda K, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091320; Okada H, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1841-8; Ostrowski SR, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0918-5; Padberg JS, 2014, ATHEROSCLEROSIS, V234, P335, DOI 10.1016/j.atherosclerosis.2014.03.016; Paulus P, 2011, BIOMARKERS, V16, pS11, DOI 10.3109/1354750X.2011.587893; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Puskarich MA, 2016, J CRIT CARE, V36, P125, DOI 10.1016/j.jcrc.2016.06.027; Rehm M, 2004, ANESTHESIOLOGY, V100, P1211, DOI 10.1097/00000542-200405000-00025; Rehm M, 2007, CIRCULATION, V116, P1896, DOI 10.1161/CIRCULATIONAHA.106.684852; Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8; RICKHAM PP, 1964, BRIT MED J, V2, P173; Roy D, 2008, NEW ENGL J MED, V358, P2667, DOI 10.1056/NEJMoa0708789; Salmon AHJ, 2012, J PATHOL, V226, P562, DOI 10.1002/path.3964; Schellings MWM, 2010, HYPERTENSION, V55, P249, DOI 10.1161/HYPERTENSIONAHA.109.137885; Suzuki K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88303-7; Teng YHF, 2012, MATRIX BIOL, V31, P3, DOI 10.1016/j.matbio.2011.10.001; Tromp J, 2014, CIRC-HEART FAIL, V7, P457, DOI 10.1161/CIRCHEARTFAILURE.113.000846; Verdecchia P, 2001, J AM COLL CARDIOL, V38, P1829, DOI 10.1016/S0735-1097(01)01663-1; Woodcock TE, 2012, BRIT J ANAESTH, V108, P384, DOI 10.1093/bja/aer515; Zhang XB, 2006, AM J PHYSIOL-HEART C, V291, pH2950, DOI 10.1152/ajpheart.01160.2005	52	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2021	16	12							e0260350	10.1371/journal.pone.0260350	http://dx.doi.org/10.1371/journal.pone.0260350			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY2LS	34879094	Green Published, gold			2023-01-03	WOS:000754625200014
J	Yusuff, KB; Mustafa, M; Al-Qahtani, NH				Yusuff, Kazeem Babatunde; Mustafa, Mariam; Al-Qahtani, Najla Hezam			Prevalence, types and severity of medication errors associated with the use of automated medication use systems in ambulatory and institutionalized care settings: A systematic review protocol	PLOS ONE			English	Review							ORDER ENTRY; ADMINISTRATION ERRORS; PATIENT SAFETY	The use of automated systems within the medication use process has significantly reduce the occurrence of medication errors and the associated clinical and financial burden. However, automated systems lull into a false sense of security and increase the risk of medication errors that are often associated with socio-technical interactions, automation bias, workarounds and overrides. The objective of the systematic review is to determine the prevalence, types and severity of medication errors that are associated the use of automated systems in ambulatory and institutionalized care settings. The search strategy will be guided by PRISMA framework. Selected databases and relevant gray literature were searched and screening was done independently by two researchers between 01 April and 29 June 2021. These covered all relevant articles published from the inception of the use of automation in the medication use process (2000) until 2020. De-duplication and screening of all studies were done independently by two researchers with a clear inclusion / exclusion criteria. Data extraction and synthesis are currently on going (started on 06 July 2021) and being conducted independently but the validity and completeness of the processes will be confirmed by the third researcher. The Cochrane Risk of Bias tool and the Hoy et al's quality assessment checklist will be used for the assessment of methodological bias while the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system will be used for the quality of evidence assessment. Detailed qualitative synthesis of key findings will be done with thematic and descriptive analyses. If the number and types of included studies permit, fixed or random effect model meta-analysis will be conducted based on the degree of homogeneity in the sampling frame used in the included studies. Heterogeneity will be assessed with I-2 statistics and I-2 > 50% will be considered a high statistical heterogeneity. The systematic review may provide new perspective especially from developing settings about the prevalence, types and severity of medication errors associated with the use of automated systems at all the stages of medication use process, and in all categories of patients. This may add to global knowledge in the research area.	[Yusuff, Kazeem Babatunde; Mustafa, Mariam; Al-Qahtani, Najla Hezam] Qatar Univ, Dept Clin Pharm & Practice, Coll Pharm, QU Hlth, Doha, Qatar	Qatar University	Yusuff, KB (corresponding author), Qatar Univ, Dept Clin Pharm & Practice, Coll Pharm, QU Hlth, Doha, Qatar.	kyusuff@qu.edu.qa	Yusuff, Kazeem/M-4500-2016	Yusuff, Kazeem/0000-0001-6512-7879				ALLAN EL, 1990, AM J HOSP PHARM, V47, P555, DOI 10.1093/ajhp/47.3.555; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bezuidenhout H., 2012, COCHRANE DB SYST REV; Chapuis C, 2010, CRIT CARE MED, V38, P2275, DOI 10.1097/CCM.0b013e3181f8569b; Cousein E, 2014, J EVAL CLIN PRACT, V20, P678, DOI 10.1111/jep.12202; GRADE Working Group, 2017, GRAD REC ASS DEV EV, DOI [10.1177/1356389017733210, DOI 10.1177/1356389017733210]; Hemens BJ, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-89; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Institute for Safe Medication Practices, NAT MED ERR REP PROG; Institute of Medicine (IOM), 2006, PREVENTING MEDICATIO; James K Lynette, 2013, Int J Pharm Pract, V21, P105, DOI 10.1111/j.2042-7174.2012.00231.x; Karsh BT, 2006, QUAL SAF HEALTH CARE, V15, pI59, DOI 10.1136/qshc.2005.015974; Koppel R, 2008, J AM MED INFORM ASSN, V15, P408, DOI 10.1197/jamia.M2616; Korb-Savoldelli V, 2018, INT J MED INFORM, V111, P112, DOI 10.1016/j.ijmedinf.2017.12.022; Li Q, 2015, J BIOMED INFORM, V57, P124, DOI 10.1016/j.jbi.2015.07.012; Lisby M, 2005, INT J QUAL HEALTH C, V17, P15, DOI 10.1093/intqhc/mzi015; Longhurst CA, 2010, PEDIATRICS, V126, P14, DOI 10.1542/peds.2009-3271; Magrabi F, 2010, J AM MED INFORM ASSN, V17, P663, DOI 10.1136/jamia.2009.002444; McKibbon KA, 2012, J AM MED INFORM ASSN, V19, P22, DOI 10.1136/amiajnl-2011-000304; Pennsylvania Patient Safety Reporting System (PA-PSRS), 2005, PAT SAF ADV, V2, P1; Poon EG, 2010, NEW ENGL J MED, V362, P1698, DOI 10.1056/NEJMsa0907115; Redwood S, 2011, BMC MED INFORM DECIS, V11, DOI 10.1186/1472-6947-11-29; Risor BW, 2018, INT J QUAL HEALTH C, V30, P457, DOI 10.1093/intqhc/mzy042; Risor BW, 2017, VALUE HEALTH, V20, P886, DOI 10.1016/j.jval.2017.03.001; Risor BW, 2016, EUR J HOSP PHARM, V23, P189, DOI 10.1136/ejhpharm-2015-000749; Roumeliotis N, 2019, J GEN INTERN MED, V34, P2210, DOI 10.1007/s11606-019-05236-8; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647; Sinnemaki J, 2013, SYST REV-LONDON, V2, DOI 10.1186/2046-4053-2-1; Sng Y, 2019, EUR J HOSP PHARM, V26, P157, DOI 10.1136/ejhpharm-2017-001424; van den Bemt PMLA, 2007, J INTELL DISABIL RES, V51, P528, DOI 10.1111/j.1365-2788.2006.00919.x; van den Bemt PMLA, 2009, J AM MED INFORM ASSN, V16, P486, DOI 10.1197/jamia.M2959; Walsh KE, 2006, PEDIATRICS, V118, P1872, DOI 10.1542/peds.2006-0810; Wolfe D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205426	34	1	1	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2021	16	12							e0260992	10.1371/journal.pone.0260992	http://dx.doi.org/10.1371/journal.pone.0260992			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY3JJ	34860852	Green Published, gold			2023-01-03	WOS:000754686900021
J	Chowdhury, IZ; Amin, MN; Chowdhury, MZ; Rahman, SM; Ahmed, M; Cader, FA				Chowdhury, Ishmum Zia; Amin, Md. Nurul; Chowdhury, Mashhud Zia; Rahman, Sharar Muhib; Ahmed, Mohsin; Cader, F. Aaysha			Pre hospital delay and its associated factors in acute myocardial infarction in a developing country	PLOS ONE			English	Article							ACUTE CORONARY SYNDROMES; 2013 ACCF/AHA GUIDELINE; PREHOSPITAL DELAY; GLOBAL BURDEN; PRIMARY ANGIOPLASTY; TIME-DELAY; TASK-FORCE; MORTALITY; OUTCOMES; MANAGEMENT	Background Early revascularization and treatment is key to improving clinical outcomes and reducing mortality in acute myocardial infarction (AMI). In low- and middle-income countries such as Bangladesh, timely management of AMI is challenging, with pre-hospital delays playing a significant role. This study was designed to investigate pre-hospital delay and its associated factors among patients presenting with AMI in the capital city of Dhaka. Methods This retrospective cohort study was conducted on 333 patients presenting with AMI over a 3-month period at two of the largest primary reperfusion-capable tertiary cardiac care centres in Dhaka. Of the total patients, 239(71.8%) were admitted in the National Institute of Cardiovascular Diseases, Dhaka and 94(28.2%) at Ibrahim Cardiac Hospital & Research Institute, Dhaka Data were collected from patients by semi-structured interview and hospital medical records. Pre-hospital delay (median and inter-quartile range) was calculated. Statistical significance was determined by Chi-square test. Multivariate logistic regression analysis was done to determine the independent predictors of pre-hospital delay. Results The mean age of the respondents was 53.8 +/- 11.2 years. Two-thirds (67.6%) of the respondents were males. Median total pre-hospital delay was 11.5 (IQR-18.3) hours with median decision time from symptom onset to seeking medical care being 3.0 (IQR: 11.0) hours. Nearly half (48.9%) of patients presented to the hospital more than 12 hours after symptom onset. On multivariate logistic regression analysis, AMI patients with absence of typical chest pain [OR 5.21; (95% CI: 2.5-9.9)], diabetes [OR: 1.7 (95% CI: 1.0-2.9)], residing/staying > 30 km away from nearest hospital at the time of onset [OR: 4.3(95% CI = 2.3-7.2)] and belonged to lower and middle class [OR: 1.9(95% CI = 1.0-3.5)] were significantly associated with pre-hospital delays. Conclusion Acute myocardial infarction (AMI) patients with atypical chest pain, diabetes, staying far away from nearest hospital and belonged to lower and middle socioeconomic strata were significantly associated with pre-hospital delays. The findings could have immense implications for improvements about timely reaching of AMI patients to the hospital within the context of their sociodemographic status and geographic barriers of the city.	[Chowdhury, Ishmum Zia; Rahman, Sharar Muhib] BIRDEM Gen Hosp, Dhaka, Bangladesh; [Amin, Md. Nurul] Ibrahim Cardiac Hosp & Res Inst, Dhaka, Bangladesh; [Chowdhury, Mashhud Zia; Cader, F. Aaysha] Ibrahim Cardiac Hosp & Res Inst, Dept Cardiol, Dhaka, Bangladesh; [Ahmed, Mohsin] Natl Inst Cardiovasc Dis, Dept Cardiol, Dhaka, Bangladesh		Chowdhury, IZ (corresponding author), BIRDEM Gen Hosp, Dhaka, Bangladesh.	ishmumchow@gmail.com		Chowdhury, Ishmum/0000-0001-7029-2369				Ahmed S, 2018, INDIAN HEART J, V70, P241, DOI 10.1016/j.ihj.2017.07.013; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; Collet JP., 2020, EUR HEART J, DOI [10.1093/eurheartj/ehaa624, DOI 10.1093/EURHEARTJ/EHAA624]; Das P.K., 2016, CARDIOVASC J, V9, P3, DOI [10.3329/cardio.v9i1.29529, DOI 10.3329/CARDIO.V9I1.29529]; De Luca G, 2004, CIRCULATION, V109, P1223, DOI 10.1161/01.CIR.0000121424.76486.20; Deharo P, 2017, CIRCULATION, V136, P1895, DOI 10.1161/CIRCULATIONAHA.117.029779; Dhaka Bangladesh, METR AR POP 1950 202; Doddipalli SR, 2018, INDIAN HEART J, V70, pS275, DOI 10.1016/j.ihj.2018.05.005; Farshidi H, 2013, IRAN RED CRESCENT ME, V15, P312, DOI 10.5812/ircmj.2367; George Linsha, 2017, J Emerg Trauma Shock, V10, P64, DOI 10.4103/0974-2700.201580; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Kakou-Guikahue M, 2016, ARCH CARDIOVASC DIS, V109, P376, DOI 10.1016/j.acvd.2015.12.005; Khan MS, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-284; Koirala P, 2019, NEPAL HEART J, V16, P50, DOI 10.3126/njh.v16i2.26318; Lawesson SS, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020211; Malhotra S, 2003, Indian Heart J, V55, P349; Mathews R, 2011, CIRCULATION, V124, P154, DOI 10.1161/CIRCULATIONAHA.110.002345; McGinn AP, 2005, AM HEART J, V150, P392, DOI 10.1016/j.ahj.2005.03.064; McKinley S, 2011, EMERG MED AUSTRALAS, V23, P153, DOI 10.1111/j.1742-6723.2011.01385.x; Moran AE, 2014, GLOB HEART, V9, P91, DOI 10.1016/j.gheart.2013.12.007; Mujtaba SF, 2021, CUREUS, V13, DOI 10.7759/cureus.12964; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Ni Putu Yusniawati Y., 2018, RES J LIFE SCI, V5, P34, DOI [10.21776/ub.rjls.2018.005.01.4, DOI 10.21776/UB.RJLS.2018.005.01.4]; Nilsson G, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-016-0271-x; O'Gara PT, 2013, J AM COLL CARDIOL, V61, P485, DOI [10.1016/j.jacc.2012.11.018, 10.1161/CIR.0b013e3182742c84]; O'Gara PT, 2013, J AM COLL CARDIOL, V61, pE78, DOI [10.1016/j.jacc.2012.11.019, 10.1161/CIR.0b013e3182742cf6]; Park YH, 2012, J KOREAN MED SCI, V27, P864, DOI 10.3346/jkms.2012.27.8.864; Poorhosseini H, 2019, ARCH ACAD EMERG MED, V7; Rafi A., PREHOSPITAL DELAY PA, DOI [10.1186/s12913-020-05505-x 32646521, DOI 10.1186/S12913-020-05505-X32646521]; Seligman B, 2016, INT J CARDIOL, V217, pS10, DOI 10.1016/j.ijcard.2016.06.213; Shrestha Nikesh R, 2013, Swiss Med Wkly, V143, pw13737, DOI 10.4414/smw.2013.13737; Stacey RB, 2019, J AM GERIATR SOC, V67, P43, DOI 10.1111/jgs.15604; Thygesen K, 2018, KARDIOL POL, V76, P1383, DOI [10.5603/KP.2018.0203, 10.1161/CIR.0000000000000617, 10.1016/j.gheart.2018.08.004]; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Xavier D, 2008, LANCET, V371, P1435, DOI 10.1016/S0140-6736(08)60623-6; Yuyun MF, 2020, GLOB HEART, V15, DOI 10.5334/gh.403; Zahn R, 2001, AM HEART J, V142, P105, DOI 10.1067/mhj.2001.115585; Zurowska-Wolak M, 2019, SCAND J TRAUMA RESUS, V27, DOI 10.1186/s13049-019-0616-4	39	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2021	16	11							e0259979	10.1371/journal.pone.0259979	http://dx.doi.org/10.1371/journal.pone.0259979			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YN4MP	34818360	gold, Green Published			2023-01-03	WOS:000747234800028
J	Abramowicz, M; Zuccotti, G; Pflomm, JM				Abramowicz, Mark; Zuccotti, Gianna; Pflomm, Jean-Marie			Higher-Dose Naloxone Nasal Spray (Kloxxado) for Opioid Overdose	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Pflomm, Jean-Marie/HDO-0765-2022					[Anonymous], 2017, MED LETT DRUGS THER, V59, P89; [Anonymous], 2016, MED LETT DRUGS THER, V58, P1; Elkattawy S, 2021, J COMM HOSP INT MED, V11, P139, DOI 10.1080/20009666.2020.1854417; Khoury D, 2021, JMIR PUBLIC HLTH SUR, V7, DOI 10.2196/29298; US Centers for Disease Control and Prevention Health Alert Network, 2020, INCR FAT DRUG OV US; US Department of Health and Human Services, NAL OPI REV DRUG SAV	6	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2021	326	18					1853	1854		10.1001/jama.2021.15948	http://dx.doi.org/10.1001/jama.2021.15948			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW8DE	34751711				2023-01-03	WOS:000718139200025
J	Leulseged, TW; Hassen, IS; Maru, EH; Zewsde, WC; Chamiso, NW; Bayisa, AB; Abebe, DS; Ayele, BT; Yegle, KT; Edo, MG; Gurara, EK; Damete, DD; Tolera, YA				Leulseged, Tigist W.; Hassen, Ishmael S.; Maru, Endalkachew H.; Zewsde, Wuletaw C.; Chamiso, Negat W.; Bayisa, Abdi B.; Abebe, Daniel S.; Ayele, Birhanu T.; Yegle, Kalkidan T.; Edo, Mesay G.; Gurara, Eyosyas K.; Damete, Dereje D.; Tolera, Yared A.			Characteristics and outcome profile of hospitalized African patients with COVID-19: The Ethiopian context	PLOS ONE			English	Article							CORONAVIRUS DISEASE 2019; CLINICAL-FEATURES	Background The COVID-19 pandemic seems to have a different picture in Africa; the first case was identified in the continent after it had already caused a significant loss to the rest of the world and the reported number of cases and mortality rate has been low. Understanding the characteristics and outcome of the pandemic in the African setup is therefore crucial. Aim To assess the characteristics and outcome of Patients with COVID-19 and to identify determinants of the disease outcome among patients admitted to Millennium COVID-19 Care Center in Ethiopia. Methods A prospective cohort study was conducted among 1345 consecutively admitted RT-PCR confirmed Patients with COVID-19 from July to September, 2020. Frequency tables, KM plots, median survival times and Log-rank test were used to describe the data and compare survival distribution between groups. Cox proportional hazard survival model was used to identify determinants of time to clinical recovery and the independent variables, where adjusted hazard ratio, P-value and 95% CI for adjusted hazard ratio were used for testing significance and interpretation of results. Binary logistic regression model was used to assess the presence of a statistically significant association between disease outcome and the independent variables, where adjusted odds ratio, P-value and 95% CI for adjusted odds ratio were used for testing significance and interpretation of results. Results Among the study population, 71 (5.3%) died, 72 (5.4%) were transferred and the rest 1202 (89.4%) were clinically improved. The median time to clinical recovery was 14 days. On the multivariable Cox proportional hazard model; temperature (AHR = 1.135, 95% CI = 1.011, 1.274, p-value = 0.032), COVID-19 severity (AHR = 0.660, 95% CI = 0.501, 0.869, p-value = 0.003), and cough (AHR = 0.705, 95% CI = 0.519, 0.959, p-value = 0.026) were found to be significant determinants of time to clinical recovery. On the binary logistic regression, the following factors were found to be significantly associated with disease outcome; SPO2 (AOR = 0.302, 95% CI = 0.193, 0.474, p-value = 0.0001), shortness of breath (AOR = 0.354, 95% CI = 0.213, 0.590, p-value = 0.0001) and diabetes mellitus (AOR = 0.549, 95% CI = 0.337, 0.894, p-value = 0.016). Conclusions The average duration of time to clinical recovery was 14 days and 89.4% of the patients achieved clinical recovery. The mortality rate of the studied population is lower than reports from other countries including those in Africa. Having severe COVID-19 disease severity and presenting with cough were found to be associated with delayed clinical recovery of the disease. On the other hand, being hyperthermic is associated with shorter disease duration (faster time to clinical recovery). In addition, lower oxygen saturation, subjective complaint of shortness of breath and being diabetic were associated with unfavorable disease outcome. Therefore, patients with these factors should be followed cautiously for a better outcome.	[Leulseged, Tigist W.; Hassen, Ishmael S.; Maru, Endalkachew H.; Zewsde, Wuletaw C.; Chamiso, Negat W.; Bayisa, Abdi B.; Abebe, Daniel S.; Ayele, Birhanu T.; Yegle, Kalkidan T.; Edo, Mesay G.; Gurara, Eyosyas K.; Damete, Dereje D.; Tolera, Yared A.] St Pauls Hosp Millennium Med Coll, Millennium COVID 19 Care Ctr, Addis Ababa, Ethiopia; [Ayele, Birhanu T.] Stellenbosch Univ, Div Epidemiol & Biostat, Fac Med & Hlth Sci, Cape Town, South Africa	Stellenbosch University	Leulseged, TW (corresponding author), St Pauls Hosp Millennium Med Coll, Millennium COVID 19 Care Ctr, Addis Ababa, Ethiopia.	tigdolly@gmail.com	Leulseged, Tigist/DQR-5143-2022	Leulseged, Tigist/0000-0002-5767-1417; Damete, Dereje Derbew/0000-0002-1440-7958; Simeneh, Daniel/0000-0003-0041-9576				Abayomi A, 2021, INT J INFECT DIS, V102, P226, DOI 10.1016/j.ijid.2020.10.024; Abraha HE, 2021, INT J INFECT DIS, V105, P776, DOI 10.1016/j.ijid.2021.03.037; Aggarwal S, 2020, DIAGNOSIS, V7, P91, DOI 10.1515/dx-2020-0046; [Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; Avula A, 2020, BRAIN BEHAV IMMUN, V87, P115, DOI 10.1016/j.bbi.2020.04.077; Bellosta R, 2020, J VASC SURG, V72, P1864, DOI 10.1016/j.jvs.2020.04.483; Bezzio C, 2021, GUT, V70, P623, DOI 10.1136/gutjnl-2020-321760; Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020; Elimian KO, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-044079; Ethiopian Federal Ministry of Health, 2020, COVID19 MAN HDB; Gupta S, 2020, JAMA INTERN MED, V180, P1436, DOI 10.1001/jamainternmed.2020.3596; Hosmer DWJ., 2008, APPL SURVIVAL ANAL; Hu Y, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104371; Kim GU, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.04.040; Lechien JR, 2020, J INTERN MED, V288, P335, DOI 10.1111/joim.13089; Leulseged TW, 2021, PAN AFR MED J, V38, DOI 10.11604/pamj.2021.38.351.28831; Leulseged TW., 2020, MEDRXIV2020202010072; Leulseged TW., 2020, MEDRXIV2020100920209; Leulseged TW, 2020, MEDRXIV, V10, DOI [10.1101/2020, DOI 10.1101/2020, 10.08.20209122]; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Mi B., 2020, BONE JOINT SURG AM; Nachega JB, 2020, AM J TROP MED HYG, V103, P2419, DOI 10.4269/ajtmh.20-1240; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Richardson S., 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI [10.1001/jama.2020.6775, DOI 10.1001/JAMA.2020.6775, 10.1001/jama.2020.7681]; Sun LJ, 2020, J MED VIROL, V92, P2055, DOI 10.1002/jmv.25966; Taxonera C, 2020, ALIMENT PHARM THER, V52, P276, DOI 10.1111/apt.15804; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; World Health Organization, 2021, WEEKL COVID 19 EP UP; Xu TM, 2020, J MED VIROL, V92, P1884, DOI 10.1002/jmv.25944; Yan YL, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001343; Yang F, 2020, J MED VIROL, V92, P2511, DOI 10.1002/jmv.25891; Yang Y, 2020, J ALLERGY CLIN IMMUN, V146, P119, DOI 10.1016/j.jaci.2020.04.027; Zangrillo A, 2020, CRIT CARE RESUSC, V22, P91	35	5	5	4	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2021	16	11							e0259454	10.1371/journal.pone.0259454	http://dx.doi.org/10.1371/journal.pone.0259454			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY0QZ	34752481	Green Submitted, gold, Green Published			2023-01-03	WOS:000754499700016
J	Rashid, N; Khan, S; Wahid, A; Ibrar, D; Irshad, S; Bakhsh, A; Hasnain, Z; Alkahtani, J; Alwahibi, MS; Gawwad, MRA; Zuan, ATK				Rashid, Nabila; Khan, Shahbaz; Wahid, Abdul; Ibrar, Danish; Irshad, Sohail; Bakhsh, Ali; Hasnain, Zuhair; Alkahtani, Jawaher; Alwahibi, Mona S.; Gawwad, Mohamed Ragab Abdel; Zuan, Ali Tan Kee			RETRACTED: Exogenous application of moringa leaf extract improves growth, biochemical attributes, and productivity of late-sown quinoa (Retracted article. See vol. 17, 2022)	PLOS ONE			English	Article; Retracted Publication							HEAT-STRESS; DROUGHT; WHEAT; CROP; RESPONSES; GENOTYPES; CULTIVAR; WILLD.; YIELD; L.	Quinoa (Chenopodium quinoa Willd.) has gained significant popularity among agricultural scientists and farmers throughout the world due to its high nutritive value. It is cultivated under a range of soil and climatic conditions; however, late sowing adversely affects its productivity and yield due to shorter growth period. Inorganic and organic phyto-stimulants are promising for improving growth, development, and yield of field crops under stressful environments. Field experiments were conducted during crop cultivation seasons of 2016-17 and 2017-18, to explore the role of inorganic (hydrogen peroxide and ascorbic acid) and organic [moringa leaf extract (MLE) and sorghum water extract (sorgaab)] phyto-stimulants in improving growth and productivity of quinoa (cultivar UAF-Q7). Hydrogen peroxide at 100 mu M, ascorbic acid at 500 mu M, MLE at 3% and sorgaab at 3% were exogenously applied at anthesis stage of quinoa cultivated under normal (November 21(st) and 19(th) during 2016 and 2017) and late-sown (December 26(th) and 25(th) during 2016 and 2017) conditions. Application of inorganic and organic phyto-stimulants significantly improved biochemical, physiological, growth and yield attributes of quinoa under late sown conditions. The highest improvement in these traits was recorded for MLE. Application of MLE resulted in higher chlorophyll a and b contents, stomatal conductance, and sub-stomatal concentration of CO2 under normal and late-sowing. The highest improvement in soluble phenolics, anthocyanins, free amino acids and proline, and mineral elements in roots, shoot and grains were observed for MLE application. Growth attributes, including plant height, plant fresh weight and panicle length were significantly improved with MLE application as compared to the rest of the treatments. The highest 1000-grain weight and grain yield per plant were noted for MLE application under normal and late-sowing. These findings depict that MLE has extensive crop growth promoting potential through improving physiological and biochemical activities. Hence, MLE can be applied to improve growth and productivity of quinoa under normal and late-sown conditions.	[Rashid, Nabila; Wahid, Abdul] Univ Agr Faisalabad, Dept Bot, Faisalabad, Pakistan; [Khan, Shahbaz; Ibrar, Danish] Natl Agr Res Ctr, Islamabad, Pakistan; [Irshad, Sohail] Muhammad Nawaz Shareef Univ Agr, Dept Agron, Multan, Pakistan; [Bakhsh, Ali] Ghazi Univ, Dept Plant Breeding & Genet, Dera Ghazi Khan, Pakistan; [Hasnain, Zuhair] Pir Mehr Ali Shah Arid Agr Univ, Rawalpindi, Pakistan; [Alkahtani, Jawaher; Alwahibi, Mona S.] King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh, Saudi Arabia; [Gawwad, Mohamed Ragab Abdel] Int Univ Sarajevo, Fac Engn & Nat Sci, Genet & Bioengn, Sarajevo, Bosnia & Herceg; [Zuan, Ali Tan Kee] Univ Putra Malaysia, Fac Agr, Dept Land Management, Serdang, Selangor, Malaysia	University of Agriculture Faisalabad; National Agricultural Research Council - Pakistan; Arid Agriculture University; King Saud University; Universiti Putra Malaysia	Rashid, N (corresponding author), Univ Agr Faisalabad, Dept Bot, Faisalabad, Pakistan.; Khan, S (corresponding author), Natl Agr Res Ctr, Islamabad, Pakistan.; Zuan, ATK (corresponding author), Univ Putra Malaysia, Fac Agr, Dept Land Management, Serdang, Selangor, Malaysia.	rasheed.nabila@yahoo.com; shahbaz2255@gmail.com; tkz@upm.edu.my	Khan, Shahbaz/U-2918-2019; Alwhibi, Mona/M-7398-2019	Khan, Shahbaz/0000-0002-4524-9630; Alwhibi, Mona/0000-0002-3420-1164; Ali Tan, Kee Zuan/0000-0003-0473-4303; Abdel Gawwad, Mohamed Ragab/0000-0002-8115-812X	King Saud University, Riyadh, Saudi Arabia [RSP2021/179, RSP-2021/193]	King Saud University, Riyadh, Saudi Arabia(King Saud University)	The authors extend their appreciation to the Researchers supporting project number (RSP2021/179) at King Saud University, Riyadh, Saudi Arabia. Authors are also thankful to the Department of Botany and Department of Agronomy, University of Agriculture, Faisalabad Pakistan, for providing filed and lab facility for analytical activities to accomplish the experimentation. There were no additional external funding involved in the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Authors are thankful to the Department of Botany and Department of Agronomy, University of Agriculture, Faisalabad-Pakistan, for providing filed and lab facility for analytical activities to accomplish the experimentation. The authors also extend their appreciation to the Researchers supporting project number (RSP-2021/193) at King Saud University, Riyadh, Saudi Arabia.	Akram MZ, 2021, ASIAN J AGR BIOL, V9, DOI 10.35495/ajab.2020.05.301; Amin A. A., 2008, Australian Journal of Basic and Applied Sciences, V2, P252; Awasthi R, 2014, FUNCT PLANT BIOL, V41, P1148, DOI 10.1071/FP13340; Azarpour E., 2014, Biological Forum, V6, P254; Basal O, 2020, ASIAN J AGR BIOL, V8, P247, DOI 10.35495/ajab.2019.11.505; Basra SMA, 2011, INT J AGRIC BIOL, V13, P1006; BATES LS, 1973, PLANT SOIL, V39, P205, DOI 10.1007/BF00018060; Bedada W, 2016, AGR ECOSYST ENVIRON, V218, P220, DOI 10.1016/j.agee.2015.11.024; Cheema ZA, 2000, AGR ECOSYST ENVIRON, V79, P105, DOI 10.1016/S0167-8809(99)00140-1; Choukri H, 2020, FRONT NUTR, V7, DOI 10.3389/fnut.2020.596307; Curti RN, 2016, FIELD CROP RES, V189, P10, DOI 10.1016/j.fcr.2016.01.014; Dolatabadian A., 2010, Notulae Scientia Biologicae, V2, P45; du Jardin P, 2015, SCI HORTIC-AMSTERDAM, V196, P3, DOI 10.1016/j.scienta.2015.09.021; Farooq M, 2013, INT J AGRIC BIOL, V15, P1367; Farooq O, 2021, ASIAN J AGR BIOL, V9, DOI 10.35495/ajab.2020.04.219; Foidle N., 2001, MIRACLE TREE MULTIPL, P45; Gaudin ACM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0113261; Geerts S, 2008, FIELD CROP RES, V108, P150, DOI 10.1016/j.fcr.2008.04.008; Glodowska M, 2016, AGRON SUSTAIN DEV, V36, DOI 10.1007/s13593-016-0356-z; Hamilton PB, 1943, J BIOL CHEM, V150, P231; Hinojosa L, 2018, PLANTS-BASEL, V7, DOI 10.3390/plants7040106; Hossain MA, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00420; Hussain HA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40362-7; Hussain M, 2018, AGR WATER MANAGE, V201, P152, DOI 10.1016/j.agwat.2018.01.028; Iqbal H, 2018, ECOTOX ENVIRON SAFE, V164, P344, DOI 10.1016/j.ecoenv.2018.08.004; Jacobsen SE, 2005, EUR J AGRON, V22, P131, DOI 10.1016/j.eja.2004.01.003; JULKUNENTIITTO R, 1985, J AGR FOOD CHEM, V33, P213, DOI 10.1021/jf00062a013; Khan S, 2020, S AFR J BOT, V129, P74, DOI 10.1016/j.sajb.2019.01.007; Khan S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0254452; Khan S, 2017, ENVIRON SCI POLLUT R, V24, P27601, DOI 10.1007/s11356-017-0336-0; Killi D, 2017, PLANTS-BASEL, V6, DOI 10.3390/plants6040049; Kreslavski V, 2008, J PLANT PHYSIOL, V165, P1592, DOI 10.1016/j.jplph.2007.12.011; Loka D. A., 2016, Australian Journal of Crop Science, V10, P741, DOI 10.21475/ajcs.2016.10.05.p7498; Long SP, 1996, J EXP BOT, V47, P1629, DOI 10.1093/jxb/47.11.1629; MUKHERJEE SP, 1983, PHYSIOL PLANTARUM, V58, P166, DOI 10.1111/j.1399-3054.1983.tb04162.x; Peterson AJ, 2015, WORLD AGRIC SER, P173; Prager A, 2018, AGRONOMY-BASEL, V8, DOI 10.3390/agronomy8100197; Rashid N, 2022, J AGRON CROP SCI, V208, P552, DOI 10.1111/jac.12482; Rashid N, 2018, INT J AGRIC BIOL, V20, P157, DOI 10.17957/IJAB/15.0469; Rehman A, 2021, ASIAN J AGR BIOL, V9, DOI 10.35495/ajab.2020.03.202; Rezouki S, 2021, ASIAN J AGR BIOL, V9, DOI 10.35495/ajab.2020.04.251; Ruiz KB, 2014, AGRON SUSTAIN DEV, V34, P349, DOI 10.1007/s13593-013-0195-0; Sarwar M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49404-6; Sattar A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232974; Seidel SJ, 2016, ENVIRON MODELL SOFTW, V81, P111, DOI 10.1016/j.envsoft.2016.04.001; Shareef HJ, 2020, ASIAN J AGR BIOL, V8, P24, DOI 10.35495/ajab.2019.02.062; Sharma P., 2012, APPL ENVIRON SOIL SC, V2012, P1, DOI [10.1155/2012/217037, DOI 10.1155/2012/650206]; Siddiqui MH, 2015, SAUDI J BIOL SCI, V22, P656, DOI 10.1016/j.sjbs.2015.06.002; Strack D, 1989, 9 ANTHOCYANINS, DOI [10.1016/B978-0-12-461011-8.50015-9, DOI 10.1016/B978-0-12-461011-8.50015-9]; Tabaxi I, 2021, ASIAN J AGR BIOL, V9, DOI 10.35495/ajab.2020.05.274; Tanga M, 2020, ASIAN J AGR BIOL, V8, P511, DOI 10.35495/ajab.2019.11.524; ul Hussan M, 2022, ASIAN J AGR BIOL, V10, DOI 10.35495/ajab.2021.02.080; Ullah A, 2017, PLANT BIOTECHNOL J, V15, P271, DOI 10.1111/pbi.12688; Vilcacundo R, 2017, CURR OPIN FOOD SCI, V14, P1, DOI 10.1016/j.cofs.2016.11.007; Walters H, 2016, AGROECOL SUST FOOD, V40, P783, DOI 10.1080/21683565.2016.1177805; Yasmeen A, 2012, CHIL J AGR RES, V72, P92, DOI 10.4067/S0718-58392012000100015; YOSHIDA S., 1971, Laboratory manual for physiological studies of rice.; Zahid N, 2021, ASIAN J AGR BIOL, V9, DOI 10.35495/ajab.2020.07.381; Zaremba LS, 2000, ANN OPER RES, V97, P131, DOI 10.1023/A:1018996712442; Zhang XB, 2005, J CLIMATE, V18, P1641, DOI 10.1175/JCLI3366.1	60	8	8	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2021	16	11							e0259214	10.1371/journal.pone.0259214	http://dx.doi.org/10.1371/journal.pone.0259214			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ4ST	34748570	Green Published, gold, Green Accepted			2023-01-03	WOS:000755468000021
J	Rourke, EJ				Rourke, Elizabeth J.			Continuity, Fragmentation, and Adam Smith	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE; HOSPITALIZATION; TRENDS; COSTS		[Rourke, Elizabeth J.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Rourke, Elizabeth J.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Rourke, EJ (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.; Rourke, EJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.							[Anonymous], 2011, PRIM CAR WORKF FACTS; BECKER GS, 1992, Q J ECON, V107, P1137, DOI 10.2307/2118383; Chamberlain G, 2020, DECONSTRUCTING TELEH; Flocke SA, 1997, J FAM PRACTICE, V45, P129; Gunderman R, 2016, NEW ENGL J MED, V375, P1011, DOI 10.1056/NEJMp1608289; Hartman M, 2020, HEALTH AFFAIR, V39, P8, DOI 10.1377/hlthaff.2019.01451; Hennen B K, 1975, J Fam Pract, V2, P371; Hoff T, 2019, MED CARE, V57, P734, DOI 10.1097/MLR.0000000000001164; Hussey PS, 2014, JAMA INTERN MED, V174, P742, DOI 10.1001/jamainternmed.2014.245; Jabbarpour Y., 2019, EXECUTIVE SUMMARY; Kletke PR, 1996, JAMA-J AM MED ASSOC, V276, P555, DOI 10.1001/jama.276.7.555; Meltzer DO, 2014, HEALTH AFFAIR, V33, P770, DOI 10.1377/hlthaff.2014.0072; Meltzer DO, 2010, J GEN INTERN MED, V25, P453, DOI 10.1007/s11606-010-1276-2; Peikes D, 2020, HEALTH AFFAIR, V39, P421, DOI 10.1377/hlthaff.2019.01430; Rodriguez HP, 2007, J GEN INTERN MED, V22, P787, DOI 10.1007/s11606-007-0182-8; Sabety AH, 2021, JAMA INTERN MED, V181, P186, DOI 10.1001/jamainternmed.2020.6288; Saultz John W, 2003, Ann Fam Med, V1, P134, DOI 10.1370/afm.23; Saultz JW, 2005, ANN FAM MED, V3, P159, DOI 10.1370/afm.285; Smith A., 2010, WEALTH NATIONS; Starfield B., 1992, PRIMARY CARE CONCEPT; Starr P., 1982, SOCIAL TRANSFORMATIO; Taylor RB, 2006, J AM BOARD FAM MED, V19, P183, DOI 10.3122/jabfm.19.2.183; Wachter RM, 2016, NEW ENGL J MED, V375, P1009, DOI 10.1056/NEJMp1607958; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413	24	1	1	2	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2021	385	19					1810	1814		10.1056/NEJMms2103844	http://dx.doi.org/10.1056/NEJMms2103844			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR0CF	34731542				2023-01-03	WOS:000714176800017
J	Ezer, N; Belga, S; Daneman, N; Chan, A; Smith, BM; Daniels, SA; Moran, K; Besson, C; Smyth, LY; Bartlett, SJ; Benedetti, A; Martin, JG; Lee, TC; McDonald, EG				Ezer, Nicole; Belga, Sara; Daneman, Nick; Chan, Adrienne; Smith, Benjamin M.; Daniels, Shay-Anne; Moran, Kristen; Besson, Charlotte; Smyth, Louisa Y.; Bartlett, Susan J.; Benedetti, Andrea; Martin, James G.; Lee, Todd C.; McDonald, Emily G.			Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To determine if inhaled and intranasal ciclesonide are superior to placebo at decreasing respiratory symptoms in adult outpatients with covid-19. DESIGN Randomised, double blind, placebo controlled trial. SETTING Three Canadian provinces (Quebec, Ontario, and British Columbia). PARTICIPANTS 203 adults aged 18 years and older with polymerase chain reaction confirmed covid-19, presenting with fever, cough, or dyspnoea. INTERVENTION Participants were randomised to receive either inhaled ciclesonide (600 mu g twice daily) and intranasal ciclesonide (200 mu g daily) or metered dose inhaler and nasal saline placebos for 14 days. MAIN OUTCOME MEASURES The primary outcome was symptom resolution at day 7. Analyses were conducted on the modified intention-to-treat population (participants who took at least one dose of study drug and completed one follow-up survey) and adjusted for stratified randomisation by sex. RESULTS The modified intention-to-treat population included 203 participants: 105 were randomly assigned to ciclesonide (excluding two dropouts and one loss to follow-up) and 98 to placebo (excluding three dropouts and six losses to follow-up). The median age was 35 years (interquartile range 27-47 years) and 54% were women. The proportion of participants with resolution of symptoms by day 7 did not differ significantly between the intervention group (42/105, 40%) and control group (34/98, 35%); absolute adjusted risk difference 5.5% (95% confidence interval -7.8% to 18.8%). Results might be limited to the population studied, which mainly included younger adults without comorbidities. The trial was stopped early, therefore could have been underpowered. CONCLUSION Compared with placebo, the combination of inhaled and intranasal ciclesonide did not show a statistically significant increase in resolution of symptoms among healthier young adults with covid-19 presenting with prominent respiratory symptoms. As evidence is insufficient to determine the benefit of inhaled and intranasal corticosteroids in the treatment of covid-19, further research is needed. TRIAL REGISTRATION ClinicalTrials.gov NCT04435795.	[Ezer, Nicole; Smith, Benjamin M.; Martin, James G.] McGill Univ Hlth Ctr, Div Respirol, Dept Med, Montreal, PQ, Canada; [Ezer, Nicole; Smith, Benjamin M.; Besson, Charlotte; Bartlett, Susan J.; Benedetti, Andrea; Martin, James G.; Lee, Todd C.; McDonald, Emily G.] McGill Univ Hlth Ctr, Res Inst, Montreal, PQ, Canada; [Belga, Sara; Daniels, Shay-Anne] Univ British Columbia, Div Infect Dis, Vancouver, BC, Canada; [Daneman, Nick; Chan, Adrienne] Univ Toronto, Div Infect Dis, Dept Med, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Moran, Kristen; Smyth, Louisa Y.; Lee, Todd C.; McDonald, Emily G.] Dept Med, Clin Practice Assessment Unit, Montreal, PQ, Canada; [Bartlett, Susan J.; Benedetti, Andrea; Lee, Todd C.; McDonald, Emily G.] McGill Univ Hlth Ctr, Div Clin Epidemiol, Dept Med, Montreal, PQ, Canada; [Lee, Todd C.] McGill Univ Hlth Ctr, Div Infect Dis, Dept Med, Montreal, PQ, Canada; [McDonald, Emily G.] McGill Univ Hlth Ctr, Div Gen Internal Med, Dept Med, Montreal, PQ, Canada	McGill University; McGill University; University of British Columbia; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; McGill University; McGill University; McGill University	Ezer, N (corresponding author), Ctr Outcomes Res & Evaluat, Montreal, PQ H4A 3S9, Canada.	nicole.ezer@mcgill.ca			McGill University Health Centre Foundation; McGill Interdisciplinary Initiative in Infection and Immunity	McGill University Health Centre Foundation; McGill Interdisciplinary Initiative in Infection and Immunity	The placebo metered dose inhaler was donated by GlaxoSmithKline. Nasal saline, and spacers for the inhalers were purchased by NE. The study drug was donated by COVIS Pharma. Glaxo Smith Kline and COVIS Pharma provided no salary support for investigators or study staff and did not contribute to the study design, analysis, or manuscript preparation. The study was funded by the McGill University Health Centre Foundation and the McGill Interdisciplinary Initiative in Infection and Immunity. The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.	Clemency BM, RANDOMIZED CONTROLLE, V2021; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI [10.1056/NEJMoa2100433, 10.1056/NEJMc2108482]; Health Canada, PROD MON; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20; Kahan BC, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5840; Matsuyama S, 2021, J VIROL, V95, DOI 10.1128/JVI.01648-20; Pilkonis PA, 2011, ASSESSMENT, V18, P263, DOI 10.1177/1073191111411667; PROMIS, DYSPNEA INSTRUMENTS; Ramakrishnan S, 2021, LANCET RESP MED, V9, P763, DOI 10.1016/S2213-2600(21)00160-0; Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207; Tardif JC, 2021, LANCET RESP MED, V9, P924, DOI 10.1016/S2213-2600(21)00222-8; Wechsler ME, 2011, NEW ENGL J MED, V365, P119, DOI 10.1056/NEJMoa1103319; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Yu L, 2012, BEHAV SLEEP MED, V10, P6, DOI 10.1080/15402002.2012.636266; Yu LM, 2021, LANCET, V398, P843, DOI 10.1016/S0140-6736(21)01744-X	16	18	18	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	2021	375								e068060	10.1136/bmj-2021-068060	http://dx.doi.org/10.1136/bmj-2021-068060			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT6NY	34728476	Green Published			2023-01-03	WOS:000715980500008
J	Masese, RV; Bulgin, D; Knisely, MR; Preiss, L; Stevenson, E; Hankins, JS; Treadwell, MJ; King, AA; Gordeuk, VR; Kanter, J; Gibson, R; Glassberg, JA; Tanabe, P; Shah, N				Masese, Rita, V; Bulgin, Dominique; Knisely, Mitchell R.; Preiss, Liliana; Stevenson, Eleanor; Hankins, Jane S.; Treadwell, Marsha J.; King, Allison A.; Gordeuk, Victor R.; Kanter, Julie; Gibson, Robert; Glassberg, Jeffrey A.; Tanabe, Paula; Shah, Nirmish		Sickle Cell Dis Implementation Con	Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium	PLOS ONE			English	Article							QUALITY-OF-LIFE; GENDER-DIFFERENCES; PREGNANCY OUTCOMES; DEPRESSION; PAIN; HYDROXYUREA; CHILDREN; ANEMIA; INDIVIDUALS; PREVALENCE	Introduction Sex-based clinical outcome differences in sickle cell disease (SCD) remain largely unknown despite evidence that female sex is associated with an increased lifespan. To better characterize sex-based differences in SCD, we assessed pain, treatment characteristics, laboratory measures and complications among males and females currently enrolled in the Sickle Cell Disease Implementation Consortium (SCDIC) registry. Methods The SCDIC consists of eight comprehensive SCD centers and one data coordinating center that received funding from the National Heart Lung and Blood Institute to improve outcomes for individuals with SCD. Eligibility criteria included: 15 to 45 years of age and a confirmed diagnosis of SCD. Self-report surveys were completed and data were also abstracted from the participants' medical records. Results A total of 2,124 participants were included (mean age: 27.8 years; 56% female). The majority had hemoglobin SS SCD genotype. Females had worse reports of pain severity (mean (SD) T-score 51.6 (9.6) vs 49.3 (10), p<0.001), more vaso-occlusive episodes (p = 0.01) and a higher occurrence of 3 or more hospital admissions in the past year (30.9% vs. 25.5, p = 0.03). On multivariable analysis, males had higher odds of acute chest syndrome (odds ratio (OR) 1.4, p = 0.002), cardiovascular (OR 1.70, p<0.001) and musculoskeletal (OR 1.33, p = 0.0034) complications and lower odds of depression (OR 0.77, p = 0.0381). Females had higher fetal hemoglobin levels with and without hydroxyurea use (9.6% vs 8.5%, p = 0.03 and 3% vs 2.2%, p = 0.0005, respectively). Conclusion Our data suggests that sex differences in clinical outcomes do occur among individuals with SCD. Future research needs to explore the mechanisms underlying these differences.	[Masese, Rita, V; Knisely, Mitchell R.; Stevenson, Eleanor; Tanabe, Paula; Shah, Nirmish] Duke Univ, Sch Nursing, Durham, NC 27708 USA; [Bulgin, Dominique] Univ Tennessee, Coll Nursing, Knoxville, TN USA; [Preiss, Liliana] RTI Int, Res Triangle Pk, NC USA; [Hankins, Jane S.] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN USA; [Treadwell, Marsha J.] Univ Calif San Francisco, Dept Pediat, Benioff Childrens Hosp, Oakland, CA USA; [King, Allison A.] Washington Univ, Sch Med, St Louis, MO USA; [Gordeuk, Victor R.] Univ Illinois, Chicago, IL USA; [Kanter, Julie] Univ Alabama Birmingham, Birmingham, AL USA; [Gibson, Robert] Augusta Univ, Med Coll Georgia, Dept Emergency Med, Augusta, GA USA; [Glassberg, Jeffrey A.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA; [Shah, Nirmish] Duke Univ, Sch Med, Durham, NC USA	Duke University; University of Tennessee System; University of Tennessee Knoxville; Research Triangle Institute; St Jude Children's Research Hospital; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Washington University (WUSTL); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Alabama System; University of Alabama Birmingham; University System of Georgia; Augusta University; Icahn School of Medicine at Mount Sinai; Duke University	Masese, RV (corresponding author), Duke Univ, Sch Nursing, Durham, NC 27708 USA.	rita.masese@duke.edu		Gibson, Robert W./0000-0002-1075-4303; Preiss, Liliana/0000-0002-2978-7260; Bulgin, Dominique/0000-0002-4030-0791; Glassberg, Jeffrey/0000-0002-8188-4412	US Federal Government from the National Heart Lung and Blood Institute [3U01HL133964-04S1, U24HL133948, U01HL133964, U01HL133990, U01HL133996, U01HL133994, U01HL133997, U01HL134004, U01HL134007, U01HL134042]; US Federal Government from the National Institute on Minority Health and Health Disparities (Bethesda, MD) [3U01HL133964-04S1, U24HL133948, U01HL133964, U01HL133990, U01HL133996, U01HL133994, U01HL133997, U01HL134004, U01HL134007, U01HL134042]	US Federal Government from the National Heart Lung and Blood Institute; US Federal Government from the National Institute on Minority Health and Health Disparities (Bethesda, MD)	The SCD Implementation Consortium was supported by US Federal Government cooperative agreements 3U01HL133964-04S1, U24HL133948, U01HL133964, U01HL133990, U01HL133996, U01HL133994, U01HL133997, U01HL134004, U01HL134007, and U01HL134042 from the National Heart Lung and Blood Institute and the National Institute on Minority Health and Health Disparities (Bethesda, MD).	Adam SS, 2017, BLOOD ADV, V1, P1983, DOI 10.1182/bloodadvances.2017006940; Adamkiewicz TV, 2008, PEDIATRICS, V121, P562, DOI 10.1542/peds.2007-0018; Albert PR, 2015, J PSYCHIATR NEUROSCI, V40, P219, DOI 10.1503/jpn.150205; Arduini GAO, 2018, HEMOGLOBIN, V42, P73, DOI 10.1080/03630269.2018.1452760; Ataga KI, 2007, HAEMATOLOGICA, V93, P20, DOI 10.3324/haematol.11763; Ballas SK, 2016, BLOOD, V128, P2367, DOI 10.1182/blood-2016-05-715946; Ballas SK, 2009, J NATL MED ASSOC, V101, P1046, DOI 10.1016/S0027-9684(15)31072-5; Ballas SK, 2005, AM J HEMATOL, V79, P17, DOI 10.1002/ajh.20336; Barton-Gooden A, 2019, PSYCHOL HEALTH MED, V24, P470, DOI 10.1080/13548506.2018.1533985; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Blake A, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28198; Boafor TK, 2016, BJOG-INT J OBSTET GY, V123, P691, DOI 10.1111/1471-0528.13786; Brandow AM, 2014, PEDIATR BLOOD CANCER, V61, P512, DOI 10.1002/pbc.24838; Brandow AM, 2010, EXPERT REV HEMATOL, V3, P255, DOI 10.1586/EHM.10.22; Chinegwundoh FI, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004198.pub4; Cohen RT, 2010, BLOOD, V115, P3852, DOI 10.1182/blood-2010-01-265819; Conran N, 2009, HEMOGLOBIN, V33, P1, DOI 10.1080/03630260802625709; de Abood M, 1997, CONTRACEPTION, V56, P313, DOI 10.1016/S0010-7824(97)00156-X; DeBaun MR, 2019, BLOOD, V133, P615, DOI 10.1182/blood-2018-10-880575; DiMartino LD, 2018, AM J HEMATOL, V93, pE391, DOI 10.1002/ajh.25282; Farooq Sajid, 2018, Hosp Pract (1995), V46, P144, DOI 10.1080/21548331.2018.1464363; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; Glassberg JA, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01457-x; Haddad LB, 2012, CONTRACEPTION, V85, P527, DOI 10.1016/j.contraception.2011.10.008; Halasa NB, 2007, CLIN INFECT DIS, V44, P1428, DOI 10.1086/516781; Hamideh D, 2013, PEDIATR BLOOD CANCER, V60, P1482, DOI 10.1002/pbc.24557; Hassell KL, 2010, AM J PREV MED, V38, pS512, DOI 10.1016/j.amepre.2009.12.022; Kato Gregory J, 2009, Am J Hematol, V84, P618, DOI 10.1002/ajh.21475; Levenson JL, 2008, PSYCHOSOM MED, V70, P192, DOI 10.1097/PSY.0b013e31815ff5c5; Martin C, 2018, BRIT J SPORT MED, V52, P214, DOI 10.1136/bjsports-2015-095317; Masese RV, 2021, J IMMIGR MINOR HEALT, V23, P725, DOI 10.1007/s10903-020-01102-6; Mayor E, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00779; McClish DK, 2006, J WOMENS HEALTH, V15, P146, DOI 10.1089/jwh.2006.15.146; McClish Donna K, 2005, Health Qual Life Outcomes, V3, P50, DOI 10.1186/1477-7525-3-50; McLean CP, 2011, J PSYCHIATR RES, V45, P1027, DOI 10.1016/j.jpsychires.2011.03.006; Minniti Caterina P, 2010, Am J Hematol, V85, P831, DOI 10.1002/ajh.21838; National Heart Lung and Blood Institute (NHLBI), 2014, EVIDENCE BASED MANAG; Ngo ST, 2014, FRONT NEUROENDOCRIN, V35, P347, DOI 10.1016/j.yfrne.2014.04.004; NOGUCHI CT, 1993, BAILLIERE CLIN HAEM, V6, P57, DOI 10.1016/S0950-3536(05)80066-6; Palermo TM, 2008, J PAIN, V9, P833, DOI 10.1016/j.jpain.2008.04.002; Patel V, 2018, WORLD PSYCHIATRY, V17, P76, DOI 10.1002/wps.20492; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Smith-Whitley K, 2014, BLOOD, V124, P3538, DOI 10.1182/blood-2014-07-577619; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001/jama.289.13.1645; Steinberg MH, 1999, NEW ENGL J MED, V340, P1021, DOI 10.1056/NEJM199904013401307; Torres LS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165833; Treadwell MJ, 2014, CLIN J PAIN, V30, P902, DOI 10.1097/AJP.0000000000000054; Yoong W C, 2002, J Obstet Gynaecol, V22, P399	48	3	3	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2021	16	10							e0258638	10.1371/journal.pone.0258638	http://dx.doi.org/10.1371/journal.pone.0258638			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8NO	34714833	Green Published, gold			2023-01-03	WOS:000755042500012
J	Gupta, A; Gonzalez-Rojas, Y; Juarez, E; Casal, MC; Moya, J; Falci, DR; Sarkis, E; Solis, J; Zheng, HZ; Scott, N; Cathcart, AL; Hebner, CM; Sager, J; Mogalian, E; Tipple, C; Peppercorn, A; Alexander, E; Pang, PS; Free, A; Brinson, C; Aldinger, M; Shapiro, AE				Gupta, Anil; Gonzalez-Rojas, Yaneicy; Juarez, Erick; Casal, Manuel Crespo; Moya, Jaynier; Falci, Diego R.; Sarkis, Elias; Solis, Joel; Zheng, Hanzhe; Scott, Nicola; Cathcart, Andrea L.; Hebner, Christy M.; Sager, Jennifer; Mogalian, Erik; Tipple, Craig; Peppercorn, Amanda; Alexander, Elizabeth; Pang, Phillip S.; Free, Almena; Brinson, Cynthia; Aldinger, Melissa; Shapiro, Adrienne E.		COMET-ICE Investigators	Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (<= 5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a dose of 500 mg or placebo. The primary efficacy outcome was hospitalization (for >24 hours) for any cause or death within 29 days after randomization. RESULTS In this prespecified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, had disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; P=0.002). In the placebo group, 5 patients were admitted to the intensive care unit, including 1 who died by day 29. Safety was assessed in 868 patients (430 in the sotrovimab group and 438 in the placebo group). Adverse events were reported by 17% of the patients in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively). CONCLUSIONS Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified.	[Gupta, Anil] William Osler Hlth Ctr, Albion Finch Med Ctr, Toronto, ON, Canada; [Gonzalez-Rojas, Yaneicy] Pines Care Res Ctr, Optimus U, Miami, FL USA; [Juarez, Erick] Florida Int Med Res, Miami, FL USA; [Moya, Jaynier] Pines Care Res Ctr, Pembroke Pines, FL USA; [Sarkis, Elias] Sarkis Clin Trials, Gainesville, FL USA; [Casal, Manuel Crespo] IIS Galicia Sur, Alvaro Cunqueiro Hosp, Vigo, Spain; [Falci, Diego R.] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Solis, Joel] Centex Studies, Mcallen, TX USA; [Brinson, Cynthia] Cent Texas Clin Res, Austin, TX USA; [Zheng, Hanzhe; Cathcart, Andrea L.; Hebner, Christy M.; Sager, Jennifer; Mogalian, Erik; Alexander, Elizabeth; Pang, Phillip S.; Aldinger, Melissa] Vir Biotechnol, San Francisco, CA USA; [Scott, Nicola; Tipple, Craig] GlaxoSmithKline, Stevenage, Herts, England; [Peppercorn, Amanda] GlaxoSmithKline, Cambridge, MA USA; [Free, Almena] Pinnacle Res Grp, Anniston, AL USA; [Shapiro, Adrienne E.] Univ Washington, Dept Global Hlth, Seattle, WA USA; [Shapiro, Adrienne E.] Fred Hutchinson Canc Res Ctr, Mailstop 110,1100 Fairview Ave N, Seattle, WA 98109 USA	GlaxoSmithKline; GlaxoSmithKline; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Shapiro, AE (corresponding author), Fred Hutchinson Canc Res Ctr, Mailstop 110,1100 Fairview Ave N, Seattle, WA 98109 USA.	aeshapir@uw.edu	Shapiro, Adrienne E/GQZ-4527-2022	Shapiro, Adrienne E/0000-0002-3106-1258	GlaxoSmithKline; Vir Biotechnology	GlaxoSmithKline(GlaxoSmithKline); Vir Biotechnology	Supported by Vir Biotechnology and GlaxoSmithKline.	Angulo FJ, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.33706; [Anonymous], 2020, COVID 19 DEV DRUGS B; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x; Cathcart A.L., 2021, DUAL FUNCTION MONOCL, DOI [10.1101/2021.03.09. 434607, DOI 10.1101/2021.03.09.434607, 10.1101/2021.03.09.434607]; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6915e4; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Focosi D, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2231; Gaudinski MR, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002493; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; HWANG IK, 1990, STAT MED, V9, P1439, DOI 10.1002/sim.4780091207; Ko SY, 2014, NATURE, V514, P642, DOI 10.1038/nature13612; Lempp F.A., 2021, MEMBRANE LECTINS ENH, DOI [10.1101/ 2021.04.03.438258, DOI 10.1101/2021.04.03.438258]; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; Liu H., 2021, 501YV2 501YV3 VARIAN; McCallum M, 2021, SCIENCE, V373, P648, DOI 10.1126/science.abi7994; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Reese H., 2020, CLIN INFECT DIS, DOI DOI 10.1093/CID/CIAA1780; Starr TN, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100255; Tada Takuya, 2021, bioRxiv, DOI 10.1101/2021.02.18.431897; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Zalevsky J, 2010, NAT BIOTECHNOL, V28, P157, DOI 10.1038/nbt.1601	26	336	344	4	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2021	385	21					1941	1950		10.1056/NEJMoa2107934	http://dx.doi.org/10.1056/NEJMoa2107934		OCT 2021	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WY8NB	34706189	Green Submitted, Bronze			2023-01-03	WOS:000711616300001
J	Palvan, S; Zareii, K; Hoseini, ASS; Haghani, H				Palvan, Somayeh; Zareii, Khadijah; Hoseini, Akram Sadat Sadat; Haghani, Hamid			The effect of exchanging drawings with peers on the happiness of children with cancer, aged 7-11 years: A clinical trial	PLOS ONE			English	Article							THERAPY; HEALTH; ART	Introduction Improving the mental status of children with cancer is part of nurses' duties in planning nursing care and is achieved in different ways. This study attempts to combine drawing with peer interaction to improve the mental status of sick children and investigate the effect of exchanging drawings with peers on these children's happiness. Method This clinical trial was conducted on a sample of 66 children with cancer, ages 7-11 years, who were randomly assigned to two groups. The intervention was carried out over five weeks by the exchange of drawings between healthy children at school and children with cancer. Both groups of children drew one drawing each week. The children's happiness was measured by the researcher before and after the intervention (i.e., week five) using a questionnaire. Results The results showed no significant differences between the two groups in terms of happiness after the intervention. The happiness score was 3.15 0.34 in the control group and 3.02 +/- 0.3 in the intervention group before the intervention; afterwards, this score was 3.022 +/- 0.22 among the controls and 3.11 +/- 0.25 among the patients. The comparison of the two groups using the t-test showed P = 0.075 before the intervention and P = 0.11 after the intervention. Conclusion Given the results obtained, future studies are recommended to administer lengthier interventions and enable the physical presence of healthy peers along sick children or to use the exchange of drawings with peers in combination with other psychological interventions so as to promote happiness in children with cancer.	[Palvan, Somayeh; Zareii, Khadijah] Univ Tehran Med Sci, Sch Nursing & Midwifery, Tehran, Iran; [Hoseini, Akram Sadat Sadat] Univ Tehran Med Sci, Sch Nursing & Midwifery, Dept Pediat, Tehran, Iran; [Hoseini, Akram Sadat Sadat] Univ Tehran Med Sci, Sch Nursing & Midwifery, NICU, Tehran, Iran; [Hoseini, Akram Sadat Sadat] Univ Tehran Med Sci, Quran & Med Sci, Tehran, Iran; [Haghani, Hamid] Shahid Beheshti Univ, Dept Biostat, Tehran, Iran	Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Shahid Beheshti University	Hoseini, ASS (corresponding author), Univ Tehran Med Sci, Sch Nursing & Midwifery, Dept Pediat, Tehran, Iran.; Hoseini, ASS (corresponding author), Univ Tehran Med Sci, Sch Nursing & Midwifery, NICU, Tehran, Iran.; Hoseini, ASS (corresponding author), Univ Tehran Med Sci, Quran & Med Sci, Tehran, Iran.	ashoseini@tums.ac.ir			Tehran University of Medical Sciences [9311700002]	Tehran University of Medical Sciences(Tehran University of Medical Sciences)	This research did not receive any funding for publication but took grant NO 9311700002 of Tehran University of Medical Sciences for research process.	Ackerman C, WHAT IS POSITIVE PSY; Askary P., 2018, POSITIVE PSYCHOL, V3, P15; Badri M, 2018, INT J CHILD CARE EDU, V12, DOI 10.1186/s40723-018-0056-z; Barfarazi H., 2018, EVIDENCE BASED CARE, V8, P17; Barrera ME, 2002, PSYCHO-ONCOL, V11, P379, DOI 10.1002/pon.589; Beebe A, 2010, J ALLERGY CLIN IMMUN, V126, P263, DOI 10.1016/j.jaci.2010.03.019; Bekhet AK, 2008, NURS FORUM, V43, P12, DOI 10.1111/j.1744-6198.2008.00091.x; Borzou R, 2014, IRANIAN J MED ED, V14, P767; Chaves C, 2016, J HAPPINESS STUD, V17, P1051, DOI 10.1007/s10902-015-9631-y; Dickie K, HAPPINESS CHILDREN; Durualp E, 2012, J PEDIATR ONCOL NURS, V29, P232, DOI 10.1177/1043454212446616; Gariepy N, 2003, CHILD CARE HLTH DEV, V29, P523, DOI 10.1046/j.1365-2214.2003.00372.x; Heisler M, 2007, DIABETES SPECTR, V20, P214, DOI [10.2337/diaspect.20.4.214, DOI 10.2337/DIASPECT.20.4.214]; Hendriks T, 2020, J HAPPINESS STUD, V21, P357, DOI 10.1007/s10902-019-00082-1; Hockenberry M.J., 2021, WONGS ESSENTIALS PED; Holder MD, 2012, J HAPPINESS STUD, V13, P261, DOI 10.1007/s10902-011-9262-x; Jafroodi M ., 2000, J GUILAN U MED SCI, V68, P14; Katz C, 2013, CHILD YOUTH SERV REV, V35, P877, DOI 10.1016/j.childyouth.2013.02.007; Khaw C, 2016, INT J MED EDUC, V7, P188, DOI 10.5116/ijme.5749.7b8b; Khodabakhshi Koolaee A., 2016, CASPIAN J PEDIAT, V2, P135; Kubzansky LD, 2016, LANCET, V388, P27, DOI 10.1016/S0140-6736(16)30896-0; Lee SL, 2016, ART PSYCHOTHER, V51, P24, DOI 10.1016/j.aip.2016.08.005; Mahon Noreen E, 2002, Clin Nurs Res, V11, P306, DOI 10.1177/10573802011003006; Mehranfar M, 2012, IRAN J CANCER PREV, V5, P1; Michalos AC ., 2014, ENCY QUALITY LIFE WE, V1th ed., P6622; Michel G, 2010, J CLIN ONCOL, V28, P1740, DOI 10.1200/JCO.2009.23.4534; Mirzaie M., 2010, J GUILAN FM, V19, P32; Motevaselian M., 2014, IRANIAN J MED ED, V14, P670; Pinto SMO, 2013, NURS RES PRACT, V2013, DOI 10.1155/2013/291767; Philis-Tsimikas A, 2011, DIABETES CARE, V34, P1926, DOI 10.2337/dc10-2081; Priharjo Robert, 2011, Nurs Stand, V25, P40; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; Rogers MAM, 2003, AM J PUBLIC HEALTH, V93, P288, DOI 10.2105/AJPH.93.2.288; Rollins Judy A, 2005, J Pediatr Oncol Nurs, V22, P203, DOI 10.1177/1043454205277103; Sanjari M, 2005, IRAN J NUR, V18, P111; Veenhoven R, 2008, J HAPPINESS STUD, V9, P449, DOI 10.1007/s10902-006-9042-1; Verkooijen H M Lenny, 2012, Ned Tijdschr Geneeskd, V156, pA5752; Zareapour A, 2009, SJKU, V14, P64	38	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2021	16	10							e0257867	10.1371/journal.pone.0257867	http://dx.doi.org/10.1371/journal.pone.0257867			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ7YW	34653193	Green Published, gold			2023-01-03	WOS:000755689200011
J	Neto, R; Pereira, L; Magalhaes, J; Quelhas-Santos, J; Frazao, J				Neto, Ricardo; Pereira, Luciano; Magalhaes, Juliana; Quelhas-Santos, Janete; Frazao, Joao			Low bone turnover is associated with plain X-ray vascular calcification in predialysis patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CORONARY-ARTERY CALCIFICATION; CKD PATIENTS; RENAL BONE; SCLEROSTIN; HISTOMORPHOMETRY; OSTEOPROTEGERIN; PATHOGENESIS; MECHANISMS; MORTALITY	Background Vascular calcification (VC) is a common finding in chronic kidney disease (CKD) patients and predicts subsequent cardiovascular morbidity and mortality in this population. Vascular calcification is linked to disordered mineral metabolism and has been associated with bone histomorphometry changes in CKD. However, data on predialysis patients is scarce. Methods A cross-sectional study was conducted on a cohort of 56 CKD patients not yet on dialysis, who underwent a transiliac bone biopsy for histomorphometric evaluation after double tetracycline labeling. Patients had no previous exposure to calcium salts, vitamin D agents, steroids or bisphosphonates. Vascular calcification was assessed at the time of biopsy, using Kauppila (plain X-ray of the lateral lumbar spine) and AdragAo (plain X-ray of the pelvis and hands) scores. Results Vascular calcification was seen in two-thirds of the cohort. Subjects with VC were more likely to be male and have diabetes, and had significantly higher sclerostin and osteoprotegerin circulating levels than those without VC. The histomorphometric analysis showed that bone formation rate was significantly lower in VC compared to non-VC patients. In the multivariable logistic regression analysis, bone formation rate was independently associated with the presence of VC. Conclusions Vascular calcification is highly prevalent in predialysis patients, especially in those with diabetes. The independent association between bone formation rate and VC provides evidence of an important interaction between bone and vessel in CKD. Our results suggest that low bone turnover is a non-traditional risk factor for cardiovascular disease in predialysis patients.	[Neto, Ricardo; Pereira, Luciano; Magalhaes, Juliana; Frazao, Joao] Univ Porto, Nephrol & Infect Dis Res Grp, Inst Biomed Engn INEB, Inst Innovat & Hlth Res I3S, Porto, Portugal; [Neto, Ricardo; Pereira, Luciano; Frazao, Joao] Ctr Hosp Univ Sao Joao, Dept Nephrol, Porto, Portugal; [Neto, Ricardo; Pereira, Luciano; Quelhas-Santos, Janete; Frazao, Joao] Univ Porto, Fac Med, Porto, Portugal	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto	Neto, R (corresponding author), Univ Porto, Nephrol & Infect Dis Res Grp, Inst Biomed Engn INEB, Inst Innovat & Hlth Res I3S, Porto, Portugal.; Neto, R (corresponding author), Ctr Hosp Univ Sao Joao, Dept Nephrol, Porto, Portugal.; Neto, R (corresponding author), Univ Porto, Fac Med, Porto, Portugal.	ricardoneto76@gmail.com	Frazão, João/J-9811-2013; Frazão, João/AGX-6125-2022; Santos, Janete Quelhas/GPX-7913-2022; Quelhas-Santos, Janete/ABD-9908-2020	Frazão, João/0000-0002-8081-5474; Frazão, João/0000-0002-8081-5474; Santos, Janete Quelhas/0000-0002-8388-1848; 				Abedin M, 2004, ARTERIOSCL THROM VAS, V24, P1161, DOI 10.1161/01.ATV.0000133194.94939.42; Adragao T, 2004, NEPHROL DIAL TRANSPL, V19, P1480, DOI 10.1093/ndt/gfh217; Adragao T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179868; Adragao T, 2009, CLIN J AM SOC NEPHRO, V4, P450, DOI 10.2215/CJN.01870408; Adragao T, 2009, NEPHROL DIAL TRANSPL, V24, P997, DOI 10.1093/ndt/gfn584; Barreto DV, 2008, AM J KIDNEY DIS, V52, P1139, DOI 10.1053/j.ajkd.2008.06.024; Behets GJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176411; Bellasi A, 2006, KIDNEY INT, V70, P1623, DOI 10.1038/sj.ki.5001820; Bernardi S, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0625-3; Claes KJ, 2013, J CLIN ENDOCR METAB, V98, P3221, DOI 10.1210/jc.2013-1521; Coen G, 1996, NEPHROL DIAL TRANSPL, V11, P813, DOI 10.1093/oxfordjournals.ndt.a027404; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; Delanaye P, 2015, KIDNEY INT, V88, P1221, DOI 10.1038/ki.2015.258; Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805; Dos Reis LM, 2007, J BONE MINER METAB, V25, P400, DOI 10.1007/s00774-007-0778-4; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Evenepoel P, 2015, KIDNEY INT, V88, P235, DOI 10.1038/ki.2015.156; Garland JS, 2008, AM J KIDNEY DIS, V52, P849, DOI 10.1053/j.ajkd.2008.04.012; Giachelli CM, 2004, J AM SOC NEPHROL, V15, P2959, DOI 10.1097/01.ASN.0000145894.57533.C4; Glorieux FH, 2000, BONE, V26, P103, DOI 10.1016/S8756-3282(99)00257-4; Gorriz JL, 2015, CLIN J AM SOC NEPHRO, V10, P654, DOI 10.2215/CJN.07450714; Kauppila LI, 1997, ATHEROSCLEROSIS, V132, P245, DOI 10.1016/S0021-9150(97)00106-8; Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001; Lenhard MJ, 2017, AM J NEPHROL, V46, P37, DOI 10.1159/000477381; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levin A, 2013, KIDNEY INT, V83, P1001, DOI 10.1038/ki.2013.91; Liabeuf S, 2014, NEPHROL DIAL TRANSPL, V29, P1275, DOI 10.1093/ndt/gft368; London GM, 2004, J AM SOC NEPHROL, V15, P1943, DOI 10.1097/01.asn.0000129337.50739.48; Madhavan MV, 2014, J AM COLL CARDIOL, V63, P1703, DOI 10.1016/j.jacc.2014.01.017; Massy Z, 2017, J NEPHROL, V30, P629, DOI 10.1007/s40620-017-0397-7; Moe SM, 2006, EUR J CLIN INVEST, V36, P51, DOI 10.1111/j.1365-2362.2006.01665.x; Moe SM, 2008, J AM SOC NEPHROL, V19, P213, DOI 10.1681/ASN.2007080854; Moe SM, 2005, KIDNEY INT, V67, P2295, DOI 10.1111/j.1523-1755.2005.00333.x; Mohammadpour Amir Hooshang, 2012, Thrombosis, V2012, P306263, DOI 10.1155/2012/306263; Morena M, 2015, NEPHROL DIAL TRANSPL, V30, P1345, DOI 10.1093/ndt/gfv081; Nelson AJ, 2020, JACC-BASIC TRANSL SC, V5, P398, DOI 10.1016/j.jacbts.2020.02.002; Schlieper G, 2016, NEPHROL DIAL TRANSPL, V31, P31, DOI 10.1093/ndt/gfv111; Tomiyama C, 2010, J BONE MINER RES, V25, P499, DOI 10.1359/jbmr.090735; Van Campenhout A, 2009, ATHEROSCLEROSIS, V204, P321, DOI 10.1016/j.atherosclerosis.2008.09.033; Verbeke F, 2011, CLIN J AM SOC NEPHRO, V6, P153, DOI 10.2215/CJN.05120610; Vervloet MG, 2014, LANCET DIABETES ENDO, V2, P427, DOI 10.1016/S2213-8587(14)70059-2; Znorko B, 2017, ADV MED SCI-POLAND, V62, P52, DOI 10.1016/j.advms.2016.08.001	42	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2021	16	10							e0258284	10.1371/journal.pone.0258284	http://dx.doi.org/10.1371/journal.pone.0258284			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR9CY	34644326	Green Published, gold			2023-01-03	WOS:000732519500033
J	Coratella, G; Longo, S; Rampichini, S; Doria, C; Borrelli, M; Limonta, E; Michielon, G; Ce, E; Esposito, F				Coratella, Giuseppe; Longo, Stefano; Rampichini, Susanna; Doria, Christian; Borrelli, Marta; Limonta, Eloisa; Michielon, Giovanni; Ce, Emiliano; Esposito, Fabio			Passive stretching decreases muscle efficiency in balance tasks	PLOS ONE			English	Article							SKELETAL-MUSCLE; ELECTROMECHANICAL DELAY; POSTURAL STABILITY; TIME-COURSE; FORCE; STIFFNESS; MECHANOMYOGRAM; RESPONSES; MIDDLE	The current study aimed to verify whether or not passive static stretching affects balance control capacity. Thirty-eight participants (19 women and 19 men) underwent a passive static stretching session, involving the knee extensor/flexor and dorsi/plantarflexor muscles, and a control session (no stretching, CTRL). Before (PRE), immediately after (POST), after 15 (POST15) and 30 min (POST30) from stretching (or rest in CTRL), balance control was evaluated under static and dynamic conditions, with open/closed eyes, and with/without somatosensory perturbation (foam under the feet). During tests, centre of pressure (CoP) sway area and perimeter and antero-posterior and medio-lateral sway mean speed were computed. Surface electromyography root mean square (sEMG RMS) was calculated from the vastus lateralis, biceps femoris, gastrocnemius medialis, and tibialis anterior muscles during MVC and during the balance tests. Hip flexion/extension and dorsi/plantarflexion range of motion (ROM), maximum voluntary contraction (MVC) and sEMG RMS during MVC were measured at the same time points. After stretching, ROM increased (approximate to 6.5%; P < 0.05), while MVC and sEMG RMS decreased (approximate to 9% and approximate to 7.5%, respectively; P < 0.05). Regardless of the testing condition, CoP sway area and the perimeter remained similar, while antero-posterior and medio-lateral sway mean speed decreased by approximate to 8% and approximate to 12%, respectively (P < 0.05). sEMG RMS during the balance tests increased in all muscles in POST (approximate to 7%, P < 0.05). All variables recovered in POST30. No changes occurred in CTRL. Passive static stretching did not affect the overall balance control ability. However, greater muscle activation was required to maintain similar CoP sway, thus suggesting a decrease in muscle efficiency.	[Coratella, Giuseppe; Longo, Stefano; Rampichini, Susanna; Doria, Christian; Borrelli, Marta; Limonta, Eloisa; Michielon, Giovanni; Ce, Emiliano; Esposito, Fabio] Univ Milan, Dept Biomed Sci Hlth SCIBIS, Milan, Italy; [Limonta, Eloisa; Ce, Emiliano; Esposito, Fabio] IRCCS Galeazzi Orthoped Inst, Milan, Italy	University of Milan; IRCCS Istituto Ortopedico Galeazzi	Coratella, G (corresponding author), Univ Milan, Dept Biomed Sci Hlth SCIBIS, Milan, Italy.	giuseppe.coratella@unimi.it	; Longo, Stefano/D-5486-2012; Esposito, Fabio/E-9340-2011	CORATELLA, GIUSEPPE/0000-0001-7523-9102; Longo, Stefano/0000-0001-5806-8305; Esposito, Fabio/0000-0002-4420-2611	Department of Biomedical Sciences for Health, Universita degli Studi di Milano	Department of Biomedical Sciences for Health, Universita degli Studi di Milano	The present study was funded by a dedicated grant (PSR Fondi Linea 2 -Tipologia A - 2019) assigned to FE and GM from the Department of Biomedical Sciences for Health, Universita degli Studi di Milano. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Avela J, 1999, J APPL PHYSIOL, V86, P1283, DOI 10.1152/jappl.1999.86.4.1283; Behm DG, 2004, MED SCI SPORT EXER, V36, P1397, DOI 10.1249/01.MSS.0000135788.23012.5F; Belkhiria-Turki L, 2014, J SPORT MED PHYS FIT, V54, P279; Bisconti AV, 2020, J PHYSIOL-LONDON, V598, P3645, DOI 10.1113/JP279866; Budini F, 2019, J MUSCULOSKEL NEURON, V19, P30; Budini F, 2017, EXP PHYSIOL, V102, P901, DOI 10.1113/EP086374; Ce E, 2018, SCAND J MED SCI SPOR, V28, P2443, DOI 10.1111/sms.13240; Ce E, 2020, MED SCI SPORT EXER, V52, P1294, DOI 10.1249/MSS.0000000000002255; Ce E, 2015, J ELECTROMYOGR KINES, V25, P469, DOI 10.1016/j.jelekin.2015.03.001; Cohen HS, 2019, J NEUROPHYSIOL, V122, P81, DOI 10.1152/jn.00819.2018; Cohen J., 2013, STAT POWER ANAL BEHA; Costa PB, 2009, J STRENGTH COND RES, V23, P141, DOI 10.1519/JSC.0b013e31818eb052; Esposito F, 2016, NEUROMUSCULAR DISORD, V26, P60, DOI 10.1016/j.nmd.2015.09.013; Esposito F, 2011, J ELECTROMYOGR KINES, V21, P795, DOI 10.1016/j.jelekin.2011.07.012; Esposito F, 2011, EUR J APPL PHYSIOL, V111, P485, DOI 10.1007/s00421-010-1659-4; Handrakis JP, 2010, J STRENGTH COND RES, V24, P825, DOI 10.1519/JSC.0b013e3181ad4f89; Hemmati L, 2016, ANN REHABIL MED-ARM, V40, P845, DOI 10.5535/arm.2016.40.5.845; Hermens H. J., 1999, ROESSINGH RES DEV, V8, P13, DOI DOI 10.1016/S1050-6411(00)00027-4; Hrysomallis C, 2011, SPORTS MED, V41, P221, DOI 10.2165/11538560-000000000-00000; Lee IC, 2018, GAIT POSTURE, V59, P117, DOI 10.1016/j.gaitpost.2017.09.014; Lewis NL, 2009, ARCH PHYS MED REHAB, V90, P454, DOI 10.1016/j.apmr.2008.09.570; Lima BN, 2014, J SPORT SCI MED, V13, P564; Longo S, 2014, EXP PHYSIOL, V99, P1359, DOI 10.1113/expphysiol.2014.080366; Magnusson SP, 1996, J PHYSIOL-LONDON, V497, P291, DOI 10.1113/jphysiol.1996.sp021768; Nelson AG, 2012, J STRENGTH COND RES, V26, P3095, DOI 10.1519/JSC.0b013e3182430185; Palmer TB, 2018, PHYSICIAN SPORTSMED, V46, P78, DOI 10.1080/00913847.2018.1421396; Paneroni M, 2020, SPORT SCI HLTH, DOI [10.1007/s11332-020-00694-8, DOI 10.1007/S11332-020-00694-8]; Pulverenti TS, 2020, J NEUROPHYSIOL, V123, P1896, DOI 10.1152/jn.00578.2019; Pulverenti TS, 2019, EUR J APPL PHYSIOL, V119, P2287, DOI 10.1007/s00421-019-04212-8; Rey MCB, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00631; Sung ES, 2018, J EXERC REHABIL, V14, P638, DOI 10.12965/jer.1836266.133; Trajano GS, 2017, SPORTS MED, V47, P1531, DOI 10.1007/s40279-017-0682-6; Venturelli M, 2019, J APPL PHYSIOL, V127, P376, DOI 10.1152/japplphysiol.00823.2018; Venturelli M, 2017, J APPL PHYSIOL, V122, P112, DOI 10.1152/japplphysiol.00721.2016; WIESENDANGER R, 1985, EXP BRAIN RES, V59, P105	35	1	1	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2021	16	9							e0256656	10.1371/journal.pone.0256656	http://dx.doi.org/10.1371/journal.pone.0256656			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YS4WS	34550984	gold, Green Published, Green Submitted			2023-01-03	WOS:000750679800006
J	Makker, V; Colombo, N; Herraez, AC; Santin, A; Colomba, E; Miller, DS; Fujiwara, K; Pignata, S; Baron, H; Ray, OQAR; Shapira, RROE; Ushijima, K; Sakata, J; Yonemori, K; Kim, YM; Guerra, E; Sanli, A; McCormack, MM; Smith, A; Keefe, S; Bird, S; Dutta, L; Orlowski, R; Lorusso, D				Makker, V; Colombo, N.; Casado Herraez, A.; Santin, A. D.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Baron-Hay, S.; Ray-Coquard, I; Shapira-Frommer, R.; Ushijima, K.; Sakata, J.; Yonemori, K.; Kim, Y. M.; Guerra, E. M.; Sanli, U. A.; McCormack, M. M.; Smith, A. D.; Keefe, S.; Bird, S.; Dutta, L.; Orlowski, R. J.; Lorusso, D.		Study 309 KEYNOTE-775 Investigator	Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II; OPEN-LABEL; COMBINATION; MULTICENTER; CARCINOMA; EFFICACY; SAFETY; TRIAL; WOMEN	BACKGROUND Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously received at least one platinum-based chemotherapy regimen to receive either lenvatinib (20 mg, administered orally once daily) plus pembrolizumab (200 mg, administered intravenously every 3 weeks) or chemotherapy of the treating physician's choice (doxorubicin at 60 mg per square meter of body-surface area, administered intravenously every 3 weeks, or paclitaxel at 80 mg per square meter, administered intravenously weekly [with a cycle of 3 weeks on and 1 week off]). The two primary end points were progression-free survival as assessed on blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1, and overall survival. The end points were evaluated in patients with mismatch repair-proficient (pMMR) disease and in all patients. Safety was also assessed. RESULTS A total of 827 patients (697 with pMMR disease and 130 with mismatch repair-deficient disease) were randomly assigned to receive lenvatinib plus pembrolizumab (411 patients) or chemotherapy (416 patients). The median progression-free survival was longer with lenvatinib plus pembrolizumab than with chemotherapy (pMMR population: 6.6 vs. 3.8 months; hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.50 to 0.72; P<0.001; overall: 7.2 vs. 3.8 months; hazard ratio, 0.56; 95% CI, 0.47 to 0.66; P<0.001). The median overall survival was longer with lenvatinib plus pembrolizumab than with chemotherapy (pMMR population: 17.4 vs. 12.0 months; hazard ratio for death, 0.68; 95% CI, 0.56 to 0.84; P<0.001; overall: 18.3 vs. 11.4 months; hazard ratio, 0.62; 95% CI, 0.51 to 0.75; P<0.001). Adverse events of grade 3 or higher occurred in 88.9% of the patients who received lenvatinib plus pembrolizumab and in 72.7% of those who received chemotherapy. CONCLUSIONS Lenvatinib plus pembrolizumab led to significantly longer progression-free survival and overall survival than chemotherapy among patients with advanced endometrial cancer.	[Makker, V] Mem Sloan Kettering Canc Ctr, Dept Med, Weill Cornell Med Ctr, St 5, New York, NY 10065 USA; [Colombo, N.] Univ Milano Bicocca, European Inst Oncol IRCCS, Milan, Italy; [Pignata, S.] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy; [Lorusso, D.] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy; [Lorusso, D.] Univ Cattolica Sacro Cuore, Rome, Italy; [Casado Herraez, A.] San Carlos Univ Teaching Hosp, Madrid, Spain; [Guerra, E. M.] Hosp Univ Ramon y Cajal, Madrid, Spain; [Santin, A. D.] Yale Univ, Sch Med, New Haven, CT USA; [Colomba, E.] Gustave Roussy Cancerol Inst, Grp Investigateurs Nationaux Etud Canc Ovariens G, Villejuif, France; [Ray-Coquard, I] Univ Claude Bernard, Ctr Leon Berard, GLNECO, Lyon, France; [Miller, D. S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Fujiwara, K.] Saitama Med Univ, Int Med Ctr, Hidaka, Japan; [Ushijima, K.] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan; [Sakata, J.] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan; [Yonemori, K.] Natl Canc Ctr, Kokuritsu Gan Kenkyu Ctr Chuo Byoin, Tokyo, Japan; [Baron-Hay, S.] Royal North Shore Hosp, St Leonards, NSW, Australia; [Shapira-Frommer, R.] Sheba Med Ctr, Ramat Gan, Israel; [Kim, Y. M.] Univ Ulsan, Asan Med Ctr, Seoul, South Korea; [Sanli, U. A.] Ege Univ, Izmir, Turkey; [McCormack, M. M.] Univ Coll London Hosp NHS Fdn Trust, London, England; [Smith, A. D.] Eisai, Hatfield, Herts, England; [Keefe, S.; Bird, S.; Orlowski, R. J.] Merck, Kenilworth, NJ USA; [Dutta, L.] Eisai, Woodcliff Lake, NJ USA	Cornell University; Memorial Sloan Kettering Cancer Center; IRCCS European Institute of Oncology (IEO); University of Milano-Bicocca; IRCCS Fondazione Pascale; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Hospital Universitario Ramon y Cajal; Yale University; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; University of Texas System; University of Texas Southwestern Medical Center Dallas; Saitama Medical University; Kurume University; Aichi Cancer Center; National Cancer Center - Japan; Royal North Shore Hospital; Chaim Sheba Medical Center; University of Ulsan; Ege University; University College London Hospitals NHS Foundation Trust; University of London; University College London; Eisai Co Ltd; Merck & Company; Eisai Co Ltd	Makker, V (corresponding author), Mem Sloan Kettering Canc Ctr, 300 E 66th St, New York, NY 10065 USA.	makkerv@mskcc.org	de Melo, Andreia/C-8133-2019; Altundag, Ozden/W-9219-2019; Tarnawski, Rafal/N-7526-2016; Miller, David Scott/H-4604-2011	de Melo, Andreia/0000-0002-1201-4333; Altundag, Ozden/0000-0003-0197-6622; Tarnawski, Rafal/0000-0001-6802-5093; Miller, David Scott/0000-0002-8215-5887	Eisai; Merck Sharp and Dohme	Eisai(Eisai Co Ltd); Merck Sharp and Dohme(Merck & Company)	Supported by Eisai and Merck Sharp and Dohme, a subsidiary of Merck.	[Anonymous], 2021, KEYTRUDA PEMBROLIZUM; [Anonymous], 2020, LENVIMA LENVATINIB P; Bonneville R, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00073; Brooks RA, 2019, CA-CANCER J CLIN, V69, P258, DOI 10.3322/caac.21561; Brose MS, 2020, ANN ONCOL, V31, pS1409, DOI 10.1016/j.annonc.2020.10.418; Concin N, 2021, INT J GYNECOL CANCER, V31, P12, DOI 10.1136/ijgc-2020-002230; Emons G, 2016, GYNECOL ONCOL, V140, P450, DOI 10.1016/j.ygyno.2015.12.025; Heudel PE, 2017, BRIT J CANCER, V116, P303, DOI 10.1038/bjc.2016.430; How Jeffrey A, 2021, Gynecol Oncol, V162, P24, DOI 10.1016/j.ygyno.2021.04.034; Howlader NR, 2020, BREAST CANCER RES TR, V182, P739, DOI 10.1007/s10549-020-05738-8; Konecny GE, 2015, LANCET ONCOL, V16, P686, DOI 10.1016/S1470-2045(15)70159-2; Lorenzi M, 2020, J ONCOL, V2020, DOI 10.1155/2020/1807929; Lortet-Tieulent J, 2018, JNCI-J NATL CANCER I, V110, P354, DOI 10.1093/jnci/djx214; Makker V, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.02627; Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105; McMeekin S, 2015, GYNECOL ONCOL, V138, P18, DOI 10.1016/j.ygyno.2015.04.026; Miller DS, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.5503; Motzer RJ, 2015, LANCET ONCOL, V16, P1473, DOI 10.1016/S1470-2045(15)00290-9; National Comprehensive Cancer Network, CLIN PRACTICE GUIDEL; O'Malley D, 2019, ANN ONCOL, V30; Ott PA, 2017, J CLIN ONCOL, V35, P2535, DOI 10.1200/JCO.2017.72.5952; Oza AM, 2015, J CLIN ONCOL, V33, P3576, DOI 10.1200/JCO.2014.58.8871; Pal SK., 2020, INT KIDN CANC S IKCS, V18, P34; Pautier P, 2017, INT J GYNECOL CANCER, V27, P258, DOI 10.1097/IGC.0000000000000862; Prendergast EN, 2019, GYNECOL ONCOL, V154, P461, DOI 10.1016/j.ygyno.2019.06.016; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Schlumberger M, 2015, NEW ENGL J MED, V372, P621, DOI 10.1056/NEJMoa1406470; Soumerai TE, 2018, CLIN CANCER RES, V24, P5939, DOI 10.1158/1078-0432.CCR-18-0412; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Taylor M, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw373.4; Vale CL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003915.pub4; Vergote I TM, 2013, J CLIN ONCOL S, V31, P5520, DOI DOI 10.1200/jco.2013.31.15_suppl.5520; Vergote I, 2020, GYNECOL ONCOL, V156, P575, DOI 10.1016/j.ygyno.2019.12.039; Zhang S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01440	35	80	80	14	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2022	386	5					437	448		10.1056/NEJMoa2108330	http://dx.doi.org/10.1056/NEJMoa2108330		JAN 2022	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR1JU	35045221	Bronze			2023-01-03	WOS:000744900700001
J	Liston, C; Roberts, A; Dzirasa, K; Geschwind, D; Ahmari, SE; Luscher, C				Liston, Conor; Roberts, Angela; Dzirasa, Kafui; Geschwind, Dan; Ahmari, Susanne E.; Luscher, Christian			Understanding the biological basis of psychiatric disease: What's next	CELL			English	Editorial Material								Psychiatric disease is one of the greatest health challenges of our time. The pipeline for conceptually novel therapeutics remains low, in part because uncovering the biological mechanisms of psychiatric disease has been difficult. We asked experts researching different aspects of psychiatric disease: what do you see as the major urgent questions that need to be addressed? Where are the next frontiers, and what are the current hurdles to understanding the biological basis of psychiatric disease?	[Liston, Conor] Weill Cornell Med, New York, NY 10065 USA; [Roberts, Angela] Univ Cambridge, Cambridge, England; [Dzirasa, Kafui] Howard Hughes Med Inst, Chevy Chase, MD USA; [Dzirasa, Kafui] Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, Durham, NC 27706 USA; [Dzirasa, Kafui] Duke Univ, Dept Neurobiol, Med Ctr, Durham, NC 27706 USA; [Dzirasa, Kafui] Duke Univ, Dept Neurosurg, Med Ctr, Durham, NC 27706 USA; [Dzirasa, Kafui] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Geschwind, Dan] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Ahmari, Susanne E.] Wellcome Leap, Multichannel Psych, Los Angeles, CA USA; [Ahmari, Susanne E.] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Luscher, Christian] Univ Geneva, Dept Basic Neurosci, Geneva, Switzerland; [Luscher, Christian] Geneva Univ Hosp, Dept Clin Neurosci, Geneva, Switzerland	Cornell University; University of Cambridge; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; Duke University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Geneva; University of Geneva	Liston, C (corresponding author), Weill Cornell Med, New York, NY 10065 USA.		, Conor Liston/GQH-8931-2022; Dzirasa, Kafui/GQB-1424-2022						0	1	1	2	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 6	2022	185	1					1	3						3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	YL5FO	34995512				2023-01-03	WOS:000745916700001
J	Gottlieb, RL; Vaca, CE; Paredes, R; Mera, J; Webb, BJ; Perez, G; Oguchi, G; Ryan, P; Nielsen, BU; Brown, M; Hidalgo, A; Sachdeva, Y; Mittal, S; Osiyemi, O; Skarbinski, J; Juneja, K; Hyland, RH; Osinusi, A; Chen, S; Camus, G; Abdelghany, M; Davies, S; Behenna-Renton, N; Duff, F; Marty, FM; Katz, MJ; Ginde, AA; Brown, SM; Schiffer, JT; Hill, JA				Gottlieb, R. L.; Vaca, C. E.; Paredes, R.; Mera, J.; Webb, B. J.; Perez, G.; Oguchi, G.; Ryan, P.; Nielsen, B. U.; Brown, M.; Hidalgo, A.; Sachdeva, Y.; Mittal, S.; Osiyemi, O.; Skarbinski, J.; Juneja, K.; Hyland, R. H.; Osinusi, A.; Chen, S.; Camus, G.; Abdelghany, M.; Davies, S.; Behenna-Renton, N.; Duff, F.; Marty, F. M.; Katz, M. J.; Ginde, A. A.; Brown, S. M.; Schiffer, J. T.; Hill, J. A.		GS-US-540-9012 PINETREE Investigat	Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLUENZA	BACKGROUND Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for disease progression prevents hospitalization is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving non-hospitalized patients with Covid-19 who had symptom onset within the previous 7 days and who had at least one risk factor for disease progression (age >= 60 years, obesity, or certain coexisting medical conditions). Patients were randomly assigned to receive intravenous remdesivir (200 mg on day 1 and 100 mg on days 2 and 3) or placebo. The primary efficacy end point was a composite of Covid-19-related hospitalization or death from any cause by day 28. The primary safety end point was any adverse event. A secondary end point was a composite of a Covid-19-related medically attended visit or death from any cause by day 28. RESULTS A total of 562 patients who underwent randomization and received at least one dose of remdesivir or placebo were included in the analyses: 279 patients in the remdesivir group and 283 in the placebo group. The mean age was 50 years, 47.9% of the patients were women, and 41.8% were Hispanic or Latinx. The most common coexisting conditions were diabetes mellitus (61.6%), obesity (55.2%), and hypertension (47.7%). Covid-19-related hospitalization or death from any cause occurred in 2 patients (0.7%) in the remdesivir group and in 15 (5.3%) in the placebo group (hazard ratio, 0.13; 95% confidence interval [CI], 0.03 to 0.59; P=0.008). A total of 4 of 246 patients (1.6%) in the remdesivir group and 21 of 252 (8.3%) in the placebo group had a Covid-19-related medically attended visit by day 28 (hazard ratio, 0.19; 95% CI, 0.07 to 0.56). No patients had died by day 28. Adverse events occurred in 42.3% of the patients in the remdesivir group and in 46.3% of those in the placebo group. CONCLUSIONS Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo.	[Gottlieb, R. L.] Baylor Univ, Med Ctr, Dallas, TX 75246 USA; [Gottlieb, R. L.] Baylor Scott & White Res Inst, Dallas, TX USA; [Mittal, S.] Care United Res, Forney, TX USA; [Vaca, C. E.] Nuren Med & Res Ctr, Miami, FL USA; [Perez, G.] Evolut Clin Trials, Hialeah Gardens, FL USA; [Oguchi, G.] Midland Florida Clin Res Ctr, Deland, FL USA; [Hidalgo, A.] Luminous Clin Res South Florida Urgent Care, Pembroke Pines, FL USA; [Osiyemi, O.] Triple O Res Inst Profess Assoc, W Palm Beach, FL USA; [Paredes, R.] Hosp Univ Germans Trias I Pujol, Barcelona, Spain; [Paredes, R.] IrsiCaixa AIDS Res Inst, Barcelona, Spain; [Ryan, P.] Hosp Univ Infanta Leonor, Madrid, Spain; [Ryan, P.] Gregorio Maranon Hlth Res Inst, Madrid, Spain; [Mera, J.] Cherokee Nat Outpatient Hlth Ctr, Tahlequah, OK USA; [Webb, B. J.; Brown, S. M.] Intermt Healthcare, Murray, KY USA; [Brown, S. M.] Univ Utah, Sch Med, Murray, KY USA; [Nielsen, B. U.] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark; [Brown, M.] Univ Coll London Hosp NHS Fdn Trust, London, England; [Brown, M.] London Sch Hyg & Trop Med, London, England; [Sachdeva, Y.] Inst Liver Hlth, Mesa, AZ USA; [Skarbinski, J.] Kaiser Permanente, Oakland, CA USA; [Juneja, K.; Hyland, R. H.; Osinusi, A.; Chen, S.; Camus, G.; Abdelghany, M.; Davies, S.; Behenna-Renton, N.; Duff, F.] Gilead Sci, Foster City, CA USA; [Marty, F. M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Marty, F. M.] Harvard Med Sch, Boston, MA 02115 USA; [Katz, M. J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Ginde, A. A.] Univ Colorado, Sch Med, Aurora, CO USA; [Schiffer, J. T.; Hill, J. A.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Schiffer, J. T.; Hill, J. A.] Univ Washington, Sch Med, Seattle, WA USA	Baylor University; Baylor University Medical Center; Baylor Health Care System; Baylor University Medical Center; Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa; Hospital Universitario Infanta Leonor; Utah System of Higher Education; University of Utah; Rigshospitalet; University of Copenhagen; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; Kaiser Permanente; Gilead Sciences; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Johns Hopkins University; University of Colorado System; University of Colorado Anschutz Medical Campus; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Gottlieb, RL (corresponding author), Baylor Univ, Med Ctr, Ctr Adv Heart & Lung Dis, 3410 Worth St,Ste 250, Dallas, TX 75246 USA.	robert.gottlieb@bswhealth.org	Ryan, Pablo/AAM-1924-2021; Gottlieb, Robert/AAM-8310-2020; RYAN, PABLO/GRF-3462-2022	Ryan, Pablo/0000-0002-4212-7419; Gottlieb, Robert/0000-0001-8376-8709; RYAN, PABLO/0000-0002-4212-7419; Mccann, Naina/0000-0001-5864-1175; Carroll, Samantha/0000-0003-2135-4361; Mateu, Lourdes/0000-0001-7223-7611; Staerke, Nina Breinholt/0000-0002-5834-2033	Gilead Sciences	Gilead Sciences(Gilead Sciences)	Supported by Gilead Sciences.	Ader Florence, 2022, Lancet Infect Dis, V22, P209, DOI 10.1016/S1473-3099(21)00485-0; [Anonymous], 2020, WHO DIR GEN OP REM M; [Anonymous], 2021, COVID 19 DEV DRUGS B; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cevik M, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3862; Chen RE, 2021, NATURE, V596, P103, DOI 10.1038/s41586-021-03720-y; Dougan M, 2021, NEW ENGL J MED, V385, P1382, DOI 10.1056/NEJMoa2102685; Du Pont V., 2021, INT SOC INFL OTH RES; Fintzi J, 2022, CLIN INFECT DIS, V74, P2209, DOI 10.1093/cid/ciab712; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Marin BG, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2146; Mozaffari E, 2022, CLIN INFECT DIS, V75, pE450, DOI 10.1093/cid/ciab875; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Muthuri SG, 2014, LANCET RESP MED, V2, P395, DOI 10.1016/S2213-2600(14)70041-4; Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1; Pizzorno A, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100059; Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653; Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2; Wang D, 2020, J AEROSPACE ENG, V33, DOI 10.1061/(ASCE)AS.1943-5525.0001149; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Williamson BN, 2020, NATURE, V585, P273, DOI 10.1038/s41586-020-2423-5; Won, 2021, THERAPEUTIC EFFICACY, DOI [10.1101/2021.09.13.460111v3, DOI 10.1101/2021.09.13.460111V3]; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737	29	273	274	14	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2022	386	4					305	315		10.1056/NEJMoa2116846	http://dx.doi.org/10.1056/NEJMoa2116846		DEC 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW6UB	34937145	Green Published, Bronze			2023-01-03	WOS:000732955300001
J	Sampaio, F; Nogueira, P; Ascencao, R; Henriques, A; Costa, A				Sampaio, Filipa; Nogueira, Paulo; Ascencao, Raquel; Henriques, Adriana; Costa, Andreia			The epidemiology of falls in Portugal: An analysis of hospital admission data	PLOS ONE			English	Article							RISK-FACTORS; OLDER-PEOPLE; BURDEN; INJURIES	Background Falls are a common cause of injury and pose an increased risk of morbidity, mortality, and lifelong disability. Falls encompass a troublesome definition and can pose challenges in epidemiological studies. Data on fall-related hospital admissions in Portugal remain unpublished. This study aimed to examine the epidemiology of fall-related hospital admissions in the Portuguese population between 2010 and 2018. It also aimed to examine annual rates of fall-related hospital admissions using three methodological approaches. Methods The Portuguese Hospital Morbidity Database was used to identify all cases resulting in one or more inpatient admission in public hospitals related to falls from 2010 to 2018. Fall-related hospital admissions were described by age groups, sex, geographical area of residence, and type of fall. Annual rates were computed using three approaches: i) based on the number of inpatient admissions with an ICD code of fall, ii) based on the number of patients admitted to inpatient care with an ICD code of fall, and iii) based on the number of inpatient admissions with a principal diagnosis of injury. Results Between 2010 and 2018, 383,016 fall-related admissions occurred in 344,728 patients, corresponding to 2.1% of the total number of hospitalizations during the same period. Higher rates were seen among the younger (20-25) and the oldest age groups (+85), males until the age of 60, females from the age of 60, and areas of residence with a higher aging index. An overall rate of falls per 100,000 population was estimated at 414 (based on number of admissions), 373 (based on number of patients) and 353 (based on number of admissions with a principal diagnosis of injury). Conclusions This study provides an overall picture of the landscape of falls in a scarcely explored setting. The results aim to contribute to identifying appropriate preventive interventions and policies for these populations.	[Sampaio, Filipa] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden; [Nogueira, Paulo; Henriques, Adriana; Costa, Andreia] Univ Lisbon, Fac Med, Inst Saude Ambiental ISAMB, Lisbon, Portugal; [Nogueira, Paulo; Ascencao, Raquel] Univ Lisbon, Fac Med, Inst Med Prevent & Saude Publ, Lisbon, Portugal; [Nogueira, Paulo] Univ Lisbon, Fac Med, Area Disciplinar Autonoma Bioestat, Lab Biomatemat, Lisbon, Portugal; [Nogueira, Paulo; Henriques, Adriana; Costa, Andreia] Nursing Sch Lisbon, Nursing Res Innovat & Dev Ctr Lisbon CIDNUR, Lisbon, Portugal; [Ascencao, Raquel] Univ Lisbon, Fac Med, Ctr Estudos Med Baseada Evidencia, Lisbon, Portugal; [Ascencao, Raquel] Inst Politecn Lisboa, Escola Super Tecnol Saude, Lisbon, Portugal	Uppsala University; Universidade de Lisboa; Universidade de Lisboa; Universidade de Lisboa; Universidade de Lisboa; Polytechnic Institute of Lisbon	Sampaio, F (corresponding author), Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden.	filipa.sampaio@pubcare.uu.se	Nogueira, Paulo/HDL-7482-2022; Nogueira, Paulo Jorge/AAR-5605-2020; Henriques, Maria Adriana/ABA-9541-2020	Nogueira, Paulo Jorge/0000-0001-8316-5035; Henriques, Maria Adriana/0000-0003-0288-6653; Costa, Andreia/0000-0002-2727-4402; Sampaio, Filipa/0000-0002-5540-9853	FCT; FEDER [01/SAICT/2016, 022153]	FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); FEDER(European Commission)	The author Paulo Nogueira received computational support of INCD - Instituto Nacional de Computacao Distribuida - which is funded by FCT and FEDER under the project 01/SAICT/2016 No. 022153. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9; Alves T., 2017, ACIDENTES DOMESTICOS; Alves T, 2019, FALLS OLDER PEOPLE D; [Anonymous], 2013, FALLS ASSESSMENT PRE; Chang AY, 2019, LANCET PUBLIC HEALTH, V4, pE159, DOI 10.1016/S2468-2667(19)30019-2; Cheng PX, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15030498; Deandrea S, 2010, EPIDEMIOLOGY, V21, P658, DOI 10.1097/EDE.0b013e3181e89905; Ek S, 2019, J AM GERIATR SOC, V67, P246, DOI 10.1111/jgs.15657; Gale CR, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0806-3; Gale CR, 2016, AGE AGEING, V45, P789, DOI 10.1093/ageing/afw129; James SL, 2020, INJURY PREV, V26, P3, DOI 10.1136/injuryprev-2019-043286; Kusljic S, 2018, EXP AGING RES, V44, P221, DOI 10.1080/0361073X.2018.1449588; Marques AJ, 2019, ACTA REUMATOL PORT, V44, P288; OECD, 2019, PROM HLTH AG BACKGR; Paul SS, 2017, PUBLIC HEALTH RES PR, V27, DOI 10.17061/phrp27341701; Peel NM, 2002, INJ PREV, V8, P280, DOI 10.1136/ip.8.4.280; Polinder S, 2012, BRIT J SURG, V99, P114, DOI 10.1002/bjs.7708; R Core Team Rf.., 2013, R LANG ENV STAT COMP; Rubenstein LZ, 2006, AGE AGEING, V35, P37, DOI 10.1093/ageing/afl084; Simoes JD, 2017, HEALT SYST TRANSIT, V19, P1; Statistics Portugal [Instituto Nacional de Estatistica], RES POP; Stevens JA, 2005, INJURY PREV, V11, P115, DOI 10.1136/ip.2004.005835; The Directorate-General of Health of Portugal [Direcao-Geral da Saude], 2017, ESTRATEGIA NACL ENVE; Wadman MC, 2003, ANN EMERG MED, V42, P468, DOI 10.1067/S0196-0644(03)00489-X; Wei Feifei, 2014, J Gerontol Geriatr Res, V3, P152; WHO, 2007, WHO GLOB REP FALLP	27	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2021	16	12							e0261456	10.1371/journal.pone.0261456	http://dx.doi.org/10.1371/journal.pone.0261456			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ1OD	34936669	Green Published, gold			2023-01-03	WOS:000755251000035
J	Hedlin, M				Hedlin, Margot			The Web We Weave	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Hedlin, Margot] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Hedlin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.							Gomez-Virseda C, 2020, BMC MED ETHICS, V21, DOI 10.1186/s12910-020-00495-1; Nedelsky J, 1989, YALE J L FEMINISM, V1	2	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2021	385	23					2119	2121		10.1056/NEJMp2109820	http://dx.doi.org/10.1056/NEJMp2109820		NOV 2021	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YE4VC	34890501				2023-01-03	WOS:000722950800001
J	Jang, HW; An, JH; Kim, KB; Lee, JH; Oh, YI; Park, SM; Chae, HK; Youn, HY				Jang, Hee-Won; An, Ju-Hyun; Kim, Kyeong Bo; Lee, Jeong-Hwa; Oh, Ye-In; Park, Su-Min; Chae, Hyung-Kyu; Youn, Hwa-Young			Canine peripheral blood mononuclear cell-derived B lymphocytes pretreated with lipopolysaccharide enhance the immunomodulatory effect through macrophage polarization	PLOS ONE			English	Article							T-CELLS; IL-10; RESPONSES; MODEL	Background Preconditioning with lipopolysaccharide (LPS) is used to improve the secretion of anti-inflammatory agents in B cells. However, there are only a few studies on canine B cells. Objective This study aimed to evaluate the immune regulatory capacity of canine peripheral blood mononuclear cell-derived B cells pretreated with LPS. Methods Canine B cells were isolated from canine peripheral blood mononuclear cells, which were obtained from three healthy canine donors. The B cells were preconditioned with LPS, and then cell viability and the expression of the regulatory B cell marker were assessed. Finally, RNA extraction and immunofluorescence analysis were performed. Results LPS primed B cells expressed the interleukin (IL)-10 surface marker and immunoregulatory gene expression, such as IL-10, programmed death-ligand 1, and transforming growth factor beta. Macrophages in the inflammatory condition cocultured with primed B cells were found to have significantly down-regulated pro-inflammatory cytokine, such as tumor necrosis factor-alpha, and up-regulated anti-inflammatory cytokines such as IL-10. Additionally, it was revealed that co-culture with primed B cells re-polarized M1 macrophages to M2 macrophages. Conclusions This study revealed that LPS-primed B cells have an anti-inflammatory effect and can repolarize macrophages, suggesting the possibility of using LPS-primed B cells as a therapeutic agent for its anti-inflammatory effects and immune modulation.	[Jang, Hee-Won; An, Ju-Hyun; Kim, Kyeong Bo; Lee, Jeong-Hwa; Oh, Ye-In; Park, Su-Min; Chae, Hyung-Kyu; Youn, Hwa-Young] Seoul Natl Univ, Coll Vet Med, Dept Vet Clin Sci, Lab Vet Internal Med, Seoul, South Korea	Seoul National University (SNU)	Youn, HY (corresponding author), Seoul Natl Univ, Coll Vet Med, Dept Vet Clin Sci, Lab Vet Internal Med, Seoul, South Korea.	hyyoun@snu.ac.kr		-Lee, Jeong-Hwa/0000-0003-1716-8152; Kim, Kyeongbo/0000-0002-2356-1965; Youn, Hwa-Young/0000-0002-0283-1348	Research Institute for Veterinary Science, Seoul National University	Research Institute for Veterinary Science, Seoul National University	This study was supported by the Research Institute for Veterinary Science, Seoul National University. The fund contributed to the collection, analysis, and interpretation of data generated in this study.	Banko Z, 2017, J IMMUNOL, V198, P1512, DOI 10.4049/jimmunol.1600218; Bouaziz JD, 2008, IMMUNOL REV, V224, P201, DOI 10.1111/j.1600-065X.2008.00661.x; Burdin N, 1997, METHODS, V11, P98, DOI 10.1006/meth.1996.0393; Cao J, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-6314; CASSELL DJ, 1994, J EXP MED, V180, P1829, DOI 10.1084/jem.180.5.1829; Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366; Davis MJ, 2013, MBIO, V4, DOI 10.1128/mBio.00264-13; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; Geng YY, 2020, CHEM SCI, V11, P8231, DOI 10.1039/d0sc02792h; Guan HG, 2016, SCI REP-UK, V6, DOI 10.1038/srep35651; Hartley G, 2017, VET COMP ONCOL, V15, P534, DOI 10.1111/vco.12197; Hu GR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01998; Jain S, 2015, BIOMATERIALS, V61, P162, DOI 10.1016/j.biomaterials.2015.05.028; Ju-Hyun A., 2020, SCI REPORTS NATURE P, V10; Jung YC, 2014, IMMUNOPHARM IMMUNOT, V36, P426, DOI 10.3109/08923973.2014.968257; Kambara K, 2015, AM J PATHOL, V185, P162, DOI 10.1016/j.ajpath.2014.09.005; Kang JW, 2008, STEM CELLS DEV, V17, P681, DOI 10.1089/scd.2007.0153; Kim M, 2016, J VET MED SCI, V78, P619, DOI 10.1292/jvms.15-0361; Klar AS, 2018, PEDIATR SURG INT, V34, P129, DOI 10.1007/s00383-017-4179-z; Lee KM, 2014, EUR J IMMUNOL, V44, P1728, DOI 10.1002/eji.201344062; Li Q, 2017, IN VIVO, V31, P349, DOI 10.21873/invivo.11066; Lopes RL, 2016, CYTOKINE, V85, P123, DOI 10.1016/j.cyto.2016.06.018; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; Mauri C, 2017, J CLIN INVEST, V127, P772, DOI 10.1172/JCI85113; Minguet S, 2008, EUR J IMMUNOL, V38, P2475, DOI 10.1002/eji.200738094; Mizoguchi E, 2000, INT IMMUNOL, V12, P597, DOI 10.1093/intimm/12.5.597; Mobarak E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31926-0; Moore DK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213832; Mount NM, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2015.0017; Murphy K., 2016, JANEWAYS IMMUNOBIOLO, DOI DOI 10.1201/9781315533247; Oberholzer A, 2002, CRIT CARE MED, V30, pS58, DOI 10.1097/00003246-200201001-00008; Parekh VV, 2003, J IMMUNOL, V170, P5897, DOI 10.4049/jimmunol.170.12.5897; Park SM, 2020, VET IMMUNOL IMMUNOP, V219, DOI 10.1016/j.vetimm.2019.109973; Ponzoni M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071953; Salih Sarmad Ali, 2014, Fisheries and Aquatic Sciences, V17, P27, DOI 10.5657/FAS.2014.0027; Siewe B, 2013, J LEUKOCYTE BIOL, V93, P811, DOI 10.1189/jlb.0912436; Song R, 2012, VET IMMUNOL IMMUNOP, V146, P143, DOI 10.1016/j.vetimm.2012.02.008; Soukou Shiwa, 2018, Crit Rev Immunol, V38, P415, DOI 10.1615/CritRevImmunol.2018026850; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Tripathy A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01033-7; Wu JJ, 2019, INT IMMUNOPHARMACOL, V68, P218, DOI 10.1016/j.intimp.2018.12.066; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Xu H, 2008, IMMUNOLOGY, V125, P218, DOI 10.1111/j.1365-2567.2008.02832.x; Yao MY, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118658	45	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2021	16	11							e0256651	10.1371/journal.pone.0256651	http://dx.doi.org/10.1371/journal.pone.0256651			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ6IU	34807933	gold, Green Published			2023-01-03	WOS:000755579000002
J	Du, XL; Simpson, LM; Tandy, BC; Bettencourt, JL; Davis, BR				Du, Xianglin L.; Simpson, Lara M.; Tandy, Brian C.; Bettencourt, Judith L.; Davis, Barry R.			Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker	PLOS ONE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONVERTING ENZYME-INHIBITOR; LIPID-LOWERING TREATMENT; LOW-DOSE ASPIRIN; ANTIHYPERTENSIVE DRUGS; OLDER PATIENTS; SYSTOLIC HYPERTENSION; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; NIFEDIPINE GITS	Objectives This post-trial data linkage analysis was to utilize the data of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants linked with their Medicare data to examine the risk of hospitalized and non-hospitalized gastrointestinal (GI) bleeding associated with antihypertensives. Settings ALLHAT was a multicenter, randomized, double-blind, active-controlled trial conducted in a total of 42,418 participants aged >= 55 years with hypertension in 623 North American centers. Data for ALLHAT participants who were aged at >= 65 have been linked with their Medicare claims data. Participants A total of 16,676 patients (4,480 for lisinopril, 4,537 for amlodipine, and 7,659 for chlorthalidone) with complete Medicare claims data were available for the final analysis. Results The cumulative incidences through March 31, 2002 of hospitalized GI bleeding were 5.4%, 5.8% and 5.4% for amlodipine, lisinopril, and chlorthalidone arms, respectively, but were not statistically significant among the 3 arms after adjusting for confounders in Cox regression models. The cumulative incidences of non-hospitalized GI bleeding were also similar across the 3 arms (12.0%, 12.2% and 12.0% for amlodipine, lisinopril, and chlorthalidone, respectively). The increased risk of GI bleeding by age was statistically significant after adjusting for confounders (HR = 1.04 per year, 95% CI: 1.03-1.05). Smokers also had a significantly higher risk of having hospitalized GI bleeding (1.45, 1.19-1.76). Hispanics, those who used aspirin or atenolol in-trial, had diabetes, more education, and a history of stroke had a significantly lower risk of having GI bleeding than their counterparts. Other factors such as gender, history of CHD, prior antihypertensive use, use of estrogen in women, and obesity did not have significant effects on the risk of GI bleeding. Conclusion There were no statistically significant differences on the risk of hospitalized or non-hospitalized GI bleeding among the 3 ALLHAT trial arms (amlodipine, lisinopril, and chlorthalidone) during the entire in-trial follow-up.	[Du, Xianglin L.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA; [Simpson, Lara M.; Tandy, Brian C.; Bettencourt, Judith L.; Davis, Barry R.] Univ Texas Hlth Sci Ctr Houston, Coordinating Ctr Clin Trials, Sch Publ Hlth, Dept Biostat & Data Sci, Houston, TX USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	Du, XL (corresponding author), Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.	Xianglin.L.Du@uth.tmc.edu			National Institutes of Health (NIH) [R01AG058971]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by the National Institutes of Health (NIH) grant Number R01AG058971 (PI: Dr. Du; Co-I's: Dr. Davis and Dr. Simpson). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Black HR, 2003, JAMA-J AM MED ASSOC, V289, P2073, DOI 10.1001/jama.289.16.2073; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Celis H, 2001, J HUM HYPERTENS, V15, P613, DOI 10.1038/sj.jhh.1001235; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; He Y, 2015, ALIMENT PHARM THER, V41, P1246, DOI 10.1111/apt.13211; Jansen A, 2009, WORLD J GASTROENTERO, V15, P457, DOI 10.3748/wjg.15.457; Kaplan RC, 2000, ARCH INTERN MED, V160, P1849, DOI 10.1001/archinte.160.12.1849; Kaplan RC, 2002, AGE AGEING, V31, P217, DOI 10.1093/ageing/31.3.217; Kelly JP, 1999, LANCET, V353, P559, DOI 10.1016/S0140-6736(98)05202-7; Lanas A, 2003, EUR J GASTROEN HEPAT, V15, P173, DOI 10.1097/00042737-200302000-00011; Leenen FHH, 2006, HYPERTENSION, V48, P374, DOI 10.1161/01.HYP.0000231662.77359.de; Nagata N, 2015, J GASTROEN HEPATOL, V30, P292, DOI 10.1111/jgh.12805; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PETRUK KC, 1988, J NEUROSURG, V68, P505, DOI 10.3171/jns.1988.68.4.0505; Phillips W, 2013, J CLIN HYPERTENS, V15, P825, DOI 10.1111/jch.12180; Pilotto A, 1996, LANCET, V347, P1761; Poole-Wilson PA, 2006, CARDIOVASC DRUG THER, V20, P45, DOI 10.1007/s10557-006-6312-4; Rodriguez LAG, 1998, ARCH INTERN MED, V158, P33, DOI 10.1001/archinte.158.1.33; Rosei EA, 1997, J HYPERTENS, V15, P1337, DOI 10.1097/00004872-199715110-00019; Smalley WE, 1998, AM J EPIDEMIOL, V148, P350; Staessen JA, 1998, ARCH INTERN MED, V158, P1681, DOI 10.1001/archinte.158.15.1681; Staessen JA, 2001, SAMJ S AFR MED J, V91, P1060; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Suh Seungchul, 2012, Korean J Gastroenterol, V60, P349; Suissa S, 1998, AM J MED, V105, P230, DOI 10.1016/S0002-9343(98)00239-3; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; Weil J, 2000, GUT, V46, P27, DOI 10.1136/gut.46.1.27; Yamada A, 2008, DIS COLON RECTUM, V51, P116, DOI 10.1007/s10350-007-9137-8; Zuccala G, 2000, CLIN PHARMACOL THER, V67, P314, DOI 10.1067/mcp.2000.104787	32	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2021	16	11							e0260107	10.1371/journal.pone.0260107	http://dx.doi.org/10.1371/journal.pone.0260107			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2NY	34793552	Green Published, gold			2023-01-03	WOS:000755319200099
J	Aggarwal, AN; Agarwal, R; Dhooria, S; Prasad, KT; Sehgal, IS; Muthu, V				Aggarwal, Ashutosh Nath; Agarwal, Ritesh; Dhooria, Sahajal; Prasad, Kuruswamy Thurai; Sehgal, Inderpaul Singh; Muthu, Valliappan			Active pulmonary tuberculosis and coronavirus disease 2019: A systematic review and meta-analysis	PLOS ONE			English	Review							RISK-FACTORS; CAPE-TOWN; COVID-19; HIV; COMORBIDITIES; PREVALENCE; CONFIDENCE; MORTALITY; CHILDREN; DEATHS	Objective The proportion of COVID-19 patients having active pulmonary tuberculosis, and its impact on COVID-19 related patient outcomes, is not clear. We conducted this systematic review to evaluate the proportion of patients with active pulmonary tuberculosis among COVID-19 patients, and to assess if comorbid pulmonary tuberculosis worsens clinical outcomes in these patients. Methods We queried the PubMed and Embase databases for studies providing data on (a) proportion of COVID-19 patients with active pulmonary tuberculosis or (b) severe disease, hospitalization, or mortality among COVID-19 patients with and without active pulmonary tuberculosis. We calculated the proportion of tuberculosis patients, and the relative risk (RR) for each reported outcome of interest. We used random-effects models to summarize our data. Results We retrieved 3,375 citations, and included 43 studies, in our review. The pooled estimate for proportion of active pulmonary tuberculosis was 1.07% (95% CI 0.81%-1.36%). COVID-19 patients with tuberculosis had a higher risk of mortality (summary RR 1.93, 95% CI 1.56-2.39, from 17 studies) and for severe COVID-19 disease (summary RR 1.46, 95% CI 1.05-2.02, from 20 studies), but not for hospitalization (summary RR 1.86, 95% CI 0.91-3.81, from four studies), as compared to COVID-19 patients without tuberculosis. Conclusion Active pulmonary tuberculosis is relatively common among COVID-19 patients and increases the risk of severe COVID-19 and COVID-19-related mortality.	[Aggarwal, Ashutosh Nath; Agarwal, Ritesh; Dhooria, Sahajal; Prasad, Kuruswamy Thurai; Sehgal, Inderpaul Singh; Muthu, Valliappan] Postgrad Inst Med Educ & Res, Dept Pulm Med, Chandigarh, India	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh	Aggarwal, AN (corresponding author), Postgrad Inst Med Educ & Res, Dept Pulm Med, Chandigarh, India.	aggarwal.ashutosh@outlook.com	Sehgal, Inderpaul/GYE-2441-2022; Agarwal, Ritesh/A-3063-2009	Agarwal, Ritesh/0000-0003-2547-7668; Aggarwal, Ashutosh Nath/0000-0001-8556-3600				Abraha HE, 2021, INT J INFECT DIS, V105, P776, DOI 10.1016/j.ijid.2021.03.037; Al Kuwari HM, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-040428; Baujat B, 2002, STAT MED, V21, P2641, DOI 10.1002/sim.1221; Biswas M, 2021, INTERVIROLOGY, V64, P36, DOI 10.1159/000512592; Boulle A., 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1198, DOI 10.1093/CID/CIAA1198]; Chen TL, 2020, J GERONTOL A-BIOL, V75, P1788, DOI 10.1093/gerona/glaa089; Chen Yajuan, 2020, Journal of Third Military Medical University, V42, P549, DOI 10.16016/j.1000-5404.202002097; Chidambaram V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241541; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Dai M, 2020, INT J MED SCI, V17, P2653, DOI 10.7150/ijms.51159; Dave JA, 2021, DIABETES RES CLIN PR, V177, DOI 10.1016/j.diabres.2021.108925; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dorjee K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243191; du Bruyn E., MEDRXIV2021051121256, V2021, DOI [10.1101/2021.05.11.21256479, DOI 10.1101/2021.05.11.21256479]; Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Figliozzi S, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13362; FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756; Gajbhiye RK, 2021, INT J GYNECOL OBSTET, V153, P176, DOI 10.1002/ijgo.13588; Gao Y, 2021, J MED VIROL, V93, P194, DOI 10.1002/jmv.26311; Gupta N, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.03408-2020; Hesse R, 2021, ADV EXP MED BIOL, V1321, P183, DOI 10.1007/978-3-030-59261-5_16; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Himwaze CM, 2021, INT J INFECT DIS, V108, P363, DOI 10.1016/j.ijid.2021.06.013; Ibrahim OR, 2020, AM J TROP MED HYG, V103, P2376, DOI 10.4269/ajtmh.20-0759; Javanmardi F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241265; Kapoor D, 2021, INDIAN PEDIATR, V58, P572, DOI 10.1007/s13312-021-2244-0; Kumar MS, 2021, INT J TUBERC LUNG D, V25, P250, DOI 10.5588/ijtld.20.0947; Lagrutta L, 2021, MEDICINA-BUENOS AIRE, V81, P143; Lee SG, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17228559; Li GD, 2021, AGING-US, V13, P27, DOI 10.18632/aging.202456; Li SM, 2021, NEURAL COMPUT APPL, DOI 10.1007/s00521-020-05592-1; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Liberati A, 2009, PLOS MED, V6, DOI DOI 10.1186/s13643-016-0384-4; Liu J, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00706-3; Liu SJ., 2020, LAB MED, V35, P551; Lu YJ, 2021, ANN CLIN MICROB ANTI, V20, DOI 10.1186/s12941-020-00412-9; Maciel EL, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.1590/S1679-49742020000400022, 10.5123/S1679-49742020000400022]; Meng M, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06094-8; Mesas AE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241742; Mithal A, 2021, DIABETES METAB SYND, V15, P169, DOI 10.1016/j.dsx.2020.12.029; Moolla MS, 2021, SAMJ S AFR MED J, V111, P575, DOI [10.7196/samj.2021.v111i6.15590, 10.7196/SAMJ.2021.v111i6.15590]; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; Motta I, 2020, PULMONOLOGY, V26, P233, DOI 10.1016/j.pulmoe.2020.05.002; Mwananyanda L, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n334; Nachega JB, 2020, AM J TROP MED HYG, V103, P2419, DOI 10.4269/ajtmh.20-1240; Oh TK, 2021, BMC PULM MED, V21, DOI 10.1186/s12890-020-01387-1; Parker A, 2020, SAMJ S AFR MED J, V110, P982, DOI [10.7196/SAMJ.2020.v110i10.15067, 10.7196/samj.2020.v110i10.15067]; Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010; Petrone L, 2021, INT J INFECT DIS, V113, pS82, DOI 10.1016/j.ijid.2021.02.090; Silverio A, 2021, BMC CARDIOVASC DISOR, V21, DOI 10.1186/s12872-020-01816-3; Song J, 2021, ALLERGY, V76, P483, DOI 10.1111/all.14517; Stochino C, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01708-2020; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sun Y, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102473; Sy KTL, 2020, INFECT DIS-NOR, V52, P902, DOI 10.1080/23744235.2020.1806353; Tadolini M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01398-2020; Tamuzi JL, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05450-4; van der Zalm MM., 2021, CLIN INFECT DIS, V72, pe938, DOI [DOI 10.1093/cid/ciaa1666, 10.1093/cid/ciaa1666]; Verma R, 2021, J CLIN DIAGN RES, V15, DOI 10.7860/JCDR/2021/48983.14827; Viechtbauer W, 2010, RES SYNTH METHODS, V1, P112, DOI 10.1002/jrsm.11; Wang YD, 2021, J MED VIROL, V93, P5682, DOI 10.1002/jmv.27119; Wells GA, 2021, NEWCASTLE OTTAWA SCA; WHO, 2019, 10 THREATS GLOB HLTH; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; World Health Organization, COMP TB COVID 19 STU; World Health Organization (WHO), 2020, INF NOT TUB COVID 19; Yan BD, 2021, WORLD ALLERGY ORGAN, V14, DOI 10.1016/j.waojou.2021.100521; Yan M, 2020, BIOMED ENVIRON SCI, V33, P893, DOI 10.3967/bes2020.123; Yang CT, 2021, J MED VIROL, V93, P1639, DOI 10.1002/jmv.26515; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Yu HH, 2020, THROMB RES, V195, P219, DOI 10.1016/j.thromres.2020.07.047; Zeng JH, 2020, INFECTION, V48, P861, DOI 10.1007/s15010-020-01473-w; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zhang W, 2021, RESULTS PHYS, V22, DOI 10.1016/j.rinp.2021.103881; [张应涛 Zhang Yingtao], 2020, [中华流行病学杂志, Chinese Journal of Epidemiology], V41, P1999; Zhang YT, 2021, CURR MED RES OPIN, V37, P385, DOI 10.1080/03007995.2021.1876005; Zheng BW, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8840835	78	10	11	5	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2021	16	10							e0259006	10.1371/journal.pone.0259006	http://dx.doi.org/10.1371/journal.pone.0259006			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7VP	34673822	Green Published, gold			2023-01-03	WOS:000755680200058
J	Sholzberg, M; Tang, GH; Rahhal, H; AlHamzah, M; Kreuziger, LB; Ainle, FN; Alomran, F; Alayed, K; Alsheef, M; AlSumait, F; Pompilio, CE; Sperlich, C; Tangri, S; Tang, T; Jaksa, P; Suryanarayan, D; Almarshoodi, M; Castellucci, LA; James, PD; Lillicrap, D; Carrier, M; Beckett, A; Colovos, C; Jayakar, J; Arsenault, MP; Wu, C; Doyon, K; Andreou, ER; Dounaevskaia, V; Tseng, EK; Lim, G; Fralick, M; Middeldorp, S; Lee, AYY; Zuo, F; da Costa, BR; Thorpe, KE; Negri, EM; Cushman, M; Juni, P				Sholzberg, Michelle; Tang, Grace H.; Rahhal, Hassan; AlHamzah, Musaad; Kreuziger, Lisa Baumann; Ainle, Fionnuala Ni; Alomran, Faris; Alayed, Khalid; Alsheef, Mohammed; AlSumait, Fahad; Pompilio, Carlos Eduardo; Sperlich, Catherine; Tangri, Sabrena; Tang, Terence; Jaksa, Peter; Suryanarayan, Deepa; Almarshoodi, Mozah; Castellucci, Lana A.; James, Paula D.; Lillicrap, David; Carrier, Marc; Beckett, Andrew; Colovos, Christos; Jayakar, Jai; Arsenault, Marie-Pier; Wu, Cynthia; Doyon, Karine; Andreou, E. Roseann; Dounaevskaia, Vera; Tseng, Eric K.; Lim, Gloria; Fralick, Michael; Middeldorp, Saskia; Lee, Agnes Y. Y.; Zuo, Fei; da Costa, Bruno R.; Thorpe, Kevin E.; Negri, Elnara Marcia; Cushman, Mary; Juni, Peter		RAPID Trial Investigators	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To evaluate the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital wards. DESIGN Randomised controlled, adaptive, open label clinical trial. SETTING 28 hospitals in Brazil, Canada, Ireland, Saudi Arabia, United Arab Emirates, and US. PARTICIPANTS 465 adults admitted to hospital wards with covid-19 and with increased D-dimer levels were recruited between 29 May 2020 and 12 April 2021 and were randomly assigned to therapeutic dose heparin (n=228) or prophylactic dose heparin (n=237). INTERVENTIONS Therapeutic dose or prophylactic dose heparin (low molecular weight or unfractionated heparin), to be continued until hospital discharge, day 28, or death.	[Sholzberg, Michelle] Univ Toronto, Li Ka Shing Knowledge Inst, Dept Med, St Michaels Hosp, Toronto, ON, Canada; [Sholzberg, Michelle] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Tang, Grace H.] Univ Toronto, Haematol Oncol Clin Res Grp, St Michaels Hosp, Toronto, ON, Canada; [Rahhal, Hassan; Pompilio, Carlos Eduardo] Univ Sao Paulo, Univ Sao Paulo HCFMUSP, Internal Med Dept, Hosp Clin,Fac Med, Sao Paulo, Brazil; [AlHamzah, Musaad] King Saud Univ, Coll Med, Dept Surg, Riyadh, Saudi Arabia; [AlHamzah, Musaad] King Saud Univ Med City, Div Vasc Surg, Riyadh, Saudi Arabia; [Kreuziger, Lisa Baumann] Med Coll Wisconsin, Versiti, Milwaukee, WI 53226 USA; [Ainle, Fionnuala Ni] Mater Misericordiae Univ Hosp, Dublin, Ireland; [Ainle, Fionnuala Ni] Univ Coll Dublin, Sch Med, Dublin, Ireland; [Ainle, Fionnuala Ni] Irish Network Venous Thromboembolism Res, Dublin, Ireland; [Alomran, Faris] King Faisal Specialist Hosp & Res Ctr, Dept Vasc Surg, Riyadh, Saudi Arabia; [Alayed, Khalid] King Saud Univ, Coll Med, Dept Med, Riyadh, Saudi Arabia; [Alsheef, Mohammed; AlSumait, Fahad] King Fahad Med City, Med Specialties Dept, Riyadh, Saudi Arabia; [Sperlich, Catherine] Univ Sherbrooke, Charles Lemoyne Hosp, CISSS Monteregie Ctr, Greenfield Pk, PQ, Canada; [Tangri, Sabrena] William Osler Hlth Syst, Dept Med, Brampton, ON, Canada; [Tang, Terence] Univ Toronto, Inst Better Hlth, Dept Med, Trillium Hlth Partners, Toronto, ON, Canada; [Jaksa, Peter] Univ Toronto, Dept Med, Unity Hlth Toronto, St Josephs Hlth Ctr, Toronto, ON, Canada; [Suryanarayan, Deepa] Univ Calgary, Libin Cardiovasc Inst Alberta, Dept Med, Calgary, AB, Canada; [Almarshoodi, Mozah] Tawam Hosp, SEHA, Al Ain, U Arab Emirates; [Castellucci, Lana A.; Carrier, Marc] Univ Ottawa, Dept Med, Ottawa Hosp Res Inst, Ottawa, ON, Canada; [James, Paula D.] Queens Univ, Dept Med, Kingston, ON, Canada; [Lillicrap, David] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada; [Beckett, Andrew; Tseng, Eric K.; Lim, Gloria] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada; [Beckett, Andrew] Canadian Forces Hlth Serv, Ottawa, ON, Canada; [Colovos, Christos] Univ Vermont, Med Ctr, Dept Surg, Div Acute Care Surg, Burlington, VT 05405 USA; [Colovos, Christos] Univ Vermont, Larner Coll Med, Burlington, VT USA; [Jayakar, Jai] Univ Toronto, Southlake Reg Hlth Ctr, Newmarket, ON, Canada; [Arsenault, Marie-Pier] Univ Montreal, Maisonneuve Rosemont Hosp, Montreal, PQ, Canada; [Wu, Cynthia] Univ Alberta, Univ Alberta Hosp, Div Haematol, Edmonton, AB, Canada; [Doyon, Karine] Univ Montreal, Hosp Sacred Heart Montreal, Montreal, PQ, Canada; [Andreou, E. Roseann] Univ Toronto, Michael Garron Hosp, Toronto, ON, Canada; [Dounaevskaia, Vera] Univ Toronto, Dept Med, St Michaels Hosp, Toronto, ON, Canada; [Fralick, Michael] Univ Toronto, Sinai Hlth, Gen Internal Med, Toronto, ON, Canada; [Middeldorp, Saskia] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Middeldorp, Saskia] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands; [Lee, Agnes Y. Y.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Vancouver, BC, Canada; [Zuo, Fei; da Costa, Bruno R.; Thorpe, Kevin E.; Juni, Peter] Univ Toronto, Appl Hlth Res Ctr, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada; [da Costa, Bruno R.] Univ Bern, Inst Primary Hlth Care, Bern, Switzerland; [Thorpe, Kevin E.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Negri, Elnara Marcia] Univ Sao Paulo FMUSP, Dept Pathol, Lab Med Invest LIM 59, Cellular Biol,Fac Med, Sao Paulo, Brazil; [Cushman, Mary] Univ Vermont, Med Ctr, Larner Coll Med, Dept Med, Burlington, VT USA; [Cushman, Mary] Univ Vermont, Med Ctr, Larner Coll Med, Dept Pathol & Lab Med, Burlington, VT USA; [Juni, Peter] Univ Toronto, Dept Med, Toronto, ON, Canada; [Juni, Peter] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Universidade de Sao Paulo; King Saud University; King Saud University; Medical College of Wisconsin; Mater Misericordiae University Hospital; University College Dublin; University College Dublin; King Faisal Specialist Hospital & Research Center; King Saud University; King Fahad Medical City; University of Sherbrooke; University of Toronto; Trillium Health Partners; University of Toronto; University Toronto Affiliates; Saint Joseph's Health Centre, Toronto; Western University (University of Western Ontario); Libin Cardiovascular Institute Of Alberta; University of Calgary; University of Ottawa; Ottawa Hospital Research Institute; Queens University - Canada; McMaster University; Queens University - Canada; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Vermont; University of Vermont Medical Center; University of Vermont; Southlake Regional Health Centre; University of Toronto; Universite de Montreal; University of Alberta; Universite de Montreal; University of Toronto; Toronto East General Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Radboud University Nijmegen; Radboud University Nijmegen; University of British Columbia; Vancouver Coastal Health Research Institute; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Bern; University of Toronto; Universidade de Sao Paulo; University of Vermont; University of Vermont Medical Center; University of Vermont; University of Vermont Medical Center; University of Toronto; University of Toronto	Sholzberg, M (corresponding author), Univ Toronto, Li Ka Shing Knowledge Inst, Dept Med, St Michaels Hosp, Toronto, ON, Canada.; Sholzberg, M (corresponding author), Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	michelle.sholzberg@unityhealth.to	Rahhal, Hassan/AFQ-9857-2022; BaHammam, Ahmed S/D-7521-2011; Juni, Peter/Q-8700-2016; BaHammam, Ahmed Salem/B-9037-2008; Pompilio, Carlos/C-6051-2014; Middeldorp, Saskia/ABI-8197-2020	Rahhal, Hassan/0000-0001-7841-7322; BaHammam, Ahmed S/0000-0002-1706-6167; Juni, Peter/0000-0002-5985-0670; BaHammam, Ahmed Salem/0000-0002-1706-6167; Pompilio, Carlos/0000-0003-2559-8689; Middeldorp, Saskia/0000-0002-1006-6420; Binnie, Alexandra/0000-0003-2969-8177; Colovos, Christos/0000-0003-1054-5656; Abuzied, Yacoub/0000-0003-1388-4549; Raissi, Afsaneh/0000-0003-2718-5327; Stocco, Fernando/0000-0002-7702-7901; Ni Ainle, Fionnuala/0000-0003-0163-792X	Task 54, Defense Research Development Canada, Department of National Defense, Ottawa, Canada; St Michael's Hospital Foundation, Toronto, Canada; St Joseph's Health Centre Foundation, Toronto, Canada; 2020 TD Community Health Solutions Fund -COVID-19 research grant; Michael Garron Hospital, Toronto, Canada; The Ottawa Hospital Foundation COVID-19 Emergency Response Fund, Ottawa, Canada; International Network of Venous Thromboembolism Clinical Research Networks (INVENT) Kickstarter Award; Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding [20/COV/0157]; SEAMO (South-eastern Ontario Academic Medical Organization) COVID-19 Innovation Fund; National Institute of General Medical Sciences, National Institutes of Health [P20 GM135007]; University of Vermont Medical Center Fund Grant; College of Medicine Research Center; King Saud University, Riyadh, Saudi Arabia	Task 54, Defense Research Development Canada, Department of National Defense, Ottawa, Canada; St Michael's Hospital Foundation, Toronto, Canada; St Joseph's Health Centre Foundation, Toronto, Canada; 2020 TD Community Health Solutions Fund -COVID-19 research grant; Michael Garron Hospital, Toronto, Canada; The Ottawa Hospital Foundation COVID-19 Emergency Response Fund, Ottawa, Canada; International Network of Venous Thromboembolism Clinical Research Networks (INVENT) Kickstarter Award; Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding; SEAMO (South-eastern Ontario Academic Medical Organization) COVID-19 Innovation Fund; National Institute of General Medical Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); University of Vermont Medical Center Fund Grant; College of Medicine Research Center; King Saud University, Riyadh, Saudi Arabia(King Saud University)	This study was funded by Task 54, Defense Research Development Canada, Department of National Defense, Ottawa, Canada; St Michael's Hospital Foundation, Toronto, Canada; St Joseph's Health Centre Foundation, Toronto, Canada; 2020 TD Community Health Solutions Fund -COVID-19 research grant; Michael Garron Hospital, Toronto, Canada; The Ottawa Hospital Foundation COVID-19 Emergency Response Fund, Ottawa, Canada; International Network of Venous Thromboembolism Clinical Research Networks (INVENT) Kickstarter Award; Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding Call 20/COV/0157; SEAMO (South-eastern Ontario Academic Medical Organization) COVID-19 Innovation Fund; P20 GM135007 from the National Institute of General Medical Sciences, National Institutes of Health; University of Vermont Medical Center Fund Grant; College of Medicine Research Center, and Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. The funders had no role in the trial design; conduct, collection, management, analysis, or interpretation of data; or in preparation or review of the manuscript or the approval of the manuscript for submission.	Doi SA, 2022, J CLIN EPIDEMIOL, V142, P271, DOI 10.1016/j.jclinepi.2020.08.019; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI [10.1056/NEJMoa2100433, 10.1056/NEJMc2108482]; Government of Ontario, HOSP COVID 19 ONT; Government of Ontario, CAS NUMB SPREAD COVI; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x; Houston BL, 2020, CLIN TRIALS, V17, P491, DOI 10.1177/1740774520943846; Iba T, 2020, CRIT CARE MED, V48, P1358, DOI 10.1097/CCM.0000000000004458; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026; Lawler PR, 2021, NEW ENGL J MED, V385, P790, DOI 10.1056/NEJMoa2105911; Li Lu, 2019, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V31, P1363, DOI 10.3760/cma.j.issn.2095-4352.2019.11.010; Liu J, 2020, RES PRACT THROMB HAE, V4, P518, DOI 10.1002/rth2.12353; Lopes RD, 2021, LANCET, V397, P2253, DOI 10.1016/S0140-6736(21)01203-4; McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1; Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888; Mu ST, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0925-6; Negri EM, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.573044; Nopp S, 2020, RES PRACT THROMB HAE, V4, P1178, DOI 10.1002/rth2.12439; Page Clive, 2013, ISRN Pharmacol, V2013, P910743, DOI 10.1155/2013/910743; Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Sadeghipour P, 2021, JAMA-J AM MED ASSOC, V325, P1620, DOI 10.1001/jama.2021.4152; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Schunemann HJ, 2018, BLOOD ADV, V2, P3198, DOI 10.1182/bloodadvances.2018022954; Sholzberg M, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05076-0; Talasaz AH, 2021, J AM COLL CARDIOL, V77, P1903, DOI 10.1016/j.jacc.2021.02.035; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; ten Cate H, 2021, NEW ENGL J MED, V385, P845, DOI 10.1056/NEJMe2111151; Thachil J, 2020, RES PRACT THROMB HAE, V4, P731, DOI 10.1002/rth2.12372; Tritschler T, 2020, J THROMB HAEMOST, V18, P2958, DOI 10.1111/jth.15094; Wang CS, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0563-4; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	36	103	105	4	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 14	2021	375								n2400	10.1136/bmj.n2400	http://dx.doi.org/10.1136/bmj.n2400			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM9UB	34649864	Green Published, hybrid			2023-01-03	WOS:000711422300013
J	Hirabayashi, G; Yokose, Y; Nagata, K; Oshika, H; Saito, M; Akihisa, Y; Maruyama, K; Andoh, T				Hirabayashi, Go; Yokose, Yuuki; Nagata, Kohei; Oshika, Hiroyuki; Saito, Minami; Akihisa, Yuki; Maruyama, Koichi; Andoh, Tomio			Changes in dead space components during pressure-controlled inverse ratio ventilation: A secondary analysis of a randomized trial	PLOS ONE			English	Article							LAPAROSCOPIC RADICAL PROSTATECTOMY; PULMONARY GAS-EXCHANGE; VOLUMETRIC CAPNOGRAPHY; RESPIRATORY MECHANICS; OXYGENATION; PARAMETERS	Background We previously reported that there were no differences between the lung-protective actions of pressure-controlled inverse ratio ventilation and volume control ventilation based on the changes in serum cytokine levels. Dead space represents a ventilation-perfusion mismatch, and can enable us to understand the heterogeneity and elapsed time changes in ventilation-perfusion mismatch. Methods This study was a secondary analysis of a randomized controlled trial of patients who underwent robot-assisted laparoscopic radical prostatectomy. The inspiratory to expiratory ratio was adjusted individually by observing the expiratory flow-time wave in the pressure-controlled inverse ratio ventilation group (n = 14) and was set to 1:2 in the volume-control ventilation group (n = 13). Using volumetric capnography, the physiological dead space was divided into three dead space components: airway, alveolar, and shunt dead space. The influence of pressure-controlled inverse ratio ventilation and time factor on the changes in each dead space component rate was analyzed using the Mann-Whitney U test and Wilcoxon's signed rank test. Results The physiological dead space and shunt dead space rate were decreased in the pressure-controlled inverse ratio ventilation group compared with those in the volume control ventilation group (p < 0.001 and p = 0.003, respectively), and both dead space rates increased with time in both groups. The airway dead space rate increased with time, but the difference between the groups was not significant. There were no significant changes in the alveolar dead space rate. Conclusions Pressure-controlled inverse ratio ventilation reduced the physiological dead space rate, suggesting an improvement in the total ventilation/perfusion mismatch due to improved inflation of the alveoli affected by heterogeneous expansion disorder without hyperinflation of the normal alveoli. However, the shunt dead space rate increased with time, suggesting that atelectasis developed with time in both groups.	[Hirabayashi, Go; Yokose, Yuuki; Nagata, Kohei; Oshika, Hiroyuki; Saito, Minami; Akihisa, Yuki; Maruyama, Koichi; Andoh, Tomio] Teikyo Univ, Mizonokuchi Hosp, Sch Med, Dept Anaesthesiol, Kawasaki, Kanagawa, Japan	Teikyo University	Hirabayashi, G (corresponding author), Teikyo Univ, Mizonokuchi Hosp, Sch Med, Dept Anaesthesiol, Kawasaki, Kanagawa, Japan.	goh@med.teikyo-u.ac.jp						Balick-Weber CC, 2007, BRIT J ANAESTH, V99, P429, DOI 10.1093/bja/aem166; CHAN K, 1992, CHEST, V102, P1556, DOI 10.1378/chest.102.5.1556; Choi EM, 2011, J CLIN ANESTH, V23, P183, DOI 10.1016/j.jclinane.2010.08.006; Cinnella G, 2013, ANESTHESIOLOGY, V118, P114, DOI 10.1097/ALN.0b013e3182746a10; FLETCHER R, 1981, BRIT J ANAESTH, V53, P77, DOI 10.1093/bja/53.1.77; FOWLER WS, 1948, AM J PHYSIOL, V154, P405, DOI 10.1152/ajplegacy.1948.154.3.405; Futier E, 2014, CURR OPIN CRIT CARE, V20, P426, DOI 10.1097/MCC.0000000000000121; Hirabayashi G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243971; Hirabayashi G, 2018, EUR J ANAESTH, V35, P307, DOI 10.1097/EJA.0000000000000732; Karsten J, 2011, ACTA ANAESTH SCAND, V55, P878, DOI 10.1111/j.1399-6576.2011.02467.x; Kilpatrick B, 2010, BRIT J ANAESTH, V105, pI108, DOI 10.1093/bja/aeq299; Kim MS, 2018, INT J MED SCI, V15, P1522, DOI 10.7150/ijms.28442; LAIN DC, 1989, CHEST, V95, P1081, DOI 10.1378/chest.95.5.1081; Lee HJ, 2013, KOREAN J ANESTHESIOL, V65, P244, DOI 10.4097/kjae.2013.65.3.244; Maracaja-Neto LF, 2009, ACTA ANAESTH SCAND, V53, P210, DOI 10.1111/j.1399-6576.2008.01826.x; Musch G, 2004, ANESTHESIOLOGY, V100, P323, DOI 10.1097/00000542-200402000-00022; O'Gara B, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3030; Ogurlu M, 2010, J MINIM INVAS GYN, V17, P295, DOI 10.1016/j.jmig.2009.10.007; Park JH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003269; Suarez-Sipmann F, 2014, CURR OPIN CRIT CARE, V20, P333, DOI 10.1097/MCC.0000000000000095; THARRATT RS, 1988, CHEST, V94, P755, DOI 10.1378/chest.94.4.755; Tusman G, 2013, J CLIN MONIT COMPUT, V27, P281, DOI 10.1007/s10877-013-9433-x; Tusman G, 2012, ANESTH ANALG, V114, P866, DOI 10.1213/ANE.0b013e318247f6cc; TWEED WA, 1992, CAN J ANAESTH, V39, P1036, DOI 10.1007/BF03008371; TWEED WA, 1991, CAN J ANAESTH, V38, P311, DOI 10.1007/BF03007620; Wang SH, 2002, AM J SURG, V183, P151, DOI 10.1016/S0002-9610(01)00870-4; Zavala E, 1998, ANESTHESIOLOGY, V88, P35, DOI 10.1097/00000542-199801000-00008	27	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2021	16	10							e0258504	10.1371/journal.pone.0258504	http://dx.doi.org/10.1371/journal.pone.0258504			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR9CY	34644352	gold, Green Published			2023-01-03	WOS:000732519500055
J	Gao, SS; Soares, F; Wang, SY; Wong, CC; Chen, HR; Yang, ZJ; Liu, WX; Go, MYY; Ahmed, M; Zeng, Y; O'Brien, CA; Sung, JJY; He, HH; Yu, J				Gao, Shanshan; Soares, Fraser; Wang, Shiyan; Wong, Chi Chun; Chen, Huarong; Yang, Zhenjie; Liu, Weixin; Go, Minnie Y. Y.; Ahmed, Musaddeque; Zeng, Yong; O'Brien, Catherine Adell; Sung, Joseph J. Y.; He, Housheng Hansen; Yu, Jun			CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer	ONCOGENE			English	Article							COLORECTAL-CANCER; TGF-BETA; INITIATING CELLS; SELF-RENEWAL; ENDOCRINE THERAPY; ZOLEDRONIC ACID; BREAST; ID1; IDENTIFICATION; INHIBITORS	Cancer stem cells (CSCs) are responsible for tumor progression, recurrence, and drug resistance. To identify genetic vulnerabilities of colon cancer, we performed targeted CRISPR dropout screens comprising 657 Drugbank targets and 317 epigenetic regulators on two patient-derived colon CSC-enriched spheroids. Next-generation sequencing of pooled genomic DNAs isolated from surviving cells yielded therapeutic candidates. We unraveled 44 essential genes for colon CSC-enriched spheroids propagation, including key cholesterol biosynthetic genes (HMGCR, FDPS, and GGPS1). Cholesterol biosynthesis was induced in colon cancer tissues, especially CSC-enriched spheroids. The genetic and pharmacological inhibition of HMGCR/FDPS impaired self-renewal capacity and tumorigenic potential of the spheroid models in vitro and in vivo. Mechanistically, HMGCR or FDPS depletion impaired cancer stemness characteristics by activating TGF-beta signaling, which in turn downregulated expression of inhibitors of differentiation (ID) proteins, key regulators of cancer stemness. Cholesterol and geranylgeranyl diphosphate (GGPP) rescued the growth inhibitory and signaling effect of HMGCR/FDPS blockade, implying a direct role of these metabolites in modulating stemness. Finally, cholesterol biosynthesis inhibitors and 5-FU demonstrated antitumor synergy in colon CSC-enriched spheroids, tumor organoids, and xenografts. Taken together, our study unravels novel genetic vulnerabilities of colon CSC-enriched spheroids and suggests cholesterol biosynthesis as a potential target in conjunction with traditional chemotherapy for colon cancer treatment.	[Gao, Shanshan; Wong, Chi Chun; Chen, Huarong; Yang, Zhenjie; Liu, Weixin; Go, Minnie Y. Y.; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Gao, Shanshan; Wong, Chi Chun; Chen, Huarong; Yang, Zhenjie; Liu, Weixin; Go, Minnie Y. Y.; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China; [Gao, Shanshan; Soares, Fraser; Wang, Shiyan; Ahmed, Musaddeque; Zeng, Yong; O'Brien, Catherine Adell; He, Housheng Hansen] Univ Hlth Network, Princess Margaret Canc Ctr, Ontario, ON, Canada; [He, Housheng Hansen] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China.; He, HH (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Ontario, ON, Canada.; He, HH (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.	hansenhe@uhnresearch.ca; junyu@cuhk.edu.hk	chen, huarong/ABH-8561-2020; Chen, Huarong/ABZ-5810-2022	chen, huarong/0000-0003-2192-1864; Soares, Fraser/0000-0002-3977-7939; Wong, Chi Chun/0000-0003-1362-3541; Zeng, Yong/0000-0001-5719-1272	National Natural Science Foundation of China (NSFC) [81972576]; RGC-CRF Hong Kong [C4039-19G, C7065-18G]; RGC-GRF Hong Kong [14110819, 14163817, 14108718, 24100520]; HMRF Hong Kong [06170686]; Princess Margaret Cancer Foundation [886012001223]; NSERC discovery Grants [498706]; CIHR operating Grants [142246, 152863, 152864, 159567]; Terry Fox New Frontiers Program Project Grant [1090 P3]; TFRI New Investigator Awards; CIHR New Investigator Awards; OMIR Early Researcher Award; Vice-Chancellor's Discretionary Fund CUHK	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); RGC-CRF Hong Kong; RGC-GRF Hong Kong(Hong Kong Research Grants Council); HMRF Hong Kong; Princess Margaret Cancer Foundation(University of Toronto); NSERC discovery Grants(Natural Sciences and Engineering Research Council of Canada (NSERC)); CIHR operating Grants(Canadian Institutes of Health Research (CIHR)); Terry Fox New Frontiers Program Project Grant; TFRI New Investigator Awards; CIHR New Investigator Awards(Canadian Institutes of Health Research (CIHR)); OMIR Early Researcher Award; Vice-Chancellor's Discretionary Fund CUHK	This project was supported by National Natural Science Foundation of China (NSFC; 81972576), RGC-CRF Hong Kong (C4039-19G, C7065-18G), RGC-GRF Hong Kong (14110819, 14163817, 14108718, 24100520), HMRF Hong Kong (06170686), the Princess Margaret Cancer Foundation (886012001223 to HHH), NSERC discovery Grants (498706 to HHH), CIHR operating Grants (142246, 152863, 152864, and 159567 to HHH), Terry Fox New Frontiers Program Project Grant (1090 P3 to HHH). HHH was supported by TFRI New Investigator Awards and CIHR New Investigator Awards. HHH holds an OMIR Early Researcher Award, Vice-Chancellor's Discretionary Fund CUHK.	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Carpentino JE, 2009, CANCER RES, V69, P8208, DOI 10.1158/0008-5472.CAN-09-1132; Chen CL, 2008, J CELL PHYSIOL, V215, P223, DOI 10.1002/jcp.21303; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031864; Cheung KS, 2019, GUT, V68, P1979, DOI 10.1136/gutjnl-2018-317714; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Ehmsen S, 2019, CELL REP, V27, P3927, DOI 10.1016/j.celrep.2019.05.104; Gabitova-Cornell L, 2020, CANCER CELL, V38, P567, DOI 10.1016/j.ccell.2020.08.015; Ginestier C, 2012, STEM CELLS, V30, P1327, DOI 10.1002/stem.1122; Gnant M, 2015, ANN ONCOL, V26, P313, DOI 10.1093/annonc/mdu544; Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285; Griffith M, 2013, NAT METHODS, V10, P1209, DOI [10.1038/nmeth.2689, 10.1038/NMETH.2689]; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Haynes J, 2018, CLIN CANCER RES, V24, P2116, DOI 10.1158/1078-0432.CCR-17-1715; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Katsuno Y, 2012, J PATHOL, V228, P391, DOI 10.1002/path.4020; Kloudova A, 2017, TRENDS ENDOCRIN MET, V28, P485, DOI 10.1016/j.tem.2017.03.002; Kodach LL, 2007, GASTROENTEROLOGY, V133, P1272, DOI 10.1053/j.gastro.2007.08.021; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Kurata M, 2018, J HUM GENET, V63, P179, DOI 10.1038/s10038-017-0376-9; Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638; Li HY, 2003, BLOOD, V101, P3628, DOI 10.1182/blood-2002-07-2283; Liang YY, 2009, CELL RES, V19, P140, DOI 10.1038/cr.2008.321; Liu CG, 2013, CANCER LETT, V339, P60, DOI 10.1016/j.canlet.2013.07.022; MacLeod G, 2019, CELL REP, V27, P971, DOI 10.1016/j.celrep.2019.03.047; Meng DL, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.152595; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Mishra L, 2005, ONCOGENE, V24, P5775, DOI 10.1038/sj.onc.1208924; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; O'Brien CA, 2012, CANCER CELL, V21, P777, DOI 10.1016/j.ccr.2012.04.036; Park HJ, 1999, P NATL ACAD SCI USA, V96, P11525, DOI 10.1073/pnas.96.20.11525; Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rodriguez-Vita J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003959; Shen Y, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw023; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Teng CF, 2018, CELL TRANSPLANT, V27, P1313, DOI 10.1177/0963689718779777; Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078-0432.CCR-12-0489; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Voorneveld PW, 2017, GASTROENTEROLOGY, V153, P470, DOI 10.1053/j.gastro.2017.05.011; Wang B, 2018, CELL STEM CELL, V22, P206, DOI 10.1016/j.stem.2017.12.017; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041; Wang XX, 2017, CANCER RES, V77, P4947, DOI 10.1158/0008-5472.CAN-17-0114; Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098; Xia Y, 2018, CELL, V175, P1059, DOI 10.1016/j.cell.2018.08.070; Zhao ZQ, 2019, ONCOGENE, V38, P2076, DOI 10.1038/s41388-018-0570-z	52	7	7	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6601	6613		10.1038/s41388-021-01882-7	http://dx.doi.org/10.1038/s41388-021-01882-7		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34621019	Green Published, hybrid			2023-01-03	WOS:000705775200001
J	Lomis, N; Westfall, S; Shum-Tim, D; Prakash, S				Lomis, Nikita; Westfall, Susan; Shum-Tim, Dominique; Prakash, Satya			Synthesis and characterization of peptide conjugated human serum albumin nanoparticles for targeted cardiac uptake and drug delivery	PLOS ONE			English	Article							HEART-FAILURE; MILRINONE; HYPERTROPHY; OVEREXPRESSION; COMBINATION; CHALLENGES; RECEPTOR; THERAPY; CELLS; H9C2	Congestive heart failure, a prominent cardiovascular disease results primarily from myocardial infarction or ischemia. Milrinone (MRN), a widely used clinical drug for heart failure, improves myocardial contractility and cardiac function through its inotropic and vasodilatory effects. However, lacking target specificity, it exhibits low bioavailability and lower body retention time. Therefore, in this study, angiotensin II (AT1) peptide conjugated human serum albumin nanoparticles (AT1-HSA-MRN-NPs) have been synthesized for targeted delivery of MRN to the myocardium, overexpressing AT1 receptors under heart failure. The NPs were surface functionalized through a covalent conjugation reaction between HSA and AT1. Nanoparticle size was 215.2 +/- 4.7 nm and zeta potential -28.8 +/- 2.7 mV and cumulative release of MRN was similar to 72% over 24 hrs. The intracellular uptake of nanoparticles and cell viability was studied in H9c2 cells treated with AT1-MRN-HSA-NPs vs the control non-targeted drug, MRN Lactate under normal, hypoxic and hypertrophic conditions. The uptake of AT1-HSA-MRN-NPs in H9c2 cells was significantly higher as compared to non-targeted nanoparticles, and the viability of H9c2 cells treated with AT1-MRN-HSA-NPs vs MRN Lactate was 73.4 +/- 1.4% vs 44.9 +/- 1.4%, respectively. Therefore, AT1-HSA-MRN-NPs are safe for in vivo use and exhibit superior targeting and drug delivery characteristics for treatment of heart failure.	[Lomis, Nikita; Prakash, Satya] Dept Biomed Engn, Biomed Technol & Cell Therapy Res Lab, Montreal, PQ, Canada; [Lomis, Nikita; Prakash, Satya] Div Expt Med, Montreal, PQ, Canada; [Westfall, Susan] McGill Univ, Dept Microbiol & Immunol, Meakins Christie Labs, Montreal, PQ, Canada; [Shum-Tim, Dominique] Royal Victoria Hosp, Div Cardiac Surg & Surg Res, Montreal, PQ, Canada	McGill University; McGill University; Royal Victoria Hospital	Prakash, S (corresponding author), Dept Biomed Engn, Biomed Technol & Cell Therapy Res Lab, Montreal, PQ, Canada.; Prakash, S (corresponding author), Div Expt Med, Montreal, PQ, Canada.	satya.prakash@mcgill.ca		/0000-0002-4902-2353	Canadian Institute of Health Research (CIHR) [CIHR-PJT-166003]	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This work is supported by the research funding granted to Dr. Satya Prakash by the Canadian Institute of Health Research (CIHR) grant (CIHR-PJT-166003). No additional external funding was received for this study.	Abbasi S, 2012, J DRUG DELIV, V2012, DOI 10.1155/2012/686108; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Al Kindi H, 2014, J THORAC CARDIOV SUR, V148, P2316, DOI 10.1016/j.jtcvs.2014.07.033; ALOUSI AA, 1986, CIRCULATION, V73, P10; BAIM DS, 1983, NEW ENGL J MED, V309, P748, DOI 10.1056/NEJM198309293091302; Barton P, 1996, CHEST, V109, P1302, DOI 10.1378/chest.109.5.1302; Benjamin, 2018, CIRCULATION, V137, pE493, DOI 10.1161/CIR.0000000000000573; Clayton D, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00005; Cuffe MS, 2002, JAMA-J AM MED ASSOC, V287, P1541, DOI 10.1001/jama.287.12.1541; de Boer RA, 2008, CARDIOVASC DRUG THER, V22, P261, DOI 10.1007/s10557-008-6107-x; Dickhout JG, 2011, CIRC RES, V108, P629, DOI 10.1161/CIRCRESAHA.110.226803; Doenst T, 2019, J AM COLL CARDIOL, V73, P964, DOI 10.1016/j.jacc.2018.11.053; Dvir T, 2011, NANO LETT, V11, P4411, DOI 10.1021/nl2025882; Feneck R, 2007, BJA EDUC, V7, P203, DOI 10.1093/bjaceaccp/mkm039; Feric NT, 2016, STEM CELL TRANSL MED, V5, P410, DOI 10.5966/sctm.2015-0288; Guo DF, 2001, CELL RES, V11, P165, DOI 10.1038/sj.cr.7290083; HARASHIMA H, 1994, PHARM RES-DORDR, V11, P402, DOI 10.1023/A:1018965121222; Hennig R, 2015, J DRUG TARGET, V23, P681, DOI 10.3109/1061186X.2015.1035276; Inamdar AA, 2016, J CLIN MED, V5, DOI 10.3390/jcm5070062; Ji SR, 2012, CANCER BIOL THER, V13, DOI 10.4161/cbt.13.4.18692; Jithan AV, 2011, INT J PHARM INVESTIG, V1, P119, DOI 10.4103/2230-973X.82432; Khan MS, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.117.003956; Kuznetsov AV, 2015, BBA-MOL CELL RES, V1853, P276, DOI 10.1016/j.bbamcr.2014.11.015; Langer K, 2008, INT J PHARMACEUT, V347, P109, DOI 10.1016/j.ijpharm.2007.06.028; Langer K, 2003, INT J PHARM, V257, P169, DOI 10.1016/S0378-5173(03)00134-0; Lomis N., PHARMACEUTICALS-BASE, V14, P697; Lomis N., 2017, MOL PHARMACEUT; Lomis N, 2018, MOL PHARMACEUT, V15, P2489, DOI 10.1021/acs.molpharmaceut.7b00360; Lomis N, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6060116; Longmire M, 2008, NANOMEDICINE-UK, V3, P703, DOI 10.2217/17435889.3.5.703; Look J, 2015, MOL PHARMACEUT, V12, P3202, DOI 10.1021/acs.molpharmaceut.5b00153; Loureiro A, 2016, CURR PHARM DESIGN, V22, P1371, DOI 10.2174/1381612822666160125114900; Mudshinge SR, 2011, SAUDI PHARM J, V19, P129, DOI 10.1016/j.jsps.2011.04.001; Nanayakkara S, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015026; Owens DE, 2006, INT J PHARMACEUT, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010; Paradis P, 2000, P NATL ACAD SCI USA, V97, P931, DOI 10.1073/pnas.97.2.931; Reboucas JD, 2016, ARQ BRAS CARDIOL, V107, P271, DOI 10.5935/abc.20160097; Rivard K, 2011, AM J PHYSIOL-HEART C, V301, pH2018, DOI 10.1152/ajpheart.01092.2010; Ruan CH, 2018, ACTA PHARM SIN B, V8, P85, DOI 10.1016/j.apsb.2017.09.008; Sebak S, 2010, INT J NANOMED, V5, P525; Siddiqui M., 2009, ASIAN J SCI RES, V2, P135, DOI DOI 10.3923/AJSR.2009.135.145; Song R, 2015, CARDIOVASC TOXICOL, V15, P23, DOI 10.1007/s12012-014-9264-0; Stewart D, 2017, HEART FAIL REV, V22, P525, DOI 10.1007/s10741-017-9632-5; Tai CH, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0686-z; Tang XY, 2015, BASIC CLIN PHARMACOL, V117, P186, DOI 10.1111/bcpt.12385; Tang Y, 2014, NANOMED-NANOTECHNOL, V10, P1711, DOI 10.1016/j.nano.2014.06.001; Taylor CJ, 2017, FAM PRACT, V34, P161, DOI 10.1093/fampra/cmw145; Wang ZG, 2015, CLIN DRUG INVEST, V35, P707, DOI 10.1007/s40261-015-0325-3; Wu DL, 2011, JOVE-J VIS EXP, DOI 10.3791/2899; Xiao K, 2011, BIOMATERIALS, V32, P3435, DOI 10.1016/j.biomaterials.2011.01.021; Xu J, 2007, AM J PHYSIOL-HEART C, V293, pH1900, DOI 10.1152/ajpheart.00379.2007; Yu H, 2017, MAT SCI ENG C-MATER, V75, P25, DOI 10.1016/j.msec.2017.02.018; Yu XZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep31539; Zhang ZW, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.902936	54	3	3	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2021	16	9							e0254305	10.1371/journal.pone.0254305	http://dx.doi.org/10.1371/journal.pone.0254305			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YI5QV	34591850	Green Published, Green Submitted, gold			2023-01-03	WOS:000743903000003
J	Yamin, R; Jones, AT; Hoffmann, HH; Schafer, A; Kao, KVS; Francis, RL; Sheahan, TP; Baric, RS; Rice, CM; Ravetch, JV; Bournazos, S				Yamin, Rachel; Jones, Andrew T.; Hoffmann, Hans-Heinrich; Schafer, Alexandra; Kao, Kevin S.; Francis, Rebecca L.; Sheahan, Timothy P.; Baric, Ralph S.; Rice, Charles M.; Ravetch, Jeffrey V.; Bournazos, Stylianos			Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy	NATURE			English	Article							NEUTRALIZING ANTIBODIES; EFFECTOR FUNCTIONS; MOUSE MODEL; PROTECTION; RECEPTOR	Monoclonal antibodies with neutralizing activity against SARS-CoV-2 have demonstrated clinical benefits in cases of mild-to-moderate SARS-CoV-2 infection, substantially reducing the risk for hospitalization and severe disease(1-4). Treatment generally requires the administration of high doses of these monoclonal antibodies and has limited efficacy in preventing disease complications or mortality among hospitalized patients with COVID-19(5). Here we report the development and evaluation of anti-SARS-CoV-2 monoclonal antibodies with optimized Fc domains that show superior potency for prevention or treatment of COVID-19. Using several animal disease models of COVID-19(6,7), we demonstrate that selective engagement of activating Fc. receptors results in improved efficacy in both preventing and treating disease-induced weight loss and mortality, significantly reducing the dose required to confer full protection against SARS-CoV-2 challenge and for treatment of pre-infected animals. Our results highlight the importance of Fc. receptor pathways in driving antibody-mediated antiviral immunity and exclude the possibility of pathogenic or disease-enhancing effects of Fc. receptor engagement of anti-SARS-CoV-2 antibodies upon infection. These findings have important implications for the development of Fc-engineered monoclonal antibodies with optimal Fc-effector function and improved clinical efficacy against COVID-19 disease.	[Yamin, Rachel; Jones, Andrew T.; Kao, Kevin S.; Francis, Rebecca L.; Ravetch, Jeffrey V.; Bournazos, Stylianos] Rockefeller Univ, Lab Mol Genet & Immunol, 1230 York Ave, New York, NY 10021 USA; [Hoffmann, Hans-Heinrich; Rice, Charles M.] Rockefeller Univ, Lab Virol & Infect Dis, New York, NY 10021 USA; [Schafer, Alexandra; Sheahan, Timothy P.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA	Rockefeller University; Rockefeller University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ravetch, JV; Bournazos, S (corresponding author), Rockefeller Univ, Lab Mol Genet & Immunol, 1230 York Ave, New York, NY 10021 USA.	ravetch@rockefeller.edu; sbournazos@rockefeller.edu	Francis, Rebecca/GZM-2367-2022; Bournazos, Stylianos/ABH-1578-2021; Sheahan, Timothy/J-8201-2019	Sheahan, Timothy/0000-0001-9181-2183; Jones, Andrew/0000-0002-3739-2322; Francis, Rebecca/0000-0003-3027-1170; Ravetch, Jeffrey/0000-0003-2024-9041; Baric, Ralph/0000-0001-6827-8701	NIH Core Grant [P30CA008748]; National Institute of Allergy and Infectious Diseases [R01AI137276, R01AI157155, U19AI111825, R01AI145870]; Bill and Melinda Gates Foundation [INV023152]; G. Harold and Leila Y. Mathers Charitable Foundation; Bawd Foundation; Fast Grants, a part of Emergent Ventures at the Mercatus Center, George Mason University; Rockefeller University; Vir Biotechnology	NIH Core Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); G. Harold and Leila Y. Mathers Charitable Foundation; Bawd Foundation; Fast Grants, a part of Emergent Ventures at the Mercatus Center, George Mason University; Rockefeller University; Vir Biotechnology	We thank P. Smith, E. Lam, R.Peraza, L. Smith, A. M. Mozqueda and T. Martinez for technical assistance and for maintaining and genotyping the mouse colonies used in this study; all the members of the Laboratory of the Molecular Genetics and Immunology (Rockefeller University) for discussions; S. Borghi for providing the recombinant SARS-CoV-2 RBD; P. Bieniasz for providing the HT1080-ACE2 cell line and plasmids for generating pseudoviruses; A. Viale for providing the SARS-CoV-2 NYC clinical isolate; A. Ashbrook andG. McNab foradvice on handling BSL-3 agents and processing of tissues from infected animals; D. Martinez for technical assistance; S. Carrasco; staff from the Laboratory Comparative Pathology for histopathology support (with funding from NIH Core Grant P30CA008748). Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases (R01AI137276, R01AI157155, U19AI111825, and R01AI145870) and the Bill and Melinda Gates Foundation (INV023152). This work was in part made possible with funding from the G. Harold and Leila Y. Mathers Charitable Foundation, the Bawd Foundation and Fast Grants (www.fastgrants.org), a part of Emergent Ventures at the Mercatus Center, George Mason University. We acknowledge support from the Rockefeller University and Vir Biotechnology. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	ACTIV-3 TICO LY-CoV555 Study Grp, 2021, NEW ENGL J MED, V384, P905, DOI 10.1056/NEJMoa2033130; Atyeo C, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.143129; Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Bournazos S, 2020, NATURE, V588, P485, DOI 10.1038/s41586-020-2838-z; Bournazos S, 2020, NAT REV IMMUNOL, V20, P633, DOI 10.1038/s41577-020-00410-0; Bournazos S, 2019, P NATL ACAD SCI USA, V116, P20054, DOI 10.1073/pnas.1911842116; Bournazos S, 2019, CURR TOP MICROBIOL, V423, P1, DOI 10.1007/82_2019_149; Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023; Chakraborty S, 2021, NAT IMMUNOL, V22, P67, DOI [10.1038/s41590-020-00828-7, 10.1101/2020.05.15.20103341]; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Cleary SJ, 2020, BRIT J PHARMACOL, V177, P4851, DOI 10.1111/bph.15143; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Dougan M, 2021, NEW ENGL J MED, V385, P1382, DOI 10.1056/NEJMoa2102685; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106; Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI [10.1172/JCI140200, 10.1101/2020.05.12.20099879]; Larsen MD, 2021, SCIENCE, V371, P907, DOI 10.1126/science.abc8378; Leist SR, 2020, CELL, V183, P1070, DOI 10.1016/j.cell.2020.09.050; Li Dapeng, 2021, bioRxiv, DOI 10.1101/2020.12.31.424729; Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279; Lucas C, 2021, NAT MED, V27, P1178, DOI 10.1038/s41591-021-01355-0; Martinez DR, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109450; McCann KE, 2017, SCI REP-UK, V7, DOI 10.1038/srep40472; Pietzsch J, 2012, P NATL ACAD SCI USA, V109, P15859, DOI 10.1073/pnas.1213409109; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Schafer A, 2021, J EXP MED, V218, DOI 10.1084/jem.20201993; Schmidt Fabian, 2020, J Exp Med, V217, DOI [10.1101/2020.06.08.140871, 10.1084/jem.20201181]; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; Smith P, 2012, P NATL ACAD SCI USA, V109, P6181, DOI 10.1073/pnas.1203954109; Suryadevara Naveenchandra, 2021, bioRxiv, DOI [10.1016/j.cell.2021.03.029, 10.1101/2021.01.19.427324]; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; Ullah Irfan, 2021, bioRxiv, DOI 10.1101/2021.03.22.436337; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1038/s41586-021-03324-6, 10.1101/2021.01.15.426911]; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Winkler ES, 2021, CELL, V184, P1804, DOI 10.1016/j.cell.2021.02.026; Wu XJ, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.00350-21	37	42	43	2	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 18	2021	599	7885					465	+		10.1038/s41586-021-04017-w	http://dx.doi.org/10.1038/s41586-021-04017-w		SEP 2021	21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ6DP	34547765	Green Published, Green Submitted, Green Accepted, Bronze			2023-01-03	WOS:000714336400001
J	Heesakkers, H; van der Hoeven, JG; Corsten, S; Janssen, I; Ewalds, E; Simons, KS; Westerhof, B; Rettig, TCD; Jacobs, C; van Santen, S; Slooter, AJC; van der Woude, MCE; van den Boogaard, M; Zegers, M				Heesakkers, Hidde; van der Hoeven, Johannes G.; Corsten, Stijn; Janssen, Inge; Ewalds, Esther; Simons, Koen S.; Westerhof, Brigitte; Rettig, Thijs C. D.; Jacobs, Cretien; van Santen, Susanne; Slooter, Arjen J. C.; van der Woude, Margaretha C. E.; van den Boogaard, Mark; Zegers, Marieke			Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL ANXIETY; DEPRESSION SCALE; FRAILTY	IMPORTANCE One-year outcomes in patients who have had COVID-19 and who received treatment in the intensive care unit (ICU) are unknown. OBJECTIVE To assess the occurrence of physical, mental, and cognitive symptoms among patients with COVID-19 at 1 year after ICU treatment. DESIGN, SETTING, AND PARTICIPANTS An exploratory prospective multicenter cohort study conducted in ICUs of 11 Dutch hospitals. Patients (N = 452) with COVID-19, aged 16 years and older, and alive after hospital discharge following admission to 1 of the 11 ICUs during the first COVID-19 surge (March 1, 2020, until July 1, 2020) were eligible for inclusion. Patients were followed up for 1 year, and the date of final follow-up was June 16, 2021. EXPOSURES Patients with COVID-19 who received ICU treatment and survived 1 year after ICU admission. MAIN OUTCOMES AND MEASURES The main outcomeswere self-reported occurrence of physical symptoms (frailty [Clinical Frailty Scale score >= 5], fatigue [Checklist Individual Strength-fatigue subscale score >= 27], physical problems), mental symptoms (anxiety [Hospital Anxiety and Depression {HADS} subscale score >= 8], depression [HADS subscale score >= 8], posttraumatic stress disorder [mean Impact of Event Scale score >= 1.75]), and cognitive symptoms (Cognitive Failure Questionnaire-14 score >= 43) 1 year after ICU treatment and measured with validated questionnaires. CONCLUSIONS AND RELEVANCE In this exploratory study of patients in 11 Dutch hospitals who survived 1 year following ICU treatment for COVID-19, physical, mental, or cognitive symptoms were frequently reported.	[Heesakkers, Hidde; van der Hoeven, Johannes G.; van den Boogaard, Mark; Zegers, Marieke] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Intens Care, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands; [Corsten, Stijn] Canisius Wilhelmina Hosp, Dept Intens Care Med, Nijmegen, Netherlands; [Janssen, Inge] Maasziekenhuis Pantein, Dept Intens Care Med, Beugen, Netherlands; [Ewalds, Esther] Bernhoven Hosp, Dept Intens Care Med, Uden, Netherlands; [Simons, Koen S.] Jeroen Bosch Hosp, Dept Intens Care Med, Shertogenbosch, Netherlands; [Westerhof, Brigitte] Rijnstate Hosp, Dept Intens Care Med, Arnhem, Netherlands; [Rettig, Thijs C. D.] Amphia Hosp, Dept Anesthesiol Intens Care & Pain Med, Breda, Netherlands; [Jacobs, Cretien] Elkerliek Hosp, Dept Intens Care Med, Helmond, Netherlands; [van Santen, Susanne] Maastricht Univ, Dept Intens Care Med, Med Ctr, Maastricht, Netherlands; [Slooter, Arjen J. C.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Intens Care Med, Utrecht, Netherlands; [Slooter, Arjen J. C.] Univ Utrecht, Univ Med Ctr Utrecht, UMC Utrecht Brain Ctr, Utrecht, Netherlands; [Slooter, Arjen J. C.] UZ Brussel, Dept Neurol, Brussels, Belgium; [Slooter, Arjen J. C.] Vrije Univ Brussel, Brussels, Belgium; [van der Woude, Margaretha C. E.] Heerlen Med Ctr, Dept Intens Care, Heerlen, Netherlands; [van der Woude, Margaretha C. E.] Heerlen Med Ctr, Dept Qual & Safety, Heerlen, Netherlands	Radboud University Nijmegen; Canisius-Wilhelmina Hospital; Jeroen Bosch Ziekenhuis; Rijnstate Hospital; Amphia Hospital; Maastricht University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University Hospital Brussels; Vrije Universiteit Brussel	Heesakkers, H (corresponding author), Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Intens Care, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.	hidde.heesakkers@radboudumc.nl; marieke.zeger@radboudumc.nl	van den Boogaard, M./N-5857-2014	van den Boogaard, M./0000-0003-4233-2903; Zegers, Marieke/0000-0002-7472-6184				Ahmed H, 2020, J REHABIL MED, V52, DOI 10.2340/16501977-2694; Bell Melanie L, 2016, BMC Res Notes, V9, P479; Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575; Biehl Michelle, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc055; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Carenzo L, 2021, ANN INTENSIVE CARE, V11, DOI 10.1186/s13613-021-00881-x; De Biase S, 2020, AGE AGEING, V49, P696, DOI 10.1093/ageing/afaa118; Desai SV, 2011, CRIT CARE MED, V39, P371, DOI 10.1097/CCM.0b013e3181fd66e5; Geense W, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018006; Geense WW, 2021, AM J RESP CRIT CARE, V203, P1512, DOI 10.1164/rccm.202009-3381OC; Griffiths J, 2013, CRIT CARE, V17, DOI 10.1186/cc12745; Halpin SJ, 2021, J MED VIROL, V93, P1013, DOI 10.1002/jmv.26368; Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hodgson CL, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03794-0; Hosey MM, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2553-z; Iwashyna TJ, 2021, J HOSP MED, V16, P531, DOI 10.12788/jhm.3660; Knoop H, 2007, PSYCHOTHER PSYCHOSOM, V76, P171, DOI 10.1159/000099844; Medrinal C, 2021, BMC ANESTHESIOL, V21, DOI 10.1186/s12871-021-01274-0; Miskowiak KW, 2021, EUR NEUROPSYCHOPHARM, V46, P39, DOI 10.1016/j.euroneuro.2021.03.019; Morin L, 2021, JAMA-J AM MED ASSOC, V325, P1525, DOI 10.1001/jama.2021.3331; Muscedere J, 2017, INTENS CARE MED, V43, P1105, DOI 10.1007/s00134-017-4867-0; Nelliot A, 2019, ANN AM THORAC SOC, V16, P731, DOI 10.1513/AnnalsATS.201812-851OC; Peach BC, 2021, WORLD MED HEALTH POL, V13, P373, DOI 10.1002/wmh3.401; Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051; Schandl A, 2021, ACTA ANAESTH SCAND, V65, P1285, DOI 10.1111/aas.13939; Tan E, 2021, CHEST, V159, P524, DOI 10.1016/j.chest.2020.10.014; Turnbull AE, 2016, CRIT CARE MED, V44, P1267, DOI 10.1097/CCM.0000000000001651; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; Wassenaar A, 2018, CRIT CARE MED, V46, P79, DOI 10.1097/CCM.0000000000002806; Wynne SC, 2020, CHRON RESP DIS, V17, DOI 10.1177/1479973120933292; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	32	47	47	10	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2022	327	6					559	565		10.1001/jama.2022.0040	http://dx.doi.org/10.1001/jama.2022.0040		JAN 2022	7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD5RT	35072716	Bronze, Green Published			2023-01-03	WOS:000747991900001
J	Sourimant, J; Lieber, CM; Aggarwal, M; Cox, RM; Wolf, JD; Yoon, JJ; Toots, M; Ye, C; Sticher, Z; Kolykhalov, AA; Martinez-Sobrido, L; Bluemling, GR; Natchus, MG; Painter, GR; Plemper, RK				Sourimant, Julien; Lieber, Carolin M.; Aggarwal, Megha; Cox, Robert M.; Wolf, Josef D.; Yoon, Jeong-Joong; Toots, Mart; Ye, Chengin; Sticher, Zachary; Kolykhalov, Alexander A.; Martinez-Sobrido, Luis; Bluemling, Gregory R.; Natchus, Michael G.; Painter, George R.; Plemper, Richard K.			4 '-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication	SCIENCE			English	Review							MECHANISM; LOAD	The COVID-19 pandemic has underscored the critical need for broad-spectrum therapeutics against respiratory viruses. Respiratory syncytial virus (RSV) is a major threat to pediatric patients and older adults. We describe 4'-fluorouridine (4'-FlU, EIDD-2749), a ribonucleoside analog that inhibits RSV, related RNA viruses, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with high selectivity index in cells and human airway epithelia organoids. Polymerase inhibition within in vitro RNA-dependent RNA polymerase assays established for RSV and SARS-CoV-2 revealed transcriptional stalling after incorporation. Once-daily oral treatment was highly efficacious at 5 milligrams per kilogram (mg/kg) in RSV-infected mice or 20 mg/kg in ferrets infected with different SARS-CoV-2 variants of concern, initiated 24 or 12 hours after infection, respectively. These properties define 4'-FlU as a broad-spectrum candidate for the treatment of RSV, SARS-CoV-2, and related RNA virus infections.	[Sourimant, Julien; Lieber, Carolin M.; Aggarwal, Megha; Cox, Robert M.; Wolf, Josef D.; Yoon, Jeong-Joong; Toots, Mart; Plemper, Richard K.] Georgia State Univ, Ctr Translat Antiviral Res, Atlanta, GA 30303 USA; [Ye, Chengin; Martinez-Sobrido, Luis] Texas Biomed Res Inst, San Antonio, TX 78227 USA; [Sticher, Zachary; Kolykhalov, Alexander A.; Bluemling, Gregory R.; Natchus, Michael G.; Painter, George R.] Emory Univ, Emory Inst Drug Dev, Atlanta, GA 30322 USA; [Kolykhalov, Alexander A.; Bluemling, Gregory R.; Painter, George R.] Drug Innovat Ventures & Emory Dr, Atlanta, GA 30322 USA; [Painter, George R.] Emory Univ, Dept Pharmacol, Sch Med, Atlanta, GA 30322 USA; [Plemper, Richard K.] Emory Univ, Dept Pediat, Sch Med, Atlanta, GA 30322 USA	University System of Georgia; Georgia State University; Texas Biomedical Research Institute; Emory University; Emory University; Emory University	Plemper, RK (corresponding author), Georgia State Univ, Ctr Translat Antiviral Res, Atlanta, GA 30303 USA.; Plemper, RK (corresponding author), Emory Univ, Dept Pediat, Sch Med, Atlanta, GA 30322 USA.	rplemper@gsu.edu	Martinez-Sobrido, Luis/ACJ-7853-2022	Martinez-Sobrido, Luis/0000-0001-7084-0804; Wolf, Josef/0000-0003-2507-6944; Yoon, JeongJoong/0000-0001-9379-0416; Sourimant, Julien/0000-0002-1660-1666; Sticher, Zachary/0000-0002-7022-1410; Ye, Chengjin/0000-0002-1934-9494	Public Health Service grants from the NIH/NIAID [AI153400, AI071002, AI141222]	Public Health Service grants from the NIH/NIAID	This work was supported in part by Public Health Service grants AI153400, AI071002, and AI141222 (to R.K.P.) from the NIH/NIAID. The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.	Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cockerill GS, 2019, J MED CHEM, V62, P3206, DOI 10.1021/acs.jmedchem.8b01361; Coleman SM, 2015, FUTURE VIROL, V10, P169, DOI 10.2217/FVL.14.96; Cox RM, 2021, NAT MICROBIOL, V6, P11, DOI 10.1038/s41564-020-00835-2; Cox RM, 2018, J BIOL CHEM, V293, P16761, DOI 10.1074/jbc.RA118.004862; Dangerfield T. L., 2021, STAR PROTOC, V2, P100357, DOI DOI 10.1016/XPR0.2021.100357MEDLINE; DeVincenzo J, 2022, J INFECT DIS, V225, P2087, DOI 10.1093/infdis/jiaa716; El Saleeby CM, 2011, J INFECT DIS, V204, P996, DOI 10.1093/infdis/jir494; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Fearns R, 2017, VIRUS RES, V234, P87, DOI 10.1016/j.virusres.2017.01.008; Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082; Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679; Kokic G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20542-0; Luby SP, 2013, ANTIVIR RES, V100, P38, DOI 10.1016/j.antiviral.2013.07.011; Ludeke B, 2020, VIROLOGY, V540, P66, DOI 10.1016/j.virol.2019.11.002; Marroquin LD, 2007, TOXICOL SCI, V97, P539, DOI 10.1093/toxsci/kfm052; Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103; Moore ML, 2009, J VIROL, V83, P4185, DOI 10.1128/JVI.01853-08; Oberfeld B, 2020, CELL, V181, P954, DOI 10.1016/j.cell.2020.04.013; Painter GR, 2019, ANTIVIR RES, V171, DOI 10.1016/j.antiviral.2019.104597; Rameix-Welti MA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6104; Rha B, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-3611; Richardson P, 2021, EXPERT OPIN DRUG DIS, V16, P1261, DOI 10.1080/17460441.2021.1933427; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Shi T, 2020, J INFECT DIS, V222, pS577, DOI 10.1093/infdis/jiz059; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565; Tchesnokov EP, 2020, J BIOL CHEM, V295, P16156, DOI 10.1074/jbc.AC120.015720; Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326; Toots M, 2020, TRANSL RES, V218, P16, DOI 10.1016/j.trsl.2019.12.002; Toots M, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax5866; Ye CJ, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2111593118; Yoon Jeong-Joong, 2018, Antimicrob Agents Chemother, V62, DOI [10.1128/AAC.00766-18, 10.1128/aac.00766-18]	33	12	12	18	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2022	375	6577					161	+		10.1126/science.abj5508	http://dx.doi.org/10.1126/science.abj5508			54	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG3OI	34855509				2023-01-03	WOS:000742401600027
J	Arnold, C				Arnold, Carrie			SPURRED BY COVID, PUBLIC HEALTH GETS PRECISE	NATURE			English	News Item						Infection; Health care; Society	NEW-YORK-CITY											Alfonso YN, 2021, HEALTH AFFAIR, V40, P664, DOI 10.1377/hlthaff.2020.01084; [Anonymous], 1988, FUT PUBL HLTH; Greene SK, 2021, JMIR PUBLIC HLTH SUR, V7, P180, DOI 10.2196/25538; Greene SK, 2016, EMERG INFECT DIS, V22, P1808, DOI 10.3201/eid2210.160097; Latash J, 2020, MMWR-MORBID MORTAL W, V69, P815, DOI 10.15585/mmwr.mm6926a2; Myers KD, 2019, LANCET DIGIT HEALTH, V1, pE393, DOI 10.1016/S2589-7500(19)30150-5; Ritchie JB, 2021, HERED CANCER CLIN PR, V19, DOI 10.1186/s13053-021-00188-9	7	1	1	6	31	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 6	2022	601	7891					18	20		10.1038/d41586-021-03819-2	http://dx.doi.org/10.1038/d41586-021-03819-2			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB0AX	34983989				2023-01-03	WOS:000738686800005
J	Hansen, N; Bryant, A; McCormack, R; Johnson, H; Lindsay, T; Stelck, K; Bernards, MT				Hansen, Niko; Bryant, Adriana; McCormack, Roslyn; Johnson, Hannah; Lindsay, Travis; Stelck, Kael; Bernards, Matthew T.			Assessment of the performance of nonfouling polymer hydrogels utilizing citizen scientists	PLOS ONE			English	Article							BRUSHES; RESISTANCE; ADHESION; SCIENCE	To facilitate longer duration space travel, flight crew sickness and disease transmission amongst the crew must be eliminated. High contact surfaces within space vehicles provide an opportunity for bacterial adhesion, which can lead to biofilm formation or disease transmission. This study evaluates the performance of several nonfouling polymers using citizen science, to identify the best performing chemistry for future applications as bacteria resistant coatings. The specific polymer chemistries tested were zwitterionic sulfobetaine methacrylate (SBMA), and polyampholytes composed of [2-(acryloyloxy)ethyl] trimethylammonium chloride and 2-carboxyethyl acrylate (TMA/CAA), or TMA and 3-sulfopropyl methacrylate (TMA/SA). Each polymer chemistry is known to exhibit bacteria resistance, and this study provides a direct side-by-side comparison between the chemistries using a citizen science approach. Nearly 100 citizen scientists returned results comparing the performance of these polymers over repeat exposure to bacteria and 30 total days of growth. The results demonstrate that TMA/CAA polyampholyte hydrogels show the best long-term resistance to bacteria adhesion.	[Hansen, Niko; Bryant, Adriana; McCormack, Roslyn; Johnson, Hannah; Lindsay, Travis; Stelck, Kael; Bernards, Matthew T.] Univ Idaho, Dept Chem & Biol Engn, Moscow, ID 83843 USA	Idaho; University of Idaho	Bernards, MT (corresponding author), Univ Idaho, Dept Chem & Biol Engn, Moscow, ID 83843 USA.	mbernards@uidaho.edu		Bernards, Matthew/0000-0002-5234-1910	National Aeronautics and Space Administration (NASA) as part of the Student Payload Opportunity with Citizen Science (SPOCS) program [80NSSC17M0021]	National Aeronautics and Space Administration (NASA) as part of the Student Payload Opportunity with Citizen Science (SPOCS) program	This research was funded by the National Aeronautics and Space Administration (NASA) as part of the Student Payload Opportunity with Citizen Science (SPOCS) program under Federal Award No 80NSSC17M0021, as a subaward to the University of Idaho. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, B ECOL SOC AM, DOI DOI 10.1002/BES2.1336; Bernards M, 2014, J BIOMAT SCI-POLYM E, V25, P1479, DOI 10.1080/09205063.2014.938976; Bernards MT, 2008, MACROMOLECULES, V41, P4216, DOI 10.1021/ma800185y; Castro VA, 2004, MICROB ECOL, V47, P119, DOI 10.1007/s00248-003-1030-y; Cheng G, 2007, BIOMATERIALS, V28, P4192, DOI 10.1016/j.biomaterials.2007.05.041; Cheng G, 2009, BIOMATERIALS, V30, P5234, DOI 10.1016/j.biomaterials.2009.05.058; Davis JR., 2010, 22538 JSC NAT AER SP; del Pozo JL, 2007, CLIN PHARMACOL THER, V82, P204, DOI 10.1038/sj.clpt.6100247; Dickinson JL, 2010, ANNU REV ECOL EVOL S, V41, P149, DOI 10.1146/annurev-ecolsys-102209-144636; Dobbins SC, 2012, J PHYS CHEM B, V116, P14346, DOI 10.1021/jp307588b; Grant DM, 2005, HEAT TRANSFER ENG, V26, P44, DOI 10.1080/01457630590890166; Haag SL, 2020, LANGMUIR, V36, P3292, DOI 10.1021/acs.langmuir.0c00114; Laschewsky A, 2014, POLYMERS-BASEL, V6, P1544, DOI 10.3390/polym6051544; Mi L, 2010, BIOMATERIALS, V31, P2919, DOI 10.1016/j.biomaterials.2009.12.038; Palmer J, 2007, J IND MICROBIOL BIOT, V34, P577, DOI 10.1007/s10295-007-0234-4; Schroeder ME, 2013, BIOMACROMOLECULES, V14, P3112, DOI 10.1021/bm4007369; Tah T, 2012, COLLOID SURFACE B, V93, P195, DOI 10.1016/j.colsurfb.2012.01.004; Tsai WB, 1999, J BIOMED MATER RES, V44, P130, DOI 10.1002/(SICI)1097-4636(199902)44:2<130::AID-JBM2>3.0.CO;2-9; Vu B, 2009, MOLECULES, V14, P2535, DOI 10.3390/molecules14072535; Wiggins A, 2019, AM J BIOETHICS, V19, P3, DOI 10.1080/15265161.2019.1619859; Wu H, 2015, INT J ORAL SCI, V7, P1, DOI 10.1038/ijos.2014.65; Yang J, 2018, METHOD MICROBIOL, V45, P3, DOI 10.1016/bs.mim.2018.07.002	22	0	0	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2021	16	12							e0261817	10.1371/journal.pone.0261817	http://dx.doi.org/10.1371/journal.pone.0261817			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ9AO	34972139	Green Published, gold			2023-01-03	WOS:000773555700057
J	Djonor, SK; Ako-Nnubeng, IT; Owusu, EA; Akuffo, KO; Nortey, P; Agyei-Manu, E; Danso-Appiah, A				Djonor, Sampson Kafui; Ako-Nnubeng, Ignatius Terence; Owusu, Ewurama Ampadu; Akuffo, Kwadwo Owusu; Nortey, Pricillia; Agyei-Manu, Eldad; Danso-Appiah, Anthony			Determinants of blood glucose control among people with Type 2 diabetes in a regional hospital in Ghana	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; MANAGEMENT; ASSOCIATION; UPDATE; ADULTS; LIFE	Aims To assess the determinants of glycaemic control among patients with Type 2 diabetes mellitus (T2DM) presenting at the Greater Accra Regional Hospital, Ghana. Methods The study employed semi-structured questionnaires and review of clinical records of patients 16 years and above with Type 2 Diabetes. Results The mean age of participants was 56.6 13.8 years, with majority (71.6%) being females. A total of 161 (59.4%) of patients had poor glycaemic control (HbA1c >= 8.1%; 95% CI: 53.6 to 65.3%). Poor glycaemic control was significantly associated with high body mass index of the patient (AOR 13.22; 95% CI: 1.95 to 89.80), having only elementary education (AOR 5.22, 95% CI 2.12-12.86, p<0.0001) and being on insulin therapy (AOR 2.88; 95% CI: 1.05 to 7.88). On the other hand, seldom coffee intake (AOR: 0.27; 95% CI: 0.11 to 0.64), high physical activity (AOR 1.57, 95% CI 1.06-2.35, p = 0.025) and having a cardiovascular disease (AOR: 0.15; 95% CI: 0.05 to 0.46) appeared to positively influence glycaemic control. Self-monitoring of blood glucose and diet interventions did not appear to influence glycaemic control. Conclusions The study results showing that a high proportion of patients attending the Diabetes Clinic with uncontrolled diabetes has serious implications for the management of T2DM diabetes as it suggests that current hospital-based treatment measures are less effective. Comprehensive management of T2DM targeting all the key factors identified in this study and incorporating a multispectral collaborative effort based on holistic approach, combined with non-pharmacological components are strongly warranted.	[Djonor, Sampson Kafui; Ako-Nnubeng, Ignatius Terence; Nortey, Pricillia; Danso-Appiah, Anthony] Univ Ghana, Coll Hlth Sci, Sch Publ Hlth, Dept Epidemiol & Dis Control, Legon, Ghana; [Djonor, Sampson Kafui] Korle Bu Teaching Hosp, Cent Lab, Korle Bu, Accra, Ghana; [Owusu, Ewurama Ampadu] Univ Ghana, Coll Hlth Sci, Sch Biomed & Allied Hlth Sci, Dept Med Lab Sci, Legon, Ghana; [Akuffo, Kwadwo Owusu; Agyei-Manu, Eldad] Kwame Nkrumah Univ Sci & Technol, Coll Sci, Dept Optometry & Visual Sci, Kumasi, Ghana; [Danso-Appiah, Anthony] Univ Ghana, Ctr Evidence Synth & Policy, Sch Publ Hlth, Legon, Accra, Ghana; [Danso-Appiah, Anthony] Univ Ghana, Sch Publ Hlth, Dept Epidemiol & Dis Control, Legon, Ghana	University of Ghana; University of Ghana; Kwame Nkrumah University Science & Technology; University of Ghana; University of Ghana	Danso-Appiah, A (corresponding author), Univ Ghana, Coll Hlth Sci, Sch Publ Hlth, Dept Epidemiol & Dis Control, Legon, Ghana.; Danso-Appiah, A (corresponding author), Univ Ghana, Ctr Evidence Synth & Policy, Sch Publ Hlth, Legon, Accra, Ghana.; Danso-Appiah, A (corresponding author), Univ Ghana, Sch Publ Hlth, Dept Epidemiol & Dis Control, Legon, Ghana.	adanso-appiah@ug.edu.ph	Akuffo, Kwadwo Owusu/J-2036-2019; Agyei-Manu, Eldad/AAS-8273-2020	Akuffo, Kwadwo Owusu/0000-0001-6683-249X; Agyei-Manu, Eldad/0000-0002-2712-0198; Djonor, Sampson Kafui/0000-0002-9962-7051; Danso-Appiah, Anthony/0000-0003-1747-0060				Acik Yasemin, 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P1012; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; [Anonymous], 2015, DIABETES CARE, V38, pS8, DOI 10.2337/dc15-S005; Asamoah-Boaheng M, 2019, INT HEALTH, V11, P83, DOI 10.1093/inthealth/ihy067; Blundell JE, 2003, P NUTR SOC, V62, P651, DOI 10.1079/PNS2003286; Bosi E, 2013, DIABETES CARE, V36, P2887, DOI 10.2337/dc13-0092; Cefalu WT, 2019, DIABETES CARE, V42, pS61, DOI 10.2337/dc19-S006; Cefalu WT, 2019, DIABETES CARE, V42, pS81, DOI 10.2337/dc19-S008; Cefalu WT, 2019, DIABETES CARE, V42, pS46, DOI 10.2337/dc19-S005; Chawla Aastha, 2016, Indian J Endocrinol Metab, V20, P546, DOI 10.4103/2230-8210.183480; Cheng HL, 2016, RESEARCHGATE, DOI DOI 10.13140/RG.2.2.21067.80165; Chung JK, 2017, FRONTIERS LAB MED, V1, P76, DOI DOI 10.1016/J.FLM.2017.06.002; Cilia S., 2007, Malta Medical Journal, V19, P6; Cooke D, 2015, J BEHAV MED, V38, P817, DOI 10.1007/s10865-015-9649-y; Cosson E, 2018, DIABETES METAB, V44, P200, DOI 10.1016/j.diabet.2018.01.014; Cushman WC, 2010, NEW ENGL J MED, V362, P1575, DOI 10.1056/NEJMoa1001286; Danne T, 2017, DIABETES CARE, V40, P1631, DOI 10.2337/dc17-1600; Dhatariya K, 2017, ENDOTEXT; Dinneen SF, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-88; Dworatzek PD, 2013, CAN J DIABETES, V37, pS45, DOI 10.1016/j.jcjd.2013.01.019; Ghana_Health_Service, 2015, HLTH SYST DAT RES IN; Ghana_Health_Service, 2018, GHAN HLTH SERV YEARL; Gosse Suzanne, 2014, Medsurg Nurs, V23, P317; Gray, 2019, NUTR RECOMMENDATIONS; Greater_Accra_Regional_Hospital, 2018, LAB RES SAMPL HBA1C; Gupta S., 2017, J NANOMED RES, V5, P00120, DOI DOI 10.15406/JNMR.2017.05.00120; Inzucchi SE, 2015, DIABETOLOGIA, V58, P429, DOI 10.1007/s00125-014-3460-0; Marin-Penalver JJ, 2016, WORLD J DIABETES, V7, P354, DOI 10.4239/wjd.v7.i17.354; Lalic Nebojsa, 2013, J Diabetes Sci Technol, V7, P285; McIntyre HD, 2014, DIABETES METAB J, V38, P87, DOI 10.4093/dmj.2014.38.2.87; Petrie JR, 2018, CAN J CARDIOL, V34, P575, DOI 10.1016/j.cjca.2017.12.005; Raaijmakers LGM, 2015, J BEHAV MED, V38, P450, DOI 10.1007/s10865-014-9609-y; Raveendran Arkiath V, 2018, Eur Endocrinol, V14, P31, DOI 10.17925/EE.2018.14.2.31; Saeedi P, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107843; Schnell Oliver, 2013, J Diabetes Sci Technol, V7, P478; Selvin E, 2004, ANN INTERN MED, V141, P421, DOI 10.7326/0003-4819-141-6-200409210-00007; Sherwani SI, 2016, BIOMARK INSIGHTS, V11, P95, DOI [10.4137/BMI.S38440, 10.4137/BMIMI.S38440]; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Szkudelski T, 2015, BBA-MOL BASIS DIS, V1852, P1145, DOI 10.1016/j.bbadis.2014.10.013; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4	40	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2021	16	12							e0261455	10.1371/journal.pone.0261455	http://dx.doi.org/10.1371/journal.pone.0261455			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ1OD	34936668	Green Published, gold			2023-01-03	WOS:000755251000034
J	Chanie, ES; Gelaye, GA; Tadesse, TY; Feleke, DG; Admas, WT; Alemu, EM; Azanaw, MM; Tiruneh, SA; Gebremariam, AD; Birhane, BM; Bayih, WA; Aragie, G				Chanie, Ermias Sisay; Gelaye, Getnet Asmare; Tadesse, Tesfaye Yimer; Feleke, Dejen Getaneh; Admas, Wubet Taklual; Alemu, Eshetie Molla; Azanaw, Melkalem Mamoye; Tiruneh, Sofonyas Abebaw; Gebremariam, Alemayehu Digssie; Birhane, Binyam Minuye; Bayih, Wubet Alebachew; Aragie, Getachew			Estimation of lifetime survival and predictors of mortality among TB with HIV co-infected children after test and treat strategies launched in Northwest, Ethiopia, 2021; a multicentre historical follow-up study	PLOS ONE			English	Article							ANTIRETROVIRAL TREATMENT; TUBERCULOSIS; COINFECTION	Introduction In resource-limited settings, the mortality rate among tuberculosis and human Immunodeficiency virus co-infected children is higher. However, there is no adequate evidence in Ethiopia in general and in the study area in particular. Hence, this study aims to estimate lifetime survival and predictors of mortality among TB with HIV co-infected children after test and treat strategies launched in Northwest Ethiopia Hospitals, 2021. Methods Institution-based historical follow-up study was conducted in Northwest Ethiopia Hospitals among 227 Tuberculosis and Human Immunodeficiency Virus co-infected children from March 1, 2014, to January 12, 2021. The data were entered into Epi info-7 and then exported to STATA version 14 for analysis. The log-rank test was used to estimate the curve difference of the predictor variables. Bivariable cox-proportional hazard models were employed for each predictor variable. Additionally, those variables having a p-value < 0.25 in bivariate analysis were fitted into a multivariable cox-proportional hazards model. P-value < 0.05 was used to declare significance associated with the dependent variable. Results From a total of 227 TB and HIV co-infected children, 39 died during the follow-up period. The overall mortality rate was 3.7 (95% CI (confidence interval): 2.9-4.7) per 100 personyears with a total of 1063.2-year observations. Cotrimoxazole preventive therapy (CPT) non-users [Adjusted Hazarded Ratio (AHR) = 3.8 (95% CI: 1.64-8.86)], presence of treatment failure [AHR = 3.0 (95% CI: 1.14-78.17)], and Cluster of differentiation 4(CD4) count below threshold [AHR = 2.7 (95% CI: 1.21-6.45)] were significant predictors of mortality. Conclusion In this study, the mortality rate among TB and HIV co-infected children was found to be very high. The risk of mortality among TB and HIV co-infected children was associated with treatment failure, CD4 count below the threshold, and cotrimoxazole preventive therapy nonusers. Further research should conduct to assess and improve the quality of ART service in Northwest Ethiopia Hospitals.	[Chanie, Ermias Sisay; Gelaye, Getnet Asmare; Feleke, Dejen Getaneh; Aragie, Getachew] Debre Tabor Univ, Dept Pediat & Child Hlth Nursing, Coll Hlth Sci, Debra Tabor, Ethiopia; [Tadesse, Tesfaye Yimer] Debre Tabor Univ, Dept Pharmacol, Coll Hlth Sci, Debra Tabor, Ethiopia; [Admas, Wubet Taklual; Alemu, Eshetie Molla; Azanaw, Melkalem Mamoye; Tiruneh, Sofonyas Abebaw; Gebremariam, Alemayehu Digssie] Debre Tabor Univ, Coll Hlth Sci, Publ Hlth, Debra Tabor, Ethiopia; [Birhane, Binyam Minuye; Bayih, Wubet Alebachew] Debre Tabor Univ, Dept Matern & Neonatal Hlth Nursing, Coll Hlth Sci, Debra Tabor, Ethiopia		Chanie, ES (corresponding author), Debre Tabor Univ, Dept Pediat & Child Hlth Nursing, Coll Hlth Sci, Debra Tabor, Ethiopia.	ermisis1888@gmail.com	Chanie, Ermias Sisay/ABG-5569-2021; Bayih, Wubet Alebachew/AAF-5099-2019	Chanie, Ermias Sisay/0000-0002-3124-5380; Bayih, Wubet Alebachew/0000-0003-1439-4402; Getaneh Feleke, Dejen/0000-0002-0816-1744				AIDSinfo, HIV TUB TB UND HIV A; [Anonymous], 2019, HIV AIDS HIV BAS HIV; [Anonymous], 2020, TREATM LIV HIV HIV B; [Anonymous], 2020, TB HIV COINF DIAGN T; Atalell KA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197145; Au-Yeung Christopher, 2011, Clin Epidemiol, V3, P21, DOI 10.2147/CLEP.S15574; Aung ZZ, 2019, INT J INFECT DIS, V80, P10, DOI 10.1016/j.ijid.2018.12.008; Berkley JA, 2016, LANCET GLOB HEALTH, V4, pE464, DOI 10.1016/S2214-109X(16)30096-1; Butler Amanda., UNDERDEVELOPED HEALT; Daniel OJ, 2015, PUBLIC HEALTH ACTION, V5, P165, DOI 10.5588/pha.15.0027; Daniels B, 2019, LANCET GLOB HEALTH, V7, pE1717, DOI 10.1016/S2214-109X(19)30422-X; Ebonyi Augustine O, 2016, Germs, V6, P139, DOI 10.11599/germs.2016.1099; Fry SHL, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00159; Gezae K. E., 2020, PREDICTORS TIME DEAT, V5, P7; Gupta RK, 2015, AIDS, V29, P1987, DOI 10.1097/QAD.0000000000000802; Kumar A, 2007, CURR HIV RES, V5, P499, DOI 10.2174/157016207781662434; Lawn SD, 2006, AIDS, V20, P1605, DOI 10.1097/01.aids.0000238406.93249.cd; Mabunda TE, 2014, AFR HEALTH SCI, V14, DOI 10.4314/ahs.v14i4.12; Mugusi FM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-409; Myhre J., WHAT HIV TREATMENT F; Nega J, 2020, AIDS RES THER, V17, DOI 10.1186/s12981-020-00294-z; Okechukwu A. A., 2011, J CLIN PRACT, V14, DOI [10.4314/njcp.v14i2, DOI 10.4314/NJCP.V14I2]; Peabody JW, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1293; Refera H, 2013, ETHIOP J HEALTH DEV, V27, P88; Ruphine P.Ansot Anzats, 2019, ARCH INT MED RES, V2, DOI [10.26502/aimr.006, DOI 10.26502/AIMR.006]; TB and HIV, TB HIV; Teklu AM, 2017, ETHIOP J HEALTH SCI, V27, P29, DOI 10.4314/ejhs.v27i1.4S; Tesfaye B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203986; Tshitenge Stephane, 2018, Afr J Prim Health Care Fam Med, V10, pe1, DOI 10.4102/phcfm.v10i1.1765; Venturini E, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-S1-S5; Walker UA, 2006, CURR OPIN RHEUMATOL, V18, P389, DOI 10.1097/01.bor.0000231908.57913.2f; WebMD, CHILDR HIV AIDS OV; WHO, TB CAUS 1 3 HIV DEAT; WHO, 2019, 10 THREATS GLOB HLTH	34	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2021	16	12							e0258964	10.1371/journal.pone.0258964	http://dx.doi.org/10.1371/journal.pone.0258964			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0X1HA	34932563	gold, Green Published			2023-01-03	WOS:000789464700002
J	Liyew, EF; Chernet, M; Belay, H; Maddren, R; Landeryou, T; Kalahasti, S; Ower, AK; Mekete, K; Phillips, AE; Anjulo, U; Endrias, T; Tamiru, A; Gidey, B; Mehari, Z; Mengistu, B; Tollera, G; Tasew, G				Liyew, Ewnetu Firdawek; Chernet, Melkie; Belay, Habtamu; Maddren, Rosie; Landeryou, Toby; Kalahasti, Suprabhath; Ower, Alison K.; Mekete, Kalkidan; Phillips, Anna E.; Anjulo, Ufaysa; Endrias, Tujuba; Tamiru, Adugna; Gidey, Bokretsion; Mehari, Zelalem; Mengistu, Birhan; Tollera, Getachew; Tasew, Geremew			Coverage evaluation surveys following soil-transmitted helminthiasis and schistosomiasis mass drug administration in Wolaita Zone of Ethiopia-The Geshiyaro project	PLOS ONE			English	Article							INFECTIONS	Introduction The Geshiyaro project aims to break transmission of soil-transmitted helminths and schistosomiasis in the Wolaita Zone of Ethiopia through a combination of two interventions: behavior change communication (BCC) for increased water, sanitation and hygiene (WaSH) infrastructure use alongside preventive chemotherapy (PC) using albendazole (ALB) and praziquantel (PZQ), targeted to reach 90% treatment coverage. Coverage evaluation surveys (CES) were conducted post-treatment, and the resultant survey coverage was compared to reported administrative coverage. This provided a secondary confirmation of the Geshiyaro project coverages, and is used to monitor the success of each Mass Drug Administration (MDA) round. Methods A community-based cross-sectional study was conducted in 13 woredas (districts) of the Wolaita Zone. All eligible individuals from the selected households were invited for an interview. The study design, sample size, analysis and report writing were conducted according to the World Health Organization (WHO) CES guidelines for PC. Results The study interviewed a total of 3,568 households and 18,875 individuals across 13 woredas in the Wolaita Zone. Overall, the survey coverage across all studied woredas was 81.5% (95% CI; 80.9-82.0%) for both ALB and PZQ. Reported administrative coverage across all studied woredas was higher than survey coverage, 92.7% and 91.2% for ALB and PZQ, respectively. A significant portion of individuals (17.6%) were not offered PC. The predominant reason for not achieving the target coverage of 90% was beneficiary absenteeism during MDA (6.6% ALB, 6.8% PZQ), followed by drug distributors failing to reach all households (4.7% ALB, 4.8% PZQ), and beneficiaries not informed of the program (1.3% ALB, 1.7% PZQ). Conclusion Programmatic actions will need to be taken during the next MDA campaign to achieve the targeted Geshiyaro project coverage threshold across data collection and program engagement. Adequate training and supervision on recording and reporting administrative coverage should be provided, alongside improved social mobilization of treated communities to increase participation, and strengthened institutional partnerships and communication.	[Liyew, Ewnetu Firdawek; Chernet, Melkie; Belay, Habtamu; Mekete, Kalkidan; Endrias, Tujuba; Gidey, Bokretsion; Tollera, Getachew; Tasew, Geremew] Ethiopian Publ Hlth Inst, Bacterial Parasit & Zoonot Dis Res Directorate, Addis Ababa, Ethiopia; [Maddren, Rosie; Landeryou, Toby; Kalahasti, Suprabhath; Ower, Alison K.; Phillips, Anna E.] Imperial Coll London, Sch Publ Hlth, Dept Infect Dis Epidemiol, Fac Med, London, England; [Maddren, Rosie; Landeryou, Toby; Ower, Alison K.; Phillips, Anna E.] London Ctr Neglected Trop Dis Res, London, England; [Anjulo, Ufaysa] Minist Hlth, Dis Prevent & Hlth Promot Core Proc, Wolaita, Ethiopia; [Tamiru, Adugna] Minist Hlth, Dis Prevent & Control Directorate, Addis Ababa, Ethiopia; [Mehari, Zelalem; Mengistu, Birhan] Childrens Investment Fund Fdn, London, England	Imperial College London	Liyew, EF (corresponding author), Ethiopian Publ Hlth Inst, Bacterial Parasit & Zoonot Dis Res Directorate, Addis Ababa, Ethiopia.	ewnetuliyew@gmail.com		Landeryou, Toby/0000-0001-6025-1336; Tasew, Geremew/0000-0002-2797-824X	Children's Investment Fund Foundation (CIFF), UK [R-1805-02741]	Children's Investment Fund Foundation (CIFF), UK	This research was funded by the Children's Investment Fund Foundation (CIFF), UK through a grant to Ethiopian Public Health Institute, Ethiopia under grant number R-1805-02741. The funders had no role in the design of the study, collection, analysis and interpretation of the data. The finding and conclusion of the study reflect the view of the Authors only.	Asfaw MA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235281; David WT, 2006, PREVENTIVE CHEMOTHER; Ethiopian Public Health Institute (EPHI) and ICF [Ethiopia], 2019, ETH MIN HLTH SURV 20; Leta GT, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04317-6; Maddren R, 2021, PARASITE VECTOR, V14, DOI 10.1186/s13071-021-04600-0; Mekete K, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3757-4; Mupfasoni D, 2019, INFECT DIS POVERTY, V8, DOI 10.1186/s40249-019-0589-6; Negussu Nebiyu, 2017, Ethiop Med J, V55, P75; Pilnick AR, 2021, SCI REP-UK, V11, DOI [10.1155/2014/139030, 10.1038/s41598-021-90564-1, 10.18280/isi.270101]; Pullan RL, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-37; van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9; Webster Joanne P, 2014, Philos Trans R Soc Lond B Biol Sci, V369, P20130434, DOI 10.1098/rstb.2013.0434; WHO, 2010, WORKING TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES: FIRST WHO REPORT ON NEGLECTED TROPICAL DISEASES, P1; World Health Organization, 2012, SOIL TRANSM HELM EL; World Health Organization, 2019, FIELD MANUAL IMPLEME; World Health Organization (WHO), 2020, END NEGL ATT SUST DE	16	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2021	16	12							e0260722	10.1371/journal.pone.0260722	http://dx.doi.org/10.1371/journal.pone.0260722			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0X1HA	34932602	gold, Green Published			2023-01-03	WOS:000789464700008
J	Volodina, M; Smetanin, N; Lebedev, M; Ossadtchi, A				Volodina, Maria; Smetanin, Nikolai; Lebedev, Mikhail; Ossadtchi, Alexei			Cortical and autonomic responses during staged Taoist meditation: Two distinct meditation strategies	PLOS ONE			English	Article							FRONTAL-MIDLINE-THETA; HEART-RATE; MINDFULNESS; ATTENTION; AWARENESS; STRESS; CONNECTIVITY; EXPERIENCE; REDUCTION; STATES	Meditation is a consciousness state associated with specific physiological and neural correlates. Numerous investigations of these correlates reported controversial results which prevented a consistent depiction of the underlying neurophysiological processes. Here we investigated the dynamics of multiple neurophysiological indicators during a staged meditation session. We measured the physiological changes at rest and during the guided Taoist meditation in experienced meditators and naive subjects. We recorded EEG, respiration, galvanic skin response, and photoplethysmography. All subjects followed the same instructions split into 16 stages. In the experienced meditators group we identified two subgroups with different physiological markers dynamics. One subgroup showed several signs of general relaxation evident from the changes in heart rate variability, respiratory rate, and EEG rhythmic activity. The other subgroup exhibited mind concentration patterns primarily noticeable in the EEG recordings while no autonomic responses occurred. The duration and type of previous meditation experience or any baseline indicators we measured did not explain the segregation of the meditators into these two groups. These results suggest that two distinct meditation strategies could be used by experienced meditators, which partly explains the inconsistent results reported in the earlier studies evaluating meditation effects. Our findings are also relevant to the development of the high-end biofeedback systems.	[Volodina, Maria; Smetanin, Nikolai; Lebedev, Mikhail; Ossadtchi, Alexei] HSE Univ, Ctr Bioelect Interfaces, Moscow, Russia; [Ossadtchi, Alexei] Artificial Intelligence Res Inst, Moscow, Russia	HSE University (National Research University Higher School of Economics)	Ossadtchi, A (corresponding author), HSE Univ, Ctr Bioelect Interfaces, Moscow, Russia.; Ossadtchi, A (corresponding author), Artificial Intelligence Res Inst, Moscow, Russia.	aossadtchi@hse.ru	Volodina, Maria A/H-4758-2014	Ossadtchi, Alex/0000-0001-8827-9429	Center for Bioelectric Interfaces NRU HSE, RF Government [075-15-2021-624]	Center for Bioelectric Interfaces NRU HSE, RF Government	This work is supported by the Center for Bioelectric Interfaces NRU HSE, RF Government grant, AG. No. 075-15-2021-624. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aftanas L, 2005, INT J NEUROSCI, V115, P893, DOI 10.1080/00207450590897969; Ahani A, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-87; Amihai I, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/731579; Amihai I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102990; Arnau S, 2020, PSYCHOPHYSIOLOGY, V57, DOI 10.1111/psyp.13581; Baevsky RM, 2017, CARDIOMETRY, P66, DOI 10.12710/cardiometry.2017.10.6676; Bazanova OM, 2014, NEUROSCI BIOBEHAV R, V44, P94, DOI 10.1016/j.neubiorev.2013.05.007; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger AM, 2018, NEUROSCIENCE, V378, P189, DOI 10.1016/j.neuroscience.2017.06.007; Black DS, 2019, CURR OPIN PSYCHOL, V28, P302, DOI 10.1016/j.copsyc.2019.06.004; Boccia M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/419808; Bostic JQ, 2015, CHILD ADOL PSYCH CL, V24, P245, DOI 10.1016/j.chc.2014.11.010; Britton WB, 2014, ANN NY ACAD SCI, V1307, P64, DOI 10.1111/nyas.12279; Cahn BR, 2010, COGN PROCESS, V11, P39, DOI 10.1007/s10339-009-0352-1; Camm AJ, 1996, EUR HEART J, V17, P354; Clarke Tainya C, 2015, Natl Health Stat Report, P1; Compton RJ, 2019, COGN AFFECT BEHAV NE, V19, P1184, DOI 10.3758/s13415-019-00745-9; Crivelli D, 2019, MINDFULNESS, V10, P301, DOI 10.1007/s12671-018-0975-3; Das I., 2012, PSYCHOL THOUGHT INTE, V5; DeLosAngeles D, 2016, INT J PSYCHOPHYSIOL, V110, P27, DOI 10.1016/j.ijpsycho.2016.09.020; Ditto B, 2006, ANN BEHAV MED, V32, P227, DOI 10.1207/s15324796abm3203_9; Doppelmayr A, 2008, NEUROPSYCHOLOGIA, V46, P1463, DOI 10.1016/j.neuropsychologia.2007.12.026; Dor-Ziderman Y, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00582; ELSON BD, 1977, PSYCHOPHYSIOLOGY, V14, P52, DOI 10.1111/j.1469-8986.1977.tb01155.x; Faber PL, 2015, COGN PROCESS, V16, P87, DOI 10.1007/s10339-014-0637-x; Fan JQ, 1998, J AM STAT ASSOC, V93, P1007, DOI 10.2307/2669845; Garrison KA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00440; Gotink RA, 2016, BRAIN COGNITION, V108, P32, DOI 10.1016/j.bandc.2016.07.001; Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018; Harmony T, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00083; Hilton L, 2017, ANN BEHAV MED, V51, P199, DOI 10.1007/s12160-016-9844-2; Hinterberger T, 2018, COMPLEMENT MED RES, V25, P313, DOI 10.1159/000489342; Hinterberger T, 2016, APPL PSYCHOPHYS BIOF, V41, P315, DOI 10.1007/s10484-016-9332-2; Hinterberger T, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00099; Hood MM, 2017, GASTROENTEROL CLIN N, V46, P859, DOI 10.1016/j.gtc.2017.08.008; Jaseja H, 2006, MED HYPOTHESES, V66, P925, DOI 10.1016/j.mehy.2005.11.043; Kaur Chamandeep, 2015, Adv Prev Med, V2015, P614723, DOI 10.1155/2015/614723; Klimesch W, 2001, COGNITIVE BRAIN RES, V12, P33, DOI 10.1016/S0926-6410(01)00024-6; KOIZUMI K, 1985, J AUTONOM NERV SYST, V12, P251, DOI 10.1016/0165-1838(85)90065-7; Kubota Y, 2001, COGNITIVE BRAIN RES, V11, P281, DOI 10.1016/S0926-6410(00)00086-0; Kuijpers HJH, 2007, PSYCHOPATHOLOGY, V40, P461, DOI 10.1159/000108125; Last N, 2017, J ALZHEIMERS DIS, V56, P275, DOI 10.3233/JAD-160899; Lazar SW, 2005, NEUROREPORT, V16, P1893, DOI 10.1097/01.wnr.0000186598.66243.19; Lee DJ, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00178; Lee SH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015574; Lehmann D, 2012, NEUROIMAGE, V60, P1574, DOI 10.1016/j.neuroimage.2012.01.042; Lehrer P, 1999, PSYCHOSOM MED, V61, P812, DOI 10.1097/00006842-199911000-00014; Leonard A, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00062; Levine GN, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.002218; Lim S, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19071669; Lomas T, 2015, NEUROSCI BIOBEHAV R, V57, P401, DOI 10.1016/j.neubiorev.2015.09.018; Luders E, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00186; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; Manna A, 2010, BRAIN RES BULL, V82, P46, DOI 10.1016/j.brainresbull.2010.03.001; Moak JP, 2007, HEART RHYTHM, V4, P1523, DOI 10.1016/j.hrthm.2007.07.019; Mole TB, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00613; Pascoe MC, 2017, J PSYCHIATR RES, V95, P156, DOI 10.1016/j.jpsychires.2017.08.004; Pasquini H, 2015, ELECTROPHYSIOLOGICAL; Peng CK, 1999, INT J CARDIOL, V70, P101, DOI 10.1016/S0167-5273(99)00066-2; Peng CK, 2004, INT J CARDIOL, V95, P19, DOI 10.1016/j.ijcard.2003.02.006; Ritter P, 2009, HUM BRAIN MAPP, V30, P1168, DOI 10.1002/hbm.20585; Rubia K, 2009, BIOL PSYCHOL, V82, P1, DOI 10.1016/j.biopsycho.2009.04.003; Rubik B, 2011, J ALTERN COMPLEM MED, V17, P109, DOI 10.1089/acm.2009.0191; Sauseng P, 2007, EUR J NEUROSCI, V25, P587, DOI 10.1111/j.1460-9568.2006.05286.x; Schlosser M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216643; Schoenberg PLA, 2018, CONSCIOUS COGN, V57, P41, DOI 10.1016/j.concog.2017.11.003; Schubert R, 2009, J COGNITIVE NEUROSCI, V21, P2407, DOI 10.1162/jocn.2008.21174; Shaffer F, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00258; Shapiro D H Jr, 1992, Int J Psychosom, V39, P62; Sieverdes John C, 2017, Mhealth, V3, P44, DOI 10.21037/mhealth.2017.09.04; SILVERMAN BW, 1981, J ROY STAT SOC B MET, V43, P97; Smetanin N, 2018, FRONT NEUROINFORM, V12, DOI 10.3389/fninf.2018.00100; Steinhubl SR., 2015, CARDIOVASCULAR NERVO, V9, P1; Tang YY, 2009, P NATL ACAD SCI USA, V106, P8865, DOI 10.1073/pnas.0904031106; Thomas J, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00197; Tomasino B, 2014, BRAIN COGNITION, V90, P32, DOI 10.1016/j.bandc.2014.03.013; Tyagi A, 2016, APPL PSYCHOPHYS BIOF, V41, P381, DOI 10.1007/s10484-016-9340-2; van Lutterveld R, 2017, NEUROIMAGE, V151, P117, DOI 10.1016/j.neuroimage.2016.02.047; Vickery CE, 2016, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.02025; Whitmarsh S, 2014, NEUROIMAGE, V85, P803, DOI 10.1016/j.neuroimage.2013.07.031; Wu SD, 2008, BIOMED RES-TOKYO, V29, P245, DOI 10.2220/biomedres.29.245; ZEIER H, 1984, BIOFEEDBACK SELF-REG, V9, P497, DOI 10.1007/BF01000565	82	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2021	16	12							e0260626	10.1371/journal.pone.0260626	http://dx.doi.org/10.1371/journal.pone.0260626			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XW0CT	34855823	gold, Green Published, Green Submitted			2023-01-03	WOS:000735299000080
J	Akinyemi, AI; Erinfolami, TP; Adebayo, SO; Shah, I; Elewonbi, R; Omoluabi, E				Akinyemi, Akanni Ibukun; Erinfolami, Temitope Peter; Adebayo, Samuel Olinapekun; Shah, Iqbal; Elewonbi, Reni; Omoluabi, Elizabeth			Family context and individual characteristics in antenatal care utilization among adolescent childbearing mothers in urban slums in Nigeria	PLOS ONE			English	Article							HIGH-RISK BIRTHS; CHILD HEALTH-SERVICES; CONTRACEPTIVE USE; REPRODUCTIVE HEALTH; DETERMINANTS; WOMEN; PREGNANCY; COMMUNITY; PATTERNS; PEOPLE	Introduction Adolescent pregnancy contributes significantly to the high maternal mortality in Nigeria. Research evidence from developing countries consistently underscores Antenatal Care (ANC) among childbearing adolescents as important to reducing high maternal mortality. However, more than half of pregnant adolescents in Nigeria do not attend ANC. A major gap in literature is on the influence of family context in pregnant adolescent patronage of ANC services. Methods The study utilized a cross-sectional survey with data collected among adolescent mothers in urban slums in three Nigerian states namely, Kaduna, Lagos, and Oyo. The survey used a multi-stage sampling design. The survey covered a sample of 1,015, 1,009 and 1,088 childbearing adolescents from each of Kaduna, Lagos, and Oyo states respectively. Data were analyzed at the three levels: univariate, bivariate and multivariate. Results Overall, about 70 percent of female adolescents in our sample compared with 75 percent in the Demographic and Health Survey (DHS) had any antenatal care (ANC) visit. About 62 percent in our sample compared with 70 percent in the DHS had at least 4 ANC visits, and, about 55 percent in our sample compared with 41 percent of the DHS that had 4 ANC visits in a health facility with skilled attendant (4ANC+). Those who have both parents alive and the mother with post-primary education have higher odds of attending 4ANC+ visits. The odds of attending 4ANC+ for those who have lost both parents is almost 60% less than those whose parents are alive, and, about 40% less than those whose mothers are alive. The influence of mother's education on 4ANC+ attendance is more significant with large disparity when both parents are dead. Conclusion The study concludes that identifying the role of parents and community in expanding access to ANC services among adolescent mothers is important in improving maternal health in developing countries.	[Akinyemi, Akanni Ibukun; Shah, Iqbal; Elewonbi, Reni] Harvard Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Akinyemi, Akanni Ibukun; Erinfolami, Temitope Peter] Obafemi Awolowo Univ, Dept Demog & Social Stat, Ife, Nigeria; [Adebayo, Samuel Olinapekun; Omoluabi, Elizabeth] Ctr Res Evaluat Resources & Dev CRERD, Ife, Nigeria	Harvard University; Harvard T.H. Chan School of Public Health; Obafemi Awolowo University	Akinyemi, AI (corresponding author), Harvard Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.; Akinyemi, AI (corresponding author), Obafemi Awolowo Univ, Dept Demog & Social Stat, Ife, Nigeria.	akakanni@yahoo.ca	Akinyemi, Akanni/S-2975-2018	Akinyemi, Akanni/0000-0001-8652-9359; Adebayo, Samuel/0000-0002-5679-5063; Erinfolami, Temitope/0000-0001-6576-398X				Abimbola JM, 2016, AFR HEALTH SCI, V16, P962, DOI 10.4314/ahs.v16i4.12; Akinyemi A, 2015, GLOBAL HEALTH ACTION, V8, P45, DOI 10.3402/gha.v8.29745; Anastasi E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177190; Aransiola JO, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-869; Babalola S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-43; Banke-Thomas A, 2017, SEX REPROD HEALTHC, V12, P37, DOI 10.1016/j.srhc.2017.02.004; Banke-Thomas Oluwasola, 2016, Int J Adolesc Med Health, V30, DOI 10.1515/ijamh-2016-0042; Bayou YT, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0930-z; Brown W, 2015, SEMIN PERINATOL, V39, P338, DOI 10.1053/j.semperi.2015.06.006; Challa S, 2018, WOMEN HEALTH, V58, P434, DOI 10.1080/03630242.2017.1306607; Chikalipo MC, 2018, MALAWI MED J, V30, P25, DOI 10.4314/mmj.v30i1.6; Corburn J, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14040342; Das M, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0738-8; Ebonwu J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191903; Efendi F, 2017, WOMEN HEALTH, V57, P614, DOI 10.1080/03630242.2016.1181136; Elizabeth Adhapillil Mathai, 2015, J Educ Health Promot, V4, P87, DOI 10.4103/2277-9531.171800; Ezeh A, 2017, LANCET, V389, P547, DOI 10.1016/S0140-6736(16)31650-6; Fatema K, 2020, SSM-POPUL HLTH, V11, DOI 10.1016/j.ssmph.2020.100614; Govender D, 2018, AFR J PRIM HEALTH CA, V10, DOI 10.4102/phcfm.v10i1.1685; Gronvik T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204327; Gumede S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4347-z; Hackett K, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2326-3; Hall KS, 2015, J ADOLESCENT HEALTH, V56, P330, DOI 10.1016/j.jadohealth.2014.11.008; Hindin MJ, 2013, B WORLD HEALTH ORGAN, V91, P10, DOI 10.2471/BLT.12.107565; Hounton S, 2015, GLOBAL HEALTH ACTION, V8, P53, DOI 10.3402/gha.v8.29737; Iacoella F, 2019, PUBLIC HEALTH, V177, P1, DOI 10.1016/j.puhe.2019.07.002; Idowu A, 2017, ETHIOP J HEALTH SCI, V27, P291, DOI 10.4314/ejhs.v27i3.11; Jahromi LB, 2014, CHILD DEV, V85, P593, DOI 10.1111/cdev.12160; James Sindiwe, 2012, Curationis, V35, P43, DOI 10.4102/curationis.v35i1.43; Kuyinu Yetunde A, 2017, Int J Adolesc Med Health, V32, DOI 10.1515/ijamh-2017-0104; Lilford RJ, 2017, LANCET, V389, P559, DOI [10.1016/S0140-6736(16)31848-7, 10.1016/s0140-6736(16)31848-7]; Maiga A, 2015, GLOBAL HEALTH ACTION, V8, P21, DOI 10.3402/gha.v8.29736; McNicoll G, 2016, POPUL DEV REV, V43; Mmari K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166032; Mollborn S, 2017, CHILD DEV PERSPECT, V11, P63, DOI 10.1111/cdep.12205; Muchie KF, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1488-0; Nagata JM, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.010501; NPC & ICF-International, 2014, NIG DEM HLTH SURV 20; Ochako R, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-1; POOLE CJ, 1982, J ADOLESCENT HEALTH, V3, P41, DOI 10.1016/S0197-0070(82)80027-2; Rai RK, 2014, MATERN CHILD HLTH J, V18, P592, DOI 10.1007/s10995-013-1276-z; Rai RK, 2012, WOMEN HEALTH ISS, V22, pE407, DOI 10.1016/j.whi.2012.05.001; Renzaho AMN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169721; Reynolds HW, 2006, INT FAM PLAN PERSPEC, V32, P6, DOI 10.1363/3200606; Ruedinger E, 2012, CURR OPIN PEDIATR, V24, P446, DOI 10.1097/MOP.0b013e3283557b89; Sahito A, 2018, INT J HEALTH POLICY, V7, P699, DOI 10.15171/ijhpm.2017.148; Samano R, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1570-7; Singh A, 2014, PEERJ, V2, DOI 10.7717/peerj.592; Stover J, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S4; Urquia ML, 2017, J WOMENS HEALTH, V26, P234, DOI 10.1089/jwh.2015.5627; Wang SC, 2012, PUBLIC HEALTH, V126, P1038, DOI 10.1016/j.puhe.2012.08.014; Weng YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114843	52	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2021	16	11							e0260588	10.1371/journal.pone.0260588	http://dx.doi.org/10.1371/journal.pone.0260588			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YU5IH	34843583	Green Published, gold			2023-01-03	WOS:000752076100105
J	Goldsbury, DE; Feletto, E; Weber, MF; Haywood, P; Pearce, A; Lew, JB; Worthington, J; He, E; Steinberg, J; O'Connell, DL; Canfell, K				Goldsbury, David E.; Feletto, Eleonora; Weber, Marianne F.; Haywood, Philip; Pearce, Alison; Lew, Jie-Bin; Worthington, Joachim; He, Emily; Steinberg, Julia; O'Connell, Dianne L.; Canfell, Karen			Health system costs and days in hospital for colorectal cancer patients in New South Wales, Australia	PLOS ONE			English	Article							CARE; DRUGS	Introduction Colorectal cancer (CRC) care costs the Australian healthcare system more than any other cancer. We estimated costs and days in hospital for CRC cases, stratified by site (colon/rectal cancer) and disease stage, to inform detailed analyses of CRC-related healthcare. Methods Incident CRC patients were identified using the Australian 45 and Up Study cohort linked with cancer registry records. We analysed linked hospital admission records, emergency department records, and reimbursement records for government-subsidised medical services and prescription medicines. Cases' health system costs (2020 Australian dollars) and hospital days were compared with those for cancer-free controls (matched by age, sex, geography, smoking) to estimate excess resources by phase of care, analysed by sociodemographic, health, and disease characteristics. Results 1200 colon and 546 rectal cancer cases were diagnosed 2006-2013, and followed up to June 2016. Eighty-nine percent of cases had surgery, chemotherapy or radiotherapy, and excess costs were predominantly for hospitalisations. Initial phase (12 months post-diagnosis) mean excess health system costs were $50,434 for colon and $60,877 for rectal cancer cases, with means of 16 and 18.5 excess hospital days, respectively. The annual continuing mean excess costs were $6,779 (colon) and $8,336 (rectal), with a mean of 2 excess hospital days each. Resources utilised (costs and days) in these phases increased with more advanced disease, comorbidities, and younger age. Mean excess costs in the year before death were $74,952 (colon) and $67,733 (rectal), with means of 34 and 30 excess hospital days, respectively-resources utilised were similar across all characteristics, apart from lower costs for cases aged >= 75 at diagnosis. Conclusions Health system costs and hospital utilisation for CRC care are greater for people with more advanced disease. These findings provide a benchmark, and will help inform future cost-effectiveness analyses of potential approaches to CRC screening and treatment.	[Goldsbury, David E.; Feletto, Eleonora; Weber, Marianne F.; Lew, Jie-Bin; Worthington, Joachim; He, Emily; Steinberg, Julia; O'Connell, Dianne L.; Canfell, Karen] Univ Sydney, Daffodil Ctr, Sydney, NSW, Australia; [Goldsbury, David E.; Haywood, Philip; Pearce, Alison] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia; [Haywood, Philip] Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW, Australia; [He, Emily] Concord Hosp, Gastroenterol & Liver Dept, Sydney, NSW, Australia; [O'Connell, Dianne L.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia; [Canfell, Karen] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of Technology Sydney; Concord Repatriation General Hospital; University of Newcastle; University of New South Wales Sydney	Goldsbury, DE (corresponding author), Univ Sydney, Daffodil Ctr, Sydney, NSW, Australia.; Goldsbury, DE (corresponding author), Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia.	davidg@nswcc.org.au		Lew, Jie-Bin/0000-0003-2837-3565; Haywood, Philip/0000-0001-5031-8648; Steinberg, Julia/0000-0002-0585-2312; Weber, Marianne/0000-0001-5731-9651; Goldsbury, David/0000-0001-6247-2706; Worthington, Joachim/0000-0002-8830-0520	Australian Government Medical Research Future Fund (MRFF) - Preventive and Public Health Research Initiative - 2019 Targeted Health System and Community Organization Research Grant Opportunity [MRF1200535]; National Health and Medical Research Council of Australia [APP1194679, APP1194784]; Victorian Cytology Service (VCS); Roche Molecular Systems; Ventana	Australian Government Medical Research Future Fund (MRFF) - Preventive and Public Health Research Initiative - 2019 Targeted Health System and Community Organization Research Grant Opportunity; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Cytology Service (VCS); Roche Molecular Systems; Ventana	DEG, EF, MFW, PH, JS and KC are investigators on a study of cancer patient population projections, funded by the Australian Government Medical Research Future Fund (MRFF) - Preventive and Public Health Research Initiative - 2019 Targeted Health System and Community Organization Research Grant Opportunity (MRF1200535). No funder had a role in study design, analysis, decision to publish, or preparation of the manuscript. KC and JBL received grants from the National Health and Medical Research Council of Australia (APP1194679 and APP1194784, respectively) during the conduct of the study. KC is an investigator on an unrelated investigator-initiated trial of cytology and primary HPV screening in Australia (Compass), which is conducted and funded by the Victorian Cytology Service (VCS), a government-funded health promotion charity. The VCS has received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and Ventana. However, neither the authors nor the authors' organisations receive direct funding from industry for this trial or any other project.	Ananda S, 2016, ASIA-PAC J CLIN ONCO, V12, P33, DOI 10.1111/ajco.12350; Aravani A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005064; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Australian Bureau of Statistics, 2006, 20390 AUSTR BUR STAT; Australian Bureau of Statistics, 2020, CONS PRIC IND; Australian Bureau of Statistics, 2018, AUSTR STAT GEOGR STA; Australian Government Department of Health, NAT BOW CANC SCREEN; Australian Inst Hlth Welf, 2016, ASIA-PAC J CLIN ONCO, V12, P22, DOI 10.1111/ajco.12452; Australian Institute of Health and Welfare, 2019, CANC AUSTR 2019; Australian Institute of Health and Welfare, CANC SCREEN PROGR Q; Australian Institute of Health and Welfare, 2013, HLTH SYST EXP CANC O, V81; Banks E, 2008, INT J EPIDEMIOL, V37, P941, DOI 10.1093/ije/dym184; Blakely T, 2015, MED CARE, V53, P302, DOI 10.1097/MLR.0000000000000330; Cancer Council Australia Colorectal Cancer Guidelines Working Party, 2017, CLIN PRACTICE GUIDEL; Cancer Council New South Wales, 2021, POLICY1 BOW 2021; Cancer Institute NSW, CANC NEW S WAL ONL S; Centre for Health Record Linkage, CTR HLTH REC LINK; Creighton N, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0537-3; Daghar H., 2020, BINATIONAL COLORECTA; Goldsbury DE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201552; Goldsbury DE, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-387; Goldsbury DE, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-253; Independent Hospital Pricing Authority, 2012, NAT HOSP COST DAT CO; International Agency for Research on Cancer, 2020, CANC TOD GLOBOCAN 20; Johnson CM, 2013, CANCER CAUSE CONTROL, V24, P1207, DOI 10.1007/s10552-013-0201-5; Kardamanidis K, 2007, MED J AUSTRALIA, V187, P383, DOI 10.5694/j.1326-5377.2007.tb01306.x; Karikios DJ, 2014, INTERN MED J, V44, P458, DOI 10.1111/imj.12399; Ladwa R, 2018, CLIN BREAST CANCER, V18, pE1181, DOI 10.1016/j.clbc.2018.04.016; Langton JM, 2014, PALLIATIVE MED, V28, P1167, DOI 10.1177/0269216314533813; Lauby-Secretan B, 2018, NEW ENGL J MED, V378, P1734, DOI 10.1056/NEJMsr1714643; Laudicella M, 2016, BRIT J CANCER, V114, P1286, DOI 10.1038/bjc.2016.77; Lew JB, 2018, CANCER EPIDEM BIOMAR, V27, P1450, DOI [10.1158/1055-9965.EPI-18-0128, 10.1158/1055-9965.epi-18-0128]; Lew JB, 2018, INT J CANCER, V143, P269, DOI 10.1002/ijc.31314; Lew JB, 2017, LANCET PUBLIC HEALTH, V2, pE331, DOI 10.1016/S2468-2667(17)30105-6; Lorgelly PK, 2016, PHARMACOECONOMICS, V34, P139, DOI 10.1007/s40273-015-0343-2; Luo QW, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014259; Mariotto AB, 2011, JNCI-J NATL CANCER I, V103, P117, DOI 10.1093/jnci/djq495; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Steffen A, 2014, MED J AUSTRALIA, V201, P523, DOI 10.5694/mja14.00197; Tie J, 2013, INTERN MED J, V43, P23, DOI 10.1111/j.1445-5994.2012.02750.x; Ward RL, 2015, ASIA-PAC J CLIN ONCO, V11, P178, DOI 10.1111/ajco.12354; Worthington J, 2020, PUBLIC HEALTH, V179, P90, DOI 10.1016/j.puhe.2019.10.003; Worthington J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227899	43	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2021	16	11							e0260088	10.1371/journal.pone.0260088	http://dx.doi.org/10.1371/journal.pone.0260088			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU5IH	34843520	Green Published, gold			2023-01-03	WOS:000752076100040
J	Higi, L; Lisibach, A; Beeler, PE; Lutters, M; Blanc, AL; Burden, AM; Stampfli, D				Higi, Lukas; Lisibach, Angela; Beeler, Patrick E.; Lutters, Monika; Blanc, Anne-Laure; Burden, Andrea M.; Staempfli, Dominik			External validation of the PAR-Risk Score to assess potentially avoidable hospital readmission risk in internal medicine patients	PLOS ONE			English	Article							MULTIVARIABLE PREDICTION MODEL; INDIVIDUAL PROGNOSIS; DIAGNOSIS TRIPOD; DERIVATION	Background Readmission prediction models have been developed and validated for targeted in-hospital preventive interventions. We aimed to externally validate the Potentially Avoidable Readmission-Risk Score (PAR-Risk Score), a 12-items prediction model for internal medicine patients with a convenient scoring system, for our local patient cohort. Methods A cohort study using electronic health record data from the internal medicine ward of a Swiss tertiary teaching hospital was conducted. The individual PAR-Risk Score values were calculated for each patient. Univariable logistic regression was used to predict potentially avoidable readmissions (PARs), as identified by the SQLape algorithm. For additional analyses, patients were stratified into low, medium, and high risk according to tertiles based on the PAR-Risk Score. Statistical associations between predictor variables and PAR as outcome were assessed using both univariable and multivariable logistic regression. Results The final dataset consisted of 5,985 patients. Of these, 340 patients (5.7%) experienced a PAR. The overall PAR-Risk Score showed rather poor discriminatory power (C statistic 0.605, 95%-CI 0.575-0.635). When using stratified groups (low, medium, high), patients in the high-risk group were at statistically significant higher odds (OR 2.63, 95%-CI 1.33-5.18) of being readmitted within 30 days compared to low risk patients. Multivariable logistic regression identified previous admission within six months, anaemia, heart failure, and opioids to be significantly associated with PAR in this patient cohort. Conclusion This external validation showed a limited overall performance of the PAR-Risk Score, although higher scores were associated with an increased risk for PAR and patients in the high-risk group were at significantly higher odds of being readmitted within 30 days. This study highlights the importance of externally validating prediction models.	[Higi, Lukas] Univ Basel, Dept Pharmaceut Sci, Basel, Switzerland; [Higi, Lukas] PEDeus Ltd, Zurich, Switzerland; [Lisibach, Angela; Lutters, Monika; Staempfli, Dominik] Cantonal Hosp Baden, Dept Med Serv, Clin Pharm, Baden, Switzerland; [Lisibach, Angela] Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland; [Lisibach, Angela] Univ Lausanne, Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Lausanne, Switzerland; [Beeler, Patrick E.] Univ Zurich, Epidemiol Biostat & Prevent Inst, Div Occupat & Environm Med, Zurich, Switzerland; [Blanc, Anne-Laure] Pharm Eastern Vaud Hosp, Clin Pharm, Rennaz, Switzerland; [Burden, Andrea M.; Staempfli, Dominik] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, Zurich, Switzerland	University of Basel; University of Geneva; University of Geneva; University of Lausanne; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Stampfli, D (corresponding author), Cantonal Hosp Baden, Dept Med Serv, Clin Pharm, Baden, Switzerland.; Stampfli, D (corresponding author), Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, Zurich, Switzerland.	dominik.staempfli@pharma.ethz.ch	Stämpfli, Dominik/AAT-7229-2020; Burden, Andrea/B-3004-2016	Stämpfli, Dominik/0000-0001-5293-134X; Lutters, Monika/0000-0001-7063-578X; Lisibach, Angela Edith/0000-0001-8697-492X; Burden, Andrea/0000-0001-7082-8530				Alassaad A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007259; Allaudeen N, 2011, J HOSP MED, V6, P54, DOI 10.1002/jhm.805; [Anonymous], 2021, SQLAPE HEALTHCARE IN; Blanc AL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219348; Bundesamt fur Gesundheit (BAG), 2020, KENNZ SCHWEIZ SPIT 2; Chin DL, 2016, HEALTH AFFAIR, V35, P1867, DOI 10.1377/hlthaff.2016.0205; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.7326/M14-0697, 10.1161/CIRCULATIONAHA.114.014508, 10.1038/bjc.2014.639, 10.1136/bmj.g7594, 10.1016/j.eururo.2014.11.025, 10.1016/j.jclinepi.2014.11.010, 10.7326/M14-0698, 10.1002/bjs.9736, 10.1186/s12916-014-0241-z]; Dalleur O, 2021, J PATIENT SAF, V17, pE379, DOI 10.1097/PTS.0000000000000346; Donze J, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7171; Donze J, 2013, JAMA INTERN MED, V173, P632, DOI 10.1001/jamainternmed.2013.3023; Donze JD, 2016, JAMA INTERN MED, V176, P496, DOI 10.1001/jamainternmed.2015.8462; Falconer N, 2018, BRIT J CLIN PHARMACO, V84, P846, DOI 10.1111/bcp.13514; Golinvaux NS, 2014, SPINE, V39, P2019, DOI 10.1097/BRS.0000000000000598; Groenveld HF, 2008, J AM COLL CARDIOL, V52, P818, DOI 10.1016/j.jacc.2008.04.061; Halfon P, 2002, J CLIN EPIDEMIOL, V55, P573, DOI 10.1016/S0895-4356(01)00521-2; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Harrell F. E., 2020, RMS REGRESSION MODEL; He HB, 2009, IEEE T KNOWL DATA EN, V21, P1263, DOI 10.1109/TKDE.2008.239; Herrin J, 2015, HEALTH SERV RES, V50, P20, DOI 10.1111/1475-6773.12177; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Kuhn M, 2020, R J; Lisibach A, HIGH ANTICHOLINERGIC; Mahmoudi E, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m958; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Moons KGM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001744; Nationaler Verein fur Qualitatsentwicklung in Spitalern und Kliniken, 2020, NAT VERG MESS 2020; Parekh N, 2018, BRIT J CLIN PHARMACO, V84, P1789, DOI 10.1111/bcp.13613; R Core Team Rf.., 2013, R LANG ENV STAT COMP; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Ruiz B, 2008, EUR J CLIN PHARMACOL, V64, P715, DOI 10.1007/s00228-008-0473-y; Steyerberg E., 2019, CLIN PREDICTION MODE, DOI 10.1007/978-3-030-16399-0; Taha M, 2014, INT J QUAL HEALTH C, V26, P271, DOI 10.1093/intqhc/mzu038; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; Wickham H., 2019, J OPEN SOURCE SOFTWA, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/JOSS.01686]; Wickham H, 2011, J STAT SOFTW, V40, P1, DOI 10.18637/jss.v040.i01; Zapatero A, 2012, EUR J INTERN MED, V23, P451, DOI 10.1016/j.ejim.2012.01.005; Zhao Y, 2018, J HEALTHC ENG, V2018, DOI 10.1155/2018/6275435; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	38	0	0	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2021	16	11							e0259864	10.1371/journal.pone.0259864	http://dx.doi.org/10.1371/journal.pone.0259864			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ8YK	34813625	Green Published, gold			2023-01-03	WOS:000755756800014
J	Kneebone, R; Houstoun, W; Houghton, N				Kneebone, Roger; Houstoun, Will; Houghton, Natasha			Medicine, magic, and online performance	LANCET			English	Editorial Material									[Kneebone, Roger] Imperial Coll London, Fac Med, Dept Surg & Canc, Surg Educ,Div Surg, London, England; [Kneebone, Roger; Houghton, Natasha] Chelsea & Westminster Hosp, Acad Surg, Ctr Engagement & Simulat Sci, London SW10 9NH, England; [Houstoun, Will] Imperial Coll London, Fac Med, London, England; [Houstoun, Will] Ctr Performance Sci, Magician Residence, London, England	Imperial College London; Imperial College London; Imperial College London	Kneebone, R (corresponding author), Imperial Coll London, Fac Med, Dept Surg & Canc, Surg Educ,Div Surg, London, England.; Kneebone, R (corresponding author), Chelsea & Westminster Hosp, Acad Surg, Ctr Engagement & Simulat Sci, London SW10 9NH, England.	r.kneebone@imperial.ac.uk			Medical Education Research Unit (MERU) at Imperial College London	Medical Education Research Unit (MERU) at Imperial College London	We acknowledge the support of the Medical Education Research Unit (MERU) at Imperial College London.		0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2021	398	10314					1868	1869						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XA8TI	34801098	Green Published, Bronze			2023-01-03	WOS:000720912600016
J	Lolli, F; Salimova, M; Scarpino, M; Lanzo, G; Cossu, C; Bastianelli, M; Occupati, B; Gori, F; Del Vecchio, A; Ercolini, A; Pascolo, S; Cimino, V; Meneghin, N; Fierinil, F; D'Anna, G; Innocenti, M; Ballerini, A; Pallanti, S; Grippo, A; Mannaioni, G				Lolli, Francesco; Salimova, Maya; Scarpino, Maenia; Lanzo, Giovanni; Cossu, Cesarina; Bastianelli, Maria; Occupati, Brunelle; Gori, Filippo; Del Vecchio, Amedeo; Ercolini, Anita; Pascolo, Silvia; Cimino, Virginia; Meneghin, Nicole; Fierinil, Fabio; D'Anna, Giulio; Innocenti, Matteo; Ballerini, Andrea; Pallanti, Stefano; Grippo, Antonello; Mannaioni, Guido			A randomised, double-blind, sham-controlled study of left prefrontal cortex 15 Hz repetitive transcranial magnetic stimulation in cocaine consumption and craving	PLOS ONE			English	Article							IMPULSIVITY; DEPRESSION; PATHWAYS; DISORDER; ALCOHOL; RELAPSE; DRUG	Background Cocaine use disorder (CUD) is a global health issue with no effective treatment. Repetitive Transcranial Magnetic Stimulation (rTMS) is a recently proposed therapy for CUD. Methods We conducted a single-center, randomised, sham-controlled, blinded, parallel-group research with patients randomly allocated to rTMS (15 Hz) or Sham group (1:1) using a computerised block randomisation process. We enrolled 62 of 81 CUD patients in two years. Patients were followed for eight weeks after receiving 15 15 Hz rTMS/sham sessions over the left dorsolateral prefrontal cortex (DLPFC) during the first three weeks of the study. We targeted the DLFPC following the 5 cm method. Cocaine lapses in twice a week urine tests were the primary outcome. The secondary outcomes were craving severity, cocaine use pattern, and psychometric assessments. Findings We randomly allocated patients to either an active rTMS group (32 subjects) or a sham treatment group (30 subjects). Thirteen (42%) and twelve (43.3%) of the subjects in rTMS and sham groups, respectively, completed the full trial regimen, displaying a high dropout rate. Ten/30 (33%) of rTMS-treated patients tested negative for cocaine in urine, in contrast to 4/27 of placebo controls (p = 0.18, odd ratio 2.88, CI 0.9-10). The Kaplan-Meier survival curve did not state a significant change between the treated and sham groups in the time of cocaine urine negativisation (p = 0.20). However, the severity of cocaine-related cues mediated craving (VAS peak) was substantially decreased in the rTMS treated group (p<0.03) after treatment at T1, corresponding to the end of rTMS treatment. Furthermore, in the rTMS and sham groups, self-reported days of cocaine use decreased significantly (p<0.03). Finally, psychometric impulsivity parameters improved in rTMS-treated patients, while depression scales improved in both groups. Conclusions In CUD, rTMS could be a useful tool for lowering cocaine craving and consumption.	[Lolli, Francesco; Salimova, Maya; Gori, Filippo; Del Vecchio, Amedeo; Ercolini, Anita; Pascolo, Silvia; Cimino, Virginia; Meneghin, Nicole; Fierinil, Fabio; D'Anna, Giulio; Innocenti, Matteo; Pallanti, Stefano; Mannaioni, Guido] Univ Firenze, Dept Biomed Expt & Clin Sci Mario Serio, Dept Neurosci Psychol Drug Res & Child Hlth NEU R, Dept Hlth Sci DSS, Florence, Italy; [Lolli, Francesco; Scarpino, Maenia; Lanzo, Giovanni; Cossu, Cesarina; Bastianelli, Maria; Grippo, Antonello] Azienda Osped Univ Careggi, Neurophysiol Unit, Florence, Italy; [Occupati, Brunelle; Mannaioni, Guido] Azienda Osped Univ Careggi, Clin Toxicol & Poison Control Ctr, Florence, Italy; [Ballerini, Andrea] Azienda Osped Univ Careggi, Clin Psychiat, Florence, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi	Lolli, F (corresponding author), Univ Firenze, Dept Biomed Expt & Clin Sci Mario Serio, Dept Neurosci Psychol Drug Res & Child Hlth NEU R, Dept Hlth Sci DSS, Florence, Italy.; Lolli, F (corresponding author), Azienda Osped Univ Careggi, Neurophysiol Unit, Florence, Italy.	lolli@unifi.it	Pallanti, Stefano/HIR-2040-2022	mannaioni, guido/0000-0002-8273-7377; Innocenti, Matteo/0000-0003-2457-0959; Lolli, Francesco/0000-0001-7181-6806	Fondazione Cassa di Risparmio di Firenze	Fondazione Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze)	Guido Mannaioni-Azienda Ospedaliera Universitaria di Careggi, Fondazione Cassa di Risparmio di Firenze. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AlKhadhrawi N, 2019, J BODYW MOV THER, V23, P532, DOI 10.1016/j.jbmt.2019.05.016; Bolloni C, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00133; Burke MJ, 2019, ANN NEUROL, V85, P12, DOI 10.1002/ana.25387; Camprodon JA, 2007, DRUG ALCOHOL DEPEN, V86, P91, DOI 10.1016/j.drugalcdep.2006.06.002; Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Chen TZ, 2020, EBIOMEDICINE, V60, DOI 10.1016/j.ebiom.2020.103027; De Crescenzo F, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002715; Diana M, 2017, NAT REV NEUROSCI, V18, P685, DOI 10.1038/nrn.2017.113; Diana Marco, 2011, Front Psychiatry, V2, P64, DOI 10.3389/fpsyt.2011.00064; Fitzgerald PB, 2021, BRAIN STIMUL, V14, P730, DOI 10.1016/j.brs.2021.04.018; Garza-Villarreal EA, 2021, BIOL PSYCHIAT-COGN N, V6, P745, DOI 10.1016/j.bpsc.2021.01.003; Hanlon CA, 2017, DRUG ALCOHOL DEPEN, V178, P310, DOI 10.1016/j.drugalcdep.2017.03.039; Hanlon CA, 2015, BRAIN RES, V1628, P199, DOI 10.1016/j.brainres.2015.02.053; Health Quality Ontario, 2016, Ont Health Technol Assess Ser, V16, P1; Lee J. W., 2002, ADDICT DISORD TREAT, V1, P140, DOI [10.1097/00132576-200211000-00005, DOI 10.1097/00132576-200211000-00005]; Lefaucheur JP, 2020, CLIN NEUROPHYSIOL, V131, P474, DOI 10.1016/j.clinph.2019.11.002; Lister JJ, 2015, ADDICT BEHAV, V41, P1, DOI 10.1016/j.addbeh.2014.09.017; Madeo G, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00158; Mahoney JJ, 2020, EXP CLIN PSYCHOPHARM, V28, P1, DOI 10.1037/pha0000289; Martinez D, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00080; Moretti J, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00137; Pahwal P, 2008, DRUG ALCOHOL DEPEN, V93, P252, DOI 10.1016/j.drugalcdep.2007.10.002; Pani PP, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002950.pub3; PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Pettorruso M, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00621; Politi E, 2008, AM J ADDICTION, V17, P345, DOI 10.1080/10550490802139283; Rapinesi C, 2016, NEUROSCI LETT, V629, P43, DOI 10.1016/j.neulet.2016.06.049; Samet S, 2013, ADDICTION, V108, P115, DOI 10.1111/j.1360-0443.2012.04010.x; Scarpino M, 2019, NEUROPHYSIOL CLIN, V49, P1, DOI 10.1016/j.neucli.2018.10.002; Shen Y, 2016, BIOL PSYCHIAT, V80, pE13, DOI 10.1016/j.biopsych.2016.02.006; Spano MC, 2019, CNS NEUROSCI THER, V25, P1229, DOI 10.1111/cns.13230; Sparing R, 2008, HUM BRAIN MAPP, V29, P82, DOI 10.1002/hbm.20360; Terraneo A, 2016, EUR NEUROPSYCHOPHARM, V26, P37, DOI 10.1016/j.euroneuro.2015.11.011; Torres A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00043; Verdejo-Garcia A, 2007, DRUG ALCOHOL DEPEN, V91, P213, DOI 10.1016/j.drugalcdep.2007.05.025; Volkow ND, 2017, NAT REV NEUROSCI, V18, P741, DOI 10.1038/nrn.2017.130; Yang CC, 2018, BRAIN COGNITION, V128, P37, DOI 10.1016/j.bandc.2018.11.003; Ziemann U, 2000, TRANSCRANIAL MAGNETI, P59	40	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2021	16	11							e0259860	10.1371/journal.pone.0259860	http://dx.doi.org/10.1371/journal.pone.0259860			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ1XV	34784373	gold, Green Published			2023-01-03	WOS:000755277300023
J	Cornejo, MA; Dhillon, J; Nishiyama, A; Nakano, D; Ortiz, RM				Cornejo, Manuel A.; Dhillon, Jaapna; Nishiyama, Akira; Nakano, Daisuke; Ortiz, Rudy M.			Mass recovery following caloric restriction reverses lipolysis and proteolysis, but not gluconeogenesis, in insulin resistant OLETF rats	PLOS ONE			English	Article							FATTY-ACIDS; AMINO-ACID; STARVATION; DISEASE; GLUCOSE; METABOLISM; MECHANISMS; OXIDATION; PROFILES; OBESITY	Caloric restriction (CR) is one of the most important behavioral interventions to reduce excessive abdominal adiposity, which is a risk factor for the development of insulin resistance. Previous metabolomics studies have characterized substrate metabolism during healthy conditions; however, the effects of CR and subsequent mass recovery on shifts in substrate metabolism during insulin resistance (IR) have not been widely investigated. To assess the effects of acute CR and the subsequent mass recovery on shifts in substrate metabolism, a cohort of 15-week old Long Evans Tokushima Otsuka (LETO) and Otsuka Long Evans Tokushima Fatty (OLETF) rats were calorie restricted (CR: 50% x 10 days) with or without partial body mass recovery (PR; 73% x 7 days), along with their respective ad libitum controls. End-of-study plasma samples were analyzed for primary carbon metabolites by gas chromatography (GC) time-of-flight (TOF) mass spectrometry (MS) data acquisition. Data analysis included PCA, Pearson correlation vs previously reported variables (adipose and body masses, and insulin resistance index, IRI), and metabolomics maps (MetaMapp) generated for the most significant group comparisons. All treatments elicited a significant group differentiation in at least one principal component. CR improved TCA cycle in OLETF, and increased lipolysis and proteolysis. These changes were reversed after PR except for gluconeogenesis. Plasma lipid concentrations were inversely correlated to IRI in LETO, but not OLETF. These shifts in substrate metabolism suggest that the CR-induced decreases in adipose may not be sufficient to more permanently alter substrate metabolism to improve IR status during metabolic syndrome.	[Cornejo, Manuel A.; Ortiz, Rudy M.] Univ Calif, Sch Nat Sci, Merced, CA 95343 USA; [Dhillon, Jaapna] Univ Missouri, Dept Nutr & Exercise Physiol, Columbia, MO USA; [Nishiyama, Akira; Nakano, Daisuke] Kagawa Univ, Fac Med, Dept Pharmacol, Takamatsu, Kagawa, Japan; [Cornejo, Manuel A.] Univ Calif Merced, Merced, CA 95343 USA	University of California System; University of California Merced; University of Missouri System; University of Missouri Columbia; Kagawa University; University of California System; University of California Merced	Cornejo, MA (corresponding author), Univ Calif, Sch Nat Sci, Merced, CA 95343 USA.; Cornejo, MA (corresponding author), Univ Calif Merced, Merced, CA 95343 USA.	mcornejo3@ucmerced.edu		Cornejo, Manuel/0000-0002-2446-8674; Dhillon, Jaapna/0000-0003-4798-9111	Doctoral fellowship UC MEXUS-CONACYT [440553]; National Institute on Minority Health and Health Disparities [9T37MD001480]	Doctoral fellowship UC MEXUS-CONACYT; National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	MAC was supported in part by 1) Doctoral fellowship UC MEXUS-CONACYT 440553 https://ucmexus.ucr.edu/ 2) National Institute on Minority Health and Health Disparities grant 9T37MD001480. https://mhirt.com/ The funders had no role in study design, data collection and analysis,	Abbasi F, 2002, J AM COLL CARDIOL, V40, P937, DOI 10.1016/S0735-1097(02)02051-X; Bajaj M, 2003, J NUCL CARDIOL, V10, P311, DOI 10.1016/S1071-3581(03)00520-8; Bales CW, 2013, J CARDIOPULM REHABIL, V33, P201, DOI 10.1097/HCR.0b013e318295019e; Barupal DK, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-99; Benjamini Y., 1995, J R STAT SOC, V57, P289; Bock G, 2007, DIABETES, V56, P1703, DOI 10.2337/db06-1776; Borrego SL, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0148-6; CAHILL GF, 1976, CLIN ENDOCRINOL META, V5, P397, DOI 10.1016/S0300-595X(76)80028-X; CASAZZA JP, 1986, BIOCHEM J, V236, P635, DOI 10.1042/bj2360635; Collet TH, 2017, J CLIN ENDOCR METAB, V102, P4486, DOI 10.1210/jc.2017-01020; Cornejo MA, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00363; Dhillon J, 2018, NUTRIENTS, V10, DOI 10.3390/nu10080960; Dror Y, 2013, JPEN-PARENTER ENTER, V37, P109, DOI 10.1177/0148607112443260; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Fiehn O., 2016, CURR PROTOC MOL BIOL, V114, DOI [10.1002/0471142727.mb3004s114, DOI 10.1002/0471142727.MB3004S114]; Gaster M, 2009, BIOCHEM BIOPH RES CO, V387, P651, DOI 10.1016/j.bbrc.2009.07.064; GOODMAN MN, 1980, AM J PHYSIOL, V239, pE277; Goodpaster AM, 2011, CHEMOMETR INTELL LAB, V109, P162, DOI 10.1016/j.chemolab.2011.08.009; Gupte SA, 2010, DRUG DEVELOP RES, V71, P161, DOI 10.1002/ddr.20359; Hagstrom-Toft E, 2001, DIABETES, V50, P1604, DOI 10.2337/diabetes.50.7.1604; Hall KD, 2015, CELL METAB, V22, P427, DOI 10.1016/j.cmet.2015.07.021; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; KAWANO K, 1992, DIABETES, V41, P1422, DOI 10.2337/diabetes.41.11.1422; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Kubota T, 2011, CELL METAB, V13, P294, DOI 10.1016/j.cmet.2011.01.018; Lee CG, 2011, J AM GERIATR SOC, V59, P1217, DOI 10.1111/j.1532-5415.2011.03472.x; Manouze H, 2019, ENEURO, V6, DOI 10.1523/ENEURO.0179-18.2019; McCarty MF, 2015, AGE, V37, DOI 10.1007/s11357-015-9823-8; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Nelson JL, 2011, J ANAL TOXICOL, V35, P617, DOI 10.1093/anatox/35.9.617; Nestel PJ, 2014, AM J CLIN NUTR, V99, P46, DOI 10.3945/ajcn.113.071712; Piccolo BD, 2016, AM J PHYSIOL-ENDOC M, V310, pE958, DOI 10.1152/ajpendo.00052.2016; Rector RS, 2010, J HEPATOL, V52, P727, DOI 10.1016/j.jhep.2009.11.030; Rodriguez R, 2018, J ENDOCRINOL, V237, P271, DOI [10.1530/JOE-17-0678, 10.1530/joe-17-0678]; Rodriguez R, 2012, ENDOCRINOLOGY, V153, P1684, DOI 10.1210/en.2011-1885; Ruiz-Perez D, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-019-3310-7; SAUDEK CD, 1976, AM J MED, V60, P117, DOI 10.1016/0002-9343(76)90540-4; Selman C, 2006, PHYSIOL GENOMICS, V27, P187, DOI 10.1152/physiolgenomics.00084.2006; Steinhauser ML, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121434; Tai ES, 2010, DIABETOLOGIA, V53, P757, DOI 10.1007/s00125-009-1637-8; Vazquez-Medina JP, 2013, AM J PHYSIOL-HEART C, V305, pH599, DOI 10.1152/ajpheart.00101.2013; Viscarra JA, 2013, METABOLISM, V62, P889, DOI 10.1016/j.metabol.2012.12.014; YANG MU, 1976, J CLIN INVEST, V58, P722, DOI 10.1172/JCI108519; Yokoi N, 2015, METABOLOMICS, V11, P1277, DOI 10.1007/s11306-015-0784-9	44	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2021	16	11							e0252360	10.1371/journal.pone.0252360	http://dx.doi.org/10.1371/journal.pone.0252360			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8OO	34727112	Green Submitted, Green Published, gold			2023-01-03	WOS:000755045200002
J	Bigand, F; Prigent, E; Berret, B; Braffort, A				Bigand, Felix; Prigent, Elise; Berret, Bastien; Braffort, Annelies			Decomposing spontaneous sign language into elementary movements: A principal component analysis-based approach	PLOS ONE			English	Article							MOTOR PRIMITIVES; HAND SYNERGIES; IDENTIFICATION; CONSTRAINTS; ADAPTATION; GAIT	Sign Language (SL) is a continuous and complex stream of multiple body movement features. That raises the challenging issue of providing efficient computational models for the description and analysis of these movements. In the present paper, we used Principal Component Analysis (PCA) to decompose SL motion into elementary movements called principal movements (PMs). PCA was applied to the upper-body motion capture data of six different signers freely producing discourses in French Sign Language. Common PMs were extracted from the whole dataset containing all signers, while individual PMs were extracted separately from the data of individual signers. This study provides three main findings: (1) although the data were not synchronized in time across signers and discourses, the first eight common PMs contained 94.6% of the variance of the movements; (2) the number of PMs that represented 94.6% of the variance was nearly the same for individual as for common PMs; (3) the PM subspaces were highly similar across signers. These results suggest that upper-body motion in unconstrained continuous SL discourses can be described through the dynamic combination of a reduced number of elementary movements. This opens up promising perspectives toward providing efficient automatic SL processing tools based on heavy mocap datasets, in particular for automatic recognition and generation.	[Bigand, Felix; Prigent, Elise; Braffort, Annelies] Univ Paris Saclay, LISN, CNRS, Orsay, France; [Berret, Bastien] Univ Paris Saclay, Inst Univ France, CIAMS, Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut Universitaire de France; UDICE-French Research Universities; Universite Paris Saclay	Bigand, F (corresponding author), Univ Paris Saclay, LISN, CNRS, Orsay, France.	felix.bigand@universite-paris-saclay.fr		Bigand, Felix/0000-0002-6343-0433	Bpifrance investment project "Grands defis du numerique", as part of the ROSETTA project (RObot for Subtitling and intElligent adapTed TranslAtion)	Bpifrance investment project "Grands defis du numerique", as part of the ROSETTA project (RObot for Subtitling and intElligent adapTed TranslAtion)	This work has been funded by the Bpifrance (https://www.bpifrance.fr/) investment project "Grands defis du numerique", as part of the ROSETTA project (RObot for Subtitling and intElligent adapTed TranslAtion). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajiboye AB, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/3/036004; [Anonymous], 1967, COORDINATION REGULAT; Belissen V, 2020, LREC 2020; Benchiheub M, 2016, 7 INT C LANG RES EV, P7; Benchiheub M E F, 2017, CONTRIBUTION ANAL MO; Benchiheub MEF, 2016, MOCAP1; Berret B, 2009, J NEUROSCI, V29, P191, DOI 10.1523/JNEUROSCI.3426-08.2009; Bigand F, 2021, EUR SIGNAL PR CONF, P711, DOI 10.23919/EUSIPCO54536.2021.9616097; Bigand F, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.710132; Braffort A, 2011, GW 2011; Brown CY, 2007, 2007 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS, VOLS 1-9, P2883; Bruton M, 2018, J NEUROPHYSIOL, V120, P2761, DOI 10.1152/jn.00052.2018; Ciocarlie M, 2007, 2007 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS, VOLS 1-9, P3276; d'Avella A, 2016, ADV EXP MED BIOL, V957, P3, DOI 10.1007/978-3-319-47313-0_1; Daffertshofer A, 2004, CLIN BIOMECH, V19, P415, DOI 10.1016/j.clinbiomech.2004.01.005; ElKoura G., 2003, ACM SIGGRAPH/Eurographics Symposium on Computer Animation, P110; Federolf P, 2014, SCAND J MED SCI SPOR, V24, P491, DOI 10.1111/j.1600-0838.2012.01455.x; Federolf PA, 2013, J BIOMECH, V46, P2173, DOI 10.1016/j.jbiomech.2013.06.032; Federolf P, 2013, J BIOMECH, V46, P2626, DOI 10.1016/j.jbiomech.2013.08.008; Federolf PA, 2016, J BIOMECH, V49, P364, DOI 10.1016/j.jbiomech.2015.12.030; Filhol M, 2020, WORKSH REPR PROC SIG; Filhol M, 2017, LECT NOTES COMPUT SC, V10278, P27, DOI 10.1007/978-3-319-58703-5_3; Flash T, 2005, CURR OPIN NEUROBIOL, V15, P660, DOI 10.1016/j.conb.2005.10.011; Foulds RA, 2004, IEEE T NEUR SYS REH, V12, P65, DOI 10.1109/TNSRE.2003.821371; Furuya S, 2011, J NEUROPHYSIOL, V106, P2849, DOI 10.1152/jn.00378.2011; Gibet S., 2018, WORKSH REPR PROC SIG; Giszter SF, 2015, CURR OPIN NEUROBIOL, V33, P156, DOI 10.1016/j.conb.2015.04.004; Haid TH, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00022; Jerde TE, 2003, IEEE T BIO-MED ENG, V50, P265, DOI 10.1109/TBME.2002.807640; Kipp Michael, 2011, Intelligent Virtual Agents. Proceedings 11th International Conference, IVA 2011, P113, DOI 10.1007/978-3-642-23974-8_13; Koech C. C., 2006, KINEMATIC ANAL SIGN; Koller O., 2016, P BRIT MACHINE VISIO, V136, P1; Lamoth CJC, 2009, HUM MOVEMENT SCI, V28, P371, DOI 10.1016/j.humov.2008.10.001; Longo A, 2019, J BIOMECH, V82, P397, DOI 10.1016/j.jbiomech.2018.11.031; Lu P., 2010, P NAACL HLT 2010 WOR, P89; of the Deaf WF, 2016, OUR WORK; OTOOLE AJ, 1993, J OPT SOC AM A, V10, P405, DOI 10.1364/JOSAA.10.000405; Promsri A, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00480; Rethwilm R, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00345; Santello M, 1998, J NEUROSCI, V18, P10105; Santello M, 2016, PHYS LIFE REV, V17, P1, DOI 10.1016/j.plrev.2016.02.001; Sigal L, 2010, LECT NOTES COMPUT SC, V6313, P243; Singh RE, 2018, BIOMED CIRC SYST C, P1, DOI 10.1080/02699052.2018.1483028; Stetter BJ, 2020, FRONT SPORTS ACT LIV, V2, DOI 10.3389/fspor.2020.596063; TARTTER VC, 1981, NATURE, V289, P676, DOI 10.1038/289676a0; Tits M, 2015, ICMC; Todorov E, 2004, P ANN INT IEEE EMBS, V26, P4637; Tresch MC, 2009, CURR OPIN NEUROBIOL, V19, P601, DOI 10.1016/j.conb.2009.09.002; Troje NF, 2002, J VISION, V2, P371, DOI 10.1167/2.5.2; Vinjamuri R, 2014, COMPUT INTEL NEUROSC, V2014, DOI 10.1155/2014/373957; Wachholz F, 2019, ENTROPY-SWITZ, V21, DOI 10.3390/e21060614; Wang XG, 2013, NEURAL REGEN RES, V8, P662, DOI 10.3969/j.issn.1673-5374.2013.07.011; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Wolfe R., 2011, P INT WORKSHOP SIGN; Yan YK, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17404-0; Young C, 2014, HUM MOVEMENT SCI, V36, P107, DOI 10.1016/j.humov.2014.05.009; Zago M, 2017, CLIN BIOMECH, V48, P103, DOI 10.1016/j.clinbiomech.2017.07.016; Zago M, 2017, HUM MOVEMENT SCI, V54, P144, DOI 10.1016/j.humov.2017.04.013; Zago M, 2017, J SPORT SCI, V35, P1515, DOI 10.1080/02640414.2016.1223332; Zhang ZH, 2005, NEUROCOMPUTING, V69, P250, DOI 10.1016/j.neucom.2005.06.002	61	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2021	16	10							e0259464	10.1371/journal.pone.0259464	http://dx.doi.org/10.1371/journal.pone.0259464			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8NO	34714862	gold, Green Published			2023-01-03	WOS:000755042500059
J	Modrak, M; Burkner, PC; Sieger, T; Slisz, T; Vasakova, M; Meseznikov, G; Casas-Mendez, LF; Vajter, J; Taborsky, J; Kubricht, V; Suk, D; Horejsek, J; Jedlicka, M; Mifkova, A; Jaros, A; Kubiska, M; Vachalova, J; Sin, R; Veverkova, M; Pospisil, Z; Vohryzkova, J; Pokrievkova, R; Hrusak, K; Christozova, K; Leos-Barajas, V; Fiser, K; Hyanek, T				Modrak, Martin; Buerkner, Paul-Christian; Sieger, Tomas; Slisz, Tomas; Vasakova, Martina; Meseznikov, Grigorij; Casas-Mendez, Luis Fernando; Vajter, Jaromir; Taborsky, Jan; Kubricht, Viktor; Suk, Daniel; Horejsek, Jan; Jedlicka, Martin; Mifkova, Adriana; Jaros, Adam; Kubiska, Miroslav; Vachalova, Jana; Sin, Robin; Veverkova, Marketa; Pospisil, Zbysek; Vohryzkova, Julie; Pokrievkova, Rebeka; Hrusak, Kristian; Christozova, Kristina; Leos-Barajas, Vianey; Fiser, Karel; Hyanek, Tomas			Disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic in March-October 2020: An exploratory analysis	PLOS ONE			English	Article								We collected a multi-centric retrospective dataset of patients (N = 213) who were admitted to ten hospitals in Czech Republic and tested positive for SARS-CoV-2 during the early phases of the pandemic in March-October 2020. The dataset contains baseline patient characteristics, breathing support required, pharmacological treatment received and multiple markers on daily resolution. Patients in the dataset were treated with hydroxychloroquine (N = 108), azithromycin (N = 72), favipiravir (N = 9), convalescent plasma (N = 7), dexamethasone (N = 4) and remdesivir (N = 3), often in combination. To explore association between treatments and patient outcomes we performed multiverse analysis, observing how the conclusions change between defensible choices of statistical model, predictors included in the model and other analytical degrees of freedom. Weak evidence to constrain the potential efficacy of azithromycin and favipiravir can be extracted from the data. Additionally, we performed external validation of several proposed prognostic models for Covid19 severity showing that they mostly perform unsatisfactorily on our dataset.	[Modrak, Martin] Czech Acad Sci, Inst Microbiol, Bioinformat Core Facil, Prague, Czech Republic; [Buerkner, Paul-Christian] Univ Stuttgart, Cluster Excellence SimTech, Stuttgart, Germany; [Sieger, Tomas] Czech Tech Univ, Fac Elect Engn, Dept Cybernet, Prague, Czech Republic; [Slisz, Tomas; Vasakova, Martina] Charles Univ Prague, Fac Med 1, Dept Resp Med, Prague, Czech Republic; [Slisz, Tomas; Vasakova, Martina] Thomayer Univ Hosp, Prague, Czech Republic; [Meseznikov, Grigorij; Casas-Mendez, Luis Fernando; Vajter, Jaromir] Motol Univ Hosp, Prague, Czech Republic; [Taborsky, Jan] AGEL Hosp Novy Jicin, Novy Jicin, Czech Republic; [Kubricht, Viktor] Kralovske Vinohrady Univ Hosp, Prague, Czech Republic; [Suk, Daniel; Horejsek, Jan] Gen Univ Hosp Prague, Prague, Czech Republic; [Jedlicka, Martin; Mifkova, Adriana] Mil Hosp Olomouc, Olomouc, Czech Republic; [Jaros, Adam; Hyanek, Tomas] Homolce Hosp, Prague, Czech Republic; [Kubiska, Miroslav; Vachalova, Jana; Sin, Robin] Charles Univ Prague, Univ Hosp Pilsen, Fac Med Pilsen, Dept Infect Dis & Travel Med, Plzen, Czech Republic; [Veverkova, Marketa] Horovice Hosp, Horovice, Czech Republic; [Pospisil, Zbysek] Trebic Hosp, Trebic, Czech Republic; [Vohryzkova, Julie; Hrusak, Kristian; Christozova, Kristina] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Pokrievkova, Rebeka] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Leos-Barajas, Vianey] Univ Toronto, Dept Stat Sci, Toronto, ON, Canada; [Fiser, Karel] Charles Univ Prague, Fac Med 2, Dept Bioinformat, Prague, Czech Republic	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Stuttgart; Czech Technical University Prague; Charles University Prague; Thomayer Hospital; Motol University Hospital; University Hospital Vinohrady; General University Hospital Prague; Na Homolce Hospital; Charles University Prague; Charles University Prague; Charles University Prague; University of Toronto; Charles University Prague	Modrak, M (corresponding author), Czech Acad Sci, Inst Microbiol, Bioinformat Core Facil, Prague, Czech Republic.	martin.modrak@biomed.cas.cz	Vajter, Jaromir/GSD-7608-2022; Modrak, Martin/P-9821-2017	Fiser, Karel/0000-0002-7265-3268; Sieger, Tomas/0000-0003-4960-1934; Modrak, Martin/0000-0002-8886-7797; Vajter, Jaromir/0000-0001-6277-2151; Burkner, Paul-Christian/0000-0001-5765-8995	ELIXIR CZ research infrastructure project (Ministry of Youth, Education and Sports of the Czech Republic) [LM2018131]	ELIXIR CZ research infrastructure project (Ministry of Youth, Education and Sports of the Czech Republic)	MM was supported by ELIXIR CZ research infrastructure project (Ministry of Youth, Education and Sports of the Czech Republic, Grant No: LM2018131, https://www.msmt.cz/) including access to computing and storage facilities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal A., 2020, MANY PLACID TRIAL CO, DOI [10.1101/2020.09.03.20187252, DOI 10.1101/2020.09.03.20187252]; Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; [Anonymous], COVID 19 CR OT DAT S; Arah OA, 2019, EPIDEMIOLOGY, V30, P517, DOI 10.1097/EDE.0000000000001033; AUGUST DA, 1985, CANCER-AM CANCER SOC, V55, P1490, DOI 10.1002/1097-0142(19850401)55:7<1490::AID-CNCR2820550712>3.0.CO;2-N; Brat Gabriel A., 2020, npj Digital Medicine, V3, DOI 10.1038/s41746-020-00308-0; Burkner PC, 2018, R J, V10, P395; Caramelo F, 2020, ESTIMATION RISK FACT, DOI [10.1101/2020.02.24.20027268, DOI 10.1101/2020.02.24.20027268]; Catteau L, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106144; Chen X., 2020, EARLY PREDICTION MOR, DOI 10.1101/2020.04.13.20064329; Chen YM, 2021, THER INNOV REGUL SCI, V55, P197, DOI 10.1007/s43441-020-00206-3; COVID-19 RISK and Treatments (CORIST) Collaboration, 2020, Eur J Intern Med, V82, P38, DOI 10.1016/j.ejim.2020.08.019; COVID-19 Treatment Guidelines Panel, COR DIS 2019 COVID 1; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; Gupta RK, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.03498-2020; Hernan MA, 2016, J CLIN EPIDEMIOL, V79, P70, DOI 10.1016/j.jclinepi.2016.04.014; Hood K., 2020, STAT REV EFFICACY SA, DOI [10.5281/zenodo.3779933, DOI 10.5281/ZENODO.3779933]; Hood K., 2020, STAT REV REMDESIVIR; Horby P, 2020, NEW ENGL J MED, V383, P2030, DOI 10.1056/NEJMoa2022926; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Janiaud P, 2021, JAMA-J AM MED ASSOC, V325, P1185, DOI 10.1001/jama.2021.2747; Liu STH, 2020, NAT MED, V26, P1708, DOI 10.1038/s41591-020-1088-9; Lodi S, 2019, AM J EPIDEMIOL, V188, P1569, DOI 10.1093/aje/kwz100; Lu J., 2020, ACP RISK GRADE SIMPL, DOI [10.1101/2020.02.20.20025510, DOI 10.1101/2020.02.20.20025510]; Maeda T, 2021, J MED VIROL, V93, P463, DOI 10.1002/jmv.26365; Meier AS, 2003, BIOMETRICS, V59, P947, DOI 10.1111/j.0006-341X.2003.00109.x; Parackova Z, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102206; R Development Core Team, BOOK R LANG ENV STAT, P2021; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019; Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Smith G, 2018, J BIG DATA-GER, V5, DOI 10.1186/s40537-018-0143-6; Steegen S, 2016, PERSPECT PSYCHOL SCI, V11, P702, DOI 10.1177/1745691616658637; Stefan M, 2021, COVID 19 DIAGNOSTIKA; Steyerberg EW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001381; Therneau TM., 2000, MODELING SURVIVAL DA; Thoresen M, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0667-2; Tobaiqy M, 2020, Infect Prev Pract, V2, P100061, DOI 10.1016/j.infpip.2020.100061; Williams JP, 2020, J AM STAT ASSOC, V115, P16, DOI 10.1080/01621459.2019.1594831; Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328; Bello-Chavolla OY, 2020, J CLIN ENDOCR METAB, V105, P2752, DOI 10.1210/clinem/dgaa346	43	1	1	7	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2021	16	10							e0245103	10.1371/journal.pone.0245103	http://dx.doi.org/10.1371/journal.pone.0245103			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ9DX	34613965	Green Published, gold			2023-01-03	WOS:000749604400003
J	Hernandez-Cardenas, C; Thirion-Romero, I; Rodriguez-Llamazares, S; Rivera-Martinez, NE; Meza-Meneses, P; Remigio-Luna, A; Perez-Padilla, R				Hernandez-Cardenas, Carmen; Thirion-Romero, Ireri; Rodriguez-Llamazares, Sebastian; Rivera-Martinez, Norma E.; Meza-Meneses, Patricia; Remigio-Luna, Arantxa; Perez-Padilla, Rogelio		Res Grp Hydroxychloroquine COVID-1	Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial	PLOS ONE			English	Article							CORONAVIRUS	Introduction The novel coronavirus pandemic (COVID-19) represents a major public health problem and it is key to find a treatment that reduces mortality. Our objective was to estimate whether treatment with 400 mg/day of Hydroxychloroquine for 10 days reduces in-hospital mortality in subjects with severe respiratory disease due to COVID-19 compared with placebo. Material and methods A double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of Hydroxychloroquine for the treatment of severe disease by COVID-19 through an intentionto-treat analysis. Eligible for the study were adults aged more than 18 years with COVID-19 confirmed by RT-PCR and lung injury requiring hospitalization with or without mechanical ventilation. Primary outcome was 30-day mortality. Secondary outcomes: days of mechanical ventilation, days of hospitalization and cumulative incidence of serious adverse events. Results A total of 214 patients with COVID-19 were recruited, randomized and analyzed. They were hypoxemic with a mean SpO(2) of 65% +/- 20, tachycardic (pulse rate 108 +/- 17 min-(1)) and tachypneic (32 +/- 10 min-(1)); 162 were under mechanical ventilation at randomization. Thirty-day mortality was similar in both groups (38% in Hydroxychloroquine vs. 41% in placebo, hazard ratio [HR] 0.88, 95% Confidence Interval [95%CI] 0.51-1.53). In the surviving participants, no significant difference was found in secondary outcomes. Conclusion No beneficial effect or significant harm could be demonstrated in our randomized controlled trial including 214 patients, using relatively low doses of Hydroxychloroquine compared with placebo in hospitalized patients with severe COVID-19.	[Hernandez-Cardenas, Carmen; Thirion-Romero, Ireri; Rodriguez-Llamazares, Sebastian; Remigio-Luna, Arantxa; Perez-Padilla, Rogelio] Inst Nacl Enfermedades Respiratorias, Mexico City, DF, Mexico; [Rivera-Martinez, Norma E.] Hosp Reg Alta Especialidad Oaxaca, Oaxaca, Oaxaca, Mexico; [Meza-Meneses, Patricia] Hosp Reg Alta Especialidad Ixtapaluca, Estado De Mexico, Mexico		Perez-Padilla, R (corresponding author), Inst Nacl Enfermedades Respiratorias, Mexico City, DF, Mexico.	perezpad@gmail.com		Rivera-Martinez, Norma Erendira/0000-0002-6716-1234; Hernandez, Carmen/0000-0002-0311-2978; Perez-Padilla, Rogelio/0000-0002-1132-5308; MEZA MENESES, PATRICIA ALEJANDRA/0000-0002-3931-3114	CONACYT (National Council of Science and Technology of Mexico); SANOFI	CONACYT (National Council of Science and Technology of Mexico)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); SANOFI	CONACYT (National Council of Science and Technology of Mexico) and SANOFI participated. SANOFI provided the tested drug and identical placebo. The authors designed the trial, performed the analysis and wrote the manuscript.	Axfors C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22446-z; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Kumar J, 2021, J INFECT CHEMOTHER, V27, P882, DOI 10.1016/j.jiac.2021.02.021; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834; Moher David, 2012, Int J Surg, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; National Institutes of Health, 2020, NIH HALTS CLIN TRIAL; RECOVERY (Randomised Evaluation of COVID-19 Therapy), 2020, NO CLIN BEN US HYDR; Saitz R, 2020, JAMA-J AM MED ASSOC, V324, P443, DOI 10.1001/jama.2020.12535; Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; WHO, 2020, 179 WHO; World Health Organization, 2020, WHO DISC HYDR LOP RI; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	17	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2021	16	9							e0257238	10.1371/journal.pone.0257238	http://dx.doi.org/10.1371/journal.pone.0257238			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2D4JQ	34582477	Green Published, gold, Green Submitted			2023-01-03	WOS:000811515800007
J	Ezzalfani, M; Porcher, R; Savignoni, A; Delaloge, S; Filleron, T; Robain, M; Perol, D				Ezzalfani, Monia; Porcher, Raphael; Savignoni, Alexia; Delaloge, Suzette; Filleron, Thomas; Robain, Mathieu; Perol, David			Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project	PLOS ONE			English	Article							PACLITAXEL PLUS BEVACIZUMAB; PROPENSITY SCORE METHODS; SURVIVAL	Purpose Observational studies using routinely collected data are faced with a number of potential shortcomings that can bias their results. Many methods rely on controlling for measured and unmeasured confounders. In this work, we investigate the use of instrumental variables (IV) and quasi-trial analysis to control for unmeasured confounders in the context of a study based on the retrospective Epidemiological Strategy and Medical Economics (ESME) database, which compared overall survival (OS) with paclitaxel plus bevacizumab or paclitaxel alone as first-line treatment in patients with HER2-negative metastatic breast cancer (MBC). Patients and methods Causal interpretations and estimates can be made from observation data using IV and quasi-trial analysis. Quasi-trial analysis has the same conceptual basis as IV, however, instead of using IV in the analysis, a "superficial" or "pseudo" randomized trial is used in a Cox model. For instance, in a multicenter trial, instead of using the treatment variable, quasi-trial analysis can consider the treatment preference in each center, which can be informative, and then comparisons of results between centers or clinicians can be informative. Results In the original analysis, the OS adjusted for major factors was significantly longer with paclitaxel and bevacizumab than with paclitaxel alone. Using the center-treatment preference as an instrument yielded to concordant results. For the quasi-trial analysis, a Cox model was used, adjusted on all factors initially used. The results consolidate those obtained with a conventional multivariate Cox model. Conclusion Unmeasured confounding is a major concern in observational studies, and IV or quasi-trial analysis can be helpful to complement analysis of studies of this nature.	[Ezzalfani, Monia; Savignoni, Alexia] Inst Curie, Dept Biostat, Pole Biometrie, Paris, France; [Porcher, Raphael] Univ Paris, Ctr Res Epidemiol & Stat, INSERM, U1153, Paris, France; [Delaloge, Suzette] Inst Gustave Roussy, Dept Canc Med, Villejuif, France; [Filleron, Thomas] IUCT Oncopole, Biostat Unit, Toulouse, France; [Robain, Mathieu] R&D Unicanc, Dept Res & Dev, Paris, France; [Perol, David] Ctr Leon Berard, Dept Biostat, DRCI, Lyon, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; UNICANCER; UNICANCER; Centre Leon Berard	Ezzalfani, M (corresponding author), Inst Curie, Dept Biostat, Pole Biometrie, Paris, France.	monia.ezzalfani@curie.fr	d, p/GWC-4283-2022; filleron, thomas/C-3554-2014	filleron, thomas/0000-0003-0724-0659; Ezzalfani, Monia/0000-0002-2062-7041	Roche; Pfizer; AstraZeneca; MSD; Eisai; Daiichi Sankyo; RD Unicancer	Roche(Roche Holding); Pfizer(Pfizer); AstraZeneca(AstraZeneca); MSD; Eisai(Eisai Co Ltd); Daiichi Sankyo(Daiichi Sankyo Company Limited); RD Unicancer	The ESME MBC database receives financial support from an industrial consortium comprising Roche, Pfizer, AstraZeneca, MSD, Eisai and Daiichi Sankyo. Data collection, analysis and publication is managed entirely by R&D Unicancer independently of the industrial consortium. This work was supported by R&D Unicancer. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AALEN OO, 1989, STAT MED, V8, P907, DOI 10.1002/sim.4780080803; Austin PC, 2013, STAT MED, V32, P2837, DOI 10.1002/sim.5705; Baiocchi M, 2014, STAT MED, V33, P2297, DOI 10.1002/sim.6128; Baiocchia Michael., TUTORIAL BIOSTATISTI; Brookhart MA, 2010, PHARMACOEPIDEM DR S, V19, P537, DOI 10.1002/pds.1908; Brueckner M, 2019, BIOMETRICS, V75, P110, DOI 10.1111/biom.12952; Buyse M, 2017, ANN ONCOL, V28, P182, DOI 10.1093/annonc/mdw539; Campbell D.T., 2002, EXPT QUASIEXPERIMENT, DOI [10.1093/obo/9780195389678-0053, DOI 10.1093/OBO/9780195389678-0053]; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; de Gramont A, 2007, J CLIN ONCOL, V25, P3224, DOI 10.1200/JCO.2006.10.4380; Delaloge S, 2016, ANN ONCOL, V27, P1725, DOI 10.1093/annonc/mdw260; Ezzalfani M., 2018, REV EPIDEMIOLOGIE SA, V66, pS141; Gayat E, 2012, PHARM STAT, V11, P222, DOI 10.1002/pst.537; Hemkens LG, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i493; Kwiatkowski F, 2007, B CANCER, V94, P680; Li JL, 2015, BIOMETRICS, V71, P122, DOI 10.1111/biom.12244; Martinez-Camblor P., 2017, BIOSTATISTICS, DOI [10.1093/biostatistics/kxx062/4753665, DOI 10.1093/BIOSTATISTICS/KXX062/4753665]; Martinussen T., 2017, BIOSTAT OXF ENGL; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Perol D, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023568; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Tchetgen EJT, 2015, EPIDEMIOLOGY, V26, P402, DOI 10.1097/EDE.0000000000000262; Terza JV, 2008, J HEALTH ECON, V27, P531, DOI 10.1016/j.jhealeco.2007.09.009; Terza JV, 2008, HEALTH SERV RES, V43, P1102, DOI 10.1111/j.1475-6773.2007.00807.x; VAUPEL JW, 1979, DEMOGRAPHY, V16, P439, DOI 10.2307/2061224; Wan F, 2015, STAT MED, V34, P2235, DOI 10.1002/sim.6470	27	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2021	16	9							e0255017	10.1371/journal.pone.0255017	http://dx.doi.org/10.1371/journal.pone.0255017			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG6DR	34525119	Green Published, gold			2023-01-03	WOS:000707084400007
J	Mutumba, M				Mutumba, Massy			Mass media influences on family planning knowledge, attitudes and method choice among sexually active men in sub-Saharan Africa	PLOS ONE			English	Article							MODERN CONTRACEPTIVE USE; REPRODUCTIVE HEALTH; WOMENS EDUCATION; FERTILITY; COMMUNICATION; COUNTRIES; BEHAVIOR; EXPOSURE	Men are underrepresented in family planning (FP) research, and despite the widespread promotion of FP through mass media, there is no systematic evaluation on how mass media exposure influences their FP knowledge, attitudes and behavior. Using Demographic and Health Survey (DHS) data from 31 countries in Sub-Saharan Africa (SSA), collected between 2010 and 2019, this paper examines the associations between three types of traditional mass media (radio, television and print) with FP knowledge, attitudes and method choices among reproductive age men in SSA, relative to other socio-cultural factors. Estimates to quantify the relative contribution of each type of mass media, relative to other evidence-based socio-cultural influences on FP outcomes, were derived using the Shorrocks-Shapley decomposition. Radio exposure had the largest impact on FP knowledge, attitudes and method choice, accounting for 26.1% of the variance in FP knowledge, followed by Television (21.4%) and education attainment (20.7%). Mass media exposure had relatively minimal impact on FP method choice, and between the three types of mass media, television (8%) had the largest influence on FP method choice. Print media had comparatively lesser impact on FP knowledge (8%), attitudes (6.2%) and method choice (3.2%). Findings suggest that mass media exposure has positive influences on FP knowledge, attitudes and method choice but its influence on FP knowledge, attitudes and method choice is smaller relative to other socio-cultural factors such as education, household wealth and marital status. As such, efforts to increase FP uptake in Sub-Saharan Africa should take into consideration the impact of these socio-cultural economic factors.	[Mutumba, Massy] Univ Michigan, Sch Nursing, Dept Hlth Behav & Biol Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Mutumba, M (corresponding author), Univ Michigan, Sch Nursing, Dept Hlth Behav & Biol Sci, Ann Arbor, MI 48109 USA.	mmutumba@umic.edu		Mutumba, Massy/0000-0002-0636-891X				Ainsworth M, 1996, WORLD BANK ECON REV, V10, P85, DOI 10.1093/wber/10.1.85; Axinn WG, 2001, AM J SOCIOL, V106, P1219, DOI 10.1086/320818; Babalola S, 2017, J HEALTH COMMUN, V22, P885, DOI 10.1080/10810730.2017.1373874; Barber JS, 2004, J MARRIAGE FAM, V66, P1180, DOI 10.1111/j.0022-2445.2004.00086.x; Bawah AA, 2002, STUD FAMILY PLANN, V33, P185, DOI 10.1111/j.1728-4465.2002.00185.x; Blackstone SR, 2017, INT Q COMMUNITY HEAL, V37, P79, DOI 10.1177/0272684X16685254; Bloom D., 2003, DEMOGRAPHIC DIVIDEND; Brown W, 2014, STUD FAMILY PLANN, V45, P73, DOI 10.1111/j.1728-4465.2014.00377.x; Buyinza F, 2014, J INT DEV, V26, P763, DOI 10.1002/jid.2915; Cahill N, 2018, LANCET, V391, P870, DOI 10.1016/S0140-6736(17)33104-5; Canning D, 2012, LANCET, V380, P165, DOI 10.1016/S0140-6736(12)60827-7; Do M, 2020, J HEALTH COMMUN, V25, P115, DOI 10.1080/10810730.2020.1716279; Dyer SJ, 2007, J PSYCHOSOM OBST GYN, V28, P69, DOI 10.1080/01674820701409959; Emina JBO, 2014, CONTRACEPTION, V90, P154, DOI 10.1016/j.contraception.2014.02.001; Ezeanolue EE, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2216-1; Family Planning, 2020, FP2020 PARTN ACT 201; Fleming PJ, 2020, GLOB PUBLIC HEALTH, V15, P666, DOI 10.1080/17441692.2019.1692890; Greene ME, 2006, UN MILL PROJ CONTR R; Gupta N, 2003, STUD FAMILY PLANN, V34, P19, DOI 10.1111/j.1728-4465.2003.00019.x; Haider TL, 2013, INT Q COMMUNITY HEAL, V33, P403, DOI 10.2190/IQ.33.4.g; Hornik R, 2001, COMMUN THEOR, V11, P454, DOI 10.1093/ct/11.4.454; Hornik R, 2001, DIFFUSION PROCESSES AND FERTILITY TRANSITION: SELECTED PERSPECTIVES, P208; ICF International and USAID, 2015, DHS PROGR DEM HLTH S; International Conference on Population and Develop (ICPD), 1995, INT C POP DEV CAIR 1; Kincaid DL, 2000, COMMUN RES, V27, P723, DOI 10.1177/009365000027006003; Kriel Y, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0749-y; Ndong I, 1999, INT FAM PLAN PERSPEC, V25, pS53, DOI 10.2307/2991873; Ogunjuyigbe Peter O, 2009, Indian J Community Med, V34, P112, DOI 10.4103/0970-0218.51232; Okigbo CC, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0056-1; Retherford R D, 1997, Natl Fam Health Surv Bull, P1; Rutstein S.O., 2006, GUIDE DHS STAT; Singh S., 2014, ADDING IT COSTS BENE; Snow RC, 2013, AM J PUBLIC HEALTH, V103, P278, DOI 10.2105/AJPH.2012.300892; Speizer IS, 2014, GLOB HEALTH-SCI PRAC, V2, P410, DOI 10.9745/GHSP-D-14-00109; Sternberg P, 2004, HEALTH PROMOT INT, V19, P389, DOI 10.1093/heapro/dah312; UBOS Icf, 2018, UGANDA DEMOGRAPHIC H; Valente TW, 2001, J HEALTH COMMUN, V6, P303, DOI 10.1080/108107301317140805; Williamson Lisa M, 2009, Reprod Health, V6, P3, DOI 10.1186/1742-4755-6-3; Wulifan JK, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-015-0281-3; You DZ, 2015, LANCET, V386, P2275, DOI 10.1016/S0140-6736(15)00120-8	40	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0261068	10.1371/journal.pone.0261068	http://dx.doi.org/10.1371/journal.pone.0261068			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085245	Green Published, gold			2023-01-03	WOS:000779379600023
J	Memirie, ST; Yigezu, A; Zewdie, SA; Mirkuzie, AH; Bolongaita, S; Verguet, S				Memirie, Solomon Tessema; Yigezu, Amanuel; Zewdie, Samuel Abera; Mirkuzie, Alemnesh H.; Bolongaita, Sarah; Verguet, Stephane			Hospitalization costs for COVID-19 in Ethiopia: Empirical data and analysis from Addis Ababa's largest dedicated treatment center	PLOS ONE			English	Article								Background The COVID-19 pandemic has caused profound health, economic, and social disruptions globally. We assessed the full costs of hospitalization for COVID-19 disease at Ekka Kotebe COVID-19 treatment center in Addis Ababa, the largest hospital dedicated to COVID-19 patient care in Ethiopia. Methods and findings We retrospectively collected and analysed clinical and cost data on patients admitted to Ekka Kotebe with laboratory-confirmed COVID-19 infections. Cost data included personnel time and salaries, drugs, medical supplies and equipment, facility utilities, and capital costs. Facility medical records were reviewed to assess the average duration of stay by disease severity (either moderate, severe, or critical). The data collected covered the time-period March-November 2020. We then estimated the cost per treated COVID-19 episode, stratified by disease severity, from the perspective of the provider. Over the study period there were 2,543 COVID-19 cases treated at Ekka Kotebe, of which, 235 were critical, 515 were severe, and 1,841 were moderate. The mean patient duration of stay varied from 9.2 days (95% CI: 7.6-10.9; for moderate cases) to 19.2 days (17.9-20.6; for critical cases). The mean cost per treated episode was USD 1,473 (95% CI: 1,197-1,750), but cost varied by disease severity: the mean cost for moderate, severe, and critical cases were USD 1,266 (998-1,534), USD 1,545 (1,413-1,677), and USD 2,637 (1,788-3,486), respectively. Conclusions Clinical management and treatment of COVID-19 patients poses an enormous economic burden to the Ethiopian health system. Such estimates of COVID-19 treatment costs inform financial implications for resource-constrained health systems and reinforce the urgency of implementing effective infection prevention and control policies, including the rapid rollout of COVID-19 vaccines, in low-income countries like Ethiopia.	[Memirie, Solomon Tessema] Addis Ababa Univ, Coll Hlth Sci, Addis Ctr Ethics & Prior Setting, Addis Ababa, Ethiopia; [Yigezu, Amanuel; Mirkuzie, Alemnesh H.] Ethiopian Publ Hlth Inst, Natl Data Management Ctr Hlth, Addis Ababa, Ethiopia; [Zewdie, Samuel Abera] Minist Hlth, Partnership & Cooperat Directorate, Addis Ababa, Ethiopia; [Bolongaita, Sarah; Verguet, Stephane] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA	Addis Ababa University; Harvard University; Harvard T.H. Chan School of Public Health	Memirie, ST (corresponding author), Addis Ababa Univ, Coll Hlth Sci, Addis Ctr Ethics & Prior Setting, Addis Ababa, Ethiopia.	tess_soul@yahoo.com		Bolongaita, Sarah/0000-0003-0886-0454	Gavi; Bill & Melinda Gates Foundation [INV-010174]; Vaccine Alliance	Gavi; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Vaccine Alliance	SV, STM, and SB acknowledge funding support from Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation [INV-010174]. The funders of the study had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed are those of the authors and not necessarily those of the funders. Funder Name: Gavi, the Vaccine Alliance Grant Number: none Grant Recipient: Dr. Ste ' phane Verguet Funder Name: Bill & Melinda Gates Foundation Grant Number: INV-010174 Grant Recipient: Dr. Ste ' phane Verguet.	Abella BS, 2021, JAMA INTERN MED, V181, P195, DOI 10.1001/jamainternmed.2020.6319; Abrahim SA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244269; Al-Abdouh A, 2021, CONTEMP CLIN TRIALS, V101, DOI 10.1016/j.cct.2021.106272; Aloh HE, 2020, COST EFFECT RESOUR A, V18, DOI 10.1186/s12962-020-00216-w; American Hospital Association, 1998, EST US LIV DEPR HOSP; Barasa E, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004159; Biadgilign S, 2020, PAN AFR MED J, V35, DOI 10.11604/pamj.supp.2020.35.2.23906; Biswas S, 2021, MED HYPOTHESES, V146, DOI 10.1016/j.mehy.2020.110371; Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638; Edejer T, 2003, WHO GUIDE COST EFFEC; Ethiopian Public Health Institute and Ethiopia Ministry of Health, 2020, CAS MAN PROT COR VIR; Federal Democratic Republic of Ethiopia Ministry of Health, 2019, ETH HLTH ACC 2016 17; International Monetary Fund, 2018, FED DEM REP ETH SEL; International Monetary Fund, 2020, WORLD EC OUTL LONG D; Johns Hopkins University, 2021, COR RES CTR; Li XZ, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00689-0; Marahem M, 2018, CRESCENT J MED BIOL, V5, P270; Mbow M, 2020, SCIENCE, V3696504, P624; Ministry of Health Ethiopia and Ethiopian Public Health Institute, COVID 19 REP CAS ETH; Ministry of Health-Ethiopia and Ethiopian Public Health Institute, 2021, WEEKLY B; Nair VD, 2011, ETHIOP J HEALTH SCI, V21, P59; Roberton T, 2020, LANCET GLOB HEALTH, V8, pE901, DOI 10.1016/S2214-109X(20)30229-1; Tagar E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108304; Teklu S, 2020, ETHIOP J HEALTH SCI, V30, P645, DOI 10.4314/ejhs.v30i5.2; Thakur V, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030446; van Paassen J, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03400-9; Verguet S, 2021, NAT MED, V27, P380, DOI 10.1038/s41591-021-01268-y; Wallace AS, 2014, VACCINE, V32, P4505, DOI 10.1016/j.vaccine.2014.06.035; WHO, COVAX WORK GLOB EQ A; WHO, 2021, ENDING NEGLECT ATTAI; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; World Health Organization, ETH PREP ITS HLTH WO; World Health Organization, 1 CAS COVID 19 CONF; Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5	35	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0260930	10.1371/journal.pone.0260930	http://dx.doi.org/10.1371/journal.pone.0260930			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061674	Green Published, gold			2023-01-03	WOS:000791072800027
J	Videnovic, A; Babu, S; Zhao, B; Reda, HM; Linnoila, JJ				Videnovic, Aleksandar; Babu, Suma; Zhao, Brian; Reda, Haatem M.; Linnoila, Jenny J.			Case 1-2022: A 67-Year-Old Man with Motor Neuron Disease and Odd Behaviors during Sleep	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISORDER	A Man with Motor Neuron Disease and Odd Behaviors during Sleep A 67-year-old man with progressive motor neuron disease was evaluated in the sleep clinic because of dream enactment, daytime sleepiness, and apnea detected on a sleep study. Four months earlier, he had fallen asleep while washing dishes; this resulted in a fall and unstable C1 spinal fracture. A diagnostic test was performed.	[Videnovic, Aleksandar; Babu, Suma; Reda, Haatem M.; Linnoila, Jenny J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Zhao, Brian] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Videnovic, Aleksandar; Babu, Suma; Reda, Haatem M.; Linnoila, Jenny J.] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA; [Zhao, Brian] Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Videnovic, A (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.			Babu, Suma/0000-0002-2648-7625				Abboud H, 2021, J NEUROL NEUROSUR PS, V92, P757, DOI 10.1136/jnnp-2020-325300; Albdewi MA, 2018, SLEEP BREATH, V22, P277, DOI 10.1007/s11325-017-1538-x; Antelmi E, 2021, SLEEP MED REV, V60, DOI 10.1016/j.smrv.2021.101515; Cabezudo-Garcia P, 2020, ACTA NEUROL SCAND, V141, P263, DOI 10.1111/ane.13207; Gadoth A, 2017, ANN NEUROL, V82, P79, DOI 10.1002/ana.24979; Gaig C, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz133; Gresa-Arribas N, 2014, LANCET NEUROL, V13, P167, DOI 10.1016/S1474-4422(13)70282-5; Hogl B, 2018, NAT REV NEUROL, V14, P40, DOI 10.1038/nrneurol.2017.157; Honorat JA, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000385; Irfan M, 2021, NEUROTHERAPEUTICS, V18, P124, DOI 10.1007/s13311-021-01011-y; Korotun M, 2021, CLIN GERIATR MED, V37, P483, DOI 10.1016/j.cger.2021.04.008; Landa J, 2020, ANN NEUROL, V88, P1023, DOI 10.1002/ana.25857; Werner J, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000000962	13	3	3	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2022	386	2					173	180		10.1056/NEJMcpc2115844	http://dx.doi.org/10.1056/NEJMcpc2115844			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF2NZ	35020988				2023-01-03	WOS:000741651400015
J	Yan, Y; Chen, HY; Sun, LP; Zhang, W; Lu, X; Li, ZP; Xu, JL; Ren, Q				Yan, Yi; Chen, Haiyan; Sun, Leping; Zhang, Wei; Lu, Xin; Li, Zhenpeng; Xu, Jialiang; Ren, Qing			The changes of microbial diversity and flavor compounds during the fermentation of millet Huangjiu, a traditional Chinese beverage	PLOS ONE			English	Article							SACCHAROMYCES-CEREVISIAE; RICE WINE; TORULOPSIS-GLABRATA; SYNTHETIC BIOLOGY; AROMA COMPOUNDS; ACID SYNTHESIS; WHEAT QU; SP NOV.; PYRUVATE; OPTIMIZATION	Huangjiu is a national alcoholic beverage in China. Millet has congenital advantages in development and utilization of nutrient. Brewing Huangjiu with millet can increase the value of millet. Microbial community plays crucial roles in millet Huangjiu fermentation. Flavor compounds reflect the quality and health function of Huangjiu. The flavor compounds of Huangjiu are complex and their formation is closely associated with microorganisms, but the relationship between them during fermentation has been unknown. In this research, this relationship during millet Huangjiu fermentation were deeply investigated. Totally 86 volatile compounds were detected. Bacillus, Weissella, Paenibacillus, Klebsiella, Prevotella was investigated as the dominant microbes through high-throughput sequencing. 537 correlations between major flavor compounds and microbes were established to reflect the dynamic change during millet Huangjiu fermentation. The top five dominant genus of flavor producing microbes were Chryseobacterium, Sporolactobacillus, Psychrobacter, Sphingobium and Anoxybacillus. The content of malic acid and citric acid was gradually improved all through the millet Huangjiu fermentation. Malic acid and citric acid generated from millet Huangjiu fermentation shows healthy properties as liver protection and eliminating fatigue. Our research provides essential information on microbial community succession and the flavor formation during millet Huangjiu fermentation, and beneficial for development of Huangjiu products.	[Yan, Yi; Chen, Haiyan; Sun, Leping; Xu, Jialiang; Ren, Qing] Beijing Technol & Business Univ, Sch Light Ind, Beijing, Peoples R China; [Yan, Yi; Chen, Haiyan; Sun, Leping; Xu, Jialiang; Ren, Qing] Key Lab Brewing Mol Engn China Light Ind, Beijing, Peoples R China; [Zhang, Wei] Hebei Agr Univ, Coll Food Sci & Technol, Baoding, Peoples R China; [Lu, Xin; Li, Zhenpeng] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China	Beijing Technology & Business University; Hebei Agricultural University; Chinese Center for Disease Control & Prevention; National Institute for Communicable Disease Control & Prevention, Chinese Center for Disease Control & Prevention	Xu, JL; Ren, Q (corresponding author), Beijing Technol & Business Univ, Sch Light Ind, Beijing, Peoples R China.; Xu, JL; Ren, Q (corresponding author), Key Lab Brewing Mol Engn China Light Ind, Beijing, Peoples R China.	xujialiang@btbu.edu.cn; renqing@th.btbu.edu.cn	Chen, Haiyan/HGB-6216-2022; Yan, Yi/GQH-0844-2022	Sun, Leping/0000-0001-9095-1878	Fundamental Research Funding of Beijing Technology and Business University [PXM2020_014213_000017]; coarse cereals and various beans processing project of modern agricultural industrial technology system of Hebei province [HBCT2018070206]	Fundamental Research Funding of Beijing Technology and Business University; coarse cereals and various beans processing project of modern agricultural industrial technology system of Hebei province	This study was supported by Y.Y., Fundamental Research Funding of Beijing Technology and Business University (PXM2020_014213_000017) and W.Z., the coarse cereals and various beans processing project of modern agricultural industrial technology system of Hebei province (HBCT2018070206).W.Z.; Funding Acquisition; W.Z. had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alavi S, 2019, SORGHUM AND MILLETS: CHEMISTRY, TECHNOLOGY, AND NUTRITIONAL ATTRIBUTES, 2ND EDITION, P293, DOI 10.1016/B978-0-12-811527-5.00010-1; Amadou I., 2019, FERMENTED BEVERAGES, V5, P433, DOI [10.1016/B978-0-12-815271-3.00011-7, DOI 10.1016/B978-0-12-815271-3.00011-7]; [Anonymous], 2014, LIQUOR MAKING SCI TE; Atsumi S, 2008, NATURE, V451, P86, DOI 10.1038/nature06450; Bokulich NA, 2013, NAT METHODS, V10, P57, DOI [10.1038/nmeth.2276, 10.1038/NMETH.2276]; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Causey TB, 2004, P NATL ACAD SCI USA, V101, P2235, DOI 10.1073/pnas.0308171100; Chandra P, 2020, MICROB CELL FACT, V19, DOI 10.1186/s12934-020-01428-8; Chen G-M, 2021, CURR OPIN FOOD SCI; Chen J., 2008, STUDY FACTORS SHAOXI; Chen S, 2018, FLAVOUR FRAG J, V33, P263, DOI 10.1002/ffj.3440; Chen T, 2020, J SCI FOOD AGR, V100, P3297, DOI 10.1002/jsfa.10343; Chen YF, 2016, J IND MICROBIOL BIOT, V43, P1261, DOI 10.1007/s10295-016-1795-x; Chethan S, 2007, FOOD CHEM, V105, P862, DOI 10.1016/j.foodchem.2007.02.012; Council CNLI, 2008, CHIN RIC WIN; Daviot L, 2019, CATALYSTS, V9, DOI 10.3390/catal9030272; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; DICKINSON JR, 1993, FEBS LETT, V326, P29, DOI 10.1016/0014-5793(93)81754-N; Dong J, 2019, IRAN J BIOTECHNOL, V17, DOI 10.21859/ijb.1990; Dong Yan, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P559; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Etschmann MMW, 2002, APPL MICROBIOL BIOT, V59, P1, DOI 10.1007/s00253-002-0992-x; Fan GS, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.663744; Fan GS, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1470543; Fang RS, 2017, THESIS ZHEJIANG U; Fang RS, 2015, J FOOD SCI, V80, pM2265, DOI 10.1111/1750-3841.13018; Fu-Rong YE, 2013, LIQUOR MAKING, V40, P80; Gao X, 2018, BREWING TECHNOL, V1, P91; Gawas SD, 2016, APPL BIOCHEM BIOTECH, V180, P1428, DOI 10.1007/s12010-016-2177-6; Ghim CM, 2010, BIOTECHNOL BIOPROC E, V15, P11, DOI 10.1007/s12257-009-3065-5; Gil JV, 1996, J FOOD SCI, V61, P1247, DOI 10.1111/j.1365-2621.1996.tb10971.x; Goldenberger D, 2014, J CLIN MICROBIOL, V52, P3180, DOI 10.1128/JCM.00792-14; Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110; HILU KW, 1978, BIOCHEM SYST ECOL, V6, P247, DOI 10.1016/0305-1978(78)90013-3; Hong XT, 2016, SCI REP-UK, V6, DOI 10.1038/srep26621; Hu XL, 2016, APPL ENVIRON MICROB, V82, P2506, DOI 10.1128/AEM.03409-15; Hu YL, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.673670; Huang ZR, 2018, FOOD MICROBIOL, V76, P487, DOI 10.1016/j.fm.2018.07.014; Isar J, 2007, ANAEROBE, V13, P50, DOI 10.1016/j.anaerobe.2006.12.002; Ji ZW, 2018, INT J FOOD SCI TECH, V53, P1611, DOI 10.1111/ijfs.13743; Jiao JK, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.649611; Kalse S, 2016, DEV QUALITY EVALUATI, V7, P2; Karatas H, 2013, ANN MICROBIOL, V63, P45, DOI 10.1007/s13213-012-0443-6; Kariyawasam KMGMM, 2019, J DAIRY SCI, V102, P3887, DOI 10.3168/jds.2018-15360; Kawamura Y, 2015, SYST APPL MICROBIOL, V38, P104, DOI 10.1016/j.syapm.2014.11.004; Kumar MH, 2019, DRUG INVENT TODAY, V11, P2657; Li HH, 2019, FOOD CHEM, V284, P100, DOI 10.1016/j.foodchem.2019.01.102; Li LL, 2002, INT J PHARM, V237, P77, DOI 10.1016/S0378-5173(02)00029-7; Li Y, 2002, APPL MICROBIOL BIOT, V60, P101, DOI [10.1007/s0253-002-1064-y, 10.1007/s00253-002-1064-y]; Lilin S., 2021, CHINA BREWING, V40, P54; Lin H, 2020, FOOD SCI BIOTECHNOL, V29, P1037, DOI 10.1007/s10068-020-00757-z; Lin XJ, 2014, CHIN J CHROMATOGR, V32, P304, DOI 10.3724/SP.J.1123.2013.11023; Liu Jingke, 2009, Cereal & Feed Industry, P22; Liu SP, 2015, WORLD J MICROB BIOT, V31, P1907, DOI 10.1007/s11274-015-1931-1; Liu SP, 2019, INT J FOOD MICROBIOL, V303, P9, DOI 10.1016/j.ijfoodmicro.2019.05.001; Luo T, 2008, J I BREWING, V114, P172, DOI 10.1002/j.2050-0416.2008.tb00323.x; Luo W, 2016, RES IMPROVING ETHYL; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Martinez-Ruiz A, 2018, BIORESOURCE TECHNOL, V265, P52, DOI 10.1016/j.biortech.2018.05.080; Miyata R, 1999, J BIOSCI BIOENG, V88, P173, DOI 10.1016/S1389-1723(99)80197-2; Ojediran J, 2021, SOME PHYS PROPERTIES, V6; Papagianni M, 2007, BIOTECHNOL ADV, V25, P244, DOI 10.1016/j.biotechadv.2007.01.002; PELEG Y, 1989, APPL MICROBIOL BIOT, V30, P176; Pines O, 1996, APPL MICROBIOL BIOT, V46, P393, DOI 10.1007/s002530050835; Rabinovitch-Deere CA, 2013, CHEM REV, V113, P4611, DOI 10.1021/cr300361t; Ran X., 2015, THESIS ZHEJIANG A F; Rayne S, 2007, J CHROMATOGR A, V1167, P195, DOI 10.1016/j.chroma.2007.08.049; Ren DQ, 2006, LIQUOR MAKING SCI TE, V144, P39; Ren Q, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40337-8; Robles A, 2019, TRAC-TREND ANAL CHEM, V120, DOI 10.1016/j.trac.2019.115630; Rong ZX, 2013, CHINA BREWING, V32, P28; Saerens SMG, 2006, J BIOL CHEM, V281, P4446, DOI 10.1074/jbc.M512028200; Shi H, 2007, STUDY NOURISHMENT HL; Song Y, SCI TECHNOLOGY FOOD, V37, P387; Song ZW, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01294; Sun HL, 2020, FOOD CHEM, V317, DOI 10.1016/j.foodchem.2020.126420; Sun JX., 2012, MODERN FOOD SCI TECH, V28, P1541, DOI [10.13982/j.mfst.1673-9078.2012.11.033, DOI 10.13982/J.MFST.1673-9078.2012.11.033]; Syu MJ, 2001, APPL MICROBIOL BIOT, V55, P10, DOI 10.1007/s002530000486; Takahashi T, 2017, J BIOSCI BIOENG, V123, P707, DOI 10.1016/j.jbiosc.2017.01.014; Teng W, 2016, J FOOD SCI, V35; Tomar A, 2003, APPL MICROBIOL BIOT, V62, P76, DOI 10.1007/s00253-003-1234-6; Tong J, 2010, INT J SYST EVOL MICR, V60, P1135, DOI 10.1099/ijs.0.011783-0; van Maris AJA, 2004, APPL ENVIRON MICROB, V70, P159, DOI 10.1128/AEM.70.1.159-166.2004; Vogel H, 1987, BIOTECHNOL BIOENG, V29; Wang J, 2020, FOOD RES INT, V134, DOI 10.1016/j.foodres.2020.109238; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Xiao-Yu D, 2013, J DALIAN U; Xu JL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23013-1; Xu YQ, 2021, FOOD CHEM, V338, DOI 10.1016/j.foodchem.2020.128025; Yang YJ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.580247; Yoda T, 2020, BIOMIMETICS-BASEL, V5, DOI 10.3390/biomimetics5020016; Yu HY, 2021, FOOD RES INT, V145, DOI 10.1016/j.foodres.2021.110421; Yu HY, 2015, J CHROMATOGR B, V997, P129, DOI 10.1016/j.jchromb.2015.05.037; Yu LJ, 2012, J I BREWING, V118, P114, DOI 10.1002/jib.13; Zhang Y, 2021, APPL OPTICS, V60, P5480, DOI 10.1364/AO.424015; Zhu J, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0221-9	98	4	4	28	56	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2022	17	1							e0262353	10.1371/journal.pone.0262353	http://dx.doi.org/10.1371/journal.pone.0262353			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZO8DB	34986204	gold, Green Published			2023-01-03	WOS:000765956200046
J	Salian, P				Salian, Priti			"I am disabled, it doesn't mean I have no dignity"	LANCET			English	Editorial Material																			0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN	2022	399	10322					349	350						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YL7CQ	35065776				2023-01-03	WOS:000746046100010
J	Liu, HR; Forouhar, F; Seibt, T; Saneto, R; Wigby, K; Friedman, J; Xia, X; Shchepinov, MS; Ramesh, SK; Conrad, M; Stockwell, BR				Liu, Hengrui; Forouhar, Farhad; Seibt, Tobias; Saneto, Russell; Wigby, Kristen; Friedman, Jennifer; Xia, Xin; Shchepinov, Mikhail S.; Ramesh, Sanath Kumar; Conrad, Marcus; Stockwell, Brent R.			Characterization of a patient-derived variant of GPX4 for precision therapy	NATURE CHEMICAL BIOLOGY			English	Article							CELL-DEATH; SELENIUM SUPPLEMENTATION; OXIDATIVE DAMAGE; CANCER-CELLS; GLUTATHIONE; EXPRESSION; MUTANT; DEPENDENCY; PROTECTS	Glutathione peroxidase 4 (GPX4), as the only enzyme in mammals capable of reducing esterified phospholipid hydroperoxides within a cellular context, protects cells from ferroptosis. We identified a homozygous point mutation in the GPX4 gene, resulting in an R152H coding mutation, in three patients with Sedaghatian-type spondylometaphyseal dysplasia. Using structure-based analyses and cell models, including patient fibroblasts, of this variant, we found that the missense variant destabilized a critical loop, which disrupted the active site and caused a substantial loss of enzymatic function. We also found that the R152H variant of GPX4 is less susceptible to degradation, revealing the degradation mechanism of the GPX4 protein. Proof-of-concept therapeutic treatments, which overcome the impaired R152H GPX4 activity, including selenium supplementation, selective antioxidants and a deuterated polyunsaturated fatty acid were identified. In addition to revealing a general approach to investigating rare genetic diseases, we demonstrate the biochemical foundations of therapeutic strategies targeting GPX4.	[Liu, Hengrui; Stockwell, Brent R.] Columbia Univ, Dept Chem, New York, NY 10027 USA; [Forouhar, Farhad; Stockwell, Brent R.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA; [Seibt, Tobias] Klinikum Univ Munchen, Med Klin & Poliklin 4, Dept Nephrol, Munich, Germany; [Saneto, Russell] Klinikum Univ Munchen, Med Klin & Poliklin 4, Inst Metab & Cell Death, Munich, Germany; [Saneto, Russell] Univ Washington, Dept Neurol, Div Pediat Neurol, Seattle, WA 98195 USA; [Saneto, Russell] Seattle Childrens Hosp, Ctr Integrat Brain Res, Seattle, WA USA; [Wigby, Kristen; Friedman, Jennifer] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Wigby, Kristen; Friedman, Jennifer] Rady Childrens Hosp San Diego, Rady Childrens Inst Genom Med, San Diego, CA USA; [Friedman, Jennifer] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Friedman, Jennifer] Rady Childrens Hosp, Div Child Neurol, San Diego, CA USA; [Xia, Xin; Stockwell, Brent R.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Shchepinov, Mikhail S.] Retrotope Inc, Los Altos, CA USA; [Ramesh, Sanath Kumar] CureGPX4 Org, Seattle, WA USA; [Conrad, Marcus] Helmholtz Zentrum Munchen, Inst Metab & Cell Death, Neuherberg, Germany; [Conrad, Marcus] Pirogov Russian Natl Res Med Univ, Lab Expt Oncol, Moscow, Russia; [Stockwell, Brent R.] Columbia Univ, Irving Inst Canc Dynam, New York, NY 10027 USA	Columbia University; Columbia University; University of Munich; University of Munich; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; Columbia University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Pirogov Russian National Research Medical University; Columbia University	Stockwell, BR (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.; Stockwell, BR (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA.; Stockwell, BR (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.; Stockwell, BR (corresponding author), Columbia Univ, Irving Inst Canc Dynam, New York, NY 10027 USA.	bstockwell@columbia.edu	Stockwell, Brent R/AAE-7200-2019; Conrad, Marcus/E-8792-2015	Stockwell, Brent R/0000-0002-3532-3868; Conrad, Marcus/0000-0003-1140-5612; Liu, Hengrui/0000-0002-5214-1572	BMBF VIP+ program NEUROPROTEKT [03VP04260]; Ministry of Science and Higher Education of the Russian Federation [075-15-2019-1933]; European Research Council (ERC) under the European Union [GA 884754];  [P01CA87497];  [R35CA209896];  [R61NS109407]	BMBF VIP+ program NEUROPROTEKT(Federal Ministry of Education & Research (BMBF)); Ministry of Science and Higher Education of the Russian Federation; European Research Council (ERC) under the European Union(European Research Council (ERC)); ; ; 	This study was supported by P01CA87497 (B.R.S.), R35CA209896 (B.R.S.) and R61NS109407 (B.R.S.), and the BMBF VIP+ program NEUROPROTEKT (03VP04260), the Ministry of Science and Higher Education of the Russian Federation (075-15-2019-1933) and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No. GA 884754) (M.C.). We thank Q. Ran for calling to attention that three patients reported in this study shared the same homozygous variant. We are grateful to the patient with the R152H variant and the patient's parent for providing their fibroblasts for this study. We thank the staff of the High-Throughput Crystallization Screening Center of the Hauptman-Woodward Medical Research Institute for screening of crystallization conditions and the staff of the Advanced Photon Source at Argonne National Laboratory for assistance with data collection. We also thank curegpx4.org for supporting the study and patients with GPX4 variants, and the roadmap effort for GPX4 disorders46.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Akin A, 2016, J GENET GENOME RES, V3, P25; Bodnar M, 2016, CRIT REV FOOD SCI, V56, P36, DOI 10.1080/10408398.2012.709550; Borchert A, 2018, BBA-MOL CELL BIOL L, V1863, P1095, DOI 10.1016/j.bbalip.2018.06.006; Brenna JT, 2020, J PHARM SCI-US, V109, P3496, DOI 10.1016/j.xphs.2020.08.019; Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Cheff DM, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-02048-0; Elcioglu N, 1998, AM J MED GENET, V76, P410, DOI 10.1002/(SICI)1096-8628(19980413)76:5<410::AID-AJMG8>3.0.CO;2-Q; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Fedida A, 2020, EUR J MED GENET, V63, DOI 10.1016/j.ejmg.2020.104020; Gaschler MM, 2018, NAT CHEM BIOL, V14, P507, DOI 10.1038/s41589-018-0031-6; Hangauer MJ, 2017, NATURE, V551, P247, DOI 10.1038/nature24297; Hatami A, 2018, FEBS J, V285, P3002, DOI 10.1111/febs.14590; Ingold I, 2018, CELL, V172, P409, DOI 10.1016/j.cell.2017.11.048; Ingold I, 2015, J BIOL CHEM, V290, P14668, DOI 10.1074/jbc.M115.656363; Janowski R, 2016, ACTA CRYSTALLOGR F, V72, P743, DOI 10.1107/S2053230X16013686; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kaplan A, 2015, P NATL ACAD SCI USA, V112, pE2245, DOI 10.1073/pnas.1500439112; Li C, 2019, J MED CHEM, V62, P266, DOI 10.1021/acs.jmedchem.8b00315; Liu HR, 2018, BIOCHEMISTRY-US, V57, P2059, DOI [10.1021/acs.biochem.8b00307, 10.1021/acs.biochem.81300307]; Lo MC, 2004, ANAL BIOCHEM, V332, P153, DOI 10.1016/j.ab.2004.04.031; Luft JR, 2003, J STRUCT BIOL, V142, P170, DOI 10.1016/S1047-8477(03)00048-0; Mannes AM, 2011, FASEB J, V25, P2135, DOI 10.1096/fj.10-177147; Mauri P, 2003, BIOL CHEM, V384, P575, DOI 10.1515/BC.2003.065; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Romanowska M, 2007, LUNG CANCER, V55, P35, DOI 10.1016/j.lungcan.2006.09.007; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; Sakamoto K, 2017, BIOCHEM BIOPH RES CO, V482, P195, DOI 10.1016/j.bbrc.2016.11.035; Scheerer P, 2007, BIOCHEMISTRY-US, V46, P9041, DOI 10.1021/bi700840d; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Shimada K, 2016, NAT CHEM BIOL, V12, P497, DOI [10.1038/NCHEMBIO.2079, 10.1038/nchembio.2079]; Smith AC, 2014, J MED GENET, V51, P470, DOI 10.1136/jmedgenet-2013-102218; Tosatto SCE, 2008, ANTIOXID REDOX SIGN, V10, P1515, DOI 10.1089/ars.2008.2055; Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589; Viswanathan VS, 2017, NATURE, V547, P453, DOI 10.1038/nature23007; Wang Q, 2015, INT J MOL SCI, V16, P13885, DOI 10.3390/ijms160613885; Wirth EK, 2010, FASEB J, V24, P844, DOI 10.1096/fj.09-143974; Wu ZM, 2019, P NATL ACAD SCI USA, V116, P2996, DOI 10.1073/pnas.1819728116; Yang WS, 2016, P NATL ACAD SCI USA, V113, pE4966, DOI 10.1073/pnas.1603244113; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6; Yoo SE, 2012, FREE RADICAL BIO MED, V52, P1820, DOI 10.1016/j.freeradbiomed.2012.02.043; Yu Y, 2014, FREE RADICAL BIO MED, V71, P332, DOI 10.1016/j.freeradbiomed.2014.03.032; Zhu K, 2014, J CHEM INF MODEL, V54, P1932, DOI 10.1021/ci500118s	46	13	13	5	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2022	18	1					91	+		10.1038/s41589-021-00915-2	http://dx.doi.org/10.1038/s41589-021-00915-2		DEC 2021	27	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XU1KS	34931062	Green Submitted, Green Accepted			2023-01-03	WOS:000731826400001
J	Neumann, PJ; Cohen, JT; Ollendorf, DA				Neumann, Peter J.; Cohen, Joshua T.; Ollendorf, Daniel A.			Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Neumann, Peter J.; Cohen, Joshua T.; Ollendorf, Daniel A.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA 02111 USA	Tufts Medical Center	Neumann, PJ (corresponding author), Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA 02111 USA.							Cohen JT., 2021, RIGHT PRICE VALUE BA; Cookson R, 2017, VALUE HEALTH, V20, P206, DOI 10.1016/j.jval.2016.11.027; Frank RG, 2019, NEW ENGL J MED, V381, P1404, DOI 10.1056/NEJMp1909798; Lakdawalla DN, 2020, J HEALTH ECON, V72, DOI 10.1016/j.jhealeco.2020.102346; Wilensky, 2021, USC SCHAEFFER CTR	5	6	6	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2021	385	21					1923	1924		10.1056/NEJMp2113323	http://dx.doi.org/10.1056/NEJMp2113323		NOV 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WY8NB	34767318				2023-01-03	WOS:000718031300001
J	Singh, AK; Carroll, K; Perkovic, V; Solomon, S; Jha, V; Johansen, KL; Lopes, RD; Macdougall, IC; Obrador, GT; Waikar, SS; Wanner, C; Wheeler, DC; Wiecek, A; Blackorby, A; Cizman, B; Cobitz, AR; Davies, R; Dole, J; Kler, L; Meadowcroft, AM; Zhu, XY; McMurray, JJV				Singh, Ajay K.; Carroll, Kevin; Perkovic, Vlado; Solomon, Scott; Jha, Vivekanand; Johansen, Kirsten L.; Lopes, Renato D.; Macdougall, Iain C.; Obrador, Gregorio T.; Waikar, Sushrut S.; Wanner, Christoph; Wheeler, David C.; Wiecek, Andrzej; Blackorby, Allison; Cizman, Borut; Cobitz, Alexander R.; Davies, Rich; Dole, Jo; Kler, Lata; Meadowcroft, Amy M.; Zhu, Xinyi; McMurray, John J., V		ASCEND-D Study Grp	Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KIDNEY-DISEASE; HEMODIALYSIS; HYPOXIA; HEPCIDIN; TRIAL; ALPHA	BACKGROUND Among patients with chronic kidney disease (CKD), the use of recombinant human erythropoietin and its derivatives for the treatment of anemia has been linked to a possibly increased risk of stroke, myocardial infarction, and other adverse events. Several trials have suggested that hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHIs) are as effective as erythropoiesis-stimulating agents (ESAs) in increasing hemoglobin levels. METHODS In this randomized, open-label, phase 3 trial, we assigned patients with CKD who were undergoing dialysis and who had a hemoglobin level of 8.0 to 11.5 g per deciliter to receive an oral HIF-PHI (daprodustat) or an injectable ESA (epoetin alfa if they were receiving hemodialysis or darbepoetin alfa if they were receiving peritoneal dialysis). The two primary outcomes were the mean change in the hemoglobin level from baseline to weeks 28 through 52 (noninferiority margin, -0.75 g per deciliter) and the first occurrence of a major adverse cardiovascular event (a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke), with a noninferiority margin of 1.25. RESULTS A total of 2964 patients underwent randomization. The mean (+/- SD) baseline hemoglobin level was 10.4 +/- 1.0 g per deciliter overall. The mean (+/- SE) change in the hemoglobin level from baseline to weeks 28 through 52 was 0.28 +/- 0.02 g per deciliter in the daprodustat group and 0.10 +/- 0.02 g per deciliter in the ESA group (difference, 0.18 g per deciliter; 95% confidence interval [CI], 0.12 to 0.24), which met the prespecified noninferiority margin of -0.75 g per deciliter. During a median follow-up of 2.5 years, a major adverse cardiovascular event occurred in 374 of 1487 patients (25.2%) in the daprodustat group and in 394 of 1477 (26.7%) in the ESA group (hazard ratio, 0.93; 95% CI, 0.81 to 1.07), which also met the prespecified noninferiority margin for daprodustat. The percentages of patients with other adverse events were similar in the two groups. CONCLUSIONS Among patients with CKD undergoing dialysis, daprodustat was noninferior to ESAs regarding the change in the hemoglobin level from baseline and cardiovascular outcomes.	[Singh, Ajay K.; Solomon, Scott] Brigham & Womens Hosp, 75 Francis St,Med Res Bldg,4th Fl, Boston, MA 02115 USA; [Singh, Ajay K.; Solomon, Scott] Harvard Med Sch, Boston, MA 02115 USA; [Waikar, Sushrut S.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Waikar, Sushrut S.] Boston Med Ctr, Boston, MA USA; [Carroll, Kevin] KJC Stat, Cheadle, England; [Jha, Vivekanand] Imperial Coll London, Sch Publ Hlth, London, England; [Macdougall, Iain C.] Kings Coll Hosp London, London, England; [Wheeler, David C.] UCL, Dept Renal Med, London, England; [Kler, Lata; Zhu, Xinyi] GlaxoSmithKline, Brentford, England; [McMurray, John J., V] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland; [Perkovic, Vlado] Univ New South Wales, Sydney, NSW, Australia; [Jha, Vivekanand] George Inst Global Hlth, New Delhi, India; [Jha, Vivekanand] Manipal Acad Higher Educ, Prasanna Sch Publ Hlth, Manipal, Karnataka, India; [Johansen, Kirsten L.] Univ Minnesota, Hennepin Healthcare, Minneapolis, MN USA; [Lopes, Renato D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [Obrador, Gregorio T.] Univ Panamericana, Sch Med, Mexico City, DF, Mexico; [Wanner, Christoph] Univ Wurzburg, Wurzburg, Germany; [Wiecek, Andrzej] Med Univ Silesia, Katowice, Poland; [Blackorby, Allison; Cizman, Borut; Cobitz, Alexander R.; Davies, Rich; Dole, Jo; Meadowcroft, Amy M.] GlaxoSmithKline, Collegeville, PA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University; Boston Medical Center; Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; University College London; GlaxoSmithKline; University of Glasgow; University of New South Wales Sydney; Manipal Academy of Higher Education (MAHE); University of Minnesota System; University of Minnesota Twin Cities; Duke University; Universidad Panamericana - Ciudad de Mexico; University of Wurzburg; Medical University Silesia; GlaxoSmithKline	Singh, AK (corresponding author), Brigham & Womens Hosp, 75 Francis St,Med Res Bldg,4th Fl, Boston, MA 02115 USA.	ajay_singh@hms.harvard.edu	Apartsin, Konstantin/ABC-5678-2020; Prozesky, Hans Walter/ABE-6956-2020; Apartsin, Konstantin A/B-9179-2017; Apartsin, Konstantin/ACA-8088-2022; Ntounousi or Dounousi, Evangelia/AAE-7807-2022	Apartsin, Konstantin/0000-0003-0577-9001; Prozesky, Hans Walter/0000-0001-9715-3449; Apartsin, Konstantin A/0000-0003-0577-9001; Apartsin, Konstantin/0000-0003-0577-9001; Jha, Vivekanand/0000-0002-8015-9470; Galperin, Emilia/0000-0002-8743-026X; Waikar, Sushrut/0000-0003-4004-326X				Babitt JL, 2012, J AM SOC NEPHROL, V23, P1631, DOI 10.1681/ASN.2011111078; Bernhardt WM, 2010, J AM SOC NEPHROL, V21, P2151, DOI 10.1681/ASN.2010010116; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Chen N, 2019, NEW ENGL J MED, V381, P1011, DOI 10.1056/NEJMoa1901713; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Eckardt KU, 2021, NEW ENGL J MED, V384, P1601, DOI 10.1056/NEJMoa2025956; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Holdstock L, 2019, CLIN KIDNEY J, V12, P129, DOI 10.1093/ckj/sfy013; Koury MJ, 2015, NAT REV NEPHROL, V11, P394, DOI 10.1038/nrneph.2015.82; Liu QD, 2012, J CLIN INVEST, V122, P4635, DOI 10.1172/JCI63924; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P121, DOI 10.1093/ndt/gfg458; Luo JC, 2016, AM J KIDNEY DIS, V68, P763, DOI 10.1053/j.ajkd.2016.05.031; Meadowcroft AM, 2019, CLIN KIDNEY J, V12, P139, DOI 10.1093/ckj/sfy014; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Provenzano R, 2021, KIDNEY INT REP, V6, P613, DOI 10.1016/j.ekir.2020.12.018; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Singh AK., 2021, NEPHROL DIAL TRANSPL	18	34	34	5	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 16	2021	385	25					2325	2335		10.1056/NEJMoa2113379	http://dx.doi.org/10.1056/NEJMoa2113379		NOV 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE4WZ	34739194	Green Published, Green Accepted			2023-01-03	WOS:000714715500001
J	Stubbs, PW; Stabel, HH; Andersen, NBD; Smith, HR; Naess-Schmidt, ET				Stubbs, Peter W.; Stabel, Henriette H.; Andersen, Nils-Bo de Vos; Smith, Helle Ronn; Naess-Schmidt, Erhard T.			Therapist perceptions of the Danish Physiotherapy Research Database for assessing patients with chronic disease	PLOS ONE			English	Article							IMPLEMENTATION	Background The Danish Physiotherapy Research Database for chronic patients receiving Free of Charge Physiotherapy (PhysDB-FCP) was piloted over a 1-year period. The purpose of the PhysDB-FCP is to provide a user friendly digital online structured tool that standardizes initial and follow up clinical assessments generating data that can be used for clinical decision making and support future research in physiotherapy for patients with chronic disease. Although initial assessments were completed, the attrition rate was 73% and 90% at 3- and 6- months, respectively, which suggests problems with the current tool. Objective To evaluate the perspectives of the physiotherapists that used the PhysDB-FCP and propose changes to the tool based on this feedback. Materials and methods Fifty of the 103 physiotherapists introduced to the PhysDB-FCP completed an anonymous online survey. Physiotherapists were asked Likert/categorical and yes/no questions on experiences with the PhysDB-FCP within their practice, perceptions of patient experiences, suitability of the resources and support provided by the PhysDB-FCP working group and the ideal administration frequency of the assessments within the PhysDB-FCP. Open ended feedback on possible improvements to the PhysDB-FCP was also collected. Results Physiotherapists agreed that the PhysDB-FCP was useful for taking a physiotherapy assessment (74%) and the patient survey was useful for goal setting (72%). Although physiotherapists felt the PhysDB-FCP was well-defined (82%), only 36% would like to use a similar tool again. Generally, the PhysDB-FCP was too time-consuming, administered too frequently and included irrelevant items. For example, 72% of physiotherapists took >45 min to administer the assessment in the first consultation which was performed over multiple sessions. Conclusions The perspectives of physiotherapists using The PhysDB-FCP suggest specific changes that will ensure better use of the tool in future practice. Changes will likely involve administering the assessment less frequently (every 6-months to 1-year), shortening the assessment, and using diagnosis-specific assessment items.	[Stubbs, Peter W.] Univ Technol Sydney, Discipline Physiotherapy, Grad Sch Hlth, Sydney, NSW, Australia; [Stabel, Henriette H.; Naess-Schmidt, Erhard T.] Aarhus Univ, Hammel Neurorehabil Ctr, Aarhus, Denmark; [Stabel, Henriette H.; Naess-Schmidt, Erhard T.] Aarhus Univ, Univ Res Clin, Aarhus, Denmark; [Andersen, Nils-Bo de Vos] Primary Hlth Care & Qual Improvement, Viborg, Denmark; [Smith, Helle Ronn] VIA Univ Coll, Holstebro, Denmark	University of Technology Sydney; Aarhus University; Aarhus University	Naess-Schmidt, ET (corresponding author), Aarhus Univ, Hammel Neurorehabil Ctr, Aarhus, Denmark.; Naess-Schmidt, ET (corresponding author), Aarhus Univ, Univ Res Clin, Aarhus, Denmark.	erhnae@rm.dk	Næss-Schmidt, Erhard/AAP-8212-2021	Næss-Schmidt, Erhard/0000-0002-2539-0362; Roenn-Smidt, Helle/0000-0003-2987-5540; /0000-0003-4555-8019				[Anonymous], 2020, PRAKSISPLAN FYSIOTER; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; de Roos P, 2017, J PARKINSON DIS, V7, P533, DOI 10.3233/JPD-161055; Evensen KAI, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3729-y; Huijg JM, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-33; Johnsen SP, 2016, CLIN EPIDEMIOL, V8, P697, DOI 10.2147/CLEP.S103662; Knudsen AH, 2011, PATIENTER FYSIOTERAP; Kwakkel G, 2017, INT J STROKE, V12, P451, DOI 10.1177/1747493017711813; McGrath R, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1110-6; Meerhoff GA, 2017, PHYS THER, V97, P837, DOI 10.1093/ptj/pzx051; Naess-Schmidt E, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-040207; Naess-Schmidt ET, 2020, CLIN EPIDEMIOL, V12, P23, DOI 10.2147/CLEP.S223000; Voshaar MAHO, 2019, ARTHRIT CARE RES, V71, P1556, DOI 10.1002/acr.23799; Paul L, 2014, MULT SCLER J, V20, P1641, DOI 10.1177/1352458514526944; Pedersen BK, 2015, SCAND J MED SCI SPOR, V25, P1, DOI 10.1111/sms.12581; Prescott S, 2015, BRAIN INJURY, V29, P1515, DOI 10.3109/02699052.2015.1075152; Swinkels ICS, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-163	17	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2021	16	11							e0259355	10.1371/journal.pone.0259355	http://dx.doi.org/10.1371/journal.pone.0259355			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY9AG	34735522	Green Published, gold			2023-01-03	WOS:000755077100068
J	Wenger, HC; Cifu, AS; Lee, CT				Wenger, Hannah C.; Cifu, Adam S.; Lee, Cathryn T.			Home Oxygen Therapy for Adults With Chronic Obstructive Pulmonary Disease or Interstitial Lung Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COPD		[Wenger, Hannah C.] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA; [Cifu, Adam S.; Lee, Cathryn T.] Univ Chicago, Chicago, IL 60637 USA	Harvard University; Massachusetts General Hospital; University of Chicago	Wenger, HC (corresponding author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.	hwenger@mgh.harvard.edu						Albert RK, 2016, NEW ENGL J MED, V375, P1617, DOI 10.1056/NEJMoa1604344; [Anonymous], 1980, ANN INTERN MED, V93, P391; FLENLEY DC, 1981, LANCET, V1, P681; Garrod R, 2000, THORAX, V55, P539, DOI 10.1136/thorax.55.7.539; Graham HR, 2020, GLOB HEALTH-SCI PRAC, V8, P858, DOI 10.9745/GHSP-D-20-00224; Jacobs SS, 2020, AM J RESP CRIT CARE, V202, pE121, DOI 10.1164/rccm.202009-3608ST; Jacobs SS, 2018, ANN AM THORAC SOC, V15, P1369, DOI 10.1513/AnnalsATS.201809-627WS; Jones PW, 2014, AM J RESP CRIT CARE, V189, P250, DOI 10.1164/rccm.201310-1863PP; Visca D, 2018, LANCET RESP MED, V6, P759, DOI 10.1016/S2213-2600(18)30289-3	9	1	1	6	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2021	326	17					1738	1739		10.1001/jama.2021.12073	http://dx.doi.org/10.1001/jama.2021.12073			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW8DB	34726722				2023-01-03	WOS:000718138900023
J	Alam, SK; Zhang, YC; Wang, L; Zhu, Z; Hernandez, CE; Zhou, YL; Yang, N; Lei, J; Chen, XY; Zeng, L; Klein, MA; Hoeppner, LH				Alam, Sk. Kayum; Zhang, Yongchang; Wang, Li; Zhu, Zhu; Hernandez, Christina E.; Zhou, Yuling; Yang, Nong; Lei, Jian; Chen, Xiaoyan; Zeng, Liang; Klein, Mark A.; Hoeppner, Luke H.			DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; MEDIATES TRASTUZUMAB RESISTANCE; TYROSINE KINASE INHIBITORS; T-DARPP; ACQUIRED-RESISTANCE; CANCER CELLS; GEFITINIB; MUTATIONS; MEHD7945A; DOPAMINE	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-refractory lung adenocarcinoma (LUAD) progression is a major clinical problem. New approaches to predict and prevent acquired resistance to EGFR TKIs are urgently needed. Here, we show that dopamine and cyclic AMP-regulated phosphoprotein, Mr 32000 (DARPP-32) physically recruits ERBB3 (HER3) to EGFR to mediate switching from EGFR homodimers to EGFR:ERBB3 heterodimers to bypass EGFR TKI-mediated inhibition by potentiating ERBB3-dependent activation of oncogenic signaling. In paired LUAD patient-derived specimens before and after EGFR TKI-refractory disease progression, we reveal that DARPP-32 and kinase-activated EGFR and ERBB3 proteins are overexpressed upon acquired resistance. In mice, DARPP-32 ablation sensitizes gefitinib-resistant xenografts to EGFR TKIs, while DARPP-32 overexpression increases gefitinib-refractory LUAD progression in gefitinib-sensitive lung tumors. We introduce a DARPP-32-mediated, ERBB3-dependent mechanism the LUAD cells use to evade EGFR TKI-induced cell death, potentially paving the way for the development of therapies to better combat therapy-refractory LUAD progression.	[Alam, Sk. Kayum; Wang, Li; Zhu, Zhu; Hernandez, Christina E.; Hoeppner, Luke H.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Zhang, Yongchang; Zhou, Yuling; Yang, Nong; Zeng, Liang] Cent South Univ, Affiliated Canc Hosp, Hunan Canc Hosp,Dept Med Oncol, Lung Canc & Gastrointestinal Unit,Xiangya Sch Med, Changsha, Peoples R China; [Lei, Jian; Chen, Xiaoyan] Cent South Univ, Affiliated Canc Hosp, Hunan Canc Hosp, Dept Pathol,Xiangya Sch Med, Changsha, Peoples R China; [Klein, Mark A.] Minneapolis Vet Affairs Healthcare Syst, Hematol Oncol Sect, Minneapolis, MN USA; [Klein, Mark A.] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA; [Klein, Mark A.; Hoeppner, Luke H.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA	University of Minnesota System; Central South University; Central South University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Alam, SK; Hoeppner, LH (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Hoeppner, LH (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.	skalam@umn.edu; hoepp005@umn.edu	ALAM, SK KAYUM/ABA-3659-2020; Wang, Li/AAM-2454-2021	ALAM, SK KAYUM/0000-0001-5342-4542; Wang, Li/0000-0002-8969-7427; Hoeppner, Luke/0000-0003-3948-4244; Zhang, Yongchang/0000-0002-6829-7176	Elsa U. Pardee Foundation; American Cancer Society [129819-IRG-16-189-58-IRG81]; Hormel Foundation; Fifth District Eagles Cancer Telethon Postdoctoral Fellowship Award; Department of Veterans Affairs (Veterans Health Administration)	Elsa U. Pardee Foundation; American Cancer Society(American Cancer Society); Hormel Foundation; Fifth District Eagles Cancer Telethon Postdoctoral Fellowship Award; Department of Veterans Affairs (Veterans Health Administration)(US Department of Veterans Affairs)	This work was supported by The Elsa U. Pardee Foundation, Institutional Research Grant #129819-IRG-16-189-58-IRG81 from the American Cancer Society, and The Hormel Foundation (to L.H.H.) as well as the Fifth District Eagles Cancer Telethon Postdoctoral Fellowship Award (to S.K.A.). This material is based partially upon work supported by the Department of Veterans Affairs (specifically, the Veterans Health Administration). M.A.K. is an employee of the Minneapolis VA Healthcare System.	Alam SK, 2020, BRIT J CANCER, V123, P819, DOI 10.1038/s41416-020-0923-6; Alam SK, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0050-6; [Anonymous], 2021, Cancer Discov, V11, pOF6, DOI 10.1158/2159-8290.CD-NB2021-0340; Avanes A, 2019, BIOCHEM PHARMACOL, V160, P71, DOI 10.1016/j.bcp.2018.12.008; Balz LM, 2012, J PATHOL, V227, P234, DOI 10.1002/path.3991; Beckler A, 2003, CANCER, V98, P1547, DOI 10.1002/cncr.11654; Belkhiri A, 2005, CANCER RES, V65, P6583, DOI 10.1158/0008-5472.CAN-05-1433; Belkhiri A, 2008, CLIN CANCER RES, V14, P4564, DOI 10.1158/1078-0432.CCR-08-0121; Belkhiri A, 2008, CANCER RES, V68, P395, DOI 10.1158/0008-5472.CAN-07-1580; Belkhiri A, 2016, ONCOTARGET, V7, P17631, DOI 10.18632/oncotarget.7268; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Chen Z, 2016, GUT, V65, P925, DOI 10.1136/gutjnl-2014-308416; Christenson JL, 2015, ONCOTARGET, V6, P33134, DOI 10.18632/oncotarget.5311; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Cortot AB, 2014, EUR RESPIR REV, V23, P356, DOI 10.1183/09059180.00004614; El-Rifai W, 2002, CANCER RES, V62, P4061; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Fayette J, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00232; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; Hamel S, 2010, BREAST CANCER RES TR, V120, P47, DOI 10.1007/s10549-009-0364-7; Han SW, 2005, INT J CANCER, V113, P109, DOI 10.1002/ijc.20550; Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; Hoeppner LH, 2015, MOL ONCOL, V9, P270, DOI 10.1016/j.molonc.2014.08.008; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hong J, 2012, CANCER RES, V72, P4504, DOI 10.1158/0008-5472.CAN-12-1119; Huang S, 2013, CANCER RES, V73, P824, DOI 10.1158/0008-5472.CAN-12-1611; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Juchum M, 2015, DRUG RESIST UPDATE, V20, P12, DOI 10.1016/j.drup.2015.05.002; Jura N, 2009, P NATL ACAD SCI USA, V106, P21608, DOI 10.1073/pnas.0912101106; Juric D, 2015, CLIN CANCER RES, V21, P2462, DOI 10.1158/1078-0432.CCR-14-2412; Kumagai Shogo, 2021, Nat Rev Cancer, V21, P181, DOI 10.1038/s41568-020-00322-0; Lee CK, 2015, J CLIN ONCOL, V33, P1958, DOI 10.1200/JCO.2014.58.1736; Lemmon MA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020768; Lenz G, 2018, CLIN CANCER RES, V24, P1216, DOI 10.1158/1078-0432.CCR-17-0824; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Li CR, 2015, MOL CANCER THER, V14, P2049, DOI 10.1158/1535-7163.MCT-15-0155; Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6; Liu Q, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0793-1; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; McKnight BN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27454-6; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Momand J, 2017, FEBS OPEN BIO, V7, P1328, DOI 10.1002/2211-5463.12269; Mukherjee K, 2010, SURGERY, V148, P354, DOI 10.1016/j.surg.2010.05.011; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Offin M, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00126; Ono M, 2004, MOL CANCER THER, V3, P465; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Reck M, 2017, NEW ENGL J MED, V377, P849, DOI 10.1056/NEJMra1703413; Roberts TC, 2020, NAT REV DRUG DISCOV, V19, P673, DOI 10.1038/s41573-020-0075-7; Roper N, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100007; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Saba NF, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00031; Salvesen GS, 2002, CELL DEATH DIFFER, V9, P3, DOI 10.1038/sj.cdd.4400963; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shih Andrew J, 2011, Cancers (Basel), V3, P1195, DOI 10.3390/cancers3011195; Sidaway P, 2020, NAT REV CLIN ONCOL, V17, P336, DOI 10.1038/s41571-020-0366-2; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Skoulidis F, 2019, NAT REV CANCER, V19, P495, DOI 10.1038/s41568-019-0179-8; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Song XL, 2015, CANCER RES, V75, P1035, DOI 10.1158/0008-5472.CAN-13-1625; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; Tiwari A, 2020, GASTROENTEROLOGY, V159, P1882, DOI 10.1053/j.gastro.2020.07.046; Tomasello C, 2018, CRIT REV ONCOL HEMAT, V123, P149, DOI 10.1016/j.critrevonc.2018.01.013; Tumbrink HL, 2021, ONCOGENE, V40, P1, DOI 10.1038/s41388-020-01510-w; Vangamudi B, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-32; Vangamudi B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-240; WALAAS SI, 1983, J NEUROSCI, V3, P291; Wang DD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128360; Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2; Wang MSJ, 2005, INT J CLIN PRACT, V59, P58, DOI 10.1111/j.1742-1241.2004.00305.x; Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xia WL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3480; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980; Zhang X, 2021, CANCER RES, V81, P3051, DOI 10.1158/0008-5472.CAN-20-2435; Zhou Q, 2012, BRIT J PHARMACOL, V166, P1756, DOI 10.1111/j.1476-5381.2012.01875.x; Zhu SM, 2020, CANCER LETT, V491, P87, DOI 10.1016/j.canlet.2020.07.014; Zhu SM, 2019, ONCOGENE, V38, P5805, DOI 10.1038/s41388-019-0843-1; Zhu SM, 2017, GUT, V66, P802, DOI 10.1136/gutjnl-2016-312141; Zhu SM, 2011, GASTROENTEROLOGY, V141, P1738, DOI 10.1053/j.gastro.2011.06.070	94	3	3	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					83	98		10.1038/s41388-021-02028-5	http://dx.doi.org/10.1038/s41388-021-02028-5		OCT 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34675407	hybrid, Green Submitted, Green Published			2023-01-03	WOS:000709687900003
J	Xu, Y; Liu, SF; Wang, J				Xu, Yuan; Liu, Shifeng; Wang, Jun			Multiple attribute group decision-making based on interval-valued q-rung orthopair uncertain linguistic power Muirhead mean operators and linguistic scale functions	PLOS ONE			English	Article							AGGREGATION OPERATORS; BONFERRONI OPERATORS; FUZZY-SETS	Fuzzy set theory and its extended form have been widely used in multiple-attribute group decision-making (MAGDM) problems, among which the interval-valued q-rung orthopair fuzzy sets (IVq-ROFSs) got a lot of attention for its ability of capturing information denoted by interval values. Based on the previous studies, to find a better solution for fusing qualitative quantization information with fuzzy numbers, we propose a novel definition of interval-valued q-rung orthopair uncertain linguistic sets (IVq-ROULSs) based on the linguistic scale functions, as well as its corresponding properties, such as operational rules and the comparison method. Furthermore, we utilize the power Muirhead mean operators to construct the information fusion method, and provide a variety of aggregation operators based on the proposed information description environment. A model framework is constructed for solving the MAGDM problem utilizing the proposed method. Finally, we illustrate the performance of the new method and investigate its advantages and superiorities through comparative analysis.	[Xu, Yuan; Liu, Shifeng] Beijing Jiaotong Univ, Sch Econ & Management, Beijing, Peoples R China; [Wang, Jun] Beijing Univ Chem Technol, Sch Econ & Management, Beijing, Peoples R China	Beijing Jiaotong University; Beijing University of Chemical Technology	Wang, J (corresponding author), Beijing Univ Chem Technol, Sch Econ & Management, Beijing, Peoples R China.	wangjun@buct.edu.cn		Wang, Jun/0000-0001-7522-8593	Fundamental Research Funds for the Central Universities [2021YJS056]; Funds for Firstclass Discipline Construction [XK1802-5]	Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Funds for Firstclass Discipline Construction	Fundamental Research Funds for the Central Universities (2021YJS056). Funds for Firstclass Discipline Construction (XK1802-5). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali Z., 2021, REP MECH ENG, V2, P105, DOI [DOI 10.31181/RME2001020105T, 10.31181/rme2001020105t]; Ali Z, 2020, COMPUT APPL MATH, V39, DOI 10.1007/s40314-020-01145-3; ATANASSOV KT, 1986, FUZZY SET SYST, V20, P87, DOI 10.1016/S0165-0114(86)80034-3; Bai KY, 2020, INT J INTELL SYST, V35, P3, DOI 10.1002/int.22196; Bai KY, 2018, SYMMETRY-BASEL, V10, DOI 10.3390/sym10090383; Gao HX, 2019, IEEE ACCESS, V7, P74300, DOI 10.1109/ACCESS.2019.2918779; Gao H, 2018, INT J KNOWL-BASED IN, V22, P59, DOI 10.3233/KES-180375; Garg H, 2021, INT J INTELL SYST, V36, P3106, DOI 10.1002/int.22406; Garg H, 2021, EXPERT SYST, V38, DOI 10.1111/exsy.12609; Garg H, 2018, INT J INTELL SYST, V33, P1234, DOI 10.1002/int.21979; Jana C, 2019, INT J INTELL SYST, V34, P3220, DOI 10.1002/int.22191; Joshi BP, 2018, J INTELL FUZZY SYST, V35, P5225, DOI 10.3233/JIFS-169806; Ju YB, 2019, INT J INTELL SYST, V34, P2077, DOI 10.1002/int.22132; Li L, 2018, ARCH CONTROL SCI, V28, P551, DOI 10.24425/acs.2018.125483; Li L, 2018, J INTELL FUZZY SYST, V35, P2035, DOI 10.3233/JIFS-171907; Li L, 2018, SYMMETRY-BASEL, V10, DOI 10.3390/sym10050172; Liang DC, 2020, J EXP THEOR ARTIF IN, V32, P845, DOI 10.1080/0952813X.2019.1694589; Liang DC, 2019, INT J INTELL SYST, V34, P3275, DOI 10.1002/int.22194; Liu HC, 2019, INT J INTELL SYST, V34, P188, DOI 10.1002/int.22047; Liu PD, 2019, INT J FUZZY SYST, V21, P2340, DOI 10.1007/s40815-019-00705-y; Liu PD, 2019, IEEE T FUZZY SYST, V27, P834, DOI 10.1109/TFUZZ.2018.2826452; Liu PD, 2019, J INTELL FUZZY SYST, V37, P2515, DOI 10.3233/JIFS-182774; Liu PD, 2019, IEEE ACCESS, V7, P22613, DOI 10.1109/ACCESS.2019.2896107; Liu PD, 2019, INT J INTELL SYST, V34, P652, DOI 10.1002/int.22071; Liu PD, 2018, INT J INTELL SYST, V33, P259, DOI 10.1002/int.21927; Liu PD, 2018, INT J INTELL SYST, V33, P315, DOI 10.1002/int.21933; Liu PD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168767; Liu PD, 2013, APPL MATH MODEL, V37, P2430, DOI 10.1016/j.apm.2012.05.032; Liu S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212636; Liu ZM, 2019, J INTELL FUZZY SYST, V37, P7003, DOI 10.3233/JIFS-191110; Liu ZM, 2019, INT J INTELL SYST, V34, P2521, DOI 10.1002/int.22159; Liu ZM, 2018, INT J INTELL SYST, V33, P2341, DOI 10.1002/int.22032; Luo SZ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224090; Muirhead R.F., 1903, P EDINBURGH MATH SOC, V21, P144, DOI [10.1017/S001309150003460X, DOI 10.1017/S001309150003460X]; Pamuar D., 2020, OPER RES ENG SCI THE, V3, P54, DOI [10.31181/oresta2003049p, DOI 10.31181/ORESTA2003049P]; Pamucar D, 2020, FACTA UNIV-SER MECH, V18, P419, DOI 10.22190/FUME200602034P; Peng XD, 2018, INT J INTELL SYST, V33, P2255, DOI 10.1002/int.22028; Ramakrishnan KR, 2020, FACTA UNIV-SER MECH, V18, P375, DOI 10.22190/FUME200307036R; Riaz M., 2020, DECISION MAKING APPL, V3, P70, DOI DOI 10.31181/DMAME2003070R; Rong Y, 2020, INT J INTELL SYST, V35, P1749, DOI 10.1002/int.22271; Sinani F., 2020, DECIS MAKING, V3, P92, DOI DOI 10.31181/DMAME2003080F; Song YT, 2019, INT J INTELL SYST, V34, P2988, DOI 10.1002/int.22182; Wang HH, 2019, INT J INTELL SYST, V34, P1129, DOI 10.1002/int.22089; Wang JQ, 2014, INFORM SCIENCES, V288, P55, DOI 10.1016/j.ins.2014.07.034; Wang J, 2019, INT J INTELL SYST, V34, P2429, DOI 10.1002/int.22155; Wang J, 2020, NEURAL COMPUT APPL, V32, P14087, DOI 10.1007/s00521-020-04807-9; Wang J, 2019, J INTELL FUZZY SYST, V36, P5565, DOI 10.3233/JIFS-181425; Wang J, 2019, J INTELL FUZZY SYST, V36, P1599, DOI 10.3233/JIFS-18607; Wei GW, 2019, INT J INTELL SYST, V34, P50, DOI 10.1002/int.22042; Wei GW, 2018, INT J INTELL SYST, V33, P1426, DOI 10.1002/int.21985; Xing YP, 2020, NEURAL COMPUT APPL, V32, P7465, DOI 10.1007/s00521-019-04269-8; Xing YP, 2019, J INTELL FUZZY SYST, V37, P1123, DOI 10.3233/JIFS-182581; Xing YP, 2019, SOFT COMPUT, V23, P11627, DOI 10.1007/s00500-018-03712-7; Xing YP, 2018, INT J INTELL SYST, V33, P2189, DOI 10.1002/int.22025; Xiong SH, 2019, COMPUT IND ENG, V130, P258, DOI 10.1016/j.cie.2019.02.027; Xu WH, 2019, SYMMETRY-BASEL, V11, DOI 10.3390/sym11030441; Xu Y, 2019, IEEE ACCESS, V7, P54724, DOI 10.1109/ACCESS.2019.2912814; Xu Y, 2018, SYMMETRY-BASEL, V10, DOI 10.3390/sym10100472; Yager RR, 2017, IEEE T FUZZY SYST, V25, P1222, DOI 10.1109/TFUZZ.2016.2604005; Yager RR, 2014, IEEE T FUZZY SYST, V22, P958, DOI 10.1109/TFUZZ.2013.2278989; Yager RR, 2001, IEEE T SYST MAN CY A, V31, P724, DOI 10.1109/3468.983429; Yang W, 2019, INT J INTELL SYST, V34, P439, DOI 10.1002/int.22060; ZADEH LA, 1965, INFORM CONTROL, V8, P338, DOI 10.1016/S0019-9958(65)90241-X; Zeng SZ, 2021, ENG APPL ARTIF INTEL, V100, DOI 10.1016/j.engappai.2021.104167; Zhang BS, 2020, MATHEMATICS-BASEL, V8, DOI 10.3390/math8071125; Zhang C., 2020, IEEE T AUTOM SCI ENG, DOI [10.1109/TASE.2020.3014907, DOI 10.1109/TASE.2020.3014907]; Zhang HM, 2014, J APPL MATH, DOI 10.1155/2014/432092	67	1	1	3	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2021	16	10							e0258772	10.1371/journal.pone.0258772	http://dx.doi.org/10.1371/journal.pone.0258772			40	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7VP	34673796	Green Published, gold			2023-01-03	WOS:000755680200033
J	Wassie, GT; Belete, MB; Tesfu, AA; Bantie, SA; Ayenew, AA; Endeshaw, BA; Agdie, SM; Kiros, MD; Haile, ZT; Haider, MR; Ice, GH				Wassie, Gizachew Tadesse; Belete, Minyichil Birhanu; Tesfu, Azimeraw Arega; Bantie, Simachew Animen; Ayenew, Asteray Assmie; Endeshaw, Belaynew Adugna; Agdie, Semaw Minale; Kiros, Mengistu Desalegn; Haile, Zelalem T.; Haider, Mohammad Rifat; Ice, Gillian H.			Association between antenatal care utilization pattern and timely initiation of postnatal care checkup: Analysis of 2016 Ethiopian Demographic and Health Survey	PLOS ONE			English	Article								Background Despite significant public health intervention, maternal mortality remains high in low- and middle-income countries, including Ethiopia. Effective postnatal care is a critical service to reduce maternal mortality. In Ethiopia, only 17% of mothers received postnatal care services in 2016. Objective This study examined the association between antenatal care and timely postnatal care checkup among reproductive-age women in Ethiopia. Methods The study used the 2016 Ethiopian Demographic and Health Survey data. The current study included 4,081 women who give birth in the two years preceding the survey. Chi-square test and multivariable logistic regression analyses were used to examine the association between antenatal care and timely initiation of postnatal care. Results Postnatal care services within 2 days of delivery were received by 16.5% of women. Women who had at least four timely antenatal care visits had higher odds of timely postnatal checkups compared to women who had no antenatal care [adjusted Odds Ratio (aOR): 2.50; 95% CI 1.42-4.42]. Women who had at least four antennal care visits without timely initiation also had higher odds of postnatal check-up than their counterparts (aOR: 2.46; 95%CI: 1.22-4.97). Other factors significantly associated with timely initiation of PNC were secondary and above education (aOR: 1.64; 95%CI: 1.03-2.60), perceived distance to the nearby health facility as a significant barrier (aOR: 1.55; 95%CI: 1.15-2.09), primiparous (aOR: 0.34; 95%CI: 0.19-0.61) and institutional delivery (aOR: 14.55; 95%CI: 2.21-95.77). Conclusion The prevalence of timely initiation of postnatal care in Ethiopia is very low. Women who received recommended antenatal care services had higher odds of timely initiation of postnatal care. Thus, strengthening the existing maternal and child health programs to adhere to the recommended ANC care guidelines may improve the timely initiation of postnatal care.	[Wassie, Gizachew Tadesse] Bahir Dar Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Bahir Dar, Ethiopia; [Belete, Minyichil Birhanu] Bahir Dar Univ, Coll Med & Hlth Sci, Sch Hlth Sci, Dept Pediat & Child Hlth Nursing, Bahir Dar, Ethiopia; [Tesfu, Azimeraw Arega; Bantie, Simachew Animen; Ayenew, Asteray Assmie] Bahir Dar Univ, Coll Med & Hlth Sci, Sch Hlth Sci, Dept Midwifery, Bahir Dar, Ethiopia; [Endeshaw, Belaynew Adugna] Bahir Dar Univ, Coll Med & Hlth Sci, Sch Med, Dept Physiotherapy, Bahir Dar, Ethiopia; [Agdie, Semaw Minale] Bahir Dar Univ, Coll Med & Hlth Sci, Sch Med, Dept Gynecol & Obstet, Bahir Dar, Ethiopia; [Kiros, Mengistu Desalegn] Bahir Dar Univ, Coll Med & Hlth Sci, Sch Hlth Sci, Dept Anat, Bahir Dar, Ethiopia; [Haile, Zelalem T.] Ohio Univ, Heritage Coll Osteopath Med, Dept Social Med, Dublin, OH USA; [Haider, Mohammad Rifat] Ohio Univ, Coll Hlth Sci & Profess, Dept Social & Publ Hlth, Athens, OH 45701 USA; [Ice, Gillian H.] Ohio Univ, Heritage Coll Osteopath Med, Dept Social Med, Athens, OH 45701 USA; [Ice, Gillian H.] Ohio Univ, Coll Hlth Sci & Profess, Global Hlth Initiat, Athens, OH 45701 USA	Bahir Dar University; Bahir Dar University; Bahir Dar University; Bahir Dar University; Bahir Dar University; Bahir Dar University; University System of Ohio; Ohio University; University System of Ohio; Ohio University; University System of Ohio; Ohio University; University System of Ohio; Ohio University	Wassie, GT (corresponding author), Bahir Dar Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Bahir Dar, Ethiopia.	leulgzat@gmail.com	; Haider, Mohammad Rifat/N-9987-2016	Bante, Simachew Animen/0000-0002-7143-635X; Haile, Zelalem T./0000-0002-2912-8564; Tesfu, Azimeraw/0000-0002-9627-0931; Haider, Mohammad Rifat/0000-0002-0690-8242				Akunga D., 2014, AFR POPUL STUD, V28, P1447, DOI [10.11564/28-3-638, DOI 10.11564/28-3-638]; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Angore BN, 2018, J HEALTH POPUL NUTR, V37, DOI 10.1186/s41043-018-0140-6; Appiah F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249480; Baqui AH, 2018, LANCET GLOB HEALTH, V6, pE1297, DOI 10.1016/S2214-109X(18)30385-1; Belachew T., 2016, J WOMENS HLTH CARE, V5, DOI [10.4172/2167-0420.1000309, DOI 10.4172/2167-0420.1000309]; Berhe A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221161; Bustreo F, 2013, LANCET GLOB HEALTH, V1, pE176, DOI 10.1016/S2214-109X(13)70059-7; Bwalya BB, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1612-1; Dahiru T, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.321.6527; Ethiopia, 2016, DEM HLTH SURV 2016; Fadel SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140448; Federal Democratic Republic of Ethiopia, 2010, MAN PROT SEL OBST TO; Fekadu GA, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2216-8; Filippi V, 2016, REPROD MATERNAL NEWB, V2; Halim A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159388; Hordofa MA, 2015, SCI J PUB HLTH, V3, P686; IBM, 2013, IBM SPSS STAT WINDOW; Islam S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197693; Khanal V, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-19; Limenih Miteku Andualem, 2016, Int J Reprod Med, V2016, P7095352, DOI 10.1155/2016/7095352; Nazik E, 2013, NURS SCI QUART, V26, P360, DOI 10.1177/0894318413500402; Rwabufigiri BN, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0913-0; The Open University, ETH FED MIN HLTH POS; Titaley CR, 2009, J EPIDEMIOL COMMUN H, V63, P827, DOI 10.1136/jech.2008.081604; Titaley CR, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-61; Tuncalp O, 2017, BJOG-INT J OBSTET GY, V124, P860, DOI 10.1111/1471-0528.14599; UNICEF, UNICEF DATA; Wardlaw T., 2003, ANTENATAL CARE DEV C; Warren C, 2006, POSTNATAL CARE OPPOR, P79; WHO, POSTN CAR MOTH NEWB; World Health Organization, 2015, STRATEGIES ENDING PR; World Health Organization, 2015, TRENDS MAT MORT 1990; World Health Organization, 1998, BAS NEWB RES PRACT G; World Health Organization, 2010, WHOMPS1003; World Health Organization Department of Maternal N Child and Adolescent Health, 2013, WHO REC POSTN CAR MO; Wudineh KG, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2138-x	37	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2021	16	10							e0258468	10.1371/journal.pone.0258468	http://dx.doi.org/10.1371/journal.pone.0258468			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7ZF	34637481	gold, Green Published, Green Submitted			2023-01-03	WOS:000755690100033
J	Thein, KZK; Herberholz, C; Sandar, WP; Yadanar				Thein, Khin Zar Khaing; Herberholz, Chantal; Sandar, Win Pa; Yadanar			Caring for persons with drug use disorders in the Yangon Region, Myanmar: Socioeconomic and psychological burden, coping strategies and barriers to coping	PLOS ONE			English	Article							SUBSTANCE USE DISORDERS; CAREGIVER BURDEN; MENTAL-HEALTH; FAMILY CAREGIVERS; BIPOLAR DISORDER; STRESS; PEOPLE; SCHIZOPHRENIA; PERCEPTIONS; EXPERIENCES	Drug use disorder (DUD) is a serious health condition that imposes a heavy burden on the persons who have a drug addiction experience and their families, especially in countries, such as Myanmar, where few formal support mechanisms are in place and repressive drug laws exacerbate the situation. Yet, in Myanmar, little is known about how informal caregivers are affected. This qualitative study aims at exploring the socioeconomic and psychological burden that informal caregivers in Myanmar encounter, coping strategies they employ, as well as barriers to coping they face. Thirty primary informal caregivers were chosen purposively from a mental health hospital in Yangon for in-depth interviews. The recorded interviews were transcribed and the data were analysed using framework analysis. The results revealed that financial constraint, income loss, social limitation and negative impact on family cohesion are important dimensions of socioeconomic burden, whereas sadness, anger, helplessness, worry, fear and guilt are the main psychological distress factors encountered by caregivers of persons with DUD. Key coping strategies employed by caregivers include religious coping, financial coping, acceptance and planning. Moreover, perceived stigma towards persons with DUD and their caregivers was very high and caregivers received hardly any social support, inter alia because of the country's drug law which reinforces stigma and discrimination. Neither the government nor any other organization in Myanmar provided financial support to the caregivers. The results of this study showed that caring for persons with DUD has devastating effects on caregivers and their families. While the 2018 National Drug Control Policy can potentially help alleviate the burden on substance users and their families, further amendments of the existing drug law are urgently needed. Moreover, strengthening prevention and harm reduction approaches, improving treatment and rehabilitation services, as well as stigma-reducing educational campaigns should be considered a priority.	[Thein, Khin Zar Khaing] Natl Hlth Lab, Yangon, Myanmar; [Herberholz, Chantal] Chulalongkorn Univ, Fac Econ, Ctr Excellence Hlth Econ, Bangkok, Thailand; [Sandar, Win Pa] Univ Publ Hlth, Dept Hlth Behav & Commun, Yangon, Myanmar; [Yadanar] Univ Publ Hlth, Dept Hlth Policy & Management, Yangon, Myanmar	Chulalongkorn University	Herberholz, C (corresponding author), Chulalongkorn Univ, Fac Econ, Ctr Excellence Hlth Econ, Bangkok, Thailand.	chantal.h@chula.ac.th			Chulalongkorn University's "Scholarship Programme for ASEAN Countries"	Chulalongkorn University's "Scholarship Programme for ASEAN Countries"	The authors would like to express their sincere gratitude to the caregivers for participating in this research, as well as the YMHH staff for their support. The first author is grateful to Chulalongkorn University's "Scholarship Programme for ASEAN Countries" for supporting her graduate studies. This research article is based on her thesis.	Addo R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199830; Ae-Ngibise KA, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.26957; Aranda MP, 1997, GERONTOLOGIST, V37, P342, DOI 10.1093/geront/37.3.342; Assembly of the Union of Myanmar, ANN N MYANM COUNTR R; Biegel DE, 2007, J SOC WORK PRACT ADD, V7, P25, DOI 10.1300/J160v07n01_03; Cachia R., 2018, WILL MYANMAR COMPLET; Carretero S, 2009, ARCH GERONTOL GERIAT, V49, P74, DOI 10.1016/j.archger.2008.05.004; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; CCDAC, 2018, NAT DRUG CONTR POL; Choudhary M, 2016, INT J NURS ED RES, V4, P169, DOI [10.5958/2454-2660.2016.00034.x, DOI 10.5958/2454-2660.2016.00034.X]; CLARK RE, 1994, COMMUNITY MENT HLT J, V30, P145, DOI 10.1007/BF02188626; David R., 2018, LIBERALISM DEMOCRACY; Degenhardt L, 2018, LANCET PSYCHIAT, V5, P987, DOI 10.1016/S2215-0366(18)30337-7; Ferrell BR, 2009, GERIATRIC ONCOLOGY: TREATMENT, ASSESSMENT AND MANAGEMENT, P135, DOI 10.1007/978-0-387-89070-8_7; Florence C, 2021, DRUG ALCOHOL DEPEN, V218, DOI 10.1016/j.drugalcdep.2020.108350; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; Goossens PJJ, 2008, INT J SOC PSYCHIATR, V54, P303, DOI 10.1177/0020764008090284; Hanafiah AN, 2015, INT J MENT HEALTH SY, V9, DOI 10.1186/s13033-015-0002-1; Heflinger CA, 2006, J CHILD ADOLES SUBST, V15, P83, DOI 10.1300/J029v15n03_06; HHS Office of the Surgeon General, 2016, FAC ADD AM SURG GEN; Huang MF, 2015, AM J ALZHEIMERS DIS, V30, P694, DOI 10.1177/1533317513494446; Huang XY, 2009, J PSYCHIATR MENT HLT, V16, P874, DOI 10.1111/j.1365-2850.2009.01468.x; Iseselo MK, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0857-y; Jelsma M., 2015, HLTH LEGAL ENV REV M; Jensema E., 2016, FOUND DARK IMPACT DR; Kanato M., 2018, ASEAN DRUG MONITORIN; Kershaw T, 2004, PSYCHOL HEALTH, V19, P139, DOI 10.1080/08870440310001652687; Knight B. G., 2011, HDB PSYCHOL AGING, P353, DOI [10.1016/B978-0-12-380882-0.00023-1, DOI 10.1016/B978-0-12-380882-0.00023-1]; Knight BG, 2010, J GERONTOL B-PSYCHOL, V65, P5, DOI 10.1093/geronb/gbp096; Lander L, 2013, SOC WORK PUBLIC HLTH, V28, P194, DOI 10.1080/19371918.2013.759005; Li L, 2013, INT J DRUG POLICY, V24, P545, DOI 10.1016/j.drugpo.2013.06.007; Losada-Baltar A., 2017, ENCY GEROPSYCHOLOGY, P2268; Mattoo SK, 2013, INDIAN J MED RES, V137, P704; MEHTA SI, 1988, J SOC CLIN PSYCHOL, V7, P192, DOI 10.1521/jscp.1988.7.2-3.192; Moller-Leimkuhler AM, 2012, EUR ARCH PSY CLIN N, V262, P157, DOI 10.1007/s00406-011-0215-5; MONTGOMERY RJV, 1989, GERONTOLOGIST, V29, P457, DOI 10.1093/geront/29.4.457; MONTGOMERY RJV, 1985, FAM RELAT, V34, P19, DOI 10.2307/583753; Myint WA., 2016, ASEAN MENTAL HLTH SY, P81; Ong HC, 2016, PSYCHOL RES BEHAV MA, V9, P211, DOI 10.2147/PRBM.S112129; Orford J, 2007, DRUG-EDUC PREV POLIC, V14, P29, DOI 10.1080/09687630600997451; Paing TH., 2017, TREATING BURMAS DRUG; Papastavrou E, 2010, SCAND J CARING SCI, V24, P817, DOI 10.1111/j.1471-6712.2010.00782.x; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; Perlick DA, 2007, BIPOLAR DISORD, V9, P262, DOI 10.1111/j.1399-5618.2007.00365.x; Shah A. J., 2010, British Journal of Medical Practitioners, V3, pa327; Shamsaei F, 2015, IRAN J PSYCHIATRY BE, V9, DOI [10.17795/Thpbs-1898, 10.17795/ijpbs-1898]; Sibeko G, 2016, INT J SOC PSYCHIATR, V62, P512, DOI 10.1177/0020764016651458; Thein KZK., 2019, CARING PATIENTS DRUG; UNODC, 2019, SYNTH DRUGS E S E AS; UNODC, 2019, WORLD DRUG REPORT 20; Usher K, 2007, INT J MENT HEALTH NU, V16, P422, DOI 10.1111/j.1447-0349.2007.00497.x; von Kardorff E, 2016, NORD J PSYCHIAT, V70, P248, DOI 10.3109/08039488.2015.1084372; Wan NMA, 2019, DRUG TREATMENT MYANM; WHO, 2019, INT CLASSIFICATION D; WHO, 2015, WHOS ROL MAND ACT CO; WHO, 2017, MENTAL HLTH ATLAS 20; WHO Regional Office for South-East Asia, 2007, WHO AIMS REPORT MENT; WHO Regional Office for the Western Pacific Asia Pacific Observatory on Health Systems and Policies, 2014, REP UN MYANM HLTH SY; World Health Organization, 2003, INV MENT HLTH; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	61	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2021	16	10							e0258183	10.1371/journal.pone.0258183	http://dx.doi.org/10.1371/journal.pone.0258183			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YV0SF	34618846	Green Published, gold			2023-01-03	WOS:000752443000045
J	Tounsi, B; Acheche, A; Lelard, T; Tabka, Z; Trabelsi, Y; Ahmaidi, S				Tounsi, Bilel; Acheche, Amal; Lelard, Thierry; Tabka, Zouhair; Trabelsi, Yassine; Ahmaidi, Said			Effects of specific inspiratory muscle training combined with whole-body endurance training program on balance in COPD patients: Randomized controlled trial	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; POSTURAL CONTROL; HUMAN DIAPHRAGM; INDIVIDUALS; REHABILITATION; PEOPLE; ACTIVATION; PRESSURE	Purpose This study aims to assess the effect of inspiratory muscle training (IMT) combined with endurance training (ET) on balance in patients with chronic obstructive pulmonary disease (COPD). Methods We studied 32 male patients (62 6 years) with moderate to very severe COPD. They were randomly assigned to an experimental group (IMT+ET) n = 16 or a control group (ET) n = 16 with similar characteristics. The evaluations were carried out at inclusion and after eight weeks of the training period. Functional balance was assessed by the Berg Balance Scale (BBS), the Timed-up and Go (TUG), the Single Leg Stance test (SLS), and the Activities-specific Balance Confidence (ABC) scale. The strength of the inspiratory muscles (PImax) was assessed by maximal inspiratory mouth pressure. Functional exercise performance was assessed by the 6 minutes walking test (6MWT). IMT program consists in performing two daily sets of 30 inspirations with 50% of PImax increased by 10% every two weeks. ET program consists in performing 30 min treadmill exercise at 60% to 80% of the average speed achieved during the 6MWT three days per week. Results After the training period, the experimental group demonstrated greater improvements in BBS (IMT+ET vs. ET; p = 0.019), and in ABC (IMT+ET vs. ET; p = 0.014). However, no significant differences between groups were observed for TUG, SLS, and 6MWT. There was a significant difference between groups in PImax (IMT+ET vs. ET; p = 0.030). Significant moderate correlations were obtained between Delta PImax and Delta BBS for both groups (IMT+ET: r = 0.624, p = 0.010; ET r = 0.550, p = 0.027) as well as for Delta ABC but only in the experimental group (IMT+ET: r = 0.550, p = 0.027). Conclusion Compared to ET alone, the results suggest that IMT combined with ET enhances inspiratory muscle function and functional balance according to BBS and ABC in patients with COPD. We suggest that inspiratory muscle training might be introduced as additional training to pulmonary rehabilitation programs aimed at improving balance in COPD patients. Trial registration The trial registry name: Clinical Trials; Registration number: NCT04084405; URL: https://clinicaltrials.gov/ct2/show/NCT04084405.	[Tounsi, Bilel; Lelard, Thierry; Ahmaidi, Said] Picardie Jules Verne Univ, Sport Sci Dept, UR EA 3300, Lab Exercise Physiol & Rehabil APERE, Amiens, France; [Tounsi, Bilel; Acheche, Amal; Tabka, Zouhair; Trabelsi, Yassine] Univ Sousse, Fac Med Sousse, Res Lab Exercise Physiol Pathophysiol Integral Mo, Sousse, Tunisia; [Tounsi, Bilel; Lelard, Thierry; Ahmaidi, Said] Picardie Jules Verne Univ, Dept Sports Sci, Amiens, France; [Acheche, Amal; Tabka, Zouhair; Trabelsi, Yassine] Univ Sousse, Fac Med Sousse, Res Lab Exercise Physiol & Pathophysiol, Sousse, Tunisia	Picardie Universites; Universite de Picardie Jules Verne (UPJV); Universite de Sousse; Picardie Universites; Universite de Picardie Jules Verne (UPJV); Universite de Sousse	Tounsi, B (corresponding author), Picardie Jules Verne Univ, Sport Sci Dept, UR EA 3300, Lab Exercise Physiol & Rehabil APERE, Amiens, France.; Tounsi, B (corresponding author), Univ Sousse, Fac Med Sousse, Res Lab Exercise Physiol Pathophysiol Integral Mo, Sousse, Tunisia.; Tounsi, B (corresponding author), Picardie Jules Verne Univ, Dept Sports Sci, Amiens, France.	bilel.tounsi@u-picardie.fr		Acheche, Amal/0000-0003-1677-5508; TOUNSI, Bilel/0000-0001-9268-526X				Ambrosino N, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02285-2017; Beauchamp MK, 2009, RESP MED, V103, P1885, DOI 10.1016/j.rmed.2009.06.008; Beauchamp MK, 2010, MULTIDISCIP RESP MED, V5, P417, DOI 10.1186/2049-6958-5-6-417; Beauchamp MK, 2013, CHEST, V144, P1803, DOI 10.1378/chest.13-1093; Beauchamp MK, 2010, ARCH PHYS MED REHAB, V91, P1460, DOI 10.1016/j.apmr.2010.06.021; Beaumont M, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01107-2017; Bernard S, 1998, AM J RESP CRIT CARE, V158, P629, DOI 10.1164/ajrccm.158.2.9711023; Bohannon RW, 2006, TOP GERIATR REHABIL, V22, P70; CASABURI R, 1991, AM REV RESPIR DIS, V143, P9, DOI 10.1164/ajrccm/143.1.9; Charususin N, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003101; Crisan AF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120573; Daldoul H, 2013, INT J ENV RES PUB HE, V10, P7257, DOI 10.3390/ijerph10127257; de Castro LA, 2016, RESP CARE, V61, P1488, DOI 10.4187/respcare.04749; Delbressine JM, 2020, J CARDIOPULM REHABIL, V40, P152, DOI 10.1097/HCR.0000000000000513; Diagnosis C., 2019, GOLD REP; Evans RA, 2015, CHEST, V147, P673, DOI 10.1378/chest.14-1079; Ferraro FV, 2019, PHYSIOL REP, V7, DOI 10.14814/phy2.14076; Gosselink R, 2011, EUR RESPIR J, V37, P416, DOI 10.1183/09031936.00031810; GRILLNER S, 1978, ACTA PHYSIOL SCAND, V103, P275, DOI 10.1111/j.1748-1716.1978.tb06215.x; Hamaoui A, 2010, NEUROSCI LETT, V475, P141, DOI 10.1016/j.neulet.2010.03.064; Hodges PW, 2000, J PHYSIOL-LONDON, V522, P165, DOI 10.1111/j.1469-7793.2000.t01-1-00165.xm; Hodges PW, 1997, J PHYSIOL-LONDON, V505, P539, DOI 10.1111/j.1469-7793.1997.539bb.x; Hodges PW, 2000, J APPL PHYSIOL, V89, P967, DOI 10.1152/jappl.2000.89.3.967; Hodges PW, 2001, J PHYSIOL-LONDON, V537, P999; Holland AE, 2014, EUR RESPIR J, V44, P1428, DOI 10.1183/09031936.00150314; Hudson AL, 2010, J NEUROPHYSIOL, V103, P1622, DOI 10.1152/jn.00887.2009; Janssens L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057949; Langer D, 2015, PHYS THER, V95, P1264, DOI 10.2522/ptj.20140245; Laveneziana P, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01214-2018; Liwsrisakun C, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55050171; Marques A, 2015, J CARDIOPULM REHABIL, V35, P154, DOI 10.1097/HCR.0000000000000097; McLay R, 2020, CHRON RESP DIS, V17, DOI 10.1177/1479973120922538; McMeeken J, 1999, Physiother Res Int, V4, P55; Mesquita R, 2016, CHRON RESP DIS, V13, P344, DOI 10.1177/1479972316647178; Mkacher W, 2015, J CARDIOPULM REHABIL, V35, P207, DOI 10.1097/HCR.0000000000000109; Myers AM, 1998, J GERONTOL A-BIOL, V53, pM287, DOI 10.1093/gerona/53A.4.M287; Oliveira CC, 2013, ARCH PHYS MED REHAB, V94, P1784, DOI 10.1016/j.apmr.2013.04.012; Polkey MI, 1996, AM J RESP CRIT CARE, V154, P1310, DOI 10.1164/ajrccm.154.5.8912741; Porto EF, 2015, INT J CHRONIC OBSTR, V10, P1233, DOI 10.2147/COPD.S63955; Porto EF, 2017, J CARDIOPULM REHABIL, V37, P139, DOI 10.1097/HCR.0000000000000246; Ramirez-Sarmiento A, 2002, AM J RESP CRIT CARE, V166, P1491, DOI 10.1164/rccm.200202-075OC; Ramsook AH, 2016, MED SCI SPORT EXER, V48, P1179, DOI 10.1249/MSS.0000000000000881; RIMMER KP, 1995, J APPL PHYSIOL, V79, P1556, DOI 10.1152/jappl.1995.79.5.1556; Roig M, 2009, RESP MED, V103, P1257, DOI 10.1016/j.rmed.2009.03.022; Smith MD, 2016, GAIT POSTURE, V43, P101, DOI 10.1016/j.gaitpost.2015.09.004; Smith MD, 2010, GAIT POSTURE, V31, P456, DOI 10.1016/j.gaitpost.2010.01.022; Tinetti ME, 2010, JAMA-J AM MED ASSOC, V303, P258, DOI 10.1001/jama.2009.2024; Tinetti ME., 1994, J GERONTOL INTERNET, V49, P8; Vanfleteren LEGW, 2013, AM J RESP CRIT CARE, V187, P728, DOI 10.1164/rccm.201209-1665OC; Wouters EFM, 2002, THORAX, V57, P1067, DOI 10.1136/thorax.57.12.1067; Yamada Y, 2017, EUR J RADIOL, V87, P76, DOI 10.1016/j.ejrad.2016.12.014; Yazici O, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13901	52	2	2	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2021	16	9							e0257595	10.1371/journal.pone.0257595	http://dx.doi.org/10.1371/journal.pone.0257595			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XH8RH	34555068	Green Published, gold			2023-01-03	WOS:000725694500046
J	Radwany, S				Radwany, Steven			Our Best Judgment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Radwany, Steven] Ohio State Univ, Wexner Med Ctr, Div Palliat Med, 1581 Dodd Dr,McCampbell Hall,Fifth Floor, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Radwany, S (corresponding author), Ohio State Univ, Wexner Med Ctr, Div Palliat Med, 1581 Dodd Dr,McCampbell Hall,Fifth Floor, Columbus, OH 43210 USA.	steven.radwany@osumc.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2021	326	14					1373	1374		10.1001/jama.2021.16348	http://dx.doi.org/10.1001/jama.2021.16348		SEP 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH8VN	34529008	Bronze			2023-01-03	WOS:000696615500001
J	Kim, JG; Shin, H; Cho, JH; Choi, HY; Kim, W; Kim, J; Moon, S; Ahn, C; Lee, J; Cho, Y; Shin, DG; Lee, Y				Kim, Jae Guk; Shin, Hyungoo; Cho, Jun Hwi; Choi, Hyun Young; Kim, Wonhee; Kim, Jihoon; Moon, Shinje; Ahn, Chiwon; Lee, Juncheol; Cho, Youngsuk; Shin, Dong Geum; Lee, Yoonje			Prognostic value of changes in the cardiac arrest rhythms from the prehospital stage to the emergency department in out-of-hospital cardiac arrest patients without prehospital returns of spontaneous circulation: A nationwide observational study	PLOS ONE			English	Article							AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY-RESUSCITATION; STATE TRANSITIONS; BYSTANDER CPR; SURVIVAL; OUTCOMES; ADRENALINE; MANAGEMENT; UPDATE; FLOW	Background This study aimed to assess the prognostic value of the changes in cardiac arrest rhythms from the prehospital stage to the ED (emergency department) in out-of-hospital cardiac arrest (OHCA) patients without prehospital returns of spontaneous circulation (ROSC). Methods This retrospective analysis was performed using nationwide population-based OHCA data from South Korea between 2012 and 2016. Patients with OHCA with medical causes and without prehospital ROSC were included and divided into four groups according to the nature of their cardiac arrest rhythms (shockable or non-shockable) in the prehospital stage and in the ED: (1) the shockable and shockable (Shock-Shock) group, (2) the shockable and non-shockable (Shock-NShock) group, (3) the non-shockable and shockable (NShock-Shock) group, and (4) the non-shockable and non-shockable (NShock-NShock) group. The presence of a shockable rhythm was confirmed based on the delivery of an electrical shock. Propensity score matching and multivariate logistic regression analyses were used to assess the effect of changes in the cardiac rhythms on patient outcomes. The primary outcome was sustained ROSC in the ED; the secondary outcomes were survival to hospital discharge and good neurological outcomes at hospital discharge. Results After applying the exclusion criteria, 51,060 eligible patients were included in the study (Shock-Shock, 4223; Shock-NShock, 3060; NShock-Shock, 11,509; NShock-NShock, 32,268). The propensity score-matched data were extracted from the six comparative subgroups. For sustained ROSC in the ED, Shock-Shock showed a higher likelihood than Shock-NShock (P <0.01) and NShock-NShock (P <0.01), Shock-NShock showed a lower likelihood than NShock-Shock (P <0.01) and NShock-NShock (P <0.01), NShock-Shock showed a higher likelihood NShock-NShock (P <0.01). For survival to hospital discharge, Shock-Shock showed a higher likelihood than Shock-NShock (P <0.01), NShock-Shock (P <0.01), and NShock-NShock (P <0.01), Shock-NShock showed a higher likelihood than NShock-Shock (P <0.01) and NShock-NShock (P <0.01), of sustained ROSC in the ED. For good neurological outcomes, Shock-Shock showed higher likelihood than Shock-NShock (P <0.01), NShock-Shock (P <0.01), and NShock-NShock (P <0.01), Shock-NShock showed better likelihood than NShock-NShock (P <0.01), NShock-Shock showed a better likelihood than NShock-NShock (P <0.01). Conclusion Sustained ROSC in the ED may be expected for patients with shockable rhythms in the ED compared with those with non-shockable rhythms in the ED. For the clinical outcomes, survival to hospital discharge and neurological outcomes, patients with Shock-Shock showed the best outcome, whereas patients with NShock-NShock showed the poorest outcome and Shock-NShock showed a higher likelihood of achieving survival to hospital discharge with no significant differences in the neurological outcomes compared with NShock-Shock.	[Kim, Jae Guk; Choi, Hyun Young; Kim, Wonhee; Lee, Yoonje] Hallym Univ, Dept Emergency Med, Coll Med, Chunchon, South Korea; [Kim, Jae Guk] Kangwon Natl Univ, Grad Sch Med, Dept Emergency Med, Chunchon, South Korea; [Shin, Hyungoo] Hanyang Univ, Guri Hosp, Dept Emergency Med, Coll Med, Guri, South Korea; [Cho, Jun Hwi] Kangwon Natl Univ, Dept Emergency Med, Sch Med, Chunchon, South Korea; [Kim, Jihoon] Hallym Univ, Dept Thorac & Cardiovasc Surg, Coll Med, Chunchon, South Korea; [Moon, Shinje] Hallym Univ, Dept Internal Med, Coll Med, Seoul, South Korea; [Ahn, Chiwon] Chung Ang Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Lee, Juncheol] Hanyang Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Cho, Youngsuk] Hallym Univ, Kangdong Sacred Heart Hosp, Dept Emergency Med, Coll Med, Seoul, South Korea; [Shin, Dong Geum] Hallym Univ, Kangnam Sacred Heart Hosp, Dept Cardiol, Med Ctr, Seoul, South Korea	Hallym University; Kangwon National University; Hanyang University; Kangwon National University; Hallym University; Hallym University; Chung Ang University; Chung Ang University Hospital; Hanyang University; Hallym University; Hallym University	Cho, JH (corresponding author), Kangwon Natl Univ, Dept Emergency Med, Sch Med, Chunchon, South Korea.	cjhemd@kangwon.ac.kr	Ahn, Chiwon/ABG-4142-2021; Shin, Hyungoo/R-7752-2016	KIM, JAE GUK/0000-0002-2446-4497; Shin, Hyungoo/0000-0003-3203-1672				CHANDRA N, 1981, AM J CARDIOL, V48, P1053, DOI 10.1016/0002-9149(81)90320-9; Cournoyer A, 2019, RESUSCITATION, V140, P43, DOI 10.1016/j.resuscitation.2019.04.044; Daya MR, 2015, RESUSCITATION, V91, P108, DOI 10.1016/j.resuscitation.2015.02.003; de Visser M, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029254; DITCHEY RV, 1982, CIRCULATION, V66, P297, DOI 10.1161/01.CIR.66.2.297; Han KS, 2019, RESUSCITATION, V142, P144, DOI 10.1016/j.resuscitation.2019.07.025; Han KS, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050644; HOEKSTRA J, 1990, RESUSCITATION, V20, P97, DOI 10.1016/0300-9572(90)90046-H; HOEKSTRA JW, 1990, ANN EMERG MED, V19, P881, DOI 10.1016/S0196-0644(05)81561-6; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; Jacobs IG, 2011, RESUSCITATION, V82, P1138, DOI 10.1016/j.resuscitation.2011.06.029; Lee DE, 2019, J KOREAN MED SCI, V34, DOI 10.3346/jkms.2019.34.e134; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; Na MK, 2018, RESUSCITATION, V132, P21, DOI 10.1016/j.resuscitation.2018.08.024; Nordseth T, 2019, RESUSCITATION, V135, P45, DOI 10.1016/j.resuscitation.2019.01.006; Nordseth T, 2013, RESUSCITATION, V84, P1238, DOI 10.1016/j.resuscitation.2013.04.010; Nordseth T, 2012, RESUSCITATION, V83, P946, DOI 10.1016/j.resuscitation.2012.02.031; Ochiai K., 2017, RESUSCITATION, V118, pE86; Olasveengen TM, 2009, JAMA-J AM MED ASSOC, V302, P2222, DOI 10.1001/jama.2009.1729; Sasson C, 2009, CIRC-CARDIOVASC QUAL, V2, P361, DOI 10.1161/CIRCOUTCOMES.108.830398; Sekhon MS, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1670-9; Skogvoll E, 2008, RESUSCITATION, V78, P30, DOI 10.1016/j.resuscitation.2008.02.015; Stub D, 2011, CIRCULATION, V123, P1428, DOI 10.1161/CIRCULATIONAHA.110.988725; Wampler DA, 2012, PREHOSP EMERG CARE, V16, P451, DOI 10.3109/10903127.2012.695435; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483; Xiong Y, 2017, RESUSCITATION, V112, P28, DOI 10.1016/j.resuscitation.2016.12.013; Zhang WW, 2020, CARDIOL RES PRACT, V2020, DOI 10.1155/2020/3786408	27	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257883	10.1371/journal.pone.0257883	http://dx.doi.org/10.1371/journal.pone.0257883			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UZ3YH	34582471	gold, Green Published			2023-01-03	WOS:000702143700011
J	Kwan, A; Morris, J; Barbic, SP				Kwan, Amanda; Morris, Jonny; Barbic, Skye P.			Protocol: A mixed methods evaluation of an IPS program to increase employment and well-being for people with long-term experience of complex barriers in Vancouver's downtown and DTES	PLOS ONE			English	Article							TRANSITION-AGE YOUTH; SUPPORTED EMPLOYMENT; INDIVIDUAL PLACEMENT; VETERANS; SERVICES; OUTCOMES; QUALITY; TRIAL; WORK; CARE	Background Employment improves mental health and well-being by providing financial security, daily structure, a sense of identity and purpose, and social engagement. However, securing and sustaining employment is exceptionally challenging for vulnerable populations who experience persistent and multiple barriers, such as mental illness, homelessness, food and housing insecurity, and marginalization. Evidence-based supported employment programs, most notably individual placement and support (IPS) are becoming a more common approach for addressing the needs of these high-risk individuals. The aim of this paper is to outline the protocol for evaluating an IPS program in Vancouver's downtown and Downtown Eastside (DTES). Methods and design This prospective quasi-experimental study of persons with persistent and multiple barriers to employment will use a mixed-methods approach for evaluating a novel IPS program. The evaluation will consist of survey packages and interviews that will capture outcomes related to employment and well-being, as well as the experiential process of receiving individualized and integrated supports through the IPS program. A mixed-methods approach is appropriate for this study as quantitative data will provide an objective assessment of program impacts on employment and well-being outcomes over time, while qualitative data will provide an in-depth understanding of continued barriers and experiences. Discussion The results from this evaluation will contribute evidence within a local British Columbian (BC) context that may increase access to meaningful employment for those with long-term experience of complex barriers to employment. Further, the findings will support continued improvements, and guide decision-making around practices and policy for future implementation of IPS and employment supports across BC.	[Kwan, Amanda; Barbic, Skye P.] Univ British Columbia, Fac Med, Dept Occupat Sci & Occupat Therapy, Vancouver, BC, Canada; [Morris, Jonny] Canadian Mental Hlth Assoc BC Div, Vancouver, BC, Canada; [Barbic, Skye P.] Providence Hlth Care Res Inst, Vancouver, BC, Canada	University of British Columbia	Kwan, A (corresponding author), Univ British Columbia, Fac Med, Dept Occupat Sci & Occupat Therapy, Vancouver, BC, Canada.	amanda.kwan@ubc.ca		Kwan, Amanda/0000-0001-7367-9438				[Anonymous], 2021, LAB FORC SURV, P46; [Anonymous], 2021, SARS COV 2 VARIANTS, P43; Barbic SP, 2019, INT J MENT HEALTH SY, V13, DOI 10.1186/s13033-019-0264-0; BC Government M of SD and P, 2021, PERS PERS MULT BARR; Becker D., 2015, DARTM PSYCHIATR RES, P236; BECKER DR, 1994, COMMUNITY MENT HLT J, V30, P193, DOI 10.1007/BF02188630; Bond GR, 2020, WORLD PSYCHIATRY, V19, P390, DOI 10.1002/wps.20784; Bond GR, 2001, PSYCHIATR SERV, V52, P313, DOI 10.1176/appi.ps.52.3.313; Braun V., 2013, SUCCESSFUL QUALITATI; Burke-Miller J, 2012, PSYCHIATR REHABIL J, V35, P171, DOI 10.2975/35.3.2012.171.179; Corbiere M, 2014, PSYCHIATR REHABIL J, V37, P90, DOI 10.1037/prj0000033; Davis LL, 2012, PSYCHIAT SERV, V63, P464, DOI 10.1176/appi.ps.201100340; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Drake RE, 2016, HEALTH AFFAIR, V35, P1098, DOI 10.1377/hlthaff.2016.0001; Erickson DH, 2021, EARLY INTERV PSYCHIA, V15, P662, DOI 10.1111/eip.13005; Evans J, 2000, J Psychiatr Ment Health Nurs, V7, P15, DOI 10.1046/j.1365-2850.2000.00260.x; HATFIELD B, 1992, BRIT J SOC WORK, V22, P61; Heale Roberta, 2013, Evid Based Nurs, V16, P98, DOI 10.1136/eb-2013-101494; International QSR., 2020, NVIVO PRO; JICK TD, 1979, ADMIN SCI QUART, V24, P602, DOI 10.2307/2392366; Keetharuth AD, 2018, BRIT J PSYCHIAT, V212, P42, DOI 10.1192/bjp.2017.10; Kinoshita Y, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008297.pub2; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEHMAN AF, 1982, AM J PSYCHIAT, V139, P1271; Linden IA, 2013, J URBAN HEALTH, V90, P559, DOI 10.1007/s11524-012-9771-x; Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093; Luciano A, 2014, J VOCAT REHABIL, V40, P1, DOI 10.3233/JVR-130666; Modini M, 2016, BRIT J PSYCHIAT, V209, P14, DOI 10.1192/bjp.bp.115.165092; Mueser KT, 2001, SCHIZOPHRENIA BULL, V27, P281, DOI 10.1093/oxfordjournals.schbul.a006874; Panagio C., 2016, ADAPTING INDIVIDUAL; Pittam G, 2010, HEALTH SOC CARE COMM, V18, P598, DOI 10.1111/j.1365-2524.2010.00929.x; Pogoda TK, 2011, PSYCHIAT SERV, V62, P1289, DOI 10.1176/ps.62.11.pss6211_1289; Raphael D., 2020, ONT TU FAC HLTH SCI, V93; Reed K, 2018, WORK, V59, P3, DOI 10.3233/WOR-172665; Reme SE, 2019, SCAND J WORK ENV HEA, V45, P33, DOI 10.5271/sjweh.3753; Wehman P, 2014, INTELLECT DEV DISAB, V52, P296, DOI 10.1352/1934-9556-52.4.296	36	0	0	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2021	16	12							e0261415	10.1371/journal.pone.0261415	http://dx.doi.org/10.1371/journal.pone.0261415			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY9FU	34914771	gold, Green Published			2023-01-03	WOS:000755091500095
J	Nutt, D				Nutt, David			UK drugs strategy promises to be tough on criminals, but evidence shows this doesn't work	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PSILOCYBIN	We should invest in research, provision of new treatments, and safe injecting rooms, writes David Nutt	[Nutt, David] Imperial Coll London, London, England	Imperial College London	Nutt, D (corresponding author), Imperial Coll London, London, England.							Bogenschutz MP, 2015, J PSYCHOPHARMACOL, V29, P289, DOI 10.1177/0269881114565144; Cabral T.S., 2017, DRUG SCI POLICY L, V3, P1, DOI [10.1177/2050324516683640, DOI 10.1177/2050324516683640, 10.1177/2050324516683640,0]; Cato institute, SHIFT WAR DRUGS WAR; Department of Health and Social Care, 2021, REV DRUGS PHAS 2 REP; Iacobucci G, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n3031; Johnson MW, 2014, J PSYCHOPHARMACOL, V28, P983, DOI 10.1177/0269881114548296; Newman M, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4906; Nuffield Trust, ALCOHOL RELATED HARM; Office of National Statistics, 2020, DEATHS REL DRUG POIS; Sessa B, 2021, J PSYCHOPHARMACOL, V35, P375, DOI 10.1177/0269881121991792; Sherrington M, 2016, STOR PRIS POP 1993 2; UK CAA, 2020, FLYING SPEC CAT; Volte Face, SCOTLAND HAS EFFECTI	13	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 10	2021	375								n3066	10.1136/bmj.n3066	http://dx.doi.org/10.1136/bmj.n3066			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ2XT	34893507	Bronze			2023-01-03	WOS:000731414000005
J	Robinson, HJ; Barrington, DJ				Robinson, Hannah Jayne; Barrington, Dani Jennifer			Drivers of menstrual material disposal and washing practices: A systematic review	PLOS ONE			English	Review							ADOLESCENT GIRLS; HYGIENE MANAGEMENT; SANITATION; SCHOOLS; HEALTH; WOMEN; CHALLENGES; EXPERIENCES; KNOWLEDGE; MENARCHE	Background Disposal and washing facilities and services for menstrual materials are often designed based upon technical specifications rather than an in-depth understanding of what drives peoples' choices of practices. Objectives and data sources This systematic review identified and summarised the main behavioural drivers pertaining to the choice of disposal and washing practices of menstrual materials through the thematic content analysis and study appraisal of 82 publications (80 studies) on menstrual health and hygiene published since 1999, reporting the outcomes of primary research across 26 countries. Results Disposal and washing behaviours are primarily driven by the physical state of sanitation facilities; however, this is intrinsically linked to taboos surrounding and knowledge of menstruation. Implications Using reasons given for disposal and washing practices by menstruators or those who know them well, or inferred by authors of the reviewed studies, we identify the key considerations needed to design facilities and services which best suit the desired behaviours of both planners and those who menstruate. Inclusivity The term menstruators is used throughout to encompass all those mentioned in the studies reviewed (girls and women); although no studies explicitly stated including non-binary or transgender participants, this review uses inclusive language that represents the spectrum of genders that may experience menstruation.	[Robinson, Hannah Jayne; Barrington, Dani Jennifer] Univ Leeds, Leeds, W Yorkshire, England; [Barrington, Dani Jennifer] Univ Western Australia, Crawley, WA, Australia	University of Leeds; University of Western Australia	Robinson, HJ (corresponding author), Univ Leeds, Leeds, W Yorkshire, England.	cn16hjr@leeds.ac.uk	; Barrington, Dani/B-6182-2008	Robinson, Hannah/0000-0003-2209-600X; Barrington, Dani/0000-0002-1486-9247	Engineering and Physical Sciences Research Council [EP/S022066/1]	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	The lead author of this paper is supported by the Engineering and Physical Sciences Research Council Grant number EP/S022066/1.	ABC, 2019, WET WIP TAMP COND TA; Ahmmed F, 2022, CULT HEALTH SEX, V24, P1035, DOI 10.1080/13691058.2021.1909749; Alda-Vidal C, 2022, SOC CULT GEOGR, V23, P1057, DOI 10.1080/14649365.2021.1901974; Alda-Vidal C, 2020, WIRES WATER, V7, DOI 10.1002/wat2.1452; Alexander KT, 2014, WATER-SUI, V6, P1453, DOI 10.3390/w6051453; [Anonymous], 2018, NVIVO QUAL DAT SOFTW; [Anonymous], 2009, PRISMA 2009 CHECKLIS; APS Group Scotland, 2018, ACC SAN PROD AB PIL; Asimah SA., 2017, LOCAL ACTION INT COO; Averbach S, 2009, CONTRACEPTION, V79, P463, DOI 10.1016/j.contraception.2008.12.002; Barrington DJ, 2017, SOC SCI MED, V194, P128, DOI 10.1016/j.socscimed.2017.10.021; Bartram J, 2012, J WATER HEALTH, V10, P499, DOI 10.2166/wh.2012.205; Behera D, 2015, J HEALTH MANAG, V17, P510, DOI 10.1177/0972063415612581; Bhattacharjee M, 2019, INDIAN J GEND STUD, V26, P96, DOI 10.1177/0971521518811172; Caruso BA, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000414; Caruso BA, 2014, J WATER SANIT HYG DE, V4, P642, DOI 10.2166/washdev.2014.028; Chakravarthy V, 2019, INDIAN J GEND STUD, V26, P138, DOI 10.1177/0971521518811174; Chinyama J, 2018, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-018-6360-2; Chothe V, 2014, HEALTH PROMOT PRACT, V15, P319, DOI 10.1177/1524839914525175; Coffey D., 2014, ECON POLIT WEEKLY, P43; Connolly S, 2013, J WATER SANIT HYG DE, V3, P612, DOI 10.2166/washdev.2013.168; Coswosk ED, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6469-y; Crankshaw TL, 2020, REPROD HEALTH, V17, DOI 10.1186/s12978-020-0896-1; Crichton J, 2013, HEALTH CARE WOMEN IN, V34, P891, DOI 10.1080/07399332.2012.740112; Crofts T J., 2011, 2011 35 WEDC INT C T; Crofts T, 2012, J WATER SANIT HYG DE, V2, P50, DOI 10.2166/washdev.2012.067; Curtis VA, 2009, HEALTH EDUC RES, V24, P655, DOI 10.1093/her/cyp002; Daniels GJ, 2016, INVESTIGATING FEAR S; Dhingra R, 2009, STUD ETHNO-MED, V3, P43, DOI 10.1080/09735070.2009.11886336; Dolan CS, 2014, J INT DEV, V26, P643, DOI 10.1002/jid.2917; Elledge MF, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15112562; Ellis A., 2016, Waterlines, V35, P306, DOI 10.3362/1756-3488.2016.022; Enoch A., 2020, DISABILITY CBR INCLU, V31, P77, DOI [10.47985/dcidj.364, DOI 10.47985/DCIDJ.364]; Garikipati S, 2017, J INT DEV, V29, P32, DOI 10.1002/jid.3266; George AM., 2020, ONLINE J HLTH ALLIED, V19, P1; Girod C, 2017, J URBAN HEALTH, V94, P835, DOI 10.1007/s11524-017-0189-3; Gultie T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108644; Habtegiorgis Y, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248825; Hawkins A, 2019, P I CIVIL ENG-WAT M, V172, P163, DOI 10.1680/jwama.17.00050; Hennegan J, 2021, SEX REPROD HLTH MATT, V29, DOI 10.1080/26410397.2021.1911618; Hennegan J, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003433; Hennegan J, 2020, CULT HEALTH SEX, V22, P146, DOI 10.1080/13691058.2019.1580768; Hennegan J, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0339-9; Hennegan J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012596; Hennegan J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146985; Htun NN., 2021, J HLTH SCI MED RES J, V39, P207, DOI [10.31584/jhsmr.2021778, DOI 10.31584/JHSMR.2021778]; International Organization for Standardization, 2018, 305002018E ISO; Jahan F, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09413-x; Kambala C, 2020, REPROD HEALTH, V17, DOI 10.1186/s12978-020-01045-z; Kansiime C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-031182; Karibu K., 2019, ONSET MENARCHE ADOLE, V6, P102, DOI [10.1080/23293691.2019.1601903, DOI 10.1080/23293691.2019.1601903]; Kaur R, 2018, J ENVIRON PUBLIC HEA, V2018, DOI 10.1155/2018/1730964; Kemigisha E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17186613; Kohler P, 2019, HEALTH CARE WOMEN IN, V40, P3, DOI 10.1080/07399332.2017.1395440; Kumbeni MT, 2020, PAN AFR MED J, V37, DOI 10.11604/pamj.2020.37.190.19015; Lahme AM, 2018, GLOB HEALTH PROMOT, V25, P54, DOI 10.1177/1757975916648301; MacRae ER, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220114; Mason L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079132; Mattsson J, 2015, J ENVIRON MANAGE, V161, P188, DOI 10.1016/j.jenvman.2015.06.043; Maulingin-Gumbaketi E, 2021, BMC WOMENS HEALTH, V21, DOI 10.1186/s12905-021-01229-0; Mchenga J, 2020, PHYS CHEM EARTH, V115, DOI 10.1016/j.pce.2020.102842; Menarche Abera Y, 2004, MENSTRUATION RELATED; Michael M, 2020, SOC STUD SCI, V50, P377, DOI 10.1177/0306312720917754; Miiro G, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-017-0502-z; Mohamed Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208224; Mohammed S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241106; Mohammed Shamsudeen, 2020, Int J Reprod Med, V2020, P6872491, DOI 10.1155/2020/6872491; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Mumtaz Z, 2019, J ADOLESCENCE, V76, P152, DOI 10.1016/j.adolescence.2019.07.008; Muralidharan A, 2019, INDIAN J GEND STUD, V26, P12, DOI 10.1177/0971521518808104; Nalugya R, 2020, PILOT FEASIBILITY ST, V6, DOI 10.1186/s40814-020-00585-2; Ndlovu E, 2016, JAMBA-J DISASTER RIS, V8, DOI 10.4102/jamba.v8i2.204; Nepal WaterAid, 2009, IS MENSTR HYG MAN IS; Oche M. O., 2012, Scientific Research and Essays, V7, P410; Parker AH, 2014, DISASTER PREV MANAG, V23, P437, DOI 10.1108/DPM-04-2013-0070; Rajaraman D, 2013, J WATER SANIT HYG DE, V3, P432, DOI 10.2166/washdev.2013.114; Ramathuba Dorah U., 2015, Curationis, V38, P1, DOI 10.4102/curationis.v38i1.1551; Rastogi S, 2019, HEALTH EDUC J, V78, P839, DOI 10.1177/0017896919850209; Rees R, 2009, CHILDRENS VIEWS OBES; Rheinlander T, 2019, HEALTH CARE WOMEN IN, V40, P13, DOI 10.1080/07399332.2018.1444041; Rizvi N., 2016, J ASIAN MIDWIVES JAM, V3, P46; Roxburgh H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235339; Schmitt ML, 2021, CONFL HEALTH, V15, DOI 10.1186/s13031-021-00346-9; Schmitt ML, 2017, CONFL HEALTH, V11, DOI 10.1186/s13031-017-0121-1; Scorgie F, 2016, MED ANTHROPOL, V35, P161, DOI 10.1080/01459740.2015.1094067; Selamawit Tamiru, 2015, Waterlines, V34, P92, DOI 10.3362/1756-3488.2015.009; Shah SP, 2013, REPROD HEALTH MATTER, V21, P205, DOI 10.1016/S0968-8080(13)41691-9; Shah V, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6599-2; Sheoran P, 2020, J NURS MIDWIFERY SCI, V7, P269, DOI 10.4103/JNMS.JNMS_18_20; Shobhita Rajagopal, 2017, Gender and Development, V25, P303, DOI 10.1080/13552074.2017.1335451; Sivakami M, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010408; Sommer M, 2020, HEALTH PLACE, V66, DOI 10.1016/j.healthplace.2020.102431; Sommer M, 2015, COMPARE, V45, P589, DOI 10.1080/03057925.2013.871399; Sommer M, 2013, AM J PUBLIC HEALTH, V103, P1556, DOI 10.2105/AJPH.2013.301374; Sommer M, 2009, CULT HEALTH SEX, V11, P383, DOI 10.1080/13691050902722372; Sumpter C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062004; Tegegne TK, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1118; Trinies V., 2015, Waterlines, V34, P31, DOI 10.3362/1756-3488.2015.004; Umeora O U J, 2008, Afr J Reprod Health, V12, P109; Visaria L, 2017, J HEALTH MANAG, V19, P97, DOI 10.1177/0972063416682586; Wardell D W, 2001, J Am Acad Nurse Pract, V13, P187; Wilbur J, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10439-y; Wilson E, 2014, DEV PRACT, V24, P63, DOI 10.1080/09614524.2014.867305; World Bank, 2019, WORLD BANK COUNTRY L; WYNNE B, 1991, SCI TECHNOL HUM VAL, V16, P111, DOI 10.1177/016224399101600108; Yeasmin F, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4693-x	106	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2021	16	12							e0260472	10.1371/journal.pone.0260472	http://dx.doi.org/10.1371/journal.pone.0260472			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY3JJ	34860828	Green Published, gold			2023-01-03	WOS:000754686900004
J	Memtsa, M; Goodhart, V; Ambler, G; Brocklehurst, P; Keeney, E; Silverio, SA; Anastasiou, Z; Round, J; Khan, N; Hall, J; Barrett, G; Bender-Atik, R; Stephenson, J; Jurkovic, D				Memtsa, Maria; Goodhart, Venetia; Ambler, Gareth; Brocklehurst, Peter; Keeney, Edna; Silverio, Sergio A.; Anastasiou, Zacharias; Round, Jeff; Khan, Nazim; Hall, Jennifer; Barrett, Geraldine; Bender-Atik, Ruth; Stephenson, Judith; Jurkovic, Davor			Differences in the organisation of early pregnancy units and the effect of senior clinician presence, volume of patients and weekend opening on emergency hospital admissions: Findings from the VESPA Study	PLOS ONE			English	Article							IMPACT; CARE; MANAGEMENT	Objective To determine whether the participation of consultant gynaecologists in delivering early pregnancy care results in a lower rate of acute hospital admissions. Design Prospective cohort study and emergency hospital care audit; data were collected as part of the national prospective mixed-methods VESPA study on the "Variations in the organization of EPAUs in the UK and their effects on clinical, Service and PAtient-centred outcomes". Setting 44 Early Pregnancy Assessment Units (EPAUs) across the UK randomly selected in balanced numbers from eight pre-defined mutually exclusive strata. Participants 6606 pregnant women (>= 16 years old) with suspected first trimester pregnancy complications attending the participating EPAUs or Emergency Departments (ED) from December 2016 to July 2017. Exposures Planned and actual senior clinician presence, unit size, and weekend opening. Main outcome measures Unplanned admissions to hospital following any visit for investigations or treatment for first trimester complications as a proportion of women attending EPAUs. Results 205/6397 (3.2%; 95% CI 2.8-3.7) women were admitted following their EPAU attendance. The admission rate among 44 units ranged from 0% to 13.7% (median 2.8). Neither planned senior clinician presence (p = 0.874) nor unit volume (p = 0.247) were associated with lower admission rates from EPAU, whilst EPAU opening over the weekend resulted in lower admission rates (p = 0.027). 1445/5464 (26.4%; 95%CI 25.3 to 27.6) women were admitted from ED. There was little evidence of an association with planned senior clinician time (p = 0.280) or unit volume (p = 0.647). Keeping an EPAU open over the weekend for an additional hour was associated with 2.4% (95% CI 0.1% to 4.7%) lower odds of an emergency admission from ED. Conclusions Involvement of senior clinicians in delivering early pregnancy care has no significant impact on emergency hospital admissions for early pregnancy complications. Weekend opening, however, may be an effective way of reducing emergency admissions from ED.	[Memtsa, Maria; Goodhart, Venetia; Silverio, Sergio A.; Hall, Jennifer; Barrett, Geraldine; Stephenson, Judith; Jurkovic, Davor] UCL, Elizabeth Garrett Anderson Inst Womens Hlth, London, England; [Ambler, Gareth; Anastasiou, Zacharias] UCL, Dept Stat Sci, London, England; [Brocklehurst, Peter] Univ Birmingham, Inst Appl Hlth Res, Birmingham Clin Trials Unit, Birmingham, W Midlands, England; [Keeney, Edna; Round, Jeff] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England; [Silverio, Sergio A.] Kings Coll London, Dept Women & Childrens Hlth, London, England; [Round, Jeff] Inst Hlth Econ, Edmonton, AB, Canada; [Khan, Nazim] Modelling & Analyt Syst Solut MASS Ltd, Edinburgh, Midlothian, Scotland; [Bender-Atik, Ruth] Miscarriage Assoc, Wakefield, England	University of London; University College London; University of London; University College London; University of Birmingham; University of Bristol; University of London; King's College London	Jurkovic, D (corresponding author), UCL, Elizabeth Garrett Anderson Inst Womens Hlth, London, England.	d.jurkovic@ucl.ac.uk	Silverio, Sergio A./Y-7118-2019	Silverio, Sergio A./0000-0001-7177-3471; Round, Jeff/0000-0002-3103-6984; Memtsa, Maria/0000-0002-5237-0914; Barrett, Geraldine/0000-0002-9738-1051	NIHR Health Services & Delivery Research (HSDR) programme [14/04/41]; MASS	NIHR Health Services & Delivery Research (HSDR) programme; MASS	The VESPA study received funding from the NIHR Health Services & Delivery Research (HS&DR) programme grant number 14/04/41. The funder provided support in the form of salaries for authors MM, VG, GA, PB, EK, SS, ZA, JR, NK, JH, GB, JS, DJ; however, the funder and sponsors of the study did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the author contributions' section. The role of the commercial company MASS Ltd, as an elite researcher in workforce modelling, was advisory with regards to data collection and analysis. MASS Ltd is a business consultancy specialising in analytics, data modelling, and workforce planning and configuration. MASS (NK) was commissioned by and became a member of the VESPA coapplicants' group to provide the required workforce modelling expertise and knowledge. VESPA included the services provided by MASS in the submittal for funding to NIHR. In the submitted paper, there are no competing interests and MASS has no claim of ownership for any IP arising from or related to this paper. This commercial affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials.	Academy of Medical Royal Colleges, 2012, 7 DAY CONS PRES CAR; Bell D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061476; Bignardi T, 2010, ULTRASOUND OBST GYN, V35, P344, DOI 10.1002/uog.7523; BIGRIGG MA, 1991, BRIT MED J, V302, P577, DOI 10.1136/bmj.302.6776.577; Bottomley C, 2009, HUM REPROD, V24, P1811, DOI 10.1093/humrep/dep084; Cromb D, 2017, ARCH DIS CHILD, V102, P516, DOI 10.1136/archdischild-2016-311318; Gray DP, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014045; Haider Z, 2006, ULTRASOUND OBST GYN, V28, P207, DOI 10.1002/uog.2801; Magnus MC, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l869; New South Wales Government Health Policy Directive, MAT MAN EARL PREGN C; NHS Service, 7 DAYS WEEK FOR; NICE guidance, ECT PREGN MISC CG 15; Norton W, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023579; Public Health Scotland, 2020, QUAL MEAS FRAM EM AD; Purdy S, AVOIDING HOSP ADMISS; Rovner P, 2018, J ULTRAS MED, V37, P1533, DOI 10.1002/jum.14474; Royal College of Obstetricians and Gynaecologists, STAND GYN REP WORK P; Tan TL, 2014, J OBSTET GYNAECOL, V34, P412, DOI 10.3109/01443615.2014.896324; The Royal College of Obstetricians and Gynaecologists, 2019, ATSM AC GYN EARL PRE; van den Berg MMJ, 2015, REPROD BIOMED ONLINE, V31, P192, DOI 10.1016/j.rbmo.2015.04.008; White AL, 2010, EMERG MED J, V27, P262, DOI 10.1136/emj.2009.077842	21	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2021	16	11							e0260534	10.1371/journal.pone.0260534	http://dx.doi.org/10.1371/journal.pone.0260534			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW9KP	34847201	Green Published, gold, Green Accepted			2023-01-03	WOS:000735928900040
J	Liao, KF; Wang, XX; Han, MY; Li, LL; Nassis, GP; Li, YM				Liao, Kai-Fang; Wang, Xin-Xin; Han, Meng-Yuan; Li, Lin-Long; Nassis, George P.; Li, Yong-Ming			Effects of velocity based training vs. traditional 1RM percentage-based training on improving strength, jump, linear sprint and change of direction speed performance: A Systematic review with meta-analysis	PLOS ONE			English	Review							MOVEMENT VELOCITY; RESISTANCE; SPORT; POWER; GAINS	Background There has been a surge of interest on velocity-based training (VBT) in recent years. However, it remains unclear whether VBT is more effective in improving strength, jump, linear sprint and change of direction speed (CODs) than the traditional 1RM percentage-based training (PBT). Objectives To compare the training effects in VBT vs. PBT upon strength, jump, linear sprint and CODs performance. Data sources Web of science, PubMed and China National Knowledge Infrastructure (CNKI). Study eligibility criteria The qualified studies for inclusion in the meta-analysis must have included a resistance training intervention that compared the effects of VBT and PBT on at least one measure of strength, jump, linear sprint and CODs with participants aged >= 16 yrs. and be written in English or Chinese. Methods The modified Pedro Scale was used to assess the risk of bias. Random-effects model was used to calculate the effects via the mean change and pre-SD (standard deviation). Mean difference (MD) or Standardized mean difference (SMD) was presented correspondently with 95% confidence interval (CI). Results Six studies met the inclusion criteria including a total of 124 participants aged 16 to 30 yrs. The differences of training effects between VBT and PBT were not significant in back squat 1RM (MD = 3.03kg; 95%CI: -3.55, 9.61; I-2 = 0%) and load velocity 60%1RM (MD = 0.02m/s; 95%CI: -0.01,0.06; I-2 = 0%), jump (SMD = 0.27; 95%CI: -0.15,0.7; I-2 = 0%), linear sprint (MD = 0.01s; 95%CI: -0.06, 0.07; I-2 = 0%), and CODs (SMD = 0.49; 95%CI: -0.14, 1.07; I-2 = 0%). Conclusion Both VBT and PBT can enhance strength, jump, linear sprint and CODs performance effectively without significant group difference.	[Liao, Kai-Fang; Wang, Xin-Xin; Han, Meng-Yuan; Li, Lin-Long; Li, Yong-Ming] Shanghai Univ Sport, Sch Phys Educ & Sport Training, Shanghai, Peoples R China; [Liao, Kai-Fang] Guangdong Vocat Inst Sport, Dept Strength & Conditioning, Guangzhou, Peoples R China; [Nassis, George P.] United Arab Emirates Univ, Phys Educ Dept, Coll Educ CEDU, Abu Dhabi, U Arab Emirates; [Nassis, George P.] Univ Southern Denmark, Dept Sports Sci & Clin Biomech, SDU Sport & Hlth Sci Cluster SHSC, Odense, Denmark; [Li, Yong-Ming] China Inst Sport Sci, Beijing, Peoples R China	Shanghai University of Sport; United Arab Emirates University; University of Southern Denmark; China Institute of Sport Science	Li, YM (corresponding author), Shanghai Univ Sport, Sch Phys Educ & Sport Training, Shanghai, Peoples R China.; Li, YM (corresponding author), China Inst Sport Sci, Beijing, Peoples R China.	liyongming@sus.edu.cn	Nassis, George/AAC-4938-2020	Nassis, George/0000-0003-2953-3911; , Yongming/0000-0001-9654-0199; LIAO, kaifang/0000-0001-6893-1491	Ministry of Science and Technology of the People's Republic of China [2018YFF0300901]	Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China)	This work was supported by the Ministry of Science and Technology of the People's Republic of China [2018YFF0300901] funds to Yongming Li. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen JL, 2000, MUSCLE NERVE, V23, P1095; Banyard HG, 2021, INT J SPORT PHYSIOL, V16, P232, DOI 10.1123/ijspp.2019-0999; Banyard HG, 2019, INT J SPORT PHYSIOL, V14, P246, DOI 10.1123/ijspp.2018-0147; BEHM DG, 1993, SPORTS MED, V15, P374, DOI 10.2165/00007256-199315060-00003; Brughelli M, 2008, SPORTS MED, V38, P1045, DOI 10.2165/00007256-200838120-00007; COFFEY T H, 1946, Treat Serv Bull, V1, P8; Cohen J., 2016, CURR DIR PSYCHOL SCI, V1, P98, DOI [10.1111%2F1467-8721.ep10768783, 10.1111/1467-8721.ep10768783]; Davies TB, 2017, SPORTS MED, V47, P1603, DOI 10.1007/s40279-017-0676-4; Dorrell HF, 2020, J STRENGTH COND RES, V34, P46, DOI 10.1519/JSC.0000000000003089; Ortega JAF, 2020, APUNTS-MED ESPORT, V55, P53, DOI 10.1016/j.apunsm.2020.03.002; Galiano C, 2022, J STRENGTH COND RES, V36, P340, DOI 10.1519/JSC.0000000000003487; Gonzalez-Badillo JJ, 2010, INT J SPORTS MED, V31, P347, DOI 10.1055/s-0030-1248333; Gonzalez-Badillo JJ, 2015, J STRENGTH COND RES, V29, P1329, DOI 10.1519/JSC.0000000000000764; Held S, 2021, INT J SPORT PHYSIOL, V16, P1185, DOI 10.1123/ijspp.2020-0451; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hopkins WG, 1999, MED SCI SPORT EXER, V31, P472, DOI 10.1097/00005768-199903000-00018; Izquierdo M, 2006, J APPL PHYSIOL, V100, P1647, DOI 10.1152/japplphysiol.01400.2005; Gonzalez-Badillo JJ, 2017, INT J SPORTS MED, V38, P217, DOI 10.1055/s-0042-120324; Gonzalez-Badillo JJ, 2014, EUR J SPORT SCI, V14, P772, DOI 10.1080/17461391.2014.905987; Kaabi S, 2022, J STRENGTH COND RES, V36, P2912, DOI 10.1519/JSC.0000000000003972; Kraemer WJ, 2017, SPORTS MED, V47, P2415, DOI 10.1007/s40279-017-0779-y; Kraemer WJ, 2004, MED SCI SPORT EXER, V36, P674, DOI 10.1249/01.MSS.0000121945.36635.61; Lasevicius T, 2022, J STRENGTH COND RES, V36, P346, DOI 10.1519/JSC.0000000000003454; Lopez-Segovia M, 2010, J STRENGTH COND RES, V24, P2705, DOI 10.1519/JSC.0b013e3181cc237d; Maffiuletti NA, 2016, EUR J APPL PHYSIOL, V116, P1091, DOI 10.1007/s00421-016-3346-6; Martinez DB., 2016, VELOCITY BASED TRAIN, V24, P48; Martinez-Canton M, 2021, SCAND J MED SCI SPOR, V31, P91, DOI 10.1111/sms.13828; McGuigan MR, 2012, INT J SPORT PHYSIOL, V7, P2, DOI 10.1123/ijspp.7.1.2; Morris SB, 2008, ORGAN RES METHODS, V11, P364, DOI 10.1177/1094428106291059; Orange ST, 2020, INT J SPORT PHYSIOL, V15, P554, DOI 10.1123/ijspp.2019-0058; Pareja-Blanco F, 2017, SCAND J MED SCI SPOR, V27, P724, DOI 10.1111/sms.12678; Pareja-Blanco F, 2014, INT J SPORTS MED, V35, P916, DOI 10.1055/s-0033-1363985; Pareja-Blanco F, 2020, SCAND J MED SCI SPOR, V30, P2154, DOI 10.1111/sms.13775; Piercy KL, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.118.005263; Randell AD, 2011, J STRENGTH COND RES, V25, P87, DOI 10.1519/JSC.0b013e3181fee634; Rodriguez-Rosell D, 2020, APPL PHYSIOL NUTR ME, V45, P817, DOI 10.1139/apnm-2019-0829; SALE DG, 1988, MED SCI SPORT EXER, V20, pS135, DOI 10.1249/00005768-198810001-00009; Schoenfeld BJ, 2010, J STRENGTH COND RES, V24, P3497, DOI 10.1519/JSC.0b013e3181bac2d7; Schuenke MD, 2012, EUR J APPL PHYSIOL, V112, P3585, DOI 10.1007/s00421-012-2339-3; Seitz LB, 2014, SPORTS MED, V44, P1693, DOI 10.1007/s40279-014-0227-1; Silva JR, 2015, SPORTS MED-OPEN, V1, DOI 10.1186/s40798-015-0006-z; Song C., 1995, J BEIJING U PHYS ED, V18, P81; Suchomel TJ, 2016, SPORTS MED, V46, P1419, DOI 10.1007/s40279-016-0486-0; Van Cutsem M, 1998, J PHYSIOL-LONDON, V513, P295, DOI 10.1111/j.1469-7793.1998.295by.x; Van Hooren B, 2017, J STRENGTH COND RES, V31, P2324, DOI 10.1519/JSC.0000000000001916; Weakley J, 2021, SPORTS MED, V51, P443, DOI 10.1007/s40279-020-01382-w; Weakley J, 2020, INT J SPORT PHYSIOL, V15, P180, DOI 10.1123/ijspp.2018-1008; Weakley J, 2019, INT J SPORT PHYSIOL, V14, P1205, DOI 10.1123/ijspp.2018-0523; Weakley JJS, 2019, J STRENGTH COND RES, V33, P2420, DOI 10.1519/JSC.0000000000002133; Zhihui W, 2020, EFFECTS SQUAT VELOCI	50	3	3	16	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2021	16	11							e0259790	10.1371/journal.pone.0259790	http://dx.doi.org/10.1371/journal.pone.0259790			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2NY	34793506	gold, Green Published			2023-01-03	WOS:000755319200057
J	Avalos-Mejia, AM; Garcia-Cruz, JC; de la Pena, JE; Garrido-Acosta, O; Juarez-Cedillo, T				Marisol Avalos-Mejia, Annia; Carlos Garcia-Cruz, Juan; Escobedo de la Pena, Jorge; Garrido-Acosta, Osvaldo; Juarez-Cedillo, Teresa			Reduction of inappropriate prescriptions in older adults through the support of Asynchronous Geriatric Counseling Online (AGAlink): Implemented in primary care	PLOS ONE			English	Article							PRESCRIBING OMISSIONS; ELDERLY-PATIENTS; SCREENING TOOL; CRITERIA; ALERTS	Background/Aim Medication prescription is a fundamental component in the care of the elderly. Several characteristics of aging and geriatric medicine affect prescriptions for these people and make the selection of drug therapy a difficult and complex process. The objective of this study is to develop a geriatric portal for asynchronous online counseling (AGAlink) for use by physicians specializing in family medicine to reduce medication problems among older adult patients in the first level of care. Method A qualitative study was carried out in the first level of care at the Mexican Institute of Social Security (IMSS), 31 family doctors were interviewed to identify attitudes, preferences about the use of the AGAlink geriatric portal, as well as their recommendations for the implementation of this tool in their daily practice. For the analysis of the data obtained, a qualitative thematic content analysis was used. Results 90% of the physicians used the geriatric portal outside office hours without the need for the patient to be present. The perception of the physician towards the use of the AGAlink geriatric portal was favorable, provided relevant information and had several positive effects on the process of care for medical prescription. The barriers identified to accept the change in medication were not having the proposed therapeutic option, lack of any laboratory analysis, continuing to consider their experience for the prescription of the medication. Conclusions The AGAlink geriatric portal was a tool that was well received by physicians who expressed a positive attitude, considered an investment of a short time that allowed them to update and learn about strategies to reduce the prescription problems presented among the elderly population. However, the main barrier was the use of technology, especially in the doctors with more seniority in the service.	[Marisol Avalos-Mejia, Annia; Juarez-Cedillo, Teresa] Hosp Gen Reg, Unidad Invest Epidemiol Clin, Ctr Med Nacl Siglo 21, Actualmente Comisionada Unidad Invest, 1 Dr Carlos Mac Gregor Sanchez Navarro,IMSS, Ciudad Mexico, Mexico; [Carlos Garcia-Cruz, Juan] Hosp Especialidades Ctr Med La Raza, Hosp Especialidades, Dept Med, Ctr Med Nacl Siglo 21,Div Med Geriatr,MISS, Ciudad De Mexico, Mexico; [Escobedo de la Pena, Jorge] Hosp Gen Reg, Unidad Invest Epidemiol Clin, 1 Dr Carlos Mac Gregor Sanchez Navarro, Ciudad De Mexico, Mexico; [Garrido-Acosta, Osvaldo] UNAM, Fac Estudios Super Zaragoza, Estado De Mexico, Mexico	Instituto Mexicano del Seguro Social; Universidad Nacional Autonoma de Mexico	Juarez-Cedillo, T (corresponding author), Hosp Gen Reg, Unidad Invest Epidemiol Clin, Ctr Med Nacl Siglo 21, Actualmente Comisionada Unidad Invest, 1 Dr Carlos Mac Gregor Sanchez Navarro,IMSS, Ciudad Mexico, Mexico.	terezillo@exalumno.unam.mx	Garrido-Acosta, Osvaldo/GQH-1784-2022	Garrido-Acosta, Osvaldo/0000-0003-4065-6322; Juarez-Cedillo, Teresa/0000-0002-9442-3471	Fund for the Promotion of Research in Health, Mexican Institute of Social Security [FIS / IMSS /PROT/G11/938]	Fund for the Promotion of Research in Health, Mexican Institute of Social Security	This project was supported by donations from the Fund for the Promotion of Research in Health, Mexican Institute of Social Security, FIS / IMSS /PROT/G11/938. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barry PJ, 2007, AGE AGEING, V36, P632, DOI 10.1093/ageing/afm118; Batuwitage BT, 2007, POSTGRAD MED J, V83, P66, DOI 10.1136/pgmj.2006.051151; Creswell J.W., 2003, RES DESIGN, Vsecond; dos Santos NS, 2019, REV SAUDE PUBL, V53, DOI [10.11606/S1518-8787.2019053000781, 10.11606/s1518-8787.2019053000781]; Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767; Gallagher P, 2008, AGE AGEING, V37, P673, DOI 10.1093/ageing/afn197; Garcia C., 2008, DERMATOLOGIA REV MEX, V52, P77; Garcia Gomez J. C., 2001, El Profesional de la Informacion, V10, P4, DOI 10.1076/epri.10.7.4.9047; Garcia RM, 2006, J FAM PRACTICE, V55, P305; Hamilton Hilary J, 2009, BMC Geriatr, V9, P5, DOI 10.1186/1471-2318-9-5; Humphries TL, 2007, ANN PHARMACOTHER, V41, P1979, DOI 10.1345/aph.1K349; Kaur S, 2009, DRUG AGING, V26, P1013, DOI 10.2165/11318890-000000000-00000; Klotz U, 2009, DRUG METAB REV, V41, P67, DOI 10.1080/03602530902722679; Komiya H, 2018, GERIATR GERONTOL INT, V18, P33, DOI 10.1111/ggi.13132; Krause M, 1995, REV TEMAS EDUCACION, V7, P19; Kucher N, 2005, NEW ENGL J MED, V352, P969, DOI 10.1056/NEJMoa041533; Kuckartz U., 2014, QUALITATIVE TEXT ANA, DOI [10.1002/hbm.22668, DOI 10.1002/HBM.22668]; Lavan AH, 2016, CLIN INTERV AGING, V11, P857, DOI 10.2147/CIA.S80280; Malterud K, 2016, QUAL HEALTH RES, V26, P1753, DOI 10.1177/1049732315617444; Motter FR, 2018, EUR J CLIN PHARMACOL, V74, P679, DOI 10.1007/s00228-018-2446-0; O'Mahony D, 2020, EXPERT REV CLIN PHAR, V13, P15, DOI 10.1080/17512433.2020.1697676; Patton M. Q, 2014, SAGE; Raebel MA, 2007, J AM GERIATR SOC, V55, P977, DOI 10.1111/j.1532-5415.2007.01202.x; Tamblyn R, 2003, CAN MED ASSOC J, V169, P549; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Weingart SN, 2003, ARCH INTERN MED, V163, P2625, DOI 10.1001/archinte.163.21.2625	26	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2021	16	11							e0258414	10.1371/journal.pone.0258414	http://dx.doi.org/10.1371/journal.pone.0258414			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XW9HJ	34788287	Green Published, gold			2023-01-03	WOS:000735920500004
J	Alsayed, HAH; Sharif-Askari, FS; Sharif-Askari, NS; Hussain, AA; Hamid, Q; Halwani, R				Alsayed, Hawra Ali Hussain; Sharif-Askari, Fatemeh Saheb; Sharif-Askari, Narjes Saheb; Hussain, Ali Al Sayed; Hamid, Qutayba; Halwani, Rabih			Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study	PLOS ONE			English	Article								Objectives Remdesivir is one of the most widely recommended and used medications for COVID-19 treatment. However, different outcomes have been reported for hospitalized patients with COVID-19 treated with remdesivir. Specifically, the effect of the timing of remdesivir initiation (from patient's symptom onset) on clinical outcomes in COVID-19 patients has not been investigated. Methods This is a retrospective cohort study of patients hospitalized with COVID-19 and treated with or without remdisivir. The primary outcome was patient's recovery rate, defined as clinical improvement and patient's discharge by day 14 of symptom onset. The secondary outcome was the need for intensive care unit (ICU) admission, mechanical ventilation, and mortality within 28 days of patient's symptom onset. Results Out of 323 hospitalized adults with COVID-19, 107 (33.1%) received no remdesivir during their hospital stay, 107 (33.1%) received remdesivir early within 7 days of the symptom onset, and 109 (33.7%) received it at 8 days or later of symptom onset. At day 14 following symptom onset, higher proportion of patients recovered in the early remdesivir compared to the late remdesivir cohort, or patients who did not receive remdesivir (adjusted odds ratio, aOR, 2.65; 95% confidence interval [CI], 1.31 to 5.35). Moreover, early administration of remdesivir was associated with lower admission to intensive care unit (adjusted hazard ratio [aHR], 0.31; 95% CI, 0.15 to 0.64), less need for mechanical ventilation (aHR, 0.22; 95% CI, 0.10 to 0.51), and lower mortality at 28 days (aHR, 0.15; 95% CI, 0.04 to 0.53), as compared to the late remdesivir cohort or patients who did not receive remdesivir. Conclusion Early administration of remdesivir within 7 days of symptom onset is associated with less need for mechanical ventilation and lower 28-days mortality.	[Alsayed, Hawra Ali Hussain; Hussain, Ali Al Sayed] Dubai Hlth Author, Pharm Dept, Dubai, U Arab Emirates; [Sharif-Askari, Fatemeh Saheb; Sharif-Askari, Narjes Saheb; Hamid, Qutayba; Halwani, Rabih] Univ Sharjah, Sharjah Inst Med Res, Sharjah, U Arab Emirates; [Hamid, Qutayba; Halwani, Rabih] Univ Sharjah, Coll Med, Dept Clin Sci, Sharjah, U Arab Emirates; [Hamid, Qutayba] McGill Univ, Meakins Christie Labs, Res Inst, Hlth Ctr, Montreal, PQ, Canada; [Halwani, Rabih] King Saud Univ, Fac Med, Dept Pediat, Prince Abdullah Ben Khaled Celiac Dis Chair, Riyadh, Saudi Arabia	University of Sharjah; University of Sharjah; McGill University; King Saud University	Halwani, R (corresponding author), Univ Sharjah, Sharjah Inst Med Res, Sharjah, U Arab Emirates.; Halwani, R (corresponding author), Univ Sharjah, Coll Med, Dept Clin Sci, Sharjah, U Arab Emirates.; Halwani, R (corresponding author), King Saud Univ, Fac Med, Dept Pediat, Prince Abdullah Ben Khaled Celiac Dis Chair, Riyadh, Saudi Arabia.	rhalwani@sharjah.ac.ae	; Halwani, Rabih/E-9311-2014	Saheb Sharif-Askari, Narjes/0000-0003-0482-6777; Halwani, Rabih/0000-0002-6516-7771	COVID-19 research grant [CoV190307, 2001090275]; University of Sharjah, UAE [2001090278, 2001090283]; Sandooq Al Watan Applied Research & Development grant [SWARD-S20-007]; Al Jalila Foundation [AJF202019]; Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences [MRG/20/2020]; Prince Abdullah Ben Khalid Celiac Disease Research Chair, under the Vice Deanship of Research Chairs, King Saud University, Riyadh, Kingdom of Saudi Arabia	COVID-19 research grant; University of Sharjah, UAE; Sandooq Al Watan Applied Research & Development grant; Al Jalila Foundation(Al Jalila Foundation (AJF)); Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences; Prince Abdullah Ben Khalid Celiac Disease Research Chair, under the Vice Deanship of Research Chairs, King Saud University, Riyadh, Kingdom of Saudi Arabia	This research has been financially supported by COVID-19 research grant (CoV190307); Seed grant (Grant code: 2001090275); and by collaborative research grant (Grant code: 2001090278 and 2001090283) to RH, University of Sharjah, UAE; and by a Sandooq Al Watan Applied Research & Development grant to RH (SWARD-S20-007); by an Al Jalila Foundation (AJF202019) to RH; and by Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences (MRG/20/2020) to QH and RH; and by Prince Abdullah Ben Khalid Celiac Disease Research Chair, under the Vice Deanship of Research Chairs, King Saud University, Riyadh, Kingdom of Saudi Arabia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2020, NATL GUIDELINES CLIN; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bhapkar HR, 2020, J MED SYST, V44, DOI 10.1007/s10916-020-01668-6; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Helmy YA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041225; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Olender Susan A, 2021, Clin Infect Dis, V73, pe4166, DOI 10.1093/cid/ciaa1041; Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4; Rochwerg B, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2924; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6; Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Williamson BN, 2020, NATURE, V585, P273, DOI 10.1038/s41586-020-2423-5; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	20	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2021	16	10							e0258643	10.1371/journal.pone.0258643	http://dx.doi.org/10.1371/journal.pone.0258643			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8IO	34699552	gold, Green Published			2023-01-03	WOS:000755029000005
J	Kremeike, K; Dojan, T; Rosendahl, C; Junger, S; Romotzky, V; Bostrom, K; Frerich, G; Voltz, R				Kremeike, Kerstin; Dojan, Thomas; Rosendahl, Carolin; Juenger, Saskia; Romotzky, Vanessa; Bostroem, Kathleen; Frerich, Gerrit; Voltz, Raymond			"Withstanding ambivalence is of particular importance"-Controversies among experts on dealing with desire to die in palliative care	PLOS ONE			English	Article							HASTENED DEATH; COMMUNICATION; LIFE; WISH; RECOMMENDATIONS; CHALLENGES; ATTITUDES; REALITY; SUICIDE; PEOPLE	In order to investigate controversies surrounding the desire to die phenomenon in palliative care by analyzing expert opinions on the topic, we carried out a secondary qualitative data analysis of free text comments collected during a Delphi survey that was designed to develop a conversation aid for dealing with desire to die in everyday clinical practice. Between 01/2018 and 03/2018, a two-round Delphi survey was carried out with national (German) and international palliative care experts. Free text comments were reinvestigated to identify controversies surrounding the desire to die phenomenon. An additional in-depth analysis focused on statements expressing attitudes towards proactively addressing (potential) desires to die. Within the Delphi survey, 103 of 149 multi-professional participants (almost all of them with practical and only six with exclusively theoretical expertise in palliative care) generated 444 free text comments. Thereof, we identified three main categories related to dealing with desire to die: "outer framework", "extended care system" and "health-professional-patient-relationship". Ambivalences, taboos and uncertainties surrounding desire to die in palliative care became apparent. Experts are divided concerning the practice of proactively addressing desire to die. Even if these conversations-especially the proactive approach-are also viewed critically, we conclude that open-ended and respectful communication about desire to die between health professionals and patients can be understood as an eligible intervention in palliative care. Proactively addressing the topic is a possible way to open up such conversations.	[Kremeike, Kerstin; Dojan, Thomas; Rosendahl, Carolin; Romotzky, Vanessa; Bostroem, Kathleen; Frerich, Gerrit; Voltz, Raymond] Univ Cologne, Fac Med, Dept Palliat Med, Cologne, Germany; [Juenger, Saskia] Univ Appl Hlth Sci, Dept Community Hlth, Bochum, Germany; [Voltz, Raymond] Univ Cologne, Ctr Integrated Oncol Cologne Bonn CIO, Cologne, Germany; [Voltz, Raymond] Univ Cologne, Ctr Hlth Serv Res Cologne ZVFK, Cologne, Germany	University of Cologne; University of Cologne; University of Cologne	Kremeike, K (corresponding author), Univ Cologne, Fac Med, Dept Palliat Med, Cologne, Germany.	kerstin.kremeike@uk-koeln.de			German Federal Ministry of Education and Research [01GY1706]	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	RV, KK, VR and GF have acquired funding for the study from the German Federal Ministry of Education and Research (https://www.bmbf.de/ bmbf/en/home/home_node.html); grant number: 01GY1706. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allan A, 2020, ETHICS BEHAV, V30, P28, DOI 10.1080/10508422.2019.1592683; [Anonymous], 2010, WHO DEF PALL CAR; Bailey S-J, 2018, TALKING DYING BEGIN; Balaguer A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146184; Bausewein C, 2012, CURR OPIN SUPPORT PA, V6, P471, DOI 10.1097/SPC.0b013e32835998f5; Bernier S, 2020, CLIN GERONTOLOGIST, V43, P4, DOI 10.1080/07317115.2019.1672846; Bocquier A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080797; Breitbart W, 2018, CANCER-AM CANCER SOC, V124, P3231, DOI 10.1002/cncr.31539; Brighton LJ, 2016, POSTGRAD MED J, V92, P466, DOI 10.1136/postgradmedj-2015-133368; Brown S, 2019, CAN MED ASSOC J, V191, pE22, DOI 10.1503/cmaj.109-5691; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Colosimo K, 2018, J PSYCHOTHER INTEGR, V28, P125, DOI 10.1037/int0000078; Dazzi T, 2014, PSYCHOL MED, V44, P3361, DOI 10.1017/S0033291714001299; de Oliveira Sidney Medeiros, 2019, Clin Pract Epidemiol Ment Health, V15, P64, DOI 10.2174/1745017901915010064; De Villiers MR, 2005, MED TEACH, V27, P639, DOI 10.1080/13611260500069947; DeCou CR, 2018, SUICIDE LIFE-THREAT, V48, P531, DOI 10.1111/sltb.12368; DeForest A, 2019, NEW ENGL J MED, V380, P211, DOI 10.1056/NEJMp1810018; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Echterhoff G, 2009, PERSPECT PSYCHOL SCI, V4, P496, DOI 10.1111/j.1745-6924.2009.01161.x; Ellis M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180395; Epstein RM, 2011, ANN FAM MED, V9, P100, DOI 10.1370/afm.1239; Epstein RM, 2009, JAMA-J AM MED ASSOC, V302, P195, DOI 10.1001/jama.2009.984; Frerich G, 2020, PALLIAT SUPPORT CARE, V18, P528, DOI 10.1017/S1478951520000097; Fridriksdottir N, 2006, PALLIATIVE MED, V20, P425, DOI 10.1191/0269216306pm1148oa; Galushko M, 2016, PSYCHO-ONCOLOGY, V25, P536, DOI 10.1002/pon.3959; German Guideline Programme in Oncology, 2020, PALL CAR PAT INC CAN; Haley WE, 2002, AM BEHAV SCI, V46, P284, DOI 10.1177/000276402236680; Higgins ET, 2007, JPN PSYCHOL RES, V49, P89, DOI 10.1111/j.1468-5884.2007.00336.x; Hodiamont F, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-3961-0; Horn R, 2020, J MED ETHICS, V46, P416, DOI 10.1136/medethics-2020-106197; Houben CHM, 2014, J AM MED DIR ASSOC, V15, P477, DOI 10.1016/j.jamda.2014.01.008; Hudson PL, 2006, PALLIATIVE MED, V20, P703, DOI 10.1177/0269216306071814; Hudson Peter L, 2004, J Palliat Med, V7, P19, DOI 10.1089/109662104322737214; Jacobsen J, 2018, J PALLIAT MED, V21, P322, DOI 10.1089/jpm.2017.0109; Jansky M, 2019, BMC PALLIAT CARE, V18, DOI 10.1186/s12904-019-0392-y; Johnson SM, 2014, DEATH STUD, V38, P582, DOI 10.1080/07481187.2013.820228; Junger S, 2017, PALLIATIVE MED, V31, P684, DOI 10.1177/0269216317690685; Kremeike K, 2021, ANN PALLIAT MED, V10, P3594, DOI 10.21037/apm-20-381; Kremeike K, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00548-7; Kremeike K, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0279-3; Kuckartz U., 2014, QUALITATIVE TEXT ANA, DOI [10.1002/hbm.22668, DOI 10.1002/HBM.22668]; Linse K, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00603; Liu ZJ, 2018, CURR OPIN PSYCHOL, V23, P124, DOI 10.1016/j.copsyc.2018.03.006; Metselaar S, 2019, AM J BIOETHICS, V19, P44, DOI 10.1080/15265161.2019.1674416; Metselaar S, 2019, AM J BIOETHICS, V19, P63, DOI 10.1080/15265161.2019.1654016; Moller HJ, 2021, INT J PSYCHIAT CLIN, V25, P2, DOI 10.1080/13651501.2020.1797097; National Criminal Code, 2015, GERMAN FEDERAL LAW 1; Nissim R, 2009, SOC SCI MED, V69, P165, DOI 10.1016/j.socscimed.2009.04.021; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; Ohnsorge K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210784; Pachankis JE, 2007, PSYCHOL BULL, V133, P328, DOI 10.1037/0033-2909.133.2.328; Porta-Sales J, 2019, PALLIATIVE MED, V33, P570, DOI 10.1177/0269216318824526; Radbruch L, 2016, PALLIATIVE MED, V30, P104, DOI 10.1177/0269216315616524; Radbruch L, 2010, PALLIATIVE MED, V24, P751, DOI 10.1177/0269216310388070; Richter G., 2016, ONKOLOGE, V22, DOI [10.1007/s00761-016-0092-7, DOI 10.1007/S00761-016-0092-7]; Rizo-Baeza M, 2018, J NURS MANAGE, V26, P19, DOI 10.1111/jonm.12506; Rodin G, 2007, J PAIN SYMPTOM MANAG, V33, P661, DOI 10.1016/j.jpainsymman.2006.09.034; Rodin G, 2009, SOC SCI MED, V68, P562, DOI 10.1016/j.socscimed.2008.10.037; Rodriguez-Prat A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016659; Roter DL, 2002, JAMA-J AM MED ASSOC, V288, P756, DOI 10.1001/jama.288.6.756; Rurup ML, 2011, CRISIS, V32, P194, DOI 10.1027/0227-5910/a000079; Vaismoradi M., 2019, THEME QUALITATIVE CO, V20; VERBI Software, 2018, MAXQDA 2018; Voltz R, 2011, SUPPORT CARE CANCER, V19, P771, DOI 10.1007/s00520-010-0876-z; Willmott L, 2020, BMJ SUPPORT PALLIAT, V10, P105, DOI 10.1136/bmjspcare-2019-001887; Wilson KG, 2016, BMJ SUPPORT PALLIAT, V6, P170, DOI 10.1136/bmjspcare-2013-000604; Wise J, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3356	68	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2021	16	9							e0257382	10.1371/journal.pone.0257382	http://dx.doi.org/10.1371/journal.pone.0257382			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY2YF	34559828	Green Published, gold			2023-01-03	WOS:000754657900023
J	Yabe, H; Kono, K; Yamaguchi, T; Ishikawa, Y; Yamaguchi, Y; Azekura, H				Yabe, Hiroki; Kono, Kenichi; Yamaguchi, Tomoya; Ishikawa, Yumiko; Yamaguchi, Yoshiko; Azekura, Hisanori			Effects of intradialytic exercise for advanced-age patients undergoing hemodialysis: A randomized controlled trial	PLOS ONE			English	Article							PHYSICAL PERFORMANCE BATTERY; CHRONIC KIDNEY-DISEASE; ALL-CAUSE MORTALITY; PROGRESSIVE EXERCISE; ASSOCIATION; PREDIALYSIS; ANABOLISM; STRENGTH; PROGRAM	Previous reports have shown the benefits of intradialytic exercise to patients undergoing hemodialysis. However, most of those studies assessed the effects of exercise in middle-aged patients and little is known about advanced-age patients undergoing hemodialysis. Therefore, the present randomized controlled trial was performed to determine the effectiveness of exercise therapy in advanced-age patients undergoing hemodialysis. This non-blinded, randomized controlled parallel trial enrolled a total of 101 patients who were randomly assigned to intradialytic exercise (n = 51) or usual care (n = 50) groups. The training program included both resistance and aerobic exercises and was performed three times per week for 6 months. The aerobic exercise intensity was adjusted to a target Borg score of 13 for 20 minutes. Four types of resistance exercises were performed using elastic tubing, with three sets of 10 exercises performed at moderate intensity (13/20 on the Borg scale). The usual care group received standard care. Lower extremity muscle strength, Short Physical Performance Battery score, and 10-m walking speed were the outcomes and were evaluated before the hemodialysis session and after 6 months of training. There were statistically significant improvements in Short Physical Performance Battery score (effect size, 0.57; 95% confidence interval, 0.15-1.95) in the exercise group relative to the control group. There were no statistically significant differences in lower extremity muscle strength or in the 10-m walking speed between the two groups. These findings suggest that 6 months of intradialytic training could improve physical function in older patients undergoing hemodialysis.	[Yabe, Hiroki] Seirei Christopher Univ, Dept Phys Therapy, Sch Rehabil Sci, Kita Ku, Hamamatsu, Shizuoka, Japan; [Kono, Kenichi] Int Univ Hlth & Welf, Sch Hlth Sci Narita, Dept Phys Therapy, Chiba, Japan; [Yamaguchi, Tomoya] Seirei Fukuroi Municipal Hosp, Dept Rehabil, Shizuoka, Japan; [Ishikawa, Yumiko; Yamaguchi, Yoshiko] Sanaru Sun Clin, Dept Nursing, Naka Ku, Hamamatsu, Shizuoka, Japan; [Azekura, Hisanori] Sanaru Sun Clin, Dept Nephrol, Naka Ku, Hamamatsu, Shizuoka, Japan	International University of Health & Welfare	Yabe, H (corresponding author), Seirei Christopher Univ, Dept Phys Therapy, Sch Rehabil Sci, Kita Ku, Hamamatsu, Shizuoka, Japan.	hiroki-y@seirei.ac.jp		Yamaguchi, Tomoya/0000-0002-6536-7001				Anand S, 2014, J GERONTOL A-BIOL, V69, P315, DOI 10.1093/gerona/glt109; Andrade FP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54953-x; Cheema B, 2007, AM J KIDNEY DIS, V50, P574, DOI 10.1053/j.ajkd.2007.07.005; Cheema B, 2007, J AM SOC NEPHROL, V18, P1594, DOI 10.1681/ASN.2006121329; Cheema BSB, 2005, AM J NEPHROL, V25, P352, DOI 10.1159/000087184; Chen IR, 2014, CLIN J AM SOC NEPHRO, V9, P1183, DOI 10.2215/CJN.09810913; Chen JLT, 2010, NEPHROL DIAL TRANSPL, V25, P1936, DOI 10.1093/ndt/gfp739; Chigira Yusuke, 2017, J Phys Ther Sci, V29, P20, DOI 10.1589/jpts.29.20; Corsonello A, 2012, REJUV RES, V15, P41, DOI 10.1089/rej.2011.1215; Simo VE, 2015, NEFROLOGIA, V35, P385, DOI 10.1016/j.nefro.2015.03.006; Farrington K, 2016, NEPHROL DIAL TRANSPL, V31, P1, DOI 10.1093/ndt/gfw356; Ferrari F, 2020, J NEPHROL, V33, P251, DOI 10.1007/s40620-019-00687-y; Neto MG, 2018, CLIN REHABIL, V32, P1189, DOI 10.1177/0269215518760380; Groussard C, 2015, APPL PHYSIOL NUTR ME, V40, P550, DOI 10.1139/apnm-2014-0357; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hamer RA, 2006, BMJ-BRIT MED J, V332, P563, DOI 10.1136/bmj.332.7541.563; Hiraki K, 2013, CLIN EXP NEPHROL, V17, P225, DOI 10.1007/s10157-012-0681-8; Manfredini F, 2017, J AM SOC NEPHROL, V28, P1259, DOI 10.1681/ASN.2016030378; Matsufuji S, 2015, J RENAL NUTR, V25, P17, DOI 10.1053/j.jrn.2014.06.010; Matsuzawa R, 2017, KIDNEY INT REP, V2, P1096, DOI 10.1016/j.ekir.2017.06.008; Matsuzawa R, 2014, PHYS THER, V94, P947, DOI 10.2522/ptj.20130270; Moriyama Y, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1375-1; Nied RJ, 2002, AM FAM PHYSICIAN, V65, P419; Olsen CF, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0514-4; de Villar LO, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201035; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Riebe D, 2018, ACSMS GUIDELINES EXE; Roshanravan B, 2013, J AM SOC NEPHROL, V24, P822, DOI 10.1681/ASN.2012070702; Salhab N, 2019, J NEPHROL, V32, P549, DOI 10.1007/s40620-018-00565-z; Sawant A, 2017, HEALTHCARE-BASEL, V5, DOI 10.3390/healthcare5040092; Sheng KX, 2014, AM J NEPHROL, V40, P478, DOI 10.1159/000368722; SHINZATO T, 1994, NEPHRON, V67, P280, DOI 10.1159/000187980; Smart NA, 2013, J SCI MED SPORT, V16, P406, DOI 10.1016/j.jsams.2013.01.005; Spakova I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72542-1; Vasunilashorn S, 2009, J GERONTOL A-BIOL, V64, P223, DOI 10.1093/gerona/gln022; Volpato S, 2011, J GERONTOL A-BIOL, V66, P89, DOI 10.1093/gerona/glq167; Yabe H, 2018, NEPHROL DIAL TRANSPL, V33, P482; Yamada K, 2008, AM J CLIN NUTR, V87, P106, DOI 10.1093/ajcn/87.1.106; Yamagata K, 2019, RENAL REPLACE THER, V5, DOI 10.1186/s41100-019-0209-8; Yamaguchi T, 2021, THER APHER DIAL, V25, P458, DOI 10.1111/1744-9987.13587	40	1	1	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	10							e0257918	10.1371/journal.pone.0257918	http://dx.doi.org/10.1371/journal.pone.0257918			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XT1ZB	34679101	gold, Green Published			2023-01-03	WOS:000733392900040
J	Siuba, MT; Sadana, D; Gadre, S; Bruckman, D; Duggal, A				Siuba, Matthew T.; Sadana, Divyajot; Gadre, Shruti; Bruckman, David; Duggal, Abhijit			Acute respiratory distress syndrome readmissions: A nationwide cross-sectional analysis of epidemiology and costs of care	PLOS ONE			English	Article							30-DAY READMISSION; MORTALITY-RATES; SURVIVORS; OUTCOMES; ARDS; PREDICTORS; DISCHARGE	Background Acute Respiratory Distress Syndrome affects approximately 10% of patients admitted to intensive care units internationally, with as many as 40%-52% of patients reporting re-hospitalization within one year. Research question/aim To describe the epidemiology of patients with acute respiratory distress syndrome who require 30-day readmission, and to describe associated costs. Study design and methods A cross-sectional analysis of the 2016 Healthcare Cost and Utilization Project's Nationwide Readmission Database, which is a population-based administrative database which includes discharge data from U.S. hospitals. Inclusion criteria: hospital discharge records for adults age > 17 years old, with a diagnosis of ARDS on index admission, with associated procedure codes for endotracheal intubation and/or invasive mechanical ventilation, who were discharged alive. Primary exposure is adult hospitalization for meeting criteria as described. The primary outcome measure is 30-day readmission rate, as well as patient characteristics and time distribution of readmissions. Results Nationally, 25,170 admissions meeting criteria were identified. Index admission mortality rate was 37.5% (95% confidence interval [CI], 36.2-38.8). 15,730 records of those surviving hospitalization had complete discharge information. 30-day readmission rate was 18.4%, with 14% of total readmissions occurring within 2 calendar days of discharge; these early readmissions had higher mortality risk (odds ratio 1.82, 95% CI 1.05-6.56) compared with readmission in subsequent days. For the closest all-cause readmission within 30 days, the mean cost was $26,971, with a total national cost of over $75.6 million. Interpretation Thirty-day readmission occurred in 18.4% of patients with acute respiratory distress syndrome in this sample, and early readmission is strongly associated with increased mortality compared to late readmission. Further research is needed to clarify whether the rehospitalizations or associated mortalities are preventable.	[Siuba, Matthew T.; Gadre, Shruti; Duggal, Abhijit] Cleveland Clin, Resp Inst, Dept Crit Care Med, Cleveland, OH USA; [Sadana, Divyajot] Univ Toronto, Dept Crit Care Med, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Sadana, Divyajot] Univ Toronto, Interdepartmental Div Crit Care Med, Toronto, ON, Canada; [Bruckman, David] Cleveland Clin, Lerner Res Inst, Dept Quantitat Hlth Sci, Ctr Populat Hlth Res, Cleveland, OH USA	Cleveland Clinic Foundation; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Cleveland Clinic Foundation	Siuba, MT (corresponding author), Cleveland Clin, Resp Inst, Dept Crit Care Med, Cleveland, OH USA.	siubam@ccf.org		Siuba, Matthew/0000-0002-4321-4944				Ahmed SW, 1991, ISSUES ARISING APPL, P6; [Anonymous], 2019, ICDICD 10 CMINTERNAT; [Anonymous], NRD DATABASE DOCUMEN; Arora S, 2017, AM J CARDIOL, V119, P760, DOI 10.1016/j.amjcard.2016.11.022; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Brandstetter S, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0544-5; Brown SM, 2017, THORAX, V72, P1094, DOI 10.1136/thoraxjnl-2017-210337; Burns EM, 2012, J PUBLIC HEALTH-UK, V34, P138, DOI 10.1093/pubmed/fdr054; Cheung AM, 2006, AM J RESP CRIT CARE, V174, P538, DOI 10.1164/rccm.200505-693OC; Gacutan K., HEALTHCARE COST UTIL, P79; Gadre SK, 2019, CHEST, V155, P483, DOI 10.1016/j.chest.2018.12.008; Gelman A, 2012, J RES EDUC EFF, V5, P189, DOI 10.1080/19345747.2011.618213; Hauschildt KE, 2020, CRIT CARE MED, V48, P1103, DOI 10.1097/CCM.0000000000004378; Herridge Margaret S, 2011, N Engl J Med, V364, P1293, DOI 10.1056/NEJMoa1011802; Ho KS, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.congress-2019.OA3297; Maca J, 2017, RESP CARE, V62, P113, DOI 10.4187/respcare.04716; Mayr FB, 2017, JAMA-J AM MED ASSOC, V317, P530, DOI 10.1001/jama.2016.20468; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Ruhl AP, 2017, INTENS CARE MED, V43, P980, DOI 10.1007/s00134-017-4827-8; Ruhl AP, 2017, CRIT CARE MED, V45, P196, DOI 10.1097/CCM.0000000000002088; Shah H, 2020, CUREUS, V12, DOI 10.7759/cureus.8922; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Wodchis WP, 2016, CAN MED ASSOC J, V188, P182, DOI 10.1503/cmaj.150064; Yurkovich M, 2015, J CLIN EPIDEMIOL, V68, P3, DOI 10.1016/j.jclinepi.2014.09.010; Zambon M, 2008, CHEST, V133, P1120, DOI 10.1378/chest.07-2134	28	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2022	17	1							e0263000	10.1371/journal.pone.0263000	http://dx.doi.org/10.1371/journal.pone.0263000			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1B8ZK	35077505	Green Published, gold			2023-01-03	WOS:000792720400054
J	Barbaroux, A; Pourrat, I; Bouchez, T				Barbaroux, Adriaan; Pourrat, Isabelle; Bouchez, Tiphanie			General practitioners and sales representatives: Why are we so ambivalent?	PLOS ONE			English	Article							PHARMACEUTICAL REPRESENTATIVES; INFORMATION; PHYSICIANS; CANADA; VISITS; FRANCE	Introduction Accepting gifts from pharmaceutical sales representatives (sales reps) or meeting them is correlated with excessive, more expensive and sometimes less rational prescribing. French general practitioners (GPs) tend to hold an unfavorable opinion of the pharmaceutical industry, yet the behavior they adopt with sales reps is generally favorable. Until now, no study has sought to explain the reasons for this discrepancy. This study explores GP experiences to better understand their ambivalent behavior. Method This qualitative descriptive study was based on semi-structured face-to-face interviews with French GPs in the south-east of France. An interpretative phenomenological approach was chosen to explore individual professional practices and to model the phenomenon through in-depth analysis of semi-structured interviews. A general inductive analysis was carried out. Data were analyzed by researchers from different disciplines (psychology, sociology and general practice). Results Ten GPs were interviewed for an average of 50 minutes. The analysis revealed three forces that combine to motivate GPs to keep meeting sales reps despite their unfavorable opinion of these visits: practical reasons such as the need for a substitute for continuing education; social and cultural reasons such as courtesy towards representatives; and psychological mechanisms such as cognitive dissonance and a hidden curriculum. Discussion The GP-representative relationship is complex and involves psychological mechanisms that the medical profession often fails to recognize. GPs use reps as a convenient tool for continuing education, particularly in the setting of a private practice where GPs feel pressed for time. Cognitive dissonance is a well-supported theory in social psychology that explains how a person maintains a behavior while having an unfavorable opinion of it. Since GP meetings with sales reps start during their internship, they could also be considered as part of a hidden curriculum. The strength of this work is to combine medical, social psychological and sociological perspectives with the original interpretative phenomenological approach. When the veil is lifted on individual ambivalence, the questions raised are more social and political than individual.	[Barbaroux, Adriaan; Pourrat, Isabelle; Bouchez, Tiphanie] Univ Cote dAzur, Dept Enseignement & Rech Med Gen, RETINES, HLTH, Nice, France; [Barbaroux, Adriaan] Univ Cote dAzur, LAPCOS, Nice, France	UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur	Barbaroux, A (corresponding author), Univ Cote dAzur, Dept Enseignement & Rech Med Gen, RETINES, HLTH, Nice, France.; Barbaroux, A (corresponding author), Univ Cote dAzur, LAPCOS, Nice, France.	adriaan.barbaroux@univ-cotedazur.fr		BARBAROUX, Adriaan/0000-0002-9243-6922				Aim-Eusebi A, 2019, EXERCER, P422; Austad KE, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001037; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Barbaroux A, 2022, THERAPIE, V77, P309, DOI 10.1016/j.therap.2021.09.004; Barbaroux A, 2020, EXERCER, P233; Bardin L., 1989, ANALYSE CONTENU, V5. ed; Beaud S., 2015, GUIDE ENQUETE TERRA; Benkimoun P, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d8309; Blanchet A., 2010, LENTRETIEN; Brocvielle AL, 2009, CERTIFICATION VISITE, P92; Cauchon M., SITE MODULES AUTO AP; Chaput H., 2019, DRESS; Chimonas S, 2007, J GEN INTERN MED, V22, P184, DOI 10.1007/s11606-006-0041-z; Clinckemaillie M., MEDRXIV2021050721255, DOI [10.1101/2021.05.07.21255795, DOI 10.1101/2021.05.07.21255795]; Dusmesnil Helene, 2009, Sante Publique, V21, P355; European Parliamentary Assembly, 2015, PUBL HLTH INT PHARM; Festinger L, 2001, THEORY COGNITIVE DIS; Fickweiler F, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016408; Fischer MA, 2009, J GEN INTERN MED, V24, P795, DOI 10.1007/s11606-009-0989-6; Fournier A, 2012, PHARMACOEPIDEM DR S, V21, P343, DOI 10.1002/pds.3213; Goupil B, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6015; Greffion J., 2015, REV REGULATION CAPIT, DOI [10.4000/regulation.11272, DOI 10.4000/REGULATION.11272]; Guy-Coichard C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224193; Habibi R, 2016, J LAW MED ETHICS, V44, P602, DOI 10.1177/1073110516684803; Hadland SE, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.6007; Haute Autorite de Sante, 2009, ACT INT SANT COMPR P, P181; Haute Autorite de Sante, VIS MED ACC PROF ET; Hermange M., 2006, SENAT COMISSION AFFA; Inspection generale des Affaires Sociales, 2007, RM2007136P INSP GEN, P247; International Prescrire., 2006, REV PRESCRIRE, V15, P154; Kaufmann J-C, 2011, ARMAND COLIN; King M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f264; Larkin I, 2014, HEALTH AFFAIR, V33, P1014, DOI 10.1377/hlthaff.2013.0939; Lempp H, 2004, BMJ-BRIT MED J, V329, P770, DOI 10.1136/bmj.329.7469.770; Lenzer J, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d4007; Lincoln YS, 2013, CONSTRUCTIVIST CREDO, P7; Miles M., 2007, ANALYSE DONNEES QUAL; Mintzes B, 2013, J GEN INTERN MED, V28, P1368, DOI 10.1007/s11606-013-2411-7; Moynihan R, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1505; Mullard A, 2011, LANCET, V377, P890, DOI 10.1016/S0140-6736(11)60334-6; Oude-Engberink A, 2013, EXERCER, V24, P4; PAULHUS DL, 1984, J PERS SOC PSYCHOL, V46, P598, DOI 10.1037/0022-3514.46.3.598; Perraud G, 2021, EXERCER, P328; Pharmaceutical Research and Manufacturers of America, 2008, 2016 IND PROFI; Prosser H, 2003, BRIT J GEN PRACT, V53, P305; Reynolds E, 2018, HEALTH POLICY, V122, P250, DOI 10.1016/j.healthpol.2018.01.010; Rohrbasser A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202616; Rosman S, 2010, PRATIQUES PRESCRIPTI, P117, DOI 10.3917/ehesp.bloy.2010.01.0117; Scheffer P., 2017, PARIS FRANCE UNIVERS, P8; Scheffer P., 2016, PEDAGOGIE MED, V17, P189, DOI [10.1051/pmed/2017001, DOI 10.1051/PMED/2017001]; Scheffer P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168258; Smith J., 2009, INTERPRETATIVE PHENO; Thomas DR, 2006, AM J EVAL, V27, P237, DOI 10.1177/1098214005283748; Torgerson T, 2022, BMJ EVID-BASED MED, V27, P46, DOI 10.1136/bmjebm-2020-111503; van Manen M, 2016, NURS HEALTH SCI, V18, P4, DOI 10.1111/nhs.12274; Vega A, 2012, SCI SOC SANTE, V30, P71, DOI 10.3917/sss.303.0071; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; World Health Organization/Health Action International, 2009, UNDERSTANDING RESPON, V1st	58	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2022	17	1							e0261661	10.1371/journal.pone.0261661	http://dx.doi.org/10.1371/journal.pone.0261661			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZZ4EH	35073342	gold, Green Published			2023-01-03	WOS:000773223800017
J	Ting, S; Zang, WB; Chen, C; Chen, DP				Ting, Shi; Zang, Wenbin; Chen, Chen; Chen, Dapeng			Income distribution and health: What do we know from Chinese data?	PLOS ONE			English	Article							SELF-RATED HEALTH; MORTALITY-RATES; INEQUALITY; INFANT; COUNTRIES	In the last four decades, the problem of income inequality has gradually become one of the most serious social problems in China at both the regional and individual levels. Recently, the central government announced that the main social contradiction is that between people's growing need for a better life and unbalanced and insufficient economic development. In this study, we analyse the effects of income distribution on individuals' health using a series of indicators of income distribution and different measures of individuals' health status. By utilizing data from the China Health and Nutrition Survey (CHNS) from 1989 to 2015, our empirical findings show that self-reported health (SRH), activities of daily living (ADLs), and diabetes mellitus appear to be negatively related to the income share of rich people when average income is equalized among counties, which indicates that individuals' health will deteriorate as the income share of rich people increases. In addition, our results show that there is an inverted U-shaped relationship between income inequality, as measured by the county-level Gini coefficient, and individuals' health status. We also find that income inequality affects health through the accessibility of healthcare facilities and public infrastructures and through hazardous health behaviours such as smoking and alcohol use. These findings suggest that reducing income inequality could be an important means of improving the overall health of China's population.	[Ting, Shi] Southwestern Univ Finance & Econ, Sch Publ Adm, Chengdu, Sichuan, Peoples R China; [Zang, Wenbin] Southwestern Univ Finance & Econ, Sch Insurance, Chengdu, Sichuan, Peoples R China; [Chen, Chen] Shanxi Univ Finance & Econ, Sch Publ Finance & Econ, Taiyuan, Peoples R China; [Chen, Dapeng] Lehigh Univ, Dept Econ, Bethlehem, PA 18015 USA	Southwestern University of Finance & Economics - China; Southwestern University of Finance & Economics - China; Shanxi University Finance & Economics; Lehigh University	Chen, DP (corresponding author), Lehigh Univ, Dept Econ, Bethlehem, PA 18015 USA.	dac320@lehigh.edu						Bakkeli NZ, 2016, SOC SCI MED, V157, P39, DOI 10.1016/j.socscimed.2016.03.041; Blakely TA, 2000, J EPIDEMIOL COMMUN H, V54, P318, DOI 10.1136/jech.54.4.318; Chen Z, 2008, SOC SCI MED, V66, P2206, DOI 10.1016/j.socscimed.2008.01.016; Deaton A, 2003, J ECON LIT, V41, P113, DOI 10.1257/002205103321544710; Fone D, 2013, BRIT J PSYCHIAT, V202, P286, DOI 10.1192/bjp.bp.112.116178; Foster L, 2019, AGEING SOC, V39, P2351, DOI 10.1017/S0144686X1800048X; Gravelle H, 2002, SOC SCI MED, V54, P577, DOI 10.1016/S0277-9536(01)00053-3; GROSSMAN M, 1972, J POLIT ECON, V80, P223, DOI 10.1086/259880; Ichida Y, 2009, SOC SCI MED, V69, P489, DOI 10.1016/j.socscimed.2009.05.006; Jin Feng Y.Y., 2007, EC RES J, V1, P26; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kawachi I, 1997, AM J PUBLIC HEALTH, V87, P1491, DOI 10.2105/AJPH.87.9.1491; Kawachi I, 1999, HEALTH SERV RES, V34, P215; Kennedy BP, 1999, SOC POPULATION HLTH; Li H, 2006, J COMP ECON, V34, P668, DOI 10.1016/j.jce.2006.08.005; Lin YW, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0640-9; Lynch J, 2001, LANCET, V358, P194, DOI 10.1016/S0140-6736(01)05407-1; Mellor JM., 2001, J POLICY ANAL MANAGE, DOI [10.1002/1520-6688(200124)20:13.0.CO;2-H, DOI 10.1002/1520-6688(200124)20:13.0.CO;2-H]; Patel V, 2018, WORLD PSYCHIATRY, V17, P76, DOI 10.1002/wps.20492; Pickett KE, 2015, SOC SCI MED, V128, P316, DOI 10.1016/j.socscimed.2014.12.031; PRESTON SH, 1975, POPUL DEV REV, V1, P189, DOI 10.2307/1972220; Ramos DD, 2017, SOC SCI MED, V181, P17, DOI 10.1016/j.socscimed.2017.03.057; Ribeiro Wagner S., 2009, Rev. Bras. Psiquiatr., V31, pS49, DOI 10.1590/S1516-44462009000600003; RODGERS GB, 1979, POP STUD-J DEMOG, V33, P343, DOI 10.2307/2173539; Rutstein SO, 2000, B WORLD HEALTH ORGAN, V78, P1256; Soobader MJ, 1999, SOC SCI MED, V48, P733, DOI 10.1016/S0277-9536(98)00401-8; Spencer N, 2004, CHILD CARE HLTH DEV, V30, P699, DOI 10.1111/j.1365-2214.2004.00485.x; Subramanian SV, 2004, EPIDEMIOL REV, V26, P78, DOI 10.1093/epirev/mxh003; Vincens N, 2018, SOC SCI MED, V196, P115, DOI 10.1016/j.socscimed.2017.11.025; Wagstaff A, 2000, ANNU REV PUBL HEALTH, V21, P543, DOI 10.1146/annurev.publhealth.21.1.543; WALDMANN RJ, 1992, Q J ECON, V107, P1283, DOI 10.2307/2118389; WILKINSON RG, 1992, AM J PUBLIC HEALTH, V82, P1082, DOI 10.2105/AJPH.82.8.1082; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Xingjian H, 2007, STA RES, V24, P84, DOI [10.3969/j.issn.1002-4565.2007.08.019, DOI 10.3969/J.ISSN.1002-4565.2007.08.019]; Yu Y., 2006, EC PERSPECTIVES, P92	35	1	1	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2022	17	1							e0263008	10.1371/journal.pone.0263008	http://dx.doi.org/10.1371/journal.pone.0263008			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZZ4EH	35073367	gold, Green Published			2023-01-03	WOS:000773223800061
J	Hysong, SJ; Arredondo, K; Hughes, AM; Lester, HF; Oswald, FL; Petersen, LA; Woodard, L; Post, E; DePeralta, S; Murphy, DR; McKnight, J; Nelson, K; Haidet, P				Hysong, Sylvia J.; Arredondo, Kelley; Hughes, Ashley M.; Lester, Houston F.; Oswald, Frederick L.; Petersen, Laura A.; Woodard, LeChauncy; Post, Edward; DePeralta, Shelly; Murphy, Daniel R.; McKnight, Jason; Nelson, Karin; Haidet, Paul			An evidence-based, structured, expert approach to selecting essential indicators of primary care quality	PLOS ONE			English	Article							UNINTENDED CONSEQUENCES; PERFORMANCE-MEASUREMENT; HEALTH-CARE; SYSTEM	Background The purpose of this article is to illustrate the application of an evidence-based, structured performance measurement methodology to identify, prioritize, and (when appropriate) generate new measures of health care quality, using primary care as a case example. Primary health care is central to the health care system and health of the American public; thus, ensuring high quality is essential. Due to its complexity, ensuring high-quality primary care requires measurement frameworks that can assess the quality of the infrastructure, workforce configurations, and processes available. This paper describes the use of the Productivity Measurement and Enhancement System (ProMES) to compile a targeted set of such measures, prioritized according to their contribution and value to primary care. Methods We adapted ProMES to select and rank existing primary care measures according to value to the primary care clinic. Nine subject matter experts (SMEs) consisting of clinicians, hospital leaders and national policymakers participated in facilitated expert elicitation sessions to identify objectives of performance, corresponding measures, and priority rankings. Results The SMEs identified three fundamental objectives: access, patient-health care team partnerships, and technical quality. The SMEs also selected sixteen performance indicators from the 44 pre-vetted, currently existing measures from three different data sources for primary care. One indicator, Team 2-Day Post Discharge Contact Ratio, was selected as an indicator of both team partnerships and technical quality. Indicators were prioritized according to value using the contingency functions developed by the SMEs. Conclusion Our article provides an actionable guide to applying ProMES, which can be adapted to the needs of various industries, including measure selection and modification from existing data sources, and proposing new measures. Future work should address both logistical considerations (e.g., data capture, common data/programming language) and lingering measurement challenges, such as operationalizating measures to be meaningful and interpretable across health care settings.	[Hysong, Sylvia J.; Arredondo, Kelley; Lester, Houston F.; Petersen, Laura A.; Murphy, Daniel R.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX 77030 USA; [Hysong, Sylvia J.; Arredondo, Kelley; Lester, Houston F.; Petersen, Laura A.; Murphy, Daniel R.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA; [Hughes, Ashley M.] Univ Illinois, Dept Biomed & Hlth Informat Sci, Chicago, IL USA; [Hughes, Ashley M.] Edward Hines Jr VA Med Ctr Hines, Ctr Innovat Chron Complex Healthcare, Hines, IL USA; [Oswald, Frederick L.] Rice Univ, Dept Psychol, Houston, TX 77251 USA; [Woodard, LeChauncy] Univ Houston, Coll Med, Dept Hlth Syst & Populat Hlth Sci, Houston, TX USA; [Post, Edward] VA HSR&D Ctr Clin Management Res, Ann Arbor, MI USA; [DePeralta, Shelly] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; [McKnight, Jason] Texas A&M Hlth Sci Ctr, Dept Primary Care & Populat Hlth, Bryan, TX USA; [Nelson, Karin] VA Puget Sound Healthcare Syst, VHA Primary Care Analyt Team, Seattle, WA USA; [Haidet, Paul] Penn State Hlth West Campus Hlth & Wellness Ctr, Hershey, PA USA	Baylor College of Medicine; Baylor College of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rice University; University of Houston System; University of Houston; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Hysong, SJ (corresponding author), Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX 77030 USA.; Hysong, SJ (corresponding author), Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.	hysong@bcm.edu	Hysong, Sylvia/B-8420-2008	Hysong, Sylvia/0000-0002-9063-5207; Oswald, Fred/0000-0002-7275-5408; Arredondo, Kelley/0000-0001-6657-3379	Agency for Healthcare Research and Quality [5R01HS025982-02]; U.S. Department of Veterans Affairs Health Services Research Development [CIN 13-413]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); U.S. Department of Veterans Affairs Health Services Research Development(US Department of Veterans Affairs)	This study was funded by a grant from the Agency for Healthcare Research and Quality (www.ahrq.gov; Grant #5R01HS025982-02) provided to author SJH. The salaries of two of the authors (Hysong, Petersen) were also funded in part by U.S. Department of Veterans Affairs Health Services Research & Development grant #CIN 13-413 awarded to author LAP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2018, DECL AST; [Anonymous], 2008, MANAGING MOTIVATION; Arapovic-Johansson B, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17197285; Assurance NCfQ, 2014, PAT CTR MED HOM PCMH; Becker M, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-017-0669-2; Bodenheimer T, 2014, ANN FAM MED, V12, P166, DOI 10.1370/afm.1616; Campbell SM, 2003, BRIT MED J, V326, P816, DOI 10.1136/bmj.326.7393.816; Coleman K, 2016, AHRQ PUBLICATION NO, V16; Committee on Quality of Health Care in America, 2006, PERFORMANCE MEASUREM; Damschroder LJ, 2014, J GEN INTERN MED, V29, pS877, DOI 10.1007/s11606-014-3020-9; Dawson J., 2019, DEVELOPING EVALUATIN; DeNisi AS, 2017, J APPL PSYCHOL, V102, P421, DOI 10.1037/apl0000085; Donabedian A, 2005, MILBANK Q, V83, P691, DOI 10.1111/j.1468-0009.2005.00397.x; Donaldson MS., 1996, PRIMARY CARE AMERICA, P27; Fry J, 1995, REVIVING PRIMARY CAR, V1st; Hancock PA, 2019, HUM FACTORS, V61, P374, DOI 10.1177/0018720818809590; Hughes AM, 2019, HUM FACTORS, V61, P393, DOI 10.1177/0018720819830553; Hysong SJ., 2021, BJGP OPEN, V5, DOI [10.3399/BJGPO.2020.0185, DOI 10.3399/BJGPO.2020.0185]; Hysong SJ, 2019, IMPLEMENT SCI, V14, DOI 10.1186/s13012-019-0864-8; Hysong SJ, 2019, BMJ QUAL SAF, V28, P405, DOI 10.1136/bmjqs-2018-008856; Hysong SJ, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0335-9; Institute for Healthcare Improvement, SUCC MEAS IMPR 2021; Kansagara D, 2014, J GEN INTERN MED, V29, P607, DOI 10.1007/s11606-013-2764-y; Kringos DS, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-65; Mainz J, 2003, INT J QUAL HEALTH C, V15, P523, DOI 10.1093/intqhc/mzg081; Mannion R, 2012, INTERN MED J, V42, P569, DOI 10.1111/j.1445-5994.2012.02766.x; McCauley L., 2021, IMPLEMENTING HIGH QU, P448; National Health Service, QUALITY OUTCOMES FRA; Pacific WHOROftW, 2006, EL HLTH REC MAN DEV, P78; Patient Centered Primary Care Implementation Work Group, 2011, PAT CTR MED HOM MOD; Philip S, 2019, PATIENT CENTERED MED; Powell AA, 2012, J GEN INTERN MED, V27, P405, DOI 10.1007/s11606-011-1906-3; Pritchard RD, 2012, EVIDENCE BASED PRODU; Pritchard RD., 1990, NATL PROD REV, V9, P257; Pritchard RD, 2008, J APPL PSYCHOL, V93, P540, DOI 10.1037/0021-9010.93.3.540; Ramalho A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220888; Roland M, 2014, NEW ENGL J MED, V370, P1944, DOI 10.1056/NEJMhpr1316051; Shi L, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/432892; TANNENBAUM AS, 1982, BEHAV SCI, V27, P194, DOI 10.1002/bs.3830270212; van der Geer E, 2009, SOC SCI MED, V69, P1523, DOI 10.1016/j.socscimed.2009.08.026; Wagner EH, 2012, GUIDING TRANSFORMATI	41	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2022	17	1							e0261263	10.1371/journal.pone.0261263	http://dx.doi.org/10.1371/journal.pone.0261263			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2G1LZ	35041671	Green Published, gold			2023-01-03	WOS:000813361200011
J	Shahjalal, M; Chakma, SK; Ahmed, T; Yasmin, I; Mahumud, RA; Hossain, A				Shahjalal, Md.; Chakma, Samar Kishor; Ahmed, Tanvir; Yasmin, Irin; Mahumud, Rashidul Alam; Hossain, Ahmed			Prevalence and determinants of using complementary and alternative medicine for the treatment of chronic illnesses: A multicenter study in Bangladesh	PLOS ONE			English	Article							PREDICTORS; PATTERNS; DISEASE	Background While conventional medicine (CM) is commonly used to treat non-communicable diseases (NCDs), complementary and alternative medicine (CAM) is gaining popularity as a health-care option in Bangladesh. We aimed to investigate the prevalence and factors associated with using CAM solely and using CAM in conjunction with CM for chronic illness treatment among NCD patients in Bangladesh. Methods A multicenter cross-sectional study was conducted, including 549 adults with a confirmed chronic illness diagnosis from three tertiary care hospitals in Dhaka city. Interviews were used to gather socio-demographic data, while medical records were used to get information on chronic illnesses. A multinomial logistic regression model was used to determine the associated factors of utilizing CAM primarily and CAM use in conjunction with CM to manage the chronic disease. Results Out of 549 NCD patients (282 women [51.4%], mean [standard deviation] age 45.4 [12.8] years), 180 (32.8%) ever used CAM for the treatment of chronic illness. Also, 15.3% of patients exclusively used CAM among the NCD patients, while 17.5% used CAM in conjunction with CM. Homeopathy medicine was the most prevalent type of treatment among CAM users (52.2%). Furthermore, 55.5% of CAM users said they used it due to its less adverse effects, and 41.6% trusted its effectiveness for chronic illness. Elderly patients (>= 60 years) preferred CAM in complementary with CM, but they did not rely only on CAM. According to the multinomial regression analysis, unmarried patients, predominantly in the younger age group, adopted CAM significantly for chronic illness treatment (Relative risk ratio, RRR = 0.29, 95% CI = 0.12-0.71, reference = Unmarried). Patients in the high-income group used CAM in conjunction with CM (RRR = 6.26, 95% CI = 1.35-18.90, reference: low-income), whereas patients in the high-income group did not rely on CAM alone (RRR = 0.99, 95% CI = 0.34-2.85). Conclusion Although CM remains the mainstream of health care in Bangladesh, CAM services play an essential role in people's health care, particularly in treating chronic illnesses. Physicians of Bangladesh should be aware that their patients may be using other services and be prepared to ask and answer questions regarding the risks and benefits of using CAM in addition to regular medical care. Thus, clinicians required to follow best-practice guidelines, which are currently not practiced in Bangladesh, when disseminating information regarding integrative techniques that combine CM and CAM approaches.	[Shahjalal, Md.; Chakma, Samar Kishor; Ahmed, Tanvir; Yasmin, Irin; Hossain, Ahmed] North South Univ, Dept Publ Hlth, Dhaka, Bangladesh; [Shahjalal, Md.; Chakma, Samar Kishor; Ahmed, Tanvir; Yasmin, Irin] Res Rats, Dhaka, Bangladesh; [Mahumud, Rashidul Alam] Univ Sydney, Fac Med & Hlth, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia; [Mahumud, Rashidul Alam] Univ Southern Queensland, Sch Business, Toowoomba, Qld, Australia; [Mahumud, Rashidul Alam] Univ Southern Queensland, Ctr Hlth Res, Toowoomba, Qld, Australia; [Hossain, Ahmed] North South Univ, Global Hlth Inst, Dhaka, Bangladesh	North South University (NSU); University of Sydney; University of Southern Queensland; University of Southern Queensland; North South University (NSU)	Hossain, A (corresponding author), North South Univ, Dept Publ Hlth, Dhaka, Bangladesh.; Hossain, A (corresponding author), North South Univ, Global Hlth Inst, Dhaka, Bangladesh.	ahmed.hossain@utoronto.ca	SHAHJALAL, MD./AAC-8316-2021; Hossain, Ahmed/H-4406-2012; Mahumud, Dr Rashidul Alam/O-2477-2018	SHAHJALAL, MD./0000-0002-2218-8433; Hossain, Ahmed/0000-0003-4575-1273; Yasmin, Irin/0000-0003-2731-0343; Chakma, Samar Kishor/0000-0002-2351-3648; Mahumud, Dr Rashidul Alam/0000-0001-9788-1868				Alam D., 2013, HLTH SYSTEMS PREPARE, P1; Althoff KN, 2016, CURR OPIN HIV AIDS, V11, P527, DOI 10.1097/COH.0000000000000305; [Anonymous], WHO FACT SHEETS 2021; [Anonymous], 2019, WHO GLOBAL REPORT TR; Barnes Patricia M, 2004, Adv Data, P1; Bodeker G, 2002, AM J PUBLIC HEALTH, V92, P1582, DOI 10.2105/AJPH.92.10.1582; Camey SA, 2014, CAD SAUDE PUBLICA, V30, P21, DOI 10.1590/0102-311X00077313; Chen FP, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-26; Chung VCH, 2021, INTEGR MED RES, V10, DOI 10.1016/j.imr.2020.100469; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2000, COMPLEMENT THER MED, V8, P32, DOI 10.1016/S0965-2299(00)90833-1; Habib SH, 2010, DIABETES METAB SYND, V4, P41, DOI 10.1016/j.dsx.2008.04.005; Haque MI, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2129-5; Hasan Syed Shahzad, 2009, Complement Ther Clin Pract, V15, P152, DOI 10.1016/j.ctcp.2009.02.003; Hughes GD, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/736074; Kadayat TM, 2012, J PUBLIC HEALTH-HEID, V20, P297, DOI 10.1007/s10389-011-0446-y; Lee GBW, 2004, FAM PRACT, V21, P654, DOI 10.1093/fampra/cmh613; Metcalfe A, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-58; Nailwal D, 2021, J PUBLIC HEALTH RES, V10, DOI 10.4081/jphr.2021.2109; Peltzer K, 2015, STUD ETHNO-MED, V9, P209, DOI 10.1080/09735070.2015.11905437; Prince MJ, 2015, LANCET, V385, P549, DOI 10.1016/S0140-6736(14)61347-7; Rafi MA, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-03021-3; Shaikh BT, 2005, EVID-BASED COMPL ALT, V2, P139, DOI 10.1093/ecam/neh088; Shorofi SA, 2017, COMPLEMENT THER CLIN, V27, P37, DOI 10.1016/j.ctcp.2017.03.001; World Health Organization, 2019, NONC DIS NCD; Xin BL, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-02910-x; Yamashita H, 2002, COMPLEMENT THER MED, V10, P84, DOI 10.1054/ctim.2002.0519	27	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2022	17	1							e0262221	10.1371/journal.pone.0262221	http://dx.doi.org/10.1371/journal.pone.0262221			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZO8DB	34986159	gold, Green Published			2023-01-03	WOS:000765956200024
J	Hiramoto, S; Asano, H; Miyamoto, T; Takegami, M; Kawabata, A				Hiramoto, Shiori; Asano, Hajime; Miyamoto, Tomoyoshi; Takegami, Manabu; Kawabata, Atsufumi			Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan	PLOS ONE			English	Article							QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; DULOXETINE; BREAST; NEUROTOXICITY; GOSHAJINKIGAN; ASSOCIATION; CARBOPLATIN; IMPACT; OLDER	Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse reaction in cancer patients treated with several cytotoxic anticancer agents including paclitaxel. Duloxetine, an antidepressant known as a serotonin-noradrenalin reuptake inhibitor, is the only agent that has moderate evidence for the use to treat painful CIPN. The present retrospective cohort study aimed to analyze risk factors for paclitaxel-induced peripheral neuropathy (PIPN), and investigate ongoing prescription drug use for PIPN in Japan. Female breast and gynecologic cancer patients who underwent paclitaxel-based chemotherapy at a single center in Japan between January 2016 and December 2019 were enrolled in this study. Patients' information obtained from electronic medical records were statistically analyzed to test possible risk factors on PIPN diagnosis. Patients' age, total paclitaxel dose, the history of female hormone-related diseases, hypertension and body mass index (BMI), but not additional platinum agents, were significantly associated with increased PIPN diagnosis. Drugs prescribed for PIPN included duloxetine, pregabalin, mecobalamin and Goshajinkigan, a polyherbal medicine, regardless of poor evidence for their effectiveness against CIPN, and were greatly different between breast and gynecologic cancer patients diagnosed with PIPN at the departments of Surgery and Gynecology, respectively. Thus, older age, greater total paclitaxel dose, the history of estrogen-related diseases, hypertension and BMI are considered risk factors for PIPN in paclitaxel-based chemotherapy of female cancer patients. It appears an urgent need to establish a guideline of evidence-based pharmacotherapy for PIPN.	[Hiramoto, Shiori; Miyamoto, Tomoyoshi; Kawabata, Atsufumi] Kindai Univ, Fac Pharm, Div Pharmacol & Pathophysiol, Higashiosaka, Osaka, Japan; [Hiramoto, Shiori; Asano, Hajime; Takegami, Manabu] Kindai Univ Hosp, Div Pharm, Osakasayama, Japan	Kindai University (Kinki University)	Kawabata, A (corresponding author), Kindai Univ, Fac Pharm, Div Pharmacol & Pathophysiol, Higashiosaka, Osaka, Japan.	kawabata@phar.kindai.ac.jp						Alejandro LM, 2013, AM J CLIN ONCOL-CANC, V36, P331, DOI 10.1097/COC.0b013e318246b50d; Barginear M, 2019, ONCOLOGIST, V24, P617, DOI 10.1634/theoncologist.2018-0298; Chantalat E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082815; Dolan ME, 2017, CLIN CANCER RES, V23, P5757, DOI 10.1158/1078-0432.CCR-16-3224; Domoto R, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10081881; Driessen CML, 2012, SUPPORT CARE CANCER, V20, P877, DOI 10.1007/s00520-011-1336-0; Fattori V, 2020, PAIN, V161, P1321, DOI 10.1097/j.pain.0000000000001832; Ghoreishi Z, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4869-5; Greenwald MK, 2019, CANCER-AM CANCER SOC, V125, P269, DOI 10.1002/cncr.31798; Hershman DL, 2016, J CLIN ONCOL, V34, P3014, DOI 10.1200/JCO.2015.66.2346; Hertz DL, 2021, CANCER TREAT REV, V99, DOI 10.1016/j.ctrv.2021.102241; Hirayama Y, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000053; Hirayama Y, 2015, INT J CLIN ONCOL, V20, P866, DOI 10.1007/s10147-015-0810-y; Hoshino N, 2018, INT J CLIN ONCOL, V23, P434, DOI 10.1007/s10147-017-1229-4; Jordan B, 2019, BREAST CARE, V14, P79, DOI 10.1159/000499599; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kono T, 2013, CANCER CHEMOTH PHARM, V72, P1283, DOI 10.1007/s00280-013-2306-7; Kuriyama A, 2018, SUPPORT CARE CANCER, V26, P1051, DOI 10.1007/s00520-017-4028-6; Liu ZM, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00495; Loibl S, 2018, LANCET ONCOL, V19, P497, DOI 10.1016/S1470-2045(18)30111-6; Loprinzi CL, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01399; Mielke S, 2005, CLIN CANCER RES, V11, P4843, DOI 10.1158/1078-0432.CCR-05-0298; Miyamoto T, 2021, J PHARMACOL SCI, V146, P49, DOI 10.1016/j.jphs.2021.03.001; Mols F, 2014, SUPPORT CARE CANCER, V22, P2261, DOI 10.1007/s00520-014-2255-7; Otake A, 2015, ANTICANCER RES, V35, P359; Salat K, 2020, PHARMACOL REP, V72, P486, DOI 10.1007/s43440-020-00109-y; Schloss JM, 2017, SUPPORT CARE CANCER, V25, P195, DOI 10.1007/s00520-016-3404-y; Schloss JM, 2015, SUPPORT CARE CANCER, V23, P1843, DOI 10.1007/s00520-015-2725-6; Sekiguchi F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010367; Sekiguchi F, 2018, NEUROPHARMACOLOGY, V141, P201, DOI 10.1016/j.neuropharm.2018.08.040; Sikov WM, 2015, J CLIN ONCOL, V33, P13, DOI 10.1200/JCO.2014.57.0572; Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813; Tew WP, 2014, J CLIN ONCOL, V32, P2553, DOI 10.1200/JCO.2014.55.3073; Tsubota M, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1581-6; Xu JL, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6660087; Yang QW, 2016, REPROD SCI, V23, P163, DOI 10.1177/1933719115584449	36	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2021	16	12							e0261473	10.1371/journal.pone.0261473	http://dx.doi.org/10.1371/journal.pone.0261473			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ9AO	34972132	gold, Green Published			2023-01-03	WOS:000773555700036
J	Ramacciotti, E; Agati, LB; Calderaro, D; Aguiar, VCR; Spyropoulos, AC; de Oliveira, CCC; dos Santos, JL; Volpiani, GG; Sobreira, ML; Joviliano, EE; Bohatch, MS; da Fonseca, BAL; Ribeiro, MS; Dusilek, C; Itinose, K; Sanches, SMV; Ramos, KDA; de Moraes, NF; Tierno, PFGMM; de Oliveira, ALML; Tachibana, A; Chate, RC; Santos, MVB; Cavalcante, BBD; Moreira, RCR; Chang, C; Tafur, A; Fareed, J; Lopes, RD; Investigators, M				Ramacciotti, Eduardo; Agati, Leandro Barile; Calderaro, Daniela; Resende Aguiar, Valeria Cristina; Spyropoulos, Alex C.; Carvalho de Oliveira, Caroline Candida; dos Santos, Jessica Lins; Volpiani, Giuliano Giova; Sobreira, Marcone Lima; Joviliano, Edwaldo Edner; Bohatch Junior, Milton Sergio; Lopes da Fonseca, Benedito Antonio; Ribeiro, Mauricio Serra; Dusilek, Cesar; Itinose, Kengi; Viana Sanches, Suzanna Maria; Araujo Ramos, Karine de Almeida; de Moraes, Nara Franzin; Morando Marzocchi Tierno, Paulo Fernando Guimaraes; Malavasi Longo de Oliveira, Andre Luiz; Tachibana, Adriano; Chate, Rodrigo Caruso; Barbosa Santos, Marcus Vinicius; de Menezes Cavalcante, Bruno Bezerra; Rocha Moreira, Ricardo Cesar; Chang, Chiann; Tafur, Alfonso; Fareed, Jawed; Lopes, Renato D.; Investigators, Michelle			Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial	LANCET			English	Article							ILL; PROPHYLAXIS	Background Patients hospitalised with COVID-19 are at risk for thrombotic events after discharge; the role of extended thromboprophylaxis in this population is unknown. Methods In this open-label, multicentre, randomised trial conducted at 14 centres in Brazil, patients hospitalised with COVID-19 at increased risk for venous thromboembolism (International Medical Prevention Registry on Venous Thromboembolism [IMPROVE] venous thromboembolism [VTE] score of >= 4 or 2-3 with a D-dimer >500 ng/mL) were randomly assigned (1:1) to receive, at hospital discharge, rivaroxaban 10 mg/day or no anticoagulation for 35 days. The primary efficacy outcome in an intention-to-treat analysis was a composite of symptomatic or fatal venous thromboembolism, asymptomatic venous thromboembolism on bilateral lower-limb venous ultrasound and CT pulmonary angiogram, symptomatic arterial thromboembolism, and cardiovascular death at day 35. Adjudication was blinded. The primary safety outcome was major bleeding. The primary and safety analyses were carried out in the intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT04662684. Findings From Oct 8, 2020, to June 29, 2021, 997 patients were screened. Of these patients, 677 did not meet eligibility criteria; the remaining 320 patients were enrolled and randomly assigned to receive rivaroxaban (n=160 [50%]) or no anticoagulation (n=160 [50%]). All patients received thromboprophylaxis with standard doses of heparin during hospitalisation. 165 (52%) patients were in the intensive care unit while hospitalised. 197 (62%) patients had an IMPROVE score of 2-3 and elevated D-dimer levels and 121 (38%) had a score of 4 or more. Two patients (one in each group) were lost to follow-up due to withdrawal of consent and not included in the intention-to-treat primary analysis. The primary efficacy outcome occurred in five (3%) of 159 patients assigned to rivaroxaban and 15 (9%) of 159 patients assigned to no anticoagulation (relative risk 0.33, 95% CI 0.12-0.90; p=0.0293). No major bleeding occurred in either study group. Allergic reactions occurred in two (1%) patients in the rivaroxaban group. Interpretation In patients at high risk discharged after hospitalisation due to COVID-19, thromboprophylaxis with rivaroxaban 10 mg/day for 35 days improved clinical outcomes compared with no extended thromboprophylaxis. Copyright (C) 2021 Published by Elsevier Ltd. All rights reserved.	[Ramacciotti, Eduardo; Agati, Leandro Barile; Resende Aguiar, Valeria Cristina; Carvalho de Oliveira, Caroline Candida; dos Santos, Jessica Lins] Sci Valley Res Inst, BR-04551010 Sao Paulo, Brazil; [Ramacciotti, Eduardo; Resende Aguiar, Valeria Cristina; Carvalho de Oliveira, Caroline Candida; Volpiani, Giuliano Giova] Hosp & Maternidade Christovao Gama, Grp Leforte, Santo Andre, SP, Brazil; [Calderaro, Daniela] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Coracao,Unidade Med Interdisciplinar Cardiol, Sao Paulo, Brazil; [Spyropoulos, Alex C.] Zucker Sch Med Hohtra, Northwell & Feinstein Inst Med Res, Manhasset, NY USA; [Spyropoulos, Alex C.] IM Sechenov First Moscow State Med Univ, Dept Obstet & Gynecol, Moscow, Russia; [Sobreira, Marcone Lima] Univ Estadual Paulista, Botucatu, SP, Brazil; [Joviliano, Edwaldo Edner; Bohatch Junior, Milton Sergio; Lopes da Fonseca, Benedito Antonio; Ribeiro, Mauricio Serra] Univ Sao Paulo, Hosp Clin Ribeirao Preto, Med Sch, Ribeirao Preto, Brazil; [Dusilek, Cesar; Itinose, Kengi] Hosp Rocio, Campo Largo, Parana, Brazil; [Viana Sanches, Suzanna Maria; Araujo Ramos, Karine de Almeida] Inst Couto Maia, Salvador, BA, Brazil; [de Moraes, Nara Franzin; Morando Marzocchi Tierno, Paulo Fernando Guimaraes] Hosp Municipal Barueri, Sao Paulo, Brazil; [Malavasi Longo de Oliveira, Andre Luiz] Sao Paulo State Publ Womens Hlth Reference Ctr, Sao Paulo, Brazil; [Tachibana, Adriano; Chate, Rodrigo Caruso] Hosp Israelita Albert Einstein, Sao Paulo, Brazil; [Barbosa Santos, Marcus Vinicius] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Coracao, Sao Paulo, Brazil; [de Menezes Cavalcante, Bruno Bezerra] Inst Teaching & Res Hapvida, Fortaleza, Ceara, Brazil; [Rocha Moreira, Ricardo Cesar] Hosp Nossa Senhora Gracas, Curitiba, Parana, Brazil; [Chang, Chiann] Univ Sao Paulo, Inst Math & Stat, Dept Stat, Sao Paulo, Brazil; [Tafur, Alfonso] Northshore Univ Hlth Syst, Chicago, IL USA; [Fareed, Jawed] Loyola Univ Med Ctr, Hemostasis & Thrombosis Res Labs, Maywood, IL 60153 USA; [Lopes, Renato D.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA	Universidade de Sao Paulo; Sechenov First Moscow State Medical University; Universidade Estadual Paulista; Universidade de Sao Paulo; Hospital Israelita Albert Einstein; Universidade de Sao Paulo; Universidade de Sao Paulo; NorthShore University Health System; Loyola University Chicago; Duke University	Ramacciotti, E (corresponding author), Sci Valley Res Inst, BR-04551010 Sao Paulo, Brazil.	ramacciotti@svriglobal.com	Sobreira, Marcone Lima/B-1337-2014	Sobreira, Marcone Lima/0000-0003-2271-5878	Bayer	Bayer(Bayer AG)	Bayer.	Cohen AT, 2016, NEW ENGL J MED, V375, P534, DOI 10.1056/NEJMoa1601747; Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096; Cohen SL, 2021, THROMB HAEMOSTASIS, V121, P1043, DOI 10.1055/a-1366-9656; Gerotziafas GT, 2020, THROMB HAEMOSTASIS, V120, P1597, DOI 10.1055/s-0040-1715798; Giannis D, 2021, BLOOD, V137, P2838, DOI 10.1182/blood.2020010529; Giannis D, 2020, BLOOD, V136, DOI 10.1182/blood-2020-141901; Goldhaber SZ, 2011, NEW ENGL J MED, V365, P2167, DOI 10.1056/NEJMoa1110899; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x; Hull RD, 2010, ANN INTERN MED, V153, P8, DOI 10.7326/0003-4819-153-1-201007060-00004; Kaatz S, 2015, J THROMB HAEMOST, V13, P2119, DOI 10.1111/jth.13140; Lopes RD, 2021, LANCET, V397, P2253, DOI 10.1016/S0140-6736(21)01203-4; Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559; Patell R, 2020, BLOOD, V136, P1342, DOI 10.1182/blood.2020007938; Ramacciotti E, 2021, AM HEART J, V242, P115, DOI 10.1016/j.ahj.2021.08.016; Raskob GE, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.019459; Roberts LN, 2020, BLOOD, V136, P1347, DOI 10.1182/blood.2020008086; Spyropoulos AC, 2020, J AM COLL CARDIOL, V75, P3140, DOI 10.1016/j.jacc.2020.04.071; Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929; Spyropoulos AC, 2018, NEW ENGL J MED, V379, P1118, DOI 10.1056/NEJMoa1805090; Tritschler T, 2020, J THROMB HAEMOST, V18, P2958, DOI 10.1111/jth.15094	21	57	58	6	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2022	399	10319					50	59		10.1016/S0140-6736(21)02392-8	http://dx.doi.org/10.1016/S0140-6736(21)02392-8		DEC 2021	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA3YW	34921756	Green Published, Bronze			2023-01-03	WOS:000738273800020
J	Eisenberg, MD; McCourt, A; Stuart, EA; Rutkow, L; Tormohlen, KN; Fingerhood, MI; Quintero, L; White, SA; McGinty, EE				Eisenberg, Matthew D.; McCourt, Alexander; Stuart, Elizabeth A.; Rutkow, Lainie; Tormohlen, Kayla N.; Fingerhood, Michael I.; Quintero, Luis; White, Sarah A.; McGinty, Emma Elizabeth			Studying how state health services delivery policies can mitigate the effects of disasters on drug addiction treatment and overdose: Protocol for a mixed-methods study	PLOS ONE			English	Article							SUBSTANCE USE DISORDERS; MENTAL-HEALTH; CLIMATE-CHANGE; PRIMARY-CARE; RELAPSE; PERSPECTIVES; CHALLENGES; BARRIERS; STIGMA; ABUSE	Background The United States is experiencing a drug addiction and overdose crisis, made worse by the COVID-19 pandemic. Relative to other types of health services, addiction treatment and overdose prevention services are particularly vulnerable to disaster-related disruptions for multiple reasons including fragmentation from the general medical system and stigma, which may lead decisionmakers and providers to de-prioritize these services during disasters. In response to the COVID-19 pandemic, U.S. states implemented multiple policies designed to mitigate disruptions to addiction treatment and overdose prevention services, for example policies expanding access to addiction treatment delivered via telehealth and policies designed to support continuity of naloxone distribution programs. There is limited evidence on the effects of these policies on addiction treatment and overdose. This evidence is needed to inform state policy design in future disasters, as well as to inform decisions regarding whether to sustain these policies post-pandemic. Methods The overall study uses a concurrent-embedded design. Aims 1-2 use difference-in-differences analyses of large-scale observational databases to examine how state policies designed to mitigate the effects of the COVID-19 pandemic on health services delivery influenced addiction treatment delivery and overdose during the pandemic. Aim 3 uses a qualitative embedded multiple case study approach, in which we characterize local implementation of the state policies of interest; most public health disaster policies are enacted at the state level but implemented at the local level by healthcare systems and local public health authorities. Discussion Triangulation of results across methods will yield robust understanding of whether and how state disaster-response policies influenced drug addiction treatment and overdose during the COVID-19 pandemic. Results will inform policy enactment and implementation in future public health disasters. Results will also inform decisions about whether to sustain COVID-19 pandemic-related changes to policies governing delivery addiction and overdose prevention services long-term.	[Eisenberg, Matthew D.; McCourt, Alexander; Rutkow, Lainie; Tormohlen, Kayla N.; White, Sarah A.; McGinty, Emma Elizabeth] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA; [Fingerhood, Michael I.] Johns Hopkins Univ, Sch Med, Div Addict Med, Baltimore, MD USA; [Quintero, Luis] Johns Hopkins Univ, Carey Business Sch, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University	McGinty, EE (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA.	bmcginty@jhu.edu	Quintero, Luis/GON-5725-2022	Quintero, Luis/0000-0002-8534-8860; White, Sarah/0000-0003-1373-1809; Eisenberg, Matthew/0000-0002-8395-1877				Alexander G. C., 2020, EPIDEMIC MIDST PANDE; Allen B, 2019, SUBST ABUS, V40, P459, DOI 10.1080/08897077.2019.1640833; American Medical Association, 2020, TAK ACT OP US DIS PA; Borusyak K., 2021, ARXIV210812419; Bradizza CM, 2006, CLIN PSYCHOL REV, V26, P162, DOI 10.1016/j.cpr.2005.11.005; Butler SM, 2020, JAMA-J AM MED ASSOC, V323, P2450, DOI [10.1001/jamahealthforum.2020.0478, 10.1001/jama.2020.8484]; Cairncross Zoe F, 2018, CMAJ Open, V6, pE478, DOI 10.9778/cmajo.20180084; Callaway B, 2021, J ECONOMETRICS, V225, P200, DOI 10.1016/j.jeconom.2020.12.001; Cameron AC, 2011, J BUS ECON STAT, V29, P238, DOI 10.1198/jbes.2010.07136; Carriere G, 2018, HEALTH REP, V29, P23; Centers for Disease Control and Prevention, PROVISIONAL DRUG OVE; Centers for Disease Control and Prevention, DIS EP RESP; Clarke PB, 2020, J COUNS DEV, V98, P17, DOI 10.1002/jcad.12296; Czeisler ME, 2020, MMWR-MORBID MORTAL W, V69, P1049, DOI [10.1101/2020.04.22.20076141v1, 10.15585/mmwr.mm6932a1]; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Davoli M, 2007, ADDICTION, V102, P1954, DOI 10.1111/j.1360-0443.2007.02025.x; Fiellin DA., 2020, EPIDEMICS COLLIDE CO; Frumkin H, 2008, AM J PUBLIC HEALTH, V98, P435, DOI 10.2105/AJPH.2007.119362; Gardner J, 2 STAGE DIFFERENCES; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Goodman-Bacon A, 2021, J ECONOMETRICS, V225, P254, DOI 10.1016/j.jeconom.2021.03.014; Gostin LO, 2003, PUBLIC HEALTH REP, V118, P477, DOI 10.1016/S0033-3549(04)50280-7; Grecu AM, 2019, APPL ECON, V51, P5972, DOI 10.1080/00036846.2019.1644448; Haines A, 2006, PUBLIC HEALTH, V120, P585, DOI 10.1016/j.puhe.2006.01.002; Harvey JB, 2019, TELEMED E-HEALTH, V25, P132, DOI 10.1089/tmj.2017.0265; Henkel Dieter, 2011, Curr Drug Abuse Rev, V4, P4; Hodge JG, 2007, JAMA-J AM MED ASSOC, V297, P1708, DOI 10.1001/jama.297.15.1708; Hodge JG, 2010, STLOUIS U J HLTH LAW, V4, P33; Hodgkin D, 2003, MED CARE RES REV, V60, P101, DOI 10.1177/1077558702250248; Jennings GR, 2005, TOURISM RESEARCH METHODS: INTEGRATING THEORY WITH PRACTICE, P99, DOI 10.1079/9780851999968.0099; Kennedy-Hendricks A, 2016, DRUG ALCOHOL DEPEN, V165, P61, DOI 10.1016/j.drugalcdep.2016.05.010; Kraetschmer NM, 2009, TELEMED J E-HEALTH, V15, P655, DOI 10.1089/tmj.2009.0004; Krieger MS, 2018, INT J DRUG POLICY, V61, P52, DOI 10.1016/j.drugpo.2018.09.009; Leech BL, 2002, PS, V35, P665, DOI 10.1017/S1049096502001129; Levander X, 2020, STAT-US; Lewis CB, 2015, U MEMPHIS LAW REV, V46, P471; Lindert J, 2018, EUR J PUBLIC HEALTH, V28, P986, DOI 10.1093/eurpub/cky139; Madras BK., 2020, NAM PERSPECTIVES; Matusow H, 2018, SUBST USE MISUSE, V53, P206, DOI 10.1080/10826084.2016.1267225; McClure B, 2014, J URBAN HEALTH, V91, P999, DOI 10.1007/s11524-014-9904-5; McGinty EE, 2020, NEW ENGL J MED, V382, P1291, DOI 10.1056/NEJMp2000227; Mealer Meredith, 2014, Nurse Res, V21, P32, DOI 10.7748/nr2014.03.21.4.32.e1229; Miller GE, 2018, STAT BRIEF MED EXPEN; Molina KM, 2012, DRUG ALCOHOL DEPEN, V125, pS35, DOI 10.1016/j.drugalcdep.2012.05.027; National Academies of Sciences EaM, 2019, MED OP US DIS SAV LI; Neufeld JD, 2016, TELEMED E-HEALTH, V22, P70, DOI 10.1089/tmj.2015.0044; Newhouse JP, 1993, FREE ALL LESSONS RAN; O'Connor PG, 2011, ANN INTERN MED, V154, P56, DOI 10.7326/0003-4819-154-1-201101040-00008; OptumLabs, 2020, OPTUMLABS OPT DAT WA; Panebianco D, 2016, INT J DRUG POLICY, V27, P146, DOI 10.1016/j.drugpo.2015.09.009; Patton M. Q, 2014, SAGE; Patton M. Q., 2002, QUALITATIVE RES EVAL, V3rd; Podulka J, COMMONWEALTH FUND IS; Richter L., 2019, STIGMA ADDICTION, P93; Rubin HJ., 2011, QUALITATIVE INTERVIE; Rutkow L, 2014, AM J PUBLIC HEALTH, V104, P1601, DOI 10.2105/AJPH.2014.301948; Rutkow L, 2012, PSYCHIAT SERV, V63, P7, DOI 10.1176/appi.ps.2012000p7; Saloner B, 2018, PUBLIC HEALTH REP, V133, p24S, DOI 10.1177/0033354918793627; Saloner B, 2018, NEW ENGL J MED, V379, P4, DOI 10.1056/NEJMp1804059; Scott CK, 2018, ADDICT BEHAV, V82, P72, DOI 10.1016/j.addbeh.2018.02.025; Sommers BD, 2015, NEW ENGL J MED, V373, P2395, DOI 10.1056/NEJMp1509462; Spradley J.P., 1979, ETHNOGRAPHIC INTERVI; Stone EA, 2019, 2019 NIDA ADD HLTH S; Substance Abuse and Mental Health Services Administration, HHS PUBL NO PEP20 07; Substance Abuse and Mental Health Services Administration, FAQS PROV METH BUPR; Sun LY, 2021, J ECONOMETRICS, V225, P175, DOI 10.1016/j.jeconom.2020.09.006; Thomas EE, 2022, J TELEMED TELECARE, V28, P301, DOI 10.1177/1357633X20960638; Townley C., 2017, NATL ACAD STATE HLTH, V2017, P1; van Boekel LC, 2013, DRUG ALCOHOL DEPEN, V131, P23, DOI 10.1016/j.drugalcdep.2013.02.018; Wagenaar A, 2013, PUBLIC HLTH LAW RES; Wakeman SE, 2018, SUBST USE MISUSE, V53, P330, DOI 10.1080/10826084.2017.1363238; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Walsh L, 2015, DISASTER MED PUBLIC, V9, P403, DOI 10.1017/dmp.2015.44; Wosik J, 2020, J AM MED INFORM ASSN, V27, P957, DOI 10.1093/jamia/ocaa067; Yarmolinsky A., 1995, FEDERAL REGULATION M; Yoo HI., 2020, VCE2WAY STATA MODULE	76	1	1	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2021	16	12							e0261115	10.1371/journal.pone.0261115	http://dx.doi.org/10.1371/journal.pone.0261115			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY9FU	34914779	Green Published, gold			2023-01-03	WOS:000755091500050
J	Teakell, JM; Molony, DA				Teakell, Jade M.; Molony, Donald A.			In afebrile men with UTIs, 7 d of ciprofloxacin or trimethoprim-sulfamethoxazole was noninferior to 14 d	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Teakell, Jade M.; Molony, Donald A.] Univ Texas Houston, McGovern Med Sch, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Teakell, JM (corresponding author), Univ Texas Houston, McGovern Med Sch, Houston, TX 77030 USA.							Crellin E, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k341; Drekonja DM, 2013, JAMA INTERN MED, V173, P62, DOI 10.1001/2013.jamainternmed.829	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC	2021	174	12					JC141	JC141		10.7326/ACPJ202112210-141	http://dx.doi.org/10.7326/ACPJ202112210-141		DEC 2021	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XS0OD	34871046				2023-01-03	WOS:000729196400001
J	Nomura, K; Tarumi, R; Yoshida, K; Sado, M; Suzuki, T; Mimura, M; Uchida, H				Nomura, Kensuke; Tarumi, Ryosuke; Yoshida, Kazunari; Sado, Mitsuhiro; Suzuki, Takefumi; Mimura, Masaru; Uchida, Hiroyuki			Cancellation of outpatient appointments in patients with attention-deficit/hyperactivity disorder	PLOS ONE			English	Article							DEFICIT HYPERACTIVITY DISORDER; CHILDREN; FAMILY; DISCONTINUATION; COMORBIDITY; GIRLS	Background Regular visit to psychiatric clinic is essential for successful treatment of any psychiatric condition including attention-deficit/hyperactivity disorder (AD/HD). However, cancellation of outpatient appointments in patients with AD/HD, which represents a significant medical loss, has not been systematically investigated to our knowledge. Methods A systematic chart review was conducted for patients visiting the Shimada Ryoiku medical Center for Challenged Children in Japan at the age of <= 15 years from January to December 2013. The primary outcome measure was the cancellation rate, defined as the number of missed visits divided by the number of scheduled visits. The cancellation rates during 24 months after the first visit were compared between outpatients with AD/HD and other psychiatric disorders, including pervasive developmental disorders (PDD), and developmental coordination disorders and/or communication disorders (DCD-CD). A generalized linear model with binomial distribution was used to examine factors associated with cancellation rates exclusively in the AD/HD group. Results We included 589 patients (mean SD age, 5.6 +/- 3.4 years; 432 males) in the analysis. The cancellation rate in patients with AD/HD was 12.3% (95% confidence interval [CI]: 10.0-15.1), which was significantly higher than in those with PDD (5.6%, 95% CI: 3.8-8.3) and DCD-CD (5.3%, 95% CI: 3.6-7.8). Prescriptions of osmotic-release oral system-methylphenidate (OROS-MPH) and antipsychotics were associated with fewer cancellations in AD/HD patients (odds ratios: 0.61, 95% CI: 0.39-0.95 and 0.49, 95% CI: 0.25-0.95, respectively), although these significances did not find in the subgroup analysis including only patients with >= 6 years old. Conclusions Patients with AD/HD were more likely to miss appointments compared to those with other psychiatric disorders. The impact of AD/HD medications as well as potential psychiatric symptoms of their parents or caregivers on appointment cancellations needs to be evaluated in more detail in future investigations.	[Nomura, Kensuke; Tarumi, Ryosuke] Shimada Ryoiku Med Ctr Challenged Children, Dept Child Psychiat, Tokyo, Japan; [Tarumi, Ryosuke; Yoshida, Kazunari; Sado, Mitsuhiro; Suzuki, Takefumi; Mimura, Masaru; Uchida, Hiroyuki] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan; [Yoshida, Kazunari] Ctr Addict & Mental Hlth, Pharmacogenet Res Clin, Toronto, ON, Canada; [Yoshida, Kazunari] Azrieli Adult Neurodev Ctr, Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Yoshida, Kazunari] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Suzuki, Takefumi] Univ Yamanashi, Fac Med, Dept Neuropsychiat, Chuo, Yamanashi, Japan	Keio University; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Yamanashi	Uchida, H (corresponding author), Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan.	hiroyuki_uchida@keio.jp	Uchida, Hiroyuki/I-4867-2015	Uchida, Hiroyuki/0000-0002-0628-7036				American Psychiatric Association, 2010, DIAGN STAT MAN MENT; Arabgol F, 2015, IRAN J PEDIATR, V25, DOI 10.5812/ijp.265; Armstrong RB, 2012, J ATTEN DISORD, V16, P697, DOI 10.1177/1087054711425772; BIEDERMAN J, 1992, ARCH GEN PSYCHIAT, V49, P728; Brown RT, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e43; Buitelaar J, 2015, EUR NEUROPSYCHOPHARM, V25, P1611, DOI 10.1016/j.euroneuro.2015.06.003; Catala-Lopez F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180355; Conners K. C., 2008, CONNERS, V3e; Dickson Ruth A, 2011, Child Adolesc Psychiatry Ment Health, V5, P14, DOI 10.1186/1753-2000-5-14; Doshi JA, 2012, J AM ACAD CHILD PSY, V51, P990, DOI 10.1016/j.jaac.2012.07.008; Faraone SV, 2000, DEV REV, V20, P568, DOI 10.1006/drev.2000.0515; Faraone SV, 2001, BIOL PSYCHIAT, V50, P586, DOI 10.1016/S0006-3223(01)01146-5; Faraone SV, 2000, AM J PSYCHIAT, V157, P1077, DOI 10.1176/appi.ajp.157.7.1077; Findling RL, 2008, J CHILD ADOL PSYCHOP, V18, P347, DOI 10.1089/cap.2007.0124; Harpin V, 2016, J ATTEN DISORD, V20, P295, DOI 10.1177/1087054713486516; Le HH, 2014, EUR CHILD ADOLES PSY, V23, P587, DOI 10.1007/s00787-013-0477-8; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Marcus SC, 2011, J AM ACAD CHILD PSY, V50, P480, DOI 10.1016/j.jaac.2011.02.007; Matthews M, 2014, CURR TOP BEHAV NEURO, V16, P235, DOI 10.1007/7854_2013_249; Musser ED, 2014, J CHILD PSYCHOL PSYC, V55, P819, DOI 10.1111/jcpp.12201; Robb Jessica A, 2011, School Ment Health, V3, P169; Szatmari P, 1992, CHILD ADOLESC PSYCHI, P361; Tarver J, 2014, CHILD CARE HLTH DEV, V40, P762, DOI 10.1111/cch.12139; Varni JW, 2006, HEALTH QUAL LIFE OUT, V4, P26, DOI [DOI 10.1186/1477-7525-4-26, 10.1186/1477-7525-3-34]; Wernicke JF, 2004, J CLIN PSYCHOPHARM, V24, P30, DOI 10.1097/01.jcp.0000104907.75206.c2; WHO, 2010, INT STAT CLASS DIS R	26	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2021	16	11							e0260431	10.1371/journal.pone.0260431	http://dx.doi.org/10.1371/journal.pone.0260431			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ2TX	34797891	gold, Green Published			2023-01-03	WOS:000755334700070
J	Tsang, SMH; Szeto, GPY; Yeung, AKC; Chun, EYW; Wong, CNC; Wu, ECM; Lee, RYW				Tsang, Sharon M. H.; Szeto, Grace P. Y.; Yeung, Angelina K. C.; Chun, Eva Y. W.; Wong, Caroline N. C.; Wu, Edwin C. M.; Lee, Raymond Y. W.			Recovery of the lumbopelvic movement and muscle recruitment patterns using motor control exercise program in people with chronic nonspecific low back pain: A prospective study	PLOS ONE			English	Article							FEAR-AVOIDANCE BELIEFS; CHRONIC MUSCULOSKELETAL PAIN; LUMBAR SPINE; TRUNK STIFFNESS; SELF-EFFICACY; SWISS BALL; HIP MOTION; FLEXION; ACTIVATION; DISABILITY	This study aims to investigate the dysfunction and recovery of the lumbopelvic movement and motor control of people with chronic nonspecific low back pain after a structured rehabilitation which emphasizes on re-education and training of movement and motor control. The lumbopelvic movement and motor control pattern of 30 adults (15 with chronic low back pain, 15 healthy controls) were assessed using 3D motion and electromyographic analysis during the repeated forward bending test, in additional to the clinical outcome measures. Regional kinematics and muscle recruitment pattern of the symptomatic group was analysed before and after the 6-week rehabilitation, and compared to healthy controls. Significant improvement in back pain, functional capacity and self-efficacy of the symptomatic group was found after the rehabilitation. Patients with chronic nonspecific low back pain were capable to recover to a comparable level of the healthy controls in terms of their lumbopelvic movement and motor control pattern upon completion of a 6-week rehabilitation program, despite their dysfunction displayed at baseline. Phase specific motor control reorganization in which more profound and positive changes shown during the flexion phase. Our findings indicate that the recovery of the movement and motor control pattern in patients with chronic low back pain achieved to a comparable level of the healthy able-bodies. The improvement of both the physical outcome measures suggest that specific rehabilitation program which emphasizes on optimizing motor control during movements would help promoting the functional recovery of this specific low back pain subgroup.	[Tsang, Sharon M. H.] Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Peoples R China; [Tsang, Sharon M. H.; Yeung, Angelina K. C.; Chun, Eva Y. W.; Wong, Caroline N. C.; Wu, Edwin C. M.] Prince Wales Hosp, Dept Physiotherapy, Hong Kong, Peoples R China; [Szeto, Grace P. Y.] Tung Wah Coll, Sch Med & Hlth Sci, Hong Kong, Peoples R China; [Lee, Raymond Y. W.] Univ Portsmouth, Sch Technol, Portsmouth, Hants, England	Hong Kong Polytechnic University; Chinese University of Hong Kong; Prince of Wales Hospital; University of Portsmouth	Tsang, SMH (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Peoples R China.; Tsang, SMH (corresponding author), Prince Wales Hosp, Dept Physiotherapy, Hong Kong, Peoples R China.	Sharon.Tsang@polyu.edu.hk		Tsang, Sharon Man Ha/0000-0002-2232-9814	Departmental Research Fund, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong [1-ZE4D]	Departmental Research Fund, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong	ST received the Departmental Research Fund, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong (Reference no.: 1-ZE4D). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asgari M, 2015, CLIN BIOMECH, V30, P682, DOI 10.1016/j.clinbiomech.2015.05.005; Bayona Nestor A, 2005, Top Stroke Rehabil, V12, P58; Beurskens AJ, 1999, J MANIP PHYSIOL THER, V22, P144, DOI 10.1016/S0161-4754(99)70127-2; Chan MKY, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1674-2; D'hooge R, 2013, J ELECTROMYOGR KINES, V23, P173, DOI 10.1016/j.jelekin.2012.09.003; Dankaerts W, 2004, J ELECTROMYOGR KINES, V14, P333, DOI 10.1016/j.jelekin.2003.07.001; Davis DS, 2013, J ORTHOP SPORT PHYS, V43, P97, DOI 10.2519/jospt.2013.4382; Escamilla RF, 2010, J ORTHOP SPORT PHYS, V40, P265, DOI 10.2519/jospt.2010.3073; Esola MA, 1996, SPINE, V21, P71, DOI 10.1097/00007632-199601010-00017; Foster NE, 2018, LANCET, V391, P2368, DOI 10.1016/S0140-6736(18)30489-6; Fujii T, 2013, J ORTHOP SCI, V18, P909, DOI 10.1007/s00776-013-0448-4; Gardner-Morse MG, 2004, J BIOMECH, V37, P205, DOI 10.1016/j.jbiomech.2003.10.003; Gardner-Morse MG, 2001, J BIOMECH, V34, P457, DOI 10.1016/S0021-9290(00)00226-8; Gillespie KA, 2004, SPINE, V29, P1208, DOI 10.1097/00007632-200406010-00010; Grotle M, 2006, SPINE, V31, P1038, DOI 10.1097/01.brs.0000214878.01709.0e; Hamaoui A, 2004, NEUROSCI LETT, V357, P135, DOI 10.1016/j.neulet.2003.12.047; Hermens HJ, 2000, J ELECTROMYOGR KINES, V10, P361, DOI 10.1016/S1050-6411(00)00027-4; Hermens HJ, 2004, MED BIOL ENG COMPUT, V42, P502, DOI 10.1007/BF02350991; Hides J., 2000, INT SPORTMED J, V1; Hill JC, 2008, ARTHRIT RHEUM-ARTHR, V59, P632, DOI 10.1002/art.23563; Hodges PW, 2019, J ORTHOP SPORT PHYS, V49, P464, DOI 10.2519/jospt.2019.8827; Hodges PW, 2011, J ELECTROMYOGR KINES, V21, P220, DOI 10.1016/j.jelekin.2011.01.002; Hodges PW, 2003, J ELECTROMYOGR KINES, V13, P361, DOI 10.1016/S1050-6411(03)00042-7; Hodges PW, 1996, SPINE, V21, P2640, DOI 10.1097/00007632-199611150-00014; Hodges PW., 2013, SPINAL CONTROL REHAB, P243; Johnson CD, 2018, EUR SPINE J, V27, P925, DOI 10.1007/s00586-018-5720-z; Karayannis NV, 2016, PHYSIOTHERAPY, V102, P159, DOI 10.1016/j.physio.2015.04.005; Karayannis NV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067779; Karayannis NV, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-24; Kim MH, 2013, SPINE, V38, P1260, DOI 10.1097/BRS.0b013e318291b502; Ko Min-Joo, 2016, J Phys Ther Sci, V28, P2094, DOI 10.1589/jpts.28.2094; Konrad P., 2005, ABC EMG PRACTICAL IN, V1, P30; Laird RA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-169; MacRae CS, 2018, BMJ OPEN SPORT EXERC, V4, DOI 10.1136/bmjsem-2017-000286; Marras William S, 2004, Spine J, V4, P64, DOI 10.1016/S1529-9430(03)00424-8; MARRAS WS, 1986, ARCH PHYS MED REHAB, V67, P213; Marras WS, 2000, ERGONOMICS, V43, P880, DOI 10.1080/001401300409080; Marshall PWM, 2006, J MANIP PHYSIOL THER, V29, P550, DOI 10.1016/j.jmpt.2006.06.025; Marshall PW, 2005, ARCH PHYS MED REHAB, V86, P242, DOI 10.1016/j.apmr.2004.05.004; Martinez-Calderon J, 2018, J PAIN, V19, P10, DOI 10.1016/j.jpain.2017.08.008; McCarthy CJ., 2004, PHYS THER REV, V9; McClure PW, 1997, SPINE, V22, P552, DOI 10.1097/00007632-199703010-00019; McGill SM, 2004, J ELECTROMYOGR KINES, V14, P43, DOI 10.1016/j.jelekin.2003.09.012; Costa LDM, 2011, EUR J PAIN, V15, P213, DOI 10.1016/j.ejpain.2010.06.014; Miller RP., 1991, CLIN J PAIN, V7, P51, DOI DOI 10.1097/00002508-199103000-00053; Moorhouse KM, 2005, J BIOMECH, V38, P2000, DOI 10.1016/j.jbiomech.2004.09.014; Muceli S, 2014, J NEUROPHYSIOL, V111, P1615, DOI 10.1152/jn.00147.2013; Ng J K, 1998, Electromyogr Clin Neurophysiol, V38, P51; Nicholas MK, 2007, EUR J PAIN, V11, P153, DOI 10.1016/j.ejpain.2005.12.008; PAQUET N, 1994, SPINE, V19, P596, DOI 10.1097/00007632-199403000-00016; Parreira P, 2018, SPINE J, V18, P1715, DOI 10.1016/j.spinee.2018.05.018; Porter JL, 1997, SPINE, V22, P1508, DOI 10.1097/00007632-199707010-00017; Reeves NP, 2019, J ORTHOP SPORT PHYS, V49, P415, DOI 10.2519/jospt.2019.8144; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; Ruhe A, 2011, EUR SPINE J, V20, P358, DOI 10.1007/s00586-010-1543-2; Searle A, 2015, CLIN REHABIL, V29, P1155, DOI 10.1177/0269215515570379; Shojaei I, 2017, J BIOMECH, V53, P71, DOI 10.1016/j.jbiomech.2016.12.039; Shojaei I, 2017, CLIN BIOMECH, V41, P66, DOI 10.1016/j.clinbiomech.2016.12.005; Steiger F, 2012, EUR SPINE J, V21, P575, DOI 10.1007/s00586-011-2045-6; Sullivan MS, 2000, PHYS THER, V80, P240, DOI 10.1093/ptj/80.3.240; Taylor JB, 2014, SPINE J, V14, P2299, DOI 10.1016/j.spinee.2014.01.026; Thomas JS, 2007, HUM MOVEMENT SCI, V26, P124, DOI 10.1016/j.humov.2006.08.002; Tsang SMH, 2018, J ELECTROMYOGR KINES, V42, P10, DOI 10.1016/j.jelekin.2018.06.005; Tsang SMH, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1515-3; Tsao H, 2010, J PAIN, V11, P1120, DOI 10.1016/j.jpain.2010.02.004; van Dieen JH, 2003, J BIOMECH, V36, P1829, DOI 10.1016/S0021-9290(03)00227-6; van Dieen JH, 2003, SPINE, V28, P834, DOI 10.1097/00007632-200304150-00018; van Dieen JH, 2003, J ELECTROMYOGR KINES, V13, P333, DOI 10.1016/S1050-6411(03)00041-5; van Middelkoop M, 2011, EUR SPINE J, V20, P19, DOI 10.1007/s00586-010-1518-3; van Middelkoop M, 2010, BEST PRACT RES CL RH, V24, P193, DOI 10.1016/j.berh.2010.01.002; van Vliet PM, 2006, MANUAL THER, V11, P208, DOI 10.1016/j.math.2006.03.009; Van Wingerden JP, 2008, SPINE, V33, pE334, DOI 10.1097/BRS.0b013e318170fcf6; Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; Wertli MM, 2014, SPINE J, V14, P2658, DOI 10.1016/j.spinee.2014.02.033; Yingling VR, 1999, SPINE, V24, P1882, DOI 10.1097/00007632-199909150-00004; Youdas JW, 2015, PHYSIOTHER THEOR PR, V31, P418, DOI 10.3109/09593985.2015.1010672	77	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2021	16	11							e0259440	10.1371/journal.pone.0259440	http://dx.doi.org/10.1371/journal.pone.0259440			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2NY	34793483	gold, Green Published			2023-01-03	WOS:000755319200042
J	Serra, FE; Francisco, RPV; de Rossi, P; Brizot, MD; Rodrigues, AS				Serra, Fabiano Elisei; Vieira Francisco, Rossana Pulcineli; de Rossi, Patricia; Brizot, Maria de Lourdes; Rodrigues, Agatha Sacramento			COVID-19 outcomes in hospitalized puerperal, pregnant, and neither pregnant nor puerperal women	PLOS ONE			English	Article							DEATH; RISK	Objective To compare hospitalized reproductive age women with COVID-19 who were pregnant, puerperal, or neither one nor the other in terms of demographic and clinical characteristics and disease progression using Brazilian epidemiological data. Methods A retrospective analysis of the records of the Information System of the Epidemiological Surveillance of Influenza of the Health Ministry of Brazil was performed. It included the data of female patients aged 10 to 49 years hospitalized because of severe COVID-19 disease (RT-PCR+ for SARS-CoV-2), from February 17, 2020 to January 02, 2021. They were separated into 3 groups: pregnant, puerperal, and neither pregnant nor puerperal. General comparisons and then adjustments for confounding variables (propensity score matching [PSM]) were made, using demographic and clinical characteristics, disease progression (admission to the intensive care unit [ICU] and invasive or noninvasive ventilatory support), and outcome (cure or death). Deaths were analyzed in each group according to comorbidities, invasive or noninvasive ventilatory support, and admission to the ICU. Results As many as 40,640 reproductive age women hospitalized for COVID-19 were identified: 3,372 were pregnant, 794 were puerperal, and 36,474 were neither pregnant nor puerperal. Groups were significantly different in terms of demographic data and comorbidities (p<0.0001). Pregnant and puerperal women were less likely to be symptomatic than the women who were neither one nor the other (72.1%, 69.7% and 88.8%, respectively). Pregnant women, however, had a higher frequency of anosmia, and ageusia than the others. After PSM, puerperal women had a worse prognosis than pregnant women with respect to admission to the ICU, invasive ventilatory support, and death, with OR (95% CI) 1.97 (1.55 - 2.50), 2.71 (1.78 - 4.13), and 2.51 (1.79 - 3.52), respectively. Conclusion Puerperal women were at a higher risk for serious outcomes (need for the ICU, need for invasive and noninvasive ventilatory support, and death) than pregnant women.	[Serra, Fabiano Elisei; Vieira Francisco, Rossana Pulcineli; Brizot, Maria de Lourdes; Rodrigues, Agatha Sacramento] Univ Sao Paulo, Fac Med, Dept Obstetricia & Ginecol, Disciplina Obstetricia, Sao Paulo, SP, Brazil; [de Rossi, Patricia] Univ Santo Amaro UNISA, Curso Med, Sao Paulo, SP, Brazil; [de Rossi, Patricia] Conjunto Hosp Mandaqui, Gerencia Med Perinatal & Ginecol, Sao Paulo, SP, Brazil; [Rodrigues, Agatha Sacramento] Univ Fed Espirito Santo, Dept Estat, Vitoria, ES, Brazil	Universidade de Sao Paulo; Universidade de Santo Amaro (UNISA); Universidade Federal do Espirito Santo	Francisco, RPV; Rodrigues, AS (corresponding author), Univ Sao Paulo, Fac Med, Dept Obstetricia & Ginecol, Disciplina Obstetricia, Sao Paulo, SP, Brazil.; Rodrigues, AS (corresponding author), Univ Fed Espirito Santo, Dept Estat, Vitoria, ES, Brazil.	rossana.francisco@hc.fm.usp.br; agatha.rodrigues@ufes.br	Francisco, Rossana PV/C-5648-2012; de Lourdes Brizot, Maria/C-5706-2013	Francisco, Rossana PV/0000-0002-9981-8069; de Lourdes Brizot, Maria/0000-0002-6135-4844; Serra, Fabiano/0000-0002-5623-4936; de Rossi, Patricia/0000-0002-2971-9401	Bill & Melinda Gates Foundation [INV-027961]; CNPq [445881/2020-8]; FAPES [007/2021]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPES(Fundacao de Amparo a Pesquisa do Estado de Espiritu Santo (FAPES))	This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV-027961]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. This work is also funded by CNPq (Award Number: 445881/2020-8) and FAPES (Award Number: 007/2021). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allotey J, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3320; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; Badr DA, 2020, AM J OBSTET GYNECOL, V223, P764, DOI 10.1016/j.ajog.2020.07.045; Brasil. Ministerio da Saude, 2019, DATASUS SIST INF NAS; Brasil. Ministerio da Saude, DEF CAS NOT; Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3; Collin J, 2020, ACTA OBSTET GYN SCAN, V99, P819, DOI 10.1111/aogs.13901; Di Toro F, 2021, CLIN MICROBIOL INFEC, V27, P36, DOI 10.1016/j.cmi.2020.10.007; Elshafeey F, 2020, INT J GYNECOL OBSTET, V150, P47, DOI 10.1002/ijgo.13182; Finlayson K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231415; Greifer N., 2020, R package version 0.10.2 [software]; Hantoushzadeh S, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.04.030; Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x; Huntley BJF, 2020, OBSTET GYNECOL, V136, P303, DOI 10.1097/AOG.0000000000004010; Kamel H, 2014, NEW ENGL J MED, V370, P1307, DOI 10.1056/NEJMoa1311485; Kasraeian M, 2022, J MATERN-FETAL NEO M, V35, P1652, DOI 10.1080/14767058.2020.1763952; Kayem G, 2020, J GYNECOL OBSTET HUM, V49, DOI 10.1016/j.jogoh.2020.101826; Knight M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2107; Lee K, 2009, GLOB INST, P1; Lumbreras-Marquez MI, 2020, INT J GYNECOL OBSTET, V150, P266, DOI 10.1002/ijgo.13250; Martinez-Portilla RJ, 2021, ULTRASOUND OBST GYN, V57, P224, DOI 10.1002/uog.23575; Menezes MO, 2020, INT J GYNECOL OBSTET, V151, P415, DOI 10.1002/ijgo.13407; Mullins E, 2020, ULTRASOUND OBST GYN, V55, P586, DOI 10.1002/uog.22014; R Core Team, 2021, R LANG ENV STAT COMP; Amorim MMR, 2020, AM J OBSTET GYNECOL, V223, P298, DOI 10.1016/j.ajog.2020.04.023; Sentilhes L, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.06.022; Sobhy S, 2019, LANCET, V393, P1973, DOI 10.1016/S0140-6736(18)32386-9; Takemoto MLS, 2020, BJOG-INT J OBSTET GY, V127, P1618, DOI 10.1111/1471-0528.16470; Takemoto MLS, 2020, INT J GYNECOL OBSTET, V151, P154, DOI 10.1002/ijgo.13300; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Vallejo V, 2020, OBSTET GYNECOL, V136, P52, DOI 10.1097/AOG.0000000000003950; WHO, WHO DIR GEN OP REM M; Zaigham M, 2020, ACTA OBSTET GYN SCAN, V99, P823, DOI 10.1111/aogs.13867; Zambrano LD, 2020, MMWR-MORBID MORTAL W, V69, P1641, DOI 10.15585/mmwr.mm6944e3	34	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2021	16	11							e0259911	10.1371/journal.pone.0259911	http://dx.doi.org/10.1371/journal.pone.0259911			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2IU	34780549	gold, Green Published			2023-01-03	WOS:000755305800068
J	Yusof, NADM; Karupiah, K; Tamrin, SBM; Rasdi, I; How, V; Sambasivam, S; Jamil, PASM; Mani, KKC; Naeini, HS; Nata, DHMS				Yusof, Nur Athirah Diyana Mohammad; Karupiah, Karmegam; Tamrin, Shamsul Bahri Mohd; Rasdi, Irniza; How, Vivien; Sambasivam, Sivasankar; Jamil, Putri Anis Syahira Mohamad; Mani, Kulanthayan K. C.; Naeini, Hassan Sadeghi; Nata, Dayana Hazwani Mohd Suadi			Effectiveness of lumbar support with built-in massager system on spinal angle profiles among high-powered traffic police motorcycle riders: A randomised controlled trial	PLOS ONE			English	Article							SEATING COMFORT; CAR SEAT; DISCOMFORT; POSTURE; DESIGN	Traffic police riders are exposed to prolonged static postures causing significant angular deviation of the musculoskeletal, including the lumbar angle (L1-L5). This postural alteration contributes to awkward posture, musculoskeletal disorders and spinal injury, especially in the lower back area, as it is one of the most severe modern diseases nowadays. Thus, the study aimed to evaluate the effect of lumbar support with a built-in massager system on spinal angle profiles among traffic police riders. A randomised controlled trial (pre-testpost-test control design) was used to assess spinal angle pattern while riding the high-powered motorcycle for 20 minutes. Twenty-four traffic police riders were randomly selected to participate and 12 riders were assigned to the control group and 12 riders to the experimental group. The pre-test and post-test were conducted at a one-week interval. Each participant was required to wear a TruPosture Smart Shirt (to monitor spinal posture). The TruPosture Apps recorded the spinal angle pattern. The data indicated that the police riders using motorcycle seat with lumbar support and built-in massager system showed a huge improvement in maintaining posture which only involves slight spinal angle deviation changes from the spinal reference angle throughout the 20 minutes ride. The data collected then were analysed using the Mann-Whitney test and Wilcoxon signed-ranked test to verify a statistically significant difference between and within the control and experimental groups. There were significant differences in all sensors between the control group and experimental groups (p<0.05) and within the experimental group. According to the findings, it can be said that the ergonomic intervention prototype (lumbar support with built-in massager system) successfully helps to maintain and improve the natural curve of the spinal posture. This indirectly would reduce the risk of developing musculoskeletal disorders and spinal injury among traffic police riders.	[Yusof, Nur Athirah Diyana Mohammad; Karupiah, Karmegam; Tamrin, Shamsul Bahri Mohd; Rasdi, Irniza; How, Vivien; Sambasivam, Sivasankar; Jamil, Putri Anis Syahira Mohamad] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Environm & Occupat Hlth, Upm Serdang, Selangor, Malaysia; [Mani, Kulanthayan K. C.] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Community Hlth, Upm Serdang, Selangor, Malaysia; [Naeini, Hassan Sadeghi] Iran Univ Sci & Technol, Sch Architecture & Environm Design, Ind Design Dept, Tehran, Iran; [Nata, Dayana Hazwani Mohd Suadi] Univ Kebangsaan Malaysia, Fac Hlth Sci, Ctr Toxicol & Hlth Risk Studies, Kuala Lumpur, Malaysia	Universiti Putra Malaysia; Universiti Putra Malaysia; Iran University Science & Technology; Universiti Kebangsaan Malaysia	Karupiah, K (corresponding author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Environm & Occupat Hlth, Upm Serdang, Selangor, Malaysia.	megam@upm.edu.my	Mohd Suadi Nata, Dayana Hazwani/ABG-9084-2021; Mohammad Yusof, Nur Athirah Diyana/AAY-3373-2021; Sadeghi Naeini, Hassan/E-1218-2016	Mohd Suadi Nata, Dayana Hazwani/0000-0003-1593-1679; Mohammad Yusof, Nur Athirah Diyana/0000-0002-2875-386X; Sadeghi Naeini, Hassan/0000-0003-4094-0809; Sambasivam, Sivasankar/0000-0001-5450-6427; Karuppiah, Karmegam/0000-0002-9488-9335	Ministry of Education Malaysia (MOE) [FRGS/1/2015/SKK06/UPM/02/2]; Graduate Research Fellowship (GRF), Universiti Putra Malaysia, IPS Putra [9616000]; S-GRA [6300260]	Ministry of Education Malaysia (MOE); Graduate Research Fellowship (GRF), Universiti Putra Malaysia, IPS Putra; S-GRA	This research is supported by the Ministry of Education Malaysia (MOE) through Fundamental Research Grant Scheme (FRGS/1/2015/SKK06/UPM/02/2), Graduate Research Fellowship (GRF), Universiti Putra Malaysia, IPS Putra Grant (9616000), and S-GRA (6300260). No funding bodies had any role in decision to publish or preparation of the manuscript.	Alyami H., 2016, AM J OCCUPATIONAL TH, V70, P1; Carcone SM, 2007, APPL ERGON, V38, P755, DOI 10.1016/j.apergo.2006.11.001; Ceunen E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088482; De Carvalho DE, 2015, HUM FACTORS, V57, P976, DOI 10.1177/0018720815584866; Deros BM, 2009, IND ENG MANAG SYST, V8, P121; Diyana MYA, 2019, INT J IND ERGONOM, V74, DOI 10.1016/j.ergon.2019.102863; Diyana NA, THESIS U PUTRA MALAY; Donnelly CJ, 2009, INT J OCCUP SAF ERGO, V15, P295, DOI 10.1080/10803548.2009.11076809; Durkin JL, 2006, ERGONOMICS, V49, P28, DOI 10.1080/00140130500356882; Franz M, 2011, J MANIP PHYSIOL THER, V34, P107, DOI 10.1016/j.jmpt.2010.12.002; Gong H, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1096-0; Gouvea GR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208900; Guo LX, 2016, INT J IND ERGONOM, V53, P319, DOI 10.1016/j.ergon.2016.03.004; Karuppiah K, 2012, AN ACAD BRAS CIENC, V84, P1169, DOI 10.1590/S0001-37652012000400031; Kolich M, 2000, Int J Occup Saf Ergon, V6, P113; Kwon Y, 2018, TECHNOL HEALTH CARE, V26, pS409, DOI 10.3233/THC-174717; Ma'arof MIN, 2015, PROCEDIA MANUF, V3, P2581, DOI 10.1016/j.promfg.2015.07.575; Maarof MI, MATEC WEB C EDP SCI, V135; Makhsous M, 2003, SPINE, V28, P1113, DOI 10.1097/00007632-200306010-00006; Mansfield N, 2015, APPL ERGON, V50, P153, DOI 10.1016/j.apergo.2015.03.010; Morl F, 2013, J ELECTROMYOGR KINES, V23, P362, DOI 10.1016/j.jelekin.2012.10.002; Fernandes RDP, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3306-4; Pope MH, 2002, ANNU REV BIOMED ENG, V4, P49, DOI 10.1146/annurev.bioeng.4.092101.122107; Rashid H., 2017, J MECH ENG JMECHE, P197; Shafiei UK., 2015, J TEKNOL, V77; Sprigle S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210978; Tanaka Tim Hideaki, 2002, BMC Complement Altern Med, V2, P9, DOI 10.1186/1472-6882-2-9; van Poppel MNM, 2004, OCCUP MED-OXFORD, V54, P345, DOI 10.1093/occmed/kqh065; Voinea GD, 2017, E-HEALTH BIOENG CONF, P25, DOI 10.1109/EHB.2017.7995352; Wang SJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195670	30	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2021	16	10							e0258796	10.1371/journal.pone.0258796	http://dx.doi.org/10.1371/journal.pone.0258796			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ7WQ	34665845	Green Accepted, gold, Green Published			2023-01-03	WOS:000755683100026
J	Nguyen, QT; Ishizaki, A; Bi, XQ; Matsuda, K; Nguyen, LV; Pham, HV; Phan, CTT; Phung, TTB; Ngo, TTT; Nguyen, AV; Khu, DTK; Ichimura, H				Quynh Thi Nguyen; Ishizaki, Azumi; Bi, Xiuqiong; Matsuda, Kazunori; Lam Van Nguyen; Hung Viet Pham; Chung Thi Thu Phan; Thuy Thi Bich Phung; Tuyen Thi Thu Ngo; An Van Nguyen; Dung Thi Khanh Khu; Ichimura, Hiroshi			Alterations in children's sub-dominant gut microbiota by HIV infection and anti-retroviral therapy	PLOS ONE			English	Article							T-CELL DEPLETION; IMMUNE ACTIVATION; BACTERIA; SUPPRESSION; METABOLISM; SYSTEM	Objective We investigated the impact of human immunodeficiency virus (HIV) infection and anti-retroviral therapy (ART) on the gut microbiota of children. Design This cross-sectional study investigated the gut microbiota of children with and without HIV. Methods We collected fecal samples from 59 children with HIV (29 treated with ART [ART(+)] and 30 without ART [HIV(+)]) and 20 children without HIV [HIV(-)] in Vietnam. We performed quantitative RT-PCR to detect 14 representative intestinal bacteria targeting 16S/23S rRNA molecules. We also collected the blood samples for immunological analyses. Results In spearman's correlation analyses, no significant correlation between the number of dominant bacteria and age was found among children in the HIV(-) group. However, the number of sub-dominant bacteria, including Streptococcus, Enterococcus, and Enterobacteriaceae, positively correlated with age in the HIV(-) group, but not in the HIV(+) group. In the HIV(+) group, Clostridium coccoides group positively associated with the CD4(+) cell count and its subsets. In the ART(+) group, Staphylococcus and C. perfringens positively correlated with CD4(+) cells and their subsets and negatively with activated CD8(+) cells. C. coccoides group and Bacteroides fragilis group were associated with regulatory T-cell counts. In multiple linear regression analyses, ART duration was independently associated with the number of C. perfringens, and Th17 cell count with the number of Staphylococcus in the ART(+) group. Conclusions HIV infection and ART may influence sub-dominant gut bacteria, directly or indirectly, in association with immune status in children with HIV.	[Quynh Thi Nguyen; Ishizaki, Azumi; Bi, Xiuqiong; Ichimura, Hiroshi] Kanazawa Univ, Grad Sch Med Sci, Dept Viral Infect & Int Hlth, Kanazawa, Ishikawa, Japan; [Matsuda, Kazunori] Yakult Cent Inst, Tokyo, Japan; [Lam Van Nguyen; Hung Viet Pham; Chung Thi Thu Phan; Thuy Thi Bich Phung; Tuyen Thi Thu Ngo; An Van Nguyen; Dung Thi Khanh Khu] Vietnam Natl Childrens Hosp, Hanoi, Vietnam	Kanazawa University; Yakult Honsha Company, Limited	Ichimura, H (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Viral Infect & Int Hlth, Kanazawa, Ishikawa, Japan.	ichimura@med.kanazawa-u.ac.jp	Matsuda, Kazunori/N-5743-2018	Matsuda, Kazunori/0000-0002-5242-6332				Abange WB, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87368-8; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Bi XQ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081245; Bourke CD, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav0537; Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Derrien M, 2019, TRENDS MICROBIOL, V27, P997, DOI 10.1016/j.tim.2019.08.001; Dillon SM, 2014, MUCOSAL IMMUNOL, V7, P983, DOI 10.1038/mi.2013.116; Nguyen DTL, 2013, INT J FOOD MICROBIOL, V163, P19, DOI 10.1016/j.ijfoodmicro.2013.01.024; Flint HJ, 2012, NAT REV GASTRO HEPAT, V9, P577, DOI 10.1038/nrgastro.2012.156; Flygel TT., 2019, J INFECT DIS; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gonzalez-Hernandez LA, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3867-9; Gough EK, 2020, GUT MICROBES, V11, DOI 10.1080/19490976.2020.1717299; Harmsen HJM, 2002, APPL ENVIRON MICROB, V68, P2982, DOI 10.1128/AEM.68.6.2982-2990.2002; Hasegawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142164; Hunt PW, 2010, CURR OPIN HIV AIDS, V5, P189, DOI 10.1097/COH.0b013e32833647d9; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Imahashi M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80247-8; Ishizaki A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102185; Kamada N, 2014, GASTROENTEROLOGY, V146, P1477, DOI 10.1053/j.gastro.2014.01.060; Kamada N, 2013, NAT REV IMMUNOL, V13, P321, DOI 10.1038/nri3430; Kaur US, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35877-4; Kinter A, 2007, P NATL ACAD SCI USA, V104, P3390, DOI 10.1073/pnas.0611423104; Kiu R, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0144-8; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Kurakawa T, 2012, MICROBIOL IMMUNOL, V56, P10, DOI 10.1111/j.1348-0421.2011.00405.x; Kyosiimire-Lugemwa J, 2020, J INFECT DIS, V222, P381, DOI 10.1093/infdis/jiz494; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Lozupone CA, 2013, CELL HOST MICROBE, V14, P329, DOI 10.1016/j.chom.2013.08.006; Machiavelli A, 2019, GUT MICROBES, V10, P599, DOI 10.1080/19490976.2018.1560768; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; Mariat D, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-123; Maslowski KM, 2011, NAT IMMUNOL, V12, P5, DOI 10.1038/ni0111-5; Matsuda K, 2012, APPL ENVIRON MICROB, V78, P5111, DOI 10.1128/AEM.07990-11; Matsuda K, 2009, APPL ENVIRON MICROB, V75, P1961, DOI 10.1128/AEM.01843-08; Matsuki T, 2004, APPL ENVIRON MICROB, V70, P7220, DOI 10.1128/AEM.70.12.7220-7228.2004; McHardy IH, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-26; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Miller LS, 2011, NAT REV IMMUNOL, V11, P505, DOI 10.1038/nri3010; Ministry of Health Vietnam, 2009, GUID HIV AIDS DIAGN; Monteiro CRAV, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020448; Pinto-Cardoso S, 2018, CURR OPIN HIV AIDS, V13, P53, DOI [10.1097/COH.0000000000000428, 10.1097/coh.0000000000000428]; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; R Core Team, 2021, R LANG ENV STAT COMP; Ringel-Kulka T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064315; Sakaguchi S, 2010, J CLIN MICROBIOL, V48, P1624, DOI 10.1128/JCM.01724-09; Sengupta S, 2018, IMMUNITY, V48, P872, DOI 10.1016/j.immuni.2018.04.030; Serrano-Villar S, 2016, EBIOMEDICINE, V8, P203, DOI 10.1016/j.ebiom.2016.04.033; Singh RK, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1175-y; Stewart CJ, 2018, NATURE, V562, P583, DOI 10.1038/s41586-018-0617-x; Surono IS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245399; Telesford KM, 2015, GUT MICROBES, V6, P234, DOI 10.1080/19490976.2015.1056973; Tsuji H, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01417; Vazquez-Castellanos JF, 2015, MUCOSAL IMMUNOL, V8, P760, DOI 10.1038/mi.2014.107; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Villanueva-Millan MJ, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21526; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zheng DP, 2020, CELL RES, V30, P492, DOI 10.1038/s41422-020-0332-7; Zhou YL, 2018, J CELL MOL MED, V22, P2263, DOI 10.1111/jcmm.13508	59	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2021	16	10							e0258226	10.1371/journal.pone.0258226	http://dx.doi.org/10.1371/journal.pone.0258226			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR2PT	34634074	Green Published, gold			2023-01-03	WOS:000749839300026
J	Leiter, RE				Leiter, Richard E.			A Good Death?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PALLIATIVE CARE		[Leiter, Richard E.] Brigham & Womens Hosp, Dept Psychosocial Oncol, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; [Leiter, Richard E.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Leiter, RE (corresponding author), Brigham & Womens Hosp, Dept Psychosocial Oncol, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.; Leiter, RE (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.							Bernacki R, 2019, JAMA INTERN MED, V179, P751, DOI 10.1001/jamainternmed.2019.0077; Kelley AS, 2015, NEW ENGL J MED, V373, P747, DOI 10.1056/NEJMra1404684; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678	3	0	0	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	2021	385	16					1448	1449		10.1056/NEJMp2107941	http://dx.doi.org/10.1056/NEJMp2107941		OCT 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG2CY	34623785				2023-01-03	WOS:000704987600001
J	Kim, CJ; Park, MW; Kim, MC; Choo, EH; Hwang, BH; Lee, KY; Choi, YS; Kim, HY; Yoo, KD; Jeon, DS; Shin, ES; Jeong, YH; Seung, KB; Jeong, MH; Yim, HW; Ahn, Y; Chang, K				Kim, Chan Joon; Park, Mahn-Won; Kim, Min Chul; Choo, Eun-Ho; Hwang, Byung-Hee; Lee, Kwan Yong; Choi, Yun Seok; Kim, Hee-Yeol; Yoo, Ki-Dong; Jeon, Doo-Soo; Shin, Eun-Seok; Jeong, Young-Hoon; Seung, Ki-Bae; Jeong, Myung Ho; Yim, Hyeon Woo; Ahn, Youngkeun; Chang, Kiyuk		TALOS-AMI Investigators	Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial	LANCET			English	Article							DUAL ANTIPLATELET THERAPY; DIPHOSPHATE RECEPTOR INHIBITORS; PLATELET INHIBITION; ELUTING STENTS; ARTERY-DISEASE; PRASUGREL; EFFICACY; OUTCOMES; SAFETY; ACS	Background In patients with acute myocardial infarction receiving potent antiplatelet therapy, the bleeding risk remains high during the maintenance phase. We sought data on a uniform unguided de-escalation strategy of dual antiplatelet therapy (DAPT) from ticagrelor to clopidogrel after acute myocardial infarction. Methods In this open-label, assessor-masked, multicentre, non-inferiority, randomised trial (TALOS-AMI), patients at 32 institutes in South Korea with acute myocardial infarction receiving aspirin and ticagrelor without major ischaemic or bleeding events during the first month after index percutaneous coronary intervention (PCI) were randomly assigned in a 1:1 ratio to a de-escalation (clopidogrel plus aspirin) or active control (ticagrelor plus aspirin) group. Unguided de-escalation without a loading dose of clopidogrel was adopted when switching from ticagrelor to clopidogrel. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, or bleeding type 2, 3, or 5 according to Bleeding Academic Research Consortium (BARC) criteria from 1 to 12 months. A non-inferiority test was done to assess the safety and efficacy of de-escalation DAPT compared with standard treatment. The hazard ratio (HR) for de-escalation versus active control group in a stratified Cox proportional hazards model was assessed for non-inferiority by means of an HR margin of 1.34, which equates to an absolute difference of 3.0% in the intention-to-treat population and, if significant, a superiority test was done subsequently. To ensure statistical robustness, additional analyses were also done in the per-protocol population. This trial is registered at ClinicalTrials.gov, NCT02018055. Findings From Feb 26, 2014, to Dec 31, 2018, from 2901 patients screened, 2697 patients were randomly assigned: 1349 patients to de-escalation and 1348 to active control groups. At 12 months, the primary endpoints occurred in 59 (4.6%) in the de-escalation group and 104 (8.2%) patients in the active control group (p(non-inferiority)<0.001; HR 0.55 [95% CI 0.40-0.76], p(superiority)=0.0001). There was no significant difference in composite of cardiovascular death, myocardial infarction, or stroke between de-escalation (2.1%) and the active control group (3.1%; HR 0.69; 95% CI 0.42-1.14, p=0.15). Composite of BARC 2, 3, or 5 bleeding occurred less frequently in the de-escalation group (3.0% vs 5.6%, HR 0.52; 95% CI 0.35-0.77, p=0.0012). Interpretation In stabilised patients with acute myocardial infarction after index PCI, a uniform unguided de-escalation strategy significantly reduced the risk of net clinical events up to 12 months, mainly by reducing the bleeding events. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Kim, Chan Joon] Catholic Univ Korea, Coll Med, Uijeongbu St Marys Hosp, Dept Internal Med,Div Cardiol, Seoul, South Korea; [Park, Mahn-Won] Catholic Univ Korea, Coll Med, Daejeon St Marys Hosp, Dept Internal Med,Div Cardiol, Seoul, South Korea; [Choo, Eun-Ho; Hwang, Byung-Hee; Lee, Kwan Yong; Seung, Ki-Bae; Chang, Kiyuk] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Internal Med,Div Cardiol, Seoul 06591, South Korea; [Choi, Yun Seok] Catholic Univ Korea, Coll Med, Yeouido St Marys Hosp, Dept Internal Med,Div Cardiol, Seoul, South Korea; [Kim, Hee-Yeol] Catholic Univ Korea, Coll Med, Bucheon St Marys Hosp, Dept Internal Med,Div Cardiol, Seoul, South Korea; [Yoo, Ki-Dong] Catholic Univ Korea, Coll Med, St Vincents Hosp, Dept Internal Med,Div Cardiol, Seoul, South Korea; [Jeon, Doo-Soo] Catholic Univ Korea, Coll Med, Incheon St Marys Hosp, Dept Internal Med,Div Cardiol, Seoul, South Korea; [Yim, Hyeon Woo] Catholic Univ Korea, Coll Med, Dept Prevent Med, Seoul, South Korea; [Kim, Min Chul; Jeong, Myung Ho; Ahn, Youngkeun] Chonnam Natl Univ Hosp, Dept Cardiol, Seoul, South Korea; [Shin, Eun-Seok] Ulsan Univ Hosp, Div Cardiol, Dept Internal Med, Seoul, South Korea; [Jeong, Young-Hoon] Gyeongsang Natl Univ, Div Cardiol, Dept Internal Med, Changwon Hosp, Chang Won, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Chonnam National University; Chonnam National University Hospital; University of Ulsan; Ulsan University Hospital; Gyeongsang National University	Chang, K (corresponding author), Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Internal Med,Div Cardiol, Seoul 06591, South Korea.; Ahn, Y (corresponding author), Chonnam Natl Univ, Sch Med, Chonnam Natl Univ Hosp, Dept Cardiol, Gwangju 61469, South Korea.	cecilyk@chonnam.ac.kr; kiyuk@catholic.ac.kr	Jeong, Young-Hoon/F-3476-2015; Choo, Eun Ho/HCH-6246-2022	Jeong, Young-Hoon/0000-0003-0403-3726; Lee, Kwan yong/0000-0002-0480-1046	ChongKunDang Pharm; Medtronic; Abbott; Boston Scientific	ChongKunDang Pharm; Medtronic(Medtronic); Abbott(Abbott Laboratories); Boston Scientific(Boston Scientific)	ChongKunDang Pharm, Medtronic, Abbott, and Boston Scientific.	Amsterdam EA, 2014, J AM COLL CARDIOL, V64, pE139, DOI [10.1016/j.jacc.2014.09.016, 10.1016/j.jacc.2014.09.017]; Angiolillo DJ, 2017, CIRCULATION, V136, P1955, DOI 10.1161/CIRCULATIONAHA.117.031164; Antman EM, 2008, J AM COLL CARDIOL, V51, P2028, DOI 10.1016/j.jacc.2007.10.001; Bagai A, 2015, EUR HEART J-ACUTE CA, V4, P499, DOI 10.1177/2048872614564082; Becker RC, 2011, EUR HEART J, V32, P2933, DOI 10.1093/eurheartj/ehr422; Bikdeli B, 2019, CIRCULATION, V140, P379, DOI 10.1161/CIRCULATIONAHA.119.040214; Claassens DMF, 2019, NEW ENGL J MED, V12; Collet JP, 2021, EUR HEART J, V42, P1289, DOI 10.1093/eurheartj/ehaa575; Colombo A, 2014, J AM COLL CARDIOL, V64, P2086, DOI 10.1016/j.jacc.2014.09.008; Cuisset T, 2017, EUR HEART J, V38, P3070, DOI 10.1093/eurheartj/ehx175; Czarny MJ, 2014, CLIN CARDIOL, V37, P505, DOI 10.1002/clc.22289; De Luca L, 2017, EUROINTERVENTION, V13, P459, DOI 10.4244/EIJ-D-17-00092; Feres F, 2013, JAMA-J AM MED ASSOC, V310, P2510, DOI 10.1001/jama.2013.282183; Galli M, 2021, LANCET, V397, P1470, DOI 10.1016/S0140-6736(21)00533-X; Gwon HC, 2012, CIRCULATION, V125, P505, DOI 10.1161/CIRCULATIONAHA.111.059022; Hahn JY, 2019, JAMA-J AM MED ASSOC, V321, P2428, DOI 10.1001/jama.2019.8146; Ho PM, 2009, CIRCULATION, V119, P3028, DOI 10.1161/CIRCULATIONAHA.108.768986; Kim BK, 2012, J AM COLL CARDIOL, V60, P1340, DOI 10.1016/j.jacc.2012.06.043; Kim HS, 2013, CIRC-CARDIOVASC GENE, V6, P514, DOI 10.1161/CIRCGENETICS.113.000109; Kim HS, 2020, LANCET, V396, P1079, DOI 10.1016/S0140-6736(20)31791-8; Levine GN, 2016, CIRCULATION, V134, pE123, DOI 10.1161/CIR.0000000000000404; Mehran R, 2019, NEW ENGL J MED, V381, P2032, DOI 10.1056/NEJMoa1908419; Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449; Morrow DA, 2009, CIRCULATION, V119, P2758, DOI 10.1161/CIRCULATIONAHA.108.833665; Motovska Z, 2018, J AM COLL CARDIOL, V71, P371, DOI 10.1016/j.jacc.2017.11.008; Ndrepepa G, 2012, CIRCULATION, V125, P1424, DOI 10.1161/CIRCULATIONAHA.111.060871; Ndrepepa G, 2009, CARDIOLOGY, V113, P198, DOI 10.1159/000201273; Park MW, 2021, EUROINTERVENTION, V16, DOI 10.4244/EIJ-D-20-00187; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Sibbing D, 2021, LANCET, V397, P1423, DOI 10.1016/S0140-6736(21)00728-5; Sibbing D, 2019, JACC-CARDIOVASC INTE, V12, P1521, DOI 10.1016/j.jcin.2019.03.034; Sibbing D, 2017, LANCET, V390, P1747, DOI 10.1016/S0140-6736(17)32155-4; Takahashi K, 2019, J AM COLL CARDIOL, V74, P2015, DOI 10.1016/j.jacc.2019.08.997; Valina C, 2020, J AM COLL CARDIOL, V76, P2436, DOI 10.1016/j.jacc.2020.09.584; Velders MA, 2016, HEART, V102, P617, DOI 10.1136/heartjnl-2015-308963; Vranckx P, 2018, LANCET, V392, P940, DOI 10.1016/S0140-6736(18)31858-0; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Zettler ME, 2017, AM HEART J, V183, P62, DOI 10.1016/j.ahj.2016.10.006	40	26	26	7	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT	2021	398	10308					1305	1316						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE2YJ	34627490				2023-01-03	WOS:000705490300018
J	Siemieniuk, RAC; Bartoszko, JJ; Martinez, JPD; Kum, E; Qasim, A; Zeraatkar, D; Izcovich, A; Mangala, S; Ge, L; Han, MA; Agoritsas, T; Arnold, D; Avila, C; Chu, DK; Couban, R; Cusano, E; Darzi, AJ; Devji, T; Foroutan, F; Ghadimi, M; Khamis, A; Lamontagne, F; Loeb, M; Miroshnychenko, A; Motaghi, S; Murthy, S; Mustafa, RA; Rada, G; Rochwerg, B; Switzer, C; Vandvik, PO; Vernooij, RWM; Wang, Y; Yao, L; Guyatt, GH; Brignardello-Petersen, R				Siemieniuk, Reed A. C.; Bartoszko, Jessica J.; Martinez, Juan Pablo Diaz; Kum, Elena; Qasim, Anila; Zeraatkar, Dena; Izcovich, Ariel; Mangala, Sophia; Ge, Long; Han, Mi Ah; Agoritsas, Thomas; Arnold, Donald; Avila, Camila; Chu, Derek K.; Couban, Rachel; Cusano, Ellen; Darzi, Andrea J.; Devji, Tahira; Foroutan, Farid; Ghadimi, Maryam; Khamis, Assem; Lamontagne, Francois; Loeb, Mark; Miroshnychenko, Anna; Motaghi, Sharhzad; Murthy, Srinivas; Mustafa, Reem A.; Rada, Gabriel; Rochwerg, Bram; Switzer, Charlotte; Vandvik, Per O.; Vernooij, Robin W. M.; Wang, Ying; Yao, Liang; Guyatt, Gordon H.; Brignardello-Petersen, Romina			Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CONVALESCENT PLASMA; GRADE; CERTAINTY; EFFICACY; SAFETY	OBJECTIVE To evaluate the efficacy and safety of antiviral antibody therapies and blood products for the treatment of novel coronavirus disease 2019 (covid-19). DESIGN Living systematic review and network meta-analysis, with pairwise meta-analysis for outcomes with insufficient data. DATA SOURCES WHO covid-19 database, a comprehensive multilingual source of global covid-19 literature, and six Chinese databases (up to 21 July 2021). STUDY SELECTION Trials randomising people with suspected, probable, or confirmed covid-19 to antiviral antibody therapies, blood products, or standard care or placebo. Paired reviewers determined eligibility of trials independently and in duplicate. METHODS After duplicate data abstraction, we performed random effects bayesian meta-analysis, including network meta-analysis for outcomes with sufficient data. We assessed risk of bias using a modification of the Cochrane risk of bias 2.0 tool. The certainty of the evidence was assessed using the grading of recommendations assessment, development, and evaluation (GRADE) approach. We meta-analysed interventions with >= 100 patients randomised or >= 20 events per treatment arm. RESULTS As of 21 July 2021, we identified 47 trials evaluating convalescent plasma (21 trials), intravenous immunoglobulin (IVIg) (5 trials), umbilical cord mesenchymal stem cells (5 trials), bamlanivimab (4 trials), casirivimab-imdevimab (4 trials), bamlanivimab-etesevimab (2 trials), control plasma (2 trials), peripheral blood non-haematopoietic enriched stem cells (2 trials), sotrovimab (1 trial), anti-SARS-CoV-2 IVIg (1 trial), therapeutic plasma exchange (1 trial), XAV-19 polyclonal antibody (1 trial), CT-P59 monoclonal antibody (1 trial) and INM005 polyclonal antibody (1 trial) for the treatment of covid-19. Patients with non-severe disease randomised to antiviral monoclonal antibodies had lower risk of hospitalisation than those who received placebo: casirivimab-imdevimab (odds ratio (OR) 0.29 (95% CI 0.17 to 0.47); risk difference (RD) -4.2%; moderate certainty), bamlanivimab (OR 0.24 (0.06 to 0.86); RD -4.1%; low certainty), bamlanivimab-etesevimab (OR 0.31 (0.11 to 0.81); RD -3.8%; low certainty), and sotrovimab (OR 0.17 (0.04 to 0.57); RD -4.8%; low certainty). They did not have an important impact on any other outcome. There was no notable difference between monoclonal antibodies. No other intervention had any meaningful effect on any outcome in patients with non-severe covid-19. No intervention, including antiviral antibodies, had an important impact on any outcome in patients with severe or critical covid-19, except casirivimab-imdevimab, which may reduce mortality in patients who are seronegative. CONCLUSION In patients with non-severe covid-19, casirivimab-imdevimab probably reduces hospitalisation; bamlanivimab-etesevimab, bamlanivimab, and sotrovimab may reduce hospitalisation. Convalescent plasma, IVIg, and other antibody and cellular interventions may not confer any meaningful benefit. SYSTEMATIC REVIEW REGISTRATION This review was not registered. The protocol established a priori is included as a data supplement.	[Siemieniuk, Reed A. C.; Bartoszko, Jessica J.; Martinez, Juan Pablo Diaz; Kum, Elena; Qasim, Anila; Zeraatkar, Dena; Mangala, Sophia; Agoritsas, Thomas; Chu, Derek K.; Darzi, Andrea J.; Ghadimi, Maryam; Loeb, Mark; Miroshnychenko, Anna; Motaghi, Sharhzad; Mustafa, Reem A.; Rochwerg, Bram; Switzer, Charlotte; Wang, Ying; Yao, Liang; Guyatt, Gordon H.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON L8S 4L8, Canada; [Siemieniuk, Reed A. C.; Arnold, Donald; Chu, Derek K.; Loeb, Mark; Rochwerg, Bram; Guyatt, Gordon H.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Izcovich, Ariel] Hosp Aleman, Serv Clin Med, Buenos Aires, DF, Argentina; [Ge, Long] Lanzhou Univ, Evidence Based Social Sci Res Ctr, Sch Publ Hlth, Lanzhou, Gansu, Peoples R China; [Han, Mi Ah] Chosun Univ, Coll Med, Dept Prevent Med, Gwangju, South Korea; [Agoritsas, Thomas] Univ Hosp Geneva, Div Gen Internal Med, Geneva, Switzerland; [Agoritsas, Thomas] Univ Hosp Geneva, Div Clin Epidemiol, Geneva, Switzerland; [Avila, Camila; Rada, Gabriel] Epistemonikos Fdn, Santiago, Chile; [Couban, Rachel] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada; [Cusano, Ellen] Univ Calgary, Dept Med, Calgary, AB, Canada; [Devji, Tahira] Univ Toronto, Med Sch, Toronto, ON, Canada; [Foroutan, Farid] Univ Hlth Network, Ted Rogers Ctr Heart Res, Toronto, ON, Canada; [Khamis, Assem] Hull York Med Sch, Wolfson Palliat Care Res Ctr, Kingston Upon Hull, N Humberside, England; [Lamontagne, Francois] CHU Sherbrooke, Dept Med, Sherbrooke, PQ, Canada; [Lamontagne, Francois] CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ, Canada; [Murthy, Srinivas] Univ British Columbia, Fac Med, Dept Pediat, Vancouver, BC, Canada; [Mustafa, Reem A.] Univ Kansas, Dept Med, Med Ctr, Kansas City, MO USA; [Vandvik, Per O.] Univ Oslo, Inst Hlth & Soc, Oslo, Norway; [Vernooij, Robin W. M.] Univ Med Ctr Utrecht, Dept Nephrol & Hypertens, Utrecht, Netherlands; [Vernooij, Robin W. M.] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	McMaster University; McMaster University; Hospital Aleman; University of Buenos Aires; Lanzhou University; Chosun University; University of Geneva; University of Geneva; McMaster University; University of Calgary; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Hull; University of York - UK; University of Sherbrooke; University of Sherbrooke; University of British Columbia; University of Kansas; University of Oslo; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Siemieniuk, RAC (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON L8S 4L8, Canada.; Siemieniuk, RAC (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.	reed.siemieniuk@medportal.ca	T, E/HII-8943-2022; Couban, Rachel/AAV-1568-2021; Zeraatkar, Dena/GNM-9600-2022	Couban, Rachel/0000-0001-8672-2845; Arnold, Donald/0000-0003-0943-8853; Lamontagne, Francois/0000-0002-0360-3427; Izcovich, Ariel/0000-0001-9053-4396; Murthy, Srinivas/0000-0002-9476-839X; Qasim, Anila/0000-0001-9658-0078; Wang, Ying/0000-0002-2296-1991; Chu, Derek/0000-0001-8269-4496; Siemieniuk, Reed/0000-0002-3725-3031; Kum, Elena/0000-0002-6548-2632	Canadian Institutes of Health Research [CIHR-IRSC:0579001321]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This study was supported by the Canadian Institutes of Health Research (grant CIHR-IRSC:0579001321). The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.	ACTIV-3 TICO LY-CoV555 Study Grp, 2021, NEW ENGL J MED, V384, P905, DOI 10.1056/NEJMoa2033130; Agarwal A, CONVALESCENT PLASMA; Ali S, 2021, ECLINICALMEDICINE, V36, DOI 10.1016/j.eclinm.2021.100926; AlQahtani M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89444-5; Avendano-Sola C., 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.08.26.20182444, DOI 10.1101/2020.08.26.20182444, https://doi.org/10.1101/2020.08.26.20182444]; Bajpai M, 2020, PREPRINT, DOI [10.25.20219337, 10.1101/2020.10.25.20219337, DOI 10.1101/2020.10.25.20219337]; Balcells ME, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003415; Bandopadhyay P, 2020, ABHISHAKE LAHIRI, DOI [10.1101/2020.09.21.20199109, DOI 10.1101/2020.09.21.20199109]; Bartoszko JJ, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n949; Bennett-Guerrero E, 2021, CRIT CARE MED, V49, P1015, DOI 10.1097/CCM.0000000000005066; Bozzo J, 2017, EXPERT REV ANTI-INFE, V15, P585, DOI 10.1080/14787210.2017.1328278; Brignardello-Petersen R, 2019, J CLIN EPIDEMIOL, V108, P77, DOI 10.1016/j.jclinepi.2018.11.025; Brignardello-Petersen R, 2018, J CLIN EPIDEMIOL, V93, P36, DOI 10.1016/j.jclinepi.2017.10.005; CADTH Covid-19 Pandemic, 2020, CONV PLASM THER TREA; Centers for Disease Control and Prevention, 2020, COVIDVIEW WEEKL SURV; Centers for Disease Control and Prevention, 2020, COVID 19 RES ART DOW; Centers for Disease Control and Prevention, 2020, DAIL UPD TOT WEEK ST; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Cytel, 2020, GLOB COR COVID 19 CL; Daar E., 2021, C RETR OPP INF; Devasenapathy N, 2020, CAN MED ASSOC J, V192, pE745, DOI 10.1503/cmaj.200642; Dilogo IH, 2021, STEM CELL TRANSL MED, V10, P1279, DOI 10.1002/sctm.21-0046; Djulbegovic B, 2020, J CLIN EPIDEMIOL, V126, P164, DOI 10.1016/j.jclinepi.2020.07.002; Dougan M, 2021, NEW ENGL J MED, V385, P1382, DOI 10.1056/NEJMoa2102685; Elliott JH, 2017, J CLIN EPIDEMIOL, V91, P23, DOI 10.1016/j.jclinepi.2017.08.010; Eom JS, 2021, RES SQUARE, DOI DOI 10.21203/RS.3.RS-296518/V1; Epistemonikos Foundation, 2020, LIV EV REP COVID 19; Faqihi F, 2021, INT J ANTIMICROB AG, V57, DOI 10.1016/j.ijantimicag.2021.106334; Friedrich JO, 2011, J CLIN EPIDEMIOL, V64, P556, DOI 10.1016/j.jclinepi.2010.09.016; Gaborit B, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.01237-21; Gharbharan A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23469-2; Gharebaghi N, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05507-4; Gonzalez JLB, 2021, MEDRXIV, V2021, DOI [10.1101/2021.03.28.21254507, DOI 10.1101/2021.03.28.21254507]; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P407, DOI 10.1016/j.jclinepi.2010.07.017; Hoffmann M, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109415; Horby PW, 2021, LANCET, V397, P2049, DOI 10.1016/S0140-6736(21)00897-7; Hultcrantz M, 2017, J CLIN EPIDEMIOL, V87, P4, DOI 10.1016/j.jclinepi.2017.05.006; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Johns Hopkins University, 2020, COR RES CTR; Korper S, 2021, MEDRXIV2021051021256, V2021, DOI [10.1101/2021.05.10.21256192, DOI 10.1101/2021.05.10.21256192]; Lamontagne F, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n526; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Lanzoni G, 2021, STEM CELL TRANSL MED, V10, P660, DOI 10.1002/sctm.20-0472; Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044; Libster R, 2021, NEW ENGL J MED, V384, P610, DOI 10.1056/NEJMoa2033700; Looney RJ, 2006, BEST PRACT RES CL HA, V19, P3, DOI 10.1016/j.beha.2005.01.032; Lopardo G, 2021, ECLINICALMEDICINE, V34, DOI 10.1016/j.eclinm.2021.100843; Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396; Marshall IJ, 2018, RES SYNTH METHODS, V9, P602, DOI 10.1002/jrsm.1287; Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299; Murchu EO, 2022, ANN PHARMACOTHER, V56, P309, DOI 10.1177/10600280211028242; Norwegian Institute of Public Health, 2020, CO2 COSOURCES CONSUM; O'Donnell MR, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150646; OBrien MP, SUBCUTANEOU REGEN CO, V2021; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Pouladzadeh M, 2021, INTERN EMERG MED, V16, P2181, DOI 10.1007/s11739-021-02734-8; Pritchard M, 2020, ISARIC CLIN DATA REP, DOI [10.1101/2020.07.17.20155218, DOI 10.1101/2020.07.17.20155218]; Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630; Raman RS, 2021, J INFECT DIS, V223, P1538, DOI 10.1093/infdis/jiab098; Ray Y., 2020, INFECT DIS EXCEPT HI, V2020, p11.25.20237883, DOI 10.1101/2020.11.25.20237883; RECOVERY Collaborative group, 2021, LANCET, DOI [10.1101/2021.06.15.21258542, DOI 10.1101/2021.06.15.21258542V1]; Rover C, 2020, J STAT SOFTW, V93, P1, DOI 10.18637/jss.v093.i06; Sakoulas G, 2020, MEDRXIV, V2, DOI DOI 10.1101/2020.07.20.20157891; Salman OH, 2020, EGYPT J ANAESTH, V36, P264, DOI 10.1080/11101849.2020.1842087; Sarkis E, 2021, EARLY COVID19 TREATM, DOI [10.1101/2021.05.27.21257096, DOI 10.1101/2021.05.27.21257096]; Schandelmaier S, 2020, CAN MED ASSOC J, V192, pE901, DOI 10.1503/cmaj.200077; Sekine L, 2022, EUR RESPIR J, V59, DOI 10.1183/13993003.01471-2021; Shi L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00488-5; Shu L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01875-5; Siemieniuk RA, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i5191; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Simonovich VA, 2021, NEW ENGL J MED, V384, P619, DOI 10.1056/NEJMoa2031304; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Tabarsi P, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107205; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; The CONCOR-1 Study Group CONCOR-1 writing committeeBegin P, CONVALESCENT PLASMA, V2021; The REMAP-CAP InvestigatorsEstcourt LJ, MEDRXIV, V2021, DOI [10.1101/2021.06.11.21258760, DOI 10.1101/2021.06.11.21258760]; Torres Zambrano GM, 2020, FEATURES OUTCOMES SE, DOI [10.1101/2020.12.05.20244483, DOI 10.1101/2020.12.05.20244483]; Turner RM, 2015, STAT MED, V34, P984, DOI 10.1002/sim.6381; US Food & Drug Administration, 2021, CONV PLASM COVID 19; Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600; van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812; van Valkenhoef G, 2016, RES SYNTH METHODS, V7, P80, DOI 10.1002/jrsm.1167; Vandvik PO, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0596-4; Weinreich DM, REGEN COV ANTIBODY C, V2021; Weinreich DM, 2021, REGEN COV ANTIBODY C, V2021, DOI [10.1101/2021.06.09.21257915, DOI 10.1101/2021.06.09.21257915]; World Health Organization, 2020, TRANSMISSION SARS CO; World Health Organization, 2021, THERAPEUTICS COVID 1; Yendry Ventura C, 2021, RES SQUARE, DOI [10.21203/rs.3.rs-558653/v1, DOI 10.21203/RS.3.RS-558653/V1]	93	33	33	4	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	2021	374								n2231	10.1136/bmj.n2231	http://dx.doi.org/10.1136/bmj.n2231			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ1JE	34556486	hybrid, Green Published			2023-01-03	WOS:000701967300014
J	Ying, L; Yang, YJ; Zhou, J; Huang, HR; Du, GK				Ying, Li; Yang, Yunjia; Zhou, Jun; Huang, Hairong; Du, Guankui			Effect of chewing betel nut on the gut microbiota of Hainanese	PLOS ONE			English	Article							OBESITY; DISEASE; PREVALENCE; BUTYRATE; HEALTH; ACIDS; DIET; RISK	Betel nut chewing (BNC) is prevalent in South Asia and Southeast Asia. BNC can affect host health by modulating the gut microbiota. The aim of this study is to evaluate the effect of BNC on the gut microbiota of the host. Feces samples were obtained from 34 BNC individuals from Ledong and Lingshui, Hainan, China. The microbiota was analyzed by 16S rRNA gene sequencing. BNC decreased the microbial alpha-diversity. Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria were the predominant phyla, accounting for 99.35% of the BNC group. The Firmicutes-to-Bacteroidetes ratio was significantly increased in the BNC group compared to a control group. The abundances of the families Aerococcaceae, Neisseriaceae, Moraxellaceae, Porphyromonadaceae, and Planococcaceae were decreased in the BNC/BNC_Male/BNC_Female groups compared to the control group, whereas the abundances of Coriobacteriaceae, Streptococcaceae, Micrococcaceae, Xanthomonadaceae, Coxiellaceae, Nocardioidaceae, Rhodobacteraceae, and Succinivibrionaceae were increased. In general, the gut microbiome profiles suggest that BNC may have positive effects, such as an increase in the abundance of beneficial microbes and a reduction in the abundance of disease-related microbes. However, BNC may also produce an increase in the abundance of disease-related microbes. Therefore, extraction of prebiotic components could increase the beneficial value of betel nut.	[Ying, Li; Du, Guankui] Hainan Med Univ, Key Lab Mol Biol, Haikou, Peoples R China; [Ying, Li] Haikou Customs, Haikou, Peoples R China; [Yang, Yunjia; Huang, Hairong] Hainan Med Univ, Sch Publ Hlth, Haikou, Peoples R China; [Zhou, Jun] Hainan Med Univ, Biotechnol Major, Haikou, Peoples R China; [Du, Guankui] Hainan Med Univ, Dept Biochem & Mol Biol, Haikou, Peoples R China	Hainan Medical University; Hainan Medical University; Hainan Medical University; Hainan Medical University	Du, GK (corresponding author), Hainan Med Univ, Key Lab Mol Biol, Haikou, Peoples R China.; Du, GK (corresponding author), Hainan Med Univ, Dept Biochem & Mol Biol, Haikou, Peoples R China.	duguankui@163.com	Du, Guankui/AAG-7628-2019	Du, Guankui/0000-0002-1117-8299	Hainan Natural Science Foundation [821RC561]; Innovative research projects for graduate students in Hainan Province [Hys2020-350]	Hainan Natural Science Foundation; Innovative research projects for graduate students in Hainan Province	This study was funded by Hainan Natural Science Foundation (821RC561) and Innovative research projects for graduate students in Hainan Province (Hys2020-350). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afolayan AO, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03971; Barandouzi ZA, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00541; Brahe LK, 2013, OBES REV, V14, P950, DOI 10.1111/obr.12068; Bridgeman SC, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.105174; Chng KR, 2016, EBIOMEDICINE, V8, P195, DOI 10.1016/j.ebiom.2016.04.034; DIEKERT G, 1994, ANTON LEEUW INT J G, V66, P209, DOI 10.1007/BF00871640; Ejtahed HS, 2020, BIOSCI MICROB FOOD H, V39, P65, DOI 10.12938/bmfh.2019-026; Gong X, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.517797; Hakkak R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181451; Hashimoto Y, 2020, J DIABETES INVEST, V11, P1623, DOI 10.1111/jdi.13293; Holodniy M, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0025792, 10.1371/journal.pone.0014764]; Hu R, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10091474; Huang YT, 2020, SUBST USE MISUSE, V55, P1472, DOI 10.1080/10826084.2020.1732421; Iino C, 2020, DIGESTION, V101, P422, DOI 10.1159/000500634; Jung JW, 2016, TUBERC RESPIR DIS, V79, P165, DOI 10.4046/trd.2016.79.3.165; KENEALY WR, 1985, ARCH MICROBIOL, V141, P187, DOI 10.1007/BF00408056; Lamprecht P, 2019, J AUTOIMMUN, V97, P29, DOI 10.1016/j.jaut.2018.10.005; Larsen N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009085; Lee SY, 2021, NUTR RES, V87, P31, DOI 10.1016/j.nutres.2020.12.013; Li SJ, 2020, PEERJ, V8, DOI [10.7717/peeej.9574, 10.7717/peerj.9574]; Liu H, 2018, ADV NUTR, V9, P21, DOI 10.1093/advances/nmx009; Lo Sasso G, 2021, INFLAMM BOWEL DIS, V27, P418, DOI 10.1093/ibd/izaa188; Loomba R, 2019, CELL METAB, V30, P607, DOI 10.1016/j.cmet.2019.08.002; Lotter H, 2019, SEMIN IMMUNOPATHOL, V41, P133, DOI 10.1007/s00281-018-00728-x; Luu M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01225; Ma ZS, 2019, ADV SCI, V6, DOI 10.1002/advs.201902054; Machiels K, 2020, J CROHNS COLITIS, V14, P1535, DOI 10.1093/ecco-jcc/jjaa081; Manolidi K, 2019, J HAZARD MATER, V365, P346, DOI 10.1016/j.jhazmat.2018.10.084; Meng S, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00318; Molinero N, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0712-8; Myint SK, 2016, SE ASIAN J TROP MED, V47, P1089; Naumova N, 2020, INDIAN J MICROBIOL, V60, P451, DOI 10.1007/s12088-020-00888-1; Niu J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00439; Peng W, 2015, J ETHNOPHARMACOL, V164, P340, DOI 10.1016/j.jep.2015.02.010; Rodriguez-Daza MC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02032; Samra M, 2019, INT ARCH ALLERGY IMM, V178, P150, DOI 10.1159/000492677; Schwiertz A, 2010, OBESITY, V18, P190, DOI 10.1038/oby.2009.167; Sonnenburg JL, 2016, NATURE, V535, P56, DOI 10.1038/nature18846; Stacchiotti V, 2021, CRIT REV FOOD SCI, V61, P3211, DOI 10.1080/10408398.2020.1793728; Stanford J, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-01805-w; Suganya K, 2021, MICROB PATHOGENESIS, V152, DOI 10.1016/j.micpath.2020.104583; Tan J, 2014, ADV IMMUNOL, V121, P91, DOI 10.1016/B978-0-12-800100-4.00003-9; Tseng Chin-Hsiao, 2010, BMC Res Notes, V3, P228, DOI 10.1186/1756-0500-3-228; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Vaziri ND, 2013, KIDNEY INT, V83, P308, DOI 10.1038/ki.2012.345; Verma H, 2020, INDIAN J MICROBIOL, V60, P405, DOI 10.1007/s12088-020-00898-z; Vindegaard N, 2021, SCHIZOPHR RES, V234, P41, DOI 10.1016/j.schres.2019.12.014; Wang M, 2018, INT UROL NEPHROL, V50, P1097, DOI 10.1007/s11255-018-1819-8; Wei YT, 2017, DRUG ALCOHOL DEPEN, V180, P1, DOI 10.1016/j.drugalcdep.2017.07.035; Yang J, 2021, ORAL DIS, V27, P1366, DOI 10.1111/odi.13456; Yongxiu Du, 2016, Hua Xi Kou Qiang Yi Xue Za Zhi, V34, P391, DOI 10.7518/hxkq.2016.04.014; Yun Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213692; Zhang HJ, 2017, EUR J PHARM SCI, V109, P56, DOI 10.1016/j.ejps.2017.07.028; Zhao X, 2020, SUBST USE MISUSE, V55, P1519, DOI 10.1080/10826084.2019.1660676; Zhu LX, 2013, HEPATOLOGY, V57, P601, DOI 10.1002/hep.26093; Zhu QW, 2020, MICROBIOLOGYOPEN, V9, DOI 10.1002/mbo3.1053; Zhu YH, 2020, ACS CHEM NEUROSCI, V11, P3366, DOI 10.1021/acschemneuro.0c00475	57	0	1	4	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	10							e0258489	10.1371/journal.pone.0258489	http://dx.doi.org/10.1371/journal.pone.0258489			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9YI	34648581	gold, Green Published			2023-01-03	WOS:000729172300013
J	Lee, H; Sun, R; Niehrs, C				Lee, Hyeyoon; Sun, Rui; Niehrs, Christof			Uncoupling the BMP receptor antagonist function from the WNT agonist function of R-spondin 2 using the inhibitory peptide dendrimer RWd	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT/BETA-CATENIN; ENDOCYTOSIS; ORGANIZER; MEMBRANE; LGR5	Signaling by bone morphogenetic proteins (BMPs) plays pivotal roles in embryogenesis, adult tissue homeostasis, and disease. Recent studies revealed that the well-established WNT agonist R-spondin 2 (RSPO2) is also a BMP receptor (BMP receptor type 1A) antagonist, with roles in early Xenopus embryogenesis and human acute myeloid leukemia (AML). To uncouple the BMP antagonist function from the WNT agonist function and to promote development of AML therapeutics, here we identified a 10-mer peptide (RW) derived from the thrombospondin 1 domain of RSPO2, which specifically prevents binding between RSPO2 and BMP receptor type 1A without altering WNT signaling. We also show that a corresponding RW dendrimer (RWd) exhibiting improved half-life relieves inhibition of BMP receptor signaling by RSPO2 in human AML cells, reduces cell growth, and induces differentiation. Moreover, microinjection of RWd in Xenopus embryos ventralizes the dorsoventral embryonic patterning by upregulating BMP signaling without affecting WNT signaling. Our study corroborates the function of RSPO2 as a BMP receptor antagonist and provides a proof of concept for pharmacologically uncoupling BMP antagonist from WNT agonist functions of RSPO2 using the inhibitor peptide RWd with enhanced target selectivity and limited side effects.	[Lee, Hyeyoon; Sun, Rui; Niehrs, Christof] Deutsch Krebsforschungszentrum DKFZ, Div Mol Embryol, DKFZ ZMBH Alliance, Heidelberg, Germany; [Niehrs, Christof] Inst Mol Biol IMB, Mainz, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Institute of Molecular Biology (IMB)	Niehrs, C (corresponding author), Deutsch Krebsforschungszentrum DKFZ, Div Mol Embryol, DKFZ ZMBH Alliance, Heidelberg, Germany.; Niehrs, C (corresponding author), Inst Mol Biol IMB, Mainz, Germany.	niehrs@dkfz-heidelberg.de			Deutsche Forschungsgemeinschaft (German Research Foundation) [SFB1324-B01]	Deutsche Forschungsgemeinschaft (German Research Foundation)(German Research Foundation (DFG))	This work was funded by the Deutsche Forschungsgemeinschaft (German Research Foundation) to C. N. (grant no.: SFB1324-B01).	Antebi YE, 2017, CELL, V170, P1184, DOI 10.1016/j.cell.2017.08.015; Bracci L, 2003, J BIOL CHEM, V278, P46590, DOI 10.1074/jbc.M308615200; Cai J, 2012, FEBS LETT, V586, P1993, DOI 10.1016/j.febslet.2012.04.030; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Chang CB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021923; Chartier C, 2016, CANCER RES, V76, P713, DOI 10.1158/0008-5472.CAN-15-0561; Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055; Cui J, 2021, J MED CHEM, V64, P12572, DOI 10.1021/acs.jmedchem.1c00395; Cunningham AD, 2017, CURR OPIN STRUC BIOL, V44, P59, DOI 10.1016/j.sbi.2016.12.009; Davenport AP, 2020, NAT REV DRUG DISCOV, V19, P389, DOI 10.1038/s41573-020-0062-z; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; De Kouchkovsky I, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.50; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Dubey R, 2020, ELIFE, V9, DOI 10.7554/eLife.54469; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175; Han T, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms15945; Hao HX, 2016, CANCERS, V8, DOI 10.3390/cancers8060054; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Heldin CH, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022053; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ilmer M, 2015, CANCER RES, V75, P1883, DOI 10.1158/0008-5472.CAN-14-1327; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kim JE, 2012, J BIOMED MATER RES A, V100A, P1488, DOI 10.1002/jbm.a.34089; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Klauzinska M, 2012, J CELL PHYSIOL, V227, P1960, DOI 10.1002/jcp.22924; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Lebensohn AM, 2018, ELIFE, V7, DOI 10.7554/eLife.33126; Lee H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19373-w; Li Ming, 2008, Yichuan, V30, P885, DOI 10.3724/SP.J.1005.2008.00885; Lowery JW, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7290686; Lu HY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00315-3; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Muller PY, 2012, NAT REV DRUG DISCOV, V11, P751, DOI 10.1038/nrd3801; Nanki K, 2018, CELL, V174, P856, DOI 10.1016/j.cell.2018.07.027; Niehrs C, 2004, NAT REV GENET, V5, P425, DOI 10.1038/nrg1347; Ohkawara B, 2011, DEV CELL, V20, P303, DOI 10.1016/j.devcel.2011.01.006; Peng WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083110; de Vega MJP, 2007, CURR TOP MED CHEM, V7, P33; Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4; Sadler Kristen, 2002, J Biotechnol, V90, P195; Saito N, 2003, BIOMATERIALS, V24, P2287, DOI 10.1016/S0142-9612(03)00040-1; Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12; Salik B, 2020, CANCER CELL, V38, P263, DOI 10.1016/j.ccell.2020.05.014; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shimer AL, 2009, INJURY, V40, P32; Sugimoto H, 2012, NAT MED, V18, P396, DOI 10.1038/nm.2629; Sun Aihua, 2013, Zhejiang Da Xue Xue Bao Yi Xue Ban, V42, P125; Sun R, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109559; Suzuki Y, 2000, J BIOMED MATER RES, V50, P405, DOI 10.1002/(SICI)1097-4636(20000605)50:3<405::AID-JBM15>3.0.CO;2-Z; Szenker-Ravi E, 2018, NATURE, V557, P564, DOI 10.1038/s41586-018-0118-y; Tong Z, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49758-x; Vlieghe P, 2010, DRUG DISCOV TODAY, V15, P40, DOI 10.1016/j.drudis.2009.10.009; Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9; Yu SM, 2021, BIOCONJUGATE CHEM, V32, P376, DOI 10.1021/acs.bioconjchem.1c00008; Zebisch M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3787; Zhang HB, 2019, J CELL BIOCHEM, V120, P5813, DOI 10.1002/jcb.27867; Zhang YE, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022129; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhang YC, 2020, ANNU REV PHYSIOL, V82, P251, DOI 10.1146/annurev-physiol-021119-034500; Zylbersztejn F, 2018, EXP HEMATOL, V61, P36, DOI 10.1016/j.exphem.2018.02.005	66	0	0	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB	2022	298	2							101586	10.1016/j.jbc.2022.101586	http://dx.doi.org/10.1016/j.jbc.2022.101586			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZI1JE	35032551	Green Published, gold			2023-01-03	WOS:000761380200004
J	Safarpour, AR; Fattahi, MR; Niknam, R; Tarkesh, F; Mohammadkarimi, V; Boogar, SS; Abbasi, E; Abtahi, F; Sivandzadeh, GR; Ejtehadi, F; Afshar, M; Shamsnia, SA; Niknejad, N				Safarpour, Ali Reza; Fattahi, Mohammad Reza; Niknam, Ramin; Tarkesh, Firoozeh; Mohammadkarimi, Vahid; Boogar, Shahrokh Sadeghi; Abbasi, Elham; Abtahi, Firoozeh; Sivandzadeh, Gholam Reza; Ejtehadi, Fardad; Afshar, Mohammad; Shamsnia, Seyed Ali; Niknejad, Nasim			Alarm of non-communicable disease in Iran: Kavar cohort profile, baseline and 18-month follow up results from a prospective population-based study in urban area	PLOS ONE			English	Article							METABOLIC SYNDROME; ESOPHAGEAL CANCER; PREVALENCE; ASSOCIATION; SOUTH	Y The PERSIAN Kavar cohort study (PKCS) aims to investigate the prevalence, trends, and relevant prognostic risk factors of non-communicable diseases in participants aged 35-70 years living in the urban area of Kavar County. Kavar County is located at the center of Fars province in the southwest of Iran. Overall, 5236 adults aged 35-70 years old were invited to participate in the PKCS. From whom, 4997 people comprising 2419 men and 2578 women met the inclusion criteria and were recruited in the study (participation rate: 95.4%). This study is aimed to follow participants for at least 10 years; it is designed to perform all procedures similar to the primary phase including biological sampling, laboratory tests, physical examinations, and collecting general, nutritional, and medical data at the 5th and 10th years of follow-up. In addition, participants are annually followed-up by phone to acquire data on the history of hospitalization, any major diagnosis or death. At the enrollment phase, trained interviewers were responsible for obtaining general, nutritional, and medical data utilizing a 482-item questionnaire. The results of the baseline phase of this study show that the overweight category was the most prevalent BMI category among the registered participants (n = 2005, 40.14%). Also, almost one-third of Kavar adult population suffered from metabolic syndrome at the baseline phase (n = 1664, 33.30%). The rate of eighteen-month follow-up response was 100% in the PKCS. Hypertension (n = 116, 2.32%), cardiovascular outcomes (n = 33, 0.66%), and diabetes (n = 32, 0.64%) were the most prevalent new-onset NCDs during eighteen months of follow-up in the participants.	[Safarpour, Ali Reza; Fattahi, Mohammad Reza; Niknam, Ramin; Tarkesh, Firoozeh; Abbasi, Elham; Sivandzadeh, Gholam Reza; Ejtehadi, Fardad] Shiraz Univ Med Sci, Gastroenterohepatol Res Ctr, Shiraz, Iran; [Mohammadkarimi, Vahid; Boogar, Shahrokh Sadeghi] Shiraz Univ Med Sci, Sch Med, Dept Internal Med, Shiraz, Iran; [Abtahi, Firoozeh] Shiraz Univ Med Sci, Cardiovasc Res Ctr, Shiraz, Iran; [Afshar, Mohammad; Shamsnia, Seyed Ali] Shiraz Univ Med Sci, Kavar Hlth Syst Network, Shiraz, Iran; [Niknejad, Nasim] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada	Shiraz University of Medical Science; Shiraz University of Medical Science; Shiraz University of Medical Science; Shiraz University of Medical Science; University of British Columbia	Fattahi, MR (corresponding author), Shiraz Univ Med Sci, Gastroenterohepatol Res Ctr, Shiraz, Iran.	fattahim@sums.ac.ir	Abtahi, Firoozeh/D-2085-2018; Safarpour, Ali Reza/G-4061-2010	Abtahi, Firoozeh/0000-0002-8202-465X; Safarpour, Ali Reza/0000-0002-9880-0043	Ministry of Health and Medical Education of Iran [700/1918]	Ministry of Health and Medical Education of Iran	The Ministry of Health and Medical Education of Iran funded this study (https://behdasht.gov.ir/) under grant No: 700/1918. The grant was awarded to MR Fattahi. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbasian E., 2015, CHRONIC DIS J, V3, P87; [Anonymous], 2015, LANCET, V385, P117; Ansarimoghaddam A, 2018, DIABETES METAB SYND, V12, P195, DOI 10.1016/j.dsx.2017.11.004; Asgari S, 2020, GLOB HEART, V15, DOI 10.5334/gh.780; Askarian M, 2012, CLIN MICROBIOL INFEC, V18, P1081, DOI 10.1111/1469-0691.12021; Bentley-Lewis R, 2007, NAT CLIN PRACT ENDOC, V3, P696, DOI 10.1038/ncpendmet0616; Chegeni M, 2020, DRUG ALCOHOL REV, V39, P525, DOI 10.1111/dar.13093; Cheraghian Bahman, 2020, Med J Islam Repub Iran, V34, P141, DOI 10.34171/mjiri.34.141; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Control CfD Prevention, 2020, NAT DIAB STAT REP 20, P12; Control CfD Prevention, 2007, NATL HLTH NUTR EXAMI; Dallongeville J, 2004, ANN NUTR METAB, V48, P43, DOI 10.1159/000075304; Danaei G, 2019, LANCET, V393, P1984, DOI 10.1016/S0140-6736(18)33197-0; Esfahani FH, 2010, J EPIDEMIOL, V20, P150, DOI 10.2188/jea.JE20090083; Fatahi A, 2020, INT J PREVENTIVE MED, V11, DOI 10.4103/ijpvm.IJPVM_489_18; Fattahi Mohammad Reza, 2016, Middle East J Dig Dis, V8, P131, DOI 10.15171/mejdd.2016.18; Gandomkar A, 2017, INT J PUBLIC HEALTH, V62, P397, DOI 10.1007/s00038-016-0848-2; Ghasemian A, 2014, ARCH IRAN MED, V17, P146, DOI 0141703/AIM.004; Haghdoost A. A., 2009, Eastern Mediterranean Health Journal, V15, P591; Hakimi H, 2021, EUR J EPIDEMIOL, V36, P243, DOI 10.1007/s10654-020-00668-7; Islami F, 2009, INT J EPIDEMIOL, V38, P978, DOI 10.1093/ije/dyp195; Kaur J, 2014, CARDIOL RES PRACT, V2014, DOI 10.1155/2014/943162; Karyani AK, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7715-z; Khaledifar A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5364-2; Kheradmand M, 2019, ARCH IRAN MED, V22, P279; Mansour-Ghanaei F, 2019, ARCH IRAN MED, V22, P39; Mazloomzadeh S, 2018, IRAN J PUBLIC HEALTH, V47, P473; Mills KT, 2020, NAT REV NEPHROL, V16, P223, DOI 10.1038/s41581-019-0244-2; Moghadam MN, 2012, INT J HEALTH PLAN M, V27, pe121, DOI 10.1002/hpm.1105; Mohan V, 2020, J DIABETES COMPLICAT, V34, DOI 10.1016/j.jdiacomp.2020.107652; Moradinazar M, 2020, SUBST ABUSE TREAT PR, V15, DOI 10.1186/s13011-020-00279-1; Moradinazar M, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08809-z; Najafi F, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8322-8; Nikbakht HA, 2020, CLIN EPIDEMIOL GLOB, V8, P678, DOI 10.1016/j.cegh.2020.01.001; Oori MJ, 2019, CURR HYPERTENS REV, V15, P113, DOI 10.2174/1573402115666190118142818; Ostovar A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009597; Pasdar Y, 2019, INT J EPIDEMIOL, V48, P682, DOI 10.1093/ije/dyy296; Pourshams A, 2010, INT J EPIDEMIOL, V39, P52, DOI 10.1093/ije/dyp161; Poustchi H, 2018, AM J EPIDEMIOL, V187, P647, DOI 10.1093/aje/kwx314; Saeedi P, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107843; Sepehrimanesh M, 2020, DIABET METAB SYND OB, V13, P1449, DOI 10.2147/DMSO.S246949; Sharafi Mehdi, 2021, Med J Islam Repub Iran, V35, P78, DOI 10.47176/mjiri.35.78; World Health Organization, 2016, ICD 10 VERS 2016; World Health Organization, 2018, DHAKA NONCOMMUNICABL	44	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0260227	10.1371/journal.pone.0260227	http://dx.doi.org/10.1371/journal.pone.0260227			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085244	Green Published, gold			2023-01-03	WOS:000779379600013
J	Brusselle, GG; Koppelman, GH				Brusselle, Guy G.; Koppelman, Gerard H.			Biologic Therapies for Severe Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEVERE EOSINOPHILIC ASTHMA; QUALITY-OF-LIFE; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; PRECISION MEDICINE; NASAL POLYPOSIS; MEPOLIZUMAB; PLACEBO; BENRALIZUMAB; EFFICACY	Biologic Therapies for Severe Asthma Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.	[Brusselle, Guy G.] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium; [Brusselle, Guy G.] Erasmus MC, Dept Epidemiol & Resp Med, Rotterdam, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Dept Pediat Pulmonol & Pediat Allergol, Beatrix Childrens Hosp, Univ Med Ctr Groningen, Groningen, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Groningen Res Inst Asthma & COPD, Univ Med Ctr Groningen, Groningen, Netherlands	Ghent University; Ghent University Hospital; Erasmus University Rotterdam; Erasmus MC; University of Groningen; University of Groningen	Brusselle, GG (corresponding author), Ghent Univ Hosp, C Heymanslaan 10, B-9000 Ghent, Belgium.	guy.brusselle@ugent.be						Bacharier LB, 2021, NEW ENGL J MED, V385, P2230, DOI 10.1056/NEJMoa2106567; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bernstein JA, 2020, LANCET RESP MED, V8, P461, DOI 10.1016/S2213-2600(19)30372-8; Bleecker ER, 2020, AM J RESP CRIT CARE, V201, P276, DOI 10.1164/rccm.201904-0903SO; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brightling CE, 2021, NEW ENGL J MED, V385, P1669, DOI 10.1056/NEJMoa2030880; Brusselle G, 2017, PULM PHARMACOL THER, V43, P39, DOI 10.1016/j.pupt.2017.01.011; Buhl R, 2022, J ALLER CL IMM-PRACT, V10, P422, DOI 10.1016/j.jaip.2021.10.059; Busse WW, 2019, LANCET RESP MED, V7, P46, DOI 10.1016/S2213-2600(18)30406-5; Casale TB, 2019, J ALLER CL IMM-PRACT, V7, P156, DOI 10.1016/j.jaip.2018.04.043; Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092; Castro M, 2020, ERJ OPEN RES, V6, DOI 10.1183/23120541.00204-2019; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Christiansen SC, 2019, NEW ENGL J MED, V381, P1046, DOI 10.1056/NEJMra1800345; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X; Clinical Research Pathways, 2021, DIV CLIN TRIALS; Corren J, 2021, J ALLER CL IMM-PRACT, V9, P1224, DOI 10.1016/j.jaip.2020.10.033; Criner GJ, 2019, NEW ENGL J MED, V381, P1023, DOI 10.1056/NEJMoa1905248; Diver S, 2021, LANCET RESP MED, V9, P1299, DOI 10.1016/S2213-2600(21)00226-5; Dupin C, 2020, CLIN EXP ALLERGY, V50, P789, DOI 10.1111/cea.13614; Eger K, 2021, J ALLER CL IMM-PRACT, V9, P2913, DOI 10.1016/j.jaip.2021.02.042; Eger K, 2021, J ALLER CL IMM-PRACT, V9, P1194, DOI 10.1016/j.jaip.2020.10.010; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; FitzGerald JM, 2018, LANCET RESP MED, V6, P51, DOI 10.1016/S2213-2600(17)30344-2; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Frossing L, 2021, J ALLER CL IMM-PRACT, V9, P1267, DOI 10.1016/j.jaip.2020.09.051; Fu Z, 2021, J ASTHMA, V58, P1350, DOI 10.1080/02770903.2020.1789875; Gauvreau GM, 2020, EXPERT OPIN THER TAR, V24, P777, DOI 10.1080/14728222.2020.1783242; Global Initiative for Asthma, 2021, GLOB STRAT ASTHM MAN; Global Initiative for Asthma, 2019, DIFF TO TREAT SEV AS; Gupta A, 2019, J ALLERGY CLIN IMMUN, V144, P1336, DOI 10.1016/j.jaci.2019.08.005; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hammad H, 2021, CELL, V184, P1469, DOI 10.1016/j.cell.2021.02.016; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Harrison TW, 2021, LANCET RESP MED, V9, P260, DOI 10.1016/S2213-2600(20)30414-8; Harvey ES, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.02420-2019; Hearn AP, 2021, J ALLER CL IMM-PRACT, V9, P2093, DOI 10.1016/j.jaip.2021.01.008; Hinks TSC, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.00528-2020; Howarth P, 2020, J ALLERGY CLIN IMMUN, V145, P1713, DOI 10.1016/j.jaci.2020.02.002; Israel E, 2021, J ALLERGY CLIN IMMUN, V147, P1594, DOI 10.1016/j.jaci.2021.01.037; Israel E, 2017, NEW ENGL J MED, V377, P965, DOI 10.1056/NEJMra1608969; Kavanagh JE, 2021, CHEST, V159, P496, DOI 10.1016/j.chest.2020.08.2083; Kelsen SG, 2021, J ALLERGY CLIN IMMUN, V148, P790, DOI 10.1016/j.jaci.2021.03.044; Khatri S, 2019, J ALLERGY CLIN IMMUN, V143, P1742, DOI 10.1016/j.jaci.2018.09.033; Krings JG, 2019, J ALLER CL IMM-PRACT, V7, P1379, DOI 10.1016/j.jaip.2019.03.008; Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020; Liu S, 2021, J ALLER CL IMM-PRACT, V9, P693, DOI 10.1016/j.jaip.2020.11.054; Lugogo NL, 2020, ANN ALLERG ASTHMA IM, V125, P171, DOI 10.1016/j.anai.2020.04.011; Manka LA, 2018, ANN ALLERG ASTHMA IM, V121, P406, DOI 10.1016/j.anai.2018.07.033; Maspero JF, 2021, ALLERGY, V76, P2621, DOI 10.1111/all.14872; Menzies-Gow A, 2021, NEW ENGL J MED, V384, P1800, DOI 10.1056/NEJMoa2034975; Menzies-Gow A, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01633-2019; Menzies-Gow A, 2020, J ALLERGY CLIN IMMUN, V145, P757, DOI 10.1016/j.jaci.2019.12.006; Middleton PG, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01208-2019; Nair P, 2017, NEW ENGL J MED, V376, P2448, DOI 10.1056/NEJMoa1703501; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; NICE, 2013, OM TREAT SEV PERS AL; Oh SS, 2016, AM J RESP CRIT CARE, V193, P348, DOI 10.1164/rccm.201510-2045ED; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Pavord ID, 2017, NEW ENGL J MED, V377, P1613, DOI 10.1056/NEJMoa1708208; Pavord ID, 2018, LANCET, V391, P350, DOI 10.1016/S0140-6736(17)30879-6; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pepper AN, 2021, J ALLER CL IMM-PRACT, V9, P1081, DOI 10.1016/j.jaip.2020.10.048; Pfaller B, 2021, ALLERGY, V76, P71, DOI 10.1111/all.14282; Pijnenburg MW, 2020, LANCET RESP MED, V8, P1032, DOI 10.1016/S2213-2600(20)30399-4; Pilette C, 2018, LANCET RESP MED, V6, P581, DOI 10.1016/S2213-2600(18)30291-1; Porsbjerg CM, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00260-2020; Rabe KF, 2018, NEW ENGL J MED, V378, P2475, DOI 10.1056/NEJMoa1804093; Samedy-Bates LA, 2019, CLIN PHARMACOL THER, V106, P1133, DOI 10.1002/cpt.1555; Settipane RA, 2019, ANN ALLERG ASTHMA IM, V123, P564, DOI 10.1016/j.anai.2019.08.462; Sverrild A, 2022, EUR RESPIR J, V59, DOI 10.1183/13993003.01296-2021; Taille C, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.02345-2019; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Virchow JC, 2020, J ALLER CL IMM-PRACT, V8, P540, DOI 10.1016/j.jaip.2019.07.038; Wechsler ME, 2017, NEW ENGL J MED, V376, P1921, DOI 10.1056/NEJMoa1702079; Wechsler ME., 2020, CHEST, V14, P35450, DOI DOI 10.1016/j.chest.2020.11.060; Wechsler ME, 2021, NEW ENGL J MED, V385, P1656, DOI 10.1056/NEJMoa2024257; Wechsler ME, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01503-z; Wenzel SE, 2021, AM J RESP CRIT CARE, V203, P809, DOI 10.1164/rccm.202009-3631CI; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yancey SW, 2019, ALLERGY ASTHMA CL IM, V15, DOI 10.1186/s13223-019-0366-x	86	51	52	35	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2022	386	2					157	171		10.1056/NEJMra2032506	http://dx.doi.org/10.1056/NEJMra2032506			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF2NZ	35020986	Green Published			2023-01-03	WOS:000741651400013
J	Bikdeli, B; Talasaz, AH; Sharif-Kashani, B; Rashidi, F; Beigmohammadi, MT; Moghadam, KG; Rezaian, S; Dabbagh, A; Sezavar, SH; Farrokhpour, M; Bakhshandeh, H; Abedini, A; Aliannejad, R; Riahi, T; Yadollahzadeh, M; Lookzadeh, S; Rezaeifar, P; Matin, S; Tahamtan, O; Mohammadi, K; Zoghi, E; Rahmani, H; Hosseini, SH; Mousavian, SM; Abri, H; Sadeghipour, P; Baghizadeh, E; Rafiee, F; Jamalkhani, S; Amin, A; Mohebbi, B; Parhizgar, SE; Soleimanzadeh, M; Aghakouchakzadeh, M; Eslami, V; Payandemehr, P; Khalili, H; Talakoob, H; Tojari, T; Shafaghi, S; Ghazi, SF; Tabrizi, S; Kakavand, H; Kashefizadeh, A; Shahmirzaei, S; Najafi, A; Fathi, M; Jimenez, D; Gupta, A; Madhavan, MV; Sethi, SS; Parikh, SA; Monreal, M; Hadavand, N; Hajighasemi, A; Ansarin, K; Maleki, M; Sadeghian, S; Piazza, G; Kirtane, AJ; Van Tassell, BW; Stone, GW; Lip, GYH; Krumholz, HM; Goldhaber, SZ; Sadeghipour, P				Bikdeli, Behnood; Talasaz, Azita H.; Sharif-Kashani, Babak; Rashidi, Farid; Beigmohammadi, Mohammad Taghi; Moghadam, Keivan Gohari; Rezaian, Somaye; Dabbagh, Ali; Sezavar, Seyed Hashem; Farrokhpour, Mohsen; Bakhshandeh, Hooman; Abedini, Atefeh; Aliannejad, Rasoul; Riahi, Taghi; Yadollahzadeh, Mahdi; Lookzadeh, Somayeh; Rezaeifar, Parisa; Matin, Samira; Tahamtan, Ouria; Mohammadi, Keyhan; Zoghi, Elnaz; Rahmani, Hamid; Hosseini, Seyed Hossein; Mousavian, Seyed Masoud; Abri, Homa; Sadeghipour, Pardis; Baghizadeh, Elahe; Rafiee, Farnaz; Jamalkhani, Sepehr; Amin, Ahmad; Mohebbi, Bahram; Parhizgar, Seyed Ehsan; Soleimanzadeh, Mahshid; Aghakouchakzadeh, Maryam; Eslami, Vahid; Payandemehr, Pooya; Khalili, Hossein; Talakoob, Hamed; Tojari, Taranom; Shafaghi, Shadi; Ghazi, Samrand Fattah; Tabrizi, Sanaz; Kakavand, Hessam; Kashefizadeh, Alireza; Shahmirzaei, Shaghayegh; Najafi, Atabak; Fathi, Mohammad; Jimenez, David; Gupta, Aakriti; Madhavan, Mahesh, V; Sethi, Sanjum S.; Parikh, Sahil A.; Monreal, Manuel; Hadavand, Naser; Hajighasemi, Alireza; Ansarin, Khalil; Maleki, Majid; Sadeghian, Saeed; Piazza, Gregory; Kirtane, Ajay J.; Van Tassell, Benjamin W.; Stone, Gregg W.; Lip, Gregory Y. H.; Krumholz, Harlan M.; Goldhaber, Samuel Z.; Sadeghipour, Parham		INSPIRATION-S Investigators	Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STATIN THERAPY; PREVENTION	OBJECTIVE To assess the effect of statin treatment versus placebo on clinical outcomes in patients with covid-19 admitted to the intensive care unit (ICU). DESIGN INSPIRATION/INSPIRATION-S was a multicenter, randomized controlled trial with a 2x2 factorial design. Results for the anticoagulation randomization have been reported previously. Results for the double blind randomization to atorvastatin versus placebo are reported here. SETTING 11 hospitals in Iran. PARTICIPANTS Adults aged >= 18 years with covid-19 admitted to the ICU. INTERVENTION Atorvastatin 20 mg orally once daily versus placebo, to be continued for 30 days from randomization irrespective of hospital discharge status. MAIN OUTCOME MEASURES The primary efficacy outcome was a composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all cause mortality within 30 days from randomization. Prespecified safety outcomes included increase in liver enzyme levels more than three times the upper limit of normal and clinically diagnosed myopathy. A clinical events committee blinded to treatment assignment adjudicated the efficacy and safety outcomes. RESULTS Of 605 patients randomized between 29 July 2020 and 4 April 2021 for statin randomization in the INSPIRATION-S trial, 343 were co-randomized to intermediate dose versus standard dose prophylactic anticoagulation with heparin based regimens, whereas 262 were randomized after completion of the anticoagulation study. 587 of the 605 participants were included in the primary analysis of INSPIRATION-S, reported here: 290 were assigned to atorvastatin and 297 to placebo (median age 57 years (interquartile range 45-68 years); 256 (44%) women). The primary outcome occurred in 95 (33%) patients assigned to atorvastatin and 108 (36%) assigned to placebo (odds ratio 0.84, 95% confidence interval 0.58 to 1.21). Death occurred in 90 (31%) patients in the atorvastatin group and 103 (35%) in the placebo group (odds ratio 0.84, 95% confidence interval 0.58 to 1.22). Rates for venous thromboembolism were 2% (n=6) in the atorvastatin group and 3% (n=9) in the placebo group (odds ratio 0.71, 95% confidence interval 0.24 to 2.06). Myopathy was not clinically diagnosed in either group. Liver enzyme levels were increased in five (2%) patients assigned to atorvastatin and six (2%) assigned to placebo (odds ratio 0.85, 95% confidence interval 0.25 to 2.81). CONCLUSIONS In adults with covid-19 admitted to the ICU, atorvastatin was not associated with a significant reduction in the composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all cause mortality compared with placebo. Treatment was, however, found to be safe. As the overall event rates were lower than expected, a clinically important treatment effect cannot be excluded. TRIAL REGISTRATION ClinicalTrials.gov NCT04486508.	[Sadeghipour, Parham] Rajaie Cardiovasc Med & Res Ctr, Tehran, Iran		Sadeghipour, P (corresponding author), Rajaie Cardiovasc Med & Res Ctr, Tehran, Iran.	bbikdeli@bwh.harvard.edu; psadeghipour@hotmail.com	aghakouchakzadeh, maryam/GLU-6605-2022; rezaian, somaye/ABF-7429-2021; H Talasaz, Azita/GVT-1883-2022; Kakavand, Hessam/GLU-2851-2022	aghakouchakzadeh, maryam/0000-0003-0121-5989; H Talasaz, Azita/0000-0003-1839-3685; Kakavand, Hessam/0000-0001-6719-4856; Mazloomzadeh, Saeideh/0000-0001-6325-0662; Farrokhzadeh, Fahimeh/0000-0003-4027-3401	Rajaie Cardiovascular Medical and Research Center	Rajaie Cardiovascular Medical and Research Center	The study was funded by the Rajaie Cardiovascular Medical and Research Center. Some study authors, including the senior author, are affiliated with the Rajaie Cardiovascular Medical and Research Center. Atorvastatin and matching placebo were provided by Sobhan Darou, which is not among the study sponsors. Neither the funder nor the company who donated the study drugs had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.	Akhmerov A, 2020, CIRC RES, V126, P1443, DOI 10.1161/CIRCRESAHA.120.317055; Al-Samkari H, 2021, ANN INTERN MED, V174, P622, DOI 10.7326/M20-6739; Armstrong RA, 2020, ANAESTHESIA, V75, P1340, DOI 10.1111/anae.15201; Bassler D, 2008, J CLIN EPIDEMIOL, V61, P241, DOI 10.1016/j.jclinepi.2007.07.016; Bikdeli B, 2022, THROMB HAEMOSTASIS, V122, P131, DOI 10.1055/a-1485-2372; Bikdeli B, 2020, THROMB RES, V196, P382, DOI 10.1016/j.thromres.2020.09.027; Bikdeli B, 2020, THROMB HAEMOSTASIS, V120, P1004, DOI 10.1055/s-0040-1713152; Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031; Calfee CS, 2018, LANCET RESP MED, V6, P691, DOI 10.1016/S2213-2600(18)30177-2; Catanzaro M, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0191-1; Cummings Matthew J, 2020, medRxiv, DOI [10.1016/S0140-6736(20)31189-2, 10.1101/2020.04.15.20067157]; Davoodi L, 2021, IJC HEART VASC, V36, DOI 10.1016/j.ijcha.2021.100875; DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13; Gallastegui N, 2021, CLIN APPL THROMB-HEM, V27, DOI 10.1177/1076029621996471; Ganjali S, 2020, METABOLISM, V113, DOI 10.1016/j.metabol.2020.154375; Glynn RJ, 2009, NEW ENGL J MED, V360, P1851, DOI 10.1056/NEJMoa0900241; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3; Hendren NS, 2021, CIRCULATION, V143, P135, DOI 10.1161/CIRCULATIONAHA.120.051936; Hothersall E, 2006, THORAX, V61, P729, DOI 10.1136/thx.2005.057976; Jimenez D, 2021, CHEST, V159, P1182, DOI 10.1016/j.chest.2020.11.005; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Kunutsor SK, 2017, LANCET HAEMATOL, V4, pE83, DOI 10.1016/S2352-3026(16)30184-3; Leentjens J, 2021, LANCET HAEMATOL, V8, DOI 10.1016/S2352-3026(21)00105-8; McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285; Merx MW, 2006, CURR OPIN CRIT CARE, V12, P309, DOI 10.1097/01.ccx.0000235207.00322.96; Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888; Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5; Ramkumar S, 2016, ACTA CARDIOL SIN, V32, P631, DOI 10.6515/ACS20160611A; Sadeghipour P, 2021, JAMA-J AM MED ASSOC, V325, P1620, DOI 10.1001/jama.2021.4152; Sinha P, 2020, LANCET RESP MED, V8, P1209, DOI 10.1016/S2213-2600(20)30366-0; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Sviridov D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.574508; Talasaz AH, 2021, J AM COLL CARDIOL, V78, P1635, DOI 10.1016/j.jacc.2021.08.021; Talasaz AH, 2021, J AM COLL CARDIOL, V77, P1903, DOI 10.1016/j.jacc.2021.02.035; Undas A, 2005, ARTERIOSCL THROM VAS, V25, P287, DOI 10.1161/01.ATV.0000151647.14923.ec; Violi F, 2013, CIRCULATION, V127, P251, DOI 10.1161/CIRCULATIONAHA.112.145334; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Wise J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2058; Wu KS, 2021, ANN MED, V53, P874, DOI 10.1080/07853890.2021.1933165	40	19	19	3	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 7	2022	376									10.1136/bmj-2021-068407	http://dx.doi.org/10.1136/bmj-2021-068407			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP9GN	34996756	hybrid			2023-01-03	WOS:000748927300016
J	Asim, M; Hameed, W; Saleem, S				Asim, Muhammad; Hameed, Waqas; Saleem, Sarah			Do empowered women receive better quality antenatal care in Pakistan? An analysis of demographic and health survey data	PLOS ONE			English	Article							VIOLENCE; AFRICA; AGENCY	Introduction Quality antenatal care is a window of opportunity for improving maternal and neonatal outcomes. Numerous studies have shown a positive effect of women empowerment on improved coverage of maternal and reproductive health services, including antenatal care (ANC). However, there is scarce evidence on the association between women's empowerment and improved ANC services both in terms of coverage and quality. Addressing this gap, this paper examines the relationship between multi-dimensional measures of women empowerment on utilization of quality ANC (service coverage and consultation) in Pakistan. Methods We used Pakistan Demographic and Health Survey 2017-18 (PDHS) data which comprises of 6,602 currently married women aged between 15-49 years who had a live birth in the past five years preceding the survey. Our exposure variables were three-dimensional measures of women empowerment (social independence, decision making, and attitude towards domestic violence), and our outcome variables were quality of antenatal coverage [i.e. a composite binary measure based on skilled ANC (trained professional), timeliness (1st ANC visit during first trimester), sufficiency of ANC visits (4 or more)] and quality of ANC consultation (i.e. receiving at least 7 or more essential antenatal components out of 8). Data were analysed in Stata 16.0 software. Descriptive statistics were used to describe sample characteristics and binary logistic regression was employed to assess the association between empowerment and quality of antenatal care. Results We found that 41.4% of the women received quality ANC coverage and 30.6% received quality ANC consultations during pregnancy. After controlling for a number of socio-economic and demographic factors, all three measures of women's empowerment independently showed a positive relationship with both outcomes. Women with high autonomy (i.e. strongly opposed the notion of violence) in the domain of attitude to violence are 1.66 (95% CI 1.30-2.10) and 1.45 (95% CI 1.19-1.75) and times more likely to receive antenatal coverage and quality ANC consultations respectively, compared with women who ranked low on attitude to violence. Women who enjoy high social independence had 1.87 (95% CI 1.44-2.43) and 2.78 (95% CI 2.04-3.79) higher odds of quality antenatal coverage and consultations respectively, as compared with their counterparts. Similarly, women who had high autonomy in household decision making 1.98 (95% CI 1.60-2.44) and 1.56 (95% CI 2.17-1.91) were more likely to receive quality antenatal coverage and consultation respectively, as compared to women who possess low autonomy in household decision making. Conclusion The quality of ANC coverage and consultation with service provider is considerably low in Pakistan. Women's empowerment related to social independence, gendered beliefs about violence, and decision-making have an independent positive association with the utilisation of quality antenatal care. Thus, efforts directed towards empowering women could be an effective strategy to improve utilisation of quality antenatal care in Pakistan.	[Asim, Muhammad; Hameed, Waqas; Saleem, Sarah] Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan	Aga Khan University	Hameed, W (corresponding author), Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan.	waqas.hameed1@gmail.com						Afulani PA, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4476-4; Agha S, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0979-8; Ali PA, 2015, TRAUMA VIOLENCE ABUS, V16, P299, DOI 10.1177/1524838014526065; Ali Tazeen Saeed, 2007, JPMA Journal of the Pakistan Medical Association, V57, P27; Arsenault C, 2018, LANCET GLOB HEALTH, V6, pE1186, DOI 10.1016/S2214-109X(18)30389-9; Benova L, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000779; Bin Nisar Y, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-305; Carvajal-Aguirre L, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020501; Ewerling F, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.020434; Freedman LP, 2014, LANCET, V384, pE42, DOI 10.1016/S0140-6736(14)60859-X; GALLOWAY R, 1994, SOC SCI MED, V39, P381, DOI 10.1016/0277-9536(94)90135-X; Ghuman SJ, 2006, SOC SCI RES, V35, P1, DOI 10.1016/j.ssresearch.2004.06.001; Gladstone M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120566; Hanmer L, 2016, FEM ECON, V22, P237, DOI 10.1080/13545701.2015.1091087; Jewkes R, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001849; Kabeer N, 1999, DEV CHANGE, V30, P435, DOI 10.1111/1467-7660.00125; Khatiwada J, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03309-9; Kishor S., 1997, EMPOWERMENT WOMEN EG; Lamiday SP., 2019, JURNAL BERKALA EPIDE, V7; Lassi Zohra S, 2019, F1000Res, V8, P200, DOI 10.12688/f1000research.17828.1; Lincetto O, 2006, ANTENATAL CARE OPPOR; Mahmud KT, 2019, J POVERTY, V23, P365, DOI 10.1080/10875549.2019.1577324; Merrell LK, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17218172; Miedema SS, 2018, WORLD DEV, V110, P453, DOI 10.1016/j.worlddev.2018.05.031; Na MZ, 2015, PUBLIC HEALTH NUTR, V18, P3155, DOI 10.1017/S1368980015002621; Nadeem M, 2021, J INTERPERS VIOLENCE, V36, pNP11717, DOI 10.1177/0886260519889942; PDHS, 2018, PAK DEM HLTH SURV 20; Pratley P, 2016, SOC SCI MED, V169, P119, DOI 10.1016/j.socscimed.2016.08.001; Rowther AA, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144926; Sado L, 2014, SOC SCI MED, V114, P169, DOI 10.1016/j.socscimed.2014.05.047; Sathar ZA., 1986, DELAYED MARRIAGES PA, V25, P535; Sebayang SK, 2019, WOMEN HEALTH, V59, P1155, DOI 10.1080/03630242.2019.1593282; Sharifa Begum, 2009, Bangladesh Development Studies, V32, P69; Shibre G, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0768-8; Shimamoto K, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0591-3; Tikmani SS, 2019, SEMIN PERINATOL, V43, P297, DOI 10.1053/j.semperi.2019.03.020; Victora CG, 2016, LANCET, V387, P2049, DOI 10.1016/S0140-6736(15)00519-X; WHO, 2016, WHO TECH REP SER, V997, P1; WHO, 2015, STAT IN REPR MAT NEW; World Health Organization UNICEF UNFPA World Bank Group United Nation Population Division, 2019, TRENDS MAT MORT 2000; Zakar R, 2012, J INTERPERS VIOLENCE, V27, P3268, DOI 10.1177/0886260512441257; Zaky HHM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/403402	42	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2022	17	1							e0262323	10.1371/journal.pone.0262323	http://dx.doi.org/10.1371/journal.pone.0262323			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2J6SK	34990479	Green Published, gold			2023-01-03	WOS:000815783800023
J	Okeahialam, NA; Dworzynski, K; Jacklin, P; McClurg, D				Okeahialam, Nicola Adanna; Dworzynski, Katharina; Jacklin, Paul; McClurg, Doreen		Comm, G	Prevention and non-surgical management of pelvic floor dysfunction: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ICS JOINT REPORT; TERMINOLOGY		[Okeahialam, Nicola Adanna; Dworzynski, Katharina; Jacklin, Paul] Royal Coll Obstetricians & Gynaecologists, Natl Guideline Alliance, London, England; [Okeahialam, Nicola Adanna] Croydon Univ Hosp, Thornton Heath, England; [Okeahialam, Nicola Adanna] St Georges Univ, London, England; [McClurg, Doreen] Glasgow Caledonian Univ, Glasgow, Lanark, Scotland	Croydon University Hospital; St Georges University London; Glasgow Caledonian University	Okeahialam, NA (corresponding author), Royal Coll Obstetricians & Gynaecologists, Natl Guideline Alliance, London, England.; Okeahialam, NA (corresponding author), Croydon Univ Hosp, Thornton Heath, England.; Okeahialam, NA (corresponding author), St Georges Univ, London, England.	nicola.okeahialam@nhs.net		Okeahialam, Nicola/0000-0002-0786-2354	National Guideline Alliance at the Royal College of Obstetricians and Gynaecologists - NICE	National Guideline Alliance at the Royal College of Obstetricians and Gynaecologists - NICE	KD and PJ received support from the National Guideline Alliance at the Royal College of Obstetricians and Gynaecologists, which is commissioned and funded by NICE to develop clinical, public health, and social care guidelines and to write this BMJ summary. No authors received special funding from any other source to write this summary.	Bo K, 2017, INT UROGYNECOL J, V28, P191, DOI 10.1007/s00192-016-3123-4; First Do No Harm, 2020, REP IND MED MED DEV; Haylen BT, 2010, NEUROUROL URODYNAM, V29, P4, DOI 10.1002/nau.20798; National Institute for Health and Care Excellence, 2010, PH27 NAT I HLTH CAR; National Institute for Health and Care Excellence, 2021, NG12 NAT I HLTH CAR; National Institute for Health and Care Excellence, 2021, NG10123 NAT I HLTH C; National Institute for Health and Care Excellence, 2014, CG189 NAT I HLTH CAR; NICE, 2015, MED OPT SAF EFF US M; Royal College of Obstetricians and Gynaecologists, 2020, EACH BAB COUNTS 2019; The National Institute for Health and Care Excellence, 2018, STOP SMOK INT SERV N; UK Government, 2018, GUID EATW GUID; UK Government, 2020, GUID PHYS ACT GUID U; Wu JM, 2014, OBSTET GYNECOL, V123, P141, DOI 10.1097/AOG.0000000000000057	13	1	1	6	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	2022	376								n3049	10.1136/bmj.n3049	http://dx.doi.org/10.1136/bmj.n3049			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG5VA	34992080				2023-01-03	WOS:000742554700006
J	Chiu, L; Lo, CH; Shen, M; Chiu, N; Aggarwal, R; Lee, J; Choi, YG; Lam, H; Prsic, EH; Chow, R; Shin, HJ				Chiu, Leonard; Lo, Chun-Han; Shen, Max; Chiu, Nicholas; Aggarwal, Rahul; Lee, Jihui; Choi, Young-Geun; Lam, Henry; Prsic, Elizabeth Horn; Chow, Ronald; Shin, Hyun Joon			Colchicine use in patients with COVID-19: A systematic review and meta-analysis	PLOS ONE			English	Review								Introduction Colchicine may inhibit inflammasome signaling and reduce proinflammatory cytokines, a purported mechanism of COVID-19 pneumonia. The aim of this systematic review and meta-analysis is to report on the state of the current literature on the use of colchicine in COVID-19 and to investigate the reported clinical outcomes in COVID-19 patients by colchicine usage. Methods The literature was searched from January 2019 through January 28, 2021. References were screened to identify studies that reported the effect of colchicine usage on COVID-19 outcomes including mortality, intensive care unit (ICU) admissions, or mechanical ventilation. Studies were meta-analyzed for mortality by the subgroup of trial design (RCT vs observational) and ICU status. Studies reporting an risk ratio (RR), odds ratio (OR) and hazard ratio (HR) were analyzed separately. Results Eight studies, reporting on 16,248 patients, were included in this review. The Recovery trial reported equivalent mortality between colchicine and non-colchicine users. Across the other studies, patients who received colchicine had a lower risk of mortality-HR of 0.25 (95% CI: 0.09, 0.66) and OR of 0.22 (95% CI: 0.09, 0.57). There was no statistical difference in risk of ICU admissions between patients with COVID-19 who received colchicine and those who did not-OR of 0.26 (95% CI: 0.06, 1.09). Conclusion Colchicine may reduce the risk of mortality in individuals with COVID-19. Further prospective investigation may further determine the efficacy of colchicine as treatment in COVID-19 patients in various care settings of the disease, including post-hospitalization and long-term care.	[Chiu, Leonard; Shen, Max] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA; [Lo, Chun-Han] Harvard Univ, Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Chiu, Nicholas; Aggarwal, Rahul] Harvard Univ, Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Lee, Jihui] Weill Cornell Med, New York, NY USA; [Choi, Young-Geun] Sookmyung Womens Univ, Seoul, South Korea; [Lam, Henry] Sunnybrook Hlth Sci Ctr, Lib Serv, Toronto, ON, Canada; [Prsic, Elizabeth Horn; Chow, Ronald] Yale Univ, Yale Sch Med, Yale New Haven Hlth, New Haven, CT 06520 USA; [Chow, Ronald] Yale Univ, Yale Sch Publ Hlth, New Haven, CT 06520 USA; [Chow, Ronald; Shin, Hyun Joon] Hanyang Impact Sci Res Ctr, Seoul, South Korea; [Shin, Hyun Joon] Lemuel Shattuck Hosp, Massachusetts Dept Publ Hlth, Boston, MA 02108 USA; [Shin, Hyun Joon] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Columbia University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Cornell University; Sookmyung Women's University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Yale University; Yale University; Massachusetts Department of Public Health; Harvard University; Brigham & Women's Hospital	Chow, R (corresponding author), Yale Univ, Yale Sch Med, Yale New Haven Hlth, New Haven, CT 06520 USA.; Chow, R (corresponding author), Yale Univ, Yale Sch Publ Hlth, New Haven, CT 06520 USA.; Chow, R; Shin, HJ (corresponding author), Hanyang Impact Sci Res Ctr, Seoul, South Korea.; Shin, HJ (corresponding author), Lemuel Shattuck Hosp, Massachusetts Dept Publ Hlth, Boston, MA 02108 USA.; Shin, HJ (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	ronald.chow@yale.edu; hyun.shin@mass.gov	Lo, Chun-Han/AAT-4992-2020; Chiu, Nicholas/AAH-3639-2021	Lo, Chun-Han/0000-0001-8202-4513; Chiu, Nicholas/0000-0002-8535-8428; Lam, Henry/0000-0003-4517-5552; Chiu, Leonard/0000-0002-7803-7052				Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; [Anonymous], EFFICACY COLCHICINE, DOI [10.1101/2021.01.26.21250494v1, DOI 10.1101/2021.01.26.21250494V1]; [Anonymous], CORONAVIRUS COVID 19; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Brunetti L, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092961; Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Horby P., 2020, RANDOMISED EVALUATIO; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Kossyvakis C, HELLENIC J CARDIOL; Leung YY, 2015, SEMIN ARTHRITIS RHEU, V45, P341, DOI 10.1016/j.semarthrit.2015.06.013; Lopes MI, 2020, MEDRXIV, V2020, DOI [10.1101/2020.08.06.20169573, DOI 10.1101/2020.08.06.20169573]; Mareev VY, 2021, KARDIOLOGIYA, V61, P15, DOI 10.18087/cardio.2021.2.n1560; Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010; Pinzon AM, RES SQUARE, DOI [10.21203/rs.3.rs-266050, DOI 10.21203/RS.3.RS-266050]; Rodriguez-Nava G, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03154-4; Sandhu T, 2020, CAN J INFECT DIS MED, V2020, DOI 10.1155/2020/8865954; Scarsi M, 2020, ANN RHEUM DIS, V79, P1286, DOI 10.1136/annrheumdis-2020-217712; Slobodnick A, 2015, AM J MED, V128, P461, DOI 10.1016/j.amjmed.2014.12.010; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Stewart S, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-2120-7; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839	28	12	13	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2021	16	12							e0261358	10.1371/journal.pone.0261358	http://dx.doi.org/10.1371/journal.pone.0261358			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW9UF	34962939	Green Published, Green Submitted, gold			2023-01-03	WOS:000771548500015
J	Khayyat, SM; Nazar, Z; Nazar, H				Khayyat, Sarah M.; Nazar, Zachariah; Nazar, Hamde			A study to investigate the implementation process and fidelity of a hospital to community pharmacy transfer of care intervention	PLOS ONE			English	Article								Background Hospital to community pharmacy transfer of care medicines-related interventions for inpatients discharged home aim to improve continuity of care and patient outcomes. One such intervention has been provided for seven years within a region in England. This study reports upon the implementation process and fidelity of this intervention. Methods The process evaluation guidance issued by the Medical Research Council has informed this study. A logic model to describe the intervention and causal assumptions was developed from preliminary semi-structured interviews with project team members. Further semi-structured interviews were undertaken with intervention providers from hospital and community pharmacy, and with patient and public representatives. These aimed to investigate intervention implementation process and fidelity. The Consolidated Framework for Implementation Research and the Consolidated Framework for Intervention Fidelity informed interview topic guides and underpinned the thematic framework analysis using a combined inductive and deductive approach. Results Themes provided information about intervention fidelity and implementation that were mapped across the sub processes of implementation: planning, execution, reflection and evaluation, and engagement. Interviewees described factors such as lack of training, awareness, clarity on the service specification, governance and monitoring and information and feedback which caused significant issues with the process of intervention implementation and suboptimal intervention fidelity. Conclusions This provides in-depth insight into the implementation process and fidelity of a ToC intervention, and the extant barriers and facilitators. The findings offer learning to inform the design and implementation of similar interventions, contribute to the evidence base about barriers and facilitators to such interventions and provides in-depth description of the implementation and mechanisms of impact which have the potential to influence clinical and economic outcome evaluation.	[Khayyat, Sarah M.; Nazar, Hamde] Newcastle Univ, Sch Pharm, Newcastle Upon Tyne, Tyne & Wear, England; [Khayyat, Sarah M.] Umm Al Qura Univ, Fac Pharm, Dept Clin Pharm, Mecca, Saudi Arabia; [Nazar, Zachariah] Qatar Univ, QU Hlth, Coll Pharm, Clin Pharm & Practice Dept, Doha, Qatar	Newcastle University - UK; Umm Al Qura University; Qatar University	Nazar, Z (corresponding author), Qatar Univ, QU Hlth, Coll Pharm, Clin Pharm & Practice Dept, Doha, Qatar.	znazar@qu.edu.qa		M. Khayyat, Sarah/0000-0002-0316-1825; Nazar, Zachariah/0000-0003-4104-4221	Saudi Arabian Cultural Bureau in the UK; Umm Al-Qura University in Saudi Arabia	Saudi Arabian Cultural Bureau in the UK; Umm Al-Qura University in Saudi Arabia	(SK) This research was supported by Saudi Arabian Cultural Bureau in the UK and Umm Al-Qura University in Saudi Arabia, (Award/grant number: N/A). https://uksacb.org/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Carroll C, 2007, IMPLEMENT SCI, V2, DOI 10.1186/1748-5908-2-40; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Fereday J, 2006, INT J QUAL METH, P5, DOI [DOI 10.1177/160940690600500107, 10.1177/160940690600500107]; Fletcher A, 2016, EVALUATION-US, V22, P286, DOI 10.1177/1356389016652743; GLASER BG, 1965, SOC PROBL, V12, P436, DOI 10.1525/sp.1965.12.4.03a00070; Hitch D, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235055; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Khayyat S, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-043344; Kramer BJ, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0632-6; Liang S, 2015, IMPLEMENT SCI, V11, P1; Lincoln YS., 1985, NATURALISTIC INQUIRY, DOI 10.1016/0147-1767(85)90062-8; Lussier ME, 2020, J AM PHARM ASSOC, V60, P153, DOI 10.1016/j.japh.2019.07.002; McNab D, 2018, BMJ QUAL SAF, V27, P308, DOI 10.1136/bmjqs-2017-007087; Moore GF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1258; National Health Service England, NHS DISCH MED SERV; Nazar H, 2021, INT J PHARM PRACT, V29, P96, DOI 10.1093/ijpp/riaa004; Nazar H, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012532; Nazar H, 2015, BRIT J CLIN PHARMACO, V80, P936, DOI 10.1111/bcp.12718; OHaire C, 2011, 11EHC044EF AG HEALTH; Manteca MVR, 2021, PHARM CARE ESP, V23, P73; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; World Health Organisation, MED SAF TRANS CAR	24	2	2	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2021	16	12							e0260951	10.1371/journal.pone.0260951	http://dx.doi.org/10.1371/journal.pone.0260951			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW9UF	34962937	Green Published, gold			2023-01-03	WOS:000771548500008
J	Littler, DR; Liu, MM; McAuley, JL; Lowery, SA; Illing, PT; Gully, BS; Purcell, AW; Chandrashekaran, IR; Perlman, S; Purcell, DFJ; Quinn, RJ; Rossjohn, J				Littler, Dene R.; Liu, Miaomiao; McAuley, Julie L.; Lowery, Shea A.; Illing, Patricia T.; Gully, Benjamin S.; Purcell, Anthony W.; Chandrashekaran, Indu R.; Perlman, Stanley; Purcell, Damian F. J.; Quinn, Ronald J.; Rossjohn, Jamie			A natural product compound inhibits coronaviral replication in vitro to the conserved SARS-CoV-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; NSP9	The Nsp9 replicase is a conserved coronaviral protein that acts as an essential accessory component of the multi-subunit viral replication/transcription complex. Nsp9 is the predominant substrate for the essential nucleotidylation activity of Nsp12. Compounds specifically interfering with this viral activity would facilitate its study. Using a native mass spectrometry-based approach to screen a natural product library for Nsp9 binders, we identified an ent-kaurane natural product, oridonin, capable of binding to purified SARS-CoV-2 Nsp9 with micromolar affinities. By determining the crystal structure of the Nsp9-oridonin complex, we showed that oridonin binds through a conserved site near Nsp9's C-terminal GxxxG-helix. In enzymatic assays, oridonin's binding to Nsp9 reduces its potential to act as substrate for Nsp12's Nidovirus RdRp-Associated Nucleotidyl transferase (NiRAN) domain. We also showed using in vitro cellular assays oridonin, while cytotoxic at higher doses has broad antiviral activity, reducing viral titer following infection with either SARS-CoV-2 or, to a lesser extent, MERS-CoV. Accordingly, these preliminary findings suggest that the oridonin molecular scaffold may have the potential to be developed into an antiviral compound to inhibit the function of Nsp9 during coronaviral replication.	[Littler, Dene R.; Illing, Patricia T.; Gully, Benjamin S.; Purcell, Anthony W.; Rossjohn, Jamie] Monash Univ, Biomed Discovery Inst, Infect & Immun Program, Clayton, Vic, Australia; [Littler, Dene R.; Illing, Patricia T.; Gully, Benjamin S.; Purcell, Anthony W.; Rossjohn, Jamie] Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Liu, Miaomiao; Quinn, Ronald J.] Griffith Univ, Griffith Inst Drug Discovery, Brisbane, Qld, Australia; [McAuley, Julie L.; Purcell, Damian F. J.; Quinn, Ronald J.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Lowery, Shea A.; Perlman, Stanley] Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA USA; [Chandrashekaran, Indu R.] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia; [Perlman, Stanley] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Rossjohn, Jamie] Cardiff Univ, Inst Infect & Immun, Sch Med, Cardiff, Wales	Monash University; Monash University; Griffith University; University of Melbourne; University of Iowa; Monash University; University of Iowa; Cardiff University	Littler, DR; Rossjohn, J (corresponding author), Monash Univ, Biomed Discovery Inst, Infect & Immun Program, Clayton, Vic, Australia.; Littler, DR; Rossjohn, J (corresponding author), Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic, Australia.; Quinn, RJ (corresponding author), Griffith Univ, Griffith Inst Drug Discovery, Brisbane, Qld, Australia.; Quinn, RJ (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.; Rossjohn, J (corresponding author), Cardiff Univ, Inst Infect & Immun, Sch Med, Cardiff, Wales.	dene.littler@monash.edu; r.quinn@griffith.edu.au; jamie.rossjohn@monash.edu	Quinn, Ronald J/A-7931-2008; Liu, Miaomiao/O-7830-2017; Illing, Patricia/AAP-6045-2021	Quinn, Ronald J/0000-0002-4022-2623; Liu, Miaomiao/0000-0003-0930-3617; Illing, Patricia/0000-0002-3870-0796; Chandrashekaran, Indu/0000-0002-7080-427X; Littler, Dene/0000-0001-5904-1905; Gully, Benjamin/0000-0002-8197-0871; Purcell, Anthony/0000-0003-0532-8331	National Institutes of Health (USA) [PO1 AI060699, RO1 AI129269]; NHMRC PRF [APP1137739]; Monash University Faculty of Medicine, Nursing and Health Sciences Senior Postdoctoral Fellowship; Australian Research Council Laureate Fellowship; DHHS COVID-19 Victorian Consortium; Australian Research Council Centre of Excellence for Advanced Molecular Imaging	National Institutes of Health (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHMRC PRF(National Health and Medical Research Council (NHMRC) of Australia); Monash University Faculty of Medicine, Nursing and Health Sciences Senior Postdoctoral Fellowship; Australian Research Council Laureate Fellowship(Australian Research Council); DHHS COVID-19 Victorian Consortium; Australian Research Council Centre of Excellence for Advanced Molecular Imaging(Australian Research Council)	Funding for the work originated from the Australian Research Council Centre of Excellence for Advanced Molecular Imaging and the National Institutes of Health (USA) (PO1 AI060699, RO1 AI129269) (S. P.). A. W. P. is supported by a NHMRC PRF (APP1137739). P. T. I. was supported by a Monash University Faculty of Medicine, Nursing and Health Sciences Senior Postdoctoral Fellowship. J. R. is supported by an Australian Research Council Laureate Fellowship. D. F. J. P. and J. L. M. received antiviral program support from the DHHS COVID-19 Victorian Consortium. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Garcia PA, 2007, MOLECULES, V12, P455, DOI 10.3390/12030455; Aragao D, 2018, J SYNCHROTRON RADIAT, V25, P885, DOI 10.1107/S1600577518003120; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Banerjee AK, 2020, CELL, V183, P1325, DOI 10.1016/j.cell.2020.10.004; Bruno M, 2002, J NAT PROD, V65, P1594, DOI 10.1021/np020029b; Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569; Casanal A, 2020, PROTEIN SCI, V29, P1069, DOI 10.1002/pro.3791; Chen J, 2020, CELL, V182, P1560, DOI 10.1016/j.cell.2020.07.033; Daczkowski CM, 2017, J MOL BIOL, V429, P1661, DOI 10.1016/j.jmb.2017.04.011; Douangamath A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18709-w; Egloff MP, 2004, P NATL ACAD SCI USA, V101, P3792, DOI 10.1073/pnas.0307877101; Elnaas AR, 2020, MOLECULES, V25, DOI 10.3390/molecules25102384; Ferreira AC, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00428-w; Gunther S, 2021, SCIENCE, V372, P642, DOI 10.1126/science.abf7945; Hu X, 2020, MINI-REV MED CHEM, V20, P483, DOI 10.2174/1389557519666191029121809; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kjer-Nielsen L, 2018, IMMUNOL CELL BIOL, V96, P573, DOI 10.1111/imcb.12057; Klemm T, 2020, EMBO J, V39, DOI 10.15252/embj.2020106275; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Lei YQ, 2021, J NAT PROD, V84, P1478, DOI 10.1021/acs.jnatprod.0c01231; Li WF, 2015, INT J MOL SCI, V16, P27978, DOI 10.3390/ijms161126071; Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471; Littler DR, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101018; Littler DR, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101258; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Miknis ZJ, 2009, J VIROL, V83, P3007, DOI 10.1128/JVI.01505-08; Modi V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56499-4; Osipiuk J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21060-3; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ponnusamy R, 2008, J MOL BIOL, V383, P1081, DOI 10.1016/j.jmb.2008.07.071; Rut W, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd4596; Slanina H, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022310118; Sreelatha A, 2018, CELL, V175, P809, DOI 10.1016/j.cell.2018.08.046; Sun HD, 2006, NAT PROD REP, V23, P673, DOI 10.1039/b604174d; Sutton G, 2004, STRUCTURE, V12, P341, DOI 10.1016/j.str.2004.01.016; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang B, 2021, NUCLEIC ACIDS RES, V49, P8822, DOI 10.1093/nar/gkab677; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Wu F, 2020, NATURE, V580, pE7; Wu YC, 1996, J NAT PROD, V59, P635, DOI 10.1021/np960416j; Yan LM, 2021, CELL, V184, P3474, DOI 10.1016/j.cell.2021.05.033; Yan LM, 2021, CELL, V184, P184, DOI 10.1016/j.cell.2020.11.016; Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhang ZR, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00343-z; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	48	10	10	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC	2021	297	6							101362	10.1016/j.jbc.2021.101362	http://dx.doi.org/10.1016/j.jbc.2021.101362			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN8ZV	34756886	Green Accepted, gold, Green Published			2023-01-03	WOS:000765319800008
J	Nagata, K; Tsuji, T; Suetsugu, K; Muraoka, K; Watanabe, H; Kanaya, A; Egashira, N; Ieiri, I				Nagata, Kenichiro; Tsuji, Toshikazu; Suetsugu, Kimitaka; Muraoka, Kayoko; Watanabe, Hiroyuki; Kanaya, Akiko; Egashira, Nobuaki; Ieiri, Ichiro			Detection of overdose and underdose prescriptions-An unsupervised machine learning approach	PLOS ONE			English	Article							CLINICAL DECISION-SUPPORT; PHYSICIAN ORDER ENTRY; REDUCE ALERT FATIGUE; MEDICATION ORDERS; SYSTEMS; PREVENTION; IMPACT; RISK	Overdose prescription errors sometimes cause serious life-threatening adverse drug events, while underdose errors lead to diminished therapeutic effects. Therefore, it is important to detect and prevent these errors. In the present study, we used the one-class support vector machine (OCSVM), one of the most common unsupervised machine learning algorithms for anomaly detection, to identify overdose and underdose prescriptions. We extracted prescription data from electronic health records in Kyushu University Hospital between January 1, 2014 and December 31, 2019. We constructed an OCSVM model for each of the 21 candidate drugs using three features: age, weight, and dose. Clinical overdose and underdose prescriptions, which were identified and rectified by pharmacists before administration, were collected. Synthetic overdose and underdose prescriptions were created using the maximum and minimum doses, defined by drug labels or the UpToDate database. We applied these prescription data to the OCSVM model and evaluated its detection performance. We also performed comparative analysis with other unsupervised outlier detection algorithms (local outlier factor, isolation forest, and robust covariance). Twenty-seven out of 31 clinical overdose and underdose prescriptions (87.1%) were detected as abnormal by the model. The constructed OCSVM models showed high performance for detecting synthetic overdose prescriptions (precision 0.986, recall 0.964, and F-measure 0.973) and synthetic underdose prescriptions (precision 0.980, recall 0.794, and F-measure 0.839). In comparative analysis, OCSVM showed the best performance. Our models detected the majority of clinical overdose and underdose prescriptions and demonstrated high performance in synthetic data analysis. OCSVM models, constructed using features such as age, weight, and dose, are useful for detecting overdose and underdose prescriptions.	[Nagata, Kenichiro; Tsuji, Toshikazu; Suetsugu, Kimitaka; Muraoka, Kayoko; Kanaya, Akiko; Egashira, Nobuaki; Ieiri, Ichiro] Kyushu Univ Hosp, Dept Pharm, Fukuoka, Fukuoka, Japan; [Watanabe, Hiroyuki] Fukuoka Tokushukai Hosp, Dept Pharm, Fukuoka, Fukuoka, Japan	Kyushu University	Nagata, K (corresponding author), Kyushu Univ Hosp, Dept Pharm, Fukuoka, Fukuoka, Japan.	nagata.kenichiro.679@m.kyushu-u.ac.jp		Nagata, Kenichiro/0000-0001-5012-3488	Japan Society for the Promotion of Science (JSPS); KAKENHI [JP18K14984]	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	KN received Japan Society for the Promotion of Science (JSPS, https://www.jsps.go.jp) KAKENHI (Grant Number JP18K14984) for this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Assiri GA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019101; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; Breunig MM, 2000, SIGMOD REC, V29, P93, DOI 10.1145/335191.335388; Carroll AE, 2019, JAMA-J AM MED ASSOC, V322, P601, DOI 10.1001/jama.2019.11710; Cash JJ, 2009, AM J HEALTH-SYST PH, V66, P2098, DOI 10.2146/ajhp090181; Corny J, 2020, J AM MED INFORM ASSN, V27, P1688, DOI 10.1093/jamia/ocaa154; dos Santos HDP, 2019, IEEE J BIOMED HEALTH, V23, P874, DOI 10.1109/JBHI.2018.2828028; Garg AX, 2005, JAMA-J AM MED ASSOC, V293, P1223, DOI 10.1001/jama.293.10.1223; Goldstein M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152173; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Kanjanarat P, 2003, AM J HEALTH-SYST PH, V60, P1750, DOI 10.1093/ajhp/60.17.1750; Kesselheim AS, 2011, HEALTH AFFAIR, V30, P2310, DOI 10.1377/hlthaff.2010.1111; Kirkendall ES, 2014, APPL CLIN INFORM, V5, P25, DOI 10.4338/ACI-2013-08-RA-0057; Kohn LT, 1999, ERR IS HUMAN BUILDIN; Kuperman G J, 2001, Jt Comm J Qual Improv, V27, P509; Kuperman GJ, 2007, J AM MED INFORM ASSN, V14, P29, DOI 10.1197/jamia.M2170; Lee J, 2014, INT J MED INFORM, V83, P929, DOI 10.1016/j.ijmedinf.2014.08.006; Liu FT, 2012, ACM T KNOWL DISCOV D, V6, DOI 10.1145/2133360.2133363; Nanji KC, 2018, J AM MED INFORM ASSN, V25, P476, DOI 10.1093/jamia/ocx115; Page N, 2017, INT J MED INFORM, V105, P22, DOI 10.1016/j.ijmedinf.2017.05.011; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Phansalkar S, 2013, J AM MED INFORM ASSN, V20, P489, DOI 10.1136/amiajnl-2012-001089; Rousseeuw PJ, 1999, TECHNOMETRICS, V41, P212, DOI 10.2307/1270566; Rozenblum R, 2020, JT COMM J QUAL PATIE, V46, P3, DOI 10.1016/j.jcjq.2019.09.008; Schiff GD, 2017, J AM MED INFORM ASSN, V24, P281, DOI 10.1093/jamia/ocw171; Scholkopf B, 2001, NEURAL COMPUT, V13, P1443, DOI 10.1162/089976601750264965; Segal G, 2019, J AM MED INFORM ASSN, V26, P1560, DOI 10.1093/jamia/ocz135; Sheikh A, 2017, B WORLD HEALTH ORGAN, V95, P546, DOI 10.2471/BLT.17.198002; Van der Sijs H, 2006, J AM MED INFORM ASSN, V13, P138, DOI 10.1197/jamia.M1809; van der Walt S, 2014, PEERJ, V2, DOI 10.7717/peerj.453; Woods AD, 2014, J AM MED INFORM ASSN, V21, P569, DOI 10.1136/amiajnl-2013-002008	32	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2021	16	11							e0260315	10.1371/journal.pone.0260315	http://dx.doi.org/10.1371/journal.pone.0260315			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ2TX	34797894	gold, Green Published			2023-01-03	WOS:000755334700062
J	Chiu, L; Shen, M; Lo, CH; Chiu, N; Chen, A; Shin, HJ; Prsic, EH; Hur, C; Chow, R; Lebwohl, B				Chiu, Leonard; Shen, Max; Lo, Chun-Han; Chiu, Nicholas; Chen, Austin; Shin, Hyun Joon; Prsic, Elizabeth Horn; Hur, Chin; Chow, Ronald; Lebwohl, Benjamin			Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis	PLOS ONE			English	Review								Introduction Famotidine is a competitive histamine H2-receptor antagonist most commonly used for gastric acid suppression but thought to have potential efficacy in treating patients with Coronavirus disease 2019 (COVID-19). The aims of this systematic review and meta-analysis are to summarize the current literature and report clinical outcomes on the use of famotidine for treatment of hospitalized patients with COVID-19. Methods Five databases were searched through February 12, 2021 to identify observational studies that reported on associations of famotidine use with outcomes in COVID-19. Meta-analysis was conducted for composite primary clinical outcome (e.g. rate of death, intubation, or intensive care unit admissions) and death separately, where either aggregate odds ratio (OR) or hazard ratio (HR) was calculated. Results Four studies, reporting on 46,435 total patients and 3,110 patients treated with famotidine, were included in this meta-analysis. There was no significant association between famotidine use and composite outcomes in patients with COVID-19: HR 0.63 (95% CI: 0.35, 1.16). Across the three studies that reported mortality separated from other endpoints, there was no association between famotidine use during hospitalization and risk of death-HR 0.67 (95% CI: 0.26, 1.73) and OR 0.79 (95% CI: 0.19, 3.34). Heterogeneity ranged from 83.69% to 88.07%. Conclusion Based on the existing observational studies, famotidine use is not associated with a reduced risk of mortality or combined outcome of mortality, intubation, and/or intensive care services in hospitalized individuals with COVID-19, though heterogeneity was high, and point estimates suggested a possible protective effect for the composite outcome that may not have been observed due to lack of power. Further randomized controlled trials (RCTs) may help determine the efficacy and safety of famotidine as a treatment for COVID-19 patients in various care settings of the disease.	[Chiu, Leonard; Shen, Max; Chen, Austin] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA; [Lo, Chun-Han] Harvard Univ, Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Chiu, Nicholas] Harvard Univ, Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Shin, Hyun Joon; Chow, Ronald] Hanyang Impact Sci Res Ctr, Seoul, South Korea; [Shin, Hyun Joon] Massachusetts Dept Publ Hlth, Lemuel Shattuck Hosp, Div Cardiol, Boston, MA USA; [Shin, Hyun Joon] Brigham & Womens Hosp, Div Gen Internal Med, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Prsic, Elizabeth Horn; Chow, Ronald] Yale Univ, Yale Sch Med, Yale New Haven Hosp, New Haven, CT USA; [Lebwohl, Benjamin] Columbia Univ Irving, Med Ctr, New York Presbyterian Hosp, Div Digest & Liver Dis, New York, NY USA; [Chow, Ronald] Yale Univ, Yale Sch Publ Hlth, New Haven, CT USA	Columbia University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Massachusetts Department of Public Health; Harvard University; Brigham & Women's Hospital; Yale University; NewYork-Presbyterian Hospital; Yale University	Chow, R (corresponding author), Hanyang Impact Sci Res Ctr, Seoul, South Korea.; Chow, R (corresponding author), Yale Univ, Yale Sch Med, Yale New Haven Hosp, New Haven, CT USA.; Lebwohl, B (corresponding author), Columbia Univ Irving, Med Ctr, New York Presbyterian Hosp, Div Digest & Liver Dis, New York, NY USA.; Chow, R (corresponding author), Yale Univ, Yale Sch Publ Hlth, New Haven, CT USA.	ronald.chow@yale.edu; bl114@cumc.columbia.edu	Lo, Chun-Han/AAT-4992-2020; Chiu, Nicholas/AAH-3639-2021	Lo, Chun-Han/0000-0001-8202-4513; Chiu, Nicholas/0000-0002-8535-8428; Chiu, Leonard/0000-0002-7803-7052				ACTIV-3 TICO LY-CoV555 Study Grp, 2021, NEW ENGL J MED, V384, P905, DOI 10.1056/NEJMoa2033130; Balouch Bailey, 2021, J Voice, DOI 10.1016/j.jvoice.2021.01.007; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cheung KS, 2021, GASTROENTEROLOGY, V160, P1898, DOI 10.1053/j.gastro.2020.05.098; Chilamakuri R, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020206; CHREMOS AN, 1987, J CLIN GASTROENTEROL, V9, P7, DOI 10.1097/00004836-198707002-00003; Conigliaro J., 2020, CLINICALTRIALSGOV; Freedberg DE, 2020, GASTROENTEROLOGY, V159, P1129, DOI 10.1053/j.gastro.2020.05.053; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Janowitz T, 2021, CLINICALTRIALSGOV; Janowitz T, 2020, GUT, V69, P1592, DOI 10.1136/gutjnl-2020-321852; Kamal F, 2021, GASTROENTEROLOGY, V160, P2588, DOI 10.1053/j.gastro.2021.02.028; Li G-F., 2020, META ANAL GUT, DOI [10.1136/gutjnl-2020-323366, DOI 10.1136/GUTJNL-2020-323366]; Mather JF, 2020, AM J GASTROENTEROL, V115, P1617, DOI 10.14309/ajg.0000000000000832; O. of the Commissioner, 2020, COR COVID 19 UPD FDA; Shoaibi A, 2021, AM J GASTROENTEROL, V116, P692, DOI 10.14309/ajg.0000000000001153; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sun CY, 2021, DIGEST DIS SCI, V66, P3929, DOI 10.1007/s10620-021-06872-z; Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600; Wu CR, 2020, ACTA PHARM SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008; Xie Y, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015735; Yeramaneni S, 2021, GASTROENTEROLOGY, V160, P919, DOI 10.1053/j.gastro.2020.10.011; Zhou JD, 2021, GUT, V70, P2012, DOI 10.1136/gutjnl-2020-323668	28	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2021	16	11							e0259514	10.1371/journal.pone.0259514	http://dx.doi.org/10.1371/journal.pone.0259514			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY9AG	34735523	Green Published, gold, Green Submitted			2023-01-03	WOS:000755077100083
J	Morelle, J; Marechal, C; Yu, ZZ; Debaix, H; Corre, T; Lambie, M; Verduijn, M; Dekker, F; Bovy, P; Evenepoel, P; Bammens, B; Selgas, R; Bajo, MA; Coester, AM; Sow, A; Hautem, N; Struijk, DG; Krediet, RT; Balligand, JL; Goffin, E; Crott, R; Ripoche, P; Davies, S; Devuyst, O				Morelle, Johann; Marechal, Celine; Yu, Zanzhe; Debaix, Huguette; Corre, Tanguy; Lambie, Mark; Verduijn, Marion; Dekker, Friedo; Bovy, Philippe; Evenepoel, Pieter; Bammens, Bert; Selgas, Rafael; Bajo, Maria A.; Coester, Annemieke M.; Sow, Amadou; Hautem, Nicolas; Struijk, Dirk G.; Krediet, Raymond T.; Balligand, Jean-Luc; Goffin, Eric; Crott, Ralph; Ripoche, Pierre; Davies, Simon; Devuyst, Olivier			AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							3.86-PERCENT GLUCOSE; EQUILIBRATION TEST; ANURIC PATIENTS; ULTRAFILTRATION; AQUAPORIN-1; PERMEABILITY; EXPRESSION; MANAGEMENT; MORTALITY; CHANNELS	AQP1 Promoter Variant and Peritoneal Dialysis Variability in ultrafiltration influences prescriptions and outcomes in patients treated with peritoneal dialysis. This study showed that a common variant in AQP1, the gene that encodes the water channel aquaporin-1, was associated with decreased ultrafiltration and an increased risk of death or technique failure among such patients. Background Variability in ultrafiltration influences prescriptions and outcomes in patients with kidney failure who are treated with peritoneal dialysis. Variants in AQP1, the gene that encodes the archetypal water channel aquaporin-1, may contribute to that variability. Methods We gathered clinical and genetic data from 1851 patients treated with peritoneal dialysis in seven cohorts to determine whether AQP1 variants were associated with peritoneal ultrafiltration and with a risk of the composite of death or technique failure (i.e., transfer to hemodialysis). We performed studies in cells, mouse models, and samples obtained from humans to characterize an AQP1 variant and investigate mitigation strategies. Results The common AQP1 promoter variant rs2075574 was associated with peritoneal ultrafiltration. Carriers of the TT genotype at rs2075574 (10 to 16% of patients) had a lower mean (+/- SD) net ultrafiltration level than carriers of the CC genotype (35 to 47% of patients), both in the discovery phase (506 +/- 237 ml vs. 626 +/- 283 ml, P=0.007) and in the validation phase (368 +/- 603 ml vs. 563 +/- 641 ml, P=0.003). After a mean follow-up of 944 days, 139 of 898 patients (15%) had died and 280 (31%) had been transferred to hemodialysis. TT carriers had a higher risk of the composite of death or technique failure than CC carriers (adjusted hazard ratio, 1.70; 95% confidence interval [CI], 1.24 to 2.33; P=0.001), as well as a higher risk of death from any cause (24% vs. 15%, P=0.03). In mechanistic studies, the rs2075574 risk variant was associated with decreases in AQP1 promoter activity, aquaporin-1 expression, and glucose-driven osmotic water transport. The use of a colloid osmotic agent mitigated the effects of the risk variant. Conclusions A common variant in AQP1 was associated with decreased ultrafiltration and an increased risk of death or technique failure among patients treated with peritoneal dialysis. (Funded by the Swiss National Science Foundation and others.)	[Morelle, Johann; Goffin, Eric; Devuyst, Olivier] UCLouvain, Clin Univ St Luc, Div Nephrol, Brussels, Belgium; [Morelle, Johann; Marechal, Celine; Debaix, Huguette; Sow, Amadou; Hautem, Nicolas; Balligand, Jean-Luc; Goffin, Eric; Devuyst, Olivier] UCLouvain, Inst Rech Expt & Clin, Brussels, Belgium; [Crott, Ralph] UCLouvain, Fac Publ Hlth, Inst Rech Sante & Soc, Brussels, Belgium; [Bovy, Philippe] Katholieke Univ Leuven, Clin St Joseph, Div Nephrol, Leuven, Belgium; [Evenepoel, Pieter; Bammens, Bert] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Nephrol & Renal Transplantat Res Grp, Leuven, Belgium; [Evenepoel, Pieter; Bammens, Bert] Univ Hosp Leuven, Dept Nephrol Dialysis & Renal Transplantat, Leuven, Belgium; [Yu, Zanzhe] Shanghai Jiao Tong Univ, Sch Med, Dept Nephrol, Shanghai, Peoples R China; [Yu, Zanzhe] Renji Hosp, Shanghai, Peoples R China; [Yu, Zanzhe; Lambie, Mark; Davies, Simon] Keele Univ, Fac Med & Hlth Sci, Keele, Staffs, England; [Debaix, Huguette; Devuyst, Olivier] Univ Zurich, Inst Physiol, Zurich, Switzerland; [Corre, Tanguy] Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Lausanne, Switzerland; [Verduijn, Marion; Dekker, Friedo] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands; [Coester, Annemieke M.; Struijk, Dirk G.; Krediet, Raymond T.] Univ Amsterdam, Med Ctr, Dept Med, Div Nephrol, Amsterdam, Netherlands; [Coester, Annemieke M.] Univ Med Ctr Groningen, Dept Surg, Groningen, Netherlands; [Selgas, Rafael; Bajo, Maria A.] Univ Autonoma, Hosp Univ La Paz, Div Nephrol, Madrid, Spain; [Selgas, Rafael; Bajo, Maria A.] Univ Autonoma, Inst Invest Sanit La Paz, Red Invest Renal, Madrid, Spain; [Ripoche, Pierre] Inst Natl Transfus Sanguine, Paris, France	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Universite Catholique Louvain; KU Leuven; KU Leuven; KU Leuven; University Hospital Leuven; Shanghai Jiao Tong University; Keele University; University of Zurich; University of Lausanne; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; University of Groningen; Autonomous University of Madrid; Hospital Universitario La Paz; Autonomous University of Madrid	Morelle, J; Davies, S; Devuyst, O (corresponding author), Univ Zurich, Inst Physiol, Mech Inherited Kidney Disorders, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	johann.morelle@uclouvain.be; simonj.davies55@gmail.com; olivier.devuyst@uzh.ch	Krediet, Raymond/GLT-2390-2022; Balligand, Jean-Luc J/D-7543-2012; Bajo, Maria A/ABF-6991-2020	Krediet, Raymond/0000-0002-9851-8507; Bajo, Maria A/0000-0001-7364-557X; Goffin, Eric/0000-0001-9242-7148; Devuyst, Olivier/0000-0003-3744-4767; Lambie, Mark/0000-0002-6285-5368; Morelle, Johann/0000-0002-6925-1989				Agre P, 2004, ANGEW CHEM INT EDIT, V43, P4278, DOI 10.1002/anie.200460804; Bekri S, 2003, BLOOD, V102, P698, DOI 10.1182/blood-2002-06-1623; Brimble KS, 2006, J AM SOC NEPHROL, V17, P2591, DOI 10.1681/ASN.2006030194; Brown EA, 2003, J AM SOC NEPHROL, V14, P2948, DOI 10.1097/01.ASN.0000092146.67909.E2; Davies SJ, 2006, PERITON DIALYSIS INT, V26, P458; Davies SJ, 2003, J AM SOC NEPHROL, V14, P2338, DOI 10.1097/01.ASN.0000083904.12234.27; Davies SJ, 1998, KIDNEY INT, V54, P2207, DOI 10.1046/j.1523-1755.1998.00180.x; Devuyst O, 1998, AM J PHYSIOL-HEART C, V275, pH234, DOI 10.1152/ajpheart.1998.275.1.H234; Devuyst O, 2021, PERITON DIALYSIS INT, V41, P349, DOI 10.1177/08968608211022236; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Firmann M, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-6; Gillerot G, 2005, KIDNEY INT, V67, P2477, DOI 10.1111/j.1523-1755.2005.00357.x; Kim YL, 2017, SEMIN NEPHROL, V37, P43, DOI 10.1016/j.semnephrol.2016.10.006; King LS, 2001, NEW ENGL J MED, V345, P175, DOI 10.1056/NEJM200107193450304; King LS, 2002, P NATL ACAD SCI USA, V99, P1059, DOI 10.1073/pnas.022626499; La Milia V, 2006, KIDNEY INT, V69, P927, DOI 10.1038/sj.ki.5000183; La Milia V, 2017, PERITON DIALYSIS INT, V37, P633, DOI 10.3747/pdi.2017.00004; Li PKT, 2017, NAT REV NEPHROL, V13, P90, DOI 10.1038/nrneph.2016.181; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Mehrotra R, 2021, KIDNEY INT, V100, P1101, DOI 10.1016/j.kint.2021.05.037; Mehrotra R, 2016, J AM SOC NEPHROL, V27, P3238, DOI 10.1681/ASN.2016010112; MISTRY CD, 1987, LANCET, V2, P178; Morelle J, 2021, PERITON DIALYSIS INT, V41, P352, DOI 10.1177/0896860820982218; Morelle J, 2018, J AM SOC NEPHROL, V29, P1875, DOI 10.1681/ASN.2017080828; Morelle J, 2014, AM J PHYSIOL-RENAL, V307, pF981, DOI 10.1152/ajprenal.00098.2014; Mujais S, 2000, PERITON DIALYSIS INT, V20, pS5; Ni J, 2006, KIDNEY INT, V69, P1518, DOI 10.1038/sj.ki.5000285; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Rippe B, 2001, PERITON DIALYSIS INT, V21, pS30; Stoenoiu MS, 2003, J AM SOC NEPHROL, V14, P555, DOI 10.1097/01.ASN.0000053420.37216.9E; TWARDOWSKI ZJ, 1987, PERITON DIALYSIS INT, V7, P138; van Wijk R, 2003, BLOOD, V101, P1596, DOI 10.1182/blood-2002-07-2321; Veiras LC, 2017, J AM SOC NEPHROL, V28, P3504, DOI 10.1681/ASN.2017030295; Wang AYM, 2020, PERITON DIALYSIS INT, V40, P282, DOI 10.1177/0896860819895365; Yang BX, 1999, AM J PHYSIOL-CELL PH, V276, pC76, DOI 10.1152/ajpcell.1999.276.1.C76; Yool AJ, 2013, J AM SOC NEPHROL, V24, P1045, DOI 10.1681/ASN.2012080869	36	16	17	2	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 21	2021	385	17					1570	1580		10.1056/NEJMoa2034279	http://dx.doi.org/10.1056/NEJMoa2034279			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ4XG	34670044	Green Published, Bronze			2023-01-03	WOS:000709049000012
J	Lien, EC; Westermark, AM; Zhang, Y; Yuan, C; Li, ZQ; Lau, AN; Sapp, KM; Wolpin, BM; Vander Heiden, MG				Lien, Evan C.; Westermark, Anna M.; Zhang, Yin; Yuan, Chen; Li, Zhaoqi; Lau, Allison N.; Sapp, Kiera M.; Wolpin, Brian M.; Vander Heiden, Matthew G.			Low glycaemic diets alter lipid metabolism to influence tumour growth	NATURE			English	Article							ELECTRON-TRANSPORT CHAIN; ACID-METABOLISM; VALIDITY; REPRODUCIBILITY; QUESTIONNAIRE; DISEASE; CELLS; RISK; HEALTH; SERINE	Dietary interventions can change metabolite levels in the tumour microenvironment, which might then affect cancer cell metabolism to alter tumour growth(1-5). Although caloric restriction (CR) and a ketogenic diet (KD) are often thought to limit tumour progression by lowering blood glucose and insulin levels(6-8), we found that only CR inhibits the growth of select tumour allografts in mice, suggesting that other mechanisms contribute to tumour growth inhibition. A change in nutrient availability observed with CR, but not with KD, is lower lipid levels in the plasma and tumours. Upregulation of stearoyl-CoA desaturase (SCD), which synthesises monounsaturated fatty acids, is required for cancer cells to proliferate in a lipid-depleted environment, and CR also impairs tumour SCD activity to cause an imbalance between unsaturated and saturated fatty acids to slow tumour growth. Enforcing cancer cell SCD expression or raising circulating lipid levels through a higher-fat CR diet confers resistance to the effects of CR. By contrast, although KD also impairs tumour SCD activity, KD-driven increases in lipid availability maintain the unsaturated to saturated fatty acid ratios in tumours, and changing the KD fat composition to increase tumour saturated fatty acid levels cooperates with decreased tumour SCD activity to slow tumour growth. These data suggest that diet-induced mismatches between tumour fatty acid desaturation activity and the availability of specific fatty acid species determine whether low glycaemic diets impair tumour growth. Lien et al. show that low glycemic diets can reduce tumour growth by deregulating lipid metabolism.	[Lien, Evan C.; Westermark, Anna M.; Li, Zhaoqi; Lau, Allison N.; Sapp, Kiera M.; Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Zhang, Yin; Yuan, Chen; Wolpin, Brian M.; Vander Heiden, Matthew G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Zhang, Yin] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Li, Zhaoqi; Sapp, Kiera M.; Vander Heiden, Matthew G.] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts Institute of Technology (MIT)	Vander Heiden, MG (corresponding author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Vander Heiden, MG (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Vander Heiden, MG (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	mvh@mit.edu		Vander Heiden, Matthew/0000-0002-6702-4192; Sapp, Kiera/0000-0002-5523-1223	Damon Runyon Cancer Research Foundation [DRG-2299-17, DRG-2241-15]; NIH Pathway to Independence Award [K99CA234221]; NIH [T32GM007287, U01CA210171, P50CA127003, R35CA242379, R01CA168653, R01CA201276, P30CA14051, UM1 CA186107, U01 CA176726, P01 CA87969, U01 CA167552, R03 CA223619]; Lustgarten Foundation; Dana-Farber Cancer Institute Hale Family Center for Pancreatic Cancer Research; Stand Up To Cancer; Pancreatic Cancer Action Network; Noble Effort Fund; Wexler Family Fund; Bob Parsons Fund; Emerald Foundation; Howard Hughes Medical Institute; MIT Center for Precision Cancer Medicine; Ludwig Center at MIT; Promises for Purple	Damon Runyon Cancer Research Foundation; NIH Pathway to Independence Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lustgarten Foundation; Dana-Farber Cancer Institute Hale Family Center for Pancreatic Cancer Research; Stand Up To Cancer; Pancreatic Cancer Action Network; Noble Effort Fund; Wexler Family Fund; Bob Parsons Fund; Emerald Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); MIT Center for Precision Cancer Medicine; Ludwig Center at MIT; Promises for Purple	We thank members of the Vander Heiden laboratory for useful discussions and experimental advice. E.C.L. was supported by the Damon Runyon Cancer Research Foundation (DRG-2299-17). A.N.L. was a Robert Black Fellow of the Damon Runyon Cancer Research Foundation (DRG-2241-15) and was supported by an NIH Pathway to Independence Award (K99CA234221). Z.L. and K.M.S. were supported by NIH training grant T32GM007287. B.M.W. was supported by the Lustgarten Foundation, the Dana-Farber Cancer Institute Hale Family Center for Pancreatic Cancer Research, the NIH (U01CA210171 and P50CA127003), Stand Up To Cancer, the Pancreatic Cancer Action Network, the Noble Effort Fund, the Wexler Family Fund, Promises for Purple and the Bob Parsons Fund. M.G.V.H. acknowledges support from the Emerald Foundation, the Lustgarten Foundation, a Faculty Scholar grant from the Howard Hughes Medical Institute, Stand Up To Cancer, the MIT Center for Precision Cancer Medicine, the Ludwig Center at MIT and the NIH (R35CA242379, R01CA168653, R01CA201276 and P30CA14051). The Nurses' Health Study and the Health Professionals Follow-up Study were supported by grants UM1 CA186107, U01 CA176726, P01 CA87969, U01 CA167552 and R03 CA223619 from the NIH. The authors thank all participants and staff of the Nurses' Health Study and the Health Professionals Follow-Up Study for their contributions to this research. We are grateful for help from the following state cancer registries: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, Washington and Wyoming. The authors also thank the Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School for leading the Nurses' Health Study and the Harvard T.H. Chan School of Public Health for leading the Health Professionals Follow-Up Study. The authors assume full responsibility for analyses and interpretation of these data.	Ackerman D, 2018, CELL REP, V24, P2596, DOI 10.1016/j.celrep.2018.08.015; Antoniewicz MR, 2011, ANAL CHEM, V83, P3211, DOI 10.1021/ac200012p; Argus JP, 2018, CELL REP, V25, P2919, DOI 10.1016/j.celrep.2018.11.041; BELANGER CF, 1978, AM J NURS, V78, P1039, DOI 10.2307/3462013; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Colditz GA, 2005, NAT REV CANCER, V5, P388, DOI 10.1038/nrc1608; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Coulston AM, 1999, AM J CLIN NUTR, V70, p512S, DOI 10.1093/ajcn/70.3.512s; Danai LV, 2018, NATURE, V558, P600, DOI 10.1038/s41586-018-0235-7; Diehl FF, 2019, NAT METAB, V1, P861, DOI 10.1038/s42255-019-0108-x; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3; Gocheva V, 2017, P NATL ACAD SCI USA, V114, pE5625, DOI 10.1073/pnas.1707054114; Halton TL, 2008, AM J CLIN NUTR, V87, P339, DOI 10.1093/ajcn/87.2.339; Halton TL, 2006, NEW ENGL J MED, V355, P1991, DOI 10.1056/NEJMoa055317; Harvard T. H, 2020, HLTH PROFESSIONALS F; Heinrich P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36293-4; Hopkins BD, 2018, NATURE, V560, P499, DOI 10.1038/s41586-018-0343-4; Hosios AM, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.2876; Hu FB, 1999, AM J CLIN NUTR, V69, P243; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Kennedy AR, 2007, AM J PHYSIOL-ENDOC M, V292, pE1724, DOI 10.1152/ajpendo.00717.2006; Kim W, 2019, CELL METAB, V29, P856, DOI 10.1016/j.cmet.2018.12.023; Lewis CA, 2014, MOL CELL, V55, P253, DOI 10.1016/j.molcel.2014.05.008; Lien EC, 2019, NAT REV CANCER, V19, P651, DOI 10.1038/s41568-019-0198-5; Liu Y, 2021, HEPATOLOGY, V73, P175, DOI 10.1002/hep.31251; Maddocks ODK, 2017, NATURE, V544, P372, DOI 10.1038/nature22056; Mauvoisin D, 2011, BIOCHIMIE, V93, P78, DOI 10.1016/j.biochi.2010.08.001; Mayers JR, 2016, SCIENCE, V353, P1161, DOI 10.1126/science.aaf5171; Mukherjee P, 2002, BRIT J CANCER, V86, P1615, DOI 10.1038/sj.bjc.6600298; Nencioni A, 2018, NAT REV CANCER, V18, P707, DOI 10.1038/s41568-018-0061-0; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Peck B, 2016, FEBS J, V283, P2767, DOI 10.1111/febs.13681; Piccolis M, 2019, MOL CELL, V74, P32, DOI 10.1016/j.molcel.2019.01.036; RICHEDWARDS JW, 1994, AM J EPIDEMIOL, V140, P1016, DOI 10.1093/oxfordjournals.aje.a117191; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Siri-Tarino PW, 2015, ANNU REV NUTR, V35, P517, DOI 10.1146/annurev-nutr-071714-034449; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Sullivan MR, 2019, ELIFE, V8, DOI 10.7554/eLife.44235; Sullivan MR, 2019, CELL METAB, V29, P1410, DOI 10.1016/j.cmet.2019.02.015; Titov DV, 2016, SCIENCE, V352, P231, DOI 10.1126/science.aad4017; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Vriens K, 2019, NATURE, V566, P403, DOI 10.1038/s41586-019-0904-1; Willett W., 2012, NUTR EPIDEMIOLOGY; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Young RM, 2013, GENE DEV, V27, P1115, DOI 10.1101/gad.198630.112; Yuan CZ, 2018, AM J EPIDEMIOL, V187, P1051, DOI 10.1093/aje/kwx328; Yuan CZ, 2017, AM J EPIDEMIOL, V185, P570, DOI 10.1093/aje/kww104; Zhang J, 2018, J LIPID RES, V59, P625, DOI 10.1194/jlr.M082040	51	51	52	26	111	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 11	2021	599	7884					302	307		10.1038/s41586-021-04049-2	http://dx.doi.org/10.1038/s41586-021-04049-2		OCT 2021	6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW6KO	34671163	Green Accepted			2023-01-03	WOS:000709352200004
J	Mikkelsen, AP; Greiber, IK; Scheller, NM; Lidegaard, O				Mikkelsen, Anders Pretzmann; Greiber, Iben Katinka; Scheller, Nikolai Madrid; Lidegaard, Ojvind			Association of Labor Epidural Analgesia With Autism Spectrum Disorder in Children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Question Is epidural analgesia during labor associated with autism in offspring? Findings In this nationwide retrospective cohort study that included 479 178 Danish children, maternal epidural analgesia during labor compared with no epidural analgesia during labor was not significantly associated with autism spectrum disorder in offspring (incidence rate, 23.1 vs 18.5 per 10 000 person-years; adjusted hazard ratio, 1.05). Meaning Epidural analgesia during labor was not significantly associated with autism spectrum disorder in offspring. This nationwide retrospective cohort study among children in Denmark assesses whether maternal exposure to epidural analgesia during labor is associated with incidence of autism spectrum disorder in offspring. Importance A recent cohort study found that epidural analgesia during labor was associated with an increased risk of autism in offspring. Objective To investigate if labor epidural increases the risk of autism in offspring. Design, Setting, and Participants This nationwide retrospective cohort study identified all live-born children in Denmark between January 2006 and December 2013. Follow-up commenced at children's first birthday and ended in December 2017. Among 485 093 live-born children, 5915 were excluded because of occurrences during the first year of life including death, emigration, misregistration of birth, diagnosis of disease inherently linked to autism, or diagnosis of autism. Exposures Administration of epidural analgesia during labor, as identified by procedure code. Main Outcomes and Measures The main outcome of interest was incident diagnosis of autism spectrum disorder based on International Statistical Classification of Diseases and Related Health Problems, 10th Revision codes in the Danish Psychiatric Central Register or National Patient Register. Hazard ratios were estimated using Cox regression, adjusted for covariates describing maternal comorbidity, sociodemographic factors, lifestyle, pregnancy, psychiatric illness, psychotropic medication, medical-seeking behavior, and family history of autism. A secondary analysis used a within-mother design including only children of mothers with both exposure and nonexposure to labor epidural analgesia in different deliveries. Results The cohort included 479 178 children (233 405 girls [48.7%]; median maternal age at delivery, 30.9 [IQR, 27.6-34.2] years); of these, 92 900 (19.4%) were exposed to epidural analgesia during labor. Median follow-up was 7.0 years (IQR, 4.9-9.0 years), and by the end of follow-up, 6428 children (1.3%) had been diagnosed with autism. Exposed children had an autism diagnosis incidence rate of 23.1 per 10 000 person-years compared with 18.5 per 10 000 person-years in the unexposed group (crude hazard ratio, 1.29 [95% CI, 1.21-1.37]; adjusted hazard ratio, 1.05 [95% CI, 0.98-1.11]). A secondary within-mother analysis including 59 154 children (12.3%) estimated an autism diagnosis incidence rate of 20.8 per 10 000 person-years in the exposed group and 17.1 per 10 000 person-years in the unexposed group (adjusted hazard ratio, 1.05 [95% CI, 0.90-1.21]). Conclusions and Relevance In this nationwide cohort study of Danish children, maternal exposure to epidural analgesia during labor was not significantly associated with autism spectrum disorder in offspring.	[Mikkelsen, Anders Pretzmann; Greiber, Iben Katinka; Scheller, Nikolai Madrid; Lidegaard, Ojvind] Copenhagen Univ Hosp, Rigshosp, Juliane Marie Ctr, Dept Obstet & Gynaecol, Copenhagen, Denmark; [Mikkelsen, Anders Pretzmann; Greiber, Iben Katinka; Lidegaard, Ojvind] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark; [Scheller, Nikolai Madrid] Queen Ingrids Hosp, Dept Surg, Nuuk, Greenland	Rigshospitalet; University of Copenhagen; University of Copenhagen	Mikkelsen, AP (corresponding author), Rigshosp, Dept Gynaecol, Blegdamsvej 9,4232, DK-2100 Copenhagen, Denmark.	anders.mikkelsen@regionh.dk		Mikkelsen, Anders Pretzmann/0000-0002-7583-9826; Greiber, Iben Katinka/0000-0003-3567-4294				Anim-Somuah M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub4; Bliddal M, 2018, EUR J EPIDEMIOL, V33, P27, DOI 10.1007/s10654-018-0356-1; Bos EME, 2017, CURR OPIN ANESTHESIO, V30, P736, DOI 10.1097/ACO.0000000000000516; Butwick AJ, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.6567; COX DR, 1972, J R STAT SOC B, V34, P187; Ghali WA, 2001, JAMA-J AM MED ASSOC, V286, P1494, DOI 10.1001/jama.286.12.1494; Hviid A, 2019, ANN INTERN MED, V170, P513, DOI 10.7326/M18-2101; Hviid A, 2013, NEW ENGL J MED, V369, P2406, DOI 10.1056/NEJMoa1301449; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Lauritsen MB, 2010, J AUTISM DEV DISORD, V40, P139, DOI 10.1007/s10803-009-0818-0; Lim G, 2018, ANESTHESIOLOGY, V129, P192, DOI [10.1097/aln.0000000000002182, 10.1097/ALN.0000000000002182]; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Mors O, 2011, SCAND J PUBLIC HEALT, V39, P54, DOI 10.1177/1403494810395825; Qiu CY, 2020, JAMA PEDIATR, V174, P1168, DOI 10.1001/jamapediatrics.2020.3231; R Core Team, 2021, R LANG ENV STAT COMP; Rosero EB, 2016, ACTA ANAESTH SCAND, V60, P810, DOI 10.1111/aas.12702; Royal College of Anaesthetists, 2020, NO EV LAB EP CAUS AU; Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125; Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3; Seijmonsbergen-Schermers AE, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003103; Society for Obstetric Anesthesia and Perinatology American Society of Anesthesiologists Society for Pediatric Anesthesia American College of Obstetricians and Gynecologists Society for Maternal-Fetal Medicine, 2020, LAB EP NOT CAUS AUT; Therneau TM., 2000, MODELING SURVIVAL DA; van Buuren S, 2011, J STAT SOFTW, V45, P1; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; Wall-Wieler E, 2021, JAMA PEDIATR, V175, P698, DOI 10.1001/jamapediatrics.2021.0376	25	14	14	2	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2021	326	12					1170	1177		10.1001/jama.2021.12655	http://dx.doi.org/10.1001/jama.2021.12655			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC5VU	34581738	Bronze, Green Published			2023-01-03	WOS:000704326300019
J	Liljeroos, M; Milberg, P; Krevers, B; Milberg, A				Liljeroos, Maria; Milberg, Per; Krevers, Barbro; Milberg, Anna			Dying within dyads: Stress, sense of security and support during palliative home care	PLOS ONE			English	Article							QUALITY-OF-LIFE; FAMILY CAREGIVERS; CANCER-PATIENTS; HEART-FAILURE; ATTACHMENT; BURDEN; RELATIVES; DISTRESS; IMPACT; INSTRUMENT	Objectives To examine similarities and dissimilarities in patient and family caregiver dyads in their experience of stress, support, and sense of security. Methods 144 patients and their family caregivers participated. Patients were admitted to six Swedish specialist palliative home care units and diagnosed with a non-curable disease with an expected short survival. We analysed similarity patterns of answers within dyads (correlations) as well as dissimilarities, expressed as the difference between within-dyad responses. The latter were subjected to a model-building procedure using GLM, with 13 sociodemographic and clinical characteristics as independent variables. Results Within dyads, patients and family caregivers scored similar in their perception of support and sense of security with care. There was also dissimilarity within dyad responses in their perception of stress and support that could be attributed to sociodemographic or clinical characteristics. When patients scored higher levels of stress than family caregivers, the family caregiver was more likely to be male. Also family caregiver attachment style (attachment anxiety), patient age and the relationship of the family caregiver to the patient explained dissimilarities within the dyads. Conclusions Patients and family caregivers within the dyads often, but not always, had similar scores. We suggest that it is important that the healthcare staff identify situations in which perceptions within the dyads regarding stress and perception of support differ, such that they can recognise patients' and family caregivers' unique needs in different situations, to be able to provide adequate support and facilitate dyadic coping.	[Liljeroos, Maria; Krevers, Barbro; Milberg, Anna] Linkoping Univ, Dept Hlth Med & Caring Sci, Linkoping, Sweden; [Liljeroos, Maria] Uppsala Univ, Ctr Clin Res Sormland, Eskilstuna, Sweden; [Milberg, Per] Linkoping Univ, IFM Biol, Linkoping, Sweden; [Milberg, Anna] Linkoping Univ, Dept Adv Home Care, Norrkoping, Sweden; [Milberg, Anna] Linkoping Univ, Dept Med & Hlth Sci, Norrkoping, Sweden	Linkoping University; Uppsala University; Linkoping University; Linkoping University; Linkoping University	Liljeroos, M (corresponding author), Linkoping Univ, Dept Hlth Med & Caring Sci, Linkoping, Sweden.; Liljeroos, M (corresponding author), Uppsala Univ, Ctr Clin Res Sormland, Eskilstuna, Sweden.	maria.liljeroos@liu.se	Liljeroos, Maria/S-6410-2019	Liljeroos, Maria/0000-0002-7957-8600	Medical Research Council of Southeast Sweden [LIO-126821]; Swedish Society of Medicine [2008-21732]; Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse [104821]	Medical Research Council of Southeast Sweden(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Swedish Society of Medicine; Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse	AM This work was supported by the Medical Research Council of Southeast Sweden [grant number LIO-126821], the Swedish Society of Medicine [grant number 2008-21732], and `Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse [grant number 104821] The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arambasic J, 2019, PSYCHO-ONCOLOGY, V28, P1134, DOI 10.1002/pon.5068; Balducci C, 2008, GERONTOLOGIST, V48, P276, DOI 10.1093/geront/48.3.276; Banerjee SC, 2017, TRANSL BEHAV MED, V7, P615, DOI 10.1007/s13142-017-0473-5; Bosscher RJ, 1998, BEHAV RES THER, V36, P339, DOI 10.1016/S0005-7967(98)00025-4; Boyes AW, 2011, J AFFECT DISORDERS, V135, P184, DOI 10.1016/j.jad.2011.07.016; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Buck HG, 2018, INT J NURS STUD, V77, P232, DOI 10.1016/j.ijnurstu.2017.10.007; Chesla CA, 2003, FAM PROCESS, V42, P375, DOI 10.1111/j.1545-5300.2003.00375.x; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cook WL, 2001, CHILD DEV, V72, P1179, DOI 10.1111/1467-8624.00341; Doherty LC, 2016, EUR J CARDIOVASC NUR, V15, P203, DOI 10.1177/1474515115585237; Francis LE, 2016, SUPPORT CARE CANCER, V24, P3987, DOI 10.1007/s00520-016-3219-x; Ge LX, 2017, CANCER NURS, V40, P471, DOI 10.1097/NCC.0000000000000445; Hagedoorn M, 2008, PSYCHOL BULL, V134, P1, DOI 10.1037/0033-2909.134.1.1; Haley W E, 2001, Hosp J, V15, P1, DOI 10.1300/J011v15n04_01; Henoch I, 2007, J PAIN SYMPTOM MANAG, V34, P370, DOI 10.1016/j.jpainsymman.2006.12.005; Henoch I, 2012, J CLIN NURS, V21, P585, DOI 10.1111/j.1365-2702.2011.03923.x; Hodges LJ, 2005, SOC SCI MED, V60, P1, DOI 10.1016/j.socscimed.2004.04.018; Hudson P, 2003, MED J AUSTRALIA, V179, pS35; Krevers B, 2015, J PAIN SYMPTOM MANAG, V49, P586, DOI 10.1016/j.jpainsymman.2014.06.019; Krevers B, 2014, PSYCHO-ONCOLOGY, V23, P914, DOI 10.1002/pon.3502; Larsson BW, 2004, J CLIN NURS, V13, P226, DOI 10.1046/j.1365-2702.2003.00866.x; Lee KC, 2013, J PALLIAT MED, V16, P632, DOI 10.1089/jpm.2012.0499; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Lo C, 2009, PSYCHO-ONCOLOGY, V18, P490, DOI 10.1002/pon.1417; Macionis JJ, 2011, SOCIOLOGY GLOBAL INT, DOI [10.1016/j.jht.2011.05.003, DOI 10.1016/J.JHT.2011.05.003]; Mathews G, 2017, CURR OPIN SUPPORT PA, V11, P315, DOI 10.1097/SPC.0000000000000303; Milberg A, 2012, PSYCHO-ONCOLOGY, V21, P886, DOI 10.1002/pon.1982; Milberg A, 2014, PSYCHO-ONCOLOGY, V23, P1340, DOI 10.1002/pon.3564; Milberg A, 2011, PALLIAT SUPPORT CARE, V9, P251, DOI 10.1017/S1478951511000204; Murray SA, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2581; Nissen KG, 2016, PSYCHO-ONCOLOGY, V25, P1017, DOI 10.1002/pon.4057; O'Connor L, 2009, COLLEGIAN, V16, P201, DOI 10.1016/j.colegn.2009.04.005; Petry H, 2019, INT J NURS STUD, V96, P44, DOI 10.1016/j.ijnurstu.2018.11.008; Pitceathly C, 2003, EUR J CANCER, V39, P1517, DOI 10.1016/S0959-8049(03)00309-5; Reblin M, 2017, PSYCHO-ONCOLOGY, V26, P2285, DOI 10.1002/pon.4361; Rha SY, 2015, EUR J ONCOL NURS, V19, P376, DOI 10.1016/j.ejon.2015.01.004; Riffin C, 2018, J AM GERIATR SOC, V66, P1992, DOI 10.1111/jgs.15501; Sand L, 2009, J PAIN SYMPTOM MANAG, V37, P13, DOI 10.1016/j.jpainsymman.2008.01.013; Shaffer KM, 2017, SUPPORT CARE CANCER, V25, P965, DOI 10.1007/s00520-016-3488-4; Stajduhar KI, 2008, CANCER NURS, V31, P77, DOI 10.1097/01.NCC.0000305686.36637.b5; Tsilika E, 2015, SUPPORT CARE CANCER, V23, P87, DOI 10.1007/s00520-014-2329-6; Vehling S, 2019, J PSYCHOSOM RES, V116, P93, DOI 10.1016/j.jpsychores.2018.11.018; Vehling S, 2018, PSYCHO-ONCOLOGY, V27, P2525, DOI 10.1002/pon.4872; Ventura AD, 2014, PALLIATIVE MED, V28, P391, DOI 10.1177/0269216313511141; von Heymann-Horan A, 2019, PSYCHO-ONCOLOGY, V28, P264, DOI 10.1002/pon.4932; Watanabe SM, 2011, J PAIN SYMPTOM MANAG, V41, P456, DOI 10.1016/j.jpainsymman.2010.04.020; Yabroff KR, 2004, JNCI-J NATL CANCER I, V96, P1322, DOI 10.1093/jnci/djh255; Zaider TI, 2016, FAM SYST HEALTH, V34, P204, DOI 10.1037/fsh0000159; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	50	0	0	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2021	16	9							e0257274	10.1371/journal.pone.0257274	http://dx.doi.org/10.1371/journal.pone.0257274			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5RP	34520480	Green Published, gold			2023-01-03	WOS:000707052100017
J	Gruenewald, DA				Gruenewald, David Allan			Drifting Over the Horizon Navigating the End-of-Life Journey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Gruenewald, David Allan] Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Extended Care Serv Line, Seattle, WA USA; [Gruenewald, David Allan] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Gruenewald, DA (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, S-182-GEC,1660 S Columbian Way, Seattle, WA 98108 USA.	david.gruenewald@va.gov							0	0	0	2	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	2021	326	9					811	812		10.1001/jama.2021.14031	http://dx.doi.org/10.1001/jama.2021.14031			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ7LK	34547083				2023-01-03	WOS:000696242100009
J	Guilkey, DK; Speizer, IS				Guilkey, David K.; Speizer, Ilene S.			The direct and indirect effects of community beliefs and attitudes on postpartum contraceptive method choice among young women ages 15-24 in Nigeria	PLOS ONE			English	Article							PREGNANCY; FERTILITY; MODELS; HEALTH; IDENTIFICATION; DURATION; OUTCOMES; IMPACT; RISK	Understanding what factors influence postpartum contraceptive use among young people (ages 15-24 years) is important since this group often has closely spaced and unintended births. Using secondary data gathered for an evaluation of a Bill & Melinda Gates Foundation funded initiative designed to increase modern contraceptive use in select urban areas of Nigeria, we determine the direct and indirect effects of community beliefs and attitudes on adolescent and youth postpartum contraceptive method choice. Our statistical methods control for the endogenous timing of the initiation of sexual activity and the timing and number of births to each respondent by simultaneous estimation of equations for these choices with the choice of postpartum contraceptive method. We find that community beliefs and attitudes have important effects on our primary outcome of postpartum contraceptive use and we quantify the size of both direct and indirect effects on postpartum contraceptive method choice using simulations. The findings from this study can be used to inform programs seeking to increase young women's postpartum contraceptive use for healthy spacing and timing of births.	[Guilkey, David K.; Speizer, Ilene S.] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27515 USA; [Guilkey, David K.] Univ N Carolina, Dept Econ, Chapel Hill, NC 27515 USA; [Speizer, Ilene S.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Speizer, IS (corresponding author), Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27515 USA.; Speizer, IS (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA.	speizer@email.unc.edu		Speizer, Ilene/0000-0001-6204-1316	Bill & Melinda Gates Foundation [INV009814]; Population Research Infrastructure Program [P2C HD050924]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Population Research Infrastructure Program	This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV009814]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. We also received general support from the Population Research Infrastructure Program through an award to the Carolina Population Center (P2C HD050924) at The University of North Carolina at Chapel Hill. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of CPC or the Bill & Melinda Gates Foundation.	Ahinkorah BO, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241050; Ali MM, 2011, J ADOLESCENCE, V34, P183, DOI 10.1016/j.adolescence.2009.12.008; Angeles G, 2005, ECON DEV CULT CHANGE, V54, P165, DOI 10.1086/431261; Angrist JD, 2014, LABOUR ECON, V30, P98, DOI 10.1016/j.labeco.2014.05.008; [Anonymous], 2017, HIGH IMPACT PRACTICE; Atagame KL, 2017, STUD FAMILY PLANN, V48, P253, DOI 10.1111/sifp.12027; BHARGAVA A, 1991, REV ECON STUD, V58, P129, DOI 10.2307/2298050; Chandra-Mouli V, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-1; Conde-Agudelo A, 2006, JAMA-J AM MED ASSOC, V295, P1809, DOI 10.1001/jama.295.15.1809; Costenbader E, 2017, STUD FAMILY PLANN, V48, P377, DOI 10.1111/sifp.12040; Elfstrom KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040670; Fotso JC, 2013, J BIOSOC SCI, V45, P779, DOI 10.1017/S0021932012000570; Fruehwirth JC, 2014, REV ECON STAT, V96, P514, DOI 10.1162/REST_a_00385; Ganchimeg T, 2014, BJOG-INT J OBSTET GY, V121, P40, DOI 10.1111/1471-0528.12630; Gebreselassie T, 2008, DHS ANAL STUDIES; Greene M., 2015, CASE INVESTING RES I; Greene ME, 2014, REACHING YOUNG 1 TIM; Gueye A, 2015, INT PERSPECT SEX R H, V41, P191, DOI 10.1363/4119115; Guilkey D.K., 2014, FESTSCHRIFT P SCHMID, P5, DOI DOI 10.1007/978-1-4899-8008-3_2; Guilkey DK, 2020, DEMOGRAPHY, V57, P873, DOI 10.1007/s13524-020-00884-6; Haggerty PA., 1999, DHS COMP STUDIES; HECKMAN J, 1984, ECONOMETRICA, V52, P271, DOI 10.2307/1911491; Heckman J., 1985, LONGITUDINAL ANAL LA, P39, DOI [10.1017/ CCOL0521304539, DOI 10.1017/CCOL0521304539]; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; High Impact Practices in Family Planning (HIPs), 2017, IMM POSTP FAM PLANN; Kohler HP, 2001, DEMOGRAPHY, V38, P43, DOI 10.1353/dem.2001.0005; Krenn S, 2014, GLOB HEALTH-SCI PRAC, V2, P427, DOI 10.9745/GHSP-D-14-00009; LILLARD LA, 1993, J ECONOMETRICS, V56, P189, DOI 10.1016/0304-4076(93)90106-F; MacQuarrie K. L. D., 2014, DHS Comparative Reports; MANSKI CF, 1993, REV ECON STUD, V60, P531, DOI 10.2307/2298123; Montgomery MR, 1996, POPUL DEV REV, V22, P151, DOI 10.2307/2808010; Moore Z, 2015, CONTRACEPTION, V92, P31, DOI 10.1016/j.contraception.2015.03.007; National Population Commission (NPC) [Nigeria] and ICF, 2019, FEDERAL REPUBLIC NIG; Norton M, 2017, GLOB HEALTH-SCI PRAC, V5, P547, DOI 10.9745/GHSP-D-17-00131; Coll CDN, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0686-9; Rindfuss RR, 2007, DEMOGRAPHY, V44, P345, DOI 10.1353/dem.2007.0017; Rutstein SO., 2008, 41 DEM HLTH SURV MAC; Sambisa W., 1997, CONTRACEPTIVE USE DY; Sarder A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245923; Sedgh G, 2014, STUD FAMILY PLANN, V45, P151, DOI 10.1111/j.1728-4465.2014.00382.x; Solo J, 2019, GLOB HEALTH-SCI PRAC, V7, P371, DOI 10.9745/GHSP-D-19-00130; Speizer IS, 2013, J ADOLESCENT HEALTH, V53, P609, DOI 10.1016/j.jadohealth.2013.06.004; United Nations (UN), 2013, AD FERT INT C POP DE; Wendt A, 2012, PAEDIATR PERINAT EP, V26, P239, DOI 10.1111/j.1365-3016.2012.01285.x; WHO, 2005, P 13 INT THYROID C; Woodridge JM, 2002, ECONOMETRIC ANAL CRO; Yaya S, 2020, J MATERN-FETAL NEO M, V33, P3501, DOI 10.1080/14767058.2019.1576623	47	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0261701	10.1371/journal.pone.0261701	http://dx.doi.org/10.1371/journal.pone.0261701			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085264	Green Published, gold			2023-01-03	WOS:000779379600028
J	Lee, CD; Nelin, L; Foglia, EE				Lee, Clement D.; Nelin, Leif; Foglia, Elizabeth E.			Neonatal Resuscitation in 22-Week Pregnancies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE	Neonatal Resuscitation This interactive feature about infants born very prematurely offers a case vignette accompanied by two essays supporting resuscitation in all neonates born at 22 weeks' gestation or selective resuscitation. Vote and comment at NEJM.org.	[Nelin, Leif] Ohio State Univ, Columbus, OH 43210 USA; [Nelin, Leif] Nationwide Childrens Hosp, Columbus, OH 43205 USA; [Foglia, Elizabeth E.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Nelin, L (corresponding author), Ohio State Univ, Columbus, OH 43210 USA.; Nelin, L (corresponding author), Nationwide Childrens Hosp, Columbus, OH 43205 USA.			Lee, Clement/0000-0002-2963-4731				Backes CH, 2021, AM J OBSTET GYNECOL, V224, P158, DOI 10.1016/j.ajog.2020.07.051; Backes CH, 2019, J PERINATOL, V39, P39, DOI 10.1038/s41372-018-0248-y; Carbajal R, 2008, JAMA-J AM MED ASSOC, V300, P60, DOI 10.1001/jama.300.1.60; Cummings J, 2015, PEDIATRICS, V136, P588, DOI 10.1542/peds.2015-2336; Di Nardo M, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00109; Pettker CM, 2017, OBSTET GYNECOL, V129, pE150, DOI 10.1097/AOG.0000000000002046; Rysavy M, 2020, JAMA PEDIATR, V174, DOI 10.1001/jamapediatrics.2019.6294; Soderstrom F, 2021, ARCH DIS CHILD-FETAL, V106, P413, DOI 10.1136/archdischild-2020-320486; Watkins PL, 2020, J PEDIATR-US, V217, P52, DOI 10.1016/j.jpeds.2019.08.028; Wyckoff MH, 2014, SEMIN PERINATOL, V38, P12, DOI 10.1053/j.semperi.2013.07.003; Younge N, 2017, NEW ENGL J MED, V376, P617, DOI 10.1056/NEJMoa1605566	11	1	1	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2022	386	4					391	393		10.1056/NEJMclde2114954	http://dx.doi.org/10.1056/NEJMclde2114954			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW6UB	35081286				2023-01-03	WOS:000753548900019
J	Liao, CC; Tai, YH; Yeh, CC; Hsu, YH; Chen, TL; Cherng, YG				Liao, Chien-Chang; Tai, Ying-Hsuan; Yeh, Chun-Chieh; Hsu, Yung-Ho; Chen, Ta-Liang; Cherng, Yih-Giun			Effect of influenza vaccination on the outcomes of hospitalization for kidney disease in a geriatric population: A propensity-score matched study	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; ACUTE CORONARY SYNDROME; ELDERLY-PATIENTS; REDUCES HOSPITALIZATION; CARDIOVASCULAR EVENTS; DIALYSIS PATIENTS; MORTALITY; RISK; INFECTION; PNEUMONIA	Background and aims The effects of influenza vaccination (IV) on the outcomes of patients with kidney disease (KD) are not completely understood. We aimed to evaluate and compare the outcomes during admission of KD between elderly patients who did or did not receive an IV within the previous 12 months. Methods We used health insurance research data in Taiwan and conducted a population-based cohort study that included 22,590 older people aged >= 65 years who were hospitalized for KD in 2008-2013. We performed propensity score matching (case-control ratio 1:1) to select 4386 eligible IV recipients and 4386 nonrecipient controls for comparison. The adjusted odds ratios (ORs) with 95% confidence intervals (Cis) of IV associated with complications and mortality during KD admission were calculated using multivariable logistic regression analyses. Results During hospitalization for KD, IV was significantly associated with lower risks of 30-day inhospital mortality (OR 0.56, 95% CI 0.39-0.82), septicemia (OR 0.77, 95% CI 0.68-0.87), and intensive care (OR 0.85, 95% CI 0.75-0.96). Additionally, IV recipients had a shorter length of hospital stay and lower medical expenditure than nonrecipients. Subgroup analyses further showed that the association of IV with reduced adverse events was confined to patients aged >= 75 years. Conclusions Previous IV was associated with reduced risks of complications and mortality and in elderly patients hospitalized for KD. We raised the possibility and suggested the need to promote IV for this susceptible population of patients with KD.	[Liao, Chien-Chang] Taipei Med Univ Hosp, Dept Anesthesiol, Taipei, Taiwan; [Liao, Chien-Chang; Chen, Ta-Liang] Taipei Med Univ Hosp, Anesthesiol & Hlth Policy Res Ctr, Taipei, Taiwan; [Liao, Chien-Chang; Tai, Ying-Hsuan; Chen, Ta-Liang; Cherng, Yih-Giun] Taipei Med Univ, Sch Med, Dept Anesthesiol, Coll Med, Taipei, Taiwan; [Liao, Chien-Chang] Taipei Med Univ, Wan Fang Hosp, Res Ctr Big Data & Meta Anal, Taipei, Taiwan; [Liao, Chien-Chang] China Med Univ, Sch Chinese Med, Coll Chinese Med, Taichung, Taiwan; [Tai, Ying-Hsuan; Cherng, Yih-Giun] Taipei Med Univ, Shuang Ho Hosp, Dept Anesthesiol, New Taipei, Taiwan; [Yeh, Chun-Chieh] China Med Univ Hosp, China Med Univ, Dept Surg, Taichung, Taiwan; [Yeh, Chun-Chieh] Univ Illinois, Dept Surg, Chicago, IL USA; [Hsu, Yung-Ho] Taipei Med Univ, Shuan Ho Hosp, Dept Nephrol, New Taipei, Taiwan; [Chen, Ta-Liang] Taipei Med Univ, Wan Fang Hosp, Dept Anesthesiol, Taipei, Taiwan	Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; China Medical University Taiwan; Taipei Medical University; Shuang Ho Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Taipei Medical University; Shuang Ho Hospital; Taipei Medical University; Taipei Municipal WanFang Hospital	Cherng, YG (corresponding author), Taipei Med Univ, Sch Med, Dept Anesthesiol, Coll Med, Taipei, Taiwan.; Cherng, YG (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Dept Anesthesiol, New Taipei, Taiwan.	stainless@s.tmu.edu.tw	tai, yh/GRR-4574-2022					Berry BB, 2001, VACCINE, V19, P3493, DOI 10.1016/S0264-410X(01)00068-8; Bikbov B, 2020, LANCET, V395, P709, DOI 10.1016/S0140-6736(20)30045-3; Bond TC, 2012, AM J KIDNEY DIS, V60, P959, DOI 10.1053/j.ajkd.2012.04.018; Bosaeed M, 2018, HUM VACC IMMUNOTHER, V14, P1311, DOI 10.1080/21645515.2018.1445446; Campbell KL, 2008, CLIN NUTR, V27, P537, DOI 10.1016/j.clnu.2008.05.002; Castrucci MR, 2018, HUM VACC IMMUNOTHER, V14, P637, DOI 10.1080/21645515.2017.1338547; Chen CI, 2016, MEDICINE, V95, P1, DOI 10.1097/MD.0000000000002588; Cody JD, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003266.pub3; Fang YA, 2016, ACTA CARDIOL SIN, V32, P290, DOI 10.6515/ACS20150424L; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Hassan HIC, 2016, KIDNEY INT, V90, P897, DOI 10.1016/j.kint.2016.07.013; Herzog NS, 2003, AM J MED, V115, P454, DOI 10.1016/S0002-9343(03)00440-6; Hounkpatin HO, 2020, CLIN KIDNEY J, V13, P245, DOI 10.1093/ckj/sfz113; Huang HH, 2019, J MICROBIOL IMMUNOL, V52, P22, DOI 10.1016/j.jmii.2017.08.014; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013, KIDNEY INT S, V3, P1, DOI DOI 10.1038/KISUP.2012.64; Kim DK, 2018, ANN INTERN MED, V168, P210, DOI 10.7326/M17-3439; Kosmadakis G, 2018, SEMIN DIALYSIS, V31, P507, DOI 10.1111/sdi.12709; Kumar D, 2011, AM J TRANSPLANT, V11, P2020, DOI 10.1111/j.1600-6143.2011.03753.x; Kurts C, 2013, NAT REV IMMUNOL, V13, P738, DOI 10.1038/nri3523; Lam F, 2019, ATHEROSCLEROSIS, V282, P85, DOI 10.1016/j.atherosclerosis.2019.01.008; Liu WC, 2018, J INFECT DIS, V217, P816, DOI 10.1093/infdis/jix616; Lorenzo MMG, 2013, CHEST, V143, P502, DOI 10.1378/chest.12-1711; MacIntyre CR, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3548-0; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Nichol KL, 2007, NEW ENGL J MED, V357, P1373, DOI 10.1056/NEJMoa070844; Noh JY, 2016, HUM VACC IMMUNOTHER, V12, P2902, DOI 10.1080/21645515.2016.1191717; O'Hare AM, 2007, J AM SOC NEPHROL, V18, P2758, DOI 10.1681/ASN.2007040422; Sung LC, 2014, VACCINE, V32, P3843, DOI 10.1016/j.vaccine.2014.04.064; Talbot HK, 2017, INFECT DIS CLIN N AM, V31, P757, DOI 10.1016/j.idc.2017.07.005; Taylor DM, 2018, NEPHROL DIAL TRANSPL, V33, P1545, DOI 10.1093/ndt/gfx293; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Troeger CE, 2019, LANCET RESP MED, V7, P69, DOI [10.1016/S2213-2600(18)30496-X, 10.1016/s2213-2600(18)30496-x]; Voordouw ACG, 2004, JAMA-J AM MED ASSOC, V292, P2089, DOI 10.1001/jama.292.17.2089; Wakasugi M, 2012, THER APHER DIAL, V16, P226, DOI 10.1111/j.1744-9987.2012.01062.x; Walker TA, 2020, J INFECT DIS, V221, P183, DOI 10.1093/infdis/jiz570; Wang IK, 2016, NEPHROL DIAL TRANSPL, V31, P269, DOI 10.1093/ndt/gfv360; Wang IK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058317	40	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2022	17	1							e0262420	10.1371/journal.pone.0262420	http://dx.doi.org/10.1371/journal.pone.0262420			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1B8ZK	35077480	gold, Green Published			2023-01-03	WOS:000792720400026
J	Qian, JL; Wu, HH; Sun, SW; Wang, M; Yu, XY				Qian, Jialu; Wu, Honghe; Sun, Shiwen; Wang, Man; Yu, Xiaoyan			Psychometric properties of the Chinese version of the Perinatal Bereavement Care Confidence Scale (C-PBCCS) in nursing practice	PLOS ONE			English	Article							EXPERIENCES; STILLBIRTH; DEATH; NEEDS	Background The Perinatal Bereavement Care Confidence Scale (PBCCS) was designed to evaluate midwives' and nurses' confidence and its psychosocial factors to provide bereavement care in Ireland. However, it is unknown whether this scale is valid and reliable for use with midwives and nurses in China. The aim of this study was to translate the English version into Chinese (C-PBCCS) and determine its validity and reliability in a population of Chinese midwives and nurses. Methods In this cross-sectional observational study, after translating the English version of the PBCCS into Chinese and ensuring the linguistic adequacy and clarity of the language, we evaluated the validity and reliability of the C-PBCCS with Chinese midwives and nurses (n = 608). Participants were recruited using convenience sampling from 10 maternity hospitals in Zhejiang and Jiangsu Provinces. Exploratory factor analysis (EFA) was conducted to determine the construct validity (n = 304). Another sample of 304 midwives and nurses was used for confirmatory factor analysis (CFA) to verify the quality of the factor structures. Cronbach's alpha coefficient and Guttman split-half coefficient were adopted for the evaluation of internal consistency. The STROBE was followed in reporting the results. Results The 43-item PBCCS was reduced to 40 items. Bereavement support knowledge (13 items, three factors), Bereavement support skills (eight items, two factors), Self-awareness (eight items, two factors), and Organizational support (11 items, two factors). The CFA suggested that the four scales in the C-PBCCS had acceptable fit indices. The Cronbach's alpha ranged from 0.835-0.901. The Guttman split-half coefficient was between 0.868-0.933. Conclusion The C-PBCCS was found to be a psychometrically sound measurement tool to evaluate Chinese-speaking midwives' and nurses' confidence and the psychosocial factors that affect their confidence in providing perinatal bereavement care.	[Qian, Jialu; Wang, Man] Zhejiang Univ Sch Med, Hangzhou, Zhejiang, Peoples R China; [Qian, Jialu; Sun, Shiwen; Wang, Man; Yu, Xiaoyan] Zhejiang Univ, Womens Hosp Sch Med, Dept Obstet, Hangzhou, Zhejiang, Peoples R China; [Wu, Honghe] Nantong Maternal & Child Hlth Hosp, Dept Obstet, Nantong, Jiangsu, Peoples R China	Zhejiang University	Yu, XY (corresponding author), Zhejiang Univ, Womens Hosp Sch Med, Dept Obstet, Hangzhou, Zhejiang, Peoples R China.	yuxy@zju.edu.cn			Zhejiang Medical and Health Research Project [2020KY173]	Zhejiang Medical and Health Research Project	The study was funded by Zhejiang Medical and Health Research Project (Foundation Number: 2020KY173). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agnese Paola, 2017, EUROPEAN J CONTRACEP; Ahmed HM, 2020, REPROD HEALTH, V17, DOI 10.1186/s12978-020-0894-3; Armour S, 2018, WOMEN BIRTH, V31, pS14, DOI 10.1016/j.wombi.2018.08.048; Asplin N, 2014, MIDWIFERY, V30, P620, DOI 10.1016/j.midw.2013.10.013; Babu RS, 2013, J CLIN DIAGN RES, V7, P1276, DOI 10.7860/JCDR/2013/6336.3187; Bagozzi RP, 2012, J ACAD MARKET SCI, V40, P8, DOI 10.1007/s11747-011-0278-x; Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014; Bereavement Care Standards Group, 2016, NAT STAND BER CAR FO; Boyle FM, 2020, WOMEN BIRTH, V33, P107, DOI 10.1016/j.wombi.2019.01.008; Brislin R, 1986, FIELD METHODS CROSS, V8; Burden C, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0800-8; Chambers HMCF., 2000, COCHRANE DB SYST REV; Chan MF, 2009, J CLIN NURS, V18, P2344, DOI 10.1111/j.1365-2702.2008.02689.x; Chiappetta-Swanson CA, 2001, PROCESS CARING NURSE; DiMarco Marguerite, 2002, J Contin Educ Nurs, V33, P180; Doherty J., 2018, BRIT J MIDWIFERY, V26, P523, DOI [10.12968/bjom.2018.26.8.523, DOI 10.12968/BJOM.2018.26.8.523]; Doherty J, 2018, MIDWIFERY, V66, P1, DOI 10.1016/j.midw.2018.06.026; Emond T, 2019, J CLIN NURSING; Fenwick Jennifer, 2007, Women Birth, V20, P153, DOI 10.1016/j.wombi.2007.09.002; FITZSIMONS M, 2017, BMC PREGNANCY CHILDB, V17, DOI DOI 10.5334/IJIC.3643; Georgsson S, 2019, J ADV NURS, V75, P3006, DOI 10.1111/jan.14132; Hair J.F., 1998, MULTIVARIATE DATA AN; Harries J, 2009, AFRICAN J NURSING MI, V9, P296; Hou J, 2004, STRUCTURAL EQUATIONS; Hu YL, 2019, BMC PALLIAT CARE, V18, DOI 10.1186/s12904-019-0409-6; Kalu FA, 2020, WOMEN BIRTH, V33, pE311, DOI 10.1016/j.wombi.2019.07.001; Kalu FA, 2018, MIDWIFERY, V64, P69, DOI 10.1016/j.midw.2018.06.011; Kline R. B, 2015, PRINCIPLES PRACTICE, V2nd; Kuti O, 2011, INT J GYNECOL OBSTET, V113, P205, DOI 10.1016/j.ijgo.2010.11.025; Lisy K, 2016, BIRTH-ISS PERINAT C, V43, P6, DOI 10.1111/birt.12217; LYNN MR, 1986, NURS RES, V35, P382; Martin CJH, 2016, NURS EDUC TODAY, V39, P99, DOI 10.1016/j.nedt.2015.12.023; Mayers PM, 2008, HLTH SA GESONDHEID, V10; McKenna L, 2011, CONTEMP NURSE, V38, P76, DOI 10.5172/conu.2011.38.1-2.76; Mulvihill A, 2014, BRIT J SOC WORK, V44, P2290, DOI 10.1093/bjsw/bct078; Nuzum D, 2014, BJOG-INT J OBSTET GY, V121, P1020, DOI 10.1111/1471-0528.12695; Odukoya JA, 2018, QUAL QUANT, V52, P983, DOI 10.1007/s11135-017-0499-2; Peters MDJ, 2015, WOMEN BIRTH, V28, P272, DOI 10.1016/j.wombi.2015.07.003; Polit-OHara D, 1999, STUDY GUIDE ACCOMPAN; Qian JL, 2021, J ADV NURS, V77, P3644, DOI 10.1111/jan.14853; Qian JL, 2021, NURS EDUC TODAY, V103, DOI 10.1016/j.nedt.2021.104962; Sands Australia, 2018, SANDS AUSTR PRINC BE; Sereshti Manije, 2016, Electron Physician, V8, P2006, DOI 10.19082/2006; Shaikh F, 2016, GOMAL J MED SCI, V14, P160; Shakespeare C, 2020, INT J GYNECOL OBSTET, V149, P137, DOI 10.1002/ijgo.13110; Shaw A, 2014, BIOETHICS, V28, P84, DOI 10.1111/bioe.12047; Shorey S, 2017, INT J NURS STUD, V68, P25, DOI 10.1016/j.ijnurstu.2016.12.007; Singh S, 2018, LANCET GLOB HEALTH, V6, pE111, DOI 10.1016/s2214-109x(17)30453-9; Sutherland MA, 2014, J AM ASSOC NURSE PRA, V26, P567, DOI 10.1002/2327-6924.12101; Teffo ME, 2018, J OBSTET GYNAECOL RE, V44, P1202, DOI 10.1111/jog.13665; WHO, 2012, SAF UNS IND AB GLOB; Wu M.L., 2009, STRUCTURAL EQUATION; Xiaoli Z., 2020, CHIN J NURS, V942-946, P254	53	2	2	3	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0262965	10.1371/journal.pone.0262965	http://dx.doi.org/10.1371/journal.pone.0262965			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061840	gold, Green Published			2023-01-03	WOS:000791072800191
J	Zheng, S; Yang, J; Tan, TC; Belani, S; Law, D; Pravoverov, LV; Kim, SS; Go, AS				Zheng, Sijie; Yang, Jingrong; Tan, Thida C.; Belani, Sharina; Law, David; Pravoverov, Leonid V.; Kim, Susan S.; Go, Alan S.			Dialysis therapy and mortality in older adults with heart failure and advanced chronic kidney disease: A high-dimensional propensity-matched cohort study	PLOS ONE			English	Article							STAGE RENAL-DISEASE; CONSERVATIVE MANAGEMENT; EJECTION FRACTION; STARTING DIALYSIS; PROGNOSTIC VALUE; ELDERLY-PATIENTS; SURVIVAL; DEATH; CARE; RISKS	Background Heart failure (HF) and chronic kidney disease (CKD) frequently coexist, and the combination is linked to poor outcomes, but limited data exist to guide optimal management. We evaluated the outcome of dialysis therapy in older patients with HF and advanced CKD. Methods We examined adults aged >= 70 years with HF and eGFR <= 20 ml/min/1.73 m(2) between 2008-2012 and no prior renal replacement therapy, cancer, cirrhosis or organ transplant. We identified patients who initiated chronic dialysis through 2013 and matched patients who did not initiate dialysis on age, gender, diabetes status, being alive on dialysis initiation date, and a high-dimensional propensity score for starting dialysis. Deaths were identified through 2013. We used Cox regression to evaluate the association of chronic dialysis and all-cause death. Results Among 348 adults with HF and advanced CKD who initiated dialysis and 947 matched patients who did not start dialysis, mean age was 80 +/- 5 years, 51% were women and 33% were Black. The crude rate of death was high overall but lower in those initiating vs. not initiating chronic dialysis (26.1 vs. 32.1 per 100 person-years, respectively, P = 0.02). In multivariable analysis, dialysis was associated with a 33% (95% Confidence Interval:17-46%) lower adjusted rate of death compared with not initiating dialysis. Conclusions Among older adults with HF and advanced CKD, dialysis initiation was associated with lower mortality, but absolute rates of death were very high in both groups. Randomized trials should evaluate net outcomes of dialysis vs. conservative management on length and quality of life in this high-risk population.	[Zheng, Sijie; Law, David; Pravoverov, Leonid V.] Kaiser Permanente, Dept Nephrol, Oakland Med Ctr, Oakland, CA USA; [Zheng, Sijie; Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Zheng, Sijie; Yang, Jingrong; Tan, Thida C.; Kim, Susan S.; Go, Alan S.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA 94612 USA; [Belani, Sharina] Kaiser Permanente, Dept Nephrol, San Rafael Med Ctr, San Rafael, CA USA; [Go, Alan S.] Kaiser Permanente, Dept Hlth Syst Sci, Bernard J Tyson Sch Med, Pasadena, CA 91107 USA; [Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA; [Go, Alan S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA; [Go, Alan S.] Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94305 USA; [Go, Alan S.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Palo Alto, CA 94305 USA	Kaiser Permanente; University of California System; University of California San Francisco; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Stanford University	Go, AS (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.; Go, AS (corresponding author), Kaiser Permanente Northern Calif, Div Res, Oakland, CA 94612 USA.; Go, AS (corresponding author), Kaiser Permanente, Dept Hlth Syst Sci, Bernard J Tyson Sch Med, Pasadena, CA 91107 USA.; Go, AS (corresponding author), Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.; Go, AS (corresponding author), Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.; Go, AS (corresponding author), Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94305 USA.; Go, AS (corresponding author), Stanford Univ, Sch Med, Dept Hlth Res & Policy, Palo Alto, CA 94305 USA.	Alan.S.Go@kp.org			National Institute of Diabetes, Digestive and Kidney Diseases [U01 DK060902, U01 DK082223]; National Heart, Lung and Blood Institute [R01 HL142834, R01 HL132640]; Kaiser Permanente Northern California Community Benefit Fund; Permanente Medical Group Division of Research	National Institute of Diabetes, Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Kaiser Permanente Northern California Community Benefit Fund; Permanente Medical Group Division of Research	Dr. Go has received related research funding from the National Institute of Diabetes, Digestive and Kidney Diseases (U01 DK060902, U01 DK082223) and the National Heart, Lung and Blood Institute (R01 HL142834, R01 HL132640). Dr. Law received a research grant from the Kaiser Permanente Northern California Community Benefit Fund and support from The Permanente Medical Group Division of Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The other authors have no relevant disclosures.	ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; Brunori G, 2007, AM J KIDNEY DIS, V49, P569, DOI 10.1053/j.ajkd.2007.02.278; Carson RC, 2009, CLIN J AM SOC NEPHRO, V4, P1611, DOI 10.2215/CJN.00510109; Chandna SM, 2011, NEPHROL DIAL TRANSPL, V26, P1608, DOI 10.1093/ndt/gfq630; CURB JD, 1985, AM J EPIDEMIOL, V121, P754, DOI 10.1093/aje/121.5.754; Da Silva-Gane M, 2012, CLIN J AM SOC NEPHRO, V7, P2002, DOI 10.2215/CJN.01130112; Freeman JV, 2013, CIRC-CARDIOVASC QUAL, V6, P525, DOI 10.1161/CIRCOUTCOMES.111.000079; Testal AG, 2021, THER APHER DIAL, V25, P24, DOI 10.1111/1744-9987.13493; Go AS, 2006, JAMA-J AM MED ASSOC, V296, P2105, DOI 10.1001/jama.296.17.2105; Go AS, 2006, CIRCULATION, V113, P2713, DOI 10.1161/CIRCULATIONAHA.105.577577; Go AS, 2018, CLIN J AM SOC NEPHRO, V13, P833, DOI 10.2215/CJN.12591117; Go AS, 2006, ANN INTERN MED, V144, P229, DOI 10.7326/0003-4819-144-4-200602210-00004; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Gordon NP, 2013, CHARACTERISTICS ADUL; HARNETT JD, 1995, KIDNEY INT, V47, P884, DOI 10.1038/ki.1995.132; Hussain JA, 2013, PALLIATIVE MED, V27, P829, DOI 10.1177/0269216313484380; Jassal SV, 2007, CAN MED ASSOC J, V177, P1033, DOI 10.1503/cmaj.061765; Jassal SV, 2009, NEW ENGL J MED, V361, P1612, DOI 10.1056/NEJMc0905289; Joly D, 2003, J AM SOC NEPHROL, V14, P1012, DOI 10.1097/01.ASN.0000054493.04151.80; Karter AJ, 2017, JAMA INTERN MED, V177, P1461, DOI 10.1001/jamainternmed.2017.3844; Kotrlik J., 2011, J AGR ED, DOI [DOI 10.5032/JAE.2011.01132, 10.5032/jae.2011.01132]; Kurella M, 2007, ANN INTERN MED, V146, P177, DOI 10.7326/0003-4819-146-3-200702060-00006; Leskovar B, 2017, CLIN NEPHROL, V88, pS57, DOI 10.5414/CNP88FX14; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Lo LJ, 2009, KIDNEY INT, V76, P893, DOI 10.1038/ki.2009.289; Echevers YM, 2016, NEFROLOGIA, V36, P283, DOI 10.1016/j.nefro.2015.11.006; McIntyre CW, 2010, SEMIN DIALYSIS, V23, P449, DOI 10.1111/j.1525-139X.2010.00782.x; Morton RL, 2012, CAN MED ASSOC J, V184, pE277, DOI 10.1503/cmaj.111355; O'Connor NR, 2012, J PALLIAT MED, V15, P228, DOI 10.1089/jpm.2011.0207; Postorino M, 2007, NEPHROL DIAL TRANSPL, V22, P1377, DOI 10.1093/ndt/gfl813; Raghavan D, 2016, ADV CHRONIC KIDNEY D, V23, P51, DOI 10.1053/j.ackd.2015.08.003; Rea L, 2014, DESIGNING CONDUCTING; Reindl-Schwaighofer R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181345; Santoro A, 2010, J NEPHROL, V23, pS80; Schneeweiss S, 2009, EPIDEMIOLOGY, V20, P512, DOI 10.1097/EDE.0b013e3181a663cc; Smith DH, 2013, CIRC-CARDIOVASC QUAL, V6, P333, DOI 10.1161/CIRCOUTCOMES.113.000221; Stack AG, 2003, KIDNEY INT, V64, P1071, DOI 10.1046/j.1523-1755.2003.00165.x; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; United States Renal Data System, 2020, 2020 USRDS ANN DAT R; van Loon IN, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1268-3; Verberne WR, 2016, CLIN J AM SOC NEPHRO, V11, P633, DOI 10.2215/CJN.07510715; Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757; Yamada S, 2010, CLIN J AM SOC NEPHRO, V5, P1793, DOI 10.2215/CJN.00050110	45	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0262706	10.1371/journal.pone.0262706	http://dx.doi.org/10.1371/journal.pone.0262706			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061809	gold, Green Published			2023-01-03	WOS:000791072800157
J	Hvarfner, A; Al-Djaber, A; Ekstrom, H; Enarsson, M; Castegren, M; Baker, T; Schell, CO				Hvarfner, Anna; Al-Djaber, Ahmed; Ekstrom, Hampus; Enarsson, Malin; Castegren, Markus; Baker, Tim; Schell, Carl Otto			Oxygen provision to severely ill COVID-19 patients at the peak of the 2020 pandemic in a Swedish district hospital	PLOS ONE			English	Article							CARE; MANAGEMENT; MORBIDITY; MORTALITY; CAPACITY; SEPSIS; SYSTEM	Oxygen is a low-cost and life-saving therapy for patients with COVID-19. Yet, it is a limited resource in many hospitals in low income countries and in the 2020 pandemic even hospitals in richer countries reported oxygen shortages. An accurate understanding of oxygen requirements is needed for capacity planning. The World Health Organization estimates the average flow-rate of oxygen to severe COVID-19-patients to be 10 l/min. However, there is a lack of empirical data about the oxygen provision to patients. This study aimed to estimate the oxygen provision to COVID-19 patients with severe disease in a Swedish district hospital. A retrospective, medical records-based cohort study was conducted in March to May 2020 in a Swedish district hospital. All adult patients with severe COVID-19 -those who received oxygen in the ward and had no ICU-admission during their hospital stay-were included. Data were collected on the oxygen flow-rates provided to the patients throughout their hospital stay, and summary measures of oxygen provision calculated. One-hundred and twenty-six patients were included, median age was 70 years and 43% were female. On admission, 27% had a peripheral oxygen saturation of <= 91% and 54% had a respiratory rate of >= 25/min. The mean oxygen flow-rate to patients while receiving oxygen therapy was 3.0 l/min (SD 2.9) and the mean total volume of oxygen provided per patient admission was 16,000 l (SD 23,000). In conclusion, the provision of oxygen to severely ill COVID-19-patients was lower than previously estimated. Further research is required before global estimates are adjusted.	[Hvarfner, Anna] Uppsala Univ, Ctr Clin Res Dalarna, Falun, Sweden; [Hvarfner, Anna; Baker, Tim; Schell, Carl Otto] Karolinska Inst, Dept Global Publ Hlth, Stockholm, Sweden; [Al-Djaber, Ahmed; Ekstrom, Hampus; Enarsson, Malin; Castegren, Markus; Schell, Carl Otto] Uppsala Univ, Ctr Clin Res Sormland, Eskilstuna, Sweden; [Al-Djaber, Ahmed; Ekstrom, Hampus] Nykoping Hosp, Dept Med, Nykoping, Sweden; [Enarsson, Malin] Eskilstuna Hosp, Dept Infect Dis, Eskilstuna, Sweden; [Castegren, Markus] Karolinska Inst, CLINTEC, Stockholm, Sweden; [Castegren, Markus] Karolinska Inst, FyFa, Stockholm, Sweden; [Baker, Tim] London Sch Hyg & Trop Med, Dept Clin Res, London, England	Uppsala University; Karolinska Institutet; Uppsala University; Karolinska Institutet; Karolinska Institutet; University of London; London School of Hygiene & Tropical Medicine	Hvarfner, A (corresponding author), Uppsala Univ, Ctr Clin Res Dalarna, Falun, Sweden.; Hvarfner, A (corresponding author), Karolinska Inst, Dept Global Publ Hlth, Stockholm, Sweden.	anna.hvarfner@gmail.com		Schell, Carl Otto/0000-0002-7904-1336; Hvarfner, Anna/0000-0002-1718-0007; Baker, Tim/0000-0001-8727-7018; Castegren, Markus/0000-0002-9292-0298	Regional Research Council in Mid Sweden [RFR-931271]	Regional Research Council in Mid Sweden	This work was supported by the Regional Research Council in Mid Sweden grant number RFR-931271. The funders had no role in the design of the study.	Alhazzani Waleed, 2020, Crit Care Med, V48, pe440, DOI [10.1007/s00134-020-06022-5, 10.1097/CCM.0000000000004363]; [Anonymous], WHO DIRECTOR GEN OPE; [Anonymous], 2021, BBC NEWS 0115; [Anonymous], PNEUM CHILDR STAT; [Anonymous], COVID 19 MAP INTERNE; [Anonymous], AV LENGTH STAY HOSP; [Anonymous], WHO MODEL LIST ESSEN; Average length of stay in hospital, HLTH GLANC EUR 2020; Baker T, 2020, LANCET, V395, P1253, DOI 10.1016/S0140-6736(20)30793-5; Belle J, 2010, J INFECT DEV COUNTR, V4, P419, DOI 10.3855/jidc.859; Bradley BD, 2016, INT J TUBERC LUNG D, V20, P1130, DOI 10.5588/ijtld.15.0889; Brosnahan SB, 2020, ARTERIOSCL THROM VAS, V40, P2586, DOI 10.1161/ATVBAHA.120.314515; Charlson Comorbidity index (CCI), MDCALC; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; Consortium ISAR I., 2020, MEDRXIV; Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI [10.1097/CCM.0b013e31827e83af, 10.1007/s00134-012-2769-8]; Demony VWCatarina., 2021, REUTERS 0128; Denis Campbell H., 2021, GUARDIAN 0111; Dondorp AM, 2020, AM J TROP MED HYG, V102, P1191, DOI 10.4269/ajtmh.20-0283; Duke T, 2008, LANCET, V372, P1328, DOI 10.1016/S0140-6736(08)61164-2; Fore HH, 2020, LANCET, V396, P1709, DOI 10.1016/S0140-6736(20)32348-5; Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3; Hong L, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05528-z; Jimenez E, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-042398; Katira BH, 2019, RESP CARE, V64, P629, DOI 10.4187/respcare.07055; Kayambankadzanja RK, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0256361; Kwee TC, 2020, RADIOGRAPHICS, V40, P1848, DOI 10.1148/rg.2020200159; Ma XY, 2020, J CRIT CARE, V58, P96, DOI 10.1016/j.jcrc.2020.04.012; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Michaelson R, 2021, GUARDIAN 0112; Mock C, 2004, GUIDELINES ESSENTIAL, P93; Naidoo Y., 2021, STAFF OXYGEN SHORTAG; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Royal College of Physicians, 2012, NAT EARL WARN SCOR N; Schell CO, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2219-2; Neto AS, 2021, AM J TROP MED HYG, V104, P60, DOI 10.4269/ajtmh.20-0796; The Public Health Agency of Sweden, 2020, VECK COV 19 VECK 21; Tompkins L., 2021, NEW YORK TIMES INTER; Usher AD, 2021, LANCET, V397, P868, DOI 10.1016/S0140-6736(21)00561-4; Dat VQ, 2017, J CRIT CARE, V42, P109, DOI 10.1016/j.jcrc.2017.07.020; WHO, 2020, CLIN CAR SEV AC RESP, P196; World Health Organization, 2020, CLIN MAN COVID 19; World Health Organization, WHO2019NCOVOXYGENSOU; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Xie J, 2020, MAYO CLIN PROC, V95, P1138, DOI 10.1016/j.mayocp.2020.04.006; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	47	2	2	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2022	17	1							e0249984	10.1371/journal.pone.0249984	http://dx.doi.org/10.1371/journal.pone.0249984			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3B4UH	35051180	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000827937300001
J	Lupenza, ET; Gasarasi, DB; Minzi, OM				Lupenza, Eliza T.; Gasarasi, Dinah B.; Minzi, Omary M.			Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania	PLOS ONE			English	Article							IMPLEMENTATION; PROGRESS	Background Lymphatic filariasis (LF) affects more than 120 million people globally. In Tanzania, nearly six million people are estimated to live with clinical manifestations of the disease. The National LF control program was established in 2000 using Mass drug administration (MDA) of Ivermectin and Albendazole to individuals aged 5years and above. This study assessed the infection status in individuals aged 15 years and above who are eligible for participation in MDA. The level of compliance to MDA and the reasons for non-compliance to MDA were also assessed. Methods A community based cross-sectional study was conducted in two villages of Masasi District. A total of 590 participants aged 15 years and above were screened for the circulating filarial antigen (CFA) using the rapid diagnostic test. Night blood samples from CFA positive individuals were further analyzed for detection and quantification of Wuchereria bancrofti microfilaria (Mf) using the counting chamber technique. A pre-tested questionnaire was administered to collect information on compliance to MDA and the factors affecting continued transmission. Data were analyzed using SPSS Version 20. Chi-square test was used to compare the prevalence of CFA by gender and village where a P-value <= 0.05 was considered statistically significant. Results Out of 590 participants, 30 (5.1%) were positive for CFA and one (0.2%) was found positive for microfilaria of Wuchereria bancrofti. Compliance during the last round of MDA, in the year 2019 was 56% which is below the minimum coverage recommended by WHO. Absence from home during MDA and perceptions of being free from hydrocele or elephantiasis were the major reasons for non-compliance. Conclusion There is a significant decline in LF transmission in Masasi District after seven rounds of MDA. However, the presence of individuals who are persistently non-compliant may delay elimination of LF in the District.	[Lupenza, Eliza T.; Gasarasi, Dinah B.] Muhimbili Univ Hlth & Allied Sci, Sch Publ Hlth & Social Sci, Dept Parasitol & Med Entomol, Dar Es Salaam, Tanzania; [Minzi, Omary M.] Muhimbili Univ Hlth & Allied Sci, Sch Pharm, Dept Clin Pharm, Dar Es Salaam, Tanzania	Muhimbili University of Health & Allied Sciences; Muhimbili University of Health & Allied Sciences	Lupenza, ET (corresponding author), Muhimbili Univ Hlth & Allied Sci, Sch Publ Hlth & Social Sci, Dept Parasitol & Med Entomol, Dar Es Salaam, Tanzania.	elupenza1@gmail.com						Babu B, 2004, TROP MED INT HEALTH, V9, P702, DOI 10.1111/j.1365-3156.2004.01247.x; Babu BV, 2014, T ROY SOC TROP MED H, V108, P538, DOI 10.1093/trstmh/tru057; Biritwum NK, 2016, T ROY SOC TROP MED H, V110, P690, DOI 10.1093/trstmh/trx007; Boyd A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000640; Center or Disese control and prevention, TREATM LYMPHT FIL 20; Derua YA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005938; Fimbo AM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051550; Fraser M, 2005, AM J TROP MED HYG, V73, P753, DOI 10.4269/ajtmh.2005.73.753; Garcia E, 2016, GLOBAL PROGRAMME ELI, P92; Jones C, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3156-2; Jones C, 2017, INT J INFECT DIS, V61, P38, DOI 10.1016/j.ijid.2017.05.009; JOSKOW J, 1965, J AM STAT ASSOC, V60, P678, DOI 10.2307/2282703; Kamgno J, 2020, LANCET GLOB HEALTH, V8, pE1108, DOI 10.1016/S2214-109X(20)30323-5; Kisoka WJ, 2014, PLOS ONE, V9, DOI [10.1371/j, 10.1371/journal.pone.0109316]; Krentel A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005027; Krentel A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002447; Lahariya Chandrakant, 2008, Journal of Vector Borne Diseases, V45, P313; Lupenza E, 2021, INFECT DIS POVERTY, V10, DOI 10.1186/s40249-021-00808-5; Malecela MN., 2009, J LYMPHOEDEMA, V4, P10; Mohammed KA, 2006, TRENDS PARASITOL, V22, P340, DOI 10.1016/j.pt.2006.05.010; Njomo DW, 2012, ANN TROP MED PUBLIC, V5, P103, DOI 10.4103/1755-6783.95962; Ottesen EA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000317; Parker M, 2013, J BIOSOC SCI, V45, P517, DOI 10.1017/S0021932012000466; Shuford KV, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1311-1; Simonsen PE, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0507-5; World Health Organization, LYMPHATIC FILARIASIS, DOI DOI 11/44679/INDEX.HTM; World Health Organization, 2002, WHOCDSCPECEE200228; World Health Organization, 2017, GUID ALT MASS DRUG A; World Health Organization, 2013, HAND BOOK NAT EL PRO; Wynd S, 2007, B WORLD HEALTH ORGAN, V85, P493, DOI 10.2471/BLT.06.031047	30	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2022	17	1							e0262693	10.1371/journal.pone.0262693	http://dx.doi.org/10.1371/journal.pone.0262693			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0S7XH	35045109	Green Published, gold			2023-01-03	WOS:000786483800049
J	John, LN; Beiras, CG; Houinei, W; Medappa, M; Sabok, M; Kolmau, R; Jonathan, E; Maika, E; Wangi, JK; Pospisilova, P; Smajs, D; Ouchi, D; Galvan-Femenia, I; Beale, MA; Giacani, L; Clotet, B; Mooring, EQ; Marks, M; Vall-Mayans, M; Mitja, O				John, Lucy N.; Beiras, Camila G.; Houinei, Wendy; Medappa, Monica; Sabok, Maria; Kolmau, Reman; Jonathan, Eunice; Maika, Edward; Wangi, James K.; Pospisilova, Petra; Smajs, David; Ouchi, Dan; Galvan-Femenia, Ivan; Beale, Mathew A.; Giacani, Lorenzo; Clotet, Bonaventura; Mooring, Eric Q.; Marks, Michael; Vall-Mayans, Marti; Mitja, Oriol			Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINGLE-DOSE AZITHROMYCIN; PAPUA-NEW-GUINEA; HAEMOPHILUS-DUCREYI; SKIN ULCERS; RESISTANCE; SELECTION; CHILDREN	BACKGROUND Treponema pallidum subspecies pertenue causes yaws. Strategies to better control, eliminate, and eradicate yaws are needed. METHODS In an open-label, cluster-randomized, community-based trial conducted in a yaws-endemic area of Papua New Guinea, we randomly assigned 38 wards (i.e., clusters) to receive one round of mass administration of azithromycin followed by two rounds of target treatment of active cases (control group) or three rounds of mass administration of azithromycin (experimental group); round 1 was administered at baseline, round 2 at 6 months, and round 3 at 12 months. The coprimary end points were the prevalence of active cases of yaws, confirmed by polymerase-chain-reaction assay, in the entire trial population and the prevalence of latent yaws, confirmed by serologic testing, in a subgroup of asymptomatic children 1 to 15 years of age; prevalences were measured at 18 months, and the between-group differences were calculated. RESULTS Of the 38 wards, 19 were randomly assigned to the control group (30,438 persons) and 19 to the experimental group (26,238 persons). A total of 24,848 doses of azithromycin were administered in the control group (22,033 were given to the participants at round 1 and 207 and 2608 were given to the participants with yaws-like lesions and their contacts, respectively, at rounds 2 and 3 (combined)), and 59,852 doses were administered in the experimental group. At 18 months, the prevalence of active yaws had decreased from 0.46% (102 of 22,033 persons) at baseline to 0.16% (47 of 29,954 persons) in the control group and from 0.43% (87 of 20,331 persons) at baseline to 0.04% (10 of 25,987 persons) in the experimental group (relative risk adjusted for clustering, 4.08; 95% confidence interval (CI), 1.90 to 8.76). The prevalence of other infectious ulcers decreased to a similar extent in the two treatment groups. The prevalence of latent yaws at 18 months was 6.54% (95% CI, 5.00 to 8.08) among 994 children in the control group and 3.28% (95% CI, 2.14 to 4.42) among 945 children in the experimental group (relative risk adjusted for clustering and age, 2.03; 95% CI, 1.12 to 3.70). Three cases of yaws with resistance to macrolides were found in the experimental group. CONCLUSIONS The reduction in the community prevalence of yaws was greater with three rounds of mass administration of azithromycin at 6-month intervals than with one round of mass administration of azithromycin followed by two rounds of targeted treatment. Monitoring for the emergence and spread of antimicrobial resistance is needed.	[John, Lucy N.; Houinei, Wendy] Aopi Ctr, Natl Dept Hlth, Port Moresby, Papua N Guinea; [John, Lucy N.; Mitja, Oriol] Univ Papua New Guinea, Sch Med & Hlth Sci, Port Moresby, Papua N Guinea; [Wangi, James K.] WHO, Representat Off Papua New Guinea, Port Moresby, Papua N Guinea; [Sabok, Maria; Jonathan, Eunice; Maika, Edward] New Ireland Prov Hlth Author, Kavieng, Papua N Guinea; [Kolmau, Reman; Mitja, Oriol] Int SOS, Lihir Med Ctr, Lihir Isl, Papua N Guinea; [John, Lucy N.; Beiras, Camila G.; Ouchi, Dan; Clotet, Bonaventura; Vall-Mayans, Marti; Mitja, Oriol] Hosp Badalona Germans Trias & Pujol, Infect Dis Dept, Badalona, Spain; [John, Lucy N.; Beiras, Camila G.; Ouchi, Dan; Clotet, Bonaventura; Vall-Mayans, Marti; Mitja, Oriol] Hosp Badalona Germans Trias & Pujol, Fight AIDS & Infect Dis Fdn, Badalona, Spain; [Galvan-Femenia, Ivan] Inst Hlth Sci Res Germans Trias & Pujol, Genomes Life Genomes Catalonia Lab Grp, Badalona, Spain; [Clotet, Bonaventura] IrsiCaixa AIDS Res Inst, Badalona, Spain; [John, Lucy N.] Univ Barcelona, Fac Med, Barcelona Inst Global Hlth, Barcelona, Spain; [Galvan-Femenia, Ivan] Barcelona Inst Sci & Technol, Inst Res Biomed, Barcelona, Spain; [Clotet, Bonaventura; Mitja, Oriol] Univ Vic Univ Cent Catalunya, Vic, Spain; [Medappa, Monica; Pospisilova, Petra; Smajs, David] Masaryk Univ, Fac Med, Dept Biol, Brno, Czech Republic; [Beale, Mathew A.] Wellcome Sanger Inst, Parasites & Microbes Programme, Hinxton, England; [Marks, Michael] London Sch Hyg & Trop Med, Clin Res Dept, London, England; [Marks, Michael] Univ Coll London Hosp, Hosp Trop Dis, London, England; [Giacani, Lorenzo] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA; [Giacani, Lorenzo] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Mooring, Eric Q.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	University of Papua New Guinea; World Health Organization; Hospital Germans Trias i Pujol; Hospital Germans Trias i Pujol; Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol (IGTP); Institut de Recerca de la Sida - IrsiCaixa; ISGlobal; University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); Masaryk University Brno; Wellcome Trust Sanger Institute; University of London; London School of Hygiene & Tropical Medicine; University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; University College London; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Harvard T.H. Chan School of Public Health	John, LN (corresponding author), Natl Dept Hlth, Div Publ Hlth, POB 807, Waigani 131, NCD, Papua N Guinea.; Mitja, O (corresponding author), Hosp Germans Trias Pujol, Sexually Transmitted Infect & Skin Neglected Trop, Dept Infect Dis, Carretera Canyet SN, Badalona 08916, Spain.; Mitja, O (corresponding author), Hosp Germans Trias Pujol, Fight AIDS & Infect Dis Fdn, Carretera Canyet SN, Badalona 08916, Spain.	lucyninmongojohn@gmail.com; oriolmitja@hotmail.com	; Mitja, Oriol/W-4181-2018	Beale, Mathew/0000-0002-4740-3187; Galvan Femenia, Ivan/0000-0002-6124-3730; Marks, Michael/0000-0002-7585-4743; Mitja, Oriol/0000-0003-3266-8868; Medappa, Monica/0000-0002-7486-3058; Gonzalez-Beiras, Camila/0000-0001-6617-0748; Ouchi, Dan/0000-0002-8630-152X	Fundacio "la Caixa," Diputacio de Barcelona; Fundacio Barbera Solidaria; Wellcome [206194]; National Institute of Allergy and Infectious Diseases [T32 AI 007535]; European Research Council [850450]	Fundacio "la Caixa," Diputacio de Barcelona; Fundacio Barbera Solidaria; Wellcome; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); European Research Council(European Research Council (ERC)European Commission)	Supported by Fundacio "la Caixa," Diputacio de Barcelona, and Fundacio Barbera Solidaria. The Papua New Guinea National Department of Health provided logistic and personnel support and disseminated information to raise awareness in communities and among local stakeholders. Dr. Beale was supported by Wellcome funding to the Sanger Institute (grant 206194), Dr. Mooring by the National Institute of Allergy and Infectious Diseases (grant T32 AI 007535), and Dr. Mitja by the European Research Council under Grant Agreement number 850450 (European Union's Horizon 2020 Research and Innovation Program, ERC-2019-STG funding scheme).	Abdulai AA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006303; Ayove T, 2014, LANCET GLOB HEALTH, V2, pE415, DOI 10.1016/S2214-109X(14)70231-1; Beale MA, 2020, LANCET MICROBE, V1, pE263, DOI 10.1016/S2666-5247(20)30113-0; Cui J, 2007, STATA J, V7, P209, DOI 10.1177/1536867X0700700205; Dyson L, 2018, AM J EPIDEMIOL, V187, P837, DOI 10.1093/aje/kwx305; Fitzpatrick C, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003165; G-Beiras C, 2021, DERMATOL CLIN, V39, P15, DOI 10.1016/j.det.2020.08.002; Godornes C, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006113; Gonzalez-Beiras C, 2017, CLIN INFECT DIS, V65, P2085, DOI 10.1093/cid/cix723; Griesenauer B, 2021, MBIO, V12, DOI 10.1128/mBio.03162-20; Grillova L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200773; Hetzel MW, 2018, PAPUA NEW GUINEA MAL; Holmes A, 2020, EMERG INFECT DIS, V26, P2685, DOI 10.3201/eid2611.191491; Lee K, 2009, GLOB INST, P1; Marks M, 2017, EMERG INFECT DIS, V23, P22, DOI 10.3201/eid2301.160487; Marks M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004927; Marks M, 2016, CLIN INFECT DIS, V63, P627, DOI 10.1093/cid/ciw348; Mitja O, 2018, LANCET, V391, P1599, DOI 10.1016/S0140-6736(18)30204-6; Mitja O, 2015, NEW ENGL J MED, V372, P703, DOI 10.1056/NEJMoa1408586; Mitja O, 2014, LANCET GLOB HEALTH, V2, pE235, DOI 10.1016/S2214-109X(14)70019-1; Mitja O, 2013, LANCET, V381, P763, DOI 10.1016/S0140-6736(12)62130-8; Mitja O, 2012, LANCET, V379, P342, DOI 10.1016/S0140-6736(11)61624-3; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Ngono JPN, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009180; Orle KA, 1996, J CLIN MICROBIOL, V34, P49, DOI 10.1128/JCM.34.1.49-54.1996; Smajs D, 2018, LANCET, V391, P1555, DOI 10.1016/S0140-6736(18)30205-8; WHO, 2012, SUMM REP CONS ER YAW; WHO, 2018, CROP STORAGE RES; World Health Organization, 2018, REP GLOB M YAWS ER S	29	1	1	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2022	386	1					47	56		10.1056/NEJMoa2109449	http://dx.doi.org/10.1056/NEJMoa2109449			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC1QX	34986286	Green Published, Green Accepted			2023-01-03	WOS:000739473800010
J	Patton, R; Cook, J; Haraldsdottir, E; Brown, D; Dolan, RD; McMillan, DC; Skipworth, RJE; Fallon, M; Laird, BJA				Patton, Rebekah; Cook, Jane; Haraldsdottir, Erna; Brown, Duncan; Dolan, Ross D.; McMillan, Donald C.; Skipworth, Richard J. E.; Fallon, Marie; Laird, Barry J. A.			REVOLUTION (Routine EValuatiOn of people LivIng with caNcer)-Protocol for a prospective characterisation study of patients with incurable cancer	PLOS ONE			English	Article							SYSTEMIC INFLAMMATORY RESPONSE; QUALITY-OF-LIFE; PERFORMANCE STATUS; RELIABILITY; CYTOKINES; SYMPTOMS; VALIDITY; OUTCOMES; THERAPY; SURGERY	Introduction There is a pressing need for a holistic characterisation of people with incurable cancer. In this group, where quality of life and improvement of symptoms are therapeutic priorities, the physical and biochemical manifestations of cancer are often studied separately, giving an incomplete picture. In order to improve care, spur therapeutic innovation, provide meaningful endpoints for trials and set priorities for future research, work must be done to explore how the tumour influences the clinical phenotype. Characterisation of the host-tumour interaction may also provide information regarding prognosis, allowing appropriate planning of investigations, treatment and referral to palliative medicine services. Methods Routine EValuatiOn of people LivIng with caNcer (REVOLUTION) is a prospective observational study that aims to characterise people with incurable cancer around five key areas, namely body composition, physical activity, systemic inflammatory response, symptoms, and quality of life by developing a bio-repository. Participants will initially be recruited from a single centre in the UK and will have assessments of body composition (bio-impedance analysis [BIA] and computed tomography [CT]), assessment of physical activity using a physical activity monitor, measurement of simple markers of inflammation and plasma cytokine proteins and three symptom and quality of life questionnaires. Discussion This study aims to create a comprehensive biochemical and clinical characterisation of people with incurable cancer. Data in this study can be used to give a better understanding of the 'symptom phenotype' and quality of life determinants, development of a profile of the systemic inflammatory response and a detailed characterisation of body composition.	[Patton, Rebekah; Cook, Jane; Haraldsdottir, Erna; Brown, Duncan; Laird, Barry J. A.] St Columbas Hosp, Edinburgh, Midlothian, Scotland; [Dolan, Ross D.; McMillan, Donald C.] Univ Glasgow, Acad Surg Unit, Sch Med, Glasgow Royal Infirm, Glasgow, Lanark, Scotland; [Skipworth, Richard J. E.] Univ Edinburgh, Surg Clin, Royal Infirm Edinburgh, Edinburgh, Midlothian, Scotland; [Fallon, Marie; Laird, Barry J. A.] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Glasgow; Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Patton, R (corresponding author), St Columbas Hosp, Edinburgh, Midlothian, Scotland.	rpatton@stcolumbashospice.org.uk		Fallon, Marie/0000-0001-9214-0091; Patton, Rebekah/0000-0001-5544-5128				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Ando M, 2001, BRIT J CANCER, V85, P1634, DOI 10.1054/bjoc.2001.2162; Argiles JM, 2014, NAT REV CANCER, V14, P754, DOI 10.1038/nrc3829; Balstad TR, 2019, PATIENT PREFER ADHER, V13, P1391, DOI 10.2147/PPA.S204188; Baracos VE, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.105; Belafsky PC, 2008, ANN OTO RHINOL LARYN, V117, P919, DOI 10.1177/000348940811701210; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dev R, 2019, ANN PALLIAT MED, V8, P24, DOI 10.21037/apm.2018.08.07; Dolan RD, 2019, J CACHEXIA SARCOPENI, V10, P111, DOI 10.1002/jcsm.12357; Dolan RD, 2017, CRIT REV ONCOL HEMAT, V116, P134, DOI 10.1016/j.critrevonc.2017.06.002; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Ferriolli E, 2012, J PAIN SYMPTOM MANAG, V43, P1025, DOI 10.1016/j.jpainsymman.2011.06.013; Fosbol MO, 2015, CLIN PHYSIOL FUNCT I, V35, P81, DOI 10.1111/cpf.12152; Giraldo NA, 2019, BRIT J CANCER, V120, P45, DOI 10.1038/s41416-018-0327-z; Gresham G, 2018, CONTEMP CLIN TRIALS, V64, P13, DOI 10.1016/j.cct.2017.11.002; Gupta A, 2018, JCO CLIN CANCER INFO, V2, DOI 10.1200/CCI.17.00152; Hopkins JJ, 2019, DIS COLON RECTUM, V62, P549, DOI 10.1097/DCR.0000000000001352; Jang RW, 2014, J ONCOL PRACT, V10, pE335, DOI 10.1200/JOP.2014.001457; Kays JK, 2020, CANCERS, V12, DOI 10.3390/cancers12061605; Kays JK, 2018, J CACHEXIA SARCOPENI, V9, P673, DOI 10.1002/jcsm.12307; Laird BJ, 2013, ONCOLOGIST, V18, P1050, DOI 10.1634/theoncologist.2013-0120; Laird BJA, 2016, J CLIN ONCOL, V34, P2769, DOI 10.1200/JCO.2015.65.7742; Laird BJA, 2011, PAIN, V152, P460, DOI 10.1016/j.pain.2010.10.035; Low CA, 2018, ANN BEHAV MED, V52, P88, DOI 10.1093/abm/kax022; Maddocks M, 2010, SUPPORT CARE CANCER, V18, P1539, DOI 10.1007/s00520-009-0776-2; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Patton R, 2021, CRIT REV ONCOL HEMAT, V159, DOI 10.1016/j.critrevonc.2021.103222; Paulsen O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177620; Ramage MI, 2018, CURR OPIN SUPPORT PA, V12, P439, DOI 10.1097/SPC.0000000000000381; Rich T, 2005, CLIN CANCER RES, V11, P1757, DOI 10.1158/1078-0432.CCR-04-2000; SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187; Scheede-Bergdahl C, 2012, CLIN NUTR, V31, P85, DOI 10.1016/j.clnu.2011.07.010; Sergi G, 2017, AGING CLIN EXP RES, V29, P591, DOI 10.1007/s40520-016-0622-6; Shepshelovich D, 2019, J THORAC ONCOL, V14, P1594, DOI 10.1016/j.jtho.2019.05.031; Simmonds M, 2002, J PAIN SYMPTOM MANAG, V24, P404, DOI 10.1016/S0885-3924(02)00502-X; Temel JS, 2016, LANCET ONCOL, V17, P519, DOI 10.1016/S1470-2045(15)00558-6; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2021	16	12							e0261175	10.1371/journal.pone.0261175	http://dx.doi.org/10.1371/journal.pone.0261175			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY9FU	34914733	Green Accepted, gold, Green Published			2023-01-03	WOS:000755091500059
J	Hajek, P; Przulj, D; Pesola, F; McRobbie, H; Peerbux, S; Phillips-Waller, A; Bisal, N; Smith, KM				Hajek, Peter; Przulj, Dunja; Pesola, Francesca; McRobbie, Hayden; Peerbux, Sarrah; Phillips-Waller, Anna; Bisal, Natalie; Smith, Katie Myers			A randomised controlled trial of the 5:2 diet	PLOS ONE			English	Article							CONTINUOUS ENERGY RESTRICTION; DISEASE RISK MARKERS; WEIGHT-LOSS; INTERMITTENT ENERGY; OVERWEIGHT; MORTALITY; REGIMEN; FAT	Objective The 5:2 diet is a popular intermittent energy restriction method of weight management that awaits further evaluation. We compared the effects of one-off 5:2 instructions with the effects of one-off standard multicomponent weight-management advice; and also examined whether additional behavioural support enhances 5:2 adherence and efficacy compared to one-off instructions. Methods Three hundred adults with obesity were randomised to receive a Standard Brief Advice (SBA) covering diet and physical activity (N = 100); 5:2 self-help instructions (5:2SH) (N = 100); or 5:2SH plus six once-weekly group support sessions (N = 100). Participants were followed up for one year. Results Adherence to 5:2SH was initially high (74% at 6 weeks), but it declined over time (31% at 6 months and 22% at one year). 5:2SH and SBA achieved similar weight-loss at six months (-1.8kg (SD = 3.5) vs -1.7kg (SD = 4.4); b = 0.23, 95%CI:-0.79-1.27, p = 0.7) and at one year (-1.9kg (SD = 4.9) vs -1.8kg (SD = 5.7), b = 0.20, 95%CI:-1.21-1.60, p = 0.79), with 18% vs 15% participants losing >= 5% of their body weight with 5:2SH and SBA, respectively at one year (RR = 0.83, 95%CI:0.44-1.54, p = 0.55). Both interventions received positive ratings, but 5:2SH ratings were significantly higher. 5:2SH had no negative effect on fat and fiber intake and physical activity compared to SBA. Compared to 5:2SH, 5:2G generated a greater weight loss at 6 weeks (-2.3kg vs -1.5kg; b = 0.74, 95%CI:1.37-0.11, p = 0.02), but by one year, the difference was no longer significant (-2.6kg vs -1.9kg, p = 0.37; >= 5% body weight loss 28% vs 18%, p = 0.10). Conclusions Simple 5:2 advice and multicomponent weight management advice generated similar modest results. The 5:2 diet did not undermine other health behaviours, and it received more favourable ratings. Adding initial group support enhanced 5:2 adherence and effects, but the impact diminished over time. Health professionals who provide brief weight management advice may consider including the 5:2 advice as an option.	[Hajek, Peter; Przulj, Dunja; Pesola, Francesca; McRobbie, Hayden; Peerbux, Sarrah; Phillips-Waller, Anna; Bisal, Natalie; Smith, Katie Myers] Queen Mary Univ London, Wolfson Inst Populat Hlth, Hlth & Lifestyle Res Unit, London, England	University of London; Queen Mary University London	Smith, KM (corresponding author), Queen Mary Univ London, Wolfson Inst Populat Hlth, Hlth & Lifestyle Res Unit, London, England.	Katie.smith@qmul.ac.uk	Smith, Katie Elizabeth/GXH-2114-2022; McRobbie, Hayden/B-4552-2018	Bisal, Natalie/0000-0002-5938-0349; McRobbie, Hayden/0000-0002-7777-1845; Myers Smith, Katherine/0000-0003-1837-3924; Peerbux, Sarrah/0000-0001-5560-0749	Medical Research Council	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The study was funded by the Medical Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, BBC 0806; Antoni R, 2018, BRIT J NUTR, V119, P507, DOI [10.1017/s0007114517003890, 10.1017/S0007114517003890]; Arguin H, 2012, MENOPAUSE, V19, P870, DOI 10.1097/gme.0b013e318250a287; Ayala-Marin AM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00423; Batterham MJ, 2013, NUTRITION, V29, P1024, DOI 10.1016/j.nut.2013.01.017; Bluher M, 2019, NAT REV ENDOCRINOL, V15, P288, DOI 10.1038/s41574-019-0176-8; Brown A, 2019, NUTR BULL, V44, P7, DOI 10.1111/nbu.12372; Brown JE, 2013, BR J DIABETES VASC D, V13, P68, DOI [DOI 10.1177/1474651413486496, 10.1177/1474651413486496]; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Davis CS, 2016, EUR J CLIN NUTR, V70, P292, DOI 10.1038/ejcn.2015.195; Elobeid MA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006624; Eshghinia S, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-4; Fisher R., 2019, BBC GOOD FOOD 0916; Hall KD, 2018, MED CLIN N AM, V102, P183, DOI 10.1016/j.mcna.2017.08.012; Harper H, 2016, COUNTING CALORIES; Harris Leanne, 2018, JBI Database System Rev Implement Rep, V16, P507, DOI 10.11124/JBISRIR-2016-003248; Harvie MN, 2011, INT J OBESITY, V35, P714, DOI 10.1038/ijo.2010.171; Harvie M, 2013, BRIT J NUTR, V110, P1534, DOI 10.1017/S0007114513000792; He SS, 2021, OBESITY, V29, P108, DOI 10.1002/oby.23023; Headland ML, 2019, INT J OBESITY, V43, P2028, DOI 10.1038/s41366-018-0247-2; HILL JO, 1989, AM J CLIN NUTR, V50, P248, DOI 10.1093/ajcn/50.2.248; Jorgensen AW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111964; Klempel MC, 2013, METABOLISM, V62, P137, DOI 10.1016/j.metabol.2012.07.002; Klempel MC, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-98; Klempel MC, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-35; Kroeger CM, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-98; Lean MEJ, 2018, LANCET, V391, P541, DOI 10.1016/S0140-6736(17)33102-1; Lewis E, 2019, INT J BEHAV MED, V26, P580, DOI 10.1007/s12529-019-09815-1; Mosley M., 2013, FAST DIET; Office for National Statistics, 2016, GOVT STAT SERV PERSP; Poobalan AS, 2007, OBES REV, V8, P503, DOI 10.1111/j.1467-789X.2007.00393.x; Shannon J, 1997, CANCER EPIDEM BIOMAR, V6, P355; Trepanowski JF, 2017, JAMA INTERN MED, V177, P930, DOI 10.1001/jamainternmed.2017.0936; Varady KA, 2011, OBES REV, V12, pE593, DOI 10.1111/j.1467-789X.2011.00873.x; Varady KA, 2009, AM J CLIN NUTR, V90, P1138, DOI 10.3945/ajcn.2009.28380; Welton S, 2020, CAN FAM PHYSICIAN, V66, P117; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Williams KV, 1998, DIABETES CARE, V21, P2, DOI 10.2337/diacare.21.1.2; WING RR, 1984, BEHAV RES THER, V22, P445, DOI 10.1016/0005-7967(84)90086-X; Zaninotto P, 2009, J EPIDEMIOL COMMUN H, V63, P140, DOI 10.1136/jech.2008.077305	40	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2021	16	11							e0258853	10.1371/journal.pone.0258853	http://dx.doi.org/10.1371/journal.pone.0258853			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW9HJ	34788298	Green Published, gold			2023-01-03	WOS:000735920500008
J	Mekonnen, H; Seid, A; Fenta, GM; Gebrecherkos, T				Mekonnen, Habtamu; Seid, Abdurahaman; Fenta, Genet Molla; Gebrecherkos, Teklay			Antimicrobial resistance profiles and associated factors of Acinetobacter and Pseudomonas aeruginosa nosocomial infection among patients admitted at Dessie comprehensive specialized Hospital, North-East Ethiopia. A cross-sectional study	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; RISK-FACTORS; SUSCEPTIBILITY PATTERNS; TEACHING HOSPITALS; POINT PREVALENCE; BAUMANNII; UNIVERSITY; BACTERIA	Introduction Hospital admitted patients are at increased risk of nosocomial infections (NIs) with multi-drug resistant (MDR) pathogens which are prevalent in the hospital environment. Pseudomonas aeruginosa (P. aeruginosa) and Acinetobacter baumannii (A. baumannii) are common causes of NIs worldwide. The objective of this study is to determine antimicrobial resistance profiles and associated factors of Acinetobacter spp and P. aeruginosa NIs among hospitalized patients. Methods A cross-sectional study was conducted at Dessie comprehensive specialized hospital, North-East Ethiopia, from February 1 to April 30, 2020. A total of 254 patients who were suspected of the bloodstream, urinary tract, or surgical site nosocomial infections were enrolled consecutively. Socio-demographic and other variables of interest were collected using a structured questionnaire. Specimens were collected and processed following standard microbiological procedures. Antimicrobial susceptibility was determined using the Kirby-Bauer disk diffusion method following Clinical and Laboratory Standards Institute guidelines. Data were analyzed with SPSS version 23 and p-value < 0.05 was considered statistically significant. Results Overall, 13% of patients had nosocomial Acinetobacter spp and/or P. aeruginosa infections. The culture positivity rate was 16(6.3%) for Acinetobacter spp and 18(7.1%) for P. aeruginosa. Patients admitted in the surgical ward (Adjusted odds ratio (AOR):10.66;95% confidence interval (CI):1.22-93.23), pediatric ward (AOR:14.37;95%CI:1.4-148.5), intensive care unit (AOR:41.93;95%CI:4.7-374.7) and orthopedics (AOR:52.21;95%CI:7.5-365) were significantly at risk to develop NIs compared to patients admitted in the medical ward. Patients who took more than two antimicrobial types at admission were 94% (AOR:0.06; 95% CI:0.004-0.84) times more protected from NIs compared to those who did not take any antimicrobial. About 81% of Acinetobacter spp and 83% of P. aeruginosa isolates were MDR. Amikacin and meropenem showed promising activity against Acinetobacter spp and P. aeruginosa isolates. Conclusion The high prevalence of MDR Acinetobacter spp and P. aeruginosa nosocomial isolates enforce treating of patients with NIs based on antimicrobial susceptibility testing results.	[Mekonnen, Habtamu] Amhara Publ Hlth Inst, Dept Med Microbiol, Dessie Branch, Dessie, Ethiopia; [Seid, Abdurahaman; Fenta, Genet Molla] Wollo Univ, Coll Med & Hlth Sci, Dept Med Microbiol, Dessie, Ethiopia; [Gebrecherkos, Teklay] Univ Gondar, Coll Med & Hlth Sci, Dept Med Microbiol, Gondar, Ethiopia	University of Gondar	Seid, A (corresponding author), Wollo Univ, Coll Med & Hlth Sci, Dept Med Microbiol, Dessie, Ethiopia.	gechdk2000@yahoo.com						Agaba Peter, 2017, BMC Res Notes, V10, P349, DOI 10.1186/s13104-017-2695-5; Al-Gethamy MM, 2017, J INT MED RES, V45, P1181, DOI 10.1177/0300060517706284; AL-Rawajfah OM, 2013, AM J INFECT CONTROL, V41, P607, DOI 10.1016/j.ajic.2012.08.014; Alemayehu T., 2019, ETHIOPIAN MED J, V58; Alemu AY, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-020-00263-2; Ayobami Olaniyi, 2019, Emerg Microbes Infect, V8, P1747, DOI 10.1080/22221751.2019.1698273; Bereket W, 2012, EUR REV MED PHARMACO, V16, P1039; Cheesbrough M, 2006, DISTRICT LAB PRACTIC, V2nd; Chernet AZ, 2020, DRUG HEALTHC PATIENT, V12, P177, DOI 10.2147/DHPS.S251827; Clinical and Laboratory Standards Institute, 2019, CLSI SUPPLEMENT M100, V28th; Cobos-Trigueros N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0916-7; Dash M, 2014, SAUDI J HLTH SCI, V3, P15; Davoudi AR, 2014, CASP J INTERN MED, V5, P227; De Francesco MA, 2013, J INFECT PUBLIC HEAL, V6, P179, DOI 10.1016/j.jiph.2012.11.006; Deptula A, 2015, J HOSP INFECT, V90, P310, DOI 10.1016/j.jhin.2015.03.005; European Centre for Disease Prevention and Control, 2016, POINT PREV SURV HEAL; Gailiene G, 2012, MED LITH, V48, P399; Gashaw M, 2018, ANTIMICROB RESIST IN, V7, DOI 10.1186/s13756-018-0431-0; Gomez-Zorrilla S, 2015, ANTIMICROB AGENTS CH, V59, P5213, DOI 10.1128/AAC.04636-14; Gootz TD, 2008, EXPERT REV ANTI-INFE, V6, P309, DOI 10.1586/14787210.6.3.309; Hoang S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193300; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Huang HP, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-017-2932-5; Kateete DP, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2986-7; Kolpa M, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010112; Kumar P, 2017, NAT CHEM BIOL, V13, P54, DOI [10.1038/NCHEMBIO.2237, 10.1038/nchembio.2237]; LEVINE NS, 1976, J TRAUMA, V16, P89, DOI 10.1097/00005373-197602000-00002; Lin MF, 2014, WORLD J CLIN CASES, V2, P787, DOI 10.12998/wjcc.v2.i12.787; Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x; Mahmoud A.B., 2013, J VIROLOGY MICROBIOL, V2013, P1, DOI [10.5171/2013.290047, DOI 10.5171/2013.290047]; Mirzaei B, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-020-05224-w; Morales E, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-122; Motbainor H, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4811-8; Nasiri MJ, 2019, NBM, V7, P64; Ozdemir H, 2011, TURKISH J PEDIATR, V53, P255; Petignat C, 2006, INFECT CONT HOSP EP, V27, P953, DOI 10.1086/506409; Playford EG, 2007, J HOSP INFECT, V65, P204, DOI 10.1016/j.jhin.2006.11.010; Ramazanzadeh R., 2016, PAJOUHAN SCI J, V14, P11; Rezai MS, 2017, CASP J INTERN MED, V8, P76, DOI 10.22088/cjim.8.2.76; Rods GP., 2014, PUBLIC HEALTH; Shaifali I, 2012, N AM J MED SCI, V4, P163, DOI 10.4103/1947-2714.94940; Sharma D., 2014, Nepal Journal of Medical Sciences, V3, P101, DOI 10.3126/njms.v3i2.13452; Shi XH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247418; Shlaes David M, 2018, Pathog Immun, V3, P19, DOI 10.20411/pai.v3i1.231; Strateva T, 2009, J MED MICROBIOL, V58, P1133, DOI 10.1099/jmm.0.009142-0; Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/s1473-3099(17)30753-3, 10.1016/S1473-3099(17)30753-3]; Tolera Moti, 2018, Adv Med, V2018, P2127814, DOI 10.1155/2018/2127814; Tran GM, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2529-z; Uwingabiye Jean, 2017, Germs, V7, P193, DOI 10.18683/germs.2017.1126; WHO, 2011, WHO LIB CAT PUBL DAT; Yallew WW, 2016, DRUG HEALTHC PATIENT, V8, P71, DOI 10.2147/DHPS.S107344	51	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2021	16	11							e0257272	10.1371/journal.pone.0257272	http://dx.doi.org/10.1371/journal.pone.0257272			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2IU	34780494	gold, Green Submitted, Green Published			2023-01-03	WOS:000755305800007
J	Blazkova, K; Beranova, J; Hradilek, M; Kostka, L; Subr, V; Etrych, T; Sacha, P; Konvalinka, J				Blazkova, Kristyna; Beranova, Jana; Hradilek, Martin; Kostka, Libor; Subr, Vladimir; Etrych, Tomas; Sacha, Pavel; Konvalinka, Jan			The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE CARBOXYPEPTIDASE-II; PHAGE; LIBRARIES; POLYMERS; POLYMERIZATION; INHIBITION; PROTEINS; GCPII	Peptide display methods are a powerful tool for discovering new ligands of pharmacologically relevant targets. However, the selected ligands often suffer from low affinity. Using phage display, we identified a new bicyclic peptide binder of prostatespecific membrane antigen (PSMA), a metalloprotease frequently overexpressed in prostate cancer. We show that linking multiple copies of a selected low-affinity peptide to a biocompatible water-soluble N-(2-hydroxypropyl)methacrylamide copolymer carrier (iBody) improved binding of the conjugate by several orders of magnitude. Furthermore, using ELISA, enzyme kinetics, confocal microscopy, and other approaches, we demonstrate that the resulting iBody can distinguish between different conformations of the target protein. The possibility to develop stable, fully synthetic, conformationselective antibody mimetics has potential applications for molecular recognition, diagnosis and treatment of many pathologies. This strategy could significantly contribute to more effective drug discovery and design.	[Blazkova, Kristyna; Beranova, Jana; Hradilek, Martin; Sacha, Pavel; Konvalinka, Jan] Czech Acad Sci, Inst Organ Chem & Biochem, Prague, Czech Republic; [Blazkova, Kristyna; Konvalinka, Jan] Charles Univ Prague, Fac Sci, Dept Cell & Dev Biol, Prague, Czech Republic; [Beranova, Jana] Charles Univ Prague, Med Fac 1, Prague, Czech Republic; [Kostka, Libor; Subr, Vladimir; Etrych, Tomas] Czech Acad Sci, Inst Macromol Chem, Prague, Czech Republic	Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; Charles University Prague; Charles University Prague; Czech Academy of Sciences; Institute of Macromolecular Chemistry of the Czech Academy of Sciences	Sacha, P; Konvalinka, J (corresponding author), Czech Acad Sci, Inst Organ Chem & Biochem, Prague, Czech Republic.; Konvalinka, J (corresponding author), Charles Univ Prague, Fac Sci, Dept Cell & Dev Biol, Prague, Czech Republic.	pavelsacha@gmail.com; jan.konvalinka@uochb.cas.cz	Šubr, Vladimír/G-3488-2014; Kostka, Libor/H-4182-2014; Etrych, Tomas/G-3420-2014; Sacha, Pavel/G-9729-2014; Blazkova, Kristyna/S-4587-2017	Kostka, Libor/0000-0002-7770-1855; Etrych, Tomas/0000-0001-5908-5182; Sacha, Pavel/0000-0001-6198-9826; Blazkova, Kristyna/0000-0002-7146-5177; Beranova, Jana/0000-0002-7185-5917	Czech Science Foundation [21-04166S, 19-05649S]; European Regional Development Fund; OP RDE [CZ.02.1.01/0.0/0.0/16_019/0000729]; Charles University Grant Agency [1352219]	Czech Science Foundation(Grant Agency of the Czech Republic); European Regional Development Fund(European Commission); OP RDE; Charles University Grant Agency	We thank Dr Christian Heinis (EPFL) for kindly providing us with phage display libraries and Dr Tereza Ormsby (IOCB Prague) for critical reading of this manuscript and Dr Hillary Hoffman for language editing. We also thank Jana Starkova and KarolinaSramkova for excellent technical support, Martin Pehr, Lenka Barton, and Filip Trajhan for reproduction of some experiments, and Frantisek Sedlak for his methodological help. The study was supported by the Czech Science Foundation (No. 21-04166S and 19-05649S), by the European Regional Development Fund; OP RDE (No.CZ.02.1.01/0.0/0.0/16_019/0000729) and by the Charles University Grant Agency, project No. 1352219.	Barinka C, 2002, J NEUROCHEM, V80, P477, DOI 10.1046/j.0022-3042.2001.00715.x; Beranova J, 2019, CATALYSTS, V9, DOI 10.3390/catal9121011; Chen SY, 2012, CHEMBIOCHEM, V13, P1032, DOI 10.1002/cbic.201200049; Chytil P, 2010, EUR J PHARM SCI, V41, P473, DOI 10.1016/j.ejps.2010.08.003; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Derda R, 2019, CURR OPIN CHEM BIOL, V50, P128, DOI 10.1016/j.cbpa.2019.03.014; Dvorakova P, 2017, J MED CHEM, V60, P8385, DOI 10.1021/acs.jmedchem.7b00767; Heinis C, 2009, NAT CHEM BIOL, V5, P502, DOI 10.1038/nchembio.184; Ishitake K, 2009, ANGEW CHEM INT EDIT, V48, P1991, DOI 10.1002/anie.200805168; Knedlik T, 2014, PROSTATE, V74, P768, DOI 10.1002/pros.22796; Marshall Catherine Handy, 2020, Cancer Treat Res Commun, V23, P100164, DOI 10.1016/j.ctarc.2020.100164; Matochko WL, 2012, METHODS, V58, P47, DOI 10.1016/j.ymeth.2012.07.006; Mesters JR, 2007, ACTA CRYSTALLOGR D, V63, P508, DOI 10.1107/S090744490700902X; Mimmi S, 2019, TRENDS PHARMACOL SCI, V40, P87, DOI 10.1016/j.tips.2018.12.005; Ng S, 2015, METHODS MOL BIOL, V1248, P155, DOI 10.1007/978-1-4939-2020-4_11; Paduch M, 2013, METHODS, V60, P3, DOI 10.1016/j.ymeth.2012.12.010; Perrier S, 2005, MACROMOLECULES, V38, P2033, DOI 10.1021/ma047611m; Pospisilova K, 2019, ACS OMEGA, V4, P6746, DOI 10.1021/acsomega.9b00596; Powers E, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00978-z; Rebollo IR, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku940; Rebollo IR, 2013, MEDCHEMCOMM, V4, P145, DOI 10.1039/c2md20171b; Sacha P, 2016, ANGEW CHEM INT EDIT, V55, P2356, DOI 10.1002/anie.201508642; Simon P, 2018, ACS CHEM BIOL, V13, P3333, DOI 10.1021/acschembio.8b00791; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; Subr V, 2006, REACT FUNCT POLYM, V66, P1525, DOI 10.1016/j.reactfunctpolym.2006.05.002; Tykvart J, 2012, PROTEIN EXPRES PURIF, V82, P106, DOI 10.1016/j.pep.2011.11.016; Tykvart J, 2014, BIOORGAN MED CHEM, V22, P4099, DOI 10.1016/j.bmc.2014.05.061; Upadhyaya P, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001762; Wang FJ, 2022, PROSTATE CANCER P D, V25, P11, DOI 10.1038/s41391-021-00394-5; Yu XW, 2017, ANNU REV ANAL CHEM, V10, P293, DOI 10.1146/annurev-anchem-061516-045205	30	0	0	6	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2021	297	5							101342	10.1016/j.jbc.2021.101342	http://dx.doi.org/10.1016/j.jbc.2021.101342			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE0WY	34710374	Green Published, gold			2023-01-03	WOS:000723119000013
J	Mohammed, SA; Kahissay, MH; Hailu, AD				Mohammed, Solomon Ahmed; Kahissay, Mesfin Haile; Hailu, Abel Demerew			Pharmaceuticals wastage and pharmaceuticals waste management in public health facilities of Dessie town, North East Ethiopia	PLOS ONE			English	Article							AVAILABILITY; MEDICINES; HOSPITALS; SERBIA; CARE	Background Pharmaceuticals wastes are drugs and medicines that can no longer be used. The improper disposal of unused medicines is a growing problem throughout the world. This study assessed the pharmaceutical wastage rate and pharmaceutical waste management for the year 2015 to 2017 in the public health facility of Dessie, Ethiopia. Methodology A cross-section study design was used to review logistic data retrospectively from health commodity management information systems and manual records in 8 health facilities. Health professionals' (135) pharmaceutical waste management practices were assessed using the world health organization waste management checklist. Descriptive and inferential statistics were made using a statistical package for social sciences version 20. Result Supplies were the leading class of pharmaceuticals with an overall wastage rate of 37.1%. Tablet and injectable constituted the highest class of pharmaceuticals dosage form with the overall wastage rate of 20.78% and 16.49%. The overall pharmaceutical wastage rate was 3.68% amounting to USD 159,762.66 and expiry (92.05%) was the major reason for wastage. The pharmaceutical wastage rate of health centers was nearly twofold higher than hospitals. Pharmaceutical waste management was practiced by 105 (77%; 95% CI; 69.9%, 84.9%) health professionals. Determinants of pharmaceutical waste management were being male (P value = 0.08, AOR = 3.72), receiving training (P value = 0.01, AOR = 4.34), writing label (P value = 0.02, AOR = 5.04), storage of segregated waste in dispensing unit (P value = 0.01, AOR = 0.72) and the presence of disposal plan (P value = 0.002, AOR = 16.93). Conclusions Supplies and tablets constituted the highest wastage class of pharmaceuticals and dosage form. The pharmaceutical wastage rate was higher than the standard and increasing in successive years. Pharmaceutical waste management was not fully practiced. Appropriate inventory control and waste management are recommended.	[Mohammed, Solomon Ahmed; Kahissay, Mesfin Haile] Wollo Univ, Coll Med & Hlth Sci, Dept Pharm, Dessie, Ethiopia; [Hailu, Abel Demerew] Dessie Hlth Sci Coll, Dept Pharm, Dessie, Ethiopia	University of Gondar	Mohammed, SA (corresponding author), Wollo Univ, Coll Med & Hlth Sci, Dept Pharm, Dessie, Ethiopia.	ahmedsolomon21@gmail.com		Mohammed, Solomon Ahmed/0000-0002-6498-8455				Abah S. O., 2011, Journal of Public Health and Epidemiology, V3, P99; Aditya S, 2013, INT J PHARM LIFE SCI, V4, P2476; Ahmed N., 2014, J APPL IND SCI, V2, P201; Akum FA., 2014, MERIT RES J ENV SCI, V2, P27; Amin R., 2013, PESHAWAR PROFESSIONA, P20; Azage M, 2010, ETHIOP J HEALTH DEV, V24, P119; Babar ZUD, 2013, PHARMACOECONOMICS, V31, P1063, DOI 10.1007/s40273-013-0095-9; Bataduwaarachchi VR, 2018, INT J BASIC CLIN PHA, V5, P2290, DOI [10.18203/2319-2003.ijbcp20164081, DOI 10.18203/2319-2003.IJBCP20164081]; Becker J., HLTH CARE HARM HLTH; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Chartier Y., 2014, SAFE MANAGEMENT WAST; Debere MK, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-28; Desalegn AA, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-170; Doh Manila, HLTH CARE WASTE MANA; Dwivedi S, 2012, PHARM INNOV, V1, P125; EFMHACA, 2014, NAT ESS MED LIST, VFifth Edition; Federal Ministry of Health of Ethiopia, 2010, HLTH SECTOR DEV 4 HS; Fentie M., 2015, J PHARMASCITECH, V4, P54; Ferreira V., 2009, PORTUGAL GOOGLE SCHO; Gusca J, 2015, ENRGY PROCED, V72, P175, DOI 10.1016/j.egypro.2015.06.025; Habash M., 2012, WORLD APPL SCI J, V19, P880, DOI [10.5829/idosi.wasj.2012.19.06.775, DOI 10.5829/IDOSI.WASJ.2012.19.06.775]; Harhay MO, 2009, TROP MED INT HEALTH, V14, P1414, DOI 10.1111/j.1365-3156.2009.02386.x; International Committee of the Red Cross, 2011, MED WAST MAN; Jovanovic V, 2016, INDIAN J PHARM EDUC, V50, P695, DOI 10.5530/ijper.50.4.22; Kadam A., 2016, INDIAN J PHARM PRACT, V9, P3, DOI [10.5530/ijopp.9.1.2, DOI 10.5530/IJOPP.9.1.2]; Kagashe G. A., 2014, Journal of Applied Pharmaceutical Science, V4, P98; Kagashe GA., 2012, INT J PHARMACEUT, V2, P252, DOI DOI 10.9790/3013-25502125; Law AV, 2015, RES SOC ADMIN PHARM, V11, P571, DOI 10.1016/j.sapharm.2014.10.003; Manojlovic J, 2015, INDIAN J PHARM EDUC, V49, P106, DOI 10.5530/ijper.49.2.5; Manyele S., 2010, AFRICAN J ENV SCI TE, V4; Meleko A, 2018, ANN REV RES, V1; Moges Feleke, 2014, BMC Res Notes, V7, P215, DOI 10.1186/1756-0500-7-215; Nwachukwu NC., 2013, CURR TOPIC PUBLIC HL, V2, P149, DOI [10.5772/53196, DOI 10.5772/53196, http%3A//dx.doi.org/10.5772/53196]; Population Censeus Commission, 2008, POPULATION SIZE AGE; Rachmania I. N., 2013, MANAGEMENT, V3, P1, DOI [10.1016/S0140-6736(08)61762-6, DOI 10.1016/S0140-6736(08)61762-6]; de Almeida MAR, 2016, REV ESC ENFERM USP, V50, P922, DOI [10.1590/S0080-623420160000700007, 10.1590/s0080-623420160000700007]; Renukadevi R., 2010, STUDY INVENTORY CONT, DOI [10.1039/c0mt00062k, DOI 10.1039/C0MT00062K]; Romero A, 2013, P WORLD C ENG COMP S; Rushton L, 2003, BRIT MED BULL, V68, P183, DOI 10.1093/bmb/ldg034; Sasu S, 2012, WASTE MANAGE RES, V30, P625, DOI 10.1177/0734242X11423286; Shaaban H., 2018, ENV CONTAMINATION PH; Shalini S., 2012, NATL J COMMUNITY MED, V3, P80; Susan W., 2015, INT J SCI RES PUBLIC, V5; Sweileh WM, 2010, INT J CLIN PHARM TH, V48, P59; Tadesse E., 2017, ASSESSMENT MED WASTA; Teferi Gedif Fenta BethelhemGulelat., 2016, OUTCOMES AUDITABLE P; Tumwine Y, 2010, TROP J PHARM RES, V9, P557; Uddin MN., 2014, J WASTE MANAGEMENT, V2014, DOI [10.1016/j.wasman.2014.06.029, DOI 10.1016/J.WASMAN.2014.06.029]; USAID Deliver Project, 2008, TASK ORDER; West LM., 2015, J MALTA COLL PHARM P, V21, P25; WHO, 2017, SAFE MANAGEMENT WAST; World Health Organization, 2007, DRUG FIN ETH; World Health Organization, 2021, REG STAT REP DROWN S; World Health Organization, 2011, WAST HLTH CAR ACT; World Health Organization (WHO), 2005, MAN SOL HLTH CAR WAS	55	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2021	16	10							e0259160	10.1371/journal.pone.0259160	http://dx.doi.org/10.1371/journal.pone.0259160			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ6CS	34710189	gold, Green Published			2023-01-03	WOS:000755563200076
J	Siedner, MJ; Moosa, MYS; McCluskey, S; Gilbert, RF; Pillay, S; Aturinda, I; Ard, K; Muyindike, W; Musinguzi, N; Masette, G; Pillay, M; Moodley, P; Brijkumar, J; Rautenberg, T; George, G; Gandhi, RT; Johnson, BA; Sunpath, H; Bwana, MB; Marconi, VC				Siedner, Mark J.; Moosa, Mahomed-Yunus S.; McCluskey, Suzanne; Gilbert, Rebecca F.; Pillay, Selvan; Aturinda, Isaac; Ard, Kevin; Muyindike, Winnie; Musinguzi, Nicholas; Masette, Godfrey; Pillay, Melendhran; Moodley, Pravikrishnen; Brijkumar, Jaysingh; Rautenberg, Tamlyn; George, Gavin; Gandhi, Rajesh T.; Johnson, Brent A.; Sunpath, Henry; Bwana, Mwebesa B.; Marconi, Vincent C.			Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa An Unblinded Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; LOPINAVIR PLUS RALTEGRAVIR; ANTIRETROVIRAL THERAPY; DRUG-RESISTANCE; VIRAL LOAD; 2ND-LINE; ADULTS; TRANSMISSION; NUCLEOSIDE	Background: Virologic failure in HIV predicts the development of drug resistance and mortality. Genotypic resistance testing (GRT), which is the standard of care after virologic failure in high-income settings, is rarely implemented in sub-Saharan Africa. Objective: To estimate the effectiveness of GRT for improving virologic suppression rates among people with HIV in sub-Saharan Africa for whom first-line therapy fails. Design: Pragmatic, unblinded, randomized controlled trial. (ClinicalTrials.gov: NCT02787499) Setting: Ambulatory HIV clinics in the public sector in Uganda and South Africa. Patients: Adults receiving first-line antiretroviral therapy with a recent HIV RNA viral load of 1000 copies/mL or higher. Intervention: Participants were randomly assigned to receive standard of care (SOC), including adherence counseling sessions and repeated viral load testing, or immediate GRT. Measurements: The primary outcome of interest was achievement of an HIV RNA viral load below 200 copies/mL 9 months after enrollment. Results: The trial enrolled 840 persons, divided equally between countries. Approximately half (51%) were women. Most (72%) were receiving a regimen of tenofovir, emtricitabine, and efavirenz at enrollment. The rate of virologic suppression did not differ 9 months after enrollment between the GRT group (63% [263 of 417]) and SOC group (61% [256 of 423]; odds ratio [OR], 1.11 [95% CI, 0.83 to 1.49]; P = 0.46). Among participants with persistent failure (HIV RNA viral load .1000 copies/mL) at 9 months, the prevalence of drug resistance was higher in the SOC group (76% [78 of 103] vs. 59% [48 of 82]; OR, 2.30 [CI, 1.22 to 4.35]; P = 0.014). Other secondary outcomes, including 9-month survival and retention in care, were similar between groups. Limitation: Participants were receiving nonnucleoside reverse transcriptase inhibitor-based therapy at enrollment limiting the generalizability of the findings. Conclusion: The addition of GRT to routine care after firstline virologic failure in Uganda and South Africa did not improve rates of resuppression.	[Siedner, Mark J.; McCluskey, Suzanne; Gilbert, Rebecca F.; Ard, Kevin; Gandhi, Rajesh T.] Massachusetts Gen Hosp, 55 Fruit St,GRJ 504, Boston, MA 02114 USA; [Siedner, Mark J.; McCluskey, Suzanne; Ard, Kevin; Gandhi, Rajesh T.] Harvard Med Sch, Boston, MA 02115 USA; [Siedner, Mark J.; Aturinda, Isaac; Muyindike, Winnie; Musinguzi, Nicholas; Masette, Godfrey; Bwana, Mwebesa B.] Mbarara Univ Sci & Technol, Mbarara Kabale High Way,POB 1410, Mbarara, Uganda; [Siedner, Mark J.] Africa Hlth Res Inst, Kwa Zulu, South Africa; [Siedner, Mark J.; Moosa, Mahomed-Yunus S.; Pillay, Selvan; Brijkumar, Jaysingh; George, Gavin; Sunpath, Henry] Univ KwaZulu Natal, Westville Campus,J Block 4th Floor, ZA-4041 Durban, South Africa; [Pillay, Melendhran; Moodley, Pravikrishnen] Natl Hlth Lab Serv, Durban, South Africa; [Rautenberg, Tamlyn] Griffith Univ, Brisbane, Qld, Australia; [Johnson, Brent A.] Univ Rochester, Rochester, NY USA; [Marconi, Vincent C.] Emory Univ, Sch Med, Atlanta, GA USA; [Marconi, Vincent C.] Rollins Sch Publ Hlth, Atlanta, GA USA; [Siedner, Mark J.; Gilbert, Rebecca F.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, 100 Cambridge St,Suite 1600, Boston, MA 02114 USA; [Moosa, Mahomed-Yunus S.] Nelson Mandela Sch Med, Dept Infect Dis, Div Internal Med, Room Z319,3rd Floor,719 Umbilo Rd, ZA-4013 Congella, Kzn, South Africa; [McCluskey, Suzanne] 100 Cambridge St,Suite 1600, Boston, MA 02114 USA; [Pillay, Selvan] 111 Granada St, ZA-4093 Shallcross, South Africa; [Aturinda, Isaac] Mbarara Univ, Grants Off, Box 1410, Mbarara, Uganda; [Musinguzi, Nicholas] Plot 10-24,Lower Circular Rd, Mbarara, Uganda; [Pillay, Melendhran; Moodley, Pravikrishnen] Inkosi Albert Luthuli Cent Hosp, 800 Vusi Mzimela Rd, ZA-4091 Durban, South Africa; [Brijkumar, Jaysingh] 157 Hillhead Rd, ZA-4052 Durban, South Africa; [Rautenberg, Tamlyn] Griffith Univ, Ctr Appl Hlth Econ, N78,Level 2,Room 2-34,Nathan Campus, Nathan, Qld 4111, Australia; [Johnson, Brent A.] 601 Elmwood Ave,Box 630, Rochester, NY 14642 USA; [Sunpath, Henry] POB 70820, ZA-4067 Overport, South Africa; [Marconi, Vincent C.] 1760 Haygood Dr NE,Room W325, Atlanta, GA 30322 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Mbarara University of Science & Technology; Africa Health Research Institute; University of Kwazulu Natal; Griffith University; University of Rochester; Emory University; Emory University; Rollins School Public Health; Harvard University; Massachusetts General Hospital; University of Kwazulu Natal; Mbarara University of Science & Technology; Griffith University	Siedner, MJ (corresponding author), Massachusetts Gen Hosp, Med Practice Evaluat Ctr, 100 Cambridge St,Suite 1600, Boston, MA 02114 USA.	msiedner@mgh.harvard.edu	Marconi, Vincent/N-3210-2014; Rautenberg, Tamlyn/AAU-7799-2020; Marconi, Vincent/GRJ-4553-2022; Marconi, Vincent/AFK-5812-2022	Marconi, Vincent/0000-0001-8409-4689; Rautenberg, Tamlyn/0000-0002-3912-3740; Marconi, Vincent/0000-0001-8409-4689; Gilbert, Rebecca/0000-0003-1761-4626; Siedner, Mark/0000-0003-3506-842X; Muyindike, Winnie/0000-0002-6694-2645; Musinguzi, Nicholas/0000-0002-1269-4623	President's Emergency Plan for AIDS Relief [NIH R01 AI124718]; National Institute of Allergy and Infectious Diseases [R01AI098558-01A1, R01AI098558-04S1]; Emory Center for AIDS Research [P30AI050409]; Harvard University Center for AIDS Research (NIH) [P30 AI060354]; AIDS Clinical Trials Group (NIH/NIAID) [2 UMAI069412-09]	President's Emergency Plan for AIDS Relief(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Emory Center for AIDS Research; Harvard University Center for AIDS Research (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AIDS Clinical Trials Group (NIH/NIAID)	By grant NIH R01 AI124718 fromthe President's Emergency Plan for AIDS Relief and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Dr. Marconi also received support from the National Institute of Allergy and Infectious Diseases (R01AI098558-01A1 and R01AI098558-04S1) and the Emory Center for AIDS Research (P30AI050409). Dr. Gandhi also received support from the Harvard University Center for AIDS Research (NIH P30 AI060354) and the AIDS Clinical Trials Group (NIH/NIAID 2 UMAI069412-09).	Aboud M, 2019, LANCET INFECT DIS, V19, P253, DOI 10.1016/S1473-3099(19)30036-2; Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Boyd MA, 2013, LANCET, V381, P2091, DOI 10.1016/S0140-6736(13)61164-2; Ciaffi L, 2015, AIDS, V29, P1473, DOI 10.1097/QAD.0000000000000709; Cohen CJ, 2002, AIDS, V16, P579, DOI 10.1097/00002030-200203080-00009; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; El-Khatib Ziad, 2011, J AIDS Clin Res, V2; Glass TR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220337; Grabowski MK, 2021, J INFECT DIS, V223, P1150, DOI 10.1093/infdis/jiab021; Grimsrud A, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21484; Gupta-Wright A, 2020, LANCET HIV, V7, pE620, DOI 10.1016/S2352-3018(20)30172-7; Hakim JG, 2018, LANCET INFECT DIS, V18, P47, DOI [10.1016/S1473-3099(17)30630-8, 10.1016/s1473-3099(17)30630-8]; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Haubrich RH, 2005, AIDS, V19, P295; Hermans LE, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003037; Hoffmann CJ, 2009, CLIN INFECT DIS, V49, P1928, DOI 10.1086/648444; Inzaule Seth C, 2016, Lancet Infect Dis, V16, pe267, DOI 10.1016/S1473-3099(16)30118-9; Iwuji CC, 2020, HIV MED, V21, P457, DOI 10.1111/hiv.12877; Jobanputra K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116144; Kerkhoff AD, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003107; Nachega JB, 2018, CLIN INFECT DIS, V66, P1487, DOI 10.1093/cid/ciy008; Palombi L, 2009, CLIN INFECT DIS, V48, P115, DOI 10.1086/593312; Panel of Antiretroviral Guidelines for Adults and Adolescents, GUIDELINES USE ANTIR; Paton NI, 2021, NEW ENGL J MED, V385, P330, DOI 10.1056/NEJMoa2101609; Petersen ML, 2014, AIDS, V28, P2097, DOI 10.1097/QAD.0000000000000349; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rautenberg TA, 2020, J MED ECON, V23, P221, DOI 10.1080/13696998.2019.1705314; Siedner MJ, 2017, HIV CLIN TRIALS, V18, P149, DOI 10.1080/15284336.2017.1349028; Ssempijja V, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2680-6; Tsai AC, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001906; Tural C, 2002, AIDS, V16, P209, DOI 10.1097/00002030-200201250-00010; Vandormael A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13473-y; Venter W F, 2016, S Afr Med J, V107, P28, DOI 10.7196/SAMJ.2016.v107.i1.12058; Wensing Annemarie M, 2019, Top Antivir Med, V27, P111; World Health Organization, 2018, UPD REC 1 LIN 2 LIN	35	2	2	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC	2021	174	12					1683	+		10.7326/M21-2229	http://dx.doi.org/10.7326/M21-2229		OCT 2021	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XS0OD	34698502	Green Accepted			2023-01-03	WOS:000729195700001
J	Essien, UR; Dusetzina, SB; Gellad, WF				Essien, Utibe R.; Dusetzina, Stacie B.; Gellad, Walid F.			A Policy Prescription for Reducing Health Disparities-Achieving Pharmacoequity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint discusses pharmacoequity, which is the goal of ensuring that all individuals have access to the highest-quality medications required to manage their health needs, and ways in which this can be achieved.	[Essien, Utibe R.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 3609 Forbes Ave,Ste 2, Pittsburgh, PA 15213 USA; [Essien, Utibe R.; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA USA; [Dusetzina, Stacie B.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Vanderbilt University	Essien, UR (corresponding author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 3609 Forbes Ave,Ste 2, Pittsburgh, PA 15213 USA.	uessien@pitt.edu	Essien, Utibe/ABG-2508-2021; Essien, Utibe R./AAB-2320-2022	Essien, Utibe R./0000-0002-4494-5028	HSRD VA [IK2 HX003176] Funding Source: Medline	HSRD VA		Conti R, 2020, HEALTH AFFAIR, V39, P445, DOI 10.1377/hlthaff.2019.01432; Essien UR, 2018, JAMA CARDIOL, V3, P1174, DOI 10.1001/jamacardio.2018.3945; Guadamuz JS, 2021, HEALTH AFFAIR, V40, P802, DOI 10.1377/hlthaff.2020.01699; Luo J, 2019, ANN INTERN MED, V171, P605, DOI 10.7326/M18-1138; Mahajan S, 2021, JAMA-J AM MED ASSOC, V326, P637, DOI 10.1001/jama.2021.9907; Martin AB, 2021, HEALTH AFFAIR, V40, P14, DOI 10.1377/hlthaff.2020.02022; Rivera DR, 2020, CANCER DISCOV, V10, P1514, DOI 10.1158/2159-8290.CD-20-0941; Rodriguez F, 2021, CIRCULATION, V143, P2332, DOI 10.1161/CIRCULATIONAHA.120.052278; Sumarsono A, 2021, CIRC-CARDIOVASC QUAL, V14, P58, DOI 10.1161/CIRCOUTCOMES.120.007492; Suresh KV, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.5499	10	29	29	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2021	326	18					1793	1794		10.1001/jama.2021.17764	http://dx.doi.org/10.1001/jama.2021.17764		OCT 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WW8DE	34677579				2023-01-03	WOS:000709920900002
J	Munch, MW; Myatra, SN; Vijayaraghavan, BKT; Saseedharan, S; Benfield, T; Wahlin, RR; Rasmussen, BS; Andreasen, AS; Poulsen, LM; Cioccari, L; Khan, MS; Kapadia, F; Divatia, JV; Brochner, AC; Bestle, MH; Helleberg, M; Michelsen, J; Padmanaban, A; Bose, N; Moller, A; Borawake, K; Kristiansen, KT; Shukla, U; Chew, MS; Dixit, S; Ulrik, CS; Amin, PR; Chawla, R; Wamberg, CA; Shah, MS; Darfelt, IS; Jorgensen, VL; Smitt, M; Granholm, A; Kjaer, MBN; Moller, MH; Meyhoff, TS; Vesterlund, GK; Hammond, NE; Micallef, S; Bassi, A; John, O; Jha, A; Cronhjort, M; Jakob, SM; Gluud, C; Lange, T; Kadam, V; Marcussen, KV; Hollenberg, J; Hedman, A; Nielsen, H; Schjorring, OL; Jensen, MQ; Leistner, JW; Jonassen, TB; Kristensen, CM; Clapp, EC; Hjortso, CJS; Jensen, TS; Halstad, LS; Bak, ERB; Zaabalawi, R; Metcalf-Clausen, M; Abdi, S; Hatley, EV; Aksnes, TS; Gleipner-Andersen, E; Alarcon, AF; Yamin, G; Heymowski, A; Berggren, A; La Cour, K; Weihe, S; Pind, AH; Engstrom, J; Jha, V; Venkatesh, B; Perner, A				Munch, Marie W.; Myatra, Sheila N.; Vijayaraghavan, Bharath Kumar Tirupakuzhi; Saseedharan, Sanjith; Benfield, Thomas; Wahlin, Rebecka R.; Rasmussen, Bodil S.; Andreasen, Anne Sofie; Poulsen, Lone M.; Cioccari, Luca; Khan, Mohd S.; Kapadia, Farhad; Divatia, Jigeeshu V.; Brochner, Anne C.; Bestle, Morten H.; Helleberg, Marie; Michelsen, Jens; Padmanaban, Ajay; Bose, Neeta; Moller, Anders; Borawake, Kapil; Kristiansen, Klaus T.; Shukla, Urvi; Chew, Michelle S.; Dixit, Subhal; Ulrik, Charlotte S.; Amin, Pravin R.; Chawla, Rajesh; Wamberg, Christian A.; Shah, Mehul S.; Darfelt, Iben S.; Jorgensen, Vibeke L.; Smitt, Margit; Granholm, Anders; Kjaer, Maj-Brit N.; Moller, Morten H.; Meyhoff, Tine S.; Vesterlund, Gitte K.; Hammond, Naomi E.; Micallef, Sharon; Bassi, Abhinav; John, Oommen; Jha, Anubhuti; Cronhjort, Maria; Jakob, Stephan M.; Gluud, Christian; Lange, Theis; Kadam, Vaijayanti; Marcussen, Klaus V.; Hollenberg, Jacob; Hedman, Anders; Nielsen, Henrik; Schjorring, Olav L.; Jensen, Marie Q.; Leistner, Jens W.; Jonassen, Trine B.; Kristensen, Camilla M.; Clapp, Esben C.; Hjortso, Carl J. S.; Jensen, Thomas S.; Halstad, Liv S.; Bak, Emilie R. B.; Zaabalawi, Reem; Metcalf-Clausen, Matias; Abdi, Suhayb; Hatley, Emma V.; Aksnes, Tobias S.; Gleipner-Andersen, Emil; Alarcon, Arif F.; Yamin, Gabriel; Heymowski, Adam; Berggren, Anton; La Cour, Kirstine; Weihe, Sarah; Pind, Alison H.; Engstrom, Janus; Jha, Vivekanand; Venkatesh, Balasubramanian; Perner, Anders			Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia The COVID STEROID 2 Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTICENTER	Question What is the effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support at 28 days in patients with COVID-19 and severe hypoxemia? Findings In this randomized trial that included 1000 patients with COVID-19 and severe hypoxemia, treatment with 12 mg/d of dexamethasone resulted in 22.0 days alive without life support at 28 days compared with 20.5 days in those receiving 6 mg/d of dexamethasone. This difference was not statistically significant. Meaning Compared with 6 mg of dexamethasone, 12 mg of dexamethasone did not statistically significantly reduce the number of days alive without life support at 28 days. This multicenter randomized clinical trial compares the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia. IMPORTANCE A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in patients with severe and critical COVID-19, but a higher dose may benefit those with more severe disease. OBJECTIVE To assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia. DESIGN, SETTING, AND PARTICIPANTS A multicenter, randomized clinical trial was conducted between August 2020 and May 2021 at 26 hospitals in Europe and India and included 1000 adults with confirmed COVID-19 requiring at least 10 L/min of oxygen or mechanical ventilation. End of 90-day follow-up was on August 19, 2021. INTERVENTIONS Patients were randomized 1:1 to 12 mg/d of intravenous dexamethasone (n = 503) or 6 mg/d of intravenous dexamethasone (n = 497) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was the number of days alive without life support (invasive mechanical ventilation, circulatory support, or kidney replacement therapy) at 28 days and was adjusted for stratification variables. Of the 8 prespecified secondary outcomes, 5 are included in this analysis (the number of days alive without life support at 90 days, the number of days alive out of the hospital at 90 days, mortality at 28 days and at 90 days, and >= 1 serious adverse reactions at 28 days). RESULTS Of the 1000 randomized patients, 982 were included (median age, 65 [IQR, 55-73] years; 305 [31%] women) and primary outcome data were available for 971 (491 in the 12 mg of dexamethasone group and 480 in the 6 mg of dexamethasone group). The median number of days alive without life support was 22.0 days (IQR, 6.0-28.0 days) in the 12 mg of dexamethasone group and 20.5 days (IQR, 4.0-28.0 days) in the 6 mg of dexamethasone group (adjusted mean difference, 1.3 days [95% CI, 0-2.6 days]; P = .07). Mortality at 28 days was 27.1% in the 12 mg of dexamethasone group vs 32.3% in the 6 mg of dexamethasone group (adjusted relative risk, 0.86 [99% CI, 0.68-1.08]). Mortality at 90 days was 32.0% in the 12 mg of dexamethasone group vs 37.7% in the 6 mg of dexamethasone group (adjusted relative risk, 0.87 [99% CI, 0.70-1.07]). Serious adverse reactions, including septic shock and invasive fungal infections, occurred in 11.3% in the 12 mg of dexamethasone group vs 13.4% in the 6 mg of dexamethasone group (adjusted relative risk, 0.83 [99% CI, 0.54-1.29]). CONCLUSIONS AND RELEVANCE Among patients with COVID-19 and severe hypoxemia, 12 mg/d of dexamethasone compared with 6 mg/d of dexamethasone did not result in statistically significantly more days alive without life support at 28 days. However, the trial may have been underpowered to identify a significant difference.	[Myatra, Sheila N.; Granholm, Anders; Kjaer, Maj-Brit N.; Moller, Morten H.; Meyhoff, Tine S.; Vesterlund, Gitte K.; Hammond, Naomi E.; Leistner, Jens W.; Jonassen, Trine B.; Kristensen, Camilla M.; Clapp, Esben C.; Hjortso, Carl J. S.; Jensen, Thomas S.; Halstad, Liv S.; Bak, Emilie R. B.; Zaabalawi, Reem; Metcalf-Clausen, Matias; Abdi, Suhayb; Hatley, Emma V.; Aksnes, Tobias S.; Gleipner-Andersen, Emil; Alarcon, Arif F.; Perner, Anders] Copenhagen Univ Hosp, Dept Intens Care, Rigshosp, Copenhagen, Denmark; [Myatra, Sheila N.; Divatia, Jigeeshu V.] Tata Mem Hosp, Homi Bhabha Natl Inst, Mumbai, India; [Vijayaraghavan, Bharath Kumar Tirupakuzhi; Perner, Anders] Apollo Hosp, Chennai, India; [Saseedharan, Sanjith] SL Raheja Hosp, Mumbai, India; [Benfield, Thomas] Copenhagen Univ Hosp Amager & Hvidovre, Dept Infect Dis, Hvidovre, Denmark; [Wahlin, Rebecka R.; Hollenberg, Jacob; Hedman, Anders; Alarcon, Arif F.; Yamin, Gabriel; Heymowski, Adam; Berggren, Anton] Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden; [Rasmussen, Bodil S.; Nielsen, Henrik; Schjorring, Olav L.] Aalborg Univ Hosp, Aalborg Univ, Aalborg, Denmark; [Rasmussen, Bodil S.; Nielsen, Henrik; Schjorring, Olav L.] Copenhagen Univ Hosp, Gentofte Hosp, Dept Anaesthesia & Intens Care, Herlev, Denmark; [Poulsen, Lone M.; Weihe, Sarah; Pind, Alison H.] Zealand Univ Hosp, Dept Anaesthesia & Intens Care, Koege, Denmark; [Cioccari, Luca; Jakob, Stephan M.] Univ Bern, Bern Univ Hosp, Inselspital, Bern, Switzerland; [Khan, Mohd S.] Rajendra Inst Med Sci, Ranchi, India; [Kapadia, Farhad] Hinduja Hosp, Mumbai, India; [Brochner, Anne C.] Kolding Cty Hosp, Dept Anaesthesia & Intens Care, Kolding, Denmark; [Bestle, Morten H.] Copenhagen Univ Hosp, Dept Anaesthesia & Intens Care, Hillerod, Denmark; [Helleberg, Marie] Copenhagen Univ Hosp, Dept Infect Dis, Rigshosp, Copenhagen, Denmark; [Michelsen, Jens] Odense Univ Hosp, Dept Anaesthesia & Intens Care, Odense, Denmark; [Bose, Neeta] Gotri Gen Hosp, Gotri, Gujarat, India; [Moller, Anders; Marcussen, Klaus V.] Slagelse Hosp, Dept Anaesthesia & Intens Care, Slagelse, Denmark; [Borawake, Kapil] Vishwaraj Hosp, Pune, India; [Kristiansen, Klaus T.] Copenhagen Univ Hosp, Dept Anaesthesia & Intens Care, Hvidovre, Denmark; [Shukla, Urvi] Symbiosis Univ Hosp, Res Centre, Lavale, India; [Chew, Michelle S.] Linkoping Univ, Dept Anaesthes & Intens Care Med, BioMed & Clin Sci, Linkoping, Sweden; [Dixit, Subhal] Sanjeevan Hosp, Pune, India; [Ulrik, Charlotte S.] Copenhagen Univ Hosp, Dept Resp Dis, Hvidovre, Denmark; [Amin, Pravin R.] Bombay Hosp Inst Med Sci, Mumbai, India; [Chawla, Rajesh] Indraprastha Apollo Hosp, New Delhi, India; [Wamberg, Christian A.] Frederiksberg Univ Hosp, Dept Anaesthesia & Intens Care, Bispebjerg, Copenhagen, Denmark; [Shah, Mehul S.] Sir HN Reliance Fdn Hosp & Res Ctr, Mumbai, Maharashtra, India; [Darfelt, Iben S.] Herning Hosp, Dept Anaesthesia & Intens Care, Herning, Denmark; [Jorgensen, Vibeke L.] Copenhagen Univ Hosp, Dept Thorac Anaesthesia, Rigshosp, Copenhagen, Denmark; [Smitt, Margit] Copenhagen Univ Hosp, Dept Neurointens Care, Rigshosp, Copenhagen, Denmark; [Hammond, Naomi E.; Micallef, Sharon; Jha, Vivekanand; Venkatesh, Balasubramanian; Perner, Anders] Univ New South Wales, George Inst Global Hlth, Sydney, Australia; [Hammond, Naomi E.] Royal North Shore Hosp, Malcolm Fisher Dept Intens Care, Sydney, Australia; [Bassi, Abhinav; John, Oommen; Jha, Anubhuti; Venkatesh, Balasubramanian] George Inst Global Hlth, New Delhi, India; [John, Oommen; Jha, Vivekanand] Manipal Acad Med Sci, Prasanna Sch Publ Hlth, Manipal, India; [Gluud, Christian; Engstrom, Janus] Copenhagen Univ Hosp, Centre Clin Intervent Res, Copenhagen Trial Unit, Rigshosp, Copenhagen, Denmark; [Gluud, Christian] Univ Southern Denmark, Fac Hlth Sci, Dept Reg Hlth Res, Odense, Denmark; [Lange, Theis] Univ Copenhagen, Sect BioStat, Copenhagen, Denmark; [Jha, Vivekanand] Imperial Coll, Sch Publ Hlth, London, England; [Venkatesh, Balasubramanian] Wesley Hosp, Dept Intens Care, Brisbane, Australia	Rigshospitalet; University of Copenhagen; Homi Bhabha National Institute; Tata Memorial Centre (TMC); Tata Memorial Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Aalborg University; Aalborg University Hospital; University of Copenhagen; University of Bern; University Hospital of Bern; Kolding Hospital; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Southern Denmark; Odense University Hospital; University of Copenhagen; Linkoping University; University of Copenhagen; Bombay Hospital & Medical Research Centre; Aarhus University; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; Royal North Shore Hospital; Rigshospitalet; University of Copenhagen; University of Southern Denmark; University of Copenhagen; Imperial College London; Wesley Hospital	Perner, A (corresponding author), Rigshosp, Dept Intens Care, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	anders.perner@regionh.dk	Khan, Mohd Saif/GNM-8857-2022; Munch, Marie Warrer/GPS-7525-2022; Gluud, Christian/HGB-3191-2022; Wahlin, Rebecka Rubenson/AAH-6519-2020; Cronhjort, Maria/AAH-8819-2021	Wahlin, Rebecka Rubenson/0000-0003-3890-8236; Micallef, Sharon/0000-0002-8496-2324; SHUKLA, URVI/0000-0001-9001-6898; Cioccari, Luca/0000-0003-4993-427X; HELLEBERG, MARIE/0000-0002-2370-1657; Jha, Vivekanand/0000-0002-8015-9470; Benfield, Thomas/0000-0003-0698-9385; Rajbhandari, Dorrilyn/0000-0001-8883-0428; Bestle, Morten/0000-0001-6585-2659; Lange, Theis/0000-0001-6807-8347; Rasmussen, Bodil Steen/0000-0003-2190-145X; Meno Kristensen, Camilla/0000-0003-4380-3180; Gluud, Christian/0000-0002-8861-0799	Novo Nordisk Foundation; Research Council at Rigshospitalet	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Research Council at Rigshospitalet	This trial was funded by the Novo Nordisk Foundation and supported by the Research Council at Rigshospitalet.	Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; Clofibrate, 2012, LIVERTOX CLIN RES IN; Dequin PF, 2020, JAMA-J AM MED ASSOC, V324, P1298, DOI 10.1001/jama.2020.16761; Fleishaker DL, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1135-3; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Granholm A., HIGHER VS STANDARD D; Granholm A, 2021, ACTA ANAESTH SCAND, V65, P702, DOI 10.1111/aas.13793; Haase N, 2021, ACTA ANAESTH SCAND, V65, P68, DOI 10.1111/aas.13701; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Kryger Jensen A, 2019, ARXIV191012267STATME; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Landoni G, 2015, CRIT CARE MED, V43, P1559, DOI 10.1097/CCM.0000000000000974; Munch MW, 2021, ACTA ANAESTH SCAND, V65, P1421, DOI 10.1111/aas.13941; Munch MW, 2021, ACTA ANAESTH SCAND, V65, P834, DOI 10.1111/aas.13795; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Raut A, 2021, LANCET RESP MED, V9, pE77, DOI 10.1016/S2213-2600(21)00265-4; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Singh AK, 2021, DIABETES METAB SYND, V15, DOI 10.1016/j.dsx.2021.05.019; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021; Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5; Williams DM, 2018, RESP CARE, V63, P655, DOI 10.4187/respcare.06314	23	66	66	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2021	326	18					1807	1817		10.1001/jama.2021.18295	http://dx.doi.org/10.1001/jama.2021.18295		OCT 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW8DE	34673895	Green Published, Bronze			2023-01-03	WOS:000709921700003
J	Mullachery, PH; Bilal, U				Mullachery, Pricila H.; Bilal, Usama			Urban scaling of opioid analgesic sales in the United States	PLOS ONE			English	Article								Opioid misuse is a public health crisis in the United States. The origin of this crisis is associated with a sharp increase in opioid analgesic prescribing. We used the urban scaling framework to analyze opioid prescribing patterns in US commuting zones (CZs), i.e., groups of counties based on commuting patterns. The urban scaling framework postulates that a set of scaling relations can be used to predict health outcomes and behaviors in cities. We used data from the Drug Enforcement Administration's Automated Reports and Consolidated Ordering System (ARCOS) to calculate counts of oxycodone/hydrocodone pills distributed to 607 CZs in the continental US from 2006 to 2014. We estimated the scaling coefficient of opioid pill counts by regressing log(pills) on log(population) using a piecewise linear spline with a single knot at 82,363. Our results show that CZs with populations below the knot scaled superlinearly (beta = 1.36), i.e., larger CZs had disproportionally larger pill counts compared to smaller CZs. On the other hand, CZs with populations above the knot scaled sublinearly (beta = 0.92), i.e., larger CZs had disproportionally smaller pill counts compared to smaller CZs. This dual scaling pattern was consistent across US census regions. For CZs with population below the knot, the superlinear scaling of pills is consistent with the explanation that an increased number of successful matches between prescribers and users will lead to higher prescribing rates. The non-linear scaling behavior observed could be the result of a combination of factors, including stronger health care systems and prescribing regulation in largely populated commuting zones, as well as high availability of other opioids such as heroin in these commuting zones. Future research should explore potential mechanisms for the non-linearity of prescription opioid pills.	[Mullachery, Pricila H.; Bilal, Usama] Drexel Dornsife Sch Publ Hlth, Urban Hlth Collaborat, Philadelphia, PA 19104 USA; [Bilal, Usama] Drexel Dornsife Sch Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA USA	Drexel University; Drexel University	Mullachery, PH (corresponding author), Drexel Dornsife Sch Publ Hlth, Urban Hlth Collaborat, Philadelphia, PA 19104 USA.	phm32@drexel.edu		Bilal, Usama/0000-0002-9868-7773; Mullachery, Pricila H./0000-0003-4758-3875	Office of the Director of the National Institutes of Health [DP5OD026429]	Office of the Director of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was supported by Office of the Director of the National Institutes of Health under award number DP5OD026429. This grant was awarded to UB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2019, WASH POST; Arbesman S, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.016115; Arcaute E, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.0745; Bettencourt LMA, 2007, P NATL ACAD SCI USA, V104, P7301, DOI 10.1073/pnas.0610172104; Bettencourt LMA, 2013, SCIENCE, V340, P1438, DOI 10.1126/science.1235823; Brown JH, 2000, SFI S SCI C, P1; Cerda M, 2017, ADDICTION, V112, P103, DOI 10.1111/add.13543; Clauset A, 2009, SIAM REV, V51, P661, DOI 10.1137/070710111; Cottineau C, 2017, COMPUT ENVIRON URBAN, V63, P80, DOI 10.1016/j.compenvurbsys.2016.04.006; Douthit N, 2015, PUBLIC HEALTH, V129, P611, DOI 10.1016/j.puhe.2015.04.001; Drug Enforcement Administration, 2021, 2020 NAT DRUG THREAT; Fowler CS, 2016, POPUL RES POLICY REV, V35, P263, DOI 10.1007/s11113-016-9386-0; Haddox JD, 1997, PAIN FORUM, V6, P77; Jalal H, 2018, SCIENCE, V361, P1218, DOI 10.1126/science.aau1184; Leitao JC, 2016, ROY SOC OPEN SCI, V3, DOI 10.1098/rsos.150649; McDonald DC, 2012, J PAIN, V13, P988, DOI 10.1016/j.jpain.2012.07.007; Paone D, 2015, MMWR-MORBID MORTAL W, V64, P491; Pardo B., 2019, UNDERSTANDING AM SUR; Patterson-Lomba O, 2018, ARXIV180900277; Patterson-Lomba O, 2015, SEX TRANSM INFECT, V91, P610, DOI 10.1136/sextrans-2014-051932; Puga D, 2010, J REGIONAL SCI, V50, P203, DOI 10.1111/j.1467-9787.2009.00657.x; Rocha LEC, 2015, J URBAN HEALTH, V92, P785, DOI 10.1007/s11524-015-9976-x; Rutkow L, 2015, JAMA INTERN MED, V175, P1642, DOI 10.1001/jamainternmed.2015.3931; U.S. General Accounting Office, 2003, PRESCR DRUGS OXYCONT; United States Census Bureau, 2013, 2013 TIGER LIN SHAP; United States. Census Bureau, INT POP EST	26	1	1	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2021	16	10							e0258526	10.1371/journal.pone.0258526	http://dx.doi.org/10.1371/journal.pone.0258526			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7ZF	34637453	Green Published, gold			2023-01-03	WOS:000755690100038
J	Liu, KD; Tao, XR; Su, J; Li, F; Mu, F; Zhao, S; Lu, XM; Li, J; Chen, S; Dong, TW; Duan, JL; Wei, PF; Xi, MM				Liu, Kedi; Tao, Xingru; Su, Jing; Li, Fei; Mu, Fei; Zhao, Shi; Lu, Xinming; Li, Jing; Chen, Sha; Dong, Taiwei; Duan, Jialin; Wei, Peifeng; Xi, Miaomiao			Network pharmacology and molecular docking reveal the effective substances and active mechanisms of Dalbergia Odoriferain protecting against ischemic stroke	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITIES; INJURY; BRAIN; FLAVONOIDS; HEARTWOOD; PATHWAYS; BUTEIN; TARGET	Dalbergia Odorifera (DO) has been widely used for the treatment of cardiovascular and cerebrovascular diseasesinclinical. However, the effective substances and possible mechanisms of DO are still unclear. In this study, network pharmacology and molecular docking were used toelucidate the effective substances and active mechanisms of DO in treating ischemic stroke (IS). 544 DO-related targets from 29 bioactive components and 344 IS-related targets were collected, among them, 71 overlapping common targets were got. Enrichment analysis showed that 12 components were the possible bioactive components in DO, which regulating 9 important signaling pathways in 3 biological processes including 'oxidative stress' (KEGG:04151, KEGG:04068, KEGG:04915), 'inflammatory response'(KEGG:04668, KEGG:04064) and 'vascular endothelial function regulation'(KEGG:04066, KEGG:04370). Among these, 5 bioactive components with degree >= 20 among the 12 potential bioactive components were selected to be docked with the top5 core targets using Auto-dockVina software. According to the results of molecular docking, the binding sites of core target protein AKT1 and MOL002974, MOL002975, and MOL002914 were 9, 8, and 6, respectively, and they contained 2, 1, and 0 threonine residues, respectively. And some binding sites were consistent, which may be the reason for the similarities and differences between the docking results of the 3 core bioactive components. The results of in vitro experiments showed that OGD/R could inhibit cell survival and AKT phosphorylation which were reversed by the 3 core bioactive components. Among them, MOL002974 (butein) had a slightly better effect. Therefore, the protective effect of MOL002974 (butein) against cerebral ischemia was further evaluated in a rat model of middle cerebral artery occlusion (MCAO) by detecting neurological score, cerebral infarction volume and lactate dehydrogenase (LDH) level. The results indicated that MOL002974 (butein) could significantly improve the neurological score of rats, decrease cerebral infarction volume, and inhibit the level of LDH in the cerebral tissue and serum in a dose-dependent manner. In conclusion, network pharmacology and molecular docking predicate the possible effective substances and mechanisms of DO in treating IS. And the results are verified by the in vitro and in vivo experiments. This research reveals the possible effective substances from DO and its active mechanisms for treating IS and provides a new direction for the secondary development of DO for treating IS.	[Liu, Kedi; Tao, Xingru; Su, Jing; Zhao, Shi; Dong, Taiwei] Shaanxi Univ Chinese Med, Coll Pharm, Xianyang, Shaanxi, Peoples R China; [Liu, Kedi; Tao, Xingru; Su, Jing; Zhao, Shi; Xi, Miaomiao] TANK Med Biol Inst Xian, Xian, Shaanxi, Peoples R China; [Li, Fei] Fourth Mil Med Univ, Tangdu Hosp, Dept Pharm, Xian, Shaanxi, Peoples R China; [Mu, Fei] Fourth Mil Med Univ, Xijing Hosp, Dept Pharm, Xian, Shaanxi, Peoples R China; [Lu, Xinming; Li, Jing; Chen, Sha] YouYi Clin Labs Shaanxi, Xian, Shaanxi, Peoples R China; [Duan, Jialin] Northwestern Polytech Univ, Inst Med Res, Xian, Shaanxi, Peoples R China; [Wei, Peifeng; Xi, Miaomiao] Shaanxi Univ Chinese Med, Affiliated Hosp 2, Natl Drug Clin Trial Inst, Xianyang, Shaanxi, Peoples R China	Shaanxi University of Chinese Medicine; Air Force Military Medical University; Air Force Military Medical University; Northwestern Polytechnical University; Shaanxi University of Chinese Medicine	Xi, MM (corresponding author), TANK Med Biol Inst Xian, Xian, Shaanxi, Peoples R China.; Duan, JL (corresponding author), Northwestern Polytech Univ, Inst Med Res, Xian, Shaanxi, Peoples R China.; Wei, PF; Xi, MM (corresponding author), Shaanxi Univ Chinese Med, Affiliated Hosp 2, Natl Drug Clin Trial Inst, Xianyang, Shaanxi, Peoples R China.	dogson1986@163.com; weipefing@163.com; miaomiaoxi2014@163.com		Li, Fei/0000-0002-7679-1641	National Natural Science Foundation of China [81470174, 81903832]; Subject Innovation Team of the Second Affiliated Hospital of Shaanxi University of Chinese Medicine [2020XKTDA04]; Outstanding Innovation Team of Shaanxi University of Chinese Medicine	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Subject Innovation Team of the Second Affiliated Hospital of Shaanxi University of Chinese Medicine; Outstanding Innovation Team of Shaanxi University of Chinese Medicine	This study is supported by the National Natural Science Foundation of China(NO. 81470174 and 81903832), the Subject Innovation Team of the Second Affiliated Hospital of Shaanxi University of Chinese Medicine (NO.2020XKTDA04) and the Outstanding Innovation Team of Shaanxi University of Chinese Medicine (No.ZYTD04). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An RB, 2008, CHEM PHARM BULL, V56, P1722, DOI 10.1248/cpb.56.1722; Atik I, 2016, AM J EMERG MED, V34, P2379, DOI 10.1016/j.ajem.2016.08.062; Candelario-Jalil E, 2009, CURR OPIN INVEST DR, V10, P644; Cao Q, 2017, TOXICOL APPL PHARM, V319, P80, DOI 10.1016/j.taap.2017.01.019; Chan SC, 1998, PLANTA MED, V64, P153, DOI 10.1055/s-2006-957394; Chen CS, 2013, NEUROENDOCRINOLOGY, V97, P232, DOI 10.1159/000342692; Cheng ZJ, 1998, BBA-LIPID LIPID MET, V1392, P291, DOI 10.1016/S0005-2760(98)00043-5; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; [多玥荷 Duo Yuehe], 2013, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V28, P3055; Husain S, 2012, CURR PHARM DESIGN, V18, P6101, DOI 10.2174/138161212803582441; Intiso D, 2004, NEUROL SCI, V24, P390, DOI 10.1007/s10072-003-0194-z; Jia-Lin D, 2017, PROGR MODERN BIOMEDI; Lai ZM, 2016, BRAIN RES, V1630, P25, DOI 10.1016/j.brainres.2015.10.050; Liu Rongxia., 2005, RES QUALITY CONTROL; Maddahi A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-107; Martelli AM, 2010, ONCOTARGET, V1, P89, DOI 10.18632/oncotarget.114; Morris Garrett M., 2008, V443, P365, DOI 10.1007/978-1-59745-177-2_19; Mu Fei, 2016, Chinese Pharmacological Bulletin, V32, P1377, DOI 10.3969/j.issn.1001-1978.2016.10.010; Sairanen T, 2001, STROKE, V32, P1750, DOI 10.1161/01.STR.32.8.1750; Seiffge DJ, 2019, LANCET NEUROL, V18, P117, DOI 10.1016/S1474-4422(18)30356-9; Shichita T, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00319; Tao Y, 2010, FITOTERAPIA, V81, P393, DOI 10.1016/j.fitote.2009.11.012; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Wang HC, 2016, WORLD NEUROSURG, V87, P463, DOI 10.1016/j.wneu.2015.10.010; Wang W, 2000, FOOD CHEM, V71, P45, DOI 10.1016/S0308-8146(00)00123-0; Wei Zhiquan, 2011, Zhongguo Zhong Yao Za Zhi, V36, P1798; Wu CH, 2015, SCI REP-UK, V5, DOI 10.1038/srep16151; Xu TF, 2017, J PHARMACEUT BIOMED, V141, P95, DOI 10.1016/j.jpba.2017.04.012; Yang Zhi-Hong, 2013, Zhongguo Zhong Yao Za Zhi, V38, P1679; Yepes M, 2009, TRENDS NEUROSCI, V32, P48, DOI 10.1016/j.tins.2008.09.006; YU SM, 1995, EUR J PHARMACOL, V280, P69, DOI 10.1016/0014-2999(95)00190-V; Yu XL, 2007, FOOD CHEM, V104, P715, DOI 10.1016/j.foodchem.2006.10.081; Zhang Bo, 2014, CHINESE PHARMACIST, V17, P1403; Zhang W, 2005, J CEREBR BLOOD F MET, V25, P30, DOI 10.1038/sj.jcbfm.9600004; Zhang Z. N., 2020, J PRACTICAL MED, V36, P689; Zhao XS, 2020, J ETHNOPHARMACOL, V248, DOI 10.1016/j.jep.2019.112328	36	1	1	12	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2021	16	9							e0255736	10.1371/journal.pone.0255736	http://dx.doi.org/10.1371/journal.pone.0255736			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2D4JQ	34582494	Green Published, gold			2023-01-03	WOS:000811515800004
J	[Anonymous]				[Anonymous]			Oral versus Intravenous Antibiotics for Endocarditis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Oral versus Intravenous Antibiotics for Endocarditis This interactive feature about the treatment of endocarditis offers a case vignette accompanied by two essays supporting a full 6-week course of intravenous antibiotics or a switch from intravenous to oral antibiotics after several weeks.										Baddour LM, 2015, CIRCULATION, V132, P1435, DOI 10.1161/CIR.0000000000000296; Batki SL, 2002, DRUG ALCOHOL DEPEN, V66, P283, DOI 10.1016/S0376-8716(01)00208-3; Bundgaard H, 2019, NEW ENGL J MED, V380, P1373, DOI 10.1056/NEJMc1902096; Chambers HF, 2020, NEW ENGL J MED, V383, P567, DOI 10.1056/NEJMcp2000400; Iversen K, 2019, NEW ENGL J MED, V380, P415, DOI 10.1056/NEJMoa1808312; Le, 2021, CLIN INFECT DIS; Schuckit MA, 2016, NEW ENGL J MED, V375, P357, DOI 10.1056/NEJMra1604339; Serota DP, 2020, INFECT DIS CLIN N AM, V34, P539, DOI 10.1016/j.idc.2020.06.010	8	2	2	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2021	385	12					1141	1143		10.1056/NEJMclde2108866	http://dx.doi.org/10.1056/NEJMclde2108866			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ4IT	34525290				2023-01-03	WOS:000696029600019
J	Palmer, PK; Wehrmeyer, K; Florian, MP; Raison, C; Idler, E; Mascaro, JS				Palmer, Patricia K.; Wehrmeyer, Kathryn; Florian, Marianne P.; Raison, Charles; Idler, Ellen; Mascaro, Jennifer S.			The prevalence, grouping, and distribution of stressors and their association with anxiety among hospitalized patients	PLOS ONE			English	Article							QUALITY-OF-LIFE; TRAIT ANXIETY; SOCIOECONOMIC-STATUS; HEALTH-CARE; DEPRESSION; SURGERY; ILLNESS; CANCER; STATE; PAIN	Anxiety is prevalent among hospital inpatients and it has harmful effects on patient well-being and clinical outcomes. We aimed to characterize the sources of hospital distress and their relationship to anxiety. We conducted a cross-sectional study of inpatients (n = 271) throughout two Southeastern U.S. metropolitan hospitals. Participants completed a survey to identify which of 38 stressors they were experiencing. They also completed the State Trait Anxiety Inventory six-item scale. We evaluated the prevalence of stressors, their distribution, and crude association with anxiety. We then used multivariate logistic regression to estimate the association between stressors and clinically relevant anxiety, with and without adjusting for demographic variables. We used factor analysis to describe the interrelationships among stressors and to examine whether groups of stressors tend to be endorsed together. The following stressors were highly endorsed across all unit types: pain, being unable to sleep, feelings of frustration, being overwhelmed, and fear of the unknown. Stressors relating to isolation/meaninglessness and fear/frustration tend to be endorsed together. Stressors were more frequently endorsed by younger, female, and uninsured or Medicaid-insured patients and being female and uninsured was associated with anxiety in bivariate analysis. After controlling for the sources of distress in multivariate linear analysis, gender and insurance status no longer predicted anxiety. Feelings of isolation, lack of meaning, frustration, fear, or a loss of control were predictive. Study results suggest that multiple stressors are prevalent among hospital inpatients and relatively consistent across hospital unit and disease type. Interventions for anxiety or emotional/spiritual burden may be best targeted to stressors that are frequently endorsed or associated with anxiety, especially among young and female patients.	[Palmer, Patricia K.; Raison, Charles; Mascaro, Jennifer S.] Emory Univ, Dept Spiritual Hlth, Woodruff Hlth Sci Ctr, Atlanta, GA 30322 USA; [Wehrmeyer, Kathryn; Mascaro, Jennifer S.] Emory Univ, Sch Med, Dept Family & Prevent Med, Atlanta, GA USA; [Florian, Marianne P.] Emory Univ, Grad Div Relig, Atlanta, GA 30322 USA; [Raison, Charles] Univ Wisconsin Madison, Sch Human Ecol, Madison, WI USA; [Idler, Ellen] Emory Univ, Dept Sociol, Atlanta, GA 30322 USA; [Idler, Ellen] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; University of Wisconsin System; University of Wisconsin Madison; Emory University; Emory University; Rollins School Public Health	Palmer, PK (corresponding author), Emory Univ, Dept Spiritual Hlth, Woodruff Hlth Sci Ctr, Atlanta, GA 30322 USA.	pkpalme@emory.edu						Addolorato G, 1999, J PSYCHOSOM RES, V46, P283, DOI 10.1016/S0022-3999(98)00109-3; Al Rahbi F, 2020, SAUDI J KIDNEY DIS T, V31, P1351, DOI 10.4103/1319-2442.308344; AlBekairy A, 2017, MED PRIN PRACT, V26, P547, DOI 10.1159/000484929; Arpey NC, 2017, J PRIM CARE COMMUNIT, V8, P169, DOI 10.1177/2150131917697439; Babinska D, 2017, LANGENBECK ARCH SURG, V402, P719, DOI 10.1007/s00423-016-1457-5; Beeler PE, 2020, EUR J INTERN MED, V73, P59, DOI 10.1016/j.ejim.2019.11.012; Benzer JK, 2012, PSYCHIAT SERV, V63, P672, DOI 10.1176/appi.ps.201100457; Bibbo J, 2019, ANTHROZOOS, V32, P541, DOI 10.1080/08927936.2019.1621541; Bradt J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006577.pub3; Bradt J, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006911.pub2, 10.1002/14651858.CD006911]; Brown L, 2019, PSYCHOSOM MED, V81, P595, DOI 10.1097/PSY.0000000000000722; BROWN SM, 1990, J ADV NURS, V15, P962, DOI 10.1111/j.1365-2648.1990.tb01952.x; Bu FF, 2020, THORAX, V75, P597, DOI 10.1136/thoraxjnl-2019-214445; Buxton OM, 2012, ANN INTERN MED, V157, P170, DOI [10.7326/0003-4819-156-12-201208070-00472, 10.7326/0003-4819-157-3-201208070-00472]; Caldeira S, 2017, INT J NURS KNOWL, V28, P44, DOI 10.1111/2047-3095.12105; Chlan Linda, 2003, J Nurs Meas, V11, P283, DOI 10.1891/jnum.11.3.283.61269; CHRISTENSEN KS, 1985, J AM DIET ASSOC, V85, P704; Dheensa S, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-4924-1; Eagly A. H., 2016, WILEY BLACKWELL ENCY, P1, DOI 10.1002/9781118663219.wbegss183; Eberhart L, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-02552-w; Fattouh N, 2019, PERSPECT PSYCHIATR C, V55, P592, DOI 10.1111/ppc.12369; Feuchtinger J, 2014, J CLIN NURS, V23, P1900, DOI 10.1111/jocn.12467; Fillary Julie, 2015, Br J Nurs, V24, P536, DOI 10.12968/bjon.2015.24.10.536; Folkman S, 2000, PSYCHO-ONCOL, V9, P11, DOI 10.1002/(SICI)1099-1611(200001/02)9:1<11::AID-PON424>3.3.CO;2-Q; Garland EL, 2017, J GEN INTERN MED, V32, P1106, DOI 10.1007/s11606-017-4116-9; Giammanco MD, 2016, QUAL LIFE RES, V25, P2941, DOI 10.1007/s11136-016-1323-5; Gooding PA, 2012, INT J GERIATR PSYCH, V27, P262, DOI 10.1002/gps.2712; Greenwood KL, 2019, POPUL HEALTH MANAG, V22, P196, DOI 10.1089/pop.2018.0074; Gullich Inês, 2013, Rev. bras. epidemiol., V16, P644, DOI 10.1590/S1415-790X2013000300009; Handzo GF, 2008, J HEALTH CARE CHAPL, V14, P39, DOI 10.1080/08854720802053853; Hellstadius Y, 2016, Dis Esophagus, V29, P1128, DOI 10.1111/dote.12437; Hofmann S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179415; Idler EL, 2015, J SCI STUD RELIG, V54, P722, DOI 10.1111/jssr.12235; Johnson KS, 2011, J GEN INTERN MED, V26, P751, DOI 10.1007/s11606-011-1656-2; JOHNSTON M, 1980, PSYCHOL MED, V10, P145, DOI 10.1017/S0033291700039684; Julian LJ, 2011, ARTHRIT CARE RES, V63, pS467, DOI 10.1002/acr.20561; Karanci AN, 2003, J PSYCHOSOM RES, V55, P363, DOI 10.1016/S0022-3999(02)00631-1; Katon W, 2007, GEN HOSP PSYCHIAT, V29, P147, DOI 10.1016/j.genhosppsych.2006.11.005; Kepka S, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-134; Khan P, 2019, CUREUS, V11, DOI 10.7759/cureus.4254; Kvaal K, 2001, INT J GERIATR PSYCH, V16, P980, DOI 10.1002/gps.458; Lane DA, 2009, J PSYCHOSOM RES, V66, P203, DOI 10.1016/j.jpsychores.2008.10.007; Lee K, 2019, CLIN PSYCHOPHARM NEU, V17, P183, DOI 10.9758/cpn.2019.17.2.183; Mako C, 2006, J PALLIAT MED, V9, P1106, DOI 10.1089/jpm.2006.9.1106; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Mascaro JS, 2017, BEHAV NEUROSCI, V131, P262, DOI 10.1037/bne0000199; McKenzie DP, 2010, PSYCHOSOMATICS, V51, P302, DOI 10.1176/appi.psy.51.4.302; Morris AC, 2009, J ROY COLL PHYS EDIN, V39, P292, DOI 10.4997/JRCPE.2009.401; Nesami MB, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.25407; Nikayin S, 2016, GEN HOSP PSYCHIAT, V43, P23, DOI 10.1016/j.genhosppsych.2016.08.005; Park EM, 2018, PSYCHOSOMATICS, V59, P251, DOI 10.1016/j.psym.2018.01.007; Patel R, 2014, ACAD EMERG MED, V21, P1478, DOI 10.1111/acem.12543; Raubenheimer J., 2004, SA J IND PSYCHOL, DOI [10.4102/sajip.v30i4.168, DOI 10.4102/SAJIP.V30I4.168, 10.10520/EJC89023]; Refsgaard B, 2013, CANCER NURS, V36, P221, DOI 10.1097/NCC.0b013e318268f983; Rosiek A, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1248396; Rosselli M, 2015, ASIAN J PSYCHIATR, V18, P91, DOI 10.1016/j.ajp.2015.08.003; Roy-Byrne PP, 2008, GEN HOSP PSYCHIAT, V30, P208, DOI 10.1016/j.genhosppsych.2007.12.006; Santos PR, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0619-1; Shah M, 2008, AM J HOSP PALLIAT ME, V25, P88, DOI 10.1177/1049909107310138; Strang P, 2004, J PAIN SYMPTOM MANAG, V27, P241, DOI 10.1016/j.jpainsymman.2003.07.003; Taub DE., 2003, SOCIOL FOCUS, V36, P159; Tesfaw G, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1037-9; Tluczek A, 2009, J NURS MEAS, V17, P19, DOI 10.1891/1061-3749.17.1.19; Umbrello M, 2019, MINERVA ANESTESIOL, V85, P886, DOI 10.23736/S0375-9393.19.13526-2; van den Brekel L, 2020, J PAIN SYMPTOM MANAG, V60, P522, DOI 10.1016/j.jpainsymman.2020.04.005; van Ryn M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X; Walker J, 2018, PSYCHOL MED, V48, P2285, DOI 10.1017/S0033291718000624; Whelan CT, 2004, ARCH INTERN MED, V164, P175, DOI 10.1001/archinte.164.2.175; Wiesmann U, 2018, J HAPPINESS STUD, V19, P817, DOI 10.1007/s10902-017-9850-5; Yuan LL, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-02796-6	70	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	12							e0260921	10.1371/journal.pone.0260921	http://dx.doi.org/10.1371/journal.pone.0260921			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XM1MC	34871325	gold, Green Published			2023-01-03	WOS:000728598900002
J	Perri, G; d'Angelo, M; Smaniotto, C; Del Pin, M; Ruscio, E; Londero, C; Brunelli, L; Castriotta, L; Brusaferro, S				Perri, Giuseppe; d'Angelo, Matteo; Smaniotto, Cecilia; Del Pin, Massimo; Ruscio, Edoardo; Londero, Carla; Brunelli, Laura; Castriotta, Luigi; Brusaferro, Silvio			Do medical students and residents impact the quality of patient care? An assessment from different stakeholders in an Italian academic hospital, 2019	PLOS ONE			English	Article							PATIENTS SATISFACTION; HEALTH-CARE; ATTITUDES	Medical students and residents play an important role in patient care and ward activities, thus they should follow hospital procedures and ensure best practices and patient safety. A survey concerning staff on training was conducted to assess the perceived quality of healthcare from healthcare workers (HCWs), residents, medical students and patients in Udine Academic Hospital, Italy. Between December, 2018 and March, 2019, a 5-point Likert-scale questionnaire was administered in 21 units, covering four thematic areas: patients and medical staff satisfaction with the quality of care provided by residents and students, patient privacy, clinical risk management, patient perception of staff on training. Data analysis included descriptive analysis and ordered logistic regressions. A total of 596/1,863 questionnaires were collected from: HCWs (165/772), residents (110/355), students (121/389), and patients (200/347). Residents were rated high both by patients (median = 5, IQR = 4-5, OR 0.49, 95%CI 0.26-0.93) and HCWs (median = 4, IQR = 3-5, OR 0.14, 95%CI 0.08-0.26), with a lower score for medical students on the same topic, both by patients (median = 4, IQR = 3-5, OR 2.94, 95%CI 1.49-5.78) and HCWs (median = 3, IQR = 2-3, OR 0.41, 95%CI 0.25-0.67). Therefore, the role of staff on training in quality and safety of healthcare deserves integrated regular evaluation, since direct interaction with patients contributes to patients' perception of healthcare.	[Perri, Giuseppe; d'Angelo, Matteo; Smaniotto, Cecilia; Del Pin, Massimo; Ruscio, Edoardo; Brunelli, Laura; Brusaferro, Silvio] Univ Udine, Dept Med, Udine, Italy; [Londero, Carla; Brunelli, Laura] Friuli Cent Healthcare Univ Trust, Accreditat Clin Risk Management & Performance Ass, Udine, Italy; [Castriotta, Luigi] Friuli Cent Healthcare Univ Trust, Inst Hyg & Clin Epidmiol, Udine, Italy	University of Udine	Smaniotto, C (corresponding author), Univ Udine, Dept Med, Udine, Italy.	smaniotto.cecilia@spes.uniud.it	Smaniotto, Cecilia/AAR-8384-2021; Brunelli, Laura/AGA-8169-2022	Smaniotto, Cecilia/0000-0003-2465-4212; Brunelli, Laura/0000-0002-5475-0021				[Anonymous], 2001, CROSSING QUALITY CHA, DOI [10.17226/10027, DOI 10.17226/10027]; [Anonymous], 2017, CODICE DEONTOLOGIA M; Avgar AC, 2011, IND LABOR RELAT REV, V64, P423, DOI 10.1177/001979391106400301; Barksby Justine, 2014, Nurs Times, V110, P23; Boscarino JA, 1996, INT J QUAL HEALTH C, V8, P467, DOI 10.1093/intqhc/8.5.467; Calamandrei C., 2008, DIRIGENZA INFERMIERI; DONABEDIAN A, 1981, AM J PUBLIC HEALTH, V71, P409, DOI 10.2105/AJPH.71.4.409; Donabedian A, 1992, Qual Health Care, V1, P247, DOI 10.1136/qshc.1.4.247; Fineschi V, 1997, J MED ETHICS, V23, P239, DOI 10.1136/jme.23.4.239; Graber MA, 2003, ACAD EMERG MED, V10, P1329, DOI 10.1197/S1069-6563(03)00554-2; GROGAN S, 1995, BRIT J GEN PRACT, V45, P525; Haffling AC, 2008, MED TEACH, V30, P622, DOI 10.1080/01421590802043827; Howe A, 2003, BRIT MED J, V327, P326, DOI 10.1136/bmj.327.7410.326; Ivers N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub3; Karazivan P, 2015, ACAD MED, V90, P437, DOI 10.1097/ACM.0000000000000603; Kringos DS, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0906-0; Massagli TL, 2018, AM J PHYS MED REHAB, V97, P673, DOI 10.1097/PHM.0000000000000947; Ministero della Salute, 2011, DIP GOV CLIN INT TRA; Montgomery K, 2011, MILBANK Q, V89, P381, DOI 10.1111/j.1468-0009.2011.00633.x; Naidu A, 2009, INT J HEALTH CARE Q, V22, P366, DOI 10.1108/09526860910964834; Pelletier M, 1999, CAN J SURG, V42, P451; Ramani S, 2016, MED TEACH, V38, P642, DOI 10.3109/0142159X.2016.1147540; Richards T, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2614; Silvestro A., 2009, CODICE DEONTOLOGI CO; Tan SSL, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.5729; Tricarico P, 2017, INT J QUAL HEALTH C, V29, P243, DOI 10.1093/intqhc/mzx004; Unruh KP, 2013, J SURG EDUC, V70, P345, DOI 10.1016/j.jsurg.2013.01.004; Voogt JJ, 2016, INT J QUAL HEALTH C, V28, P665, DOI 10.1093/intqhc/mzw091; Williams R, 2016, J MATH SOCIOL, V40, P7, DOI 10.1080/0022250X.2015.1112384	29	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	10							e0258633	10.1371/journal.pone.0258633	http://dx.doi.org/10.1371/journal.pone.0258633			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XM9YI	34648577	gold, Green Published			2023-01-03	WOS:000729172300026
J	Saito, H; Wada, N; Iida, K				Saito, Hazuki; Wada, Naoko; Iida, Kaoruko			Isonitrogenous low-carbohydrate diet elicits specific changes in metabolic gene expression in the skeletal muscle of exercise-trained mice	PLOS ONE			English	Article							HIGH-FAT DIETS; KETOGENIC DIET; COLORIMETRIC MICROMETHOD; BETA-HYDROXYBUTYRATE; CALORIC RESTRICTION; DIABETES MANAGEMENT; LIPID-METABOLISM; CHRONIC KETOSIS; KETONE-BODIES; SHORT-TERM	With the renewed interest in low-carbohydrate diets (LCDs) in the sports field, a few animal studies have investigated their potential. However, most rodent studies have used an LCD containing low protein, which does not recapitulate a human LCD, and the muscle-specific adaptation in response to an LCD remains unclear. Therefore, we investigated the effects of two types of LCDs, both containing the same proportion of protein as a regular diet (isonitrogenous LCD; INLCD), on body composition, exercise performance, and metabolic fuel selection at the genetic level in the skeletal muscles of exercise-trained mice. Three groups of mice (n = 8 in each group), one fed a regular AIN-93G diet served as the control, and the others fed either of the two INLCDs containing 20% protein and 10% carbohydrate (INLCD-10%) or 20% protein and 1% carbohydrate (INLCD-1%) had a regular exercise load (5 times/week) for 12 weeks. Body weight and muscle mass did not decrease in either of the INLCD-fed groups, and the muscle glycogen levels and endurance capacity did not differ among the three groups. Only in the mice fed INLCD-1% did the plasma ketone concentration significantly increase, and gene expression related to glucose utilization significantly declined in the muscles. Both INLCD-1% and INLCD-10% consumption increased gene expression related to lipid utilization. These results suggest that, although INLCD treatment did not affect endurance capacity, it helped maintain muscle mass and glycogen content regardless of the glucose intake restrictions in trained mice. Moreover, an INLCD containing a low carbohydrate content might present an advantage by increasing lipid oxidation without ketosis and suppressing muscle glucose utilization.	[Saito, Hazuki; Wada, Naoko; Iida, Kaoruko] Ochanomizu Univ, Grad Sch Human & Sci, Dept Food & Nutr Sci, Bunkyo, Tokyo, Japan; [Iida, Kaoruko] Ochanomizu Univ, Inst Human Life Innovat, Bunkyo Ku, Tokyo, Japan	Ochanomizu University; Ochanomizu University	Iida, K (corresponding author), Ochanomizu Univ, Grad Sch Human & Sci, Dept Food & Nutr Sci, Bunkyo, Tokyo, Japan.; Iida, K (corresponding author), Ochanomizu Univ, Inst Human Life Innovat, Bunkyo Ku, Tokyo, Japan.	iida.kaoruko@ocha.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT) [JP21H00805]	Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by a Grant-inAid for Scientific Research (Grant Number JP21H00805) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bailey CP, 2020, J INT SOC SPORT NUTR, V17, DOI 10.1186/s12970-020-00362-9; Bielohuby M, 2011, ENDOCRINOLOGY, V152, P1948, DOI 10.1210/en.2010-1423; Bielohuby M, 2011, AM J PHYSIOL-ENDOC M, V300, pE65, DOI 10.1152/ajpendo.00478.2010; Bowler AL, 2020, SPORTS BASEL, V8, DOI [10.3390/sports8100131, DOI 10.3390/SP0RTS8100131]; Brouns F, 2018, EUR J NUTR, V57, P1301, DOI 10.1007/s00394-018-1636-y; Bueno NB, 2013, BRIT J NUTR, V110, P1178, DOI 10.1017/S0007114513000548; Cameron-Smith D, 2003, AM J CLIN NUTR, V77, P313, DOI 10.1093/ajcn/77.2.313; Cao JG, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082896; Carey AL, 2001, J APPL PHYSIOL, V91, P115, DOI 10.1152/jappl.2001.91.1.115; Caton SJ, 2012, PHYSIOL BEHAV, V106, P185, DOI 10.1016/j.physbeh.2012.02.003; Chusyd DE, 2016, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00010; Dhandapani PK, 2019, PHYSIOL REP, V7, DOI 10.14814/phy2.14159; Domouzoglou EM, 2011, AM J CLIN NUTR, V93, p901S, DOI 10.3945/ajcn.110.001941; Dowis K, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051654; Durkalec-Michalski K, 2021, NUTRIENTS, V13, DOI 10.3390/nu13030864; Feinman RD, 2015, NUTRITION, V31, P1, DOI 10.1016/j.nut.2014.06.011; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Giralt M, 2015, MOL CELL ENDOCRINOL, V418, P66, DOI 10.1016/j.mce.2015.09.018; Good CA, 1933, J BIOL CHEM, V100, P485; Gregory R.M., 2017, INT J SPORT EXERC ME, V3, P54, DOI [DOI 10.23937/2469-5718/1510054, 10.23937/2469-5718/1510054]; Helge JW, 1996, J PHYSIOL-LONDON, V492, P293, DOI 10.1113/jphysiol.1996.sp021309; Holland AM, 2016, AM J PHYSIOL-REG I, V311, pR337, DOI 10.1152/ajpregu.00156.2016; Honors MA, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-46; Huang QY, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101339; Hussain TA, 2012, NUTRITION, V28, P1016, DOI 10.1016/j.nut.2012.01.016; Iwasaki H, 2012, AM J PHYSIOL-ENDOC M, V302, pE896, DOI 10.1152/ajpendo.00204.2011; KEMP A, 1954, BIOCHEM J, V56, P646, DOI 10.1042/bj0560646; Kennedy AR, 2007, AM J PHYSIOL-ENDOC M, V292, pE1724, DOI 10.1152/ajpendo.00717.2006; Klaus S, 2005, J NUTR, V135, P1854, DOI 10.1093/jn/135.8.1854; LAMBERT EV, 1994, EUR J APPL PHYSIOL O, V69, P287, DOI 10.1007/BF00392032; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma SH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060673; McAinch AJ, 2003, OBES RES, V11, P1471, DOI 10.1038/oby.2003.197; MENDEL B, 1954, BIOCHEM J, V56, P639, DOI 10.1042/bj0560639; MILLER WJ, 1985, AM J CLIN NUTR, V41, P526, DOI 10.1093/ajcn/41.3.526; Naude CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100652; Newman JC, 2017, ANNU REV NUTR, V37, P51, DOI 10.1146/annurev-nutr-071816-064916; Nilsson J, 2016, NUTR METAB, V13, DOI 10.1186/s12986-016-0132-8; Ogura Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241382; Paoli AA, 2021, J INT SOC SPORT NUTR, V18, DOI 10.1186/s12970-021-00459-9; Paoli A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020374; Paoli A, 2012, J INT SOC SPORT NUTR, V9, DOI 10.1186/1550-2783-9-34; PHINNEY SD, 1983, METABOLISM, V32, P769, DOI 10.1016/0026-0495(83)90106-3; PHINNEY SD, 1983, METABOLISM, V32, P757, DOI 10.1016/0026-0495(83)90105-1; Pitsiladis YP, 1999, MED SCI SPORT EXER, V31, P1570, DOI 10.1097/00005768-199911000-00012; Puchalska P, 2017, CELL METAB, V25, P262, DOI 10.1016/j.cmet.2016.12.022; Ribeiro LC, 2008, MOL NUTR FOOD RES, V52, P1365, DOI 10.1002/mnfr.200700415; ROBINSON AM, 1980, PHYSIOL REV, V60, P143, DOI 10.1152/physrev.1980.60.1.143; Rojas-Morales P, 2016, CELL SIGNAL, V28, P917, DOI 10.1016/j.cellsig.2016.04.005; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Schefer V, 1996, EXP GERONTOL, V31, P387, DOI 10.1016/0531-5565(95)02032-2; Schnyder S, 2017, AM J PHYSIOL-ENDOC M, V312, pE437, DOI 10.1152/ajpendo.00361.2016; Shimizu K, 2018, NUTR RES, V60, P77, DOI 10.1016/j.nutres.2018.09.004; Song GY, 2012, CLIN EXP PHARMACOL P, V39, P1011, DOI 10.1111/1440-1681.12017; Stotzer US, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207951; Tay J, 2015, AM J CLIN NUTR, V102, P780, DOI 10.3945/ajcn.115.112581; Vargas S, 2018, J INT SOC SPORT NUTR, V15, DOI 10.1186/s12970-018-0236-9; Volek JS, 2016, METABOLISM, V65, P100, DOI 10.1016/j.metabol.2015.10.028; Webster CC, 2016, J PHYSIOL-LONDON, V594, P4389, DOI 10.1113/JP271934; Wentz AE, 2010, J BIOL CHEM, V285, P24447, DOI 10.1074/jbc.M110.100651; Westman EC, 2007, AM J CLIN NUTR, V86, P276, DOI 10.1093/ajcn/86.2.276	61	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0262875	10.1371/journal.pone.0262875	http://dx.doi.org/10.1371/journal.pone.0262875			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061842	Green Published, gold			2023-01-03	WOS:000791072800182
J	Tadesse, WT; Adankie, BT; Shibeshi, W; Amogne, W; Aklillu, E; Engidawork, E				Tadesse, Wondmagegn Tamiru; Adankie, Birhanemeskel T.; Shibeshi, Workineh; Amogne, Wondwossen; Aklillu, Eleni; Engidawork, Ephrem			Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy	PLOS ONE			English	Article							TYPE-2 DIABETES-MELLITUS; INSULIN SENSITIVITY; GENDER-DIFFERENCES; RISK; LOPINAVIR/RITONAVIR; COMPLICATIONS; TOLERANCE; SEX	Objective We investigated prevalence and predictors of glucose metabolism disorders (GMDs) among People Living with HIV (PLWH) on efavirenz- and atazanavir/ritonavir-based combination antiretroviral therapy (cART). Methods This cross-sectional study involved adult PLWH on efavirenz- (n = 240) and atazanavir/ritonavir-based (n = 111) cART. The prevalence of GMDs was determined by fasting serum glucose, insulin, and homeostasis model assessment. A logistic regression model was used to determine predictors. Results The overall prevalence of GMDs for all regimens was 27.6% (97/351) [95% CI 23.0-32.6%] s, with 31.1% (75/240) [95% CI 25.4-37.5%] for efavirenz-based and 19.8% (22/111) [95% CI 12.9-28.5%)] for atazanavir/ritonavir-based cART group. The prevalence of impaired fasting glycemia was significantly higher (p = 0.026) in the efavirenz- [(15.4%) (37/240); 95%CI (11.1-20.6%)] than atazanavir/ritonavir-based [(7.2%) (8/111), (95%CI (3.2-13.7%)] cART. However, no significant difference was observed in the prevalence of diabetes mellitus and insulin resistance between the two regimens. Age >= 46 years old and specific type of ARV contained in cART, such as TDF, were independent predictors of GMD in both groups. Whereas the male gender and BMI category were predictors of GMDs among EFV-based cART group, AZT- and ABC- containing regimens and triglyceride levels were predictors in the ATV/r-based group. Conclusions GMDs were highly prevalent among adults on EFV- than ATV/r-based cARTs. Age >= 46 years and TDF-containing cARTs are common predictors in both regimens. Close monitoring for impaired fasting glucose during long-term EFV-based cART is recommended for early diagnosis of type-2 diabetes and management.	[Tadesse, Wondmagegn Tamiru; Shibeshi, Workineh; Engidawork, Ephrem] Addis Ababa Univ, Coll Hlth Sci, Sch Pharm, Dept Pharmacol & Clin Pharmacol, Addis Ababa, Ethiopia; [Adankie, Birhanemeskel T.] St Paul Specialized Hosp Millennium Med Coll, Dept Med Microbiol, Sch Med, Addis Ababa, Ethiopia; [Amogne, Wondwossen] Addis Ababa Univ, Coll Hlth Sci, Sch Med, Dept Internal Med, Addis Ababa, Ethiopia; [Aklillu, Eleni] Karolinska Inst, Dept Lab Med, Div Clin Pharmacol, Stockholm, Sweden	Addis Ababa University; Addis Ababa University; Karolinska Institutet	Engidawork, E (corresponding author), Addis Ababa Univ, Coll Hlth Sci, Sch Pharm, Dept Pharmacol & Clin Pharmacol, Addis Ababa, Ethiopia.	ephrem.engidawork@aau.edu.et	Engidawork, Ephrem/K-7551-2019	Engidawork, Ephrem/0000-0002-9931-6421; Tadesse, Wondmagegn Tamiru/0000-0001-6143-0387; Aklillu, Eleni/0000-0002-9788-0790				Abebe SM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011175; Animaw W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187670; Araujo S, 2014, EUR J ENDOCRINOL, V171, P545, DOI 10.1530/EJE-14-0337; Belete AM, 2021, HIV AIDS-RES PALLIAT, V13, P217, DOI 10.2147/HIV.S296170; Borel AL, 2015, INT J OBESITY, V39, P495, DOI 10.1038/ijo.2014.163; Brown TT, 2005, ARCH INTERN MED, V165, P1179, DOI 10.1001/archinte.165.10.1179; Buell KG, 2016, AIDS CARE, V28, P242, DOI 10.1080/09540121.2015.1074653; Charan Jaykaran, 2013, Indian J Psychol Med, V35, P121, DOI 10.4103/0253-7176.116232; Chimbetete C, 2017, TROP MED INT HEALTH, V22, P839, DOI 10.1111/tmi.12896; d'Ettorre G, 2016, INT J STD AIDS, V27, P638, DOI 10.1177/0956462415590724; Da W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203032; Dave JA, 2011, JAIDS-J ACQ IMM DEF, V57, P284, DOI 10.1097/QAI.0b013e318221863f; Dwyer-Lindgren L, 2019, NATURE, V570, P189, DOI 10.1038/s41586-019-1200-9; Eggleton J. S., 2022, STATPEARLS; Fiseha T, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4402-1; Floridia M, 2008, PHARMACOL RES, V58, P173, DOI 10.1016/j.phrs.2008.07.007; Gebreyesus HA, 2015, INT J PHARM SCI RES, V6, P440; Gebrie A, 2020, DIABETOL METAB SYNDR, V12, DOI 10.1186/s13098-020-00527-1; Giordano TP, 2004, HIV CLIN TRIALS, V5, P74, DOI 10.1310/JFXH-G3X2-EYM6-D6UG; Guillen MA, 2015, DIABETOL METAB SYNDR, V7, DOI 10.1186/s13098-015-0046-z; Hilawe EH, 2013, B WORLD HEALTH ORGAN, V91, P671, DOI 10.2471/BLT.12.113415; IDF, 2020, IDF AFR MEMB ETH; Jamil AS, 2015, REPROD HEALTH, V12, DOI 10.1186/1742-4755-12-7; Jeremiah K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230723; Karamchand S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002844; Kautzky-Willer A, 2016, ENDOCR REV, V37, P278, DOI 10.1210/er.2015-1137; Kharsany Ayesha B M, 2016, Open AIDS J, V10, P34, DOI 10.2174/1874613601610010034; Lagathu C, 2019, EXPERT OPIN DRUG SAF, V18, P829, DOI 10.1080/14740338.2019.1644317; Ledergerber B, 2007, CLIN INFECT DIS, V45, P111, DOI 10.1086/518619; Levitt NS, 2016, DIABETES RES CLIN PR, V119, P41, DOI 10.1016/j.diabres.2016.03.012; Maganga E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134410; Ministry of Health of Ethiopia,WHO | Regional Office for Africa, 2018, NAT CONS GUID COMPR; Mokdad AH, 2018, INT J PUBLIC HEALTH, V63, P123, DOI 10.1007/s00038-017-1023-0; Muniyappa R., 2000, ASSESSING INSULIN SE; Nguyen QM, 2010, ARCH PEDIAT ADOL MED, V164, P124, DOI 10.1001/archpediatrics.2009.268; Njuguna B, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/6916497; Noor MA, 2006, AIDS, V20, P1813, DOI 10.1097/01.aids.0000244200.11006.55; Organization WH, 2011, WAIST CIRCUMFERENCE; Santiprabhob J, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7481597; Shankalala P, 2017, J DIABETES METAB DIS, V16, DOI 10.1186/s40200-017-0310-x; Sinxadi PZ, 2016, MEDICINE, V95, P1, DOI 10.1097/MD.0000000000002385; Tadesse BT, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040430; Tadesse WT, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-32; Thet D, 2020, HIV AIDS-RES PALLIAT, V12, P507, DOI 10.2147/HIV.S275314; WHO, IND MET REG DET; World Health Organization & International Diabetes Federation, 2006, DEF DIAGN DIAB MELL; World Health Organization (WHO), 2016, WHO DIAB COUNTR PROF; Yifter H., 2020, EMJ, V58	48	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2022	17	1							e0262604	10.1371/journal.pone.0262604	http://dx.doi.org/10.1371/journal.pone.0262604			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0S7XH	35045105	gold, Green Published			2023-01-03	WOS:000786483800043
J	Shagaro, SS; Gebabo, TF; Mulugeta, BT				Shagaro, Sewunet Sako; Gebabo, Teshale Fikadu; Mulugeta, Be'emnet Tekabe			Four out of ten married women utilized modern contraceptive method in Ethiopia: A Multilevel analysis of the 2019 Ethiopia mini demographic and health survey	PLOS ONE			English	Article								Background Modern contraceptive method is a product or medical procedure that interferes with reproduction from acts of sexual intercourse. Globally in 2019, 44% of women of reproductive age were using a modern method of contraception but it was 29% in sub-Saharan Africa. Therefore, the main aim of this analysis was to assess the prevalence of modern contraceptive utilization and associated factors among married women in Ethiopia. Method The current study used the 2019 Ethiopia mini demographic and health survey dataset. Both descriptive and multilevel mixed-effect logistic regression analysis were done using STATA version 14. A p-value of less than 0.05 and an adjusted odds ratio with a 95% confidence interval were used to report statistically significant factors with modern contraceptive utilization. Result The overall modern contraceptive utilization among married women in Ethiopia was 38.7% (95% CI: 37.3% to 40.0%). Among the modern contraceptive methods, injectables were the most widely utilized modern contraceptive method (22.82%) followed by implants (9.65%) and pills (2.71%). Maternal age, educational level, wealth index, number of living children, number of births in the last three years, number of under 5 children in the household, religion, and geographic region were independent predictors of modern contraceptive utilization. Conclusion In the current study only four out of ten married non-pregnant women of reproductive age utilized modern contraceptive methods. Furthermore, the study has identified both individual and community-level factors that can affect the utilization of modern contraceptive methods by married women in the country. Therefore, concerned bodies need to improve access to reproductive health services, empower women through community-based approaches, and minimize region wise discrepancy to optimize the utilization.	[Shagaro, Sewunet Sako; Mulugeta, Be'emnet Tekabe] Arba Minch Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Hlth Informat, Arba Minch, Ethiopia; [Gebabo, Teshale Fikadu] Arba Minch Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Publ Hlth, Arba Minch, Ethiopia	Arba Minch University; Arba Minch University	Shagaro, SS (corresponding author), Arba Minch Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Hlth Informat, Arba Minch, Ethiopia.	zesew1lalem@gmail.com	Shagaro, Sewunet Sako/AFS-0391-2022	Shagaro, Sewunet/0000-0003-0126-0165; Fikadu, Teshale/0000-0002-4177-9159				Abate MG, 2019, ARCH PUBLIC HEALTH, V77, DOI 10.1186/s13690-019-0371-z; Adane AA, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8010327; Akinyemi JO., 2021, REPROD HLTH INTERNET, V18, P1, DOI [10.1186/s12978-020-01058-8, DOI 10.1186/S12978-020-01058-8]; Alemayehu GA, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0611-3; Alemayehu M, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0321-7; [Anonymous], 2016, REP INT AG EXP GROUP; [Anonymous], 2015, EPIDEMIOL OPEN ACCES, V05; Apanga PA, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.10.5301; Aviisah PA, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0634-9; Belda SS, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2115-5; Beson P, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0649-2; Central Statistical Agency (CSA) (Ethiopia) and ICF, ETH DEM HLTH SURV 20; Croft TN, 2018, GUIDE DHS STAT; Debebe S, 2017, INT J REPROD BIOMED, V15, P367; Deloitte, 2018, EDITION WHATS NEW TH; Dey A.K., 2019, INT J COMMUNITY MED, V6, P738, DOI [10.18203/2394-6040.ijcmph20190200, DOI 10.18203/2394-6040.IJCMPH20190200]; Edition T., 2020, FEDERAL DEMOCRATIC R, VThird, P1; Endriyas M, 2017, CONTRACEP REPROD MED, V2, DOI 10.1186/s40834-016-0036-z; Ethiopian Public Health Institute (EPHI) and ICF [Ethiopia], 2019, ETH MIN HLTH SURV 20; Fertility World. and Planning Family, 2020, 2020 HIGHLIGHTS WORL; FMOH Performance report, 2012, FED MIN HLTH ETH PER, P487; Gebre MN, 2020, BMC WOMENS HEALTH, V20, DOI 10.1186/s12905-020-00923-9; Geremew Alehegn Bishaw, 2018, Womens Midlife Health, V4, P13, DOI 10.1186/s40695-018-0044-z; Godfrey EM, 2011, BMC WOMENS HEALTH, V11, DOI 10.1186/1472-6874-11-5; Haq Iqramul, 2017, Med Sci (Basel), V5, DOI 10.3390/medsci5040031; Hubacher D, 2015, CONTRACEPTION, V92, P420, DOI 10.1016/j.contraception.2015.08.008; Johnson OE, 2017, AFR J REPROD HEALTH, V21, P89, DOI 10.29063/ajrh2017/v21i3.8; Kassa GM, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0640-2; Kibria GMA., 2016, J MOL STUD MED RES, V2, P70, DOI [10.18801/jmsmr.020116.09, DOI 10.18801/JMSMR.020116.09]; Melash Belachew Asresie., 2020, HINDAWI ADV PUBLIC H; Mohammed A, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-13; Njotang PN., 2017, BMC RES NOTES, V10, P4, DOI [10.1186/s13104-016-2343-5, DOI 10.1186/S13104-016-2343-5]; O'Regan A, 2017, CONTRACEP REPROD MED, V2, DOI 10.1186/s40834-017-0053-6; Oumer M, 2020, OPEN ACCESS J CONTR, V11, P53, DOI 10.2147/OAJC.S252970; Region M, 2020, HLTH GENDER, P4; Samuel Andualem., 2017, EC GYNAECOL, V6.2, P36; Schaapveld A, 2018, REPROD HEALTH, V2; Sheet F, 2018, CONTRACEPTIVE USE E, P1; TB Kassa GDZB., 2015, N W ETHIOP, V2, P507; Tekelab T, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0208-z; Tessema ZT, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247992; Tsegaye AT, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0649-6; World Health Organization, 2014, AD PREGN FACT SHEET; Zegeye B, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10252-7	44	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2022	17	1							e0262431	10.1371/journal.pone.0262431	http://dx.doi.org/10.1371/journal.pone.0262431			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2F3FM	35030213	gold, Green Published			2023-01-03	WOS:000812798500045
J	Dziwenka, M; Dolan, L; Mitchell, J				Dziwenka, Margitta; Dolan, Laurie; Mitchell, Jason			Toxicological safety of VOHO Hemp Oil; a supercritical fluid extract from the aerial parts of hemp	PLOS ONE			English	Article								VOHO Hemp Oil (Verdant Nature LLC (in collaboration with HempFusion)) is an extract of the aerial parts of hemp (Cannabis sativa L) manufactured using a supercritical CO2 extraction process. The results of four safety studies are reported here including a bacterial reverse mutation assay, an in vivo mammalian micronucleus study, a maximum tolerated dose study in rats and a 90-day repeat dose subchronic toxicity study in rats. VOHO Hemp oil can contain up to 30% phytocannabinoids and less than 0.2% is tetrahydrocannabinol (THC). VOHO Hemp Oil was found to be non-mutagenic in the bacterial reverse mutation assay and was negative for inducing micronuclei in the rat bone marrow micronucleus assay. The maximum tolerated dose in male and female Wistar rats was 2250 mg/kg bw/day. A 90-day repeat dose study was conducted in male and female Wistar rats according to OECD Guideline 408 and included a 21-day recovery period. The doses used in the study were 0, 25, 90 and 324 mg/kg bw per day in the main study, and in the recovery phase a control and 324 mg/kg bw/day group were included. One mortality was reported during the study, a high dose female, and test substance-related adverse clinical signs were reported in the high dose group. Other test substance-related changes noted in the high dose group included changes in body weights, activated partial thromboplastin time (APTT) values, and in absolute and relative organ weights. Based on the results of the study, the no observed adverse effect level (NOAEL) for VOHO Hemp Oil was determined to be 90 mg/kg bw/day in both male and female Wistar rats.	[Dziwenka, Margitta; Dolan, Laurie] GRAS Associates LLC, North Bethesda, MD 20852 USA; [Mitchell, Jason] HempFusion, Denver, CO USA		Dziwenka, M (corresponding author), GRAS Associates LLC, North Bethesda, MD 20852 USA.	dziwenka@gras-associates.com		Dziwenka, Margitta/0000-0003-4392-3473	Verdant Nature LLC; GRAS Associates LLC; Hempfusion	Verdant Nature LLC; GRAS Associates LLC; Hempfusion	Commercial companies: Verdant Nature LLC (funded study; https://verdantoasis.com/) and GRAS Associates LLC (funded 2 authors -MD and LD; http://www.nutrasource.ca/about/nutrasourcecompanies/) and Hempfusion (funded 1 author JM; https://www.hempfusion.com/).All named companies played a role in the decision to publish and Hempfusion and GRAS Associates were involved in the preparation of the manuscript.	Andre CM, 2016, FRONT PLANT SCI, V7, DOI [10.3389/fpls.2016.00463, 10.3389/fpls.2016.00019]; [Anonymous], 2018, TEST 408 REP DOS 90; [Anonymous], 2009, ICH GUID M3 R2 NONCL; [Anonymous], 2001, GUIDANCE DOCUMENT AC; Bailey SA, 2004, TOXICOL PATHOL, V32, P448, DOI 10.1080/01926230490465874; Bonini SA, 2018, J ETHNOPHARMACOL, V227, P300, DOI 10.1016/j.jep.2018.09.004; Brenneisen Rudolf, 2007, P17, DOI 10.1007/978-1-59259-947-9_2; Carrier EJ, 2006, P NATL ACAD SCI USA, V103, P7895, DOI 10.1073/pnas.0511232103; Council NR, 2011, GUIDE CARE USE LAB A, VEighth; Dziwenka M, 2020, TOXICOL REP, V7, P376, DOI 10.1016/j.toxrep.2020.02.014; EU, 2008, COUNC REG EC 440 200; FDA, 2007, REDB 2000 GUID IND T; FDA, 2018, AGN RESP LETT GRAS N; Lewis RW, 2002, TOXICOL PATHOL, V30, P66, DOI 10.1080/01926230252824725; Lopez HL, 2020, J DIET SUPPL, V17, P561, DOI 10.1080/19390211.2020.1765941; Marx TK, 2018, J TOXICOL-US, V2018, DOI 10.1155/2018/8143582; OECD, 2016, TEST 474 MAMM ER MIC; OECD, 2020, TEST 471 BACT REV MU; OECD, 1997, OECD SER PRINC GOOD; Redbook, 2000, GUID TOX STUD; WHO. WHO Expert Committee on Drug Dependence Pre-Review, 2018, EXTR TINCT CANN	21	0	0	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2021	16	12							e0261900	10.1371/journal.pone.0261900	http://dx.doi.org/10.1371/journal.pone.0261900			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ9AO	34972167	gold, Green Published			2023-01-03	WOS:000773555700067
J	Meng, WS; Zhao, CY; Gao, YH				Meng, Wenshu; Zhao, Chenyang; Gao, Youhe			Comparison of urine proteome among rat models by intraperitoneal injection with single bacteria and co-injection with two bacteria	PLOS ONE			English	Article							STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; INFECTIONS; BIOMARKER; LPS	Purpose To explore and compare urine proteome changes among rat models by intraperitoneal injection with single bacteria and co-injection with two bacteria. Method Escherichia coli and Staphylococcus aureus are two common human pathogens. Three rat models were established: (i) the intraperitoneal co-injection of E. coli and S. aureus model (ES model), (ii) intraperitoneal injection of E. coli model (E model), and (iii) intraperitoneal injection of S. aureus model (S model). Urinary proteomes on days 0, 1 and 2 of the three models were analyzed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Results A total of 111, 34 and 94 differential proteins were identified in the ES model, E model and S model, respectively. Among them, some differential proteins were reported to be associated with bacterial infection. Approximately 47% differential proteins in the E model overlapped with ES model, and 37% differential proteins in the S model overlapped with ES model. Compared with the E model and S model, a total of 71 unique differential proteins were identified in the ES model. Conclusion Our results indicated that (1) the urine proteome could distinguish different bacterial intraperitoneal injections models and (2) the effects of co-injection with two bacteria on the urine proteome were not simple superposition of single injection.	[Meng, Wenshu; Zhao, Chenyang; Gao, Youhe] Beijing Normal Univ, Coll Life Sci, Gene Engn Drug & Biotechnol Beijing Key Lab, Beijing, Peoples R China	Beijing Normal University	Gao, YH (corresponding author), Beijing Normal Univ, Coll Life Sci, Gene Engn Drug & Biotechnol Beijing Key Lab, Beijing, Peoples R China.	gaoyouhe@bnu.edu.cn	Gao, Youhe/F-9245-2014	Gao, Youhe/0000-0001-7159-2558	National Key Research and Development Program of China [2018YFC0910202, 2016YFC1306300]; Fundamental Research Funds for the Central Universities [2020KJZX002]; Beijing Natural Science Foundation [7172076]; Beijing cooperative construction project [110651103]; Beijing Normal University [11100704]; Peking Union Medical College Hospital [20162.27]	National Key Research and Development Program of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Beijing cooperative construction project; Beijing Normal University; Peking Union Medical College Hospital	This work was supported by the National Key Research and Development Program of China (2018YFC0910202, 2016YFC1306300); the Fundamental Research Funds for the Central Universities (2020KJZX002); the Beijing Natural Science Foundation (7172076); the Beijing cooperative construction project (110651103); the Beijing Normal University (11100704); and the Peking Union Medical College Hospital (20162.27). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allocati N, 2013, INT J ENV RES PUB HE, V10, P6235, DOI 10.3390/ijerph10126235; Becker P, 2001, APPL ENVIRON MICROB, V67, P2958, DOI 10.1128/AEM.67.7.2958-2965.2001; Brosseau C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02316; Cui LL, 2021, PARASITE VECTOR, V14, DOI 10.1186/s13071-021-04713-6; Curtin F, 1998, BIOL PSYCHIAT, V44, P775, DOI 10.1016/S0006-3223(98)00043-2; Gao YH, 2013, SCI CHINA LIFE SCI, V56, P1145, DOI 10.1007/s11427-013-4574-1; Armitage EG, 2015, ELECTROPHORESIS, V36, P3050, DOI 10.1002/elps.201500352; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jia LL, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00338; Jung E, 1998, AM J MED SCI, V315, P307, DOI 10.1097/00000441-199805000-00004; Langford BJ, 2020, CLIN MICROBIOL INFEC, V26, P1622, DOI 10.1016/j.cmi.2020.07.016; Le Roy D, 1999, J IMMUNOL, V162, P7454; Li RL, 2016, CLINICS, V71, P271, DOI 10.6061/clinics/2016(05)05; Loimaranta V, 2018, J LEUKOCYTE BIOL, V104, P777, DOI 10.1002/JLB.3VMR0118-036R; Ni Yanying, 2017, Sheng Wu Gong Cheng Xue Bao, V33, P1145, DOI 10.13345/j.cjb.170019; Prima V, 2011, INT IMMUNOPHARMACOL, V11, P1180, DOI 10.1016/j.intimp.2011.03.016; Pulido D, 2012, ANTIMICROB AGENTS CH, V56, P2378, DOI 10.1128/AAC.06107-11; Roine I, 2014, PEDIATR INFECT DIS J, V33, P675, DOI 10.1097/INF.0000000000000249; Soliman MM, 2015, MOL MED REP, V12, P8306, DOI 10.3892/mmr.2015.4486; Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14; Wang CQ, 2012, CLIN BIOCHEM, V45, P215, DOI 10.1016/j.clinbiochem.2011.11.009; Wang HB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.694928; Wiegers HMG, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4468-3; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]	24	1	1	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2021	16	12							e0261488	10.1371/journal.pone.0261488	http://dx.doi.org/10.1371/journal.pone.0261488			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ9AO	34972134	Green Published, gold			2023-01-03	WOS:000773555700038
J	Fabricius, PK; Andersen, O; Steffensen, KD; Kirk, JW				Fabricius, Pia Keinicke; Andersen, Ove; Steffensen, Karina Dahl; Kirk, Jeanette Wassar			The challenge of involving old patients with polypharmacy in their medication during hospitalization in a medical emergency department: An ethnographic study	PLOS ONE			English	Article							SHARED DECISION-MAKING; QUALITATIVE RESEARCH; BOUNDARY OBJECTS; STANDARDS	Background More than 70% of patients admitted to emergency departments (EDs) in Denmark are older patients with multimorbidity and polypharmacy vulnerable to adverse events and poor outcomes. Research suggests that patient involvement and shared decision-making (SDM) could optimize the treatment of older patients with polypharmacy. The patients become more aware of potential outcomes and, therefore, often tend to choose less medication. However, implementing SDM in clinical practice is challenging if it does not fit into existing workflows and healthcare systems. Aim The aim was to explore the determinants of patient involvement in decisions made in the ED about the patient's medication. Methods The design was a qualitative ethnographic study. We observed forty-eight multidisciplinary healthcare professionals in two medical EDs focusing on medication processes and patient involvement in medication. Based on field notes, we developed a semi-structured interview guide. We conducted 20 semi-structured interviews with healthcare professionals to elaborate on the findings. Data were analyzed with thematic analyses. Findings We found five themes (determinants) which affected patient involvement in decisions about medicine in the ED: 1) blurred roles among multidisciplinary healthcare professionals, 2) older patients with polypharmacy increase complexity, 3) time pressure, 4) faulty IT-systems, and 5) the medicine list as a missed enabler of patient involvement. Conclusion There are several barriers to patient involvement in decisions about medicine in the ED and some facilitators. A tailored medication conversation guide based on the SDM methodology combined with the patient's printed medicine list and well-functioning IT-systems can function as a boundary object, ensuring the treatment is optimized and aligned with the patient's preferences and goals.	[Fabricius, Pia Keinicke; Andersen, Ove; Kirk, Jeanette Wassar] Copenhagen Univ Hosp, Dept Clin Res, Copenhagen, Denmark; [Fabricius, Pia Keinicke; Andersen, Ove] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark; [Andersen, Ove] Copenhagen Univ Hosp Hvidovre, Emergency Dept, Hvidovre, Denmark; [Steffensen, Karina Dahl] Univ Hosp Southern Denmark, Lillebaelt Hosp, Dept Oncol, Vejle, Denmark; [Steffensen, Karina Dahl] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark; [Steffensen, Karina Dahl] Univ Hosp Southern Denmark, Lillebaelt Hosp, Ctr Shared Decis Making, Vejle, Denmark; [Kirk, Jeanette Wassar] Aarhus Univ, Dept Publ Hlth, Nursing, Aarhus C, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Southern Denmark; Lillebaelt Hospital; University of Southern Denmark; University of Southern Denmark; Lillebaelt Hospital; Aarhus University	Fabricius, PK (corresponding author), Copenhagen Univ Hosp, Dept Clin Res, Copenhagen, Denmark.; Fabricius, PK (corresponding author), Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.	pia.keinicke.fabricius@regionh.dk	Kirk, Jeanette/R-8671-2017; Andersen, Ove/D-3091-2019	Andersen, Ove/0000-0002-2274-548X; Dahl Steffensen, Karina/0000-0002-9217-3907; Fabricius, Pia/0000-0001-8199-9730; Wassar Kirk, Jeanette/0000-0002-2680-0917				Aarts J, 2013, STUD HEALTH TECHNOL, V183, P327, DOI 10.3233/978-1-61499-203-5-327; [Anonymous], Person-centred care made simple.; Ayalew Mohammed Biset, 2019, Bull Emerg Trauma, V7, P339, DOI 10.29252/beat-070401; Baier N, 2019, HEALTH POLICY, V123, P1, DOI 10.1016/j.healthpol.2018.11.001; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Barry MJ, 2012, NEW ENGL J MED, V366, P780, DOI 10.1056/NEJMp1109283; Belcher VN, 2006, J GEN INTERN MED, V21, P298, DOI 10.1111/j.1525-1497.2006.00329.x; Berg Olsen J-K, 2001, NORSK FILOSOFISK TID, P36; Braun V, 2021, QUAL RES PSYCHOL, V18, P328, DOI 10.1080/14780887.2020.1769238; Coulter A, 2011, ENGAGING PATIENTS HE; Cribb PA., 2011, INVOLVEMENT SHARED D, P60; Durand MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094670; Ecks S, 2021, CULT MED PSYCHIAT, V45, P507, DOI 10.1007/s11013-020-09699-x; European Association of Pharmacy Technicians, 2017, PHARM TECHN EUR; Flottorp SA, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-35; Fox NJ, 2011, SOCIOLOGY, V45, P70, DOI 10.1177/0038038510387196; Frolich A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214183; Frosch DL, 2016, SHARED DECISION MAKI; Garfield S, 2020, BMJ QUAL SAF, V29, P764, DOI 10.1136/bmjqs-2019-010194; Gravel K, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-16; Green J., 2004, QUALITATIVE METHODS; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Jansen J, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2893; Jensen LD, 2014, INT J CLIN PHARM-NET, V36, P570, DOI 10.1007/s11096-014-9940-y; Joseph-Williams N, 2021, MED DECIS MAKING, V41, P907, DOI 10.1177/0272989X20978208; Justesen L, 2010, QUALITATIVE METHODS, V1; Kirk JW., 2020, HDB IMPLEMENTATION S, P480, DOI [10.4337/9781788975995.00032, DOI 10.4337/9781788975995.00032]; Kvale S, 2009, INTERVIEW INTRODUKTI, V2nd; Legare F, 2014, PATIENT EDUC COUNS, V96, P281, DOI 10.1016/j.pec.2014.06.014; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; Mc Namara KP, 2017, AGE AGEING, V46, P291, DOI 10.1093/ageing/afw200; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; Olling K., 2021, CANC CARE RES ONLINE, V1, pe0007, DOI [10.1097/CR9. 0000000000000007, DOI 10.1097/CR9.0000000000000007]; Probst MA, 2017, ANN EMERG MED, V70, P688, DOI 10.1016/j.annemergmed.2017.03.063; Reay V, WHY WE WONT HAVE PAP; Schiotz ML, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4314-8; Scholl I, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0731-z; Sinnott C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003610; Spradley J.P., 2016, PARTICIPANT OBSERVAT; STAR SL, 1989, SOC STUD SCI, V19, P387, DOI 10.1177/030631289019003001; Steffensen KD, 2017, Z EVIDENZ FORTBILD Q, V123-124, P36, DOI 10.1016/j.zefq.2017.05.005; The Danish health Data Authority, SHAR MED CARD DAN FA; The World Medical Association, 2018, WMA THE WORLD MED AS; Tjornhoj-Thomsen T., 2003, WORLD PRIMER ANTHROP, V1; van der Geest S, 2004, SOC SCI MED, V59, P1995, DOI 10.1016/j.socscimed.2004.03.004; World Health Organisation, 2019, MED SAF POL; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053	49	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2021	16	12							e0261525	10.1371/journal.pone.0261525	http://dx.doi.org/10.1371/journal.pone.0261525			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	0C7TD	34968394	Green Published, gold			2023-01-03	WOS:000775510400011
J	Chaturvedi, S; Vasen, G; Pablo, M; Chen, XY; Beutler, N; Kumar, A; Tanner, E; Illouz, S; Rahgoshay, D; Burnett, J; Holguin, L; Chen, PY; Ndjamen, B; Ott, M; Rodick, R; Rogers, T; Smith, DM; Weinberger, LS				Chaturvedi, Sonali; Vasen, Gustavo; Pablo, Michael; Chen, Xinyue; Beutler, Nathan; Kumar, Arjun; Tanner, Elizabeth; Illouz, Sylvia; Rahgoshay, Donna; Burnett, John; Holguin, Leo; Chen, Pei-Yi; Ndjamen, Blaise; Ott, Melanie; Rodick, Robert; Rogers, Thomas; Smith, Davey M.; Weinberger, Leor S.			Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance	CELL			English	Article							VIRUS; CORONAVIRUS; INFLUENZA; IMMUNITY; VACCINE; PATHOGENESIS; DYNAMICS; DESIGN; RNAS; LIVE	Viral-deletion mutants that conditionally replicate and inhibit the wild-type virus (i.e., defective interfering particles, DIPs) have long been proposed as single-administration interventions with high genetic barriers to resistance. However, theories predict that robust, therapeutic DIPs (i.e., therapeutic interfering particles, TIPs) must conditionally spread between cells with R-0 >1. Here, we report engineering of TIPs that conditionally replicate with SARS-CoV-2, exhibit R-0 >1, and inhibit viral replication 10- to 100-fold. Inhibition occurs via competition for viral replication machinery, and a single administration of TIP RNA inhibits SARS-CoV-2 sustainably in continuous cultures. Strikingly, TIPs maintain efficacy against neutralization-resistant variants (e.g., B.1.351). In hamsters, both prophylactic and therapeutic intranasal administration of lipid-nanoparticle TIPs durably suppressed SARS-CoV-2 by 100-fold in the lungs, reduced pro-inflammatory cytokine expression, and prevented severe pulmonary edema. These data provide proof of concept for a class of single-administration antivirals that may circumvent current requirements to continually update medical countermeasures against new variants.	[Chaturvedi, Sonali; Vasen, Gustavo; Pablo, Michael; Chen, Xinyue; Kumar, Arjun; Tanner, Elizabeth; Weinberger, Leor S.] Gladstone Inst, Gladstone UCSF Ctr Cell Circuitry, San Francisco, CA 94158 USA; [Chaturvedi, Sonali; Vasen, Gustavo; Pablo, Michael; Chen, Xinyue; Kumar, Arjun; Tanner, Elizabeth; Chen, Pei-Yi; Ott, Melanie; Weinberger, Leor S.] Gladstone Inst, Gladstone Inst Virol, San Francisco, CA 94158 USA; [Ndjamen, Blaise] Gladstone Inst, Histol & Light Microscopy Core, San Francisco, CA 94158 USA; [Weinberger, Leor S.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA; [Weinberger, Leor S.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; [Illouz, Sylvia; Rahgoshay, Donna; Rodick, Robert] VxBiosciences Inc, Berkeley, CA 94707 USA; [Beutler, Nathan; Rogers, Thomas; Smith, Davey M.] Univ Calif San Diego, Dept Med, San Diego, CA 92121 USA; [Burnett, John; Holguin, Leo] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Diego; City of Hope; Beckman Research Institute of City of Hope	Weinberger, LS (corresponding author), Gladstone Inst, Gladstone UCSF Ctr Cell Circuitry, San Francisco, CA 94158 USA.; Weinberger, LS (corresponding author), Gladstone Inst, Gladstone Inst Virol, San Francisco, CA 94158 USA.; Weinberger, LS (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA.; Weinberger, LS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA.	sonali.chaturvedi@gladstone.ucsf.edu; leor.weinberger@gladstone.ucsf.edu	chen, xinyue/HHR-9308-2022	Pablo, Michael/0000-0001-9738-8109; Burnett, John/0000-0002-8817-6064; Chaturvedi, Sonali/0000-0002-9175-8110; Vasen, Gustavo/0000-0002-5968-2312; HOLGUIN, LEO/0000-0002-8462-187X; Chen, Xinyue/0000-0001-8288-7685; Beutler, Nathan/0000-0003-3240-9524; Kumar, Arjun/0000-0002-4354-5612; Tanner, Elizabeth/0000-0001-9445-6620	NIH [P30 AI027763, S10 RR028962]; James B. Pendleton Trust; Gladstone Genomics Core; US Army Medical Infectious Disease Research Program [MTEC 2020-492]; NIH NIDA [DP1DA051144-01S1]; Histology Core	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James B. Pendleton Trust; Gladstone Genomics Core; US Army Medical Infectious Disease Research Program; NIH NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Histology Core	We thank the late Dr. John Holland for many wonderful insightful discussions, J. Gimlett and S. Kumar for initiating the DARPA INTERCEPT program, which drove significant expansion of the TIP initiative, and the US Army Medical In-fectious Diseases Research Program (MIDRP) for invaluable support without which this work would not have been possible. We thank D. Finzi (NIAID) for bridge funding enabling this work. We thank K. Claiborn for editing; S. Larkin for administrative support; L. Minall, F.N.N. Pitchai, T. Tabata, L. Buie, S. Ab-dullah, and J. Doudna for technical guidance; and the Gladstone-UCSF CFAR flow-cytometry core, funded by NIH grants P30 AI027763 and S10 RR028962 and the James B. Pendleton Trust, as well as the Gladstone Genomics and Histology Cores, and D. Bulkley (UCSF EM Core) . This work was sup-ported by Pamela and Edward Taft (to L.S.W.) , US Army Medical Infectious Disease Research Program (MTEC 2020-492) (to L.S.W.) , and NIH NIDA DP1DA051144-01S1 (to L.S.W.) .	Aaskov J, 2006, SCIENCE, V311, P236, DOI 10.1126/science.1115030; Abdelnabi R, 2021, EBIOMEDICINE, V72, DOI 10.1016/j.ebiom.2021.103595; Abdelnabi R, 2021, J INFECT DIS, V224, P749, DOI 10.1093/infdis/jiab361; Akpinar F, 2016, J VIROL, V90, P1599, DOI 10.1128/JVI.02190-15; BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988; Batra, SCIENCE, V370; Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Burt A, 2003, P ROY SOC B-BIOL SCI, V270, P921, DOI 10.1098/rspb.2002.2319; Cele S, 2021, NATURE, V593, P142, DOI 10.1038/s41586-021-03471-w; CHAN AP, 2020, BIORXIV, V2006; Chen RE, 2021, NATURE, V596, P103, DOI 10.1038/s41586-021-03720-y; Chen SC, 2010, VIROLOGY, V401, P29, DOI 10.1016/j.virol.2010.02.007; CHRISTENSON B, 1994, VACCINE, V12, P129, DOI 10.1016/0264-410X(94)90049-3; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cotter G, 2001, CURR OPIN CARDIOL, V16, P159, DOI 10.1097/00001573-200105000-00001; Cox RJ, 2004, SCAND J IMMUNOL, V59, P1, DOI 10.1111/j.0300-9475.2004.01382.x; Daugherty MD, 2012, ANNU REV GENET, V46, P677, DOI 10.1146/annurev-genet-110711-155522; Dm K., 1990, VIROLOGY, P77; Fischer A.H., 2008, COLD SPRING HARBOR P, V2008, DOI [10.1101/pdb.prot073411, DOI 10.1101/PDB.PROT073411, DOI 10.1101/PDB.PROT4986, 10.1101/pdb.prot4986]; Goldberg DE, 2012, CELL, V148, P1271, DOI 10.1016/j.cell.2012.02.021; Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386; Goyal A, 2021, ELIFE, V10, DOI 10.7554/eLife.63537; Graham, 2001, 427948 BIORXIV, V2021; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Han YL, 2021, NATURE, V589, P270, DOI 10.1038/s41586-020-2901-9; Hayden FG, 2004, J INFECT DIS, V189, P440, DOI 10.1086/381128; HORSTMANN DM, 1985, REV INFECT DIS, V7, pS80; Hurt C ., 2021, TOP ANTIVIR MED, V29, P33; Iserman C, 2020, MOL CELL, V80, P1078, DOI 10.1016/j.molcel.2020.11.041; Johnson BA, 2021, NATURE, V591, P293, DOI 10.1038/s41586-021-03237-4; JOHNSON PR, 1986, J INFECT DIS, V154, P121, DOI 10.1093/infdis/154.1.121; Jones TC, 2021, SCIENCE, V373, P180, DOI 10.1126/science.abi5273; Kaur N, 2021, INFECT GENET EVOL, V89, DOI 10.1016/j.meegid.2020.104490; Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011; Kim KS, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001128; Kreye J, 2020, CELL, V183, P1058, DOI 10.1016/j.cell.2020.09.049; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; MAKINO S, 1990, J VIROL, V64, P6045, DOI 10.1128/JVI.64.12.6045-6053.1990; Manly B.F.J., 2006, RANDOMIZATION BOOTST, VThird, DOI DOI 10.1201/9781315273075; Martinez DR, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109450; Metzger VT, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002015; Meylan S, 2018, CELL, V172, P1228, DOI 10.1016/j.cell.2018.01.037; Nelson J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6893; Neuhauser M, 2004, PSYCHOL REP, V94, P189; Notton T, 2021, MBIO, V12, DOI 10.1128/mBio.01724-20; Patalon, 2021, COMP SARS COV 2 NATU, DOI [10.1101/2021., DOI 10.1101/2021]; Perelson, 2020, 20201772 MEDRXIV, V2009; Perelson AS, 1997, AIDS, V11, pS17; Perelson AS, 2002, NAT REV IMMUNOL, V2, P28, DOI 10.1038/nri700; Petrova VN, 2018, NAT REV MICROBIOL, V16, P60, DOI [10.1038/nrmicro.2017.146, 10.1038/nrmicro.2017.118]; Rangan R, 2020, RNA, V26, P937, DOI 10.1261/rna.076141.120; Rast LI, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004799; Rogers Thomas F, 2020, bioRxiv, DOI 10.1101/2020.05.11.088674; Rosenke K, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22580-8; Rouzine IM, 2013, J VIROL, V87, P2081, DOI 10.1128/JVI.02741-12; Sachs N, 2019, EMBO J, V38, DOI 10.15252/embj.2018100300; Sahoo Debashis, 2021, bioRxiv, DOI 10.1101/2020.09.21.305698; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SCHNIPPER LE, 1980, P NATL ACAD SCI-BIOL, V77, P2270, DOI 10.1073/pnas.77.4.2270; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; Tapia F, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00275; Turner PE, 1999, NATURE, V398, P441, DOI 10.1038/18913; Tuttle J ., 2021, TOP ANTIVIR MED, V29, P32; Vignuzzi M, 2019, NAT MICROBIOL, V4, P1075, DOI 10.1038/s41564-019-0465-y; VONMAGNUS P, 1954, ADV VIRUS RES, V2, P59, DOI 10.1016/S0065-3527(08)60529-1; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Weinberger LS, 2003, J VIROL, V77, P10028, DOI 10.1128/JVI.77.18.10028-10036.2003; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhou J, 2018, P NATL ACAD SCI USA, V115, P6822, DOI 10.1073/pnas.1806308115; Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017	73	10	10	3	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 9	2021	184	25					6022	+		10.1016/j.cell.2021.11.004	http://dx.doi.org/10.1016/j.cell.2021.11.004		DEC 2021	34	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XP3FJ	34838159	Green Published, Bronze			2023-01-03	WOS:000730754300006
J	Kabir, MR				Kabir, Md Ruhul			Adopting Andersen's behavior model to identify factors influencing maternal healthcare service utilization in Bangladesh	PLOS ONE			English	Article							MEDICAL-CARE; DETERMINANTS	Background Equitable maternal healthcare service access and it's optimum utilization remains a challenge for many developing countries like Bangladesh, and different predisposing, enabling, and need-based factors affect the level of maternal healthcare use. The evidently poor maternal healthcare service utilization and disparities among groups in Bangladesh are concerning considering its effect on maternal health outcomes. The study aimed to identify the factors that influence maternal healthcare service (MHS) utilization in Bangladesh by adopting Andersen's behavior model of health service use as the theoretical framework. Methods The 2017-18 Bangladesh Demographic Health Survey (2017-18 BDHS) data were used which is nationally representative. The survey study used two-stage stratified sampling to select study households, and data were collected through face-to-face interviews. The desirable, moderate, and undesirable maternal health service (MHS) package was developed based on antenatal, and delivery care services use during pregnancy and childbirth. Multinomial logistic regression and discriminant analysis were performed to analyze the factors that affect MHS use. Results Out of 5,011 ever-married women, only 31.2% of women utilized the desirable level of MHS. The likelihood of using the desirable level of MHS package, relative to the undesirable category, was 9.38 times (OR: 9.38, 95% CI: 4.30-20.44) higher for women with a higher level of education compared to illiterate women, and the same trend was noticed for husband's education. The wealth index had the highest standardized function coefficients (Beta coefficient: 0.49) in discriminatory function. Women with the richest wealth index were more than 23 times (OR: 23.27, 95% CI: 12.69-42.68) likely to have utilized desirable MHS than their poorest counterparts. The likelihood of service uses also varied according to the child's birth order, administrative regions, and area of residence (rural vs. urban). Conclusions Policies and interventions directed towards poverty reduction, universal education, and diminishing geographical disparities of healthcare access might influence the desirable use of maternal healthcare services in Bangladesh.	[Kabir, Md Ruhul] Hong Kong Baptist Univ, Sch Commun, Kowloon Tong, Hong Kong, Peoples R China; [Kabir, Md Ruhul] Noakhali Sci & Technol Univ, Dept Food Technol & Nutr Sci, Noakhali, Bangladesh	Hong Kong Baptist University; Noakhali Science & Technology University (NSTU)	Kabir, MR (corresponding author), Hong Kong Baptist Univ, Sch Commun, Kowloon Tong, Hong Kong, Peoples R China.; Kabir, MR (corresponding author), Noakhali Sci & Technol Univ, Dept Food Technol & Nutr Sci, Noakhali, Bangladesh.	20481713@life.hkbu.edu.hk						Adjiwanou V, 2013, SOC SCI MED, V86, P26, DOI 10.1016/j.socscimed.2013.02.047; Ahmed S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011190; Alkarkhi AFM, 2019, EASY STATISTICS FOR FOOD SCIENCE WITH R, P161, DOI 10.1016/B978-0-12-814262-2.00010-8; Amin R, 2010, INT J EQUITY HEALTH, V9, DOI 10.1186/1475-9276-9-9; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; Andersen R. M., 1968, THESIS; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2019, TRENDS MATERNAL MORT; [Anonymous], 2011, SAGE DICT QUANTITATI; Babalola S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-43; Begum T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188074; Bradley EH, 2002, HEALTH SERV RES, V37, P1221, DOI 10.1111/1475-6773.01053; Chakraborty N, 2003, HEALTH PROMOT INT, V18, P327, DOI 10.1093/heapro/dag414; Dapaah J. M., 2019, Advances in Public Health, V2019, DOI 10.1155/2019/5487293; Dhakal Sulochana, 2007, BMC Pregnancy Childbirth, V7, P19, DOI 10.1186/1471-2393-7-19; Fekadu GA, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3370-9; Haider MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181408; Hodgins S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160562; HUBERTY CJ, 1986, MULTIVAR BEHAV RES, V21, P479, DOI 10.1207/s15327906mbr2104_7; Islam MM., 2021, J HEALTH RES; Joshi C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-94; Kabir MR., 2019, FOOD PUBLIC HLTH, V9, P21, DOI [10.5923/j.fph.20190901.04, DOI 10.5923/J.FPH.20190901.04]; Kabir R, 2020, CLIN EPIDEMIOL GLOB, V8, P983, DOI 10.1016/j.cegh.2020.03.008; Khan MMI, 2021, J PEDIATR NURS, V58, DOI 10.1016/j.pedn.2020.12.017; Khan MN, 2020, SAGE OPEN, V10, DOI 10.1177/2158244020914394; Langer Ana, 2002, BMC Womens Health, V2, P7, DOI 10.1186/1472-6874-2-7; Lassi ZS, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-S1-S2; Lowe M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163653; Ntambue MLA, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-66; Nuamah GB, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-018-2159-5; Pervin J, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257782; Research NIoP Training-NIPORT Health Mo Family Welfare ICF, 2020, BANGL DEM HLTH SURV; Rutaremwa G, 2012, AFRICAN POPULATION S, P26; Rutaremwa G, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0943-8; Sanogo NA, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4036830; Singh P, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-03607-w; Unicef, 2014, TRENDS MAT MORT 1990, DOI [10.1016/S2214-109X(14)70316-X, DOI 10.1016/S2214-109X(14)70316-X]; Wong M, 2009, HEALTH SERV INSIGHTS, V2, P1	38	3	3	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2021	16	11							e0260502	10.1371/journal.pone.0260502	http://dx.doi.org/10.1371/journal.pone.0260502			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU5IH	34843566	Green Published, gold			2023-01-03	WOS:000752076100092
J	Sherrill, JD; Finlay, D; Binder, RL; Robinson, MK; Wei, XT; Tiesman, JP; Flagler, MJ; Zhao, WZ; Miller, C; Loftus, JM; Kimball, AB; Bascom, CC; Isfort, RJ				Sherrill, Joseph D.; Finlay, Deborah; Binder, Robert L.; Robinson, Michael K.; Wei, Xingtao; Tiesman, Jay P.; Flagler, Michael J.; Zhao, Wenzhu; Miller, Catherine; Loftus, Jean M.; Kimball, Alexa B.; Bascom, Charles C.; Isfort, Robert J.			Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatment	PLOS ONE			English	Article							CARBON-DIOXIDE LASER; FACIAL REJUVENATION; PROFILING ANALYSIS; CO2-LASER; EXPRESSION; RESPONSES; EFFICACY; THERAPY; ACID; RETINOL	Ablative fractional laser treatment is considered the gold standard for skin rejuvenation. In order to understand how fractional laser works to rejuvenate skin, we performed microarray profiling on skin biopsies to identify temporal and dose-response changes in gene expression following fractional laser treatment. The backs of 14 women were treated with ablative fractional laser (Fraxel (R)) and 4 mm punch biopsies were collected from an untreated site and at the treated sites 1, 3, 7, 14, 21 and 28 days after the single treatment. In addition, in order to understand the effect that multiple fractional laser treatments have on skin rejuvenation, several sites were treated sequentially with either 1, 2, 3, or 4 treatments (with 28 days between treatments) followed by the collection of 4 mm punch biopsies. RNA was extracted from the biopsies, analyzed using Affymetrix U219 chips and gene expression was compared between untreated and treated sites. We observed dramatic changes in gene expression as early as 1 day after fractional laser treatment with changes remaining elevated even after 1 month. Analysis of individual genes demonstrated significant and time related changes in inflammatory, epidermal, and dermal genes, with dermal genes linked to extracellular matrix formation changing at later time points following fractional laser treatment. When comparing the age-related changes in skin gene expression to those induced by fractional laser, it was observed that fractional laser treatment reverses many of the changes in the aging gene expression. Finally, multiple fractional laser treatments, which cover different regions of a treatment area, resulted in a sustained or increased dermal remodeling response, with many genes either differentially regulated or continuously upregulated, supporting previous observations that maximal skin rejuvenation requires multiple fractional laser treatments. In conclusion, fractional laser treatment of human skin activates a number of biological processes involved in wound healing and tissue regeneration.	[Sherrill, Joseph D.; Finlay, Deborah; Binder, Robert L.; Robinson, Michael K.; Wei, Xingtao; Tiesman, Jay P.; Flagler, Michael J.; Zhao, Wenzhu; Bascom, Charles C.; Isfort, Robert J.] Procter & Gamble Co, Cincinnati, OH 45202 USA; [Miller, Catherine; Loftus, Jean M.] Loftus Plast Surg Ctr, Ft Wright, KY USA; [Kimball, Alexa B.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Kimball, Alexa B.] Harvard Med Sch, Boston, MA 02115 USA	Procter & Gamble; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Bascom, CC (corresponding author), Procter & Gamble Co, Cincinnati, OH 45202 USA.	bascom.cc@pg.com	Robinson, Michael/Q-3263-2017	Robinson, Michael/0000-0002-6914-8543; Tiesman, Jay/0000-0002-0632-0369	Procter Gamble Company	Procter Gamble Company(Procter & Gamble)	This work was funded by the Procter & Gamble Company.	Allemann IB, 2010, LASER MED SCI, V25, P137, DOI 10.1007/s10103-009-0734-8; Amann PM, 2016, LASER MED SCI, V31, P397, DOI 10.1007/s10103-015-1863-x; Bedi VP, 2007, LASER SURG MED, V39, P145, DOI 10.1002/lsm.20406; Blumenberg M, 2019, SEMIN CUTAN MED SURG, V38, pE12, DOI 10.12788/j.sder.2019.004; Brightman LA, 2009, DERMATOL CLIN, V27, P479, DOI 10.1016/j.det.2009.08.009; Buis J, 2007, ANN CHIR PLAST ESTH, V52, P222, DOI 10.1016/j.anplas.2006.11.004; Canales RD, 2006, NAT BIOTECHNOL, V24, P1115, DOI 10.1038/nbt1236; Cho BA, 2018, AGING-US, V10, P1609, DOI 10.18632/aging.101496; Cohen SR, 2017, AESTHET PLAST SURG, V41, P171, DOI 10.1007/s00266-016-0767-x; El-Domyati M, 2014, J COSMET DERMATOL-US, V13, P30, DOI 10.1111/jocd.12079; El-Domyati M, 2013, J AM ACAD DERMATOL, V68, P103, DOI 10.1016/j.jaad.2012.09.014; El-Domyati MM, 2007, DERMATOL SURG, V33, P668, DOI 10.1111/j.1524-4725.2007.33141.x; Fathi R, 2015, CLIN DERMATOL, V33, P207, DOI 10.1016/j.clindermatol.2014.10.012; Fernandes D, 2008, CLIN DERMATOL, V26, P192, DOI 10.1016/j.clindermatol.2007.09.006; Fitzpatrick RE, 1996, ARCH DERMATOL, V132, P469, DOI 10.1001/archderm.132.4.469; Goldman A, 2010, CLIN INTERV AGING, V5, P293, DOI 10.2147/CIA.S13215; Grunewald S, 2011, INT J HYPERTHER, V27, P811, DOI 10.3109/02656736.2011.595380; Hantash BM, 2007, LASER SURG MED, V39, P96, DOI 10.1002/lsm.20468; Haustead DJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26846; Helbig D., 2010, International Journal of Cosmetic Science, V32, P458, DOI 10.1111/j.1468-2494.2010.00573.x; Helbig D, 2011, WOUNDS, V23, P59; Helbig D, 2011, SKIN RES TECHNOL, V17, P119, DOI 10.1111/j.1600-0846.2010.00477.x; Helbig D, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3275479; Holzscheck N, 2020, AGING-US, V12, P12393, DOI 10.18632/aging.103499; Humphrey S, 2016, DERMATOL SURG, V42, pS83, DOI 10.1097/DSS.0000000000000747; Huth L, 2020, J DRUGS DERMATOL, V19, P897, DOI [10.36849/JDD.2020.4856, 10.36849/JDD.2020.10.36849/JDD.2020.4856]; Jiang X, 2014, LASER MED SCI, V29, P681, DOI 10.1007/s10103-013-1383-5; Jiang X, 2012, LASER MED SCI, V27, P599, DOI 10.1007/s10103-011-0996-9; KATAYAMA K, 1991, BIOCHEMISTRY-US, V30, P7097, DOI 10.1021/bi00243a009; KATAYAMA K, 1993, J BIOL CHEM, V268, P9941; Kim D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10811-y; Kim JE, 2013, DERMATOL SURG, V39, P1033, DOI 10.1111/dsu.12170; Kimball AB, 2018, J AM ACAD DERMATOL, V78, P29, DOI 10.1016/j.jaad.2017.09.012; Kislevitz M, 2020, LASER SURG MED, V52, P822, DOI 10.1002/lsm.23233; Kohl E, 2014, BRIT J DERMATOL, V170, P858, DOI 10.1111/bjd.12807; Kong R, 2016, J COSMET DERMATOL-US, V15, P49, DOI 10.1111/jocd.12193; Kuehne A, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3547-3; Laubach HJ, 2006, LASER SURG MED, V38, P142, DOI 10.1002/lsm.20254; Lener T, 2006, EXP GERONTOL, V41, P387, DOI 10.1016/j.exger.2006.01.012; Loffek S, 2011, EUR RESPIR J, V38, P191, DOI 10.1183/09031936.00146510; Longo C, 2013, LASER MED SCI, V28, P769, DOI 10.1007/s10103-012-1145-9; Lucas T, 2010, J IMMUNOL, V184, P3964, DOI 10.4049/jimmunol.0903356; Makrantonaki E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050393; Marquardt Y, 2015, LASER SURG MED, V47, P257, DOI 10.1002/lsm.22341; Natari S, 2020, LASER SURG MED, V52, P1010, DOI 10.1002/lsm.23258; Nogita T, 2017, J DERMATOL, V44, P207, DOI 10.1111/1346-8138.13526; Nunan R, 2015, CELL REP, V13, P1380, DOI 10.1016/j.celrep.2015.09.085; Orringer JS, 2008, ARCH DERMATOL, V144, P1296, DOI 10.1001/archderm.144.10.1296; Orringer JS, 2012, DERMATOL SURG, V38, P1668, DOI 10.1111/j.1524-4725.2012.02518.x; Ortiz AE, 2010, LASER SURG MED, V42, P168, DOI 10.1002/lsm.20885; Palumbo-Zerr K, 2015, NAT MED, V21, P150, DOI 10.1038/nm.3777; Papadavid E, 2003, INT J DERMATOL, V42, P480, DOI 10.1046/j.1365-4362.2003.01784.x; Park SH, 2012, J PLAST RECONSTR AES, V65, P1305, DOI 10.1016/j.bjps.2012.04.028; Prignano F, 2009, DERMATOL THER, V22, pS8, DOI 10.1111/j.1529-8019.2009.01265.x; Prignano F, 2012, J COSMET LASER THER, V14, P267, DOI 10.3109/14764172.2012.738820; Pryor L, 2011, AESTHET PLAST SURG, V35, P1151, DOI 10.1007/s00266-011-9730-z; Qu Y, 2019, J COSMET LASER THER, V21, P19, DOI 10.1080/14764172.2018.1439967; Rahman Z, 2009, LASER SURG MED, V41, P78, DOI 10.1002/lsm.20715; Reilly MJ, 2010, ARCH FACIAL PLAST S, V12, P321, DOI 10.1001/archfacial.2010.38; Robati RM, 2017, LASER MED SCI, V32, P283, DOI 10.1007/s10103-016-2111-8; Sadick NS, 2009, J COSMET LASER THER, V11, P29, DOI 10.1080/14764170802612992; Schagen S.K., 2017, COSMETICS-BASEL, V4, P16, DOI [10.3390/cosmetics4020016, DOI 10.3390/COSMETICS4020016]; Schmitt L, 2018, LASER MED SCI, V33, P765, DOI 10.1007/s10103-017-2409-1; Schmitt L, 2017, LASER MED SCI, V32, P805, DOI 10.1007/s10103-017-2175-0; Sextius P, 2015, ARCH DERMATOL RES, V307, P351, DOI 10.1007/s00403-015-1551-5; Shao Y, 2017, INT J COSMETIC SCI, V39, P56, DOI 10.1111/ics.12348; Shi Y, 2020, MOL MED REP, V22, P1811, DOI 10.3892/mmr.2020.11268; Sole-Boldo L, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0922-4; Starnes AM, 2012, DERMATOL SURG, V38, P51, DOI 10.1111/j.1524-4725.2011.02136.x; Strbo N, 2014, ADV WOUND CARE, V3, P492, DOI 10.1089/wound.2012.0435; Tan J, 2014, LASER SURG MED, V46, P750, DOI 10.1002/lsm.22304; Tierney EP, 2011, DERMATOL THER, V24, P41, DOI 10.1111/j.1529-8019.2010.01377.x; Trelles MA, 2008, LASER SURG MED, V40, P174, DOI 10.1002/lsm.20607; Xu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165913; Xu XG, 2011, DERMATOL SURG, V37, P1141, DOI 10.1111/j.1524-4725.2011.02062.x; Yan W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061946; Zheng Z, 2014, WOUND REPAIR REGEN, V22, P660, DOI 10.1111/wrr.12212; Zou ZR, 2021, DEV CELL, V56, P383, DOI 10.1016/j.devcel.2020.11.002	78	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2021	16	11							e0260095	10.1371/journal.pone.0260095	http://dx.doi.org/10.1371/journal.pone.0260095			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU5IH	34843523	Green Submitted, gold, Green Published			2023-01-03	WOS:000752076100042
J	Qian, YY; Zhang, JJ; Li, JY; Weng, ZY				Qian, Yiyi; Zhang, Jiajun; Li, Jiangya; Weng, Zhiying			A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation	PLOS ONE			English	Article							STROKE PREVENTION; EPIDEMIOLOGY; MANAGEMENT; BURDEN; RISK	Background The incidence of atrial fibrillation (AF) is increasing, and effective anticoagulation therapy can prevent adverse events. Selecting the appropriate OAC based on patient characteristics has become a challenge. Interventions are going to be a potential area of focus. Objectives To explore the discrepancies between clinician prescriptions and recommended guidelines of oral anticoagulants (OACs) for patients with atrial fibrillation (AF), and to provide direction for improving anticoagulation strategies for treating patients with AF. Materials and methods Data were collected from the electronic medical record system of Fuwai Yunnan Cardiovascular Hospital between July 2019 and January 2020. The suitability of prescribed OACs for patients with AF was assessed according to the Rules for Avoiding Prescription Inappropriateness, the prescribed medicine label, and any relevant antithrombotic guidelines for treating patients with AF. Results A total of 460 patients met the inclusion criteria. Of these, 53.7% received an appropriate prescription and 46.3% received an inappropriate prescription. Of the patients who received inappropriate prescriptions, 15.4% were prescribed without the presenting appropriate indicators, 1.3% were prescribed inappropriate drug selection, and 29.6% were prescribed inappropriate drug doses. For patients prescribed without providing appropriate indicators, 2.2% had no indication for medication and 13.3% had an indication for medication, but not a specific OAC. For patients with inappropriate drug selection, 1, 5 patients were on rivaroxaban, dabigatran respectively. The distribution of NOAC doses was as follows: dabigatran standard dose (45.2%), the low dose (54.8%). Rivaroxaban standard dose (58.9%), low dose (36.8%), high dose (4.3%). A total of 44 patients (9.6%) experienced bleeding events, 12 patients (2.6%) experienced embolic events, and 7 patients experienced other adverse events after dosing. Conclusions In clinical practice, it is common for patients with AF to receive inappropriate prescriptions of OACs. Therefore there is a need to enhance anticoagulation management in patients with AF to improve the appropriate use of OACs.	[Qian, Yiyi] Fuwai Yunnan Cardiovasc Hosp, Dept Pharm, Kunming, Yunnan, Peoples R China; [Zhang, Jiajun] Yunnan Med Hlth Coll, Sch Pharmaceut Sci, Kunming, Yunnan, Peoples R China; [Li, Jiangya; Weng, Zhiying] Kunming Med Univ, Sch Pharmaceut Sci, Yunnan Key Lab Pharmacol Nat Prod, Kunming, Yunnan, Peoples R China	Kunming Medical University	Qian, YY (corresponding author), Fuwai Yunnan Cardiovasc Hosp, Dept Pharm, Kunming, Yunnan, Peoples R China.; Weng, ZY (corresponding author), Kunming Med Univ, Sch Pharmaceut Sci, Yunnan Key Lab Pharmacol Nat Prod, Kunming, Yunnan, Peoples R China.	qian_yiyi@qq.com; weng_zy@sina.com			Scientific Research Fund Project of Yunnan Provincial Department of Education [2018JS245]; Hospital-level scientific research fund project of Fuwai Yunnan Cardiovascular Hospital [2019YFKT08]	Scientific Research Fund Project of Yunnan Provincial Department of Education; Hospital-level scientific research fund project of Fuwai Yunnan Cardiovascular Hospital	This research was funded by Scientific Research Fund Project of Yunnan Provincial Department of Education (Program No.2018JS245) and Hospital-level scientific research fund project of Fuwai Yunnan Cardiovascular Hospital (Program No.2019YFKT08).	Abed HS, 2013, JAMA-J AM MED ASSOC, V310, P2050, DOI 10.1001/jama.2013.280521; Chang TY, 2018, IJC HEART VASC, V20, P56, DOI 10.1016/j.ijcha.2018.08.003; Chen. Wenwen, 2017, CHIN J HOSP PHARM, V37, P2072, DOI DOI 10.13286/j.cnki.chinhosppharmacyj.2017.20.15; Cheng WH, 2019, STROKE, V50, P2574, DOI 10.1161/STROKEAHA.119.025623; Chugh SS, 2014, CIRCULATION, V129, P837, DOI 10.1161/CIRCULATIONAHA.113.005119; Franchi C, 2018, BRIT J CLIN PHARMACO, V84, P2010, DOI 10.1111/bcp.13631; January CT, 2019, J AM COLL CARDIOL, V74, P104, DOI 10.1016/j.jacc.2019.01.011; Kakkar AK, 2012, AM HEART J, V163, P13, DOI 10.1016/j.ahj.2011.09.011; Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210; Lee SR, 2019, STROKE, V50, P1140, DOI 10.1161/STROKEAHA.118.024210; Lip GYH, 2018, CHEST, V154, P1121, DOI 10.1016/j.chest.2018.07.040; Lippi G, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.65; Mant J, 2007, LANCET, V370, P493, DOI 10.1016/S0140-6736(07)61233-1; Moudallel S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01220; Pritchett RV, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232484; Rahman F, 2014, NAT REV CARDIOL, V11, P639, DOI 10.1038/nrcardio.2014.118; Steinberg BA, 2017, AM HEART J, V194, P132, DOI 10.1016/j.ahj.2017.08.011; Zhang. Shu, 2017, CHINESE J ARRHYTHMIA, V2018, P17	18	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2021	16	11							e0259199	10.1371/journal.pone.0259199	http://dx.doi.org/10.1371/journal.pone.0259199			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2MY	34762667	Green Published, gold			2023-01-03	WOS:000755316600016
J	Deshpande, S; Kallioinen, M; Harding, K				Deshpande, Shalmali; Kallioinen, Maija; Harding, Kate		Guideline Comm	Routine antenatal care for women and their babies: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Deshpande, Shalmali; Kallioinen, Maija] Royal Coll Obstetricians & Gynaecologists, Natl Guideline Alliance, London, England; [Harding, Kate] Guys & St Thomas Fdn Trust, London, England		Deshpande, S (corresponding author), Royal Coll Obstetricians & Gynaecologists, Natl Guideline Alliance, London, England.	SDeshpande@RCOG.ORG.UK	Alwan, Nisreen/A-5081-2014	Alwan, Nisreen/0000-0002-4134-8463	National Guideline Alliance (NGA) at the Royal College of Obstetricians and Gynaecologists (RCOG) - NICE	National Guideline Alliance (NGA) at the Royal College of Obstetricians and Gynaecologists (RCOG) - NICE	SD and MK received support from the National Guideline Alliance (NGA) at the Royal College of Obstetricians and Gynaecologists (RCOG), which is commissioned and funded by NICE to develop clinical, public health, and social care guidelines and to write this BMJ summary. No authors received special funding from any other source to write this summary.	Matthews A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007575.pub4; Mothers and Babies, 2020, MOTHERS BABIES; Mothers and Babies, 2020, PERINATAL MORTALITY; National Institute for Clinical Excellence (NICE), 2010, SMOK STOPP PREGN CHI; National Institute for Health and Care Excellence, 2017, VIT D SUPPL US SPEC; National Institute for Health and Care Excellence, 2014, MATERN CHILD NUTR; National Institute for Health and Care Excellence, 2021, ANT CAR ROUT ANT CAR; National Institute for Health and Care Excellence, 2019, GASTR OES REFL DIS D; National Institute for Heath and Care Excellence, 2021, ANT CAR; Royal College of Obstetricians and Gynaecologists, 2015, PELV GIRDL PAIN PREG	10	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 29	2021	375								n2484	10.1136/bmj.n2484	http://dx.doi.org/10.1136/bmj.n2484			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WS1RQ	34716150				2023-01-03	WOS:000714967200013
J	Xie, YH; Liu, CW; Zhang, YC; Li, AM; Sun, C; Li, R; Xing, YR; Shi, MH; Wang, Q				Xie, Yinghai; Liu, Changwei; Zhang, Yinci; Li, Amin; Sun, Chong; Li, Rui; Xing, Yingru; Shi, Minghong; Wang, Qi			PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair	PLOS ONE			English	Article							STEREOTACTIC BODY RADIOTHERAPY; SQUAMOUS-CELL CARCINOMA; RADIOFREQUENCY ABLATION; SIGNALING PATHWAY; MECHANISMS; SORAFENIB; MTOR; NANOPARTICLES; APOPTOSIS; OUTCOMES	Radiation is an important therapeutic strategy for hepatocellular (HCC). In this study, we evaluated the role of the dual PI3K/mTOR inhibitor, PKI-587, on radiosensitization of HCC and its possible mechanism. MTT, colony formation, flow cytometry, and immunofluorescence were used to analyze the proliferation, cell cycle, formation of residual gamma-H2AX foci, and apoptosis of HCC cells. A SK-Hep1 xenograft HCC model was used to assess the effects of PKI-587 in combination with ionizing radiation in vivo. The activation levels of PI3K/AKT/mTOR and DNA damage repair pathways and their downstream effector molecules were detected with Western blot. It was found that PKI-587 sensitized HCC cells to radiation by increasing DNA damage, enhancing G0/G1 cell-cycle arrest, and inducing apoptosis. In vivo, the combination of radiation with PKI-587 significantly inhibited tumor growth. These findings suggest the usefulness of PKI-587 on radiosensitization of HCC cells by inhibiting the PI3K/AKT/mTOR and DNA damage repair pathways. The combination of ionizing radiation and PKI-587 may be a strategy to improve the efficacy of treating HCC.	[Xie, Yinghai; Liu, Changwei; Sun, Chong; Li, Rui; Wang, Qi] Anhui Univ Sci & Technol, Huainan Peoples Hosp 1, Huainan, Peoples R China; [Xie, Yinghai; Liu, Changwei; Sun, Chong; Li, Rui; Wang, Qi] Anhui Univ Sci & Technol, Affiliated Hosp 1, Med Sch, Huainan, Peoples R China; [Zhang, Yinci; Li, Amin] Anhui Univ Sci & Technol, Med Sch, Huainan, Peoples R China; [Zhang, Yinci; Li, Amin] Anhui Univ Sci & Technol Wuhu, Inst Environm Friendly Mat & Occupat Hlth, Wuhu, Peoples R China; [Xing, Yingru; Shi, Minghong] Anhui Univ Sci & Technol, Affiliated Canc Hosp, Huainan, Peoples R China	Anhui University of Science & Technology; Anhui University of Science & Technology; Anhui University of Science & Technology; Anhui University of Science & Technology	Wang, Q (corresponding author), Anhui Univ Sci & Technol, Huainan Peoples Hosp 1, Huainan, Peoples R China.; Wang, Q (corresponding author), Anhui Univ Sci & Technol, Affiliated Hosp 1, Med Sch, Huainan, Peoples R China.	y0123yth@163.com			National Natural Science Fund of China [82071862, 81872017, 81572431]; University Natural Science Research Project of Anhui Province [KJ2018ZD011, KJ2019A0093]; Anhui Provincial Science and Technology program [202004j07020053, 1604a0802094]; Research Foundation of the Institute of Environment-friendly Materials and Occupational Health (Wuhu), Anhui University of Science and Technology [ALW2020YF11]; Huainan Science and Technology Project [2017B41]	National Natural Science Fund of China(National Natural Science Foundation of China (NSFC)); University Natural Science Research Project of Anhui Province(Natural Science Foundation of Anhui Province); Anhui Provincial Science and Technology program; Research Foundation of the Institute of Environment-friendly Materials and Occupational Health (Wuhu), Anhui University of Science and Technology; Huainan Science and Technology Project	The National Natural Science Fund of China (grant nos. 82071862, 81872017 and 81572431), The University Natural Science Research Project of Anhui Province (grant nos. KJ2018ZD011 and KJ2019A0093), The Anhui Provincial Science and Technology program (grant nos. 202004j07020053 and 1604a0802094), The Research Foundation of the Institute of Environment-friendly Materials and Occupational Health (Wuhu), Anhui University of Science and Technology (grant no. ALW2020YF11) and The Huainan Science and Technology Project (grant no. 2017B41) funded this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aoki M, 2017, CURR TOP MICROBIOL, V407, P153, DOI 10.1007/82_2017_6; Bamodu OA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030746; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carrassa L, 2017, CANCER TREAT REV, V60, P139, DOI 10.1016/j.ctrv.2017.08.013; Chatterjee N, 2017, ENVIRON MOL MUTAGEN, V58, P235, DOI 10.1002/em.22087; Chen YH, 2019, CANCERS, V11, DOI 10.3390/cancers11081204; Chino F, 2018, CANCER-AM CANCER SOC, V124, P3476, DOI 10.1002/cncr.31334; Choi SH, 2018, CLIN MOL HEPATOL, V24, P114, DOI 10.3350/cmh.2017.0073; Crocetti L, 2017, CLIN RADIOL, V72, P626, DOI 10.1016/j.crad.2017.01.013; Du J, 2018, DNA REPAIR, V70, P67, DOI 10.1016/j.dnarep.2018.09.002; Eggert T, 2017, DIGESTION, V96, P1, DOI 10.1159/000464282; Facciorusso A, 2016, INT J HYPERTHER, V32, P339, DOI 10.3109/02656736.2015.1127434; Fatehi D, 2018, PATHOL RES PRACT, V214, P889, DOI 10.1016/j.prp.2018.04.001; Freitag H, 2017, NEUROENDOCRINOLOGY, V105, P90, DOI 10.1159/000448843; Gan HY, 2018, MAT SCI ENG C-MATER, V91, P395, DOI 10.1016/j.msec.2018.05.011; Gol TM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246316; Han MW, 2018, ORAL ONCOL, V78, P56, DOI 10.1016/j.oraloncology.2018.01.014; Hua H, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0754-1; Huang RX, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0150-x; Karimian A, 2019, J CELL BIOCHEM, V120, P10248, DOI 10.1002/jcb.28309; Lee SY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0577-4; Leiker AJ, 2015, CLIN CANCER RES, V21, P2792, DOI 10.1158/1078-0432.CCR-14-3279; Li AM, 2019, AM J TRANSL RES, V11, P5573; Liu TX, 2014, BIOCHEM BIOPH RES CO, V449, P49, DOI 10.1016/j.bbrc.2014.04.147; Liu Y, 2017, NEOPLASMA, V64, P655, DOI 10.4149/neo_2017_502; del Campo JM, 2016, GYNECOL ONCOL, V142, P62, DOI 10.1016/j.ygyno.2016.04.019; Miyahara H, 2017, CANCER LETT, V400, P110, DOI 10.1016/j.canlet.2017.04.019; Mueck K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112473; Murray JM, 2018, CURR OPIN CELL BIOL, V52, P120, DOI 10.1016/j.ceb.2018.03.006; Pretre V, 2018, SEMIN CANCER BIOL, V48, P70, DOI 10.1016/j.semcancer.2017.04.011; Sage E, 2017, FREE RADICAL BIO MED, V107, P125, DOI 10.1016/j.freeradbiomed.2016.12.008; Sangiovanni A, 2016, LIVER INT, V36, P124, DOI 10.1111/liv.13028; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Sheng HL, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000340; Shi JJ, 2019, CANCER LETT, V459, P145, DOI 10.1016/j.canlet.2019.05.040; Tang XL, 2018, J BIOMED NANOTECHNOL, V14, P396, DOI 10.1166/jbn.2018.2529; Tang XL, 2015, AM J TRANSL RES, V7, P460; Teraoka Y, 2018, HEPATOL RES, V48, P193, DOI 10.1111/hepr.12916; Toulany M, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.72; Toulany M, 2015, SEMIN CANCER BIOL, V35, P180, DOI 10.1016/j.semcancer.2015.07.003; Wada Y, 2018, INTERNAL MED, V57, P1345, DOI 10.2169/internalmedicine.9826-17; Wahl DR, 2016, J CLIN ONCOL, V34, P452, DOI 10.1200/JCO.2015.61.4925; Wang JY, 2019, BIOMED PHARMACOTHER, V110, P646, DOI 10.1016/j.biopha.2018.11.080; Wang LF, 2006, J BIOL CHEM, V281, P24293, DOI 10.1074/jbc.M603566200; Yao AJ, 2015, BIOCHEM BIOPH RES CO, V465, P696, DOI 10.1016/j.bbrc.2015.08.049; Yoon HI, 2016, LIVER CANCER, V5, P139, DOI 10.1159/000367762; Yu CC, 2017, ONCOTARGET, V8, P68641, DOI 10.18632/oncotarget.19817; Zhang YC, 2019, AM J TRANSL RES, V11, P5134; Zhang ZW, 2017, NUTR RES, V38, P27, DOI 10.1016/j.nutres.2017.01.003; Zhou MG, 2019, LANCET, V394, P1145, DOI 10.1016/S0140-6736(19)30427-1	50	4	4	4	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2021	16	10							e0258817	10.1371/journal.pone.0258817	http://dx.doi.org/10.1371/journal.pone.0258817			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7WQ	34665844	Green Published, gold			2023-01-03	WOS:000755683100029
J	Peruzzo, D; Guedes, M; Larkin, JW; Yokoyama, G; dos Santos, TL; Pecoits, R; Ribeiro, SC; Ramos, A; Barretti, P; de Moraes, TP				Peruzzo, Daniela; Guedes, Murilo; Larkin, John W.; Yokoyama, Guilherme; dos Santos, Taynara Lopes; Pecoits-Filho, Roberto; Ribeiro, Silvia Carreira; Ramos, Alfonso; Barretti, Pasqual; de Moraes, Thyago Proenca		BRAZPD Investigators	Peritoneal dialysis modality transition and impact on phosphate and potassium serum levels	PLOS ONE			English	Article							TRANSPORT; SOLUTE; CAPD; CLEARANCE; REMOVAL; FLUID; APD	Peritoneal dialysis (PD) modalities affect solute removal differently. However, the impacts of switching PD modalities on serum levels of biomarkers of different sizes are not known. Our objective was to analyze whether a change in the PD modality associates with the levels of two routine biochemical laboratories. In this multicentric prospective cohort study. we selected all patients who remained on a PD modality for at least 6 months and switched PD modality. Patients were also required to be treated with the same PD modality for at least 3 months before and after the modality change. The primary outcome was change in potassium and phosphate serum levels. We identified 737 eligible patients who switched their PD modality during the study. We found mean serum phosphate levels increased during the 3 months after switching from CAPD to APD and conversely decreased after switching to from APD to CAPD. In contrast, for potassium the difference in the mean serum levels was comparable between groups switching from CAPD to APD, and vice versa. In conclusion, CAPD seems to be as efficient as APD for the control of potassium serum levels, but more effective for the control of phosphate serum levels. The effect of a higher removal of middle size molecules as result of PD modalities in terms of clinical and patient-reported outcomes should be further explored.	[Peruzzo, Daniela; Guedes, Murilo; Larkin, John W.; Yokoyama, Guilherme; dos Santos, Taynara Lopes; Pecoits-Filho, Roberto; Ribeiro, Silvia Carreira; de Moraes, Thyago Proenca] Pontificia Univ Catolica Parana PUCPR, Curitiba, Parana, Brazil; [Larkin, John W.] Global Med Off, Fresenius Med Care, Waltham, MA USA; [Ramos, Alfonso] Baxter Healthcare, Mexico City, DF, Mexico; [Barretti, Pasqual] Univ Estadual Paulista UNESP, Botucatu, SP, Brazil	Pontificia Universidade Catolica do Parana; Universidade Estadual Paulista	Barretti, P (corresponding author), Univ Estadual Paulista UNESP, Botucatu, SP, Brazil.	pbarretti@uol.com.br	Guedes, Murilo/AFQ-5692-2022; Larkin, John/G-1880-2018	Guedes, Murilo/0000-0002-3495-852X; Ramos-Sanchez, Alfonso/0000-0002-2156-3553; Larkin, John/0000-0001-8873-8971	Baxter Healthcare; Fresenius Medical Care	Baxter Healthcare; Fresenius Medical Care	The funders (Baxter Healthcare and Fresenius Medical Care) support in the form of salaries for authors [AR and JWL, respectively], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Badve SV, 2008, CLIN J AM SOC NEPHRO, V3, P1711, DOI 10.2215/CJN.00190108; Bammens B, 2005, AM J KIDNEY DIS, V46, P512, DOI 10.1053/j.ajkd.2005.05.016; Vega LB, 2019, NEFROLOGIA, V39, P277, DOI 10.1016/j.nefro.2018.11.011; Blake P.G., 2015, HDB DIALYSIS, V5th ed., P392; Brophy DF, 1999, PERITON DIALYSIS INT, V19, P534; Courivaud C, 2016, PERITON DIALYSIS INT, V36, P85, DOI 10.3747/pdi.2014.00173; de Moraes TP, 2014, PERITON DIALYSIS INT, V34, P714, DOI 10.3747/pdi.2013.00282; Eloot S, 2015, PERITON DIALYSIS INT, V35, P436, DOI 10.3747/pdi.2013.00202; HEIMBURGER O, 1992, KIDNEY INT, V41, P1320, DOI 10.1038/ki.1992.196; Khanna R, 2017, AM J KIDNEY DIS, V69, P461, DOI 10.1053/j.ajkd.2016.11.007; Li PKT, 2017, NAT REV NEPHROL, V13, P90, DOI 10.1038/nrneph.2016.181; Moor V, 2017, KIDNEY BLOOD PRESS R, V42, P257, DOI 10.1159/000477422; Ribeiro SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127453; Rippe B, 2004, PERITON DIALYSIS INT, V24, P10; Torlen K, 2012, CLIN J AM SOC NEPHRO, V7, P1272, DOI 10.2215/CJN.00960112; Zhang YF, 2016, RENAL FAILURE, V38, P1594, DOI 10.3109/0886022X.2015.1128237	16	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2021	16	10							e0257140	10.1371/journal.pone.0257140	http://dx.doi.org/10.1371/journal.pone.0257140			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7YW	34653195	gold, Green Published			2023-01-03	WOS:000755689200007
J	Vespa, A; Spatuzzi, R; Fabbietti, P; Penna, M; Giulietti, MV				Vespa, Anna; Spatuzzi, Roberta; Fabbietti, Paolo; Penna, Martina; Giulietti, Maria Velia			Association between care burden, depression and personality traits in Alzheimer's caregiver: A pilot study	PLOS ONE			English	Article							QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; NEUROPSYCHIATRIC SYMPTOMS; PSYCHOLOGICAL SYMPTOMS; FAMILY CAREGIVERS; DEMENTIA; HEALTH; DIAGNOSIS; THERAPY; DISEASE	Introduction In this study correlations between care burden, depression, and personality at intrapsychic level in caregivers of Alzheimer's disease patients were evaluated. Materials and methods Caregivers: n.40. Tests: Social-schedule; CBI; BDI; SASB-Structural-Analysis of Social Behaviours- Form-A- intrapsychic behaviours (8 Cluster); ECOG. Patients:MMSE. Statistical analysis: Chi-squared test; Anova one way F test; Pearson's R coefficient. Results Correlations: CBI-total and NPI(p < .001); CBI-total-ECOG (p = .042); CBI-total-BDI(p< .001); CBI- total-SASB-Cl7(p = .014); SASB-CL8(p<0.000); BDI and SASB-Cl 2 (p = .018), SASB-Cl 3 (p = .004), SASB-Cl7(p < .000), SASB-CL8 (p < .000). High CBI is correlated with high depression, neuropsychiatry symptoms, low cognitive patient's functions. Caregivers have the following intrapsychic behaviors: poor self-care, poor ability to take care of themselves; they exercise control over themselves and do not consider and/or ignore their basic needs at emotional and physical levels. These intrapsychic behaviours are indicators of depression (SASB Model) and are correlated with high care burden-CBI and high depression-CDQ. Discussion Care burden is closely related to the depression and individual personality (intrapsychic experience) of the caregiver. This may reveal a source of strength and may suggest areas of multidimensional and psychotherapeutic interventions.	[Vespa, Anna; Penna, Martina; Giulietti, Maria Velia] IRCCS INRCA Natl Inst Sci & Hlth Aging, Dept Neurol, Ancona, Italy; [Spatuzzi, Roberta] ASP Healthcare Serv, Dept Mental Hlth, Potenza, Italy; [Fabbietti, Paolo] IRCCS INRCA Natl Inst Sci & Hlth Aging, Biostat Ctr, Ancona, Italy		Vespa, A (corresponding author), IRCCS INRCA Natl Inst Sci & Hlth Aging, Dept Neurol, Ancona, Italy.	a.vespa@inrca.it	Fabbietti, Paolo/K-6365-2016	Fabbietti, Paolo/0000-0003-2130-3070; Vespa, Anna/0000-0002-0503-7852				Aboulafia-Brakha T, 2014, AGING MENT HEALTH, V18, P801, DOI 10.1080/13607863.2014.880406; Arnarson PO, 2008, NORD J PSYCHIAT, V62, P360, DOI 10.1080/08039480801962681; Baranzini F, 2013, RIV PSICHIATR, V48, P335, DOI 10.1708/1319.14631; Benjamin L.S., 1996, INTERPERSONAL DIAGNO, V2; BENJAMIN LS, 1979, PSYCHIATRY, V42, P1; Berger G, 2005, J GERIATR PSYCH NEUR, V18, P119, DOI 10.1177/0891988704273375; Critchfield KL, 2010, J PERS ASSESS, V92, P480, DOI 10.1080/00223891.2010.513286; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Dawood S, 2016, JCPSP-J COLL PHYSICI, V26, P892; Deardorff WJ, 2019, HAND CLINIC, V165, P5, DOI 10.1016/B978-0-444-64012-3.00002-2; Delfino LL, 2018, GERIATR GERONTOL INT, V18, P1177, DOI 10.1111/ggi.13437; Farias ST, 2011, ALZHEIMERS DEMENT, V7, P593, DOI 10.1016/j.jalz.2011.02.007; Ferrara M, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-93; Garand L, 2014, AM J GERIAT PSYCHIAT, V22, P771, DOI 10.1016/j.jagp.2013.07.007; Geary C, 2011, J ALTERN COMPLEM MED, V17, P939, DOI 10.1089/acm.2010.0335; Jobst KA., 1997, INT PSYCHOGERIATR, V9, P247; Liu S, 2017, J CLIN NURS, V26, P1291, DOI 10.1111/jocn.13601; Llado A, 2008, NEUROLOGIA, V23, P294; Lu Yueh-Feng Yvonne, 2007, Am J Alzheimers Dis Other Demen, V22, P273, DOI 10.1177/1533317507301367; Martin-Carrasco M, 2014, ALZ DIS ASSOC DIS, V28, P79, DOI 10.1097/WAD.0000000000000003; Mausbach BT, 2013, AM J GERIAT PSYCHIAT, V21, P5, DOI 10.1016/j.jagp.2012.10.001; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Montgomery W, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0831-2; Moore RC, 2013, BEHAV RES THER, V51, P623, DOI 10.1016/j.brat.2013.07.005; Morganti F, 2018, DEMENT GER COGN D EX, V8, P306, DOI 10.1159/000490380; Nieuwenhuis-Mark RE, 2010, J GERIATR PSYCH NEUR, V23, P151, DOI 10.1177/0891988710363714; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; Oken BS, 2010, J ALTERN COMPLEM MED, V16, P1031, DOI 10.1089/acm.2009.0733; Onor Maria Luisa, 2007, Am J Alzheimers Dis Other Demen, V22, P261, DOI 10.1177/1533317507302071; Papastavrou E, 2007, J ADV NURS, V58, P446, DOI 10.1111/j.1365-2648.2007.04250.x; Passoni S, 2014, ALZ DIS ASSOC DIS, V28, P275, DOI 10.1097/WAD.0000000000000033; Pudelewicz A, 2019, SCAND J CARING SCI, V33, P336, DOI 10.1111/scs.12626; Rosenberg PB, 2005, AM J GERIAT PSYCHIAT, V13, P822, DOI 10.1176/appi.ajgp.13.9.822; Savaskan E, 2015, THER UMSCH, V72, P255, DOI 10.1024/0040-5930/a000673; Sink KM, 2006, J AM GERIATR SOC, V54, P796, DOI 10.1111/j.1532-5415.2006.00697.x; Thomas P, 2006, INT J GERIATR PSYCH, V21, P50, DOI 10.1002/gps.1422; Wang YP, 2013, REV BRAS PSIQUIATR, V35, P416, DOI 10.1590/1516-4446-2012-1048; Xiong C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231848	38	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2021	16	9							e0251813	10.1371/journal.pone.0251813	http://dx.doi.org/10.1371/journal.pone.0251813			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5RU	34587159	Green Published, gold			2023-01-03	WOS:000707052600007
J	Coathup, V; Carson, C; Kurinczuk, JJ; Macfarlane, AJ; Boyle, E; Johnson, S; Petrou, S; Quigley, MA				Coathup, Victoria; Carson, Claire; Kurinczuk, Jennifer J.; Macfarlane, Alison J.; Boyle, Elaine; Johnson, Samantha; Petrou, Stavros; Quigley, Maria A.			Associations between gestational age at birth and infection-related hospital admission rates during childhood in England: Population-based record linkage study	PLOS ONE			English	Article							RESPIRATORY-INFECTION; PRETERM BIRTH; WEIGHT; INTERVENTIONS; DELIVERY; OUTCOMES; RISK	Background Children born preterm (<37 completed weeks' gestation) have a higher risk of infection-related morbidity than those born at term. However, few large, population-based studies have investigated the risk of infection in childhood across the full spectrum of gestational age. The objectives of this study were to explore the association between gestational age at birth and infection-related hospital admissions up to the age of 10 years, how infection-related hospital admission rates change throughout childhood, and whether being born small for gestational age (SGA) modifies this relationship. Methods and findings Using a population-based, record-linkage cohort study design, birth registrations, birth notifications and hospital admissions were linked using a deterministic algorithm. The study population included all live, singleton births occurring in NHS hospitals in England from January 2005 to December 2006 (n = 1,018,136). The primary outcome was all infection-related inpatient hospital admissions from birth to 10 years of age, death or study end (March 2015). The secondary outcome was the type of infection-related hospital admission, grouped into broad categories. Generalised estimating equations were used to estimate adjusted rate ratios (aRRs) with 95% confidence intervals (CIs) for each gestational age category (<28, 28-29, 30-31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 and 42 weeks) and the models were repeated by age at admission (<1, 1-2, 3-4, 5-6, and 7-10 years). An interaction term was included in the model to test whether SGA status modified the relationship between gestational age and infection-related hospital admissions. Gestational age was strongly associated with rates of infection-related hospital admissions throughout childhood. Whilst the relationship attenuated over time, at 7-10 years of age those born before 40 weeks gestation were still significantly higher in comparison to those born at 40 weeks. Children born <28 weeks had an aRR of 6.53 (5.91-7.22) during infancy, declining to 3.16 (2.50-3.99) at ages 7-10 years, in comparison to those born at 40 weeks; whilst in children born at 38 weeks, the aRRs were 1 center dot 24 (1.21-1.27) and 1.18 (1.13-1.23), during infancy and aged 7-10 years, respectively. SGA status modified the effect of gestational age (interaction P<0.0001), with the highest rate among the children born at <28 weeks and SGA. Finally, study findings indicated that the associations with gestational age varied by subgroup of infection. Whilst upper respiratory tract infections were the most common type of infection experienced by children in this cohort, lower respiratory tract infections (LRTIs) (<28 weeks, aRR = 10.61(9.55-11.79)) and invasive bacterial infections (<28 weeks, aRR = 6.02 (4.56-7.95)) were the most strongly associated with gestational age at birth. Of LRTIs experienced, bronchiolitis (<28 weeks, aRR = 11.86 (10.20-13.80)), and pneumonia (<28 weeks, aRR = 9.49 (7.95-11.32)) were the most common causes. Conclusions Gestational age at birth was strongly associated with rates of infection-related hospital admissions during childhood and even children born a few weeks early remained at higher risk at 7-10 years of age. There was variation between clinical subgroups in the strength of relationships with gestational age. Effective infection prevention strategies should include focus on reducing the number and severity of LRTIs during early childhood.	[Coathup, Victoria; Carson, Claire; Kurinczuk, Jennifer J.; Quigley, Maria A.] Univ Oxford, Nuffield Dept Populat Hlth NDPH, Natl Perinatal Epidemiol Unit NPEU, Oxford, England; [Macfarlane, Alison J.] Univ London, Sch Hlth Sci, London, England; [Boyle, Elaine; Johnson, Samantha] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; [Petrou, Stavros] Univ Oxford, Nuffield Dept Primary Hlth Care Sci, Oxford, England	University of Oxford; University of London; University of Leicester; University of Oxford	Coathup, V (corresponding author), Univ Oxford, Nuffield Dept Populat Hlth NDPH, Natl Perinatal Epidemiol Unit NPEU, Oxford, England.	victoria.coathup@npeu.ox.ac.uk	Boyle, Elaine/I-6298-2018; Petrou, Stavros/ABD-8323-2021	Boyle, Elaine/0000-0002-5038-3148; Petrou, Stavros/0000-0003-3121-6050; Kurinczuk, Jennifer/0000-0001-9554-6337; Quigley, Maria/0000-0002-8058-6181; Carson, Claire/0000-0001-5490-699X; Macfarlane, Alison/0000-0003-0977-7214	Medical Research Council [MR/M01228X/1]	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The TIGAR study was funded by a research grant from the Medical Research Council (MR/M01228X/1). MQ was the recipient of the award. MRC website: https://mrc.ukri.org/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel GA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012750; Allen EC, 2004, PEDIATRICS, V113, P267, DOI 10.1542/peds.113.2.267; Almqvist C, 2020, CLIN EXP ALLERGY, V50, P222, DOI 10.1111/cea.13542; Althubaiti A, 2016, J MULTIDISCIP HEALTH, V9, P211, DOI 10.2147/JMDH.S104807; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; Bentley JP, 2018, ACTA OBSTET GYN SCAN, V97, P988, DOI 10.1111/aogs.13371; Bentley JP, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0591-0; Biasucci G, 2010, EARLY HUM DEV, V86, pS13, DOI 10.1016/j.earlhumdev.2010.01.004; Bolton CE, 2015, THORAX, V70, P574, DOI 10.1136/thoraxjnl-2014-206590; Coathup V, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4075; Coathup V, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037885; Crippa BL, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020312; Datta-Nemdharry P, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001088; Drife J, 2006, BJOG-INT J OBSTET GY, V113, P81, DOI 10.1111/j.1471-0528.2006.01129.x; Frank Nicole M, 2019, BMC Pediatr, V19, P339, DOI 10.1186/s12887-019-1693-2; Fuchs F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191002; Green CA, 2016, ARCH DIS CHILD, V101, P140, DOI 10.1136/archdischild-2015-308723; Hawker JI, 2003, RESP MED, V97, P1219, DOI 10.1016/S0954-6111(03)00252-X; Heidkamp R, 2017, J NUTR, V147, p2188S, DOI 10.3945/jn.116.243667; Helfrich AM, 2015, EARLY HUM DEV, V91, P541, DOI 10.1016/j.earlhumdev.2015.06.009; Johnson L, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-3922-7; Jones LL, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-5; Keeble E., 2017, FOCUS EMERGENCY HOSP, P1; Koshy E, 2012, ARCH DIS CHILD, V97, P1064, DOI 10.1136/archdischild-2012-301755; Kotecha SJ, 2013, THORAX, V68, P760, DOI 10.1136/thoraxjnl-2012-203079; Li YM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195146; Macfarlane A., 2019, HEAL SERV DELIV RES, V7, P1, DOI [10.3310/hsdr07180, DOI 10.3310/HSDR07180]; Macfarlane PI, 2003, ARCH DIS CHILD-FETAL, V88, P199, DOI 10.1136/fn.88.3.F199; Melville JM, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00079; Miller JE, 2016, LANCET INFECT DIS, V16, P952, DOI 10.1016/S1473-3099(16)00150-X; Miller JE, 2018, INT J EPIDEMIOL, V47, P561, DOI 10.1093/ije/dyx272; Montgomery S, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-004034; Morris RK, 2013, ACTA OBSTET GYN SCAN, V92, P143, DOI 10.1111/aogs.12029; Murray J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089186; Ospina M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-033296; Paranjothy S, 2013, PEDIATRICS, V132, pE1562, DOI 10.1542/peds.2013-1737; Pelkonen AS, 1999, ARCH DIS CHILD-FETAL, V81, pF188, DOI 10.1136/fn.81.3.F188; Public Health England NHS Digital, 2020, CHILDH VACC COV STAT, P5; Ray Kristin N, 2013, Hosp Pediatr, V3, P194; Reeves Shane, 2008, Expert Rev Obstet Gynecol, V3, P719, DOI 10.1586/17474108.3.6.719; Romero R, 2007, NUTR REV, V65, pS194, DOI [10.1111/j.1753-4887.2007.tb00362.x, 10.1301/nr.2007.dec.S194-S202]; Sebghati M, 2021, BEST PRACT RES CL OB, V76, P53, DOI 10.1016/j.bpobgyn.2021.03.007; Shah PS, 2011, MATERN CHILD HLTH J, V15, P1097, DOI 10.1007/s10995-010-0654-z; Shah PS, 2010, ACTA OBSTET GYN SCAN, V89, P862, DOI 10.3109/00016349.2010.486827; Shan J, 2021, INFLUENZA OTHER RESP, V15, P539, DOI 10.1111/irv.12850; Skirrow H, 2019, ARCH DIS CHILD, V104, P658, DOI 10.1136/archdischild-2018-316317; Srinivasjois R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130535; StataCorp, 2015, STAT STAT SOFTW REL; Taylor LK, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-210; Tickell KD, 2016, J MATERN-FETAL NEO M, V29, P1871, DOI 10.3109/14767058.2015.1066774; van den Elsen LWJ, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00047; Videholm S, 2019, ARCH DIS CHILD, V104, P58, DOI 10.1136/archdischild-2017-314628; Williams TC, 2021, ARCH DIS CHILD, V106, P911, DOI 10.1136/archdischild-2020-321008; Zhang DD, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0702-2; Zhuge Y., 2020, SCI REP-UK, V10, P1, DOI [10.1038/s41598-019-56847-4, DOI 10.1038/S41598-019-56847-4]	55	3	3	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2021	16	9							e0257341	10.1371/journal.pone.0257341	http://dx.doi.org/10.1371/journal.pone.0257341			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XH8RH	34555039	Green Published, gold, Green Accepted			2023-01-03	WOS:000725694500025
J	Karagiannidis, C; Hentschker, C; Westhoff, M; Weber-Carstens, S; Janssens, U; Kluge, S; Pfeifer, M; Spies, C; Welte, T; Rossaint, R; Mostert, C; Windisch, W				Karagiannidis, Christian; Hentschker, Corinna; Westhoff, Michael; Weber-Carstens, Steffen; Janssens, Uwe; Kluge, Stefan; Pfeifer, Michael; Spies, Claudia; Welte, Tobias; Rossaint, Rolf; Mostert, Carina; Windisch, Wolfram			Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19	PLOS ONE			English	Article							NONINVASIVE VENTILATION; RESPIRATORY-FAILURE; MANAGEMENT; ADULTS; 1ST	Background The role of non-invasive ventilation (NIV) in severe COVID-19 remains a matter of debate. Therefore, the utilization and outcome of NIV in COVID-19 in an unbiased cohort was determined. Aim The aim was to provide a detailed account of hospitalized COVID-19 patients requiring non-invasive ventilation during their hospital stay. Furthermore, differences of patients treated with NIV between the first and second wave are explored. Methods Confirmed COVID-19 cases of claims data of the Local Health Care Funds with non-invasive and/or invasive mechanical ventilation (MV) in the spring and autumn pandemic period in 2020 were comparable analysed. Results Nationwide cohort of 17.023 cases (median/IQR age 71/61-80 years, 64% male) 7235 (42.5%) patients primarily received IMV without NIV, 4469 (26.3%) patients received NIV without subsequent intubation, and 3472 (20.4%) patients had NIV failure (NIV-F), defined by subsequent endotracheal intubation. The proportion of patients who received invasive MV decreased from 75% to 37% during the second period. Accordingly, the proportion of patients with NIV exclusively increased from 9% to 30%, and those failing NIV increased from 9% to 23%. Median length of hospital stay decreased from 26 to 21 days, and duration of MV decreased from 11.9 to 7.3 days. The NIV failure rate decreased from 49% to 43%. Overall mortality increased from 51% versus 54%. Mortality was 44% with NIV-only, 54% with IMV and 66% with NIV-F with mortality rates steadily increasing from 62% in early NIV-F (day 1) to 72% in late NIV-F (>4 days). Conclusions Utilization of NIV rapidly increased during the autumn period, which was associated with a reduced duration of MV, but not with overall mortality. High NIV-F rates are associated with increased mortality, particularly in late NIV-F.	[Karagiannidis, Christian; Windisch, Wolfram] Witten Herdecke Univ Hosp, Cologne Merheim Hosp, ARDS & ECMO Ctr, Dept Pneumol & Crit Care Med,Kliniken Stadt Koln, Cologne, Germany; [Hentschker, Corinna; Mostert, Carina] Res Inst Local Hlth Care Funds, Berlin, Germany; [Westhoff, Michael] Lungenklin Hemer, Dept Pneumol Sleep & Crit Care Med, Hemer, Germany; [Westhoff, Michael] Univ Witten Herdecke, Witten, Germany; [Weber-Carstens, Steffen; Spies, Claudia] Charite Univ Med Berlin, Dept Anesthesiol & Operat Intens Care Med CCM, CVK, Berlin, Germany; [Janssens, Uwe] St Antonius Hosp, Med Clin & Med Intens Care Med, Eschweiler, Germany; [Kluge, Stefan] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Pfeifer, Michael] Univ Hosp Regensburg, Dept Internal Med 2, Regensburg, Germany; [Pfeifer, Michael] Donaustauf Hosp, Dept Pneumol, Donaustauf, Germany; [Welte, Tobias] Hannover Med Sch, Dept Resp Med, Hannover, Germany; [Welte, Tobias] Hannover Med Sch, German Ctr Lung Res DZL, Hannover, Germany; [Rossaint, Rolf] Rhein Westfal TH Aachen, Dept Anesthesiol, Univ Hosp Aachen, Aachen, Germany	Witten Herdecke University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Saint Antonius Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Regensburg; Hannover Medical School; Hannover Medical School; RWTH Aachen University; RWTH Aachen University Hospital	Karagiannidis, C (corresponding author), Witten Herdecke Univ Hosp, Cologne Merheim Hosp, ARDS & ECMO Ctr, Dept Pneumol & Crit Care Med,Kliniken Stadt Koln, Cologne, Germany.	Christian.Karagiannidis@uni-wh.de	Windisch, Wolfram/AFV-2171-2022		Federal Association of the Local Health Care Funds	Federal Association of the Local Health Care Funds	Institutional support and physical resources were provided by the University Witten/Herdecke and Kliniken der Stadt Ko<spacing diaeresis> ln and the Federal Association of the Local Health Care Funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alhazzani W, 2021, CRIT CARE MED, V49, pE219, DOI 10.1097/CCM.0000000000004899; Aliberti S, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01935-2020; Alqahtani JS, 2020, J MULTIDISCIP HEALTH, V13, P1635, DOI 10.2147/JMDH.S279031; Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; Bauer J, 2020, INTENS CARE MED, V46, P2026, DOI 10.1007/s00134-020-06229-6; Bellani G, 2021, ANN AM THORAC SOC, V18, P1020, DOI 10.1513/AnnalsATS.202008-1080OC; Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP; Coppo A, 2020, LANCET RESP MED, V8, P765, DOI 10.1016/S2213-2600(20)30268-X; Crimi C, 2010, EUR RESPIR J, V36, P362, DOI 10.1183/09031936.00123509; Crimi C, 2020, MINERVA ANESTESIOL, V86, P1190, DOI 10.23736/S0375-9393.20.14785-0; Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Fan E, 2020, LANCET RESP MED, V8, P816, DOI 10.1016/S2213-2600(20)30304-0; Franco C, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02130-2020; Girou E, 2000, JAMA-J AM MED ASSOC, V284, P2361, DOI 10.1001/jama.284.18.2361; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Karagiannidis C, 2021, AM J RESP CRIT CARE, V204, P991, DOI 10.1164/rccm.202105-1145LE; Karagiannidis C, 2021, LANCET RESP MED, V9, pE47, DOI 10.1016/S2213-2600(21)00101-6; Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7; Kluge S, 2021, DTSCH ARZTEBL INT, V118, P1, DOI 10.3238/arztebl.m2021.0110; Oranger M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01692-2020; Pasin L, 2020, J CARDIOTHOR VASC AN, V34, P2341, DOI 10.1053/j.jvca.2020.05.005; Pfeifer M, 2020, RESPIRATION, V99, P521, DOI 10.1159/000509104; Raoof S, 2020, CHEST, V158, P1992, DOI 10.1016/j.chest.2020.07.013; Sartini C, 2020, JAMA-J AM MED ASSOC, V323, P2338, DOI 10.1001/jama.2020.7861; Schmidt M, 2021, INTENS CARE MED, V47, P60, DOI 10.1007/s00134-020-06294-x; Sivaloganathan AA, 2020, BRIT J ANAESTH, V125, pE368, DOI 10.1016/j.bja.2020.07.008; Tonelli R, 2020, AM J RESP CRIT CARE, V202, P558, DOI 10.1164/rccm.201912-2512OC; Tuffet S, 2020, AM J RESP CRIT CARE, V202, P769, DOI 10.1164/rccm.202005-1565LE; Vianello A, 2020, THORAX, V75, P998, DOI 10.1136/thoraxjnl-2020-214993; Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE; Wang ZF, 2021, INT J INFECT DIS, V106, P254, DOI 10.1016/j.ijid.2021.03.078; Windisch W, 2020, DTSCH ARZTEBL INT, V117, P528, DOI 10.3238/arztebl.2020.0528	34	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2022	17	1							e0262315	10.1371/journal.pone.0262315	http://dx.doi.org/10.1371/journal.pone.0262315			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2F3FM	35030205	Green Published, gold			2023-01-03	WOS:000812798500038
J	Vora, BMK; Munk, PL; Somasundaram, N; Ouellette, HA; Mallinson, PI; Sheikh, A; Kadir, HA; Tan, TJ; Yan, YY				Vora, Bimal Mayur Kumar; Munk, Peter L.; Somasundaram, Nagavalli; Ouellette, Hugue A.; Mallinson, Paul, I; Sheikh, Adnan; Kadir, Hanis Abdul; Tan, Tien Jin; Yan, Yet Yen			Cryotherapy in extra-abdominal desmoid tumors: A systematic review and meta-analysis	PLOS ONE			English	Article							FOCUSED ULTRASOUND TREATMENT; CRYOABLATION; ABLATION	Introduction Desmoid tumor is a locally-invasive neoplasm that causes significant morbidity. There is recent interest in cryotherapy for treatment of extra-abdominal desmoid tumors. This systematic review assesses evidence on safety and efficacy of cryotherapy in the treatment of extra-abdominal desmoid tumors. Materials and methods The systematic review was conducted with reference to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Literature search was performed using MEDLINE and the Cochrane Central Register of Controlled Trials. 9 full text papers were reviewed and meta-analysis was performed for measures of safety, efficacy and symptom relief. Results The estimated pooled proportion of major and minor complications was 4.2% (95% CI, 1.8-9.6; I-2 = 0%) and 10.2% (95% CI, 5.7-17.8; I-2 = 0%) respectively. The estimated pooled proportion of non-progressive disease rate of all studies was 85.8% (95% CI, 73.4-93.0; I-2 = 32.9%). The estimated progression free survival rate at 1 year was 84.5% (95% CI:74.6-95.8) and 78.0% at 3 years (95% CI: 63.8-95.3). As for pain control, the estimated pooled proportion of patients with decrease in visual analogue scale (VAS) > = 3 for those with VAS > = 3 before treatment for 2 studies was 87.5% (95% CI, 0.06-100; I-2 = 71.5%) while 37.5% to 96.9% of patients were reported to have experienced partial or complete symptom relief in the other studies. Conclusion Cryotherapy is a safe and effective treatment modality for extra-abdominal desmoid tumors with efficacy similar to those treated with traditional strategies in the short to medium term.	[Vora, Bimal Mayur Kumar] Singapore Gen Hosp, Dept Diagnost Radiol, Singapore, Singapore; [Munk, Peter L.; Ouellette, Hugue A.; Mallinson, Paul, I; Sheikh, Adnan] Univ British Columbia, Vancouver Gen Hosp, Dept Radiol, Musculoskeletal Sect, Vancouver, BC, Canada; [Somasundaram, Nagavalli] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore; [Kadir, Hanis Abdul] Singapore Gen Hosp, Hlth Serv Res Unit, Singapore, Singapore; [Tan, Tien Jin; Yan, Yet Yen] Changi Gen Hosp, Dept Radiol, Singapore, Singapore	Singapore General Hospital; University of British Columbia; National Cancer Centre Singapore (NCCS); Singapore General Hospital; Changi General Hospital	Vora, BMK (corresponding author), Singapore Gen Hosp, Dept Diagnost Radiol, Singapore, Singapore.	Vora.bimal.mayur.kumar@singhealth.com.sg		Vora, Bimal Mayur Kumar/0000-0001-8394-2017				Ahmed M, 2014, RADIOLOGY, V273, P241, DOI 10.1148/radiol.14132958; Alman B, 2020, EUR J CANCER, V127, P96, DOI 10.1016/j.ejca.2019.11.013; Auloge P, 2021, INT J CLIN ONCOL, V26, P1147, DOI 10.1007/s10147-021-01887-y; Bouhamama A., 2019, LOCAL CONTROL ANALGE, DOI [10.1007/s00270-019-02323-5, DOI 10.1007/S00270-019-02323-5]; Choi SH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198134; Clark TWI, 2003, J VASC INTERV RADIOL, V14, P629, DOI 10.1097/01.RVI.0000064861.87207.3E; Cobianchi L, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-361; Crago AM, 2013, ANN SURG, V258, P347, DOI 10.1097/SLA.0b013e31828c8a30; Cuomo P, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08189-6; Di Staso M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129021; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Efrima B, 2021, J SURG ONCOL, V124, P627, DOI 10.1002/jso.26528; Fiore M, 2015, EUR J CANCER, V51, P2800, DOI 10.1016/j.ejca.2015.08.026; Ghanouni P, 2017, EUR RADIOL, V27, P732, DOI 10.1007/s00330-016-4376-5; Gounder MM, 2018, NEW ENGL J MED, V379, P2417, DOI 10.1056/NEJMoa1805052; Gronchi A, 2019, JAMA ONCOL, V5, P567, DOI 10.1001/jamaoncol.2018.6449; Guyot P, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-9; Havez M, 2014, CARDIOVASC INTER RAD, V37, P1500, DOI 10.1007/s00270-013-0830-9; Ilaslan H, 2010, SKELETAL RADIOL, V39, P169, DOI 10.1007/s00256-009-0807-6; Kasper B, 2017, ANN ONCOL, V28, P2399, DOI 10.1093/annonc/mdx323; Kummar S, 2017, J CLIN ONCOL, V35, P1561, DOI 10.1200/JCO.2016.71.1994; Kurtz JE, 2021, EUR J CANCER, V143, P78, DOI 10.1016/j.ejca.2020.10.035; Li ZW, 2014, TUMOR BIOL, V35, P10841, DOI 10.1007/s13277-014-2374-2; Liu YE, 2020, WORLD J GASTRO ONCOL, V12, DOI 10.4251/wjgo.v12.i2.237; Looi WS, 2021, CURR TREAT OPTION ON, V22, DOI 10.1007/s11864-021-00831-6; Martinez-Martinez A, 2021, KOREAN J RADIOL, V22, P944, DOI 10.3348/kjr.2020.0768; Mohan H, 2015, J VASC INTERV RADIOL, V26, P935, DOI 10.1016/j.jvir.2014.12.009; Nieuwenhuis MH, 2011, INT J CANCER, V129, P256, DOI 10.1002/ijc.25664; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Palassini E, 2017, CANCER J, V23, P86, DOI 10.1097/PPO.0000000000000254; Quast DR, 2016, FAM CANCER, V15, P31, DOI 10.1007/s10689-015-9830-z; Ruspi L, 2021, EJSO-EUR J SURG ONC, V47, P1196, DOI 10.1016/j.ejso.2020.08.009; Saltiel S, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10080556; Schmitz JJ, 2016, AM J ROENTGENOL, V207, P190, DOI 10.2214/AJR.15.14391; Subhawong TK., 2021, IMAGING CANC, V3, pe210016, DOI [10.1148/rycan.2021210016, DOI 10.1148/RYCAN.2021210016]; Toulmonde M, 2019, LANCET ONCOL, V20, P1263, DOI 10.1016/S1470-2045(19)30276-1; Tremblay KR, 2019, J SURG ONCOL, V120, P366, DOI 10.1002/jso.25597; von Mehren Margaret, 2020, J Natl Compr Canc Netw, V18, P1604, DOI 10.6004/jnccn.2020.0058; Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135; Wang Y, 2011, INT J HYPERTHER, V27, P648, DOI 10.3109/02656736.2011.597047; Yan YY, 2021, J VASC INTERV RADIOL, V32, P1277, DOI 10.1016/j.jvir.2021.05.025	41	4	4	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2021	16	12							e0261657	10.1371/journal.pone.0261657	http://dx.doi.org/10.1371/journal.pone.0261657			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ1OP	34941915	gold, Green Published			2023-01-03	WOS:000755252200060
J	Rolles, S				Rolles, Steve			UK drugs strategy: promised new approach is identical to previous strategies	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Rolles, Steve] Transform Drug Policy Fdn, Bristol, Avon, England		Rolles, S (corresponding author), Transform Drug Policy Fdn, Bristol, Avon, England.							Transform Drug Policy Foundation, 2021, BLACK REV STRONG TRE; Transform Drug Policy Foundation, DRUG DIV UK; Transform Drug Policy Foundation, DRUG POL FIT 21 CENT; Transform Drug Policy Foundation, 2021, DRUG DECR PORT SETT	4	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 21	2021	375								n3129	10.1136/bmj.n3129	http://dx.doi.org/10.1136/bmj.n3129			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP9AR	34933902	Bronze			2023-01-03	WOS:000748911700006
J	Mwaiswelo, RO; Mmbando, BP; Chacky, F; Molteni, F; Mohamed, A; Lazaro, S; Mkalla, SF; Samuel, B; Ngasala, B				Mwaiswelo, Richard O.; Mmbando, Bruno P.; Chacky, Frank; Molteni, Fabrizio; Mohamed, Ally; Lazaro, Samwel; Mkalla, Sylvia F.; Samuel, Bushukatale; Ngasala, Billy			Malaria infection and anemia status in under-five children from Southern Tanzania where seasonal malaria chemoprevention is being implemented	PLOS ONE			English	Article							INTERVENTION; MALNUTRITION; HOUSEHOLD; IMPACT; RISK	Background Malaria and anemia remain major public health challenges in Tanzania. Household socioeconomic factors are known to influence these conditions. However, it is not clear how these factors influence malaria transmission and anemia in Masasi and Nanyumbu Districts. This study presents findings on malaria and anemia situation in under-five children and its influencing socioeconomic factors in Masasi and Nanyumbu Districts, surveyed as part of an ongoing seasonal malaria chemoprevention operational study. Methods A community-based cross-sectional survey was conducted between August and September 2020. Finger-prick blood samples collected from children aged 3-59 months were used to test for malaria infection using malaria rapid diagnostic test (mRDT), thick smears for determination of asexual and sexual parasitemia, and thin smear for parasite speciation. Hemoglobin concentration was measured using a HemoCue spectrophotometer. A structured questionnaire was used to collect household socioeconomic information from parents/caregivers of screened children. The prevalence of malaria was the primary outcome. Chi-square tests, t-tests, and logistic regression models were used appropriately. Results Overall mRDT-based malaria prevalence was 15.9% (373/2340), and was significantly higher in Nanyumbu (23.7% (167/705) than Masasi District (12.6% (206/1635), p<0.001. Location (Nanyumbu), no formal education, household number of people, household number of under-fives, not having a bed net, thatched roof, open/partially open eave, sand/soil floor, and low socioeconomic status were major risks for malaria infection. Some 53.9% (1196/2218) children had anemia, and the majority were in Nanyumbu (63.5% (458/705), p<0.001. Location (Nanyumbu), mRDT positive, not owning a bed net, not sleeping under bed net, open/partially open eave, thatched window, sex of the child, and age of the child were major risk factors for anemia. Conclusion Prevalence of malaria and anemia was high and was strongly associated with household socioeconomic factors. Improving household socioeconomic status is expected to reduce the prevalence of the conditions in the area.	[Mwaiswelo, Richard O.] Hubert Kairuki Mem Univ, Dept Microbiol Immunol & Parasitol, Dar Es Salaam, Tanzania; [Mmbando, Bruno P.] Tanga Res Ctr, Natl Inst Med Res, Tanga, Tanzania; [Chacky, Frank; Molteni, Fabrizio; Mohamed, Ally; Lazaro, Samwel] Minist Hlth Community Dev Gender Elderly & Childr, Natl Malaria Control Programme, Dodoma, Tanzania; [Mkalla, Sylvia F.] Tanzania Commiss Sci & Technol, Directorate Res Coordinat & Promot, Dar Es Salaam, Tanzania; [Samuel, Bushukatale; Ngasala, Billy] Muhimbili Univ Hlth & Allied Sci, Dept Med Parasitol & Entomol, Dar Es Salaam, Tanzania	National Institute of Medical Research; Muhimbili University of Health & Allied Sciences	Mwaiswelo, RO (corresponding author), Hubert Kairuki Mem Univ, Dept Microbiol Immunol & Parasitol, Dar Es Salaam, Tanzania.	richiemwai@yahoo.com		Mwaiswelo, Richard/0000-0002-1341-4304; Mmbando, Bruno/0000-0001-7232-8708	BN Global Fund	BN Global Fund	BN Global Fund Funders did not play any role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	Ayele DG, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-195; Chirebvu Elijah, 2014, Malar Res Treat, V2014, P403069, DOI 10.1155/2014/403069; Coleman M, 2010, T ROY SOC TROP MED H, V104, P143, DOI 10.1016/j.trstmh.2009.07.010; Custodio E, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-225; Deressa W, 2007, T ROY SOC TROP MED H, V101, P939, DOI 10.1016/j.trstmh.2007.04.018; Dobbs KR, 2016, PARASITOLOGY, V143, P129, DOI 10.1017/S0031182015001626; Duggan MB, 2010, ANN TROP PAEDIATR, V30, P1, DOI 10.1179/146532810X12637745451834; Edwards HM, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2852-5; Ehrhardt S, 2006, J INFECT DIS, V194, P108, DOI 10.1086/504688; EMA, 2016, GUID GOOD CLIN PRACT, V6; Gahutu JB, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-134; Ghebreyesus TA, 2000, T ROY SOC TROP MED H, V94, P17, DOI 10.1016/S0035-9203(00)90424-3; Ghosh K, 2007, PARASITOL RES, V101, P1463, DOI 10.1007/s00436-007-0742-1; GILLIES MT, 1980, B ENTOMOL RES, V70, P525, DOI 10.1017/S0007485300007811; Guerra M, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2354-x; Haldar Kasturi, 2009, Hematology Am Soc Hematol Educ Program, P87, DOI 10.1182/asheducation-2009.1.87; Hassan TH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005395; Kateera F, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0973-z; Khatib RA, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2446-7; Kinung'hi SM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0864-5; Klinkenberg E, 2006, TROP MED INT HEALTH, V11, P578, DOI 10.1111/j.1365-3156.2006.01609.x; Lowassa A, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-129; Mazigo Humphrey D, 2010, Malar Res Treat, V2010, P794261, DOI 10.4061/2010/794261; Mazigo Humphrey D, 2011, BMC Res Notes, V4, P359, DOI 10.1186/1756-0500-4-359; Mazigo HD, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-44; Mmbando BP, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-165; Murphy SC, 2001, AM J TROP MED HYG, V64, P57, DOI 10.4269/ajtmh.2001.64.57; National Malaria Control Programme (NMCP), 2014, NAT MAL STRAT PLAN 2; NBS, 2017, MAL IND SURV 2017; Oladeinde BH, 2012, IRAN J PARASITOL, V7, P31; Ong'echa JM, 2006, AM J TROP MED HYG, V74, P376, DOI 10.4269/ajtmh.2006.74.376; Papaioannou I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47614-6; Patz JA, 2006, P NATL ACAD SCI USA, V103, P5635, DOI 10.1073/pnas.0601493103; PMI, 2019, TANZ MAL OP PLAN FIS; PMI, 2014, TANZ MAL OP PLAN FIS; PMI, 2017, TANZ MAL OP PLAN 201; Rahmani S., 2015, Journal of Nutrition and Food Sciences, V5, P333; Reynaldi A, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2657-6; Ronald LA, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-105; Sakwe N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218442; Salim N, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003660; Siza JE, 2015, KOREAN J PARASITOL, V53, P525, DOI 10.3347/kjp.2015.53.5.525; Somi MF, 2007, AM J TROP MED HYG, V77, P1020, DOI 10.4269/ajtmh.2007.77.1020; Spitzen J, 2008, PHYSIOL ENTOMOL, V33, P116, DOI 10.1111/j.1365-3032.2008.00612.x; Sultana M, 2017, TROP MED HEALTH, V45, DOI 10.1186/s41182-017-0066-5; Tahita MC, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-464; Urbaniak G.C., 2013, RES RANDOMIZER VERSI; Vajda EA, 2017, TROP MED INFECT DIS, V2, DOI 10.3390/tropicalmed2010004; Weatherall David J, 2002, Hematology Am Soc Hematol Educ Program, P35; West PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065787; White NJ, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2509-9; WHO, 2010, WORLD MALARIA REPORT 2010, P1; WHO, 2018, UN ACC COR MAL INT H; WHO, 2017, DEPRESSION; WHO, 2006, WHO GENEVA; World Health Organization (WHO), 2015, WORLD MALARIA REPORT; Yadav K, 2014, INFECT DIS POVERTY, V3, DOI 10.1186/2049-9957-3-19; Yeka A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118901	58	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2021	16	12							e0260785	10.1371/journal.pone.0260785	http://dx.doi.org/10.1371/journal.pone.0260785			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW0CT	34855878	gold, Green Published			2023-01-03	WOS:000735299000120
J	Fu, EL; Evans, M; Carrero, JJ; Putter, H; Clase, CM; Caskey, FJ; Szymczak, M; Torino, C; Chesnaye, NC; Jager, KJ; Wanner, C; Dekker, FW; van Diepen, M				Fu, Edouard L.; Evans, Marie; Carrero, Juan-Jesus; Putter, Hein; Clase, Catherine M.; Caskey, Fergus J.; Szymczak, Maciej; Torino, Claudia; Chesnaye, Nicholas C.; Jager, Kitty J.; Wanner, Christoph; Dekker, Friedo W.; van Diepen, Merel			Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-PRACTICE GUIDELINE; STAGE RENAL-DISEASE; PERITONEAL-DIALYSIS; START DIALYSIS; HEMODIALYSIS; SURVIVAL; IMPACT; COMORBIDITY; OUTCOMES; THERAPY	OBJECTIVE To identify the optimal estimated glomerular filtration rate (eGFR) at which to initiate dialysis in people with advanced chronic kidney disease. DESIGN Nationwide observational cohort study. SETTING National Swedish Renal Registry of patients referred to nephrologists. PARTICIPANTS Patients had a baseline eGFR between 10 and 20 mL/min/1.73 m(2) and were included between 1 January 2007 and 31 December 2016, with follow-up until 1 June 2017. MAIN OUTCOME MEASURES The strict design criteria of a clinical trial were mimicked by using the cloning, censoring, and weighting method to eliminate immortal time bias, lead time bias, and survivor bias. A dynamic marginal structural model was used to estimate adjusted hazard ratios and absolute risks for five year all cause mortality and major adverse cardiovascular events (composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) for 15 dialysis initiation strategies with eGFR values between 4 and 19 mL/min/1.73 m(2) in increments of 1 mL/min/1.73 m(2). An eGFR between 6 and 7 mL/min/1.73 m(2) (eGFR(6-7)) was taken as the reference. RESULTS Among 10 290 incident patients with advanced chronic kidney disease (median age 73 years; 3739 (36%) women; median eGFR 16.8 mL/min/1.73 m(2)), 3822 started dialysis, 4160 died, and 2446 had a major adverse cardiovascular event. A parabolic relation was observed for mortality, with the lowest risk for eGFR(15-16). Compared with dialysis initiation at eGFR(6-7), initiation at eGFR(15-16) was associated with a 5.1% (95% confidence interval 2.5% to 6.9%) lower absolute five year mortality risk and 2.9% (0.2% to 5.5%) lower risk of a major adverse cardiovascular event, corresponding to hazard ratios of 0.89 (95% confidence interval 0.87 to 0.92) and 0.94 (0.91 to 0.98), respectively. This 5.1% absolute risk difference corresponded to a mean postponement of death of 1.6 months over five years of follow-up. However, dialysis would need to be started four years earlier. When emulating the intended strategies of the Initiating Dialysis Early and Late (IDEAL) trial (eGFR(10-14)v eGFR(5-7)) and the achieved eGFRs in IDEAL (eGFR(7-10)v eGFR(5-7)), hazard ratios for all cause mortality were 0.96 (0.94 to 0.99) and 0.97 (0.94 to 1.00), respectively, which are congruent with the findings of the randomised IDEAL trial. CONCLUSIONS Very early initiation of dialysis was associated with a modest reduction in mortality and cardiovascular events. For most patients, such a reduction may not outweigh the burden of a substantially longer period spent on dialysis.	[Fu, Edouard L.; Dekker, Friedo W.; van Diepen, Merel] Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands; [Evans, Marie] Karolinska Inst, Dept Clin Intervent & Technol, Stockholm, Sweden; [Carrero, Juan-Jesus] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Putter, Hein] Leiden Univ, Dept Biomed Data Sci, Med Ctr, Leiden, Netherlands; [Clase, Catherine M.] McMaster Univ, Dept Med & Hlth Res Methods, Evidence & Impact, Hamilton, ON, Canada; [Caskey, Fergus J.] Univ Bristol, Sch Med, Populat Hlth Sci, Bristol, Avon, England; [Szymczak, Maciej] Wroclaw Med Univ, Dept Nephrol & Transplantat Med, Wroclaw, Poland; [Torino, Claudia] IFC CNR, Clin Epidemiol & Pathophysiol Renal Dis & Hyperte, Reggio Di Calabria, Italy; [Chesnaye, Nicholas C.; Jager, Kitty J.] Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Acad Univ Med Ctr, ERA EDTA Registry,Dept Med Informat, Amsterdam, Netherlands; [Wanner, Christoph] Univ Hosp Wurzburg, Div Nephrol, Wurzburg, Germany	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Karolinska Institutet; Karolinska Institutet; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; McMaster University; University of Bristol; Wroclaw Medical University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Amsterdam; Vrije Universiteit Amsterdam; University of Wurzburg	Fu, EL (corresponding author), Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands.	edfu@bwh.harvard.edu	Chesnaye, Nicholas/G-5707-2013; Fu, Edouard L./AAR-4751-2020; Putter, Hein/C-2244-2018	Chesnaye, Nicholas/0000-0003-4883-9174; Fu, Edouard L./0000-0002-9698-6825; Szymczak, Maciej/0000-0002-1248-081X; Clase, Catherine/0000-0002-4538-5958; Putter, Hein/0000-0001-5395-1422; Caskey, Fergus/0000-0002-5199-3925	Swedish Research Council [2019-01059]; Center of Innovative Medicine (CIMED) Karolinska; Stockholm City Council (ALF Medicine)	Swedish Research Council(Swedish Research CouncilEuropean Commission); Center of Innovative Medicine (CIMED) Karolinska; Stockholm City Council (ALF Medicine)	JJC obtained support from the Swedish Research Council (2019-01059). ME was supported by the Center of Innovative Medicine (CIMED) Karolinska and Stockholm City Council (ALF Medicine). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.	Beddhu S, 2003, J AM SOC NEPHROL, V14, P2305, DOI 10.1097/01.ASN.0000080184.67406.11; Bozorgmehri S, 2021, HEMODIAL INT, V25, P188, DOI 10.1111/hdi.12912; Brooke HL, 2017, EUR J EPIDEMIOL, V32, P765, DOI 10.1007/s10654-017-0316-1; Buchanan AL, 2014, AIDS RES HUM RETROV, V30, P1170, DOI [10.1089/aid.2014.0037, 10.1089/AID.2014.0037]; Cain LE, 2010, INT J BIOSTAT, V6, DOI 10.2202/1557-4679.1212; Chan CT, 2019, KIDNEY INT, V96, P37, DOI 10.1016/j.kint.2019.01.017; Chau EM., 2016, CAN J KIDNEY HEALTH, V3; Clark WF, 2011, CAN MED ASSOC J, V183, P47, DOI 10.1503/cmaj.100349; Cohen LM, 2014, CLIN J AM SOC NEPHRO, V9, P840, DOI 10.2215/CJN.02690314; Cole SR, 2004, COMPUT METH PROG BIO, V75, P45, DOI 10.1016/j.cmpb.2003.10.004; Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164; Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; Coronel F, 2009, SCAND J UROL NEPHROL, V43, P148, DOI 10.1080/00365590802602903; Couillerot-Peyrondet AL, 2017, EUR J HEALTH ECON, V18, P459, DOI 10.1007/s10198-016-0801-6; Crews DC, 2014, AM J KIDNEY DIS, V63, P806, DOI 10.1053/j.ajkd.2013.12.010; Dabrowska-Bender M, 2018, PATIENT PREFER ADHER, V12, P577, DOI 10.2147/PPA.S156356; Daugirdas JT, 2015, AM J KIDNEY DIS, V66, P884, DOI 10.1053/j.ajkd.2015.07.015; Eriksson JK, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012062; Evans M, 2011, J INTERN MED, V269, P289, DOI 10.1111/j.1365-2796.2010.02280.x; Evans M, 2017, NEPHROL DIAL TRANSPL, V32, P1892, DOI 10.1093/ndt/gfw328; Fink JC, 1999, AM J KIDNEY DIS, V34, P694, DOI 10.1016/S0272-6386(99)70395-1; Fu EL, 2021, CLIN KIDNEY J, V14, P1317, DOI 10.1093/ckj/sfaa242; Fu EL, 2021, J AM SOC NEPHROL, V32, P424, DOI 10.1681/ASN.2020050682; Fu EL, 2021, AM J KIDNEY DIS, V77, P719, DOI 10.1053/j.ajkd.2020.10.006; Fu EL, 2019, NEPHROL DIAL TRANSPL, V34, P1629, DOI 10.1093/ndt/gfy283; Hernan MA, 2006, BASIC CLIN PHARMACOL, V98, P237, DOI 10.1111/j.1742-7843.2006.pto_329.x; Hernan MA, 2016, J CLIN EPIDEMIOL, V79, P70, DOI 10.1016/j.jclinepi.2016.04.014; Hernan MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254; Hernan MA, 2011, EPIDEMIOLOGY, V22, P368, DOI 10.1097/EDE.0b013e3182109296; Hsu CY, 2020, JAMA INTERN MED, V180, P1647, DOI 10.1001/jamainternmed.2020.5009; Hwang SJ, 2010, NEPHROL DIAL TRANSPL, V25, P2616, DOI 10.1093/ndt/gfq308; Jain AK, 2014, AM J KIDNEY DIS, V63, P798, DOI 10.1053/j.ajkd.2013.10.054; Janmaat CJ, 2017, CLIN EPIDEMIOL, V9, P217, DOI 10.2147/CLEP.S127695; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Kazmi WH, 2005, AM J KIDNEY DIS, V46, P887, DOI 10.1053/j.ajkd.2005.08.005; Kloecker DE, 2020, ANN INTERN MED, V172, P541, DOI 10.7326/M19-3286; Korevaar JC, 2001, LANCET, V358, P1046, DOI 10.1016/S0140-6736(01)06180-3; Lassalle M, 2010, KIDNEY INT, V77, P700, DOI 10.1038/ki.2010.14; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levin A, 2013, KIDNEY INT, V83, P1001, DOI 10.1038/ki.2013.91; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Mann Bikaramjit S, 2014, Can J Kidney Health Dis, V1, P3, DOI 10.1186/2054-3581-1-3; Maringe C, 2020, INT J EPIDEMIOL, V49, P1719, DOI 10.1093/ije/dyaa057; Mazairac AHA, 2013, NEPHROL DIAL TRANSPL, V28, P1865, DOI 10.1093/ndt/gft045; Mohnen SM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220800; Murphy E, 2021, NEPHROL DIAL TRANSPL, V36, P975, DOI 10.1093/ndt/gfaa209; Nacak H, 2016, NEPHROL DIAL TRANSPL, V31, P306, DOI 10.1093/ndt/gfv431; Nesrallah GE, 2014, CAN MED ASSOC J, V186, P112, DOI 10.1503/cmaj.130363; Rosansky SJ, 2011, ARCH INTERN MED, V171, P396, DOI 10.1001/archinternmed.2010.415; Safiri S, 2019, ANN RHEUM DIS, V78, P1463, DOI 10.1136/annrheumdis-2019-215920; Sawhney S, 2009, NEPHROL DIAL TRANSPL, V24, P3186, DOI 10.1093/ndt/gfp189; Shiao CC, 2008, PERITON DIALYSIS INT, V28, P73; Sjolander A, 2011, AM J EPIDEMIOL, V174, P1204, DOI 10.1093/aje/kwr249; Stel VS, 2009, NEPHROL DIAL TRANSPL, V24, P3175, DOI 10.1093/ndt/gfp264; Susantitaphong P, 2012, AM J KIDNEY DIS, V59, P829, DOI 10.1053/j.ajkd.2012.01.015; Swedish Renal Registry, ANN REP; Tang SCW, 2007, NEPHROL DIAL TRANSPL, V22, P1926, DOI 10.1093/ndt/gfm109; Tangri N, 2021, J AM SOC NEPHROL, V32, P1791, DOI 10.1681/ASN.2020091254; Tattersall J, 2011, NEPHROL DIAL TRANSPL, V26, P2082, DOI 10.1093/ndt/gfr168; Traynor JP, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025294.40179.E8; United States Renal Data System, 2020, 2020 USRDS ANN DAT R; van Geloven N, 2017, NEPHROL DIAL TRANSPL, V32, P53, DOI 10.1093/ndt/gfx012; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Watanabe Y, 2015, THER APHER DIAL, V19, P67, DOI 10.1111/1744-9987.12294; Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294; Wright S, 2010, CLIN J AM SOC NEPHRO, V5, P1828, DOI 10.2215/CJN.06230909; Young JG, 2020, STAT MED, V39, P1199, DOI 10.1002/sim.8471	68	7	7	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 29	2021	375								e066306	10.1136/bmj-2021-066306	http://dx.doi.org/10.1136/bmj-2021-066306			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE1NC	34844936	Green Published, hybrid			2023-01-03	WOS:000740896100015
J	Tajima, H; Matsuse, H; Hashida, R; Nago, T; Bekki, M; Iwanaga, S; Higashi, E; Shiba, N				Tajima, Hiroshi; Matsuse, Hiroo; Hashida, Ryuki; Nago, Takeshi; Bekki, Masafumi; Iwanaga, Sohei; Higashi, Eriko; Shiba, Naoto			Electrically stimulated eccentric contraction during non-weight bearing knee bending exercise in the supine position increases oxygen uptake: A randomized, controlled, exploratory crossover trial	PLOS ONE			English	Article							HEART-FAILURE; RESISTANCE; VOLUNTARY; STRENGTH; ATROPHY; SYSTEM; MASS	It is well known that prolonged bed rest induces muscle weakness, muscle atrophy, cardiovascular deconditioning, bone loss, a loss of functional capacity, and the development of insulin resistance. Neuromuscular electrical stimulation is anticipated to be an interventional strategy for disuse due to bed rest. A hybrid training system (HTS), synchronized neuromuscular electrical stimulation for voluntary exercise using an articular motion sensor, may increase the exercise load though bed rest. We assessed oxygen uptake or heart rate during knee bending exercise in the supine position on a bed both simultaneously combined with HTS and without HTS to evaluate exercise intensity on different days in ten healthy subjects (8 men and 2 women) by a randomized controlled crossover trial. The values of relative oxygen uptake during knee bending exercise with HTS were significantly greater than those during knee bending exercise without HTS (7.29 +/- 0.91 ml/kg/min vs. 8.29 +/- 1.06 ml/kg/min; p = 0.0115). That increment with HTS was a mean of 14.42 +/- 13.99%. Metabolic equivalents during knee bending exercise with HTS and without HTS were 2.08 +/- 0.26 and 2.39 +/- 0.30, respectively. The values of heart rate during knee bending exercise with HTS were significantly greater than those during knee bending exercise without HTS (80.82 +/- 9.19 bpm vs. 86.36 +/- 5.50 bpm; p = 0.0153). HTS could increase exercise load during knee bending exercise which is easy to implement on a bed. HTS might be a useful technique as a countermeasure against the disuse due to bed rest, for example during acute care or the quarantine for infection prophylaxis.	[Tajima, Hiroshi; Matsuse, Hiroo; Hashida, Ryuki; Nago, Takeshi; Bekki, Masafumi; Iwanaga, Sohei; Higashi, Eriko; Shiba, Naoto] Kurume Univ, Rehabil Ctr, Kurume, Fukuoka, Japan	Kurume University	Matsuse, H (corresponding author), Kurume Univ, Rehabil Ctr, Kurume, Fukuoka, Japan.	matsuse_hiroh@kurume-u.ao.jp		MATSUSE, HIROO/0000-0001-9741-6640				Alkner BA, 2004, ACTA PHYSIOL SCAND, V181, P345, DOI 10.1111/j.1365-201X.2004.01293.x; BERG HE, 1994, AVIAT SPACE ENVIR MD, V65, P752; Bloomfield SA, 1997, MED SCI SPORT EXER, V29, P197, DOI 10.1097/00005768-199702000-00006; Brower Roy G, 2009, Crit Care Med, V37, pS422, DOI 10.1097/CCM.0b013e3181b6e30a; Burke D, 2016, CLIN RESPIR J, V10, P407, DOI 10.1111/crj.12234; Cameron S, 2015, J CRIT CARE, V30, P664, DOI 10.1016/j.jcrc.2015.03.032; Dalise S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11260-7; Dirks ML, 2018, J APPL PHYSIOL, V125, P850, DOI 10.1152/japplphysiol.00985.2016; DUDLEY GA, 1991, AVIAT SPACE ENVIR MD, V62, P543; Cerqueira TCF, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013012; Forestieri P, 2018, CLIN REHABIL, V32, P66, DOI 10.1177/0269215517715762; Gaesser G A, 1996, Exerc Sport Sci Rev, V24, P35; Neto MG, 2016, J CARDIOPULM REHABIL, V36, P157, DOI 10.1097/HCR.0000000000000151; HAINAUT K, 1992, SPORTS MED, V14, P100, DOI 10.2165/00007256-199214020-00003; Hamada T, 2004, J APPL PHYSIOL, V96, P911, DOI 10.1152/japplphysiol.00664.2003; Iwanaga S, 2020, TOHOKU J EXP MED, V252, P23, DOI 10.1620/tjem.252.23; Iwasaki T, 2006, TOHOKU J EXP MED, V209, P33, DOI 10.1620/tjem.209.33; Iwatsu K, 2015, ARCH PHYS MED REHAB, V96, P63, DOI 10.1016/j.apmr.2014.08.012; Liu M, 2020, INT J NURS SCI, V7, P228, DOI 10.1016/j.ijnss.2020.03.002; Maffiuletti NA, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01031; Matsuse H, 2006, AVIAT SPACE ENVIR MD, V77, P581; Matsuse H, 2020, AM J PHYS MED REHAB, V99, P56, DOI 10.1097/PHM.0000000000001319; Matsuse H, 2013, J REHABIL RES DEV, V50, P545, DOI 10.1682/JRRD.2012.04.0067; Nagaraja Mamta Patel, 2014, Life-Basel, V4, P117, DOI 10.3390/life4020117; Nakamura K, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03080-5; Numata H, 2016, J ORTHOP SCI, V21, P53, DOI 10.1016/j.jos.2015.09.003; Oates BR, 2010, MUSCLE NERVE, V42, P539, DOI 10.1002/mus.21721; Omoto M, 2013, J NOV PHYSIOTHER, V3, P185; Paillard T, 2008, SPORTS MED, V38, P161, DOI 10.2165/00007256-200838020-00005; Pain MTG, 2013, J BIOMECH, V46, P645, DOI 10.1016/j.jbiomech.2012.11.052; Rabe KG, 2018, PM&R, V10, P1301, DOI 10.1016/j.pmrj.2018.05.014; Seger JY, 2000, ACTA PHYSIOL SCAND, V169, P63; Swain DP, 1997, MED SCI SPORT EXER, V29, P410, DOI 10.1097/00005768-199703000-00018; Takano Y, 2010, TOHOKU J EXP MED, V221, P77, DOI 10.1620/tjem.221.77; Theurel J, 2007, RESP PHYSIOL NEUROBI, V157, P341, DOI 10.1016/j.resp.2006.12.002; Tsukada Yuya, 2020, Kurume Med J, V65, P145, DOI 10.2739/kurumemedj.MS654007; Valenzuela PL, 2018, AGEING RES REV, V47, P80, DOI 10.1016/j.arr.2018.07.003; Voet NBM, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003907.pub5; Ward AR, 2002, PHYS THER, V82, P1019, DOI 10.1093/ptj/82.10.1019	39	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2021	16	11							e0259856	10.1371/journal.pone.0259856	http://dx.doi.org/10.1371/journal.pone.0259856			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2NY	34793521	Green Published, gold			2023-01-03	WOS:000755319200061
J	Safdar, ME; Wang, XK; Abbas, M; Ozaslan, C; Asif, M; Adnan, M; Zuan, ATK; Wang, WQ; Gasparovic, K; Nasif, O; Ansari, MJ				Safdar, Muhammad Ehsan; Wang, Xiukang; Abbas, Mudasar; Ozaslan, Cumali; Asif, Muhammad; Adnan, Muhammad; Zuan, Ali Tan Kee; Wang, Wenqiang; Gasparovic, Kristina; Nasif, Omaima; Ansari, Mohammad Javed			The impact of aqueous and N-hexane extracts of three Fabaceae species on seed germination and seedling growth of some broadleaved weed species	PLOS ONE			English	Article							TRIANTHEMA-PORTULACASTRUM L.; PARTHENIUM-HYSTEROPHORUS; INTERFERENCE; PERFORMANCE; ECOLOGY; PLANTS	Weed infestation is a persistent problem for centuries and continues to be major yield reducing issue in modern agriculture. Chemical weed control through herbicides results in numerous ecological, environmental, and health-related issues. Moreover, numerous herbicides have evolved resistance against available herbicides. Plant extracts are regarded as an alternative to herbicides and a good weed management option. The use of plant extracts is environmentally safe and could solve the problem of herbicide resistance. Therefore, laboratory and wire house experiments were conducted to evaluate the phytotoxic potential of three Fabaceae species, i.e., Cassia occidentalis L. (Coffee senna), Sesbania sesban (L.) Merr. (Common sesban) and Melilotus alba Medik. (White sweetclover) against seed germination and seedling growth of some broadleaved weed species. Firstly, N-hexane and aqueous extracts of these species were assessed for their phytotoxic effect against lettuce (Lactuca sativa L.). The extracts found more potent were further tested against germination and seedling growth of four broadleaved weed species, i.e., Parthenium hysterophorus L. (Santa-Maria), Trianthema portulacastrum L. (Pigweed), Melilotus indica L (Indian sweetclover). and Rumex dentatus L. (Toothed dock) in Petri dish and pot experiments. Aqueous extracts of all species were more toxic than their N-hexane forms for seed germination and seedling growth of lettuce; therefore, aqueous extracts were assessed for their phytotoxic potential against four broadleaved weed species. Aqueous extracts of all species proved phytotoxic against T. portulacastrum, P. hysterophorus, M. indica and R. dentatus and retarder their germination by 57, 90, 100 and 58%, respectively. Nevertheless, foliar spray of C. occidentalis extract was the most effective against T. portulacastrum as it reduced its dry biomass by 72%, while M. alba was effective against P. hysterophorus, R. dentatus and M. indica and reduced their dry biomass by 55, 68 and 81%, respectively. It is concluded that aqueous extracts of M. alba, S. sesban and C. occidentalis could be used to retard seed germination of T. portulacastrum, P. hysterophorus, M. indica and R. dentatus. Similarly, aqueous extracts of C. occidentalis can be used to suppress dry biomass of T. portulacastrum, and those of M. alba against P. hysterophorus, R. dentatus. However, use of these extracts needs their thorough testing under field conditions.	[Safdar, Muhammad Ehsan; Abbas, Mudasar; Asif, Muhammad; Adnan, Muhammad] Univ Sargodha, Coll Agr, Dept Agron, Sargodha, Pakistan; [Wang, Xiukang; Wang, Wenqiang] Yanan Univ, Coll Life Sci, Yanan, Peoples R China; [Ozaslan, Cumali] Dicle Univ, Fac Agr, Dept Plant Protect, Diyarbakir, Turkey; [Zuan, Ali Tan Kee] Univ Putra Malaysia, Fac Agr, Dept Land Management, Upm Serdang, Selangor, Malaysia; [Gasparovic, Kristina] Slovak Univ Agr, Inst Plant & Environm Sci, Nitra, Slovakia; [Nasif, Omaima] King Saud Univ, Coll Med, Dept Physiol, Riyadh, Saudi Arabia; [Nasif, Omaima] King Saud Univ, King Khalid Univ Hosp, Riyadh, Saudi Arabia; [Ansari, Mohammad Javed] Mahatma Jyotiba Phule Rohilkhand Univ Bareilly, Dept Bot, Hindu Coll Moradabad, Moradabad, India	University of Sargodha; Yanan University; Dicle University; Universiti Putra Malaysia; Slovak University of Agriculture Nitra; King Saud University; King Saud University; King Khalid University Hospital	Wang, XK; Wang, WQ (corresponding author), Yanan Univ, Coll Life Sci, Yanan, Peoples R China.; Ozaslan, C (corresponding author), Dicle Univ, Fac Agr, Dept Plant Protect, Diyarbakir, Turkey.; Zuan, ATK (corresponding author), Univ Putra Malaysia, Fac Agr, Dept Land Management, Upm Serdang, Selangor, Malaysia.	wangxiukang@yau.edu.cn; cumali.ozaslan@dicle.edu.tr; tkz@upm.edu.my; wenqiangwang@yau.edu.cn	Ansari, Muhammad/GQI-1517-2022; Adnan, Muhammad/ABF-2904-2020; ÖZASLAN, Cumali/ABI-4376-2020; Ansari, Mohammad Javed/E-9303-2014; Safdar, Muhammad/AFO-2376-2022	Adnan, Muhammad/0000-0002-7582-4675; ÖZASLAN, Cumali/0000-0002-8660-5451; Ansari, Mohammad Javed/0000-0002-8718-3078; Safdar, Muhammad/0000-0002-1865-5182; Ali Tan, Kee Zuan/0000-0003-0473-4303				Abdul Majeed, 2017, Azarian Journal of Agriculture, V4, P69; Anjum T, 2010, PHILIPP AGRIC SCI, V93, P365; [Anonymous], 2021, INT HERBICIDE RESIST; Asad S., 2005, NATL WEED SCI C, P28; Association of Official Seed Analysis (AOSA), 1990, J SEED TECHNOL, V12, P1; Bajwa A. A., 2013, Pakistan Journal of Weed Science Research, V19, P157; Chou CH, 2006, ALLELOPATHY: A PHYSIOLOGICAL PROCESS WITH ECOLOGICAL IMPLICATIONS, P1, DOI 10.1007/1-4020-4280-9_1; COOLBEAR P, 1984, J EXP BOT, V35, P1609, DOI 10.1093/jxb/35.11.1609; Coolbear P., 2020, INDIAN J AGR SCI, V37, P88, DOI [10.1093/jxb/35.11.1609, DOI 10.1093/JXB/35.11.1609]; Davis AS, 2017, PEST MANAG SCI, V73, P2209, DOI 10.1002/ps.4643; Devi S, 2020, INDIAN J AGR SCI, V90, P2113; Dhawan D., 2017, INT J BIOL CHEM, V11, P17; Farooq N., 2020, COEVOLUTION SECONDAR, P505, DOI [10.1007/978-3-319-96397-6_16, DOI 10.1007/978-3-319-96397-6_16]; Fujii Y, 1992, P INT S BIOL CONTR I, P305; Ghani A., 2014, Journal of Medicinal Plants Research, V8, P1031; Hirsch AM, 2010, AM J BOT, V97, P395, DOI 10.3732/ajb.0900152; Holm L., 1997, WORLD WEEDS NATURAL; HUSSAIN F, 1981, OECOLOGIA, V51, P284, DOI 10.1007/BF00540616; Hussain S, 2007, PAK J BOT, V39, P1145; IBM C., 2012, SPSS STAT WIND; Jabran K, 2017, SPRINGERBR PLANT SCI, P1, DOI 10.1007/978-3-319-53186-1; Jabran K., 2018, NONCHEMICAL WEED CON, DOI [10.1016/C2016-0-00092-X, DOI 10.1016/C2016-0-00092-X]; Jabran K, 2017, SPRINGERBR PLANT SCI, P65, DOI 10.1007/978-3-319-53186-1_8; Javaid MM, 2014, WEED RES, V54, P565, DOI 10.1111/wre.12111; KANG S S, 1988, Archives of Pharmacal Research (Seoul), V11, P197, DOI 10.1007/BF02861309; Kapoor D, 2019, PLANTS-BASEL, V8, DOI 10.3390/plants8120552; Karar H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236340; Khan M. Ajmal, 2006, V42, P129; Khan MB, 2012, J ANIM PLANT SCI, V22, P339; Khan N. U., 2003, Pakistan Journal of Weed Science Research, V9, P185; Khuram Mubeen, 2011, Pakistan Journal of Life and Social Sciences, V9, P7; Knox J, 2011, TURK J BOT, V35, P111, DOI 10.3906/bot-1001-275; Kolhe S. S., 1998, Indian Journal of Weed Science, V30, P216; Komal Arora, 2013, Indian Journal of Fundamental and Applied Life Sciences, V3, P1; Macias FA., 1998, P 7 INT C EC FLOR IT, P266; Makatiani ET, 2007, AGROFOREST SYST, V70, P211, DOI 10.1007/s10457-007-9054-9; Mehmood K, 2011, PAK J BOT, V43, P3007; Mortensen DA, 2000, WEED RES, V40, P49, DOI 10.1046/j.1365-3180.2000.00174.x; Mutisya MD., 2014, INT J AGRON AGR RES, V4, P10; Mutlu C, 2020, PHYTOPARASITICA, V48, P191, DOI 10.1007/s12600-020-00785-9; Naeem M, 2021, PHYTOPARASITICA, V49, P751, DOI 10.1007/s12600-021-00900-4; Naeem M, 2021, AGRONOMY-BASEL, V11, DOI 10.3390/agronomy11010008; Narwal SS, 2006, ALLELOPATHY: A PHYSIOLOGICAL PROCESS WITH ECOLOGICAL IMPLICATIONS, P537, DOI 10.1007/1-4020-4280-9_24; ORCHARD TJ, 1977, SEED SCI TECHNOL, V5, P61; Oudhia P., 2000, Crop Research (Hisar), V19, P357; Oyun M. B., 2006, American Journal of Agricultural and Biological Sciences, V1, P44; Parihar SS, 2000, ALLELOPATHY IN ECOLOGICAL AGRICULTURE AND FORESTRY, P237; Peterson MA, 2018, PEST MANAG SCI, V74, P2246, DOI 10.1002/ps.4821; Raman R., 2005, Legume Research, V28, P128; Randhawa M. A., 2002, International Journal of Agriculture and Biology, V4, P383; Ruan S, 2002, SEED SCI TECHNOL, V30, P61; Saeed M, 2010, PAK J BOT, V42, P173; Safdar M. E., 2019, Journal of Research in Weed Science, V2, P358, DOI 10.26655/JRWEEDSCI.2019.4.6; Safdar ME, 2016, PLANTA DANINHA, V34, P109, DOI 10.1590/S0100-83582016340100011; Safdar ME., 2021, PLANT CELL BIOTECHNO, P271; Safdar ME, 2015, CROP PROT, V70, P77, DOI 10.1016/j.cropro.2015.01.010; SAHID IB, 1993, WEED SCI, V41, P303, DOI 10.1017/S0043174500076219; Shabbir A., 2018, Proceedings of the XV International Symposium on Biological Control of Weeds, Engelberg, Switzerland, 26-31 August 2018., P63; Shah A, 2017, J ETHNOPHARMACOL, V200, P84, DOI 10.1016/j.jep.2017.02.005; Steel R. G. D., 1980, Principles and procedures of statistics, a biometrical approach.; Tamado T, 2004, WEED TECHNOL, V18, P100, DOI 10.1614/WT-03-033R; Tanveer A, 2012, CHIL J AGR RES, V72, P495, DOI 10.4067/S0718-58392012000400006; Tariq MA., 2014, HERBOLOGIA, V14; Teke MA, 2021, J PLANT DIS PROTECT, V128, P109, DOI 10.1007/s41348-020-00377-z; Wakjira M, 2009, AFR J AGR RES, V4, P1325; Wink M, 2013, S AFR J BOT, V89, P164, DOI 10.1016/j.sajb.2013.06.006; Wu CX, 2015, ALLELOPATHY J, V36, P75; Zhang W, 2003, WEED TECHNOL, V17, P876, DOI 10.1614/wt-03-003r; Zhang Y, 2016, PLANT BREEDING, V135, P476, DOI 10.1111/pbr.12374	70	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2021	16	11							e0258920	10.1371/journal.pone.0258920	http://dx.doi.org/10.1371/journal.pone.0258920			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY7XS	34739485	Green Published, gold			2023-01-03	WOS:000755000800010
J	Foley, H; Steel, A; McIntyre, E; Harnett, J; Sibbritt, D; Adams, J				Foley, Hope; Steel, Amie; McIntyre, Erica; Harnett, Joanna; Sibbritt, David; Adams, Jon			Disclosure of conventional and complementary medicine use to medical doctors and complementary medicine practitioners: A survey of rates and reasons amongst those with chronic conditions	PLOS ONE			English	Article							PERCEPTIONS; CARE	Chronic conditions are prolonged and complex, leading patients to seek multiple forms of care alongside conventional treatment, including complementary medicine (CM). These multiple forms of care are often used concomitantly, requiring patient-provider communication about treatments used in order to manage potential risks. In response, this study describes rates and reasons for disclosure/non-disclosure of conventional medicine use to CM practitioners, and CM use to medical doctors, by individuals with chronic conditions. A survey was conducted online in July and August 2017 amongst the Australian adult population. Participants with chronic conditions were asked about their disclosure-related communication with CM practitioners (massage therapist, chiropractor, acupuncturist, naturopath) and medical doctors. Patients consulting different professions reported varying disclosure rates and reasons. Full disclosure (disclosed ALL) to medical doctors was higher (62.7%-79.5%) than full disclosure to CM practitioners (41.2%-56.9%). The most strongly reported reason for disclosing to both MDs and CM practitioners was I wanted them to fully understand my health status, while for non-disclosure it was They did not ask me about my CM/medicine use. Reasons regarding concerns or expectations around the consultation or patient-provider relationship were also influential. The findings suggest that patient disclosure of treatment use in clinical consultation for chronic conditions may be improved through patient education about its importance, direct provider inquiry, and supportive patient-provider partnerships. Provision of optimal patient care for those with chronic conditions requires greater attention to patient-provider communication surrounding patients' wider care and treatment use.	[Foley, Hope; Steel, Amie; McIntyre, Erica; Harnett, Joanna; Sibbritt, David; Adams, Jon] Univ Technol Sydney, Australian Res Ctr Complementary & Integrat Med, Fac Hlth, Ultimo, NSW, Australia; [Harnett, Joanna] Univ Sydney, Sch Pharm, Fac Med & Hlth, Sydney, NSW, Australia	University of Technology Sydney; University of Sydney	Foley, H (corresponding author), Univ Technol Sydney, Australian Res Ctr Complementary & Integrat Med, Fac Hlth, Ultimo, NSW, Australia.	hope.m.foley@student.uts.edu.au		Steel, Amie/0000-0001-6643-9444; Foley, Hope/0000-0003-4901-8300				Australian Health Ministers' Advisory Council, 2017, NATL STRATEGIC FRAME, P11643; Australian Institute of Health and Welfare, 2018, AUSTR HLTH SER, V16; Batavia M., 2004, J BODYW MOV THER, V8, P48, DOI [10.1016/S1360-8592(03)00084-6, DOI 10.1016/S1360-8592(03)00084-6]; Ben-Arye E, 2014, COMPLEMENT THER MED, V22, P304, DOI 10.1016/j.ctim.2014.01.005; Bishop FL, 2008, AM J PUBLIC HEALTH, V98, P1700, DOI 10.2105/AJPH.2007.110072; Boullata JI, 2012, J ACAD NUTR DIET, V112, P506, DOI 10.1016/j.jada.2011.09.002; Busse JW, 2005, MAYO CLIN PROC, V80, P616, DOI 10.4065/80.5.616; Foley H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38279-8; Foley H, 2017, PATIENT EDUC COUNS, V100, P212, DOI 10.1016/j.pec.2016.09.015; Fortune LD, 2015, J BODYW MOV THER, V19, P25, DOI 10.1016/j.jbmt.2014.01.005; Fox S, 2008, J AM ACAD NURSE PRAC, V20, P109, DOI 10.1111/j.1745-7599.2007.00295.x; Grace S, 2010, J ALTERN COMPLEM MED, V16, P945, DOI 10.1089/acm.2009.0437; Granello DH, 2004, J COUNS DEV, V82, P387, DOI 10.1002/j.1556-6678.2004.tb00325.x; Griffith LE, 2017, J EPIDEMIOL COMMUN H, V71, P381, DOI 10.1136/jech-2016-207982; Levine MAH, 2009, AM J GERIATR PHARMAC, V7, P383, DOI 10.1016/j.amjopharm.2009.12.003; Lin V, 2015, HEALTH EXPECT, V18, P2651, DOI 10.1111/hex.12239; Mamindla S, 2016, INT J PHARM SCI RES, V7, P3576, DOI 10.13040/IJPSR.0975-8232.7(9).3576-86; Matthews SM, 2009, PATIENT EDUC COUNS, V76, P31, DOI 10.1016/j.pec.2008.11.022; McIntyre E, 2021, RES SOC ADMIN PHARM, V17, P1791, DOI 10.1016/j.sapharm.2021.01.015; McIntyre E, 2020, PATIENT EDUC COUNS, V103, P1237, DOI 10.1016/j.pec.2020.01.008; Reid R, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1143-8; Sherman Karen J, 2005, BMC Complement Altern Med, V5, P13, DOI 10.1186/1472-6882-5-13; Steel A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35508-y; Tilburt JC, 2007, J AM BOARD FAM MED, V20, P489, DOI 10.3122/jabfm.2007.05.060205; Wardle J, 2017, J INTERPROF CARE, V31, P734, DOI 10.1080/13561820.2017.1351424; Wardle J, 2016, VACCINE, V34, P4484, DOI 10.1016/j.vaccine.2016.07.026; Wardle JL, 2013, CHIROPR MAN THER, V21, DOI 10.1186/2045-709X-21-5; White A, 2014, EUR J INTEGR MED, V6, P404, DOI 10.1016/j.eujim.2013.09.006; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; World Health Organization, 2016, WHO TRADITIONAL MED; World Health Organization, 2015, WHO GLOB STRAT PEOPL	31	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2021	16	11							e0258901	10.1371/journal.pone.0258901	http://dx.doi.org/10.1371/journal.pone.0258901			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY9AG	34735474	Green Published, gold			2023-01-03	WOS:000755077100038
J	Barnett, ML; Bitton, A; Souza, J; Landon, BE				Barnett, Michael L.; Bitton, Asaf; Souza, Jeff; Landon, Bruce E.			Trends in Outpatient Care for Medicare Beneficiaries and Implications for Primary Care, 2000 to 2019	ANNALS OF INTERNAL MEDICINE			English	Article							PATIENT-SHARING NETWORKS; HEALTH-CARE; UNITED-STATES; MANAGEMENT CODES; DATA ALGORITHMS; PHYSICIANS; SPECIALIZATION; PAYMENTS; SYSTEMS; VISITS	Background: Despite the central role of primary care in improving health system performance, there are little recent data on how use of primary care and specialists has evolved over time and its implications for the range of care coordination needed in primary care. Objective: To describe trends in outpatient care delivery and the implications for primary care provider (PCP) care coordination. Design: Descriptive, repeated, cross-sectional study using Medicare claims from 2000 to 2019, with direct standardization used to control for changes in beneficiary characteristics over time. Setting: Traditional fee-for-service Medicare. Patients: 20% sample of Medicare beneficiaries. Measurements: Annual counts of outpatient visits and procedures, the number of distinct physicians seen, and the number of other physicians seen by a PCP's assigned Medicare patients. Results: The proportion of Medicare beneficiaries with any PCP visit annually only slightly increased from 61.2% in 2000 to 65.7% in 2019. The mean annual number of primary care office visits per beneficiary also changed little from 2000 to 2019 (2.99 to 3.00), although the mean number of PCPs seen increased from 0.89 to 1.21 (36.0% increase). In contrast, the mean annual number of visits to specialists increased 20% from 4.05 to 4.87, whereas the mean number of unique specialists seen increased 34.2% from 1.63 to 2.18. The proportion of beneficiaries seeing 5 or more physicians annually increased from 17.5% to 30.1%. In 2000, a PCP's Medicare patient panel saw a median of 52 other physicians (interquartile range, 23 to 87), increasing to 95 (interquartile range, 40 to 164) in 2019. Limitation: Data were limited to Medicare beneficiaries and, because of the use of a 20% sample, may underestimate the number of other physicians seen across a PCP's entire panel. Conclusion: Outpatient care for Medicare beneficiaries has shifted toward more specialist care received from more physicians without increased primary care contact. This represents a substantial expansion of the coordination burden faced by PCPs.	[Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Barnett, Michael L.; Bitton, Asaf] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Bitton, Asaf] Harvard Med Sch, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Souza, Jeff; Landon, Bruce E.] Harvard Med Sch, Boston, MA 02115 USA; [Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Barnett, ML (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,Kresge 411, Boston, MA 02115 USA.	mbarnett@hsph.harvard.edu		Barnett, Michael/0000-0002-4884-6609	National Institute on Aging of the National Institutes of Health [K23 AG058806, P01 AG032952]	National Institute on Aging of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By the National Institute on Aging of the National Institutes of Health (grants K23 AG058806 to Dr. Barnett and P01 AG032952 to Dr. Landon).	Agarwal SD, 2020, HEALTH AFFAIR, V39, P828, DOI 10.1377/hlthaff.2019.00329; Agarwal SD, 2018, JAMA-J AM MED ASSOC, V320, P2596, DOI 10.1001/jama.2018.16116; Agha L, 2018, NATL BUREAU EC RES W; American Association of Nurse Practitioners, NP FACT SHEET; American College of Physicians, IMP COLL PRIM CAR ME; American Medical Association, CPT EV MAN; Auerbach DI, 2020, HEALTH AFFAIR, V39, P273, DOI 10.1377/hlthaff.2019.00686; Barnes H, 2018, HEALTH AFFAIR, V37, P908, DOI 10.1377/hlthaff.2017.1158; Barnett ML, 2012, ARCH INTERN MED, V172, P163, DOI 10.1001/archinternmed.2011.722; Barnett ML, 2012, MED CARE, V50, P152, DOI 10.1097/MLR.0b013e31822dcef7; Basu S, 2019, JAMA INTERN MED, V179, P506, DOI 10.1001/jamainternmed.2018.7624; Basu S, 2017, HEALTH AFFAIR, V36, P1599, DOI 10.1377/hlthaff.2017.0367; Bitton A, 2017, J GEN INTERN MED, V32, P566, DOI 10.1007/s11606-016-3898-5; Bitton A, 2010, J GEN INTERN MED, V25, P584, DOI 10.1007/s11606-010-1262-8; Bodenheimer T, 2008, NEW ENGL J MED, V358, P1064, DOI 10.1056/NEJMhpr0706165; Bodenheimer T, 2009, NEW ENGL J MED, V360, P2693, DOI 10.1056/NEJMp0902909; Cassel CK, 2011, NEW ENGL J MED, V364, P1169, DOI 10.1056/NEJMsb1012647; Centers for Medicare & Medicaid Services, REV CONS SERV PAYM P; Centers for Medicare & Medicaid Services, COMPR PRIM CAR PLUS; Centers for Medicare & Medicaid Services, PROP POL PAYM QUAL P; Centers for Medicare & Medicaid Services, MLN MATT ANN WELLN V; Dalen JE, 2019, AM J MED, V132, P132, DOI 10.1016/j.amjmed.2018.07.031; Dartmouth Atlas Project, ATL REP; Detsky AS, 2012, JAMA-J AM MED ASSOC, V307, P463, DOI 10.1001/jama.2012.44; DuGoff EH, 2018, MED CARE, V56, pe16, DOI 10.1097/MLR.0000000000000709; Edwards ST, 2014, J GEN INTERN MED, V29, P947, DOI 10.1007/s11606-014-2808-y; Finkelstein A, 2016, Q J ECON, V131, P1681, DOI 10.1093/qje/qjw023; Hing Esther, 2017, Natl Health Stat Report, P1; Ibrahim AM, 2018, JAMA INTERN MED, V178, P290, DOI 10.1001/jamainternmed.2017.6148; Jarrin OF, 2020, MED CARE, V58, pE1, DOI 10.1097/MLR.0000000000001216; Landon BE, 2019, NEW ENGL J MED, V380, P507, DOI 10.1056/NEJMp1810848; Landon BE, 2018, JAMA INTERN MED, V178, P66, DOI 10.1001/jamainternmed.2017.5034; Landon BE, 2012, JAMA-J AM MED ASSOC, V308, P265, DOI 10.1001/jama.2012.7615; Layton, 2015, 21222 NAT BUR EC RES; National Center for Health Statistics, TABL 77 VIS PRIM CAR; National Center for Health Statistics, 2017, HLTH US 2016 CHARTB; National Commission on Certification of Physician Assistants, 2018 STAT PROF CERT; Neprash HT, 2020, ANN INTERN MED, V172, P568, DOI 10.7326/M19-2838; O'Malley AJ, 2021, HEALTH SERV RES, V56, P323, DOI 10.1111/1475-6773.13568; Obermeyer Z, 2019, SCIENCE, V366, P447, DOI 10.1126/science.aax2342; Overhage JM, 2020, ANN INTERN MED, V172, P169, DOI 10.7326/M18-3684; Papanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150; Pham HH, 2007, NEW ENGL J MED, V356, P1130, DOI 10.1056/NEJMsa063979; Pham HH, 2009, ANN INTERN MED, V150, P236, DOI 10.7326/0003-4819-150-4-200902170-00004; Prasad K, 2020, J GEN INTERN MED, V35, P465, DOI 10.1007/s11606-019-05343-6; Rural Health Research Center, RUR COMM AR COD RUCA; Sandy LG, 2009, HEALTH AFFAIR, V28, P1136, DOI 10.1377/hlthaff.28.4.1136; Shah BR, 2007, HEALTH SERV RES, V42, P1783, DOI 10.1111/j.1475-6773.2006.00681.x; Song YJ, 2010, NEW ENGL J MED, V363, P45, DOI 10.1056/NEJMsa0910881; Staiger DO, 2010, JAMA-J AM MED ASSOC, V303, P747, DOI 10.1001/jama.2010.168; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x	52	6	6	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC	2021	174	12					1658	+		10.7326/M21-1523	http://dx.doi.org/10.7326/M21-1523		NOV 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XS0OD	34724406	Green Accepted			2023-01-03	WOS:000729198700001
J	Lo, CKL; Chagla, Z				Lo, Carson K. L.; Chagla, Zain			In patients hospitalized for COVID-19, tocilizumab reduces mortality at 28 d	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Lo, Carson K. L.; Chagla, Zain] McMaster Univ, Hamilton, ON, Canada	McMaster University	Lo, CKL (corresponding author), McMaster Univ, Hamilton, ON, Canada.		Lo, Carson/HGA-9375-2022	Lo, Carson/0000-0002-1620-2868				Bhimraj A, INFECT DIS SOC AM GU; Gout T, 2011, CLIN RHEUMATOL, V30, P1471, DOI 10.1007/s10067-011-1827-x; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Kow CS, 2021, CHEST, V159, P2108, DOI 10.1016/j.chest.2020.11.073; World Health Organization, 2021, THER COVID 19 LIV	5	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV	2021	174	11					JC125	JC125		10.7326/ACPJ202111160-125	http://dx.doi.org/10.7326/ACPJ202111160-125			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YI2OV	34724398				2023-01-03	WOS:000743694300007
J	Bayoumi, MMM; Khonji, LMA; Gabr, WFM				Bayoumi, Magda Mohamed Mohamed; Khonji, Leena Mohammad Abdulla; Gabr, Wessam Fathy Mohamed			Are nurses utilizing the non-pharmacological pain management techniques in surgical wards?	PLOS ONE			English	Article							CHILDRENS POSTOPERATIVE PAIN; KNOWLEDGE; PERCEPTIONS; PATIENT	The non-pharmacological pain management therapies have a valuable effect in managing moderate to mild pain intensity, especially if demonstrated in the pre-operative phase. The study aimed to explore the nurses' practice toward using non-pharmacological pain management techniques in surgical wards. In a cross-sectional research design, a convenient sample of 47 nurses in the surgical wards in Egyptian hospital (Third Level) participated in the study. Data gathered using modified Non-pharmacological Methods Questionnaire. Results of the study indicated that nurse's perception regarding applying the cognitive-behavioral methods as a distraction and Positive reinforcement techniques were more common (68.1%,53.2%), whereas most of them used emotional support (93.6%) and preferred to demonstrate physical methods. Meanwhile, nurses addressed the barriers to apply nonpharmacological pain management as lack of time, patient unwillingness, and patients' health beliefs. Nevertheless, nurses reported the non-pharmacological pain management is less expensive and has fewer side effects than medication and can demonstrated post-discharge. Nurses play a key role in applying effective and different non-pharmacological therapies in surgical wards. Thus, nurses should be encouraged to demonstrate the non-pharmacological pain management therapies with patients undergoing surgical procedures.	[Bayoumi, Magda Mohamed Mohamed; Gabr, Wessam Fathy Mohamed] Beni Suef Univ, Fac Nursing, Dept Med Surg Nursing, Bani Suwayf, Egypt; [Bayoumi, Magda Mohamed Mohamed; Khonji, Leena Mohammad Abdulla] Univ Bahrain, Coll Hlth & Sport Sci, Nursing Dept, Zallaq, Bahrain	Egyptian Knowledge Bank (EKB); Beni Suef University; University of Bahrain	Bayoumi, MMM (corresponding author), Beni Suef Univ, Fac Nursing, Dept Med Surg Nursing, Bani Suwayf, Egypt.; Bayoumi, MMM (corresponding author), Univ Bahrain, Coll Hlth & Sport Sci, Nursing Dept, Zallaq, Bahrain.	mbayoumi@nursing.bsu.edu.eg	; Bayoumi, Magda/M-6286-2016	Gabr, Wessam/0000-0002-5351-4529; Bayoumi, Magda/0000-0003-2808-3103; Khonji, Leena/0000-0002-6482-4514				Adams SDM, 2020, PAIN RES MANAG, V2020, DOI 10.1155/2020/4893707; ALBAQAWI HMH., 2016, INT J HLTH SCI RES, V6, P150; Ali S., 2013, LIFE SCI J, V10, P1327; American Pain Society, 2008, PRINC AN US TREATM A; Becker WC, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0608-2; Bicek E, 2004, HONORS PROJECTS; Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55; Chlan L, 2013, AM J CRIT CARE, V22, P528, DOI 10.4037/ajcc2013998; Cooley LF, 2018, ALTERN THER HEALTH M, V24, P48; Dimitriou V, 2017, J PERIANESTH NURS, V32, P530, DOI 10.1016/j.jopan.2016.12.003; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Gan TJ, 2014, CURR MED RES OPIN, V30, P149, DOI 10.1185/03007995.2013.860019; Gelinas C, 2013, NURS CRIT CARE, V18, P307, DOI 10.1111/j.1478-5153.2012.00531.x; Gostautait S., 2017, VISUOMENES SVEIKATA, V27, P71, DOI [10.5200/sm-hs.2017.099, DOI 10.5200/SM-HS.2017.099]; He HG, 2005, J ADV NURS, V51, P335, DOI 10.1111/j.1365-2648.2005.03505.x; He HG, 2010, J ADV NURS, V66, P2398, DOI 10.1111/j.1365-2648.2010.05402.x; Hinkle J., 2018, BRUNNER SUDDARTHS TX, V14th; Jira L, 2020, J PAIN RES, V13, P2917, DOI 10.2147/JPR.S265544; Kahsay DT, 2019, BMC NURS, V18, DOI 10.1186/s12912-019-0380-9; Karabulut N., 2016, J NURSING SOCIAL SCI, V1, P23, DOI [10.1016/j.kontakt.2015.12.00, DOI 10.1016/J.KONTAKT.2015.12.00]; Kidanemariam BY, 2020, BMC NURS, V19, DOI 10.1186/s12912-020-00492-0; Kiwanuka F., 2018, J RES CLIN MED, V6, P72, DOI 10.15171/jarcm.2018.011; Kizza IB., 2012, NURSES KNOWLEDGE PRA; Lehne R. A., 2013, PHARM NURSING CARE; Vzquez JLM, 2019, CYBERPSYCH BEH SOC N, V22, P15, DOI 10.1089/cyber.2017.0714; Mwanza E, 2019, PAIN RES TREAT, V2019, DOI 10.1155/2019/2703579; Naeem Badr M, 2015, EGYPT J NURS, V10, P28; Pasero C, 2011, PAIN CLIN MANUAL; Pasero C, 2009, CHEST, V135, P1665, DOI 10.1378/chest.08-2333; Polkki T, 2001, J ADV NURS, V34, P483, DOI 10.1046/j.1365-2648.2001.01777.x; Poulsen MJ, 2018, PAIN MANAG NURS, V19, P172, DOI 10.1016/j.pmn.2017.09.003; Salantera S, 1999, J PAIN SYMPTOM MANAG, V18, P289, DOI 10.1016/S0885-3924(99)00065-2; Thomas E M, 2000, Cancer Control, V7, P157; Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160; Tse Mimi M Y, 2004, J Pain Palliat Care Pharmacother, V18, P47; Ung A, 2016, BRIT J PAIN, V10, P8, DOI 10.1177/2049463715583142; Voshall B, 2013, PAIN MANAG NURS, V14, pE226, DOI 10.1016/j.pmn.2012.02.001; Yaban Z.S., 2019, INT J CARING SCI, V12, P529; Zahed Pasha Y., 2017, J BABOL U MED SCI, V19, P20	39	0	0	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2021	16	10							e0258668	10.1371/journal.pone.0258668	http://dx.doi.org/10.1371/journal.pone.0258668			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ7VP	34673781	gold, Green Published			2023-01-03	WOS:000755680200027
J	Baker, TB; Piper, ME; Smith, SS; Bolt, DM; Stein, JH; Fiore, MC				Baker, Timothy B.; Piper, Megan E.; Smith, Stevens S.; Bolt, Daniel M.; Stein, James H.; Fiore, Michael C.			Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPLACEMENT THERAPY; TOBACCO CESSATION; ABSTINENCE; PLACEBO	Question Does combining varenicline with the nicotine patch or extending cessation treatment duration increase smoking abstinence compared with the standard length of therapy with varenicline only? Findings In this randomized clinical trial that included 1251 participants smoking 5 cigarettes/d or more, treatment with varenicline monotherapy for 12 weeks, varenicline plus nicotine patch for 12 weeks, varenicline monotherapy for 24 weeks, and varenicline plus nicotine patch for 24 weeks resulted in 7-day point prevalence abstinence rates at 52 weeks of 25.1%, 23.6%, 24.4%, and 25.1%, respectively. None of the comparisons was statistically significant. Meaning These findings do not support the use of combined varenicline plus nicotine patch vs varenicline monotherapy or of 24-week vs 12-week treatment for smoking cessation. Importance Smoking cessation medications are routinely used in health care. Research suggests that combining varenicline with the nicotine patch, extending the duration of varenicline treatment, or both, may increase cessation effectiveness. Objective To compare combinations of varenicline plus the nicotine or placebo patch vs combinations used for either 12 weeks (standard duration) or 24 weeks (extended duration). Design, Settings, and Participants Double-blind, 2 x 2 factorial randomized clinical trial conducted from November 11, 2017, to July 9, 2020, at 1 research clinic in Madison, Wisconsin, and at 1 clinic in Milwaukee, Wisconsin. Of the 5836 adults asked to participate in the study, 1251 who smoked 5 cigarettes/d or more were randomized. Interventions All participants received cessation counseling and were randomized to 1 of 4 medication groups: varenicline monotherapy for 12 weeks (n = 315), varenicline plus nicotine patch for 12 weeks (n = 314), varenicline monotherapy for 24 weeks (n = 311), or varenicline plus nicotine patch for 24 weeks (n = 311). Main Outcomes and Measures The primary outcome was carbon monoxide-confirmed self-reported 7-day point prevalence abstinence at 52 weeks. Results Among 1251 patients who were randomized (mean [SD] age, 49.1 [11.9] years; 675 [54.0%] women), 751 (60.0%) completed treatment and 881 (70.4%) provided final follow-up. For the primary outcome, there was no significant interaction between the 2 treatment factors of medication type and medication duration (odds ratio [OR], 1.03 [95% CI, 0.91 to 1.17]; P = .66). For patients randomized to 24-week vs 12-week treatment duration, the primary outcome occurred in 24.8% (154/622) vs 24.3% (153/629), respectively (risk difference, -0.4% [95% CI, -5.2% to 4.3%]; OR, 1.01 [95% CI, 0.89 to 1.15]). For patients randomized to varenicline combination therapy vs varenicline monotherapy, the primary outcome occurred in 24.3% (152/625) vs 24.8% (155/626), respectively (risk difference, 0.4% [95% CI, -4.3% to 5.2%]; OR, 0.99 [95% CI, 0.87 to 1.12]). Nausea occurrence ranged from 24.0% to 30.9% and insomnia occurrence ranged from 24.4% to 30.5% across the 4 groups. Conclusions and Relevance Among adults smoking 5 cigarettes/d or more, there were no significant differences in 7-day point prevalence abstinence at 52 weeks among those treated with combined varenicline plus nicotine patch therapy vs varenicline monotherapy, or among those treated for 24 weeks vs 12 weeks. These findings do not support the use of combined therapy or of extended treatment duration. This randomized clinical trial compares combinations of varenicline plus the nicotine or placebo patch vs combinations used for either 12 weeks (standard duration) or 24 weeks (extended duration) for smoking cessation in adults who smoked 5 cigarettes/d or more.	[Baker, Timothy B.; Piper, Megan E.; Smith, Stevens S.; Fiore, Michael C.] Univ Wisconsin, Ctr Tobacco Res & Intervent, Sch Med & Publ Hlth, 1930 Monroe St,Ste 200, Madison, WI 53711 USA; [Baker, Timothy B.; Piper, Megan E.; Smith, Stevens S.; Fiore, Michael C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53711 USA; [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53711 USA; [Stein, James H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Cardiovasc Med, Madison, WI 53711 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Baker, TB (corresponding author), Univ Wisconsin, Ctr Tobacco Res & Intervent, Sch Med & Publ Hlth, 1930 Monroe St,Ste 200, Madison, WI 53711 USA.	tbb@ctri.medicine.wisc.edu						Aubin HJ, 2008, THORAX, V63, P717, DOI 10.1136/thx.2007.090647; Baker TB, 2021, CLIN PSYCHOL SCI, V9, P995, DOI 10.1177/2167702621994551; Baker TB, 2016, JAMA-J AM MED ASSOC, V315, P371, DOI 10.1001/jama.2015.19284; Barua RS, 2018, J AM COLL CARDIOL, V72, P3332, DOI 10.1016/j.jacc.2018.10.027; Benowitz NL, 2020, NICOTINE TOB RES, V22, P1086, DOI 10.1093/ntr/ntz132; Chang PH, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2055-0; Evins AE, 2014, JAMA-J AM MED ASSOC, V311, P145, DOI 10.1001/jama.2013.285113; Gonzales D, 2014, CLIN PHARMACOL THER, V96, P390, DOI 10.1038/clpt.2014.124; Gonzales D, 2006, JAMA-J AM MED ASSOC, V296, P47, DOI 10.1001/jama.296.1.47; Hajek P, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-140; Hedeker D, 2007, ADDICTION, V102, P1564, DOI 10.1111/j.1360-0443.2007.01946.x; Hughes JR, 2018, ADDICT BEHAV, V76, P68, DOI 10.1016/j.addbeh.2017.07.023; Koegelenberg CFN, 2014, JAMA-J AM MED ASSOC, V312, P155, DOI 10.1001/jama.2014.7195; Krist AH, 2021, JAMA-J AM MED ASSOC, V325, P265, DOI 10.1001/jama.2020.25019; Kulak J, 2016, NICOTINE TOB RES, V18, pS79, DOI 10.1093/ntr/ntv228; Leone FT, 2020, AM J RESP CRIT CARE, V202, pE5, DOI 10.1164/rccm.202005-1982ST; Lindson N, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013308; LITTLE RJA, 1993, J AM STAT ASSOC, V88, P125, DOI 10.1080/01621459.1993.10594302; Livingstone-Banks J, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003999.pub5; Nollen NL, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.32053; Patnode CD, 2021, JAMA-J AM MED ASSOC, V325, P280, DOI 10.1001/jama.2020.23541; Ramon JM, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0172-8; Schlam TR, 2016, ADDICTION, V111, P142, DOI 10.1111/add.13153; Schnoll RA, 2015, JAMA INTERN MED, V175, P504, DOI 10.1001/jamainternmed.2014.8313; Smith SS, 2010, NICOTINE TOB RES, V12, P489, DOI 10.1093/ntr/ntq032; Williams KE, 2007, CURR MED RES OPIN, V23, P793, DOI 10.1185/030079907X182185	26	10	10	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2021	326	15					1485	1493		10.1001/jama.2021.15333	http://dx.doi.org/10.1001/jama.2021.15333			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WN1OX	34665204	Bronze, Green Published			2023-01-03	WOS:000711546300015
J	Faverio, P; Ornaghi, S; Stainer, A; Invernizzi, F; Borelli, M; Brunetti, F; La Milia, L; Paolini, V; Rona, R; Foti, G; Luppi, F; Vergani, P; Pesci, A				Faverio, Paola; Ornaghi, Sara; Stainer, Anna; Invernizzi, Francesca; Borelli, Mara; Brunetti, Federica; La Milia, Laura; Paolini, Valentina; Rona, Roberto; Foti, Giuseppe; Luppi, Fabrizio; Vergani, Patrizia; Pesci, Alberto			Feasibility of CPAP application and variables related to worsening of respiratory failure in pregnant women with SARS-CoV-2 pneumonia: Experience of a tertiary care centre	PLOS ONE			English	Article							COVID-19; PRESSURE; HELMET	Continuous positive airway pressure (CPAP) has been successfully applied to patients with COVID-19 to prevent endotracheal intubation. However, experience of CPAP application in pregnant women with acute respiratory failure (ARF) due to SARS-CoV-2 pneumonia is scarce. This study aimed to describe the natural history and outcome of ARF in a cohort of pregnant women with SARS-CoV-2 pneumonia, focusing on the feasibility of helmet CPAP (h-CPAP) application and the variables related to ARF worsening. A retrospective, observational study enrolling 41 consecutive pregnant women hospitalised for SARS-CoV-2 pneumonia in a tertiary care center between March 2020 and March 2021. h-CPAP was applied if arterial partial pressure of oxygen to fraction of inspired oxygen ratio (PaO2/FiO(2)) was inferior to 200 and/or patients had respiratory distress despite adequate oxygen supplementation. Characteristics of patients requiring h-CPAP vs those in room air or oxygen only were compared. Twenty-seven (66%) patients showed hypoxemic ARF requiring oxygen supplementation and h-CPAP was needed in 10 cases (24%). PaO2/FiO(2) was significantly improved during h-CPAP application. The device was well-tolerated in all cases with no adverse events. Higher serum C reactive protein and more extensive (>= 3 lobes) involvement at chest X-ray upon admission were observed in the h-CPAP group. Assessment of temporal distribution of cases showed a substantially increased rate of CPAP requirement during the third pandemic wave (January-March 2021). In conclusion, h-CPAP was feasible, safe, well-tolerated and improved oxygenation in pregnant women with moderate-to-severe ARF due to SARS-CoV-2 pneumonia. Moderate-to-severe ARF was more frequently observed during the third pandemic wave.	[Faverio, Paola; Stainer, Anna; Borelli, Mara; Paolini, Valentina; Rona, Roberto; Foti, Giuseppe; Luppi, Fabrizio; Pesci, Alberto] Univ Milano Bicocca, San Gerardo Hosp, Sch Med & Surg, Resp Unit,ASST Monza, Monza, Italy; [Ornaghi, Sara; Invernizzi, Francesca; La Milia, Laura; Vergani, Patrizia] Univ Milano Bicocca, MBBM Fdn Onlus, Sch Med & Surg, Obstetr Unit,San Gerardo Hosp, Monza, Italy; [Brunetti, Federica] Desio Hosp, Dept Obstet & Gynaecol, ASST Monza, Desio, Italy; [Rona, Roberto; Foti, Giuseppe] ASST Monza, Dept Anesthesia & Intens Care Med, Monza, Italy	San Gerardo Hospital; University of Milano-Bicocca; San Gerardo Hospital; University of Milano-Bicocca	Faverio, P (corresponding author), Univ Milano Bicocca, San Gerardo Hosp, Sch Med & Surg, Resp Unit,ASST Monza, Monza, Italy.	paola.faverio@unimib.it	Rona, Roberto/ADO-9946-2022; Ornaghi, Sara/GXW-2481-2022; Ornaghi, Sara/K-4261-2018	Rona, Roberto/0000-0003-3907-3074; Ornaghi, Sara/0000-0001-6898-7217; faverio, paola/0000-0002-0360-1237				Alhazzani Waleed, 2020, Crit Care Med, V48, pe440, DOI [10.1007/s00134-020-06022-5, 10.1097/CCM.0000000000004363]; Alsayyed Farah, 2020, Case Rep Obstet Gynecol, V2020, P8891787, DOI 10.1155/2020/8891787; Antonelli M, 2002, CRIT CARE MED, V30, P602, DOI 10.1097/00003246-200203000-00019; Carvalho ARS, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.577609; Coppo A, 2020, LANCET RESP MED, V8, P765, DOI 10.1016/S2213-2600(20)30268-X; Cosentini R, 2010, CHEST, V138, P114, DOI 10.1378/chest.09-2290; Melguizo SC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050853; Elavarasi A, 2020, J GEN INTERN MED, V35, P3308, DOI 10.1007/s11606-020-06146-w; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Kadiwar S, 2021, LANCET, V397, P1539, DOI 10.1016/S0140-6736(21)00716-9; Kayem G, 2020, J GYNECOL OBSTET HUM, V49, DOI 10.1016/j.jogoh.2020.101826; Khalil A, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100446; Khatib MY, 2021, CLIN CASE REP, V9, P1721, DOI 10.1002/ccr3.3886; Liu F, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104370; Paolini V, 2018, PEERJ, V6, DOI 10.7717/peerj.4211; Polcer Rasha El-Ahmad, 2021, Case Rep Obstet Gynecol, V2021, P8868822, DOI 10.1155/2021/8868822; Reindorf M, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2020-238055; Savasi VM, 2020, OBSTET GYNECOL, V136, P252, DOI 10.1097/AOG.0000000000003979; Vitacca M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00632-2020; Wei SQ, 2021, CAN MED ASSOC J, V193, pE540, DOI 10.1503/cmaj.202604; Yan J, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.04.014	22	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2021	16	10							e0258754	10.1371/journal.pone.0258754	http://dx.doi.org/10.1371/journal.pone.0258754			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7WQ	34665818	gold, Green Published			2023-01-03	WOS:000755683100019
J	Zainordin, NA; Warman, NAE; Mohamad, AF; Abu Yazid, FA; Ismail, NH; Chen, XW; Koshy, M; Rahman, THA; Ismail, NM; Ghani, RA				Zainordin, Nur Aisyah; Warman, Nur' Aini Eddy; Mohamad, Aimi Fadilah; Abu Yazid, Fatin Aqilah; Ismail, Nazrul Hadi; Chen, Xin Wee; Koshy, Marymol; Rahman, Thuhairah Hasrah Abdul; Ismail, Nafeeza Mohd; Ghani, Rohana Abdul			Safety and efficacy of very low carbohydrate diet in patients with diabetic kidney disease-A randomized controlled trial	PLOS ONE			English	Article							C-REACTIVE PROTEIN; LOW-FAT DIETS; CORONARY-HEART-DISEASE; WEIGHT-LOSS; MANAGEMENT; INFLAMMATION; METAANALYSIS; PREDICTORS; DROPOUT; OBESITY	Introduction There is limited data on the effects of low carbohydrate diets on renal outcomes particularly in patients with underlying diabetic kidney disease. Therefore, this study determined the safety and effects of very low carbohydrate (VLCBD) in addition to low protein diet (LPD) on renal outcomes, anthropometric, metabolic and inflammatory parameters in patients with T2DM and underlying mild to moderate kidney disease (DKD). Materials and methods This was an investigator-initiated, single-center, randomized, controlled, clinical trial in patients with T2DM and DKD, comparing 12-weeks of low carbohydrate diet (<20g daily intake) versus standard low protein (0.8g/kg/day) and low salt diet. Patients in the VLCBD group underwent 2-weekly monitoring including their 3-day food diaries. In addition, Dual-energy x-ray absorptiometry (DEXA) was performed to estimate body fat percentages. Results The study population (n = 30) had a median age of 57 years old and a BMI of 30.68kg/m2. Both groups showed similar total calorie intake, i.e. 739.33 (IQR288.48) vs 789.92 (IQR522.4) kcal, by the end of the study. The VLCBD group showed significantly lower daily carbohydrate intake 27 (IQR25) g vs 89.33 (IQR77.4) g, p<0.001, significantly higher protein intake per day 44.08 (IQR21.98) g vs 29.63 (IQR16.35) g, p<0.05 and no difference in in daily fat intake. Both groups showed no worsening of serum creatinine at study end, with consistent declines in HbA1c (1.3(1.1) vs 0.7(1.25) %) and fasting blood glucose (1.5(3.37) vs 1.3(5.7) mmol/L). The VLCBD group showed significant reductions in total daily insulin dose (39(22) vs 0 IU, p<0.001), increased LDL-C and HDL-C, decline in IL-6 levels; with contrasting results in the control group. This was associated with significant weight reduction (-4.0(3.9) vs 0.2(4.2) kg, p = <0.001) and improvements in body fat percentages. WC was significantly reduced in the VLCBD group, even after adjustments to age, HbA1c, weight and creatinine changes. Both dietary interventions were well received with no reported adverse events. Conclusion This study demonstrated that dietary intervention of very low carbohydrate diet in patients with underlying diabetic kidney disease was safe and associated with significant improvements in glycemic control, anthropometric measurements including weight, abdominal adiposity and IL-6. Renal outcomes remained unchanged. These findings would strengthen the importance of this dietary intervention as part of the management of patients with diabetic kidney disease.	[Zainordin, Nur Aisyah; Warman, Nur' Aini Eddy; Mohamad, Aimi Fadilah; Abu Yazid, Fatin Aqilah; Ghani, Rohana Abdul] Univ Teknol MARA UiTM, Dept Internal Med, Endocrine Unit, Fac Med, Shah Alam, Malaysia; [Ismail, Nazrul Hadi] Univ Teknol MARA UiTM, Ctr Dietet Studies, Fac Hlth Sci, Puncak Alam, Selangor, Malaysia; [Chen, Xin Wee] Univ Teknol MARA UiTM, Dept Publ Hlth Med, Fac Med, Shah Alam, Malaysia; [Koshy, Marymol] Univ Teknol MARA UiTM, Dept Radiol, Fac Med, Shah Alam, Malaysia; [Rahman, Thuhairah Hasrah Abdul] Univ Teknol MARA UiTM, Dept Pathol, Fac Med, Shah Alam, Malaysia; [Ismail, Nafeeza Mohd] Int Med Univ IMU, Dept Pharmacol & Therapeut, Lumpur, Malaysia; [Ghani, Rohana Abdul] Univ Teknol MARA UiTM, Inst Pathol Lab & Forens Med I PPerForM, Shah Alam, Malaysia	Universiti Teknologi MARA; Universiti Teknologi MARA; Universiti Teknologi MARA; Universiti Teknologi MARA; Universiti Teknologi MARA; Universiti Teknologi MARA	Ghani, RA (corresponding author), Univ Teknol MARA UiTM, Dept Internal Med, Endocrine Unit, Fac Med, Shah Alam, Malaysia.; Ghani, RA (corresponding author), Univ Teknol MARA UiTM, Inst Pathol Lab & Forens Med I PPerForM, Shah Alam, Malaysia.	agrohana@gmail.com	XIN WEE, DR CHEN/CAF-0753-2022	XIN WEE, DR CHEN/0000-0002-4785-7189; Abdul Ghani, Rohana/0000-0002-3520-8472; Ismail, Nazrul Hadi/0000-0001-5366-7296; Zainordin, Nur Aisyah/0000-0002-3970-8511				[Anonymous], 2013, Kidney Int Suppl (2011), V3, P19; Batterham M, 2016, OBES RES CLIN PRACT, V10, P189, DOI 10.1016/j.orcp.2015.05.005; Brown E, 2019, OBES REV, V20, P816, DOI 10.1111/obr.12841; Bruci A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020333; Chawla S, 2020, NUTRIENTS, V12, DOI 10.3390/nu12123774; COHEN J, 1988, APPL PSYCH MEAS, V12, P425, DOI 10.1177/014662168801200410; Crane MM, 2017, AM J MENS HEALTH, V11, P369, DOI 10.1177/1557988316681221; Despres JP, 2012, CIRCULATION, V126, P1301, DOI 10.1161/CIRCULATIONAHA.111.067264; Farhadnejad H, 2019, J RENAL NUTR, V29, P343, DOI 10.1053/j.jrn.2018.10.007; Foster GD, 2010, ANN INTERN MED, V153, P147, DOI 10.7326/0003-4819-153-3-201008030-00005; Friedman AN, 2012, CLIN J AM SOC NEPHRO, V7, P1103, DOI 10.2215/CJN.11741111; Garrett A., 2020, THESIS, P691; Gerich JE, 2003, ARCH INTERN MED, V163, P1306, DOI 10.1001/archinte.163.11.1306; Gill RS, 2012, CAN J SURG, V55, P239, DOI 10.1503/cjs.035710; Goday A, 2016, NUTR DIABETES, V6, DOI 10.1038/nutd.2016.36; Goh B.L., 2014, 21 REPORT MALAYSIAN; Hickson M, 2009, J HUM NUTR DIET, V22, P72, DOI 10.1111/j.1365-277X.2008.00927.x; Hooi LS, 2013, KIDNEY INT, V84, P1034, DOI 10.1038/ki.2013.220; Jonasson L, 2014, ANN MED, V46, P182, DOI 10.3109/07853890.2014.894286; Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7; Kelly T, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072557; Ko GJ, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080824; Li JB, 2021, OBESITY FACTS, V14, P108, DOI 10.1159/000512294; Lin YC, 2019, J CACHEXIA SARCOPENI, V10, P756, DOI 10.1002/jcsm.12423; Liu SM, 2002, AM J CLIN NUTR, V75, P492, DOI 10.1093/ajcn/75.3.492; Macdiarmid J, 1998, NUTR RES REV, V11, P231, DOI 10.1079/NRR19980017; Mitchell NS, 2020, ANN NY ACAD SCI, V1461, P25, DOI 10.1111/nyas.13997; Moroshko I, 2011, OBES REV, V12, P912, DOI 10.1111/j.1467-789X.2011.00915.x; National Health and Morbidity Survey, NHMS 2015, V2; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; Oyabu C, 2016, BRIT J NUTR, V116, P632, DOI 10.1017/S0007114516002178; Rolland C, 2009, J DIABETES, V1, P207, DOI 10.1111/j.1753-0407.2009.00033.x; Ruggenenti P, 2017, DIABETES, V66, P75, DOI 10.2337/db16-0607; Ruth MR, 2013, METABOLISM, V62, P1779, DOI 10.1016/j.metabol.2013.07.006; Ryan A., 2007, ENCY GERONTOLOGY, P177, DOI DOI 10.1016/B0-12-370870-2/00024-X; Sharman MJ, 2004, J NUTR, V134, P880, DOI 10.1093/jn/134.4.880; World Health Organization, FACT SHEET DIAB; Yamada Y, 2014, INTERNAL MED, V53, P13, DOI [10.2169/internalmedicine.53.0861, 10.2169/interna]; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3	39	0	0	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2021	16	10							e0258507	10.1371/journal.pone.0258507	http://dx.doi.org/10.1371/journal.pone.0258507			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR9CY	34644368	gold, Green Published			2023-01-03	WOS:000732519500056
J	Neuman, MD; Feng, R; Carson, JL; Gaskins, LJ; Dillane, D; Sessler, DI; Sieber, F; Magaziner, J; Marcantonio, ER; Mehta, S; Menio, D; Ayad, S; Stone, T; Papp, S; Schwenk, ES; Elkassabany, N; Marshall, M; Jaffe, JD; Luke, C; Sharma, B; Azim, S; Hymes, RA; Chin, KJ; Sheppard, R; Perlman, B; Sappenfield, J; Hauck, E; Hoeft, MA; Giska, M; Ranganath, Y; Tedore, T; Choi, S; Li, J; Kwofie, MK; Nader, A; Sanders, RD; Allen, BFS; Vlassakov, K; Kates, S; Fleisher, LA; Dattilo, J; Tierney, A; Stephens-Shields, AJ; Ellenberg, SS				Neuman, M. D.; Feng, R.; Carson, J. L.; Gaskins, L. J.; Dillane, D.; Sessler, D., I; Sieber, F.; Magaziner, J.; Marcantonio, E. R.; Mehta, S.; Menio, D.; Ayad, S.; Stone, T.; Papp, S.; Schwenk, E. S.; Elkassabany, N.; Marshall, M.; Jaffe, J. D.; Luke, C.; Sharma, B.; Azim, S.; Hymes, R. A.; Chin, K-J; Sheppard, R.; Perlman, B.; Sappenfield, J.; Hauck, E.; Hoeft, M. A.; Giska, M.; Ranganath, Y.; Tedore, T.; Choi, S.; Li, J.; Kwofie, M. K.; Nader, A.; Sanders, R. D.; Allen, B. F. S.; Vlassakov, K.; Kates, S.; Fleisher, L. A.; Dattilo, J.; Tierney, A.; Stephens-Shields, A. J.; Ellenberg, S. S.		REGAIN Investigators	Spinal Anesthesia or General Anesthesia for Hip Surgery in Older Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPY AMERICAN-SOCIETY; REGIONAL-ANESTHESIA; FRACTURE; TIME; RANDOMIZATION; VARIABLES; HEALTH; TRIALS; DEATH	Spinal or General Anesthesia for Hip Surgery A randomized trial evaluating spinal as compared with general anesthesia for hip-fracture surgery in adults 50 years of age or older did not show superiority of spinal anesthesia with respect to a composite of death or an inability to walk unassisted at 60 days. Postoperative delirium occurred in similar percentages of patients in the two groups. Background The effects of spinal anesthesia as compared with general anesthesia on the ability to walk in older adults undergoing surgery for hip fracture have not been well studied. Methods We conducted a pragmatic, randomized superiority trial to evaluate spinal anesthesia as compared with general anesthesia in previously ambulatory patients 50 years of age or older who were undergoing surgery for hip fracture at 46 U.S. and Canadian hospitals. Patients were randomly assigned in a 1:1 ratio to receive spinal or general anesthesia. The primary outcome was a composite of death or an inability to walk approximately 10 ft (3 m) independently or with a walker or cane at 60 days after randomization. Secondary outcomes included death within 60 days, delirium, time to discharge, and ambulation at 60 days. Results A total of 1600 patients were enrolled; 795 were assigned to receive spinal anesthesia and 805 to receive general anesthesia. The mean age was 78 years, and 67.0% of the patients were women. A total of 666 patients (83.8%) assigned to spinal anesthesia and 769 patients (95.5%) assigned to general anesthesia received their assigned anesthesia. Among patients in the modified intention-to-treat population for whom data were available, the composite primary outcome occurred in 132 of 712 patients (18.5%) in the spinal anesthesia group and 132 of 733 (18.0%) in the general anesthesia group (relative risk, 1.03; 95% confidence interval [CI], 0.84 to 1.27; P=0.83). An inability to walk independently at 60 days was reported in 104 of 684 patients (15.2%) and 101 of 702 patients (14.4%), respectively (relative risk, 1.06; 95% CI, 0.82 to 1.36), and death within 60 days occurred in 30 of 768 (3.9%) and 32 of 784 (4.1%), respectively (relative risk, 0.97; 95% CI, 0.59 to 1.57). Delirium occurred in 130 of 633 patients (20.5%) in the spinal anesthesia group and in 124 of 629 (19.7%) in the general anesthesia group (relative risk, 1.04; 95% CI, 0.84 to 1.30). Conclusions Spinal anesthesia for hip-fracture surgery in older adults was not superior to general anesthesia with respect to survival and recovery of ambulation at 60 days. The incidence of postoperative delirium was similar with the two types of anesthesia. (Funded by the Patient-Centered Outcomes Research Institute; REGAIN ClinicalTrials.gov number, .)	[Neuman, M. D.; Gaskins, L. J.; Elkassabany, N.; Fleisher, L. A.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, 308 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19106 USA; [Feng, R.; Stephens-Shields, A. J.; Ellenberg, S. S.] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19106 USA; [Mehta, S.] Univ Penn, Perelman Sch Med, Dept Orthoped Surg, Philadelphia, PA 19106 USA; [Neuman, M. D.; Gaskins, L. J.; Elkassabany, N.; Fleisher, L. A.] Univ Penn, Perelman Sch Med, Ctr Perioperat Outcomes Res & Transformat, Philadelphia, PA 19106 USA; [Feng, R.; Dattilo, J.; Tierney, A.; Stephens-Shields, A. J.; Ellenberg, S. S.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19106 USA; [Schwenk, E. S.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Anesthesiol, Philadelphia, PA 19107 USA; [Menio, D.] Temple Univ, Lewis Katz Sch Med, Ctr Advocacy Rights & Interests Elderly, Philadelphia, PA 19122 USA; [Hauck, E.] Temple Univ, Lewis Katz Sch Med, Dept Anesthesiol, Philadelphia, PA 19122 USA; [Carson, J. L.] Rutgers Robert Wood Johnson Med Sch, Div Gen Internal Med, New Brunswick, NJ USA; [Dillane, D.] Univ Alberta Hosp, Dept Anesthesiol & Pain Med, Edmonton, AB, Canada; [Stone, T.] Univ British Columbia, Dept Orthopaed, Vancouver, BC, Canada; [Papp, S.] Ottawa Hosp, Div Orthopaed, Civ Campus, Ottawa, ON, Canada; [Chin, K-J] Univ Toronto, Dept Anesthesiol & Pain Med, Toronto, ON, Canada; [Choi, S.] Sunnybrook Hlth Sci Ctr, Dept Anesthesia, Toronto, ON, Canada; [Kwofie, M. K.] Dalhousie Univ, Dept Anesthesia Pain Management & Perioperat Med, Halifax, NS, Canada; [Sessler, D., I; Ayad, S.] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA; [Sieber, F.] Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Magaziner, J.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Marcantonio, E. R.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA; [Vlassakov, K.] Harvard Med Sch, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Sharma, B.] Lahey Hosp & Med Ctr, Dept Anesthesiol, Burlington, MA USA; [Marshall, M.] New York Univ Langone Hlth, Dept Anesthesiol Perioperat Care & Pain Med, New York, NY USA; [Tedore, T.] New York Presbyterian Weill Cornell Med Ctr, Dept Anesthesiol, New York, NY USA; [Azim, S.] SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY 11794 USA; [Jaffe, J. D.] Wake Forest Sch Med, Dept Anesthesiol, Winston Salem, NC 27101 USA; [Luke, C.] Univ Pittsburgh Med Ctr, Dept Anesthesiol, Pittsburgh, PA USA; [Hymes, R. A.] Dept Orthoped Surg, Inova Fairfax Med Campus, Falls Church, VA USA; [Kates, S.] Virginia Commonwealth Univ, Dept Orthoped Surg, Richmond, VA USA; [Sheppard, R.] Hartford Hosp, Dept Anesthesiol, Hartford, CT 06115 USA; [Li, J.] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA; [Perlman, B.] Oregon Hlth & Sci Univ, Div Hosp Med, Portland, OR 97201 USA; [Sappenfield, J.] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL USA; [Hoeft, M. A.] Univ Vermont, Larner Sch Med, Dept Anesthesiol, Burlington, VT USA; [Giska, M.] Henry Ford Hlth Syst, Dept Anesthesiol Pain Management & Perioperat Med, Detroit, MI USA; [Ranganath, Y.] Univ Iowa, Dept Anesthesia, Carver Coll Med, Iowa City, IA 52242 USA; [Nader, A.] Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA; [Sanders, R. D.] Univ Sydney, Specialty Anaesthet, Sydney, NSW, Australia; [Allen, B. F. S.] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Div Multispecialty Anesthesiol, Nashville, TN USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Alberta; University of British Columbia; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Dalhousie University; Cleveland Clinic Foundation; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Lahey Hospital & Medical Center; New York University; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Wake Forest University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Inova Fairfax Hospital; Virginia Commonwealth University; Hartford Hospital; Yale University; Oregon Health & Science University; State University System of Florida; University of Florida; University of Vermont; Henry Ford Health System; Henry Ford Hospital; University of Iowa; Northwestern University; Feinberg School of Medicine; University of Sydney; Vanderbilt University	Neuman, MD (corresponding author), Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, 308 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19106 USA.	neumanm@pennmedicine.upenn.edu	Marcantonio, Edward R/U-3929-2017; Ranganath, Yatish Siddapura/AAR-9003-2020; Kwofie, Kwesi/V-1628-2019; Bryson, Gregory Lyle/AAG-5108-2019	Marcantonio, Edward R/0000-0002-2911-4250; Ranganath, Yatish Siddapura/0000-0002-6106-4687; Kwofie, Kwesi/0000-0002-0509-4064; Bryson, Gregory Lyle/0000-0003-3583-9802; Schwenk, Eric/0000-0003-3464-4149; AYAD, SABRY/0000-0002-6728-9297; Choi, Stephen/0000-0003-3662-9073; Allen, Brian/0000-0002-6279-9757	Patient-Centered Outcomes Research Institute [1406-18876]	Patient-Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI)	\The authors, who make up the REGAIN Investigators Writing Committee, assume responsibility for the content of this article. The views presented in this article are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute, its board of governors, or its methodology committee. Supported by a grant (1406-18876) from the Patient-Centered Outcomes Research Institute. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.	Ahn EJ, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029245; Biboulet P, 2012, REGION ANESTH PAIN M, V37, P433, DOI 10.1097/AAP.0b013e318252e901; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Chu CC, 2015, ANESTHESIOLOGY, V123, P136, DOI 10.1097/ALN.0000000000000695; Diehr P, 2005, J CLIN EPIDEMIOL, V58, P1115, DOI 10.1016/j.jclinepi.2005.05.002; Diehr P, 2003, ANN INTERN MED, V139, P416, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00007; Fuzier R, 2011, REGION ANESTH PAIN M, V36, P322, DOI 10.1097/AAP.0b013e318217a68e; Guay J, 2016, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000521.PUB3; Haghighi M, 2017, ARCH BONE JT SURG-AB, V5, P226; Hernan MA, 2017, NEW ENGL J MED, V377, P1391, DOI 10.1056/NEJMsm1605385; Hogan JW, 2004, STAT METHODS MED RES, V13, P17, DOI 10.1191/0962280204sm351ra; Horlocker TT, 2018, REGION ANESTH PAIN M, V43, P263, DOI 10.1097/AAP.0000000000000763; Horlocker TT, 2010, REGION ANESTH PAIN M, V35, P64, DOI 10.1097/AAP.0b013e3181c15c70; Hruslinski J, 2021, BRIT J ANAESTH, V126, P395, DOI 10.1016/j.bja.2020.09.052; Juelsgaard P, 1998, EUR J ANAESTH, V15, P656, DOI 10.1097/00003643-199811000-00006; LACHIN JM, 1988, CONTROL CLIN TRIALS, V9, P365, DOI 10.1016/0197-2456(88)90049-9; Marcantonio ER, 2014, ANN INTERN MED, V161, P554, DOI 10.7326/M14-0865; Matsui S, 2005, BIOMETRICS, V61, P816, DOI 10.1111/j.1541-0420.2005.00339.x; MATTS JP, 1988, CONTROL CLIN TRIALS, V9, P327, DOI 10.1016/0197-2456(88)90047-5; Maxwell BG, 2020, JAMA SURG, V155, P167, DOI 10.1001/jamasurg.2019.4471; MUNHALL RJ, 1988, ANESTH ANALG, V67, P843; Neuman MD, 2020, CONTEMP CLIN TRIALS, V98, DOI 10.1016/j.cct.2020.106171; Neuman MD, 2018, CLIN TRIALS, V15, P107, DOI 10.1177/1740774517735536; Neuman MD, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013473; Neuman MD, 2014, JAMA-J AM MED ASSOC, V311, P2508, DOI 10.1001/jama.2014.6499; Neuman MD, 2012, ANESTHESIOLOGY, V117, P72, DOI 10.1097/ALN.0b013e3182545e7c; Neuman MD, 2010, MED CARE, V48, P314, DOI 10.1097/MLR.0b013e3181ca4126; Parker MJ, 2015, INJURY, V46, P1562, DOI 10.1016/j.injury.2015.05.004; Ravi B, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0111; Salkeld G, 2000, BMJ-BRIT MED J, V320, P341, DOI 10.1136/bmj.320.7231.341; Sieber F, 2019, BRIT J ANAESTH, V122, P480, DOI 10.1016/j.bja.2018.12.021; Sieber FE, 2018, JAMA SURG, V153, P987, DOI 10.1001/jamasurg.2018.2602; Tajeu GS, 2014, J GERONTOL A-BIOL, V69, P346, DOI 10.1093/gerona/glt105; Tzimas P, 2018, INJURY, V49, P2221, DOI 10.1016/j.injury.2018.09.023; Ustun T. B., 2010, Measuring health and disability: manual for WHO Disability Assessment Schedule (WHODAS 2.0)	36	50	52	2	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2021	385	22					2025	2035		10.1056/NEJMoa2113514	http://dx.doi.org/10.1056/NEJMoa2113514		OCT 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC3KG	34623788	Green Published			2023-01-03	WOS:000704987900001
J	Dummer, R; Gyorki, DE; Hyngstrom, J; Berger, AC; Conry, R; Demidov, L; Sharma, A; Treichel, SA; Radcliffe, H; Gorski, KS; Anderson, A; Chan, E; Faries, M; Ross, MI				Dummer, R.; Gyorki, D. E.; Hyngstrom, J.; Berger, A. C.; Conry, R.; Demidov, L.; Sharma, A.; Treichel, S. A.; Radcliffe, H.; Gorski, K. S.; Anderson, A.; Chan, E.; Faries, M.; Ross, M. I.			Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial	NATURE MEDICINE			English	Article							III MELANOMA; BIOCHEMOTHERAPY; INTERFERON-ALPHA-2B; MULTICENTER; THERAPY; RISK	Intralesional injection of an oncolytic virus prior to surgery shows favorable clinical activity over surgery alone in patients with locally advanced, resectable melanoma, supporting further evaluation in the neoadjuvant setting for this population. Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional oncolytic immunotherapy approved for the treatment of unresectable melanoma. The present, ongoing study aimed to estimate the treatment effect of neoadjuvant T-VEC on recurrence-free survival (RFS) of patients with advanced resectable melanoma. An open-label, phase 2 trial (NCT02211131) was conducted in 150 patients with resectable stage IIIB-IVM1a melanoma who were randomized to receive T-VEC followed by surgery (arm 1, n = 76) or surgery alone (arm 2, n = 74). The primary endpoint was a 2-year RFS in the intention-to-treat population. Secondary and exploratory endpoints included overall survival (OS), pathological complete response (pCR), safety and biomarker analyses. The 2-year RFS was 29.5% in arm 1 and 16.5% in arm 2 (overall hazard ratio (HR) = 0.75, 80% confidence interval (CI) = 0.58-0.96). The 2-year OS was 88.9% for arm 1 and 77.4% for arm 2 (overall HR = 0.49, 80% CI = 0.30-0.79). The RFS and OS differences between arms persisted at 3 years. In arm 1, 17.1% achieved a pCR. Increased CD8(+) density correlated with clinical outcomes in an exploratory analysis. Arm 1 adverse events were consistent with previous reports for T-VEC. The present study met its primary endpoint and estimated a 25% reduction in the risk of disease recurrence for neoadjuvant T-VEC plus surgery versus upfront surgery for patients with resectable stage IIIB-IVM1a melanoma.	[Dummer, R.] Univ Hosp Zurich, Zurich, Switzerland; [Gyorki, D. E.] Austin Hlth, Olivia Newton John Canc Ctr, Heidelberg, Vic, Australia; [Hyngstrom, J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Berger, A. C.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA; [Conry, R.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; [Demidov, L.] NN Blokhin Russian Canc Res Ctr, Moscow, Russia; [Sharma, A.; Anderson, A.; Chan, E.] Amgen Inc, Thousand Oaks, CA 91320 USA; [Treichel, S. A.; Gorski, K. S.] Amgen Inc, San Francisco, CA USA; [Radcliffe, H.] Amgen Inc, Uxbridge, Middx, England; [Faries, M.] John Wayne Canc Inst, Santa Monica, CA USA; [Ross, M. I.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Berger, A. C.] Canc Inst New Jersey, New Brunswick, NJ USA; [Faries, M.] Angeles Clin & Res Inst, Los Angeles, CA USA	University of Zurich; University Zurich Hospital; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; La Trobe University; Olivia Newton-John Cancer Research Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Jefferson University; University of Alabama System; University of Alabama Birmingham; N.N. Blokhin Russian Cancer Research Center; Amgen; Amgen; Amgen; Amgen Limited; John Wayne Cancer Institute; University of Texas System; UTMD Anderson Cancer Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Angeles Clinic & Research Institute	Dummer, R (corresponding author), Univ Hosp Zurich, Zurich, Switzerland.	Reinhard.Dummer@usz.ch			Amgen Inc.	Amgen Inc.(Amgen)	Medical writing support was provided by C. Nosala of Amgen Inc. The authors thank J. Gansert of Amgen Inc. for designing the study and R. Andtbacka for contributions to study design. This study was sponsored by Amgen Inc.	Amaria RN, 2019, LANCET ONCOL, V20, pE378, DOI 10.1016/S1470-2045(19)30332-8; Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Amaria RN, 2018, LANCET ONCOL, V19, P181, DOI 10.1016/S1470-2045(18)30015-9; Andtbacka RHI, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0623-z; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Buzaid AC, 1998, MELANOMA RES, V8, P549, DOI 10.1097/00008390-199812000-00010; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eggermont AMM, 2008, LANCET, V372, P117, DOI 10.1016/S0140-6736(08)61033-8; Garutti M, 2020, CANCERS, V12, DOI 10.3390/cancers12071941; Gogas H, 2018, ANN ONCOL, V29, P443; Helmink B, 2019, LANCET ONCOL, V20, P892, DOI 10.1016/S1470-2045(19)30377-8; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Koyanagi K, 2005, J CLIN ONCOL, V23, P8057, DOI 10.1200/JCO.2005.02.0958; Larocca CA, 2020, AM J CLIN DERMATOL, V21, P821, DOI 10.1007/s40257-020-00554-8; Lewis KD, 2006, J CLIN ONCOL, V24, P3157, DOI 10.1200/JCO.2005.04.5344; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; Long GV, 2019, LANCET ONCOL, V20, P961, DOI 10.1016/S1470-2045(19)30331-6; Menzies AM, 2021, NAT MED, V27, P301, DOI 10.1038/s41591-020-01188-3; Michielin O, 2019, ANN ONCOL, V30, P1884, DOI 10.1093/annonc/mdz411; Miller CJ, 2017, J AM ACAD DERMATOL, V77, P333, DOI 10.1016/j.jaad.2017.03.025; Moschos SJ, 2006, J CLIN ONCOL, V24, P3164, DOI 10.1200/JCO.2005.05.2498; O'Donnell JS, 2019, CLIN CANCER RES, V25, P5743, DOI 10.1158/1078-0432.CCR-18-2641; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Rozeman EA, 2019, LANCET ONCOL, V20, P948, DOI 10.1016/S1470-2045(19)30151-2; Versluis JM, 2020, NAT MED, V26, P475, DOI 10.1038/s41591-020-0829-0	28	16	16	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1789	+		10.1038/s41591-021-01510-7	http://dx.doi.org/10.1038/s41591-021-01510-7		OCT 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34608333				2023-01-03	WOS:000703378900007
J	Kebede, AA; Cherkos, EA; Taye, EB; Eriku, GA; Taye, BT; Chanie, WF; Dey, A; Spradley, FT; Spradley, FT				Kebede, Azmeraw Ambachew; Cherkos, Endeshaw Admasu; Taye, Eden Bishaw; Eriku, Getachew Azeze; Taye, Birhan Tsegaw; Chanie, Wagaye Fentahun; Dey, Avanti; Spradley, Frank T.; Spradley, Frank T.			Married women's decision-making autonomy in the household and maternal and neonatal healthcare utilization and associated factors in Debretabor, northwest Ethiopia	PLOS ONE			English	Article							POWER	Background Women's decision-making autonomy is very crucial for the improvement of women empowerment, and maternal, neonatal, and child healthcare utilization. As time immemorial, Ethiopian culture is largely gender stratified, and the position of women is subordinate to men in various household and health-seeking decision-making matters. However, there is a dearth of empirical evidence on women's decision-making autonomy, especially in the household and on maternal and newborn healthcare utilization. Therefore, this study assessed married women's decision-making autonomy in the household and on maternal and neonatal healthcare utilization and associated factors in Debretabor, Northwest Ethiopia. Methods A community-based cross-sectional study was conducted from October 1(st) to 30(th), 2019. A two-stage sampling technique was used to select 730 married women. Data were collected using a structured, pretested, and interviewer-administered questionnaire. Data were entered into EPI INFO 7 and analyzed by SPSS version 23. Multivariable logistic regression model was fitted to identify factors associated with women's decision-making autonomy in the household and maternal and neonatal healthcare utilization. The adjusted odds ratio with its 95% confidence interval was computed to determine the level of significance at a p-value of <= 0.05. Results A total of 730 married women were included in the analysis. Thus, three-fourths (75.1%) of women had higher decision-making autonomy on their health, neonatal health, and other socio-economic aspects. Besides, the proportion of four and above antenatal visits, delivery at a health facility, postnatal checkup, knowledge of neonatal danger signs, and appropriate health-seeking practices for sick newborns among autonomous women were 52.1%, 56.1%, 71.4%, 32%, and 80% respectively. Age greater than 35 years old (AOR = 2.08; 95% CI: 1.19, 3.62), monthly income of > 5000 ETB (AOR = 3.1; 95% CI: 1.36, 7.07), husband involvement (AOR = 2.36; 95% CI: 1.55, 3.43), and adequate knowledge of neonatal danger signs (AOR = 2.11; 95% CI: 1.4, 3.2) were factors independently associated with women's decision-making autonomy on maternal and neonatal healthcare utilization and other socio-economic affairs. Conclusion Our findings show that women's decision-making autonomy in the household and maternal and neonatal healthcare utilization was optimal. Increasing household income level, promotion of husband's involvement starting from the prenatal period, and increasing women's knowledge of maternal and neonatal danger signs will have a great role in the improvement of women's decision-making autonomy.	[Kebede, Azmeraw Ambachew; Taye, Eden Bishaw] Univ Gondar, Sch Midwifery, Coll Med & Hlth Sci, Dept Clin Midwifery, Gondar, Ethiopia; [Cherkos, Endeshaw Admasu] Univ Gondar, Sch Midwifery, Coll Med & Hlth Sci, Dept Womens & Family Hlth, Gondar, Ethiopia; [Eriku, Getachew Azeze] Univ Gondar, Sch Med, Coll Med & Hlth Sci, Dept Physiotherapy, Gondar, Ethiopia; [Taye, Birhan Tsegaw] Debre Berhan Univ, Coll Med & Hlth Sci, Dept Midwifery, Debre Berhan, Ethiopia; [Chanie, Wagaye Fentahun] Univ Gondar, Coll Med & Hlth Sci, UNFPA Supported Maternal Hlth Project Coordinator, Gondar, Ethiopia	University of Gondar; University of Gondar; University of Gondar; University of Gondar	Kebede, AA (corresponding author), Univ Gondar, Sch Midwifery, Coll Med & Hlth Sci, Dept Clin Midwifery, Gondar, Ethiopia.	azmuzwagholic@gmail.com	Taye, Birhan Tsegaw/AAX-6617-2021; Kebede, Azmeraw Ambachew/ABE-1909-2021	Taye, Birhan Tsegaw/0000-0003-2174-3797; Kebede, Azmeraw Ambachew/0000-0003-0831-8470; Bishaw, Eden/0000-0003-2904-2450				Akuma Adugna Olani, 2019, INT J MULTIDISCIP RE; Alemayehu B, 2020, OPEN ACCESS J CONTR, V11, P43, DOI 10.2147/OAJC.S250462; Alemayehu M, 2017, INT J WOMENS HEALTH, V9, P213, DOI 10.2147/IJWH.S131139; Amadiume PI., 2015, MALE DAUGHTERS FEMAL, P248; Angel-Urdinola Diego., 2011, MUNICH PERS REPEC AR; [Anonymous], 2019, ETHIOPIA MINIDEMOGRA; [Anonymous], 2019, TRENDS MATERNAL MORT; Asweto CO, 2014, AM J PUBLIC HLTH RES, V2, P153; Belay AD, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0290-x; Centeral statical agency of Ethiopia and ICF, 2016, ETH DEM HLTH SURV; Duah HO, 2017, INT J WOMENS HLTH WE, V3, P1; Durrani H.M., 2015, UNIVERS J PUBLIC HLT, V3, P49; Ghose B., 2017, BMJ OPEN, P1; Hou XH, 2013, HEALTH POLICY PLANN, V28, P176, DOI 10.1093/heapol/czs042; Jahan F., 2015, INT J RES APPL, V3, P133; Jemberia Mekdes Mengesha, 2018, Matern Health Neonatol Perinatol, V4, P5, DOI 10.1186/s40748-018-0073-5; Jennings L, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-297; Kariman N, 2014, IRAN RED CRESCENT ME, V16, DOI 10.5812/ircmj.13629; NibretTiruneh F., 2017, BMC HEALTH SERV RES, V17, P1, DOI [10.1186/s12913-016-1943-z, DOI 10.1186/S12913-016-1943-Z]; Nigatu D, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-79; Nigatu Solomon Gedlu, 2015, BMC Res Notes, V8, P309, DOI 10.1186/s13104-015-1278-6; Osamor P, 2018, J BIOSOC SCI, V50, P70, DOI 10.1017/S0021932017000037; Osamor PE, 2016, INT J WOMENS HEALTH, V8, P191, DOI 10.2147/IJWH.S105483; Pandey KK., 2017, J STAT APPL PROBAB L, V1, P1, DOI 10.18576/jsapl/040101; Pratley P, 2016, SOC SCI MED, V169, P119, DOI 10.1016/j.socscimed.2016.08.001; Rahman AE, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1882-2; Saaka M, 2020, J NUTR SCI, V9, DOI 10.1017/jns.2020.30; Skakoon-Sparling S, 2016, ARCH SEX BEHAV, V45, P33, DOI 10.1007/s10508-015-0589-y; Sougou NM, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09003-x; Tadele A, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0813-7; Thankian K, 2020, J SCI RES REPORTS, V26, P109, DOI 10.9734/jsrr/2020/v26i430252; Tunku U., 2011, J APPL SCI RES, V2014; UNICEF WHO World Bank and U-DPD., 2017, LEV TRENDS EST DEV U; United Nations Transforming Our World, 2016, TRANSF OUR WORLD 203; Wado YD, 2018, WOMEN HEALTH, V58, P729, DOI 10.1080/03630242.2017.1353573; Zaman SBin., 2018, BMC RES NOTES, P4, DOI DOI 10.1186/S13104-017-3111-X	36	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0255021	10.1371/journal.pone.0255021	http://dx.doi.org/10.1371/journal.pone.0255021			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XM7DR	34570781	gold, Green Published			2023-01-03	WOS:000728983400048
J	Leshoid, E; Newhart, D; Reno, L; Sleeper, S; Nary, J; Gutowski, J; Yu, S; Walsh, E; Vargas, R; Riedy, D; Mayo, R				Leshoid, Emil; Newhart, Donna; Reno, Lisa; Sleeper, Scott; Nary, Julia; Gutowski, Jennifer; Yu, Stephanie; Walsh, Edward; Vargas, Roberto; Riedy, Dawn; Mayo, Robert			Effectiveness of various cleaning strategies in acute and long-term care facilities during novel corona virus 2019 disease pandemic-related staff shortages	PLOS ONE			English	Article							COVID-19	Background Cleanliness of hospital surfaces helps prevent healthcare-associated infections, but comparative evaluations of various cleaning strategies during COVID-19 pandemic surges and worker shortages are scarce. Purpose and methods To evaluate the effectiveness of daily, enhanced terminal, and contingency-based cleaning strategies in an acute care hospital (ACH) and a long-term care facility (LTCF), using SARS-CoV-2 RT-PCR and adenosine triphosphate (ATP) assays. Daily cleaning involved light dusting and removal of visible debris while a patient is in the room. Enhanced terminal cleaning involved wet moping and surface wiping with disinfectants after a patient is permanently moved out of a room followed by ultraviolet light (UV-C), electrostatic spraying, or room fogging. Contingency-based strategies, performed only at the LTCF, involved cleaning by a commercial environmental remediation company with proprietary chemicals and room fogging. Ambient surface contamination was also assessed randomly, without regard to cleaning times. Near-patient or high-touch stationary and non-stationary environmental surfaces were sampled with pre-moistened swabs in viral transport media. Results At the ACH, SARS-CoV-2 RNA was detected on 66% of surfaces before cleaning and on 23% of those surfaces immediately after terminal cleaning, for a 65% post-cleaning reduction (p = 0.001). UV-C enhancement resulted in an 83% reduction (p = 0.023), while enhancement with electrostatic bleach application resulted in a 50% reduction (p = 0.010). ATP levels on RNA positive surfaces were not significantly different from those of RNA negative surfaces. LTCF contamination rates differed between the dementia, rehabilitation, and residential units (p = 0.005). 67% of surfaces had RNA after room fogging without terminal-style wiping. Fogging with wiping led to a -11% change in the proportion of positive surfaces. At the LTCF, mean ATP levels were lower after terminal cleaning (p = 0.016). Conclusion Ambient surface contamination varied by type of unit and outbreak conditions, but not facility type. Removal of SARS-CoV-2 RNA varied according to cleaning strategy.	[Leshoid, Emil; Newhart, Donna; Reno, Lisa; Sleeper, Scott; Nary, Julia; Gutowski, Jennifer; Yu, Stephanie; Vargas, Roberto; Riedy, Dawn; Mayo, Robert] Rochester Reg Hlth, Rochester, NY USA; [Walsh, Edward] Univ Rochester, Sch Med & Dent, Rochester, NY USA	University of Rochester	Leshoid, E (corresponding author), Rochester Reg Hlth, Rochester, NY USA.	carolinelesho@yahoo.com						Brown N, FIGHT MASKS HOSP JAN; Carling PC, 2008, INFECT CONT HOSP EP, V29, P1, DOI 10.1086/524329; Centers for Medicare and Medicaid Services, NURS HOM COVID 19 DA; Chin AWH, 2020, LANCET MICROBE, V1, pE10, DOI [10.1016/S2666-5247(20)30003-3, 10.1016/S2666-5247(20)30095-1]; Clifford R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155779; Colaneri M, 2020, J HOSP INFECT, V105, P474, DOI 10.1016/j.jhin.2020.03.018; Dancer SJ, 2014, CLIN MICROBIOL REV, V27, P665, DOI 10.1128/CMR.00020-14; Ducharme J., NO ONE MENTIONS PEOP; Feng BH, 2021, J HAZARD MATER, V402, DOI 10.1016/j.jhazmat.2020.123771; Gaur S, 2020, INFECT CONT HOSP EP, V41, P729, DOI 10.1017/ice.2020.98; Goldman E, 2020, LANCET INFECT DIS, V20, P892, DOI 10.1016/S1473-3099(20)30561-2; Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885; Kwiatkowski M, NATL DISGRACE 40600; Lesho E, 2020, NEW ENGL J MED, V382, P1963, DOI 10.1056/NEJMc2007942; Lesho E, 2015, INFECT CONT HOSP EP, V36, P1130, DOI 10.1017/ice.2015.151; Litwin AS, 2017, ILR REV, V70, P610, DOI 10.1177/0019793916654482; Memmott J., KEEPING HOSP SAFE SO; Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227; Pastorino B, 2020, EMERG INFECT DIS, V26, P2256, DOI 10.3201/eid2609.201788; Rupp ME, 2013, INFECT CONT HOSP EP, V34, P100, DOI 10.1086/668779; Ryu BH, 2020, AM J INFECT CONTROL, V48, P875, DOI 10.1016/j.ajic.2020.05.027; Wu SJ, 2020, AM J INFECT CONTROL, V48, P910, DOI 10.1016/j.ajic.2020.05.003; Ye GM, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.04.034	23	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0261365	10.1371/journal.pone.0261365	http://dx.doi.org/10.1371/journal.pone.0261365			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061676	Green Published, gold			2023-01-03	WOS:000791072800039
J	Liao, XH; Chen, H; Ge, B				Liao, Xianhui; Chen, Hao; Ge, Beihai			The effect of mind-body exercise on cervical spine mobility of people with neck discomfort: A systemic review and meta-analysis of randomised controlled trials	PLOS ONE			English	Review							3-DIMENSIONAL MOTION ANALYSIS; OLDER-ADULTS; NORMAL RANGE; RELIABILITY; PAIN; VALIDITY; THERAPY	Background Long-term and high-intensity work can lead to considerable discomfort in people's cervical spines. Objectives This study sought to explore the effect of mind-body exercise intervention on the cervical spine mobility of people with neck discomfort through meta-analysis. Methods This study's researchers were searched a total of five research databases for data retrieval: China National Knowledge Infrastructure (from 1979), Web of Science (from 1950), PubMed (from 1965), Cochrane (from 1991), and EBSCO (from 1949) (Date of retrieval: March 10, 2021). Two authors independently searched literature records, scanned titles, abstracts, and full texts, collected data, and assessed materials for risk of bias. Stata14.0 software was used for the data analysis (Registration number: INPLASY202140126). Results Four articles were finally included with a total of 208 participants, and their age range was 18-65 years old. (1) Mind-body exercise intervention had a significant improving effect on Cervical extension, effect size of [SMD = 0.51 (95% CI 0.13 to 0.88), p < 0.01; I2 = 45.2%], there was moderate heterogeneity; Mind-body exercise intervention had a significant improving effect on Cervical flexion, effect size of [SMD = 0.61 (95% CI 0.32 to 0.90), p < 0.01; I2 = 5.7%], no heterogeneity; (2) Mind-body exercise intervention was no effect on the other four cervical range of motions; (3) The difference in participant's neck discomfort was the source of heterogeneity, and all results had the potential risk of publication bias. Conclusion This study showed that mind-body exercise had a positive effect on the extension and flexion of people with neck discomfort. However, further research and more reliable evidence were needed to prove that mind-body exercise could be used for the treatment of neck discomfort.	[Liao, Xianhui] Wuhan EQ IQ Sch, Dept Sports, Wuhan, Hubei, Peoples R China; [Chen, Hao] Wuhan Business Univ, Inst Phys Educ & Int Equestrian, Wuhan, Hubei, Peoples R China; [Ge, Beihai] Guangxi Zhuang Autonomous Region Brain Hosp, Dept Neurol, Liuzhou, Guangxi, Peoples R China	Wuhan Business University	Ge, B (corresponding author), Guangxi Zhuang Autonomous Region Brain Hosp, Dept Neurol, Liuzhou, Guangxi, Peoples R China.	gebeihai@126.com		beihai, ge/0000-0002-3743-8132	Guangxi Natural Science Foundation [2020GXNSFAA297115]	Guangxi Natural Science Foundation(National Natural Science Foundation of Guangxi Province)	This study was supported by Guangxi Natural Science Foundation (General Program, 2020GXNSFAA297115); (2) The full name of each funder and its URL: Beihai Ge, http://www.gxnkyy.com:8081/ksjs_zjview.aspx?sid=37 & id=162; (3) Funder roles: the funders had roles in Data Curation, Methodology, Resources, Supervision, Writing-Original Draft Preparation, and WritingReview & Editing.	Berman RLH, 2009, J PAIN, V10, P68, DOI 10.1016/j.jpain.2008.07.006; Bhutta ZA, 2000, AM J CLIN NUTR, V72, P1516; Bi JJ, 2021, JMIR MHEALTH UHEALTH, V9, DOI 10.2196/23548; Cagnie B, 2007, J MANIP PHYSIOL THER, V30, P450, DOI 10.1016/j.jmpt.2007.05.003; Can HB, 2020, CRANIO; Chen J, 1999, SPINE, V24, P1571, DOI 10.1097/00007632-199908010-00011; Chiu TTW, 2002, CLIN REHABIL, V16, P851, DOI 10.1191/0269215502cr550oa; de Wit AE, 2021, PSYCHONEUROENDOCRINO, V126, DOI 10.1016/j.psyneuen.2021.105128; Huang N., 2020, FUJIAN CHIN MED, V51, P19, DOI [10.13260/j.cnki.jfjtcm.011959, DOI 10.13260/J.CNKI.JFJTCM.011959]; Hyong IH, 2013, J PHYS THER SCI, V25, P113, DOI 10.1589/jpts.25.113; Inokuchi H, 2015, EUR SPINE J, V24, P2807, DOI 10.1007/s00586-015-3913-2; Jordan K, 2000, RHEUMATOLOGY, V39, P382, DOI 10.1093/rheumatology/39.4.382; Kiwerski Jerzy E, 2008, Ortop Traumatol Rehabil, V10, P620; Kuc J, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00200; Lam LCW, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2012.03.008; Lam LCW, 2011, INT J GERIATR PSYCH, V26, P733, DOI 10.1002/gps.2602; Li YN, 2019, THESIS; Li YX, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014649; LIND B, 1989, ARCH PHYS MED REHAB, V70, P692; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; Minguez-Zuazo A, 2016, J EXERC REHABIL, V12, P216, DOI 10.12965/jer.1632564.282; Mishra R, 2021, BRIT J NEUROSURG, DOI 10.1080/02688697.2021.1886244; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Morone NE, 2007, PAIN MED, V8, P359, DOI 10.1111/j.1526-4637.2007.00312.x; Morone NE, 2016, JAMA INTERN MED, V176, P329, DOI 10.1001/jamainternmed.2015.8033; Naja AS, 2021, CLIN J PAIN, V37, P133, DOI 10.1097/AJP.0000000000000904; Noyez Luc, 2009, Interact Cardiovasc Thorac Surg, V9, P494, DOI 10.1510/icvts.2009.204768; Okamura Kenta, 2003, Masui, V52, P1181; Pospiech J, 1996, NEUROSURG REV, V19, P73, DOI 10.1007/BF00418071; Povlsen B, 2008, J HAND THER, V21, P69, DOI 10.1197/j.jht.2007.09.004; Pringle R Kevin, 2003, J Chiropr Med, V2, P91, DOI 10.1016/S0899-3467(07)60051-2; Schreiber TU, 2001, PHYS MED REHAB KUROR, V11, P113, DOI 10.1055/s-2001-16443; Shang Y, 2017, CHINESE NURSING RES, V31, P4017; Sung YH, 2020, J EXERC REHABIL, V16, P385, DOI 10.12965/jer.2040612.306; Tawashy AE, 2010, PHYS THER, V90, P427, DOI 10.2522/ptj.20090023; Thongtipmak S, 2020, HEALTHC INFORM RES, V26, P50, DOI 10.4258/hir.2020.26.1.50; Tsauo JY, 2007, J OCCUP REHABIL, V17, P171, DOI 10.1007/s10926-007-9076-1; Verges S, 2007, AM J PHYSIOL-REG I, V292, pR1246, DOI 10.1152/ajpregu.00409.2006; Whitcroft KL, 2010, SPINE, V35, pE976, DOI 10.1097/BRS.0b013e3181cd6176; Williams MA, 2010, J MANIP PHYSIOL THER, V33, P138, DOI 10.1016/j.jmpt.2009.12.009; Xie Z, 2018, THESIS; Yadegaripour M, 2021, INT J HUM-COMPUT INT, V37, P459, DOI 10.1080/10447318.2020.1825204; Yeh GY, 2004, AM J MED, V117, P541, DOI 10.1016/j.amjmed.2004.04.016; YOUDAS JW, 1992, PHYS THER, V72, P770, DOI 10.1093/ptj/72.11.770; Zou SH, 2017, EUR SPINE J, V26, P985, DOI 10.1007/s00586-016-4655-5	46	1	1	10	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0262429	10.1371/journal.pone.0262429	http://dx.doi.org/10.1371/journal.pone.0262429			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061772	gold, Green Published			2023-01-03	WOS:000791072800135
J	Ashour, A; Phipps, DL; Ashcroft, DM				Ashour, Ahmed; Phipps, Denham L.; Ashcroft, Darren M.			Predicting dispensing errors in community pharmacies: An application of the Systematic Human Error Reduction and Prediction Approach (SHERPA)	PLOS ONE			English	Article							FAILURE MODE; RISK ANALYSIS; HEALTH-CARE; MEDICATION	Introduction The objective of this study was to use a prospective error analysis method to examine the process of dispensing medication in community pharmacy settings and identify remedial solutions to avoid potential errors, categorising them as strong, intermediate, or weak based on an established patient safety action hierarchy tool. Method Focus group discussions and non-participant observations were undertaken to develop a Hierarchical Task Analysis (HTA), and subsequent focus group discussions applied the Systematic Human Error Reduction and Prediction Approach (SHERPA) focusing on the task of dispensing medication in community pharmacies. Remedial measures identified through the SHERPA analysis were then categorised as strong, intermediate, or weak based on the Veteran Affairs National Centre for Patient Safety action hierarchy. Non-participant observations were conducted at 3 pharmacies, totalling 12 hours, based in England. Additionally, 7 community pharmacists, with experience ranging from 8 to 38 years, participated in a total of 4 focus groups, each lasting between 57 to 85 minutes, with one focus group discussing the HTA and three applying SHERPA. A HTA was produced consisting of 10 sub-tasks, with further levels of sub-tasks within each of them. Results Overall, 88 potential errors were identified, with a total of 35 remedial solutions proposed to avoid these errors in practice. Sixteen (46%) of these remedial measures were categorised as weak, 14 (40%) as intermediate and 5 (14%) as strong according to the Veteran Affairs National Centre for Patient Safety action hierarchy. Sub-tasks with the most potential errors were identified, which included 'producing medication labels' and 'final checking of medicines'. The most common type of error determined from the SHERPA analysis related to omitting a check during the dispensing process which accounted for 19 potential errors. Discussion This work applies both HTA and SHERPA for the first time to the task of dispensing medication in community pharmacies, detailing the complexity of the task and highlighting potential errors and remedial measures specific to this task. Future research should examine the effectiveness of the proposed remedial solutions to improve patient safety.	[Ashour, Ahmed; Phipps, Denham L.; Ashcroft, Darren M.] Univ Manchester, Fac Biol Med & Hlth, Ctr Pharmacoepidemiol & Drug Safety, Sch Hlth Sci,Div Pharm & Optometry, Manchester, Lancs, England; [Ashour, Ahmed; Ashcroft, Darren M.] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Greater Manchester Patient Safety Translat R, Manchester, Lancs, England; [Ashcroft, Darren M.] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Sch Primary Care Res, Manchester, Lancs, England	University of Manchester; University of Manchester; University of Manchester	Ashour, A (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Ctr Pharmacoepidemiol & Drug Safety, Sch Hlth Sci,Div Pharm & Optometry, Manchester, Lancs, England.; Ashour, A (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Greater Manchester Patient Safety Translat R, Manchester, Lancs, England.	ahmed.ashour@postgrad.manchester.ac.uk		Ashour, Ahmed/0000-0003-1645-1810	National Institute for Health Research (NIHR) through the Greater Manchester Patient Safety Translational Research Centre [PSTRC-2016-003]	National Institute for Health Research (NIHR) through the Greater Manchester Patient Safety Translational Research Centre(National Institute for Health Research (NIHR))	This work was funded by the National Institute for Health Research (NIHR) through the Greater Manchester Patient Safety Translational Research Centre (award number: PSTRC-2016-003). The views expressed are those of the author (s) and not necessarily those of the NIHR or the Department of Health and Social Care.	Annett J., 2004, HDB HUMAN FACTORS ER, P355; Ashley Laura, 2010, J Patient Saf, V6, P210, DOI 10.1097/PTS.0b013e3181fc98d7; Ashley L, 2010, JT COMM J QUAL PATIE, V36, P351, DOI 10.1016/S1553-7250(10)36053-3; Ashour A, 2021, APPL ERGON, V93, DOI 10.1016/j.apergo.2021.103372; Aspden P., 2006, I MED, P26; Bowie P, 2016, EDUC PRIM CARE, V27, P86, DOI 10.1080/14739879.2016.1152658; CIEHF, 2016, HUM FACT BARR MAN; Donaldson LJ, 2017, LANCET, V389, P1680, DOI 10.1016/S0140-6736(17)31047-4; Elliott RA, 2021, BMJ QUAL SAF, V30, P96, DOI 10.1136/bmjqs-2019-010206; Embrey D., 2014, PROC INT S HUM FACTO, V3, P246; Embrey DE., 1986, SHERPA SYSTEMATIC HU; Greenall J., 2007, CAN PHARM J REV PHAR, V140, P191, DOI [10.1177/171516350714000324, DOI 10.1177/171516350714000324]; Habraken MMP, 2009, ERGONOMICS, V52, P809, DOI 10.1080/00140130802578563; Harris D, 2005, AEROSP SCI TECHNOL, V9, P525, DOI 10.1016/j.ast.2005.04.002; Harvey J, 2015, RES SOC ADMIN PHARM, V11, P216, DOI 10.1016/j.sapharm.2014.06.005; Kessels-Habraken M, 2009, INT J QUAL HEALTH C, V21, P427, DOI 10.1093/intqhc/mzp043; Knudsen P, 2007, QUAL SAF HEALTH CARE, V16, P285, DOI 10.1136/qshc.2006.022053; Li YF, 2020, QUAL RELIAB ENG INT, V36, P1657, DOI 10.1002/qre.2652; Mandal S, 2015, EXPERT SYST APPL, V42, P7195, DOI 10.1016/j.eswa.2015.05.033; McLeod RW, 2017, PROCESS SAF ENVIRON, V110, P31, DOI 10.1016/j.psep.2017.01.012; Napier P, 2018, RES SOC ADMIN PHARM, V14, P382, DOI 10.1016/j.sapharm.2017.05.002; National Patient Safety Foundation, 2016, RCA2 IMPR ROOT CAUS; NHS Digital, 2019, GEN PHARM SERV ENGL; Panagioti M, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4185; Phipps D, 2008, BRIT J ANAESTH, V100, P333, DOI 10.1093/bja/aem392; Phipps DL, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-158; Raduma-Tomas MA, 2012, BMJ QUAL SAF, V21, P211, DOI 10.1136/bmjqs-2011-000220; Roberts Alison S, 2005, Res Social Adm Pharm, V1, P546, DOI 10.1016/j.sapharm.2005.09.003; Shebl NA, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-150; Shebl Nada Atef, 2009, J Patient Saf, V5, P86, DOI 10.1097/PTS.0b013e3181a6f040; Sheikh A, 2017, B WORLD HEALTH ORGAN, V95, P546, DOI 10.2471/BLT.17.198002; Stanton N.A., 2013, HUMAN FACTORS METHOD, DOI DOI 10.1201/9781315587394; Stojkovic T, 2021, J PATIENT SAF, V17, pe515, DOI 10.1097/PTS.0000000000000403; Stojkovic T, 2018, INT J HEALTH PLAN M, V33, pE320, DOI 10.1002/hpm.2479; Stojkovic T, 2017, RES SOC ADMIN PHARM, V13, P1159, DOI 10.1016/j.sapharm.2016.11.009; Sujan MA, 2020, RELIAB ENG SYST SAFE, V194, DOI 10.1016/j.ress.2018.06.017; Vosper Helen, 2018, Am J Pharm Educ, V82, P6184, DOI 10.5688/ajpe6184; Weir NM, 2020, RES SOC ADMIN PHARM, V16, P637, DOI 10.1016/j.sapharm.2019.08.029; Wetterneck TB, 2006, AM J HEALTH-SYST PH, V63, P1528, DOI 10.2146/ajhp050515; Wood LJ, 2020, INT J QUAL HEALTH C, V32, P438, DOI 10.1093/intqhc/mzaa068	40	0	0	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2022	17	1							e0261672	10.1371/journal.pone.0261672	http://dx.doi.org/10.1371/journal.pone.0261672			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3L5MO	34982776	Green Published, gold			2023-01-03	WOS:000834805700011
J	Brown, K; Donato, AA				Brown, Krysta; Donato, Anthony A.			In hypertension, a quadpill containing quarter doses of 4 BP drugs reduced BP at 12 wk vs. standard-dose monotherapy	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Brown, Krysta; Donato, Anthony A.] Tower Hlth Reading Hosp, W Reading, PA 19611 USA		Brown, K (corresponding author), Tower Hlth Reading Hosp, W Reading, PA 19611 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN	2022	175	1					JC3	JC3		10.7326/J21-0003	http://dx.doi.org/10.7326/J21-0003		JAN 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	0Y3LO	34978861				2023-01-03	WOS:000790293700010
J	Hendley, SA; Bhargava, A; Holland, CK; Wool, GD; Ahmed, O; Paul, JD; Bader, KB				Hendley, Samuel A.; Bhargava, Aarushi; Holland, Christy K.; Wool, Geoffrey D.; Ahmed, Osman; Paul, Jonathan D.; Bader, Kenneth B.			(More than) doubling down: Effective fibrinolysis at a reduced rt-PA dose for catheter-directed thrombolysis combined with histotripsy	PLOS ONE			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; PULSED FOCUSED ULTRASOUND; DEEP VENOUS THROMBOSIS; IN-VITRO; VEIN THROMBOSIS; HIGH-INTENSITY; CAVITATION; THERAPY; DEGRADATION; MECHANISMS	Deep vein thrombosis is a major source of morbidity and mortality worldwide. For acute proximal deep vein thrombosis, catheter-directed thrombolytic therapy is an accepted method for vessel recanalization. Thrombolytic therapy is not without risk, including the potential for hemorrhagic bleeding that increases with lytic dose. Histotripsy is a focused ultrasound therapy that generates bubble clouds spontaneously in tissue at depth. The mechanical activity of histotripsy increases the efficacy of thrombolytic therapy at doses consistent with current pharmacomechanical treatments for venous thrombosis. The objective of this study was to determine the influence of lytic dose on histotripsy-enhanced fibrinolysis. Human whole blood clots formed in vitro were exposed to histotripsy and a thrombolytic agent (recombinant tissue plasminogen activator, rt-PA) in a venous flow model perfused with plasma. Lytic was administered into the clot via an infusion catheter at concentrations ranging from 0 (control) to 4.54 mu g/mL (a common clinical dose for catheter-directed thrombolysis). Following treatment, perfusate samples were assayed for markers of fibrinolysis, hemolysis, and intact red blood cells and platelets. Fibrinolysis was equivalent between the common clinical dose of rt-PA (4.54 mu g/mL) and rt-PA at a reduction to one-twentieth of the common clinical dose (0.23 mu g/mL) when combined with histotripsy. Minimal changes were observed in hemolysis for treatment arms with or without histotripsy, potentially due to clot damage from insertion of the infusion catheter. Likewise, histotripsy did not increase the concentration of red blood cells or platelets in the perfusate following treatment compared to rt-PA alone. At the highest lytic dose, a refined histotripsy exposure scheme was implemented to cover larger areas of the clot. The updated exposure scheme improved clot mass loss and fibrinolysis relative to administration of lytic alone. Overall, the data collected in this study indicate the rt-PA dose can be reduced by more than a factor of ten and still promote fibrinolysis when combined with histotripsy.	[Hendley, Samuel A.; Bader, Kenneth B.] Univ Chicago, Comm Med Phys, Chicago, IL 60637 USA; [Bhargava, Aarushi; Ahmed, Osman; Bader, Kenneth B.] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA; [Holland, Christy K.] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA; [Holland, Christy K.] Univ Cincinnati, Dept Biomed Engn, Cincinnati, OH USA; [Wool, Geoffrey D.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Paul, Jonathan D.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Chicago; University of Chicago	Bader, KB (corresponding author), Univ Chicago, Comm Med Phys, Chicago, IL 60637 USA.; Bader, KB (corresponding author), Univ Chicago, Dept Radiol, Chicago, IL 60637 USA.	baderk@uchicago.edu			National Heart, Lung, and Blood Institute [R01 HL133334]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by the National Heart, Lung, and Blood Institute (https://www.nhlbi.nih.gov/), Grant Number R01 HL133334. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acconcia C, 2013, APPL PHYS LETT, V103, DOI 10.1063/1.4816750; Bader KB, 2021, IEEE T BIO-MED ENG, V68, P1220, DOI 10.1109/TBME.2020.3023630; Bader KB, 2019, ULTRASOUND MED BIOL, V45, P1056, DOI 10.1016/j.ultrasmedbio.2018.10.035; Bader KB, 2018, PHYS MED BIOL, V63, DOI 10.1088/1361-6560/aab79b; Bader KB, 2016, PHYS MED BIOL, V61, P5253, DOI 10.1088/0031-9155/61/14/5253; Bader KB, 2016, ULTRASOUND MED BIOL, V42, P1701, DOI 10.1016/j.ultrasmedbio.2016.02.010; Bader KB, 2016, ADV EXP MED BIOL, V880, P339, DOI 10.1007/978-3-319-22536-4_19; Bader KB, 2015, ULTRASOUND MED BIOL, V41, P187, DOI 10.1016/j.ultrasmedbio.2014.08.018; Bajd Franci, 2012, Microcirculation, V19, P632, DOI 10.1111/j.1549-8719.2012.00198.x; Bajd F, 2010, THROMB RES, V126, P137, DOI 10.1016/j.thromres.2010.04.012; Bollen T, 2020, ULTRASOUND MED BIOL, V46, P336, DOI 10.1016/j.ultrasmedbio.2019.10.009; BRENNER B, 1990, CIRCULATION, V81, P1818, DOI 10.1161/01.CIR.81.6.1818; Chen JX, 2016, RADIOGRAPHICS, V36, P1565, DOI 10.1148/rg.2016150138; Coviello C, 2015, J ACOUST SOC AM, V137, P2573, DOI 10.1121/1.4916694; Czaplicki C, 2017, CARDIOVASC DIAGN THE, V7, pS186, DOI 10.21037/cdt.2017.11.05; Duck F., 1990, COMPREHENSIVE REFERE; Go AS, 2013, CIRCULATION, V127, pE841, DOI 10.1161/CIR.0b013e31829ae08c; Goel L, 2021, ULTRASOUND MED BIOL, V47, P3231, DOI 10.1016/j.ultrasmedbio.2021.07.018; Goel L, 2021, MICROSYST NANOENG, V7, DOI 10.1038/s41378-020-00228-9; Graham SM, 2014, J CONTROL RELEASE, V178, P101, DOI 10.1016/j.jconrel.2013.12.016; Haworth KJ, 2017, IEEE T ULTRASON FERR, V64, P177, DOI 10.1109/TUFFC.2016.2620492; Haynes W., 2013, ENCY SYSTEMBIOL, P2354, DOI [10.1007/978-1-4419-9863-7_1185, DOI 10.1007/978-1-4419-9863-7_1185]; Hendley SA, 2021, IEEE T ULTRASON FERR, V68, P2942, DOI 10.1109/TUFFC.2021.3052393; Hilleman DE, 2008, J VASC INTERV RADIOL, V19, P377, DOI 10.1016/j.jvir.2007.10.027; Hitchcock KE, 2011, ULTRASOUND MED BIOL, V37, P1240, DOI 10.1016/j.ultrasmedbio.2011.05.011; Holland CK, 2008, THROMB RES, V121, P663, DOI 10.1016/j.thromres.2007.07.006; Jensen CT, 2017, J ULTRAS MED, V36, P1867, DOI 10.1002/jum.14220; Khokhlova VA, 2015, INT J HYPERTHER, V31, P145, DOI 10.3109/02656736.2015.1007538; Kieran K, 2007, J UROLOGY, V178, P672, DOI 10.1016/j.juro.2007.03.093; Kleven RT, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83442-3; Kolbel T, 2008, J ENDOVASC THER, V15, P605, DOI 10.1583/08-2462.1; Lafond M, 2021, ULTRASOUND MED BIOL, V47, P693, DOI 10.1016/j.ultrasmedbio.2020.10.010; Li T, 2015, CANCER RES, V75, P3738, DOI 10.1158/0008-5472.CAN-15-0296; Lin KW, 2014, IEEE T ULTRASON FERR, V61, P1123, DOI 10.1109/TUFFC.2014.3012; Maxwell AD, 2022, IEEE T ULTRASON FERR, V69, P156, DOI 10.1109/TUFFC.2021.3113635; Maxwell AD, 2017, IEEE T ULTRASON FERR, V64, P1542, DOI 10.1109/TUFFC.2017.2739649; Maxwell AD, 2014, PHYS MED BIOL, V59, P4927, DOI 10.1088/0031-9155/59/17/4927; Maxwell AD, 2013, ULTRASOUND MED BIOL, V39, P449, DOI 10.1016/j.ultrasmedbio.2012.09.004; Maxwell AD, 2011, J ACOUST SOC AM, V130, P1888, DOI 10.1121/1.3625239; Maxwell AD, 2011, J VASC INTERV RADIOL, V22, P369, DOI 10.1016/j.jvir.2010.10.007; Mercado-Shekhar KP, 2018, ULTRASOUND MED BIOL, V44, P2710, DOI 10.1016/j.ultrasmedbio.2018.08.005; Mewissen MW, 1999, RADIOLOGY, V211, P39, DOI 10.1148/radiology.211.1.r99ap4739; Miller R.G, 1981, SIMULTANEOUS STAT IN, DOI DOI 10.1007/978-1-4613-8122-8; Nyamekye I, 2012, PHLEBOLOGY, V27, P61, DOI 10.1258/phleb.2012.012S37; Rathbun S, 2009, CIRCULATION, V119, pE480, DOI 10.1161/CIRCULATIONAHA.108.841403; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Sharafuddin MJA, 1998, J VASC INTERV RADIOL, V9, P15, DOI 10.1016/S1051-0443(98)70477-4; Shaw George J, 2009, BMC Res Notes, V2, P117, DOI 10.1186/1756-0500-2-117; Spencer FA, 2006, J GEN INTERN MED, V21, P722, DOI 10.1111/j.1525-1497.2006.00458.x; TURI ZG, 1993, AM J CARDIOL, V71, P1009, DOI 10.1016/0002-9149(93)90564-S; Vedantham S, 2017, NEW ENGL J MED, V377, P2240, DOI 10.1056/NEJMoa1615066; Vedantham S, 2016, J THROMB THROMBOLYS, V41, P68, DOI 10.1007/s11239-015-1318-z; Virani SS, 2021, CIRCULATION, V143, pe254, DOI 10.1161/CIR.0000000000000950; Vlaisavljevich E, 2016, ULTRASOUND MED BIOL, V42, P931, DOI 10.1016/j.ultrasmedbio.2015.11.027; Vlaisavljevich E, 2014, PHYS MED BIOL, V59, P253, DOI 10.1088/0031-9155/59/2/253; Waheed SM., 2021, DEEP VEIN THROMBOSIS; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Wang TY, 2012, ULTRASOUND MED BIOL, V38, P753, DOI 10.1016/j.ultrasmedbio.2012.01.013; Wolf MF, 2021, J BIOMED MATER RES B, V109, P358, DOI 10.1002/jbm.b.34705; Wright CC, 2012, IEEE T BIO-MED ENG, V59, P842, DOI 10.1109/TBME.2011.2180904; Xu Z, 2021, INT J HYPERTHER, V38, P561, DOI 10.1080/02656736.2021.1905189; Zhang X, 2017, ULTRASOUND MED BIOL, V43, P1378, DOI 10.1016/j.ultrasmedbio.2017.01.028; Zhang X, 2015, IEEE T ULTRASON FERR, V62, P1342, DOI 10.1109/TUFFC.2015.007016	63	2	2	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2022	17	1							e0261567	10.1371/journal.pone.0261567	http://dx.doi.org/10.1371/journal.pone.0261567			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3L5MO	34982784	gold, Green Published			2023-01-03	WOS:000834805700010
J	Boehmer, KR; Pine, KH; Whitman, S; Organick, P; Thota, A; Suarez, NRE; LaVecchia, CM; Lee, A; Behnken, E; Thorsteinsdottir, B; Pawar, AS; Beck, A; Lorenz, EC; Albright, RC				Boehmer, Kasey R.; Pine, Kathleen H.; Whitman, Samantha; Organick, Paige; Thota, Anjali; Suarez, Nataly R. Espinoza; LaVecchia, Christina M.; Lee, Alexander; Behnken, Emma; Thorsteinsdottir, Bjorg; Pawar, Aditya S.; Beck, Annika; Lorenz, Elizabeth C.; Albright, Robert C.			Do patients with high versus low treatment and illness burden have different needs? A mixed-methods study of patients living on dialysis	PLOS ONE			English	Article							STAGE RENAL-DISEASE; QUALITY-OF-LIFE; HEALTH-CARE; END; HEMODIALYSIS; INTRUSIVENESS; MORTALITY; ADHERENCE; PEOPLE; IMPACT	Background Approximately 750,000 people in the U.S. live with end-stage kidney disease (ESKD); the majority receive dialysis. Despite the importance of adherence to dialysis, it remains suboptimal, and one contributor may be patients' insufficient capacity to cope with their treatment and illness burden. However, it is unclear what, if any, differences exist between patients reporting high versus low treatment and illness burden. Methods We sought to understand these differences using a mixed methods, explanatory sequential design. We enrolled adult patients receiving dialysis, including in-center hemodialysis, home hemodialysis, and peritoneal dialysis. Descriptive patient characteristics were collected. Participants' treatment and illness burden was measured using the Illness Intrusiveness Scale (IIS). Participants scoring in the highest quartile were defined as having high burden, and participants scoring in the lowest quartile as having low burden. Participants in both quartiles were invited to participate in interviews and observations. Results Quantitatively, participants in the high burden group were significantly younger (mean = 48.4 years vs. 68.6 years respectively, p = < 0.001). No other quantitative differences were observed. Qualitatively, we found differences in patient self-management practices, such as the high burden group having difficulty establishing a new rhythm of life to cope with dialysis, greater disruption in social roles and self-perception, fewer appraisal focused coping strategies, more difficulty maintaining social networks, and more negatively portrayed experiences early in their dialysis journey. Conclusions and relevance Patients on dialysis reporting the greatest illness and treatment burden have difficulties that their low-burden counterparts do not report, which may be amenable to intervention.	[Boehmer, Kasey R.; Organick, Paige; Thota, Anjali; Suarez, Nataly R. Espinoza; LaVecchia, Christina M.; Behnken, Emma; Thorsteinsdottir, Bjorg] Mayo Clin, Knoweldge & Evaluat Res KER Unit, Rochester, MN 55905 USA; [Pine, Kathleen H.] Arizona State Univ, Coll Hlth Solut, Phoenix, AZ USA; [Whitman, Samantha] Arizona State Univ, Human & Social Dimens Sci & Technol, Phoenix, AZ USA; [LaVecchia, Christina M.] Neumann Univ, Aston, PA USA; [Lee, Alexander] Mayo Clin, Hlth Serv Res, Rochester, MN USA; [Thorsteinsdottir, Bjorg] Mayo Clin, Community Internal Med, Rochester, MN USA; [Pawar, Aditya S.; Lorenz, Elizabeth C.; Albright, Robert C.] Mayo Clin, Neprhol & Hypertens, Rochester, MN USA; [Pawar, Aditya S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Beck, Annika] Mayo Clin, Bioeth, Rochester, MN USA	Mayo Clinic; Arizona State University; Arizona State University-Downtown Phoenix; Arizona State University; Arizona State University-Downtown Phoenix; Mayo Clinic; Mayo Clinic; Mayo Clinic; Harvard University; Beth Israel Deaconess Medical Center; Mayo Clinic	Boehmer, KR (corresponding author), Mayo Clin, Knoweldge & Evaluat Res KER Unit, Rochester, MN 55905 USA.	boehmer.kasey@mayo.edu		Thorsteinsdottr, Bjorg/0000-0002-4397-728X; LaVecchia, Christina/0000-0001-5607-2618; ESPINOZA, NATALY/0000-0003-4644-5809	Mayo Clinic; ASU Alliance for Healthcare Collaboration Research Seed Grant Program; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [DK 123313]; Agency for Healthcare Research and Quality [T32HS026379]; Dr. Kasey Boehmer Patient-Centered Outcomes Research Institute [K12HS026379]; Dr. Kasey Boehmer National Center for Advancing Translational Sciences [KL2TR002492]	Mayo Clinic; ASU Alliance for Healthcare Collaboration Research Seed Grant Program; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Dr. Kasey Boehmer Patient-Centered Outcomes Research Institute; Dr. Kasey Boehmer National Center for Advancing Translational Sciences	This project was funded by the Mayo Clinic and ASU Alliance for Healthcare Collaboration Research Seed Grant Program. Additionally, Dr. Lorenz is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (Award Number DK 123313). Further, Dr. Boehmer's time is supported by the following awards. Agency for Healthcare Research and Quality, T32HS026379, Dr. Kasey Boehmer Patient-Centered Outcomes Research Institute, K12HS026379, Dr. Kasey Boehmer National Center for Advancing Translational Sciences, KL2TR002492, Dr. Kasey Boehmer The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Arabi S, 2006, NEPHROL NURS J, V33, P285; Baumbusch J, 2010, J SPEC PEDIATR NURS, V15, P255, DOI 10.1111/j.1744-6155.2010.00243.x; Boehmer Kasey R, 2020, Mayo Clin Proc Innov Qual Outcomes, V4, P190, DOI 10.1016/j.mayocpiqo.2019.11.002; Boehmer KR, 2019, MAYO CLIN PROC, V94, P278, DOI 10.1016/j.mayocp.2018.08.021; Boehmer KR, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0525-9; Boehmer KR, 2016, J CLIN EPIDEMIOL, V74, P227, DOI 10.1016/j.jclinepi.2016.01.006; Bourbonnais FF, 2012, NEPHROL NURS J, V39, P13; Bristowe K, 2019, ANN PALLIAT MED, V8, P121, DOI 10.21037/apm.2018.12.06; Bury M, 1982, Sociol Health Illn, V4, P167, DOI 10.1111/1467-9566.ep11339939; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Chen JCY, 2018, CLIN J AM SOC NEPHRO, V13, P1172, DOI 10.2215/CJN.00590118; Commission MPA., 2007, PROM GRE EFF MED REP; Corbin J. M.., 2015, BASICS QUALITATIVE R; DEVINS GM, 1990, HEALTH PSYCHOL, V9, P117, DOI 10.1037/0278-6133.9.2.117; DEVINS GM, 1984, INT J PSYCHIAT MED, V13, P327, DOI 10.2190/5DCP-25BV-U1G9-9G7C; DEVINS GM, 1990, PAIN, V42, P279, DOI 10.1016/0304-3959(90)91140-E; Duggleby W, 2012, J ADV NURS, V68, P1211, DOI 10.1111/j.1365-2648.2011.05919.x; Eton DT, 2013, PATIENT-RELAT OUTCOM, V4, P7, DOI 10.2147/PROM.S44694; Fisher EB, 2014, ANNU REV PUBL HEALTH, V35, P363, DOI 10.1146/annurev-publhealth-032013-182450; Gallacher K, 2011, ANN FAM MED, V9, P235, DOI 10.1370/afm.1249; Hartzler A, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1728; Harwood Lori, 2005, Nephrol Nurs J, V32, P295; Hickson LJ, 2015, AM J KIDNEY DIS, V65, P592, DOI 10.1053/j.ajkd.2014.10.015; Hickson LJ, 2014, AM J KIDNEY DIS, V64, P104, DOI 10.1053/j.ajkd.2013.11.018; Ho A, 2019, PATIENT-RELAT OUTCOM, V10, P217, DOI 10.2147/PROM.S162476; Inouye SK, 2003, MED CARE, V41, P70, DOI 10.1097/00005650-200301000-00010; Leggat JE, 2005, SEMIN DIALYSIS, V18, P137, DOI 10.1111/j.1525-139X.2005.18212.x; Llewellyn H, 2014, SOC SCI MED, V114, P49, DOI 10.1016/j.socscimed.2014.05.037; Mechanic R, 2014, NEW ENGL J MED, V370, P692, DOI 10.1056/NEJMp1315607; Murtagh FEM, 2007, ADV CHRONIC KIDNEY D, V14, P82, DOI 10.1053/j.ackd.2006.10.001; O'Hare AM, 2019, SEMIN DIALYSIS; Roberti J, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023507; Saran R, 2003, KIDNEY INT, V64, P254, DOI 10.1046/j.1523-1755.2003.00064.x; Saran R, 2020, AM J KIDNEY DIS, V75, pSVI, DOI 10.1053/j.ajkd.2019.09.003; Saran R, 2016, AM J KIDNEY DIS, V67, pS1, DOI 10.1053/j.ajkd.2015.12.014; Sav A, 2013, HEALTH SOC CARE COMM, V21, P665, DOI 10.1111/hsc.12052; Schmid H, 2009, EUR J MED RES, V14, P185, DOI 10.1186/2047-783X-14-5-185; Shippee ND, 2012, J CLIN EPIDEMIOL, V65, P1041, DOI 10.1016/j.jclinepi.2012.05.005; Smith SL, 2019, J VASC SURG, V70, P996, DOI 10.1016/j.jvs.2019.01.079; Stanford Patient Education Research Center, ADAPT ILLN INTR RAT; Tran V-T, 2019, MAYO CLIN PROC; US Renal Data System, ESRD INC COUNT BETA; Tran VT, 2020, MAYO CLIN PROC, V95, P504, DOI 10.1016/j.mayocp.2019.09.004	43	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2021	16	12							e0260914	10.1371/journal.pone.0260914	http://dx.doi.org/10.1371/journal.pone.0260914			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW9UF	34962932	gold, Green Published			2023-01-03	WOS:000771548500007
J	Caro-Astorga, J; Ellis, T				Caro-Astorga, Joaquin; Ellis, Tom			Self-healing through adhesion	NATURE CHEMICAL BIOLOGY			English	News Item								The design of biological materials with tunable properties is an emerging challenge for the twenty-first century. A new approach to direct engineered cells to stick together improves biomaterial performance and simplifies self-healing.	[Caro-Astorga, Joaquin; Ellis, Tom] Imperial Coll London, Dept Bioengn, London, England	Imperial College London	Ellis, T (corresponding author), Imperial Coll London, Dept Bioengn, London, England.	t.ellis@imperial.ac.uk		Caro-Astorga, Joaquin/0000-0003-4650-6376; Ellis, Thomas/0000-0001-5392-976X				Caro-Astorga J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25350-8; Chen BZ, 2022, NAT CHEM BIOL, V18, P289, DOI 10.1038/s41589-021-00934-z; Gilbert C, 2021, NAT MATER, V20, P691, DOI 10.1038/s41563-020-00857-5; Glass DS, 2018, CELL, V174, P649, DOI 10.1016/j.cell.2018.06.041; Nguyen PQ, 2018, ADV MATER, V30, DOI 10.1002/adma.201704847; Rivera-Tarazona LK, 2021, SOFT MATTER, V17, P785, DOI 10.1039/d0sm01905d; Schaffner M, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao6804; Srubar WV, 2021, TRENDS BIOTECHNOL, V39, P574, DOI 10.1016/j.tibtech.2020.10.009	8	1	1	5	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAR	2022	18	3					239	240		10.1038/s41589-021-00946-9	http://dx.doi.org/10.1038/s41589-021-00946-9		DEC 2021	2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZJ6UU	34934186				2023-01-03	WOS:000732504600004
J	Tsunemitsu, T; Kataoka, Y; Matsumoto, M; Hashimoto, T; Suzuki, T				Tsunemitsu, Takefumi; Kataoka, Yuki; Matsumoto, Masaru; Hashimoto, Takashi; Suzuki, Takao			Effect of enterally administered sleep-promoting medication on the intravenous sedative dose and its safety and cost profile in mechanically ventilated patients: A retrospective cohort study	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; PROPOFOL; DELIRIUM; METAANALYSIS; DISRUPTION; INSOMNIA; QUALITY; ADULTS	Background The clinical effect of enteral administration of sleep-promoting medication (SPM) in mechanically ventilated patients remains unclear. This study aimed to investigate the relationship between enteral SPM administration and the intravenous sedative dose and examine the safety and cost of enteral SPM administration. Methods This single-center retrospective cohort study was conducted in a Japanese tertiary hospital intensive care unit (ICU). The exposure was enteral SPM administration during mechanical ventilation. The outcome was the average daily propofol dose per body weight administered as a continuous sedative during mechanical ventilation. Patients were divided into three groups based on the timing of SPM administration at ICU admission: "administration within 48 hours (early administration [EA])," "administration after 48 hours (late administration [LA])," and "no administration (NA)." We used multiple linear regression models. Results Of 123 included patients, 37, 50, and 36 patients were assigned to the EA, LA, and NA groups, respectively. The average daily propofol dose per body weight was significantly lower in the EA group than in the LA and NA groups (beta -5.13 [95% confidence interval (CI) -8.93 to -1.33] and beta -4.51 [95% CI -8.59 to -0.43], respectively). Regarding safety, enteral SPM administration did not increase adverse events, including self-extubation. The total cost of neuroactive drugs tended to be lower in the EA group than in the LA and NA groups. Conclusions Early enteral SPM administration reduced the average daily propofol dose per body weight without increasing adverse events.	[Tsunemitsu, Takefumi; Matsumoto, Masaru; Suzuki, Takao] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Emergency & Crit Care Med, Amagasaki, Hyogo, Japan; [Kataoka, Yuki] Hosp Care Res Unit, Hyogo Prefectural Amagasaki Gen Med Ctr, Amagasaki, Hyogo, Japan; [Hashimoto, Takashi] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Pharm, Amagasaki, Hyogo, Japan		Tsunemitsu, T (corresponding author), Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Emergency & Crit Care Med, Amagasaki, Hyogo, Japan.	tsunemitsu0730@yahoo.co.jp	KATAOKA, Yuki/GRR-4808-2022; KATAOKA, Yuki/I-6026-2019	KATAOKA, Yuki/0000-0001-7982-5213; KATAOKA, Yuki/0000-0001-7982-5213; Tsunemitsu, Takefumi/0000-0002-2716-6989				Bourne RS, 2008, CRIT CARE, V12, DOI 10.1186/cc6871; Boyko Y, 2019, SLEEP BREATH, V23, P379, DOI 10.1007/s11325-018-1718-3; Brito RA, 2020, SLEEP BREATH, V24, P25, DOI 10.1007/s11325-019-01902-7; Campo FR, 2010, CRIT CARE MED, V38, P477, DOI 10.1097/CCM.0b013e3181bc8243; Chawla N, 2017, CURR OPIN ANESTHESIO, V30, P507, DOI 10.1097/ACO.0000000000000487; Cooper AB, 2000, CHEST, V117, P809, DOI 10.1378/chest.117.3.809; Devlin JW, 2018, CRIT CARE MED, V46, P1532, DOI [10.1097/CCM.0000000000003299, 10.1097/CCM.0000000000003259]; Dube KM, 2018, J PHARM PRACT, V31, P292, DOI 10.1177/0897190017711875; Elliott R, 2013, CRIT CARE, V17, DOI 10.1186/cc12565; Fadayomi AB, 2018, CRIT CARE MED, V46, pE1204, DOI 10.1097/CCM.0000000000003400; Freedman NS, 2001, AM J RESP CRIT CARE, V163, P451, DOI 10.1164/ajrccm.163.2.9912128; Hatta K, 2017, J CLIN PSYCHIAT, V78, pE970, DOI 10.4088/JCP.16m11194; Herring WJ, 2019, SLEEP MED, V56, P219, DOI 10.1016/j.sleep.2018.09.010; Jackson DL, 2009, CRIT CARE, V13, DOI 10.1186/cc8212; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kok L, 2018, CRIT CARE MED, V46, P1673, DOI 10.1097/CCM.0000000000003300; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kondili E, 2012, INTENS CARE MED, V38, P1640, DOI 10.1007/s00134-012-2623-z; Kuriyama A, 2014, SLEEP MED, V15, P385, DOI 10.1016/j.sleep.2013.11.788; Lewis SR, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012455.pub2; Lewis SR, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012454.pub2; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; MCCOLLUM JSC, 1985, POSTGRAD MED J, V61, P85; Mistraletti G, 2019, CRIT CARE, V23, DOI 10.1186/s13054-018-2280-x; Owen GD, 2019, J INTENSIVE CARE, V7, DOI 10.1186/s40560-019-0379-z; Pisani MA, 2020, CHEST, V157, P977, DOI 10.1016/j.chest.2019.12.003; Riemann D, 2017, J SLEEP RES, V26, P675, DOI 10.1111/jsr.12594; Shehabi Y, 2018, CRIT CARE MED, V46, P850, DOI 10.1097/CCM.0000000000003071; Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037; Tanaka LMS, 2014, CRIT CARE, V18, DOI 10.1186/cc13995; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; Spiegel K, 2002, JAMA-J AM MED ASSOC, V288, P1471, DOI 10.1001/jama.288.12.1471-a; Xia ZQ, 2013, J SURG RES, V185, P833, DOI 10.1016/j.jss.2013.06.062; Yi XY, 2018, SLEEP MED, V45, P25, DOI 10.1016/j.sleep.2018.01.010	34	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2021	16	12							e0261305	10.1371/journal.pone.0261305	http://dx.doi.org/10.1371/journal.pone.0261305			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ0QU	34928967	Green Published, gold			2023-01-03	WOS:000755188900033
J	Saposnik, G; Del Rio, B; Bueno-Gil, G; Sempere, AP; Lendinez-Mesa, A; Rodriguez-Antiguedad, A; Terzaghi, M; Medrano, N; Maurino, J				Saposnik, Gustavo; Del Rio, Beatriz; Bueno-Gil, Guillermo; Sempere, Angel P.; Lendinez-Mesa, Alejandro; Rodriguez-Antigueedad, Alfredo; Terzaghi, Maria; Medrano, Nicolas; Maurino, Jorge			Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain	PLOS ONE			English	Article							THERAPEUTIC INERTIA; REGRET; VALIDATION; PEOPLE; SCALE	Background Nurse practitioners (NPs) play a critical role in the multidisciplinary management of patients with multiple sclerosis (MS). Neurologists behavioral characteristics have been associated with suboptimal clinical decisions. However, limited information is available on their impact among NPs involved in MS care. The aim of this study was to assess nurses therapeutic choices to understand behavioral factors influencing their decision making process. Methods A non-interventional, cross-sectional, web-based study was conducted. NPs actively involved in the care of patients with MS were invited to participate in the study by the Spanish Society of Neurology Nursing. Participants answered questions regarding their standard practice and therapeutic management of seven simulated relapsing-remitting MS (RRMS) case scenarios. A behavioral battery was used to measure participants ' life satisfaction, mood, positive social behaviors, feeling of helpfulness, attitudes toward adoption of evidence-based innovations, occupational burnout, and healthcare-related regret. The outcome of interest was therapeutic inertia (TI), defined as the lack of treatment escalation when there is clinical and radiological evidence of disease activity. A score to quantify TI was created based on the number of simulated scenarios where treatment intensification was warranted. Results Overall, 331 NPs were invited to participate, 130 initiated the study, and 96 (29%) completed the study. The mean age (SD) was 44.6 (9.8) years and 91.7% were female. Seventy-three participants (76.0%) felt their opinions had a significant influence on neurologists ' therapeutic decisions. Sixteen NPs (16.5%) showed severe emotional exhaustion related to work and 13 (13.5%) had depressive symptoms. The mean (SD) TI score was 0.97 (1.1). Fifty-six of NPs showed TI in at least one case scenario. Higher years of nursing experience (p = 0.014), feeling of helpfulness (p = 0.014), positive attitudes toward innovations (p = 0.046), and a higher intensity of care-related regret (p = 0.021) were associated with a lower risk of TI (adjusted R-2 = 0.28). Burnout was associated with higher risk of TI (p = 0.001). Conclusions Although NPs cannot prescribe MS treatments in Spain, their behavioral characteristics may influence the management of patients with RRMS. Continuing education and specific strategies for reducing occupational burnout may lead to better management skills and improve MS care.	[Saposnik, Gustavo] Univ Toronto, St Michaels Hosp, Div Neurol, Dept Med, Toronto, ON, Canada; [Saposnik, Gustavo; Terzaghi, Maria] Univ Toronto, Li Ka Shing Inst, Decis Neurosci Unit, Toronto, ON, Canada; [Saposnik, Gustavo] Univ Zurich, Dept Econ, Lab Social & Neural Syst Res, Zurich, Switzerland; [Del Rio, Beatriz] Hosp Univ La Princesa, Dept Nursing, Madrid, Spain; [Bueno-Gil, Guillermo; Medrano, Nicolas; Maurino, Jorge] Roche Pharma, Dept Med, Madrid, Spain; [Sempere, Angel P.] Hosp Gen Univ Alicante, Dept Neurol, Alicante, Spain; [Lendinez-Mesa, Alejandro] Univ Alfonso X el Sabio, Sch Med, Dept Nursing, Madrid, Spain; [Lendinez-Mesa, Alejandro] Spanish Soc Neurol Nursing SEDENE, Madrid, Spain; [Rodriguez-Antigueedad, Alfredo] Hosp Univ Cruces, Dept Neurol, Bilbao, Spain	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Zurich; Hospital de La Princesa; Roche Holding; General University Hospital of Alicante; Universidad Alfonso X el Sabio (UAX); Hospital Universitario Cruces	Maurino, J (corresponding author), Roche Pharma, Dept Med, Madrid, Spain.	jorge.maurino@roche.com	Saposnik, Gustavo/M-3937-2017	Saposnik, Gustavo/0000-0002-5950-9886; RODRIGUEZ-ANTIGUEDAD, ALFRED/0000-0002-4566-2329; Maurino, Jorge/0000-0001-9858-3555; Perez-Sempere, Angel/0000-0002-0195-2834				Aarons Gregory A, 2004, Ment Health Serv Res, V6, P61, DOI 10.1023/B:MHSR.0000024351.12294.65; Almusalam N, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.7093; [Anonymous], 2019, Neurology, V92, P112, DOI 10.1212/WNL.0000000000006722; Baumsteiger R, 2019, J PERS ASSESS, V101, P305, DOI 10.1080/00223891.2017.1411918; Benedict RHB, 2003, MULT SCLER J, V9, P393, DOI 10.1191/1352458503ms902oa; Burke Therese, 2011, Int J MS Care, V13, P105, DOI 10.7224/1537-2073-13.3.105; Cameron E, 2019, MULT SCLER RELAT DIS, V27, P378, DOI 10.1016/j.msard.2018.11.023; Courvoisier DS, 2013, MED CARE, V51, P285, DOI 10.1097/MLR.0b013e318280f02c; Courvoisier DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023138; Dall'Ora C, 2020, HUM RESOUR HEALTH, V18, DOI 10.1186/s12960-020-00469-9; Di Battista G, 2014, MULT SCLER INT, V2014, DOI 10.1155/2014/752318; Djulbegovic M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134038; Linker Ralf A, 2019, Neurol Res Pract, V1, P5, DOI 10.1186/s42466-019-0005-5; Maslach C, 2018, MASLACH BURNOUT INVE; Matthys E, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0698-x; Meehan M, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2019.101918; Montalban X, 2018, MULT SCLER J, V24, P96, DOI 10.1177/1352458517751049; Negri L, 2022, NEUROL SCI, V43, P1903, DOI 10.1007/s10072-021-05520-8; O'Connor PJ, 2005, ADV PATIENT SAFETY R, V2; Patel RS, 2018, BEHAV SCI-BASEL, V8, DOI 10.3390/bs8110098; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Peloquin S, 2021, MULT SCLER RELAT DIS, V50, DOI 10.1016/j.msard.2021.102854; Rahn AC, 2018, INT J NURS STUD, V78, P26, DOI 10.1016/j.ijnurstu.2017.08.011; Rodrigues R, 2021, MULT SCLER RELAT DIS, V55, DOI 10.1016/j.msard.2021.103176; Saposnik G, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.675520; Saposnik Gustavo, 2019, MDM Policy Pract, V4, p2381468319855642, DOI 10.1177/2381468319855642; Saposnik Gustavo, 2018, Front Neurol, V9, P174, DOI 10.3389/fneur.2018.00174; Saposnik G, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00065; Schmid F, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18126537; Sorum PC, 2004, MED DECIS MAKING, V24, P149, DOI 10.1177/0272989X04263163; Terzaghi MA, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2019.101887; Wilson A, 2017, WORLD J SURG, V41, P1454, DOI 10.1007/s00268-017-3895-9	32	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2021	16	12							e0261050	10.1371/journal.pone.0261050	http://dx.doi.org/10.1371/journal.pone.0261050			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY2LS	34879095	Green Published, gold			2023-01-03	WOS:000754625200045
J	Landrum, AR; Davis, B; Huxster, J; Carrasco, H				Landrum, Asheley R.; Davis, Brady; Huxster, Joanna; Carrasco, Heather			Influences of study design on the effectiveness of consensus messaging: The case of medicinal cannabis	PLOS ONE			English	Article							GATEWAY BELIEF MODEL; SCIENTIFIC CONSENSUS; CLIMATE-CHANGE; PERCEPTIONS; UNDERMINE	This study examines to what extent study design decisions influence the perceived efficacy of consensus messaging, using medicinal cannabis as the context. We find that researchers' decisions about study design matter. A modified Solomon Group Design was used in which participants were either assigned to a group that had a pretest (within-subjects design) or a posttest only group (between-subjects design). Furthermore, participants were exposed to one of three messages-one of two consensus messages or a control message-attributed to the National Academies of Sciences, Engineering and Medicine. A consensus message describing a percent (97%) of agreeing scientists was more effective at shifting public attitudes than a consensus message citing substantial evidence, but this was only true in the between-subject comparisons. Participants tested before and after exposure to a message demonstrated pre-sensitization effects that undermined the goals of the messages. Our results identify these nuances to the effectiveness of scientific consensus messaging, while serving to reinforce the importance of study design.	[Landrum, Asheley R.; Davis, Brady] Texas Tech Univ, Coll Media & Commun, Lubbock, TX 79409 USA; [Huxster, Joanna] Eckerd Coll, Dept Environm Studies, St Petersburg, FL 33733 USA; [Carrasco, Heather] Texas Tech Univ, Rawls Coll Business, Lubbock, TX 79409 USA	Texas Tech University System; Texas Tech University; Texas Tech University System; Texas Tech University	Landrum, AR (corresponding author), Texas Tech Univ, Coll Media & Commun, Lubbock, TX 79409 USA.	A.Landrum@ttu.edu	; Landrum, Asheley/J-2360-2015	Carrasco, Heather/0000-0001-9604-0100; Landrum, Asheley/0000-0002-3074-804X				Aklin M, 2014, ENVIRON SCI POLICY, V38, P173, DOI 10.1016/j.envsci.2013.10.006; Bolin JH, 2014, J EDUC MEAS, V51, P335, DOI 10.1111/jedm.12050; Bolsen T, 2018, GROUP PROCESS INTERG, V21, P389, DOI 10.1177/1368430217737855; Booker B., 2020, NPRORG 0318; BRAVER MCW, 1988, PSYCHOL BULL, V104, P150, DOI 10.1037/0033-2909.104.1.150; Chinn S, 2021, ENVIRON COMMUN, DOI 10.1080/17524032.2021.1910530; Chinn S, 2018, PUBLIC UNDERST SCI, V27, P807, DOI 10.1177/0963662518791094; Cook J, 2016, ENVIRON RES LETT, V11, DOI 10.1088/1748-9326/11/4/048002; Danieller A., 2019, 2 THIRDS AMERICANS S; Deryugina T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151469; Dixon G, 2016, J COMMUN, V66, P888, DOI 10.1111/jcom.12260; Earlenbaugh E, 2020, FORBES; FDA, 2020, WHAT YOU NEED KNOW W; Huff C, 2015, RES POLITICS, V2, DOI 10.1177/2053168015604648; Hughes T, 2020, USA TODAY; Intemann K., 2017, PUBLIC AFF Q, V31, P189; Kerr JR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200295; Kerr JR, 2018, J ENVIRON PSYCHOL, V59, P107, DOI 10.1016/j.jenvp.2018.08.012; Khan S, 2020, REUTERS 0524; Laitman L., 2005, CHANGING CULTURE COL, P1; Landrum AR, 2020, ENVIRON COMMUN, V14, P1033, DOI 10.1080/17524032.2020.1776746; Landrum AR, 2019, ENVIRON COMMUN, V13, P51, DOI 10.1080/17524032.2018.1502201; Ma YN, 2019, ENVIRON COMMUN, V13, P71, DOI 10.1080/17524032.2018.1548369; Mayo Clinic, WHAT YOU CAN EXP MED; Myers TA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120985; Natl Acad Sci Engn Med, 2017, HEALTH EFFECTS OF CANNABIS AND CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH, P1, DOI 10.17226/24625; Navarro M.A., 2018, SAGE ENCY ED RES MEA; Pew Research Center, 2015, PUBL SCIENT VIEWS SC; Slater M, 2021, SHOULD FOOTBALL SCRA, DOI [10.31219/osf.io/yehsp, DOI 10.31219/OSF.IO/YEHSP]; van der Linden S, 2019, J ENVIRON PSYCHOL, V62, P49, DOI 10.1016/j.jenvp.2019.01.009; van der Linden SL, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2541-4; van der Linden SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118489; Zhang M, 2020, POLITICO	33	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2021	16	11							e0260342	10.1371/journal.pone.0260342	http://dx.doi.org/10.1371/journal.pone.0260342			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU5IH	34843557	Green Published, gold			2023-01-03	WOS:000752076100067
J	Paget, LDA; Reurink, G; de Vos, RJ; Weir, A; Moen, MH; Bierma-Zeinstra, SMA; Stufkens, SAS; Kerkhoffs, GMMJ; Tol, JL				Paget, Liam D. A.; Reurink, Gustaaf; de Vos, Robert-Jan; Weir, Adam; Moen, Maarten H.; Bierma-Zeinstra, Sita M. A.; Stufkens, Sjoerd A. S.; Kerkhoffs, Gino M. M. J.; Tol, Johannes L.		PRIMA Study Grp	Effect of Platelet-Rich Plasma Injections vs Placebo on Ankle Symptoms and Function in Patients With Ankle Osteoarthritis: A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; END-STAGE ANKLE; KNEE OSTEOARTHRITIS; DOUBLE-BLIND; HYALURONIC-ACID; HINDFOOT; OUTCOMES; HEALTH; SCORE; PAIN	IMPORTANCE Approximately 3.4% of adults have ankle (tibiotalar) osteoarthritis and, among younger patients, ankle osteoarthritis is more common than knee and hip osteoarthritis. Few effective nonsurgical interventions exist, but platelet -rich plasma (PRP) injections are widely used, with some evidence of efficacy in knee osteoarthritis. OBJECTIVE To determine the effect of PRP injections on symptoms and function in patients with ankle osteoarthritis. DESIGN, SETTING, AND PARTICIPANTS A multicenter, block-randomized, double -blinded, placebo -controlled clinical trial performed at 6 sites in the Netherlands that included 100 patients with pain greater than 40 on a visual analog scale (range, 0-100) and tibiotalar joint space narrowing. Enrollment began on August 24, 2018, and follow-up was completed on December 3, 2020. INTERVENTIONS Patients were randomly assigned (1:1) to receive 2 ultrasonography-guided intra-articular injections of either PRP (n = 48) or placebo (saline; n = 52). MAIN OUTCOMES AND MEASURES The primary outcome was the validated American Orthopaedic Foot and Ankle Society score (range, 0-100; higher scores indicate less pain and better function; minimal clinically important difference, 12 points) over 26 weeks. RESULTS Among 100 randomized patients (mean age, 56 years; 45 [45%] women), no patients were lost to follow-up for the primary outcome. Compared with baseline values, the mean American Orthopaedic Foot and Ankle Society score improved by 10 points in the PRP group (from 63 to 73 points [95% CI, 6-14]; P <.001) and 11 points in the placebo group (from 64 to 75 points [95% CI, 7-15]; P <.001). The adjusted between -group difference over 26 weeks was -1([95% CI, -6 to 3]; P =.56). One serious adverse event was reported in the placebo group, which was unrelated to the intervention; there were 13 other adverse events in the PRP group and 8 in the placebo group. CONCLUSIONS AND RELEVANCE Among patients with ankle osteoarthritis, intra-articular PRP injections, compared with placebo injections, did not significantly improve ankle symptoms and function over 26 weeks. The results of this study do not support the use of PRP injections for ankle osteoarthritis.	[Paget, Liam D. A.; Reurink, Gustaaf; Stufkens, Sjoerd A. S.; Kerkhoffs, Gino M. M. J.] Univ Amsterdam, Amsterdam UMC, Dept Orthoped Surg, Amsterdam Movement Sci, POB 22660, NL-1100 DD Amsterdam, Netherlands; [Paget, Liam D. A.; Reurink, Gustaaf; Stufkens, Sjoerd A. S.; Kerkhoffs, Gino M. M. J.; Tol, Johannes L.] Acad Ctr Evidence Based Sports Med ACES, Amsterdam, Netherlands; [Paget, Liam D. A.; Reurink, Gustaaf; Stufkens, Sjoerd A. S.; Kerkhoffs, Gino M. M. J.; Tol, Johannes L.] AMC VUmc IOC Res Ctr, Amsterdam Collaborat Hlth & Safety Sports ACHSS, Amsterdam, Netherlands; [Reurink, Gustaaf; Moen, Maarten H.] OLVG, Dept Sports Med, Sport Phys Grp, Amsterdam, Netherlands; [de Vos, Robert-Jan; Weir, Adam; Bierma-Zeinstra, Sita M. A.] Erasmus MC Univ Med Ctr, Dept Orthoped Surg & Sports Med, Rotterdam, Netherlands; [Weir, Adam] Aspetar Orthoped & Sports Med Hosp, Aspetar Sports Groin Pain Ctr, Doha, Qatar; [Weir, Adam] Sport Med & Exercise Clin Haarlem SBK, Haarlem, Netherlands; [Moen, Maarten H.] Bergman Clin, Dept Sports Med, Naarden, Netherlands; [Bierma-Zeinstra, Sita M. A.] Erasmus MC, Dept Gen Practice, Rotterdam, Netherlands; [Tol, Johannes L.] Aspetar Orthoped & Sports Med Hosp, Doha, Qatar	University of Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC; Aspetar Orthopaedic & Sports Medicine Hospital; Erasmus University Rotterdam; Erasmus MC; Aspetar Orthopaedic & Sports Medicine Hospital	Paget, LDA (corresponding author), Univ Amsterdam, Amsterdam UMC, Dept Orthoped Surg, Amsterdam Movement Sci, POB 22660, NL-1100 DD Amsterdam, Netherlands.	L.d.paget@amsterdamumc.nl			Dutch Arthritis Society	Dutch Arthritis Society	This study was supported by a grant from the Dutch Arthritis Society.	Angthong C, 2013, J FOOT ANKLE SURG, V52, P475, DOI 10.1053/j.jfas.2013.04.005; [Anonymous], 2021, PLATELET RICH PLASMA; [Anonymous], 2019, GLOBAL PLATELET RICH; Bradley JD, 2002, ARTHRITIS RHEUM-US, V46, P100, DOI 10.1002/1529-0131(200201)46:1<100::AID-ART10037>3.0.CO;2-V; Castillo TN, 2011, AM J SPORT MED, V39, P266, DOI 10.1177/0363546510387517; Cole BJ, 2017, AM J SPORT MED, V45, P339, DOI 10.1177/0363546516665809; de Boer AS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017040; de Vos RJ, 2010, JAMA-J AM MED ASSOC, V303, P144, DOI 10.1001/jama.2009.1986; Dong YJ, 2021, CLIN RHEUMATOL, V40, P263, DOI 10.1007/s10067-020-05185-2; Filardo G, 2015, KNEE SURG SPORT TR A, V23, P2459, DOI 10.1007/s00167-013-2743-1; Glazebrook M, 2008, J BONE JOINT SURG AM, V90A, P499, DOI 10.2106/JBJS.F.01299; Glazebrook M, 2021, FOOT ANKLE SURG, V27, P326, DOI 10.1016/j.fas.2020.10.005; Gormeli G, 2017, KNEE SURG SPORT TR A, V25, P958, DOI 10.1007/s00167-015-3705-6; Halasi T, 2004, AM J SPORT MED, V32, P899, DOI 10.1177/0363546503262181; Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140-6736(19)30417-9; Jarvinen TLN, 2014, J CLIN EPIDEMIOL, V67, P769, DOI 10.1016/j.jclinepi.2013.11.011; Lamers LM, 2005, NED TIJDSCHR GENEES, V149, P1574; Leopoldino AO, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013273; Madeley NJ, 2012, FOOT ANKLE INT, V33, P57, DOI 10.3113/FAI.2012.0057; Mariani E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041328; McDermott MM, 2020, JAMA-J AM MED ASSOC, V323, P2135, DOI 10.1001/jama.2020.4689; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; Murray C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193662; Paget LDA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030961; Patel S, 2013, AM J SPORT MED, V41, P356, DOI 10.1177/0363546512471299; Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P389, DOI 10.1016/j.joca.2004.02.001; Reurink G, 2014, NEW ENGL J MED, V370, P2546, DOI 10.1056/NEJMc1402340; Rozendaal RM, 2008, ANN INTERN MED, V148, P268, DOI 10.7326/0003-4819-148-4-200802190-00005; Saltzman BM, 2017, AM J SPORT MED, V45, P2647, DOI 10.1177/0363546516680607; Saltzman CL, 2006, J BONE JOINT SURG AM, V88A, P2366, DOI 10.2106/JBJS.F.00295; Sierevelt IN, 2015, KNEE SURG SPORT TR A, V23, P2413, DOI 10.1007/s00167-014-3017-2; Smith PA, 2016, AM J SPORT MED, V44, P884, DOI 10.1177/0363546515624678; Sun SF, 2021, J FOOT ANKLE SURG, V60, P676, DOI 10.1053/j.jfas.2020.12.003; Suo HQ, 2020, ORTHOP SURG, V12, P1108, DOI 10.1111/os.12707; Turner-Stokes L, 2009, CLIN REHABIL, V23, P362, DOI 10.1177/0269215508101742; VanDijk CN, 1997, J BONE JOINT SURG BR, V79B, P280, DOI 10.1302/0301-620X.79B2.0790280; Vannabouathong C, 2018, FOOT ANKLE INT, V39, P1141, DOI 10.1177/1071100718779375; Witteveen AGH, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010643.pub2; Wu YT, 2018, AM J PHYS MED REHAB, V97, P248, DOI 10.1097/PHM.0000000000000874; Zhu Y, 2013, OSTEOARTHR CARTILAGE, V21, P1627, DOI 10.1016/j.joca.2013.07.017	40	15	15	3	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2021	326	16					1595	1605		10.1001/jama.2021.16602	http://dx.doi.org/10.1001/jama.2021.16602			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YI2LG	34698782	Bronze, Green Published			2023-01-03	WOS:000743685000018
J	Lun, CN; Aung, T; Mya, KS				Lun, Ciin Ngaih; Aung, Thida; Mya, Kyaw Swa			Utilization of modern contraceptive methods and its determinants among youth in Myanmar: Analysis of Myanmar Demographic and Health Survey (2015-2016)	PLOS ONE			English	Article								Reproductive health service is crucial for youth to reduce maternal and child mortality. However, many young women face unintended pregnancies and pregnancy-related complications due to insufficient knowledge of contraceptive methods and low contraceptive utilization. This study aims to assess the modern contraceptive prevalence rates among youth and identify factors influencing modern contraceptive utilization among youth. We used Myanmar Demographic and Health Survey (2015-2016) data. This study included 1,423 men and 3,677 women aged 15-24 years from all states and regions of Myanmar. We used multivariable binary logistic regression analysis and reported the results using adjusted Odds Ratios (AOR) with 95% Confidence Intervals (CI). Data analysis was done by STATA software (version 15.1). Ever-married youth used mainly injectable contraception, followed by oral contraceptive pills. Never-married male youth mainly used oral contraceptive pills; however, almost all never-married female youth did not use contraception. The modern contraceptive prevalence rates were 14.9% among total youth, 10% among males, 16.8% among females, 1.5% among never-married males, 44.7% among ever-married males, and 54% among ever-married female youth. The knowledge on modern contraceptive methods favored the utilization. Sexually active youth utilized more contraception than sexually inactive youth. We also found geographical variation and low utilization among rural youth. The desire for more children was also a significant predictor of contraceptive utilization among married youth. The utilization of modern contraception was low among Myanmar youth. Reproductive health program needs to be emphasized on the youth population especially in the area with low utilization to have equitable access to quality reproductive health services. Moreover, the revitalization of Youth Information Corner and youth-friendly reproductive health education programs should be implemented to increase reproductive health knowledge and prevent unsafe sex, unintended pregnancies, and abortions which might help in reducing maternal and child mortality. We warranted conducting mixed method studies to explore the barriers and challenges of contraceptive utilization and male involvement in the choice of contraception among youth.	[Lun, Ciin Ngaih] Mingalar Taung Nyunt Township Publ Hlth Dept, Yangon, Myanmar; [Aung, Thida] Univ Publ Hlth, Dept Populat & Family Hlth, Yangon, Myanmar; [Mya, Kyaw Swa] Univ Publ Hlth, Dept Biostat & Med Demog, Yangon, Myanmar		Mya, KS (corresponding author), Univ Publ Hlth, Dept Biostat & Med Demog, Yangon, Myanmar.	kyawswamya@gmail.com		Lun, Ciin/0000-0002-2130-2644; , Kyaw Swa Mya/0000-0003-1286-1409				Ajmal S., 2018, DHS Working Papers; Alo OD, 2020, BMC WOMENS HEALTH, V20, DOI 10.1186/s12905-020-01059-6; [Anonymous], 2015, 2014 MYANM POP HOUS, V2; Aung-Mon Myat-Hsu-Paing-Thaw, 2018, FACTORS INFLUENCING; Aye-Thida-Win, 2014, THESIS U PUBLIC HLTH; Brown A., 2001, WHORHR018; Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4; Darroch JE., 2016, ADDING IT COSTS BENE, V19; DMR-POLB DoPH DMS and UNFPA, 2019, 2018 HLTH FAC ASS RE, P1; Ei-Ei-Maung, 2013, THESIS U PUBLIC HLTH; Finer LB, 2013, PEDIATRICS, V131, P886, DOI 10.1542/peds.2012-3495; Guleria S, 2017, ACTA OBSTET GYN SCAN, V96, P286, DOI 10.1111/aogs.13088; Htwe Thida., 2019, DHS WORKING PAPERS, V144; Juan Christina P., 2019, DHS FURTHER ANAL REP, V127; Khan M, 2012, ASIAN SOCL SCI, V8, P181, DOI 10.5539/ass.v8n12p181; Khatiwada N., 2013, SEXUAL REPROD HLTH A; MacPhail C, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-31; MacQuarrie KLD, 2015, DHS ANAL STUDIES, V49; Ministry of Health and Sports (MoHS) and ICF, 2017, MYANM DEM HLTH SURV; Ministry of Immigration and Population, 2016, THEM REP FERT NUPT A, V4; MOHS, 2018, PAMPHL CONTR MOHS PD; MOHS and UNFPA, 2017, NAT YOUTH INF CORN S; MOHS UNFPA WHO, 2016, 5 YEAR STRAT PLAN YO; Mon MM, 2012, ASIA-PAC J PUBLIC HE, V24, P151, DOI 10.1177/1010539510381918; Moore Z, 2008, TRENDS YOUTH REPROD; Mulatu T, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6096280; Munakampe MN, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3722-5; Mya K.S., 2020, INT J COMMUNITY MED, V7, P815; Nwe Tin Nwe, 2019, 145 DHS ICF; Nyarko SH, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0221-2; O'Regan A, 2017, CONTRACEP REPROD MED, V2, DOI 10.1186/s40834-017-0053-6; Paul M., 2019, CONTRACEPTION ADOLES; Soe Pa Pa., 2019, 155 DHS ICF; Subedi Ranjeeta, 2018, J Nepal Health Res Counc, V16, P251; Thet-Thet-Win, 2017, FACTORS INFLUENCING; United Nations. Department of Economic and Social Affairs, 2014, DEF YOUTH; WHO, 2013, PMNCH 2013 REP CHAPT; Worku AG, 2014, TRENDS DETERMINANTS; World Health Organization, 2016, SUSTAINABLE DEV GOAL; Zegeye B, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10252-7	40	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2021	16	10							e0258142	10.1371/journal.pone.0258142	http://dx.doi.org/10.1371/journal.pone.0258142			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ9DX	34614023	gold, Green Published			2023-01-03	WOS:000749604400043
J	Redondo-Sanchez, J; Del Cura-Gonzalez, I; Diez-Izquierdo, L; Rodriguez-Barrientos, R; Rodriguez-Cabrera, F; Polentinos-Castro, E; Lopez-Miguel, M; Marina-Ono, L; Llamosas-Falcon, L; Gil-de Miguel, A				Redondo-Sanchez, Jesus; Del Cura-Gonzalez, Isabel; Diez-Izquierdo, Laura; Rodriguez-Barrientos, Ricardo; Rodriguez-Cabrera, Francisco; Polentinos-Castro, Elena; Lopez-Miguel, Miguel; Marina-Ono, Lucas; Llamosas-Falcon, Laura; Gil-de Miguel, Angel			Trends in urinary tract infection hospitalization in older adults in Spain from 2000-2015	PLOS ONE			English	Article							DISEASE HOSPITALIZATIONS; UNITED-STATES; MANAGEMENT; RESISTANCE; COMMUNITY	Objective To analyze trends in urinary tract infection hospitalization (cystitis, pyelonephritis, prostatitis and non-specified UTI) among patients over 65 years in Spain from 2000-2015. Methods We conducted a retrospective observational study using the Spanish Hospitalization Minimum Data Set (CMBD), with codifications by the International Classification of Diseases (ICD-9). We collected data on sex, age, type of discharge, main diagnosis, comorbid diagnosis, length of stay, and global cost. All the hospitalizations were grouped by age into three categories: 65-74 years old, 75-84 years old, and 85 years old and above. In the descriptive statistical analysis, crude rates were defined as hospitalizations per 1,000 inhabitants aged >= 65. To identify trends over time, we performed a Joinpoint regression. Results From 2000-2015, we found 387,010 hospitalizations coded as UTIs (54,427 pyelonephritis, 15,869 prostatitis, 2643 cystitis and 314,071 non-specified UTI). The crude rate of hospitalization for UTIs between 2000 and 2015 ranged from 2.09 in 2000 to 4.33 in 2015 Rates of hospitalization were higher in men than in women, except with pyelonephritis. By age group, higher rates were observed in patients aged 85 years or older, barring prostatitis-related hospitalizations. Joinpoint analyses showed an average annual percentage increase (AAPC) in incidence rates of 4.9% (95% CI 3.2;6.1) in UTI hospitalizations. We observed two joinpoints, in 2010 and 2013, that found trends of 5.5% between 2000 and 2010 (95% CI 4.7;6.4), 1.5% between 2010 and 2013 (95% CI -6.0;9.6) and 6.8% between 2013 and 2015 (95% CI -0.3;14.4). Conclusions The urinary infection-related hospitalization rate in Spain doubled during the period 2000-2015. The highest hospitalization rates occurred in men, in the >= 85 years old age group, and in non-specified UTIs. There were increases in all types of urinary tract infection, with non-specified UTIs having the greatest growth. Understanding these changing trends can be useful for health planning.	[Redondo-Sanchez, Jesus] Ramon y Cajal Hlth Care Ctr, Alcorcon, Spain; [Redondo-Sanchez, Jesus] Madrid Hlth Serv, Primary Care Management, Madrid, Spain; [Redondo-Sanchez, Jesus; Del Cura-Gonzalez, Isabel; Gil-de Miguel, Angel] Univ Rey Juan Carlos, Dept Med Specialties & Publ Hlth, Madrid, Spain; [Del Cura-Gonzalez, Isabel; Rodriguez-Barrientos, Ricardo; Polentinos-Castro, Elena] Madrid Hlth Serv, Res Unit, Primary Care Management, Madrid, Spain; [Del Cura-Gonzalez, Isabel; Rodriguez-Barrientos, Ricardo; Polentinos-Castro, Elena] Hlth Serv Res Chron Patients Network REDISSEC ISC, Madrid, Spain; [Diez-Izquierdo, Laura] Infanta Sofia Univ Hosp, Madrid, Spain; [Rodriguez-Barrientos, Ricardo] Biosanit Res & Innovat Fdn Primary Care FIIBAP, Madrid, Spain; [Rodriguez-Cabrera, Francisco] Inst Salud Carlos III, Natl Sch Hlth, Madrid, Spain; [Lopez-Miguel, Miguel] Ciudades Hlth Care Ctr, Getafe, Spain; [Lopez-Miguel, Miguel] South Family & Community Care Teaching Unit, Madrid, Spain; [Marina-Ono, Lucas] Getafe Univ Hosp, Madrid, Spain; [Llamosas-Falcon, Laura] 12 Octubre Univ Hosp, Prevent Med & Publ Hlth, Madrid, Spain	Universidad Rey Juan Carlos; Hospital Universitario Infanta Sofia; Instituto de Salud Carlos III; Hospital Universitario de Getafe; Hospital Universitario 12 de Octubre	Rodriguez-Barrientos, R (corresponding author), Madrid Hlth Serv, Res Unit, Primary Care Management, Madrid, Spain.; Rodriguez-Barrientos, R (corresponding author), Hlth Serv Res Chron Patients Network REDISSEC ISC, Madrid, Spain.; Rodriguez-Barrientos, R (corresponding author), Biosanit Res & Innovat Fdn Primary Care FIIBAP, Madrid, Spain.	ricardo.rodriguez@salud.madrid.org	; POLENTINOS-CASTRO, ELENA/B-7373-2019	Llamosas-Falcon, Laura/0000-0003-4718-9376; Rodriguez-Barrientos, Ricardo/0000-0003-0440-6588; Rodriguez-Cabrera, Francisco/0000-0002-4845-7347; POLENTINOS-CASTRO, ELENA/0000-0001-9460-2966	Instituto de Salud Carlos III [PI19/01700]; European Regional Development Fund (ERDF) "A way of shaping Europe"; Community of Madrid; Fundacion de Investigacion e Innovacion Biosanitaria en Atencion Primaria (FIIBAP)	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund (ERDF) "A way of shaping Europe"; Community of Madrid(Comunidad de Madrid); Fundacion de Investigacion e Innovacion Biosanitaria en Atencion Primaria (FIIBAP)	This study has been funded by Instituto de Salud Carlos III through the project "PI19/01700", as part of the Plan Estatal de I+D+I 20172020 co-funded by European Regional Development Fund (ERDF) "A way of shaping Europe". In addition, the principal investigator JRS received support to increase his research activities and to publish this manuscript from the 2020 funding program of the Fundacion de Investigacion e Innovacion Biosanitaria en Atencion Primaria (FIIBAP), Community of Madrid.	Aguilar-Duran S, 2012, J INFECTION, V64, P478, DOI 10.1016/j.jinf.2012.01.010; Ahmed H, 2019, PHARMACOEPIDEM DR S, V28, P857, DOI 10.1002/pds.4791; Ahmed H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190521; Artero EA, 2019, REV CLIN ESP, V219, P189, DOI 10.1016/j.rce.2018.10.009; Blunt I., TRENDS EMERGENCY ADM; Brede CM, 2011, NAT REV UROL, V8, P207, DOI 10.1038/nrurol.2011.22; Bruxvoort KJ, 2020, CLIN INFECT DIS, V71, P100, DOI 10.1093/cid/ciz764; Buonaiuto VA, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0639-4; Caljouw MAA, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-57; Christensen KLY, 2009, CLIN INFECT DIS, V49, P1025, DOI 10.1086/605562; Curns AT, 2005, ARCH INTERN MED, V165, P2514, DOI 10.1001/archinte.165.21.2514; Eliakim-Raz N, 2018, CLIN INFECT DIS, DOI [10.1093/cid/ciy418, DOI 10.1093/CID/CIY418]; Esteban-Vasallo MD, 2016, J INFECTION, V72, P70, DOI 10.1016/j.jinf.2015.10.003; Ferre Losa Carles, 2019, Rev Esp Geriatr Gerontol, V54, P143, DOI 10.1016/j.regg.2018.11.002; Foxman B, 2007, CLIN INFECT DIS, V45, P281, DOI 10.1086/519267; Gharbi M, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l525; Gill BC, 2016, CURR OPIN INFECT DIS, V29, P86, DOI 10.1097/QCO.0000000000000222; Goldstein E, 2019, INT J ANTIMICROB AG, V54, P23, DOI 10.1016/j.ijantimicag.2019.03.004; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Linhares I, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-19; Lopez N, 2018, PAPILLOMAVIRUS RES, V5, P80, DOI 10.1016/j.pvr.2018.02.001; Medina-Polo J, 2015, ACTAS UROL ESP, V39, P104, DOI 10.1016/j.acuro.2014.08.001; Palacios-Cena D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185869; Pescatore R, 2019, WEST J EMERG MED, V20, P573, DOI 10.5811/westjem.2019.5.42096; Rosello A, 2018, EPIDEMIOL INFECT, V146, P37, DOI 10.1017/S095026881700259X; Rowe T.A., 2013, AGING HLTH, V9, P519, DOI [10.2217/ahe.13.38, DOI 10.2217/AHE.13.38]; Rowe TA, 2014, INFECT DIS CLIN N AM, V28, P75, DOI 10.1016/j.idc.2013.10.004; RUBEN FL, 1995, AM J EPIDEMIOL, V141, P145, DOI 10.1093/oxfordjournals.aje.a117402; Simmering JE, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofw281; Spoorenberg V, 2014, CLIN INFECT DIS, V58, P164, DOI 10.1093/cid/cit688; Tandogdu Z, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214710; Vallejo-Torres L, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020251; Zilberberg MD, 2013, INFECT CONT HOSP EP, V34, P940, DOI 10.1086/671740	33	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2021	16	9							e0257546	10.1371/journal.pone.0257546	http://dx.doi.org/10.1371/journal.pone.0257546			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5RU	34587191	Green Published, gold			2023-01-03	WOS:000707052600028
J	Frush, BW				Frush, Benjamin W.			Cool Water	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Frush, Benjamin W.] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA; [Frush, Benjamin W.] Monroe Carrell Jr Childrens Hosp, Nashville, TN 37232 USA	Vanderbilt University	Frush, BW (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA.; Frush, BW (corresponding author), Monroe Carrell Jr Childrens Hosp, Nashville, TN 37232 USA.								0	0	0	3	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2021	385	14					1254	1255		10.1056/NEJMp2104545	http://dx.doi.org/10.1056/NEJMp2104545		SEP 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC5SW	34569729				2023-01-03	WOS:000698987200001
J	Kirkland, SW; Clua, MG; Kruhlak, M; Villa-Roel, C; Couperthwaite, S; Yang, ESH; Elwi, A; O'Neill, B; Duggan, S; Brisebois, A; Rowe, BH				Kirkland, Scott W.; Garrido Clua, Miriam; Kruhlak, Maureen; Villa-Roel, Cristina; Couperthwaite, Stephanie; Yang, Esther H.; Elwi, Adam; O'Neill, Barbara; Duggan, Shelley; Brisebois, Amanda; Rowe, Brian H.			Comparison of characteristics and management of emergency department presentations between patients with met and unmet palliative care needs	PLOS ONE			English	Article							SCREENING TOOL; ILL PATIENTS; SERIOUSLY ILL; VALIDATION	Introduction This study examined emergency department (ED) presentations of patients with end of life (EOL) conditions and patients having met and unmet palliative care needs were compared. Methods Presentations for EOL conditions were prospectively identified and screened for palliative care needs. Descriptive data were reported as proportions, means or medians. Bi-variable analysis for dichotomous and continuous variables were performed by chi-squared and T-tests (p <= 0.01), respectively. A multivariable logistic regression model identified factors associated with having unmet palliative needs and reported adjusted odds ratios (aOR) with 95% confidence intervals (CI). Results Overall, 663 presentations for EOL conditions were identified; 518 (78%) involved patients with unmet palliative care needs. Presentations by patients with unmet palliative needs were more likely to involve consultations (80% vs. 67%, p = 0.001) and result in hospitalization (69% vs. 51%, p<0.001) compared to patients whose palliative needs were met. Patients with unmet palliative care needs were more likely to have previous ED visits (73% unmet vs. 48% met; p<0.001). While medication, procedures, investigations and imaging ordering were high across all patients with EOL conditions, there were no significant differences between the groups. Consultations with palliative specialists in the ED (6% unmet vs. 1% met) and following discharge (29% unmet vs. 18% met) were similarly uncommon. Patients having two or more EOL conditions (aOR = 2.41; 95% CI: 1.16, 5.00), requiring hospitalization (aOR = 1.93; 95% CI: 1.30, 2.87), and dying during the ED visit (aOR = 2.15; 95% CI: 1.02, 4.53) were strongly associated with having unmet palliative care needs. Conclusions Most ED presentations for EOL conditions were made by patients with unmet palliative care needs, who were significantly more likely to require consultation, hospitalization, and to die. Referrals to palliative care services during and after the ED visit were infrequent, indicating important opportunities to promote these services.	[Kirkland, Scott W.; Kruhlak, Maureen; Villa-Roel, Cristina; Couperthwaite, Stephanie; Yang, Esther H.; Rowe, Brian H.] Univ Alberta, Dept Emergency Med, Edmonton, AB, Canada; [Garrido Clua, Miriam] St Josephs Healthcare Hamilton, Hamilton, ON, Canada; [Elwi, Adam; O'Neill, Barbara] Alberta Hlth Serv, Edmonton, AB, Canada; [Duggan, Shelley; Brisebois, Amanda] Grey Nun Hosp, Covenant Hlth, Edmonton, AB, Canada; [Duggan, Shelley; Brisebois, Amanda; Rowe, Brian H.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Rowe, Brian H.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada	University of Alberta; McMaster University; Alberta Health Services (AHS); University of Alberta; University of Alberta	Rowe, BH (corresponding author), Univ Alberta, Dept Emergency Med, Edmonton, AB, Canada.; Rowe, BH (corresponding author), Univ Alberta, Dept Med, Edmonton, AB, Canada.; Rowe, BH (corresponding author), Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada.	brian.rowe@ualberta.ca						Aaronson EL, 2019, J PAIN SYMPTOM MANAG, V57, P944, DOI 10.1016/j.jpainsymman.2019.02.007; Bullard MJ, 2017, CAN J EMERG MED, V19, pS18, DOI 10.1017/cem.2017.365; Chan GK, 2004, ACAD EMERG MED, V11, P79, DOI 10.1197/S1069-6563(03)00592-X; Cotogni P, 2017, MINERVA ANESTESIOL, V83, P474, DOI 10.23736/S0375-9393.16.11703-1; Duffy J., 2019, CAN J EMERG MED, V21, pS75; Ethier JL, 2018, J PALLIAT CARE, V33, P125, DOI 10.1177/0825859718762287; George N, 2016, J PAIN SYMPTOM MANAG, V51, P108, DOI 10.1016/j.jpainsymman.2015.07.017; George N, 2015, ACAD EMERG MED, V22, P823, DOI 10.1111/acem.12710; Grudzen CR, 2010, ACAD EMERG MED, V17, P1253, DOI 10.1111/j.1553-2712.2010.00907.x; Haydar SA, 2019, CLIN EXP EMERG MED, V6, P70, DOI 10.15441/ceem.17.293; Kostenberger M, 2019, WIEN KLIN WOCHENSCHR, V131, P404, DOI 10.1007/s00508-019-1530-5; Lawson BJ, 2008, J PALLIAT CARE, V24, P247, DOI 10.1177/082585970802400404; Ouchi K, 2018, J PALLIAT MED, V21, P236, DOI 10.1089/jpm.2017.0192; Ouchi K, 2017, J PALLIAT MED, V20, P69, DOI 10.1089/jpm.2016.0213; Richards CT, 2011, J PALLIAT MED, V14, P757, DOI 10.1089/jpm.2010.0456; Tardy B, 2002, INTENS CARE MED, V28, P1625, DOI 10.1007/s00134-002-1517-x; Tripp D, 2021, J GEN INTERN MED, V36, P2656, DOI 10.1007/s11606-020-06512-8; Verhoef MJ, 2020, J PALLIAT MED, V23, P801, DOI 10.1089/jpm.2019.0413; Yang C, 2020, J CHIN MED ASSOC, V83, P500, DOI 10.1097/JCMA.0000000000000297	19	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257501	10.1371/journal.pone.0257501	http://dx.doi.org/10.1371/journal.pone.0257501			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM7DR	34570790	Green Published, gold			2023-01-03	WOS:000728983400017
J	Aybek, S; Perez, DL				Aybek, Selma; Perez, David L.			Diagnosis and management of functional neurological disorder	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PSYCHOGENIC NONEPILEPTIC SEIZURES; QUALITY-OF-LIFE; TRANSCRANIAL MAGNETIC STIMULATION; COGNITIVE-BEHAVIORAL THERAPY; LABORATORY-SUPPORTED CRITERIA; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CLINICAL-TRIAL; MOVEMENT-DISORDERS; CONVERSION DISORDER; MOTOR SYMPTOMS	Functional neurological disorder (FND), previously regarded as a diagnosis of exclusion, is now a rule-in diagnosis with available treatments. This represents a major step toward destigmatizing the disorder, which was often doubted and deemed untreatable. FND is prevalent, generally affecting young and middle aged adults, and can cause severe disability in some individuals. An early diagnosis, with subsequent access to evidence based rehabilitative and/or psychological treatments, can promote recovery-albeit not all patients respond to currently available treatments. This review presents the latest advances in the use of validated rule-in examination signs to guide diagnosis, and the range of therapeutic approaches available to care for patients with FND. The article focuses on the two most frequently identified subtypes of FND: motor (weakness and/or movement disorders) and seizure type symptoms. Twenty two studies on motor and 27 studies on seizure type symptoms report high specificities of clinical signs (64-100%), and individual signs are reviewed. Rehabilitative interventions (physical and occupational therapy) are treatments of choice for functional motor symptoms, while psychotherapy is an emerging evidence based treatment across FND subtypes. The literature to date highlights heterogeneity in responses to treatment, underscoring that more research is needed to individualize treatments and develop novel interventions.	[Aybek, Selma] Univ Alberta Hosp, Edmonton, AB, Canada; [Perez, David L.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Perez, David L.] VA Pittsburgh Geriatr Res Educ & Clin Ctr GRECC, Pittsburgh, PA USA	University of Alberta; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Aybek, S (corresponding author), Univ Alberta Hosp, Edmonton, AB, Canada.	selma.aybek@med.unibe.ch		Perez, David/0000-0003-2721-583X	Swiss National Science Foundation [PP00P3_176985]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	SA was supported by the Swiss National Science Foundation grant PP00P3_176985.	Aboud O, 2019, J CLIN NEUROSCI, V59, P141, DOI 10.1016/j.jocn.2018.10.113; Altalib HH, 2016, EPILEPSY BEHAV, V64, P4, DOI 10.1016/j.yebeh.2016.08.032; Anderson JR, 2019, SEMIN NEUROL, V39, P102, DOI 10.1055/s-0038-1676844; Anderson KE, 2007, MOVEMENT DISORD, V22, P2204, DOI 10.1002/mds.21687; Arain AM, 2007, EPILEPSY BEHAV, V11, P409, DOI 10.1016/j.yebeh.2007.07.017; Asadi-Pooya AA, 2020, EPILEPSY BEHAV, V104, DOI 10.1016/j.yebeh.2019.106895; Asadi-Pooya AA, 2016, EPILEPSY BEHAV, V59, P1, DOI 10.1016/j.yebeh.2016.03.012; Aybek S, 2020, J NEUROPSYCH CLIN N, V32, P79, DOI 10.1176/appi.neuropsych.19040083; Aybek S, 2019, J NEUROL NEUROSUR PS, V90, P845, DOI 10.1136/jnnp-2019-320597; Azar NJ, 2008, EPILEPSIA, V49, P132, DOI 10.1111/j.1528-1167.2007.01215.x; Babinski, 1900, GAZETTE HOPITAUX, V73, P533; Baizabal-Carvallo JF, 2017, J NEUROL, V264, P1482, DOI 10.1007/s00415-017-8551-7; Baizabal-Carvallo JF, 2017, J NEUROL, V264, P359, DOI 10.1007/s00415-016-8356-0; Baker J, 2021, J NEUROL NEUROSUR PS, V92, P1112, DOI 10.1136/jnnp-2021-326767; BAKER JHE, 1987, J NEUROL NEUROSUR PS, V50, P375, DOI 10.1136/jnnp.50.4.375; Ball HA, 2020, BRAIN, V143, P2895, DOI 10.1093/brain/awaa224; Barry JJ, 2008, EPILEPSY BEHAV, V13, P624, DOI 10.1016/j.yebeh.2008.06.013; Baslet G, 2021, J NEUROPSYCH CLIN N, V33, P27, DOI 10.1176/appi.neuropsych.19120354; Baslet G, 2020, EPILEPSY BEHAV, V103, DOI 10.1016/j.yebeh.2019.106534; Battle DE, 2013, CODAS, V25, P191; Bazil CW, 1997, EPILEPSIA, V38, P56, DOI 10.1111/j.1528-1157.1997.tb01077.x; Begue I, 2019, NEUROIMAGE-CLIN, V22, DOI 10.1016/j.nicl.2019.101798; Bell WL, 1998, ARCH NEUROL-CHICAGO, V55, P1456, DOI 10.1001/archneur.55.11.1456; Benbadis SR, 2010, NEUROLOGY, V75, P84, DOI 10.1212/WNL.0b013e3181e6216f; Benbadis SR, 1996, NEUROLOGY, V47, P63, DOI 10.1212/WNL.47.1.63; Binzer M, 1997, J NEUROL NEUROSUR PS, V63, P83, DOI 10.1136/jnnp.63.1.83; Bravo TP, 2013, NEUROLOGIST, V19, P30, DOI 10.1097/NRL.0b013e31827c6bfd; Brigo F, 2013, SEIZURE-EUR J EPILEP, V22, P85, DOI 10.1016/j.seizure.2012.10.011; Brough JL, 2015, J PSYCHOSOM RES, V79, P420, DOI 10.1016/j.jpsychores.2015.09.009; Bullock K, 2020, J NEUROPSYCH CLIN N, V32, P90, DOI 10.1176/appi.neuropsych.19030071; Bullock KD, 2015, J NEUROPSYCH CLIN N, V27, P240, DOI 10.1176/appi.neuropsych.13120359; Burke MJ, 2020, J NEUROPSYCH CLIN N, V32, P101, DOI 10.1176/appi.neuropsych.19030077; Burke MJ, 2019, JAMA NEUROL, V76, P1417, DOI 10.1001/jamaneurol.2019.3043; Carlson P, 2017, SEIZURE-EUR J EPILEP, V45, P142, DOI 10.1016/j.seizure.2016.12.007; Carson A, 2016, HAND CLINIC, V139, P47, DOI 10.1016/B978-0-12-801772-2.00005-9; Carson A, 2011, J NEUROL NEUROSUR PS, V82, P810, DOI 10.1136/jnnp.2010.220640; Carson AJ, 2000, J NEUROL NEUROSUR PS, V68, P207, DOI 10.1136/jnnp.68.2.207; Carson Alan, 2016, Pract Neurol, V16, P56, DOI 10.1136/practneurol-2015-001242; Cervenka MC, 2013, EPILEPSY BEHAV, V28, P217, DOI 10.1016/j.yebeh.2013.05.016; CHABROL H, 1995, EUR PSYCHIAT, V10, P317, DOI 10.1016/0924-9338(96)80314-2; Charcot J.-M., 1889, CLIN LECT DIS NERVOU; Chen DK, 2008, EPILEPSY BEHAV, V13, P115, DOI 10.1016/j.yebeh.2008.02.018; Chen DK, 2014, EPILEPSIA, V55, P156, DOI 10.1111/epi.12481; Chung SS, 2006, NEUROLOGY, V66, P1730, DOI 10.1212/01.wnl.0000218160.31537.87; Conwill M, 2014, EPILEPSY BEHAV, V34, P68, DOI 10.1016/j.yebeh.2014.03.012; Cope SR, 2021, EUR J NEUROL, V28, P40, DOI 10.1111/ene.14525; Criswell S, 2010, PARKINSONISM RELAT D, V16, P197, DOI 10.1016/j.parkreldis.2009.11.007; Cronje G, 2013, EPILEPSY BEHAV, V29, P581, DOI 10.1016/j.yebeh.2013.09.045; Dallocchio C, 2016, PSYCHOTHER PSYCHOSOM, V85, P381, DOI 10.1159/000446660; Daum C, 2015, J NEUROL NEUROSUR PS, V86, P425, DOI 10.1136/jnnp-2013-307381; Daum C, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-31; De Paola L, 2016, EPILEPSY BEHAV, V54, P40, DOI 10.1016/j.yebeh.2015.10.025; Deeley Q, 2016, HAND CLINIC, V139, P585, DOI 10.1016/B978-0-12-801772-2.00047-3; Demartini B, 2015, EUR J NEUROL, V22, P527, DOI 10.1111/ene.12609; Demartini B, 2020, PARKINSONISM RELAT D, V76, P108, DOI 10.1016/j.parkreldis.2019.05.004; DeToledo JC, 1996, NEUROLOGY, V47, P621, DOI 10.1212/WNL.47.3.621; Devinsky O, 1996, NEUROLOGY, V46, P1530, DOI 10.1212/WNL.46.6.1530; Ding JM, 2017, GEN HOSP PSYCHIAT, V45, P51, DOI 10.1016/j.genhosppsych.2016.12.009; Ding JM, 2016, J PSYCHOSOM RES, V91, P55, DOI 10.1016/j.jpsychores.2016.10.012; Drane DL, 2021, CNS SPECTRUMS, V26, P555, DOI 10.1017/S1092852920001789; Drane DL, 2016, EPILEPSY BEHAV, V54, P34, DOI 10.1016/j.yebeh.2015.10.026; Dreissen YEM, 2019, J NEUROL NEUROSUR PS, V90, P1244, DOI 10.1136/jnnp-2018-320071; Dufresne D, 2019, SEIZURE-EUR J EPILEP, V66, P39, DOI 10.1016/j.seizure.2019.02.005; Duncan R, 2020, EPILEPSY BEHAV, V102, DOI 10.1016/j.yebeh.2019.106667; Duncan R, 2011, EPILEPSY BEHAV, V20, P308, DOI 10.1016/j.yebeh.2010.10.022; Edwards MJ, 2019, BRAIN, V142, P1855, DOI 10.1093/brain/awz194; Edwards MJ, 2014, MOVEMENT DISORD, V29, P849, DOI 10.1002/mds.25562; Edwards MJ, 2012, BRAIN, V135, P3495, DOI 10.1093/brain/aws129; Edwards MJ, 2011, MOVEMENT DISORD, V26, P917, DOI 10.1002/mds.23562; Espay AJ, 2009, MOVEMENT DISORD, V24, P1366, DOI 10.1002/mds.22618; Fahn S, 2014, MOVEMENT DISORD, V29, P853, DOI 10.1002/mds.25899; Farias ST, 2003, EPILEPSY BEHAV, V4, P424, DOI 10.1016/S1525-5050(03)00143-4; Fasano A, 2012, MOVEMENT DISORD, V27, P1544, DOI 10.1002/mds.25190; Fekete R, 2012, J NEUROL NEUROSUR PS, V83, P202, DOI 10.1136/jnnp-2011-300733; Baizabal-Carvallo JF, 2020, NEUROL SCI, V41, P911, DOI 10.1007/s10072-019-04185-8; Frucht L, 2021, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.605262; Gambini O, 2014, EPILEPSY BEHAV, V41, P140, DOI 10.1016/j.yebeh.2014.09.076; Ganos C, 2019, NEUROLOGY, V93, P750, DOI 10.1212/WNL.0000000000008372; Garcin B, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00338; Garcin B, 2013, J NEUROL NEUROSUR PS, V84, P1043, DOI 10.1136/jnnp-2012-304062; GATES JR, 1985, ARCH NEUROL-CHICAGO, V42, P1183, DOI 10.1001/archneur.1985.04060110065017; Gelauff EM, 2019, BRAIN, V142, P2137, DOI 10.1093/brain/awz138; Gelauff JM, 2018, J NEUROL, V265, P1803, DOI 10.1007/s00415-018-8915-7; Gelauff J, 2014, J NEUROL NEUROSUR PS, V85, P220, DOI 10.1136/jnnp-2013-305321; Gelauff JM, 2020, NEUROLOGY, V95, pE1883, DOI 10.1212/WNL.0000000000010381; Gendre T, 2019, J PSYCHOSOM RES, V116, P10, DOI 10.1016/j.jpsychores.2018.11.006; Geyer JD, 2000, NEUROLOGY, V54, P227, DOI 10.1212/WNL.54.1.227; Goldstein LH, 2010, NEUROLOGY, V74, P1986, DOI 10.1212/WNL.0b013e3181e39658; Goldstein LH, 2020, LANCET PSYCHIAT, V7, P491, DOI 10.1016/S2215-0366(20)30128-0; Goleva SB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.27920; Gutkin M, 2020, J NEUROL NEUROSUR PS, V5; Hall-Patch L, 2010, EPILEPSIA, V51, P70, DOI 10.1111/j.1528-1167.2009.02099.x; Hallett M, 2006, CURR NEUROL NEUROSCI, V6, P269, DOI 10.1007/s11910-006-0015-x; Horn D, 2017, MOV DISORD CLIN PRAC, V4, P597, DOI 10.1002/mdc3.12492; Izadyar S, 2018, EPILEPSY BEHAV, V88, P123, DOI 10.1016/j.yebeh.2018.08.020; Jacob AE, 2018, J NEUROL NEUROSUR PS, V89, P1011, DOI 10.1136/jnnp-2017-316523; Jacob AE, 2018, PM&R, V10, P1164, DOI 10.1016/j.pmrj.2018.05.011; Jankovic J, 2014, MOVEMENT DISORD, V29, P1697, DOI 10.1002/mds.26040; Jedrzejczak J, 1999, EUR J NEUROL, V6, P473, DOI 10.1046/j.1468-1331.1999.640473.x; Jones B, 2016, EPILEPSIA, V57, P171, DOI 10.1111/epi.13268; Jordbru AA, 2014, J REHABIL MED, V46, P181, DOI 10.2340/16501977-1246; Kanaan R, 2009, PATIENT EDUC COUNS, V77, P296, DOI 10.1016/j.pec.2009.05.021; Kanaan R, 2009, BRAIN, V132, P2889, DOI 10.1093/brain/awp060; Kanaan RA, 2011, J NEUROL NEUROSUR PS, V82, P961, DOI 10.1136/jnnp.2010.233114; Karakis I, 2020, EPILEPSY BEHAV, V111, DOI 10.1016/j.yebeh.2020.107269; Kaski D, 2015, LANCET NEUROL, V14, P1196, DOI 10.1016/S1474-4422(15)00226-4; Kerr WT, 2020, EPILEPSY BEHAV, V105, DOI 10.1016/j.yebeh.2020.107002; Keynejad RC, 2017, LANCET PSYCHIAT, V4, pE2, DOI 10.1016/S2215-0366(17)30036-6; Koehler PJ, 2004, NEUROLOGY, V63, P1693, DOI 10.1212/01.WNL.0000142977.21104.94; Kompoliti K, 2014, PARKINSONISM RELAT D, V20, P60, DOI 10.1016/j.parkreldis.2013.09.018; Kutlubaev MA, 2018, EPILEPSY BEHAV, V89, P70, DOI 10.1016/j.yebeh.2018.10.010; Kuyk J, 1999, EPILEPSIA, V40, P485, DOI 10.1111/j.1528-1157.1999.tb00745.x; LaFaver K, 2020, EUR J NEUROL, V27, P975, DOI 10.1111/ene.14200; LaFaver K, 2014, MOVEMENT DISORD, V29, P1698, DOI 10.1002/mds.26035; LaFrance WC, 2010, NEUROLOGY, V75, P1166, DOI 10.1212/WNL.0b013e3181f4d5a9; LaFrance WC, 2014, JAMA PSYCHIAT, V71, P997, DOI 10.1001/jamapsychiatry.2014.817; LaFrance WC, 2013, EPILEPSIA, V54, P2005, DOI 10.1111/epi.12356; LaFrance WC, 2011, EPILEPSIA, V52, P292, DOI 10.1111/j.1528-1167.2010.02765.x; LaFrance WC, 2010, NEUROLOGY, V75, P87, DOI 10.1212/WNL.0b013e3181e62181; LaFrance WC, 2009, NEUROLOGY, V73, P366, DOI 10.1212/WNL.0b013e3181b04c83; LaFrance WC, 2020, EPILEPSIA, V61, P2572, DOI 10.1111/epi.16689; Lagrand T, 2021, EUR J NEUROL, V28, P33, DOI 10.1111/ene.14488; LANG AE, 1995, CAN J NEUROL SCI, V22, P136, DOI 10.1017/S031716710004021X; Laub HN, 2015, MOV DISORD CLIN PRAC, V2, P29, DOI 10.1002/mdc3.12102; Lenio S, 2021, EPILEPSY BEHAV, V116, DOI 10.1016/j.yebeh.2021.107767; Lombardi TL, 2014, J NEUROL NEUROSUR PS, V85, P165, DOI 10.1136/jnnp-2012-304314; Ludwig L, 2018, LANCET PSYCHIAT, V5, P307, DOI 10.1016/S2215-0366(18)30051-8; MACE CJ, 1991, J ROY SOC MED, V84, P471, DOI 10.1177/014107689108400808; Maggio J, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa156; Maggio JB, 2020, J NEUROPSYCH CLIN N, V32, P85, DOI 10.1176/appi.neuropsych.19030068; Mayor R, 2012, EPILEPSY BEHAV, V25, P676, DOI 10.1016/j.yebeh.2012.09.033; Mayor R, 2013, SEIZURE-EUR J EPILEP, V22, P760, DOI 10.1016/j.seizure.2013.06.008; McCormack R, 2014, J NEUROL NEUROSUR PS, V85, P893, DOI 10.1136/jnnp-2013-305716; McKee K, 2018, PSYCHOSOMATICS, V59, P358, DOI 10.1016/j.psym.2017.12.006; McWhirter L, 2016, J PSYCHOSOM RES, V89, P102, DOI 10.1016/j.jpsychores.2016.08.010; McWhirter L, 2011, J PSYCHOSOM RES, V71, P384, DOI 10.1016/j.jpsychores.2011.09.003; Medina M, 2021, ACAD PSYCHIATR, V45, P185, DOI 10.1007/s40596-020-01324-8; Mitchell JW, 2012, EPILEPSY BEHAV, V25, P307, DOI 10.1016/j.yebeh.2012.08.022; Moene FC, 2003, INT J CLIN EXP HYP, V51, P29, DOI 10.1076/iceh.51.1.29.14067; Moene FC, 2002, PSYCHOTHER PSYCHOSOM, V71, P66, DOI 10.1159/000049348; Myers L, 2017, EPILEPSY BEHAV, V66, P86, DOI 10.1016/j.yebeh.2016.10.019; Nicholson C, 2020, J NEUROL NEUROSUR PS, V91, P1037, DOI 10.1136/jnnp-2019-322281; Nicholson TRJ, 2016, HAND CLINIC, V139, P619, DOI 10.1016/B978-0-12-801772-2.00050-3; Nicholson TR, 2020, J NEUROPSYCH CLIN N, V32, P33, DOI 10.1176/appi.neuropsych.19060128; Nielsen G, 2017, J NEUROL NEUROSUR PS, V88, P484, DOI 10.1136/jnnp-2016-314408; Nielsen G, 2015, J NEUROL, V262, P674, DOI 10.1007/s00415-014-7631-1; Nielsen G, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1461-9; Nielsen G, 2015, J NEUROL NEUROSUR PS, V86, P1113, DOI 10.1136/jnnp-2014-309255; Nielsen G, 2013, J PSYCHOSOM RES, V75, P93, DOI 10.1016/j.jpsychores.2013.05.006; Nightscales R, 2020, NEUROLOGY, V95, pE643, DOI 10.1212/WNL.0000000000009855; Nonnekes J, 2020, NEUROLOGY, V94, P1093, DOI 10.1212/WNL.0000000000009649; Nunez-Wallace KR, 2015, EPILEPSY RES, V114, P114, DOI 10.1016/j.eplepsyres.2015.05.002; Okun MS, 2007, NEUROLOGIST, V13, P87, DOI 10.1097/01.nrl.0000256358.52613.cc; Oliva M, 2008, EPILEPSIA, V49, P962, DOI 10.1111/j.1528-1167.2008.01554.x; Park JE, 2015, MOV DISORD CLIN PRAC, V2, P286, DOI 10.1002/mdc3.12177; PEGUERO E, 1995, EPILEPSIA, V36, P586, DOI 10.1111/j.1528-1157.1995.tb02572.x; Perez DL, 2020, NEUROL-CLIN PRACT, V10, P484, DOI 10.1212/CPJ.0000000000000779; Perez DL, 2021, J NEUROPSYCH CLIN N, V33, P14, DOI 10.1176/appi.neuropsych.19120357; Perez DL, 2020, LANCET PSYCHIAT, V7, P464, DOI 10.1016/S2215-0366(20)30143-7; Perez DL, 2019, NEUROL-CLIN PRACT, V9, P165, DOI 10.1212/CPJ.0000000000000573; Perez DL, 2016, COGN BEHAV NEUROL, V29, P197, DOI 10.1097/WNN.0000000000000106; Perez DL, 2015, CLIN EEG NEUROSCI, V46, P4, DOI 10.1177/1550059414555905; Peterson KT, 2018, PSYCHOSOMATICS, V59, P601, DOI 10.1016/j.psym.2018.03.001; Pick S, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037198; Pick S, 2020, J NEUROL NEUROSUR PS, V91, P638, DOI 10.1136/jnnp-2019-322180; Pintor L, 2010, J NEUROPSYCH CLIN N, V22, P401, DOI 10.1176/appi.neuropsych.22.4.401; Pizza F, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy026; Polara GF, 2018, J NEUROL SCI, V387, P37, DOI 10.1016/j.jns.2018.01.022; Popkirov Stoyan, 2018, Pract Neurol, V18, P5, DOI 10.1136/practneurol-2017-001809; Popkirov S, 2015, EPILEPSY BEHAV, V46, P88, DOI 10.1016/j.yebeh.2015.04.020; Quigg M, 2002, EPILEPSY BEHAV, V3, P455, DOI 10.1016/S1525-5050(02)00524-3; Rawlings GH, 2017, EPILEPSY BEHAV, V68, P153, DOI 10.1016/j.yebeh.2016.10.035; Razvi S, 2012, EPILEPSY BEHAV, V23, P7, DOI 10.1016/j.yebeh.2011.10.009; Reiter J, 2015, TAKING CONTROL YOUR, DOI [10.1093/me d:psych/9780199335015.001.0001, DOI 10.1093/MED:PSYCH/9780199335015.001.0001]; Reuber M, 2019, PRACT NEUROL, V19, P332, DOI 10.1136/practneurol-2018-002177; Reuber M, 2016, NEUROLOGY, V87, P625, DOI 10.1212/WNL.0000000000002948; Robson C, 2018, SEIZURE-EUR J EPILEP, V55, P93, DOI 10.1016/j.seizure.2018.01.001; Rockliffe-Fidler Claire, 2019, Pract Neurol, V19, P259, DOI 10.1136/practneurol-2018-002100; Roper Louise S, 2013, Pract Neurol, V13, P396, DOI 10.1136/practneurol-2013-000549; Salinsky M, 2016, EPILEPSY BEHAV, V60, P107, DOI 10.1016/j.yebeh.2016.04.007; SAYGI S, 1992, NEUROLOGY, V42, P1274, DOI 10.1212/WNL.42.7.1274; Schrag A, 2004, BRAIN, V127, P2360, DOI 10.1093/brain/awh262; Schwingenschuh P, 2016, MOVEMENT DISORD, V31, P555, DOI 10.1002/mds.26525; Schwingenschuh P, 2011, MOVEMENT DISORD, V26, P2509, DOI 10.1002/mds.23922; Selkirk M, 2008, EPILEPSIA, V49, P1446, DOI 10.1111/j.1528-1167.2008.01611.x; Sen A, 2007, EPILEPSY RES, V77, P62, DOI 10.1016/j.eplepsyres.2007.07.009; Seneviratne U, 2017, EPILEPSY BEHAV, V66, P127, DOI 10.1016/j.yebeh.2016.10.024; Sharpe M, 2011, NEUROLOGY, V77, P564, DOI 10.1212/WNL.0b013e318228c0c7; SHEN W, 1990, NEUROLOGY, V40, P756, DOI 10.1212/WNL.40.5.756; Sigurdardottir KR, 1998, EPILEPSIA, V39, P749, DOI 10.1111/j.1528-1157.1998.tb01161.x; SLATER JD, 1995, EPILEPSIA, V36, P580, DOI 10.1111/j.1528-1157.1995.tb02571.x; Sonoo M, 2004, J NEUROL NEUROSUR PS, V75, P121; Spina JP, 2019, J AFFECT DISORDERS, V258, P50, DOI 10.1016/j.jad.2019.07.061; STEFANSSON JG, 1976, ACTA PSYCHIAT SCAND, V53, P119, DOI 10.1111/j.1600-0447.1976.tb00066.x; Stephen CD, 2021, JAMA NEUROL, V78, P88, DOI 10.1001/jamaneurol.2020.3753; STEVENS DL, 1989, J NEUROL NEUROSUR PS, V52, P439, DOI 10.1136/jnnp.52.4.439; Stone J, 2005, BRIT MED J, V331, P989, DOI 10.1136/bmj.38628.466898.55; Stone J, 2016, HAND CLINIC, V139, P543, DOI 10.1016/B978-0-12-801772-2.00044-8; Stone J, 2014, NEUROPHYSIOL CLIN, V44, P363, DOI 10.1016/j.neucli.2014.01.002; Stone J, 2003, J NEUROL NEUROSUR PS, V74, P591, DOI 10.1136/jnnp.74.5.591; Stone J, 2002, BRIT MED J, V325, P1449, DOI 10.1136/bmj.325.7378.1449; Stone J, 2010, CLIN NEUROL NEUROSUR, V112, P747, DOI 10.1016/j.clineuro.2010.05.011; Stone J, 2006, PRACT NEUROL, V6, P64, DOI [10.1136/jnnp.2005.012345, DOI 10.1136/JNNP.2005.012345]; Stone JC, 2012, I COULDNT VIEW THIS; Stone J, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3745; Stone Jon, 2017, Pract Neurol, V17, P417, DOI 10.1136/practneurol-2017-001660; Stone Jon, 2015, Continuum (Minneap Minn), V21, P818, DOI 10.1212/01.CON.0000466669.02477.45; Stone J, 2014, J PSYCHOSOM RES, V76, P165, DOI 10.1016/j.jpsychores.2013.10.003; Stone J, 2012, NEUROLOGY, V79, P282, DOI 10.1212/WNL.0b013e31825fdf63; Stone J, 2010, BRAIN, V133, P1537, DOI 10.1093/brain/awq068; Sundararajan T, 2016, SEIZURE-EUR J EPILEP, V35, P11, DOI 10.1016/j.seizure.2015.12.011; Syed TU, 2011, ANN NEUROL, V69, P997, DOI 10.1002/ana.22345; Szaflarski JP, 2003, EPILEPSIA, V44, P236, DOI 10.1046/j.1528-1157.2003.35302.x; Taib S, 2019, MOVEMENT DISORD, V34, P1210, DOI 10.1002/mds.27727; Tatum WO, 2020, JAMA NEUROL, V77, P593, DOI 10.1001/jamaneurol.2019.4785; Teodoro T, 2019, NEURO-OPHTHALMOLOGY, V43, P240, DOI 10.1080/01658107.2018.1536998; Testa SM, 2007, EPILEPSIA, V48, P973, DOI 10.1111/j.1528-1167.2006.00965.x; Thenganatt MA, 2014, TREMOR OTHER HYPERK, V4, DOI 10.7916/D8FJ2F0Q; Thomsen BLC, 2020, J NEUROL NEUROSUR PS, V91, P1261, DOI 10.1136/jnnp-2020-323141; Tinazzi M, 2008, MOVEMENT DISORD, V23, P2415, DOI 10.1002/mds.22268; Tolchin B, 2020, EPILEPSY BEHAV, V112, DOI 10.1016/j.yebeh.2020.107364; Tolchin B, 2019, EPILEPSIA, V60, P986, DOI 10.1111/epi.14728; Trimble M, 2016, HAND CLINIC, V139, P3, DOI 10.1016/B978-0-12-801772-2.00001-1; van der Stouwe AMM, 2016, PARKINSONISM RELAT D, V30, P23, DOI 10.1016/j.parkreldis.2016.06.008; Vanek J, 2021, NAT SCI SLEEP, V13, P209, DOI 10.2147/NSS.S289190; Vechetova G, 2018, J PSYCHOSOM RES, V115, P32, DOI 10.1016/j.jpsychores.2018.10.001; Villagran A, 2021, EPILEPSIA, V62, P1528, DOI 10.1111/epi.16949; Vizcarra JA, 2019, PARKINSONISM RELAT D, V63, P174, DOI 10.1016/j.parkreldis.2019.02.009; Vogrig A, 2019, EPILEPSY BEHAV, V90, P172, DOI 10.1016/j.yebeh.2018.11.030; Voon V, 2005, J CLIN PSYCHIAT, V66, P1529, DOI 10.4088/JCP.v66n1206; Vossler DG, 2004, NEUROLOGY, V63, P516, DOI 10.1212/01.WNL.0000133208.57562.CB; Walczak TS, 1996, EPILEPSIA, V37, P208, DOI 10.1111/j.1528-1157.1996.tb00013.x; WALCZAK TS, 1994, NEUROLOGY, V44, P2191, DOI 10.1212/WNL.44.11.2191; Walther K, 2019, EPILEPSIA, V60, P669, DOI 10.1111/epi.14682; Walzl D, 2022, J NEUROL, V269, P654, DOI 10.1007/s00415-021-10436-6; Wasserman D, 2017, EPILEPSY BEHAV, V73, P42, DOI 10.1016/j.yebeh.2017.04.020; Williams C, 2017, OVERCOMING FUNCTIONA, DOI [10.1201/b13567, DOI 10.1201/B13567]; Wissel BD, 2018, J NEUROL NEUROSUR PS, V89, P566, DOI 10.1136/jnnp-2017-317378; Wolf LD, 2015, EPILEPSY BEHAV, V43, P81, DOI 10.1016/j.yebeh.2014.12.010; Yugue I, 2004, SPINE, V29, P1910, DOI 10.1097/01.brs.0000137055.55350.37; Zeuner KE, 2003, NEUROLOGY, V61, P548, DOI 10.1212/01.WNL.0000076183.34915.CD	241	13	13	4	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	2022	376								064	10.1136/bmj.064	http://dx.doi.org/10.1136/bmj.064			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YS4MD	35074803				2023-01-03	WOS:000750652200007
J	Yeemard, F; Srichan, P; Apidechkul, T; Luerueang, N; Tamornpark, R; Utsaha, S				Yeemard, Fartima; Srichan, Peeradone; Apidechkul, Tawatchai; Luerueang, Naphat; Tamornpark, Ratipark; Utsaha, Suphaphorn			Prevalence and predictors of suboptimal glycemic control among patients with type 2 diabetes mellitus in northern Thailand: A hospital-based cross-sectional control study	PLOS ONE			English	Article							CARE	Background Suboptimal glycemic control among patients with type 2 diabetes mellitus (DM) is a significant public health problem, particularly among people living with poor education and economic statuses, including those with a unique dietary culture. This study aimed to estimate the prevalence and identify the factors associated with suboptimal glycemic control among patients with type 2 DM during the coronavirus disease-2019 (COVID-19) pandemic. Methods A hospital-based cross-sectional study was used to elicit information from DM patients attending six hospitals located in Chiang Rai Province, northern Thailand, between February and May 2021. A validated questionnaire and 5 mL blood specimens were used as the research tools. Glycated hemoglobin (HbA1c) greater than 7.0% among DM patients at least two years after diagnosis was defined as suboptimal glycemic control. Chi-square tests and logistic regression were used to identify the associations between variables at the significance level alpha = 0.05. Results A total of 967 patients were recruited for this study; 54.8% 530 had suboptimal glycemic control, 58.8% were female, 66.5% were aged 50-69 years, and 78.5% were married (78.5%). Six variables were found to be associated with suboptimal glycemic control in multivariable logistic regression. Participants aged <49, 50-59, and 60-69 years had 3.32 times (95% CI = 1.99-5.53), 2.61 times (95% CI = 1.67-4.08), and 1.93 times (95% CI = 1.26-2.95) greater odds of having suboptimal glycemic control, respectively, than those aged >= 70 years. Married individuals had 1.64 times (95% CI = 1.11-2.41) greater odds of having suboptimal glycemic control than those ever married. Participants who consumed sticky rice had 1.61 times (95% CI = 1.19-2.61) greater odds of having suboptimal glycemic control than those who did not consume sticky rice in daily life. Participants who had been diagnosed with DM for 11-20 years and >= 21 years had 1.98 times (95% CI = 1.37-2.86) and 2.46 times (1.50-4.04) greater odds of having suboptimal glycemic control, respectively, than those who had been diagnosed <= 10 years. Participants who had experienced forgetting to take their medication had 2.10 times (95% CI = 1.43-3.09) greater odds of having suboptimal glycemic control than those who did not, and those who had their medical expenses covered by the national scheme had 2.67 times (95% CI = 1.00-7.08) greater odds of suboptimal glycemic control than those who self-paid. Conclusion Effective health interventions to control blood glucose among DM patients during ongoing treatment are urgently required. The interventions should focus on patients aged less than 69 years, marital status, forgetting to take their medication, and a longer time since diagnosis, including reducing their sticky rice consumption. The effects of copayments should also be considered.	[Yeemard, Fartima; Srichan, Peeradone; Apidechkul, Tawatchai; Tamornpark, Ratipark] Mae Fah Luang Univ, Ctr Excellence Hill Tribe Hlth Res, Chiang Rai, Thailand; [Srichan, Peeradone; Apidechkul, Tawatchai; Tamornpark, Ratipark; Utsaha, Suphaphorn] Mae Fah Luang Univ, Sch Hlth Sci, Chiang Rai, Thailand; [Luerueang, Naphat] Mae Lao Dist Publ Hlth Off, Chiang Rai, Thailand	Mae Fah Luang University; Mae Fah Luang University	Apidechkul, T (corresponding author), Mae Fah Luang Univ, Ctr Excellence Hill Tribe Hlth Res, Chiang Rai, Thailand.; Apidechkul, T (corresponding author), Mae Fah Luang Univ, Sch Hlth Sci, Chiang Rai, Thailand.	Tawatchai.api@mfu.ac.th		Apidechkul, Tawatchai/0000-0001-8301-2055	Center of Excellence for the Hill tribe Health Research, Mae Fah Lung University, Thailand [1-2021]	Center of Excellence for the Hill tribe Health Research, Mae Fah Lung University, Thailand	This research was supported by the Center of Excellence for the Hill tribe Health Research, Mae Fah Lung University, Thailand (Grant Number 1-2021). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aekplakorn W, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/1654530; Akhmad Priyadi, 2019, Journal of Advanced Pharmacy Education and Research, V9, P53; Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI 10.2337/dc11-S011; Anusuya S., 2018, INT J COMMUNITY MED, V5, P5200; Basu S, 2019, J HEALTH POPUL NUTR, V38, DOI 10.1186/s41043-019-0198-9; Buraphunt R., 2013, KKU J PUBLIC HLTH RE, V6, P102; Chanpiwat P, 2019, ENVIRON MONIT ASSESS, V191, DOI 10.1007/s10661-019-7836-y; Charan Jaykaran, 2013, Indian J Psychol Med, V35, P121, DOI 10.4103/0253-7176.116232; Cheong AT, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-188; Deerochanawong C, 2013, GLOBALIZATION HEALTH, V9, DOI 10.1186/1744-8603-9-11; Department of Disease Control Ministry of Public Health, 2020, DIAB SIT THAIL 2020; Department of Mental Health, STRESS TEST 5; Department of Mental Health, STRESS TEST 5 ST 5; Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00028-20; Fiagbe J., 2017, DIABETES MANAGEMENT, V7, P343; Fiseha Temesgen, 2018, BMC Res Notes, V11, P316, DOI 10.1186/s13104-018-3423-5; Foundation of Thai Gerontology Research and Development Institute, 2018, SIT THAI ELD; Gebrie A, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05655; Haghighatpanah Mohammad, 2018, Osong Public Health Res Perspect, V9, P167, DOI 10.24171/j.phrp.2018.9.4.05; Kanglee K., 2014, J ROYAL THAI ARMY NU, V15, P256; Kassahun Tefera, 2016, BMC Res Notes, V9, P78, DOI 10.1186/s13104-016-1896-7; Khamis AA., 2018, GLOBAL J HLTH SCI, V10, P39; Kirigia JM, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-6; Kitchanapaibul S, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11145-5; Manjunath K, 2014, J Family Med Prim Care, V3, P396, DOI 10.4103/2249-4863.148124; Ministry of Public Health Thailand, HDB INT PEOPL CTR HL; Mirzaei M, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8267-y; Moucheraud C, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001258; Nyunt SW, 2010, SE ASIAN J TROP MED, V41, P943; Omar Saeed M, 2018, BMC Res Notes, V11, P373, DOI 10.1186/s13104-018-3480-9; Panyasai S, 2016, GENET TEST MOL BIOMA, V20, P37, DOI 10.1089/gtmb.2015.0182; Radwan M, 2018, THER ADV ENDOCRINOL, V9, P3, DOI 10.1177/2042018817742070; Riaz F, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14168; Sahaspot S., 2015, BURAPHA SCI J, V20, P1; Sanmuangken O., 2017, J HEALTH SCI, V26, pS227; Siddiqui FJ, 2015, DIABETES RES CLIN PR, V107, P148, DOI 10.1016/j.diabres.2014.09.025; Sompong Narong, 2015, International Journal of Information and Education Technology, V5, P664, DOI 10.7763/IJIET.2015.V5.588; Suwattanakul T, 2018, J HLTH SYSTEM RESAER, V12, P515; Thailand, MIN PUBL HLTH; The World Bank, LAB MARK THAIL; United Nations Population Fund (UNPD), IMPACT DEMOGRAPHIC C; Wandell PE, 2005, SCAND J PRIM HEALTH, V23, P68, DOI 10.1080/02813430510015296; WHO, BOD MASS IND BMI; WHO, DIABETES; World Health Organization, DIAB KEY FACTS; World Health Organization (WHO), GUIDELINE MANAGEMENT; World Health Organization (WHO), THAIL DIAB	47	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2022	17	1							e0262714	10.1371/journal.pone.0262714	http://dx.doi.org/10.1371/journal.pone.0262714			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2G1LZ	35041704	gold, Green Published			2023-01-03	WOS:000813361200045
J	Edward, A; Jung, Y; Ettyang, G; Chhorvann, C; Risko, C; Ghee, AE; Chege, J				Edward, Anbrasi; Jung, Younghee; Ettyang, Grace; Chhorvann, Chhea; Risko, Casey; Ghee, Annette E.; Chege, Jane			A comparative study of adult and adolescent maternal care continuum following community-oriented interventions in Cambodia, Guatemala, Kenya, and Zambia	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; MIDDLE-INCOME COUNTRIES; HEALTH-SERVICES; FACILITY DELIVERY; ANTENATAL CARE; CHILD HEALTH; SOCIAL ACCOUNTABILITY; NEWBORN HEALTH; MOTHERS; DETERMINANTS	Background The coverage for reproductive care continuum is a growing concern for communities in low- income economies. Adolescents (15-19 years) are often at higher odds of maternal morbidity and mortality due to other underlying factors including biological immaturity, social, and economic differences. The aim of the study was to examine a) differences in care-seeking and continuum of care (4 antenatal care (ANC4+), skilled birth attendance (SBA) and postnatal care (PNC) within 24h) between adult (20-49 Years) and adolescents and b) the effect of multilevel community-oriented interventions on adolescent and adult reproductive care-seeking in Cambodia, Guatemala, Kenya, and Zambia using a quasi-experimental study design. Methods In each country, communities in two districts/sub-districts received timed community health worker (CHW) household health promotion and social accountability interventions with community scorecards. Two matched districts/sub-districts were selected for comparison and received routine healthcare services. Results Results from the final evaluation showed that there were no significant differences in the care continuum for adolescents and adults except for Kenya (26.1% vs 18.8%, p<0.05). SBA was significantly higher for adolescents compared to adult women for Guatemala (64% vs 55.5%, p<0.05). Adolescents in the intervention sites showed significantly higher ANC utilization for Kenya (95.3% vs 84.8%, p<0.01) and Zambia (87% vs 72.7%, p<0.05), ANC4 for Cambodia (83.7% vs 43.2%, p<0.001) and Kenya (65.9% vs 48.1%, p<0.05), SBA for Cambodia (100% vs 88.9%, p<0.05), early PNC for Cambodia (91.8% vs 72.8%, p<0.01) and Zambia (56.5% vs 16.9%, p<0.001) compared to the comparison sites. However, the findings from Guatemala illustrated significantly lower care continuum for intervention sites (aOR:0.34, 95% CI 0.28-0.42, p<0.001). The study provides some evidence on the potential of multilevel community-oriented interventions to improve adolescent healthcare seeking in rural contexts. The predictors of care continuum varied across countries, indicating the importance of contextual factors in designing interventions.	[Edward, Anbrasi; Risko, Casey] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Jung, Younghee] World Hlth Org, Neglected Trop Dis, Dili, Timor-Leste; [Ettyang, Grace] Moi Univ, Sch Publ Hlth, Coll Hlth Sci, Kesses, Kenya; [Chhorvann, Chhea] Natl Inst Publ Hlth, Phnom Penh, Cambodia; [Ghee, Annette E.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Chege, Jane] World Vis Int, Washington, DC USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; World Health Organization; Moi University; University of Washington; University of Washington Seattle	Edward, A (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.	aedward1@jhu.edu			World Vision [113543]	World Vision	The study was conducted through a research grant #113543 to Johns Hopkins University from World Vision (www.worldvision.org).AE, YJ, CC, GE, and CR were partially funded to conduct the research study and analysis. The funders had no role in data collection and analysis, decision to publish, or preparation of the manuscript.	Abebe E, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7854-2; [Anonymous], STATA 14 COMPUTER PR; August F, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0916-x; Banke-Thomas A, 2017, SEX REPROD HEALTHC, V12, P37, DOI 10.1016/j.srhc.2017.02.004; Banke-Thomas Oluwasola, 2016, Int J Adolesc Med Health, V30, DOI 10.1515/ijamh-2016-0042; Banke-Thomas OE, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1246-3; Bhowmik J, 2019, PUBLIC HEALTH, V170, P113, DOI 10.1016/j.puhe.2019.02.027; Blake C, 2016, INT J GYNECOL OBSTET, V135, P372, DOI 10.1016/j.ijgo.2016.10.004; Chaka EE, 2019, INT J PREVENTIVE MED, V10, DOI 10.4103/ijpvm.IJPVM_26_19; Conde-Agudelo A, 2005, AM J OBSTET GYNECOL, V192, P342, DOI 10.1016/j.ajog.2004.10.593; Demographic Health Survey, DHS OV; Edward A, 2019, J Prev Med Hyg, V60, pE93, DOI 10.15167/2421-4248/jpmh2019.60.2.1088; Edward A, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03223-0; Edward A, 2020, INT J QUAL HEALTH C, V32, P364, DOI 10.1093/intqhc/mzaa052; Edward A, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0946-5; Fund UNP, 2014, MOTHERHOOD CHILDHOOD; Gabrysch S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-34; George A, 2015, SOC SCI MED, V133, P159, DOI 10.1016/j.socscimed.2015.03.049; Gilmore B, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-847; Global Fund, 2010, COMM SYST STRENGTH F; Hamal M, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3453-7; Hendriks S., 2015, LEAVE NO ONE; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Kyei-Nimakoh M, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0503-x; Magadi MA, 2007, SOC SCI MED, V64, P1311, DOI 10.1016/j.socscimed.2006.11.004; Mayor S., 2004, BRIT MEDICAL J PUBLI; Mohan D, 2017, HEALTH POLICY PLANN, V32, P791, DOI 10.1093/heapol/czx005; Montagu D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017155; Moyer Cheryl A, 2013, Afr J Reprod Health, V17, P30; Moyer CA, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-40; Nove A, 2014, LANCET GLOB HEALTH, V2, pE155, DOI 10.1016/S2214-109X(13)70179-7; Perry HB, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.010906; Pervin J, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-111; Reynolds HW, 2006, INT FAM PLAN PERSPEC, V32, P6, DOI 10.1363/3200606; Schaaf M, 2017, HEALTH POLICY PLANN, V32, P847, DOI 10.1093/heapol/czx024; Shibanuma A, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000786; Wang WJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0497-0; Yaya S, 2019, HEALTH EQUITY, V3, P145, DOI 10.1089/heq.2018.0082; Yeji F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142849	39	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2022	17	1							e0261161	10.1371/journal.pone.0261161	http://dx.doi.org/10.1371/journal.pone.0261161			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H0VF	35025914	Green Published, gold			2023-01-03	WOS:000796264200013
J	[Anonymous]				[Anonymous]			Update to living WHO guideline on drugs for covid-19	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	7	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2022	376								o80	10.1136/bmj.o80	http://dx.doi.org/10.1136/bmj.o80			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE9IW	35027394				2023-01-03	WOS:000759191400008
J	Craven, AJ; Pegram, C; Packer, RMA; Jarvis, S; McGreevy, PD; Warnes, C; Church, DB; Brodbelt, DC; O'Neill, DG				Craven, Annabel J.; Pegram, Camilla; Packer, Rowena M. A.; Jarvis, Susan; McGreevy, Paul D.; Warnes, Caroline; Church, David B.; Brodbelt, Dave C.; O'Neill, Dan G.			Veterinary drug therapies used for undesirable behaviours in UK dogs under primary veterinary care	PLOS ONE			English	Article							FLUOXETINE CHEWABLE TABLETS; SEPARATION ANXIETY; RISK-FACTORS; AGGRESSIVE-BEHAVIOR; TRAINING METHODS; NOISE PHOBIA; DOUBLE-BLIND; BREED; PREVALENCE; MANAGEMENT	Undesirable behaviours (UBs) in dogs are common and important issues with serious potential welfare consequences for both the dogs and their owners. This study aimed to investigate the usage of drug therapy for UBs in dogs and assess demographic risk factors for drug-prescribed UBs within the dog population under primary-care veterinary care in the UK in 2013. Dogs receiving drug therapy for UB were identified through the retrospective analysis of anonymised electronic patient records in VetCompass (TM). Risk factor analysis used multivariable logistic regression modelling. The study population comprised 103,597 dogs under veterinary care in the UK during 2013. There were 413 drug-prescribed UBs recorded among 404 dogs. The prevalence of dogs with at least one UB event treated with a drug in 2013 was 0.4%. Multivariable modelling identified 3 breeds with increased odds of drug-prescribed UB compared with crossbred dogs: Toy Poodle (OR 2.75), Tibetan Terrier (OR 2.68) and Shih-tzu (OR 1.95). Increasing age was associated with increased odds of drug-prescribed UB, with dogs >= 12 years showing 3.1 times the odds compared with dogs < 3 years. Neutered males (OR 1.82) and entire males (OR 1.50) had increased odds compared with entire females. The relatively low prevalence of dogs with at least one UB event that was treated with a drug in 2013 could suggest that opportunities for useful psychopharmaceutical intervention in UBs may be being missed in first opinion veterinary practice. While bodyweight was not a significant factor, the 3 individual breeds at higher odds of an UB treated with a behaviour modifying drug all have a relatively low average bodyweight. The current results also support previous research of a male predisposition to UBs and it is possible that this higher risk resulted in the increased likelihood of being prescribed a behaviour modifying drug, regardless of neuter status.	[Craven, Annabel J.] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland; [Pegram, Camilla; Brodbelt, Dave C.; O'Neill, Dan G.] Royal Vet Coll, Pathobiol & Populat Sci, Hawkshead Lane, Hatfield, Herts, England; [Packer, Rowena M. A.; Church, David B.] Royal Vet Coll, Clin Sci & Serv, Hawkshead Lane, Hatfield, Herts, England; [Jarvis, Susan] Univ Edinburgh, Global Acad Agr & Food Secur, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland; [McGreevy, Paul D.] Univ New England, Sch Environm & Rural Sci, Fac Sci Agr Business & Law, Armidale, NSW, Australia	University of Edinburgh; University of London; University of London Royal Veterinary College; University of London; University of London Royal Veterinary College; University of Edinburgh; University of New England	Craven, AJ (corresponding author), Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.	annabel_craven@hotmail.com	Brodbelt, David/C-6005-2009	Brodbelt, David/0000-0001-5628-4194	Kennel Club Charitable Trust	Kennel Club Charitable Trust	This study was supported at the RVC by an award from the Kennel Club Charitable Trust. Neither the Kennel Club Charitable Trust nor the Kennel Club had any input in the design of the study, the collection, analysis and interpretation of data or in writing the manuscript.	[Anonymous], 2020, NOAH COMPENDIUM; Arhant C, 2010, APPL ANIM BEHAV SCI, V123, P131, DOI 10.1016/j.applanim.2010.01.003; Bamberger M, 2006, JAVMA-J AM VET MED A, V229, P1591, DOI 10.2460/javma.229.10.1591; Barcelos AM, 2015, VET REC, V176, P466, DOI 10.1136/vr.102823; BLACKSHAW JK, 1991, APPL ANIM BEHAV SCI, V30, P351, DOI 10.1016/0168-1591(91)90140-S; Blackwell EJ, 2013, APPL ANIM BEHAV SCI, V145, P15, DOI 10.1016/j.applanim.2012.12.004; Blackwell EJ, 2008, J VET BEHAV, V3, P207, DOI 10.1016/j.jveb.2007.10.008; BORCHELT PL, 1983, APPL ANIM ETHOL, V10, P45, DOI 10.1016/0304-3762(83)90111-6; Bowen J., 2005, BEHAV PROBLEMS SMALL; Boyd C, 2018, ANIM WELFARE, V27, P251, DOI 10.7120/09627286.27.3.251; Bradshaw JWS, 2002, VET REC, V151, P43, DOI 10.1136/vr.151.2.43; Buller K, 2020, J VET BEHAV, V37, P41, DOI 10.1016/j.jveb.2020.04.003; Christiansen FO, 2001, APPL ANIM BEHAV SCI, V72, P115, DOI 10.1016/S0168-1591(00)00202-1; Cracknell NR, 2008, VET J, V177, P80, DOI 10.1016/j.tvjl.2007.04.007; Crowell-Davis S.L., 2019, VET PSYCHOPHARMACOLO; Denenberg S, 2005, CURRENT ISSUES AND RESEARCH IN VETERINARY BEHAVIORAL MEDICINE, P56; Dinwoodie IR, 2021, J VET BEHAV, V43, P46, DOI 10.1016/j.jveb.2021.02.002; Dohoo I., 2009, METHODS EPIDEMIOLOGI, V2nd ed.; Egenvall A, 2009, ACTA VET SCAND, V51, DOI 10.1186/1751-0147-51-42; EPI INFO 7 CDC, 2020 CDCP US INTR EP; Erath JR, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00169; Fatjo J, 2007, J VET BEHAV, V2, P158, DOI 10.1016/j.jveb.2007.07.008; Fatjo J, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10030383; Gaultier E, 2005, VET REC, V156, P533, DOI 10.1136/vr.156.17.533; Ghasemi A, 2012, INT J ENDOCRINOL MET, V10, P486, DOI 10.5812/ijem.3505; Martinez AG, 2011, J VET BEHAV, V6, P225, DOI 10.1016/j.jveb.2011.01.006; Guy NC, 2001, APPL ANIM BEHAV SCI, V74, P15, DOI 10.1016/S0168-1591(01)00153-8; Herron ME, 2008, JAVMA-J AM VET MED A, V233, P1420, DOI 10.2460/javma.233.9.1420; Hiby EF, 2004, ANIM WELFARE, V13, P63; Hobbs SL., 2020, SCI REP-UK, V10, P1, DOI [10.1038/s41598-019-56847-4, DOI 10.1038/S41598-019-56847-4]; Horwitz D., 2002, BSAVA MANUAL CANINE, V1; Hosmer DW, 2013, WILEY SER PROBAB ST, P1, DOI 10.1002/9781118548387; Hsu YY, 2003, J AM VET MED ASSOC, V223, P1293, DOI 10.2460/javma.2003.223.1293; Ibanez M, 2009, J VET BEHAV, V4, P223, DOI 10.1016/j.jveb.2009.04.001; Irion DN, 2003, J HERED, V94, P81, DOI 10.1093/jhered/esg004; Jagoe A, 1996, APPL ANIM BEHAV SCI, V47, P31, DOI 10.1016/0168-1591(95)01008-4; Jokinen TS, 2015, J VET INTERN MED, V29, P1081, DOI 10.1111/jvim.12611; Karagiannis CI, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0373-1; Katz MH., 2011, MULTIVARIABLE ANAL P, V3 ed, DOI [DOI 10.1017/CBO9780511974175, 10.1017/CBO9780511974175]; King JN, 2000, APPL ANIM BEHAV SCI, V67, P255, DOI 10.1016/S0168-1591(99)00127-6; Kirkwood B. R., 2003, MED STAT; Landsberg G., 2012, BEHAV PROBLEMS DOG C, V3rd ed; Landsberg GM, 2008, J VET BEHAV, V3, P12, DOI 10.1016/j.jveb.2007.09.001; Fagundes ALL, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00017; Lund JD, 1996, PREV VET MED, V28, P33, DOI 10.1016/0167-5877(96)01015-X; McGreevy P, 2017, VET J, V229, P1, DOI 10.1016/j.tvjl.2017.10.015; McGreevy PD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080529; McLean A, 2013, P 9 INT EQUITATION S, P50; Menard SW., 2008, APPL LOGISTIC REGRES, V2nd; Mills DS, 2003, APPL ANIM BEHAV SCI, V81, P265, DOI 10.1016/S0168-1591(02)00286-1; Murray JK, 2015, VET REC, V177, DOI 10.1136/vr.103223; Murray JK, 2010, VET REC, V166, P163, DOI 10.1136/vr.b4712; Myers R., 1990, CLASSICAL AND MODERN; Bosch MN, 2012, CURR ALZHEIMER RES, V9, P298; O'Neill D, 2012, J SMALL ANIM PRACT, V53, P217, DOI 10.1111/j.1748-5827.2011.01190.x; O'Neill DG, 2013, VET J, V198, P638, DOI 10.1016/j.tvjl.2013.09.020; O'Neill DG, 2013, J VET INTERN MED, V27, P814, DOI 10.1111/jvim.12090; O'Neill Dan G, 2018, Canine Genet Epidemiol, V5, P9, DOI 10.1186/s40575-018-0065-9; O'Neill DG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090501; Overall K., 2013, MANUAL CLIN BEHAV ME; Overall K L, 1998, J Am Vet Med Assoc, V212, P1702; Overall KL, 2004, CLIN TECH SMALL AN P, V19, P250, DOI 10.1053/j.ctsap.2004.10.007; Overall KL, 2001, J AM VET MED ASSOC, V219, P467, DOI 10.2460/javma.2001.219.467; OVERALL KL, 1995, J AM VET MED ASSOC, V206, P629; Overall KL, 1997, CLIN BEHAV MED SMALL, V1; Packer RMA, 2018, APPL ANIM BEHAV SCI, V200, P106, DOI 10.1016/j.applanim.2017.11.008; Packer RMA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192182; Packer RMA, 2016, EPILEPSY BEHAV, V55, P62, DOI 10.1016/j.yebeh.2015.11.014; Pegram C, 2021, J SMALL ANIM PRACT, V62, P521, DOI 10.1111/jsap.13325; Pegram C, 2019, J SMALL ANIM PRACT, V60, P723, DOI 10.1111/jsap.13072; Powell L, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87649-2; Radulescu SM, 2020, J VET INTERN MED, V34, P1993, DOI 10.1111/jvim.15869; Ramsey I., 2011, BSAVA SMALL ANIMAL F, V7; Ramsey I., 2014, BSAVA SMALL ANIMAL F, V8; Reisner IR, 2003, VET CLIN N AM-SMALL, V33, P303, DOI 10.1016/S0195-5616(02)00132-8; Roshier AL, 2013, VET REC, V172, DOI 10.1136/vr.101125; Salvin HE, 2010, VET J, V184, P277, DOI 10.1016/j.tvjl.2009.11.007; Scarlett J M, 1999, J Appl Anim Welf Sci, V2, P41, DOI 10.1207/s15327604jaws0201_4; Scott M, 2012, J SMALL ANIM PRACT, V53, P372, DOI 10.1111/j.1748-5827.2012.01231.x; Seksel K, 2001, AUST VET J, V79, P252, DOI 10.1111/j.1751-0813.2001.tb11976.x; Simpson BS, 2007, VET THER, V8, P18; Shihab N, 2011, EPILEPSY BEHAV, V21, P160, DOI 10.1016/j.yebeh.2011.03.018; Simpson BS, 2003, VET CLIN N AM-SMALL, V33, P365, DOI 10.1016/S0195-5616(02)00130-4; Sinn L, 2018, VET CLIN N AM-SMALL, V48, P457, DOI 10.1016/j.cvsm.2017.12.011; Stephens MJ, 2014, VET REC, V175, DOI 10.1136/vr.102431; Stone HR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149403; Storengen LM, 2014, APPL ANIM BEHAV SCI, V159, P82, DOI 10.1016/j.applanim.2014.07.006; Takeuchi Y, 2001, APPL ANIM BEHAV SCI, V70, P297, DOI 10.1016/S0168-1591(00)00156-8; Takeuchi Y, 2000, J AM VET MED ASSOC, V217, P342, DOI 10.2460/javma.2000.217.342; The Kennel Club Limited 2021, BREED STAND; The VeNom Coding Group, 2020 VENOM VET NOM V; VANDERBORG JAM, 1991, APPL ANIM BEHAV SCI, V32, P237, DOI 10.1016/S0168-1591(05)80047-4; Waite MR, 2021, LEARN MOTIV, V74, DOI 10.1016/j.lmot.2021.101726; Watson Fraje, 2020, Vet Rec, V186, P93, DOI 10.1136/vr.105222; Wells DL, 2000, APPL ANIM BEHAV SCI, V69, P55, DOI 10.1016/S0168-1591(00)00118-0; WHITE RAS, 1989, VET REC, V125, P478, DOI 10.1136/vr.125.19.478; Wilsson E, 1997, APPL ANIM BEHAV SCI, V53, P279, DOI 10.1016/S0168-1591(96)01174-4; Winter J, 2018, VET REC, V182, DOI 10.1136/vr.104603; WRIGHT JC, 1987, APPL ANIM BEHAV SCI, V19, P169, DOI 10.1016/0168-1591(87)90213-9; Yu Y, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11020493	100	1	1	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2022	17	1							e0261139	10.1371/journal.pone.0261139	http://dx.doi.org/10.1371/journal.pone.0261139			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3K6TH	35020726	gold, Green Published			2023-01-03	WOS:000834207700013
J	Gal, A; Cuttance, W; Cave, N; Lopez-Villalobos, N; Herndon, A; Giles, J; Burchell, R				Gal, Arnon; Cuttance, Williams; Cave, Nick; Lopez-Villalobos, Nicolas; Herndon, Aaron; Giles, Juila; Burchell, Richard			Less is more? Ultra-low carbohydrate diet and working dogs' performance	PLOS ONE			English	Article							METABOLIC RESPONSES; GLUCOSE; EXERCISE; HYPOGLYCEMIA; GLUCAGON; INSULIN	New Zealand farm working dogs are supreme athletes that are crucial to agriculture in the region. The effects that low or high dietary carbohydrate (CHO) content might have on their interstitial glucose (IG) and activity during work are unknown. The goals of the study were to determine if the concentration of IG and delta-g (a measurement of activity) will be lower in dogs fed an ultra-low CHO high fat diet in comparison to dogs fed a high CHO low fat diet, and to determine if low concentrations of IG are followed by reduced physical activity. We hypothesized that feeding working farm dogs an ultra-low CHO diet would reduce their IG concentrations which in turn would reduce physical activity during work. We prospectively recruited 22 farm dogs from four farms. At each farm, dogs were randomized to one of two diets and had a month of dietary acclimation to their allocated diet. The macronutrient proportions as a percentage of metabolizable energy (%ME) for the high CHO low fat diet (Diet 1) were 23% protein, 25% fat, and 52% CHO, and for the ultra-low CHO high fat diet (Diet 2) 37% protein, 63% fat, and 1% CHO. Following the acclimation period, we continuously monitored IG concentrations with flash glucose monitoring devices, and delta-g using triaxial accelerometers for 96 h. Dogs fed Diet 2 had a lower area under the curve (+/- SE) for IG (AUC (Diet 2) = 497 +/- 4 mmol/L/96h, AUC (Diet 1) = 590 +/- 3 mmol/L/96h; P = 0.002) but a higher area under the curve (+/- SE) for delta-g (AUC (Diet 2) = 104,122 +/- 6,045 delta-g/96h, AUC (Diet 1) = 80,904 +/- 4,950 delta-g/96h; P< 0.001). Interstitial glucose concentrations increased as the activity level increased (P < 0.001) and were lower for Diet 2 within each activity level (P < 0.001). The overall incidence of low IG readings (< 3.5 mmol/L) was 119/3810 (3.12%), of which 110 (92.4%) readings occurred in the Diet 2 group (P = 0.001). In the Diet 2 group, 99/110 (90%) of the low IG events occurred during the resting period (19:00-06:00). We conclude that feeding Diet 2 (ultra-low CHO high fat diet) to working farm dogs was associated with increased delta-g despite decreased IG concentrations. Interstitial glucose concentrations were positively associated with dogs' activity levels independent of diet. Lastly, events of low IG occurred at a low incidence and were predominantly seen between 19:00-06:00 in dogs fed the ultra-low CHO high fat diet.	[Gal, Arnon] Univ Illinois, Coll Vet Med, Dept Vet Clin Med, Urbana, IL 61801 USA; [Cuttance, Williams] VetEnt Te Kuiti, Hamilton, New Zealand; [Cave, Nick] Massey Univ, Sch Vet Sci, Palmerston North, New Zealand; [Lopez-Villalobos, Nicolas] Massey Univ, Sch Agr & Environm, Palmerston North, New Zealand; [Herndon, Aaron] Univ Queensland, Sch Vet Sci, Gatton, Qld, Australia; [Giles, Juila] Totally Vets, Feilding, New Zealand; [Burchell, Richard] North Coast Vet Specialist & Referral Ctr, Sunshine Coast, Qld, Australia	University of Illinois System; University of Illinois Urbana-Champaign; Massey University; Massey University; University of Queensland	Gal, A (corresponding author), Univ Illinois, Coll Vet Med, Dept Vet Clin Med, Urbana, IL 61801 USA.	agal2@illinois.edu	Burchell, Richard/Q-9453-2019	Burchell, Richard/0000-0002-8527-9308; Gal`, Arnon/0000-0002-6449-2812	Working Dog Centre, Massey University, New Zealand	Working Dog Centre, Massey University, New Zealand	AG received funding for this study from the Working Dog Centre, Massey University, New Zealand (http://workingdogs.massey.ac.nz/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AHMED M, 1976, DIABETOLOGIA, V12, P61, DOI 10.1007/BF01221966; Albright JD, 2017, PEERJ, V5, DOI 10.7717/peerj.3659; Bermingham EN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109681; Butler D., 2009, ASREML USER GUIDE RE; Corradini S, 2016, J VET INTERN MED, V30, P983, DOI 10.1111/jvim.14355; Dalton C., 2013, FARM DOGS ARA THE EN; Del Baldo F, 2020, J VET INTERN MED, V34, P2296, DOI 10.1111/jvim.15930; FELIG P, 1969, ARCH INTERN MED, V123, P293, DOI 10.1001/archinte.123.3.293; HAMMEL EP, 1977, AM J CLIN NUTR, V30, P409, DOI 10.1093/ajcn/30.3.409; Jauch-Chara K, 2007, DIABETIC MED, V24, P684, DOI 10.1111/j.1464-5491.2007.02116.x; Jauch-Chara K, 2007, DIABETES, V56, P1938, DOI 10.2337/db07-0044; Jones TW, 1998, NEW ENGL J MED, V338, P1657, DOI 10.1056/NEJM199806043382303; Kaneko JJ, 2008, CLINICAL BIOCHEMISTRY OF DOMESTIC ANIMALS, 6TH EDITION, P45, DOI 10.1016/B978-0-12-370491-7.00003-9; KRONFELD DS, 1977, AM J CLIN NUTR, V30, P419, DOI 10.1093/ajcn/30.3.419; Lee AH, 2021, J ANIM SCI, V99, DOI 10.1093/jas/skab204; Littell RC, 1998, J ANIM SCI, V76, P1216; Malerba E, 2020, J VET INTERN MED, V34, P83, DOI 10.1111/jvim.15657; Mejia S, 2019, VET J, V252, DOI 10.1016/j.tvjl.2019.105355; Murray AJ, 2016, FASEB J, V30, P4021, DOI 10.1096/fj.201600773R; Pencek RR, 2005, CAN J APPL PHYSIOL, V30, P292, DOI 10.1139/h05-122; Pratt-Phillips SE, 2018, COMP EXERC PHYSIOL, V14, P19, DOI 10.3920/CEP170024; Richter EA, 2013, PHYSIOL REV, V93, P993, DOI 10.1152/physrev.00038.2012; Roberts TJ, 1996, J EXP BIOL, V199, P1651; ROMSOS DR, 1981, J NUTR, V111, P678, DOI 10.1093/jn/111.4.678; Rutherford W J, 1990, Nutr Health, V6, P173; Schauf S, 2018, J ANIM PHYSIOL AN N, V102, pE21, DOI 10.1111/jpn.12696; Schnurr Theresia M, 2015, Biochem Biophys Rep, V2, P45; Schnurr TM, 2014, INT J BIOCHEM CELL B, V55, P227, DOI 10.1016/j.biocel.2014.09.009; Schultes Bernd, 2007, PLoS Med, V4, pe69, DOI 10.1371/journal.pmed.0040069; Serisier S, 2008, BRIT J NUTR, V99, P1208, DOI 10.1017/S0007114507862386; Shea EK, 2021, J VET INTERN MED, V35, P843, DOI 10.1111/jvim.16046; Silva DD, 2021, DOMEST ANIM ENDOCRIN, V74, DOI 10.1016/j.domaniend.2020.106525; Volek JS, 2016, METABOLISM, V65, P100, DOI 10.1016/j.metabol.2015.10.028; WASSERMAN DH, 1995, ANNU REV PHYSIOL, V57, P191; White IMS, 1999, J DAIRY SCI, V82, P632, DOI 10.3168/jds.S0022-0302(99)75277-X	35	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2021	16	12							e0261506	10.1371/journal.pone.0261506	http://dx.doi.org/10.1371/journal.pone.0261506			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ1OP	34941910	gold, Green Published			2023-01-03	WOS:000755252200047
J	Nagano, H; Shin, JH; Morishita, T; Takada, D; Kunisawa, S; Fushimi, K; Imanaka, Y				Nagano, Hiroyuki; Shin, Jung-Ho; Morishita, Tetsuji; Takada, Daisuke; Kunisawa, Susumu; Fushimi, Kiyohide; Imanaka, Yuichi			Hospitalization for ischemic stroke was affected more in independent cases than in dependent cases during the COVID-19 pandemic: An interrupted time series analysis	PLOS ONE			English	Article							CARE; POPULATION; MANAGEMENT	Background The pandemic of the coronavirus disease 2019 (COVID-19) has affected health care systems globally. The aim of our study is to assess the impact of the COVID-19 pandemic on the number of hospital admissions for ischemic stroke by severity in Japan. Methods We analysed administrative (Diagnosis Procedure Combination-DPC) data for cases of inpatients aged 18 years and older who were diagnosed with ischemic stroke and admitted during the period April 1 2018 to June 27 2020. Levels of change of the weekly number of inpatient cases with ischemic stroke diagnosis after the declaration of state of emergency were assessed using interrupted time-series (ITS) analysis. The numbers of patients with various characteristics and treatment approaches were compared. We also performed an ITS analysis for each group ("independent" or "dependent") divided based on components of activities of daily living (ADL) and level of consciousness at hospital admission. Results A total of 170,294 cases in 567 hospitals were included. The ITS analysis showed a significant decrease in the weekly number of ischemic stroke cases hospitalized (estimated decrease: -156 cases; 95% confidence interval (CI): -209 to -104), which corresponds to -10.4% (95% CI: -13.6 to -7.1). The proportion of decline in the independent group (-21.3%; 95% CI: -26.0 to -16.2) was larger than that in the dependent group (-8.6%; 95% CI: -11.7 to -5.4). Conclusions Our results show a marked reduction in hospital admissions due to ischemic stroke after the declaration of the state of emergency for the COVID-19 pandemic. The independent cases were affected more in proportion than dependent cases.	[Nagano, Hiroyuki; Shin, Jung-Ho; Morishita, Tetsuji; Takada, Daisuke; Kunisawa, Susumu; Imanaka, Yuichi] Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Kyoto, Japan; [Fushimi, Kiyohide] Tokyo Med & Dent Univ, Grad Sch Med, Dept Hlth Policy & Informat, Bunkyo Ku, Tokyo, Japan	Kyoto University; Tokyo Medical & Dental University (TMDU)	Imanaka, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Kyoto, Japan.	imanaka-y@umin.net	KUNISAWA, Susumu/HCH-1094-2022; Yuichi, Imanaka/GYR-2098-2022; SHIN, Jung-ho/HCH-1481-2022	Yuichi, Imanaka/0000-0003-4613-2159; 				Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098; Campbell BCV, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0118-8; Diegoli H, 2020, STROKE, V51, P2315, DOI 10.1161/STROKEAHA.120.030481; Hammad TA, 2021, CATHETER CARDIO INTE, V97, P208, DOI 10.1002/ccd.28997; Handschu R, 2003, STROKE, V34, P1005, DOI 10.1161/01.STR.0000063366.98459.1F; Hoyer C, 2020, STROKE, V51, P2224, DOI 10.1161/STROKEAHA.120.030395; Katan M, 2018, SEMIN NEUROL, V38, P208, DOI 10.1055/s-0038-1649503; Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5; Ministry of Health Labor and Welfare in Japan, 2021, REP STUD GROUP DEV D; Ministry of Health Labour and Welfare., 2018, DISTR MED SUPPL EM R; Ministry of Health Labour and Welfare, 2018, REP SURV DISCH PAT S; Nogueira RG, 2021, INT J STROKE, V16, P573, DOI 10.1177/1747493021991652; Petty GW, 1998, NEUROLOGY, V50, P208, DOI 10.1212/WNL.50.1.208; Powers WJ, 2020, NEW ENGL J MED, V383, P252, DOI 10.1056/NEJMcp1917030; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Prasad K, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k5130; Prime Minister of Japan and His Cabinet, DECL STAT EM RESP NO; Rosenbaum L, 2020, NEW ENGL J MED, V382, P2368, DOI 10.1056/NEJMms2009984; Rudilosso S, 2020, STROKE, V51, P1991, DOI 10.1161/STROKEAHA.120.030329; Shin JH, 2020, J CLIN EPIDEMIOL, V126, P141, DOI 10.1016/j.jclinepi.2020.06.011; Takashima N, 2017, CIRC J, V81, P1636, DOI 10.1253/circj.CJ-17-0177; Zhao J, 2020, STROKE, V51, P1996, DOI 10.1161/STROKEAHA.120.030225; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	23	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2021	16	12							e0261587	10.1371/journal.pone.0261587	http://dx.doi.org/10.1371/journal.pone.0261587			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ0LO	34919571	Green Published, gold			2023-01-03	WOS:000755175100051
J	Glei, DA; Weinstein, M				Glei, Dana A.; Weinstein, Maxine			Disadvantaged Americans are suffering the brunt of rising pain and physical limitations	PLOS ONE			English	Article							SOCIOECONOMIC-STATUS; HEALTH RESEARCH; BACK-PAIN; TRENDS; DISABILITY; DISPARITIES; PATHWAY	Using data from three national surveys of US adults (one cohort and two cross-sectional studies, covering the period from the mid-1990s to the mid-2010s), we quantify the degree to which disparities by socioeconomic status (SES) in self-reported pain and physical limitations widened and explore whether they widened more in midlife than in later life. Unlike most prior studies that use proxy measures of SES (e.g., education), we use a multidimensional measure of SES that enables us to evaluate changes over time in each outcome for fixed percentiles of the population, thereby avoiding the problem of lagged selection bias. Results across multiple datasets demonstrate that socioeconomic disparities in pain and physical limitations consistently widened since the late 1990s, and if anything, widened even more in midlife than in late life (above 75). For those aged 50-74, the SES disparities in most outcomes widened by more than 50% and in some cases, the SES gap more than doubled. In contrast, the magnitude of SES widening was much smaller above age 75 and, in the vast majority of cases, not significant. Pain prevalence increased at all levels of SES, but disadvantaged Americans suffered the largest increases. Physical function deteriorated for those with low SES, but there was little change and perhaps improvement among the most advantaged Americans. At the 10th percentile of SES, the predicted percentage with a physical limitation at age 50 increased by 6-10 points between the late-1990s and the 2010s, whereas at the 90th percentile of SES, there was no change in two surveys and in the third survey, the corresponding percentage declined from 31% in 1996-99 to 22% in 2016-18. The worst-off Americans are being left behind in a sea of pain and physical infirmity, which may have dire consequences for their quality of life and for society as a whole (e.g., lost productivity, public costs).	[Glei, Dana A.; Weinstein, Maxine] Georgetown Univ, Ctr Populat & Hlth, Washington, DC 20057 USA	Georgetown University	Glei, DA (corresponding author), Georgetown Univ, Ctr Populat & Hlth, Washington, DC 20057 USA.	dag77@georgetown.edu		Glei, Dana/0000-0002-2865-9355	National Institute on Aging [P01 AG020166, U19AG051426]; Graduate School of Arts and Sciences, Georgetown University	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Graduate School of Arts and Sciences, Georgetown University	This work was supported by the National Institute on Aging [https://www.nia.nih.gov/, grant numbers P01 AG020166 and U19AG051426 to Carol Ryff (PI of the MIDUS project)] and the Graduate School of Arts and Sciences, Georgetown University (https://grad.georgetown.edu/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrews JS, 2013, J AM GERIATR SOC, V61, P583, DOI 10.1111/jgs.12172; Azevedo LF, 2012, J PAIN, V13, P773, DOI 10.1016/j.jpain.2012.05.012; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Brim OG, 2016, TECHNICAL REPORT MET; Case A, 2020, P NATL ACAD SCI USA, V117, P24785, DOI 10.1073/pnas.2012350117; Coe C., 2016, MIDLIFE US MIDUS REF, DOI 10.3886/ICPSR36532.v2; Covinsky KE, 2009, J AM GERIATR SOC, V57, P1556, DOI 10.1111/j.1532-5415.2009.02388.x; Cutler DM, 2020, W27974 NAT BUR EC RE; Di Iorio A, 2007, SPINE, V32, pE809, DOI 10.1097/BRS.0b013e31815cd422; Dowd JB, 2014, INT J EPIDEMIOL, V43, P983, DOI 10.1093/ije/dyu120; Edmond SL, 2003, J AM GERIATR SOC, V51, P1702, DOI 10.1046/j.1532-5415.2003.51553.x; Freedman VA, 2013, DEMOGRAPHY, V50, P661, DOI 10.1007/s13524-012-0167-z; Glei DA, 2022, J AGING HEALTH, V34, P78, DOI 10.1177/08982643211028121; Glei DA, 2020, SOC SCI MED, V246, DOI 10.1016/j.socscimed.2020.112789; Glei DA, 2019, J AGING HEALTH, V31, P1067, DOI 10.1177/0898264318759378; Harris KM, 2021, JAMA-J AM MED ASSOC, V325, P2045, DOI 10.1001/jama.2021.4073; Iezzoni LI, 2014, DISABIL HEALTH J, V7, P402, DOI 10.1016/j.dhjo.2014.05.007; Institute for Social Research, 2019, HTLH RET STUD 2018 C; Institute of Medicine, 2011, REL AM BLUEPR TRANS, DOI [10.17226/13172, DOI 10.17226/13172]; Leveille SG, 2007, PAIN, V128, P69, DOI 10.1016/j.pain.2006.08.031; Li Z., 2018, R45419, P21; Ljungvall A, 2012, SOC SCI MED, V75, P109, DOI 10.1016/j.socscimed.2012.03.003; Maestas N, 2020, P NATL ACAD SCI USA, V117, P26559, DOI 10.1073/pnas.2018650117; Martin LG, 2014, DISABIL HEALTH J, V7, pS4, DOI 10.1016/j.dhjo.2013.06.007; Morden NE, 2014, MED CARE, V52, P852, DOI 10.1097/MLR.0000000000000183; National Academies of Sciences Engineering and Medicine 2021, 2021, HIGH RIS MORT RAT WO, DOI [10.17226/25976, DOI 10.17226/25976]; National Center for Health Statistics, 2018, HLTH US 2018, P65; National Center for Health Statistics, 2019, NAT HLTH INT SURV; Oakes JM, 2003, SOC SCI MED, V56, P769, DOI 10.1016/S0277-9536(02)00073-4; Oakes M., 2020, E SOURCE BEHAV SOCIA; Ogden Cynthia L, 2010, NCHS Data Brief, P1; Reid MC, 2005, J GERONTOL A-BIOL, V60, P793, DOI 10.1093/gerona/60.6.793; Schoeni RF, 2005, AM J PUBLIC HEALTH, V95, P2065, DOI 10.2105/AJPH.2004.048744; Scudds RJ, 2001, DISABIL REHABIL, V23, P654, DOI 10.1080/09638280110043942; Seeman TE, 2010, AM J PUBLIC HEALTH, V100, P100, DOI 10.2105/AJPH.2008.157388; StataCorp, 2019, STAT REL 16 STAT SOF; Stokes AC, 2020, SSM-POPUL HLTH, V12, DOI 10.1016/j.ssmph.2020.100644; University of California Berkeley (USA) and Max Planck Institute for Demographic Research (Germany), 2021, HUMAN MORTALITY DATA; Yu Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167193; Zajacova A, 2021, DEMOGRAPHY, V58, P711, DOI 10.1215/00703370-8977691; Zajacova A, 2017, BIODEMOGR SOC BIOL, V63, P21, DOI 10.1080/19485565.2016.1263150; Zimmer Z, 2020, J GERONTOL B-PSYCHOL, V75, P436, DOI 10.1093/geronb/gbx162	43	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2021	16	12							e0261375	10.1371/journal.pone.0261375	http://dx.doi.org/10.1371/journal.pone.0261375			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8LQ	34882731	Green Published, gold			2023-01-03	WOS:000755037200067
J	Salson, C; Majer, C; Pautier, P; Gouy, S; Morice, P				Salson, Claire; Majer, Chaef; Pautier, Patricia; Gouy, Sebastien; Morice, Philippe			Unexplained uterine atrophy following neoadjuvant chemotherapy in fertility sparing management of cervical cancer	LANCET			English	Editorial Material									[Salson, Claire; Gouy, Sebastien; Morice, Philippe] Inst Gustave Roussy, Dept Surg, Canc Campus, F-94805 Villejuif, France; [Majer, Chaef] Inst Gustave Roussy, Dept Imaging, Canc Campus, Villejuif, France; [Pautier, Patricia] Inst Gustave Roussy, Dept Med Oncol, Canc Campus, Villejuif, France; [Morice, Philippe] Univ Paris Saclay, Lnserm U 1030, Le Kremlin Bicetre, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Morice, P (corresponding author), Inst Gustave Roussy, Dept Surg, Canc Campus, F-94805 Villejuif, France.	philippe.morice@gustaveroussy.fr							0	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	2021	398	10315					E17	E17						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD7PT	34838181				2023-01-03	WOS:000722897200001
J	Burtscher, D; Van den Bergh, R; Nasim, M; Mahama, G; Au, S; Williams, A; Sattar, A; Penfold, S; Van Overloop, C; Bajis, S				Burtscher, Doris; Van den Bergh, Rafael; Nasim, Masood; Mahama, Gbane; Au, Sokhieng; Williams, Anita; Sattar, Abdul; Penfold, Suzanne; Van Overloop, Catherine; Bajis, Sahar			'They eat it like sweets': A mixed methods study of antibiotic perceptions and their use among patients, prescribers and pharmacists in a district hospital in Kabul, Afghanistan	PLOS ONE			English	Article							HEALTH-SEEKING BEHAVIOR; SELF-MEDICATION; DOCTORS PERCEPTIONS; RESISTANCE; ABUSE; PRESCRIPTION; EXPECTATIONS; PREVALENCE; INFECTION; COUNTRIES	Background Antibiotic resistance is a growing public health threat. In Afghanistan, high levels of indiscriminate antibiotic use exist, and healthcare programmes are not informed by understanding of local attitudes towards rational antibiotic use. Medecins Sans Frontieres is an international non-governmental organization providing healthcare services to the Ahmad Shah Baba (ASB) District Hospital in Kabul, Afghanistan, since 2009. This mixed-methods study aimed to explore the perceptions and attitudes toward antibiotics among patients, prescribers, and pharmacists in the ASB District hospital outpatient department. Methods and findings Knowledge of antibiotics including their purpose and function, how and why they are used, and drivers for choice of antibiotic was examined at patient, prescriber, and provider-level. The first phase of the study, an exploratory qualitative component using an interpretative approach, was used to inform the second phase, a structured survey. Thirty-six interviews were conducted with 39 participants (21 patients or caretakers and 18 hospital health workers). Three hundred and fifty-one (351) patients and caretakers completed the second phase, the structured survey. This study found that poor knowledge of antibiotics and antibiotic resistance is a driving factor for inappropriate use of antibiotics. Participant perceptions of living in a polluted environment drove the high demand and perceived 'need' for antibiotics: patients, doctors and pharmacists alike consider dirty and dusty living conditions as causes of 'disease' in the body, requiring antibiotics to 'clean' and 'strengthen' it. Conclusions Findings highlight the need for strategies to improve awareness and knowledge of the general public, improve practice of doctors and pharmacists, regulate antibiotic dispensing in private pharmacies, and implement antibiotic stewardship in hospitals.	[Burtscher, Doris] Medecins Sans Frontieres, Vienna Evaluat Unit, Vienna, Austria; [Van den Bergh, Rafael; Mahama, Gbane; Au, Sokhieng; Van Overloop, Catherine] Medecins Sans Frontieres, Operat Ctr Brussels, Brussels, Belgium; [Nasim, Masood] Medecins Sans Frontieres Afghanistan, Kabul, Afghanistan; [Williams, Anita] Medecins Sans Frontieres, Operat Res LuxOR Unit, Luxembourg, Luxembourg; [Williams, Anita] Medecins Sans Frontieres, Middle East Med Unit MEMU, Beirut, Lebanon; [Sattar, Abdul] Minist Publ Hlth, Ahmad Shah Baba Hosp, Kabul, Afghanistan; [Bajis, Sahar] UNSW Sydney, Kirby Inst, Sydney, NSW, Australia	Doctors Without Borders; Doctors Without Borders; Doctors Without Borders; University of New South Wales Sydney; Kirby Institute	Burtscher, D (corresponding author), Medecins Sans Frontieres, Vienna Evaluat Unit, Vienna, Austria.	doris.burtscher@vienna.msf.org		Van den Bergh, Rafael/0000-0001-6277-8713; Williams, Anita/0000-0002-5295-8451				Adhikari B, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-005829; Afghanistan Ministry of Public Health, 2017, AFGH NAT ACT PLAN AM; Al-Azzam Sayer I., 2007, International Journal of Occupational Medicine and Environmental Health, V20, P373, DOI 10.2478/v10001-007-0038-9; Al-Faham Z, 2011, J INFECT DEV COUNTR, V5, P396, DOI 10.3855/jidc.1248; Auta A, 2019, J INFECTION, V78, P8, DOI 10.1016/j.jinf.2018.07.001; Ayukekbong JA, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-017-0208-x; Baps S, 2014, PUBLIC HEALTH ACTION, V4, P259, DOI 10.5588/pha.14.0068; Barker AK, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4261-4; Beckerleg S, 1999, SOC SCI MED, V49, P1489, DOI 10.1016/S0277-9536(99)00212-9; Bi P, 2000, SOC SCI MED, V50, P1445, DOI 10.1016/S0277-9536(99)00304-4; Britten N, 1997, BRIT MED J, V315, P1506, DOI 10.1136/bmj.315.7121.1506; Calhoun JH, 2008, CLIN ORTHOP RELAT R, V466, P1356, DOI 10.1007/s11999-008-0212-9; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; Currie J, 2011, J HEALTH ECON, V30, P933, DOI 10.1016/j.jhealeco.2011.05.009; Davis ME, 2017, ANTIBIOTICS-BASEL, V6, DOI 10.3390/antibiotics6040023; Ekambi GAE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212875; Elmasry AAG, 2013, EGYPT J CHEST DIS TU, V62, P189, DOI 10.1016/j.ejcdt.2013.02.010; Geertz Clifford., 1973, INTERPRETATION CULTU; Green J., 2004, QUALITATIVE METHODS; Green T., 2009, AFGHANISTAN MED USE; Hancock B., 1998, INTRO QUALITATIVE RE; Hawkings NJ, 2007, J ANTIMICROB CHEMOTH, V59, P1155, DOI 10.1093/jac/dkm103; Horvat OJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180799; Hulscher MEJL, 2010, INT J MED MICROBIOL, V300, P351, DOI 10.1016/j.ijmm.2010.04.003; IACG, 2019, REP SECR UN; Kardas P, 2005, INT J ANTIMICROB AG, V26, P106, DOI 10.1016/j.ijantimicag.2005.04.017; Kotwani A, 2012, J CLIN PHARM THER, V37, P308, DOI 10.1111/j.1365-2710.2011.01293.x; Kristiansson C, 2008, TROP MED INT HEALTH, V13, P434, DOI 10.1111/j.1365-3156.2008.02019.x; Kumar S, 2003, BMJ-BRIT MED J, V326, P138, DOI 10.1136/bmj.326.7381.138; MacKian S, 2004, HEALTH POLICY PLANN, V19, P137, DOI 10.1093/heapol/czh017; Mangione-Smith R, 1999, PEDIATRICS, V103, P711, DOI 10.1542/peds.103.4.711; Mayring P., 2010, HDB QUALITATIVE FORS, DOI DOI 10.1007/978-3-531-92052-8_42; Mboya EA, 2018, PAN AFR MED J, V31, DOI 10.11604/pamj.2018.31.165.15991; Monaghan K, 2005, ENVIRON HEALTH-GLOB, DOI [10.3316/INFORMIT.203900011691648, DOI 10.3316/INFORMIT.203900011691648]; Morikawa MJ, 2005, INT J ANTIMICROB AG, V25, P182, DOI 10.1016/j.ijantimicag.2004.11.002; Mousavi SH, 2018, EUR J INTERN MED, V55, pE13, DOI 10.1016/j.ejim.2018.06.013; Nair M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219002; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084177; Negarandeh R, 2021, J PHARM HEALTH SERV, V12, P271, DOI 10.1093/jphsr/rmaa015; Nepal G, 2018, CUREUS, V10, DOI 10.7759/cureus.2428; Hoa NQ, 2011, T ROY SOC TROP MED H, V105, P628, DOI 10.1016/j.trstmh.2011.07.015; Norris P, 2013, ANTIBIOTICS-BASEL, V2, P465, DOI 10.3390/antibiotics2040465; O'Neill J., 2016, Tackling drug-resistant infections globally: final report and recommendations; O'Reilly M, 2013, QUAL RES, V13, P190, DOI 10.1177/1468794112446106; Okeke IN, 2005, LANCET INFECT DIS, V5, P481, DOI 10.1016/S1473-3099(05)70189-4; Okumura J, 2002, SOC SCI MED, V54, P1875, DOI 10.1016/S0277-9536(01)00155-1; Om C, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-017-0187-y; Parimi Neeta, 2004, BMC Fam Pract, V5, P28, DOI 10.1186/1471-2296-5-28; Pechere JC, 2001, CLIN INFECT DIS, V33, pS170, DOI 10.1086/321844; Radyowijati A, 2003, SOC SCI MED, V57, P733, DOI 10.1016/S0277-9536(02)00422-7; Reeler AV, 2000, B WORLD HEALTH ORGAN, V78, P135; Roien R, 2022, EXPERT REV ANTI-INFE, V20, P315, DOI 10.1080/14787210.2021.1951229; Sutter DE, 2011, INFECT CONT HOSP EP, V32, P854, DOI 10.1086/661284; vanderGeest S, 1996, ANNU REV ANTHROPOL, V25, P153, DOI 10.1146/annurev.anthro.25.1.153; Vuckovic N, 1997, SOC SCI MED, V44, P1285, DOI 10.1016/S0277-9536(96)00257-2; Who, 2015, GUID START ANT THER; Zapor MJ, 2008, INFECT CONT HOSP EP, V29, P661, DOI 10.1086/588702	58	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2021	16	11							e0260096	10.1371/journal.pone.0260096	http://dx.doi.org/10.1371/journal.pone.0260096			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ2TX	34797865	Green Published, gold			2023-01-03	WOS:000755334700031
J	Cader, MZ; Kaser, A				Cader, M. Zaeem; Kaser, Arthur			Finding the right target for drug-resistant inflammatory bowel disease	NATURE MEDICINE			English	Editorial Material							MAINTENANCE THERAPY; INDUCTION; VEDOLIZUMAB	A translational study reveals a role for interleukin-1-fibroblast-neutrophil signaling in drug-resistant inflammatory bowel disease, opening a potential path to targeted treatment.	[Kaser, Arthur] Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis, Jeffrey Cheah Biomed Ctr, Cambridge, England; Univ Cambridge, Dept Med, Cambridge, England	University of Cambridge; University of Cambridge	Kaser, A (corresponding author), Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis, Jeffrey Cheah Biomed Ctr, Cambridge, England.	ak729@cam.ac.uk						Bersudsky M, 2014, GUT, V63, P598, DOI 10.1136/gutjnl-2012-303329; Buechler MB, 2021, NATURE, V593, P575, DOI 10.1038/s41586-021-03549-5; D'Haens GR, 2021, GUT, V70, P1396, DOI 10.1136/gutjnl-2019-320022; Feagan BG, 2016, NEW ENGL J MED, V375, P1946, DOI 10.1056/NEJMoa1602773; Feagan BG, 2013, NEW ENGL J MED, V369, P699, DOI 10.1056/NEJMoa1215734; Friedrich M, NAT MED, DOI [10.1038/s41591-021-01520-5(2021), DOI 10.1038/S41591-021-01520-5(2021)]; Kinchen J, 2018, CELL, V175, P372, DOI 10.1016/j.cell.2018.08.067; Sandborn WJ, 2017, NEW ENGL J MED, V376, P1723, DOI 10.1056/NEJMoa1606910; Sandborn WJ, 2013, NEW ENGL J MED, V369, P711, DOI 10.1056/NEJMoa1215739; Thomas MG, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023765; West NR, 2017, NAT MED, V23, P579, DOI 10.1038/nm.4307; Zhou L, 2019, NATURE, V568, P405, DOI 10.1038/s41586-019-1082-x	12	0	0	4	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1870	1871		10.1038/s41591-021-01551-y	http://dx.doi.org/10.1038/s41591-021-01551-y		NOV 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34750554				2023-01-03	WOS:000715714300001
J	Quincho-Lopez, A; Benites-Ibarra, CA; Hilario-Gomez, MM; Quijano-Escate, R; Taype-Rondan, A				Quincho-Lopez, Alvaro; Benites-Ibarra, Christeam A.; Hilario-Gomez, Maryori M.; Quijano-Escate, Renatta; Taype-Rondan, Alvaro			Self-medication practices to prevent or manage COVID-19: A systematic review	PLOS ONE			English	Review							PREVALENCE; CARE; AZITHROMYCIN; POPULATION; COUNTRIES; STANDARD	Background Previous studies have assessed the prevalence and characteristics of self-medication in COVID-19. However, no systematic review has summarized their findings. Objective We conducted a systematic review to assess the prevalence of self-medication to prevent or manage COVID-19. Methods We used different keywords and searched studies published in PubMed, Scopus, Web of Science, Embase, two preprint repositories, Google, and Google Scholar. We included studies that reported original data and assessed self-medication to prevent or manage COVID-19. The risk of bias was assessed using the Newcastle-Ottawa Scale (NOS) modified for cross-sectional studies. Results We identified eight studies, all studies were cross-sectional, and only one detailed the question used to assess self-medication. The recall period was heterogeneous across studies. Of the eight studies, seven assessed self-medication without focusing on a specific symptom: four performed in the general population (self-medication prevalence ranged between <4% to 88.3%) and three in specific populations (range: 33.9% to 51.3%). In these seven studies, the most used medications varied widely, including antibiotics, chloroquine or hydroxychloroquine, acetaminophen, vitamins or supplements, ivermectin, and ibuprofen. The last study only assessed self-medication for fever due to COVID-19. Most studies had a risk of bias in the "representativeness of the sample" and "assessment of outcome" items of the NOS. Conclusions Studies that assessed self-medication for COVID-19 found heterogeneous results regarding self-medication prevalence and medications used. More well-designed and adequately reported studies are warranted to assess this topic.	[Quincho-Lopez, Alvaro; Hilario-Gomez, Maryori M.] Univ Nacl Mayor San Marcos, Soc Cient San Fernando, Lima, Peru; [Benites-Ibarra, Christeam A.] Univ Nacl Santa, Soc Cient Estudiantes Med, Nuevo Chimbote, Ancash, Peru; [Benites-Ibarra, Christeam A.] Univ Nacl San Luis Gonzaga, Soc Cient Estudiantes Med Ica, Ica, Peru; [Taype-Rondan, Alvaro] Univ San Ignacio Loyola, Unidad Invest Generac & Sintesis Evidencias Salud, Ica, Peru	Universidad Nacional Mayor de San Marcos; Universidad Nacional San Luis Gonzaga; Universidad San Ignacio de Loyola	Taype-Rondan, A (corresponding author), Univ San Ignacio Loyola, Unidad Invest Generac & Sintesis Evidencias Salud, Ica, Peru.	alvaro.taype.r@gmail.com	Benites-Ibarra, Christeam A./AAY-7465-2021; Quincho-Lopez, Alvaro/AAW-9335-2020	Benites-Ibarra, Christeam A./0000-0002-4213-5048; Quincho-Lopez, Alvaro/0000-0003-3556-0086; Quijano-Escate, Renatta/0000-0002-4428-424X; Hilario Gomez, Maryori Miriam/0000-0003-0315-3902				Andrade C, 2020, INDIAN J PSYCHOL MED, V42, P575, DOI 10.1177/0253717620957496; Azami-Aghdash S, 2015, IRAN J PUBLIC HEALTH, V44, P1580; Bartoszko JJ, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n949; Behzadifar M, 2020, E MEDITERR HEALTH J, V26, P846, DOI 10.26719/emhj.20.052; Bennadi Darshana, 2013, J Basic Clin Pharm, V5, P19, DOI 10.4103/0976-0105.128253; Butler CC, 2021, LANCET, V397, P1063, DOI 10.1016/S0140-6736(21)00461-X; Choi Bernard, 2010, Rev. costarric. salud pública, V19, P106; Dare S., 2021, MEDRXIV20248576V1, DOI [10.1101/2021.01.02.20248576, DOI 10.1101/2021.01.02.20248576]; Quispe-Canari JF, 2021, SAUDI PHARM J, V29, P1, DOI 10.1016/j.jsps.2020.12.001; Furtado RHM, 2020, LANCET, V396, P959, DOI 10.1016/S0140-6736(20)31862-6; Herzog R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-154; Hinks TSC, 2021, LANCET RESP MED, V9, P1130, DOI 10.1016/S2213-2600(21)00263-0; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hughes CM, 2001, DRUG SAFETY, V24, P1027, DOI 10.2165/00002018-200124140-00002; Infectious Diseases Society of America (IDSA), 2021, IDSA GUID TREATM MAN; Jerez-Roig J, 2014, DRUG AGING, V31, P883, DOI 10.1007/s40266-014-0217-x; Joint Statement by the International Pharmaceutical Federation and The World Self-Medication Industry, 1999, RESP SELF MED; Kim MS, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003501; Lam S, 2020, EUR J PHARMACOL, V886, DOI 10.1016/j.ejphar.2020.173451; Lee K, 2009, GLOB INST, P1; Leelavanich D, 2020, RISK MANAG HEALTHC P, V13, P2753, DOI 10.2147/RMHP.S281629; Limaye D., 2017, INT J COMMUNITY MED, V4, P2620, DOI DOI 10.18203/2394-6040.IJCMPH20173192; Lopez-Medina E, 2021, JAMA-J AM MED ASSOC, V325, P1426, DOI 10.1001/jama.2021.3071; Mansuri FMA, 2020, J TAIBAH UNIV MED SC, V15, P278, DOI 10.1016/j.jtumed.2020.06.003; Minan-Tapia A., 2020, ASS FACTORS SELF MED, DOI [10.1590/SciELOPreprints.1225, DOI 10.1590/SCIELOPREPRINTS.1225]; Morgan DJ, 2011, LANCET INFECT DIS, V11, P692, DOI 10.1016/S1473-3099(11)70054-8; Murai IH, 2021, JAMA-J AM MED ASSOC, V325, P1053, DOI 10.1001/jama.2020.26848; Nasir M., 2020, INT J BASIC CLIN PHA, V9, P1325, DOI DOI 10.18203/2319-2003.IJBCP20203522; Ng TSB, 2021, CAN FAM PHYSICIAN, V67, P171, DOI 10.46747/cfp.6703171; Oldenburg CE, 2021, JAMA-J AM MED ASSOC, V326, P490, DOI 10.1001/jama.2021.11517; Onchonga D, 2020, SAUDI PHARM J, V28, P1149, DOI 10.1016/j.jsps.2020.08.003; Rashid M, 2020, CURR CLIN PHARMACOL, V15, P90, DOI 10.2174/1574884714666191122103953; Sadio AJ, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-020-10145-1; Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647; Shehnaz SI, 2014, J ADOLESCENT HEALTH, V55, P467, DOI 10.1016/j.jadohealth.2014.07.001; Sisay M, 2018, BMC PHARMACOL TOXICO, V19, DOI 10.1186/s40360-018-0248-8; Stull DE, 2009, CURR MED RES OPIN, V25, P929, DOI [10.1185/03007990902774765, 10.1185/03007990902774765 ]; Tasnim Samia, 2020, J Prev Med Public Health, V53, P171, DOI 10.3961/jpmph.20.094; Thomas S, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0369; Torres NF, 2019, PUBLIC HEALTH, V168, P92, DOI 10.1016/j.puhe.2018.11.018; Vallejos J, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06348-5; Wegbom AI, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.606801; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; World Health Organization, 2000, REG GUID TEL PROD; World Medical Association, 2017, WMA STAT SELF MED; Yanez J.A., 2021, ENV HLTH MANAGEMENT, P379, DOI DOI 10.1016/B978-0-323-85780-2.00001-9; Zavala-Flores Ernesto, 2020, Acta méd. Peru, V37, P393, DOI 10.35663/amp.2020.373.1277	48	19	19	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2021	16	11							e0259317	10.1371/journal.pone.0259317	http://dx.doi.org/10.1371/journal.pone.0259317			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8OO	34727126	gold, Green Published			2023-01-03	WOS:000755045200023
J	Lalonde, S; Truchetti, G; Otis, C; Beauchamp, G; Troncy, E				Lalonde, Sophie; Truchetti, Geoffrey; Otis, Colombe; Beauchamp, Guy; Troncy, Eric			Management of veterinary anaesthesia and analgesia in small animals: A survey of English-speaking practitioners in Canada	PLOS ONE			English	Article							CONFIDENTIAL INQUIRY; AAHA ANESTHESIA; RESPONSE RATES; GUIDELINES; DOGS; DEATH; CATS; NSAIDS; RISK	Objective To describe how small animal anaesthesia and analgesia is performed in English-speaking Canada, document any variation among practices especially in relation to practice type and veterinarian's experience and compare results to published guidelines. Design Observational study, electronic survey. Sample 126 respondents. Procedure A questionnaire was designed to assess current small animal anaesthesia and analgesia practices in English-speaking Canadian provinces, mainly in Ontario, Alberta and British Columbia. The questionnaire was available through SurveyMonkey (R) and included four parts: demographic information about the veterinarians surveyed, evaluation and management of anaesthetic risk, anaesthesia procedure, monitoring and safety. Year of graduation and type of practice were evaluated as potential risk factors. Exact chi-square tests were used to study the association between risk factors and the association between risk factors and survey responses. For ordinal data, the Mantel-Haenszel test was used instead. Results Response rate over a period of 3 months was 12.4% (126 respondents out of 1 016 invitations). Current anaesthesia and analgesia management failed to meet international guidelines for a sizable number of participants, notably regarding patient evaluation and preparation, safety and monitoring. Nearly one third of the participants still consider analgesia as optional for routine surgeries. Referral centres tend to follow guidelines more accurately and are better equipped than general practices. Conclusions and clinical relevance A proportion of surveyed Canadian English-speaking general practitioners do not follow current small animal anaesthesia and analgesia guidelines, but practitioners working in referral centres are closer to meet these recommendations.	[Lalonde, Sophie; Truchetti, Geoffrey] Ctr Veterinaire Rive Sud, Brossard, PQ, Canada; [Truchetti, Geoffrey] Ctr Veterinaire Laval, Laval, PQ, Canada; [Otis, Colombe; Beauchamp, Guy; Troncy, Eric] Univ Montreal, Fac Vet Med, Grp Rech Pharmacol Anim Quebec GREPAQ, St Hyacinthe, PQ, Canada	Universite de Montreal	Troncy, E (corresponding author), Univ Montreal, Fac Vet Med, Grp Rech Pharmacol Anim Quebec GREPAQ, St Hyacinthe, PQ, Canada.	eric.troncy@umontreal.ca	Troncy, Eric/J-6650-2013	Troncy, Eric/0000-0003-0209-5261	Natural Sciences and Engineering Research Council of Canada [441651-2013, RDCPJ 491953-2016]; MITACS Canada Elevation postdoctoral scholarship [IT11643]; company Dispomed Inc.	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); MITACS Canada Elevation postdoctoral scholarship; company Dispomed Inc.	There was not proprietary interest or funding directly provided for this project. This work was indirectly supported (ETR) by a Discovery grant (#441651-2013, supporting salaries) and a Collaborative Research and Development grant (#RDCPJ 491953-2016 supporting operations and salaries in partnership with ArthroLab Inc.) from the Natural Sciences and Engineering Research Council of Canada. COT is a recipient of a MITACS Canada Elevation postdoctoral scholarship (#IT11643). The authors got support from the company Dispomed Inc., i.e. to deliver the electronic survey to their clients. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberta Veterinary Medical Association, 2019, ALB VET MED ASS PRAC; American College of Veterinary Anesthesia and Analgesia, 2009, GUID POS STAT DOC; Bednarski R.M., 2015, VET ANESTHESIA ANALG, P819; Bednarski R, 2011, J AM ANIM HOSP ASSOC, V47, P377, DOI 10.5326/JAAHA-MS-5846; Brodbelt DC, 2007, BRIT J ANAESTH, V99, P617, DOI 10.1093/bja/aem229; Brodbelt D.C., 2015, LUMB JONESVETERINARY, P11; Brodbelt DC, 2008, VET ANAESTH ANALG, V35, P365, DOI 10.1111/j.1467-2995.2008.00397.x; Canadian Veterinary Medical Association, VET DEM 2020; CARLEY- BAXTER L. R, 2009, SURVEY PRACTICE, V2, P1, DOI DOI 10.29115/SP-2009-0033; Clark WT, 2002, AUST VET J, V80, P37, DOI 10.1111/j.1751-0813.2002.tb12830.x; Clarke K. W., 1990, Journal of the Association of Veterinary Anaesthetists of Great Britain and Ireland, V17, P4; College of Veterinarians of British Columbia, 2019, PROFESSIONAL PRACTIC; College of Veterinarians of Ontario, 2017, MIN STAND VET FAC ON; Cook C, 2000, EDUC PSYCHOL MEAS, V60, P821, DOI 10.1177/00131640021970934; David H, 2013, AAHA AAFP FLUID THER; Drugs.com, 2020, ONS SOL INJ DOGS CAN; Drugs.com, 2020, MET 0 5 INJ CAN; Dyson DH, 1998, J AM ANIM HOSP ASSOC, V34, P325, DOI 10.5326/15473317-34-4-325; Epstein ME, 2015, J FELINE MED SURG, V17, P251, DOI 10.1177/1098612X15572062; Farnworth MJ, 2014, NEW ZEAL VET J, V62, P117, DOI 10.1080/00480169.2013.852447; Gates MC, 2020, VET ANAESTH ANALG, V47, P38, DOI 10.1016/j.vaa.2019.06.008; Grubb T, 2020, J AM ANIM HOSP ASSOC, V56, P59, DOI 10.5326/JAAHA-MS-7055; Hall LW, 2000, VET ANAESTHESIA; Hoehne SN, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00439; Johnson TP, 2012, JAMA-J AM MED ASSOC, V307, P1805, DOI 10.1001/jama.2012.3532; Lascelles BDX, 2005, VET THER, V6, P237; LLC ZS, 2019, RIM; Matthews NS, 2017, JAVMA-J AM VET MED A, V250, P655, DOI 10.2460/javma.250.6.655; Mckelvey D., 2003, VET ANAESTH ANALG; Ochroch EA, 2003, DRUGS, V63, P2709, DOI 10.2165/00003495-200363240-00002; Pandya C., 2020, WHAT IS ACCEPTABLE R; Portier K, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00204; Robertson SA, 2018, J FELINE MED SURG, V20, P602, DOI [10.1177/1098612X18781391, 10.1177/1098612x18781391]; Seymour C, 2007, BSAVA MANUAL CANINE; Simon BT, 2017, J SMALL ANIM PRACT, V58, P543, DOI 10.1111/jsap.12717; Truchetti G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227204; Warne LN, 2018, AUST VET J, V96, P413, DOI 10.1111/avj.12762; WSAVA Global Pain Council, 2015, The Veterinary Nurse, V6, P166	38	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2021	16	9							e0257448	10.1371/journal.pone.0257448	http://dx.doi.org/10.1371/journal.pone.0257448			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2D4JQ	34582482	Green Published, gold			2023-01-03	WOS:000811515800013
J	Li, XH; Li, J; Zhang, P; Deng, HF; Yang, MG; He, HB; Wang, RR				Li, Xuehan; Li, Jun; Zhang, Pei; Deng, Huifei; Yang, Mingan; He, Hongbo; Wang, Rurong			The minimum effective concentration (MEC90) of ropivacaine for ultrasound-guided caudal block in anorectal surgery. A dose finding study	PLOS ONE			English	Article							LOCAL ANALGESIC CONCENTRATION; EPIDURAL-ANESTHESIA; SEX-DIFFERENCES; SACRAL HIATUS; PAIN; AGE; BUPIVACAINE; CHILDREN; VOLUME; SPACE	Background Caudal epidural block (CEB) provides reliable anesthesia for adults undergoing anorectal surgery. Despite the widely utilization, the minimum effective concentration for 90% patients (MEC90) of ropivacaine for CEB remains unknown. Objective To estimate MEC of ropivacaine for CEB in anorectal surgery. Design A prospective dose-finding study using biased coin design up-and-down sequential method. Setting Operating room and postoperative recovery area of Chengdu Shangjin Nanfu Hospital, from October 2019 to January 2020. Patients 50 males and 51 females scheduled for anorectal surgery. Interventions We conducted two independent biased coin design up-and down trials by genders. The concentration of ropivacaine administered to the first patient of male and female were 0.25% with fixed volume of 14ml for male and 12ml for female patients based on our previous study. In case of failure, the concentration was increased by 0.05% in the next subject. Otherwise, the next subject was randomized to a concentration 0.05% less with a probability of 0.11, or the same concentration with a probability of 0.89. Success was defined as complete sensory blockade of perineal area 15 min after the block evidenced by the presence of a lax anal sphincter and pain-free surgery. Main outcome measures The MEC of ropivacaine to achieve a successful CEB in 90%(MEC90) of the patients. Results The MEC90 of ropivacaine for CEB were estimated to be 0.35% (95% CI 0.29 to 0.4%) for male and 0.353% (95%CI 0.22 to 0.4%) for female. By extrapolation to MEC in 99% of subjects (MEC99) and pooled adjacent violators algorithm (PAVA) adjusted responses, it would be optimal to choose 0.4% ropivacaine with a volume of 14ml for male and 12ml for female. Conclusions A concentration of 0.35% ropivacaine with a volume of 14ml provided a successful CEB in 90% of the male patients, while 0.353% ropivacaine with a volume of 12ml provided a successful CEB in 90% of the female patients. A concentration of 0.4% and a volume of 14ml for male and 12 ml for female would be successful in 99% of the patients. Trial registration Chictr.org.cn identifier: No. ChiCTR 1900024315.	[Li, Xuehan; Li, Jun; Zhang, Pei; Deng, Huifei; Wang, Rurong] Sichuan Univ, Dept Anesthesiol, Lab Anesthesia & Intens Care Med, West China Hosp, Chengdu, Sichuan, Peoples R China; [Yang, Mingan] San Diego State Univ, Div Biostat & Epidemiol, Sch Publ Hlth, San Diego, CA 92182 USA; [He, Hongbo] Sichuan Univ, Benign Coloproctol Dis Ctr, West China Hosp, Chengdu, Sichuan, Peoples R China	Sichuan University; California State University System; San Diego State University; Sichuan University	Wang, RR (corresponding author), Sichuan Univ, Dept Anesthesiol, Lab Anesthesia & Intens Care Med, West China Hosp, Chengdu, Sichuan, Peoples R China.	wangrurong@scu.edu.cn		wang, rurong/0000-0002-9213-3104	National Natural Science Foundation of China [81900064]; Science and Technology Support Project of Sichuan Province [2018SZ0113]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Support Project of Sichuan Province	Dr Xuehan Li has no conflict of interest to declare. She received a grant from National Natural Science Foundation of China (Grant No. 81900064) and a grant from Science and Technology Support Project of Sichuan Province (No. 2020YJ0050) for this study. Dr Hongbo He has no conflict of interest to declare. He received a grant from Science and Technology Support Project of Sichuan Province (No. 2018SZ0113) for this study. Dr. Jun Li, Dr Pei Zhang, Dr Huifei Deng, Dr Mingan Yang and Dr Rurong Wang have no conflict of interest to declare and did not receive funds for this study.	Abukawa Y, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0082-0; Aggarwal A, 2009, SURG RADIOL ANAT, V31, P793, DOI 10.1007/s00276-009-0529-4; Ala-Kokko TI, 2000, ACTA ANAESTH SCAND, V44, P1099, DOI 10.1034/j.1399-6576.2000.440911.x; Asghar A, 2013, J CLIN DIAGN RES, V7, P2659, DOI 10.7860/JCDR/2013/6287.3724; Campesi Ilaria, 2012, Handb Exp Pharmacol, P265, DOI 10.1007/978-3-642-30726-3_13; Casati A, 2002, ANESTH ANALG, V94, P987, DOI 10.1097/00000539-200204000-00039; Chen CP, 2010, ARCH PHYS MED REHAB, V91, P358, DOI 10.1016/j.apmr.2009.11.019; Chia YY, 2002, CAN J ANAESTH, V49, P249, DOI 10.1007/BF03020523; Ciccone GK, 1999, BRIT J ANAESTH, V82, P255, DOI 10.1093/bja/82.2.255; Crighton IM, 1997, BRIT J ANAESTH, V78, P391, DOI 10.1093/bja/78.4.391; Da Conceicao MJ, 1998, BRIT J ANAESTH, V80, P507, DOI 10.1093/bja/80.4.507; Deng XM, 2010, ANAESTHESIA, V65, P991, DOI 10.1111/j.1365-2044.2010.06454.x; Fam MD, 2018, J NEUROL SURG PART B, V79, P614, DOI 10.1055/s-0038-1651501; Forestier J, 2017, BRIT J ANAESTH, V119, P972, DOI 10.1093/bja/aex280; Gudaityte Jurate, 2004, Medicina (Kaunas), V40, P101; Higuchi H, 2004, ANESTHESIOLOGY, V101, P451, DOI 10.1097/00000542-200408000-00027; Huang BW, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024912; Ingelmo P, 2009, ANESTH ANALG, V108, P805, DOI 10.1213/ane.0b013e3181935aa5; Ivanova A, 2003, STAT MED, V22, P69, DOI 10.1002/sim.1336; Kao SC, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9217145; Khalil S, 1999, ANESTHESIOLOGY, V91, P1279, DOI 10.1097/00000542-199911000-00018; Lee B, 2017, BRIT J ANAESTH, V118, P781, DOI 10.1093/bja/aex078; Li YH, 2006, ANESTH ANALG, V102, P1847, DOI 10.1213/01.ane.0000215999.60513.da; Li YH, 2010, ANESTH ANALG, V110, P1490, DOI 10.1213/ANE.0b013e3181d6bade; Maurer AJ, 2016, PAIN MANAG, V6, P285, DOI 10.2217/pmt-2015-0002; Nofal WH, 2017, EGYPT J ANAESTH, V33, P67, DOI 10.1016/j.egja.2016.10.008; PARK WY, 1979, ANESTHESIOLOGY, V51, P81, DOI 10.1097/00000542-197907000-00019; Parrish AB, 2018, WORLD J SURG, V42, P1929, DOI 10.1007/s00268-017-4414-8; Robinson ME, 1998, PAIN, V77, P143, DOI 10.1016/S0304-3959(98)00088-8; Sanghvi C., 2020, CAUDAL ANESTHESIA ST; Sekiguchi M, 2004, CLIN J PAIN, V20, P51, DOI 10.1097/00002508-200401000-00010; Senoglu N, 2005, BRIT J ANAESTH, V95, P692, DOI 10.1093/bja/aei236; Siddiqui ZI, 2007, J CLIN ANESTH, V19, P269, DOI 10.1016/j.jclinane.2006.12.004; Simpson D, 2005, DRUGS, V65, P2675, DOI 10.2165/00003495-200565180-00013; Stylianou M, 2003, STAT MED, V22, P535, DOI 10.1002/sim.1351; Stylianou M, 2002, BIOMETRICS, V58, P171, DOI 10.1111/j.0006-341X.2002.00171.x; Wiegele M, 2019, BRIT J ANAESTH, V122, P509, DOI 10.1016/j.bja.2018.11.030; Xuehan Li PZ, 2020, EUR J ANAESTH, V37, P7; Ye F, 2007, J INT MED RES, V35, P307, DOI 10.1177/147323000703500304	39	1	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2021	16	9							e0257283	10.1371/journal.pone.0257283	http://dx.doi.org/10.1371/journal.pone.0257283			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5ZQ	34534232	Green Published, gold			2023-01-03	WOS:000707073300022
J	Kusztrits, I; Marquardt, L; Hugdahl, K; Hirnstein, M				Kusztrits, Isabella; Marquardt, Lynn; Hugdahl, Kenneth; Hirnstein, Marco			Transcranial direct current stimulation (tDCS) enhances internal source monitoring abilities in healthy participants	PLOS ONE			English	Article							HALLUCINATING PATIENTS; AUDITORY HALLUCINATIONS; PREFRONTAL CORTEX; BROCAS AREA; INFORMATION; SPEECH; SCHIZOPHRENIA; METAANALYSIS; MECHANISMS; HANDEDNESS	Source monitoring refers to the ability to identify the origin of a memory, for example, whether you remember saying something or thinking about it, and confusions of these sources have been associated with the experience of auditory verbal hallucinations (AVHs). Both AVHs and source confusions are reported to originate from dysfunctional brain activations in the prefrontal cortex (PFC) and the superior temporal gyrus (STG); specifically, it is assumed that a hypoactive PFC and a hyperactive STG gives rise to AVHs and source confusions. We set out to test this assumption by trying to mimic this hypertemporal/hypofrontal model in healthy individuals with transcranial direct current stimulation (tDCS): the inhibitory cathode was placed over the left PFC and the excitatory anode over the left dorsolateral STG. Participants completed a reality monitoring task (distinguishing between external and internal memory sources) and an internal source monitoring task (distinguishing between two or more internal memory sources) in two separate experiments (offline vs. online tDCS). In the offline experiment (n = 34), both source monitoring tasks were completed after tDCS stimulation, and in the online experiment (n = 27) source monitoring tasks were completed while simultaneously being stimulated with tDCS. We found that internal source monitoring abilities were significantly enhanced during active online tDCS, while reality monitoring abilities were unaffected by stimulation in both experiments. We speculate, based on combining the present findings with previous studies, that there might be different brain areas involved in reality and internal source monitoring. While internal source monitoring seems to involve speech production areas, specifically Broca's area, as suggested in the present study, reality monitoring seems to rely more on the STG and DLPFC, as shown in other studies of the field.	[Kusztrits, Isabella; Marquardt, Lynn; Hugdahl, Kenneth; Hirnstein, Marco] Univ Bergen, Dept Biol & Med Psychol, Bergen, Norway; [Kusztrits, Isabella; Marquardt, Lynn; Hugdahl, Kenneth; Hirnstein, Marco] Univ Bergen, NORMENT Norwegian Ctr Mental Hlth Disorders Res, Bergen, Norway; [Kusztrits, Isabella; Marquardt, Lynn; Hugdahl, Kenneth; Hirnstein, Marco] Haukeland Hosp, Bergen, Norway; [Hugdahl, Kenneth] Haukeland Hosp, Dept Radiol, Bergen, Norway; [Hugdahl, Kenneth] Haukeland Hosp, Div Psychiat, Bergen, Norway	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital	Kusztrits, I (corresponding author), Univ Bergen, Dept Biol & Med Psychol, Bergen, Norway.; Kusztrits, I (corresponding author), Univ Bergen, NORMENT Norwegian Ctr Mental Hlth Disorders Res, Bergen, Norway.; Kusztrits, I (corresponding author), Haukeland Hosp, Bergen, Norway.	isabella_kusztrits@hotmail.com	Hirnstein, Marco/D-2450-2013	Hirnstein, Marco/0000-0002-6291-0929	Bergen Research Foundation [BFS2016REK03]; European Research Council (ERC) [693124]	Bergen Research Foundation; European Research Council (ERC)(European Research Council (ERC)European Commission)	The current research has been funded by the Bergen Research Foundation (grant BFS2016REK03 to MH). The contribution of KH was funded by a grant from the European Research Council (ERC), #693124. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aleman A, 2003, SCHIZOPHR RES, V64, P175, DOI 10.1016/S0920-9964(03)00060-4; Allen P, 2007, BRIT J PSYCHIAT, V190, P162, DOI 10.1192/bjp.bp.106.025700; World Medical Association, 2013, JAMA, V310, P2191, DOI 10.1001/jama.2013.281053; BRADLEY MM, 1994, J BEHAV THER EXP PSY, V25, P49, DOI 10.1016/0005-7916(94)90063-9; Brunelin J, 2006, SCHIZOPHR RES, V81, P41, DOI 10.1016/j.schres.2005.10.009; Brunelin J, 2006, EUR PSYCHIAT, V21, P259, DOI 10.1016/j.eurpsy.2006.01.015; Brunelin J, 2015, BRAIN STIMUL, V8, P1225, DOI 10.1016/j.brs.2015.08.002; Brunelin J, 2012, AM J PSYCHIAT, V169, P719, DOI 10.1176/appi.ajp.2012.11071091; Brunoni AR, 2011, INT J NEUROPSYCHOPH, V14, P1133, DOI 10.1017/S1461145710001690; Buch ER, 2017, CLIN NEUROPHYSIOL, V128, P589, DOI 10.1016/j.clinph.2017.01.004; Burgess PW, 2007, TRENDS COGN SCI, V11, P290, DOI 10.1016/j.tics.2007.05.004; Carey DP, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01128; Chein JM, 2002, PHYSIOL BEHAV, V77, P635, DOI 10.1016/S0031-9384(02)00899-5; Chen CMA, 2011, J COGNITIVE NEUROSCI, V23, P2892, DOI 10.1162/jocn.2010.21589; Dedoncker J, 2016, BRAIN STIMUL, V9, P501, DOI 10.1016/j.brs.2016.04.006; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Flinker A, 2015, P NATL ACAD SCI USA, V112, P2871, DOI 10.1073/pnas.1414491112; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Garrison JR, 2017, CORTEX, V91, P197, DOI 10.1016/j.cortex.2016.11.011; Guevara ER, 2010, P NAACL HLT 2010 6 W; Henquet C, 2005, PSYCHIAT RES, V133, P57, DOI 10.1016/j.psychres.2004.08.009; Hugdahl K, 2015, WORLD J PSYCHIATR, V5, P193, DOI 10.5498/wjp.v5.i2.193; Hugdahl K, 2009, SCAND J PSYCHOL, V50, P553, DOI 10.1111/j.1467-9450.2009.00775.x; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; JOHNSON MK, 1993, PSYCHOL BULL, V114, P3, DOI 10.1037/0033-2909.114.1.3; JOHNSON MK, 1981, PSYCHOL REV, V88, P67, DOI 10.1037/0033-295X.88.1.67; Keefe RSE, 1999, PSYCHOL MED, V29, P903, DOI 10.1017/S0033291799008673; Kompus K, 2011, NEUROPSYCHOLOGIA, V49, P3361, DOI 10.1016/j.neuropsychologia.2011.08.010; LANSKY LM, 1988, NEUROPSYCHOLOGIA, V26, P465, DOI 10.1016/0028-3932(88)90099-1; Marquardt L, 2021, EUR J NEUROSCI, V53, P449, DOI 10.1111/ejn.14932; Martin DM, 2014, EXP BRAIN RES, V232, P3345, DOI 10.1007/s00221-014-4022-x; Maxwell SE, 2017, DESIGNING EXPT ANAL; Mitchell KJ, 2017, CORTEX, V96, P129, DOI 10.1016/j.cortex.2017.07.009; Mitchell KJ, 2009, PSYCHOL BULL, V135, P638, DOI 10.1037/a0015849; Mondino M, 2018, J ECT, V34, P164, DOI 10.1097/YCT.0000000000000525; Mondino M, 2016, NEUROPSYCHOLOGIA, V89, P478, DOI 10.1016/j.neuropsychologia.2016.07.022; Mondino M, 2015, SCHIZOPHR RES, V161, P515, DOI 10.1016/j.schres.2014.10.054; Moseley P, 2018, NEUROPSYCHOLOGIA, V120, P113, DOI 10.1016/j.neuropsychologia.2018.10.001; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Palm U, 2013, BRAIN STIMUL, V6, P690, DOI 10.1016/j.brs.2013.01.005; Rasmussen T, 1977, Ann N Y Acad Sci, V299, P355, DOI 10.1111/j.1749-6632.1977.tb41921.x; Sahin NT, 2009, SCIENCE, V326, P445, DOI 10.1126/science.1174481; Schoemann A. M., 2020, MONTE CARLO POWER AN; Simons JS, 2006, NEUROIMAGE, V32, P696, DOI 10.1016/j.neuroimage.2006.04.209; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Sugimori E, 2014, PSYCHOL SCI, V25, P403, DOI 10.1177/0956797613505776; Wang B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199002; Waters F, 2012, SCHIZOPHRENIA BULL, V38, P741, DOI 10.1093/schbul/sbq144; Zvyagintsev M, 2013, EUR J NEUROSCI, V37, P1421, DOI 10.1111/ejn.12140	51	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2021	16	9							e0257010	10.1371/journal.pone.0257010	http://dx.doi.org/10.1371/journal.pone.0257010			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5YY	34529676	Green Published, gold			2023-01-03	WOS:000707071500025
J	AbdelGhaffar, MM; Omran, D; Elgebaly, A; Bahbah, EI; Afify, S; AlSoda, M; El-Shiekh, M; ElSayed, ES; Shaaban, SS; AbdelHafez, S; Elkelany, K; Eltayar, AA; Ali, OS; Kamal, L; Heiba, AM; El Askary, A; Shousha, HI				AbdelGhaffar, Muhammad M.; Omran, Dalia; Elgebaly, Ahmed; Bahbah, Eshak, I; Afify, Shimaa; AlSoda, Mohamed; El-Shiekh, Mohamed; ElSayed, Enass S.; Shaaban, Soha S.; AbdelHafez, Samah; Elkelany, Khaled; Eltayar, Ayman A.; Ali, Omnia S.; Kamal, Lamiaa; Heiba, Ahmed M.; El Askary, Ahmad; Shousha, Hend Ibrahim			Prediction of mortality in hospitalized Egyptian patients with Coronavirus disease-2019: A multicenter retrospective study	PLOS ONE			English	Article							COVID-19; ANTICOAGULATION	We aimed to assess the epidemiological, clinical, and laboratory characteristics associated with mortality among hospitalized Egyptian patients with COVID-19. A multicenter, retrospective study was conducted on all polymerase chain reaction (PCR)-confirmed COVID-19 cases admitted through the period from April to July 2020. A generalized linear model was reconstructed with covariates based on predictor's statistical significance and clinically relevance. The odds ratio (OR) was calculated by using stepwise logistic regression modeling. A total of 3712 hospitalized patients were included; of them, 900 deaths were recorded (24.2%). Compared to survived patients, non-survived patients were more likely to be older than 60 years (65.7%), males (53.6%) diabetic (37.6%), hypertensive (37.2%), and had chronic renal insufficiency (9%). Non-survived patients were less likely to receive azithromycin (p <0.001), anticoagulants (p <0.001), and steroids (p <0.001). We found that age >= 60 years old (OR = 2.82, 95% CI 2.05-3.86; p <0.0001), diabetes mellitus (OR = 1.58, 95% CI 1.14-2.19; p = 0.006), hypertension (OR = 1.69, 95% CI 1.22-2.36; p = 0.002), chronic renal insufficiency (OR = 3.15, 95% CI 1.84-5.38; p <0.0001), tachycardia (OR = 1.65, 95% CI 1.22-2.23; p <0.001), hypoxemia (OR = 5.69, 95% CI 4.05-7.98; p <0.0001), GCS <13 (OR 515.2, 95% CI 148.5-1786.9; p <0.0001), the use of therapeutic dose of anticoagulation (OR = 0.4, 95% CI 0.22-0.74, p = 0.003) and azithromycin (OR = 0.16, 95% CI 0.09-0.26; p <0.0001) were independent negative predictors of mortality. In conclusion, age >60 years, comorbidities, tachycardia, hypoxemia, and altered consciousness level are independent predictors of mortality among Egyptian hospitalized patients with COVID-19. On the other hand, the use of anticoagulants and azithromycin is associated with reduced mortality.	[AbdelGhaffar, Muhammad M.; AbdelHafez, Samah; Heiba, Ahmed M.] Ahmed Maher Teaching Hosp, Gastroenterol & Infect Dis Dept, Cairo, Egypt; [AbdelGhaffar, Muhammad M.; Omran, Dalia; AlSoda, Mohamed] Gen Org Teaching Hosp & Inst GOTHI, Cairo, Egypt; [Omran, Dalia; Shousha, Hend Ibrahim] Cairo Univ, Fac Med, Endem Med Dept, Cairo, Egypt; [Elgebaly, Ahmed; Bahbah, Eshak, I] Al Azhar Univ, Fac Med, Cairo, Egypt; [Afify, Shimaa] Natl Hepatol & Trop Med Res Inst, Gastroenterol Dept, Cairo, Egypt; [El-Shiekh, Mohamed] Matareya Teaching Hosp, Chest Unit, Cairo, Egypt; [ElSayed, Enass S.] Ahmed Maher Teaching Hosp, Nephrol Dept, Cairo, Egypt; [Shaaban, Soha S.] El Matareya Educ Hosp, Rheumatol Dept, Cairo, Egypt; [Elkelany, Khaled] Shebin Elkom Teaching Hosp, Pediat Dept, Shibin Al Kawm, Egypt; [Eltayar, Ayman A.] Damanhour Teaching Hosp, Intens Care Dept, Damanhour, Egypt; [Ali, Omnia S.] Ahmed Maher Teaching Hosp, Clin & Chem Pathol Dept, Cairo, Egypt; [Kamal, Lamiaa] Sahel Gen Hosp, Clin & Chem Pathol Dept, Cairo, Egypt; [Heiba, Ahmed M.] Natl Res Ctr, Internal Med Dept, Cairo, Egypt; [El Askary, Ahmad] Taif Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Taif, Saudi Arabia	Egyptian Knowledge Bank (EKB); General Organization of Teaching Hospitals & Institutes (GOTHI); Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Al Azhar University; Egyptian Knowledge Bank (EKB); National Hepatology & Tropical Medicine Research Institute (NHTMRI); Egyptian Knowledge Bank (EKB); General Organization of Teaching Hospitals & Institutes (GOTHI); Egyptian Knowledge Bank (EKB); General Organization of Teaching Hospitals & Institutes (GOTHI); Egyptian Knowledge Bank (EKB); Damanhour University; General Organization of Teaching Hospitals & Institutes (GOTHI); Egyptian Knowledge Bank (EKB); General Organization of Teaching Hospitals & Institutes (GOTHI); Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Taif University	Shousha, HI (corresponding author), Cairo Univ, Fac Med, Endem Med Dept, Cairo, Egypt.	hendshousha@yahoo.com	Bahbah, Eshak I/I-4504-2019; heiba, ahmed/GQI-1599-2022; Afify, Shimaa/AAB-6018-2021	Bahbah, Eshak I/0000-0002-6168-9134; Afify, Shimaa/0000-0001-5937-4240; Omran, Dalia/0000-0002-5513-6955; Heiba, Ahmed/0000-0002-5200-5458; Shousha, Hend Ibrahim/0000-0002-0928-4738; Elgebaly, Ahmed/0000-0002-8324-0960	Taif University, Taif, Saudi Arabia [TURSP-2020/82]	Taif University, Taif, Saudi Arabia	The authors acknowledge the support of Taif University Researchers Supporting Project number (TURSP-2020/82), Taif University, Taif, Saudi Arabia.	Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS11, DOI 10.2337/dc10-S011; [Anonymous], 2020, EP UPD MONK MULT OUT; [Anonymous], 2020, US; [Anonymous], 2013, KIDNEY INT SUPPL, V3, P5, DOI [10.1038/kisup.2012.77, DOI 10.1038/KISUP.2012.77]; Boettler T, 2020, JHEP REP, V2, DOI 10.1016/j.jhepr.2020.100169; Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; Chen Y., 2020, PREPRINT, DOI [10.20944/preprints202002.0258.v2, DOI 10.20944/PREPRINTS202002.0258.V2]; Chen YY, 2021, AGEING RES REV, V65, DOI 10.1016/j.arr.2020.101205; Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003; Cuker A., 2020, UPTODATE; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644; Gebhard C, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00304-9; Griesbeck M, 2015, J IMMUNOL, V195, P5327, DOI 10.4049/jimmunol.1501684; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Harrison SL, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003321; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096; Klein S, 2020, J CLIN INVEST, V130, P6141, DOI 10.1172/JCI142004; Kragholm K, 2021, CLIN INFECT DIS, V73, pE4025, DOI 10.1093/cid/ciaa924; Lee K, 2009, GLOB INST, P1; Lim S, 2021, NAT REV ENDOCRINOL, V17, P11, DOI 10.1038/s41574-020-00435-4; McBane RD, 2020, MAYO CLIN PROC, V95, P2467, DOI 10.1016/j.mayocp.2020.08.030; Middleton PM, 2012, AUSTRALAS EMERG NURS, V15, P170, DOI 10.1016/j.aenj.2012.06.002; Ministry of Health and Population, 2020, EG MAN PROT COVID 19; Nasiri MJ, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00459; O'Driscoll M, 2020, NATURE, DOI 10.1038/s41586-020-2918-0; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Pawelec G, 2018, EXP GERONTOL, V105, P4, DOI 10.1016/j.exger.2017.10.024; Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Singh S, 2020, GASTROENTEROLOGY, V159, P768, DOI 10.1053/j.gastro.2020.04.064; Tiwari NR, 2020, J CRIT CARE MED, V6, P217, DOI 10.2478/jccm-2020-0033; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Walker JL, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10427-2; Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xie P, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00189; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Zhang BC, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00157; Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954	45	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2022	17	1							e0262348	10.1371/journal.pone.0262348	http://dx.doi.org/10.1371/journal.pone.0262348			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2I2NI	35015782	Green Published, gold			2023-01-03	WOS:000814820600012
J	Yu, JY; Kim, JS; Hong, CM; Lee, KY; Cho, NJ; Park, S; Gil, HW; Lee, EY				Yu, Jin Young; Kim, Ji Sun; Hong, Chae-Min; Lee, Ka Young; Cho, Nam-Jun; Park, Samel; Gil, Hyo-Wook; Lee, Eun Young			Psychological distress of patients with end-stage kidney disease undergoing dialysis during the 2019 coronavirus disease pandemic: A cross-sectional study in a University Hospital	PLOS ONE			English	Article							DEPRESSION; VALIDATION; ANXIETY; IMPACT	Introduction Previous studies have revealed that the COVID-19 pandemic can cause psychological distress such as depression and anxiety. Patients with chronic kidney disease (CKD) might be more vulnerable to psychological distress due to the COVID-19 pandemic. Its impact could be different according to dialysis modality. The aim of this study was to investigate COVID-19-related psychological stress experienced by end-stage kidney disease (ESKD) patients and identify differences in concerns about COVID-19 between hemodialysis (HD) and peritoneal dialysis (PD) patients. Methods This cross-sectional study included 148 dialysis patients at Soonchunhyang University Cheonan Hospital from August 2020 to September 2020. These patients responded to a questionnaire covering mental health status and COVID-19 related concerns. Symptoms of depression, anxiety, stress, and insomnia were measured using a 9-item Patient Health Questionnaire (PHQ-9), a 7-item Generalized Anxiety Disorder (GAD-7) scale, a 22-item Impact of Event Scale-Revised (IES-R), and a 7-item Insomnia severity Index (ISI), respectively. Outcomes of HD and PD patients were compared by propensity score matching analysis. Results Dialysis patients reported psychological distress including symptoms of depression, anxiety, stress, and insomnia. HD patients showed higher scores for depression (p = 0.018), anxiety(p = 0.005), stress(p<0.001), and insomnia(p = 0.006) than the PD patients. After propensity score matching, HD was associated with depression(p = 0.0131), anxiety(p = 0.0143), and stress(p = 0.000415). Conclusion Dialysis patients showed psychological distress during the COVID-19 pandemic period, with HD patients having more severe symptoms than PD patients.	[Yu, Jin Young; Lee, Ka Young; Cho, Nam-Jun; Park, Samel; Gil, Hyo-Wook; Lee, Eun Young] Soonchunhyang Univ, Cheonan Hosp, Dept Internal Med, Cheonan, South Korea; [Kim, Ji Sun] Soonchunhyang Univ, Cheonan Hosp, Dept Psychiat, Cheonan, South Korea; [Hong, Chae-Min] Soonchunhyang Univ, Coll Med, Dept Med, Cheonan, South Korea; [Lee, Eun Young] Soonchunhyang Univ, Inst Tissue Regenerat, Coll Med, Cheonan, South Korea; [Lee, Eun Young] Soonchunhyang Univ, BK21 Project 4, Coll Med, Cheonan, South Korea	Soonchunhyang University; Soonchunhyang University; Soonchunhyang University; Soonchunhyang University; Soonchunhyang University	Lee, EY (corresponding author), Soonchunhyang Univ, Cheonan Hosp, Dept Internal Med, Cheonan, South Korea.; Lee, EY (corresponding author), Soonchunhyang Univ, Inst Tissue Regenerat, Coll Med, Cheonan, South Korea.; Lee, EY (corresponding author), Soonchunhyang Univ, BK21 Project 4, Coll Med, Cheonan, South Korea.	eylee@sch.ac.kr		Lee, Eun Young/0000-0002-4513-9888	National Research Foundation (NRF) of Korea - Korea government (Ministry of Science and ICT) [2020R1A2C2003438]; Soonchunhyang University Research Fund	National Research Foundation (NRF) of Korea - Korea government (Ministry of Science and ICT); Soonchunhyang University Research Fund	This work was supported by the National Research Foundation (NRF) of Korea grant funded by the Korea government (Ministry of Science and ICT) (2020R1A2C2003438) and Soonchunhyang University Research Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Addis SG, 2021, DIABETES METAB SYND, V15, P129, DOI 10.1016/j.dsx.2020.12.019; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Benedetto U, 2018, EUR J CARDIO-THORAC, V53, P1112, DOI 10.1093/ejcts/ezy167; Bonenkamp AA, 2021, J NEPHROL, V34, P337, DOI 10.1007/s40620-021-01005-1; Covic, 2010, NEPHROL DIAL TRANSPL; Dubey S, 2020, DIABETES METAB SYND, V14, P779, DOI 10.1016/j.dsx.2020.05.035; Gadia P, 2020, J FAM MED PRIM CARE, V9, P4282, DOI 10.4103/jfmpc.jfmpc_840_20; Hedayati SS, 2009, AM J KIDNEY DIS, V54, P741, DOI 10.1053/j.ajkd.2009.05.003; Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954; Izcovich A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241955; Kalender, 2007, INT J CLINPRACT; Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976; Park HC, 2020, KIDNEY RES CLIN PRAC, V39, P145, DOI 10.23876/j.krcp.20.046; Roy CM, 2021, EUR J PUBLIC HEALTH, V31, P634, DOI 10.1093/eurpub/ckab047; Rubin DB, 1996, BIOMETRICS, V52, P249, DOI 10.2307/2533160; Schudy A, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.589973; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Tsai YC, 2012, AM J KIDNEY DIS, V60, P54, DOI 10.1053/j.ajkd.2012.02.325; Valeri AM, 2020, J AM SOC NEPHROL, V31, P1409, DOI 10.1681/ASN.2020040470; Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729; Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689; Wang YL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244630; Weiss Daniel S., 1997, P399; Wong TW, 2005, EUR J EMERG MED, V12, P13, DOI 10.1097/00063110-200502000-00005; Wu TC, 2021, J AFFECT DISORDERS, V281, P91, DOI 10.1016/j.jad.2020.11.117; Yamada T, 2020, INT UROL NEPHROL, V52, P1405, DOI 10.1007/s11255-020-02494-y	27	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2021	16	12							e0260929	10.1371/journal.pone.0260929	http://dx.doi.org/10.1371/journal.pone.0260929			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY3JJ	34860844	Green Published, gold			2023-01-03	WOS:000754686900011
J	Bishop, JA; Javed, HA; El-Bouri, R; Zhu, TT; Taylor, T; Peto, T; Watkinson, P; Eyre, DW; Clifton, DA				Bishop, Jennifer A.; Javed, Hamza A.; El-Bouri, Rasheed; Zhu, Tingting; Taylor, Thomas; Peto, Tim; Watkinson, Peter; Eyre, David W.; Clifton, David A.			Improving patient flow during infectious disease outbreaks using machine learning for real-time prediction of patient readiness for discharge	PLOS ONE			English	Article							LENGTH-OF-STAY; MORTALITY	Background Delays in patient flow and a shortage of hospital beds are commonplace in hospitals during periods of increased infection incidence, such as seasonal influenza and the COVID-19 pandemic. The objective of this study was to develop and evaluate the efficacy of machine learning methods at identifying and ranking the real-time readiness of individual patients for discharge, with the goal of improving patient flow within hospitals during periods of crisis. Methods and performance Electronic Health Record data from Oxford University Hospitals was used to train independent models to classify and rank patients' real-time readiness for discharge within 24 hours, for patient subsets according to the nature of their admission (planned or emergency) and the number of days elapsed since their admission. A strategy for the use of the models' inference is proposed, by which the model makes predictions for all patients in hospital and ranks them in order of likelihood of discharge within the following 24 hours. The 20% of patients with the highest ranking are considered as candidates for discharge and would therefore expect to have a further screening by a clinician to confirm whether they are ready for discharge or not. Performance was evaluated in terms of positive predictive value (PPV), i.e., the proportion of these patients who would have been correctly deemed as 'ready for discharge' after having the second screening by a clinician. Performance was high for patients on their first day of admission (PPV = 0.96/0.94 for planned/emergency patients respectively) but dropped for patients further into a longer admission (PPV = 0.66/0.71 for planned/emergency patients still in hospital after 7 days). Conclusion We demonstrate the efficacy of machine learning methods at making operationally focused, next-day discharge readiness predictions for all individual patients in hospital at any given moment and propose a strategy for their use within a decision-support tool during crisis periods.	[Bishop, Jennifer A.; Javed, Hamza A.; El-Bouri, Rasheed; Zhu, Tingting; Taylor, Thomas; Clifton, David A.] Univ Oxford, Dept Engn Sci, Oxford, England; [Peto, Tim; Watkinson, Peter; Eyre, David W.] Oxford Univ Hosp NHS Fdn Trust, Oxford, England; [Eyre, David W.] Univ Oxford, Big Data Inst, Nuffield Dept Populat Hlth, Oxford, England	University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford	Javed, HA (corresponding author), Univ Oxford, Dept Engn Sci, Oxford, England.	hjaved202@gmail.com	Eyre, David/P-6887-2016	Eyre, David/0000-0001-5095-6367; Taylor, Thomas/0000-0002-4017-7113; Bishop, Jennifer/0000-0003-2646-7445	National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University; Public Health England (PHE) [NIHR200915]; NIHR Biomedical Research Centre, Oxford; EPSRC [EP/009824/1, EP/N020774/1]	National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University; Public Health England (PHE); NIHR Biomedical Research Centre, Oxford(National Institute for Health Research (NIHR)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with Public Health England (PHE) (NIHR200915), and the NIHR Biomedical Research Centre, Oxford. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health or Public Health England. DWE is a Robertson Foundation Fellow and an NIHR Oxford BRC Senior Fellow. DAC received funding from EPSRC grants EP/009824/1 and EP/N020774/1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, CLIN CLASSIFICATIONS; Barnes S, 2016, J AM MED INFORM ASSN, V23, pE2, DOI 10.1093/jamia/ocv106; Cai XC, 2016, J AM MED INFORM ASSN, V23, P553, DOI 10.1093/jamia/ocv110; Cavallo Joseph J, 2020, JAMA Health Forum, V1, pe200345, DOI 10.1001/jamahealthforum.2020.0345; Daghistani TA, 2019, INT J CARDIOL, V288, P140, DOI 10.1016/j.ijcard.2019.01.046; Gao C, 2017, STUD HEALTH TECHNOL, V245, P1019, DOI 10.3233/978-1-61499-830-3-1019; Greene CS, 2009, BIODATA MIN, V2, DOI 10.1186/1756-0381-2-5; Hall R., 2013, REASON MORALITY LAW, V2nd ed.; Harutyunyan H, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0103-9; Hilton CB, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0249-z; Karakusevic S, 2016, UNDERSTANDING PATIEN; Lacobucci G, 2018, BMJ, V360, P19; Launay CP, 2015, EUR J INTERN MED, V26, P478, DOI 10.1016/j.ejim.2015.06.002; Lee Joon, 2013, World J Cardiovasc Surg, V3, P163; Levin S, 2021, BMJ INNOV, V7, P414, DOI 10.1136/bmjinnov-2020-000420; Liu P, 2006, 2006 3RD INTERNATIONAL IEEE CONFERENCE INTELLIGENT SYSTEMS, VOLS 1 AND 2, P815; Majeed MU, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-410; Meo Nicholas, 2018, BMJ Open Qual, V7, pe000174, DOI 10.1136/bmjoq-2017-000174; Mortona A, 2014, 2014 13TH INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND APPLICATIONS (ICMLA), P428, DOI 10.1109/ICMLA.2014.76; Muhlestein WE, 2019, NEUROSURGERY, V85, P384, DOI 10.1093/neuros/nyy343; Paterson R, 2006, CLIN MED, V6, P281, DOI 10.7861/clinmedicine.6-3-281; Proudlove Nathan, 2007, J Nurs Manag, V15, P34, DOI 10.1111/j.1365-2934.2006.00632.x; Rajkomar A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0029-1; Ramkumar PN, 2019, J ARTHROPLASTY, V34, P2220, DOI 10.1016/j.arth.2019.05.034; Riffenburgh R.H., STAT MED, DOI [10.1016/B978-0-12-384864-2.00010-X, DOI 10.1016/B978-0-12-384864-2.00010-X]; Rojas-Garcia A, 2018, HEALTH EXPECT, V21, P41, DOI 10.1111/hex.12619; Safavi KC, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.17221; Shickel B, 2018, IEEE J BIOMED HEALTH, V22, P1589, DOI 10.1109/JBHI.2017.2767063; Siccoli A, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.2.FOCUS18723; Steele RJ, 2019, 2019 IEEE 9TH ANNUAL COMPUTING AND COMMUNICATION WORKSHOP AND CONFERENCE (CCWC), P127, DOI 10.1109/CCWC.2019.8666598; Tsai PF, 2016, J HEALTHC ENG, V2016, DOI 10.1155/2016/7035463; Tsoukalas A, 2015, JMIR MED INF, V3, DOI 10.2196/medinform.3445; Turgeman L, 2017, EXPERT SYST APPL, V78, P376, DOI 10.1016/j.eswa.2017.02.023; Walczak S, 2003, DECIS SUPPORT SYST, V34, P445, DOI 10.1016/S0167-9236(02)00071-4	34	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2021	16	11							e0260476	10.1371/journal.pone.0260476	http://dx.doi.org/10.1371/journal.pone.0260476			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ8YK	34813632	Green Published, gold			2023-01-03	WOS:000755756800037
J	Castro-Granell, V; Garin, N; Jaen, A; Cenoz, S; Galindo, MJ; Apodaca, MJFR				Castro-Granell, Vanessa; Garin, Noe; Jaen, Angeles; Cenoz, Santiago; Jose Galindo, Maria; Fuster-Ruizde Apodaca, Maria Jose			Prevalence, beliefs and impact of drug-drug interactions between antiretroviral therapy and illicit drugs among people living with HIV in Spain	PLOS ONE			English	Article							FATAL INTERACTION; TREATMENT-NAIVE; REGIMENS; MEN; NONADHERENCE; INHIBITORS; EFAVIRENZ; BEHAVIOR; OUTCOMES; ABUSE	Drug use implies important challenges related to HIV management, particularly due to an increased risk of potential interactions between antiretroviral therapy (ART) and illicit drugs (pDDIs). This study analyses the prevalence and severity of pDDIs among people living with HIV (PLHIV). It also explores their awareness of pDDIs and their beliefs about the toxicity that they may cause, as well as the impact of pDDIs on selected health variables. We conducted an on-line cross-sectional survey across 33 Spanish hospitals and NGOs to collect demographics and clinical data. pDDIs were checked against the Interaction Checker developed by Liverpool University. The sample of the present study was composed of 694 PLHIV who used illicit drugs. They represented 49.5% of the 1,401 PLHIV that participated in the survey. After excluding 38 participants due to lack of information on their ART or illicit drug use, 335 (51.1%) participants consuming drugs presented with some potentially significant pDDIs between their ART and illicit drugs, with a mean of 2.1 +/- 1.7 (1-10) pDDIs per patient. The drugs most frequently involved in pDDIs were cocaine, cannabis, MDMA and nitrates ("poppers"). The prevalence of pDDIs across ART regimens was: protease inhibitors (41.7%); integrase inhibitor-boosted regimens (32.1%), and non-nucleoside reverse transcriptase inhibitors (26.3%). An awareness of pDDIs and beliefs about their potential toxicity correlated positively with intentional non-adherence (p<0.0001). Participants with pDDIs exhibited a higher prevalence of intentional non-adherence (2.19 +/- 1.04 vs. 1.93 +/- 0.94; p = 0.001). The presence of pDDIs was not associated with poorer results in the clinical variables analysed. A significant proportion of PLHIV who use drugs experience pDDIs, thereby requiring close monitoring. pDDIs should be considered in the clinical management of HIV patients. Adequate information about pDDIs and indicators about how to manage ART when PLHIV use drugs could improve ART non-adherence.	[Castro-Granell, Vanessa] Granada Univ, Doctoral Programme Pharm, Granada, Spain; [Castro-Granell, Vanessa] Hosp Marina Baixa, Dept Pharm, Alicante, Spain; [Garin, Noe] Univ Autonoma Barcelona, Dept Pharm, Hosp Santa Creu & St Pau, Barcelona, Spain; [Garin, Noe] Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain; [Garin, Noe] Univ Ramon Llull, Sch Hlth Sci Blanquerna, Barcelona, Spain; [Jaen, Angeles] Univ Barcelona, Res Unit, Fundacio Docencia & Recerca Mutua Terrassa, Barcelona, Spain; [Cenoz, Santiago] ViiV Healthcare, Med Dept, Madrid, Spain; [Jose Galindo, Maria; Fuster-Ruizde Apodaca, Maria Jose] Spanish Interdisciplinary AIDS Soc, SEISIDA, Soc Espanola Interdisciplinaria, Madrid, Spain; [Jose Galindo, Maria] Hosp Clin Univ, Dept Infect Dis, Valencia, Spain; [Fuster-Ruizde Apodaca, Maria Jose] Univ Nacl Educ Distancia UNED, Dept Social & Org Psychol, Madrid, Spain	University of Granada; Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Instituto de Salud Carlos III; Universitat Ramon Llull; University of Barcelona; Sanofi-Aventis; Hospital Clinic Universitari de Valencia; Universidad Nacional de Educacion a Distancia (UNED)	Castro-Granell, V (corresponding author), Granada Univ, Doctoral Programme Pharm, Granada, Spain.; Castro-Granell, V (corresponding author), Hosp Marina Baixa, Dept Pharm, Alicante, Spain.	vanemcg@hotmail.com		Garin, Noe/0000-0002-1559-9453	ViiV Healthcare [001/2016]	ViiV Healthcare	This study was funded by ViiV Healthcare (www.viivhealthcare.com) (grant no: 001/2016), and ViiV Healthcare was involved in the study design and preparation of the manuscript, without influencing the data collection and analysis or the decision to publish.	Abbott KL, 2020, DRUG METAB REV, V52, P44, DOI 10.1080/03602532.2019.1697283; Antoniou T, 2002, ANN PHARMACOTHER, V36, P1598, DOI 10.1345/aph.1A447; Back D, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25449; Baecke C, 2017, NETH J MED, V75, P235; Bourne A, 2015, SEX TRANSM INFECT, V91, P564, DOI 10.1136/sextrans-2015-052052; Bracchi M, 2015, AIDS, V29, P1585, DOI 10.1097/QAD.0000000000000786; Cascorbi I, 2012, DTSCH ARZTEBL INT, V109, P546, DOI 10.3238/arztebl.2012.0546; Cashman SB, 2008, AM J PUBLIC HEALTH, V98, P1407, DOI 10.2105/AJPH.2007.113571; Daskalopoulou M, 2016, AIDS, V30, P810, DOI 10.1097/QAD.0000000000000994; Daskalopoulou M, 2014, LANCET HIV, V1, pE22, DOI 10.1016/S2352-3018(14)70001-3; Degenhardt L, 2010, INT J DRUG POLICY, V21, P347, DOI 10.1016/j.drugpo.2009.11.007; Fuster-RuizdeApodaca MJ, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1208-8; Garin N, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014105; Garin N, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00690; Grabovac I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26413-5; Hales G, 2000, ANTIVIR THER, V5, P19; Haubrich RH, 2009, AIDS, V23, P1109, DOI 10.1097/QAD.0b013e32832b4377; Henry JA, 1998, LANCET, V352, P1751, DOI 10.1016/S0140-6736(05)79824-X; Iniesta-Navalon C, 2015, HIV MED, V16, P273, DOI 10.1111/hiv.12205; Jakeman B, 2017, ANN PHARMACOTHER, V51, P365, DOI 10.1177/1060028016685115; Fuster-RuizdeApodaca MJ, 2020, AIDS RES THER, V17, DOI 10.1186/s12981-020-00279-y; Fuster-RuizdeApodaca MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211252; Kalichman S, 2004, AIDS CARE, V16, pS6, DOI 10.1080/09540120412331315312; Kalichman SC, 2015, JAIDS-J ACQ IMM DEF, V70, P503, DOI 10.1097/QAI.0000000000000776; Kalichman SC, 2013, J GEN INTERN MED, V28, P399, DOI 10.1007/s11606-012-2231-1; Kumar S, 2015, EXPERT OPIN DRUG MET, V11, P343, DOI 10.1517/17425255.2015.996546; Lennox JL, 2010, JAIDS-J ACQ IMM DEF, V55, P39, DOI 10.1097/QAI.0b013e3181da1287; Liverpool HIV Pharmacology Group (LHPG), HIV DRUG INT WEBP; Livio F, 2019, THER ADV DRUG SAF, V10, DOI 10.1177/2042098619880122; Mor Z, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7747-4; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; ONUSIDA, 2020, HOJ INF ULT EST EST; Oreagba IA, 2019, J POPUL THER CLIN PH, V26, pE1, DOI 10.22374/1710-6222.26.1.1; Panel of Antiretroviral Guidelines for Adults and Adolescents, GUIDELINES USE ANTIR; Patel N, 2011, ANN PHARMACOTHER, V45, P317, DOI 10.1345/aph.1P576; Pedroso B, 2010, AIDS CARE, V22, P361, DOI 10.1080/09540120903111502; Pirmohamed M, 2010, WIEN KLIN WOCHENSCHR, V122, P62, DOI 10.1007/s00508-010-1309-1; Priyanka PSSL, 2017, INT J RISK SAF MED, V29, P25, DOI [10.3233/JRS-170738, 10.3233/jrs-170738]; Puls RL, 2010, CLIN INFECT DIS, V51, P855, DOI 10.1086/656363; Rajasingham R, 2012, AIDS PATIENT CARE ST, V26, P36, DOI 10.1089/apc.2011.0153; Remor E, 2016, 11 C NAC PSIC SAUD L; Schmidt AJ, 2016, INT J DRUG POLICY, V38, P4, DOI 10.1016/j.drugpo.2016.09.007; Serrano Lopez de las Hazas J.I., 2011, FARM HOSP, V35, P36, DOI [10.1016/j.farma.2010.01.018, DOI 10.1016/J.FARMA.2010.01.018]; Shapiro LE, 2002, J AM ACAD DERMATOL, V47, P467, DOI 10.1067/mjd.2002.126823; Staltari Orietta, 2014, Recent Pat CNS Drug Discov, V9, P153; Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961; Unidad de vigilancia del VIH ITS y hepatitis, 2020, ACT CONT AT VIH ESP; Wallerstein NB, 2006, HEALTH PROMOT PRACT, V7, P312, DOI 10.1177/1524839906289376; Yiu PY, 2011, PHARMACOTHERAPY, V31, P480, DOI 10.1592/phco.31.5.480; Zhou J, 2013, INT J STD AIDS, V24, P667, DOI 10.1177/0956462413479894	50	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2021	16	11							e0260334	10.1371/journal.pone.0260334	http://dx.doi.org/10.1371/journal.pone.0260334			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ2TX	34797882	Green Published, gold			2023-01-03	WOS:000755334700066
J	Kruszecka-Krowka, A; Cepuch, G; Gniadek, A; Smolen, E; Piskorz-Ogorek, K; Micek, A				Kruszecka-Krowka, Agnieszka; Cepuch, Grazyna; Gniadek, Agnieszka; Smolen, Ewa; Piskorz-Ogorek, Krystyna; Micek, Agnieszka			Selected predictors of parental satisfaction with child nursing care in paediatric wards in Poland-Cross-sectional study	PLOS ONE			English	Article							QUALITY	Background Assessment of parental satisfaction with child nursing is the key issue in evaluation of the care quality, enabling the adjustment of the services provided to the needs and expectations of recipients, and thus ensuring safety and achieving better long-term health effects. Aim Assessment of parental satisfaction with child nursing in paediatric wards including its determinants. Material and methods The study covered 1030 parents of children hospitalised in paediatric and surgical wards of seven hospitals of different levels of health security in Poland. The Polish adaptation of the Empathic standardised questionnaire for assessment of the level of parents' satisfaction with nursing care, developed by Latour et al. and the self-constructed summary of socio-demographic data were applied in the study. Results More than 90% of respondents expressed high level of satisfaction with nurses' Availability, the lowest, but still high score of respondents' satisfaction was observed for Parental Participation. The highest satisfaction was observed among the parents of children at the preschool, early school and puberty stage, admitted to the hospital on the elective basis, referred for diagnostic assessment and with the length of hospital stay less than 7 and longer than 28 days. Achieving preschool age was the strongest factor which increased assessment of satisfaction in most domains. Conclusions There is a need for optimising nursing care especially in the area of parental participation. The nursing care' quality improvement plan in paediatric departments should focus particularly on early childhood patients and their parents who are the most critical in satisfaction' assessment.	[Kruszecka-Krowka, Agnieszka; Cepuch, Grazyna; Gniadek, Agnieszka; Micek, Agnieszka] Jagiellonian Univ Med Coll, Fac Hlth Sci, Nursing & Midwifery Inst, Krakow, Poland; [Smolen, Ewa] Med Univ Lublin, Fac Hlth Sci, Chair & Dept Management Nursing, Lublin, Poland; [Piskorz-Ogorek, Krystyna] Univ Warmia & Mazury, Med Coll, Sch Publ Hlth, Dept Nursing, Olsztyn, Poland	Jagiellonian University; Collegium Medicum Jagiellonian University; Medical University of Lublin; University of Warmia & Mazury	Kruszecka-Krowka, A (corresponding author), Jagiellonian Univ Med Coll, Fac Hlth Sci, Nursing & Midwifery Inst, Krakow, Poland.	agnieszka.kruszecka-krowka@uj.edu.pl	Cepuch, Grażyna/AGS-4319-2022; Micek, Agnieszka/AAC-4838-2019	Micek, Agnieszka/0000-0001-8557-1774				Aarthun A, 2014, J NURS MANAGE, V22, P177, DOI 10.1111/j.1365-2834.2012.01457.x; Abdeldafie SY., 2017, IOSR JNHS, V6, P96, DOI [10.9790/1959-06030196102, DOI 10.9790/1959-06030196102]; Abuqamar M, 2016, J PEDIATR NURS, V31, pE177, DOI 10.1016/j.pedn.2015.12.009; Akbiyik A, 2020, CREAT NURS, V26, pE8, DOI 10.1891/1078-4535.26.1.e8; Alloubani A, 2019, INT J HEALTH CARE Q, V32, P1022, DOI 10.1108/IJHCQA-06-2018-0138; Aslanabadi S., 2014, IRAN J NURS, V26, P61; Ding X, 2019, AUST CRIT CARE, V32, P63, DOI 10.1016/j.aucc.2018.10.007; Divecha C., 2018, PEDIATR CRIT CARE ME, V19, P254, DOI [10.1097/01.pcc.0000538120.64286.dc, DOI 10.1097/01.PCC.0000538120.64286.DC]; Dunsch F, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000694; Fidanci BE., 2014, TRANSL MED, V4, P137, DOI 10.4172/2161-1025.1000137; Forsner M, 2021, PEDIATR QUAL SAF, V6, DOI 10.1097/pq9.0000000000000381; Franck LS, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2529-0; Hosseinian M, 2015, IRAN RED CRESCENT ME, V17, DOI 10.5812/ircmj.23333; Israel-Aina YT., 2017, J COMMUNITY MED PRIM, V29, P33; Kinder Frances DiAnna, 2016, Pediatr Nurs, V42, P138; Kruszecka-Krowka A, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16101774; Latour JM, 2011, INTENS CARE MED, V37, P310, DOI 10.1007/s00134-010-2042-y; Legrow K., 2014, EJPCH, V2, P383; Matziou V, 2011, JPN J NURS SCI, V8, P163, DOI 10.1111/j.1742-7924.2010.00171.x; Mol C, 2018, SOUTH AFR J CRIT CAR, V34, P50, DOI [10.7196/SAJCC.201.v34i2.366, 10.7196/sajcc.201.v34i2.366]; Mucuk SP., 2017, INT J CARING SCI, V10, P1643; Nagarajan N, 2017, CLIN PEDIATR, V56, P619, DOI 10.1177/0009922816668497; Nurmeksela A, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913-021-06288-5; Rea KE, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-1883; Reuter-Rice K, 2017, J PEDIATR NURS, V34, P84, DOI 10.1016/j.pedn.2016.12.017; Sam Cenita James, 2017, J Indian Assoc Pediatr Surg, V22, P226, DOI 10.4103/jiaps.JIAPS_212_16; Sharew NT, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021107; Smolen E., 2015, MED BIOL SCI, V29, P41, DOI DOI 10.12775/MBS.2015.006; Smolen E., 2014, PRZEDSIEBIORCZOSCI Z, V15, P215; Smolen E, 2015, MED PR, V66, P549, DOI 10.13075/mp.5893.00165; Tavallali AG, 2017, SCAND J CARING SCI, V31, P54, DOI 10.1111/scs.12314; Tsironi S, 2018, J CHILD HEALTH CARE, V22, P175, DOI 10.1177/1367493517749327; Ursin L, 2018, PEDIATRICS, V142, pS567, DOI 10.1542/peds.2018-0478H; Uysal G, 2014, PROCD SOC BEHV, V152, P435, DOI 10.1016/j.sbspro.2014.09.227; Von Elm E., STRENGTHENING REPORT; Willebrand M, 2018, J CRIT CARE, V43, P256, DOI 10.1016/j.jcrc.2017.08.037; Yoo SY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155452; Zaklad Monitorowania i Analiz Stanu Zdrowia Ludnosci, 2019, BAD CHOR SZPIT OG	38	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2021	16	11							e0260504	10.1371/journal.pone.0260504	http://dx.doi.org/10.1371/journal.pone.0260504			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2TX	34797888	Green Published, gold			2023-01-03	WOS:000755334700072
J	Jiang, J; Liu, H; Wang, ZD; Tian, HL; Wang, S; Yang, JY; Ren, JY				Jiang, Jing; Liu, Hao; Wang, Zidong; Tian, Huiling; Wang, Shun; Yang, Jiayi; Ren, Jingyu			Electroacupuncture could balance the gut microbiota and improve the learning and memory abilities of Alzheimer's disease animal model	PLOS ONE			English	Article							CEREBROVASCULAR-DISEASE; MOUSE MODEL; PATHOGENESIS; ROLES; MICE	Alzheimer's disease (AD), as one of most common dementia, mainly affects older people from the worldwide. In this study, we intended to explore the possible mechanism of improving cognitive function and protecting the neuron effect by electroacupuncture. Method: We applied senescence-accelerated mouse prone 8 (SAMP8) mice as AD animal model, used Morris water maze, HE staining, 16S rDNA amplicon sequencing of gut microbiota and ELISA to demonstrate our hypothesis. Results: electroacupuncture improved the learning and memory abilities in SAMP8 mice (P<0.05) and could protect the frontal lobe cortex and hippocampus of SAMP8 mice; electroacupuncture significantly decreased the expression of IL-1 beta (P<0.01), IL-6 (P<0.01) and TNF-alpha (P<0.01 in hippocampus, P<0.05 in serum) in serum and hippocampus; electroacupuncture balanced the quantity and composition of gut microbiome, especially of the relative abundance in Delta-proteobacteria (P<0.05) and Epsilon-proteobacteria (P<0.05). Conclusion: electroacupuncture treatment could inhibit the peripheral and central nerve system inflammatory response by balancing the gut microbiota.	[Jiang, Jing; Liu, Hao; Wang, Zidong; Tian, Huiling; Wang, Shun; Yang, Jiayi; Ren, Jingyu] Beijing Univ Chinese Med, Beijing, Peoples R China	Beijing University of Chinese Medicine	Jiang, J (corresponding author), Beijing Univ Chinese Med, Beijing, Peoples R China.	yingxi7847@126.com	Wang, Zhiquan/HHS-6768-2022	Jiang, Jing/0000-0003-2731-4766	National Natural Science Foundation of China Youth Fund Project [818041787]	National Natural Science Foundation of China Youth Fund Project	This study was supported by the National Natural Science Foundation of China Youth Fund Project (Grant No. 818041787).	Aguilera M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158336; Askarova S, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00104; Astudillo AA, 2021, CUREUS, V13, DOI 10.7759/cureus.14519; Bachiller S, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00488; Bauerl C, 2018, LETT APPL MICROBIOL, V66, P464, DOI 10.1111/lam.12882; Barage SH, 2015, NEUROPEPTIDES, V52, P1, DOI 10.1016/j.npep.2015.06.008; Bonfili L, 2021, FEBS J, V288, P2836, DOI 10.1111/febs.15571; Bostanciklioglu M, 2019, J APPL MICROBIOL, V127, P954, DOI 10.1111/jam.14264; Brandscheid C, 2017, J ALZHEIMERS DIS, V56, P775, DOI 10.3233/JAD-160926; Browning KN, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00413; Castillo-Alvarez F, 2022, NEUROLOGIA, V37, P492, DOI 10.1016/j.nrl.2019.03.017; Chen C, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba0466; Chen JY, 2020, AGING-US, V12, P8434, DOI 10.18632/aging.103150; Chen YJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8456596; Chew H, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00598; Coman V, 2020, EXP GERONTOL, V141, DOI 10.1016/j.exger.2020.111095; Cui B, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1223-4; Ding N, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00037; Ding N, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/3435891; Dodiya HB, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64797-5; Domingues C, 2017, CURR ALZHEIMER RES, V14, P870, DOI 10.2174/1567205014666170317113606; Goyal D, 2021, PROG NEURO-PSYCHOPH, V106, DOI 10.1016/j.pnpbp.2020.110112; Guest FL, 2020, ADV EXP MED BIOL, V1260, P175, DOI 10.1007/978-3-030-42667-5_8; Guo MY, 2021, J ALZHEIMERS DIS, V80, P299, DOI 10.3233/JAD-201040; He C, 2021, IRAN J BASIC MED SCI, V24, P341, DOI 10.22038/ijbms.2021.49147.11256; Iadecola C, 2018, CIRC RES, V123, P406, DOI 10.1161/CIRCRESAHA.118.313400; International Asd, 2020, WORLD ALZHEIMER REPO; Jia YJ, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2064-x; Jiang J, 2019, ACUPUNCT MED, V37, P64, DOI 10.1136/acupmed-2016-011310; Jiang J, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/8296824; Jiang J, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/3131586; Jiang J, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/142129; Jin GH, 2020, MOL THER-NUCL ACIDS, V20, P13, DOI 10.1016/j.omtn.2020.01.037; Kao YC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041505; Khan MS, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040853; Koh A, 2020, MOL CELL, V78, P584, DOI 10.1016/j.molcel.2020.03.005; Kuang H, 2020, CNS NEUROSCI THER, V26, P155, DOI 10.1111/cns.13216; Leblhuber F, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020361; Li Z, 2020, J NEUROCHEM, V155, P448, DOI 10.1111/jnc.15031; Lin CX, 2019, COMPUT STRUCT BIOTEC, V17, P1309, DOI 10.1016/j.csbj.2019.09.008; Lin DC, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1842992; Liu MH, 2020, NEUROIMAGE, V208, DOI 10.1016/j.neuroimage.2019.116459; Liu S, 2020, MOL NEUROBIOL, V57, P5026, DOI 10.1007/s12035-020-02073-3; Louca P, 2020, AM J HYPERTENS, V33, P473, DOI 10.1093/ajh/hpaa022; Love S, 2016, ACTA NEUROPATHOL, V131, P645, DOI 10.1007/s00401-015-1522-0; Lu J, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/8302950; Luca M, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4730539; Maccioni RB, 2020, J ALZHEIMERS DIS, V76, P1199, DOI 10.3233/JAD-191014; Minter MR, 2016, SCI REP-UK, V6, DOI 10.1038/srep30028; Mishra R, 2020, AGING DIS, V11, P1567, DOI 10.14336/AD.2020.0312; Mondragon-Rodriguez S, 2020, NEURAL PLAST, V2020, DOI 10.1155/2020/2960343; Muralidar S, 2020, INT J BIOL MACROMOL, V163, P1599, DOI 10.1016/j.ijbiomac.2020.07.327; Ng A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30487-6; Panza F, 2019, BRAIN, V142, P2905, DOI 10.1093/brain/awz244; Peirce JM, 2019, J NEUROSCI RES, V97, P1223, DOI 10.1002/jnr.24476; Peng WJ, 2018, AGING-US, V10, P4054, DOI 10.18632/aging.101693; Revi M, 2020, ADV EXP MED BIOL, V1195, P105, DOI 10.1007/978-3-030-32633-3_15; Ricciarelli R, 2017, CURR NEUROPHARMACOL, V15, P926, DOI 10.2174/1570159X15666170116143743; Saito S, 2016, CURR OPIN PSYCHIATR, V29, P168, DOI 10.1097/YCO.0000000000000239; Saji N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55851-y; Saksida T, 2018, J ALZHEIMERS DIS, V61, P619, DOI 10.3233/JAD-170538; Salazar N, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081765; Sanchez JMS, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01959-2; Schirmer M, 2018, NAT MICROBIOL, V3, P337, DOI 10.1038/s41564-017-0089-z; Sheehan PW, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00703; Shen L, 2019, APPL MICROBIOL BIOT, V103, P7141, DOI 10.1007/s00253-019-09950-5; Shen L, 2017, J ALZHEIMERS DIS, V56, P385, DOI 10.3233/JAD-160884; Shinohara M, 2019, ADV EXP MED BIOL, V1128, P85, DOI 10.1007/978-981-13-3540-2_5; Shiro Y, 2021, PAIN MED, V22, P1522, DOI 10.1093/pm/pnaa401; Shukla PK, 2022, NUTR NEUROSCI, V25, P871, DOI 10.1080/1028415X.2020.1819105; Song YF, 2020, AM J CHINESE MED, V48, P77, DOI 10.1142/S0192415X20500044; Stoye NM, 2020, FASEB J, V34, P11883, DOI 10.1096/fj.201903128RR; Sun J, 2020, MOL NUTR FOOD RES, V64, DOI 10.1002/mnfr.201900636; Sun ZZ, 2020, APPL MICROBIOL BIOT, V104, P3507, DOI 10.1007/s00253-020-10461-x; Sureda A, 2020, PHARMACOL RES, V151, DOI 10.1016/j.phrs.2019.104582; Tian HL, 2019, JOVE-J VIS EXP, DOI 10.3791/60055; Tu CH, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00014; van Thiel IAM, 2020, AM J PHYSIOL-GASTR L, V318, pG1034, DOI 10.1152/ajpgi.00196.2019; Vancamelbeke M, 2017, EXPERT REV GASTROENT, V11, P821, DOI 10.1080/17474124.2017.1343143; Wang HY, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/4958294; Wang QJ, 2020, AGING-US, V12, P628, DOI 10.18632/aging.102645; Wang T, 2015, BENEF MICROBES, V6, P707, DOI 10.3920/BM2014.0177; Wang XH, 2021, J CLIN ENDOCR METAB, V106, pE4641, DOI 10.1210/clinem/dgab454; Wang XR, 2021, EUR J NUTR, V60, P3473, DOI 10.1007/s00394-021-02528-w; Wang XR, 2020, J AFFECT DISORDERS, V275, P290, DOI 10.1016/j.jad.2020.06.043; Wang Y, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01873-7; Webers A, 2020, IMMUNOL CELL BIOL, V98, P28, DOI 10.1111/imcb.12301; Wu YL, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-00924-0; Yan XT, 2018, PROG NEURO-PSYCHOPH, V83, P64, DOI 10.1016/j.pnpbp.2017.12.016; Yang XQ, 2020, ACTA PHARM SIN B, V10, P475, DOI 10.1016/j.apsb.2019.07.001; Yu CC, 2019, CHIN J INTEGR MED, V25, P631, DOI 10.1007/s11655-018-2993-3; Zhan GF, 2018, AGING-US, V10, P1257, DOI 10.18632/aging.101464; Zhang FQ, 2021, HUM GENET, V140, P1267, DOI 10.1007/s00439-021-02288-x; Zhang FQ, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI145942; Zhang LL, 2020, MED RES REV, V40, P431, DOI 10.1002/med.21624; Zhang LY, 2021, DIABET METAB SYND OB, V14, P2595, DOI 10.2147/DMSO.S306861; Zhao Y, 2020, AGING DIS, V11, P1594, DOI 10.14336/AD.2020.0205; Zheng SY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02415; Zheng WM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196933; Zhu SB, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-1705-z	100	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2021	16	11							e0259530	10.1371/journal.pone.0259530	http://dx.doi.org/10.1371/journal.pone.0259530			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ4ST	34748592	Green Published, gold			2023-01-03	WOS:000755468000034
J	Ko, SJ; Cho, J; Choi, SM; Park, YS; Lee, CH; Yoo, CG; Lee, J; Lee, SM				Ko, Sung Jun; Cho, Jaeyoung; Choi, Sun Mi; Park, Young Sik; Lee, Chang-Hoon; Yoo, Chul-Gyu; Lee, Jinwoo; Lee, Sang-Min			Impact of staffing model conversion from a mandatory critical care consultation model to a closed unit model in the medical intensive care unit	PLOS ONE			English	Article							MORTALITY; ICU; OUTCOMES; ASSOCIATION; PATTERNS; VOLUME	Background The intensive care unit (ICU) staffing model affects clinical outcomes of critically ill patients. However, the benefits of a closed unit model have not been extensively compared to those of a mandatory critical care consultation model. Methods This retrospective before-after study included patients admitted to the medical ICU. Anthropometric data, admission reason, Acute Physiology and Chronic Health Evaluation II score, Eastern Cooperative Oncology Group grade, survival status, length of stay (LOS) in the ICU, duration of mechanical ventilator care, and occurrence of ventilator-associated pneumonia (VAP) were recorded. The staffing model of the medical ICU was changed from a mandatory critical care consultation model to a closed unit model in September 2017, and indices before and after the conversion were compared. Results A total of 1,526 patients were included in the analysis. The mean age was 64.5 years, and 954 (62.5%) patients were men. The mean LOS in the ICU among survivors was shorter in the closed unit model than in the mandatory critical care consultation model by multiple regression analysis (5.5 vs. 6.7 days; p= 0.005). Central venous catheter insertion (38.5% vs. 51.9%; p< 0.001) and VAP (3.5% vs. 8.6%; p< 0.001) were less frequent in the closed unit model group than in the mandatory critical care consultation model group. After adjusting for confounders, the closed unit model group had decreased ICU mortality (adjusted odds ratio 0.65; p< 0.001) and shortened LOS in the ICU compared to the mandatory critical care consultation model group. Conclusion The closed unit model was superior to the mandatory critical care consultation model in terms of ICU mortality and LOS among ICU survivors.	[Ko, Sung Jun] Wonkwang Univ, Dept Internal Med, Sanbon Hosp, Gunpo, South Korea; [Cho, Jaeyoung; Choi, Sun Mi; Park, Young Sik; Lee, Chang-Hoon; Yoo, Chul-Gyu; Lee, Jinwoo; Lee, Sang-Min] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Seoul, South Korea	Wonkwang University; Seoul National University (SNU); Seoul National University Hospital	Lee, J; Lee, SM (corresponding author), Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Seoul, South Korea.	realrain7@gmail.com; sangmin2@snu.ac.kr	Lee, Jinwoo/L-7420-2016	Lee, Jinwoo/0000-0003-0958-106X				Barbaro RP, 2015, AM J RESP CRIT CARE, V191, P894, DOI 10.1164/rccm.201409-1634OC; Campbell SJ, 2018, CLIN CHEST MED, V39, P79, DOI 10.1016/j.ccm.2017.11.005; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; Checkley W, 2014, CRIT CARE MED, V42, P344, DOI 10.1097/CCM.0b013e3182a275d7; Chittawatanarat Kaweesak, 2009, Journal of the Medical Association of Thailand, V92, P1627; Costa DK, 2015, CRIT CARE MED, V43, P2275, DOI 10.1097/CCM.0000000000001259; El-Kersh K, 2016, AM J INFECT CONTROL, V44, P1744, DOI 10.1016/j.ajic.2016.04.240; Gutsche JT, 2013, CURR ANESTHESIOL REP, V3, P65, DOI 10.1007/s40140-013-0010-0; Hackner Dani, 2009, Hosp Pract (1995), V37, P40, DOI 10.3810/hp.2009.12.253; Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993; Kim Dong Jung, 2020, Korean J Thorac Cardiovasc Surg, V53, P8, DOI 10.5090/kjtcs.2020.53.1.8; Kim Dong-Chan, 2009, Acute and Critical Care, V24, P117; Kim JH, 2020, ACUTE CRIT CARE, V35, P110, DOI 10.4266/acc.2020.00275; Kim WY, 2019, TUBERC RESPIR DIS, V82, P251, DOI 10.4046/trd.2018.0061; Kwon JE, 2020, ACUTE CRIT CARE, V35, P87, DOI 10.4266/acc.2019.00752; Lee J, 2020, TUBERC RESPIR DIS, V83, pS12, DOI 10.4046/trd.2020.0149; Levy MM, 2008, ANN INTERN MED, V148, P801, DOI 10.7326/0003-4819-148-11-200806030-00002; Manasia AR, 2005, J CARDIOTHOR VASC AN, V19, P155, DOI 10.1053/j.jvca.2005.01.023; Manna SS, 2006, INTENS CARE MED, V32, P2026, DOI 10.1007/s00134-006-0351-y; Multz AS, 1998, AM J RESP CRIT CARE, V157, P1468, DOI 10.1164/ajrccm.157.5.9708039; Nathens AB, 2006, ANN SURG, V244, P545, DOI 10.1097/01.sla.0000239005.26353.49; Ogura T, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0322-8; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Sharayah AM., 2019, D44 CRITICAL CARE EN, V199, pA6472; Topeli A, 2005, CRIT CARE MED, V33, P299, DOI 10.1097/01.CCM.0000153414.41232.90; Treggiari MM, 2007, AM J RESP CRIT CARE, V176, P685, DOI 10.1164/rccm.200701-165OC; van der Sluis FJ, 2011, BMC SURG, V11, DOI 10.1186/1471-2482-11-18; Wilcox ME, 2013, CRIT CARE MED, V41, P2253, DOI 10.1097/CCM.0b013e318292313a; Yang Q, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016261	29	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2021	16	10							e0259092	10.1371/journal.pone.0259092	http://dx.doi.org/10.1371/journal.pone.0259092			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7EW	34705879	Green Published, gold			2023-01-03	WOS:000755636500046
J	Valenti, B; Campidonico, L; Natalello, A; Lanza, M; Salami, SA; Priolo, A; Serra, A; Pauselli, M; Luciano, G				Valenti, Bernardo; Campidonico, Luca; Natalello, Antonio; Lanza, Massimiliano; Salami, Saheed A.; Priolo, Alessandro; Serra, Andrea; Pauselli, Mariano; Luciano, Giuseppe			Fatty acid metabolism in lambs supplemented with different condensed and hydrolysable tannin extracts	PLOS ONE			English	Article							VEGETABLE-OIL SUPPLEMENTATION; CISTUS-LADANIFER L.; GRAPE SEED EXTRACT; LINOLEIC-ACID; RUMINAL BIOHYDROGENATION; CARCASS CHARACTERISTICS; QUEBRACHO TANNINS; REDBERRY JUNIPER; ADIPOSE-TISSUE; CLA ISOMERS	Five groups of lambs (n = 9 each) were used to test the effect of plant extracts rich in hydrolysable (HT) or condensed tannin (CT) on animal performance, fatty acid composition of rumen content, liver and meat. The control group (CO) received a concentrate-based diet without tannins supplementation. The other groups received the same diet as the control lambs plus 4% chestnut (CH) and tara (TA) extracts as a source of HT and mimosa (MI) and gambier (GA) extracts as a source of CT. One-way ANOVA was used to assess the overall effect of dietary treatments, tannins supplementation (CO vs. CH+TA+MI+GA) and the effect of tannin type (HT vs. CT: CH+TA vs. MI+GA) on animal performance, rumen content, liver and intramuscular FA. Dietary CH negatively affected animal performance. The rumen content of the different groups showed similar levels of 18:3 c9c12c15, 18:2 c9c12, 18:2 c9t11, 18:1 t11 and 18:0, whereas 18:1 t10 was greater in CO. Also, 18:1 t10 tended to be lower in the rumen of HT than CT-fed lambs. These data were partially confirmed in liver and meat, where CO showed a greater percentage of individual trans 18:1 fatty acids in comparison with tannins-fed groups. Our findings challenge some accepted generalizations on the use of tannins in ruminant diets as they were ineffective to favour the accumulation of dietary PUFA or healthy fatty acids of biohydrogenation origin in the rumen content and lamb meat, but suggest a generalized influence on BH rather than on specific steps.	[Valenti, Bernardo; Pauselli, Mariano] Univ Perugia, Dipartimento Sci Agrarie & Alimentari Ambientali, Perugia, Italy; [Campidonico, Luca; Natalello, Antonio; Lanza, Massimiliano; Priolo, Alessandro; Luciano, Giuseppe] Univ Catania, Dipartimento Agricoltura Alimentaz & Ambiente Di, Catania, Italy; [Salami, Saheed A.] Univ Coll Cork, Coll Sci Engn & Food Sci, Sch Food & Nutr Sci, Cork, Ireland; [Serra, Andrea] Univ Pisa, Dipartimento Sci Agrarie Alimentari & Agroambie, Pisa, Italy	University of Perugia; University of Catania; University College Cork; University of Pisa	Natalello, A (corresponding author), Univ Catania, Dipartimento Agricoltura Alimentaz & Ambiente Di, Catania, Italy.	antonio.natalello@unict.it	Serra, Andrea/AFO-7144-2022	NATALELLO, Antonio/0000-0002-9802-2501; LANZA, Massimiliano/0000-0002-1011-9924; Salami, Saheed/0000-0001-8554-0193	University of Perugia, Department of Agricultural, Food and Environmental Sciences; University of Catania, Department of Agriculture, Food and Environment	University of Perugia, Department of Agricultural, Food and Environmental Sciences; University of Catania, Department of Agriculture, Food and Environment	This research was funded by University of Perugia, Department of Agricultural, Food and Environmental Sciences (DSA3; project "Ricerca di Base di Ateneo DSA3/2018") and by the University of Catania, Department of Agriculture, Food and Environment (project "QUALIGEN"; Linea 2-Piano di Incentivi per la Ricerca di Ateneo 2020/2022; Principal investigator: Giuseppe Luciano).	Aldai N, 2013, EUR J LIPID SCI TECH, V115, P1378, DOI 10.1002/ejlt.201300072; Alves SP, 2007, EUR J LIPID SCI TECH, V109, P879, DOI 10.1002/ejlt.200700035; Alves SP, 2017, ANIM FEED SCI TECH, V225, P157, DOI 10.1016/j.anifeedsci.2017.01.018; AOAC, 1995, OFFICIAL METHODS ANA, V16th; Bessa RJB, 2007, EUR J LIPID SCI TECH, V109, P868, DOI 10.1002/ejlt.200600311; Bhat TK, 1998, BIODEGRADATION, V9, P343, DOI 10.1023/A:1008397506963; Buccioni A, 2015, J DAIRY SCI, V98, P1145, DOI 10.3168/jds.2014-8651; Buccioni A, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/4969076; Campidonico L, 2016, J ANIM SCI, V94, P1550, DOI 10.2527/jas.2015-9922; Carreno D, 2015, ANIM FEED SCI TECH, V202, P42, DOI 10.1016/j.anifeedsci.2015.02.003; CHRISTIE WW, 1982, J LIPID RES, V23, P1072; Costa M, 2018, J AGR FOOD CHEM, V66, P3367, DOI 10.1021/acs.jafc.7b04770; DESCHAMPS AM, 1983, J FERMENT TECHNOL, V61, P55; DESCHAMPS AM, 1984, BIOTECHNOL LETT, V6, P237, DOI 10.1007/BF00140043; Dias LG, 2008, FOOD CHEM, V109, P840, DOI 10.1016/j.foodchem.2008.01.008; Fievez V, 2012, ANIM FEED SCI TECH, V172, P51, DOI 10.1016/j.anifeedsci.2011.12.008; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frutos P., 2004, Spanish Journal of Agricultural Research, V2, P191; Frutos P, 2020, ANIM FEED SCI TECH, V269, DOI 10.1016/j.anifeedsci.2020.114623; Garcia PT, 2008, MEAT SCI, V79, P500, DOI 10.1016/j.meatsci.2007.10.019; Huws SA, 2015, MICROB BIOTECHNOL, V8, P331, DOI 10.1111/1751-7915.12164; Jeronimo E., 2016, TANNINS RUMINANT NUT, P121, DOI DOI 10.1111/J.1750-8606.2008.00055.X; Jeronimo E, 2012, MEAT SCI, V92, P841, DOI 10.1016/j.meatsci.2012.07.011; Jeronimo E, 2010, J AGR FOOD CHEM, V58, P10710, DOI 10.1021/jf1021626; JONES WT, 1977, J SCI FOOD AGR, V28, P126, DOI 10.1002/jsfa.2740280204; Kramer JKG, 2008, LIPIDS, V43, P259, DOI 10.1007/s11745-007-3143-4; Makkar HPS, 2003, SMALL RUMINANT RES, V49, P241, DOI 10.1016/S0921-4488(03)00142-1; McCann JC, 2014, BIOINFORM BIOL INSIG, V8, P109, DOI 10.4137/BBI.S15389; McLeod M. N., 1974, Nutrition Abstracts and Reviews, V44, P803; Min BR, 2003, ANIM FEED SCI TECH, V106, P3, DOI 10.1016/S0377-8401(03)00041-5; Morales R, 2015, CHIL J AGR RES, V75, P239, DOI 10.4067/S0718-58392015000200014; Mueller-Harvey I, 2006, J SCI FOOD AGR, V86, P2010, DOI 10.1002/jsfa.2577; Natalello A, 2020, ANIM FEED SCI TECH, V259, DOI 10.1016/j.anifeedsci.2019.114355; Natalello A, 2019, J AGR FOOD CHEM, V67, P4472, DOI 10.1021/acs.jafc.9b00307; Patra AK, 2011, J SCI FOOD AGR, V91, P24, DOI 10.1002/jsfa.4152; Patra AK, 2009, ANTON LEEUW INT J G, V96, P363, DOI 10.1007/s10482-009-9364-1; Pellikaan WF, 2011, ANIM FEED SCI TECH, V166-67, P377, DOI 10.1016/j.anifeedsci.2011.04.072; Piperova LS, 2002, J NUTR, V132, P1235, DOI 10.1093/jn/132.6.1235; REED JD, 1995, J ANIM SCI, V73, P1516; Salami SA, 2018, FEMS MICROBIOL ECOL, V94, DOI 10.1093/femsec/fiy061; Shingfield KJ, 2010, ANIMAL, V4, P1140, DOI 10.1017/S1751731110000510; Toral PG, 2013, J DAIRY SCI, V96, P431, DOI 10.3168/jds.2012-5622; Valenti B, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9050283; Valenti B, 2018, MEAT SCI, V145, P63, DOI 10.1016/j.meatsci.2018.06.009; Valenti B, 2017, RAPID COMMUN MASS SP, V31, P737, DOI 10.1002/rcm.7840; VANSOEST PJ, 1991, J DAIRY SCI, V74, P3583, DOI 10.3168/jds.S0022-0302(91)78551-2; Vargas-Magana JJ, 2013, ANIMAL, V7, P1921, DOI 10.1017/S1751731113001651; Vasta V, 2019, J DAIRY SCI, V102, P3781, DOI 10.3168/jds.2018-14985; Vasta V, 2009, J ANIM SCI, V87, P2674, DOI 10.2527/jas.2008-1761; Vasta V, 2009, BRIT J NUTR, V102, P82, DOI 10.1017/S0007114508137898; Vlaeminck B, 2006, ANIM FEED SCI TECH, V131, P389, DOI 10.1016/j.anifeedsci.2006.06.017; Waghorn GC, 2003, P NUTR SOC, V62, P383, DOI 10.1079/PNS2003245; Whitney TR, 2015, MEAT SCI, V104, P1, DOI 10.1016/j.meatsci.2015.01.010; Whitney TR, 2011, MEAT SCI, V89, P160, DOI 10.1016/j.meatsci.2011.04.010; Willems H, 2014, SMALL RUMINANT RES, V116, P153, DOI 10.1016/j.smallrumres.2013.11.002	55	1	1	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2021	16	10							e0258265	10.1371/journal.pone.0258265	http://dx.doi.org/10.1371/journal.pone.0258265			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ9DX	34614022	gold, Green Published			2023-01-03	WOS:000749604400059
J	Pereira, CCD; Martins, M; Lima, SML; de Andrade, CLT; Soares, FRG; Portela, MC				de Aguiar Pereira, Claudia Cristina; Martins, Monica; Lima, Sheyla Maria Lemos; Tavares de Andrade, Carla Lourenco; Gameleira Soares, Fernando Ramalho; Portela, Margareth Crisostomo			Geographical variation in demand, utilization, and outcomes of hospital services for COVID-19 in Brazil: A descriptive serial cross-sectional study	PLOS ONE			English	Article							MORTALITY	Objective To analyze the geographical variation in the provision of health services, namely in demand, patterns of utilization, and effectiveness in the Brazilian Health Regions in four different periods of the COVID-19 pandemic, from February 2020 to March 2021. Methods Descriptive serial cross-sectional study based on secondary data on COVID-19 hospitalizations from SIVEP-Gripe, a public and open-access database of Severe Acute Respiratory Illness records collected by the Brazilian Ministry of Health, and COVID-19 case notification data from Brasil.io, a repository of public data. Fifty-six epidemiological weeks were split into four periods. The following variables were considered for each Brazilian Health Region, per period: number of hospitalizations, hospitalizations per 100,000 inhabitants, hospitalizations per 100 new cases notified in the Health Region, percentage of hospitalizations with ICU use, percentages of hospitalizations with invasive and non-invasive ventilatory support, percentage of hospitalizations resulting in death and percentage of hospitalizations with ICU use resulting in death. Descriptive statistics of the variables were obtained across all 450 Health Regions in Brazil over the four defined pandemic periods. Maps were generated to capture the spatiotemporal variation and trends during the first year of the COVID-19 pandemic in Brazil. Results There was great variation in how COVID-19 hospitalizations grew and spread among Health Regions, with higher numbers between June and August 2020, and, especially, from mid-December 2020 to March 2021. The variation pattern in the proportion of ICU use in the hospitalizations across the Health Regions was broad, with no intensive care provision in large areas in the North, Northeast, and Midwest. The proportions of hospitalizations and hospitalizations with ICU use resulting in deaths were remarkably high, reaching medians of 34.0% and 62.0% across Health Regions, respectively. Conclusion The Heath Regions in Brazil are highly diverse, showing broad disparities in the capacity to respond to the demands imposed by COVID-19, services provided, use and outcomes.	[de Aguiar Pereira, Claudia Cristina; Martins, Monica; Lima, Sheyla Maria Lemos; Tavares de Andrade, Carla Lourenco; Gameleira Soares, Fernando Ramalho; Portela, Margareth Crisostomo] Oswaldo Cruz Fdn Fiocruz, Sergio Arouca Natl Sch Publ Hlth, Rio De Janeiro, RJ, Brazil; [Gameleira Soares, Fernando Ramalho] Brazilian Inst Geog & Stat IBGE, Rio De Janeiro, RJ, Brazil	Fundacao Oswaldo Cruz	Portela, MC (corresponding author), Oswaldo Cruz Fdn Fiocruz, Sergio Arouca Natl Sch Publ Hlth, Rio De Janeiro, RJ, Brazil.	mportela@ensp.fiocruz.br	Portela, Margareth C/G-6699-2012	Portela, Margareth C/0000-0002-9858-9276	Brazilian National Council of Scientific and Technological Development (CNPq)	Brazilian National Council of Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	MCP, CCAP, andMMare recipients of productivity fellowships from the Brazilian National Council of Scientific and Technological Development (CNPq).	Baqui P, 2020, LANCET GLOB HEALTH, V8, P1018, DOI 10.1016/S2214-109X(20)30285-0; Castro MC, 2021, SCIENCE, V372, P821, DOI 10.1126/science.abh1558; Castro RR, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821000479; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644Article, 10.1126/science.abh2644, 10.1101/2021.02.26.21252554]; Fiocruz, B OBS COV 19 SEM EP; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Kameda K, 2021, CAD SAUDE PUBLICA, V37, DOI [10.1590/0102-311X00277420, 10.1590/0102-311x00277420]; Noronha KVMD, 2020, CAD SAUDE PUBLICA, V36, DOI 10.1590/0102-311X00115320; Moreira RD, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311x00080020, 10.1590/0102-311X00080020]; MRC Centre for Global Infectious Disease Analysis Imperial College London, SIT REP COVID 19 BRA; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Pereira RHM, 2021, SOC SCI MED, V273, DOI 10.1016/j.socscimed.2021.113773; Peres IT, 2021, PUBLIC HEALTH, V192, P15, DOI 10.1016/j.puhe.2021.01.005; Portela M., Mendeley Data, VV1, DOI 10.17632/2ggr5m5gk4.1; Portela M.C., 1 ENSPFIOCRUZ; Ranzani OT, 2021, LANCET RESP MED, V9, P407, DOI 10.1016/S2213-2600(20)30560-9; Ribeiro KB, 2021, INT J EPIDEMIOL, V50, P732, DOI 10.1093/ije/dyab022; Rocha R, 2021, LANCET GLOB HEALTH, V9, pE782, DOI 10.1016/S2214-109X(21)00081-4; Soares FRG, SAUDE CAPACIDADE INS; de Andrade CLT, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243126; von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/j.ypmed.2007.08.012	21	2	2	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2021	16	9							e0257643	10.1371/journal.pone.0257643	http://dx.doi.org/10.1371/journal.pone.0257643			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YI5QV	34591896	Green Published, gold			2023-01-03	WOS:000743903000021
J	Brunie, A; Nwala, AA; Stankevitz, K; Lydon, M; Danna, K; Afolabi, K; Rademacher, KH				Brunie, Aurelie; Nwala, Anthony Adindu; Stankevitz, Kayla; Lydon, Megan; Danna, Kendal; Afolabi, Kayode; Rademacher, Kate H.			Factors affecting uptake of the levonorgestrel-releasing intrauterine device: A mixed-method study of social franchise clients in Nigeria	PLOS ONE			English	Article							IMPLANT REMOVAL SERVICES; SYSTEM; ACCESS; QUALITY; REASONS; WOMEN	Background Despite the positive characteristics of the levonorgestrel-releasing intrauterine device (IUD)-a long-acting, highly effective contraceptive with important non-contraceptive attributes-the method has not been widely available in low- and middle-income countries. This study of hormonal IUD, copper IUD, implant and injectable users in Nigeria compares their characteristics, reasons for method choice, and experiences obtaining their method. Methods We conducted a phone survey with 888 women who received a hormonal IUD, copper IUD, contraceptive implant or injectable from 40 social franchise clinics across 18 states in Nigeria. We analyzed survey data descriptively by method and assessed factors associated with hormonal IUD use through multivariate logistic regression models. Follow-up in-depth interviews conducted with 32 women were analyzed thematically. Results There were few differences by method used in the socio-demographic profiles and contraceptive history of participants. Among users choosing a long-acting, reversible method, the top reasons for method choice included perceptions that the method was "right for my body," long duration, recommended by provider, recommended by friends/family, few or manageable side effects, and high effectiveness. Among hormonal IUD users, 17% mentioned reduced bleeding (inclusive of lighter, shorter, or no period), and 16% mentioned treatment of heavy or painful periods. Qualitative data supported these findings. Among survey respondents, between 25% and 33% said they would have chosen no method if the method they received had not been available. Both quantitative and qualitative data indicated that partner support can affect contraceptive use, with in-depth interviews revealing that women typically needed partner permission to use contraception, but men were less influential in method choice. Conclusions Expanding access to the hormonal IUD as part of a full method mix provides an opportunity to expand contraceptive choice for women in Nigeria. Findings are timely as the government is poised to introduce the method on a wider scale.	[Brunie, Aurelie] FHI 360, Washington, DC USA; [Nwala, Anthony Adindu] Soc Family Hlth, Abuja, Nigeria; [Stankevitz, Kayla; Lydon, Megan; Rademacher, Kate H.] FHI 360, Durham, NC 27701 USA; [Danna, Kendal] Populat Serv Int, Washington, DC USA; [Afolabi, Kayode] Fed Minist Hlth, Abuja, Nigeria	FHI 360	Rademacher, KH (corresponding author), FHI 360, Durham, NC 27701 USA.	krademacher@fhi360.org		Rademacher, Kate/0000-0001-7015-5073; Lydon, Megan/0000-0001-8417-8735; Danna, Kendal/0000-0003-2681-9834; Brunie, Aurelie/0000-0002-9515-1420	Bill & Melinda Gates Foundation [INV-008333]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	KR Investment number: INV-008333 Project title: Learning about Expanded Access and Potential of the LNG-IUS (LEAP) Initiative Funder: Bill & Melinda Gates Foundation https://www.gatesfoundation.org/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akamike IC, 2020, CONTRACEP REPROD MED, V5, DOI 10.1186/s40834-020-00120-x; [Anonymous], 2015, UPTAKE DISCONTINUATI; Aransiola JO., 2020, BMC PUBLIC HEALTH, V14, P1; Bahamondes L, 2020, BEST PRACT RES CL OB, V66, P28, DOI 10.1016/j.bpobgyn.2019.12.002; Balogun O, 2016, ETHIOP J HEALTH SCI, V26, P439, DOI 10.4314/ejhs.v26i5.5; Benova L, 2017, INT PERSPECT SEX R H, V43, P183, DOI 10.1363/43e5217; Brunie Aurelie, 2020, Gates Open Res, V4, P119, DOI 10.12688/gatesopenres.13135.1; Callahan R, 2020, GLOB HEALTH-SCI PRAC, V8, P220, DOI 10.9745/GHSP-D-20-00013; Christofield M, 2016, GLOB HEALTH-SCI PRAC, V4, P366, DOI 10.9745/GHSP-D-16-00096; Eva G, 2018, GLOB HEALTH-SCI PRAC, V6, P680, DOI 10.9745/GHSP-D-18-00242; Fraser IS, 2010, CONTRACEPTION, V82, P396, DOI 10.1016/j.contraception.2010.05.005; Goldstuck ND, 2014, AFR J REPROD HEALTH, V18, P15; Howett R, 2019, AFR J REPROD HEALTH, V23, P19, DOI 10.29063/ajrh2019/v23i4.3; Hubacher D, 2015, GLOB HEALTH-SCI PRAC, V3, P532, DOI 10.9745/GHSP-D-15-00178; Hubacher D, 2013, CONTRACEPTION, V88, P97, DOI 10.1016/j.contraception.2013.03.001; Jacobstein R, 2015, GLOB HEALTH-SCI PRAC, V3, P538, DOI 10.9745/GHSP-D-15-00330; Lowe RF, 2013, CONTRACEPTION, V87, P486, DOI 10.1016/j.contraception.2012.09.025; Namey E, 2016, AM J EVAL, V37, P425, DOI 10.1177/1098214016630406; Nanda G, 2018, EUR J CONTRACEP REPR, V23, P303, DOI 10.1080/13625187.2018.1499892; National Population Commission, 2019, NIG DEM HLTH SURV 20; Nyarko P, 2009, ACCEPTABILITY PROMOT; Polis CB, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0561-0; Rademacher KH, 2018, GLOB HEALTH-SCI PRAC, V6, P635, DOI 10.9745/GHSP-D-18-00383; Rademacher KH, 2018, GLOB HEALTH-SCI PRAC, V6, P603, DOI 10.9745/GHSP-D-18-00093; Shelton JD, 2016, GLOB HEALTH-SCI PRAC, V4, P179, DOI 10.9745/GHSP-D-16-00135; U.S. Agency for International Development, 2020, HORM IUD UPD NEW INS; World Health Organization, 2018, FAM PLANN GLOB HDB P	27	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2021	16	9							e0257769	10.1371/journal.pone.0257769	http://dx.doi.org/10.1371/journal.pone.0257769			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5RU	34587200	gold, Green Published			2023-01-03	WOS:000707052600033
J	Weinreich, DM; Sivapalasingam, S; Norton, T; Ali, S; Gao, H; Bhore, R; Xiao, J; Hooper, AT; Hamilton, JD; Musser, BJ; Rofail, D; Hussein, M; Im, J; Atmodjo, DY; Perry, C; Pan, C; Mahmood, A; Hosain, R; Davis, JD; Turner, KC; Baum, A; Kyratsous, CA; Kim, Y; Cook, A; Kampman, W; Roque-Guerrero, L; Acloque, G; Aazami, H; Cannon, K; Simon-Campos, JA; Bocchini, JA; Kowal, B; DiCioccio, AT; Soo, Y; Geba, GP; Stahl, N; Lipsich, L; Braunstein, N; Herman, G; Yancopoulos, GD				Weinreich, D. M.; Sivapalasingam, S.; Norton, T.; Ali, S.; Gao, H.; Bhore, R.; Xiao, J.; Hooper, A. T.; Hamilton, J. D.; Musser, B. J.; Rofail, D.; Hussein, M.; Im, J.; Atmodjo, D. Y.; Perry, C.; Pan, C.; Mahmood, A.; Hosain, R.; Davis, J. D.; Turner, K. C.; Baum, A.; Kyratsous, C. A.; Kim, Y.; Cook, A.; Kampman, W.; Roque-Guerrero, L.; Acloque, G.; Aazami, H.; Cannon, K.; Simon-Campos, J. A.; Bocchini, J. A.; Kowal, B.; DiCioccio, A. Thomas; Soo, Y.; Geba, G. P.; Stahl, N.; Lipsich, L.; Braunstein, N.; Herman, G.; Yancopoulos, G. D.		Trial Investigators	REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND In the phase 1-2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019 (Covid-19). REGEN-COV has activity in vitro against current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. METHODS In the phase 3 portion of an adaptive trial, we randomly assigned outpatients with Covid-19 and risk factors for severe disease to receive various doses of intravenous REGEN-COV or placebo. Patients were followed through day 29. A prespecified hierarchical analysis was used to assess the end points of hospitalization or death and the time to resolution of symptoms. Safety was also evaluated. RESULTS Covid-19-related hospitalization or death from any cause occurred in 18 of 1355 patients in the REGEN-COV 2400-mg group (1.3%) and in 62 of 1341 patients in the placebo group who underwent randomization concurrently (4.6%) (relative risk reduction [1 minus the relative risk], 71.3%; P<0.001); these outcomes occurred in 7 of 736 patients in the REGEN-COV 1200-mg group (1.0%) and in 24 of 748 patients in the placebo group who underwent randomization concurrently (3.2%) (relative risk reduction, 70.4%; P = 0.002). The median time to resolution of symptoms was 4 days shorter with each REGEN-COV dose than with placebo (10 days vs. 14 days; P<0.001 for both comparisons). REGEN-COV was efficacious across various subgroups, including patients who were SARS-CoV-2 serum antibody-positive at baseline. Both REGEN-COV doses reduced viral load faster than placebo; the least-squares mean difference in viral load from baseline through day 7 was -0.71 log(10) copies per milliliter (95% confidence interval [CI], -0.90 to -0.53) in the 1200-mg group and -0.86 log(10) copies per milliliter (95% CI, -1.00 to -0.72) in the 2400-mg group. Serious adverse events occurred more frequently in the placebo group (4.0%) than in the 1200-mg group (1.1%) and the 2400-mg group (1.3%); infusion-related reactions of grade 2 or higher occurred in less than 0.3% of the patients in all groups. CONCLUSIONS REGEN-COV reduced the risk of Covid-19-related hospitalization or death from any cause, and it resolved symptoms and reduced the SARS-CoV-2 viral load more rapidly than placebo.	[Weinreich, D. M.; Norton, T.; Ali, S.; Gao, H.; Bhore, R.; Xiao, J.; Hooper, A. T.; Hamilton, J. D.; Musser, B. J.; Rofail, D.; Hussein, M.; Im, J.; Atmodjo, D. Y.; Perry, C.; Pan, C.; Mahmood, A.; Hosain, R.; Davis, J. D.; Turner, K. C.; Baum, A.; Kyratsous, C. A.; Kim, Y.; Cook, A.; Kampman, W.; Kowal, B.; DiCioccio, A. Thomas; Soo, Y.; Geba, G. P.; Stahl, N.; Lipsich, L.; Braunstein, N.; Herman, G.; Yancopoulos, G. D.] Regeneron Pharmaceut, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA; [Sivapalasingam, S.] Excis BioTherapeut, New York, NY USA; [Roque-Guerrero, L.] Biomed Res, Miami, FL USA; [Acloque, G.] Universal Med & Res Ctr, Miami, FL USA; [Aazami, H.] Hope Clin Res, Canoga Pk, CA USA; [Cannon, K.] PMG Res Wilmington, Wilmington, NC USA; [Simon-Campos, J. A.] Hosp Gen Agustin OHoran, Kohler & Milstein Res, Merida, Yucatan, Mexico; [Bocchini, J. A.] Willis Knighton Phys Network, Shreveport, LA USA	Regeneron	Weinreich, DM (corresponding author), Regeneron Pharmaceut, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	david.weinreich@regeneron.com	Narayanan, Shivakumar/AGO-6664-2022	Narayanan, Shivakumar/0000-0003-3440-0259; Andrews, Jason/0000-0002-5967-251X; SIMON CAMPOS, JESUS ABRAHAM/0000-0001-9630-7792; Hooper, Andrea/0000-0003-1131-1229	Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Biomedical Advanced Research and Development Authority of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response [HHSO100201700020C]	Regeneron Pharmaceuticals(Regeneron); F. Hoffmann-La Roche(Hoffmann-La Roche); Biomedical Advanced Research and Development Authority of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response	Supported by Regeneron Pharmaceuticals, F. Hoffmann-La Roche, and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (contract number HHSO100201700020C).	[Anonymous], 2021, WHO CORONAVIRUS COVI; [Anonymous], 2021, CORONAVIRUS DIS 19 C; [Anonymous], 2021, LETT AUTHORIZATION E; [Anonymous], 2021, PEOPLE CERTAIN MEDIC; Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Challen R, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n579; Copin R, 2021, CELL, V184, P3949, DOI 10.1016/j.cell.2021.06.002; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; del Rio C, 2020, JAMA-J AM MED ASSOC, V324, P1723, DOI 10.1001/jama.2020.19719; FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Logue JK, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0830; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Rofail D., 2021, DEV CONTENT VALIDATI, DOI [10.1101/2021.07.06.21259654v1, DOI 10.1101/2021.07.06.21259654V1]; Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Weinreich DM., 2020, REGEN COV ANTIBODY C, DOI [10.1101/2021.06.09.21257915v1, DOI 10.1101/2021.06.09.21257915V1]; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]	23	372	378	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2021	385	23								10.1056/NEJMoa2108163	http://dx.doi.org/10.1056/NEJMoa2108163		SEP 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE4VC	34587383	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000701160000001
J	Ahmed, F; Oni, FA; Hossen, SS				Ahmed, Firoz; Oni, Fahmida Akter; Hossen, Sk Sharafat			Does gender inequality matter for access to and utilization of maternal healthcare services in Bangladesh?	PLOS ONE			English	Article							INTIMATE PARTNER VIOLENCE; SKILLED BIRTH ATTENDANCE; ANTENATAL CARE; WOMENS EMPOWERMENT; AUTONOMY; STRATEGIES; PREGNANCY; NEPAL	There is a high prevalence of gender gap in Bangladesh which might affect women's likelihood to receive maternal healthcare services. In this backdrop, we aim to investigate how gender inequality measured by intrahousehold bargaining power (or autonomy) of women and their attitudes towards intimate partner violence (IPV) affects accessing and utilizing maternal health care services. We used Bangladesh Demographic and Health Survey (BDHS) data of 2014 covering 5460 women who gave birth at least one child in the last three years preceding the survey. We performed logistic regression to estimate the effect of women's autonomy and their attitude towards IPV on access to and utilization of maternal healthcare services. Besides, we employed different channels to understand the heterogeneous effect of gender inequality on access to maternal healthcare services. We observed that women having autonomy positively influenced attaining five required antenatal care (ANC) services (AOR: 1.17; 95% CI: 0.98-1.41) and women's negative attitudes towards IPV were positively associated with five ANC services (AOR: 1.42; 95% CI: 1.02-1.97), sufficient ANC visits (COR: 1.55; CI: 1.19-2.01), skilled birth attendant (SBA) (AOR: 1.43; 95% CI: 1.05-1.94) and postnatal care (PNC) services (AOR: 1.44; 95% CI: 1.12-1.84). Besides, rural residency, religion, household wealth, education of both women and husband were found to have some of the important channels which were making stronger effect of gender inequality on access to maternal healthcare services. The findings of our study indicate a significant association between access to maternal healthcare services and women's autonomy as well as attitude towards IPV in Bangladesh. We, therefore, recommend to protect women from violence at home and mprove their intrahousehold bargaining power to increase their access to and utilization of required maternal healthcare services.	[Ahmed, Firoz; Oni, Fahmida Akter; Hossen, Sk Sharafat] Khulna Univ, Social Sci Sch, Econ Discipline, Khulna, Bangladesh	Khulna University	Ahmed, F (corresponding author), Khulna Univ, Social Sci Sch, Econ Discipline, Khulna, Bangladesh.	firoz.ahmed@econ.ku.ac.bd	Oni, Fahmida Akter/HCI-0931-2022; Ahmed, Firoz/F-9760-2014	Oni, Fahmida/0000-0001-8580-4080; Ahmed, Firoz/0000-0003-4978-3993				Acharya DR, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-15; Adegoke AA, 2009, BJOG-INT J OBSTET GY, V116, P33, DOI 10.1111/j.1471-0528.2009.02336.x; Adjiwanou V, 2014, HEALTH PLACE, V29, P67, DOI 10.1016/j.healthplace.2014.06.001; Amin A, 2015, J INT AIDS SOC, V18, P4, DOI 10.7448/IAS.18.6.20302; [Anonymous], 2019, TRENDS MATERNAL MORT; Ashraf N, 2014, AM ECON REV, V104, P2210, DOI 10.1257/aer.104.7.2210; Austin A, 2015, INT J WOMENS HEALTH, V7, P345, DOI 10.2147/IJWH.S79573; Banda PC, 2017, WOMEN HEALTH, V57, P405, DOI 10.1080/03630242.2016.1170092; Bangladesh Bureau of Statistics, 2016, REP VIOL WOM VAW SUR; Banik BK, 2017, J HEALTH MANAG, V19, P523, DOI 10.1177/0972063417727614; Bengesai AV, 2021, CULT HEALTH SEX, V23, P927, DOI 10.1080/13691058.2020.1743880; Bhalotra S, 2011, J PUBLIC ECON, V95, P286, DOI 10.1016/j.jpubeco.2010.10.016; Bhowmik J, 2019, PUBLIC HEALTH, V170, P113, DOI 10.1016/j.puhe.2019.02.027; Biswas RK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187884; Bloom SS, 2001, DEMOGRAPHY, V38, P67, DOI 10.1353/dem.2001.0001; Bullough C, 2005, BJOG-INT J OBSTET GY, V112, P1180, DOI 10.1111/j.1471-0528.2005.00718.x; Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Chandrasekhar S, 2011, POPUL RES POLICY REV, V30, P25, DOI 10.1007/s11113-010-9175-0; Chola M., INT J POPULATION RES, V2016, P1; Field E, 2010, AM ECON REV, V100, P125, DOI 10.1257/aer.100.2.125; Gage AJ, 2007, SOC SCI MED, V65, P1666, DOI 10.1016/j.socscimed.2007.06.001; Garcia-Moreno C, 2006, LANCET, V368, P1260, DOI 10.1016/S0140-6736(06)69523-8; Islam MA, 2019, J BIOMOL STRUCT DYN, V37, P4104, DOI 10.1080/07391102.2018.1544509; Islam TM, 2015, J FAM VIOLENCE, V30, P433, DOI 10.1007/s10896-015-9683-0; Joshi S, 2013, DEMOGRAPHY, V50, P149, DOI 10.1007/s13524-012-0172-2; Kifle D, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-016-0270-5; Kitui J, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-40; Klomegah RY, 2008, J COMP FAM STUD, V39, P557, DOI 10.3138/jcfs.39.4.557; Klugman J., 2014, VOICE AGENCY EMPOWER; Mai V, 2020, J HEALTH RES, V34, P100, DOI 10.1108/JHR-03-2019-0046; Ministry of Health and Family Welfare (MOHFW), 2019, HLTH POP NUTR ETOOLK; Mishra PS, 2021, CLIN EPIDEMIOL GLOB, V11, DOI 10.1016/j.cegh.2021.100744; Namasivayam A, 2012, INT J WOMENS HEALTH, V4, P351, DOI 10.2147/IJWH.S32569; National Institute of Population Research and Training Mitra and Associates ICF International, 2015, BANGL DEM HLTH SURV; Naved RT., 2017, UNDERSTANDING INTIMA; Neupane S, 2012, J COMMUN HEALTH, V37, P865, DOI 10.1007/s10900-011-9521-0; NIPORT Mitra and Associates ICF International and ICBBRB, 2012, BANGL MAT MORT HLTH; Ochako R, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-1; Ononokpono D.N., 2014, PAN AFR MED J, V17 Suppl 1, P2, DOI [10.11694/pamj.supp.2014.17.1.3596, DOI 10.11694/PAMJ.SUPP.2014.17.1.3596, https://doi.org/10.11694/pamj.supp.2014.17.1.3596]; Pallikadavath S, 2004, SOC SCI MED, V59, P1147, DOI 10.1016/j.socscimed.2003.11.045; Rahman M, 2011, J FAM VIOLENCE, V26, P411, DOI 10.1007/s10896-011-9375-3; Rahman M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082423; Ridgeway CL, 2004, J SOC ISSUES, V60, P683, DOI 10.1111/j.0022-4537.2004.00380.x; Sado L, 2014, SOC SCI MED, V114, P169, DOI 10.1016/j.socscimed.2014.05.047; Schuler SR, 2018, WORLD DEV, V101, P284, DOI 10.1016/j.worlddev.2017.09.005; Sen Amartya, 1999, DEV FREEDOM; Shahabuddin ASM, 2015, TROP MED INT HEALTH, V20, P822, DOI 10.1111/tmi.12503; Shimamoto K, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0591-3; Silverman JG, 2007, BJOG-INT J OBSTET GY, V114, P1246, DOI 10.1111/j.1471-0528.2007.01481.x; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Singh Kavita, 2012, Afr J Reprod Health, V16, P123; Subramanian SV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018962; Tenkorang EY, 2018, INT PERSPECT SEX R H, V44, P51, DOI 10.1363/44e6118; Vrana-Diaz CJ., 2019, GLOB SOC WELFARE, P1, DOI [10.1007/s40609-019-00144-5, DOI 10.1007/S40609-019-00144-5]; Wado YD, 2018, WOMEN HEALTH, V58, P729, DOI 10.1080/03630242.2017.1353573; WHO, 2016, WHO TECH REP SER, V997, P1; World Health Organisation, 2015, MDG 5 IMPR MAT HLTH; World Health Organization, 2009, WOMEN AND HEALTH: TODAY'S EVIDENCE TOMORROW'S AGENDA, P1	59	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2021	16	9							e0257388	10.1371/journal.pone.0257388	http://dx.doi.org/10.1371/journal.pone.0257388			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WG5YY	34529701	Green Published, gold			2023-01-03	WOS:000707071500052
J	dos Santos Neto, JMD; de Carvalho, CC; de Andrade, LB; Dos Santos, TGB; Andrade, RGAD; Fernandes, RAML; de Orange, FA				dos Santos Neto, Jayme Marques; de Carvalho, Clistenes Cristian; de Andrade, Livia Barboza; Dos Santos, Thiago Gadelha Batista; Andrade, Rebeca Gonelli Albanez da Cunha; Fernandes, Raphaella Amanda Maria Leite; de Orange, Flavia Augusta			Continuous positive airway pressure to reduce the risk of early peripheral oxygen desaturation after onset of apnoea in children: A double-blind randomised controlled trial	PLOS ONE			English	Article							GENERAL-ANESTHESIA; PRE-OXYGENATION; PREOXYGENATION; INDUCTION; DURATION; COMPLICATIONS; INSUFFLATION; INTUBATION; MANAGEMENT; INFANTS	Continuous positive airway pressure (CPAP) during anaesthesia induction improves oxygen saturation (SpO(2)) outcomes in adults subjected to airway manipulation, and could similarly support oxygenation in children. We evaluated whether CPAP ventilation and passive CPAP oxygenation in children would defer a SpO(2) decrease to 95% after apnoea onset compared to the regular technique in which no positive airway pressure is applied. In this double-blind, parallel, randomised controlled clinical trial, 68 children aged 2-6 years with ASA I-II who underwent surgery under general anaesthesia were divided into CPAP and control groups (n = 34 in each group). The intervention was CPAP ventilation and passive CPAP oxygenation using an anaesthesia workstation. The primary outcome was the elapsed time until SpO(2) decreased to 95% during a follow-up period of 300 s from apnoea onset (T1). We also recorded the time required to regain baseline levels from an SpO(2) of 95% aided by positive pressure ventilation (T2). The median T1 was 278 s (95% confidence interval [CI]: 188-368) in the CPAP group and 124 s (95% CI: 92-157) in the control group (median difference: 154 s; 95% CI: 58-249; p = 0.002). There were 17 (50%) and 32 (94.1%) primary events in the CPAP and control groups, respectively. The hazard ratio was 0.26 (95% CI: 0.14-0.48; p<0.001). The median for T2 was 21 s (95% CI: 13-29) and 29 s (95% CI: 22-36) in the CPAP and control groups, respectively (median difference: 8 s; 95% CI: -3 to 19; p = 0.142). SpO(2) was significantly higher in the CPAP group than in the control group throughout the consecutive measures between 60 and 210 s (with p ranging from 0.047 to <0.001). Thus, in the age groups examined, CPAP ventilation and passive CPAP oxygenation deferred SpO(2) decrease after apnoea onset compared to the regular technique with no positive airway pressure.	[dos Santos Neto, Jayme Marques; Dos Santos, Thiago Gadelha Batista; de Orange, Flavia Augusta] Fed Univ, Pernambucos Teaching Hosp, Support & Therapeut Diag Div, Anesthesiol & Postanesthet Care Unit, Recife, PE, Brazil; [de Carvalho, Clistenes Cristian; de Andrade, Livia Barboza; Andrade, Rebeca Gonelli Albanez da Cunha; Fernandes, Raphaella Amanda Maria Leite; de Orange, Flavia Augusta] Inst Med Integral Prof Fernando Figueira, Dept Postgrad, Recife, PE, Brazil; [de Carvalho, Clistenes Cristian] Univ Fed Campina Grande, Dept Surg, Campina Grande, PB, Brazil	Instituto de Medicina Integral Professor Fernando Figueira (IMIP); Universidade Federal de Campina Grande	dos Santos Neto, JMD (corresponding author), Fed Univ, Pernambucos Teaching Hosp, Support & Therapeut Diag Div, Anesthesiol & Postanesthet Care Unit, Recife, PE, Brazil.	jaymemed@yahoo.com.br						Bouroche G, 2015, MINERVA ANESTESIOL, V81, P910; Chiron B, 2007, PEDIATR ANESTH, V17, P963, DOI 10.1111/j.1460-9592.2007.02259.x; Crawford MW, 2006, ANESTHESIOLOGY, V105, P45, DOI 10.1097/00000542-200607000-00011; De Jong A, 2014, ANN FR ANESTH, V33, P457, DOI 10.1016/j.annfar.2014.08.001; Ehsan Z, 2016, LARYNGOSCOPE, V126, P270, DOI 10.1002/lary.25399; Faria DAS, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009134.pub2; Fiadjoe JE, 2016, LANCET RESP MED, V4, P37, DOI 10.1016/S2213-2600(15)00508-1; Gander S, 2005, ANESTH ANALG, V100, P580, DOI 10.1213/01.ANE.0000143339.40385.1B; Gross JB, 2014, ANESTHESIOLOGY, V120, P268, DOI 10.1097/ALN.0000000000000053; Harbut P, 2014, ACTA ANAESTH SCAND, V58, P675, DOI 10.1111/aas.12317; Harless Jeff, 2014, Int J Crit Illn Inj Sci, V4, P65, DOI 10.4103/2229-5151.128015; Hedenstierna G, 2015, BEST PRACT RES-CLIN, V29, P273, DOI 10.1016/j.bpa.2015.08.008; Herriger A, 2004, ANAESTHESIA, V59, P243, DOI 10.1111/j.1365-2044.2004.03615.x; Humphreys S, 2017, BRIT J ANAESTH, V118, P232, DOI 10.1093/bja/aew401; Jat KR, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010473.pub3; Jimenez-Ruiz F, 2018, J APPL PHYSIOL, V124, P915, DOI 10.1152/japplphysiol.01004.2017; King MR, 2016, J CLIN ANESTH, V32, P181, DOI 10.1016/j.jclinane.2016.02.026; Lee JH, 2019, PEDIATR ANESTH, V29, P331, DOI 10.1111/pan.13594; Lee JH, 2018, CAN J ANESTH, V65, P1288, DOI 10.1007/s12630-018-1183-2; Long E, 2014, PEDIATR ANESTH, V24, P1204, DOI 10.1111/pan.12490; Lyons C, 2019, ANAESTHESIA, V74, P497, DOI 10.1111/anae.14565; Nimmagadda U, 2017, ANESTH ANALG, V124, P507, DOI 10.1213/ANE.0000000000001589; Overmann KM, 2019, AM J EMERG MED, V37, P1416, DOI 10.1016/j.ajem.2018.10.030; Pelosi P, 2016, TURK J ANAESTHESIOL, V44, P163, DOI 10.5152/TJAR.2016.002; Rajan Sunil, 2018, Anesth Essays Res, V12, P229, DOI 10.4103/aer.AER_219_17; Sinha IP, 2015, CHEST, V148, P810, DOI 10.1378/chest.14-1589; Sreejit MS, 2015, INDIAN J ANAESTH, V59, P216, DOI 10.4103/0019-5049.154998; THORSTEINSSON A, 1990, ANESTHESIOLOGY, V73, P876, DOI 10.1097/00000542-199011000-00014; Tignanelli CJ, 2019, JAMA SURG, V154, P74, DOI 10.1001/jamasurg.2018.4318; Tusman G, 2003, ANESTHESIOLOGY, V98, P14, DOI 10.1097/00000542-200301000-00006; von Ungern-Sternberg BS, 2010, LANCET, V376, P773, DOI 10.1016/S0140-6736(10)61193-2; Windpassinger M, 2016, ANESTH ANALG, V122, P1153, DOI 10.1213/ANE.0000000000001189	32	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	10								10.1371/journal.pone.0256950	http://dx.doi.org/10.1371/journal.pone.0256950			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4Y2FG	34597324	Green Published, gold			2023-01-03	WOS:000861345400044
J	Nasir, N; Tajuddin, S; Khaskheli, S; Khan, N; Niamatullah, H; Nasir, N				Nasir, Noreen; Tajuddin, Salma; Khaskheli, Sarah; Khan, Naveera; Niamatullah, Hammad; Nasir, Nosheen			Clinical outcomes of immunomodulatory therapies in the management of COVID-19: A tertiary-care experience from Pakistan	PLOS ONE			English	Article								The pharmacological management of COVID-19 has evolved significantly and various immunomodulatory agents have been repurposed. However, the clinical efficacy has been variable and a search for cure for COVID-19 continues. A retrospective cohort study was conducted on 916 patients hospitalized with polymerase chain reaction (PCR)-confirmed COVID-19 between February 2020 and October 2020 at a tertiary care academic medical center in Karachi, Pakistan. The median age was 57 years (interquartile range (IQR) 46-66 years). The most common medications administered were Methylprednisolone (65.83%), Azithromycin (50.66%), and Dexamethasone (46.6%). Majority of the patients (70%) had at least two or more medications used in combination and the most frequent combination was methylprednisolone with azithromycin. Overall in-hospital mortality was 13.65% of patients. Mortality was found to be independently associated with age greater than or equal to 60 years (OR = 4.98; 95%CI: 2.78-8.91), critical illness on admission (OR = 13.75; 95%CI: 7.27-25.99), use of hydrocortisone (OR = 12.56; 95%CI: 6.93-22.7), Ferritin> = 1500(OR = 2.07; 95%CI: 1.18-3.62), Creatinine(OR = 2.33; 95%CI: 1.31-4.14) and D-Dimer> = 1.5 (OR = 2.27; 95%CI: 1.26-4.07). None of the medications whether used as monotherapy or in combination were found to have a mortality benefit. Our study highlights the desperate need for an effective drug for the management of critical COVID-19 which necessitates usage of multiple drug combinations in patients particularly Azithromycin which has long term implications for antibiotic resistance particularly in low-middle income countries.	[Nasir, Noreen; Tajuddin, Salma; Nasir, Nosheen] Aga Khan Univ, Dept Med, Karachi, Pakistan; [Khaskheli, Sarah; Khan, Naveera; Niamatullah, Hammad] Aga Khan Univ, Med Coll, Karachi, Pakistan	Aga Khan University; Aga Khan University	Nasir, N (corresponding author), Aga Khan Univ, Dept Med, Karachi, Pakistan.	Nosheen.nasir@aku.edu		Khan, Naveera/0000-0001-5208-3600; , Nosheen/0000-0003-1610-8748				Abate SM, 2021, ANN MED SURG, V64, DOI 10.1016/j.amsu.2021.102204; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Burnett GW, 2021, J ANESTH, V35, P366, DOI 10.1007/s00540-020-02860-1; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Coomes EA, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2141; Coppock D, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252591; Edalatifard M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02808-2020; Ejaz H, 2020, J INFECT PUBLIC HEAL, V13, P1833, DOI 10.1016/j.jiph.2020.07.014; Fan XZ, 2021, INT J GEN MED, V14, P267, DOI 10.2147/IJGM.S290118; Furtado RHM, 2020, LANCET, V396, P959, DOI 10.1016/S0140-6736(20)31862-6; Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Izda V, 2021, CLIN IMMUNOL, V222, DOI 10.1016/j.clim.2020.108634; Lee K, 2009, GLOB INST, P1; Liu JL, 2020, J MED VIROL, V92, P1484, DOI 10.1002/jmv.25965; Maxwell D, 2021, AM J TROP MED HYG, V105, P584, DOI 10.4269/ajtmh.21-0200; Melo AKG, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253894; Nasir N, 2021, ADV RESPIR MED, V89, P254, DOI 10.5603/ARM.a2021.0049; Novelli L, 2021, PANMINERVA MED, V63, P51, DOI 10.23736/S0031-0808.20.04063-X; Patrucco F, 2021, POL ARCH INTERN MED, V131, P854, DOI 10.20452/pamw.16077; Perrone F, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02573-9; Jeronimo CMP, 2021, CLIN INFECT DIS, V72, pE373, DOI 10.1093/cid/ciaa1177; Prats-Uribe A, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1038; Prescott HC, 2020, JAMA-J AM MED ASSOC, V324, P1292, DOI 10.1001/jama.2020.16747; Rosenthal N, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.29058; Saber-Ayad M, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13050096; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Sharifpour M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242400; Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849; Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Yao YM, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00466-z; Yousefi H, 2021, BIOCHEM PHARMACOL, V183, DOI 10.1016/j.bcp.2020.114296	34	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2022	17	1							e0262608	10.1371/journal.pone.0262608	http://dx.doi.org/10.1371/journal.pone.0262608			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0I4GM	35085312	gold, Green Published			2023-01-03	WOS:000779379600068
J	Harvey, MJ; Zhong, Y; Morris, E; Beverage, JN; Epstein, RS; Chawla, AJ				Harvey, Michael J.; Zhong, Yi; Morris, Eric; Beverage, Jacob N.; Epstein, Robert S.; Chawla, Anita J.			Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma	PLOS ONE			English	Article							CELL HEMATOLOGIC MALIGNANCIES; DRUG-DELIVERY; BUDGET IMPACT; CANCER CARE; SAFETY; TRASTUZUMAB; EFFICACY; QUALITY; SABRINA	Subcutaneous (SC) administration of rituximab provides an opportunity for reduced patient treatment burden and increased healthcare efficiencies as an alternative to intravenous (IV) rituximab. There is minimal evidence comparing costs associated with SC and IV rituximab in a US setting. This research assessed the impact of transitioning patients from IV to SC rituximab for treatment of non-Hodgkin's lymphoma (NHL) from the US payer, provider, and patient perspective. We developed a model to estimate cost differences for transitioning 20% of a patient cohort from IV to SC rituximab. We included patients with incident diffuse large B-cell lymphoma, incident and recurrent follicular lymphoma, and incident and recurrent chronic lymphocytic leukemia. In the model, each patient received the same number of doses and that there was no difference in discontinuation between cohorts due to non-inferior efficacy and a similar safety profile. Model inputs were collected from published literature and publicly available data. Scenario analyses tested the impact of availability of low-cost biosimilars. In the base case (1,000,000 covered lives), we estimated a total of 157 patients, with 769 total drug administrations. A transition of 20% of patients from IV to SC was projected to generate $153,000 in payer savings, increase provider capacity by 270 hours, and free 470 hours of patient time. Scenario analyses suggest SC administration will be cost saving for payers even with a market where biosimilars approach 50% market share. A 20% transition to SC rituximab in a single cohort of patients has the potential to generate significant US health system value in the form of payer savings, increased practice capacity, and patient time.	[Harvey, Michael J.] Anal Grp Inc, London, England; [Zhong, Yi; Morris, Eric; Chawla, Anita J.] Anal Grp Inc, Menlo Pk, CA USA; [Beverage, Jacob N.] Halozyme Therapeut, San Diego, CA USA; [Epstein, Robert S.] Epstein Hlth LLC, Woodcliff Lake, NJ USA	Analysis Group Inc.; Analysis Group Inc.; Halozyme	Harvey, MJ (corresponding author), Anal Grp Inc, London, England.	Michael.harvey@analysisgroup.com			Halozyme Therapeutics, Inc.	Halozyme Therapeutics, Inc.	This study was funded by Halozyme Therapeutics, Inc. Jake Beverage is an employee of Halozyme Therapeutics, Inc. and owns stock/stock options. Michael J. Harvey, Yi Zhong, Eric Morris, and Anita J. Chawla are employees of Analysis Group Inc., which has received consultancy fees from Halozyme Therapeutics, Inc. Robert Epstein has received consultancy fees from Halozyme Therapeutics, Inc.	Afzali A, 2017, J MED ECON, V20, P409, DOI 10.1080/13696998.2017.1285779; Aguiar-Bujanda D, 2015, CANCER MANAG RES, V7, P319, DOI 10.2147/CMAR.S69145; Amgen Inc, AMG 2020 BIOS TRENDS; Anderson KC, 2019, FUTURE ONCOL, V15, P3267, DOI 10.2217/fon-2019-0368; Baker SD, 2002, JNCI-J NATL CANCER I, V94, P1883, DOI 10.1093/jnci/94.24.1883; Berry LL, 2016, HEALTHCARE-J DEL SCI, V4, P312, DOI 10.1016/j.hjdsi.2016.01.003; Bittner B, 2018, BIODRUGS, V32, P425, DOI 10.1007/s40259-018-0295-0; Census Bureau U.S., 2017, DIVISION POPULATION; Centers for Medicare and Medicaid Services, 2021 ASP DRUG PRIC F; Centers for Medicare & Medicaid Services, 2021 MED PHYS FEE SC; Collins DS, 2020, J CONTROL RELEASE, V321, P475, DOI 10.1016/j.jconrel.2020.02.036; Davies A, 2017, ADV THER, V34, P2210, DOI 10.1007/s12325-017-0610-z; Davies A, 2017, LANCET HAEMATOL, V4, pE272, DOI 10.1016/S2352-3026(17)30078-9; Davies A, 2014, LANCET ONCOL, V15, P343, DOI 10.1016/S1470-2045(14)70005-1; De Cock E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157957; Dychter SS, 2012, J INFUS MURS, V35, P154, DOI 10.1097/NAN.0b013e31824d2271; Fargier E, 2018, ANN HEMATOL, V97, P123, DOI 10.1007/s00277-017-3147-y; Favier M, 2018, B CANCER, V105, P862, DOI 10.1016/j.bulcan.2018.07.014; Franken MG, 2018, ANTI-CANCER DRUG, V29, P791, DOI 10.1097/CAD.0000000000000648; Hansen RN, 2018, VALUE HEALTH, V21, pS22, DOI 10.1016/j.jval.2018.04.137; Hess Lisa M, 2016, Hosp Pharm, V51, P452, DOI 10.1310/hpj5106-452; Howlader N., 2013, SEER CANC STAT REV 1; IBM Watson Health, MICR EL VERS; Laughlin AI., 2020, NEJM CATALYST INNOVA, V1; Locke KW, 2019, DRUG DELIV, V26, P98, DOI 10.1080/10717544.2018.1551442; Lugtenburg P, 2017, HAEMATOLOGICA, V102, P1913, DOI 10.3324/haematol.2017.173583; McBride A, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-113283; Mihajlovic J, 2017, CLIN THER, V39, P1221, DOI 10.1016/j.clinthera.2017.05.342; Mountainside Medical Equipment, MOUNT MED EQ WHOL ME; Pierce Christine A, 2004, J Infus Nurs, V27, P232, DOI 10.1097/00129804-200407000-00008; Ponzetti C, 2016, CLINICOECONOMIC OUTC, V8, P227, DOI 10.2147/CEOR.S97319; Rule Simon, 2014, J Med Econ, V17, P459, DOI 10.3111/13696998.2014.914033; Rummel M, 2017, ANN ONCOL, V28, P836, DOI 10.1093/annonc/mdw685; Salles G, 2017, ADV THER, V34, P2232, DOI 10.1007/s12325-017-0612-x; Shinder GA, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-370; Shpilberg O, 2013, BRIT J CANCER, V109, P1556, DOI 10.1038/bjc.2013.371; Spinks TE, 2014, HEALTHCARE-J DEL SCI, V2, P53, DOI 10.1016/j.hjdsi.2013.11.003; Stewart D, 2020, CURR ONCOL, V27, P113, DOI 10.3747/co.27.6041; Stewart DA, 2018, CURR ONCOL, V25, P300, DOI 10.3747/co.25.4231; Stoner KL, 2015, PATIENT, V8, P145, DOI 10.1007/s40271-014-0075-y; Turner MR, 2018, J PHARM SCI-US, V107, P1247, DOI 10.1016/j.xphs.2018.01.007; U.S. Bureau of Labor Statistics, 2018 STAND OCC CLASS; U.S. Food and Drug Administration, 2020, PRESCR INF DARZ FASP; U.S. Food and Drug Administration, 2020, PRESCR INF RIT HYC R; U.S. Food and Drug Administration, 2020, PRESCR INF PHESG PER; Viola M, 2018, J CONTROL RELEASE, V286, P301, DOI 10.1016/j.jconrel.2018.08.001; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Young RA., TIME MOTION STUDY PR	48	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2022	17	1							e0261336	10.1371/journal.pone.0261336	http://dx.doi.org/10.1371/journal.pone.0261336			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ4EH	35073335	gold, Green Published			2023-01-03	WOS:000773223800014
J	Lin, ML; Chu, KH				Lin, Min-Ling; Chu, Kuei-Hui			The experience of urgent dialysis patients with end-stage renal disease: A qualitative study	PLOS ONE			English	Article							HEMODIALYSIS; TAIWAN	Purpose Taiwan is among the countries with the highest global prevalence of chronic renal disease. However, when advised to undergo dialysis therapy, patients with end-stage renal disease often hesitate. Attitudes toward medication and Taiwanese cultures are the main reasons for this delay, and delay conditioning requires urgent dialysis. This study aimed to explore the experience of urgent dialysis patients with end-stage renal disease. Methods This study used a purposive sampling strategy with semi-structured interviews leading to in-depth interviews. Patients were recruited from the nephrology ward and hemodialysis center of a northern Taiwanese hospital. All participants were aged over 20 years with end-stage renal disease. Although advised by doctors to undergo dialysis, these patients delayed their treatment and later suffered severe complications. After emergency hospitalization, the patients' condition improved. Data were analyzed by content analysis. Results Interviews with five participants suffering from end-stage renal disease identified six themes: "experiencing a sudden jolt," "silent organ brings the most pain," "feeling angry: why me?," "facing a dilemma," "taking risks," and "facing consequences." Conclusion These patients delayed their treatment and later suffered severe complications, even though doctors advised them to undergo dialysis. Health professionals play an important role in communication and coordination, assisting patients in coping with their situation. The analysis of the reasons for the delay in undergoing dialysis, therefore, should help health professionals provide proper guidance and care to patients who are faced with the decision to accept dialysis treatment.	[Lin, Min-Ling] Mackay Mem Hosp, Taipei, Taiwan; [Chu, Kuei-Hui] Ching Kuo Inst Management & Hlth, Dept Nursing, Keelung, Taiwan	Mackay Memorial Hospital	Chu, KH (corresponding author), Ching Kuo Inst Management & Hlth, Dept Nursing, Keelung, Taiwan.	kueihuichu@gmail.com	Chu, Kuei hui/GQO-9535-2022	Chu, Kuei-Hui/0000-0002-4845-3901	Taiwan Nurses Association [1062002]	Taiwan Nurses Association	Initials of the authors who received each award:Kuei Hui Chu Source of Funding This study was funded by the Taiwan Nurses Association [grant no 1062002]. URL of each funder website: https://www.twna.org.tw/frontend/un10open/welcome.asp The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chang YK, 2015, NEPHROLOGY, V20, P243, DOI 10.1111/nep.12380; Chen C.C., 2013, TAIPEI CITY MED J, V10, P101, DOI [10.6200/TCMJ.2013.10.2.01, DOI 10.6200/TCMJ.2013.10.2.01]; Chen NH, 2018, J CLIN NURS, V27, pE138, DOI 10.1111/jocn.13890; ChenM K, 2014, J KAOHSIUNG BEHAV SC, V4, P29; Chiang HH, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-78; El Shayeb Mohamed, 2012, BMC Res Notes, V5, P269, DOI 10.1186/1756-0500-5-269; Lin CC, 2013, J NURS RES, V21, P120, DOI 10.1097/jnr.0b013e3182921fb8; McPherson L, 2017, CLIN TRANSPLANT, V31, DOI 10.1111/ctr.12991; Ministry of Health and Welfare, 2019, DEATH CAUS STAT; Prieto-Velasco M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138811; Sellars M, 2018, AM J KIDNEY DIS, V71, P216, DOI 10.1053/j.ajkd.2017.07.021; Tchape ODM, 2018, PAN AFR MED J, V30, DOI 10.11604/pamj.2018.30.49.15180; United States Renal Data System, 2016, END STAGE REN DIS US; Wu CY, 2016, KAOHSIUNG J NURSING, V33, P53, DOI [10.6692/ KJN-2016-33-1-6, DOI 10.6692/KJN-2016-33-1-6]; Wu MY, 2018, NEPHROLOGY, V23, P112, DOI 10.1111/nep.13460; Yang YC, 2013, J TAIWAN NEPHROLOGY, V12, P87; Yu IC, 2013, J ADV NURS, V69, P1943, DOI 10.1111/jan.12055	17	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0261941	10.1371/journal.pone.0261941	http://dx.doi.org/10.1371/journal.pone.0261941			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061747	gold, Green Published			2023-01-03	WOS:000791072800075
J	Lingvay, I; Sumithran, P; Cohen, RV; Le Roux, CW				Lingvay, Ildiko; Sumithran, Priya; Cohen, Ricardo, V; le Roux, Carel W.			Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation	LANCET			English	Review							LIFE-STYLE INTERVENTION; GASTRIC BYPASS-SURGERY; SEMAGLUTIDE 2.4 MG; WEIGHT-LOSS; BARIATRIC SURGERY; CARDIOVASCULAR OUTCOMES; 5-YEAR OUTCOMES; MEDICAL THERAPY; BODY-WEIGHT; TERM	Obesity is now recognised as a disease that is associated with serious morbidity and increased mortality. One of its main metabolic complications is type 2 diabetes, as the two conditions share key pathophysiological mechanisms. Weight loss is known to reverse the underlying metabolic abnormalities of type 2 diabetes and, as such, improve glucose control; loss of 15% or more of bodyweight can have a disease-modifying effect in people with type 2 diabetes, an outcome that is not attainable by any other glucose-lowering intervention. Furthermore, weight loss in this population exerts benefits that extend beyond glycaemic control to improve risk factors for cardiometabolic disease and quality of life. We review the evidence supporting the role of weight loss in the management of type 2 diabetes and propose that many patients with type 2 diabetes would benefit from having a primary weight-centric approach to diabetes treatment. We discuss the logistical challenges to implementing a new weight-centric primary treatment goal in people with type 2 diabetes.	[Lingvay, Ildiko] Univ Texas Southwestern Med Ctr Dallas, Div Endocrinol, Dept Internal Med, Dallas, TX 75390 USA; [Lingvay, Ildiko] Univ Texas Southwestern Med Ctr Dallas, Dept Populat & Data Sci, Dallas, TX 75390 USA; [Sumithran, Priya] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia; [Sumithran, Priya] Austin Hlth, Dept Endocrinol, Melbourne, Vic, Australia; [Cohen, Ricardo, V] Oswaldo Cruz German Hosp, Ctr Obes & Diabet, Sao Paulo, Brazil; [le Roux, Carel W.] Univ Coll Dublin, Diabet Complicat Res Ctr, Sch Med, Conway Inst, Dublin, Ireland; [le Roux, Carel W.] Ulster Univ, Diabet Res Ctr, Coleraine, Londonderry, North Ireland	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; St Vincent's Hospital Melbourne; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University College Dublin; Ulster University	Lingvay, I (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Div Endocrinol, Dept Internal Med, Dallas, TX 75390 USA.	ildiko.lingvay@utsouthwestern.edu						Adams TD, 2017, NEW ENGL J MED, V377, P1143, DOI 10.1056/NEJMoa1700459; Amer Diabet Assoc, 2021, DIABETES CARE, V44, pS111, DOI 10.2337/dc21-S009; Amer Diabet Assoc, 2016, DIABETES CARE, V39, pS47, DOI 10.2337/dc16-S009; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Aminian A, 2019, JAMA-J AM MED ASSOC, V322, P1271, DOI 10.1001/jama.2019.14231; [Anonymous], 2015, DIABETES CARE, V38, pS1, DOI 10.2337/dc15-S001; Apovian CM, 2015, J CLIN ENDOCR METAB, V100, P342, DOI 10.1210/jc.2014-3415; Arnett DK, 2019, J AM COLL CARDIOL, V74, pE177, DOI 10.1016/j.jacc.2019.03.010; Aroda VR, 2019, DIABETES METAB, V45, P409, DOI 10.1016/j.diabet.2018.12.001; Aronne LJ, 2021, OBESITY, V29, pS9, DOI 10.1002/oby.23086; Aschner P, 2010, DIABETES OBES METAB, V12, P252, DOI 10.1111/j.1463-1326.2009.01187.x; Batterham RL, 2016, DIABETES CARE, V39, P893, DOI 10.2337/dc16-0145; Bays HE, 2011, J AM COLL CARDIOL, V57, P2461, DOI 10.1016/j.jacc.2011.02.038; Benotti PN, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005126; Buse JB, 2009, DIABETES CARE, V32, P2133, DOI 10.2337/dc09-9036; Cefalu WT, 2015, DIABETES CARE, V38, P1567, DOI 10.2337/dc15-1081; Cohen RV, 2020, JAMA SURG, V155, DOI 10.1001/jamasurg.2020.0420; Cosentino F., 2020, EUR HEART J, V41, P255, DOI [10.1093/eurheartj/ehz486, DOI 10.1093/eurheartj/ehz486]; Courcoulas AP, 2020, J CLIN ENDOCR METAB, V105, P866, DOI 10.1210/clinem/dgaa006; Davies M, 2021, LANCET, V397, P971, DOI 10.1016/S0140-6736(21)00213-0; Davies MJ, 2015, JAMA-J AM MED ASSOC, V314, P687, DOI 10.1001/jama.2015.9676; Dixon JB, 2011, DIABETIC MED, V28, P628, DOI 10.1111/j.1464-5491.2011.03306.x; Dixon JB, 2008, JAMA-J AM MED ASSOC, V299, P316, DOI 10.1001/jama.299.3.316; Enebo LB, 2021, LANCET, V397, P1736, DOI 10.1016/S0140-6736(21)00845-X; English WJ, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.01.88; Franz MJ, 2007, J AM DIET ASSOC, V107, P1755, DOI 10.1016/j.jada.2007.07.017; Frias JP, 2021, NEW ENGL J MED, V385, P503, DOI 10.1056/NEJMoa2107519; Gadde KM, 2011, LANCET, V377, P1341, DOI 10.1016/S0140-6736(11)60205-5; Garvey WT, 2014, DIABETES CARE, V37, P3309, DOI 10.2337/dc14-0930; Gregg EW, 2016, LANCET DIABETES ENDO, V4, P913, DOI 10.1016/S2213-8587(16)30162-0; Gregg EW, 2012, JAMA-J AM MED ASSOC, V308, P2489, DOI 10.1001/jama.2012.67929; Haddock CK, 2002, INT J OBESITY, V26, P262, DOI 10.1038/sj.ijo.0801889; Heneghan HM, 2011, AM J CARDIOL, V108, P1499, DOI 10.1016/j.amjcard.2011.06.076; Hernandez AF, 2018, LANCET, V392, P1519, DOI 10.1016/S0140-6736(18)32261-X; Hollander PA, 2003, DIABETES CARE, V26, P784, DOI 10.2337/diacare.26.3.784; Hollander P, 2013, DIABETES CARE, V36, P4022, DOI 10.2337/dc13-0234; Ikramuddin S, 2018, JAMA-J AM MED ASSOC, V319, P266, DOI 10.1001/jama.2017.20813; Inzucchi SE, 2018, DIABETES CARE, V41, P356, DOI 10.2337/dc17-1096; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Kelley DE, 2002, DIABETES CARE, V25, P1033, DOI 10.2337/diacare.25.6.1033; Khera R, 2018, GASTROENTEROLOGY, V154, P1309, DOI 10.1053/j.gastro.2017.12.024; Khera R, 2016, JAMA-J AM MED ASSOC, V315, P2424, DOI 10.1001/jama.2016.7602; Knowler WC, 2014, LANCET DIABETES ENDO, V2, P801, DOI 10.1016/S2213-8587(14)70156-1; Kristensen SL, 2019, LANCET DIABETES ENDO, V7, P776, DOI 10.1016/S2213-8587(19)30249-9; Lau DCW, LANCET; Lean MEJ, 2019, LANCET DIABETES ENDO, V7, P344, DOI 10.1016/S2213-8587(19)30068-3; Lean MEJ, 2018, LANCET, V391, P541, DOI 10.1016/S0140-6736(17)33102-1; Lee MMY, 2020, ARTERIOSCL THROM VAS, V40, P506, DOI 10.1161/ATVBAHA.119.311904; Lewis KH, 2019, OBESITY, V27, P591, DOI 10.1002/oby.22430; Ludvik B, 2021, LANCET, V398, P583, DOI 10.1016/S0140-6736(21)01443-4; Maciejewski ML, 2016, JAMA SURG, V151, P1046, DOI 10.1001/jamasurg.2016.2317; Madsen LR, 2019, DIABETOLOGIA, V62, P611, DOI 10.1007/s00125-019-4816-2; Magkos F, 2016, CELL METAB, V23, P591, DOI 10.1016/j.cmet.2016.02.005; Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827; McGuire DK, 2021, JAMA CARDIOL, V6, P148, DOI 10.1001/jamacardio.2020.4511; Mechanick JI, 2017, ENDOCR PRACT, V23, P372, DOI 10.4158/EP161688.PS; Mingrone G, 2021, LANCET, V397, P293, DOI 10.1016/S0140-6736(20)32649-0; Nahra R, 2021, DIABETES CARE, V44, P1433, DOI 10.2337/dc20-2151; Navaneethan SD, 2009, CLIN J AM SOC NEPHRO, V4, P1565, DOI 10.2215/CJN.02250409; Palaniappan LP, 2002, DIABETES CARE, V25, P1351, DOI 10.2337/diacare.25.8.1351; Palmer SC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.m4573; Panunzi S, 2016, DIABETES CARE, V39, P166, DOI 10.2337/dc15-0575; Park CH, 2019, OBES SURG, V29, P2180, DOI 10.1007/s11695-019-03831-6; PISUNYER FX, 1993, ANN INTERN MED, V119, P722, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00019; Polemiti E, 2021, DIABETOLOGIA, V64, P814, DOI 10.1007/s00125-020-05362-7; Riddle Matthew C, 2021, Diabetologia, V64, P2359, DOI 10.1007/s00125-021-05542-z; Rosenstock J, 2021, LANCET, V398, P143, DOI 10.1016/S0140-6736(21)01324-6; Schauer PR, 2017, NEW ENGL J MED, V376, P641, DOI 10.1056/NEJMoa1600869; Simonson DC, 2018, DIABETES CARE, V41, P670, DOI 10.2337/dc17-0487; Sjoholm K, 2016, DIABETES CARE, V39, P625, DOI 10.2337/dc15-1407; Sjoholm K, 2015, DIABETOLOGIA, V58, P1448, DOI 10.1007/s00125-015-3591-y; Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254; Sjostrom L, 2014, JAMA-J AM MED ASSOC, V311, P2297, DOI 10.1001/jama.2014.5988; Smith SR, 2010, NEW ENGL J MED, V363, P245, DOI 10.1056/NEJMoa0909809; Stefan N, 2013, LANCET DIABETES ENDO, V1, P152, DOI 10.1016/S2213-8587(13)70062-7; Sumithran P, 2013, CLIN SCI, V124, P231, DOI 10.1042/CS20120223; Teufel F, 2021, LANCET, V398, P238, DOI 10.1016/S0140-6736(21)00844-8; Tuomi T, 2014, LANCET, V383, P1084, DOI 10.1016/S0140-6736(13)62219-9; Vandvik O, LANCET; Wadden TA, 2013, INT J OBESITY, V37, P1443, DOI 10.1038/ijo.2013.120; Wadden TA, 2021, JAMA-J AM MED ASSOC, V325, P1403, DOI 10.1001/jama.2021.1831; WALL JR, 1973, BMJ-BRIT MED J, V1, P577, DOI 10.1136/bmj.1.5853.577; Wentworth JM, 2017, DIABETES CARE, V40, pE44, DOI 10.2337/dc16-2149; who, OBESITY; Wilding JPH, 2021, NEW ENGL J MED, V384, P989, DOI 10.1056/NEJMoa2032183; Wilding JPH, 2018, DIABETOLOGIA, V61, P265, DOI 10.1007/s00125-017-4288-1; Wing R, 2013, NEW ENGL J MED, V369, P145, DOI 10.1056/NEJMoa1212914; Zelniker TA, 2019, CIRCULATION, V139, P2022, DOI 10.1161/CIRCULATIONAHA.118.038868; Zelniker TA, 2019, LANCET, V393, P31, DOI 10.1016/S0140-6736(18)32590-X	89	53	54	71	132	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN	2022	399	10322					394	405		10.1016/S0140-6736(21)01919-X	http://dx.doi.org/10.1016/S0140-6736(21)01919-X			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL7CQ	34600604				2023-01-03	WOS:000746046100023
J	Sander, B; Finkelstein, Y; Lu, H; Nagamuthu, C; Graves, E; Ramsay, LC; Kwong, JC; Schuh, S				Sander, Beate; Finkelstein, Yaron; Lu, Hong; Nagamuthu, Chenthila; Graves, Erin; Ramsay, Lauren C.; Kwong, Jeffrey C.; Schuh, Suzanne			Healthcare cost attributable to bronchiolitis: A population-based cohort study	PLOS ONE			English	Article							PROSPECTIVE MULTICENTER; RISK-FACTORS; CHILDREN; HOSPITALIZATIONS; MANAGEMENT; DIAGNOSIS; INFECTIONS; PREDICTORS; GUIDELINE; DISCHARGE	Objective To determine 1-year attributable healthcare costs of bronchiolitis. Methods Using a population-based matched cohort and incidence-based cost analysis approach, we identified infants <12 months old diagnosed in an emergency department (ED) or hospitalized with bronchiolitis between April 1, 2003 and March 31, 2014. We propensity-score matched infants with and without bronchiolitis on sex, age, income quintile, rurality, co-morbidities, gestational weeks, small-for-gestational-age status and pre-index healthcare cost deciles. We calculated mean attributable 1-year costs using a generalized estimating equation model and stratified costs by age, sex, income quintile, rurality, co-morbidities and prematurity. Results We identified 58,375 infants with bronchiolitis (mean age 15495 days, 61.3% males, 4.2% with comorbidities). Total 1-year mean bronchiolitis-attributable costs were $4,313 per patient (95%CI: $4,148-4,477), with $2,847 (95%CI: $2,712-2,982) spent on hospitalizations, $610 (95%CI: $594-627) on physician services, $562 (95%CI: $556-567)] on ED visits, $259 (95%CI: $222-297) on other healthcare costs and $35 ($27-42) on drugs. Attributable bronchiolitis costs were $2,765 (95%CI: $2735-2,794) vs $111 (95%CI: $102-121) in the initial 10 days post index date, $4,695 (95%CI: $4,589-4,800) vs $910 (95%CI: $847-973) in the initial 180 days and $1,158 (95%CI: $1,104-1213) vs $639 (95%CI: $599-679) during days 181-360. Mean 1-year bronchiolitis costs were higher in infants <3 months old [$5,536 (95%CI: $5,216-5,856)], those with co-morbidities [$17,530 (95%CI: $14,683-20,377)] and with low birthweight [$5,509 (95%CI: $4,927-6,091)]. Conclusions Compared to no bronchiolitis, bronchiolitis incurs five-time and two-time higher healthcare costs within the initial and subsequent six-months, respectively. Most expenses occur in the initial 10 days and relate to hospitalization.	[Sander, Beate; Ramsay, Lauren C.; Kwong, Jeffrey C.] Univ Hlth Network, Toronto, ON, Canada; [Sander, Beate; Finkelstein, Yaron; Ramsay, Lauren C.; Kwong, Jeffrey C.; Schuh, Suzanne] Univ Toronto, Toronto, ON, Canada; [Sander, Beate; Finkelstein, Yaron; Lu, Hong; Nagamuthu, Chenthila; Graves, Erin; Kwong, Jeffrey C.] ICES, Toronto, ON, Canada; [Sander, Beate; Kwong, Jeffrey C.] Publ Hlth Ontario, Toronto, ON, Canada; [Finkelstein, Yaron; Schuh, Suzanne] Hosp Sick Children, Dept Paediat, Toronto, ON, Canada; [Finkelstein, Yaron; Schuh, Suzanne] Hosp Sick Children, Res Inst, Div Child Hlth Evaluat Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Sander, B (corresponding author), Univ Hlth Network, Toronto, ON, Canada.; Sander, B (corresponding author), Univ Toronto, Toronto, ON, Canada.; Sander, B (corresponding author), ICES, Toronto, ON, Canada.; Sander, B (corresponding author), Publ Hlth Ontario, Toronto, ON, Canada.	beate.sander@uhnresearch.ca	Sander, Beate/P-7665-2018	Sander, Beate/0000-0003-2128-9133	Physicians Services Incorporated (P.S.I.) Foundation; ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC); Canada Research Chair [CRC-950-232429]	Physicians Services Incorporated (P.S.I.) Foundation; ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	This study was funded by The Physicians Services Incorporated (P.S.I.) Foundation. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Parts of this material are based on data and information compiled and provided by the MOHLTC, Canadian Institute for Health Information and Cancer Care Ontario. We thank IMS Brogan Inc. for use of their Drug Information Database. This research was supported, in part, by a Canada Research Chair held by Beate Sander (CRC-950-232429). The analyses, conclusions, opinions and statements expressed herein are those of the authors and do not necessarily reflect those of the funding or data sources; no endorsement is intended or should be inferred. The funder had no role in the study design, data collection, analysis or interpretation of data, writing of the manuscript or the decision to submit the manuscript for publication.	Akenroye AT, 2014, PEDIATRICS, V133, pE227, DOI 10.1542/peds.2013-1991; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Barben J, 2008, THORAX, V63, P1103, DOI 10.1136/thx.2007.094706; Bryan MA, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-3432; Cunningham S, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19710; Diez-Domingo J, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0544-x; Ehlken B, 2005, EUR J PEDIATR, V164, P607, DOI 10.1007/s00431-005-1705-0; Evans J, 2012, PEDIATR PULM, V47, P381, DOI 10.1002/ppul.21549; Feudtner C, 2000, PEDIATRICS, V106, P205; Friedman JN, 2014, PAED CHILD HEALT-CAN, V19, P484, DOI 10.1093/pch/19.9.485; Gong C, 2019, PEDIATR EMERG CARE, V35, P323, DOI 10.1097/PEC.0000000000001145; Government of Ontario, 2017, ONT REN EARL YEARS C; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Hasegawa K, 2013, PEDIATRICS, V132, P28, DOI 10.1542/peds.2012-3877; Jamal A, 2019, LANCET CHILD ADOLESC, V3, P539, DOI 10.1016/S2352-4642(19)30193-2; Kramer R, 2018, VACCINE, V36, P6591, DOI 10.1016/j.vaccine.2018.09.029; LEBEL M H, 1989, Archives of Disease in Childhood, V64, P1431; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; Mansbach JM, 2005, PEDIATR EMERG CARE, V21, P242, DOI 10.1097/01.pec.0000161469.19841.86; Mansbach JM, 2012, PEDIATRICS, V130, pE492, DOI 10.1542/peds.2012-0444; Marlais M, 2011, ARCH DIS CHILD, V96, P648, DOI 10.1136/adc.2010.201079; Mecklin M, 2014, ACTA PAEDIATR, V103, P946, DOI 10.1111/apa.12671; National Institute for Health and Care Excellence, 2016, NICE TECHN APPR GUID; Norwood A, 2010, ACAD EMERG MED, V17, P376, DOI 10.1111/j.1553-2712.2010.00699.x; O'Brien S, 2019, J PAEDIATR CHILD H, V55, P42, DOI 10.1111/jpc.14104; Pelletier AJ, 2006, PEDIATRICS, V118, P2418, DOI 10.1542/peds.2006-1193; Prodhan P, 2011, AM J EMERG MED, V29, P168, DOI 10.1016/j.ajem.2009.08.020; Ralston S, 2013, J HOSP MED, V8, P25, DOI 10.1002/jhm.1982; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Ray JG, 2012, J OBSTET GYNAECOL CA, V34, P159, DOI 10.1016/S1701-2163(16)35159-3; Rodriguez-Martinez CE, 2019, J EVAL CLIN PRACT, V25, P682, DOI 10.1111/jep.13157; Schlapbach LJ, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01648-2016; Schuh S, 2018, J PEDIATR-US, V199, P217, DOI 10.1016/j.jpeds.2018.04.010; Schuh S, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0842; Scottish Intercollegiate Guidelines Network, 2006, BRONCH CHILDR NATL C; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Sumner A, 2010, PEDIATRICS, V126, P623, DOI 10.1542/peds.2009-3663; TISSING WJE, 1993, EUR J PEDIATR, V152, P125, DOI 10.1007/BF02072488; Turner T, 2008, Aust Fam Physician, V37, P6; WANG EEL, 1995, J PEDIATR-US, V126, P212, DOI 10.1016/S0022-3476(95)70547-3; Willwerth BM, 2006, ANN EMERG MED, V48, P441, DOI 10.1016/j.annemergmed.2006.03.021; Wodchis WP., 2013, GUIDELINES PERSON LE; Yorita KL, 2008, PEDIATRICS, V121, P244, DOI 10.1542/peds.2007-1392	43	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2021	16	12							e0260809	10.1371/journal.pone.0260809	http://dx.doi.org/10.1371/journal.pone.0260809			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW0CT	34855892	Green Published, gold			2023-01-03	WOS:000735299000129
J	Moustaqim-Barrette, A; Papamihali, K; Williams, S; Ferguson, M; Moe, J; Purssell, R; Buxton, JA				Moustaqim-Barrette, Amina; Papamihali, Kristi; Williams, Sierra; Ferguson, Max; Moe, Jessica; Purssell, Roy; Buxton, Jane A.			Adverse events related to bystander naloxone administration in cases of suspected opioid overdose in British Columbia: An observational study	PLOS ONE			English	Article							INTRAMUSCULAR NALOXONE; USERS; INTRANASAL; PREVENTION; PROGRAM; SAFETY; TRIAL	Introduction Take-Home Naloxone programs have been introduced across North America in response to rising opioid overdose deaths. There is currently limited real-world data on bystander naloxone administration, overdose outcomes, and evidence related to adverse events following bystander naloxone administration. Methods The research team used descriptive statistics from Take-Home Naloxone administration forms. We explored reported demographic variables and adverse events among people who received by-stander administered naloxone in a suspected opioid overdose event between August 31, 2012 and December 31, 2018 in British Columbia. We examined and contextualized differences across years given policy, program and drug toxicity changes. We used multivariate logistic regression to examine whether an association exists between number of ampoules of naloxone administered and the odds that the recipient will experience withdrawal symptoms. Results A large majority (98.1%) of individuals who were administered naloxone survived their overdose and 69.2% had no or only mild withdrawal symptoms. Receiving three (Adjusted Odds Ratio (AOR) 1.64 (95% Confidence Interval (CI): 1.08-2.48)) or four or more (AOR 2.19 (95% CI: 1.32-3.62)) ampoules of naloxone was significantly associated with odds of moderate or severe withdrawal compared to receiving one ampoule of naloxone. Conclusions This study provides evidence from thousands of bystander reversed opioid overdoses using Take-Home Naloxone kits in British Columbia, and suggests bystander-administered naloxone is safe and effective for opioid overdose reversal. Data suggests an emphasis on titration during bystander naloxone training in situations where the person experiencing overdose can be adequately ventilated may help avoid severe withdrawal symptoms. We identified a decreasing trend in the likelihood of moderate or severe withdrawal over the study period.	[Moustaqim-Barrette, Amina; Papamihali, Kristi; Williams, Sierra; Ferguson, Max; Moe, Jessica; Purssell, Roy; Buxton, Jane A.] BC Ctr Dis Control, Vancouver, BC, Canada; [Moe, Jessica; Purssell, Roy] Univ British Columbia, Fac Med, Dept Emergency Med, Vancouver, BC, Canada; [Buxton, Jane A.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada	University of British Columbia; University of British Columbia	Buxton, JA (corresponding author), BC Ctr Dis Control, Vancouver, BC, Canada.; Buxton, JA (corresponding author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.	jane.buxton@bccdc.ca		Moustaqim-Barrette, Amina/0000-0003-1601-1604; Ferguson, Max/0000-0002-1911-0117				[Anonymous], 2020, WORLD HLTH ORG, DOI DOI 10.1080/09639284.2021.1971095; [Anonymous], STEP FUNCTION R DOCU; Azur MJ, 2011, INT J METH PSYCH RES, V20, P40, DOI 10.1002/mpr.329; BC Centre for Disease Control, 2021, CLIN PREVENTION SERV; BC Centre for Disease Control, 2020, HEART; Bennett AS, 2011, J URBAN HEALTH, V88, P1020, DOI 10.1007/s11524-011-9600-7; Bluthenthal RN, 2020, DRUG ALCOHOL DEPEN, V211, DOI 10.1016/j.drugalcdep.2020.107932; Coffin PO, 2007, ACAD EMERG MED, V14, P616, DOI [10.1197/j.aem.2007.04.005, 10.1111/j.1553-2712.2007.tb01846.x]; Commissioner O of the, 2021, FDA APPR HIGH DOS NA; Connors NJ, 2016, J MED TOXICOL, V12, P276, DOI 10.1007/s13181-016-0559-3; CUSS FM, 1984, BRIT MED J, V288, P363, DOI 10.1136/bmj.288.6414.363; Enteen L, 2010, J URBAN HEALTH, V87, P931, DOI 10.1007/s11524-010-9495-8; Fischer B, 2014, ADDICTION, V109, P177, DOI 10.1111/add.12224; Giglio Rebecca E, 2015, Inj Epidemiol, V2, P10; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Health Canada, 2021, DRUG AN SERV, P2021; Health Canada, 2019, CAN DIET GUID; Hill LG, 2022, INT J DRUG POLICY, V99, DOI 10.1016/j.drugpo.2021.103457; Hosmer DW, 2013, WILEY SER PROBAB ST, P89; Irvine MA, 2019, ADDICTION, V114, P1602, DOI 10.1111/add.14664; Kelly AM, 2005, MED J AUSTRALIA, V182, P24, DOI 10.5694/j.1326-5377.2005.tb06550.x; Kerr D, 2009, ADDICTION, V104, P2067, DOI 10.1111/j.1360-0443.2009.02724.x; Kim HK, 2015, EXPERT OPIN DRUG SAF, V14, P1137, DOI 10.1517/14740338.2015.1037274; LOIMER N, 1994, INT J ADDICT, V29, P819, DOI 10.3109/10826089409047912; Long V, 2020, REPORT BRIT COLUMBIA; Maxwell S, 2006, J ADDICT DIS, V25, P89, DOI 10.1300/J069v25n03_11; McDonald R, 2016, ADDICTION, V111, P1177, DOI 10.1111/add.13326; Moe J., NALOXONE DOSING ERA, V9; Moe J, 2020, CAN J EMERG MED, V22, P178, DOI 10.1017/cem.2019.471; Moustaqim-Barrette A, 2019, DRUG ALCOHOL DEPEN, V205, DOI 10.1016/j.drugalcdep.2019.107609; Moustaqim-Barrette Amina, 2019, ENV SCAN NALOXONE AC; Nath Soumya Shankar, 2009, Indian J Med Sci, V63, P72; NGAI SH, 1976, ANESTHESIOLOGY, V44, P398, DOI 10.1097/00000542-197605000-00008; Purssell R, 2021, B C MED J, V63, P177; Purssell R, 2021, CLIN TOXICOL, V59, P38, DOI 10.1080/15563650.2020.1758325; REED CR, 1991, CHEST, V100, P1120, DOI 10.1378/chest.100.4.1120; Rowe C, 2015, ADDICTION, V110, P1301, DOI 10.1111/add.12961; Sporer KA, 2001, CHEST, V120, P1628, DOI 10.1378/chest.120.5.1628; Take Home Naloxone Sites, HEART; The R Foundation, 2019, R R PROJ STAT COMP; Toward the Heart BC Centre for Disease Control (BCCDC), 2018, TAK HOM NAL OV RESP; Wermeling DP, 2015, THER ADV DRUG SAF, V6, P20, DOI 10.1177/2042098614564776; Young S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030046	44	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2021	16	10							e0259126	10.1371/journal.pone.0259126	http://dx.doi.org/10.1371/journal.pone.0259126			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY8NO	34714854	Green Published, gold			2023-01-03	WOS:000755042500028
J	Sell, SL; Prough, DS; Weisz, HA; Widen, SG; Hellmich, HL				Sell, Stacy L.; Prough, Donald S.; Weisz, Harris A.; Widen, Steve G.; Hellmich, Helen L.			Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19	PLOS ONE			English	Article							SARS-CORONAVIRUS; INNATE; IMMUNITY; MITOCHONDRIA; EXPRESSION; DISEASE	Many important questions remain regarding severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the viral pathogen responsible for COVID-19. These questions include the mechanisms explaining the high percentage of asymptomatic but highly infectious individuals, the wide variability in disease susceptibility, and the mechanisms of long-lasting debilitating effects. Bioinformatic analysis of four coronavirus datasets representing previous outbreaks (SARS-CoV-1 and MERS-CoV), as well as SARS-CoV-2, revealed evidence of diverse host factors that appear to be coopted to facilitate virus-induced suppression of interferon-induced innate immunity, promotion of viral replication and subversion and/or evasion of antiviral immune surveillance. These host factors merit further study given their postulated roles in COVID-19-induced loss of smell and brain, heart, vascular, lung, liver, and gut dysfunction.	[Sell, Stacy L.; Prough, Donald S.; Weisz, Harris A.; Hellmich, Helen L.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Widen, Steve G.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Hellmich, HL (corresponding author), Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA.	hhellmic@utmb.edu						Akbar AN, 2020, SCIENCE, V369, P256, DOI 10.1126/science.abb0762; Akhova O, 2005, J VIROL, V79, P14708, DOI 10.1128/JVI.79.23.14708-14718.2005; Allers K, 2015, CURR OPIN VIROL, V14, P24, DOI 10.1016/j.coviro.2015.06.007; Bansal M, 2020, DIABETES METAB SYND, V14, P247, DOI 10.1016/j.dsx.2020.03.013; Barrat FJ, 2019, NAT IMMUNOL, V20, P1574, DOI 10.1038/s41590-019-0466-2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Buchanan AH, 2020, GENET MED, DOI 10.1038/s41436-020-0876-4; Buckland MS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19761-2; Chambers C, 2020, JAMA-J AM MED ASSOC, V324, P1347, DOI 10.1001/jama.2020.15580; Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757; Cui AY, 2019, DIABETES, V68, DOI 10.2337/db19-311-OR; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; del Rio C, 2020, JAMA-J AM MED ASSOC, V324, P1723, DOI 10.1001/jama.2020.19719; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El Moheb M, 2020, JAMA-J AM MED ASSOC, V324, P1899, DOI 10.1001/jama.2020.19400; Elnagdy S, 2020, ACS PHARMACOL TRANSL, V3, P780, DOI 10.1021/acsptsci.0c00059; Fahed AC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17374-3; Fatoki TH, 2021, J BIOMOL STRUCT DYN, V39, P6195, DOI 10.1080/07391102.2020.1794971; Fields GB, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090984; Finkel Y, 2021, NATURE, V594, P240, DOI 10.1038/s41586-021-03610-3; Fontes M, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-307; Frieman M, 2008, VIRUS RES, V133, P101, DOI 10.1016/j.virusres.2007.03.015; Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758; Gao XX, 2018, J INNATE IMMUN, V10, P315, DOI 10.1159/000489832; Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056; Huang SY, 2019, MOL THER-NUCL ACIDS, V17, P10, DOI 10.1016/j.omtn.2019.04.028; Huang W, 2017, GUT, V66, P301, DOI 10.1136/gutjnl-2015-309363; Jain U, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.9540; Jolliffe IT, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0202; Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727; Lechien JR, 2021, J INTERN MED, V290, P451, DOI 10.1111/joim.13209; Lee S, 2020, JAMA INTERN MED, V180, P1447, DOI 10.1001/jamainternmed.2020.3862; Lieberman NAP, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000849; Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134; Mesev EV, 2019, NAT MICROBIOL, V4, P914, DOI 10.1038/s41564-019-0421-x; MURTAGH F, 1983, COMPUT J, V26, P354, DOI 10.1093/comjnl/26.4.354; Ness TL, 2004, J IMMUNOL, V173, P6938, DOI 10.4049/jimmunol.173.11.6938; Newby AC, 2016, EXP PHYSIOL, V101, P1327, DOI 10.1113/EP085567; Nicolai L, 2020, CIRCULATION, V142, P1176, DOI 10.1161/CIRCULATIONAHA.120.048488; Ooi EE, 2020, LANCET INFECT DIS, V20, P996, DOI 10.1016/S1473-3099(20)30460-6; Park MS, 2018, BIOMOL THER, V26, P242, DOI 10.4062/biomolther.2017.172; Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026; Poon LLM, 2020, NAT MED, V26, P317, DOI 10.1038/s41591-020-0796-5; Qiu SH, 2018, HUM VACC IMMUNOTHER, V14, P1763, DOI 10.1080/21645515.2018.1450122; Rajpal S, 2021, JAMA CARDIOL, V6, P116, DOI 10.1001/jamacardio.2020.4916; Roman GC, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116884; Rubino F, 2020, NEW ENGL J MED, V383, P789, DOI [10.1056/NEJMc2018688, 10.1056/NEJMc2021832]; Sariol A, 2020, IMMUNITY, V53, P248, DOI 10.1016/j.immuni.2020.07.005; Sechet E, 2018, P NATL ACAD SCI USA, V115, pE9869, DOI 10.1073/pnas.1805298115; Sell SL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234185; Shao MJ, 2020, J GERIATR CARDIOL, V17, P224, DOI 10.11909/j.issn.1671-5411.2020.04.009; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Shi CS, 2014, J IMMUNOL, V193, P3080, DOI 10.4049/jimmunol.1303196; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; Wadman M., 2020, SCI 0605; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; Weinberg SE, 2015, IMMUNITY, V42, P406, DOI 10.1016/j.immuni.2015.02.002; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; World Health Organization, 2020, COR DIS COVID 19 PAN; Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435; Yaqinuddin A, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109777; Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560; Zhang R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077256; Zhao T, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00303-7	64	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2021	16	9							e0257965	10.1371/journal.pone.0257965	http://dx.doi.org/10.1371/journal.pone.0257965			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5RU	34587192	Green Published, gold			2023-01-03	WOS:000707052600047
J	alvarez-Villarreal, M; Velarde-Garcia, JF; Garcia-Bravo, C; Carrasco-Garrido, P; Jimenez-Antona, C; Moro-Lopez-Menchero, P; Palacios-Cena, D				alvarez-Villarreal, Miriam; Velarde-Garcia, Juan Francisco; Garcia-Bravo, Cristina; Carrasco-Garrido, Pilar; Jimenez-Antona, Carmen; Moro-Lopez-Menchero, Paloma; Palacios-Cena, Domingo			The experience of being a mother with end stage renal disease: A qualitative study of women receiving treatment at an ambulatory dialysis unit	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; PREGNANCY OUTCOMES; PERSPECTIVES; SEXUALITY; CHILDREN; BORN	Background End-stage kidney disease (ESKD) has considerable effects on the quality of life, impairing daily activities and leading to lifestyle changes. The purpose of this study was therefore to explore the experience of motherhood and taking care of children in women with ESKD. Methods A qualitative exploratory study was conducted based on an interpretive framework. Participants were recruited using non-probabilistic purposeful sampling. In total, 14 women with ESKD were included, who were treated at the dialysis unit of a Spanish hospital. In-depth interviews (unstructured and semi-structured interviews) and researchers' field notes were used to collect the data. A systematic text condensation analysis was performed. The techniques performed and application procedures used to control trustworthiness were credibility, transferability, dependability, and confirmability. Results Three themes emerged from the data. "Coping with being a mother" described how women are faced with the decision to become mothers and assess the risks of pregnancy. The second theme, called "Children and the experience of illness", highlighted the women's struggle to prevent the disease from affecting their children emotionally or disrupting their lives. The third theme, "Fear of genetic transmission", was based on the women's fear of passing the disease on to their children. Conclusions Deciding to become a mother and taking care of children represents a challenge for women with ESKD, coupled with the losses in their lives caused by the disease. These findings are only relevant to women on dialysis.	[alvarez-Villarreal, Miriam] Hosp Univ Infanta Cristina, Dialysis Unit, Parla, Spain; [Velarde-Garcia, Juan Francisco] Univ Autonoma Madrid, Inst Invest Sanitaria Gregorio Mara, Dept Nursing, Spanish Red Cross, Madrid, Spain; [Garcia-Bravo, Cristina] Funct & Disabil Univ Rey Juan Carlos IDI, Dept Phys Therapy Occupat Therapy Phys Med & Reha, Res Grp Evaluat & Assessment Capac, Alcorcon, Spain; [Carrasco-Garrido, Pilar] Univ Rey Juan Carlos, Dept Med Specialties & Publ Hlth, Alcorcon, Spain; [Jimenez-Antona, Carmen; Moro-Lopez-Menchero, Paloma; Palacios-Cena, Domingo] Univ Rey Juan Carlos Hum&QRinHS, Dept Phys Therapy Occupat Therapy Phys Med & Reha, Res Grp Humanities & Qualitat Res Hlth Sci, Alcorcon, Spain	Autonomous University of Madrid; Universidad Rey Juan Carlos	Velarde-Garcia, JF (corresponding author), Univ Autonoma Madrid, Inst Invest Sanitaria Gregorio Mara, Dept Nursing, Spanish Red Cross, Madrid, Spain.	jvg@cruzroja.es	García, Juan Francisco Velarde/ABE-3322-2020; García-Bravo, Cristina/X-6928-2019; PALACIOS-CEÑA, DOMINGO/B-6944-2015	García, Juan Francisco Velarde/0000-0002-5801-4857; García-Bravo, Cristina/0000-0002-6437-6758; PALACIOS-CEÑA, DOMINGO/0000-0003-0669-6339; MORO, PALOMA/0000-0003-4577-2680				Alvarez-Rangel Luis Enrique, 2019, Rev Med Inst Mex Seguro Soc, V57, P348; Beanlands H, 2020, CAN J KIDNEY HEALTH, V7, DOI 10.1177/2054358120945475; Bramham K, 2012, J NEPHROL, V25, P450, DOI 10.5301/jn.5000130; Cabiddu G, 2018, J NEPHROL, V31, P665, DOI 10.1007/s40620-018-0499-x; Fitzpatrick A, 2016, INT J WOMENS HEALTH, V8, DOI 10.2147/IJWH.S76819; Fu SH, 2013, AGING CLIN EXP RES, V25, P385, DOI 10.1007/s40520-013-0059-0; García Avendaño David Jahel, 2016, Rev Cuid, V7, P1144, DOI 10.15649/cuidarte.v7i1.167; Gupta R, 2021, SEMIN VASC SURG, V34, P71, DOI 10.1053/j.semvascsurg.2021.02.010; Hladunewich MA, 2017, SEMIN NEPHROL, V37, P337, DOI 10.1016/j.semnephrol.2017.05.005; Holdaas H., 2012, KIDNEY INT S, V2, P337, DOI [DOI 10.1038/KISUP.2012.46, 10.1038/kisup.2012.46]; Holley JL, 2013, ADV CHRONIC KIDNEY D, V20, P240, DOI 10.1053/j.ackd.2013.01.003; James MT, 2010, LANCET, V375, P1296, DOI 10.1016/S0140-6736(09)62004-3; Jesudason S, 2014, CLIN J AM SOC NEPHRO, V9, P143, DOI 10.2215/CJN.03560413; Lawrence C, 2013, J REN CARE, V39, P118, DOI 10.1111/j.1755-6686.2013.12012.x; Levin A, 2013, KIDNEY INT, V83, P1001, DOI 10.1038/ki.2013.91; Lewis H, 2015, CHRONIC ILLN, V11, P184, DOI 10.1177/1742395314566823; Lewis S, 2015, HEALTH PROMOT PRACT, V16, P473, DOI 10.1177/1524839915580941; Luders C, 2010, AM J KIDNEY DIS, V56, P77, DOI 10.1053/j.ajkd.2010.01.018; Malterud K, 2012, SCAND J PUBLIC HEALT, V40, P795, DOI 10.1177/1403494812465030; Munkhaugen J, 2009, NEPHROL DIAL TRANSPL, V24, P3744, DOI 10.1093/ndt/gfp320; Nadeau-Fredette AC, 2013, ADV CHRONIC KIDNEY D, V20, P246, DOI 10.1053/j.ackd.2013.01.010; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; Oliverio AL, 2020, ADV CHRONIC KIDNEY D, V27, P477, DOI 10.1053/j.ackd.2020.06.001; Phillips-Pula L, 2011, J PEDIATR HEALTH CAR, V25, P67, DOI 10.1016/j.pedhc.2010.09.004; Piccoli GB, 2018, KIDNEY INT REP, V3, P225, DOI 10.1016/j.ekir.2018.01.001; Piccoli GB, 2018, NEPHROLOGY, V23, P199, DOI 10.1111/nep.13193; Piccoli GB, 2018, J CLIN MED, V7, DOI 10.3390/jcm7060135; Piccoli GB, 2016, NEPHROL DIAL TRANSPL, V31, P1915, DOI 10.1093/ndt/gfv395; Piccoli GB, 2015, NEPHROL DIAL TRANSPL, V30, P1193, DOI 10.1093/ndt/gfv127; Piccoli GB, 2014, NEPHROL DIAL TRANSPL, V29, P1578, DOI 10.1093/ndt/gfu092; Provenzano M, 2020, NEPHROL DIAL TRANSPL, V35, P138, DOI 10.1093/ndt/gfy217; Ramirez-Ochoa M. C., 2008, Revista de Enfermeria del Instituto Mexicano des Seguro Social, V16, P145; Ramirez-Pereira M, 2018, REV NEFROL DIAL TRAS, V38, P35; Rojas Wilmer Gerardo, 2015, Acta Med Colomb, V40, P318; Saunders H, 2021, STATPEARLS; Segev DL, 2009, J AM SOC NEPHROL, V20, P621, DOI 10.1681/ASN.2008060591; Stevens LA, 2010, AM J KIDNEY DIS, V56, P486, DOI 10.1053/j.ajkd.2010.03.026; Stewart M, 2013, J ADV NURS, V69, P1704, DOI 10.1111/jan.12028; Tong A, 2015, AM J KIDNEY DIS, V66, P951, DOI 10.1053/j.ajkd.2015.08.023; Tong A, 2015, NEPHROL DIAL TRANSPL, V30, P652, DOI 10.1093/ndt/gfu378; Wadd KM, 2014, J RENAL CARE, V40, P140, DOI 10.1111/jorc.12066; Wyld ML, 2013, AM J TRANSPLANT, V13, P3173, DOI 10.1111/ajt.12452; Xiao J, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1860-0	43	0	0	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257691	10.1371/journal.pone.0257691	http://dx.doi.org/10.1371/journal.pone.0257691			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM7DR	34570806	gold, Green Published			2023-01-03	WOS:000728983400035
J	Laxminarayan, R				Laxminarayan, Ramanan			Supporting bereaved family members: three steps in the right direction	LANCET			English	Editorial Material							CARE		[Laxminarayan, Ramanan] Ctr Dis Dynam Econ & Policy, Washington, DC 20005 USA; [Laxminarayan, Ramanan] Global Antibiot Res & Dev Partnership, Geneva, Switzerland		Laxminarayan, R (corresponding author), Ctr Dis Dynam Econ & Policy, Washington, DC 20005 USA.; Laxminarayan, R (corresponding author), Global Antibiot Res & Dev Partnership, Geneva, Switzerland.	ramanan@cddep.org						Barnato AE, 2017, CRIT CARE MED, V45, P35, DOI 10.1097/CCM.0000000000002009; Crowe S, 2021, INTENS CRIT CARE NUR, V63, DOI 10.1016/j.iccn.2020.102999; Davidson JE, 2017, CRIT CARE MED, V45, P103, DOI 10.1097/CCM.0000000000002169; Downar J, 2018, INTENS CARE MED, V44, P521, DOI 10.1007/s00134-017-5027-2; Downar J, 2014, J CRIT CARE, V29, DOI 10.1016/j.jcrc.2013.11.024; Efstathiou N, 2019, J CRIT CARE, V50, P177, DOI 10.1016/j.jcrc.2018.11.026; Kentish-Barnes N, 2022, LANCET, V399, P656, DOI 10.1016/S0140-6736(21)02176-0; Shear MK, 2015, NEW ENGL J MED, V372, P153, DOI 10.1056/NEJMcp1315618; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; Vanderspank-Wright B, 2018, INT J NURS STUD, V77, P15, DOI 10.1016/j.ijnurstu.2017.09.012	10	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB	2022	399	10325					607	609		10.1016/S0140-6736(21)02446-6	http://dx.doi.org/10.1016/S0140-6736(21)02446-6		FEB 2022	4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YY1RO	35065010				2023-01-03	WOS:000754571600003
J	van Egmond, S; van Vliet, ED; Wakkee, M; Hollestein, LM; Pouwels, XGLV; Koffijberg, H; Misirli, Y; Bakkum, RSLA; Bastiaens, MT; Kukutsch, NA; Oosting, AJ; Plasmeijer, EI; van Rengen, A; de Roos, KP; Nijsten, TEC; de Vries, E; de Bekker-Grob, EW				van Egmond, Sven; van Vliet, Ella D.; Wakkee, Marlies; Hollestein, Loes M.; Pouwels, Xavier G. L., V; Koffijberg, Hendrik; Misirli, Yesim; Bakkum, Rachel S. L. A.; Bastiaens, Maarten T.; Kukutsch, Nicole A.; Oosting, Albert J.; Plasmeijer, Elsemieke, I; van Rengen, Annik; de Roos, Kees-Peter; Nijsten, Tamar E. C.; de Vries, Esther; de Bekker-Grob, Esther W.			Efficacy, cost-minimization, and budget impact of a personalized discharge letter for basal cell carcinoma patients to reduce low-value follow-up care	PLOS ONE			English	Article							KERATINOCYTE CARCINOMA; ISPOR; IMPLEMENTATION; TRENDS; TRIALS; RISK	Background The incidence of keratinocyte carcinomas is high and rapidly growing. Approximately 80% of keratinocyte carcinomas consist of basal cell carcinomas (BCC) with 50% of these being considered as low-risk tumors. Nevertheless, 83% of the low-risk BCC patients were found to receive more follow-up care than recommended according to the Dutch BCC guideline, which is one visit post-treatment for this group. More efficient management could reduce unnecessary follow-up care and related costs. Objectives To study the efficacy, cost-utility, and budget impact of a personalized discharge letter for low-risk BCC patients compared with usual care (no personalized letter). Methods In a multi-center intervention study, a personalized discharge letter in addition to usual care was compared to usual care in first-time BCC patients. Model-based cost-utility and budget impact analyses were conducted, using individual patient data gathered via surveys. The outcome measures were number of follow-up visits, costs and quality adjusted life years (QALY) per patient. Results A total of 473 first-time BCC patients were recruited. The personalized discharge letter decreased the number of follow-up visits by 14.8% in the first year. The incremental costs after five years were -Euro24.45 per patient. The QALYs were 4.12 after five years and very similar in both groups. The national budget impact was -Euro2,7 million after five years. Conclusions The distribution of a personalized discharge letter decreases the number of unnecessary follow-up visits and implementing the intervention in a large eligible population would results in substantial cost savings, contributing to restraining the growing BCC costs.	[van Egmond, Sven; Wakkee, Marlies; Hollestein, Loes M.; Nijsten, Tamar E. C.] Erasmus MC Canc Inst, Dept Dermatol, Rotterdam, Netherlands; [van Vliet, Ella D.; Pouwels, Xavier G. L., V; Koffijberg, Hendrik] Univ Twente, Dept Hlth Technol & Serv Res, Enschede, Netherlands; [Hollestein, Loes M.; Misirli, Yesim] Netherlands Comprehens Canc Org IKNL, Dept Res, Utrecht, Netherlands; [Bakkum, Rachel S. L. A.] Alrijne Ziekenhuis, Dept Dermatol, Leiderdorp, Netherlands; [Bastiaens, Maarten T.] Elisabeth TweeSteden Hosp, Dept Dermatol, Tilburg, Netherlands; [Kukutsch, Nicole A.] Leiden Univ, Dept Dermatol, Med Ctr, Leiden, Netherlands; [Oosting, Albert J.] Spaarne Ziekenhuis, Dept Dermatol, Hoofddorp, Netherlands; [Plasmeijer, Elsemieke, I] Antoni van Leeuwenhoek, Dept Dermatol, Netherlands Canc Inst, Amsterdam, Netherlands; [van Rengen, Annik] Mohs Klinieken, Dept Dermatol, Dordrecht, Netherlands; [de Roos, Kees-Peter] DermaPark, Dept Dermatol, Uden, Netherlands; [de Vries, Esther] Pontificia Univ Javeriana, Dept Clin Epidemiol & Biostat, Bogota, Colombia; [de Bekker-Grob, Esther W.] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of Twente; Elisabeth-TweeSteden Ziekenhuis (ETZ); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Spaarne Hospital; Netherlands Cancer Institute; Pontificia Universidad Javeriana; Erasmus University Rotterdam	van Egmond, S (corresponding author), Erasmus MC Canc Inst, Dept Dermatol, Rotterdam, Netherlands.; van Vliet, ED (corresponding author), Univ Twente, Dept Hlth Technol & Serv Res, Enschede, Netherlands.	s.vanegmond@erasmusmc.nl; e.van.vliet95@gmail.com	de Vries, Esther/A-6603-2009; Plasmeijer, Elsemieke/AFT-5200-2022; Pouwels, Xavier/AAQ-2092-2021; Hollestein, Loes/AFL-0006-2022	de Vries, Esther/0000-0002-5560-2258; Plasmeijer, Elsemieke/0000-0002-8846-1930; Pouwels, Xavier/0000-0003-3563-0013; Hollestein, Loes/0000-0001-8922-6791; van Vliet, Ella/0000-0001-6226-5491; van Egmond, Sven/0000-0002-1323-4928	Citrienfonds (Dutch Ministry of Health, Welfare and Sport); VGZ (Health insurance company)	Citrienfonds (Dutch Ministry of Health, Welfare and Sport); VGZ (Health insurance company)	This project was funded by Citrienfonds (Dutch Ministry of Health, Welfare and Sport, https://www.citrienfonds.nl/, received by TN) and VGZ (Health insurance company, https://www.vgz.nl/, received by EdV). The funders were not involved in study design, data collection, data analysis, and manuscript preparation.	Attema AE, 2018, PHARMACOECONOMICS, V36, P745, DOI 10.1007/s40273-018-0672-z; Briggs AH, 2012, VALUE HEALTH, V15, P835, DOI 10.1016/j.jval.2012.04.014; Buurman BM, 2016, INT J QUAL HEALTH C, V28, P384, DOI 10.1093/intqhc/mzw046; Cameron MC, 2019, J AM ACAD DERMATOL, V80, P303, DOI 10.1016/j.jaad.2018.03.060; Chinem VP, 2011, AN BRAS DERMATOL, V86, P292, DOI 10.1590/S0365-05962011000200013; de Vries E, 2018, J EUR ACAD DERMATOL, V32, pE351, DOI 10.1111/jdv.14924; de Vroome EMM., 2010, TSG, V88, P71, DOI [10.1007/BF03089552, DOI 10.1007/BF03089552]; Deckers EA, 2020, ANN SURG ONCOL, V27, P1407, DOI 10.1245/s10434-019-07825-7; Dinnes J, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011901.pub2; Fenwick E, 2020, VALUE HEALTH, V23, P139, DOI 10.1016/j.jval.2020.01.001; Fischer F, 2016, HEALTHCARE-BASEL, V4, DOI 10.3390/healthcare4030036; Flohil S, 2017, DATA BEZOEKEN BCC PC; Flohil SC, 2013, EUR J CANCER, V49, P2365, DOI 10.1016/j.ejca.2013.03.010; Flohil SC, 2013, J INVEST DERMATOL, V133, P913, DOI 10.1038/jid.2012.431; Flohil SC, 2011, ACTA DERM-VENEREOL, V91, P24, DOI 10.2340/00015555-1009; Genootschap NH, 2017, NHG STANDAARD VERDAC; Gordon LG, 2015, EUR J CANCER PREV, V24, P141, DOI 10.1097/CEJ.0000000000000056; Groenwold RHH, 2012, AM J EPIDEMIOL, V175, P210, DOI 10.1093/aje/kwr302; Gupta N, 2020, J CLIN EXP HEPATOL, V10, P177, DOI 10.1016/j.jceh.2019.11.001; Hakkaart-van Roijen L, 2016, KOSTENHANDLEIDING ME, P1; Husereau D, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-80; Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223; Ma KL, 2012, IEEE COMPUT GRAPH, V32, P12, DOI 10.1109/MCG.2012.24; Michalowsky B, 2020, EUR J HEALTH ECON, V21, P717, DOI 10.1007/s10198-020-01166-z; Misirli Y., 2016, 16 BIENN EUR C LOND; Nehal KS, 2018, NEW ENGL J MED, V379, P363, DOI 10.1056/NEJMra1708701; Noels E, 2020, ACTA DERM-VENEREOL, V100, DOI 10.2340/00015555-3463; Organization WH, 2019, WHO GUID REC DIG INT; Ostermann J, 2017, PATIENT, V10, P511, DOI 10.1007/s40271-017-0251-y; Planbureau voor de Leefomgeving, 2019, RIJKSINSTITUUT VOLKS; Ramsey SD, 2015, VALUE HEALTH, V18, P161, DOI 10.1016/j.jval.2015.02.001; Richtlijn-Richtlijnendatabase, 2019, MEL DET NIEUW KANK; Schmults CD, 2013, JAMA DERMATOL, V149, P541, DOI 10.1001/jamadermatol.2013.2139; Schreuder K., 2019, HUIDKANKER NEDERLAND; Schubbe D, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023300; Shen WD, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2438-3; Sullivan SD, 2014, VALUE HEALTH, V17, P5, DOI 10.1016/j.jval.2013.08.2291; The Netherlands Federation of University Medical Centres website, PROJ ER BAS FOLL STU; Tromme I, 2014, BRIT J DERMATOL, V171, P1443, DOI 10.1111/bjd.13262; Tummers L, 2011, INT REV ADM SCI, V77, P555, DOI 10.1177/0020852311407364; van Egmond S, 2019, BRIT J DERMATOL, V180, P1420, DOI 10.1111/bjd.17594; van Egmond S, 2019, BRIT J DERMATOL, V180, P122, DOI 10.1111/bjd.16900; van Urk F., 2020, ZONMW; Vektis, 2015, CUT MAL 29499; Venerologie NVvDe., 2016, RICHTLIJN BASAALCELC; Verkerk EW, 2018, INT J QUAL HEALTH C, V30, P736, DOI 10.1093/intqhc/mzy100; Wakkee M, 2019, EUR J CANCER, V117, P32, DOI 10.1016/j.ejca.2019.05.010; Wu Q, 2018, ADDICTION, V113, P708, DOI 10.1111/add.14086; Zhang P, 2003, INT STAT REV, V71, P581; Ziekenhuizen NVv, 2017, SALARISTABELLEN MEDI; Zorginstituut Nederland., 2016, RICHTL UITV EC EV GE	51	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2022	17	1							e0260978	10.1371/journal.pone.0260978	http://dx.doi.org/10.1371/journal.pone.0260978			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZZ4EH	35073333	Green Published, gold			2023-01-03	WOS:000773223800012
J	Shoukat, H; Pervaiz, F; Khan, M; Rehman, S; Akram, F; Abid, U; Noreen, S; Nadeem, M; Qaiser, R; Ahmad, R; Farooq, I				Shoukat, Hina; Pervaiz, Fahad; Khan, Mehran; Rehman, Sadia; Akram, Faizan; Abid, Usman; Noreen, Sobia; Nadeem, Muhammad; Qaiser, Rubina; Ahmad, Rizwan; Farooq, Irshad			Development of beta-cyclodextrin/polyvinypyrrolidone-co-poly (2-acrylamide-2-methylpropane sulphonic acid) hybrid nanogels as nano-drug delivery carriers to enhance the solubility of Rosuvastatin: An in vitro and in vivo evaluation	PLOS ONE			English	Article							DISSOLUTION RATE; RESPONSIVE NANOGEL; CYCLODEXTRIN; HYDROGELS; PH; MICROPARTICLES; FORMULATION; RELEASE; SYSTEM; CHLORTHALIDONE	The present study is aimed at enhancing the solubility of rosuvastatin (RST) by designing betacyclodextrin/polyvinypyrrolidone-co-poly (2-acrylamide-2-methylpropane sulphonic acid) crosslinked hydrophilic nanogels in the presence of crosslinker methylene bisacrylamide through free-radical polymerization method. Various formulations were fabricated by blending different amounts of betacyclodextrin, polyvinylpyrrolidone, 2-acrylamide-2-methylpropane sulphonic acid, and methylene bisacrylamide. The developed chemically crosslinked nanogels were characterized by FTIR, SEM, PXRD, TGA, DSC, sol-gel analysis, zeta size, micromeritics properties, drug loading percentage, swelling, solubility, and release studies. The FTIR spectrum depicts the leading peaks of resultant functional groups of blended constituents while a fluffy and porous structure was observed through SEM images. Remarkable reduction in crystallinity of RST in developed nanogels revealed by PXRD. TGA and DSC demonstrate the good thermal stability of nanogels. The size analysis depicts the particle size of the developed nanogels in the range of 178.5 +/- 3.14 nm. Drug loading percentage, swelling, solubility, and release studies revealed high drug loading, solubilization, swelling, and drug release patterns at 6.8 pH paralleled to 1.2 pH. In vivo experiments on developed nanogels in comparison to marketed brands were examined and better results regarding pharmacokinetic parameters were observed. The compatibility and non-toxicity of fabricated nanogels to biological systems was supported by a toxicity study that was conducted on rabbits. Efficient fabrication, excellent physicochemical properties, improved dissolution, high solubilization, and nontoxic nanogels might be a capable approach for the oral administration of poorly water-soluble drugs.	[Shoukat, Hina; Pervaiz, Fahad; Khan, Mehran; Rehman, Sadia; Akram, Faizan; Noreen, Sobia; Qaiser, Rubina; Ahmad, Rizwan; Farooq, Irshad] Islamia Univ Bahawalpur, Dept Pharmaceut, Fac Pharm, Bahawalpur, Pakistan; [Abid, Usman] Bahauddin Zakariya Univ, Dept Pharm, Multan, Pakistan; [Nadeem, Muhammad] Shalamar Hosp Lahore, Lahore, Pakistan	Islamia University of Bahawalpur; Bahauddin Zakariya University	Pervaiz, F (corresponding author), Islamia Univ Bahawalpur, Dept Pharmaceut, Fac Pharm, Bahawalpur, Pakistan.	fahad.pervaiz@iub.edu.pk	Noreen, Sobia/AAT-8296-2021	Noreen, Sobia/0000-0002-4407-6002; Pervaiz, Fahad/0000-0003-1941-082X; ahmad, Rizwan/0000-0001-9683-3530				Abou Taleb M, 2014, INT J POLYM MATER PO, V63, P840, DOI 10.1080/00914037.2014.886221; Ali L, 2015, CELL CHEM TECHNOL, V49, P143; Borba PAA, 2016, CARBOHYD POLYM, V137, P350, DOI 10.1016/j.carbpol.2015.10.070; Asghar S, 2021, AAPS PHARMSCITECH, V22, DOI 10.1208/s12249-021-02054-2; Atta AM, 2013, POLYM ADVAN TECHNOL, V24, P986, DOI 10.1002/pat.3174; Badshah SF, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118931; Beloshe SP, 2010, ASIAN J PHARM, V4, P168, DOI 10.4103/0973-8398.68470; Bode C, 2019, J CONTROL RELEASE, V306, P97, DOI 10.1016/j.jconrel.2019.05.039; Challa R, 2005, AAPS PHARMSCITECH, V6, DOI 10.1208/pt060243; Chavda HV, 2011, INT J PHARM INVESTIG, V1, P17, DOI 10.4103/2230-973X.76724; Cirri M, 2012, EUR J PHARM BIOPHARM, V80, P46, DOI 10.1016/j.ejpb.2011.07.015; Dangre Pankaj V., 2016, Journal of Pharmaceutical Investigation, V46, P633, DOI 10.1007/s40005-016-0243-2; Ghosh I, 2011, INT J PHARMACEUT, V409, P260, DOI 10.1016/j.ijpharm.2011.02.051; Giulbudagian M, 2018, NANOSCALE, V10, P469, DOI 10.1039/c7nr04480a; Guo C, 2019, MOLECULES, V49, P7; Guo YS, 2013, TRAC-TREND ANAL CHEM, V49, P137, DOI 10.1016/j.trac.2013.06.002; Hassanpour S, 2017, J POLYM RES, V24, P1, DOI 10.1007/s10965-017-1246-z; Hayati M, 2020, INORG NANO-MET CHEM, V50, P1189, DOI 10.1080/24701556.2020.1737821; Hazer O, 2008, J MACROMOL SCI A, V45, P45, DOI 10.1080/10601320701683223; Hecq J, 2005, INT J PHARMACEUT, V299, P167, DOI 10.1016/j.ijpharm.2005.05.014; Jain S., 2019, ASIAN J PHARM RES DE, V7, P47, DOI [10.22270/ajprd.v7i2.482, DOI 10.22270/AJPRD.V7I2.482]; Kabanov AV, 2009, ANGEW CHEM INT EDIT, V48, P5418, DOI 10.1002/anie.200900441; Kabiri K, 2003, EUR POLYM J, V39, P1341, DOI 10.1016/S0014-3057(02)00391-9; Khadka P, 2014, ASIAN J PHARM SCI, V9, P304, DOI 10.1016/j.ajps.2014.05.005; Khalid Q, 2018, ADV POLYM TECH, V37, P2171, DOI 10.1002/adv.21876; Khan KU, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01694-0; Khanum H, 2018, INT J BIOL MACROMOL, V120, P1624, DOI 10.1016/j.ijbiomac.2018.09.184; Ku MS, 2012, PHARM DEV TECHNOL, V17, P285, DOI 10.3109/10837450.2010.535826; Lanzalaco S, 2017, ELECTROCHIM ACTA, V246, P812, DOI 10.1016/j.electacta.2017.06.097; Lederle FA, 2016, ANN INTERN MED, V165, P663, DOI 10.7326/M16-1208; Li MQ, 2013, POLYM CHEM-UK, V4, P1199, DOI 10.1039/c2py20871g; Mahmood A, 2018, ADV POLYM TECH, V37, DOI 10.1002/adv.21711; Mahmood A, 2016, ACTA POL PHARM, V73, P1311; Malik NS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172727; Mao JS, 2003, BIOMATERIALS, V24, P1621, DOI 10.1016/S0142-9612(02)00549-5; Minhas MU, 2016, CELL CHEM TECHNOL, V50, P233; Mohammed W.H., 2018, J PHARM SCI RES, V10, P2747; NANDA J, 2013, INDIAN J ENG MAT, V2013, DOI DOI 10.1155/2013/392470; Nita LE, 2016, INT J PHARMACEUT, V515, P165, DOI 10.1016/j.ijpharm.2016.10.017; Omar SM, 2019, J AEROSOL MED PULM D, V32, P78, DOI 10.1089/jamp.2018.1460; Pereira P, 2015, TOXICOL IN VITRO, V29, P638, DOI 10.1016/j.tiv.2014.11.004; Perrut M, 2005, INT J PHARMACEUT, V288, P3, DOI 10.1016/j.ijpharm.2004.09.007; Qasim M, 2014, MACROMOL RES, V22, P1125, DOI 10.1007/s13233-014-2162-2; Quirk J, 2003, NAT REV DRUG DISCOV, V2, P769, DOI 10.1038/nrd1205; Qureshi MA, 2019, J SCI-ADV MATER DEV, V4, P201, DOI 10.1016/j.jsamd.2019.04.004; Rajesh Babu V, 2010, J PHARM RES, V3, P141; Ren XT, 2019, ACTA PHARM SIN B, V9, P118, DOI 10.1016/j.apsb.2018.05.004; Sadeghi M., 2012, CURR WORLD ENVIRON, V7, P69, DOI DOI 10.12944/CWE.7.1.12; Sahiner N, 2006, COLLOID POLYM SCI, V284, P1121, DOI 10.1007/s00396-006-1489-4; Sahu P, 2017, J CONTROL RELEASE, V253, P122, DOI 10.1016/j.jconrel.2017.03.023; Sarfraz RM, 2020, POLYM-PLAST TECH MAT, V59, P1109, DOI 10.1080/25740881.2020.1719148; Sarfraz RM, 2018, POLYM-PLAST TECHNOL, V57, P1175, DOI 10.1080/03602559.2017.1373401; Sarfraz RM, 2017, DRUG DES DEV THER, V11, P3083, DOI 10.2147/DDDT.S143712; Sharma D., 2016, ASIAN J PHARM, V1; Shoukat H, 2020, POLYM BULL, V77, P1869, DOI 10.1007/s00289-019-02837-5; Singh B, 2014, CARBOHYD POLYM, V101, P928, DOI 10.1016/j.carbpol.2013.10.022; Singh HA., 2018, ASIAN J PHARM CLIN R, V11, P436, DOI [10.22159/ajpcr.2018.v11i7.26177, DOI 10.22159/AJPCR.2018.V11I7.26117]; Song QL, 2017, NANO LETT, V17, P6366, DOI 10.1021/acs.nanolett.7b03186; Tiwari G, 2010, J PHARM BIOALLIED SC, V2, P72, DOI 10.4103/0975-7406.67003; Ullah K, 2019, INT J PHARMACEUT, V556, P236, DOI 10.1016/j.ijpharm.2018.12.020; Watanabe M, 1997, BIOORGAN MED CHEM, V5, P437, DOI 10.1016/S0968-0896(96)00248-9; Xin JY, 2010, INT J PHARMACEUT, V386, P221, DOI 10.1016/j.ijpharm.2009.11.024; Yao YS, 2016, EUR J PHARM SCI, V91, P144, DOI 10.1016/j.ejps.2016.06.014; Yin LC, 2007, BIOMATERIALS, V28, P1258, DOI 10.1016/j.biomaterials.2006.11.008; Yu JP, 2011, NANOMED-NANOTECHNOL, V7, P146, DOI 10.1016/j.nano.2010.08.001; Zhang YN, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201806693	66	6	6	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0263026	10.1371/journal.pone.0263026	http://dx.doi.org/10.1371/journal.pone.0263026			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061861	Green Published, gold			2023-01-03	WOS:000791072800192
J	VanBlargan, LA; Errico, JM; Halfmann, PJ; Zost, SJ; Crowe, JE; Purcell, LA; Kawaoka, Y; Corti, D; Fremont, DH; Diamond, MS				VanBlargan, Laura A.; Errico, John M.; Halfmann, Peter J.; Zost, Seth J.; Crowe, James E., Jr.; Purcell, Lisa A.; Kawaoka, Yoshihiro; Corti, Davide; Fremont, Daved H.; Diamond, Michael S.			An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies	NATURE MEDICINE			English	Article								The emergence of the highly transmissible B.1.1.529 Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. In this study, we tested a panel of anti-receptor-binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 (sotrovimab)), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Eli Lilly (LY-CoV555 and LY-CoV016) and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987 and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2-2196 and COV2-2130 combination, similar to 12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use might lose efficacy against the B.1.1.529 Omicron variant.	[VanBlargan, Laura A.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Errico, John M.; Fremont, Daved H.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Halfmann, Peter J.; Kawaoka, Yoshihiro] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Influenza Res Inst, Madison, WI 53706 USA; [Zost, Seth J.; Crowe, James E., Jr.] Vanderbilt Univ, Vanderbilt Vaccine Ctr, Med Ctr, Nashville, TN USA; [Zost, Seth J.; Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Crowe, James E., Jr.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN USA; [Purcell, Lisa A.] Vir Biotechnol, St Louis, MO USA; [Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol, Tokyo, Japan; [Kawaoka, Yoshihiro] Natl Ctr Global Hlth & Med Res Inst, Res Ctr Global Viral Dis, Tokyo, Japan; [Corti, Davide] Humabs BioMed SA, Bellinzona, Switzerland; [Fremont, Daved H.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; [Fremont, Daved H.] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; [Diamond, Michael S.] Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol, St Louis, MO 63110 USA; [Diamond, Michael S.] Washington Univ, Sch Med, Immunotherapy Programs, St Louis, MO 63110 USA; [Diamond, Michael S.] Washington Univ, Sch Med, Ctr Vaccines & Immun Microbial Pathogens, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Tokyo; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Immunotherapy Programs, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Ctr Vaccines & Immun Microbial Pathogens, St Louis, MO 63110 USA.	mdiamond@wustl.edu	Crowe, James/B-5549-2009	Crowe, James/0000-0002-0049-1079; VanBlargan, Laura/0000-0002-8922-8946; Corti, Davide/0000-0002-5797-1364; Zost, Seth/0000-0001-6712-5076; Fremont, Daved/0000-0002-8544-2689; Errico, John/0000-0002-4452-8152	National Institues of Health [R01 AI157155, U01 AI151810, 75N93021C00014, HHSN272201700060C, 75N93019C00062, 75N93019C00051]; Defense Advanced Research Project Agency [HR0011-18-2-0001]; Japan Program for Infectious Diseases Research and Infrastructure from the Japan Agency for Medical Research and Development [JP21wm0125002]; Dolly Parton COVID-19 Research Fund at Vanderbilt University Medical Center	National Institues of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Defense Advanced Research Project Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Japan Program for Infectious Diseases Research and Infrastructure from the Japan Agency for Medical Research and Development; Dolly Parton COVID-19 Research Fund at Vanderbilt University Medical Center	This study was supported by grants and contracts from the National Institues of Health (R01 AI157155 (to M.S.D. and J.E.C), U01 AI151810 (to M.S.D.), 75N93021C00014 (to Y.K.), HHSN272201700060C (to D.H.F.), 75N93019C00062 (D.H.F. and M.S.D.), and 75N93019C00051 (to M.S.D.)); the Defense Advanced Research Project Agency (HR0011-18-2-0001 (to J.E.C. and M.S.D)); the Japan Program for Infectious Diseases Research and Infrastructure (JP21wm0125002) from the Japan Agency for Medical Research and Development (to Y.K.); and the Dolly Parton COVID-19 Research Fund at Vanderbilt University Medical Center (to J.E.C.). We thank R. Nargi, R. Carnahan, T. Tan and L. Schimanski for assistance and generosity with mAb generation and purification and S. A. Turner from the Center for Pathogen Evolution at the University of Cambridge for evaluating B.1.1.529 sequences. AZD7442 (AZD8895 and AZD1061) was supplied by AstraZeneca under a material transfer agreement.	Bailey AL, 2021, CELL, V184, P15, DOI 10.1016/j.cell.2020.12.003; Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Callaway E, 2021, NATURE, V600, P367, DOI 10.1038/d41586-021-03672-3; Callaway E, 2021, NATURE, V600, P197, DOI 10.1038/d41586-021-03614-z; Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]; Cao Y.R., BIORXIV, DOI [10.1101/ 2021.12.07.470392, DOI 10.1101/2021.12.07.470392]; Case JB, 2020, CELL HOST MICROBE, V28, P475, DOI 10.1016/j.chom.2020.06.021; Cathcart A.L., 2021, DUAL FUNCTION MONOCL, DOI [10.1101/2021.03.09. 434607, DOI 10.1101/2021.03.09.434607, 10.1101/2021.03.09.434607]; Cele S., 2021, SARS COV 2 OMICRON H, DOI [10.1101/2021.12.08.21267417v1, DOI 10.1101/2021.12.08.21267417V1]; Chen Jiahui, 2021, ArXiv; Chen RE, 2021, NATURE, V596, P103, DOI 10.1038/s41586-021-03720-y; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Dejnirattisai W, 2022, LANCET, V399, P234, DOI 10.1016/S0140-6736(21)02844-0; Ford C.T., 2022, FRONT VIROL, V2, DOI 10.1101/2021.12.03.471024; Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235; Golcuk M., 2021, OMICRON VARINT INCRE, DOI [10.1101/2021.12.06.471377, 10.1101/2021.12.06.471377v1]; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Greaney AJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24435-8; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI 10.1073/pnas.2009799117; Johnson BA, 2021, NATURE, V591, P293, DOI 10.1038/s41586-021-03237-4; Jones BE, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1906; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kim C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20602-5; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Lempp FA, 2021, NATURE, V598, P342, DOI 10.1038/s41586-021-03925-1; Liu ZM, 2021, CELL HOST MICROBE, V29, P477, DOI 10.1016/j.chom.2021.01.014; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; Schafer A, 2021, J EXP MED, V218, DOI 10.1084/jem.20201993; Sempowski GD, 2020, CELL, V181, P1458, DOI 10.1016/j.cell.2020.05.041; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Starr TN, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100255; Suryadevara Naveenchandra, 2021, bioRxiv, DOI [10.1016/j.cell.2021.03.029, 10.1101/2021.01.19.427324]; Tada Takuya, 2021, bioRxiv, DOI 10.1101/2021.02.05.430003; Torjesen I, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2943; Tortorici MA, 2020, SCIENCE, V370, P950, DOI 10.1126/science.abe3354; VanBlargan LA, 2021, IMMUNITY, V54, P2399, DOI 10.1016/j.immuni.2021.08.016; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1038/s41586-021-03324-6, 10.1101/2021.01.15.426911]; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Wilhelm A, 2021, MMWR MORB MORTAL WKL, V2021, DOI [10.1101/ 2021.12.07.21267432, DOI 10.15585/MMWR.MM7011A1EXTERNALICON, 10.1101/2021.12.07.21267432]; Winkler ES, 2021, CELL, V184, P1804, DOI 10.1016/j.cell.2021.02.026; Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582; Zohar T, 2020, CELL, V183, P1508, DOI 10.1016/j.cell.2020.10.052; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6; Zost SJ, 2020, NAT MED, V26, DOI [10.1101/2020.05.12.091462, 10.1038/s41591-020-0998-x]	51	221	224	20	37	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					490	+		10.1038/s41591-021-01678-y	http://dx.doi.org/10.1038/s41591-021-01678-y		JAN 2022	8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35046573	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000745735100001
J	Hendriksen, RB; van der Gaag, EJ				Hendriksen, Rosanne Barbra; van der Gaag, Ellen Jose			Effect of a dietary intervention including minimal and unprocessed foods, high in natural saturated fats, on the lipid profile of children, pooled evidence from randomized controlled trials and a cohort study	PLOS ONE			English	Article							TRANS-PALMITOLEIC ACID; CALCIUM INTAKE; ATHEROSCLEROSIS; METAANALYSIS; ASSOCIATION; OVERWEIGHT; OBESITY; ADULTS; MILK	Aim To study the possible effects of a dietary intervention with minimal and unprocessed foods, high in natural saturated fats on the lipid profile and body mass index of children. Method This study combines three intervention studies; one non-randomized retrospective cohort study and two randomized controlled trials, to a pooled analysis. The intervention group received a dietary intervention of minimal and unprocessed foods for three to six months, consisting of five times per week green vegetables, three times per week beef, daily 200300 mL whole cow's milk (3.4% fat) and whole dairy butter (80% fat) on each slice of bread. The control group continued their usual dietary habits. Raw data of the three intervention studies where combined into one single dataset for data analysis, using mixed effects analysis of covariance to test the effects of the dietary advice on the main study outcomes, which are measurements of the lipid profile. Results In total, 267 children aged 1 to 16 years were followed. 135 children were included in the intervention group and 139 children in the control group. Characteristics (age, gender and follow-up period) were equally distributed between the groups at baseline. In the intervention group HDL-cholesterol increased significantly from 1.22 mmol/L, 95% confidence interval (CI) 1.14-1.32 to 1.42 mmol/L 95% CI 1.30-1.65 (p = 0.007). The increase over time in HDL cholesterol in the intervention group was significantly different compared to the increase in the control group (from 1.26 mmol/L, 95% CI 1.19-1.35, to 1.30 mmol/L, 95% CI 1.26-1.37) (p = 0.04). Due to the increased HDL concentration in the intervention group, the total cholesterol/HDL cholesterol ratio decreased significantly from 3.70 mmol/L, 95% CI 3.38-3.87, to 3.25 mmol/L, 95% CI 2.96-3.31 (p = 0.05). Conclusion Consumption of minimal and unprocessed foods (high in natural saturated fats) has favourable effects on HDL cholesterol in children. Therefore, this dietary advice can safely be recommended to children.	[Hendriksen, Rosanne Barbra] Wageningen Univ & Res WUR, MSc Nutr & Hlth, Wageningen, Netherlands; [van der Gaag, Ellen Jose] Hosp Grp Twente ZGT, Dept Pediat, Hengelo, Netherlands	Wageningen University & Research	Hendriksen, RB (corresponding author), Wageningen Univ & Res WUR, MSc Nutr & Hlth, Wageningen, Netherlands.	rosannebh@gmail.com						Berneis KK, 2002, J LIPID RES, V43, P1363, DOI 10.1194/jlr.R200004-JLR200; Bhateja PK, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/572013; Silverio RNC, 2019, DIABETES RES CLIN PR, V154, P9, DOI 10.1016/j.diabres.2019.06.005; Cornwell B, 2018, PUBLIC HEALTH NUTR, V21, P142, DOI 10.1017/S1368980017000891; Costa CS, 2019, NUTR METAB CARDIOVAS, V29, P177, DOI 10.1016/j.numecd.2018.11.003; Davies KM, 2000, J CLIN ENDOCR METAB, V85, P4635, DOI 10.1210/jc.85.12.4635; Engel S, 2018, EUR J CLIN NUTR, V72, P249, DOI 10.1038/s41430-017-0042-5; Fredriks AM, 2005, ACTA PAEDIATR, V94, P496, DOI [10.1080/08035250410024240, 10.1111/j.1651-2227.2005.tb01923.x]; Gillman MW, 1997, JAMA-J AM MED ASSOC, V278, P2145, DOI 10.1001/jama.278.24.2145; Kohnke R, 2009, SCAND J GASTROENTERO, V44, P712, DOI 10.1080/00365520902803499; Kratz M, 2013, EUR J NUTR, V52, P1, DOI 10.1007/s00394-012-0418-1; Lee AK, 2014, CONSUMPTION LESS 10; Lewis K, 2010, INFLAMM BOWEL DIS, V16, P1138, DOI 10.1002/ibd.21177; Liu XR, 2013, BRIT J NUTR, V109, P1695, DOI 10.1017/S0007114513000196; Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146; Mozaffarian D, 2004, AM J CLIN NUTR, V80, P1175, DOI 10.1093/ajcn/80.5.1175; Mozaffarian D, 2013, AM J CLIN NUTR, V97, P854, DOI 10.3945/ajcn.112.045468; Mozaffarian D, 2010, ANN INTERN MED, V153, P790, DOI 10.7326/0003-4819-153-12-201012210-00005; Murphy SP, 2003, J NUTR, V133, p3932S, DOI 10.1093/jn/133.11.3932S; Ohlsson L, 2010, EUR J CLIN NUTR, V64, P1344, DOI 10.1038/ejcn.2010.164; Rauber F, 2015, NUTR METAB CARDIOVAS, V25, P116, DOI 10.1016/j.numecd.2014.08.001; Roberts JL, 2016, FOOD FUNCT, V7, P3337, DOI [10.1039/c6fo00051g, 10.1039/C6FO00051G]; Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397; SHRAPNEL WS, 1992, MED J AUSTRALIA, V156, pS9; Siri-Tarino PW, 2010, AM J CLIN NUTR, V91, P535, DOI 10.3945/ajcn.2009.27725; Skinner JD, 2003, J AM DIET ASSOC, V103, P1626, DOI 10.1016/j.jada.2003.09.020; UNICEF, VERL NAAR GEZ 2020; van der Gaag E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103689; van der Gaag E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010272; van der Gaag EJ, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050518; Vanderhout SM, 2020, AM J CLIN NUTR, V111, P266, DOI 10.1093/ajcn/nqz276; Vandevijvere S, 2019, EUR J NUTR, V58, P3267, DOI 10.1007/s00394-018-1870-3; Wang HF, 2011, OBESITY, V19, P2404, DOI 10.1038/oby.2011.234; WHO, OB OV 2020; Willett W, 2019, LANCET, V393, P447, DOI 10.1016/S0140-6736(18)31788-4; Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132	36	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2022	17	1							e0261446	10.1371/journal.pone.0261446	http://dx.doi.org/10.1371/journal.pone.0261446			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZO8DB	34986194	gold, Green Published			2023-01-03	WOS:000765956200010
J	Kumar, A; Siddharth, V; Singh, SI; Narang, R				Kumar, Atul; Siddharth, Vijaydeep; Singh, Soubam Iboyaima; Narang, Rajiv			Cost analysis of treating cardiovascular diseases in a super-specialty hospital	PLOS ONE			English	Article							MEDICAL-CARE COSTS	Cardiovascular care is expensive; hence, economic evaluation is required to estimate resources being consumed and to ensure their optimal utilization. There is dearth of data regarding cost analysis of treating various diseases including cardiac diseases from developing countries. The study aimed to analyze resource consumption in treating cardio-vascular disease patients in a super-specialty hospital. An observational and descriptive study was carried out from April 2017 to June 2018 in the Department of Cardiology, Cardio-Thoracic (CT) Centre of All India Institute of Medical Sciences, New Delhi, India. As per World Health Organization, common cardiovascular diseases i.e. Coronary Artery Disease (CAD), Rheumatic Heart Disease (RHD), Cardiomyopathy, Congenital heart diseases, Cardiac Arrhythmias etc. were considered for cost analysis. Medical records of 100 admitted patients (Ward & Cardiac Care Unit) of cardiovascular diseases were studied till discharge and number of patient records for a particular CVD was identified using prevalence-based ratio of admitted CVD patient data. Traditional Costing and Time Driven Activity Based Costing (TDABC) methods were used for cost computation. Per bed per day cost incurred by the hospital for admitted patients in Cardiac Care Unit, adult and pediatric cardiology ward was calculated to be Indian Rupee (INR) 28,144 (US$ 434), INR 22,210 (US$ 342) and INR 18,774 (US$ 289), respectively. Inpatient cost constituted almost 70% of the total cost and equipment cost accounted for more than 50% of the inpatient cost followed by human resource cost (28%). Per patient cost of treating any CVD was computed to be INR 2,47,822 (US $ 3842). Cost of treating Rheumatic Heart Disease was the highest among all CVDs followed by Cardiomyopathy and other CVDs. Cost of treating cardiovascular diseases in India is less than what has been reported in developed countries. Findings of this study would aid policy makers considering recent radical changes and massive policy reforms ushered in by the Government of India in healthcare delivery.	[Kumar, Atul; Siddharth, Vijaydeep; Singh, Soubam Iboyaima] All India Inst Med Sci AIIMS, Dept Hosp Adm, New Delhi, India; [Narang, Rajiv] AIIMS, Cardiothorac Ctr, Dept Cardiol, New Delhi, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi	Siddharth, V (corresponding author), All India Inst Med Sci AIIMS, Dept Hosp Adm, New Delhi, India.	dr.siddharthmamc@gmail.com	Kumar, Dr. Atul/H-2076-2018	Kumar, Dr. Atul/0000-0002-2813-3951; Siddharth, Vijaydeep/0000-0002-4703-9733				American Heart Association, 2017, CARD DIS COSTL BURD, P7; Celermajer DS, 2012, J AM COLL CARDIOL, V60, P1207, DOI 10.1016/j.jacc.2012.03.074; Deloitte, 2011, INT HEART PROT SUMM, P1; Ding JM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009341; Drummond Michael F., 2015, METHODS EC EVALUATIO, VFourth, P464; Edbrooke DL, 1997, INTENS CARE MED, V23, P645, DOI 10.1007/s001340050388; Emamgholipour S, 2018, INT CARDIOVASC RES J, V12, P1; Gajuryal SH, 2017, INDIAN J NUCL MED, V32, P1, DOI 10.4103/0972-3919.198438; Gheorghe A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5806-x; Horngren CT, 2012, COST ACCOUNTING MANA, DOI [10.1097/IAE.0b013-318248e6ba, DOI 10.1097/IAE.0B013-318248E6BA]; Huffman MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020821; Imani A, 2016, JUNDISHAPUR J HLTH S, V8; Kankeu HT, 2013, HEALTH RES POLICY SY, V11, DOI 10.1186/1478-4505-11-31; Kastor A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196106; Kausar M, 2021, INDIAN J PUBLIC HLTH, V65, P45, DOI 10.4103/ijph.IJPH_431_20; Khan M, 2017, J BIOEQUIV BIOAVAILA, V09, P353; Kumar P, 2014, GSTF J NURS HEALTHC, V1, P6; Nichols GA, 2002, DIABETES CARE, V25, P482, DOI 10.2337/diacare.25.3.482; Nichols GA, 2010, AM J MANAG CARE, V16, pE86; Parissis J, 2015, INT J CARDIOL, V180, P46, DOI 10.1016/j.ijcard.2014.11.123; Prabhakaran D, 2018, LANCET GLOB HEALTH, V6, pE1339, DOI 10.1016/S2214-109X(18)30407-8; Prabhakaran D, 2018, J AM COLL CARDIOL, V72, P79, DOI 10.1016/j.jacc.2018.04.042; Rahman MM, 2017, JAMA INTERN MED, V177, P1297, DOI 10.1001/jamainternmed.2017.3133; Siddharth V, 2015, INDIAN J SURG, V77, pS530, DOI 10.1007/s12262-013-0908-2; Silva MP, 2016, INT ARCH MED, P1; Singh Sheetal, 2016, J Emerg Trauma Shock, V9, P133, DOI 10.4103/0974-2700.193347; Wang SN, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000837; WHO, 2018, CARDIOVASCULAR DIS C, P1; World Health Organization, 2014, NONCOMMUNICABLE DIS, P1, DOI [10.1111/jgs.12171, DOI 10.1111/JGS.12171]; World Health Organization, 2011, GLOBAL ATLAS CARDIOV; World Health Organization, 2017, CARD DIS CVDS	31	2	2	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2022	17	1							e0262190	10.1371/journal.pone.0262190	http://dx.doi.org/10.1371/journal.pone.0262190			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZO8DB	34986193	Green Submitted, Green Published, gold			2023-01-03	WOS:000765956200022
J	MacDougall, P				MacDougall, Peter			In long-term, higher-dose opioid use, dose tapering was linked to overdose and mental health crises	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							GUIDELINE		[MacDougall, Peter] Dalhousie Univ, Halifax, NS, Canada	Dalhousie University	MacDougall, P (corresponding author), Dalhousie Univ, Halifax, NS, Canada.							Ahonle Zaccheus J, 2020, Fed Pract, V37, P420, DOI 10.12788/fp.0025; Busse JW, 2017, CAN MED ASSOC J, V189, pE659, DOI 10.1503/cmaj.170363; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN	2022	175	1					JC11	JC11		10.7326/J21-0005	http://dx.doi.org/10.7326/J21-0005		JAN 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	0Y3LO	34978849				2023-01-03	WOS:000742139800001
J	Alem, AZ; Yeshaw, Y; Liyew, AM; Tesema, GA; Alamneh, TS; Worku, MG; Teshale, AB; Tessema, ZT				Alem, Adugnaw Zeleke; Yeshaw, Yigizie; Liyew, Alemneh Mekuriaw; Tesema, Getayeneh Antehunegn; Alamneh, Tesfa Sewunet; Worku, Misganaw Gabrie; Teshale, Achamyeleh Birhanu; Tessema, Zemenu Tadesse			Timely initiation of antenatal care and its associated factors among pregnant women in sub-Saharan Africa: A multicountry analysis of Demographic and Health Surveys	PLOS ONE			English	Article							GLOBAL LEVELS; MORTALITY; TRENDS	BackgroundTimely initiation of antenatal care (ANC) is an important component of ANC services that improve the health of the mother and the newborn. Mothers who begin attending ANC in a timely manner, can fully benefit from preventive and curative services. However, evidence in sub-Saharan Africa (sSA) indicated that the majority of pregnant mothers did not start their first visit timely. As our search concerned, there is no study that incorporates a large number of sub-Saharan Africa countries. Thus, the objective of this study was to assess the prevalence of timely initiation of ANC and its associated factors in 36 sSA countries. MethodsThe Demographic and Health Survey (DHS) of 36 sSA countries were used for the analysis. The total weighted sample of 233,349 women aged 15-49 years who gave birth in the five years preceding the survey and who had ANC visit for their last child were included. A multi-level logistic regression model was used to examine the individual and community-level factors that influence the timely initiation of ANC. Results were presented using adjusted odds ratio (AOR) with 95% confidence interval (CI). ResultsIn this study, overall timely initiation of ANC visit was 38.0% (95% CI: 37.8-38.2), ranging from 14.5% in Mozambique to 68.6% in Liberia. In the final multilevel logistic regression model:- women with secondary education (AOR = 1.08; 95% CI: 1.06, 1.11), higher education (AOR = 1.43; 95% CI: 1.36, 1.51), women aged 25-34 years (AOR = 1.20; 95% CI: 1.17, 1.23), >= 35 years (AOR = 1.30; 95% CI: 1.26, 1.35), women from richest household (AOR = 1.19; 95% CI: 1.14, 1.22), women perceiving distance from the health facility as not a big problem (AOR = 1.05; 95%CI: 1.03, 1.07), women exposed to media (AOR = 1.29; 95%CI: 1.26, 1.32), women living in communities with medium percentage of literacy (AOR = 1.51; 95%CI: 1.40, 1.63), and women living in communities with high percentage of literacy (AOR = 1.56; 95%CI: 1.38, 1.76) were more likely to initiate ANC timely. However, women who wanted their pregnancy later (AOR = 0.84; 95%CI: 0.82, 0.86), wanted no more pregnancy (AOR = 0.80; 95%CI: 0.77, 0.83), and women residing in the rural area (AOR = 0.90; 95%CI: 0.87, 0.92) were less likely to initiate ANC timely. ConclusionEven though the WHO recommends all women initiate ANC within 12 weeks of gestation, sSA recorded a low overall prevalence of timely initiation of ANC. Maternal education, pregnancy intention, residence, age, wealth status, media exposure, distance from health facility, and community-level literacy were significantly associated with timely initiation of ANC. Therefore, intervention efforts should focus on the identified factors in order to improve timely initiation of ANC in sSA. This can be done through the providing information and education to the community on the timing and importance of attending antenatal care and family planning to prevent unwanted pregnancy, especially in rural settings.	[Alem, Adugnaw Zeleke; Yeshaw, Yigizie; Liyew, Alemneh Mekuriaw; Tesema, Getayeneh Antehunegn; Alamneh, Tesfa Sewunet; Teshale, Achamyeleh Birhanu; Tessema, Zemenu Tadesse] Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Gondar, Ethiopia; [Yeshaw, Yigizie] Univ Gondar, Sch Med, Dept Physiol, Coll Med & Hlth Sci, Gondar, Ethiopia; [Worku, Misganaw Gabrie] Univ Gondar, Sch Med, Dept Human Anat, Coll Med & Hlth Sci, Gondar, Ethiopia	University of Gondar; University of Gondar; University of Gondar	Alem, AZ (corresponding author), Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Gondar, Ethiopia.	aduzeleke2201@gmail.com	Teshale, Achamyeleh/HHN-8416-2022	Alemneh, Tesfa Sewunet/0000-0002-4830-931X; Yeshaw, Yigizie/0000-0003-4587-7925				Akhtar F, 2018, CUREUS, V10, DOI 10.7759/cureus.2078; Alemu Y, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0646-9; Aliyu Alhaji Abubakar, 2017, Pan Afr Med J, V26, P124, DOI 10.11604/pamj.2017.26.124.9861; Aung TZ., 2017, INT J COMMUNITY MED, V3, P900; Austin PC, 2017, STAT MED, V36, P3257, DOI 10.1002/sim.7336; Banda I, 2012, MED J ZAMBIA, V39, P29; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P137, DOI 10.4314/ejhs.v24i0.12S; Blackstone SR, 2019, WOMEN HEALTH, V59, P1141, DOI 10.1080/03630242.2019.1590496; Blencowe H, 2016, LANCET GLOB HEALTH, V4, pE98, DOI 10.1016/S2214-109X(15)00275-2; Branum AM, 2017, MATERN CHILD HLTH J, V21, P715, DOI 10.1007/s10995-016-2155-1; Chewe M. M., 2016, African Journal of Midwifery and Women's Health, V10, P169; Ejeta E, 2017, PAN AFR MED J, V27, DOI 10.11604/pamj.2017.27.184.10926; Ekholuenetale M, 2020, J EGYPT PUBLIC HEAL, V95, DOI 10.1186/s42506-020-00041-2; Emiru AA, 2020, INT J WOMENS HEALTH, V12, P463, DOI 10.2147/IJWH.S250832; Ethiopian Central Statistics Agency (ECSA), 2016, ETH DEM HLTH SURV ED; Ewunetie AA, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1748-7; Exavery A, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-35; Gebrekidan K, 2017, PRAGMAT OBS RES, V8, P223, DOI 10.2147/POR.S140733; Gebresilassie B, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2490-5; Geta M. B., 2017, Advances in Public Health, V2017, P1624245, DOI 10.1155/2017/1624245; Gidey G, 2018, ASIAN J PHARM CLIN R, V11; Goldstein H., 2002, Understanding Statistics, V1, P223, DOI 10.1207/S15328031US0104_02; Gomez GB, 2013, B WORLD HEALTH ORGAN, V91, P217, DOI 10.2471/BLT.12.107623; Gong E, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4369-6; Gross K, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-16; Gudayu TW, 2015, AFR J REPROD HEALTH, V19, P94; Haftu Abera, 2018, BMC Res Notes, V11, P872, DOI 10.1186/s13104-018-3987-0; Hanna G, TIMING 1 ANTENATAL C; Hug L, 2019, LANCET GLOB HEALTH, V7, pE710, DOI 10.1016/S2214-109X(19)30163-9; Institut National de la Statistique, 2011, ENQ DEM SANT IND MUL; Isawumi A, 2018, ONLINE J HLTH ALLIED, V7, P4; Jiwani SS, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010502; Kenya National Bureau of Statistics, 2014, KEN DEM HLTH SURV; Kisuule I, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-121; Leshabari LK., 2020, EC GYNAECOL, V93, P01; Luginaah IN, 2016, SOC SCI MED, V160, P75, DOI 10.1016/j.socscimed.2016.05.019; Manyeh AK, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-2738-0; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P443, DOI 10.1136/jech.2004.023473; Mgata S, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2576-0; Moller AB, 2017, LANCET GLOB HEALTH, V5, pE977, DOI 10.1016/S2214-109X(17)30325-X; Moore N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171136; Nigeria, 2014, NIG DEM HLTH SURV 20; Njiku F., 2017, PREVALENCE FACTORS A, V19, P1; Nwagwu AM, 2011, ANN LIBR INF STUD, V58, P270; Oates M, 2011, BJOG-INT J OBSTET GY, V118, P132, DOI 10.1111/j.1471-0528.2010.02847.x; Ochako R, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0168-2; Pena-Rosas JP., 2017, COCHRANE DB SYST REV, V7; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Service AC., 2018, BMC PREGNANCY CHILDB, V19; Sinyange Nyambe, 2016, Pan Afr Med J, V25, P109, DOI 10.11604/pamj.2016.25.109.6873; Smith C, 2019, OBSTET GYNECOL, V134, P1234, DOI 10.1097/AOG.0000000000003557; Starbird E, 2016, GLOB HEALTH-SCI PRAC, V4, P191, DOI 10.9745/GHSP-D-15-00374; Tekelab T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222566; Tesfaye G, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0412-4; Teshale AB, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235538; Tessema ZT, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-03669-w; Tolefac Paul Nkemtendong, 2017, Matern Health Neonatol Perinatol, V3, P29, DOI 10.1186/s40748-017-0067-8; Tolossa T, 2020, SYST REV-LONDON, V9, DOI 10.1186/s13643-020-01449-9; Turyasiima M, 2015, E AFR MED J, V91, P317; Weldearegawi GG, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4789-8; WHO, 2016, WHO TECH REP SER, V997, P1; Wondemagegn AT, 2018, PUBLIC HEALTH REV, V39, DOI 10.1186/s40985-018-0110-y; World Health Organization, 2002, ANT CAR RAND TRIAL M; World Health Organization, 2019, MAT DEATHS DECL SLOW; World Health Organization (WHO),S.a.r. health,, 2018, MOR WOM WORLDW REC E; WP. M, 2013, CAN J LIBR INF PR RE, V7, P19; Yeji F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142849; Zamawe COF, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0816-0; Zhao Qi, 2009, BMC Womens Health, V9, P5, DOI 10.1186/1472-6874-9-5	69	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	1							e0262411	10.1371/journal.pone.0262411	http://dx.doi.org/10.1371/journal.pone.0262411			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE3XC	35007296	Green Published, gold			2023-01-03	WOS:000741060700004
J	Lau, JYW; Pittayanon, R; Kwek, A; Tang, RS; Chan, H; Rerknimitr, R; Lee, J; Ang, TL; Suen, BY; Yu, YY; Chan, FKL; Sung, JJY				Lau, James Y. W.; Pittayanon, Rapat; Kwek, Andrew; Tang, Raymond S.; Chan, Heyson; Rerknimitr, Rungsun; Lee, June; Ang, Tiing Leong; Suen, Bing-Yee; Yu, Yuan-yuan; Chan, Francis K. L.; Sung, Joseph J. Y.			Comparison of a Hemostatic Powder and Standard Treatment in the Control of Active Bleeding From Upper Nonvariceal Lesions A Multicenter, Noninferiority, Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							HEMOSPRAY; EXPERIENCE; EFFICACY; SAFETY; ULCERS	Background: The effectiveness of the hemostatic powder TC-325 as a single endoscopic treatment for acute nonvariceal upper gastrointestinal bleeding is uncertain. Objective: To compare TC-325 with standard endoscopic hemostatic treatments in the control of active bleeding from nonvariceal upper gastrointestinal causes. Design: One-sided, noninferiority, randomized, controlled trial. (ClinicalTrials.gov: NCT02534571). Setting: University teaching hospitals in the Asia-Pacific region. Patients: 224 adult patients with acute bleeding from a nonvariceal cause on upper gastrointestinal endoscopy. Intervention: TC-325 (n = 111) or standard hemostatic treatment (n = 113). Measurements: The primary outcome was control of bleeding within 30 days. Other outcomes included failure to control bleeding during index endoscopy, recurrent bleeding after initial hemostasis, further interventions, blood transfusion, hospitalization, and death. Results: 224 patients were enrolled (136 with gastroduodenal ulcers [60.7%], 33 with tumors [14.7%], and 55 with other causes of bleeding [24.6%]). Bleeding was controlled within 30 days in 100 of 111 patients (90.1%) in the TC-325 group and 92 of 113 (81.4%) in the standard treatment group (risk difference, 8.7 percentage points [1-sided 95% CI, 0.95 percentage point]). There were fewer failures of hemostasis during index endoscopy with TC-325 (3 [2.7%] vs. 11 [9.7%]; odds ratio, 0.26 [CI, 0.07 to 0.95]). Recurrent bleeding within 30 days did not differ between groups (9 [8.1%] vs. 10 [8.8%]). The need for further interventions also did not differ between groups (further endoscopic treatment: 8 [7.2%] vs. 10 [8.8%]; angiography: 2 [1.8%] vs. 4 [3.5%]; surgery: 1 [0.9%] vs. 0). There were 14 deaths in each group (12.6% vs. 12.4%). Limitation: Clinicians were not blinded to treatment. Conclusion: TC-325 is not inferior to standard treatment in the endoscopic control of bleeding from nonvariceal upper gastrointestinal causes. Primary funding source: General Research Fund to the University Grants Committee, Hong Kong SAR Government.	[Lau, James Y. W.; Tang, Raymond S.; Chan, Heyson; Suen, Bing-Yee; Chan, Francis K. L.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Pittayanon, Rapat; Rerknimitr, Rungsun] Chulalongkorn Univ, Fac Med, Dept Med, Div Gastroenterol, Bangkok, Thailand; [Pittayanon, Rapat; Rerknimitr, Rungsun] King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Bangkok, Thailand; [Kwek, Andrew; Lee, June; Ang, Tiing Leong] Changi Gen Hosp, Singapore, Singapore; [Yu, Yuan-yuan] Prince Wales Hosp, Dept Surg, Shatin, Room 64026,Lui Chee Woo Clin Sci Bldg, Hong Kong, Peoples R China; [Sung, Joseph J. Y.] Nanyang Technol Univ, Singapore, Singapore	Chinese University of Hong Kong; Chulalongkorn University; Chulalongkorn University; Thai Red Cross Society; Changi General Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Lau, JYW (corresponding author), Prince Wales Hosp, Dept Surg, Shatin, Room 64026,Lui Chee Woo Clin Sci Bldg, Hong Kong, Peoples R China.	lau-jyw@surgery.cuhk.edu.hk	Chan, Francis K. L./F-4851-2010; Tang, Raymond/AED-4572-2022; Lau, James/O-2612-2016	Chan, Francis K. L./0000-0001-7388-2436; Lau, James/0000-0003-0122-4068; Tang, Raymond Shing-Yan/0000-0002-2433-8036	General Research Fund [2140948]	General Research Fund	By a General Research Fund to the University Grants Committee (no. 2140948), Hong Kong SAR Government.	Baracat FI, 2020, SURG ENDOSC, V34, P317, DOI 10.1007/s00464-019-06769-z; Barkun AN, 2009, GASTROINTEST ENDOSC, V69, P786, DOI 10.1016/j.gie.2008.05.031; Chen YI, 2020, GASTROINTEST ENDOSC, V91, P321, DOI 10.1016/j.gie.2019.08.005; Chen Yen-I, 2015, Gastrointest Endosc Clin N Am, V25, P535, DOI 10.1016/j.giec.2015.02.008; Haddara S, 2016, ENDOSCOPY, V48, P1084, DOI 10.1055/s-0042-116148; Holster IL, 2013, ENDOSCOPY, V45, P63, DOI 10.1055/s-0032-1325793; Kwek BEA, 2017, J DIGEST DIS, V18, P323, DOI 10.1111/1751-2980.12481; Leontiadis GI, 2005, ALIMENT PHARM THER, V21, P1055, DOI 10.1111/j.1365-2036.2005.02441.x; Masci E, 2014, SCAND J GASTROENTERO, V49, P1290, DOI 10.3109/00365521.2014.946080; Smith LA, 2014, J CLIN GASTROENTEROL, V48, pE89, DOI 10.1097/MCG.0000000000000054; Sulz MC, 2014, ENDOSCOPY, V46, P619, DOI 10.1055/s-0034-1365505; Sung JJY, 2011, ENDOSCOPY, V43, P291, DOI 10.1055/s-0030-1256311; Yau AHL, 2014, CAN J GASTROENTEROL, V28, P72, DOI 10.1155/2014/759436	13	5	5	4	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB	2022	175	2					171	+		10.7326/M21-0975	http://dx.doi.org/10.7326/M21-0975		DEC 2021	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE4HR	34871051				2023-01-03	WOS:000729195300001
J	Devi, S				Devi, Sharmila			Health warnings over UNRWA funding shortfall	LANCET			English	Editorial Material																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	2021	398	10316					2063	2063						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XJ1NQ	34863340				2023-01-03	WOS:000726564200008
J	Duque, MP; Saad, NJ; Lucaccioni, H; Costa, C; McMahon, G; Machado, F; Balasegaram, S; Machado, RS				Duque, Mariana Perez; Saad, Neil J.; Lucaccioni, Heloise; Costa, Cristina; McMahon, Geroid; Machado, Firmino; Balasegaram, Sooria; Machado, Rita Sa			Clinical and hospitalisation predictors of COVID-19 in the first month of the pandemic, Portugal	PLOS ONE			English	Article								COVID-19 mainly presents as a respiratory disease with flu-like symptoms, however, recent findings suggest that non-respiratory symptoms can occur early in the infection and cluster together in different groups in different regions. We collected surveillance data among COVID-19 suspected cases tested in mainland Portugal during the first wave of the pandemic, March-April 2020. A multivariable logistic-regression analysis was performed to ascertain the effects of age, sex, prior medical condition and symptoms on the likelihood of testing positive and hospitalisation. Of 25,926 COVID-19 suspected cases included in this study, 5,298 (20%) tested positive. Symptoms were grouped into ten clusters, of which two main ones: one with cough and fever and another with the remainder. There was a higher odds of a positive test with increasing age, myalgia and headache. The odds of being hospitalised increased with age, presence of fever, dyspnoea, or having a prior medical condition although these results varied by region. Presence of cough and other respiratory symptoms did not predict COVID-19 compared to non-COVID respiratory disease patients in any region. Dyspnoea was a strong determinant of hospitalisation, as well as fever and the presence of a prior medical condition, whereas these results varied by region.	[Duque, Mariana Perez; Lucaccioni, Heloise; Costa, Cristina; Machado, Rita Sa] Div Epidemiol & Stat, Directorate Gen Hlth, Lisbon, Portugal; [Duque, Mariana Perez; Lucaccioni, Heloise; Balasegaram, Sooria; Machado, Rita Sa] European Ctr Dis Prevent & Control ECDC, European Program Intervent Epidemiol Training EPI, Stockholm, Sweden; [Duque, Mariana Perez; Machado, Firmino] ARS Norte, Publ Hlth Unit, ACeS Porto Ocidental, Porto, Portugal; [Duque, Mariana Perez; McMahon, Geroid; Machado, Firmino] Harvard Med Sch, Res Training, Boston, MA 02115 USA; [Saad, Neil J.] United Nations Relief & Works Agcy Palestine Refu, Amman, Jordan; [McMahon, Geroid] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Machado, Firmino] Univ Porto, EPIUnit Inst Saude Publ, Porto, Portugal; [Machado, Firmino] Univ Porto, Dept Ciencias Saude Publ & Forenses & Educ Med, Fac Med, Porto, Portugal; [Balasegaram, Sooria] Publ Hlth England, London, England	European Centre for Disease Prevention & Control; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Universidade do Porto; Universidade do Porto; Public Health England	Duque, MP (corresponding author), Div Epidemiol & Stat, Directorate Gen Hlth, Lisbon, Portugal.; Duque, MP (corresponding author), European Ctr Dis Prevent & Control ECDC, European Program Intervent Epidemiol Training EPI, Stockholm, Sweden.; Duque, MP (corresponding author), ARS Norte, Publ Hlth Unit, ACeS Porto Ocidental, Porto, Portugal.; Duque, MP (corresponding author), Harvard Med Sch, Res Training, Boston, MA 02115 USA.	marianapduque@dgs.min-saude.pt	Saad, Neil J./AAI-4719-2021	Perez Duque, Mariana/0000-0001-9999-8402; Firmino-Machado, Joao/0000-0001-9410-633X				Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011; [Anonymous], 2005, STAT 2 M INT HLTH RE; Baumer Y, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.559312; Berger JR, 2020, J NEUROVIROL, V26, P143, DOI 10.1007/s13365-020-00840-5; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Jain V, 2020, INT J PUBLIC HEALTH, V65, P533, DOI 10.1007/s00038-020-01390-7; Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926; Kubota Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239385; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620; Pascarella G, 2020, J INTERN MED, V288, P192, DOI 10.1111/joim.13091; Pasteur I., 2020, PROTOCOL REAL TIME R, P1; Portuguese Directorate-General of Health, 2020, REL SIT; Portuguese Directorate-General of Health, SIST NAC VIG EP SINA; Portuguese Directorate-General of Health, NORM AB DOENT COM SU; R Core Team, 2021, R LANG ENV STAT COMP; Ribeiro AI, 2017, ACTA MEDICA PORT, V30, P17, DOI 10.20344/amp.7387; Sudre C., 2020, SYMPTOM CLUSTERS COV, P1; Sun YXH, 2020, CLIN INFECT DIS, V71, P786, DOI 10.1093/cid/ciaa322; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Tostmann A, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.16.2000508; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839	22	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2021	16	11							e0260249	10.1371/journal.pone.0260249	http://dx.doi.org/10.1371/journal.pone.0260249			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2TX	34797879	gold, Green Published			2023-01-03	WOS:000755334700049
J	Saul, H; Gursul, D				Saul, Helen; Gursul, Deniz			Self-testing for HIV could increase diagnoses in the trans community	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Saul, Helen; Gursul, Deniz] NIHR Ctr Engagement & Disseminat, Twickenham, England		Saul, H (corresponding author), NIHR Ctr Engagement & Disseminat, Twickenham, England.	NIHRAlerts@nihr.ac.uk						Witzel TC, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01835-z	1	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 10	2021	375								n2633	10.1136/bmj.n2633	http://dx.doi.org/10.1136/bmj.n2633			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE5JT	34759036				2023-01-03	WOS:000723424500011
J	Ponamgi, SP; Vallabhajosyula, S				Ponamgi, Shiva P.; Vallabhajosyula, Saraschandra			In adults with coma after out-of-hospital cardiac arrest, hypothermia vs. normothermia did not reduce 6-mo mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Ponamgi, Shiva P.] Creighton Univ, Sch Med, Omaha, NE 68178 USA; [Vallabhajosyula, Saraschandra] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC 27101 USA	Creighton University; Wake Forest University; Wake Forest Baptist Medical Center	Ponamgi, SP (corresponding author), Creighton Univ, Sch Med, Omaha, NE 68178 USA.		Vallabhajosyula, Saraschandra/I-9707-2019	Vallabhajosyula, Saraschandra/0000-0002-1631-8238				Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Lascarrou JB, 2019, NEW ENGL J MED, V381, P2327, DOI 10.1056/NEJMoa1906661; Nolan JP, 2015, INTENS CARE MED, V41, P2039, DOI 10.1007/s00134-015-4051-3	3	0	0	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV	2021	174	11					JC126	JC126		10.7326/ACPJ202111160-126	http://dx.doi.org/10.7326/ACPJ202111160-126			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YI2OV	34724397				2023-01-03	WOS:000743694300008
J	Sinclair, J; Collett, L; Abbott, J; Pate, DW; Sarris, J; Armour, M				Sinclair, Justin; Collett, Laura; Abbott, Jason; Pate, David W.; Sarris, Jerome; Armour, Mike			Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms	PLOS ONE			English	Article							IRRITABLE-BOWEL-SYNDROME; QUALITY-OF-LIFE; ENDOCANNABINOID SYSTEM; WORLD ENDOMETRIOSIS; WOMEN; FIBROMYALGIA; MIGRAINE; IMPACT	Background The use of cannabis for symptoms of endometriosis was investigated utilising retrospective archival data from Strainprint Technologies Ltd., a Canadian data technology company with a mobile phone application that tracks a range of data including dose, mode of administration, chemovar and their effects on various self-reported outcomes, including pelvic pain. Methods A retrospective, electronic record-based cohort study of Strainprint (TM) users with self-reported endometriosis was conducted. Self-rated cannabis efficacy, defined as a function of initial and final symptom ratings, was investigated across the included symptom clusters of cramps, pelvic pain, gastrointestinal pain, nausea, depression, and low libido. Cannabis dosage form, dose and cannabinoid ratio information was also recorded. Results A total number of 252 participants identifying as suffering endometriosis recorded 16193 sessions using cannabis between April 2017 and February 2020. The most common method of ingestion was inhalation (n = 10914, 67.4%), with pain as the most common reported symptom being treated by cannabis (n = 9281, 57.3%). Gastrointestinal symptoms, though a less common reason for cannabis usage (15.2%), had the greatest self-reported improvement after use. Inhaled forms had higher efficacy for pain, while oral forms were superior for mood and gastrointestinal symptoms. Dosage varied across ingestion methods, with a median dose of 9 inhalations (IQR 5 to 11) for inhaled dosage forms and 1 mg/mL (IQR 0.5 to 2) for other ingested dosage forms. The ratio of THC to CBD had a statistically significant, yet clinically small, differential effect on efficacy, depending on method of ingestion. Conclusions Cannabis appears to be effective for pelvic pain, gastrointestinal issues and mood, with effectiveness differing based on method of ingestion. The greater propensity for use of an inhaled dosage delivery may be due to the rapid onset of pain-relieving effects versus the slower onset of oral products. Oral forms appeared to be superior compared to inhaled forms in the less commonly reported mood or gastrointestinal categories. Clinical trials investigating the tolerability and effectiveness of cannabis for endometriosis pain and associated symptoms are urgently required.	[Sinclair, Justin; Pate, David W.; Sarris, Jerome; Armour, Mike] Western Sydney Univ, NICM Hlth Res Inst, Sydney, NSW, Australia; [Collett, Laura] Univ Bristol, Bristol Trials Ctr, Bristol, Avon, England; [Abbott, Jason] UNSW, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Sarris, Jerome] Univ Melbourne, Dept Psychiat, Professorial Unit, Melbourne Clin, Melbourne, Vic, Australia; [Armour, Mike] Western Sydney Univ, Translat Hlth Res Inst, Sydney, NSW, Australia	Western Sydney University; University of Bristol; University of New South Wales Sydney; University of Melbourne; Western Sydney University	Sinclair, J (corresponding author), Western Sydney Univ, NICM Hlth Res Inst, Sydney, NSW, Australia.	19948081@student.westernsydney.edu.au	; Armour, Mike/I-4853-2016	Sinclair, Justin/0000-0001-9960-3191; Armour, Mike/0000-0001-7539-9851	Strainprint Technologies Ltd.	Strainprint Technologies Ltd.	The authors wish to thank Strainprint Technologies Ltd. for their support and data access.	Adamson GD, 2010, J ENDOMETR PELVIC PA, V2, P3, DOI 10.1177/228402651000200102; [Anonymous], 2018, NAT STAT ETH COND HU; Armour M, 2021, J WOMENS HEALTH, V30, P1485, DOI 10.1089/jwh.2020.8668; Armour M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73389-2; Armour M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223316; Armour M, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2431-x; As-Sanie S, 2016, J PAIN, V17, P1, DOI 10.1016/j.jpain.2015.09.008; Bilgic E, 2017, ACTA HISTOCHEM, V119, P523, DOI 10.1016/j.acthis.2017.05.005; Bilkei-Gorzo A, 2012, PHILOS T R SOC B, V367, P3326, DOI 10.1098/rstb.2011.0388; Borrelli F, 2009, J MOL MED, V87, P1111, DOI 10.1007/s00109-009-0512-x; Bouaziz J, 2017, CANNABIS CANNABINOID, V2, P72, DOI 10.1089/can.2016.0035; Brawn J, 2014, HUM REPROD UPDATE, V20, P737, DOI 10.1093/humupd/dmu025; Campos AC, 2008, PSYCHOPHARMACOLOGY, V199, P223, DOI 10.1007/s00213-008-1168-x; Capasso R, 2008, BRIT J PHARMACOL, V154, P1001, DOI 10.1038/bjp.2008.177; Cavaggioni G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/786830; CHERRY KE, 1989, INT J AGING HUM DEV, V28, P159, DOI 10.2190/00X7-HVXQ-D3BG-MK76; D'Argenio G, 2006, FASEB J, V20, P568, DOI 10.1096/fj.05-4943fje; De Filippis D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028159; De Graaff AA, 2013, HUM REPROD, V28, P2677, DOI 10.1093/humrep/det284; DiVasta Amy D, 2021, Clin Gastroenterol Hepatol, V19, P528, DOI 10.1016/j.cgh.2020.03.014; Ek M, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0213-2; Hand S, 2019, PANIC FLARE UP CAN C; Huestis MA, 2007, CHEM BIODIVERS, V4, P1770, DOI 10.1002/cbdv.200790152; Ianieri MM, 2017, CLIN EXP OBSTET GYN, V44, P148, DOI 10.12891/ceog3306.2017; Johnson NP, 2017, HUM REPROD, V32, P315, DOI 10.1093/humrep/dew293; Lagana AS, 2017, INT J WOMENS HEALTH, V9, P323, DOI 10.2147/IJWH.S119729; Lea R, 2003, EUR J GASTROEN HEPAT, V15, P1131, DOI 10.1097/00042737-200310000-00012; Mabrouk M, 2018, ULTRASOUND OBST GYN, V52, P265, DOI 10.1002/uog.18924; MacCallum CA, 2018, EUR J INTERN MED, V49, P12, DOI 10.1016/j.ejim.2018.01.004; Madrigal J, 2018, 4 EFFECTIVE WAYS DEA; Markham R, 2019, J ENDOMETR PELVIC PA, V11, P85, DOI 10.1177/2284026519838948; Mechoulam R, 2007, CHEM BIODIVERS, V4, P1678, DOI 10.1002/cbdv.200790147; Nnoaham KE, 2011, FERTIL STERIL, V96, P366, DOI 10.1016/j.fertnstert.2011.05.090; Pertwee RG, 2000, ADDICT BIOL, V5, P37, DOI 10.1080/13556210071252; Peters J, 2018, J AM OSTEOPATH ASSOC, V118, P67, DOI 10.7556/jaoa.2018.020; Piyanoya A, 2015, MECH AGEING DEV, V150, P55, DOI 10.1016/j.mad.2015.08.005; Ramin-Wright A, 2018, HUM REPROD, V33, P1459, DOI 10.1093/humrep/dey115; Rock EM, 2011, PSYCHOPHARMACOLOGY, V215, P505, DOI 10.1007/s00213-010-2157-4; Rowlands IJ, 2021, BJOG-INT J OBSTET GY, V128, P657, DOI [10.1111/1471-0528.16466, 10.1111/1471-0528.16447]; Russo EB, 2005, NEUROCHEM RES, V30, P1037, DOI 10.1007/s11064-005-6978-1; Russo EB, 2008, NEUROENDOCRINOL LETT, V29, P192; Russo EB, 2016, CANNABIS CANNABINOID, V1, P154, DOI 10.1089/can.2016.0009; Saidi K, 2020, EUR J OBSTET GYN R B, V246, P99, DOI 10.1016/j.ejogrb.2020.01.031; Sanchez AM, 2016, REPROD SCI, V23, P1071, DOI 10.1177/1933719116630414; Simoens S, 2012, HUM REPROD, V27, P1292, DOI 10.1093/humrep/des073; Sinclair J., 2021, SHOULD I INHALE PERC; Sinclair J, 2020, J OBSTET GYNAECOL CA, V42, P256, DOI 10.1016/j.jogc.2019.08.033; van den Beld AW, 2018, LANCET DIABETES ENDO, V6, P647, DOI 10.1016/S2213-8587(18)30026-3; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wills S.I.M.O., 1998, CANNABIS GENUS CANNA, P1	50	3	3	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2021	16	10							e0258940	10.1371/journal.pone.0258940	http://dx.doi.org/10.1371/journal.pone.0258940			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8IO	34699540	gold, Green Submitted, Green Published			2023-01-03	WOS:000755029000020
J	Curtis, K; Kourouche, S; Asha, S; Considine, J; Fry, M; Middleton, S; Mitchell, R; Munroe, B; Shaban, RZ; D'Amato, A; Skinner, C; Wiseman, G; Buckley, T				Curtis, Kate; Kourouche, Sarah; Asha, Stephen; Considine, Julie; Fry, Margaret; Middleton, Sandy; Mitchell, Rebecca; Munroe, Belinda; Shaban, Ramon Z.; D'Amato, Alfa; Skinner, Clare; Wiseman, Glen; Buckley, Thomas			Impact of a care bundle for patients with blunt chest injury (ChIP): A multicentre controlled implementation evaluation	PLOS ONE			English	Article							TRAUMA; EMERGENCY; PROTOCOL; INTERVENTION; GUIDELINES; MORBIDITY; ANALGESIA; SYSTEM; RISK	Background Blunt chest injury leads to significant morbidity and mortality. The aim of this study was to evaluate the effect of a multidisciplinary chest injury care bundle (ChIP) on patient and health service outcomes. ChIP provides guidance in three key pillars of care for blunt chest injury-respiratory support, analgesia and complication prevention. ChIP was implemented using a multi-faceted implementation plan developed using the Behaviour Change Wheel. Methods This controlled pre-and post-test study (two intervention and two non-intervention sites) was conducted from July 2015 to June 2019. The primary outcome measures were unplanned Intensive Care Unit (ICU) admissions, non-invasive ventilation use and mortality. Results There were 1790 patients included. The intervention sites had a 58% decrease in non-invasive ventilation use in the post- period compared to the pre-period (95% CI 0.18-0.96). ChIP was associated with 90% decreased odds of unplanned ICU admissions (95% CI 0.04-0.29) at the intervention sites compared to the control groups in the post- period. There was no significant change in mortality. There were higher odds of health service team reviews (surgical OR 6.6 (95% CI 4.61-9.45), physiotherapy OR 2.17 (95% CI 1.52-3.11), ICU doctor OR 6.13 (95% CI 3.94-9.55), ICU liaison OR 55.75 (95% CI 17.48-177.75), pain team OR 8.15 (95% CI 5.52 --12.03), analgesia (e.g. patient controlled analgesia OR 2.6 (95% CI 1.64-3.94) and regional analgesia OR 8.8 (95% CI 3.39-22.79), incentive spirometry OR 8.3 (95% CI 4.49-15.37) and, high flow nasal oxygen OR 22.1 (95% CI 12.43-39.2) in the intervention group compared to the control group in the post- period. Conclusion The implementation of a chest injury care bundle using behaviour change theory was associated with a sustained improvement in evidence-based practice resulting in reduced unplanned ICU admissions and non-invasive ventilation requirement.	[Curtis, Kate; Kourouche, Sarah; Fry, Margaret; Munroe, Belinda; Shaban, Ramon Z.; Buckley, Thomas] Univ Sydney, Fac Med & Hlth, Susan Wakil Sch Nursing & Midwifery, Camperdown, NSW, Australia; [Curtis, Kate; Munroe, Belinda] Wollongong Hosp, Emergency Serv, Illawarra Shoalhaven Local Hlth Dist, Wollongong, NSW, Australia; [Curtis, Kate] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia; [Asha, Stephen] St George Hosp, Emergency Dept, Kogarah, NSW, Australia; [Asha, Stephen] Univ New South Wales, Fac Med, St George Clin Sch, Kogarah, NSW, Australia; [Considine, Julie] Deakin Univ, Sch Nursing & Midwifery, Geelong, Vic, Australia; [Considine, Julie] Deakin Univ, Ctr Qual & Patient Safety Experience, Inst Hlth Transformat, Geelong, Vic, Australia; [Considine, Julie] Ctr Qual & Patient Safety Experience Eastern Hlth, Box Hill, Vic, Australia; [Fry, Margaret] Univ Technol Sydney, Fac Hlth, Ultimo, NSW, Australia; [Fry, Margaret] Northern Sydney Local Hlth Dist, Hornsby, NSW, Australia; [Middleton, Sandy] St Vincents Hosp Melbourne, Nursing Res Inst, St Vincents Hlth Network Sydney, Fitzroy, Vic, Australia; [Middleton, Sandy] Australian Catholic Univ, Sydney, NSW, Australia; [Mitchell, Rebecca] Macquarie Univ, Fac Med Hlth & Human Sci, Australian Inst Hlth Innovat, Macquarie Pk, NSW, Australia; [Shaban, Ramon Z.] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Camperdown, NSW, Australia; [Shaban, Ramon Z.] Westmead Hosp, Dept Infect Prevent & Control, Div Infect Dis & Sexual Hlth, Westmead, NSW, Australia; [Shaban, Ramon Z.] Western Sydney Local Hlth Dist, Westmead, NSW, Australia; [Shaban, Ramon Z.] Western Sydney Local Hlth Dist, New South Wales Biocontainment Ctr, Warwick Farm, NSW, Australia; [Shaban, Ramon Z.] New South Wales Hlth, Warwick Farm, NSW, Australia; [D'Amato, Alfa] NSW Minist Hlth, NSW Act Based Funding Taskforce, Sydney, NSW, Australia; [Skinner, Clare] Hornsby Ku Ring Ai Hosp, Emergency Dept, Hornsby, NSW, Australia; [Wiseman, Glen] Canterbury Hosp, Emergency Serv, Campsie, NSW, Australia	University of Sydney; Wollongong Hospital; University of Wollongong; St George Hospital; University of New South Wales Sydney; Deakin University; Deakin University; University of Technology Sydney; St Vincent's Hospital Melbourne; Australian Catholic University; Macquarie University; University of Sydney; University of Sydney	Curtis, K (corresponding author), Univ Sydney, Fac Med & Hlth, Susan Wakil Sch Nursing & Midwifery, Camperdown, NSW, Australia.; Curtis, K (corresponding author), Wollongong Hosp, Emergency Serv, Illawarra Shoalhaven Local Hlth Dist, Wollongong, NSW, Australia.; Curtis, K (corresponding author), Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia.	kate.Curtis@sydney.edu.au	Middleton, Sandy/J-5526-2015; Mitchell, Rebecca/J-6105-2012	Middleton, Sandy/0000-0002-7201-4394; Mitchell, Rebecca/0000-0003-1939-1761	HCF Research Foundation Australia; HCF Research Foundation	HCF Research Foundation Australia; HCF Research Foundation	This research has been supported by funding from the HCF Research Foundation Australia (KC, SA, JC, RM, RZS, MF, SM). SK was funded by a scholarship from the HCF Research Foundation (AU). High flow oxygenation machines were donated by Fisher and Paykel. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asha SE, 2013, EMERG MED J, V30, P1024, DOI 10.1136/emermed-2012-201980; Atkins L, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0605-9; Baker E, 2020, INJURY, V51, P1733, DOI 10.1016/j.injury.2020.06.002; Bernhardt J, 2015, LANCET, V386, P46, DOI 10.1016/S0140-6736(15)60690-0; Campbell JC, 2001, ACAD EMERG MED, V8, P131, DOI 10.1111/j.1553-2712.2001.tb01277.x; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Curtis K, 2016, AUSTRALAS EMERG NURS, V19, P127, DOI 10.1016/j.aenj.2016.06.002; Dexheimer JW, 2014, INT J MED INFORM, V83, P805, DOI 10.1016/j.ijmedinf.2014.07.008; Dogrul BN, 2020, CHIN J TRAUMATOL, V23, P125, DOI 10.1016/j.cjtee.2020.04.003; Ekpe EE, 2017, ANN AFR MED, V16, P120, DOI 10.4103/aam.aam_73_16; French SD, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-38; Kim M, 2020, CURR ANESTHESIOL REP, V10, P61, DOI 10.1007/s40140-020-00374-w; Kourouche S, 2021, IMPLEMENTATION STRAT, DOI [10.21203/rs.3.rs-98328/v1, DOI 10.21203/RS.3.RS-98328/V1]; Kourouche S, 2022, AUST CRIT CARE, V35, P113, DOI 10.1016/j.aucc.2021.04.003; Kourouche S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4177-z; Kourouche S, 2018, INJURY, V49, P1008, DOI 10.1016/j.injury.2018.03.037; Lavallee JF, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0670-0; Leone M, 2012, CRIT CARE MED, V40, P3189, DOI 10.1097/CCM.0b013e31826571f2; Macheel C, 2020, J AM COLL SURGEONS, V231, P249, DOI 10.1016/j.jamcollsurg.2020.04.023; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Middleton S, 2019, STROKE, V50, P1346, DOI 10.1161/STROKEAHA.118.020701; Moon SH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008317; National Health and Medical Research Council, 2007, NAT STAT ETH COND HU; NSW Health, 2019, SHOALH HOSP; NSW Health, 2017, HOSP HLTH SERV; Nyland BA, 2016, RESP CARE, V61, P1580, DOI 10.4187/respcare.04729; Pain C, 2017, INT J QUAL HEALTH C, V29, P130, DOI 10.1093/intqhc/mzw132; Pinnock H, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6795; Rogers L, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05905-z; Sahr SM, 2013, J TRAUMA NURS, V20, P172, DOI 10.1097/JTN.0000000000000008; Scott PA, 2013, LANCET NEUROL, V12, P139, DOI 10.1016/S1474-4422(12)70311-3; Sharma OP, 2008, AM SURGEON, V74, P310; Tavender EJ, 2016, EMERG MED J, V33, P652, DOI 10.1136/emermed-2015-205053; The Bureau of Health Information, 2019, HEALTHC OBS; Todd SR, 2006, AM J SURG, V192, P806, DOI 10.1016/j.amjsurg.2006.08.048; Tohira H, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-63; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]	38	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2021	16	10							e0256027	10.1371/journal.pone.0256027	http://dx.doi.org/10.1371/journal.pone.0256027			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV0SF	34618825	Green Published, gold			2023-01-03	WOS:000752443000006
J	Turri-Silva, N; Vale-Lira, A; Verboven, K; Quaglioti Durigan, JL; Hansen, D; Cipriano, G				Turri-Silva, Natalia; Vale-Lira, Amanda; Verboven, Kenneth; Quaglioti Durigan, Joao Luiz; Hansen, Dominique; Cipriano, Gerson, Jr.			High-intensity interval training versus progressive high-intensity circuit resistance training on endothelial function and cardiorespiratory fitness in heart failure: A preliminary randomized controlled trial	PLOS ONE			English	Article							FLOW-MEDIATED DILATION; TESTING DATA ASSESSMENT; EXERCISE INTOLERANCE; MUSCLE STRENGTH; CARDIOVASCULAR PREVENTION; CLINICAL RECOMMENDATIONS; ULTRASOUND ASSESSMENT; EUROPEAN ASSOCIATION; DYSFUNCTION; IMPACT	Introduction Exercise training is strongly recommended as a therapeutic approach to treat individuals with heart failure. High-intensity exercise training modalities still controversial in this population. The study aims to preliminary assess the consequences of high-intensity exercise training modalities, aerobic interval training (HIIT) and progressive high circuit-resistance training (CRT), on primarily endothelial function and cardiorespiratory fitness, and secondly on muscle strength and physical performance in heart failure patients. Methods This preliminary multicentric randomized controlled trial comprised 23 heart failure patients, aged 56 10 years old, mainly New York Heart Association classification I and II (%), hemodynamically stable, who compromise at least 36 exercise sessions of a randomly assigned intervention (HIIT, CRT or control group). Endothelial function, cardiopulmonary exercise testing, muscle strength and physical performance were completed at baseline and post-intervention. Results Although no effects on endothelial function; both HIIT and CRT modalities were able to produce a positive effect on V_ O 2 peak (HIIT = +2.1 +/- 6.5, CRT = +3.0 +/- 4.2 and control group = -0.1 +/- 5.3 mL/kg/min, time*group p-value< 0,05) and METs (HIIT = +0.6 +/- 1.8, CRT = +0.9 +/- 1.2 and control group = 0 +/- 1.6, time*group p-value< 0,05). Only HIIT increased isokinetic torque peak (HIIT = +8.8 +/- 55.8, CRT = 0.0 +/- 60.7 and control group = 1.6 +/- 57.6 Nm) matched p-value< 0,05. Regarding the physical performance, the CRT modality reduced chair stand test completion time (HIIT = -0.7 +/- 3.1, CRT = -3.3 +/- 3.2 and control group = -0.3 +/- 2.5 s, matched p-value<0,05 and HIIT improved global physical performance(time*group p< 0,05). Conclusion This preliminary study trends to indicate for the first time that high-intensity interval training promotes a jointly superior effect compared to progressive high intensity circuit-resistance training by improving cardiorespiratory fitness, muscular strength, and physical performance. Further research with larger cohort is necessary. Clinical trial registration number ReBEC RBR-668c8v.	[Turri-Silva, Natalia; Quaglioti Durigan, Joao Luiz; Cipriano, Gerson, Jr.] Univ Brasilia, Hlth & Technol Hlth Sci Program, Brasilia, DF, Brazil; [Turri-Silva, Natalia; Verboven, Kenneth; Hansen, Dominique] Hasselt Univ, Fac Rehabil Sci, BIOMED REVAL Rehabil Res Ctr, Hasselt, Belgium; [Vale-Lira, Amanda; Quaglioti Durigan, Joao Luiz; Cipriano, Gerson, Jr.] Univ Brasilia, Fac Phys Educ, Rehabil Sci Program, Brasilia, DF, Brazil; [Hansen, Dominique; Cipriano, Gerson, Jr.] Univ Brasilia, Phys Therapy Dept, Brasilia, DF, Brazil; [Hansen, Dominique] Jessa Hosp, Heart Ctr Hasselt, Hasselt, Belgium	Universidade de Brasilia; Hasselt University; Universidade de Brasilia; Universidade de Brasilia	Turri-Silva, N (corresponding author), Univ Brasilia, Hlth & Technol Hlth Sci Program, Brasilia, DF, Brazil.; Turri-Silva, N (corresponding author), Hasselt Univ, Fac Rehabil Sci, BIOMED REVAL Rehabil Res Ctr, Hasselt, Belgium.	natalia.turridasilva@uhasselt.be	Durigan, João Luiz Quagliotti/D-1110-2012; Verboven, Kenneth/AAB-2007-2019; Hansen, Dominique/AAH-5883-2021	Durigan, João Luiz Quagliotti/0000-0002-7511-5289; 	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil (CAPES DS); Fundacao de Amparo a Pesquisa do Distrito Federal (FAPDF) - Brazil; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Special Research Fund for Bilateral scientific cooperation from Uhasselt (BOF-BILA) Belgium	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil (CAPES DS); Fundacao de Amparo a Pesquisa do Distrito Federal (FAPDF) - Brazil(Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Special Research Fund for Bilateral scientific cooperation from Uhasselt (BOF-BILA) Belgium	NTS; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil (CAPES DS), https://www.gov.br/capes/pt-br; GCJ; Fundacao de Amparo a Pesquisa do Distrito Federal (FAP-DF) - Brazil, National; http://www.fap.df.gov.br/GCJ; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); https://www.gov.br/cnpq/ptbr NTS and DH; Special Research Fund for Bilateral scientific cooperation from Uhasselt (BOF-BILA) Belgium; https://www.uhasselt.be/UH/Researchfunding/Funding-programmes/BOF-programmes/Bilateral-scientific-cooperation.html The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balady GJ, 2010, CIRCULATION, V122, P191, DOI 10.1161/CIR.0b013e3181e52e69; Borde R, 2015, SPORTS MED, V45, P1693, DOI 10.1007/s40279-015-0385-9; Boyle LJ, 2013, J APPL PHYSIOL, V115, P1519, DOI 10.1152/japplphysiol.00837.2013; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; Cipriano G, 2013, AEROBIC EXERCISE EFF; Neto MC, 2018, INT J CARDIOL, V261, P134, DOI 10.1016/j.ijcard.2018.02.076; Corretti MC, 2002, J AM COLL CARDIOL, V39, P257, DOI 10.1016/S0735-1097(01)01746-6; Dube BP, 2016, EUR RESPIR REV, V25, P317, DOI 10.1183/16000617.0048-2016; Ellingsen O, 2017, CIRCULATION, V135, P839, DOI 10.1161/CIRCULATIONAHA.116.022924; Fleg JL, 2015, CIRC-HEART FAIL, V8, P209, DOI 10.1161/CIRCHEARTFAILURE.113.001420; Gevaert AB, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4865756; Giuliano C, 2017, INT J CARDIOL, V227, P413, DOI 10.1016/j.ijcard.2016.11.023; Glickman SG, 2004, J APPL PHYSIOL, V97, P509, DOI 10.1152/japplphysiol.01234.2003; Grgic J, 2020, SPORTS MED-OPEN, V6, DOI 10.1186/s40798-020-00260-z; Guazzi M, 2016, CIRCULATION, V133, pE694, DOI 10.1161/CIR.0000000000000406; Guazzi M, 2012, CIRCULATION, V126, P2261, DOI 10.1161/CIR.0b013e31826fb946; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Gutierrez E, 2013, EUR HEART J, V34, P3175, DOI 10.1093/eurheartj/eht351; Hambrecht R, 1998, CIRCULATION, V98, P2709, DOI 10.1161/01.CIR.98.24.2709; Hansen D, 2022, EUR J PREV CARDIOL, V29, P230, DOI 10.1093/eurjpc/zwab007; Hansen D, 2019, EUR J PREV CARDIOL, V26, P1483, DOI 10.1177/2047487319847003; Harris RA, 2010, HYPERTENSION, V55, P1075, DOI 10.1161/HYPERTENSIONAHA.110.150821; Haykowsky MJ, 2015, J APPL PHYSIOL, V119, P739, DOI 10.1152/japplphysiol.00049.2015; Heidenreich PA, 2013, CIRC-HEART FAIL, V6, P606, DOI 10.1161/HHF.0b013e318291329a; Holm L, 2010, AM J PHYSIOL-ENDOC M, V298, pE257, DOI 10.1152/ajpendo.00609.2009; Hull H, 2009, J CLIN DENSITOM, V12, P95, DOI 10.1016/j.jocd.2008.09.004; Hulsmann M, 2004, EUR J HEART FAIL, V6, P101, DOI 10.1016/j.ejheart.2003.07.008; Jenkins NDM, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00331; Jones RH, 2009, NEW ENGL J MED, V360, P1705, DOI 10.1056/NEJMoa0900559; Jung ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114541; Katz SD, 2005, CIRCULATION, V111, P310, DOI 10.1161/01.CIR.0000153349.77489.CF; KELEMEN MH, 1986, J AM COLL CARDIOL, V7, P38, DOI 10.1016/S0735-1097(86)80256-X; Lavine KJ, 2017, HEART FAIL REV, V22, P179, DOI 10.1007/s10741-016-9593-0; Linke A, 2001, J AM COLL CARDIOL, V37, P392, DOI 10.1016/S0735-1097(00)01108-6; Marti CN, 2012, J AM COLL CARDIOL, V60, P1455, DOI 10.1016/j.jacc.2011.11.082; Maupoint J, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.115.002895; Mezzani A, 2012, J CARDIOPULM REHABIL, V32, P327, DOI 10.1097/HCR.0b013e3182757050; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nakamura T, 2021, CAN J CARDIOL, V37, P476, DOI 10.1016/j.cjca.2020.06.019; Nilsson KR, 2008, CURR CARDIOL REV, V4, P92, DOI 10.2174/157340308784245757; Padilla J, 2009, J VASC RES, V46, P592, DOI 10.1159/000226227; Paulus WJ, 2013, J AM COLL CARDIOL, V62, P263, DOI 10.1016/j.jacc.2013.02.092; Pearson MJ, 2017, CARDIOL RES PRACT, V2017, DOI 10.1155/2017/2450202; Pearson MJ, 2017, INT J CARDIOL, V231, P234, DOI 10.1016/j.ijcard.2016.12.145; Pelliccia A., 2020, EUR HEART J INTERNET, DOI [10.1093/eurheartj/ehaa605/5898937, DOI 10.1093/EURHEARTJ/EHAA605/5898937]; Piepoli MF, 2011, EUR J HEART FAIL, V13, P347, DOI 10.1093/eurjhf/hfr017; Piepoli MF, 2010, EUR J CARDIOV PREV R, V17, P637, DOI 10.1097/HJR.0b013e3283361dc5; Poelzl G, 2005, EUR J HEART FAIL, V7, P43, DOI 10.1016/j.ejheart.2004.04.008; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Poole DC, 2018, J APPL PHYSIOL, V124, P208, DOI 10.1152/japplphysiol.00747.2017; Ras RT, 2013, INT J CARDIOL, V168, P344, DOI 10.1016/j.ijcard.2012.09.047; Raymond MJ, 2013, ARCH PHYS MED REHAB, V94, P1458, DOI 10.1016/j.apmr.2013.02.022; Reibis R, 2016, EUR J PREV CARDIOL, V23, P452, DOI 10.1177/2047487315600815; Restaino RM, 2015, EXP PHYSIOL, V100, P829, DOI 10.1113/EP085238; Sandri M, 2016, EUR J PREV CARDIOL, V23, P349, DOI 10.1177/2047487315588391; Savage PA, 2011, MED SCI SPORT EXER, V43, P1379, DOI 10.1249/MSS.0b013e31820eeea1; Schoenfeld BJ, 2017, J STRENGTH COND RES, V31, P3508, DOI 10.1519/JSC.0000000000002200; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Stoylen A, 2012, EUR J PREV CARDIOL, V19, P813, DOI 10.1177/1741826711403252; Swank AM, 2012, CIRC-HEART FAIL, V5, P579, DOI 10.1161/CIRCHEARTFAILURE.111.965186; Takase B, 2009, ENDOTHELIAL FUNCTION, V2009; Tan R, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13597; Taylor R, 2019, JACC-HEART FAIL, V7, P691, DOI 10.1016/j.jchf.2019.04.023; Thijssen DHJ, 2011, AM J PHYSIOL-HEART C, V300, pH2, DOI 10.1152/ajpheart.00471.2010; Tomlinson DJ, 2016, BIOGERONTOLOGY, V17, P467, DOI 10.1007/s10522-015-9626-4; Toth MJ, 2010, INT J CARDIOL, V143, P276, DOI 10.1016/j.ijcard.2009.02.040; Tzanis G, 2017, J CARD FAIL, V23, P36, DOI 10.1016/j.cardfail.2016.06.007; Vuckovic KM, 2013, HEART LUNG CIRC, V22, P328, DOI 10.1016/j.hlc.2012.12.006; Williams AD, 2007, J CARD FAIL, V13, P79, DOI 10.1016/j.cardfail.2006.10.017; Wisloff U, 2007, CIRCULATION, V115, P3086, DOI 10.1161/CIRCULATIONAHA.106.675041; Xie B, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5420840	72	4	4	4	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2021	16	10							e0257607	10.1371/journal.pone.0257607	http://dx.doi.org/10.1371/journal.pone.0257607			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX5RJ	34597330	gold, Green Published			2023-01-03	WOS:000736352200013
J	Mekonnen, M; Kinati, T; Bekele, K; Tesfa, B; Hailu, D; Jemal, K				Mekonnen, Mathewos; Kinati, Tadele; Bekele, Kumera; Tesfa, Bikila; Hailu, Dejene; Jemal, Kemal			Infant and young child feeding practice among mothers of children age 6 to 23 months in Debrelibanos district, North Showa zone, Oromia region, Ethiopia	PLOS ONE			English	Article							SECONDARY DATA-ANALYSIS; DETERMINANTS	Background Inappropriate infant and young child feeding (IYCF) practice is the leading cause of malnutrition in children. Data is needed to identify children at risk of poor feeding practice and to target interventions to improve IYCF practices. Therefore, this study aimed to assess IYCF practice and associated factors among mothers of children age 6 to 23 months in Debrelibanos district, north Showa zone, Oromia region, Ethiopia. Method A community-based cross-sectional study design was conducted among 380 mothers of children age 6 to 23 months from March 1 to April 5, 2019. A simple random sampling technique was used to select the respondents. Data was collected using a structured interviewer-administered questionnaire that had been pretested. The data was entered into Epi-Data 3.1 and then transferred to SPSS 21 for analysis. Descriptive statistical analysis was done, and an association between an outcome variable and independent variables was examined in logistic regression models. Result Overall, 65.8% of mothers practiced appropriate IYCF practice. The study revealed that 70.5% of children started breastfeeding within one hour of birth, and 61.6% were breastfed exclusively for six months. Among studied mothers, 79.5% continued to breastfeed their children until 2 years, and 69.2% of the participants started complementary feeding timely at six months. Minimum dietary diversity was observed in 19.2% of children, while minimum meal frequency was found in 79.2%. The majority of mothers (77.6%) fed their babies with bottles. Mother's educational status of primary school [AOR = 4.50, 95% CI: (1.38,14.61)], husband's occupation being merchant [AOR = 6.45, 95% CI: (1.51, 27.59)]; antenatal care follows up [AOR = 3.15, % CI: (1.22, 8.12)], radio/television ownership [AOR = 7.41, 95% CI: (2.86, 19.20)], child's sex being female [AOR = 4.78, 95% CI: (2.26, 10.064) and sufficient knowledge on child feeding [AOR = 2.82, 95% CI: (1.27, 26.26)] were independent predictors for appropriate IYCF practice. Conclusion The prevalence of appropriate infant and young child feeding practice indicators was found to be rather high among the mothers in this study. The use of a bottle to feed babies, in particular is very common among the mothers who were studied. To address child malnutrition, it is critical to educate families about proper IYCF practices. This study suggests that mothers be properly educated about IYCF recommendations at health care facilities during their visits, as well as the promotion of appropriate IYCF through various media.	[Mekonnen, Mathewos; Kinati, Tadele; Bekele, Kumera; Tesfa, Bikila; Hailu, Dejene; Jemal, Kemal] Salale Univ, Dept Nursing, Coll Hlth Sci, Fiche, Oromia Region, Ethiopia		Mekonnen, M (corresponding author), Salale Univ, Dept Nursing, Coll Hlth Sci, Fiche, Oromia Region, Ethiopia.	matemek2010@gmail.com	Kassa, Dejene Hailu/GQP-9794-2022; Mohammed, kemal Jemal/AAG-2458-2021	Mohammed, kemal Jemal/0000-0001-8922-1827	Salale University	Salale University	Funding: This study was funded by Salale University. The funder had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Aakre I, 2017, INT BREASTFEED J, V12, DOI 10.1186/s13006-016-0098-1; Aemro M, 2013, J NUTR METAB, V2013, DOI 10.1155/2013/782931; Benson T., 2005, INT FOOD POLICY RES, V1, P9; Berhe H, 2013, INT J PHARM SCI RES, V4, P650, DOI 10.13040/IJPSR.0975-8232.4(2).650-60; Beyene A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1804-4; Biks Gashaw Andargie, 2018, BMC Res Notes, V11, P593, DOI 10.1186/s13104-018-3703-0; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Central Statistical Agency [Ethiopia] ICF International, 2017, ETH DEM HLTH SURV 20; Chapagain R., 2013, J NEPAL HLTH RES COU; Dangura D, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-016-0764-x; FANTA II, 2010, IND ASS INF YOUNG 3; Federal Ministry of Health, 2004, NAT STRAT INF YOUNG; Grantham-McGregor S, 2007, LANCET, V369, P60, DOI 10.1016/S0140-6736(07)60032-4; Haresh Chandwani, 2015, International Journal of Medical Science and Public Health, V4, P1414; Hasnain S, 2013, BIOMEDICA, V29; Ibegbu AO., 2016, ANNAL BIOANTHROPOL, V4, P96; Joshi N, 2012, MATERN CHILD NUTR, V8, P45, DOI 10.1111/j.1740-8709.2011.00384.x; Kabir I, 2012, MATERN CHILD NUTR, V8, P11, DOI 10.1111/j.1740-8709.2011.00379.x; Khanal V, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-131; Kimani-Murage EW, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-396; Malhotra N, 2013, PUBLIC HEALTH NUTR, V16, P1723, DOI 10.1017/S1368980012004065; McDonald CM, 2013, AM J CLIN NUTR, V97, P896, DOI 10.3945/ajcn.112.047639; Roba KT., 2016, INT J NUTR FOOD SCI, V5, P185; Sasie S., 2017, J FAMILY MED, V4, P11; Semahegn A, 2014, PAN AFR MED J, P18; Senarath U, 2012, MATERN CHILD NUTR, V8, P89, DOI 10.1111/j.1740-8709.2011.00370.x; Shumey A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1050; Sinhababu A, 2010, J HEALTH POPUL NUTR, V28, P294; Tessema M, 2013, PAN AFR MED J, V14, DOI 10.11604/pamj.2013.14.75.1630; UNICEF, 2006, STATE WORLDS CHILDRE; UNICEF, 2012, PROGR GUID INF YOUNG; UNICEF, 2007, WHO IND ASS INF YOUN; Venancio SI, 2006, PUBLIC HEALTH NUTR, V9, P40, DOI 10.1079/PHN2005760; Vitta BS, 2016, MATERN CHILD NUTR, V12, P77, DOI 10.1111/mcn.12292; Wamani H, 2005, J TROP PEDIATRICS, V51, P356, DOI 10.1093/tropej/fmi048; WHO, 2003, IMPLEMENTING GLOBAL; World Bank, 2006, REP NUTR CENTR DEV S; World Health Organization, 2003, GLOB STRAT INF YOUNG; Yemane S., 2014, INT J NUTR FOOD SCI, V3, P438; Yonas F., 2015, OPEN ACCESS LIB J, V2, P1	40	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2021	16	9							e0257758	10.1371/journal.pone.0257758	http://dx.doi.org/10.1371/journal.pone.0257758			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY2YF	34559861	Green Published, gold			2023-01-03	WOS:000754657900042
J	Takeuchi, M; Higa, Y; Esaki, A; Nabeshima, Y; Nakazono, A				Takeuchi, Masaaki; Higa, Yukie; Esaki, Akina; Nabeshima, Yosuke; Nakazono, Akemi			Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?	PLOS ONE			English	Article							SARS-COV-2 INFECTION	Background Adverse reactions are more common after the second injection of messenger RNA vaccines such as Pfizer/BioNTech's BNT162b2. We hypothesized that the degree and severity of reactogenicity after the second injection reflects the magnitude of antibody production against the SARS CoV-2 virus spike protein (spike IgG). Methods and results Blood samples were obtained from 67 Japanese healthcare workers three weeks after the first injection and two weeks after the second injection of the BNT162b2 vaccine to measure spike IgG levels. Using questionnaires, we calculated an adverse event (AE) score (0-11) for each participant. The geometric mean of spike IgG titers increased from 1,047 antibody units (AU/mL) (95% confidence interval (95% CI): 855-1282 AU/mL) after the first injection to 17,378 AU/mL (95% CI: 14,622-20,663 AU/mL) after the second injection. The median AE score increased from 2 to 5. Spike IgG levels after the second injection were negatively correlated with age and positively correlated with spike IgG after the first injection. AE scores after the second injection were not significantly associated with log-transformed spike IgG after the second injection, when adjusted for age, sex, AE score after the first injection, and log-transformed spike IgG after the first injection. Conclusions Although the sample size was relatively small, reactogenicity after the second injection may not accurately reflect antibody production.	[Takeuchi, Masaaki; Higa, Yukie; Esaki, Akina; Nakazono, Akemi] Hosp Univ Occupat & Environm Hlth, Sch Med, Dept Lab & Transfus Med, Kitakyushu, Fukuoka, Japan; [Nabeshima, Yosuke] Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Kitakyushu, Fukuoka, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Takeuchi, M (corresponding author), Hosp Univ Occupat & Environm Hlth, Sch Med, Dept Lab & Transfus Med, Kitakyushu, Fukuoka, Japan.	takeuchi@med.uoeh-u.ac.jp		Takeuchi, Masaaki/0000-0001-7606-1537				Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; Angel Y, 2021, JAMA-J AM MED ASSOC, V325, P2457, DOI 10.1001/jama.2021.7152; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Chapin-Bardales J, 2021, JAMA-J AM MED ASSOC, V325, P2201, DOI 10.1001/jama.2021.5374; Coggins SA, 2022, OPEN FORUM INFECT DI, V9, DOI [10.1101/2021.06.25.21259544, 10.1093/ofid/ofab575]; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Debes AK, 2021, JAMA INTERN MED, V181, P1660, DOI 10.1001/jamainternmed.2021.4580; Grupper A, 2021, CLIN J AM SOC NEPHRO, V16, P1037, DOI 10.2215/CJN.03500321; Hinton D, BRATCHER BOWMAN ACTI; Kounis NG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030221; Mazzoni A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI149150; Muller L, 2021, CLIN INFECT DIS, V73, P2065, DOI 10.1093/cid/ciab381; Narasimhan M, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.00388-21; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prendecki M, 2021, LANCET, V397, P1178, DOI 10.1016/S0140-6736(21)00502-X; Subbarao S, 2021, EUROSURVEILLANCE, V26, P2, DOI 10.2807/1560-7917.ES.2021.26.12.2100329; Tang L, 2021, JAMA-J AM MED ASSOC, V325, P2500, DOI 10.1001/jama.2021.6564; Velasco Maria, 2021, Open Forum Infect Dis, V8, pofab299, DOI 10.1093/ofid/ofab299; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906	19	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2021	16	9							e0257668	10.1371/journal.pone.0257668	http://dx.doi.org/10.1371/journal.pone.0257668			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG6BN	34543337	Green Published, Green Submitted, gold			2023-01-03	WOS:000707078200068
J	van de Veerdonk, FL; Giamarellos-Bourboulis, E; Pickkers, P; Derde, L; Leavis, H; van Crevel, R; Engel, JJ; Wiersinga, WJ; Vlaar, APJ; Shankar-Hari, M; van der Poll, T; Bonten, M; Angus, DC; van der Meer, JWM; Netea, MG				van de Veerdonk, Frank L.; Giamarellos-Bourboulis, Evangelos; Pickkers, Peter; Derde, Lennie; Leavis, Helen; van Crevel, Reinout; Engel, Job J.; Wiersinga, W. Joost; Vlaar, Alexander P. J.; Shankar-Hari, Manu; van der Poll, Tom; Bonten, Marc; Angus, Derek C.; van der Meer, Jos W. M.; Netea, Mihai G.			A guide to immunotherapy for COVID-19	NATURE MEDICINE			English	Review							KINASE INHIBITORS; TISSUE FACTOR; MULTICENTER; NEUTROPHILS; THROMBOSIS; IMMUNITY; C5A	This Review aims to support clinical decision-making by providing an overview of the evidence for immunotherapy strategies in patients with COVID-19. Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.	[van de Veerdonk, Frank L.; van Crevel, Reinout; Engel, Job J.; van der Meer, Jos W. M.; Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [van de Veerdonk, Frank L.; van Crevel, Reinout; Engel, Job J.; van der Meer, Jos W. M.; Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands; [Giamarellos-Bourboulis, Evangelos] Univ Athens, Attikon Hosp, Dept Infect Dis, Athens, Greece; [Pickkers, Peter] Radboud Univ Nijmegen, Med Ctr, Dept Intens Care Med, Nijmegen, Netherlands; [Pickkers, Peter] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands; [Derde, Lennie] Univ Med Ctr Utrecht, Dept Intens Care, Utrecht, Netherlands; [Leavis, Helen] Univ Med Ctr Utrecht, Dept Internal Med, Utrecht, Netherlands; [Wiersinga, W. Joost; van der Poll, Tom] Univ Amsterdam, Amsterdam UMC, Ctr Expt Mol Med CEMM, Div Infect Dis, Amsterdam, Netherlands; [Vlaar, Alexander P. J.] Univ Amsterdam, Amsterdam UMC, Dept Intens Care Med, Amsterdam, Netherlands; [Vlaar, Alexander P. J.] Univ Amsterdam, Amsterdam UMC, Lab Expt Intens Care Med & Anesthesiol, Amsterdam, Netherlands; [Shankar-Hari, Manu] Kings Coll London, Sch Immunobiol & Microbial Sci, London, England; [Bonten, Marc] Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Angus, Derek C.] UPMC, Pittsburgh, PA USA; [Angus, Derek C.] Univ Pittsburgh, Pittsburgh, PA USA; [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst, Dept Immunol & Metab, Bonn, Germany	Radboud University Nijmegen; Radboud University Nijmegen; National & Kapodistrian University of Athens; University Hospital Attikon; Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Amsterdam; University of Amsterdam; University of Amsterdam; University of London; King's College London; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Bonn	van de Veerdonk, FL (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands.; van de Veerdonk, FL (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands.; Netea, MG (corresponding author), Univ Bonn, Life & Med Sci Inst, Dept Immunol & Metab, Bonn, Germany.	frank.vandeveerdonk@radboudumc.nl; mihai.netea@radboudumc.nl	Derde, Lennie/AAF-2725-2021; Shankar-Hari, Manu/I-6948-2012	Derde, Lennie/0000-0002-3577-5629; Shankar-Hari, Manu/0000-0002-5338-2538; Giamarellos-Bourboulis, Evangelos/0000-0003-4713-3911	Netherlands Organization for Scientific Research (Vidi grant from ZonMW ZonMW) [10430012010010]; Spinoza grant of the Netherlands Association for Scientific Research	Netherlands Organization for Scientific Research (Vidi grant from ZonMW ZonMW); Spinoza grant of the Netherlands Association for Scientific Research	F.L.v.d.V. gratefully acknowledges financial support from the Netherlands Organization for Scientific Research (Vidi grant from ZonMW & ZonMW project nr 10430012010010).M.G.N. was supported by a Spinoza grant of the Netherlands Association for Scientific Research.	Aiello A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02247; Aman J, 2021, LANCET RESP MED, V9, P957, DOI 10.1016/S2213-2600(21)00237-X; Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; Azam TU, 2020, J AM SOC NEPHROL, V31, P2725, DOI 10.1681/ASN.2020060829; Bastug A, 2021, RHEUMATOL INT, V41, P993, DOI 10.1007/s00296-021-04843-1; Bendib I, 2021, CRIT CARE, V25, DOI 10.1186/s13054-020-03427-y; Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745; Bonaventura A, 2021, NAT REV IMMUNOL, V21, P319, DOI 10.1038/s41577-021-00536-9; Bost P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21702-6; Bournazos S, 2020, NAT REV IMMUNOL, V20, P633, DOI 10.1038/s41577-020-00410-0; Caricchio R, 2021, JAMA-J AM MED ASSOC, V326, P230, DOI 10.1001/jama.2021.9508; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449; Cheung EW, 2020, JAMA-J AM MED ASSOC, V324, P294, DOI 10.1001/jama.2020.10374; Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6; de Bruin S, 2021, EBIOMEDICINE, V67, DOI 10.1016/j.ebiom.2021.103378; Diao B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22781-1; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020; Egloff SAA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI151788; Estcourt LJ, 2021, JAMA-J AM MED ASSOC, V326, P1690, DOI 10.1001/jama.2021.18178; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Guimaraes PO, 2021, NEW ENGL J MED, V385, P406, DOI 10.1056/NEJMoa2101643; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1791, DOI 10.1002/art.41454; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2021, LANCET, V397, P2049, DOI 10.1016/S0140-6736(21)00897-7; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Huang I, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00453-4; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Iskander KN, 2013, PHYSIOL REV, V93, P1247, DOI 10.1152/physrev.00037.2012; Jacobs CF, 2021, BLOOD ADV, V5, P913, DOI 10.1182/bloodadvances.2020003768; Janssen NAF., 2021, J INFECT DIS, V223, p1322 1333 1; Jouan Y, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03513-9; Kalil AC, 2021, NEW ENGL J MED, V384, P795, DOI 10.1056/NEJMoa2031994; Kambas K, 2008, J IMMUNOL, V180, P7368, DOI 10.4049/jimmunol.180.11.7368; Kreutmair S, 2021, IMMUNITY, V54, P1578, DOI 10.1016/j.immuni.2021.05.002; Kyriazopoulou E, 2021, NAT MED, V27, P1752, DOI 10.1038/s41591-021-01499-z; Kyriazopoulou E, 2021, ELIFE, V10, DOI 10.7554/eLife.66125; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Laterre PF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.16485; Lawler PR, 2021, NEW ENGL J MED, V385, P790, DOI 10.1056/NEJMoa2105911; Lee PY, 2020, J CLIN INVEST, V130, P5942, DOI 10.1172/JCI141113; Libster R, 2021, NEW ENGL J MED, V384, P610, DOI 10.1056/NEJMoa2033700; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Lopes RD, 2021, LANCET, V397, P2253, DOI 10.1016/S0140-6736(21)01203-4; Mandal S, 2021, THORAX, V76, P396, DOI 10.1136/thoraxjnl-2020-215818; Mansour E, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05027-9; Marconi VC, 2021, LANCET RESP MED, V9, P1407, DOI 10.1016/S2213-2600(21)00331-3; Mariette X, 2021, LANCET RESP MED, V9, P295, DOI 10.1016/S2213-2600(20)30556-7; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; McArdle AJ, 2021, NEW ENGL J MED, V385, P11, DOI 10.1056/NEJMoa2102968; Menshawey R, 2021, CARDIOVASC ENDOCR ME, V10, P80, DOI 10.1097/XCE.0000000000000237; Monk PD, 2021, LANCET RESP MED, V9, P196, DOI 10.1016/S2213-2600(20)30511-7; Morris SB, 2020, MMWR-MORBID MORTAL W, V69, P1450, DOI 10.15585/mmwr.mm6940e1; Munoz-Rivas N, 2021, THROMB RES, V199, P132, DOI 10.1016/j.thromres.2020.12.024; Nakra NA, 2020, CHILDREN-BASEL, V7, DOI 10.3390/children7070069; Nguyen LS, 2021, INTENS CARE MED, V47, P619, DOI 10.1007/s00134-021-06377-3; O'Donnell MR, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150646; Obi AT, 2021, J VASC SURG-VENOUS L, V9, P23, DOI 10.1016/j.jvsv.2020.08.030; Ouldali N, 2021, JAMA-J AM MED ASSOC, V325, P855, DOI 10.1001/jama.2021.0694; Patel J., RANDOMIZED TRIAL OTI, DOI [10.1101/2021.04.14.21255475(2021, DOI 10.1101/2021.04.14.21255475(2021]; Payen D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580250; Pouletty M, 2020, ANN RHEUM DIS, V79, P999, DOI 10.1136/annrheumdis-2020-217960; Ramcharan T, 2020, PEDIATR CARDIOL, V41, P1391, DOI 10.1007/s00246-020-02391-2; Richeldi L, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-019-1030-4; Richeldi L, 2011, NEW ENGL J MED, V365, P1079, DOI 10.1056/NEJMoa1103690; Riollano-Cruz M, 2021, J MED VIROL, V93, P424, DOI 10.1002/jmv.26224; Ritis K, 2006, J IMMUNOL, V177, P4794, DOI 10.4049/jimmunol.177.7.4794; Rovina N, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02897-4; Ruscitti P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01130; Sadeghipour P, 2021, JAMA-J AM MED ASSOC, V325, P1620, DOI 10.1001/jama.2021.4152; Schurink B, 2020, LANCET MICROBE, V1, pE290, DOI 10.1016/S2666-5247(20)30144-0; Senefeld JW, 2021, TRANSFUSION, V61, P2503, DOI 10.1111/trf.16525; Seshan SV, 2009, BLOOD, V114, P1675, DOI 10.1182/blood-2009-01-199117; Shankar-Hari M, 2021, JAMA-J AM MED ASSOC, V326, P499, DOI 10.1001/jama.2021.11330; Shankar-Hari M, 2012, CRIT CARE, V16, DOI 10.1186/cc10597; Shatzel JJ, 2020, RES PRACT THROMB HAE, V4, P500, DOI 10.1002/rth2.12349; Son MBF, 2021, NEW ENGL J MED, V385, P23, DOI 10.1056/NEJMoa2102605; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Talasaz AH, 2021, J AM COLL CARDIOL, V77, P1903, DOI 10.1016/j.jacc.2021.02.035; The REMAP-CAP Investigators, EFF TOC SAR AN CRIT, DOI [DOI 10.3389/fimmu.2019.02247, 10.1101/2021.06.18.21259133(2021), DOI 10.1101/2021.06.18.21259133(2021)]; Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021; Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094; Uwaydah AK, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-242060; Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600; van de Veerdonk FL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.17708; van de Veerdonk FL, 2020, ELIFE, V9, DOI 10.7554/eLife.57555; van Laarhoven A, 2021, MED-CAMBRIDGE, V2, P1163, DOI 10.1016/j.medj.2021.09.003; Vlaar APJ, 2020, LANCET RHEUMATOL, V2, pE764, DOI 10.1016/S2665-9913(20)30341-6; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; ZINSSER HANS, 1930, JOUR EXP MED, V51, P847, DOI 10.1084/jem.51.6.847	104	60	60	24	40	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					39	50		10.1038/s41591-021-01643-9	http://dx.doi.org/10.1038/s41591-021-01643-9		JAN 2022	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35064248	Bronze, Green Accepted			2023-01-03	WOS:000745382200001
J	Cho, S; Hwang, S; Jung, JY; Kwak, YH; Kim, D; Lee, JH; Jung, JH; Park, JW; Kwon, H; Suh, D				Cho, Sooje; Hwang, Soyun; Jung, Jae Yun; Kwak, Young Ho; Kim, Do Kyun; Lee, Jin Hee; Jung, Jin Hee; Park, Joong Wan; Kwon, Hyuksool; Suh, Dongbum			Validation of Pediatric Emergency Care Applied Research Network (PECARN) rule in children with minor head trauma	PLOS ONE			English	Article							PREDICTION RULES; CT SCANS; INJURY; RISK	The Pediatric Emergency Care Applied Research Network (PECARN) rule is commonly used for predicting the need for computed tomography (CT) scans in children with mild head trauma. The objective of this study was to validate the PECARN rule in Korean children presenting to the pediatric emergency department (PED) with head trauma. This study was a multicenter, retrospective, observational cohort study in two teaching PEDs in Korea between August 2015 and August 2016. In this observational study, 448 patients who visited PEDs were included in the final analysis. Risk stratification was performed with clinical decision support software based on the PECARN rule, and decisions to perform CT scans were subsequently made. Patients were followed-up by phone call between 7 days and 90 days after discharge from the PED. The sensitivity and specificity were analyzed. The sensitivity was 100% for all age groups, and no cases of clinically important traumatic brain injury (ciTBI) were identified in the very-low-risk group. CT scans were performed for 14.7% of patients in this study and for 33.8% in the original PECARN study. The PECARN rule successfully identified low-risk patients, and no cases of ciTBI were missed despite the reduced proportion of patients undergoing CT scans.	[Cho, Sooje; Hwang, Soyun; Jung, Jae Yun; Kwak, Young Ho; Kim, Do Kyun; Park, Joong Wan] Seoul Natl Univ Hosp, Dept Emergency Med, Seoul, South Korea; [Lee, Jin Hee; Kwon, Hyuksool; Suh, Dongbum] Seoul Natl Univ, Dept Emergency Med, Bundang Hosp, Seongnam, South Korea; [Jung, Jin Hee] Seoul Natl Univ, Seoul Metropolitan Govt, Boramae Med Ctr, Dept Emergency Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Hwang, S (corresponding author), Seoul Natl Univ Hosp, Dept Emergency Med, Seoul, South Korea.	soyun.from.earth@gmail.com	; LEE, JIN HEE/Q-3108-2018	Suh, Dongbum/0000-0002-2449-1006; cho, sooje/0000-0002-4270-9136; LEE, JIN HEE/0000-0002-2385-2834; Hwang, Soyun/0000-0002-4290-0213				Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Bressan S, 2021, CHILD NERV SYST, V37, P55, DOI 10.1007/s00381-020-04660-0; Christian CW, 2015, PEDIATRICS, V135, pE1337, DOI 10.1542/peds.2015-0356; Dewan MC, 2016, WORLD NEUROSURG, V91, P497, DOI 10.1016/j.wneu.2016.03.045; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Gliklich RE, 2020, REGISTRIES EVALUATIN, V4th, DOI 10.23970/AHRQEPCREGISTRIES4; Ide K, 2017, ACAD EMERG MED, V24, P308, DOI 10.1111/acem.13129; Jung KY., 2015, PEDIAT EMERGENCY MED, V2, P67; Jung Sung Wun, 2019, [Pediatric Emergency Medicine Journal, 대한소아응급의학회지], V6, P63, DOI 10.22470/pemj.2019.00101; Kim HK., 2014, J TRAUMA INJURY, V27, P63; Kim JY., 2014, PEDIAT EMERG MED J, V1, P24, DOI [10.22470/pemj.2014.1.1.24, DOI 10.22470/PEMJ.2014.1.1.24]; Kobe IO, 2017, CHILD NERV SYST, V33, P2147, DOI 10.1007/s00381-017-3577-9; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lorton F, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0287-3; Magana JN, 2017, ACAD EMERG MED, V24, P382, DOI 10.1111/acem.13155; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Nakhjavan-Shahraki B, 2017, EUR J TRAUMA EMERG S, V43, P755, DOI 10.1007/s00068-017-0811-9; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Puffenbarger MS, 2019, ACAD EMERG MED, V26, P784, DOI 10.1111/acem.13666; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; 박소영, 2012, [Journal of Trauma and Injury, 대한외상학회지], V25, P152; Zarchi TB, 2020, J AM ASSOC NURSE PRA, V32, P168, DOI 10.1097/JXX.0000000000000208	25	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2022	17	1							e0262102	10.1371/journal.pone.0262102	http://dx.doi.org/10.1371/journal.pone.0262102			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2G1LZ	35041677	gold, Green Published			2023-01-03	WOS:000813361200024
J	Conery, AR; Rocnik, JL; Trojer, P				Conery, Andrew R.; Rocnik, Jennifer L.; Trojer, Patrick			Small molecule targeting of chromatin writers in cancer	NATURE CHEMICAL BIOLOGY			English	Review							REPRESSIVE COMPLEX 2; OPEN-LABEL; ARGININE METHYLTRANSFERASE; BREAST-CANCER; BETA-CATENIN; INHIBITOR; DEGRADATION; PROTEIN; CARM1; CELLS	More than a decade after the launch of DNA methyltransferase and histone deacetylase inhibitors for the treatment of cancer, 2020 heralded the approval of the first histone methyltransferase inhibitor, revitalizing the concept that targeted manipulation of the chromatin regulatory landscape can have profound therapeutic impact. Three chromatin regulatory pathways-DNA methylation, histone acetylation and methylation-are frequently implicated in human cancer but hundreds of potentially druggable mechanisms complicate identification of key targets for therapeutic intervention. In addition to human genetics and functional screening, chemical biology approaches have proven critical for the discovery of key nodes in these pathways and in an ever-increasing complexity of molecularly defined human cancer contexts. This review introduces small molecule targeting approaches, showcases chemical probes and drug candidates for epigenetic writer enzymes, illustrates molecular features that may represent epigenetic dependencies and suggests translational strategies to maximize their impact in cancer therapy.	[Conery, Andrew R.; Rocnik, Jennifer L.; Trojer, Patrick] Constellat Pharmaceut Inc, Cambridge, MA 02142 USA		Trojer, P (corresponding author), Constellat Pharmaceut Inc, Cambridge, MA 02142 USA.	patricktroj@gmail.com		CONERY, ANDREW/0000-0003-3638-7633				Aho ER, 2019, CELL REP, V26, P2916, DOI 10.1016/j.celrep.2019.02.047; Attar N, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026534; Baell JB, 2018, NATURE, V560, P253, DOI 10.1038/s41586-018-0387-5; Bassi ZI, 2018, ACS CHEM BIOL, V13, P2862, DOI 10.1021/acschembio.8b00705; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Blanc RS, 2017, MOL CELL, V65, P8, DOI 10.1016/j.molcel.2016.11.003; Bommi-Reddy A, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-4722; Borkin D, 2015, CANCER CELL, V27, P589, DOI 10.1016/j.ccell.2015.02.016; Boskovic A, 2018, ANNU REV GENET, V52, P21, DOI 10.1146/annurev-genet-120417-031404; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Buesa C, 2019, BLOOD, V134, DOI 10.1182/blood-2019-125121; Burr ML, 2019, CANCER CELL, V36, P385, DOI 10.1016/j.ccell.2019.08.008; Cai LY, 2021, CANCER RES, V81, P860, DOI 10.1158/0008-5472.CAN-20-1323; Caiado F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12983-z; Chan-Penebre E, 2015, NAT CHEM BIOL, V11, P432, DOI [10.1038/nchembio.1810, 10.1038/NCHEMBIO.1810]; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Dancy BM, 2015, CHEM REV, V115, P2419, DOI 10.1021/cr500452k; Dolle A, 2021, J MED CHEM, V64, P10682, DOI 10.1021/acs.jmedchem.1c00146; Drew AE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18446-z; Du DH, 2021, J MED CHEM, V64, P8194, DOI 10.1021/acs.jmedchem.0c02261; DuPage M, 2015, IMMUNITY, V42, P227, DOI 10.1016/j.immuni.2015.01.007; Eich ML, 2020, CANCER RES, V80, P5449, DOI 10.1158/0008-5472.CAN-20-2147; Ennishi D, 2019, CANCER DISCOV, V9, P546, DOI 10.1158/2159-8290.CD-18-1090; Farria A, 2015, ONCOGENE, V34, P4901, DOI 10.1038/onc.2014.453; Fedoriw A, 2019, CANCER CELL, V36, P100, DOI 10.1016/j.ccell.2019.05.014; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983; Gardner EE, 2017, CANCER CELL, V31, P286, DOI 10.1016/j.ccell.2017.01.006; Gerhart SV, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28002-y; Ghoneim HE, 2017, CELL, V170, DOI 10.1016/j.cell.2017.06.007; Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005; Gilmartin AG, 2021, HAEMATOLOGICA, V106, P1979, DOI 10.3324/haematol.2020.248658; Gounder M, 2020, LANCET ONCOL, V21, P1423, DOI 10.1016/S1470-2045(20)30451-4; Grebien F, 2015, NAT CHEM BIOL, V11, P571, DOI [10.1038/nchembio.1859, 10.1038/NCHEMBIO.1859]; Greenblatt SM, 2018, CANCER CELL, V33, P1111, DOI 10.1016/j.ccell.2018.05.007; Guccione E, 2019, NAT REV MOL CELL BIO, V20, P642, DOI 10.1038/s41580-019-0155-x; Gulla A, 2018, LEUKEMIA, V32, P996, DOI 10.1038/leu.2017.334; Hogg SJ, 2021, MOL CELL, V81, P2183, DOI 10.1016/j.molcel.2021.04.015; Hogg SJ, 2020, NAT REV DRUG DISCOV, V19, P776, DOI 10.1038/s41573-020-0077-5; Hsu JHR, 2020, CELL CHEM BIOL, V27, P41, DOI 10.1016/j.chembiol.2019.11.004; Huang A, 2020, NAT REV DRUG DISCOV, V19, P23, DOI 10.1038/s41573-019-0046-z; Huang H, 2020, NAT CHEM BIOL, V16, P1403, DOI 10.1038/s41589-020-0626-6; Husmann D, 2019, NAT STRUCT MOL BIOL, V26, P880, DOI 10.1038/s41594-019-0298-7; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Italiano A, 2018, LANCET ONCOL, V19, P649, DOI 10.1016/S1470-2045(18)30145-1; Ji ZQ, 2021, BIOORG MED CHEM LETT, V39, DOI 10.1016/j.bmcl.2021.127854; Jones PA, 2019, NAT REV CANCER, V19, P151, DOI 10.1038/s41568-019-0109-9; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Kong XQ, 2014, J MED CHEM, V57, P9512, DOI 10.1021/jm501230c; Krivtsov AV, 2019, CANCER CELL, V36, P660, DOI 10.1016/j.ccell.2019.11.001; Kryukov GV, 2016, SCIENCE, V351, P1214, DOI 10.1126/science.aad5214; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Lasko LM, 2017, NATURE, V550, P128, DOI 10.1038/nature24028; Laugesen A, 2019, MOL CELL, V74, P8, DOI 10.1016/j.molcel.2019.03.011; Levell JR., 2020, MED CHEM REV, V55, P319; Luo N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02630-w; MacPherson L, 2020, NATURE, V577, P266, DOI 10.1038/s41586-019-1835-6; Marjon K, 2016, CELL REP, V15, P574, DOI 10.1016/j.celrep.2016.03.043; Martin MC, 2020, J MED CHEM, V63, P15344, DOI 10.1021/acs.jmedchem.0c01344; Mavrakis KJ, 2016, SCIENCE, V351, P1208, DOI 10.1126/science.aad5944; Morel KL, 2021, NAT CANCER, V2, P444, DOI 10.1038/s43018-021-00185-w; Morschhauser F, 2020, LANCET ONCOL, V21, P1433, DOI 10.1016/S1470-2045(20)30441-1; Nakayama Kazuhide, 2018, Oncotarget, V9, P18480, DOI 10.18632/oncotarget.24883; Narita T, 2021, MOL CELL, V81, P2166, DOI 10.1016/j.molcel.2021.03.008; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Ou CY, 2011, MOL CANCER RES, V9, P660, DOI 10.1158/1541-7786.MCR-10-0223; Pappalardi MB, 2021, NAT CANCER, V2, P1002, DOI 10.1038/s43018-021-00249-x; Patel K, 2010, NUCLEIC ACIDS RES, V38, P4313, DOI 10.1093/nar/gkq187; Potjewyd F, 2020, CELL CHEM BIOL, V27, P47, DOI 10.1016/j.chembiol.2019.11.006; Reilly BM, 2021, MOL CANCER RES, V19, P451, DOI 10.1158/1541-7786.MCR-20-0453; Sachamitr P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21204-5; Schermelleh L, 2005, NAT METHODS, V2, P751, DOI 10.1038/NMETH794; Shailesh Harshita, 2018, Oncotarget, V9, P36705, DOI 10.18632/oncotarget.26404; Sharma S, 2021, CANCER RES, V81; Smith CR, 2021, CANCER RES, V81; Srour N, 2019, CANCER CELL, V36, P3, DOI 10.1016/j.ccell.2019.06.004; Stein EM, 2018, BLOOD, V131, P2661, DOI 10.1182/blood-2017-12-818948; Taplin ME, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-CT094; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Vannam R, 2021, CELL CHEM BIOL, V28, P503, DOI 10.1016/j.chembiol.2020.12.004; Wang R, 2018, MOL CANCER THER, V17, P2543, DOI 10.1158/1535-7163.MCT-18-0511; Weinert BT, 2018, CELL, V174, P231, DOI 10.1016/j.cell.2018.04.033; Wilson JE, 2020, ACS MED CHEM LETT, V11, P1324, DOI 10.1021/acsmedchemlett.0c00155; Wimalasena VK, 2020, MOL CELL, V78, P1086, DOI 10.1016/j.molcel.2020.04.023; Wu MQ, 2019, ONCOGENE, V38, P5425, DOI 10.1038/s41388-019-0799-1; Wu Q, 2021, NAT REV DRUG DISCOV, V20, P509, DOI 10.1038/s41573-021-00159-8; Xiao LB, 2018, CANCER RES, V78, P5731, DOI 10.1158/0008-5472.CAN-18-0941; Xiao WD, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108790; Yang HS, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0734-x; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Yang YX, 2020, J MED CHEM, V63, P1337, DOI 10.1021/acs.jmedchem.9b01721; Yau HL, 2021, MOL CELL, V81, P1469, DOI 10.1016/j.molcel.2021.01.038; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; Yoo CB, 2007, CANCER RES, V67, P6400, DOI 10.1158/0008-5472.CAN-07-0251; Yu J, 2019, DRUG DISCOV TODAY, V24, P2323, DOI 10.1016/j.drudis.2019.08.006; Zhang X, 2020, ONCOGENE, V39, P4770, DOI 10.1038/s41388-020-1301-9	99	5	5	4	22	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2022	18	2					124	133		10.1038/s41589-021-00920-5	http://dx.doi.org/10.1038/s41589-021-00920-5		DEC 2021	10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YS9NX	34952934				2023-01-03	WOS:000734006500001
J	Agbalajobi, OM; Gmelin, T; Moon, AM; Alexandre, W; Zhang, G; Gellad, WF; Jonassaint, N; Rogal, SS				Agbalajobi, Olufunso M.; Gmelin, Theresa; Moon, Andrew M.; Alexandre, Wheytnie; Zhang, Grace; Gellad, Walid F.; Jonassaint, Naudia; Rogal, Shari S.			Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action	PLOS ONE			English	Article							UNITED-STATES; RISK-FACTORS; VETERANS; CIRRHOSIS; OVERDOSE; HEALTH; PAIN; DAMAGE; INFLAMMATION; MEDICATIONS	Background Chronic liver disease (CLD) is among the strongest risk factors for adverse prescription opioid-related events. Yet, the current prevalence and factors associated with high-risk opioid prescribing in patients with chronic liver disease (CLD) remain unclear, making it challenging to address opioid safety in this population. Therefore, we aimed to characterize opioid prescribing patterns among patients with CLD. Methods This retrospective cohort study included patients with CLD identified at a single medical center and followed for one year from 10/1/2015-9/30/2016. Multivariable, multinomial regression was used identify the patient characteristics, including demographics, medical conditions, and liver-related factors, that were associated with opioid prescriptions and high-risk prescriptions (>= 90mg morphine equivalents per day [MME/day] or co-prescribed with benzodiazepines). Results Nearly half (47%) of 12,425 patients with CLD were prescribed opioids over a one-year period, with 17% of these receiving high-risk prescriptions. The baseline factors significantly associated with high-risk opioid prescriptions included female gender (adjusted incident rate ratio, AIRR = 1.32, 95% CI = 1.14-1.53), Medicaid insurance (AIRR = 1.68, 95% CI = 1.36-2.06), cirrhosis (AIRR = 1.22, 95% CI = 1.04-1.43) and baseline chronic pain (AIRR = 3.40, 95% CI = 2.94-4.01), depression (AIRR = 1.93, 95% CI = 1.60-2.32), anxiety (AIRR = 1.84, 95% CI = 1.53-2.22), substance use disorder (AIRR = 2.16, 95% CI = 1.67-2.79), and Charlson comorbidity score (AIRR = 1.27, 95% CI = 1.22-1.32). Non-alcoholic fatty liver disease was associated with decreased high-risk opioid prescriptions (AIRR = 0.56, 95% CI = 0.47-0.66). Conclusion Opioid medications continue to be prescribed to nearly half of patients with CLD, despite efforts to curtail opioid prescribing due to known adverse events in this population.	[Agbalajobi, Olufunso M.] Univ Pittsburgh, Med Ctr, Dept Gen Internal Med, Pittsburgh, PA USA; [Gmelin, Theresa] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA; [Moon, Andrew M.] Univ N Carolina, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA; [Alexandre, Wheytnie; Zhang, Grace] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Gellad, Walid F.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA; [Gellad, Walid F.; Rogal, Shari S.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr, Pittsburgh, PA 15240 USA; [Jonassaint, Naudia; Rogal, Shari S.] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rogal, SS (corresponding author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr, Pittsburgh, PA 15240 USA.; Rogal, SS (corresponding author), Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA.	rogalss@upmc.edu	Moon, Andrew/GXV-9316-2022	Rogal, Shari/0000-0001-8184-1546				Acharya C, 2017, ALIMENT PHARM THER, V45, P319, DOI [10.1111/apt.13858, 10.1111/apt.14585]; Beste LA, 2015, GASTROENTEROLOGY, V149, P1471, DOI 10.1053/j.gastro.2015.07.056; Bohnert ASB, 2016, MED CARE, V54, P435, DOI 10.1097/MLR.0000000000000505; Casey JA, 2018, AM J PREV MED, V54, P430, DOI 10.1016/j.amepre.2017.10.004; Centers for Disease Control and Prevention, 2020, PRESCR PRACT DRUG OV; Chandok N, 2010, MAYO CLIN PROC, V85, P451, DOI 10.4065/mcp.2009.0534; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Cicero TJ, 2017, ADDICT BEHAV, V65, P242, DOI 10.1016/j.addbeh.2016.08.024; De Minicis S, 2008, GUT, V57, DOI 10.1136/gut.2007.120303; DEARAUJO MST, 1993, VIRCHOWS ARCH A, V422, P145, DOI 10.1007/BF01607166; Dobscha SK, 2013, CLIN J PAIN, V29, P102, DOI 10.1097/AJP.0b013e3182490bdb; Dowell D, 2017, JAMA-J AM MED ASSOC, V318, P1065, DOI 10.1001/jama.2017.9308; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Dwyer JP, 2014, J GASTROEN HEPATOL, V29, P1356, DOI 10.1111/jgh.12560; Estes C, 2018, HEPATOLOGY, V67, P123, DOI 10.1002/hep.29466; Fleming JN, 2017, CLIN TRANSPLANT, V31, DOI 10.1111/ctr.13119; Fleming KM, 2010, ALIMENT PHARM THER, V32, P1343, DOI 10.1111/j.1365-2036.2010.04473.x; Frank JW, 2017, ANN INTERN MED, V167, P181, DOI 10.7326/M17-0598; Gastala N, 2017, ANN FAM MED, V15, P372, DOI 10.1370/afm.2057; Gellad WF, 2018, AM J PUBLIC HEALTH, V108, P248, DOI [10.2105/ajph.2017.304174, 10.2105/AJPH.2017.304174]; Gellad WF, 2017, JAMA INTERN MED, V177, P611, DOI 10.1001/jamainternmed.2017.0147; Ghelardini C, 2015, CLIN CASES MINER BON, V12, P219, DOI 10.11138/ccmbm/2015.12.3.219; Glare P, 2020, INTERN MED J, V50, P1185, DOI 10.1111/imj.15023; Ilic G, 2010, BOSNIAN J BASIC MED, V10, P38, DOI 10.17305/bjbms.2010.2730; Imbernon M, 2016, HEPATOLOGY, V64, P1086, DOI 10.1002/hep.28716; Kim BK, 2010, LIVER INT, V30, P546, DOI 10.1111/j.1478-3231.2009.02192.x; Klinge Matthew, 2018, Curr Hepatol Rep, V17, P42, DOI 10.1007/s11901-018-0389-7; Konerman MA, 2019, BMJ OPEN GASTROENTER, V6, DOI 10.1136/bmjgast-2018-000271; Krebs EE, 2018, JAMA-J AM MED ASSOC, V319, P872, DOI 10.1001/jama.2018.0899; Lewis JH, 2013, ALIMENT PHARM THER, V37, P1132, DOI 10.1111/apt.12324; Lin LWA, 2017, PAIN, V158, P833, DOI 10.1097/j.pain.0000000000000837; Marcin JP, 2003, AM J PUBLIC HEALTH, V93, P461, DOI 10.2105/AJPH.93.3.461; Mathieson S, 2020, DRUGS, V80, P1563, DOI 10.1007/s40265-020-01368-y; Midboe AM, 2018, PAIN MED, V19, pS46, DOI 10.1093/pm/pny085; Moon AM, 2020, DIGEST DIS; Moon AM, 2021, DIGEST DIS, V39, P247, DOI 10.1159/000511074; Moon AM, 2020, ALIMENT PHARM THER, V51, P652, DOI 10.1111/apt.15639; Moore K, 2005, AM J PATHOL, V167, P1189, DOI 10.1016/S0002-9440(10)61207-2; National Center for Health Statistics (US), 2020, HLTH US 2018 DAT FIN; Payabvash S, 2006, LIFE SCI, V79, P972, DOI 10.1016/j.lfs.2006.05.008; R Core Team Rf.., 2013, R LANG ENV STAT COMP; Rogal SS, 2019, CLIN GASTROENTEROL H, V17, P1165, DOI 10.1016/j.cgh.2018.10.021; Rogal SS, 2015, DIGEST DIS SCI, V60, P1482, DOI 10.1007/s10620-014-3453-3; Rogal SS, 2015, CLIN GASTROENTEROL H, V13, P1009, DOI 10.1016/j.cgh.2014.10.029; Rogal SS, 2013, LIVER INT, V33, P1497, DOI 10.1111/liv.12215; Rogal SS, 2013, DIGEST DIS SCI, V58, P2976, DOI 10.1007/s10620-013-2638-5; Rubin JB, 2021, HEPATOL COMMUN, V5, P1081, DOI 10.1002/hep4.1694; Schieber LZ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0665; Semenkovich Katherine, 2014, Mo Med, V111, P148; Serper M, 2016, J CLIN GASTROENTEROL, V50, P85, DOI 10.1097/MCG.0000000000000378; Strickler GK, 2020, MMWR SURVEILL SUMM, V69, P1, DOI 10.15585/mmwr.ss6901a1; Tapper EB, 2015, MAYO CLIN PROC, V90, P646, DOI 10.1016/j.mayocp.2015.03.003; Wong RJ, 2017, ALIMENT PHARM THER, V46, P974, DOI 10.1111/apt.14327; Zedler B, 2015, PAIN MED, V16, P1566, DOI 10.1111/pme.12777; Zedler B, 2014, PAIN MED, V15, P1911, DOI 10.1111/pme.12480; Zhang YT, 2004, BASIC CLIN PHARMACOL, V95, P53, DOI 10.1111/j.1742-7843.2004.950202.x	56	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2021	16	12							e0261377	10.1371/journal.pone.0261377	http://dx.doi.org/10.1371/journal.pone.0261377			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YZ0LO	34919585	Green Published, gold			2023-01-03	WOS:000755175100036
J	Woo, J; Shin, S; Cho, E; Ryu, D; Garandeau, D; Chajra, H; Frechet, M; Park, D; Jung, E				Woo, Jieun; Shin, Seoungwoo; Cho, Eunae; Ryu, Dehun; Garandeau, David; Chajra, Hanane; Frechet, Mathilde; Park, Deokhoon; Jung, Eunsun			Senotherapeutic-like effect of Silybum marianum flower extract revealed on human skin cells	PLOS ONE			English	Article							SENESCENT CELLS; SECRETORY PHENOTYPE; CELLULAR SENESCENCE; CYCLE ARREST; APOPTOSIS; MECHANISMS; TARGET; PROLIFERATION; HOMEOSTASIS; EXPRESSION	Cellular senescence causes irreversible growth arrest of cells. Prolonged accumulation of senescent cells in tissues leads to increased detrimental effects due to senescence associated secretory phenotype (SASP). Recent findings suggest that elimination of senescent cells has a beneficial effect on organismal aging and lifespan. In this study, using a validated replicative senescent human dermal fibroblasts (HDFs) model, we showed that elimination of senescent cells is possible through the activation of an apoptotic mechanism. We have shown in this replicative senescence model, that cell senescence is associated with DNA damage and cell cycle arrest (p21, p53 markers). We have shown that Silybum marianum flower extract (SMFE) is a safe and selective senolytic agent targeting only senescent cells. The elimination of the cells is induced through the activation of apoptotic pathway confirmed by annexin V/propidium iodide and caspase-3/PARP staining. Moreover, SMFE suppresses the expression of SASP factors such as IL-6 and MMP-1 in senescent HDFs. In a co-culture model of senescent and young fibroblasts, we demonstrated that senescent cells impaired the proliferative capacities of young cells. Interestingly, when the co-culture is treated with SMFE, the cell proliferation rate of young cells is increased due to the decrease of the senescent burden. Moreover, we demonstrated in vitro that senescent fibroblasts trigger senescent process in normal keratinocytes through a paracrine effect. Indeed, the conditioned medium of senescent HDFs treated with SMFE reduced the level of senescence-associated beta-galactosidase (SA-beta-Gal), p16(INK4A) and SASP factors in keratinocytes compared with CM of senescent HDFs. These results indicate that SMFE can prevent premature aging due to senescence and even reprograms aged skin. Indeed, thanks to its senolytic and senomorphic properties SMFE is a candidate for anti-senescence strategies.	[Woo, Jieun; Shin, Seoungwoo; Cho, Eunae; Ryu, Dehun; Park, Deokhoon; Jung, Eunsun] BioSpectrum Life Sci Inst, Yongin, Gyeonggi Do, South Korea; [Garandeau, David; Chajra, Hanane; Frechet, Mathilde] Clariant Prod, Toulouse, France		Jung, E (corresponding author), BioSpectrum Life Sci Inst, Yongin, Gyeonggi Do, South Korea.	bioso@biospectrum.com		Shin, Seoungwoo/0000-0001-5354-7286				Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158; Aghazadeh S, 2011, EXP TOXICOL PATHOL, V63, P569, DOI 10.1016/j.etp.2010.04.009; Alessio N, 2020, AGING-US, V12, P12609, DOI 10.18632/aging.103606; Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; Carpenter VJ, 2021, CANCERS, V13, DOI 10.3390/cancers13040723; Chen QR, 2015, ONCOTARGET, V6, P25883, DOI 10.18632/oncotarget.4540; Childs BG, 2017, NAT REV DRUG DISCOV, V16, P718, DOI 10.1038/nrd.2017.116; Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000; Chu HH, 2019, ONCOL LETT, V17, P4827, DOI 10.3892/ol.2019.10206; Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012; Eren MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124837; Fisher GJ, 2002, ARCH DERMATOL, V138, P1462, DOI 10.1001/archderm.138.11.1462; Fuhrmann-Stroissnigg H, 2018, CELL CYCLE, V17, P1048, DOI 10.1080/15384101.2018.1475828; Gonzalez-Gualda E, 2020, AGING CELL, V19, DOI 10.1111/acel.13142; Grezella C, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0857-6; Hardwick LJA, 2021, VET RES COMMUN, V45, P21, DOI 10.1007/s11259-020-09784-x; Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148; Jadoon S, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/709628; JUTLEY JK, 1993, MATRIX, V13, P235, DOI 10.1016/S0934-8832(11)80007-7; Kaur A, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00218; Kim EC, 2019, BMB REP, V52, P47, DOI 10.5483/BMBRep.2019.52.1.293; Kirkland JL, 2017, J AM GERIATR SOC, V65, P2297, DOI 10.1111/jgs.14969; Kirkland JL, 2017, EBIOMEDICINE, V21, P21, DOI 10.1016/j.ebiom.2017.04.013; Kvasnicka F, 2003, J CHROMATOGR A, V990, P239, DOI 10.1016/S0021-9673(02)01971-4; Lewinska A, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101337; Lewis DA, 2010, ONCOGENE, V29, P1475, DOI 10.1038/onc.2009.440; Lim H, 2015, BIOCHEM PHARMACOL, V96, P337, DOI 10.1016/j.bcp.2015.06.013; Maeda Y, 2018, INT J ONCOL, V52, P1661, DOI 10.3892/ijo.2018.4308; Malaquin N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063607; Malavolta M, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/4159013; Malhotra U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078343; Moiseeva O, 2013, AGING CELL, V12, P489, DOI 10.1111/acel.12075; Myrianthopoulos V, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102102; Oh JH, 2013, ONCOTARGET, V4, P474, DOI 10.18632/oncotarget.942; Perrott KM, 2017, GEROSCIENCE, V39, P161, DOI 10.1007/s11357-017-9970-1; Quan TH, 2012, J CELL BIOCHEM, V113, P3011, DOI 10.1002/jcb.24179; Rattan SIS, 2016, HEALTHY AGEING LONG, V4, P3, DOI 10.1007/978-3-319-26239-0_1; Ritschka B, 2020, GENE DEV, V34, P489, DOI 10.1101/gad.332643.119; Schosserer M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00278; Soto-Gamez A, 2017, DRUG DISCOV TODAY, V22, P786, DOI 10.1016/j.drudis.2017.01.004; Tyagi A, 2004, CARCINOGENESIS, V25, P1711, DOI 10.1093/carcin/bgh180; Wang AS, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00247; Wang KJ, 2005, J ETHNOPHARMACOL, V96, P483, DOI 10.1016/j.jep.2004.09.036; Wang Z, 2015, MOL MED REP, V11, P1105, DOI 10.3892/mmr.2014.2798; Yoon JE, 2018, THERANOSTICS, V8, P4620, DOI 10.7150/thno.26975; Yosef R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11190; Yousefzadeh MJ, 2018, EBIOMEDICINE, V36, P18, DOI 10.1016/j.ebiom.2018.09.015; Zhu Y, 2017, AGING-US, V9, P955, DOI 10.18632/aging.101202; Zhu Y, 2016, AGING CELL, V15, P428, DOI 10.1111/acel.12445; Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344	50	1	1	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2021	16	12							e0260545	10.1371/journal.pone.0260545	http://dx.doi.org/10.1371/journal.pone.0260545			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY9FU	34914725	gold, Green Published			2023-01-03	WOS:000755091500024
J	Kanjee, Z; Metlay, JP; Moskowitz, A; Reynolds, EE				Kanjee, Zahir; Metlay, Joshua P.; Moskowitz, Ari; Reynolds, Eileen E.			How Would You Treat This Patient Hospitalized With Community-Acquired Pneumonia? Grand Rounds Discussion From Beth Israel Deaconess Medical Center	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							INFECTIOUS-DISEASES-SOCIETY; IDSA/ATS MINOR CRITERIA; THORACIC-SOCIETY; ADULTS; CORTICOSTEROIDS; VALIDATION; GUIDELINES; HYDROCORTISONE; MANAGEMENT; SEVERITY	Community-acquired pneumonia is a major cause of morbidity and mortality in the United States, leading to 1.5 million hospitalizations and at least 200 000 deaths annually. The 2019 American Thoracic Society/Infectious Diseases Society of America clinical practice guideline on diagnosis and treatment of adults with community-acquired pneumonia provides an evidence-based overview of this common illness. Here, 2 experts, a general internist who served as the co-primary author of the guidelines and a pulmonary and critical care physician, debate the management of a patient hospitalized with community-acquired pneumonia. They discuss disease severity stratification methods, whether to use adjunctive corticosteroids, and when to prescribe empirical treatment for multidrug-resistant organisms such as methicillin-resistant Staphylococcus aurous and Pseudomonas aeruginosa.	[Kanjee, Zahir; Reynolds, Eileen E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Metlay, Joshua P.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Moskowitz, Ari] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Kanjee, Z (corresponding author), Beth Israel Deaconess Med Ctr, Hosp Med Off, SPAN 2, 330 Brookline Ave, Boston, MA 02215 USA.	zkanjee@bidmc.harvard.edu		Kanjee, Zahir/0000-0001-9287-4503				Annane D, 2018, NEW ENGL J MED, V378, P809, DOI 10.1056/NEJMoa1705716; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; Briel M, 2018, CLIN INFECT DIS, V66, P346, DOI 10.1093/cid/cix801; Brown SM, 2009, CRIT CARE MED, V37, P3010, DOI 10.1097/CCM.0b013e3181b030d9; Cottin V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0166462; Dangerfield B, 2014, ANTIMICROB AGENTS CH, V58, P859, DOI 10.1128/AAC.01805-13; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Guo Q, 2011, RESP MED, V105, P1543, DOI 10.1016/j.rmed.2011.06.010; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870; Kalil AC, 2016, CLIN INFECT DIS, V63, P575, DOI 10.1093/cid/ciw504; Keh D, 2016, JAMA-J AM MED ASSOC, V316, P1775, DOI 10.1001/jama.2016.14799; Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093; Li HY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001474; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Llor C, 2014, THER ADV DRUG SAF, V5, P229, DOI 10.1177/2042098614554919; Lloyd M, 2019, JAMA INTERN MED, V179, P1052, DOI 10.1001/jamainternmed.2019.1438; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Marti C, 2012, CRIT CARE, V16, DOI 10.1186/cc11447; Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST; Moskowitz A, 2016, AM J RESP CRIT CARE, V194, P256, DOI 10.1164/rccm.201605-1005ED; Parente DM, 2018, CLIN INFECT DIS, V67, P1, DOI 10.1093/cid/ciy024; Phua J, 2009, THORAX, V64, P598, DOI 10.1136/thx.2009.113795; Ramirez JA, 2017, CLIN INFECT DIS, V65, P1806, DOI 10.1093/cid/cix647; Rochwerg B, 2018, CRIT CARE MED, V46, P1411, DOI 10.1097/CCM.0000000000003262; Rothberg MB, 2015, J ANTIMICROB CHEMOTH, V70, P1573, DOI 10.1093/jac/dku533; Sager R, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0795-7; Sartori P, 1988, Epidemiol Prev, V10, P22; Seymour CW, 2017, NEW ENGL J MED, V376, P2235, DOI 10.1056/NEJMoa1703058; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Stern A, 2017, COCHRANE DB SYST REV, P1, DOI 10.1002/14651858.CD007720.pub3; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835; Waterer G, 2019, CHEST, V156, P1049, DOI 10.1016/j.chest.2019.06.017; Webb BJ, 2015, RESP MED, V109, P1, DOI 10.1016/j.rmed.2014.10.017; Yamazaki R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168164	37	0	0	2	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC	2021	174	12					1719	+		10.7326/M21-3650	http://dx.doi.org/10.7326/M21-3650		DEC 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XS0OD	34904883				2023-01-03	WOS:000732448700001
J	Stahl, K; Groene, O				Stahl, Katja; Groene, Oliver			ASK ME!-Routine measurement of patient experience with patient safety in ambulatory care: A mixed-mode survey	PLOS ONE			English	Article							GENERAL-PRACTICE; SATISFACTION; INCIDENTS; ERRORS; VALIDATION; OUTCOMES; EVENTS; RATES; MAIL; US	Objective Routine measurement of patient safety from the patients' perspective receives increasing attention as an important component of safety measurement systems. The aim of this study was to examine patients' experience with patient safety in ambulatory care and the results' implications for routine patient safety measurement in ambulatory care. Design Cross-sectional mixed-mode survey. Setting General practitioner and specialist practices. Participants Patients aged >18 years seeking care in ambulatory care practices between February and June 2020. Methods A 22-item-questionnaire was completed in the practice or at home either on paper or online. Multivariate logistic regression was used to analyse the influence of survey mode and patient characteristics on patient experience with patient safety. Results The overall response rate was 71.1%. Most patients completed the questionnaire on site (76.6%) and on paper (96.1%). Between 30.1% to 68.5% of the respondents report the most positive option for patient experience with the main domains of patient safety. A total of 2.9% of patients reported having experienced a patient-safety event (PSE) during the last 12 months. Patients who filled in the questionnaire off site were more likely to report negative experiences for the scales communication & information (OR 1.2, 95% CI 1.0-1.5), rapport & participation (OR 1.4, 95% CI 1.1-1.7) and access (OR 1.3, 95% CI 0.9-1.4) than those who completed it on site. Those who chose a paper questionnaire were more likely to report negative experiences for all five scales compared to web responders. Conclusion Routine measurement of patient experience with factors contributing to the occurrence of PSEs can achieve high response rates by offering flexible participation options. Results gained from mixed-mode surveys need to take mode-effects into account when interpreting and using the results. Further research is needed in how to adequately assess number and type of experienced events in routine measurements.	[Stahl, Katja; Groene, Oliver] OptiMedis AG, Dept Res & Innovat, Hamburg, Germany		Stahl, K (corresponding author), OptiMedis AG, Dept Res & Innovat, Hamburg, Germany.	k.stahl@optimedis.de		Stahl, Katja/0000-0001-5696-9513	German Federal Ministry of Health [ZMVI1-2519-PAT001]	German Federal Ministry of Health	KS OG Grant number: ZMVI1-2519-PAT001 Funder: German Federal Ministry of Health URL: https://www.bundesgesundheitsministerium.de/ The funder provided support in the form of salaries for authors [KS, OG], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. KS is employed as Manager Research & Innovation at OptiMedis AG. OG is Vice-Chairman of OptiMedis AG. The authors affiliations did not have role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank all practice teams and patients who participated in this study. We also thank the German Coalition for Patient Safety, the regional Association of Statutory Health Insurance Physicians (Westfalen-Lippe) for their support in the development of the questionnaire and the recruitment of the practices. Thanks are also extended to the German Agency for Quality in Medicine who supported the development process of the questionnaire with expert advice.	Anastario MP, 2010, HEALTH SERV RES, V45, P1345, DOI 10.1111/j.1475-6773.2010.01129.x; Avery AJ, 2013, BRIT J GEN PRACT, V63, pE543, DOI 10.3399/bjgp13X670679; Batbaatar E, 2017, PERSPECT PUBLIC HEAL, V137, P89, DOI 10.1177/1757913916634136; Aller MB, 2013, INT J INTEGR CARE, V13; Beattie M, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0089-0; Bjertnaes O, 2016, PATIENT PREFER ADHER, V10, P2255, DOI 10.2147/PPA.S116424; Bjertnaes O, 2015, INT J QUAL HEALTH C, V27, P26, DOI 10.1093/intqhc/mzu087; Bowling A, 2005, J PUBLIC HEALTH-UK, V27, P281, DOI 10.1093/pubmed/fdi031; Brogger J, 2007, J MED INTERNET RES, V9, DOI 10.2196/jmir.9.5.e40; Bull C, 2019, HEALTH SERV RES, V54, P1023, DOI 10.1111/1475-6773.13187; Burt J., 2017, IMPROVING PATIENT EX; Cantuaria ML, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0882-x; Chaneliere M, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0803-9; Christensen AI, 2022, SCAND J PUBLIC HEALT, V50, P180, DOI 10.1177/1403494820966534; Coulter A, 2009, POINT CARE MEASURES; Crow R, 2002, Health Technol Assess, V6, P1; Daikeler J, 2020, J SURV STAT METHODOL, V8, P513, DOI 10.1093/jssam/smz008; Elwyn G, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-S2-S14; Fricker R.D., 2002, FIELD METHOD, V14, P347; Geraedts M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034617; Giles SJ, 2019, BMJ QUAL SAF, V28, P389, DOI 10.1136/bmjqs-2018-007988; Gleeson H, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011907; Gribble RK, 2005, MED CARE, V43, P276, DOI 10.1097/00005650-200503000-00010; Guo YM, 2016, AM J PUBLIC HEALTH, V106, P1422, DOI 10.2105/AJPH.2016.303198; Hagan TL, 2017, J PAIN SYMPTOM MANAG, V54, P368, DOI 10.1016/j.jpainsymman.2017.07.005; Haggerty JL, 2012, ANN FAM MED, V10, P443, DOI 10.1370/afm.1378; Hernan AL, 2015, BMJ QUAL SAF, V24, P583, DOI 10.1136/bmjqs-2015-004049; Hoebel J, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-46; Iversen HH, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-036533; Jensen HI, 2010, SOC SCI MED, V70, P1882, DOI 10.1016/j.socscimed.2010.02.035; Kelfve S, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-01138-0; King A, 2010, QUAL SAF HEALTH CARE, V19, P148, DOI 10.1136/qshc.2008.030114; Kistler CE, 2010, ARCH INTERN MED, V170, P1480, DOI 10.1001/archinternmed.2010.288; Lawton R, 2015, BMJ QUAL SAF, V24, P369, DOI 10.1136/bmjqs-2014-003691; Levtzion-Korach O, 2010, JT COMM J QUAL PATIE, V36, P402, DOI 10.1016/S1553-7250(10)36059-4; Lin OS, 2007, GASTROINTEST ENDOSC, V65, P775, DOI 10.1016/j.gie.2006.11.032; Makeham MAB, 2008, QUAL SAF HEALTH CARE, V17, P53, DOI 10.1136/qshc.2007.022491; Mastellos N, 2014, INT J INTEGR CARE, V14; Meyer VM, 2022, ANN SURG, V275, pE75, DOI 10.1097/SLA.0000000000004078; Mlikotic R, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5068; Nakash Rachel A, 2006, BMC Med Res Methodol, V6, P5, DOI 10.1186/1471-2288-6-5; Nelson EC, 2004, MED CARE, V42, P259, DOI 10.1097/01.mlr.0000114914.32196.c7; OECD, 2019, PUTT PEOPL CTR HLTH; Panesar SS, 2016, BMJ QUAL SAF, V25, P544, DOI 10.1136/bmjqs-2015-004178; Rhodes P, 2016, HEALTH EXPECT, V19, P253, DOI 10.1111/hex.12342; Ricci-Cabello I, 2017, BRIT J GEN PRACT, V67, pE474, DOI 10.3399/bjgp17X691085; Ricci-Cabello I, 2016, ANN FAM MED, V14, P253, DOI 10.1370/afm.1935; Ricci-Cabello I, 2015, FAM PRACT, V32, P106, DOI 10.1093/fampra/cmu052; Richards S H, 2011, Prim Health Care Res Dev, V12, P68, DOI 10.1017/S1463423610000319; Rolstad S, 2011, VALUE HEALTH, V14, P1101, DOI 10.1016/j.jval.2011.06.003; Sandager M, 2016, J PATIENT EXP, V3, P63; Schrappe M., 2018, APS WEI BUCH PATIENT; Schwappach DLB, 2010, MED CARE RES REV, V67, P119, DOI 10.1177/1077558709342254; Segal LS, 2015, J PEDIATR ORTHOPED, V35, P774, DOI 10.1097/BPO.0000000000000350; Singh H, 2014, BMJ QUAL SAF, V23, P727, DOI 10.1136/bmjqs-2013-002627; Slater M, 2016, CAN FAM PHYSICIAN, V62, pE740; Slawomirski L., 2018, FLYING BLIND, DOI [10.1002/cpt.1226, DOI 10.1002/CPT.1226]; Smyth JD, 2014, SOC SCI RES, V48, P135, DOI 10.1016/j.ssresearch.2014.06.002; Stahl K., 2020, FRAG MICH FEHLERPR V; Stocks SJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017786; Stocks SJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020952; Stoyanov S, 2012, BMJ QUAL SAF, V21, P50, DOI 10.1136/bmjqs-2012-001169; van den Hombergh P, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0519-7; van Walraven C, 2008, CAN MED ASSOC J, V179, P1013, DOI 10.1503/cmaj.080430; Vincent C, 2012, CAN MED ASSOC J, V184, P15, DOI 10.1503/cmaj.111311; Ward JK, 2012, BMJ QUAL SAF, V21, P685, DOI 10.1136/bmjqs-2011-000213; Weingart SN, 2005, J GEN INTERN MED, V20, P830, DOI 10.1111/j.1525-1497.2005.0180.x; World Health Organization, 2009, CONCEPTUAL FRAMEWORK; Zuidgeest M, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1241	69	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2021	16	12							e0259252	10.1371/journal.pone.0259252	http://dx.doi.org/10.1371/journal.pone.0259252			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ9AQ	34851966	Green Published, gold			2023-01-03	WOS:000755762900009
J	Endres-Dighe, S; Jones, K; Hadley, E; Preiss, A; Kery, C; Stoner, M; Eversole, S; Rhea, S				Endres-Dighe, Stacy; Jones, Kasey; Hadley, Emily; Preiss, Alexander; Kery, Caroline; Stoner, Marie; Eversole, Susan; Rhea, Sarah			Lessons learned from the rapid development of a statewide simulation model for predicting COVID-19's impact on healthcare resources and capacity	PLOS ONE			English	Article								The first case of COVID-19 was detected in North Carolina (NC) on March 3, 2020. By the end of April, the number of confirmed cases had soared to over 10,000. NC health systems faced intense strain to support surging intensive care unit admissions and avert hospital capacity and resource saturation. Forecasting techniques can be used to provide public health decision makers with reliable data needed to better prepare for and respond to public health crises. Hospitalization forecasts in particular play an important role in informing pandemic planning and resource allocation. These forecasts are only relevant, however, when they are accurate, made available quickly, and updated frequently. To support the pressing need for reliable COVID-19 data, RTI adapted a previously developed geospatially explicit healthcare facility network model to predict COVID-19's impact on healthcare resources and capacity in NC. The model adaptation was an iterative process requiring constant evolution to meet stakeholder needs and inform epidemic progression in NC. Here we describe key steps taken, challenges faced, and lessons learned from adapting and implementing our COVID-19 model and coordinating with university, state, and federal partners to combat the COVID-19 epidemic in NC.	[Endres-Dighe, Stacy; Jones, Kasey; Hadley, Emily; Preiss, Alexander; Kery, Caroline; Stoner, Marie; Eversole, Susan; Rhea, Sarah] RTI Int, Res Triangle Pk, NC 27709 USA; [Rhea, Sarah] North Carolina State Univ, Coll Vet Med, Raleigh, NC USA	Research Triangle Institute; University of North Carolina; North Carolina State University	Endres-Dighe, S (corresponding author), RTI Int, Res Triangle Pk, NC 27709 USA.	sendres@rti.org		Kery, Caroline/0000-0002-1794-3369; Stoner, Marie/0000-0002-7189-8669; Endres-Dighe, Stacy/0000-0002-4192-2234; Rhea, Sarah/0000-0002-6183-1620; Jones, K/0000-0002-9154-9079; Hadley, Emily/0000-0003-0074-4344; Eversole, Susan/0000-0001-6280-8433	RTI International; Centers for Disease Control and Prevention; North Carolina Department of Health and Human Services	RTI International; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); North Carolina Department of Health and Human Services	The development of this manuscript was funded by RTI International. The study design, data collection and analysis were supported by the Centers for Disease Control and Prevention and the North Carolina Department of Health and Human Services.	Alfaro A, 2021, OVERVIEW AMAZON EC2; Alliance for Pandemic Preparedness, 2021, LAT REP; Bonabeau E, 2002, P NATL ACAD SCI USA, V99, P7280, DOI 10.1073/pnas.082080899; Cavallo Joseph J, 2020, JAMA Health Forum, V1, pe200345, DOI 10.1001/jamahealthforum.2020.0345; Cecil G., 2020, SHORT TERM ACUTE CAR; Cecil G., 2020, PATIENT COUNTY RESID; Centers for Disease Control and Prevention, 2017, CDC WONDER MORT DAT; Johns Hopkins University of Medicine, COVID 19 DASHB CTR S; Jones K, 2019, 2019 WINT SIM C NAT; Lutz CS, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7966-8; NC Department of Health and Human Services, 2020, N CAR ID 1 CAS COVID; NC Department of Health and Human Services, 2020, GOV COOP DIR CREAT N; NC Department of Health and Human Services Division of Health Service Regulation, 2018, NURS HOM COUNT 2018; NC Department of Health and Human Services Division of Health Service Regulation, 2018, HOSP COUNT 2018; Preiss A., 2021, OUTBREAK; Rhea S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234031; Rhea S, 2019, HEALTH SECUR, V17, P276, DOI 10.1089/hs.2019.0021; Rivers C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11067-2; RTI International, 2021, KJ8 RTIINTERNATIONAL; Tange O., 2020, GNU PARALLEL 2020062	20	1	1	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2021	16	11							e0260310	10.1371/journal.pone.0260310	http://dx.doi.org/10.1371/journal.pone.0260310			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ2NY	34793573	gold, Green Published			2023-01-03	WOS:000755319200131
J	Pope, MK; Hall, TS; Schirripa, V; Radic, P; Virdone, S; Pieper, KS; Le Heuzey, JY; Jansky, P; Fitzmaurice, DA; Cappato, R; Atar, D; Camm, AJ; Kakkar, AK				Pope, Marita Knudsen; Hall, Trygve S.; Schirripa, Valentina; Radic, Petra; Virdone, Saverio; Pieper, Karen S.; Le Heuzey, Jean-Yves; Jansky, Petr; Fitzmaurice, David A.; Cappato, Riccardo; Atar, Dan; Camm, A. John; Kakkar, Ajay K.		GARFIELD-AF Investigators	Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RHYTHM-CONTROL; ELECTRICAL CARDIOVERSION; AMIODARONE; PREDICTORS; MANAGEMENT; STROKE; RISK; LIFE	OBJECTIVE To investigate the clinical outcomes of patients who underwent cardioversion compared with those who did not have cardioverson in a large dataset of patients with recent onset non-valvular atrial fibrillation. DESIGN Observational study using prospectively collected registry data (Global Anticoagulant Registry in the FIELD-AF-GARFIELD-AF). SETTING 1317 participating sites in 35 countries. PARTICIPANTS 52 057 patients aged 18 years and older with newly diagnosed atrial fibrillation (up to six weeks' duration) and at least one investigator determined stroke risk factor. MAIN OUTCOME MEASURES Comparisons were made between patients who received cardioversion and those who had no cardioversion at baseline, and between patients who received direct current cardioversion and those who had pharmacological cardioversion. Overlap propensity weighting with Cox proportional hazards models was used to evaluate the effect of cardioversion on clinical endpoints (all cause mortality, non-haemorrhagic stroke or systemic embolism, and major bleeding), adjusting for baseline risk and patient selection. RESULTS 44 201 patients were included in the analysis comparing cardioversion and no cardioversion, and of these, 6595 (14.9%) underwent cardioversion at baseline. The propensity score weighted hazard ratio for all cause mortality in the cardioversion group was 0.74 (95% confidence interval 0.63 to 0.86) from baseline to one year follow-up and 0.77 (0.64 to 0.93) from one year to two year follow-up. Of the 6595 patients who had cardioversion at baseline, 299 had a follow-up cardioversion more than 48 days after enrolment. 7175 patients were assessed in the analysis comparing type of cardioversion: 2427 (33.8%) received pharmacological cardioversion and 4748 (66.2%) had direct current cardioversion. During one year follow-up, event rates (per 100 patient years) for all cause mortality in patients who received direct current and pharmacological cardioversion were 1.36 (1.13 to 1.64) and 1.70 (1.35 to 2.14), respectively. OBJECTIVE To investigate the clinical outcomes of patients who underwent cardioversion compared with those who did not have cardioverson in a large dataset of patients with recent onset non-valvular atrial fibrillation. DESIGN Observational study using prospectively collected registry data (Global Anticoagulant Registry in the FIELD-AF-GARFIELD-AF). SETTING 1317 participating sites in 35 countries. PARTICIPANTS 52 057 patients aged 18 years and older with newly diagnosed atrial fibrillation (up to six weeks' duration) and at least one investigator determined stroke risk factor. MAIN OUTCOME MEASURES Comparisons were made between patients who received cardioversion and those who had no cardioversion at baseline, and between patients who received direct current cardioversion and those who had pharmacological cardioversion. Overlap propensity weighting with Cox proportional hazards models was used to evaluate the effect of cardioversion on clinical endpoints (all cause mortality, non-haemorrhagic stroke or systemic embolism, and major bleeding), adjusting for baseline risk and patient selection. RESULTS 44 201 patients were included in the analysis comparing cardioversion and no cardioversion, and of these, 6595 (14.9%) underwent cardioversion at baseline. The propensity score weighted hazard ratio for all cause mortality in the cardioversion group was 0.74 (95% confidence interval 0.63 to 0.86) from baseline to one year follow-up and 0.77 (0.64 to 0.93) from one year to two year follow-up. Of the 6595 patients who had cardioversion at baseline, 299 had a follow-up cardioversion more than 48 days after enrolment. 7175 patients were assessed in the analysis comparing type of cardioversion: 2427 (33.8%) received pharmacological cardioversion and 4748 (66.2%) had direct current cardioversion. During one year follow-up, event rates (per 100 patient years) for all cause mortality in patients who received direct current and pharmacological cardioversion were 1.36 (1.13 to 1.64) and 1.70 (1.35 to 2.14), respectively. CONCLUSION In this large dataset of patients with recent onset non-valvular atrial fibrillation, a small proportion were treated with cardioversion. Direct current cardioversion was performed twice as often as pharmacological cardioversion, and there appeared to be no major difference in outcome events for these two cardioversion modalities. For the overall cardioversion group, after adjustments for confounders, a significantly lower risk of mortality was found in patients who received early cardioversion compared with those who did not receive early cardioversion. STUDY REGISTRATION ClinicalTrials.gov NCT01090362.	[Pope, Marita Knudsen; Atar, Dan] Univ Oslo, Inst Clin Med, Oslo, Norway; [Pope, Marita Knudsen] Innlandet Hosp Trust, Hamar Hosp, Hamar, Norway; [Hall, Trygve S.; Atar, Dan] Oslo Univ Hosp, Dept Cardiol, Oslo, Norway; [Schirripa, Valentina] GB Grassi Hosp, Cardiol Dept, Rome, Italy; [Radic, Petra] Univ Zagreb, Sch Med, Zagreb, Croatia; [Virdone, Saverio; Pieper, Karen S.; Kakkar, Ajay K.] Thrombosis Res Inst, London, England; [Le Heuzey, Jean-Yves] Rene Descartes Univ, Georges Pompidou Hosp, Dept Cardiol, Paris, France; [Jansky, Petr] Motol Univ Hosp, Dept Cardiovasc Surg, Prague, Czech Republic; [Fitzmaurice, David A.] Univ Warwick, Warwick Med Sch, Med Sch, Coventry, W Midlands, England; [Cappato, Riccardo] IRCCS MultiMed Grp, Arrhythmia & Electrophysiol Ctr, Milan, Italy; [Camm, A. John] St Georges Univ London, Cardiol Clin Acad Grp, Mol & Clin Sci Res Inst, London, England	University of Oslo; Innlandet Hospital Trust; University of Oslo; University of Zagreb; Thrombosis Research Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Motol University Hospital; University of Warwick; St Georges University London	Atar, D (corresponding author), Univ Oslo, Inst Clin Med, Oslo, Norway.; Atar, D (corresponding author), Oslo Univ Hosp, Dept Cardiol, Oslo, Norway.	dan.atar@medisin.uio.no	Nagibovich, Oleg Alexandrovich/J-4049-2013; Epelde, Francisco/AAT-7213-2021; Kochi, Adriano Nunes/AAN-9103-2020; Nikolaev, Konstantin/P-4750-2017; Guerra, Jose/AAH-3598-2021	Nagibovich, Oleg Alexandrovich/0000-0002-1520-0860; Epelde, Francisco/0000-0001-5547-4025; Kochi, Adriano Nunes/0000-0002-7839-2054; Nikolaev, Konstantin/0000-0003-4601-6203; Guerra, Jose/0000-0001-5397-9177; Radic, Petra/0000-0002-4842-7156; Oropallo, Alisha/0000-0001-9192-541X; Lanas, Fernando/0000-0003-3595-9759; GALINIER, Michel/0000-0003-1735-3390	Kantor Charitable Foundation for the Kantor-Kakkar Global Centre for Thrombosis Science	Kantor Charitable Foundation for the Kantor-Kakkar Global Centre for Thrombosis Science	This work is supported by Kantor Charitable Foundation for the Kantor-Kakkar Global Centre for Thrombosis Science. The funding source had no involvement in trial design, collection and analysis of data, or in the writing process of this paper.	Al-Khatib SM, 2014, ANN INTERN MED, V160, P760, DOI 10.7326/M13-1467; Camm AJ, 2011, J AM COLL CARDIOL, V57, P313, DOI 10.1016/j.jacc.2010.07.046; Chatterjee S, 2013, PACE, V36, P122, DOI 10.1111/j.1540-8159.2012.03513.x; Chevalier P, 2003, J AM COLL CARDIOL, V41, P255, DOI 10.1016/S0735-1097(02)02705-5; Cosio FG, 2008, EUROPACE, V10, P21, DOI 10.1093/europace/eum276; Crijns HJGM, 2014, INT J CARDIOL, V172, P588, DOI 10.1016/j.ijcard.2014.01.099; Dankner R, 2009, CARDIOLOGY, V112, P270, DOI 10.1159/000151703; de Denus S, 2005, ARCH INTERN MED, V165, P258, DOI 10.1001/archinte.165.3.258; Elhendy A, 2002, AM J CARDIOL, V89, P83, DOI 10.1016/S0002-9149(01)02172-5; Fox KAA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017157; Fox KAA, 2017, EUR HEART J-QUAL CAR, V3, P114, DOI 10.1093/ehjqcco/qcw058; Gallagher MM, 2001, J AM COLL CARDIOL, V38, P1498, DOI 10.1016/S0735-1097(01)01540-6; Gitt AK, 2013, CLIN RES CARDIOL, V102, P713, DOI 10.1007/s00392-013-0586-x; Hagens VE, 2004, J AM COLL CARDIOL, V43, P241, DOI 10.1016/j.jacc.2003.08.037; Hindricks G, 2021, EUR HEART J, V42, P373, DOI [10.1093/eurheartj/ehaa612, 10.15829/1560-4071-2021-4701]; January CT., 2014, J AM COLL CARDIOL, V64, P76, DOI [10.1016/j.jacc, DOI 10.1016/J.JACC.2014.03.022, 10.1016/j.jacc.2014.03.022]; Kakkar AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063479; Kakkar AK, 2012, AM HEART J, V163, P13, DOI 10.1016/j.ahj.2011.09.011; Kirchhof P, 2020, NEW ENGL J MED, V383, P1305, DOI 10.1056/NEJMoa2019422; Kirchhof P, 2009, EUR HEART J, V30, P2969, DOI 10.1093/eurheartj/ehp235; Kotecha Dipak, 2014, Evid Based Med, V19, P222, DOI 10.1136/ebmed-2014-110062; Li F, 2019, AM J EPIDEMIOL, V188, P250, DOI 10.1093/aje/kwy201; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Naccarelli GV, 2000, AM J CARDIOL, V85, p36D; Nattel S, 2008, CIRC-ARRHYTHMIA ELEC, V1, P62, DOI 10.1161/CIRCEP.107.754564; Packer DL, 2019, JAMA-J AM MED ASSOC, V321, P1261, DOI 10.1001/jama.2019.0693; Roy D, 2008, NEW ENGL J MED, V358, P2667, DOI 10.1056/NEJMoa0708789; Singh BN, 2005, NEW ENGL J MED, V352, P1861, DOI 10.1056/NEJMoa041705; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; Van Gelder IC, 2011, EUROPACE, V13, P1517, DOI 10.1093/europace/eur192; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Zhang YY, 2013, AM J CARDIOL, V112, P79, DOI 10.1016/j.amjcard.2013.02.056	32	1	1	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 27	2021	375								e066450	10.1136/bmj-2021-066450	http://dx.doi.org/10.1136/bmj-2021-066450			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WO4NB	34706884	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000712431700007
J	Younas, M; Zou, HS; Laraib, T; Rajpoot, NA; Khan, NA; Zaidi, AA; Kachelo, GA; Akhtar, MW; Hayat, S; Al-Sadi, AM; Sayed, S; Kesba, H; Ansari, MJ; Zuan, ATK; Li, YZ; Arif, M				Younas, Muhammad; Zou, Huasong; Laraib, Tasmia; Rajpoot, Nasir Ahmad; Khan, Nasir Ahmad; Zaidi, Anas Ahmad; Kachelo, Ghalib Ayaz; Akhtar, Muhammad Waqar; Hayat, Shoukat; Al-Sadi, Abdullah M.; Sayed, Samy; Kesba, Hosny; Ansari, Mohammad Javed; Zuan, Ali Tan Kee; Li, Yunzhou; Arif, Muhammad			RETRACTED: The impact of insecticides and plant extracts on the suppression of insect vector (Bemisia tabaci) of Mungbean yellow mosaic virus (MYMV) (Retracted article. See vol. 17, 2022)	PLOS ONE			English	Article; Retracted Publication							RESISTANCE; IDENTIFICATION; DISEASE; MANAGEMENT; GERMPLASM; INDIA	Mungbean yellow mosaic virus (MYMV) is an important constraint in successful production of mungbean (Vigna radiata L.) in many countries, including Pakistan. The MYMV spreads by insect vector whitefly (Bemisia tabaci Gennadius). The use of resistant cultivars is the most effective management tactics for MYMV. Twenty mungbean varieties/lines were screened against insect vector of MYMV under field condition in the current study. Resistance levels for varieties/lines were assessed through visual scoring of typical disease symptoms. Furthermore, the impacts of two insecticides 'Imidacloprid' and 'Thiamethoxam' and two plant extracts, i.e., neem (Azadirachta indica), and Eucalyptus (Eucalyptus camaldulensis) were tested on the suppression of whitefly. Field screening indicated that none of the tested varieties/lines proved immune/highly resistant, while significant variations were recorded among varieties/lines for resistance level. All varieties/lines were systemically infected with MYMV. The varieties 'AARI-2006' and 'Mung-14043' were considered as resistant to MYMV based on visual symptoms and the lowest vector population. These varieties were followed by 'NM-2006' and 'NL-31', which proved as moderately resistant to MYMV. All remaining varieties/lines were grouped as moderately to highly susceptible to MYMV based on visual symptoms' scoring. These results revealed that existing mungbean germplasm do not possess high resistance level MYMV. However, the lines showing higher resistance in the current study must be exploited in breeding programs for the development of resistant mungbean varieties/lines against MYMV. Imidacloprid proved as the most effective insecticide at all concentrations to manage whitefly population. Therefore, use of the varieties with higher resistance level and spraying Imidacloprid could lower the incidence of MYMV.	[Younas, Muhammad; Rajpoot, Nasir Ahmad; Khan, Nasir Ahmad; Kachelo, Ghalib Ayaz] Univ Agr Faisalabad, Dept Plant Pathol, Faisalabad, Pakistan; [Zou, Huasong] Fujian Agr & Forestry Univ, Coll Plant Protect, Fuzhou, Peoples R China; [Laraib, Tasmia] Univ Lahore, Inst Mol Biol & Biotechnol, Lahore, Pakistan; [Zaidi, Anas Ahmad] Islamia Univ Bahawalpur, Dept Plant Pathol, Bahawalpur, Pakistan; [Akhtar, Muhammad Waqar] Islamia Univ Bahawalpur, Dept Soil Sci, Bahawalpur, Pakistan; [Hayat, Shoukat] Islamia Univ Bahawalpur, Dept Forestry, Bahawalpur, Pakistan; [Al-Sadi, Abdullah M.] Sultan Qaboos Univ, Coll Agr & Marine Sci, Dept Plant Sci, Al Khoud, Oman; [Sayed, Samy] Taif Univ, Univ Coll Ranyah, Dept Sci & Technol, At Taif, Saudi Arabia; [Kesba, Hosny] Cairo Univ, Fac Agr, Zool & Agr Nematol Dept, Giza, Egypt; [Ansari, Mohammad Javed] Mahatma Jyotiba Phule Rohilkhand Univ Bareilly, Dept Bot, Hindu Coll Moradabad, Moradabad, India; [Zuan, Ali Tan Kee] Univ Putra Malaysia, Fac Agr, Dept Land Management, Upm, Selangor, Malaysia; [Li, Yunzhou] Guizhou Univ, Coll Agr, Dept Plant Pathol, Guiyang, Guizhou, Peoples R China; [Arif, Muhammad] Fujian Agr & Forestry Univ, Dept Plant Protect, Fuzhou, Peoples R China	University of Agriculture Faisalabad; Fujian Agriculture & Forestry University; University of Lahore; Islamia University of Bahawalpur; Islamia University of Bahawalpur; Islamia University of Bahawalpur; Sultan Qaboos University; Taif University; Egyptian Knowledge Bank (EKB); Cairo University; Universiti Putra Malaysia; Guizhou University; Fujian Agriculture & Forestry University	Hayat, S (corresponding author), Islamia Univ Bahawalpur, Dept Forestry, Bahawalpur, Pakistan.; Al-Sadi, AM (corresponding author), Sultan Qaboos Univ, Coll Agr & Marine Sci, Dept Plant Sci, Al Khoud, Oman.; Zuan, ATK (corresponding author), Univ Putra Malaysia, Fac Agr, Dept Land Management, Upm, Selangor, Malaysia.; Li, YZ (corresponding author), Guizhou Univ, Coll Agr, Dept Plant Pathol, Guiyang, Guizhou, Peoples R China.	shkrind3@gmail.com; alsadi@squ.edu.om; tkz@upm.edu.my; liyunzhou2007@126.com	LI, Yunzhou/AHD-2500-2022; Ansari, Mohammad Javed/E-9303-2014; Ansari, Muhammad/GQI-1517-2022; Sayed, Samy/AAD-2389-2020; Kesba, Hosny Hamed/A-9969-2015; Zuan, Ali Tan Kee/AAU-4242-2021; Zou, Huasong/GLN-3569-2022	Ansari, Mohammad Javed/0000-0002-8718-3078; Sayed, Samy/0000-0002-7002-568X; Kesba, Hosny Hamed/0000-0001-9396-2214; Zuan, Ali Tan Kee/0000-0003-0473-4303; 	National Natural Science Foundation of China [32060679]; Guizhou University China [GuidapeiYU[2019]52, [2017] 50]; Taif University, Taif, Saudi Arabia [TURSP2020/92]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guizhou University China; Taif University, Taif, Saudi Arabia	This work was supported by projects of the National Natural Science Foundation of China (No. 32060679) and projects of Guizhou University China (No. GuidapeiYU[2019]52 and No. [2017] 50). This study was financed by Taif University Researchers Supporting Project number (TURSP2020/92), Taif University, Taif, Saudi Arabia. There were no additional external funding involved in the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad M, 2010, J PEST SCI, V83, P409, DOI 10.1007/s10340-010-0311-8; Akhtar KP, 2011, CROP PROT, V30, P1202, DOI 10.1016/j.cropro.2011.05.012; Akram M., 2016, J FOOD LEGUMES, V29, P77; Alam AKMM, 2014, MOL BREEDING, V34, P1497, DOI 10.1007/s11032-014-0133-0; Arif M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0244931; Arif M, 2020, METHODS, V183, P43, DOI 10.1016/j.ymeth.2019.11.010; Arif M, 2018, MICROB PATHOGENESIS, V125, P210, DOI 10.1016/j.micpath.2018.09.021; Arif M, 2018, CAN J PLANT PATHOL, V40, P128, DOI 10.1080/07060661.2017.1389770; Awasthi L. P., 2008, New Botanist, V35, P65; Bashir M, 2006, PAK J BOT, V38, P1341; Bhanu A., 2017, ADV PLANTS AGR RES, V7, P00276; Bhanu AN, 2019, PLANT BREEDING, V138, P202, DOI 10.1111/pbr.12675; Binyamin R, 2011, INT J AGRIC BIOL, V13, P411; Bohra A, 2014, BIOTECHNOL ADV, V32, P1410, DOI 10.1016/j.biotechadv.2014.09.001; Cheema HK., 2017, BREEDING INSECT RESI, P353; Dhole VJ, 2012, PLANT BREEDING, V131, P414, DOI 10.1111/j.1439-0523.2012.01964.x; Dikshit HK, 2020, COMPEND PL GENOME, P43, DOI 10.1007/978-3-030-20008-4_4; Duke J.A., 2002, DUKES HDB MED PLANTS, DOI DOI 10.1201/9781420043174; Haq QMI, 2010, INDIAN J VIROL, V21, P82, DOI 10.1007/s13337-010-0003-2; Hema M, 2014, ADV VIRUS RES, V90, P431, DOI 10.1016/B978-0-12-801246-8.00009-3; Jayappa RH., 2017, INT J PURE APPL BIOS, V5, P238; Karthikeyan A., 2012, Archives of Phytopathology and Plant Protection, V45, P712, DOI 10.1080/03235408.2011.592016; Khan M. A., 2012, Agriculture and Biology Journal of North America, V3, P476, DOI 10.5251/abjna.2012.3.11.476.480; Khattak GSS, 2008, PAK J BOT, V40, P1411; Laosatit K, 2020, COMPEND PL GENOME, P133, DOI 10.1007/978-3-030-20008-4_10; Larsen RC, 2010, PLANT PATHOL, V59, P42, DOI 10.1111/j.1365-3059.2009.02198.x; Li YP, 2021, INSECTS, V12, DOI 10.3390/insects12030198; Markam NK., 2018, INT J CHEM STUD, V6, P2401; Mishra GP, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.00918; Nagaraj, 2019, PLANT GENET RESOUR-C, V17, P362, DOI [10.1017/S1479262119000121, 10.1017/s1479262119000121]; Nainu A. J., 2020, Plant Archives, V20, P6867; Noble TJ, 2019, CROP PASTURE SCI, V70, P195, DOI 10.1071/CP18541; Pandey AK, 2021, CROP PROT, V143, DOI 10.1016/j.cropro.2021.105569; Panduranga G. S., 2011, Indian Journal of Entomology, V73, P338; Ramesh S. V., 2017, Journal of Crop and Weed, V13, P64; Reddy VRP, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.537766; Sai CB, 2017, MOL BREEDING, V37, DOI 10.1007/s11032-017-0650-8; Salam S. A., 2011, Karnataka Journal of Agricultural Sciences, V24, P247; Salam SA, 2009, LEGUME RES, V32, P286; Sattar MN., 2019, BEGOMOVIRUS DIVERSIT, P343; Sehrawat N, 2016, TURK J AGRIC FOR, V40, P95, DOI 10.3906/tar-1407-169; Shad N, 2006, PAK J BOT, V38, P449; Shahid MS, 2017, J PHYTOPATHOL, V165, P204, DOI 10.1111/jph.12551; Shanmugapriya Gnanasekaran, 2015, VirusDisease, V26, P55, DOI 10.1007/s13337-015-0251-2; Singh CM, 2020, 3 BIOTECH, V10, DOI 10.1007/s13205-019-2035-7; Singh D., 2011, J FOOD LEGUMES, V24, P83; Singh S. K., 2014, Current Advances in Agricultural Sciences, V6, P85; Sudha M, 2015, PLANT GENET RESOUR-C, V13, P162, DOI 10.1017/S1479262114000859; Sudha M, 2013, CAN J PLANT PATHOL, V35, P424, DOI 10.1080/07060661.2013.827134; Sugandh Suman, 2015, Environment and Ecology, V33, P855; Tamilzharasi M., LEGUME RES INT J, V43, P728; Tsai WS, 2013, ANN APPL BIOL, V163, P367, DOI 10.1111/aab.12063; Umer Iqbal, 2011, Pakistan Journal of Phytopathology, V23, P48; Varma A, 2011, WHITEFLY, BEMISIA TABACI (HOMOPTERA: ALEYRODIDAE) INTERACTION WITH GEMINIVIRUS-INFECTED HOST PLANTS: BEMISIA TABACI, HOST PLANTS AND GEMINIVIRUSES, P205, DOI 10.1007/978-94-007-1524-0_10; Venkatesan S., 2010, Archives of Phytopathology and Plant Protection, V43, P59, DOI 10.1080/03235400701652508; Wright KH, 2002, J FOOD SCI, V67, P1383, DOI 10.1111/j.1365-2621.2002.tb10294.x	56	3	3	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2021	16	9							e0256449	10.1371/journal.pone.0256449	http://dx.doi.org/10.1371/journal.pone.0256449			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5YY	34529693	gold, Green Published			2023-01-03	WOS:000707071500013
J	Lin, MH; Lin, SC; Lee, YH; Wang, PY; Wu, HY; Hsu, HC				Lin, Mei-Hsiang; Lin, Shu-Chuan; Lee, Yu-Hsia; Wang, Pao-Yu; Wu, Hon-Yen; Hsu, Hsiu-Chin			The effectiveness of simulation education program on shared decision-making attitudes among nurses in Taiwan	PLOS ONE			English	Article							NURSING-STUDENTS; CARE; LIFE; END; EXPERIENCES	Background Shared decision-making (SDM) is significantly associated with promoting the quality of end-of-life (EOL). The attitude of nurses toward the end of life can affect EOL care, but there are few SDM-related clinical learning programs focused on EOL. In this study, therefore, we evaluated the effectiveness of an EOL-simulation education program on attitudes toward SDM among nurses, using an objective structured clinical examination (OSCE). Methods We used a quasi-experimental study design to evaluate nurses working at a medical center in Taiwan. We recruited 100 nurses and assigned them to an experimental group (n = 50) and a control group (n = 50). The experimental group received the SDM attitude (SDMA) cultivation program, and the control group did not. After the intervention, all participants were examined in an OSCE to assess the efficacy of their learning. A p value of.05 was considered statistically significant. Results The average score of the experimental group was higher than that of the control group in the dimensions "empathic communication" and "mastery learning", but these differences were not significant. SDMA score is significantly and positively correlated with SDMA global score, standardized patient survey (SPS) score, and SPS global score (r = .92, .56, and .50, respectively; p < .01). Conclusions Simulations concerning EOL care that incorporate SDM components would be effective for training clinical nurses. This study can serve as a reference for nursing-administration managers who may consider designing SDM-related education programs to improve the quality of clinical nursing care.	[Lin, Mei-Hsiang] Natl Taipei Univ Nursing & Hlth Sci, Sch Nursing, Taipei, Taiwan; [Lin, Shu-Chuan; Lee, Yu-Hsia] MacKay Mem Hosp, Taipei, Taiwan; [Wang, Pao-Yu] MacKay Jr Coll Med Nursing & Management, Dept Nursing, New Taipei, Taiwan; [Wu, Hon-Yen] Far Eastern Mem Hosp, Dept Internal Med, New Taipei, Taiwan; [Wu, Hon-Yen] Natl Yang Ming ChiaoTung Univ, Coll Med, Sch Med, Taipei, Taiwan; [Wu, Hon-Yen] Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol & Prevent Med, Taipei, Taiwan; [Wu, Hon-Yen] Natl Taiwan Univ Hosp & Coll Med, Dept Internal Med, Taipei, Taiwan; [Hsu, Hsiu-Chin] Chang Gung Univ Sci & Technol, Chang Gung Mem Hosp, Grad Inst Gerontol & Hlth Care Management, Dept Internal Med, Taipei, Taiwan	National Taipei University of Nursing & Health Science (NTUNHS); Mackay Memorial Hospital; Mackay Junior College of Medicine, Nursing & Management; Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology	Hsu, HC (corresponding author), Chang Gung Univ Sci & Technol, Chang Gung Mem Hosp, Grad Inst Gerontol & Hlth Care Management, Dept Internal Med, Taipei, Taiwan.	hchsu@mail.cgust.edu.tw			Ministry of Science and Technology, Taiwan	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by grant from the Ministry of Science and Technology, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bernard AW, 2020, J MED EDUC CURRIC DE, V7, DOI 10.1177/2382120520940663; Bernstein B., 2019, J INTERPROF ED PRACT, V15, P34, DOI DOI 10.1016/J.XJEP.2019.01.008; Blazeviciene A, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00637-7; Bos-van den Hoek DW, 2021, J ADV NURS, V77, P296, DOI 10.1111/jan.14549; Boursicot K, 2005, CLIN TEACH, V2, P16, DOI 10.1111/j.1743-498X.2005.00053.x; Brogan P, 2018, PALLIATIVE MED, V32, P123, DOI 10.1177/0269216317734434; Chung FF, 2021, BMC NURS, V20, DOI 10.1186/s12912-021-00597-0; Chung MC, 2019, J EVAL CLIN PRACT, V25, P1080, DOI 10.1111/jep.13249; Dame L, 2016, J NURS EDUC, V55, P701, DOI 10.3928/01484834-20161114-07; Elshama SS., 2021, IBEROAM J MED, V3, P51, DOI [10.5281/zenodo.4247763, DOI 10.5281/ZENODO.4247763]; Friesen-Storms JHHM, 2015, INT J NURS STUD, V52, P393, DOI 10.1016/j.ijnurstu.2014.06.012; Hajizadeh Negin, 2016, MDM Policy Pract, V1, p2381468316642237, DOI 10.1177/2381468316642237; Hamilton IJ, 2017, BRIT J GEN PRACT, V67, P104, DOI 10.3399/bjgp17X689461; Huang HL, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-0521-7; Isaacson MJ, 2018, ADV NURS SCI, V41, P2, DOI 10.1097/ANS.0000000000000186; Jo KH, 2015, INT J NURS PRACT, V21, P839, DOI 10.1111/ijn.12306; Katz P, 2017, 28 INT RES C HON SOC; Lee YH, 2020, BMC NURS, V19, DOI 10.1186/s12912-020-00500-3; Lin MH, 2020, NURS EDUC TODAY, V88, DOI 10.1016/j.nedt.2020.104385; Lynga P, 2019, NURSE EDUC PRACT, V35, P130, DOI 10.1016/j.nepr.2019.02.004; McCarter SP, 2016, WESTERN J NURS RES, V38, P1282, DOI 10.1177/0193945916650648; Miller B, 2016, JNP-J NURSE PRACT, V12, pE201, DOI 10.1016/j.nurpra.2016.01.017; Miraglia R, 2015, J NURSES PROF DEV, V31, P284, DOI 10.1097/NND.0000000000000209; Ndiwane A, 2014, CLIN SIMUL NURS, V10, pE87, DOI 10.1016/j.ecns.2013.07.002; Palmer D., 2016, CREATIVE ED, V7, P2380, DOI [10.4236/ce.2016.716229, DOI 10.4236/CE.2016.716229]; Polit D.F., 2017, NURSING RES GENERATI, V10th, DOI DOI 10.1016/J.ICCN.2015.01.005; Price Bob, 2015, Nurs Stand, V30, P50, DOI 10.7748/ns.30.15.50.s51; Razmaria Aria A, 2016, JAMA, V316, P115, DOI 10.1001/jama.2016.2440; Roodbeen R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234926; Sleeman KE, 2019, LANCET GLOB HEALTH, V7, pE883, DOI 10.1016/S2214-109X(19)30172-X; Tamaki T, 2019, NURS EDUC TODAY, V76, P1, DOI 10.1016/j.nedt.2019.01.005; Vedasto O, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913-020-06041-4; Waschwill A, 2020, PATIENT EDUC COUNS, V103, P500, DOI 10.1016/j.pec.2019.09.013; Witkamp FE, 2015, J PAIN SYMPTOM MANAG, V49, P203, DOI 10.1016/j.jpainsymman.2014.06.013; Yamamoto S, 2017, J PAIN SYMPTOM MANAG, V53, P862, DOI 10.1016/j.jpainsymman.2016.12.348; Yedidia MJ, 2003, JAMA-J AM MED ASSOC, V290, P1157, DOI 10.1001/jama.290.9.1157	36	2	2	5	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257902	10.1371/journal.pone.0257902	http://dx.doi.org/10.1371/journal.pone.0257902			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UZ3YH	34582501	Green Published, gold			2023-01-03	WOS:000702143700007
J	Suran, M				Suran, Melissa			Preparing Hospitals' Medical Oxygen Delivery Systems for a Respiratory "Twindemic"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2022	327	5					411	413						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV9QB	35019960	Bronze			2023-01-03	WOS:000753056200001
J	Lillo-Crespo, M; Riquelme-Galindo, J; De Baetselier, E; Van Rompaey, B; Dilles, T				Lillo-Crespo, Manuel; Riquelme-Galindo, Jorge; De Baetselier, Elyne; Van Rompaey, Bart; Dilles, Tinne			Understanding pharmaceutical care and nurse prescribing in Spain: A grounded theory approach through healthcare professionals' views and expectations	PLOS ONE			English	Article							COUNTRIES; FRAMEWORK	Background Pharmaceutical care has been implemented and regulated differently across Europe with no consensus among countries in relation with professional competencies and especially on nurse prescribing. Demophac Project funded by the European Commission aims to develop a Pan-European Pharmaceutical Care Model with collaboration of 14 partner teams across Europe including Spain where nurse prescribing is starting its implementation at regional level. The aim of the study was to increase understanding of the role of nurses in Pharmaceutical care in Spain after the Nurse Prescribing Regulation approved in 2018 throughout exploring the views and expectations of health professionals involved in the representative settings. Methods and findings In depth interviews were conducted in a structure previously agreed by the European Demophac partnership around four topics associated with the Nursing ideal role in pharmaceutical care and the ideal interaction with other healthcare professionals. A grounded-theory approach based on Corbin & Strauss was conducted to interpret collected data from the Spanish most representative settings (primary care, specialized care and residential care for older population). Participants were health professionals involved in pharmaceutical care that accepted to participate (nurses (n = 7), physicians (n = 8) and pharmacists (n = 9)). A pharmaceutical care comprehensive model for the Spanish context considering the recently approved Nurse Prescribing role and the interprofessional collaboration and communication was developed towards facilitating the understanding in such context and the contribution to the unified European Demophac Framework. Conclusions Nurses are primarily responsible for population's Pharmaceutical Care while other professionals pivot on them to provide quality healthcare on a multidisciplinary level. Nurse prescribing may contribute efficiently to the Spanish Health System though more consensus in terms of nurses' training nationwide and enhancement in communication among different professionals within healthcare organizations is required to achieve adequate integrated care into practice.	[Lillo-Crespo, Manuel; Riquelme-Galindo, Jorge] Univ Alicante, Fac Hlth Sci, Dept Nursing, Alicante, Spain; [De Baetselier, Elyne; Van Rompaey, Bart; Dilles, Tinne] Univ Antwerp, Dept Nursing & Pharmaceut Care, Antwerp, Belgium; [Lillo-Crespo, Manuel; Riquelme-Galindo, Jorge] Univ Alicante, Dept Nursing, San Vicent Del Raspeig, Spain; [De Baetselier, Elyne; Van Rompaey, Bart; Dilles, Tinne] Univ Antwerp, Dept Nursing & Pharmaceut Care, Antwerp, Belgium	Universitat d'Alacant; University of Antwerp; Universitat d'Alacant; University of Antwerp	Riquelme-Galindo, J (corresponding author), Univ Alicante, Fac Hlth Sci, Dept Nursing, Alicante, Spain.; Riquelme-Galindo, J (corresponding author), Univ Alicante, Dept Nursing, San Vicent Del Raspeig, Spain.	jrgrqlm@gmail.com	Van Rompaey, Bart/AAM-3215-2021; Dilles, Tinne/F-3393-2013	Van Rompaey, Bart/0000-0001-7670-0300; Dilles, Tinne/0000-0003-2817-0944	European Commission [2018-1-BE02-KA203-046861]	European Commission(European CommissionEuropean Commission Joint Research Centre)	This study was part of a work package in Demophac Project. An International Project Funded by the European Commission. Project Reference: 2018-1-BE02-KA203-046861. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agencia Estatal Boletin Oficial del Estado, 2018, ROYAL DECREE LAW 130; Charmaz K., 2006, CONSTRUCTING GROUNDE; Cipolle RJ, 2012, PHARM CAR PRACT PAT, Vthird; Conell J., 2001, CONSTRAINTS COMPROMI, V6; Consejo General de Enfermeria de Castilla la Mancha, 2011, MARC REF PRESCR ENF; Corbin J. M.., 2015, BASICS QUALITATIVE R; De Baetselier E, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251982; De-Baetselier E., 2020, BMJ-BRIT MED J, V10; Fernandez L., 2018, QUAL RES EDUC, V5, P332; Molero SF, 2019, ATEN PRIM, V51, P245, DOI 10.1016/j.aprim.2018.06.006; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Geurts Marlies M E, 2013, Inform Prim Care, V21, P53, DOI 10.14236/jhi.v21i1.40; Gielen SC, 2014, INT J NURS STUD, V51, P1048, DOI 10.1016/j.ijnurstu.2013.12.003; Gomez P., 2008, TES SERAE REV TESSER; Kroezen M, 2012, INT J NURS STUD, V49, P1002, DOI 10.1016/j.ijnurstu.2012.02.002; Lim Anecita Gigi, 2014, Nurs Prax N Z, V30, P18; Maier CB, 2016, EUR J PUBLIC HEALTH, V26, P927, DOI 10.1093/eurpub/ckw098; Morales JM., 2006, COMMON NURSE DIGITAL, V2, P49; NuPhaC Erasmus + Team, 2019, DEV MOD NURS ROL INT; Nuttall D, 2018, PRIM HEALTH CARE RES, V19, P7, DOI 10.1017/S1463423617000500; Preston P., 2018, NURS EDUC TODAY; Romero-Collado A, 2017, NURS HEALTH SCI, V19, P373, DOI 10.1111/nhs.12355; Romero-Collado A, 2014, J NURS MANAGE, V22, P394, DOI 10.1111/jonm.12139; Strauss A., 2008, BASICS QUALITATIVE R, DOI 10.4135/9781452230153; Wilkinson J, 2011, COLLEGIAN, V18, P157, DOI 10.1016/j.colegn.2011.07.001	25	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2022	17	1							e0260445	10.1371/journal.pone.0260445	http://dx.doi.org/10.1371/journal.pone.0260445			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZZ4EH	35073326	Green Published, gold			2023-01-03	WOS:000773223800009
J	Nomikos, PA; Hall, MC; Fuller, A; Ogollah, R; Valdes, AM; Doherty, M; Walsh, DA; das Nair, R; Abhishek, A				Nomikos, Polykarpos Angelos; Hall, Michelle C.; Fuller, Amy; Ogollah, Reuben; Valdes, Ana M.; Doherty, Michael; Walsh, David Andrew; das Nair, Roshan; Abhishek, Abhishek			Acceptability of a nurse-led non-pharmacological complex intervention for knee pain: Nurse and patient views and experiences	PLOS ONE			English	Article							PRIMARY-CARE; MANAGEMENT; BARRIERS; OLDER	Objectives The overall purpose of this research programme is to develop and test the feasibility of a complex intervention for knee pain delivered by a nurse, and comprising both non-pharmacological and pharmacological interventions. In this first phase, we examined the acceptability of the non-pharmacological component of the intervention; issues faced in delivery, and resolved possible challenges to delivery. Methods Eighteen adults with chronic knee pain were recruited from the community. The intervention comprised holistic assessment, education, exercise, weight-loss advice (where appropriate) and advice on adjunctive treatments such as hot/cold treatments, footwear modification and walking aids. After nurse training, the intervention was delivered in four sessions spread over five weeks. Participants had one to one semi-structured interview at the end of the intervention. The nurse was interviewed after the last visit of the last participant. These were audio recorded and transcribed verbatim. Themes were identified by one author through framework analysis of the transcripts, and cross-checked by another. Results Most participants found the advice from the nurse easy to follow and were satisfied with the package, though some felt that too much information was provided too soon. The intervention changed their perception of managing knee pain, learning that it can be improved with self-management. However, participants thought that the most challenging part of the intervention was fitting the exercise regime into their daily routine. The nurse found discussion of goal setting to be challenging. Conclusion The nurse-led package of care is acceptable within a research setting. The results are promising and will be applied in a feasibility randomised-controlled trial.	[Nomikos, Polykarpos Angelos; Fuller, Amy; Valdes, Ana M.; Doherty, Michael; Walsh, David Andrew; Abhishek, Abhishek] Univ Nottingham, Acad Rheumatol, Sch Med, Div Rheumatol Orthopaed & Rheumatol, Nottingham, England; [Nomikos, Polykarpos Angelos; Hall, Michelle C.; Fuller, Amy; Valdes, Ana M.; Doherty, Michael; Walsh, David Andrew; Abhishek, Abhishek] Univ Nottingham, NIHR Nottingham Biomed Res Ctr, Nottingham, England; [Nomikos, Polykarpos Angelos; Hall, Michelle C.; Valdes, Ana M.; Doherty, Michael; Walsh, David Andrew; das Nair, Roshan; Abhishek, Abhishek] Univ Nottingham, Pain Ctr Versus Arthrit, Nottingham, England; [Hall, Michelle C.] Univ Nottingham, Sch Hlth Sci, Nottingham, England; [Ogollah, Reuben] Univ Nottingham, Nottingham Clin Trials Unit, Nottingham, England; [das Nair, Roshan] Nottinghamshire Healthcare Fdn NHS Trust, Inst Mental Hlth, Nottingham, England; [das Nair, Roshan] Univ Nottingham, Sch Med, Div Psychiat & Appl Psychol, Nottingham, England	University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham	Nomikos, PA (corresponding author), Univ Nottingham, Acad Rheumatol, Sch Med, Div Rheumatol Orthopaed & Rheumatol, Nottingham, England.; Nomikos, PA (corresponding author), Univ Nottingham, NIHR Nottingham Biomed Res Ctr, Nottingham, England.; Nomikos, PA (corresponding author), Univ Nottingham, Pain Ctr Versus Arthrit, Nottingham, England.	Polykarpos.nomikos@nottingham.ac.uk		Doherty, Michael/0000-0002-5763-8326; Ogollah, Reuben/0000-0002-5777-4117; Hall, Michelle/0000-0003-2231-1507; Nomikos, Polykarpos/0000-0001-6827-4938; Fuller, Amy/0000-0002-9669-1816	NIHR Nottingham Biomedical Research Centre; University of Nottingham, UK; Pain Centre Versus Arthritis	NIHR Nottingham Biomedical Research Centre; University of Nottingham, UK; Pain Centre Versus Arthritis	This work was supported and co-funded by the NIHR Nottingham Biomedical Research Centre and the Pain Centre Versus Arthritis (Internal funding 2017-2022).The views expressed are those of author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The study is sponsored by the University of Nottingham, UK.	Ayala GX, 2011, J PUBLIC HEALTH DENT, V71, pS69, DOI 10.1111/j.1752-7325.2011.00241.x; Becker WC, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0608-2; Bellamy N, 2002, WOMAC OSTEOARTHRITIS, V5; Borrelli B, 2005, J CONSULT CLIN PSYCH, V73, P852, DOI 10.1037/0022-006X.73.5.852; Craig Peter, 2008, BMJ, V337, pa1655, DOI 10.1136/bmj.a1655; Cui AY, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100587; Denver EA, 2003, DIABETES CARE, V26, P2256, DOI 10.2337/diacare.26.8.2256; Doherty M, 2018, LANCET, V392, P1403, DOI 10.1016/S0140-6736(18)32158-5; Driscoll A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009889.pub2; Egerton T, 2017, OSTEOARTHR CARTILAGE, V25, P625, DOI 10.1016/j.joca.2016.12.002; Egerton T, 2018, BMC RHEUMATOL, V2, DOI 10.1186/s41927-018-0037-4; Fisher P, 2006, HOMEOPATHY, V95, P215, DOI 10.1016/j.homp.2006.07.006; Fuller A, 2020, RHEUMATOLOGY, V59, P575, DOI 10.1093/rheumatology/kez333; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Gignac MAM, 2006, ARTHRIT RHEUM-ARTHR, V55, P905, DOI 10.1002/art.22338; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Hall M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037760; Hommel KA, 2013, EUR J GASTROEN HEPAT, V25, P469, DOI 10.1097/MEG.0b013e32835c2a1b; Martinez-Gonzalez NA, 2015, HUM RESOUR HEALTH, V13, DOI 10.1186/s12960-015-0049-8; Metzler K., 2014, INTRO QUALITATIVE RE, Vfifth ed; Michie S, 2008, NHS HLTH TRAINER HDB; Michie S., 2014, BEHAVIOUR CHANGE WHE; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Millar B, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891-020-03195-4; National Institute for Health and Care Excellence, 2014, ANN DIAB CHECKS IND; Nelson AE, 2014, SEMIN ARTHRITIS RHEU, V43, P701, DOI 10.1016/j.semarthrit.2013.11.012; Nomikos PA, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-045242; Porcheret M, 2007, RHEUMATOLOGY, V46, P1694, DOI 10.1093/rheumatology/kem232; Sekhon M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2031-8; Sisk JE, 2006, ANN INTERN MED, V145, P273, DOI 10.7326/0003-4819-145-4-200608150-00007; Welch G, 2010, DIABETES RES CLIN PR, V88, P1, DOI 10.1016/j.diabres.2009.12.026	31	0	0	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2022	17	1							e0262422	10.1371/journal.pone.0262422	http://dx.doi.org/10.1371/journal.pone.0262422			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1H0VF	35025935	Green Published, gold, Green Submitted			2023-01-03	WOS:000796264200067
J	Tawbi, HA; Schadendorf, D; Lipson, EJ; Ascierto, PA; Matamala, L; Gutierrez, EC; Rutkowski, P; Gogas, HJ; Lao, CD; De Menezes, JJ; Dalle, S; Arance, A; Grob, JJ; Srivastava, S; Abaskharoun, M; Hamilton, M; Keidel, S; Simonsen, KL; Sobiesk, AM; Li, B; Hodi, FS; Long, GV				Tawbi, Hussein A.; Schadendorf, Dirk; Lipson, Evan J.; Ascierto, Paolo A.; Matamala, Luis; Gutierrez, Erika Castillo; Rutkowski, Piotr; Gogas, Helen J.; Lao, Christopher D.; De Menezes, Juliana Janoski; Dalle, Stephane; Arance, Ana; Grob, Jean-Jacques; Srivastava, Shivani; Abaskharoun, Mena; Hamilton, Melissa; Keidel, Sarah; Simonsen, Katy L.; Sobiesk, Anne Marie; Li, Bin; Hodi, F. Stephen; Long, Georgina, V		RELATIVITY-047 Investigators	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IPILIMUMAB; LAG-3; THERAPY	BACKGROUND Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking antibody, has been shown to be safe and to have antitumor activity in patients with previously treated melanoma, but the safety and activity in patients with previously untreated melanoma need investigation. METHODS In this phase 2-3, global, double-blind, randomized trial, we evaluated relatlimab and nivolumab as a fixed-dose combination as compared with nivolumab alone when administered intravenously every 4 weeks to patients with previously untreated metastatic or unresectable melanoma. The primary end point was progression-free survival as assessed by blinded independent central review. RESULTS The median progression-free survival was 10.1 months (95% confidence interval [CI], 6.4 to 15.7) with relatlimab-nivolumab as compared with 4.6 months (95% CI, 3.4 to 5.6) with nivolumab (hazard ratio for progression or death, 0.75 [95% CI, 0.62 to 0.92]; P=0.006 by the log-rank test). Progression-free survival at 12 months was 47.7% (95% CI, 41.8 to 53.2) with relatlimab-nivolumab as compared with 36.0% (95% CI, 30.5 to 41.6) with nivolumab. Progression-free survival across key subgroups favored relatlimab-nivolumab over nivolumab. Grade 3 or 4 treatment-related adverse events occurred in 18.9% of patients in the relatlimab-nivolumab group and in 9.7% of patients in the nivolumab group. CONCLUSIONS The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. Relatlimab and nivolumab in combination showed no new safety signals.	[Tawbi, Hussein A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Div Canc Med, Houston, TX 77030 USA; [Schadendorf, Dirk] Univ Hosp Essen, Dept Dermatol, Essen, Germany; [Schadendorf, Dirk] German Canc Consortium, Essen, Germany; [Lipson, Evan J.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA; [Ascierto, Paolo A.] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy; [Matamala, Luis] Inst Oncol Fdn Arturo Lopez Perez, Dept Oncol, Santiago, Chile; [Gutierrez, Erika Castillo] FAICIC Clin Res, Veracruz, Veracruz, Mexico; [Rutkowski, Piotr] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland; [Gogas, Helen J.] Natl & Kapodistrian Univ Athens, Dept Med, Athens, Greece; [Lao, Christopher D.] Univ Michigan, Rogel Canc Ctr, Michigan Med, Ann Arbor, MI 48109 USA; [De Menezes, Juliana Janoski] Hosp Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil; [Dalle, Stephane] Hosp Civils Lyon, Canc Res Ctr Lyon, Unit Dermatol, Pierre Benite, France; [Grob, Jean-Jacques] Aix Marseille Univ, CHU Timone, Marseille, France; [Arance, Ana] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain; [Arance, Ana] IDIBAPS, Barcelona, Spain; [Srivastava, Shivani; Abaskharoun, Mena; Hamilton, Melissa; Keidel, Sarah; Simonsen, Katy L.; Sobiesk, Anne Marie; Li, Bin] Bristol Myers Squibb, Princeton, NJ USA; [Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA; [Long, Georgina, V] Univ Sydney, Melanoma Inst Australia, Royal North Shore & Mater Hosp, Sydney, NSW, Australia	University of Texas System; UTMD Anderson Cancer Center; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Johns Hopkins University; Johns Hopkins Medicine; IRCCS Fondazione Pascale; National & Kapodistrian University of Athens; University of Michigan System; University of Michigan; CHU Lyon; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Bristol-Myers Squibb; Harvard University; Dana-Farber Cancer Institute; Melanoma Institute Australia; Royal North Shore Hospital; University of Sydney	Tawbi, HA (corresponding author), Univ Texas MD Anderson Canc Ctr, Div Canc Med, 1400 Holcombe Blvd, Houston, TX 77030 USA.	htawbi@mdanderson.org	de Melo, Andreia/C-8133-2019; Pigozzo, Jacopo/AAD-5994-2021; Rutkowski, Piotr/B-3907-2013; Long, Georgina/C-1771-2013	de Melo, Andreia/0000-0002-1201-4333; Pigozzo, Jacopo/0000-0003-2427-8915; Rutkowski, Piotr/0000-0002-8920-5429; Long, Georgina/0000-0001-8894-3545; Kruse, Vibeke/0000-0002-8840-3298; Svane, Inge Marie/0000-0002-9451-6037; Schadendorf, Dirk/0000-0003-3524-7858; Neyns, Bart/0000-0003-0658-5903				American Joint Committee on Cancer, 2018, AJCC CANC STAGING MA; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Ascierto PA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9520; Askew RL, 2009, VALUE HEALTH, V12, P1144, DOI 10.1111/j.1524-4733.2009.00570.x; Cormier JN, 2008, CANCER-AM CANCER SOC, V112, P2249, DOI 10.1002/cncr.23424; Dillon LM., CANCER RES, V81, P1625; Durham NM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109080; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Hemon P, 2011, J IMMUNOL, V186, P5173, DOI 10.4049/jimmunol.1002050; Hodi FS, 2018, LANCET ONCOL, V19, P1480, DOI 10.1016/S1470-2045(18)30700-9; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Lipson E., 2016, J IMMUNOTHER CANCER, V4, P232; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Michielin O, 2019, ANN ONCOL, V30, P1884, DOI 10.1093/annonc/mdz411; Phillips T, 2018, APPL IMMUNOHISTO M M, V26, P6, DOI [10.1097/PAI.0000000000000605, 10.1097/PAI.0000000000000380]; Pickard AS, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-70; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Seth R, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.00198; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wolchok JD, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.9506; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Workman CJ, 2004, J IMMUNOL, V172, P5450, DOI 10.4049/jimmunol.172.9.5450	25	183	184	24	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2022	386	1					24	34		10.1056/NEJMoa2109970	http://dx.doi.org/10.1056/NEJMoa2109970			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC1QX	34986285				2023-01-03	WOS:000739473800008
J	Yu, WQ				Yu, Weiqun			Reviving Cav1.2 as an attractive drug target to treat bladder dysfunction	FASEB JOURNAL			English	Editorial Material						calcium channel blockers; overactive bladder; smooth muscle	SPONTANEOUS PHASIC ACTIVITY; RAT URINARY-BLADDER; SMOOTH-MUSCLE; CALCIUM-CHANNEL; IN-VITRO; NIFEDIPINE; DETRUSOR; CONTRACTIONS; BAY-K-8644; VERAPAMIL	Inhibition of bladder contraction with antimuscarinics is a common approach to treat bladder hyperactivity, and the L-type voltage-gated calcium channel alpha(1C) (Cav1.2) is crucial for bladder contractility. Therefore, strategies aimed at inhibiting Cav1.2 appear warranted. However, multiple clinical trials that attempted to treat bladder overactivity with calcium channel blockers (CCBs) have been unsuccessful, creating an unsolved mystery. In contrast, cardiologists and epidemiologists have reported strong associations between CCB use and bladder hyperactivity, opposing expectations of urologists. Recent findings from our lab offer a potential explanation. We have demonstrated that ketamine which can cause cystitis, functions, like nifedipine, as a Cav1.2 antagonist. We also show that a Cav1.2 agonist which potentiates muscle contraction, rather than antagonizing it, can increase the volume of voids and reduce voiding frequency. This perspective will discuss in detail the unsuccessful urological trials of CCBs and the promise of Cav1.2 agonists as potential novel therapies for bladder dysfunctions.	[Yu, Weiqun] Beth Israel Deaconess Med Ctr, Dept Med, RN380B,99 Brookline Ave, Boston, MA 02215 USA; [Yu, Weiqun] Harvard Med Sch, RN380B,99 Brookline Ave, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Yu, WQ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, RN380B,99 Brookline Ave, Boston, MA 02215 USA.; Yu, WQ (corresponding author), Harvard Med Sch, RN380B,99 Brookline Ave, Boston, MA 02215 USA.	wyu2@bidmc.harvard.edu			NIDA [U18DA052346]	NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))	The Cav1.2 work on ketamine cystitis is funded by NIDA to W.Y (U18DA052346). I thank Drs. Mark Zeidel, Seth Alper, Warren Hill, and Aria Olumi (Beth Israel Deaconess Medical Center, Boston) for useful discussions.	ABRAHAM S, 1987, BRIT J PHARMACOL, V92, P603, DOI 10.1111/j.1476-5381.1987.tb11362.x; Andersson KE, 1999, BJU INT, V84, P923; Berridge MJ, 2008, J PHYSIOL-LONDON, V586, P5047, DOI 10.1113/jphysiol.2008.160440; BO X, 1990, BRIT J PHARMACOL, V101, P494, DOI 10.1111/j.1476-5381.1990.tb12736.x; BODEN WE, 1985, JAMA-J AM MED ASSOC, V253, P1131, DOI 10.1001/jama.253.8.1131; Buckner SA, 2002, BRIT J PHARMACOL, V135, P639, DOI 10.1038/sj.bjp.0704499; Cainazzo MM, 2005, DRUG EXP CLIN RES, V31, P115; Chen H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18167-4; Chi JT, 2007, PLOS GENET, V3, P1770, DOI 10.1371/journal.pgen.0030164; Coyne KS, 2009, BJU INT, V104, P352, DOI 10.1111/j.1464-410X.2009.08427.x; Elhebir ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066708; ELLIOTT RA, 1992, EUR J CLIN PHARMACOL, V43, P149, DOI 10.1007/BF01740662; Eroglu TE, 2020, EUR HEART J-CARD PHA, V6, P347, DOI 10.1093/ehjcvp/pvz038; FAUSTINI S, 1989, ARZNEIMITTEL-FORSCH, V39-2, P899; FLECKENSTEIN A, 1975, N-S ARCH PHARMACOL, V287, pR38; Fogari R, 2005, AM J HYPERTENS, V18, P577, DOI 10.1016/j.amjhyper.2004.11.020; FORMAN A, 1978, ACTA PHARMACOL TOX, V43, P111; FOVAEUS M, 1988, ACTA PHYSIOL SCAND, V132, P233, DOI 10.1111/j.1748-1716.1988.tb08322.x; FOVAEUS M, 1987, J UROLOGY, V137, P798, DOI 10.1016/S0022-5347(17)44214-5; Godfraind T, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00286; Griffin CS, 2018, BJU INT, V121, P959, DOI 10.1111/bju.14090; Hall SA, 2012, BJU INT, V109, P1676, DOI 10.1111/j.1464-410X.2011.10593.x; Hao Y, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122112; HENRY PD, 1980, AM J CARDIOL, V46, P1047, DOI 10.1016/0002-9149(80)90366-5; Heppner TJ, 2009, J PHYSIOL-LONDON, V587, P5275, DOI 10.1113/jphysiol.2009.178806; Hofmann F, 2014, PHYSIOL REV, V94, P303, DOI 10.1152/physrev.00016.2013; Hoggatt AM, 2002, CIRC RES, V91, P1151, DOI 10.1161/01.RES.0000047508.30800.4F; Hughes Jeffery D, 2011, Qual Prim Care, V19, P223; Huster M, 2010, FASEB J, V24, P2651, DOI 10.1096/fj.09-149856; Irwin DE, 2011, BJU INT, V108, P1132, DOI 10.1111/j.1464-410X.2010.09993.x; Ito H, 2013, NEUROUROL URODYNAM, V32, P70, DOI 10.1002/nau.22267; IVES N, 1986, EUR J PHARMACOL, V130, P169, DOI 10.1016/0014-2999(86)90265-7; Jinnah HA, 1999, P NATL ACAD SCI USA, V96, P15228, DOI 10.1073/pnas.96.26.15228; KARLINER JS, 1982, J CARDIOVASC PHARM, V4, P515, DOI 10.1097/00005344-198205000-00025; KATSURAGI T, 1990, BRIT J PHARMACOL, V100, P370, DOI 10.1111/j.1476-5381.1990.tb15811.x; LAVAL KU, 1980, UROL INT, V35, P182, DOI 10.1159/000280321; Liao P, 2007, J BIOL CHEM, V282, P35133, DOI 10.1074/jbc.M705478200; Liao P, 2010, PFLUG ARCH EUR J PHY, V460, P353, DOI 10.1007/s00424-009-0753-0; LIPE S, 1983, PHARMACOL THERAPEUT, V22, P299, DOI 10.1016/0163-7258(83)90007-4; MAGGI CA, 1988, GEN PHARMACOL, V19, P73, DOI 10.1016/0306-3623(88)90008-0; Matsui M, 2002, J NEUROSCI, V22, P10627; MATTIASSON A, 1989, J UROLOGY, V141, P174, DOI 10.1016/S0022-5347(17)40635-5; MIGNOT G, 1988, LANCET, V2, P857; MOGILNICKA E, 1988, EUR J PHARMACOL, V151, P307, DOI 10.1016/0014-2999(88)90813-8; Naglie G, 2002, J UROLOGY, V167, P586, DOI 10.1016/S0022-5347(01)69090-6; Novara G, 2008, EUR UROL, V54, P740, DOI 10.1016/j.eururo.2008.06.080; RAHWAN RG, 1979, CAN J PHYSIOL PHARM, V57, P443, DOI 10.1139/y79-069; Schneider T, 2004, J PHARMACOL EXP THER, V309, P1148, DOI 10.1124/jpet.103.063735; SCHWEIZER MWF, 1993, BRIT HEART J, V70, P252; Snider ME, 2008, VASC HEALTH RISK MAN, V4, P1249; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Striessnig J, 2015, CURR MOL PHARMACOL, V8, P110, DOI 10.2174/1874467208666150507105845; Tang ZZ, 2007, CELL CALCIUM, V41, P417, DOI 10.1016/j.ceca.2006.08.002; UCHIDA W, 1994, N-S ARCH PHARMACOL, V350, P398; Uvin P, 2013, EUR UROL, V64, P502, DOI 10.1016/j.eururo.2013.05.031; Vial C, 2000, BRIT J PHARMACOL, V131, P1489, DOI 10.1038/sj.bjp.0703720; Wegener JW, 2004, FASEB J, V18, P1159, DOI 10.1096/fj.04-1516fje; WILLIAMS G, 1986, LANCET, V1, P738; Wuest M, 2007, EUR J PHARMACOL, V565, P180, DOI 10.1016/j.ejphar.2007.02.046; Yeaw J, 2009, J MANAGE CARE PHARM, V15, P728, DOI 10.18553/jmcp.2009.15.9.728; ZDERIC SA, 1994, J UROLOGY, V152, P679, DOI 10.1016/S0022-5347(17)32679-4	61	1	1	3	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2022	36	1							e22118	10.1096/fj.202101475R	http://dx.doi.org/10.1096/fj.202101475R			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XV5OR	34939692				2023-01-03	WOS:000734992000039
J	Whittaker, HR; Gulea, C; Koteci, A; Kallis, C; Morgan, AD; Iwundu, C; Weeks, M; Gupta, R; Quint, JK				Whittaker, Hannah R.; Gulea, Claudia; Koteci, Ardita; Kallis, Constantinos; Morgan, Ann D.; Iwundu, Chukwuma; Weeks, Mark; Gupta, Rikisha; Quint, Jennifer K.			GP consultation rates for sequelae after acute covid-19 in patients managed in the community or hospital in the UK: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVES To describe the rates for consulting a general practitioner (GP) for sequelae after acute covid-19 in patients admitted to hospital with covid-19 and those managed in the community, and to determine how the rates change over time for patients in the community and after vaccination for covid-19. DESIGN Population based study. SETTING 1392 general practices in England contributing to the Clinical Practice Research Datalink Aurum database. PARTICIPANTS 456 002 patients with a diagnosis of covid-19 between 1 August 2020 and 14 February 2021 (44.7% men; median age 61 years), admitted to hospital within two weeks of diagnosis or managed in the community, and followed-up for a maximum of 9.2 months. A negative control group included individuals without covid-19 (n=38 511) and patients with influenza before the pandemic (n=21 803). MAIN OUTCOME MEASURES Comparison of rates for consulting a GP for new symptoms, diseases, prescriptions, and healthcare use in individuals admitted to hospital and those managed in the community, separately, before and after covid-19 infection, using Cox regression and negative binomial regression for healthcare use. The analysis was repeated for the negative control and influenza cohorts. In individuals in the community, outcomes were also described over time after a diagnosis of covid-19, and compared before and after vaccination for individuals who were symptomatic after covid-19 infection, using negative binomial regression. RESULTS Relative to the negative control and influenza cohorts, patients in the community (n=437 943) had significantly higher GP consultation rates for multiple sequelae, and the most common were loss of smell or taste, or both (adjusted hazard ratio 5.28, 95% confidence interval 3.89 to 7.17, P<0.001); venous thromboembolism (3.35, 2.87 to 3.91, P<0.001); lung fibrosis (2.41, 1.37 to 4.25, P=0.002), and muscle pain (1.89, 1.63 to 2.20, P<0.001); and also for healthcare use after a diagnosis of covid-19 compared with 12 months before infection. For absolute proportions, the most common outcomes >= 4 weeks after a covid-19 diagnosis in patients in the community were joint pain (2.5%), anxiety (1.2%), and prescriptions for non-steroidal anti-inflammatory drugs (1.2%). Patients admitted to hospital (n=18 059) also had significantly higher GP consultation rates for multiple sequelae, most commonly for venous thromboembolism (16.21, 11.28 to 23.31, P<0.001), nausea (4.64, 2.24 to 9.21, P<0.001), prescriptions for paracetamol (3.68, 2.86 to 4.74, P<0.001), renal failure (3.42, 2.67 to 4.38, P<0.001), and healthcare use after a covid-19 diagnosis compared with 12 months before infection. For absolute proportions, the most common outcomes >= 4 weeks after a covid-19 diagnosis in patients admitted to hospital were venous thromboembolism (3.5%), joint pain (2.7%), and breathlessness (2.8%). In patients in the community, anxiety and depression, abdominal pain, diarrhoea, general pain, nausea, chest tightness, and tinnitus persisted throughout follow-up. GP consultation rates were reduced for all symptoms, prescriptions, and healthcare use, except for neuropathic pain, cognitive impairment, strong opiates, and paracetamol use in patients in the community after the first vaccination dose for covid-19 relative to before vaccination. GP consultation rates were also reduced for ischaemic heart disease, asthma, and gastro-oesophageal disease. CONCLUSIONS GP consultation rates for sequelae after acute covid-19 infection differed between patients with covid-19 who were admitted to hospital and those managed in the community. For individuals in the community, rates of some sequelae decreased over time but those for others, such as anxiety and depression, persisted. Rates of some outcomes decreased after vaccination in this group.	[Whittaker, Hannah R.; Gulea, Claudia; Koteci, Ardita; Kallis, Constantinos; Morgan, Ann D.; Iwundu, Chukwuma; Weeks, Mark; Gupta, Rikisha; Quint, Jennifer K.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Whittaker, Hannah R.; Gulea, Claudia; Koteci, Ardita; Kallis, Constantinos; Morgan, Ann D.; Iwundu, Chukwuma; Weeks, Mark; Gupta, Rikisha; Quint, Jennifer K.] NIHR Imperial Biomed Res Ctr, London, England	Imperial College London	Quint, JK (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, London, England.; Quint, JK (corresponding author), NIHR Imperial Biomed Res Ctr, London, England.	j.quint@imperial.ac.uk	quint, jennifer/ABE-3384-2020; weeks, Mark/AAT-7258-2021	Quint, Jennifer/0000-0003-0149-4869; Gupta, Rikisha/0000-0001-9784-416X; Koteci, Ardita/0000-0002-6074-7099; Whittaker, Hannah/0000-0002-7705-0300; Kallis, Constantinos/0000-0003-0866-5421; Iwundu, Chukwuma/0000-0002-3066-1999; Gulea, Claudia/0000-0001-9607-5901	BREATHE-The Health Data Research Hub for Respiratory Health [MC_PC_19004]; UK Research and Innovation Industrial Strategy Challenge Fund	BREATHE-The Health Data Research Hub for Respiratory Health; UK Research and Innovation Industrial Strategy Challenge Fund(UK Research & Innovation (UKRI))	This work is supported by BREATHE-The Health Data Research Hub for Respiratory Health (MC_PC_19004). BREATHE is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. The funder had no role in study design, data collection, analysis or interpretation, or manuscript writing. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; Alwan NA, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3565; Antonelli M, 2022, LANCET INFECT DIS, V22, P43, DOI 10.1016/S1473-3099(21)00460-6; Arnold DT., 2021, MEDRXIV, DOI [10.1101/2021.03.11.21253225, DOI 10.1101/2021.03.11.21253225]; Augustin M, 2021, LANCET REG HEALTH-EU, V6, DOI 10.1016/j.lanepe.2021.100122; Ayoubkhani D., 2021, PREVALENCE ONGOING S; Ayoubkhani D, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n693; Daugherty SE, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1098; Di Minno A, 2020, SEMIN THROMB HEMOST, V46, P763, DOI 10.1055/s-0040-1715456; Doe G, 2021, NPJ PRIM CARE RESP M, V31, DOI 10.1038/s41533-021-00232-0; Fraser E, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3001; Goertz YMJ, 2020, ERJ OPEN RES, V6, DOI 10.1183/23120541.00542-2020; Hernandez-Romieu AC, 2021, MMWR-MORBID MORTAL W, V70, P644, DOI 10.15585/mmwr.mm7017e3; Knock ES, 2020, 41 IMP COLL LOND, DOI [10.25561/85146, DOI 10.25561/85146]; Komaroff A.L, 2021, COVID 19 RAP GUID MA; Ladds E, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-06001-y; Lopez-Leon S, 2021, SCI REP-UK, V11, DOI [10.1038/s41598-021-95565-8, 10.1101/2021.01.27.21250617]; Lund LC, 2021, LANCET INFECT DIS, V21, P1373, DOI 10.1016/S1473-3099(21)00211-5; Medicines and Healthcare products Regulatory Agency, 2021, REL NOT CPRD AUR; Metcalfe D, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0753-5; Moynihan R, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-045343; O'Dowc A, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1626; Paterson RW, 2020, BRAIN, V143, P3104, DOI 10.1093/brain/awaa240; Piroth L, 2021, LANCET RESP MED, V9, P251, DOI 10.1016/S2213-2600(20)30527-0; Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557; Rogers W, 1994, STATA TECHNICAL B, V3, P1; Rubino F, 2020, NEW ENGL J MED, V383, P789, DOI [10.1056/NEJMc2018688, 10.1056/NEJMc2021832]; Salamanna F, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.653516; Skyrud KD., 2021, MEDRXIV, DOI [10.1101/2021.02.16.21251807, DOI 10.1101/2021.02.16.21251807]; Strain WD, 2021, IMPACT COVID VACCINA; Taquet M, 2021, LANCET PSYCHIAT, V8, P130, DOI 10.1016/S2215-0366(20)30462-4; UK government, COR COV 19 DASHB; Wolf A, 2019, INT J EPIDEMIOL, V48, P1740, DOI 10.1093/ije/dyz034; World Health Organization, 2021, CLIN CAS DEF POST CO	34	11	11	3	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 29	2021	375								e065834	10.1136/bmj-2021-065834	http://dx.doi.org/10.1136/bmj-2021-065834			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH4NO	34965929	Green Published, hybrid			2023-01-03	WOS:000743145900005
J	Ayodele, O; Ren, KL; Zhao, J; Signorovitch, J; Funk, MJ; Zhu, JL; Bao, Y; Gondek, K; Keenan, H				Ayodele, Olulade; Ren, Kaili; Zhao, Jing; Signorovitch, James; Funk, Michele Jonsson; Zhu, Julia; Bao, Ying; Gondek, Kathleen; Keenan, Hillary		R D COVID Alliance	Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021	PLOS ONE			English	Article							CORONAVIRUS DISEASE 2019; UNITED-STATES	The objective of this retrospective cohort study was to describe pre-treatment characteristics, treatment patterns, health resource use, and clinical outcomes among adults hospitalized with COVID-19 in the United States (US) who initiated common treatments for COVID-19. The Optum (R) COVID-19 electronic health records database was used to identify patients > 18 years, diagnosed with COVID-19, who were admitted to an inpatient setting and received treatments of interest for COVID-19 between September 2020 and January 2021. Patients were stratified into cohorts based on index treatment use. Patient demographics, medical history, care setting, medical procedures, subsequent treatment use, patient disposition, clinical improvement, and outcomes were summarized descriptively. Among a total of 26,192 patients identified, the most prevalent treatments initiated were dexamethasone (35.4%) and dexamethasone + remdesivir (14.9%), and dexamethasone was the most common subsequent treatment. At day 14 post-index, <10% of patients received any treatments of interest. Mean (standard deviation [SD]) patient age was 65.6 (15.6) years, and the most prevalent comorbidities included hypertension (44.8%), obesity (35.4%), and diabetes (25.7%). At the end of follow-up, patients had a mean (SD) 8.1 (6.6) inpatient days and 1.4 (4.1) days with ICU care. Oxygen supplementation, non-invasive, or invasive ventilation was required by 4.5%, 3.0%, and 3.1% of patients, respectively. At the end of follow-up, 84.2% of patients had evidence of clinical improvement, 3.1% remained hospitalized, 83.8% were discharged, 4% died in hospital, and 9.1% died after discharge. Although the majority of patients were discharged alive, no treatments appeared to alleviate the inpatient morbidity and mortality associated with COVID-19. This highlights an unmet need for effective treatment options for patients hospitalized with COVID-19.	[Ayodele, Olulade; Ren, Kaili; Gondek, Kathleen; Keenan, Hillary] Takeda Pharmaceut Co Ltd, Data Sci Inst, Cambridge, MA 02139 USA; [Zhao, Jing; Signorovitch, James] Data Sci Inst, Anal Grp, Boston, MA USA; [Funk, Michele Jonsson] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA; [Zhu, Julia; Bao, Ying] Bristol Myers Squibb, Ctr Observat Res & Data Sci, Princeton, NJ USA	Analysis Group Inc.; University of North Carolina; University of North Carolina Chapel Hill; Bristol-Myers Squibb	Ayodele, O (corresponding author), Takeda Pharmaceut Co Ltd, Data Sci Inst, Cambridge, MA 02139 USA.	Lade.Ayodele@takeda.com		Ayodele, Olulade/0000-0001-6084-5900	Takeda Development Center Americas Inc.; Amgen Inc.; Bristol-Myers Squibb Co.	Takeda Development Center Americas Inc.(Takeda Pharmaceutical Company Ltd); Amgen Inc.(Amgen); Bristol-Myers Squibb Co.(Bristol-Myers Squibb)	This study was sponsored by Takeda Development Center Americas Inc.: study design, data collection and analysis, decision to publish, and preparation of the manuscript; Amgen Inc.: study design, interpretation of analyses, decision to publish, and preparation of the manuscript; and Bristol-Myers Squibb Co.: study design, interpretation of analyses, decision to publish, and preparation of the manuscript.	Adams M. L., 2020, PREPRINT, DOI [DOI 10.1101/2020.03.30.20043919, 10.1101/2020.03.30.20043919]; Adeli SH, 2020, POL ARCH INTERN MED, V130, P455, DOI 10.20452/pamw.15340; Alzghari SK, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104380; [Anonymous], 2007, OPTUM IDENTIFIED COV; [Anonymous], 2020, CORONAVIRUS DIS 2019; [Anonymous], 2020, CORONAVIRUS COVID 19; Asch DA, 2021, JAMA INTERN MED, V181, P471, DOI 10.1001/jamainternmed.2020.8193; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Best JH, 2021, J MED VIROL, V93, P5367, DOI 10.1002/jmv.27049; Beyzarov E, 2021, DRUG SAFETY, V44, DOI 10.1007/s40264-020-01035-x; Buckner FS, 2020, CLIN INFECT DIS, V71, P2167, DOI 10.1093/cid/ciaa632; Canfield Steven, 2017, Rev Urol, V19, P203, DOI 10.3909/riu0786; Centers for Disease Control and Prevention, COVID DAT TRACK; Chopra V, 2021, ANN INTERN MED, V174, P576, DOI 10.7326/M20-5661; Dalal AA, 2011, RESP MED, V105, P454, DOI 10.1016/j.rmed.2010.09.003; Di Fusco M, 2021, J MED ECON, V24, P308, DOI 10.1080/13696998.2021.1886109; Donnino MW, 2021, J GEN INTERN MED, V36, P1689, DOI 10.1007/s11606-021-06647-2; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Fan XZ, 2021, INT J GEN MED, V14, P267, DOI 10.2147/IJGM.S290118; Finelli L, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.6556; Food and Drug Administration, 2020, FDA APPR 1 TREATM CO; Food and Drug Administration, 2020, FDA ISS EM US AUTH C; Food and Drug Administration, 2020, COVID 19 UPD FDA BRO; Food and Drug Administration (US), 2020, FDA CLEARANCE K19200; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Gupta S, 2021, JAMA INTERN MED, V181, P41, DOI 10.1001/jamainternmed.2020.6252; Hasegawa K, 2016, CHEST, V150, P112, DOI 10.1016/j.chest.2016.03.037; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Imam Z, 2020, J INTERN MED, V288, P469, DOI 10.1111/joim.13119; Killerby ME, 2020, MMWR-MORBID MORTAL W, V69, P790, DOI 10.15585/mmwr.mm6925e1; Ko JY, 2021, CLIN INFECT DIS, V72, pE695, DOI 10.1093/cid/ciaa1419; Libster R, 2021, NEW ENGL J MED, V384, P610, DOI 10.1056/NEJMoa2033700; Lima FV, 2015, COPD, V12, P636, DOI 10.3109/15412555.2015.1020151; Lin KJ, 2020, DRUGS, V80, P1961, DOI 10.1007/s40265-020-01424-7; Magagnoli J, 2020, MED-CAMBRIDGE, V1, P114, DOI [10.1016/j.medj.2020.06.001, 10.1101/2020.04.16.20065920]; Marin BG, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2146; Nemer DM, 2021, J HOSP MED, V16, P7, DOI 10.12788/jhm.3510; Nguyen NT, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0417; Owusu D, 2021, CLIN INFECT DIS, V72, pE162, DOI 10.1093/cid/ciaa1806; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Rosenthal N, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.29058; Salazar E, 2020, AM J PATHOL, V190, P2290, DOI 10.1016/j.ajpath.2020.08.001; Smoke SM, 2021, INT J ANTIMICROB AG, V57, DOI 10.1016/j.ijantimicag.2020.106265; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2; U.S. Census Bureau, 2019, QUICKFACTS; U.S. Department of Health and Human Services, 2012, GUIDANCE REGARDING M; van Gerwen M, 2021, J MED VIROL, V93, P907, DOI 10.1002/jmv.26337; Watanabe JH, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.10775; Xie Y, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4677; Zhang Shengyu, 2020, Clin Drug Investig, V40, P511, DOI 10.1007/s40261-020-00917-3	56	0	0	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2021	16	12							e0261707	10.1371/journal.pone.0261707	http://dx.doi.org/10.1371/journal.pone.0261707			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW9UF	34962924	gold, Green Published			2023-01-03	WOS:000771548500020
J	Krisanti, EA; Kirana, DP; Mulia, K				Krisanti, Elsa Anisa; Kirana, Dyah Paramawidya; Mulia, Kamarza			Nanoemulsions containing Garcinia mangostana L. pericarp extract for topical applications: Development, characterization, and in vitro percutaneous penetration assay	PLOS ONE			English	Article							XANTHAN GUM; NONIONIC SURFACTANTS; SKIN; OIL; FORMULATION; PERMEATION; STABILITY; DELIVERY; PH; EMULSIFICATION	A highly stable oil-in-water nanoemulsion for topical applications, containing mangostins extracted from the pericarp of mangosteen (Garcinia mangostana L.), is a promising strategy to protect mangostins as well as to improve penetration of these important antioxidants through the skins. Nanoemulsions consisted of virgin coconut oil as the oil phase, Tween-80 and Span-80 as surfactants, and xanthan gum as the thickening agent, were prepared using the high-energy and low-energy emulsification methods. The nanoemulsions that were stable up to 28 days had oil droplet diameter of 220 nm to 353 nm and zeta potential of -46.9 mV to -63.7 mV. The accelerated stability test showed that the most stable nanoemulsions were those prepared using the low-energy emulsification method with an estimated shelf life of eleven months, composed of 11% oil phase, 17% surfactant, and 72% aqueous phase. The in vitro percutaneous penetration test for the nanoemulsion with added xanthan gum provided high cumulative skin penetration of mangostins of up to 114 mu g/cm(2). The results of this study indicate that virgin coconut oil-based nanoemulsions containing mangostins, prepared using the low-energy emulsification method, stabilized by xanthan gum and mixed at 40 degrees C can prospectively be used for topical applications.	[Krisanti, Elsa Anisa; Kirana, Dyah Paramawidya; Mulia, Kamarza] Univ Indonesia, Dept Chem Engn, Depok, Indonesia	University of Indonesia	Mulia, K (corresponding author), Univ Indonesia, Dept Chem Engn, Depok, Indonesia.	kmulia@che.ui.ac.id	Krisanti, Elsa/GQB-0562-2022		PUTI Q1 research scheme - Universitas Indonesia [NKB-1434/UN2.RST/HKP.05.00/2020]	PUTI Q1 research scheme - Universitas Indonesia	This research was funded through the PUTI Q1 research scheme awarded by Universitas Indonesia to EAK, grant number NKB-1434/UN2.RST/HKP.05.00/2020. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abd E, 2016, J PHARM SCI-US, V105, P212, DOI 10.1002/jps.24699; Aisha A. F. A., 2013, Journal of Medicinal Plants Research, V7, P29; Al-Massarani SM, 2013, MOLECULES, V18, P10599, DOI 10.3390/molecules180910599; Benbow T, 2019, DRUG DEV IND PHARM, V45, P1849, DOI 10.1080/03639045.2019.1680996; Bujak T, 2015, COLLOID SURFACE B, V135, P497, DOI 10.1016/j.colsurfb.2015.07.051; Chaiittianan R, 2014, DRUG DEV IND PHARM, V40, P1597, DOI 10.3109/03639045.2013.838580; Chityala PK, 2016, FOOD CHEM, V212, P332, DOI 10.1016/j.foodchem.2016.05.187; Davies JT, 1957, 2 INT C SURF ACT, P426; Dokania S, 2015, DRUG DELIV, V22, P675, DOI 10.3109/10717544.2014.896058; Ferreira M, 2016, INT J PHARMACEUT, V512, P14, DOI 10.1016/j.ijpharm.2016.08.008; Frelichowska J, 2009, INT J PHARMACEUT, V371, P56, DOI 10.1016/j.ijpharm.2008.12.017; Gan CY, 2011, CARBOHYD POLYM, V83, P600, DOI 10.1016/j.carbpol.2010.08.025; Garcia-Ochoa F, 2000, BIOTECHNOL ADV, V18, P549, DOI 10.1016/S0734-9750(00)00050-1; Greenwood R, 2003, ADV COLLOID INTERFAC, V106, P55, DOI 10.1016/S0001-8686(03)00105-2; Gupta A, 2016, SOFT MATTER, V12, P2826, DOI 10.1039/c5sm02958a; Habibi H, 2017, BIOCATAL AGR BIOTECH, V10, P130, DOI 10.1016/j.bcab.2017.02.013; Hong L, 2017, J MICROENCAPSUL, V34, P707, DOI 10.1080/02652048.2017.1373154; Hoppel M, 2015, J DRUG DELIV SCI TEC, V25, P16, DOI 10.1016/j.jddst.2014.11.001; Hussain A, 2016, DRUG DELIV, V23, P652, DOI 10.3109/10717544.2014.933284; Jaiswal M, 2015, 3 BIOTECH, V5, P123, DOI 10.1007/s13205-014-0214-0; Kamarza M., 2018, MATEC WEB C EDP SCI, V156, P1; Khan BA, 2013, BRAZ J PHARM SCI, V49, P763, DOI 10.1590/S1984-82502013000400016; Kohli AK, 2004, INT J PHARMACEUT, V275, P13, DOI 10.1016/j.ijpharm.2003.10.038; Komaiko J, 2015, J FOOD ENG, V146, P122, DOI 10.1016/j.jfoodeng.2014.09.003; Komaiko JS, 2016, COMPR REV FOOD SCI F, V15, P331, DOI 10.1111/1541-4337.12189; Konwar B., 2013, J BIOPROCESS BIOTECH, V3, P135; Lukic M, 2021, COSMETICS-BASEL, V8, DOI 10.3390/cosmetics8030069; Matousek JL, 2003, CAN J VET RES, V67, P56; McClements DJ, 2011, CRIT REV FOOD SCI, V51, P285, DOI 10.1080/10408398.2011.559558; McClements DJ, 2011, SOFT MATTER, V7, P2297, DOI 10.1039/c0sm00549e; Mirhosseini H, 2008, COLLOID SURFACE A, V315, P47, DOI 10.1016/j.colsurfa.2007.07.007; Mulia Kamarza, 2018, Materials Science Forum, V929, P234, DOI 10.4028/www.scientific.net/MSF.929.234; Mulia K, 2017, AIP CONF PROC, V1823, DOI 10.1063/1.4978083; Ng Shiow-Fern, 2010, Pharmaceutics, V2, P209; Pedraza-Chaverri J, 2008, FOOD CHEM TOXICOL, V46, P3227, DOI 10.1016/j.fct.2008.07.024; Pratiwi L., 2016, INT J PHARMTECH RES, V9, P380; Rachmawati H, 2015, DRUG DEV IND PHARM, V41, P560, DOI 10.3109/03639045.2014.884127; Rahate AR, 2007, J DISPER SCI TECHNOL, V28, P1077, DOI 10.1080/01932690701524802; Shilling M, 2013, J MED FOOD, V16, P1079, DOI 10.1089/jmf.2012.0303; Simon A, 2016, INT J PHARMACEUT, V512, P234, DOI 10.1016/j.ijpharm.2016.08.052; Tadros T., 2013, EMULSION FORMATION S, P1; Thomas L, 2017, INT J BIOL MACROMOL, V101, P569, DOI 10.1016/j.ijbiomac.2017.03.066; Wang QA, 2017, COLLOID SURFACE A, V522, P399, DOI 10.1016/j.colsurfa.2017.02.067; Yukuyama MN, 2016, INT J COSMETIC SCI, V38, P13, DOI 10.1111/ics.12260; Zhang SJ, 2017, LWT-FOOD SCI TECHNOL, V75, P316, DOI 10.1016/j.lwt.2016.08.046; Zorzi GK, 2016, AAPS PHARMSCITECH, V17, P844, DOI 10.1208/s12249-015-0408-8	46	0	0	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2021	16	12							e0261792	10.1371/journal.pone.0261792	http://dx.doi.org/10.1371/journal.pone.0261792			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ1OP	34941972	gold, Green Published			2023-01-03	WOS:000755252200085
J	Matthews, E				Matthews, Emily			Zoe Morgan is a critical care dietitian	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Matthews, Emily] Swansea Bay Univ Hlth Board, Swansea, W Glam, Wales		Matthews, E (corresponding author), Swansea Bay Univ Hlth Board, Swansea, W Glam, Wales.	emily.matthews@doctors.org.uk							0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 23	2021	375								n2458	10.1136/bmj.n2458	http://dx.doi.org/10.1136/bmj.n2458			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY1EL	34949595				2023-01-03	WOS:000736724700005
J	Conforti, F; Pala, L; Sala, I; Oriecuia, C; De Pas, T; Specchia, C; Graffeo, R; Pagan, E; Queirolo, P; Pennacchioli, E; Colleoni, M; Viale, G; Bagnardi, V; Gelber, RD				Conforti, Fabio; Pala, Laura; Sala, Isabella; Oriecuia, Chiara; De Pas, Tommaso; Specchia, Claudia; Graffeo, Rossella; Pagan, Eleonora; Queirolo, Paola; Pennacchioli, Elisabetta; Colleoni, Marco; Viale, Giuseppe; Bagnardi, Vincenzo; Gelber, Richard D.			Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PHASE-III TRIAL; DOXORUBICIN PLUS CYCLOPHOSPHAMIDE; DOSE-INTENSIFIED CHEMOTHERAPY; PRIMARY MEDICAL THERAPY; OPEN-LABEL; NAB-PACLITAXEL; PREOPERATIVE CHEMOTHERAPY; ADJUVANT TRASTUZUMAB; DARBEPOETIN ALPHA; DENSE DOXORUBICIN	OBJECTIVE To evaluate pathological complete response as a surrogate endpoint for disease-free survival and overall survival in regulatory neoadjuvant trials of early stage breast cancer. DESIGN Systematic review and meta-analysis. DATA SOURCES Medline, Embase, and Scopus to 1 December 2020. ELIGIBILITY CRITERIA FOR STUDY SELECTION Randomised clinical trials that tested neoadjuvant chemotherapy given alone or combined with other treatments, including anti-human epidermal growth factor 2 (anti-HER2) drugs, targeted treatments, antivascular agents, bisphosphonates, and immune checkpoint inhibitors. DATA EXTRACTION AND SYNTHESIS Trial level associations between the surrogate endpoint pathological complete response and disease-free survival and overall survival. METHODS A weighted regression analysis was performed on log transformed treatment effect estimates (hazard ratio for disease-free survival and overall survival and relative risk for pathological complete response), and the coefficient of determination (R-2) was used to quantify the association. The secondary objective was to explore heterogeneity of results in preplanned subgroups analysis, stratifying trials according treatment type in the experimental arm, definition used for pathological complete response (breast and lymph nodes v breast only), and biological features of the disease (HER2 positive or triple negative breast cancer). The surrogate threshold effect was also evaluated, indicating the minimum value of the relative risk for pathological complete response necessary to confidently predict a non-null effect on hazard ratio for disease-free survival or overall survival. RESULTS 54 randomised clinical trials comprising a total of 32 611 patients were included in the analysis. A weak association was observed between the log(relative risk) for pathological complete response and log(hazard ratio) for both disease-free survival (R (2)=0.14, 95% confidence interval 0.00 to 0.29) and overall survival (R-2=0.08, 0.00 to 0.22). Similar results were found across all subgroups evaluated, independently of the definition used for pathological complete response, treatment type in the experimental arm, and biological features of the disease. The surrogate threshold effect was 5.19 for disease-free survival but was not estimable for overall survival. Consistent results were confirmed in three sensitivity analyses: excluding small trials (<200 patients enrolled), excluding trials with short median follow-up (<24 months), and replacing the relative risk for pathological complete response with the absolute difference of pathological complete response rates between treatment arms. CONCLUSION A lack of surrogacy of pathological complete response was identified at trial level for both disease-free survival and overall survival. The findings suggest that pathological complete response should not be used as primary endpoint in regulatory neoadjuvant trials of early stage breast cancer.	[Conforti, Fabio; Pala, Laura; De Pas, Tommaso; Queirolo, Paola; Pennacchioli, Elisabetta] European Inst Oncol, Div Melanoma Sarcomas & Rare Tumors, IRCCS, IEO, Milan, Italy; [Sala, Isabella; Pagan, Eleonora; Bagnardi, Vincenzo] Univ Milano Bicocca, Dept Stat & Quantitat Methods, Milan, Italy; [Oriecuia, Chiara] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy; [Specchia, Claudia] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Graffeo, Rossella] Oncol Inst Southern Switzerland, Breast Unit Southern Switzerland, Bellinzona, Switzerland; [Colleoni, Marco] European Inst Oncol IRCCS, Div Med Senol, IEO, Milan, Italy; [Viale, Giuseppe] European Inst Oncol, Dept Pathol, IRCCS, IEO, Milan, Italy; [Viale, Giuseppe] Univ Milan, Milan, Italy; [Gelber, Richard D.] Harvard TH Chan Sch Publ Hlth, Med Sch, Boston, MA USA; [Gelber, Richard D.] Frontier Sci & Technol Res Fdn Inc, Boston, MA USA	IRCCS European Institute of Oncology (IEO); University of Milano-Bicocca; University of Brescia; University of Brescia; Institute of Oncology Research (IOR); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); University of Milan; Harvard University; Harvard T.H. Chan School of Public Health; Frontier Science Foundation	Conforti, F (corresponding author), European Inst Oncol, Div Melanoma Sarcomas & Rare Tumors, IRCCS, IEO, Milan, Italy.	fabio.conforti@ieo.it	Pala, Laura/AHD-9154-2022	Sala, Isabella/0000-0002-4404-4537				Arun BK, 2011, ONCOLOGIST, V16, P1527, DOI 10.1634/theoncologist.2011-0134; Baldini E, 2003, ANN ONCOL, V14, P227, DOI 10.1093/annonc/mdg069; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Bear HD, 2015, LANCET ONCOL, V16, P1037, DOI 10.1016/S1470-2045(15)00041-8; Berruti A, 2014, J CLIN ONCOL, V32, P3883, DOI 10.1200/JCO.2014.55.2836; Berry DA, 2015, JAMA ONCOL, V1, P875, DOI 10.1001/jamaoncol.2015.1293; Bonnefoi H, 2011, LANCET ONCOL, V12, P527, DOI 10.1016/S1470-2045(11)70094-8; Bujkiewicz S, 2016, STAT MED, V35, P1063, DOI 10.1002/sim.6776; Burstein HJ, 2020, NEW ENGL J MED, V383, P2557, DOI 10.1056/NEJMra1307118; Burzykowski T, 2001, J R STAT SOC C-APPL, V50, P405, DOI 10.1111/1467-9876.00244; Burzykowski T, 2006, PHARM STAT, V5, P173, DOI 10.1002/pst.207; Buyse M, 1998, BIOMETRICS, V54, P1014, DOI 10.2307/2533853; Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49; Buzdar AU, 2007, CLIN CANCER RES, V13, P228, DOI 10.1158/1078-0432.CCR-06-1345; Buzdar AU, 2019, JAMA ONCOL, V5, P45, DOI 10.1001/jamaoncol.2018.3691; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; Buzdar AU, 1999, J CLIN ONCOL, V17, P3412, DOI 10.1200/JCO.1999.17.11.3412; Chen X, 2012, ANN ONCOL, V23, P117; Chua S, 2005, ANN ONCOL, V16, P1435, DOI 10.1093/annonc/mdi276; Cocconi G, 2005, ANN ONCOL, V16, P1469, DOI 10.1093/annonc/mdi278; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Dawoud D, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2191; de Groot S, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1180-6; Der Elst WV, Surrogate: Evaluation of Surrogate Endpoints in Clinical Trials; Dieras V, 2004, J CLIN ONCOL, V22, P4958, DOI 10.1200/JCO.2004.02.122; Earl HM, 2017, ANN ONCOL, V28, P1817, DOI 10.1093/annonc/mdx173; Earl HM, 2014, LANCET ONCOL, V15, P201, DOI 10.1016/S1470-2045(13)70554-0; Ellis GK, 2011, J CLIN ONCOL, V29, P1014, DOI 10.1200/JCO.2009.27.6543; European Medicines Agency, EMACHMP1518532014; Evans TRJ, 2005, J CLIN ONCOL, V23, P2988, DOI 10.1200/JCO.2005.06.156; Fernandez-Martinez A, 2020, J CLIN ONCOL, V38, P4184, DOI 10.1200/JCO.20.01276; Fleming TR, 2012, STAT MED, V31, P2973, DOI 10.1002/sim.5403; Frasci G, 2010, ANN ONCOL, V21, P707, DOI 10.1093/annonc/mdp356; Gianni L, 2018, JAMA ONCOL, V4, P302, DOI 10.1001/jamaoncol.2017.4612; Gianni L, 2016, LANCET ONCOL, V17, P791, DOI 10.1016/S1470-2045(16)00163-7; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Green EM, 2008, STAT METHODS MED RES, V17, P477, DOI 10.1177/0962280207081863; Hayes Daniel F., 2015, Journal of the National Cancer Institute Monographs, P36, DOI 10.1093/jncimonographs/lgv004; Hellmann MD, 2014, LANCET ONCOL, V15, pE42, DOI 10.1016/S1470-2045(13)70334-6; Heys SD, 2005, BREAST CANCER RES TR, V90, P169, DOI 10.1007/s10549-004-1001-0; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Huober J, 2019, EUR J CANCER, V118, P169, DOI 10.1016/j.ejca.2019.04.038; Huober J, 2013, EUR J CANCER, V49, P2284, DOI 10.1016/j.ejca.2013.02.027; Hurvitz SA, 2019, J CLIN ONCOL, V37, P2206, DOI 10.1200/JCO.19.00882; Iwase M, 2020, BREAST CANCER RES TR, V180, P687, DOI 10.1007/s10549-020-05580-y; Jackisch C, 2016, EUR J CANCER, V62, P62, DOI 10.1016/j.ejca.2016.03.087; Jovanovic B, 2017, CLIN CANCER RES, V23, P4035, DOI 10.1158/1078-0432.CCR-16-3055; Kaufmann M, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.537; Kelly CM, 2012, J CLIN ONCOL, V30, P930, DOI 10.1200/JCO.2011.36.2079; Korn EL, 2005, STAT MED, V24, P163, DOI 10.1002/sim.1779; Lee KS, 2008, BREAST CANCER RES TR, V109, P481, DOI 10.1007/s10549-007-9672-y; Lenzer J, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2059; Loibl S, 2018, ANN ONCOL, V29, P2341, DOI 10.1093/annonc/mdy460; Mansi JL, 2010, BREAST CANCER RES TR, V122, P787, DOI 10.1007/s10549-010-0989-6; Masuda N, 2017, NEW ENGL J MED, V376, P2147, DOI 10.1056/NEJMoa1612645; Menzies AM, 2021, NAT MED, V27, P301, DOI 10.1038/s41591-020-01188-3; Mittendorf EA, 2020, LANCET, V396, P1090, DOI 10.1016/S0140-6736(20)31953-X; Nahleh ZA, 2016, BREAST CANCER RES TR, V158, P485, DOI 10.1007/s10549-016-3889-6; Cortes-Flores AO, 2008, CIR CIR, V76, P23; Pivot X, 2018, EUR J CANCER, V93, P19, DOI 10.1016/j.ejca.2018.01.072; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Robidoux A, 2013, LANCET ONCOL, V14, P1183, DOI 10.1016/S1470-2045(13)70411-X; Rose BS, 2016, J CLIN ONCOL, V34, P3959, DOI 10.1200/JCO.2016.68.1718; Saad ED, 2019, LANCET ONCOL, V20, P361, DOI 10.1016/S1470-2045(18)30750-2; Sargent DJ, 2005, J CLIN ONCOL, V23, P8664, DOI 10.1200/JCO.2005.01.6071; Schmid P, 2020, NEW ENGL J MED, V382, P810, DOI 10.1056/NEJMoa1910549; Schneeweiss A, 2020, ANN ONCOL, V31, pS303, DOI 10.1016/j.annonc.2020.08.282; Schneeweiss A, 2011, ANN ONCOL, V22, P609, DOI 10.1093/annonc/mdq400; Schneeweiss A, 2012, J CLIN ONCOL, V30; Sikov WM, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-S2-05; Sikov WM, 2015, J CLIN ONCOL, V33, P13, DOI 10.1200/JCO.2014.57.0572; Smith IC, 2002, J CLIN ONCOL, V20, P1456, DOI 10.1200/JCO.20.6.1456; Smith IE, 2004, ANN ONCOL, V15, P751, DOI 10.1093/annonc/mdh175; Stebbing J, 2017, LANCET ONCOL, V18, P917, DOI 10.1016/S1470-2045(17)30434-5; Symmans WF, 2021, JAMA ONCOL, V7, P1654, DOI 10.1001/jamaoncol.2021.3690; Therasse P, 2003, J CLIN ONCOL, V21, P843, DOI 10.1200/JCO.2003.05.135; Toi M, 2012, CANCER RES, V72, DOI [10.1158/0008-5472.sabcs12- p1-14-02, DOI 10.1158/0008-5472.SABCS12-P1-14-02, 10.1158/0008-5472.SABCS12-P1-14-02]; Untch M, 2011, ANN ONCOL, V22, P1988, DOI 10.1093/annonc/mdq709; Untch M, 2011, ANN ONCOL, V22, P1999, DOI 10.1093/annonc/mdq713; Untch M, 2019, J CLIN ONCOL, V37, P2226, DOI 10.1200/JCO.18.01842; Untch M, 2018, J CLIN ONCOL, V36, P1308, DOI 10.1200/JCO.2017.75.9175; Untch M, 2016, LANCET ONCOL, V17, P345, DOI 10.1016/S1470-2045(15)00542-2; Untch M, 2009, J CLIN ONCOL, V27, P2938, DOI 10.1200/JCO.2008.20.3133; US Department of Health and Human Services, US FOOD DRUG ADM CTR; van Ramshorst MS, 2018, LANCET ONCOL, V19, P1630, DOI 10.1016/S1470-2045(18)30570-9; von Minckwitz G, 2019, NEW ENGL J MED, V380, P617, DOI 10.1056/NEJMoa1814017; von Minckwitz G, 2014, ANN ONCOL, V25, P2363, DOI 10.1093/annonc/mdu455; von Minckwitz G, 2014, ANN ONCOL, V25, P81, DOI 10.1093/annonc/mdt410; von Minckwitz G, 2008, JNCI-J NATL CANCER I, V100, P542, DOI 10.1093/jnci/djn085; von Minckwitz G, 2014, LANCET ONCOL, V15, P747, DOI 10.1016/S1470-2045(14)70160-3; von Minckwitz G, 2013, J CLIN ONCOL, V31, P3623, DOI 10.1200/JCO.2012.45.0940; von Minckwitz G, 2010, J CLIN ONCOL, V28, P2015, DOI 10.1200/JCO.2009.23.8303; Vriens BEPJ, 2017, BREAST CANCER RES TR, V165, P593, DOI 10.1007/s10549-017-4364-8; Walker LG, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-179; Xie WL, 2019, JNCI CANCER SPECT, V3, DOI 10.1093/jncics/pkz002; Yau C, 2019, 2019 SAN ANT BREAST	97	12	12	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 21	2021	375								e066381	10.1136/bmj-2021-066381	http://dx.doi.org/10.1136/bmj-2021-066381			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP9AR	34933868	Green Published, hybrid			2023-01-03	WOS:000748911700007
J	Lundgren, JD; Gottlieb, RL; Sandkovsky, U; Brown, SM; Baker, JV; Ginde, AA; Chang, CC; Goodman, AL; Higgs, ES; Murray, DD; Murray, TA; Paredes, R; Phillips, AN; Cao, H; Babiker, AG; Davey, VJ; Gelijns, AC; Kan, VL; Polizzotto, MN; Thompson, BT; Lane, HC; Neaton, JD				Lundgren, J. D.; Gottlieb, R. L.; Sandkovsky, U.; Brown, S. M.; Baker, J., V; Ginde, A. A.; Chang, C. C.; Goodman, A. L.; Higgs, E. S.; Murray, D. D.; Murray, T. A.; Paredes, R.; Phillips, A. N.; Cao, H.; Babiker, A. G.; Davey, V. J.; Gelijns, A. C.; Kan, V. L.; Polizzotto, M. N.; Thompson, B. T.; Lane, H. C.; Neaton, J. D.		ACTIV-3 TICO Bamlanivimab Study Gr	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels A Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article								Background: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on an early futility assessment. Objective: To evaluate the a priori hypothesis that bamlanivimab has greater benefit in patients without detectable levels of endogenous neutralizing antibody (nAb) at study entry than in those with antibodies, especially if viral levels are high. Design: Randomized, placebo-controlled trial. (ClinicalTrials.gov: NCT04501978) Setting: Multicenter trial. Patients: Hospitalized patients with COVID-19 without endorgan failure. Intervention: Bamlanivimab (7000 mg) or placebo. Measurements: Antibody, antigen, and viral RNA levels were centrally measured on stored specimens collected at baseline. Patients were followed for 90 days for sustained recovery (defined as discharge to home and remaining home for 14 consecutive days) and a composite safety outcome (death, serious adverse events, organ failure, or serious infections). Results: Among 314 participants (163 receiving bamlanivimab and 151 placebo), the median time to sustained recovery was 19 days and did not differ between the bamlanivimab and placebo groups (subhazard ratio [sHR], 0.99 [95% CI, 0.79 to 1.22]; sHR> 1 favors bamlanivimab). At entry, 50% evidenced production of anti-spike nAbs; 50% had SARS-CoV-2 nucleocapsid plasma antigen levels of at least 1000 ng/L. Among those without and with nAbs at study entry, the sHRs were 1.24 (CI, 0.90 to 1.70) and 0.74 (CI, 0.54 to 1.00), respectively (nominal P for interaction = 0.018). The sHR (bamlanivimab vs. placebo) was also more than 1 for those with plasma antigen or nasal viral RNA levels above median level at entry and was greatest for those without antibodies and with elevated levels of antigen (sHR, 1.48 [CI, 0.99 to 2.23]) or viral RNA (sHR, 1.89 [CI, 1.23 to 2.91]). Hazard ratios for the composite safety outcome (<1 favors bamlanivimab) also differed by serostatus at entry: 0.67 (CI, 0.37 to 1.20) for those without and 1.79 (CI, 0.92 to 3.48) for those with nAbs. Limitation: Subgroup analysis of a trial prematurely stopped because of futility; small sample size; multiple subgroups analyzed. Conclusion: Efficacy and safety of bamlanivimab may differ depending on whether an endogenous nAb response has been mounted. The limited sample size of the study does not allow firm conclusions based on these findings, and further independent trials are required that assess other types of passive immune therapies in the same patient setting.			Lundgren, JD (corresponding author), Univ Copenhagen, Rigshosp, CHIP Ctr Excellence Hlth Immun & Infect, Dept Infect Dis, Copenhagen, Denmark.	jens.lundgren@regionh.dk	Holland, Thomas/AAA-6096-2022; Lundgren, Jens/AAE-6876-2019; Chia, Po Ying/GSD-9737-2022; Chia, Po Ying/AAN-9657-2020; Gottlieb, Robert/AAM-8310-2020; Brown, Samuel/E-6846-2015	Chia, Po Ying/0000-0002-8797-9527; Chia, Po Ying/0000-0002-8797-9527; Gottlieb, Robert/0000-0001-8376-8709; Staerke, Nina Breinholt/0000-0002-5834-2033; Jensen, Jens Ulrik/0000-0003-4036-0521; Mateu, Lourdes/0000-0001-7223-7611; Ashktorab, Kimia/0000-0001-6262-7560; Benfield, Thomas/0000-0003-0698-9385; Sendra Alvarez de Cienfuegos, Elena/0000-0002-4374-2173; Lundgren, Jens/0000-0001-8901-7850; johansen, isik somuncu/0000-0002-2189-9823; Barkauskas, Christina/0000-0001-8793-9050; Holland, Thomas/0000-0001-7745-9010; Knowlton, Kirk/0000-0003-3544-4130; Ostergaard, Lars/0000-0003-2459-0511; Imamichi, Tomozumi/0000-0002-1474-1796; Chang, Christina Catherine/0000-0003-0109-0725; Chen, Peter/0000-0002-5330-1718; Gibbs, Kevin/0000-0002-5272-2289; Files, Daniel Clark/0000-0002-1595-4080; Douglas, Ivor/0000-0002-4541-1431; Mayer, Kirby/0000-0003-3844-3846; Jain, Mamta/0000-0003-2292-6544; Brown, Samuel/0000-0003-1206-6261; Self, Wesley/0000-0002-9300-3045; Ong, Sean/0000-0002-8570-436X	Operation Warp Speed of the U.S. government; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [U01-AI136780]; Division of Clinical Research [HHSN261200800001E]; Leidos Biomedical Research; National Institutes of Health from the National Heart, Lung, and Blood Institute [10T2HL156812-01]; Research Triangle Institute; U.S. Department of Veterans Affairs; government of Denmark (National Research Foundation) [126]; government of Australia (National Health and Medical Research Council); government of United Kingdom (Medical Research Council) [MRC_UU_12023/23]	Operation Warp Speed of the U.S. government; National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Division of Clinical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Leidos Biomedical Research; National Institutes of Health from the National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Research Triangle Institute; U.S. Department of Veterans Affairs(US Department of Veterans Affairs); government of Denmark (National Research Foundation); government of Australia (National Health and Medical Research Council); government of United Kingdom (Medical Research Council)	The trial was primarily funded by Operation Warp Speed of the U.S. government, with the support of grant U01-AI136780 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; contract HHSN261200800001E from the Division of Clinical Research and Leidos Biomedical Research for the INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) Network; and National Institutes of Health agreement 10T2HL156812-01 from the National Heart, Lung, and Blood Institute and the Research Triangle Institute for the PETAL (Prevention & Early Treatment of Acute Lung Injury) Network and CTSN (Cardiothoracic Surgical Trials Network). Other funding and support were provided by the U.S. Department of Veterans Affairs and the governments of Denmark (National Research Foundation grant no. 126), Australia (National Health and Medical Research Council), and the United Kingdom (Medical Research Council [MRC_UU_12023/23]). Study medications were donated by Gilead Sciences and Eli Lilly.	AALEN OO, 1978, SCAND J STAT, V5, P141; ACTIV-3 TICO LY-CoV555 Study Grp, 2021, NEW ENGL J MED, V384, P905, DOI 10.1056/NEJMoa2033130; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Chen RE, 2021, NATURE, V596, P103, DOI 10.1038/s41586-021-03720-y; Cohen MS, 2021, JAMA-J AM MED ASSOC, V326, P46, DOI [10.1001/jama.2021.88282021., 10.1001/jama.2021.8828]; DONG J, NAT MICROBIOL, V6, P1233; Dougan M, 2021, 2021 C RETR OPP INF; Fajnzylber J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19057-5; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; GUPTA A, NEW ENGL J MED, V2021; Horby PW, 2021, LANCET, V397, P2049, DOI 10.1016/S0140-6736(21)00897-7; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Jones BE, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1906; Li L, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-020-02693-2; MURRAY DD, CLIN TRIALS, V2021; National Institutes of Health, ACC COVID 19 THER IN; O'Brien Meagan P, 2021, medRxiv, DOI 10.1101/2021.06.14.21258567; O'Donnell MR, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150646; Shan D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22072-9; Starr Tyler N, 2021, Cell Rep Med, V2, P100255, DOI [10.1101/2021.02.17.431683, 10.1016/j.xcrm.2021.100255]; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; U.S. Food and Drug Administration, 2021, COR COVID 19 UPD FDA; US FDA, 2020, COR COVID 19 UPD FDA; Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163; Zhou BQ, 2011, BIOMETRICS, V67, P661, DOI 10.1111/j.1541-0420.2010.01493.x	27	18	18	7	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB	2022	175	2					234	+		10.7326/M21-3507	http://dx.doi.org/10.7326/M21-3507		DEC 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE4HR	34928698	Green Accepted			2023-01-03	WOS:000734195900001
J	Cwalina, SN; McConnell, R; Benowitz, NL; Barrington-Trimis, JL				Cwalina, Sam N.; McConnell, Rob; Benowitz, Neal L.; Barrington-Trimis, Jessica L.			Tobacco-free Nicotine - New Name, Same Scheme?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Tobacco-free Nicotine - New Name, Same Scheme? E-cigarettes that claim to contain "tobacco-free" synthetic nicotine - nicotine that isn't derived from tobacco - are proliferating. Such products may threaten ongoing public health efforts to reduce e-cigarette use among adolescents and young adults.	[Cwalina, Sam N.; McConnell, Rob; Barrington-Trimis, Jessica L.] Univ Southern Calif, Keck Sch Med, Dept Populat & Publ Hlth Sci, Los Angeles, CA 90007 USA; [Benowitz, Neal L.] Univ Calif San Francisco, Div Cardiol, Clin Pharmacol Program, Dept Med, San Francisco, CA 94143 USA	University of Southern California; University of California System; University of California San Francisco	Cwalina, SN (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Populat & Publ Hlth Sci, Los Angeles, CA 90007 USA.			Cwalina, Sam/0000-0002-0117-3275				[Anonymous], 2021, LIT REL REG NOV EM N; Hellinghausen G, 2017, DRUG TEST ANAL, V9, P944, DOI 10.1002/dta.2145; Hukkanen J, 2005, PHARMACOL REV, V57, P79, DOI 10.1124/pr.57.1.3; Miech R, 2019, NEW ENGL J MED, V380, P192, DOI 10.1056/NEJMc1814130; Wang TW, 2020, MMWR-MORBID MORTAL W, V69, P1310, DOI 10.15585/mmwr.mm6937e1	5	4	4	2	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	2021	385	26					2406	2408		10.1056/NEJMp2111159	http://dx.doi.org/10.1056/NEJMp2111159		DEC 2021	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XS4FC	34919358	Green Accepted			2023-01-03	WOS:000731334400001
J	Kang, J; Choi, EK; Seo, M; Ahn, GS; Park, HY; Hong, J; Kim, MS; Keam, B; Park, HY				Kang, Jiyeon; Choi, Eun Kyung; Seo, Minjeong; Ahn, Grace S.; Park, Hye Youn; Hong, Jinui; Kim, Min Sun; Keam, Bhumsuk; Park, Hye Yoon			Care for critically and terminally ill patients and moral distress of physicians and nurses in tertiary hospitals in South Korea: A qualitative study	PLOS ONE			English	Article							OF-LIFE CARE; NURSING-CARE; END; STAFF; CHALLENGES; FAMILIES; CULTURE; ISSUES; VIEWS	Physicians and nurses working in acute care settings, such as tertiary hospitals, are involved in various stages of critical and terminal care, ranging from diagnosis of life-threatening diseases to care for the dying. It is well known that critical and terminal care causes moral distress to healthcare professionals. This study aimed to explore moral distress in critical and terminal care in acute hospital settings by analyzing the experiences of physicians and nurses from various departments. Semi-structured in-depth interviews were conducted in two tertiary hospitals in South Korea. The collected data were analyzed using grounded theory. A total of 22 physicians and nurses who had experienced moral difficulties regarding critical and terminal care were recruited via purposive maximum variation sampling, and 21 reported moral distress. The following points were what participants believed to be right for the patients: minimizing meaningless interventions during the terminal stage, letting patients know of their poor prognosis, saving lives, offering palliative care, and providing care with compassion. However, family dominance, hierarchy, the clinical culture of avoiding the discussion of death, lack of support for the surviving patients, and intensive workload challenged what the participants were pursuing and frustrated them. As a result, the participants experienced stress, lack of enthusiasm, guilt, depression, and skepticism. This study revealed that healthcare professionals working in tertiary hospitals in South Korea experienced moral distress when taking care of critically and terminally ill patients, in similar ways to the medical staff working in other settings. On the other hand, the present study uniquely identified that the aspects of saving lives and the necessity of palliative care were reported as those valued by healthcare professionals. This study contributes to the literature by adding data collected from two tertiary hospitals in South Korea.	[Kang, Jiyeon] Seoul Natl Univ, Dept Anthropol, Seoul, South Korea; [Choi, Eun Kyung] Kyungpook Natl Univ, Sch Med, Med Educ Ctr, Daegu, South Korea; [Seo, Minjeong] Gyeongsang Natl Univ, Coll Nursing, Jinju, Gyeongsangnamdo, South Korea; [Seo, Minjeong] Gyeongsang Natl Univ, Gerontol Hlth Res Ctr Inst Hlth Sci, Jinju, Gyeongsangnamdo, South Korea; [Ahn, Grace S.] Univ Calif San Diego, Sch Med, La Jolla, CA USA; [Park, Hye Youn] Seoul Natl Univ, Dept Neuropsychiatry, Bundang Hosp, Seoul, South Korea; [Hong, Jinui; Kim, Min Sun; Keam, Bhumsuk; Park, Hye Yoon] Seoul Natl Univ Hosp, Ctr Palliat Care & Clin Ethics, Seoul, South Korea; [Kim, Min Sun] Seoul Natl Univ Hosp, Dept Pediat, Seoul, South Korea; [Keam, Bhumsuk] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; [Park, Hye Yoon] Seoul Natl Univ Hosp, Dept Psychiat, Seoul, South Korea; [Park, Hye Yoon] Seoul Natl Univ, Dept Psychiat, Coll Med, Seoul, South Korea	Seoul National University (SNU); Kyungpook National University; Gyeongsang National University; Gyeongsang National University; University of California System; University of California San Diego; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Park, HY (corresponding author), Seoul Natl Univ Hosp, Ctr Palliat Care & Clin Ethics, Seoul, South Korea.; Park, HY (corresponding author), Seoul Natl Univ Hosp, Dept Psychiat, Seoul, South Korea.; Park, HY (corresponding author), Seoul Natl Univ, Dept Psychiat, Coll Med, Seoul, South Korea.	psychepark@gmail.com		Choi, Eun Kyung/0000-0003-1448-1565				[Anonymous], 2020, MMWR Morb Mortal Wkly Rep, V69, P611, DOI 10.15585/mmwr.mm6919a4; Bergenholtz H, 2015, INT J PALLIAT NURS, V21, P193, DOI 10.12968/ijpn.2015.21.4.193; Bernard H.R, 2017, RES METHODS ANTHR QU, Vsixth; Bloomer MJ, 2013, PALLIATIVE MED, V27, P757, DOI 10.1177/0269216313477176; Broad JB, 2013, INT J PUBLIC HEALTH, V58, P257, DOI 10.1007/s00038-012-0394-5; Cheon J, 2015, J HOSP PALLIAT NURS, V17, P7, DOI 10.1097/NJH.0000000000000129; Copp G, 1993, Palliat Med, V7, P19, DOI 10.1177/026921639300700104; Davis S, 2003, CANCER NURS, V26, P337, DOI 10.1097/00002820-200310000-00001; Dzeng E, 2016, J GEN INTERN MED, V31, P93, DOI 10.1007/s11606-015-3505-1; Elpern EH, 2005, AM J CRIT CARE, V14, P523, DOI 10.4037/ajcc2005.14.6.523; Flannery L, 2016, AUST CRIT CARE, V29, P97, DOI 10.1016/j.aucc.2015.07.004; Gallagher K, 2012, INT J PALLIAT NURS, V18, P197, DOI 10.12968/ijpn.2012.18.4.197; Henrich NJ, 2016, J CRIT CARE, V35, P57, DOI 10.1016/j.jcrc.2016.04.033; Heyland DK, 2005, J PALLIATIVE CARE, V21, P142, DOI 10.1177/082585970502100306; Jameton A, 1993, AWHONNS Clin Issues Perinat Womens Health Nurs, V4, P542; Johnson-Coyle Leah, 2016, Can J Crit Care Nurs, V27, P27; Jung KH., 2018, ENSURING DIGNITY OLD; K Jung Hye, 2015, [The Korean Journal of Hospice and Palliative Care, 한국호스피스완화의료학회지], V18, P179, DOI 10.14475/kjhpc.2015.18.3.179; Lamiani G, 2017, J HEALTH PSYCHOL, V22, P51, DOI 10.1177/1359105315595120; Long SO, DEATH DYING CONT JAP; McCourt R, 2013, INT J PALLIAT NURS, V19, P509, DOI 10.12968/ijpn.2013.19.10.510; Midson R, 2010, J CHILD HEALTH CARE, V14, P52, DOI 10.1177/1367493509347060; O'Hara T, 2011, INT J PALLIAT NURS, V17, P239, DOI 10.12968/ijpn.2011.17.5.239; Patton M.Q., 2014, UTILIZATION FOCUSED, V4th; Pavlish C, 2015, CLIN J ONCOL NURS, V19, P159, DOI 10.1188/15.CJON.19-02AP; Piers RD, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2010.12.014; Prentice TM, 2018, J BIOETHIC INQ, V15, P259, DOI 10.1007/s11673-018-9847-8; Rainer J, 2018, J CLIN NURS, V27, P3446, DOI 10.1111/jocn.14542; Rosenthal M Sara, 2017, AMA J Ethics, V19, P585, DOI 10.1001/journalofethics.2017.19.6.stas1-1706; Rosenwax LK, 2011, MED J AUSTRALIA, V194, P570, DOI 10.5694/j.1326-5377.2011.tb03106.x; Sanderson C, 2019, CLIN ETHICS, V14, P195, DOI [10.1177/1477750919886088, DOI 10.1177/1477750919886088]; Siddiqui Shahla, 2016, J Emerg Med, V51, P748, DOI 10.1016/j.jemermed.2016.07.084; St Ledger U, 2013, J ADV NURS, V69, P1869, DOI 10.1111/jan.12053; Strauss A., 1997, GROUNDED THEORY PRAC; Traudt Terri, 2016, J Clin Ethics, V27, P201; Virdun C, 2015, PALLIATIVE MED, V29, P774, DOI 10.1177/0269216315583032; Whitehead PB, 2015, J NURS SCHOLARSHIP, V47, P117, DOI 10.1111/jnu.12115; Willard C, 2006, PALLIATIVE MED, V20, P611, DOI 10.1177/0269216306071064; Yang GM, 2012, PALLIATIVE MED, V26, P1011, DOI 10.1177/0269216311425097; Young A, 2017, PALLIATIVE MED, V31, P853, DOI 10.1177/0269216316682894; 경민호, 2010, [The Korean Journal of Hospice and Palliative Care, 한국호스피스완화의료학회지], V13, P143	41	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2021	16	12							e0260343	10.1371/journal.pone.0260343	http://dx.doi.org/10.1371/journal.pone.0260343			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY9FU	34914723	Green Published, gold			2023-01-03	WOS:000755091500023
J	Dargaville, PA; Kamlin, COF; Orsini, F; Wang, XF; De Paoli, AG; Kutman, HGK; Cetinkaya, M; Kornhauser-Cerar, L; Derrick, M; Ozkan, H; Hulzebos, CV; Schmolzer, GM; Aiyappan, A; Lemyre, B; Kuo, S; Rajadurai, VS; O'Shea, J; Biniwale, M; Ramanathan, R; Kushnir, A; Bader, D; Thomas, MR; Chakraborty, M; Buksh, MJ; Bhatia, R; Sullivan, CL; Shinwell, ES; Dyson, A; Barker, DP; Kugelman, A; Donovan, TJ; Tauscher, MK; Murthy, V; Ali, SKM; Yossuck, P; Clark, HW; Soll, RF; Carlin, JB; Davis, PG				Dargaville, Peter A.; Kamlin, C. Omar F.; Orsini, Francesca; Wang, Xiaofang; De Paoli, Antonio G.; Kutman, H. Gozde Kanmaz; Cetinkaya, Merih; Kornhauser-Cerar, Lilijana; Derrick, Matthew; Ozkan, Hilal; Hulzebos, Christian, V; Schmolzer, Georg M.; Aiyappan, Ajit; Lemyre, Brigitte; Kuo, Sheree; Rajadurai, Victor S.; O'Shea, Joyce; Biniwale, Manoj; Ramanathan, Rangasamy; Kushnir, Alla; Bader, David; Thomas, Mark R.; Chakraborty, Mallinath; Buksh, Mariam J.; Bhatia, Risha; Sullivan, Carol L.; Shinwell, Eric S.; Dyson, Amanda; Barker, David P.; Kugelman, Amir; Donovan, Tim J.; Tauscher, Markus K.; Murthy, Vadivelam; Ali, Sanoj K. M.; Yossuck, Pete; Clark, Howard W.; Soll, Roger F.; Carlin, John B.; Davis, Peter G.		OPTIMIST-A Trial Investigators	Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome The OPTIMIST-A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NASAL CPAP; BIRTH; VENTILATION; MANAGEMENT; FAILURE; IMPACT	IMPORTANCE The benefits of surfactant administration via a thin catheter (minimally invasive surfactant therapy [MIST]) in preterm infants with respiratory distress syndrome are uncertain. OBJECTIVE To examine the effect of selective application of MIST at a low fraction of inspired oxygen threshold on survival without bronchopulmonary dysplasia (BPD). DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial including 485 preterm infants with a gestational age of 25 to 28 weeks who were supported with continuous positive airway pressure (CPAP) and required a fraction of inspired oxygen of 0.30 or greater within 6 hours of birth. The trial was conducted at 33 tertiary-level neonatal intensive care units around the world, with blinding of the clinicians and outcome assessors. Enrollment took place between December 16, 2011, and March 26, 2020; follow-up was completed on December 2, 2020. INTERVENTIONS Infants were randomized to the MIST group (n = 241) and received exogenous surfactant (200 mg/kg of poractant alfa) via a thin catheter or to the control group (n = 244) and received a sham (control) treatment; CPAP was continued thereafter in both groups unless specified intubation criteria were met. MAIN OUTCOMES AND MEASURES The primary outcome was the composite of death or physiological BPD assessed at 36 weeks' postmenstrual age. The components of the primary outcome (death prior to 36 weeks' postmenstrual age and BPD at 36 weeks' postmenstrual age) also were considered separately. RESULTS Among the 485 infants randomized (median gestational age, 27.3 weeks; 241 [49.7%] female), all completed follow-up. Death or BPD occurred in 105 infants (43.6%) in the MIST group and 121 (49.6%) in the control group (risk difference [RD], -63% [95% CI, -14.2% to 1.6%); relative risk [RR], 0.87 [95% CI, 0.74 to 1.03]; P = .10). Incidence of death before 36 weeks' postmenstrual age did not differ significantly between groups (24 [10.0%) in MIST vs 19 [7.8%) in control; RD, 2.1% [95% CI, -3.6% to 7.8%); RR, 1.27 [95% CI, 0.63 to 2.57]; P = .51), but incidence of BPD in survivors to 36 weeks' postmenstrual age was lower in the MIST group (81/217 [37.3%] vs 102/225 [45.3%) in the control group; RD, -7.8% [95% CI, -14.9% to -0.7%); RR. 0.83 [95% CI, 0.70 to 0.98]; P = .03). Serious adverse events occurred in 10.3% of infants in the MIST group and 11.1% in the control group. CONCLUSIONS AND RELEVANCE Among preterm infants with respiratory distress syndrome supported with CPAP, minimally invasive surfactant therapy compared with sham (control) treatment did not significantly reduce the incidence of the composite outcome of death or bronchopulmonary dysplasia at 36 weeks' postmenstrual age. However, given the statistical uncertainty reflected in the 95% CI, a clinically important effect cannot be excluded. (C) 2021 American Medical Association. All rights reserved.	[Dargaville, Peter A.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia; [Dargaville, Peter A.; De Paoli, Antonio G.] Royal Hobart Hosp, Dept Paediat, 48 Liverpool St, Hobart, Tas 7000, Australia; [Kamlin, C. Omar F.; Davis, Peter G.] Royal Womens Hosp, Neonatal Serv, Melbourne, Vic, Australia; [Kamlin, C. Omar F.; Davis, Peter G.] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia; [Orsini, Francesca; Wang, Xiaofang; Carlin, John B.] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia; [Kutman, H. Gozde Kanmaz] Zekai Tahir Burak Matern Teaching Hosp, Dept Neonatol, Ankara, Turkey; [Cetinkaya, Merih] Istanbul Kanuni Sultan Suleyman Training & Res Ho, Dept Pediat, Div Neonatol, Istanbul, Turkey; [Kornhauser-Cerar, Lilijana] Univ Med Ctr, Dept Perinatol, Div Gynaecol & Obstet, Ljubljana, Slovenia; [Derrick, Matthew] NorthShore Univ Hlth Syst, Div Neonatol, Evanston, IL USA; [Ozkan, Hilal] Uludag Univ, Dept Pediat, Div Neonatol, Fac Med, Bursa, Turkey; [Hulzebos, Christian, V] Univ Med Ctr Groningen, Beatrix Childrens Hosp, Div Neonatol, Groningen, Netherlands; [Schmolzer, Georg M.] Univ Alberta, Dept Pediat, Div Neonatol, Edmonton, AB, Canada; [Aiyappan, Ajit] Mercy Hosp Women, Neonatal Serv, Heidelberg, Vic, Australia; [Lemyre, Brigitte] Ottawa Hosp, Dept Obstet Gynecol & Newborn Care, Ottawa, ON, Canada; [Kuo, Sheree] Kapiolani Med Ctr Women & Children, Dept Pediat, Honolulu, HI USA; [Rajadurai, Victor S.] Duke NUS Med Sch, KK Womens & Childrens Hosp, Dept Neonatol, Singapore, Singapore; [O'Shea, Joyce] Royal Hosp Children, Neonatal Unit, Glasgow, Lanark, Scotland; [Biniwale, Manoj; Ramanathan, Rangasamy] USC, Keck Sch Med, Dept Pediat, Div Neonatol,LAC USC Med Ctr, Los Angeles, CA USA; [Biniwale, Manoj; Ramanathan, Rangasamy] USC, Keck Sch Med, Good Samaritan Hosp, Los Angeles, CA USA; [Kushnir, Alla] Cooper Univ Hlth Care, Childrens Reg Hosp, Dept Pediat, Camden, NJ USA; [Bader, David] Technion Israel Inst Technol, Bnai Zion Med Ctr, Rappaport Fac Med, Dept Neonatol, Haifa, Israel; [Thomas, Mark R.] Chelsea & Westminster Hosp NHS Fdn Trust, Dept Neonatal Med, London, England; [Chakraborty, Mallinath] Univ Hosp Wales, Reg Neonatal Intens Care Unit, Cardiff, Wales; [Buksh, Mariam J.] Auckland Hosp, Newborn Serv, Starship Child Hlth, Auckland, New Zealand; [Bhatia, Risha] Monash Childrens Hosp, Monash Newborn, Clayton, Vic, Australia; [Sullivan, Carol L.] Singleton Hosp, Dept Neonatol, Swansea, W Glam, Wales; [Shinwell, Eric S.] Bar Ilan Univ, Fac Med, Ziv Med Ctr, Dept Neonatol, Safed, Israel; [Dyson, Amanda] Canberra Hosp, Centenary Hosp Women & Children, Dept Neonatol, Woden, ACT, Australia; [Barker, David P.] Dunedin Publ Hosp, Neonatal Intens Care Unit, Dunedin, New Zealand; [Kugelman, Amir] Technion Israel Inst Technol, Rambam Med Ctr, Rappaport Fac Med, Dept Neonatol, Haifa, Israel; [Donovan, Tim J.] Royal Brisbane & Womens Hosp, Div Neonatol, Brisbane, Qld, Australia; [Tauscher, Markus K.] Peyton Manning Childrens Hosp, Div Neonatol, Ascension St Vincent, Indiana, PA USA; [Murthy, Vadivelam] Barts Hlth NHS Fdn Trust, Neonatal Intens Care Ctr, Royal London Hosp, London, England; [Ali, Sanoj K. M.] Sidra Med, Div Neonatol, Doha, Qatar; [Yossuck, Pete] WVU Med Childrens Hosp, Dept Pediat, Morgantown, WV USA; [Clark, Howard W.] Princess Anne Hosp, Neonatal Intens Care Unit, Southampton, Hants, England; [Clark, Howard W.] UCL, Fac Populat Hlth Sci, Ega Inst Womens Hlth, Dept Neonatol, London, England; [Soll, Roger F.] Univ Vermont, Larner Coll Med, Div Neonatal Perinatal Medidne, Burlington, VT USA; [Carlin, John B.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	University of Tasmania; Menzies Institute for Medical Research; Royal Hobart Hospital; University of Melbourne; Murdoch Children's Research Institute; Dr. Zekai Tahir Burak Women's Health Research & Education Hospital; Istanbul Kanuni Sultan Suleyman Training & Research Hospital; University Medical Centre Ljubljana; NorthShore University Health System; Uludag University; University of Groningen; University of Alberta; University of Ottawa; Ottawa Hospital Research Institute; KK Women's & Children's Hospital; National University of Singapore; Los Angeles County+USC Medical Center; University of Southern California; University of Southern California Keck Hospital; University of Southern California; University of Southern California Keck Hospital; Bnai Zion Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Imperial College London; Cardiff University; Auckland City Hospital; Starship Children's Hospital; Singleton Hospital; Bar Ilan University; Ziv Medical Center; Australian National University; Canberra Hospital; Dunedin Public Hospital; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Royal Brisbane & Women's Hospital; Barts Health NHS Trust; Royal London Hospital; Sidra Medical & Research Center; University of London; University College London; University of Vermont; University of Melbourne	Dargaville, PA (corresponding author), Royal Hobart Hosp, Dept Paediat, 48 Liverpool St, Hobart, Tas 7000, Australia.	peter.dargaville@ths.tas.gov.au	Kutman, Hayriye Gözde Kanmaz/AAH-9681-2021; Cetinkaya, Merih/AFP-9671-2022; Schmölzer, Georg M/E-7883-2010; Hulzebos, Christian Victor/AAY-6803-2021	Kutman, Hayriye Gözde Kanmaz/0000-0002-3177-9411; Schmölzer, Georg M/0000-0001-9798-2415; Hulzebos, Christian Victor/0000-0002-8159-7501; Ramanathan, Rangasamy/0000-0002-7358-601X; Wang, Xiaofang/0000-0003-3246-3205; Orsini, Francesca/0000-0001-5183-5946	Royal Hobart Hospital Research Foundation [11-382]; Australian National Health and Medical Research Council [1049114]	Royal Hobart Hospital Research Foundation; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This study was funded by grant 11-382 from the Royal Hobart Hospital Research Foundation and by grant 1049114 from the Australian National Health and Medical Research Council. Chiesi Farmaceutici provided the exogenous surfactant at reduced cost.	Abdel-Latif ME, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011672.pub2; Ammari A, 2005, J PEDIATR-US, V147, P341, DOI 10.1016/j.jpeds.2005.04.062; Carlo WA, 2014, PEDIATRICS, V133, P171, DOI 10.1542/peds.2013-3442; Dargaville PA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3985; Dargaville PA, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-213; Dargaville PA, 2013, NEONATOLOGY, V104, P8, DOI 10.1159/000346460; Dargaville PA, 2013, ARCH DIS CHILD-FETAL, V98, pF122, DOI 10.1136/archdischild-2011-301314; Dargaville PA, 2011, ARCH DIS CHILD-FETAL, V96, pF243, DOI 10.1136/adc.2010.192518; Dunn MS, 2011, PEDIATRICS, V128, pE1069, DOI 10.1542/peds.2010-3848; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Gopel W, 2011, LANCET, V378, P1627, DOI 10.1016/S0140-6736(11)60986-0; Isayama T, 2016, JAMA-J AM MED ASSOC, V316, P611, DOI 10.1001/jama.2016.10708; Jobe AH, 2019, PEDIATR RES, V86, P15, DOI 10.1038/s41390-019-0372-1; Jobe AH, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00049; Kanmaz HG, 2013, PEDIATRICS, V131, pE502, DOI 10.1542/peds.2012-0603; Kribs A, 2007, PEDIATR ANESTH, V17, P364, DOI 10.1111/j.1460-9592.2006.02126.x; Kribs A, 2015, JAMA PEDIATR, V169, P723, DOI 10.1001/jamapediatrics.2015.0504; Laughon MM, 2011, AM J RESP CRIT CARE, V183, P1715, DOI 10.1164/rccm.201101-0055OC; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Roberts KD, 2006, PEDIATRICS, V118, P1583, DOI 10.1542/peds.2006-0590; Sandri F, 2010, PEDIATRICS, V125, pE1402, DOI 10.1542/peds.2009-2131; Schmidt B, 2006, NEW ENGL J MED, V354, P2112, DOI 10.1056/NEJMoa054065; Schmidt B, 2003, JAMA-J AM MED ASSOC, V289, P1124, DOI 10.1001/jama.289.9.1124; Schmolzer GM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5980; Sweet DG, 2019, NEONATOLOGY, V115, P432, DOI 10.1159/000499361; Thebaud B, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0127-7; Vento M, 2019, NEONATOLOGY, V116, P211, DOI 10.1159/000502610; Walsh MC, 2004, PEDIATRICS, V114, P1305, DOI 10.1542/peds.2004-0204; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	30	24	24	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	2021	326	24					2478	2487		10.1001/jama.2021.21892	http://dx.doi.org/10.1001/jama.2021.21892		DEC 2021	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC6FM	34902013	Bronze, Green Published			2023-01-03	WOS:000731127100001
J	Gionfriddo, MR; Duboski, V; Middernacht, A; Kern, MS; Graham, J; Wright, EA				Gionfriddo, Michael R.; Duboski, Vanessa; Middernacht, Allison; Kern, Melissa S.; Graham, Jove; Wright, Eric A.			A mixed methods evaluation of medication reconciliation in the primary care setting	PLOS ONE			English	Article							IMPLEMENTATION; DISCREPANCIES	Objectives To understand the extent to which behaviors consistent with high quality medication reconciliation occurred in primary care settings and explore barriers to high quality medication reconciliation. Design Fully mixed sequential equal status design including ethnographic observations, semi-structured interviews, and surveys. Setting Primary care practices within an integrated healthcare delivery system in the United States. Participants We conducted 170 observations of patient encounters across 15 primary care clinics, 48 semi-structured interviews with staff, and 10 semi-structured interviews with patients. We also sent out surveys to 2,541 eligible staff with 616 responses (24% response rate) and to 5,132 eligible patients with 577 responses (11% response rate). Results Inconsistency emerged as a major barrier to effective medication reconciliation. This inconsistency was present across a variety of factors such as the lack of standardized workflows for conducting medication reconciliation, a lack of knowledge about medication and the process of medication reconciliation, varying levels of importance ascribed to medication reconciliation, and inadequate integration of medication reconciliation into clinical workflows. Findings were generally consistent across all data collection methods. Conclusion We have identified several barriers which impact the process of medication reconciliation in primary care settings. Our key finding is that the process of medication reconciliation is plagued by inconsistencies which contribute to inaccurate medication lists. These inconsistencies can be broken down into several categories (standardization, knowledge, importance, and inadequate integration) which can be targets for future studies and interventions.	[Gionfriddo, Michael R.; Duboski, Vanessa; Kern, Melissa S.; Graham, Jove; Wright, Eric A.] Geisinger, Ctr Pharm Innovat & Outcomes, Danville, PA 17822 USA; [Middernacht, Allison] Wilkes Univ, Sch Pharm, Wilkes Barre, PA 18766 USA; [Gionfriddo, Michael R.] Duquesne Univ, Sch Pharm, Div Pharmaceut Adm & Social Sci, Pittsburgh, PA 15219 USA	Wilkes University; Duquesne University	Gionfriddo, MR (corresponding author), Geisinger, Ctr Pharm Innovat & Outcomes, Danville, PA 17822 USA.; Gionfriddo, MR (corresponding author), Duquesne Univ, Sch Pharm, Div Pharmaceut Adm & Social Sci, Pittsburgh, PA 15219 USA.	gionfriddom@dug.edu	Gionfriddo, Michael/S-8359-2016	Gionfriddo, Michael/0000-0003-1391-7072	Geisinger Health Plan through the Geisinger Clinic Quality Pilot Fund program	Geisinger Health Plan through the Geisinger Clinic Quality Pilot Fund program	This work was funded by the Geisinger Health Plan through the Geisinger Clinic Quality Pilot Fund program for fiscal years 2020 and 2021. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson LJ, 2019, AM J HEALTH-SYST PH, V76, P2028, DOI 10.1093/ajhp/zxz236; Andrus Miranda R., 2012, Pharmacy Practice (Internet), V10, P78, DOI 10.4321/s1886-36552012000200003; Bayoumi I, 2009, ANN PHARMACOTHER, V43, P1667, DOI 10.1345/aph.1M059; Boockvar KS, 2009, QUAL SAF HEALTH CARE, V18, P32, DOI 10.1136/qshc.2007.025957; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Drenth-van Maanen AC, 2011, J AM GERIATR SOC, V59, P1976, DOI 10.1111/j.1532-5415.2011.03610_11.x; Dullabh P, 2014, DEMONSTRATING EFFECT; Freeman WJ, 2006, HEALTHCARE COST UTIL; Gardiner P, 2015, PATIENT EDUC COUNS, V98, P512, DOI 10.1016/j.pec.2014.12.010; Guisado-Gil AB, 2020, RES SOC ADMIN PHARM, V16, P995, DOI 10.1016/j.sapharm.2019.10.011; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Heyworth L, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2793; Johnson KL, 2018, J DENT EDUC, V82, P839, DOI 10.21815/JDE.018.078; Kongkaew C, 2008, ANN PHARMACOTHER, V42, P1017, DOI 10.1345/aph.1L037; Leech NL, 2009, QUAL QUANT, V43, P265, DOI 10.1007/s11135-007-9105-3; MARQUIS Investigators, 2014, MARQUIS IMPL MAN GUI; Najafzadeh M, 2016, AM J MANAG CARE, V22, P654; Nassaralla CL, 2009, QUAL SAF HEALTH CARE, V18, P402, DOI 10.1136/qshc.2007.024513; Nassaralla CL, 2007, QUAL SAF HEALTH CARE, V16, P90, DOI 10.1136/qshc.2006.021113; Penm J, 2019, RES SOC ADMIN PHARM, V15, P632, DOI 10.1016/j.sapharm.2018.07.020; Peyton L, 2010, J AM PHARM ASSOC, V50, P490, DOI 10.1331/JAPhA.2010.09055; Proctor E, 2011, ADM POLICY MENT HLTH, V38, P65, DOI 10.1007/s10488-010-0319-7; Rangachari P, 2019, QUAL MANAG HEALTH CA, V28, P84, DOI 10.1097/QMH.0000000000000208; Redmond P, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010791.pub2; Varkey P, 2007, JT COMM J QUAL PATIE, V33, P286, DOI 10.1016/S1553-7250(07)33033-X; Vogelsmeier A, 2013, RES SOC ADMIN PHARM, V9, P419, DOI 10.1016/j.sapharm.2012.08.002; World Health Organization, 2019, HIGH 5S STAND OP PRO	29	1	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2021	16	12							e0260882	10.1371/journal.pone.0260882	http://dx.doi.org/10.1371/journal.pone.0260882			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XW0CT	34855888	Green Published, gold			2023-01-03	WOS:000735299000146
J	Bharathithasan, M; Ravindran, DR; Rajendran, D; Chun, SK; Abbas, SA; Sugathan, S; Yahaya, ZS; Said, A; Oh, WD; Kotra, V; Mathews, A; Amin, MFM; Ishak, IH; Ravi, R				Bharathithasan, Madhuri; Ravindran, Darvin R.; Rajendran, Dinesh; Chun, Sim Ka; Abbas, S. A.; Sugathan, Sandheep; Yahaya, Zary Shariman; Said, Abd Rahman; Oh, Wen-Da; Kotra, Vijay; Mathews, Allan; Amin, Mohamad Faiz Mohd; Ishak, Intan H.; Ravi, Rajiv			Analysis of chemical compositions and larvicidal activity of nut extracts from Areca catechu Linn against Aedes (Diptera: Culicidae)	PLOS ONE			English	Article							AEGYPTI; RESISTANCE; ACID	Background There is a growing need to use green alternative larvicidal control for Aedes larvae compared to chemical insecticides. Substantial reliance on chemical insecticides caused insecticide resistance in mosquito populations. Thus, research for alternate chemical compounds from natural products is necessary to control Aedes larvae. This study explores the analysis of chemical compositions from Areca catechu nut as a potential larvicide for Aedes (Diptera: Culicidae). Methods The Areca catechu nut collected from Ipoh, Perak, Malaysia was grounded into powder and used for Soxhlet extraction. The chemical analysis of the extracts and their structures were identified using the GCMS-QP2010 Ultra (Shimadzu) system. National Institute of Standards and Technology (NIST) Chemistry WebBook, Standard Reference Database 69 (https://webbook.nist.gov/chemistry/) and PubChem (https://pubchem.ncbi.nlm.nih.gov/), the two databases used to retrieve the synonyms, molecular formula, molecular weight, and 2-dimensional (2D) structure of chemical compounds. Next, following WHO procedures for larval bioassays, the extracts were used to asses larvicidal activity against early 4th instar larvae of Aedes aegypti and Aedes albopictus. Results The larvicidal activities were observed against early 4th stage larvae with different concentrations in the range from 200 mg/L to 1600 mg/L. The LC50 and LC95 of Aedes aegypti were 621 mg/L and 2264 mg/L respectively; whereas the LC50 and LC95 of Aedes albopictus were 636 mg/L and 2268 mg/L respectively. Mortality was not observed in the non-target organism test. The analysis using gas chromatography and mass spectrometer recovered several chemical compounds such as Arecaidine, Dodecanoic acid, Methyl tetradecanoate, Tetradecanoic acid <n->, and n-Hexadecanoic acid bioactive components. These chemical constituents were used as additive formulations in pesticides, pest control, insect repellent, and insecticidal agents. Conclusions Our study showed significant outcomes from the extract of Areca catechu nut and it deserves further investigation in relation to chemical components and larvicidal actions between different species of Aedes mosquitoes. Even though all these findings are fundamental, it may have some interesting potentials to be developed as natural bio-larvicidal products.	[Bharathithasan, Madhuri; Chun, Sim Ka; Ravi, Rajiv] Quest Int Univ, Fac Integrated Life Sci, Sch Appl Sci, Ipoh, Perak, Malaysia; [Ravindran, Darvin R.; Sugathan, Sandheep; Said, Abd Rahman] Quest Int Univ, Fac Med, Ipoh, Perak, Malaysia; [Rajendran, Dinesh; Ishak, Intan H.] Univ Sains Malaysia, Sch Biol Sci, Insecticide Resistance Res Grp IRRG, Minden, Penang, Malaysia; [Rajendran, Dinesh; Yahaya, Zary Shariman; Ishak, Intan H.] Univ Sains Malaysia, Sch Biol Sci, Vector Control Res Unit, Minden, Penang, Malaysia; [Abbas, S. A.; Kotra, Vijay; Mathews, Allan] Quest Int Univ, Fac Pharm, Ipoh, Perak, Malaysia; [Oh, Wen-Da] Univ Sains Malaysia, Sch Chem Sci, George Town, Malaysia; [Amin, Mohamad Faiz Mohd] Univ Malaysia Kelantan, Fac Earth Sci, Jeli, Kelantan, Malaysia	Quest International University Perak; Quest International University Perak; Universiti Sains Malaysia; Universiti Sains Malaysia; Quest International University Perak; Universiti Sains Malaysia; Universiti Malaysia Kelantan	Ravi, R (corresponding author), Quest Int Univ, Fac Integrated Life Sci, Sch Appl Sci, Ipoh, Perak, Malaysia.; Ishak, IH (corresponding author), Univ Sains Malaysia, Sch Biol Sci, Insecticide Resistance Res Grp IRRG, Minden, Penang, Malaysia.; Ishak, IH (corresponding author), Univ Sains Malaysia, Sch Biol Sci, Vector Control Res Unit, Minden, Penang, Malaysia.	intanishak@usm.my; rajiv.ravi@qiu.edu.my	Kotra, Vijay/V-7340-2019; Sugathan, Dr Sandheep/D-4836-2012; Ishak, Intan H./C-8723-2016	Kotra, Vijay/0000-0002-2043-4928; Sugathan, Dr Sandheep/0000-0002-6874-0983; Ishak, Intan H./0000-0002-8916-0451	Malaysian Ministry of Higher Education [FRGS/1/2020/WAB02/QUEST/03/01]	Malaysian Ministry of Higher Education	Malaysian Ministry of Higher Education FRGS/1/2020/WAB02/QUEST/03/01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou-Senna F, 2017, AL AZHAR B SCI, V9, P111; AhbiRami R, 2014, J INSECT SCI, V14, DOI 10.1093/jisesa/ieu042; Amudhan MS, 2012, INT J PHARM SCI RES, V3, P4151, DOI 10.13040/IJPSR.0975-8232.3(11).4151-57; [Anonymous], 2018, OL AC; [Anonymous], 2018, NHEXADECANOIC AC; [Anonymous], 2018, HEXADECANOIC ACID ME; [Anonymous], 2018, 9 OCT AC Z METH EST; [Anonymous], 2018, TETRADECANOIC ACID; Baby AA., 2014, INT J PHARM PHARM SC, V6, P486; Behle R., 2014, MASS PRODUCTION BENE, P483, DOI DOI 10.1016/B978-0-12-391453-8.00014-5; Bekele D., 2016, J FERTILIZERS PESTIC, V7; Bosch OJ, 2000, CHEM SENSES, V25, P323, DOI 10.1093/oxfordjournals.chemse.a014042; Bossou AD, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-337; Dafalla O, 2019, E MEDITERR HEALTH J, V25, P905, DOI 10.26719/emhj.19.081; Enan E, 2019, INVENTORPEST CONTROL; Farjana T, 2013, J MED ENTOMOL, V50, P838, DOI 10.1603/ME12146; GEMMELL MA, 1973, B WORLD HEALTH ORGAN, V48, P649; Harada K, 2000, ENVIRON TOXICOL, V15, P114, DOI 10.1002/(SICI)1522-7278(2000)15:2<114::AID-TOX7>3.0.CO;2-P; Heatubun CD, 2012, BOT J LINN SOC, V168, P147, DOI 10.1111/j.1095-8339.2011.01199.x; Husna Zulkrnin Nor Shaida, 2018, J Parasitol Res, V2018, P1383186, DOI 10.1155/2018/1383186; Jones A, 2017, PESTICIDAL COMPOSITI; Liu NN, 2015, ANNU REV ENTOMOL, V60, P537, DOI 10.1146/annurev-ento-010814-020828; Mading M., 2018, KEMAS JURNAL KESEHAT, V13, P366; Mirgorodskaya AB, 2020, COLLOID SURFACE A, V586, DOI 10.1016/j.colsurfa.2019.124252; Nakatsuji T, 2009, J INVEST DERMATOL, V129, P2480, DOI 10.1038/jid.2009.93; National Center for Biotechnology Information, 2021, PUBCHEM COMP SUMM CI; National Center for Biotechnology Information, PUBCHEM COMP SUMM CI; Perumalsamy H, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0848-8; Qian H, 2018, J CHROMATOGR A, V1559, P86, DOI 10.1016/j.chroma.2018.04.031; Rahman M.A., 2014, BANGLADESH J MICROBI, P19; Rani S., 2018, J PHARM, V8, P56; Ravi R., 2020, SCI REP-UK, V10, P1; Ravi R, 2018, J CHEM-NY, V2018, DOI 10.1155/2018/7453816; Ravi R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206982; Ravindran DR, 2020, J CHEM-NY, V2020, DOI 10.1155/2020/3837207; Reid Byron L, 2015, Patent No. 2009123907; Sarimin R, 2019, HLTH TECHNOLOGY ASSE, P147; Silverio MRS, 2020, MOLECULES, V25, DOI 10.3390/molecules25153484; Sivakumar R, 2011, ASIAN PAC J TROP MED, V4, P706, DOI 10.1016/S1995-7645(11)60178-8; Tennyson S., 2012, INT J RES BIOL SCI, V2, P157; Thanigaivel A, 2012, PARASITOL RES, V110, P1993, DOI 10.1007/s00436-011-2728-2; Therawiwat M., 2005, COMMUNITY BASED APPR; Thomas E, 2003, SAFER ORGANOPHOSPHOR; Vajargah MF, 2021, VET RES COMMUN, V45, P373, DOI 10.1007/s11259-021-09818-y; W.H.O, 2020, DENG SIT UPD; World Health Organization, 2005, WHOCDSWHOPESGCDPP200, P1; Zuharah WanFatma., 2017, ORIENT INSECTS, V52, P30	47	2	2	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2021	16	11							e0260281	10.1371/journal.pone.0260281	http://dx.doi.org/10.1371/journal.pone.0260281			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU5IH	34843539	gold, Green Published			2023-01-03	WOS:000752076100059
J	Paludan-Muller, AS; Lundh, A; Page, MJ; Munkholm, K				Paludan-Mueller, Asger Sand; Lundh, Andreas; Page, Matthew J.; Munkholm, Klaus			Protocol: Benefits and harms of remdesivir for COVID-19 in adults: A systematic review with meta-analysis	PLOS ONE			English	Review								Background Effective drug treatments for Covid-19 are needed to decrease morbidity and mortality for the individual and to alleviate pressure on health care systems. Remdesivir showed promising results in early randomised trials but subsequently a large publicly funded trial has shown less favourable results and the evidence is interpreted differently in clinical guidelines. Systematic reviews of remdesivir have been published, but none have systematically searched for unpublished data, including regulatory documents, and assessed the risk of bias due to missing evidence. Methods We will conduct a systematic review of randomised trials comparing remdesivir to placebo or standard of care in any setting. We will include trials regardless of the severity of disease and we will include trials examining remdesivir for indications other than Covid-19 for harms analyses. We will search websites of regulatory agencies, trial registries, bibliographic databases, preprint servers and contact trial sponsors to obtain all available data, including unpublished clinical data, for all eligible trials. Our primary outcomes will be all-cause mortality and serious adverse events. Our secondary outcomes will be length of hospital stay, time to death, severe disease, and adverse events. We will assess the risk of bias using the Cochranes Risk of Bias 2 tool and the risk of bias due to missing evidence (e.g. publication bias, selective reporting bias) using the ROB-ME tool. Where appropriate we will synthesise study results by conducting random-effects meta-analysis. We will present our findings in a Summary of Findings table and rate the certainty of the evidence using the GRADE approach. Discussion By conducting a comprehensive systematic review including unpublished data (where available), we expect to be able to provide valuable information for patients and clinicians about the benefits and harms of remdesivir for the treatment of Covid-19. This will help to ensure optimal treatment for individual patients and optimal utilisation of health care resources.	[Paludan-Mueller, Asger Sand; Lundh, Andreas; Munkholm, Klaus] Univ Southern Denmark, Ctr Evidence Based Med Odense CEBMO, Dept Clin Res, Odense, Denmark; [Paludan-Mueller, Asger Sand; Lundh, Andreas; Munkholm, Klaus] Univ Southern Denmark, Cochrane Denmark, Odense, Denmark; [Paludan-Mueller, Asger Sand; Lundh, Andreas; Munkholm, Klaus] Odense Univ Hosp, Open Patient Data Exploratory Network OPEN, Odense, Denmark; [Lundh, Andreas] Hvidovre Univ Hosp, Dept Infect Dis, Hvidovre, Denmark; [Page, Matthew J.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia	University of Southern Denmark; University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of Copenhagen; Monash University	Paludan-Muller, AS (corresponding author), Univ Southern Denmark, Ctr Evidence Based Med Odense CEBMO, Dept Clin Res, Odense, Denmark.; Paludan-Muller, AS (corresponding author), Univ Southern Denmark, Cochrane Denmark, Odense, Denmark.; Paludan-Muller, AS (corresponding author), Odense Univ Hosp, Open Patient Data Exploratory Network OPEN, Odense, Denmark.	apaludanmuller@health.sdu.dk	Munkholm, Klaus/AAD-7818-2021; Paludan-Müller, Asger Sand/AAU-3648-2020	Munkholm, Klaus/0000-0001-6437-0359; Paludan-Müller, Asger Sand/0000-0002-3364-1539; Lundh, Andreas/0000-0002-4982-8680	Cochrane Denmark; Centre for Evidence-BasedMedicine Odense (CEBMO); Australian Research Council [DE200101618]	Cochrane Denmark; Centre for Evidence-BasedMedicine Odense (CEBMO); Australian Research Council(Australian Research Council)	ASP-M, AL and KM are supported by Cochrane Denmark and the Centre for Evidence-BasedMedicine Odense (CEBMO). MJP is supported by an Australian Research Council Discovery Early Career Researcher Award (DE200101618). The authors received no specific funding for this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akl EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057132; Al-Abdouh A, 2021, CONTEMP CLIN TRIALS, V101, DOI 10.1016/j.cct.2021.106272; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Borenstein M, 2017, RES SYNTH METHODS, V8, P5, DOI 10.1002/jrsm.1230; Brazeau NF., 2020, REPORT 34 COVID 19 I; Canada H, 2020, REMD VEKL YOU SHOULD; Center for Drug Evaluation and Research, 2020, FDAS APPR VEKL REMD; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489; Elsawah HK, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2187; Frediansyah A, 2021, CLIN EPIDEMIOL GLOB, V9, P123, DOI 10.1016/j.cegh.2020.07.011; Furukawa TA, 2006, J CLIN EPIDEMIOL, V59, P7, DOI 10.1016/j.jclinepi.2005.06.006; Gamble C, 2005, J CLIN EPIDEMIOL, V58, P579, DOI 10.1016/j.jclinepi.2004.09.013; Ghosn L, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013881; Higgins JPT, 2008, CLIN TRIALS, V5, P225, DOI 10.1177/1740774508091600; IntHout J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010247; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Ioannidis JPA, 2021, B WORLD HEALTH ORGAN, V99, P19, DOI 10.2471/BLT.20.265892; Kim MS, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003501; Langan D, 2019, RES SYNTH METHODS, V10, P83, DOI 10.1002/jrsm.1316; Lee K, 2009, GLOB INST, P1; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; National Institutes of Health, 2021, TREATM GUID PAN COR; Pallmann P, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1017-7; Paludan-Muller AS, 2021, BMC MED, V19, DOI 10.1186/s12916-021-01955-0; Parasher A, 2021, POSTGRAD MED J, V97, P312, DOI 10.1136/postgradmedj-2020-138577; Piscoya Alejandro, 2020, PLoS One, V15, pe0243705, DOI 10.1371/journal.pone.0243705; Schunemann H, 2013, GRADE HDB; Shrestha DB, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118663; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Struyf T, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013665; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; WHO, 2020, NAM COR DIS COVID 19; WHO, 2020, WHO DIR GEN OP REM M; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wieseler B, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001526; Wieseler B, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d8141	39	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2021	16	11							e0260544	10.1371/journal.pone.0260544	http://dx.doi.org/10.1371/journal.pone.0260544			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU5IH	34843589	Green Published, gold			2023-01-03	WOS:000752076100099
J	Beaton, A; Okello, E; Rwebembera, J; Grobler, A; Engelman, D; Alepere, J; Canales, L; Carapetis, J; DeWyer, A; Lwabi, P; Mirabel, M; Mocumbi, AO; Murali, M; Nakitto, M; Ndagire, E; Nunes, MCP; Omara, IO; Sarnacki, R; Scheel, A; Wilson, N; Zimmerman, M; Zuhlke, L; Karthikeyan, G; Sable, CA; Steer, AC				Beaton, Andrea; Okello, Emmy; Rwebembera, Joselyn; Grobler, Anneke; Engelman, Daniel; Alepere, Juliet; Canales, Lesley; Carapetis, Jonathan; DeWyer, Alyssa; Lwabi, Peter; Mirabel, Mariana; Mocumbi, Ana O.; Murali, Meghna; Nakitto, Miriam; Ndagire, Emma; Nunes, Maria C. P.; Omara, Isaac O.; Sarnacki, Rachel; Scheel, Amy; Wilson, Nigel; Zimmerman, Meghan; Zuhlke, Liesl; Karthikeyan, Ganesan; Sable, Craig A.; Steer, Andrew C.			Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SCIENTIFIC STATEMENT; CLINICAL-OUTCOMES; FOLLOW-UP; FEVER; PREVENTION; PREVALENCE; PENICILLIN; DIAGNOSIS; CHILDREN; ECHOCARDIOGRAPHY	BACKGROUND Rheumatic heart disease affects more than 40.5 million people worldwide and results in 306,000 deaths annually. Echocardiographic screening detects rheumatic heart disease at an early, latent stage. Whether secondary antibiotic prophylaxis is effective in preventing progression of latent rheumatic heart disease is unknown. METHODS We conducted a randomized, controlled trial of secondary antibiotic prophylaxis in Ugandan children and adolescents 5 to 17 years of age with latent rheumatic heart disease. Participants were randomly assigned to receive either injections of penicillin G benzathine (also known as benzathine benzylpenicillin) every 4 weeks for 2 years or no prophylaxis. All the participants underwent echocardiography at baseline and at 2 years after randomization. Changes from baseline were adjudicated by a panel whose members were unaware of the trial-group assignments. The primary outcome was echocardiographic progression of latent rheumatic heart disease at 2 years. RESULTS Among 102,200 children and adolescents who had screening echocardiograms, 3327 were initially assessed as having latent rheumatic heart disease, and 926 of the 3327 subsequently received a definitive diagnosis on the basis of confirmatory echocardiography and were determined to be eligible for the trial. Consent or assent for participation was provided for 916 persons, and all underwent randomization; 818 participants were included in the modified intention-to-treat analysis, and 799 (97.7%) completed the trial. A total of 3 participants (0.8%) in the prophylaxis group had echocardiographic progression at 2 years, as compared with 33 (8.2%) in the control group (risk difference, -7.5 percentage points; 95% confidence interval, -10.2 to -4.7; P<0.001). Two participants in the prophylaxis group had serious adverse events that were attributable to receipt of prophylaxis, including one episode of a mild anaphylactic reaction (representing <0.1% of all administered doses of prophylaxis). CONCLUSIONS Among children and adolescents 5 to 17 years of age with latent rheumatic heart disease, secondary antibiotic prophylaxis reduced the risk of disease progression at 2 years. Further research is needed before the implementation of population-level screening can be recommended.	[Beaton, Andrea] Univ Cincinnati, Sch Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45221 USA; [Beaton, Andrea] Univ Cincinnati, Sch Med, Dept Pediat, Cincinnati, OH 45221 USA; [Okello, Emmy; Rwebembera, Joselyn; Alepere, Juliet; Lwabi, Peter; Nakitto, Miriam; Ndagire, Emma; Omara, Isaac O.] Uganda Heart Inst, Kampala, Uganda; [Okello, Emmy] Makerere Univ, Dept Med, Kampala, Uganda; [Canales, Lesley; Murali, Meghna; Sarnacki, Rachel; Sable, Craig A.] Childrens Natl Hosp, Washington, DC USA; [Grobler, Anneke; Engelman, Daniel; Steer, Andrew C.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Engelman, Daniel; Steer, Andrew C.] Royal Childrens Hosp, Melbourne Childrens Global Hlth, Melbourne, Vic, Australia; [Carapetis, Jonathan] Univ Western Australia, Perth Childrens Hosp, Telethon Kids Inst, Perth, WA, Australia; [DeWyer, Alyssa] Virginia Tech, Carilion Sch Med, Roanoke, VA USA; [Mirabel, Mariana] Hop Europeen Georges Pompidou, Cardiooncol, Paris, France; [Mocumbi, Ana O.] Inst Nacl Saude, Maputo, Mozambique; [Nunes, Maria C. P.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil; [Scheel, Amy] Emory Univ, Sch Med, Atlanta, GA USA; [Wilson, Nigel] Starship Childrens Hosp, Green Lane Paediat & Congenital Cardiac Serv, Auckland, New Zealand; [Zimmerman, Meghan] Dartmouth Hitchcock Med Ctr, Geisel Sch Med, Lebanon, NH 03766 USA; [Zuhlke, Liesl] Red Cross War Mem Childrens Hosp, Dept Paediat, Div Paediat Cardiol, Cape Town, South Africa; [Zuhlke, Liesl] Groote Schuur Hosp, Dept Med, Div Cardiol, Cape Town, South Africa; [Karthikeyan, Ganesan] All India Inst Med Sci, New Delhi, India	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Makerere University; Children's National Health System; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Telethon Kids Institute; University of Western Australia; Virginia Polytechnic Institute & State University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Universidade Federal de Minas Gerais; Emory University; Starship Children's Hospital; Dartmouth College; University of Cape Town; All India Institute of Medical Sciences (AIIMS) New Delhi	Beaton, A (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	andrea.beaton@cchmc.org	Zuhlke, Liesl Joanna/AAZ-9723-2021; Carapetis, Jonathan/H-8933-2014	Zuhlke, Liesl Joanna/0000-0003-3961-2760; Grobler, Anneke/0000-0002-7809-7688; Mocumbi, Ana/0000-0002-9564-2860; Engelman, Daniel/0000-0002-4909-1287; Carapetis, Jonathan/0000-0002-1182-9792	Thrasher Research Fund; Gift of Life International; Children's National Hospital Foundation (Zachary Blumenfeld Fund); Children's National Hospital Foundation (Race for Every Child [Team Jocelyn]); Elias-Ginsburg Family; Wiley Rein; Philips Foundation; ATT Foundation; Heart Healers International; Karp Family Foundation; Huron Philanthropies; Cincinnati Children's Hospital Heart Institute Research Core	Thrasher Research Fund; Gift of Life International; Children's National Hospital Foundation (Zachary Blumenfeld Fund); Children's National Hospital Foundation (Race for Every Child [Team Jocelyn]); Elias-Ginsburg Family; Wiley Rein; Philips Foundation; ATT Foundation; Heart Healers International; Karp Family Foundation; Huron Philanthropies; Cincinnati Children's Hospital Heart Institute Research Core	Supported by the Thrasher Research Fund, Gift of Life International, Children's National Hospital Foundation (Zachary Blumenfeld Fund and Race for Every Child [Team Jocelyn]), the Elias-Ginsburg Family, Wiley Rein, Philips Foundation, AT&T Foundation, Heart Healers International, the Karp Family Foundation, Huron Philanthropies, and the Cincinnati Children's Hospital Heart Institute Research Core.	[Anonymous], 2017, 141 SESS RES DEC ANN; [Anonymous], 2014, TEXT COUNC EUR BIOET, V1, P49; Bacquelin R, 2016, INT J CARDIOL, V203, P1003, DOI 10.1016/j.ijcard.2015.11.110; Banks TA, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0854-6; Beaton A, 2019, AM HEART J, V215, P95, DOI 10.1016/j.ahj.2019.06.001; Beaton A, 2014, PEDIATR CARDIOL, V35, P1259, DOI 10.1007/s00246-014-0925-3; BLAND EF, 1951, CIRCULATION, V4, P836, DOI 10.1161/01.CIR.4.6.836; Carapetis JR, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2015.84; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Engelman D, 2017, T ROY SOC TROP MED H, V111, P154, DOI 10.1093/trstmh/trx035; Engelman D, 2017, INT J CARDIOL, V240, P422, DOI 10.1016/j.ijcard.2017.04.004; Engelman D, 2016, LANCET GLOB HEALTH, V4, pE386, DOI 10.1016/S2214-109X(16)30065-1; Gerber MA, 2009, CIRCULATION, V119, P1541, DOI 10.1161/CIRCULATIONAHA.109.191959; Gewitz MH, 2015, CIRCULATION, V131, P1806, DOI 10.1161/CIR.0000000000000205; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Karthikeyan G, 2018, LANCET, V392, P161, DOI 10.1016/S0140-6736(18)30999-1; Karthikeyan G, 2016, HEART ASIA, V8, P74, DOI 10.1136/heartasia-2016-010857; Kevat PM, 2017, CURR CARDIOL REV, V13, P155, DOI 10.2174/1573403X13666170116120828; Kumar RK, 2020, CIRCULATION, V142, pE337, DOI 10.1161/CIR.0000000000000921; Longenecker CT, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.117.004037; MAJEED HA, 1992, J CLIN EPIDEMIOL, V45, P871, DOI 10.1016/0895-4356(92)90070-4; Marantelli S, 2019, HEART ASIA, V11, DOI 10.1136/heartasia-2019-011191; Marijon E, 2007, NEW ENGL J MED, V357, P470, DOI 10.1056/NEJMoa065085; Nascimento BR, 2016, INT J CARDIOL, V219, P439, DOI 10.1016/j.ijcard.2016.06.088; Nishimura RA, 2014, J AM COLL CARDIOL, V63, P2438, DOI 10.1016/j.jacc.2014.02.537; Remenyi B, 2012, NAT REV CARDIOL, V9, P297, DOI 10.1038/nrcardio.2012.7; Roberts K, 2013, NAT REV CARDIOL, V10, P49, DOI 10.1038/nrcardio.2012.157; Roth GA, 2020, J AM COLL CARDIOL, V76, P2982, DOI 10.1016/j.jacc.2020.11.010; Rothenbuhler M, 2014, LANCET GLOB HEALTH, V2, pE717, DOI 10.1016/S2214-109X(14)70310-9; Russell K, 2014, J PAEDIATR CHILD H, V50, P112, DOI 10.1111/jpc.12400; Saxena A, 2016, LANCET GLOB HEALTH, V4, pE349, DOI 10.1016/S2214-109X(16)30077-8; Saxena A, 2013, GLOB HEART, V8, P197, DOI 10.1016/j.gheart.2013.08.004; Scheel A, 2021, INT J CARDIOL, V328, P146, DOI 10.1016/j.ijcard.2020.11.013; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Simons FER, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0080-1; Spinetto H, 2011, J PAEDIATR CHILD H, V47, P228, DOI 10.1111/j.1440-1754.2010.01942.x; Steer A, 2014, SAMJ S AFR MED J, V104, P156, DOI 10.7196/SAMJ.7880; STOLLERMAN GH, 1955, NEW ENGL J MED, V252, P787, DOI 10.1056/NEJM195505122521901; TOMPKINS DG, 1972, CIRCULATION, V45, P543, DOI 10.1161/01.CIR.45.3.543; Zuhlke L, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-016-0225-3; Zuhlke L, 2013, CURR CARDIOL REP, V15, DOI 10.1007/s11886-012-0343-1; Zuhlke L, 2016, CIRCULATION, V134, P1456, DOI 10.1161/CIRCULATIONAHA.116.024769; Zuhlke Liesl J, 2017, Curr Treat Options Cardiovasc Med, V19, P15, DOI 10.1007/s11936-017-0513-y	43	18	18	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2022	386	3					230	240		10.1056/NEJMoa2102074	http://dx.doi.org/10.1056/NEJMoa2102074		NOV 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK1UG	34767321				2023-01-03	WOS:000718031600001
J	Amboko, B; Stepniewska, K; Malla, L; Machini, B; Bejon, P; Snow, RW; Zurovac, D				Amboko, Beatrice; Stepniewska, Kasia; Malla, Lucas; Machini, Beatrice; Bejon, Philip; Snow, Robert W.; Zurovac, Dejan			Determinants of improvement trends in health workers' compliance with outpatient malaria case-management guidelines at health facilities with available "test and treat" commodities in Kenya	PLOS ONE			English	Article							QUALITY-OF-CARE; INTEGRATED MANAGEMENT; COST-EFFECTIVENESS; CHILDHOOD ILLNESS; SUPERVISION; PERFORMANCE; AFRICA; GAP; ERA	Background Health workers' compliance with outpatient malaria case-management guidelines has been improving in Africa. This study examined the factors associated with the improvements. Methods Data from 11 national, cross-sectional health facility surveys undertaken from 2010-2016 were analysed. Association between 31 determinants and improvement trends in five outpatient compliance outcomes were examined using interactions between each determinant and time in multilevel logistic regression models and reported as an adjusted odds ratio of annual trends (T-aOR). Results Among 9,173 febrile patients seen at 1,208 health facilities and by 1,538 health workers, a higher annual improvement trend in composite "test and treat" performance was associated with malaria endemicity-lake endemic (T-aOR = 1.67 annually; p<0.001) and highland epidemic (T-aOR = 1.35; p<0.001) zones compared to low-risk zone; with facilities stocking rapid diagnostic tests only (T-aOR = 1.49; p<0.001) compared to microscopy only services; with faith-based/non-governmental facilities compared to government-owned (T-aOR = 1.15; p = 0.036); with a daily caseload of >25 febrile patients (T-aOR = 1.46; p = 0.003); and with under-five children compared to older patients (T-aOR = 1.07; p = 0.013). Other factors associated with the improvement trends in the "test and treat" policy components and artemether-lumefantrine administration at the facility included the absence of previous RDT stock-outs, community health workers dispensing drugs, access to malaria case-management and Integrated Management of Childhood Illness (IMCI) guidelines, health workers' gender, correct health workers' knowledge about the targeted malaria treatment policy, and patients' main complaint of fever. The odds of compliance at the baseline were variable for some of the factors. Conclusions Targeting of low malaria risk areas, low caseload facilities, male and government health workers, continuous availability of RDTs, improving health workers' knowledge about the policy considering age and fever, and dissemination of guidelines might improve compliance with malaria guidelines. For prompt treatment and administration of the first artemether-lumefantrine dose at the facility, task-shifting duties to community health workers can be considered.	[Amboko, Beatrice; Malla, Lucas; Bejon, Philip; Snow, Robert W.; Zurovac, Dejan] KEMRI Wellcome Trust Res Programme, Nairobi, Kenya; [Stepniewska, Kasia] WorldWide Antimalarial Resistance Network, Oxford, England; [Stepniewska, Kasia; Bejon, Philip; Snow, Robert W.; Zurovac, Dejan] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England; [Machini, Beatrice] Minist Hlth, Div Natl Malaria Programme, Nairobi, Kenya	Worldwide Antimalarial Resistance Network (WWARN); University of Oxford	Amboko, B (corresponding author), KEMRI Wellcome Trust Res Programme, Nairobi, Kenya.	indimulib06@gmail.com	Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088; Amboko, Beatrice/0000-0002-5754-3853				Abdelgader TM, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-11; Amboko B, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-03479-z; Amin AA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-72; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P749; Ayieko P, 2019, IMPLEMENT SCI, V14, DOI 10.1186/s13012-019-0868-4; Barbour V, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000188; Batwala V, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-372; Bawate C, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1153-5; Bosch-Capblanch X, 2008, TROP MED INT HEALTH, V13, P369, DOI 10.1111/j.1365-3156.2008.02012.x; Bosch-Capblanch X, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006413.pub2; Boyce MR, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4398-1; Bruxvoort KJ, 2017, AM J TROP MED HYG, V97, P1170, DOI 10.4269/ajtmh.16-0955; Burchett HED, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012973; Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8; Candrinho B, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2796-9; Chanda Pascalina, 2009, Cost Eff Resour Alloc, V7, P5, DOI 10.1186/1478-7547-7-5; Chandler CIR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170998; Cundill B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0346-z; D'Acremont V, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-240; Dieleman M, 2006, IMPROVING HLTH WORKE, P5; Epstein A, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4205-z; Faust C, 2015, AM J TROP MED HYG, V93, P159, DOI 10.4269/ajtmh.14-0595; Feise Ronald J, 2002, BMC Med Res Methodol, V2, P8, DOI 10.1186/1471-2288-2-8; Gage AD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208898; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7; Graz B, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-136; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Guilbert JJ, 2006, EDUC HEALTH, V19, P385, DOI 10.1080/13576280600937911; Huicho L, 2008, LANCET, V372, P910, DOI 10.1016/S0140-6736(08)61401-4; Ikeda DJ, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1176; Institute Of Medicine (IOM), 2015, MYALGIC ENCEPHALOMYE; Jesus TS, 2020, PHYSIOTHER CAN, V72, P122, DOI 10.3138/ptc-2018-0065; Kabaghe AN, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1218-5; Kaula H, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2577-x; Klootwijk L, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4544-9; Leonard KL, 2007, HEALTH AFFAIR, V26, pW380, DOI 10.1377/hlthaff.26.3.w380; Leslie HH, 2016, HEALTH AFFAIR, V35, P1716, DOI 10.1377/hlthaff.2016.0261; Lewin S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004015.pub3; Lourenco C, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-508; Lubell Y, 2007, AM J TROP MED HYG, V77, P128, DOI 10.4269/ajtmh.2007.77.128; MalariaCare, 2016, UN DIAGN TREATM IMPR; MalariaCare, 2017, UN DIAGN TREATM IMPR; MalariaCare, 2015, UN DIAGN TREATM IMPR; Mangham-Jefferies L, 2015, HEALTH POLICY PLANN, V30, P1129, DOI 10.1093/heapol/czu118; Masanja IM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-221; Mbacham WF, 2014, LANCET GLOB HEALTH, V2, pE346, DOI 10.1016/S2214-109X(14)70201-3; Ministry of Health, KEN HLTH MAST FAC LI, DOI [10.1080/16549716.2017.1413266, DOI 10.1080/16549716.2017.1413266]; Ministry of Health, 2009, HLTH FIN POL REV; Ministry of Health, 2006, HLTH STATUS PALESTIN; Ministry of Public Health Sanitation/Ministry of Medical Services, 2010, NAT ROADM ACC ATT MD; Mohanan M, 2015, JAMA PEDIATR, V169, P349, DOI 10.1001/jamapediatrics.2014.3445; Mubi M, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-293; Namuyinga RJ, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1693-3; National Malaria Control Programme, 2016, MON OUTP MAL CAS MAN; Nguyen DTK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066030; Nursing and Midwifery Board of Australia, 2019, NURS MIDW BOARD AUST; Nyandigisi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024781; O'Boyle S, 2020, BMC MED, V18, DOI 10.1186/s12916-019-1483-6; Odhiambo F, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2018-2; Plucinski MM, 2018, AM J TROP MED HYG, V99, P670, DOI 10.4269/ajtmh.18-0312; Plucinski MM, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1843-7; Rao VB, 2013, TRENDS PARASITOL, V29, P164, DOI 10.1016/j.pt.2013.01.005; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6; Rowe AK., 2017, 66 ANN M AM SOC TROP; Rowe AK, 2018, LANCET GLOB HEALTH, V6, pE1163, DOI 10.1016/S2214-109X(18)30398-X; Rowe AK, 2012, TROP MED INT HEALTH, V17, P438, DOI 10.1111/j.1365-3156.2012.02976.x; Rowe AK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-275; Russell D, 2018, AM J INFECT CONTROL, V46, P1211, DOI 10.1016/j.ajic.2018.05.005; Selemani M, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-334; Shillcutt S, 2008, B WORLD HEALTH ORGAN, V86, P101, DOI 10.2471/BLT.07.042259; Steinhardt LC, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0910-4; Steinhardt LC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089050; Steinhardt LC, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-64; Tulloch J., 1999, Lancet (British edition), V354, P16, DOI 10.1016/S0140-6736(99)90252-0; Visser T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173093; Wanja E, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1856-2; Wasunna B, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-261; Who, 2015, GUID START ANT THER; World Health Organization, 2010, PROGR SAN DRINK WAT, P6; Zurovac D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092782; Zurovac D, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-181	83	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2021	16	11							e0259020	10.1371/journal.pone.0259020	http://dx.doi.org/10.1371/journal.pone.0259020			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY7XS	34739519	Green Published, gold			2023-01-03	WOS:000755000800015
J	Tenforde, MW; Self, WH; Adams, K; Gaglani, M; Ginde, AA; McNeal, T; Ghamande, S; Douin, DJ; Talbot, HK; Casey, JD; Mohr, NM; Zepeski, A; Shapiro, NI; Gibbs, KW; Files, DC; Hager, DN; Shehu, A; Prekker, ME; Erickson, HL; Exline, MC; Gong, MN; Mohamed, A; Henning, DJ; Steingrub, JS; Peltan, ID; Brown, SM; Martin, ET; Monto, AS; Khan, A; Hough, CL; Busse, LW; Ten Lohuis, CC; Duggal, A; Wilson, JG; Gordon, AJ; Qadir, N; Chang, SY; Mallow, C; Rivas, C; Babcock, HM; Kwon, JH; Halasa, N; Chappell, JD; Lauring, AS; Grijalva, CG; Rice, TW; Jones, ID; Stubblefield, WB; Baughman, A; Womack, KN; Rhoads, JP; Lindsell, CJ; Hart, KW; Zhu, YW; Olson, SM; Kobayashi, M; Verani, JR; Patel, MM				Tenforde, Mark W.; Self, Wesley H.; Adams, Katherine; Gaglani, Manjusha; Ginde, Adit A.; McNeal, Tresa; Ghamande, Shekhar; Douin, David J.; Talbot, H. Keipp; Casey, Jonathan D.; Mohr, Nicholas M.; Zepeski, Anne; Shapiro, Nathan, I; Gibbs, Kevin W.; Files, D. Clark; Hager, David N.; Shehu, Arber; Prekker, Matthew E.; Erickson, Heidi L.; Exline, Matthew C.; Gong, Michelle N.; Mohamed, Amira; Henning, Daniel J.; Steingrub, Jay S.; Peltan, Ithan D.; Brown, Samuel M.; Martin, Emily T.; Monto, Arnold S.; Khan, Akram; Hough, Catherine L.; Busse, Laurence W.; Ten Lohuis, Caitlin C.; Duggal, Abhijit; Wilson, Jennifer G.; Gordon, Alexandra June; Qadir, Nida; Chang, Steven Y.; Mallow, Christopher; Rivas, Carolina; Babcock, Hilary M.; Kwon, Jennie H.; Halasa, Natasha; Chappell, James D.; Lauring, Adam S.; Grijalva, Carlos G.; Rice, Todd W.; Jones, Ian D.; Stubblefield, William B.; Baughman, Adrienne; Womack, Kelsey N.; Rhoads, Jillian P.; Lindsell, Christopher J.; Hart, Kimberly W.; Zhu, Yuwei; Olson, Samantha M.; Kobayashi, Miwako; Verani, Jennifer R.; Patel, Manish M.		Influenza Other Viruses Acutely Il	Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SARS-COV-2; DESIGN	IMPORTANCE A comprehensive understanding of the benefits of COVID-19 vaccination requires consideration of disease attenuation, determined as whether people who develop COVID-19 despite vaccination have lower disease severity than unvaccinated people. OBJECTIVE To evaluate the association between vaccination with mRNA COVID-19 vaccines-mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech)-and COVID-19 hospitalization, and, among patients hospitalized with COVID-19, the association with progression to critical disease. DESIGN, SETTING, AND PARTICIPANTS A US 21-site case-control analysis of 4513 adults hospitalized between March 11 and August 15, 2021, with 28-day outcome data on death and mechanical ventilation available for patients enrolled through July 14, 2021. Date of final follow-up was August 8, 2021. EXPOSURES COVID-19 vaccination. MAIN OUTCOMES AND MEASURES Associations were evaluated between prior vaccination and (1) hospitalization for COVID-19, in which case patients were those hospitalized for COVID-19 and control patients were those hospitalized for an alternative diagnosis; and (2) disease progression among patients hospitalized for COVID-19, in which cases and controls were COVID-19 patients with and without progression to death or mechanical ventilation, respectively. Associations were measured with multivariable logistic regression. RESULTS Among 4513 patients (median age, 59 years [IQR, 45-69]; 2202 [48.8%] women; 23.0% non-Hispanic Black individuals, 15.9% Hispanic individuals, and 20.1% with an immunocompromising condition), 1983 were case patients with COVID-19 and 2530 were controls without COVID-19. Unvaccinated patients accounted for 84.2%(1669/1983) of COVID-19 hospitalizations. Hospitalization for COVID-19 was significantly associated with decreased likelihood of vaccination (cases, 15.8%; controls, 54.8%; adjusted OR, 0.15; 95% CI, 0.13-0.18), including for sequenced SARS-CoV-2 Alpha (8.7% vs 51.7%; aOR, 0.10; 95% CI, 0.06-0.16) and Delta variants (21.9% vs 61.8%; aOR, 0.14; 95% CI, 0.10-0.21). This association was stronger for immunocompetent patients (11.2% vs 53.5%; aOR, 0.10; 95% CI, 0.09-0.13) than immunocompromised patients(40.1%vs58.8%; aOR, 0.49;95% CI, 0.35-0.69)(P<.001) and weaker at more than 120 days since vaccination with BNT162b2 (5.8% vs 11.5%; aOR, 0.36; 95% CI, 0.27-0.49) than with mRNA-1273 (1.9% vs 8.3%; aOR, 0.15; 95% CI, 0.09-0.23) (P<.001). Among 1197 patients hospitalized with COVID-19, death or invasive mechanical ventilation by day 28 was associated with decreased likelihood of vaccination(12.0% vs 24.7%; aOR, 0.33; 95% CI, 0.19-0.58). CONCLUSIONS AND RELEVANCE Vaccination with an mRNA COVID-19 vaccine was significantly less likely among patients with COVID-19 hospitalization and disease progression to death or mechanical ventilation. These findings are consistent with risk reduction among vaccine breakthrough infections compared with absence of vaccination.	[Tenforde, Mark W.; Adams, Katherine; Olson, Samantha M.; Kobayashi, Miwako; Verani, Jennifer R.; Patel, Manish M.] CDC COVID 19 Response Team, Atlanta, GA USA; [Self, Wesley H.] Vanderbilt Univ, Vanderbilt Inst Clin & Translat Res, Dept Emergency Med, Med Ctr, Nashville, TN USA; [Gaglani, Manjusha; McNeal, Tresa; Ghamande, Shekhar] Texas A&M Univ, Coll Med, Baylor Scott & White Hlth, Temple, TX 76508 USA; [Ginde, Adit A.] Univ Colorado, Dept Emergency Med, Sch Med, Aurora, CO USA; [Douin, David J.] Univ Colorado, Dept Anesthesiol, Sch Med, Aurora, CO USA; [Talbot, H. Keipp; Casey, Jonathan D.; Rice, Todd W.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Talbot, H. Keipp; Grijalva, Carlos G.] Vanderbilt Univ, Dept Hlth Policy, Med Ctr, Nashville, TN USA; [Mohr, Nicholas M.; Zepeski, Anne] Univ Iowa, Dept Emergency Med, Iowa City, IA USA; [Shapiro, Nathan, I] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Gibbs, Kevin W.; Files, D. Clark] Wake Forest Sch Med, Dept Med, Winston Salem, NC 27101 USA; [Hager, David N.; Shehu, Arber] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Prekker, Matthew E.] Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA; [Erickson, Heidi L.] Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA; [Exline, Matthew C.] Ohio State Univ, Dept Med, Columbus, OH 43210 USA; [Gong, Michelle N.] Albert Einstein Coll Med, Dept Med, Montefiore Hlth Syst, Bronx, NY USA; [Mohamed, Amira] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; [Henning, Daniel J.] Univ Washington, Dept Emergency Med, Seattle, WA 98195 USA; [Steingrub, Jay S.] Baystate Med Ctr, Dept Med, Springfield, MA 01199 USA; [Peltan, Ithan D.; Brown, Samuel M.] Intermt Med Ctr, Dept Med, Murray, UT USA; [Peltan, Ithan D.; Brown, Samuel M.] Univ Utah, Salt Lake City, UT USA; [Martin, Emily T.; Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; [Khan, Akram; Hough, Catherine L.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; [Busse, Laurence W.] Emory Univ, Dept Med, Atlanta, GA 30322 USA; [Ten Lohuis, Caitlin C.] Emory Healthcare, Emory Crit Care Ctr, Atlanta, GA USA; [Duggal, Abhijit] Cleveland Clin, Dept Med, Cleveland, OH 44106 USA; [Wilson, Jennifer G.; Gordon, Alexandra June] Stanford Univ, Dept Emergency Med, Sch Med, Stanford, CA 94305 USA; [Qadir, Nida; Chang, Steven Y.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; [Mallow, Christopher; Rivas, Carolina] Univ Miami, Dept Med, Miami, FL USA; [Babcock, Hilary M.; Kwon, Jennie H.] Washington Univ, Dept Med, St Louis, MO USA; [Halasa, Natasha; Chappell, James D.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Lauring, Adam S.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Lauring, Adam S.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; [Jones, Ian D.; Stubblefield, William B.; Baughman, Adrienne] Vanderbilt Univ, Dept Emergency Med, Med Ctr, Nashville, TN USA; [Womack, Kelsey N.; Rhoads, Jillian P.] Vanderbilt Univ, Vanderbilt Inst Clin & Translat Res, Med Ctr, Nashville, TN USA; [Lindsell, Christopher J.; Hart, Kimberly W.; Zhu, Yuwei] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA	Vanderbilt University; Baylor Health Care System; Texas A&M University System; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Vanderbilt University; Vanderbilt University; University of Iowa; Harvard University; Beth Israel Deaconess Medical Center; Wake Forest University; Johns Hopkins University; Hennepin County Medical Center; Hennepin County Medical Center; University System of Ohio; Ohio State University; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Washington; University of Washington Seattle; Baystate Medical Center; Intermountain Healthcare; Intermountain Medical Center; Utah System of Higher Education; University of Utah; University of Michigan System; University of Michigan; Oregon Health & Science University; Emory University; Emory University; Cleveland Clinic Foundation; Stanford University; University of California System; University of California Los Angeles; University of Miami; Washington University (WUSTL); Vanderbilt University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Vanderbilt University; Vanderbilt University; Vanderbilt University	Tenforde, MW (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop 24-7, Atlanta, GA 30329 USA.	mtenforde@cdc.gov	Gordon, Alexandra/HDM-4097-2022; Khan, Akram/AAB-6446-2022; Peltan, Ithan/J-1853-2019; Casey, Jonathan/AAG-1211-2020; Gaglani, Manjusha/AFQ-6802-2022; Mohr, Nicholas/N-1112-2017	Khan, Akram/0000-0003-3091-632X; Peltan, Ithan/0000-0003-1730-234X; Casey, Jonathan/0000-0002-0977-290X; Gaglani, Manjusha/0000-0002-3952-9230; Gibbs, Kevin/0000-0002-5272-2289; Files, Daniel Clark/0000-0002-1595-4080; Stubblefield, William-May/0000-0003-3817-1414; Mohr, Nicholas/0000-0003-0497-5828; Adams, Katherine/0000-0002-1818-1730	CDC [75D30121F00002]	CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Primary funding for this study was provided by the CDC (75D30121F00002).	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Birhane M, 2021, MMWR-MORBID MORTAL W, V70, P792, DOI 10.15585/mmwr.mm7021e3; Centers for Disease Control and Prevention, COVID DAT TRACK; Centers for Disease Control and Prevention, COVID 19 VACC MOD SE; Centers for Disease Control and Prevention, INT CLIN CONS US COV; Cromer D, 2021, NAT REV IMMUNOL, V21, P395, DOI 10.1038/s41577-021-00550-x; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Flannery B, 2020, J INFECT DIS, V221, P8, DOI 10.1093/infdis/jiz543; Food and Drug Administration, 2021, FDA BRIEF DOC JANSS; Foppa IM, 2013, VACCINE, V31, P3104, DOI 10.1016/j.vaccine.2013.04.026; Goldshtein I, 2021, JAMA-J AM MED ASSOC, V326, P728, DOI 10.1001/jama.2021.11035; Grannis SJ, 2021, MMWR-MORBID MORTAL W, V70, P1291, DOI 10.15585/mmwr.mm7037e2; Grijalva CG, 2021, CLIN INFECT DIS, V73, P1459, DOI 10.1093/cid/ciab462; Grijalva CG, 2015, JAMA-J AM MED ASSOC, V314, P1488, DOI 10.1001/jama.2015.12160; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Halloran ME, 1999, EPIDEMIOL REV, V21, P73, DOI 10.1093/oxfordjournals.epirev.a017990; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Lewnard JA, 2021, EPIDEMIOLOGY, V32, P508, DOI 10.1097/EDE.0000000000001366; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Morin L, 2021, JAMA-J AM MED ASSOC, V325, P1525, DOI 10.1001/jama.2021.3331; Nanduri S, 2021, MMWR-MORBID MORTAL W, V70, P1163, DOI 10.15585/mmwr.mm7034e3; Patel MM, 2020, JAMA-J AM MED ASSOC, V324, P1781, DOI 10.1001/jama.2020.18796; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Quick, NCOV2 2019 SEQUENCIN; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Sadarangani M, 2021, NAT REV IMMUNOL, V21, P475, DOI 10.1038/s41577-021-00578-z; Self WH, 2021, MMWR-MORBID MORTAL W, V70, P1337, DOI 10.15585/mmwr.mm7038e1; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Steensels D, 2021, JAMA-J AM MED ASSOC, V326, P1533, DOI 10.1001/jama.2021.15125; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P1156, DOI 10.15585/mmwr.mm7034e2; Tenforde MW, 2022, CLIN INFECT DIS, V74, P1515, DOI [10.1093/cid/ciab687, 10.1101/2021.07.08.21259776]; Tenforde MW, 2021, J INFECT DIS, V224, P813, DOI 10.1093/infdis/jiaa800; The Food and Drug Administration, 2019, CDC 2019 NOV COR 201; Thompson MG, 2021, NEW ENGL J MED, V385, P320, DOI 10.1056/NEJMoa2107058	37	165	167	7	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	2021	326	20					2043	2054		10.1001/jama.2021.19499	http://dx.doi.org/10.1001/jama.2021.19499		NOV 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF3VI	34734975	Bronze, Green Published			2023-01-03	WOS:000714699000002
J	Meier, V; Czichon, F; Walsh, L; Bley, CR				Meier, Valeria; Czichon, Felicitas; Walsh, Linda; Bley, Carla Rohrer			Can volumetric modulated arc radiation therapy reduce organ at risk dose in stage 4 sinonasal tumors in dogs treated with boost irradiation?	PLOS ONE			English	Article							MALIGNANT CANINE NASAL; NORMAL TISSUE; RADIOTHERAPY; IMRT; TOLERANCE; FIELDS; BRAIN	Intensity modulated radiation therapy (IMRT) introduced marked changes to cancer treatment in animals by reducing dose to organs at risk (OAR). As the next technological step, volumetric modulated arc therapy (VMAT) has advantages (increased degrees-of-freedom, faster delivery) compared to fixed-field IMRT. Our objective was to investigate a possible advantage of VMAT over IMRT in terms of lower OAR doses in advanced-disease sinonasal tumors in dogs treated with simultaneously-integrated boost radiotherapy. A retrospective, analytical, observational study design was applied using 10 pre-existing computed tomography datasets on dogs with stage 4 sinonasal tumors. Each dataset was planned with both, 5-field IMRT and 2 arc VMAT with 10x4.83 Gy to the gross tumor volume and 10x4.2 Gy to the planning target volume. Adequate target dose coverage and normal tissue complication probability of brain <= 5% was required. Dose constraints aspired to were D60 <15 Gy for eyes, D2 <35.4 Gy for corneae, and Dmean <20 Gy for lacrimal glands. OAR dose was statistically significantly higher in IMRT plans than in VMAT plans. Median eye D60% was 18.5 Gy (interquartile range (IQR) 17.5) versus 16.1 Gy (IQR 7.4) (p = 0.007), median lacrimal gland dose 21.8 Gy (IQR 20.5) versus 18.6 Gy (IQR 7.0) (p = 0.013), and median cornea D2% 45.5 Gy (IQR 6.8) versus 39.9 Gy (IQR 10.0) (p<0.005) for IMRT versus VMAT plans, respectively. Constraints were met in 21/40 eyes, 7/40 corneae, and 24/40 lacrimal glands. Median delivery time was significantly longer for IMRT plans than for VMAT plans (p<0.01). Based on these results, VMAT plans were found to be superior in sparing doses to eyes, lacrimal glands, corneae. However, not all ocular OAR constraints could be met while ensuring adequate dose coverage and restricting brain toxicity risk for both planning techniques.	[Meier, Valeria; Czichon, Felicitas; Bley, Carla Rohrer] Univ Zurich, Vetsuisse Fac, Dept Small Anim, Div Radiat Oncol, Zurich, Switzerland; [Meier, Valeria; Walsh, Linda] Univ Zurich, Dept Phys, Zurich, Switzerland	University of Zurich; University of Zurich	Meier, V (corresponding author), Univ Zurich, Vetsuisse Fac, Dept Small Anim, Div Radiat Oncol, Zurich, Switzerland.	vmeier@vetclinics.uzh.ch	Rohrer Bley, Carla/G-1192-2013	Rohrer Bley, Carla/0000-0002-5733-2722; Meier, Valeria/0000-0003-0793-9005	Swiss National Science Foundation (SNSF) [320030-182490]	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF))	This work was supported by the Swiss National Science Foundation (SNSF), http://www. snf.ch/en, grant number: 320030-182490 (CRB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams WM, 2009, VET RADIOL ULTRASOUN, V50, P330, DOI 10.1111/j.1740-8261.2009.01545.x; Adams WM, 2005, JAVMA-J AM VET MED A, V227, P936, DOI 10.2460/javma.2005.227.936; Adams WM, 1998, VET RADIOL ULTRASOUN, V39, P475, DOI 10.1111/j.1740-8261.1998.tb01637.x; [Anonymous], 2007, QUAL CONTR INT MOD R; [Anonymous], 2010, PRESCRIBING RECORDIN; Bley CR, 2017, VET COMP ONCOL, V15, P1295, DOI 10.1111/vco.12265; Bley CR, 2019, VET RADIOL ULTRASOUN, V60, P255, DOI 10.1111/vru.12722; Bradshaw T, 2015, PHYS MED BIOL, V60, P5211, DOI 10.1088/0031-9155/60/13/5211; BRENNAN KM, 1993, RADIAT RES, V134, P43, DOI 10.2307/3578500; BURMAN C, 1991, INT J RADIAT ONCOL, V21, P123, DOI 10.1016/0360-3016(91)90172-Z; Dolera M, 2018, VET RADIOL ULTRASOUN, V59, P624, DOI 10.1111/vru.12637; Dolera M, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160617; EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109, DOI 10.1016/0360-3016(91)90171-Y; Fei ZD, 2021, J CANCER RES CLIN, V147, P2047, DOI 10.1007/s00432-020-03479-1; FIKE JR, 1988, INT J RADIAT ONCOL, V14, P63, DOI 10.1016/0360-3016(88)90052-1; Fogliata A, 2008, RADIOTHER ONCOL, V89, P254, DOI 10.1016/j.radonc.2008.07.021; Griffin LR, 2016, VET COMP ONCOL, V14, pE158, DOI 10.1111/vco.12129; Gutierrez AN, 2007, VET RADIOL ULTRASOUN, V48, P594, DOI 10.1111/j.1740-8261.2007.00304.x; Hall EJ, 2006, INT J RADIAT ONCOL, V65, P1, DOI 10.1016/j.ijrobp.2006.01.027; Hein PA, 2005, INT J RADIAT ONCOL, V62, P1540, DOI 10.1016/j.ijrobp.2005.04.013; Jeganathan VSE, 2011, INT J RADIAT ONCOL, V79, P650, DOI 10.1016/j.ijrobp.2010.09.056; Lawrence JA, 2010, VET RADIOL ULTRASOUN, V51, P561, DOI 10.1111/j.1740-8261.2010.01695.x; Lawrence YR, 2010, INT J RADIAT ONCOL, V76, pS20, DOI 10.1016/j.ijrobp.2009.02.091; LYMAN JT, 1985, RADIAT RES, V104, pS13, DOI 10.2307/3576626; Meier V, 2020, VET RADIOL ULTRASOUN, V61, P77, DOI 10.1111/vru.12815; Palma D, 2008, INT J RADIAT ONCOL, V72, P996, DOI 10.1016/j.ijrobp.2008.02.047; Pirzkall A, 2002, INT J RADIAT ONCOL, V53, P434, DOI 10.1016/S0360-3016(02)02750-5; Poirier VJ, 2020, J VET INTERN MED, V34, P867, DOI 10.1111/jvim.15744; Schwarz P, 2018, J VET INTERN MED, V32, P2013, DOI 10.1111/jvim.15324; Sharma DS, 2006, BRIT J RADIOL, V79, P331, DOI 10.1259/bjr/16208090; Shen QW, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-152; Sones E, 2013, VET RADIOL ULTRASOUN, V54, P194, DOI 10.1111/vru.12006; Soukup A, 2018, VET COMP ONCOL, V16, P441, DOI 10.1111/vco.12399; Stevens A, 2020, VET RADIOL ULTRASOUN, V61, P718, DOI 10.1111/vru.12899; THEON AP, 1993, J AM VET MED ASSOC, V202, P1469; THRALL DE, 1993, VET RADIOL ULTRASOUN, V34, P295, DOI 10.1111/j.1740-8261.1993.tb01579.x; Tome WA, 2000, INT J RADIAT ONCOL, V48, P593, DOI 10.1016/S0360-3016(00)00666-0; Tomita N, 2009, BRIT J RADIOL, V82, P756, DOI 10.1259/bjr/83758373; Van Asselt N, 2020, VET RADIOL ULTRASOUN, V61, P481, DOI 10.1111/vru.12868; Verbakel WFAR, 2009, INT J RADIAT ONCOL, V74, P252, DOI 10.1016/j.ijrobp.2008.12.033; Wang YM, 2013, CLIN IMAG, V37, P440, DOI 10.1016/j.clinimag.2012.09.006; White P, 2013, J RADIAT RES, V54, P532, DOI 10.1093/jrr/rrs111; Wolf F, 2020, VET OPHTHALMOL, V23, P596, DOI 10.1111/vop.12761	43	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2021	16	10							e0259112	10.1371/journal.pone.0259112	http://dx.doi.org/10.1371/journal.pone.0259112			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8NO	34714825	gold, Green Published, Green Accepted			2023-01-03	WOS:000755042500026
J	Vinogradova, Y; Dening, T; Hippisley-Cox, J; Taylor, L; Moore, M; Coupland, C				Vinogradova, Yana; Dening, Tom; Hippisley-Cox, Julia; Taylor, Lauren; Moore, Michael; Coupland, Carol			Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MILD COGNITIVE IMPAIRMENT; POSTMENOPAUSAL WOMEN	OBJECTIVE To assess the risks of developing dementia associated with different types and durations of menopausal hormone therapy. DESIGN Two nested case-control studies. SETTING UK general practices contributing to QResearch or the Clinical Practice Research Datalink (CPRD), using all links to hospital, mortality, and social deprivation data. PARTICIPANTS 118 501 women aged 55 and older with a primary diagnosis of dementia between 1998 and 2020, matched by age, general practice, and index date to 497 416 female controls. MAIN OUTCOME MEASURES Dementia diagnoses from general practice, mortality, and hospital records; odds ratios for menopausal hormone treatments adjusted for demographics, smoking status, alcohol consumption, comorbidities, family history, and other prescribed drugs. RESULTS Overall, 16 291 (14%) women with a diagnosis of dementia and 68 726 (14%) controls had used menopausal hormone therapy more than three years before the index date. Overall, no increased risks of developing dementia associated with menopausal hormone therapy were observed. A decreased global risk of dementia was found among cases and controls younger than 80 years who had been taking oestrogen-only therapy for 10 years or more (adjusted odds ratio 0.85, 95% confidence interval 0.76 to 0.94). Increased risks of developing specifically Alzheimer's disease were found among women who had used oestrogen-progestogen therapy for between five and nine years (1.11, 1.04 to 1.20) and for 10 years or more (1.19, 1.06 to 1.33). This was equivalent to, respectively, five and seven extra cases per 10 000 woman years. Detailed risk associations for the specific progestogens studied are also provided. CONCLUSION This study gives estimates for risks of developing dementia and Alzheimer's disease in women exposed to different types of menopausal hormone therapy for different durations and has shown no increased risks of developing dementia overall. It has shown a slightly increased risk of developing Alzheimer's disease among long term users of oestrogen-progestogen therapies.	[Vinogradova, Yana; Taylor, Lauren; Coupland, Carol] Univ Nottingham, Sch Med, Div Primary Care, Nottingham NG2 7RD, England; [Dening, Tom] Univ Nottingham, Sch Med, Mental Hlth & Clin Neurosci, Nottingham, England; [Hippisley-Cox, Julia] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England; [Moore, Michael] Univ Southampton, Fac Med, Primary Care Res Ctr, Primary Care Populat Sci & Med Educ PPM, Southampton, Hants, England	University of Nottingham; University of Nottingham; University of Oxford; University of Southampton	Vinogradova, Y (corresponding author), Univ Nottingham, Sch Med, Div Primary Care, Nottingham NG2 7RD, England.	YanaVinogradova@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020; Dening, Tom/E-1335-2013	Hippisley-Cox, Julia/0000-0002-2479-7283; Dening, Tom/0000-0003-3387-4241; Vinogradova, Yana/0000-0002-3030-5257	National Institute for Health Research (NIHR) School for Primary Care Research in Nottingham University [480]; NIHR School for Primary Care Researchin Oxford University [3372]; NIHR Schools for Primary Care Research at Nottingham; Oxford Universities; NIHR Biomedical Research Centre, Oxford, John Fell Oxford University Press Research Fund, Cancer Research UK through the Cancer Research UK Oxford Centre [C5255/A18085]; Oxford Wellcome Institutional Strategic Support Fund [204826/Z/16/Z]	National Institute for Health Research (NIHR) School for Primary Care Research in Nottingham University; NIHR School for Primary Care Researchin Oxford University; NIHR Schools for Primary Care Research at Nottingham; Oxford Universities; NIHR Biomedical Research Centre, Oxford, John Fell Oxford University Press Research Fund, Cancer Research UK through the Cancer Research UK Oxford Centre; Oxford Wellcome Institutional Strategic Support Fund	CPRD analysis was funded by the National Institute for Health Research (NIHR) School for Primary Care Research (ref FR19 No 480) in Nottingham University. QResearch analysis was funded by the NIHR School for Primary Care Research (ref FR19 No 3372) in Oxford University. The funders had no role in considering the study design or in the collection, analysis, or interpretation of data, writing of the report, or the decision to submit the article for publication. Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/and declare: support from the NIHR Schools for Primary Care Research at Nottingham and Oxford Universities; JHC has received grants from the NIHR Biomedical Research Centre, Oxford, John Fell Oxford University Press Research Fund, Cancer Research UK (grant number C5255/A18085) through the Cancer Research UK Oxford Centre, and the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z) during the conduct of the study; JHC is an unpaid director of QResearch, a not-for-profit organisation that is a partnership between the University of Oxford and EMIS Health, which supplies the QResearch database used for this work; JHC is a founder and shareholder of ClinRisk Ltd and was its medical director until 31 May 2019; ClinRisk Ltd produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems; no other relationships or activities that could appear to have influenced the submitted work.	Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Brinton RD, 2015, NAT REV ENDOCRINOL, V11, P393, DOI 10.1038/nrendo.2015.82; Delgado-Rodriguez M, 2004, J EPIDEMIOL COMMUN H, V58, P635, DOI 10.1136/jech.2003.008466; Etminan M, 2004, PHARMACOTHERAPY, V24, P1105, DOI 10.1592/phco.24.13.1105.38083; Henderson VW, 2016, NEUROLOGY, V87, P699, DOI 10.1212/WNL.0000000000002980; Irntiaz B, 2017, MATURITAS, V98, P7, DOI 10.1016/j.maturitas.2017.01.002; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; National Collaborating Centre for Women's and Children's Health (UK), 2015, MEN FULL GUID; National Institute for Health and Care Excellence, 2019, MEN DIAGN MAN NICE G; Rasgon NL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089095; Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Rymer J, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l5928; Savolainen-Peltonen H, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l665; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Song YJ, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00157; Townsend J, 1998, BRIT J GEN PRACT, V48, P955; Vinogradova Y, EMRAN 2021; Vinogradova Y, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3873; Vinogradova Y, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k4810; Wroolie TE, 2015, AM J GERIAT PSYCHIAT, V23, P1117, DOI 10.1016/j.jagp.2015.05.009; Zarate S, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00430	24	15	15	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 30	2021	374								n2182	10.1136/bmj.n2182	http://dx.doi.org/10.1136/bmj.n2182			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WI4IO	34588168	Green Published, hybrid			2023-01-03	WOS:000708326200002
J	Ingenpa, L; Abd El-Wahab, A; Ullrich, C; Kolln, M; Ahmed, MFE; Visscher, C; Kamphues, J				Ingenpa, Lena; Abd El-Wahab, Amr; Ullrich, Cristina; Koelln, Mareike; Ahmed, Marwa F. E.; Visscher, Christian; Kamphues, Josef			Nitrogen output in the urban environment using a vegetarian canine diet	PLOS ONE			English	Article							NUTRIENT DIGESTIBILITY; FERMENTATIVE ACTIVITY; DOGS; PROTEIN; ENERGY; FIBER; SIZE; CAT	Pet owners are increasingly concerned about the links between health status, animal welfare, environmental impacts, climate change and consumption of animal products. Accordingly, many owners are increasingly interested in vegetarian diets for themselves and their companion animals. However, such diets should be investigated nutritionally regards digestibility as well as on fecal quality and nitrogen output. In light of this trend, six Beagle dogs were included in a cross-over experimental design and offered a vegetarian diet containing wheat gluten (8.81%), rice protein (8.81%) and sunflower oil (6.84%) or an meat-based diet containing poultry meal (19.5%) and poultry fat (5.23%). The dogs received extruded complete diets for 12 days (adaptation and collection period, each 6 days). The dogs fed both diets showed a high and identical palatability (scoring of food intake) of the experimental diets. No significant differences occurred regarding digestibility of organic matter, crude protein and crude fat between vegetarian and meat-based diets. However, dogs fed the meat-based diet had higher (p < 0.05) nitrogen-free extract digestibility (89.5%) compared to those fed the vegetarian diet (88.6%). The amount of nitrogen excreted in feces (g)/kg BW0.75 was slightly, but not significantly, higher for dogs fed the vegetarian diet compared to those fed the meat-based diet (0.88 vs 0.79). The fecal consistency scores were considered to be within an acceptable range (well formed and firm). The mass of the feces between both groups were similar (62.9 g wet feces/100 g dry matter food) for vegetarian and meat-based diets. Additionally, the fecal dry matter content was comparable between both groups (29.0% and 29.6% for vegetarian and meat-based diets, respectively). In conclusion, the results of this study appear to indicate that virtually the only significant difference between the two diets was lower nitrogen-free extract digestibility in the vegetarian diet. However, the vegetarian diet did not result in a significant difference in amount of nitrogen excreted in feces.	[Ingenpa, Lena; Abd El-Wahab, Amr; Ullrich, Cristina; Koelln, Mareike; Visscher, Christian; Kamphues, Josef] Univ Vet Med Hannover, Inst Anim Nutr, Hannover, Germany; [Abd El-Wahab, Amr] Mansoura Univ, Fac Vet Med, Dept Nutr & Nutr Deficiency Dis, Mansoura, Egypt; [Ahmed, Marwa F. E.] Mansoura Univ, Fac Vet Med, Dept Hyg & Zoonoses, Mansoura, Egypt	University of Veterinary Medicine Hannover, Foundation; Egyptian Knowledge Bank (EKB); Mansoura University; Egyptian Knowledge Bank (EKB); Mansoura University	Ullrich, C (corresponding author), Univ Vet Med Hannover, Inst Anim Nutr, Hannover, Germany.	cristina.ullrich@tiho-hannover.de	Abd El-Wahab, Amr/U-4873-2019	Abd El-Wahab, Amr/0000-0002-2947-6737	German Research Foundation (Deutsche Forschungsgemeinschaft); University of Veterinary Medicine Hannover, Foundation, Germany; MERA Tiernahrung(C) GmbH	German Research Foundation (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); University of Veterinary Medicine Hannover, Foundation, Germany; MERA Tiernahrung(C) GmbH	This publication was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, https://www.dfg.de/) and University of Veterinary Medicine Hannover, Foundation, Germany (https://www.tiho-hannover.de/) within the funding program Open Access Publishing (CU, grant numbers not applicable). Furthermore by MERA Tiernahrung (c) GmbH (https://www.mera-petfood.com/de/) as funder of this research and supporter of LI (grant number not applicable). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	AAFCO-Association of American Feed Control Officials, 2014, MOD REG PET FOOD SPE; Abd El-Wahab A, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11020496; Alexandratos N., 2012, TECH REP, DOI 10.22004/ag.econ.288998; Zafalon RVA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227046; AOAC, 2019, OFFICIAL METHODS ANA; Bednar GE, 2000, ARCH ANIM NUTR, V53, P127, DOI 10.1080/17450390009381942; Bongaarts J., 2019, INTERGOVERNMENTAL PA; Brown W. Y., 2009, RECENT ADV ANIM NUTR, V17, P137; BURROWS CF, 1982, J NUTR, V112, P1726, DOI 10.1093/jn/112.9.1726; Debnath B. C., 2008, Indian Journal of Animal Research, V42, P219; Dodd SAS, 2021, BMC VET RES, V17, DOI 10.1186/s12917-021-02754-8; Dodd SAS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210806; Dodd SAS, 2018, JAVMA-J AM VET MED A, V253, P1425, DOI 10.2460/javma.253.11.1425; Fahey G, 1997, 97 PET FOOD FOR O MT, P12; FAHEY GC, 1990, J ANIM SCI, V68, P4221; FEDIAF-The European Pet Food Industry Federation, 2019, NUTR GUID COMPL COMP; Fricke S, 2002, VERTRAGLICHKEIT VERD; GERICKE S, 1952, FRESEN Z ANAL CHEM, V137, P15, DOI 10.1007/BF00452421; Godfray HCJ, 2018, SCIENCE, V361, DOI 10.1126/science.aam5324; Golder C, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10030541; Hall JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054405; Hill RC, 2001, J ANIM SCI, V79, P2162; HUBER TL, 1994, CANINE PRACT, V19, P11; Hussein H, 2000, RECENT ADV CANINE FE; Kamphues J., 2014, SUPPLEMENTE TIERERNA, Vtwelfth; KENDALL PT, 1982, J SCI FOOD AGR, V33, P823, DOI 10.1002/jsfa.2740330903; Kienzle E, 1998, J ANIM PHYSIOL AN N, V79, P46, DOI 10.1111/j.1439-0396.1998.tb00628.x; Knight A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253292; Knight A, 2016, ANIMALS, V6, DOI 10.3390/ani6090057; Koneswaran G, 2008, ENVIRON HEALTH PERSP, V116, P578, DOI 10.1289/ehp.11034; Laflamme D, 1997, CANINE PRACT, V22, P10; Leip A, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/11/115004; Leytem AB, 2021, AGRONOMY-BASEL, V11, DOI 10.3390/agronomy11051005; MACDONALD ML, 1984, ANNU REV NUTR, V4, P521, DOI 10.1146/annurev.nu.04.070184.002513; MERRITT AM, 1979, J AM VET MED ASSOC, V174, P59; Meyer H, 2016, ERNAHRUNG HUNDES GRU, V8; Meyer H., 1989, ADV ANIMAL PHYSL ANI; Morgan R., 2016, SLOW STEADY RISE VEG; Moxham G., 2001, WALTHAM FOCUS, V11, P24; Murray SM, 1999, J ANIM SCI, V77, P2180; Naumann C., 2012, METHODEN LANDWIRTSCH, DOI [10.1007/978-3-319-19944-3_4, DOI 10.1007/978-3-319-19944-3_4]; Nery J, 2012, J ANIM SCI, V90, P2570, DOI 10.2527/jas.2011-4112; Nery J, 2010, J ANIM SCI, V88, P159, DOI 10.2527/jas.2008-1666; NRC, 2006, NUTR REQ DOGS CATS; NRC-National Research Council, 1985, NUTR REQUIREMENTS DO; Rotz C. A., 2015, EM MAGAZINE      SEP, P12; Rubio NR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20061-y; Seto KC, 2016, SCIENCE, V352, P943, DOI 10.1126/science.aaf7439; Swanson KS, 2013, ADV NUTR, V4, P141, DOI 10.3945/an.112.003335; Tilman D, 2017, NATURE, V546, P73, DOI 10.1038/nature22900; Union IV, 2016, IVU WORLD VEGF DEF V; University College of London, 2020, UCL CONN LEARN BAS; Urrego Maria Isabel Gonzalez, 2017, J Nutr Sci, V6, pe43, DOI 10.1017/jns.2017.46; Wakefield LA, 2006, JAVMA-J AM VET MED A, V229, P70, DOI 10.2460/javma.229.1.70; Weber MP, 2004, J ANIM PHYSIOL AN N, V88, P356, DOI 10.1111/j.1439-0396.2004.00494.x; Wiernusz C. J., 1995, Veterinary Clinical Nutrition, V2, P49; Zahn S, 2010, UNTERSUCHUNGEN ZUM F; ZENTEK J, 1995, J ANIM PHYSIOL AN N, V74, P62, DOI 10.1111/j.1439-0396.1995.tb00437.x; Zieger A.L., 2015, UNTERSUCHUNGEN ZUM E; Zuo Y, 1996, J ANIM SCI, V74, P2441	60	1	1	4	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2021	16	9							e0257364	10.1371/journal.pone.0257364	http://dx.doi.org/10.1371/journal.pone.0257364			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XH8RH	34555067	gold, Green Published			2023-01-03	WOS:000725694500030
J	Shichijo, K; Takeuchi, S; Tayama, T; Takei, M; Fujioka, K; Ono, A; Shono, M; Suga, K; Kondo, R; Kaimen, T; Arima, N; Kondo, S				Shichijo, Koichi; Takeuchi, Shunsuke; Tayama, Takahiro; Takei, Mikiko; Fujioka, Keisuke; Ono, Akemi; Shono, Miki; Suga, Kenichi; Kondo, Reiko; Kaimen, Takashi; Arima, Nobuo; Kondo, Shuji			Patient attendance at a pediatric emergency referral hospital in an area with low COVID-19 incidence	PLOS ONE			English	Article							UNITED-STATES	The purpose of this study was to clarify the effects of individual infection control measures and physical distancing on pediatric medical care in a local prefecture in Japan, where the incidence of coronavirus disease (COVID-19) in pediatric patients was extremely low. We extracted data from hospital records on the number of outpatients, inpatients, infectious disease consultations, and consultations for representative pediatric diseases. We compared attendance in 2017-2019, before the COVID-19 pandemic, with 2020, when COVID-19 spread to Japan. There were no COVID-19 patients in the pediatric department during the study period. The total number outpatient visits decreased by 24.4%, and the number of hospital admissions, excluding neonatal care unit admissions, decreased by approximately 35%. There was a marked reduction in the number of hospitalizations for infectious diseases such as influenza (-74.8%) and respiratory syncytial virus infection (-93.5%), and the number of hospitalizations for bronchitis/pneumonia, Kawasaki disease, and bronchial asthma decreased. In contrast, the number of clinical psychological interventions and cases reported to the child guidance center increased. In the context of pandemic infectious diseases, it is important to control the spread of problematic infectious diseases by individual infection control measures and physical distancing. However, it is necessary to maintain social life as much as possible for the mental health and physical development of children.	[Shichijo, Koichi; Takeuchi, Shunsuke; Tayama, Takahiro; Takei, Mikiko; Fujioka, Keisuke; Ono, Akemi; Shono, Miki; Kondo, Reiko; Kondo, Shuji] Tokushima Prefectural Cent Hosp, Dept Pediat, Tokushima, Japan; [Suga, Kenichi] Tokushima Univ Hosp, Dept Pediat, Tokushima, Japan; [Kaimen, Takashi] Tokushima Prefectural Cent Hosp, Dept Psychiat, Tokushima, Japan; [Arima, Nobuo] Tokushima Prefectural Cent Hosp, Patient Support Ctr, Tokushima, Japan	Tokushima University	Shichijo, K (corresponding author), Tokushima Prefectural Cent Hosp, Dept Pediat, Tokushima, Japan.	kshichijo.32@gmail.com		Kondo, Shu/0000-0002-4625-8379				Agut H, 2017, MED MALADIES INFECT, V47, P83, DOI 10.1016/j.medmal.2016.09.004; Bautista-Rodriguez C, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-024554; Dopfer C, 2020, BMC PEDIATR, V20, DOI 10.1186/s12887-020-02303-6; Giamello JD, 2020, EUR J EMERG MED, V27, P305, DOI 10.1097/MEJ.0000000000000718; Kuitunen I, 2020, PEDIATR INFECT DIS J, V39, pE423, DOI 10.1097/INF.0000000000002845; Lin CF, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.604089; Ministry of Education Culture Sports Science and Technology, INF MEXTS MEAS COVID; Ministry of Health Labour and Welfare, MINISTRY HLTH LABOUR; Ministry of Health Labour and Welfare, VIS DAT INF COVID 19; Ministry of Health Labour and Welfare, 3 CS; Olsen SJ, 2020, AM J TRANSPLANT, V20, P3681, DOI 10.1111/ajt.16381; Prime Minister of Japan and his Cabinet, COVID 19 DECL STAT E; Rowley AH, 2018, INT J RHEUM DIS, V21, P20, DOI 10.1111/1756-185X.13213; Swedo E, 2020, MMWR-MORBID MORTAL W, V69, P1841, DOI 10.15585/mmwr.mm6949a1; Tartari F, 2020, J EUR ACAD DERMATOL, V34, pE350, DOI 10.1111/jdv.16553; Tokushima Prefecture webpage, CHANG NUMB REP SENT; World Health Organization, COVID 19 WEEKL EP UP; Xie XY, 2020, JAMA PEDIATR, V174, P898, DOI 10.1001/jamapediatrics.2020.1619; Yamamoto T, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17249382; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	20	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	10							e0258478	10.1371/journal.pone.0258478	http://dx.doi.org/10.1371/journal.pone.0258478			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9YI	34648561	gold, Green Published			2023-01-03	WOS:000729172300022
J	Cavali, J; de Souza, MLR; Kanarski, PSDO; Coradini, MF; Dantas, JV				Cavali, Jucilene; Rodrigues de Souza, Maria Luiza; de Oliveira Kanarski, Patricia Silva; Coradini, Melina Franco; Dantas Filho, Jeronimo Vieira			Tanned leather of the paiche Arapaima gigas Schinz, 1822 (Arapaimidae) with extracts of vegetable origin to replace chromium salts	PLOS ONE			English	Article								With the intensification of fish farming, the amount of residues also increased. One of the by-products generated is leather. However, several factors influence its quality, among them, the types of tanning used. Paiche (Arapaima gigas) is the largest freshwater fish in the world, and therefore has great potential in the use of leather, in addition to being one of the most cultivated fish in the Rondonia state. The aimed was to evaluate the physicomechanical resistance, histological and morphological aspects in different directions of the fibers of the paiche to evaluate the tanning with chromium oxide and vegetable tannin. Paiches with an average weight of 12.0 kg were used, skins were made and tanned using chromium and vegetable tannin as techniques. After tanning, 20 specimens were removed in longitudinal, transverse and diagonal directions to the fish body, to determine resistance in dynamometer and leather for histological analysis, scanning electron microscopy and physical-chemical analysis. The average thickness of the specimens of the leathers ranged 1.79mm to 2.82mm, in addition, there was no interaction between the type of tanning agent and the directions obtained for strength, traction and elongation. Regarding the progressive tearing test, there was also no interaction effect. However, the defined factors had relevant differences for the maximum and average amount applied, and the leathers tanned with vegetable tannin expanded to larger dimensions 110.19 and 85.52 N. According to the images obtained by histology and scanning microscopy, they presented that in the longitudinal and transverse direction the collagen fibers are presented in layers parallel to the leather surface and in the diagonal direction the interlacing is more intense, that is, in addition to the overlapping layers intercalated thinner, close to the surface, fiber bundles can also be seen crossing each other. It is concluded that leathers tanned with vegetable tannin have less resistance than leathers tanned with chromium salts for traction to rupture and greater resistance to tear.	[Cavali, Jucilene; de Oliveira Kanarski, Patricia Silva; Dantas Filho, Jeronimo Vieira] Univ Fed Rondonia UNIR, Programa Posgrad Ciencias Ambientais, Rolim De Moura, Rondonia, Brazil; [Rodrigues de Souza, Maria Luiza; Coradini, Melina Franco] Univ Estadual Maringa UEM, Lab Processamentos Peles & Couros, Maringa, Parana, Brazil	Universidade Federal de Rondonia; Universidade Estadual de Maringa	Dantas, JV (corresponding author), Univ Fed Rondonia UNIR, Programa Posgrad Ciencias Ambientais, Rolim De Moura, Rondonia, Brazil.	jeronimovdantas@gmail.com		Vieira Dantas Filho, Jeronimo/0000-0002-5965-9438; Souza, Maria Luiza/0000-0003-1135-6443; Cavali, Jucilene/0000-0002-2069-4543	CAPES; Programa Nacional de Cooperacao Academica na Amazonia -PROCAD-AM (UNIR/UFAC/USP)	CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Programa Nacional de Cooperacao Academica na Amazonia -PROCAD-AM (UNIR/UFAC/USP)	This study received financial support from CAPES, linked to the Ministry of Education of Brazil. Through Programa Nacional de Cooperacao Academica na Amazonia -PROCAD-AM (UNIR/UFAC/USP), for the granting of a postdoctoral scholarship to Jeronimo Vieira Dantas Filho.	ASSOCIACA O BRASILEIRA DE NORMAS TECNICAS, 2013, 11030 NBRISO ABNT; ASSOCIACAO BRASILEIRA DE NORMAS TECNICAS, 2017, 11036 NBRISO ABNT; ASSOCIACAO BRASILEIRA DE NORMAS TECNICAS, 2014, 11055ISSO NBR ABNT; ASSOCIACAO BRASILEIRA DE NORMAS TECNICAS, 2014, 10054 NBRISO ABNT; ASSOCIACAO BRASILEIRA DE NORMAS TECNICAS, 2014, 3376 NBRISO ABNT; ASSOCIACAO BRASILEIRA DE NORMAS TECNICAS, 2015, 2418 NBRISO ABNT; ASSOCIACAO BRASILEIRA DE NORMAS TECNICAS, 2015, 4044 NBRISO ABNT; ASSOCIACAO BRASILEIRA DE NORMAS TECNICAS, 2014, 10455 NBR ABNT; Auad P, 2020, CHEM ENG COMMUN, V207, P722, DOI 10.1080/00986445.2019.1618843; BASF S.A., 2005, VAD ME CUM CURT; Bradbury PJ, 2007, BIOINFORMATICS, V23, P2633, DOI 10.1093/bioinformatics/btm308; Flores A., 1997, REV COURO, V119, P66; Ghani A., 2011, EAJBS A ENTOMOL, V2, P9, DOI [DOI 10.21608/EAJBSH.2011.17007, 10.21608/eajbsh.2011.17007]; HEMA GS, 2013, INDIAN COUNCIL AGR R, V4, P271; Hilbig CC, J SOC LEATHER TECHNO, V97, P189; Hoinacki E, 1989, PELES COUROS ORIGENS; JUNQUEIRA LCU, 1983, BRAZ J MED BIOL RES, V16, P313; Kasim A., 2014, Media Peternakan, V37, P24, DOI 10.5398/medpet.2014.37.1.24; Luna L.G., 1968, MANUAL HISTOLOGIC ST, P32; Matiucci MA, 2021, RES SOC DEV, V10, DOI [10.33448/rsd-v10i8.17242, DOI 10.33448/RSD-V10I8.17242]; Oliveira Pedro Roberto de, 2014, Braz. J. Food Technol., V17, P67, DOI 10.1590/bjft.2014.010; Pino-Hernandez E, 2020, INT J GASTRON FOOD S, V20, DOI 10.1016/j.ijgfs.2020.100200; Rocha MPSS, 2013, THESIS; Roy U.S., 2011, ENV RES ENG MANAG, V58, P10, DOI DOI 10.5755/J01.EREM.58.4.660; Ryder K, 2017, CRIT REV ENV SCI TEC, V47, P621, DOI 10.1080/10643389.2017.1322875; Santos FV, 2021, RES SOC DEV, V10, DOI [10.33448/rsd-v10i8.17242, DOI 10.33448/RSD-V10I8.17242]; Sayed RKA, 2021, MICROSC RES TECHNIQ, V84, P1821, DOI 10.1002/jemt.23741; Vieira ECS, 2018, J FOOD PROCESS PRES, V42, DOI 10.1111/jfpp.13820; Souza M. L. R., 2003, ACTA SCI-ANIM SCI, V25, P37; Souza M. L. R. de, 2005, Acta Scientiarum -  Animal Sciences, V27, P535; Souza MLR, 2017, INT J LATEST RES SCI, V6, P8; Souza MLR, 2004, TECNOLOGIA PROCESSAM; Souza MLR, 2021, RES SOC DEV, V10, DOI [10.33448/rsd-v10i8.17240, DOI 10.33448/RSD-V10I8.17240]; Uzma A, 2020, ASIAN J RES BIOSCIEN, V2, P1; Valenti WC, 2021, AQUACULT REP, V19, DOI 10.1016/j.aqrep.2021.100611; Vieira Hoch Amanda Lilian, 2009, Acta Scientiarum Animal Sciences, V31, P411, DOI 10.4025/actascianimsci.v31i4.5592; Yoshida G. M., 2016, Archivos de Zootecnia, V65, P349	37	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0261781	10.1371/journal.pone.0261781	http://dx.doi.org/10.1371/journal.pone.0261781			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061734	gold, Green Published			2023-01-03	WOS:000791072800060
J	Cibulkova, N; Dadova K; Maskova, K; Busch, A; Kobesova, A; Varekova J; Haspicova, M; Matoulek, M				Cibulkova, Natalie; Dadova, Klara; Maskova, Katerina; Busch, Andrew; Kobesova, Alena; Varekova, Jitka; Haspicova, Marcela; Matoulek, Martin			Bariatric surgery and exercise: A pilot study on postural stability in obese individuals	PLOS ONE			English	Article							BODY-MASS INDEX; WEIGHT-LOSS; MUSCULAR STRENGTH; BALANCE CONTROL; FORCE PLATE; PRESSURE; CHILDREN; SWAY; MOVEMENT; BEHAVIOR	This study aimed to analyze the changes in postural stability of individuals with obesity after bariatric surgery, and the effect of three months of regular exercise on the static postural stability. Twenty-two subjects (7 females and 15 males) aged 31 to 68 years (Body mass index 35-55 kg.m(-2)) completed the study. Participants were divided into two groups: one group participated in an exercise program after the bariatric surgery (n = 10; age 48.9 +/- 7.5 years; Body mass index 42 +/- 5.6 kg.m(-2)) while the second group did not exercise at all after bariatric surgery (n = 12; age 44.7 +/- 13.6 years, Body mass index 42.6 +/- 6.0 kg.m(-2)). Static postural stability was measured using a Tekscan MobileMat pressure plate before and 4 months after the bariatric surgery. The exercise program included exercising three times a week including: one hour of strengthening, one hour of aerobic group exercise and at least one session of individual exercise at home. There were no significant differences in Center of force sway, Center of force ranges and average speed before and 4 months after bariatric surgery. Also, no effect of exercise was found. Post-pre differences of some parameters were negatively related to age (r from-0.46 to-0.72). Further studies are needed to explore this topic in depth.	[Cibulkova, Natalie; Dadova, Klara; Maskova, Katerina; Varekova, Jitka] Charles Univ Prague, Fac Phys Educ & Sport, Prague, Czech Republic; [Cibulkova, Natalie; Matoulek, Martin] Gen Univ Hosp Prague, Dept Internal Med 3, Prague, Czech Republic; [Busch, Andrew] Ohio Wesleyan Univ, Hlth & Human Kinet, Delaware, OH 43015 USA; [Kobesova, Alena] Charles Univ Prague, Fac Med 2, Dept Rehabil & Sports Med, Prague, Czech Republic; [Kobesova, Alena] Univ Hosp Motol, Prague, Czech Republic; [Haspicova, Marcela] Med Ctr ORP Ctr, Prague, Czech Republic	Charles University Prague; General University Hospital Prague; Ohio Wesleyan University; Charles University Prague; Motol University Hospital	Cibulkova, N (corresponding author), Charles Univ Prague, Fac Phys Educ & Sport, Prague, Czech Republic.; Cibulkova, N (corresponding author), Gen Univ Hosp Prague, Dept Internal Med 3, Prague, Czech Republic.	nat.cibulkova@gmail.com	Daďová, Klára/AAO-4920-2020; Cibulkova, Natalie/R-1024-2017	Daďová, Klára/0000-0003-3164-2236; Busch, Andrew/0000-0003-1383-4410; Cibulkova, Natalie/0000-0001-5350-5502	Ministry of Health, Czech Republic [GJIH-1599-04-1-180, 64165]; General University Hospital in Prague, Czech Republic; Programme of the institutional support for science at Charles University [Q41]	Ministry of Health, Czech Republic(Ministry of Health, Czech RepublicCzech Republic Government); General University Hospital in Prague, Czech Republic; Programme of the institutional support for science at Charles University	This study was supported by Ministry of Health, Czech Republic (GJIH-1599-04-1-180) conceptual development of research organization 64165, General University Hospital in Prague, Czech Republic, and the Programme of the institutional support for science at Charles University Progress, No. Q41 Biological aspects of the investigation of human movement. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alonso AC, 2012, CLINICS, V67, P1433, DOI 10.6061/clinics/2012(12)14; Bankoff A.D.P., 2006, MOV PERCEPCA O ESPIR, V6, P55; Benetti FA, 2016, CLINICS, V71, P78, DOI 10.6061/clinics/2016(02)05; BERGER W, 1992, ACTA OTO-LARYNGOL, V112, P22, DOI 10.3109/00016489209100778; Berrigan F, 2006, INT J OBESITY, V30, P1750, DOI 10.1038/sj.ijo.0803342; Bickley C, 2019, GAIT POSTURE, V67, P91, DOI 10.1016/j.gaitpost.2018.08.012; Birtane M, 2004, CLIN BIOMECH, V19, P1055, DOI 10.1016/j.clinbiomech.2004.07.008; Blaszczyk JW, 2009, J BIOMECH, V42, P1295, DOI 10.1016/j.jbiomech.2009.03.006; Brenton-Rule A, 2012, J FOOT ANKLE RES, V5, DOI 10.1186/1757-1146-5-21; Cawley J, 2015, J HEALTH ECON, V43, P244, DOI 10.1016/j.jhealeco.2015.03.001; Cieslinska-Swider JM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220962; Cousins SD, 2013, J FOOT ANKLE RES, V6, DOI 10.1186/1757-1146-6-36; Cruz-Gomez NS, 2011, OBESITY FACTS, V4, P212, DOI 10.1159/000329408; Daniels P, 2018, J SPORT SCI, V36, P529, DOI 10.1080/02640414.2017.1322217; Dansk Selskab for Almen Medicin, 2010, KLIN VEJL ALM PRAKS; De Lorenzo A, 2016, WORLD J GASTROENTERO, V22, P681, DOI 10.3748/wjg.v22.i2.681; Duarte M, 2010, REV BRAS FISIOTER, V14, P183, DOI 10.1590/S1413-35552010000300003; Dutil M, 2013, AGE, V35, P883, DOI 10.1007/s11357-012-9386-x; Era P, 2006, GERONTOLOGY, V52, P204, DOI 10.1159/000093652; Fabunmi A A, 2008, Afr J Med Med Sci, V37, P321; Ferreira FPM, 2003, MONOGRAFIA U ESTADO; Frankenfield DC, 2001, NUTRITION, V17, P26, DOI 10.1016/S0899-9007(00)00471-8; Goetschius J, 2018, J SPORT REHABIL, V27, DOI 10.1123/jsr.2017-0152; Gonzalez M, 2020, J BIOMECH, V100, DOI 10.1016/j.jbiomech.2019.109585; Greve J, 2007, CLINICS, V62, P717, DOI 10.1590/S1807-59322007000600010; Handrigan G, 2010, INT J OBESITY, V34, P936, DOI 10.1038/ijo.2009.300; Handrigan GA, 2010, J BIOMECH, V43, P383, DOI 10.1016/j.jbiomech.2009.08.041; Hassannejad A, 2017, OBES SURG, V27, P2792, DOI 10.1007/s11695-017-2717-3; Herrera-Rangel A, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/787202; Hills AP, 2001, INT J OBESITY, V25, P1674, DOI 10.1038/sj.ijo.0801785; Horak S, 2017, CENT EUR J PUBL HEAL, V25, P326, DOI 10.21101/cejph.a4780; Hue O, 2008, OBES SURG, V18, P1112, DOI 10.1007/s11695-008-9597-5; Hue O, 2007, GAIT POSTURE, V26, P32, DOI 10.1016/j.gaitpost.2006.07.005; Kennedy PM, 2002, J PHYSIOL-LONDON, V538, P995, DOI 10.1113/jphysiol.2001.013087; King WC, 2016, JAMA-J AM MED ASSOC, V315, P1362, DOI 10.1001/jama.2016.3010; Losco L, 2022, J INVEST SURG, V35, P620, DOI 10.1080/08941939.2021.1912220; Maffiuletti NA, 2005, J ENDOCRINOL INVEST, V28, P2, DOI 10.1007/BF03345521; Matrangola SL, 2009, MED SCI SPORT EXER, V41, P1488, DOI 10.1249/MSS.0b013e31819bd4bd; Maurer C, 2005, J NEUROPHYSIOL, V93, P189, DOI 10.1152/jn.00221.2004; Menegoni F, 2009, OBESITY, V17, P1951, DOI 10.1038/oby.2009.82; Pagnotti GM, 2020, OBESITY FACTS, V13, P499, DOI 10.1159/000509163; Raymakers JA, 2005, GAIT POSTURE, V21, P48, DOI 10.1016/j.gaitpost.2003.11.006; Rezaeipour M, 2018, MIDDLE E J REHABIL H, V5, DOI 10.5812/mejrh.81617; Riddiford-Harland DL, 2000, INT J OBESITY, V24, P541, DOI 10.1038/sj.ijo.0801192; Rogind H, 2003, CLIN PHYSIOL FUNCT I, V23, P171, DOI 10.1046/j.1475-097X.2003.00492.x; Rojhani-Shirazi Z, 2016, EUR SURG, V48, P105, DOI 10.1007/s10353-015-0379-8; Ruhe A, 2010, GAIT POSTURE, V32, P436, DOI 10.1016/j.gaitpost.2010.09.012; Son Sung Min, 2016, Osong Public Health Res Perspect, V7, P378, DOI 10.1016/j.phrp.2016.10.001; Tabesh MR, 2019, OBES SURG, V29, P3385, DOI 10.1007/s11695-019-04112-y; Teasdale N, 2007, INT J OBESITY, V31, P153, DOI 10.1038/sj.ijo.0803360; Tekscan, PRESS MAPP TECHN PRE; The WAVEWATCH III &REG;Development Group, 2016, SPORTS 2 0X US MAN R; Theriault-Proulx M, 2008, MED SCI SPORT EXER, V40, pS344, DOI 10.1249/01.mss.0000323377.84898.21; Vareka I, 2002, REHAB FYZ LEK, V9, P115; Vartanian LR, 2008, J HEALTH PSYCHOL, V13, P131, DOI 10.1177/1359105307084318; VEDEL JP, 1982, NEUROSCI LETT, V34, P289, DOI 10.1016/0304-3940(82)90190-2; Villarrasa-Sapina I, 2018, CLIN BIOMECH, V52, P1, DOI 10.1016/j.clinbiomech.2017.12.010; Villarrasa-Sapina I, 2017, CLIN BIOMECH, V41, P77, DOI 10.1016/j.clinbiomech.2016.12.008; Villarrasa-Sapina I, 2016, GAIT POSTURE, V49, P1, DOI 10.1016/j.gaitpost.2016.06.012; Wearing SC, 2006, OBES REV, V7, P13, DOI 10.1111/j.1467-789X.2006.00215.x; Winter DA, 1996, J NEUROPHYSIOL, V75, P2334, DOI 10.1152/jn.1996.75.6.2334; Zemkova E, 2017, J BACK MUSCULOSKELET, V30, P353, DOI 10.3233/BMR-160585	62	0	0	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2022	17	1							e0262651	10.1371/journal.pone.0262651	http://dx.doi.org/10.1371/journal.pone.0262651			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2F3FM	35030216	gold, Green Published			2023-01-03	WOS:000812798500062
J	Vendramini, THA; Olivindo, RFG; Zafalon, RVA; Rentas, MF; Zanini, LD; Amaral, AR; Pedrinelli, V; de Oliveira, VV; Risolia, LW; Teixeira, FA; Brunetto, MA				Annibale Vendramini, Thiago Henrique; Gomes Olivindo, Rodrigo Fernando; Amorim Zafalon, Rafael Vessecchi; Rentas, Mariana Fragoso; Zanini, Lucca Denuci; Amaral, Andressa Rodrigues; Pedrinelli, Vivian; de Oliveira, Vinicius Vasques; Risolia, Larissa Wunsche; Teixeira, Fabio Alves; Brunetto, Marcio Antonio			Profile qualitative variables on the dynamics of weight loss programs in dogs	PLOS ONE			English	Article							LIMITED FOOD-CONSUMPTION; OWNER-PERCEIVED OBESITY; RISK-FACTORS; VETERINARY PRACTICES; LEPTIN CONCENTRATIONS; PREVALENCE; OSTEOARTHRITIS; ASSOCIATION; NUTRITION; CATS	Obesity is the most common nutritional disorder in dogs and it is associated with many comorbidities. Some obesity risk factors have already been established, however, the evaluation of the effect of different individual variables on weight loss induced by calorie restriction, although very important, is still poorly explored. The weight loss protocol can be updated and improved by more precise and adjusted equations throughout the weight loss program in the clinical routine practice. Therefore, the objective of this study was to analyze weight loss program dynamics in groups according to reproductive status, age, body size, and breed, as well as to define more accurately the amount of calories per target metabolic weight throughout the program. Data of 1,053 cases, presented between 2012 and 2019 at the Veterinary Hospital of the School of Veterinary Medicine and Animal Science of the University of Sao Paulo (FMVZ-USP) were retrospectively analyzed. A total of 77 obese dogs (body condition scores 8/9 or 9/9) of different ages, breeds, sizes, and reproductive status were selected. These dogs did not have any concomitant illnesses and successfully completed the weight loss program. Statistical analysis was performed and values of p <= 0.05 were considered significant. The proposed weight loss program was based on an energy restriction protocol where daily energy intake (in kcal) was estimated as 70 kcal x target weight(0.)(75). The target weight (TW) was defined as 80% of the animal's current weight. The average calorie intake for weight loss (calories x target weight(0.75)) was lower for spayed females (62.36), differing from intact males (66.14) and neutered males (65.41), while intact females (63.66) showed intermediate values without differing between groups (p = 0.015). There were no differences between weight loss calories according to age (p = 0.473) or body size (p = 0.084), allowing the use of the same mathematical equation for intact and neutered dogs; for dogs older than 1 year and of different body sizes. Regarding the breed, the average calorie intake was lower (p = 0.002) in mixed breed dogs (61.54xTW(0.)(75)) when compared to obesity-prone purebred dogs (64.17xTW(0.)(75)) and other purebreds (65.27xTW(0.)(75)). It was concluded that spayed females and mixed breed dogs have greater difficulty in losing weight, that is, they need fewer calories per metabolic body weight for the weight loss program to succeed. A more accurate equation for energy requirement for weight loss can improve chances of success, therefore improving compliance and helping clinical management of obesity in dogs.	[Annibale Vendramini, Thiago Henrique; Amorim Zafalon, Rafael Vessecchi; Rentas, Mariana Fragoso; Zanini, Lucca Denuci; Risolia, Larissa Wunsche; Brunetto, Marcio Antonio] Univ Sao Paulo, Pet Nutrol Res Ctr, Nutr & Prod Dept, Sch Vet Med & Anim Sci, Pirassununga, Brazil; [Gomes Olivindo, Rodrigo Fernando; Amaral, Andressa Rodrigues; Pedrinelli, Vivian; de Oliveira, Vinicius Vasques; Teixeira, Fabio Alves; Brunetto, Marcio Antonio] Univ Sao Paulo, Vet Teaching Hosp, Sch Vet Med & Anim Sci, Vet Nutrol Serv, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	Brunetto, MA (corresponding author), Univ Sao Paulo, Pet Nutrol Res Ctr, Nutr & Prod Dept, Sch Vet Med & Anim Sci, Pirassununga, Brazil.; Brunetto, MA (corresponding author), Univ Sao Paulo, Vet Teaching Hosp, Sch Vet Med & Anim Sci, Vet Nutrol Serv, Sao Paulo, Brazil.	mabrunetto@usp.br		Vendramini, Thiago/0000-0003-4457-8392	Grandfood Ind. Ltd.	Grandfood Ind. Ltd.	We would like to thank Grandfood Ind. Ltd. team for maintaining the Pet Nutrology Research Center and supporting the Veterinary Nutrology Service.	Montoya-Alonso JA, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00059; Vendramini THA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238638; Bach JF, 2007, AM J VET RES, V68, P670, DOI 10.2460/ajvr.68.6.670; Brooks D, 2014, J AM ANIM HOSP ASSOC, V50, P1, DOI 10.5326/JAAHA-MS-6331; Brown DC, 1996, VET COMP ORTHOPAED, V9, P75; Brunetto MA, 2011, BRIT J NUTR, V106, pS194, DOI 10.1017/S0007114511000870; Brunetto MA, 2011, CIENC RURAL, V41, P266, DOI 10.1590/S0103-84782011005000004; Carciofi Aulus Cavalieri, 2005, Cienc. Rural, V35, P1331, DOI 10.1590/S0103-84782005000600016; CHIKAMUNE T, 1995, J VET MED SCI, V57, P595, DOI 10.1292/jvms.57.595; Colliard L, 2006, J NUTR, V136, p1951S, DOI 10.1093/jn/136.7.1951S; Corbee RJ, 2013, J ANIM PHYSIOL AN N, V97, P904, DOI 10.1111/j.1439-0396.2012.01336.x; Couillard C, 1997, DIABETOLOGIA, V40, P1178, DOI 10.1007/s001250050804; Courcier EA, 2010, J SMALL ANIM PRACT, V51, P362, DOI 10.1111/j.1748-5827.2010.00933.x; CUNNINGHAM JJ, 1991, AM J CLIN NUTR, V54, P963, DOI 10.1093/ajcn/54.6.963; Devito FC, 2020, VET ANIM SCI, V10, DOI 10.1016/j.vas.2020.100131; EDNEY ATB, 1986, VET REC, V118, P391, DOI 10.1136/vr.118.14.391; Flanagan J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184199; Freeman LM, 2012, J VET INTERN MED, V26, P3, DOI 10.1111/j.1939-1676.2011.00838.x; Gacsi M, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-31; GARLAND T, 1991, EVOLUTION, V45, P1969, DOI 10.1111/j.1558-5646.1991.tb02703.x; German AJ, 2006, J NUTR, V136, p1940S, DOI 10.1093/jn/136.7.1940S; German AJ, 2017, J NUTR SCI, V6, DOI 10.1017/jns.2017.6; German AJ, 2011, BRIT J NUTR, V106, pS93, DOI 10.1017/S0007114511000584; Porsani MYH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70937-8; Hayek MG., 1998, J ANTI-AGING MED, V1, P117, DOI [10.1089/rej.1.1998.1.117, DOI 10.1089/REJ.1.1998.1.117]; HENDRICKS JC, 1992, VET CLIN N AM-SMALL, V22, P1145, DOI 10.1016/S0195-5616(92)50306-0; Hosgood G, 2007, J VET EMERG CRIT CAR, V8, P222, DOI DOI 10.1111/J.1476-4431.1998.TB00128.X; Jeusette IC, 2005, RES VET SCI, V79, P169, DOI 10.1016/j.rvsc.2004.11.012; Kealy RD, 2000, J AM VET MED ASSOC, V217, P1678, DOI 10.2460/javma.2000.217.1678; Kealy RD, 1997, J AM VET MED ASSOC, V210, P222; Kealy RD, 2002, J AM VET MED ASSOC, V220, P1315, DOI 10.2460/javma.2002.220.1315; Laflamme D, 1997, CANINE PRACT, V22, P10; Laflamme D, 2014, VET CLIN N AM-SMALL, V44, P761, DOI 10.1016/j.cvsm.2014.03.001; Larsen JA, 2014, VET CLIN N AM-SMALL, V44, P741, DOI 10.1016/j.cvsm.2014.03.003; Lund E. M., 2006, International Journal of Applied Research in Veterinary Medicine, V4, P177; Mao JF, 2013, PREV VET MED, V112, P438, DOI 10.1016/j.prevetmed.2013.08.012; Mawby DI, 2004, J AM ANIM HOSP ASSOC, V40, P109, DOI 10.5326/0400109; McGreevy PD, 2005, VET REC, V156, P695, DOI 10.1136/vr.156.22.695; National Research Council, 2006, NUTR REQ DOGS CATS, DOI [10.17226/10668, DOI 10.17226/10668]; Neto GBP, 2010, PESQUI VET BRASIL, V30, P167, DOI 10.1590/S0100-736X2010000200012; NRC, 2006, NUTR REQ DOGS CATS; O'Neill DG, 2014, VET J, V202, P286, DOI 10.1016/j.tvjl.2014.08.004; Park HJ, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-113; Pereira-Neto GB, 2018, J ANIM PHYSIOL AN N, V102, P1743, DOI 10.1111/jpn.12963; Pereira-Neto GB, 2014, PESQUI VET BRASIL, V34, P87, DOI 10.1590/S0100-736X2014001300016; Pianka ER, 2000, EVOL ECOL, V6th, DOI [10.2307/4645, DOI 10.2307/4645]; Piantedosi D, 2016, VET J, V216, P72, DOI 10.1016/j.tvjl.2016.07.002; Raffan E, 2016, CELL METAB, V23, P893, DOI 10.1016/j.cmet.2016.04.012; Robertson ID, 2003, PREV VET MED, V58, P75, DOI 10.1016/S0167-5877(03)00009-6; Sallander M, 2010, PREV VET MED, V96, P132, DOI 10.1016/j.prevetmed.2010.05.004; SANTEN RJ, 1980, AM J PHYSIOL, V239, pE109, DOI 10.1152/ajpendo.1980.239.2.E109; Schauf S, 2016, J ANIM SCI, V94, P4239, DOI 10.2527/jas.2015-0109; Tropf M, 2017, J VET INTERN MED, V31, P1000, DOI 10.1111/jvim.14775; Usui S, 2016, ASIAN PAC J TROP BIO, V6, P338, DOI 10.1016/j.apjtb.2016.01.011; Vendramini THA, 2020, NUTR RES REV, V33, P134, DOI 10.1017/S0954422419000271; Zoran DL, 2010, VET CLIN N AM-SMALL, V40, P221, DOI 10.1016/j.cvsm.2009.10.009	56	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2022	17	1							e0261946	10.1371/journal.pone.0261946	http://dx.doi.org/10.1371/journal.pone.0261946			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3K6TH	35020762	gold, Green Published			2023-01-03	WOS:000834207700030
J	Morgan, AS; Mendonca, M; Thiele, N; David, AL				Morgan, Andrei S.; Mendonca, Marina; Thiele, Nicole; David, Anna L.			Management and outcomes of extreme preterm birth	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CHILDREN BORN; GESTATION; METAANALYSIS; ASSOCIATION; CESSATION; SURVIVAL; DELIVERY; INFANTS; CARE		[Morgan, Andrei S.] Univ Paris, Epidemiol & Stat Res Ctr CRESS, INSERM EPOPe U1153, INRA, Paris, France; [Morgan, Andrei S.; David, Anna L.] UCL, Elizabeth Garrett Anderson Inst Womens Hlth Londo, London, England; [Morgan, Andrei S.] Assoc Publ Hop Paris APHP, Dept Neonatal Med, Maternite Port Royal, Paris, France; [Mendonca, Marina] Univ Warwick, Dept Psychol, Coventry, W Midlands, England; [Mendonca, Marina] Univ Leicester, Dept Neurosci Psychol & Behav, Leicester, Leics, England; [Thiele, Nicole] European Fdn Care Newborn Infant, Munich, Germany; [David, Anna L.] UCL, Natl Inst Hlth Res, Hosp Biomed Res Ctr, London, England	INRAE; UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; University of Warwick; University of Leicester; University of London; University College London	Morgan, AS (corresponding author), Univ Paris, Epidemiol & Stat Res Ctr CRESS, INSERM EPOPe U1153, INRA, Paris, France.; Morgan, AS (corresponding author), UCL, Elizabeth Garrett Anderson Inst Womens Hlth Londo, London, England.; Morgan, AS (corresponding author), Assoc Publ Hop Paris APHP, Dept Neonatal Med, Maternite Port Royal, Paris, France.	andrei.morgan@inserm.fr		Mendonca, Marina/0000-0002-9224-4891; Morgan, Andrei/0000-0003-4143-1977; David, Anna/0000-0002-0199-6140	European Union's Horizon 2020 Research and Innovation Program RECAP Preterm Project [733280]; National Institute for Health Research University College London Hospitals Biomedical Research Centre	European Union's Horizon 2020 Research and Innovation Program RECAP Preterm Project; National Institute for Health Research University College London Hospitals Biomedical Research Centre(General Electric)	ASM, MM, and NT are supported by funding from the European Union's Horizon 2020 Research and Innovation Program RECAP Preterm Project (grant no. 733280). ALD is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.	Alenius S, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-1354; Alfirevic Z, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000078.pub3; Allotey J, 2018, BJOG-INT J OBSTET GY, V125, P16, DOI 10.1111/1471-0528.14832; AlS HDS, 2011, CURR WOMENS HEALTH R, V7, P288, DOI 10.2174/157340411796355216; Ancel PY, 2015, JAMA PEDIATR, V169, P230, DOI 10.1001/jamapediatrics.2014.3351; [Anonymous], 2020, Obstet Gynecol, V136, P1238, DOI 10.1097/AOG.0000000000004168; Barthel D, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.575429; Bickerstaff M, 2012, AUST NZ J OBSTET GYN, V52, P54, DOI 10.1111/j.1479-828X.2011.01387.x; Bilgin A, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2017-3625; Chawanpaiboon S, 2019, LANCET GLOB HEALTH, V7, pE37, DOI 10.1016/S2214-109X(18)30451-0; Chen HN, 2010, COMMUN STAT-SIMUL C, V39, P860, DOI 10.1080/03610911003650383; Cheong JLY, 2018, LANCET CHILD ADOLESC, V2, P872, DOI 10.1016/S2352-4642(18)30287-6; Cheong JLY, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4086; Day KL, 2015, CLIN PEDIATR, V54, P1339, DOI 10.1177/0009922815580770; DeMauro SB, 2021, EVOLVING RESP CARE P, V175, P1004; Doyle LW, 2021, ARCH DIS CHILD, V106, P834, DOI 10.1136/archdischild-2021-321668; Draper ES, 2021, INFANT MORTALITY MOR; Duley L, 2018, ARCH DIS CHILD-FETAL, V103, pF6, DOI 10.1136/archdischild-2016-312567; Faber T, 2017, LANCET PUBLIC HEALTH, V2, pE420, DOI 10.1016/S2468-2667(17)30144-5; Franz AP, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-1645; Gallagher K, 2014, ARCH DIS CHILD-FETAL, V99, pF245, DOI 10.1136/archdischild-2013-305191; Gao R, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.33413; Hafstrom M, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-1433; He Y, 2017, LANCET, V390, pS52, DOI 10.1016/S0140-6736(17)33190-2; Hoffman MK, 2020, LANCET, V395, P285, DOI 10.1016/S0140-6736(19)32973-3; Hurst JR, 2020, AM J RESP CRIT CARE, V202, P422, DOI 10.1164/rccm.202001-0016OC; Jayaram PM, 2019, J PERINAT MED, V47, P262, DOI 10.1515/jpm-2018-0174; Johnson S, 2019, J AM ACAD CHILD PSY, V58, P820, DOI 10.1016/j.jaac.2019.02.020; Johnson S, 2011, PEDIATR RES, V69, p11R, DOI 10.1203/PDR.0b013e318212faa0; Johnson S, 2010, J PEDIATR-US, V156, P525, DOI 10.1016/j.jpeds.2009.10.041; Katheria A, 2019, JAMA-J AM MED ASSOC, V322, P1877, DOI 10.1001/jama.2019.16004; Katheria AC, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00100; Koliouli F, 2016, NEWBORN INFANT NURS, V16, P110, DOI 10.1053/j.nainr.2016.08.003; Kwok TC, 2019, SEMIN PERINATOL, V43, DOI 10.1053/j.semperi.2019.06.007; Linsell L, 2018, ARCH DIS CHILD, V103, P363, DOI 10.1136/archdischild-2017-313414; Lykke JA, 2009, OBSTET GYNECOL, V113, P1217, DOI 10.1097/AOG.0b013e3181a66f2d; Mactier H, 2020, ARCH DIS CHILD-FETAL, V105, pF232, DOI 10.1136/fetalneonatal-2019-318402; Marlow N, 2021, ARCH DIS CHILD-FETAL, V106, P418, DOI 10.1136/archdischild-2020-320650; Mathewson KJ, 2017, PSYCHOL BULL, V143, P347, DOI 10.1037/bul0000091; Mendonca M, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6961; Meyer MP, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00046; Morgan AS, 2022, ACTA PAEDIATR, V111, P59, DOI 10.1111/apa.16084; Morgan AS, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79445-1; Morgan AS, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1206-4; Myrhaug HT, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-0933; National Institute for Clinical Excellence, 2020, NG25 NICE; National Institute for Health and Care Excellence, 2019, NG25 NICE; National Institute for Health and Care Excellence, 2021, ANT CAR NICE GUID NG; Ni YY, 2021, ARCH DIS CHILD-FETAL, V106, pF149, DOI 10.1136/archdischild-2020-319328; Norman M, 2019, JAMA-J AM MED ASSOC, V321, P1188, DOI 10.1001/jama.2019.2021; Nusinovici S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017845; O'Reilly H, 2021, MOL AUTISM, V12, DOI 10.1186/s13229-021-00414-0; Oehmke F, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00175; Patnode CD, 2021, JAMA-J AM MED ASSOC, V325, P280, DOI 10.1001/jama.2020.23541; Pierrat V, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n741; Pittara T, 2021, BJOG-INT J OBSTET GY, V128, P1421, DOI 10.1111/1471-0528.16683; Rackham O, 2019, PARENT LED WARD ROUN; Reddy UM, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.06.064; Reid SM, 2016, DEV MED CHILD NEUROL, V58, P25, DOI 10.1111/dmcn.13001; Ritchie K, 2018, J PEDIATR-US, V201, P238, DOI 10.1016/j.jpeds.2018.05.034; Rysavy MA, 2015, NEW ENGL J MED, V372, P1801, DOI 10.1056/NEJMoa1410689; Schmolzer GM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5980; Sentenac M, INT J EPIDEMIOL, V2021, DOI [10.1093/ije/dyab17, DOI 10.1093/IJE/DYAB17]; Serenius F, 2015, PEDIATRICS, V135, pE1163, DOI 10.1542/peds.2014-2988; Smith LK, 2020, BJOG-INT J OBSTET GY, V127, P314, DOI 10.1111/1471-0528.15971; Smith LK, 2018, LANCET, V392, P1639, DOI [10.1016/S0140-6736(18)31651-9, 10.1016/s0140-6736(18)31651-9]; Sneider K, 2016, ACTA OBSTET GYN SCAN, V95, P1383, DOI 10.1111/aogs.13027; Soni R, 2022, ARCH DIS CHILD-FETAL, V107, P242, DOI 10.1136/archdischild-2020-319450; Spittle A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005495.pub3; Spittle AJ, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-3410; Stephenson J, 2018, LANCET, V391, P1830, DOI [10.1016/S0140-6736(18)30311-8, 10.1016/s0140-6736(18)30311-8]; Stewart LA, 2021, LANCET, V397, P1183, DOI 10.1016/S0140-6736(21)00217-8; Story Lisa, 2019, Eur J Obstet Gynecol Reprod Biol X, V3, P100018, DOI 10.1016/j.eurox.2019.100018; Tarnow-Mordi W, 2017, NEW ENGL J MED, V377, P2445, DOI 10.1056/NEJMoa1711281; Thomson K, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-042753; Torchin H, 2020, SEMIN FETAL NEONAT M, V25, DOI 10.1016/j.siny.2020.101109; Twilhaar ES, 2018, JAMA PEDIATR, V172, P361, DOI 10.1001/jamapediatrics.2017.5323; Wang Q, 2018, ENVIRON INT, V121, P317, DOI 10.1016/j.envint.2018.09.021; Weeks A D, 2015, BMJ Innov, V1, P53; Wingert A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2017-021347; Wolke D, 2019, ANN REV DEV PSYCHOL, V1, P69, DOI [10.1146/annurev-devpsych-121318-084804, DOI 10.1146/ANNUREV-DEVPSYCH-121318-084804]; Wolke D, 2015, J PEDIATR-US, V166, P1417, DOI 10.1016/j.jpeds.2015.02.055; World Health Organization, 2018, PRET BIRTH FACTSH	83	6	6	4	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	2022	376								e055924	10.1136/bmj-2021-055924	http://dx.doi.org/10.1136/bmj-2021-055924			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP6IZ	35012942	Green Published, hybrid			2023-01-03	WOS:000748727200003
J	Kairys, P; Frese, T; Voigt, P; Horn, J; Girndt, M; Mikolajczyk, R				Kairys, Paul; Frese, Thomas; Voigt, Paul; Horn, Johannes; Girndt, Matthias; Mikolajczyk, Rafael			Development of the simulation-based German albuminuria screening model (S-GASM) for estimating the cost-effectiveness of albuminuria screening in Germany	PLOS ONE			English	Article							CONVERTING ENZYME-INHIBITORS; CHRONIC KIDNEY-DISEASE; TYPE-2 DIABETES-MELLITUS; RECEPTOR ANTAGONISTS; RENAL OUTCOMES; PREVALENCE; HYPERTENSION; POPULATION; MORTALITY; ADULTS	Background Chronic kidney disease is often asymptomatic in its early stages but constitutes a severe burden for patients and causes major healthcare systems costs worldwide. While models for assessing the cost-effectiveness of screening were proposed in the past, they often presented only a limited view. This study aimed to develop a simulation-based German Albuminuria Screening Model (S-GASM) and present some initial applications. Methods The model consists of an individual-based simulation of disease progression, considering age, gender, body mass index, systolic blood pressure, diabetes, albuminuria, glomerular filtration rate, and quality of life, furthermore, costs of testing, therapy, and renal replacement therapy with parameters based on published evidence. Selected screening scenarios were compared in a cost-effectiveness analysis. Results Compared to no testing, a simulation of 10 million individuals with a current age distribution of the adult German population and a follow-up until death or the age of 90 shows that a testing of all individuals with diabetes every two years leads to a reduction of the lifetime prevalence of renal replacement therapy from 2.5% to 2.3%. The undiscounted costs of this intervention would be 1164.10(sic)/QALY (quality-adjusted life year). Considering saved costs for renal replacement therapy, the overall undiscounted costs would be-12581.95(sic)/QALY. Testing all individuals with diabetes or hypertension and screening the general population reduced the lifetime prevalence even further (to 2.2% and 1.8%, respectively). Both scenarios were cost-saving (undiscounted, - 7127.10(sic)/QALY and-5439.23(sci)/QALY). Conclusions The S-GASM can be used for the comparison of various albuminuria testing strategies. The exemplary analysis demonstrates cost savings through albuminuria testing for individuals with diabetes, diabetes or hypertension, and for population-wide screening.	[Kairys, Paul; Frese, Thomas; Voigt, Paul] Martin Luther Univ Halle Wittenberg, Med Fac, Inst Gen Practice & Family Med, Halle, Germany; [Horn, Johannes; Mikolajczyk, Rafael] Martin Luther Univ Halle Wittenberg, Med Fac, Inst Med Epidemiol Biometry & Informat IMEBI, Halle, Germany; [Girndt, Matthias] Martin Luther Univ Halle Wittenberg, Med Fac, Dept Internal Med 2, Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Kairys, P (corresponding author), Martin Luther Univ Halle Wittenberg, Med Fac, Inst Gen Practice & Family Med, Halle, Germany.	paul.kairys@student.uni-halle.de		Kairys, Paul/0000-0002-6111-1885; Mikolajczyk, Rafael/0000-0003-1271-7204; Girndt, Matthias/0000-0003-2823-0847				Adarkwah CC, 2011, EXPERT REV PHARM OUT, V11, P215, DOI [10.1586/erp.11.18, 10.1586/ERP.11.8]; Adarkwah CC, 2010, INT J TECHNOL ASSESS, V26, P62, DOI 10.1017/S0266462309990584; Adler C, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2023-8; Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; Alagoz O, 2010, MED DECIS MAKING, V30, P474, DOI 10.1177/0272989X09353194; [Anonymous], 2015, VERBAND PRIVATARZTLI; Balijepalli C, 2014, J HUM HYPERTENS, V28, P193, DOI 10.1038/jhh.2013.85; Bundesamt Statistisches, 2017, KRANKH GES BUND; Bundesamt Statistisches, 2019, STERB 2015 2017 PER; Centalus Media GmbH, PREISV RAM 100 ST 08; Chen TT, 2018, MED J AUSTRALIA, V209, P275, DOI 10.5694/mja18.00297; COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005; da Silva GB, 2018, REV ASSOC MED BRAS, V64, P1108, DOI 10.1590/1806-9282.64.12.1108; de Vries EF, 2016, NEPHRON, V133, P89, DOI 10.1159/000446548; DEGAM e.V, 2019, VERS PAT CHRON NICHT; Excellence N.I. f.H.a.C, 2020, CHTE METH REV DISC; Gandjour A, 2015, EXPERT REV PHARM OUT, V15, P341, DOI 10.1586/14737167.2015.972375; Garg AX, 2002, KIDNEY INT, V61, P2165, DOI 10.1046/j.1523-1755.2002.00356.x; Gemeinsamer Bundesausschuss (GBA), 2020, DMP DIAB MELL TYP 1; Girndt M, 2016, DTSCH ARZTEBL INT, V113, P85, DOI 10.3238/arztebl.2016.0085; Go DS, 2019, NEPHROLOGY, V24, P56, DOI 10.1111/nep.13203; Gozzoli V, 2000, DEUT MED WOCHENSCHR, V125, P1154, DOI 10.1055/s-2000-7670; Gracchi V, 2016, NEPHROL DIAL TRANSPL, V31, P1686, DOI 10.1093/ndt/gfv407; Grams ME, 2017, AM J KIDNEY DIS, V70, P337, DOI 10.1053/j.ajkd.2017.01.050; Heerspink HJL, 2015, CLIN J AM SOC NEPHRO, V10, P1079, DOI 10.2215/CJN.11511114; Hemmelmann C, 2010, DEUT MED WOCHENSCHR, V135, P848, DOI 10.1055/s-0030-1253666; Icks A, 2011, NEPHROL DIAL TRANSPL, V26, P264, DOI 10.1093/ndt/gfq398; Icks A, 2010, NEPHROL DIAL TRANSPL, V25, P1647, DOI 10.1093/ndt/gfp672; Ku E, 2018, CLIN J AM SOC NEPHRO, V13, P693, DOI 10.2215/CJN.10360917; Levin A, 2013, KIDNEY INT, V83, P1001, DOI 10.1038/ki.2013.91; Lozano R, 2013, LANCET, V381, P991, DOI 10.1016/S0140-6736(13)60704-7; Palmer AJ, 2006, DEUT MED WOCHENSCHR, V131, P1721, DOI 10.1055/s-2006-947822; Palmer AJ, 2004, DIABETES CARE, V27, P1897, DOI 10.2337/diacare.27.8.1897; Pereira BD, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0646-4; Postma MJ, 2008, NEPHROL DIAL TRANSPL, V23, P1103, DOI 10.1093/ndt/gfl756; R Core Team Rf.., 2013, R LANG ENV STAT COMP; Rathmann W, 2010, DIABETOLOGE, V6, P170, DOI 10.1007/s11428-009-0496-8; Sarganas G, 2016, AM J HYPERTENS, V29, P104, DOI 10.1093/ajh/hpv067; Schweitzer RD, 2007, J CARDIOVASC NURS, V22, P76, DOI 10.1097/00005082-200701000-00012; Squires David A, 2011, Issue Brief (Commonw Fund), V16, P1; Statistisches Bundesamt, 2019, BEV ERW 2016 BEV GRU; Strippoli GFM, 2004, BMJ-BRIT MED J, V329, P828, DOI 10.1136/bmj.38237.585000.7C; Sugrue DM, 2019, PHARMACOECONOMICS, V37, P1451, DOI 10.1007/s40273-019-00835-z; Tajima R, 2010, CLIN EXP NEPHROL, V14, P340, DOI 10.1007/s10157-010-0304-1; Wen CP, 2014, KIDNEY INT, V86, P819, DOI 10.1038/ki.2013.553; Wilke T, 2013, DEUT MED WOCHENSCHR, V138, P69, DOI 10.1055/s-0032-1327394; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wu HY, 2014, JAMA INTERN MED, V174, P1108, DOI 10.1001/jamainternmed.2014.1363; Wyld M, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001307; Xie XF, 2016, AM J KIDNEY DIS, V67, P728, DOI 10.1053/j.ajkd.2015.10.011; Yarnoff BO, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205530; Yarnoff BO, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0497-6; Zhuo M, 2020, KIDNEY INT REP, V5, P475, DOI 10.1016/j.ekir.2019.12.011	53	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2022	17	1							e0262227	10.1371/journal.pone.0262227	http://dx.doi.org/10.1371/journal.pone.0262227			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZO8DB	34986199	gold, Green Published			2023-01-03	WOS:000765956200027
J	Issafras, H; Fan, SL; Tseng, CL; Cheng, YC; Lin, PH; Xiao, LS; Huang, YJ; Tu, CH; Hsiao, YC; Li, M; Chen, YH; Ho, CH; Li, O; Wang, YL; Chen, S; Ji, ZY; Zhang, E; Mao, YT; Liu, E; Yang, SM; Jiang, WD				Issafras, Hassan; Fan, Shilong; Tseng, Chi-Ling; Cheng, Yunchih; Lin, Peihua; Xiao, Lisa; Huang, Yun-Ju; Tu, Chih-Hsiang; Hsiao, Ya-Chin; Li, Min; Chen, Yen-Hsiao; Ho, Chien-Hsin; Li, Ou; Wang, Yanling; Chen, Sandra; Ji, Zhenyu; Zhang, Eric; Mao, Yi-Ting; Liu, Eugene; Yang, Shumin; Jiang, Weidong			Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy	PLOS ONE			English	Article							CELL; BLOCKADE; LIGAND	Cancer immunotherapies, such as checkpoint blockade of programmed cell death protein-1 (PD-1), represents a breakthrough in cancer treatment, resulting in unprecedented results in terms of overall and progression-free survival. Discovery and development of novel anti PD-1 inhibitors remains a field of intense investigation, where novel monoclonal antibodies (mAbs) and novel antibody formats (e.g., novel isotype, bispecific mAb and low-molecular-weight compounds) are major source of future therapeutic candidates. HLX10, a fully humanized IgG(4) monoclonal antibody against PD-1 receptor, increased functional activities of human T-cells and showed in vitro, and anti-tumor activity in several tumor models. The combined inhibition of PD-1/PDL-1 and angiogenesis pathways using anti-VEGF antibody may enhance a sustained suppression of cancer-related angiogenesis and tumor elimination. To elucidate HLX10's mode of action, we solved the structure of HLX10 in complex with PD-1 receptor. Detailed epitope analysis showed that HLX10 has a unique mode of recognition compared to the clinically approved PD1 antibodies Pembrolizumab and Nivolumab. Notably, HLX10's epitope was closer to Pembrolizumab's epitope than Nivolumab's epitope. However, HLX10 and Pembrolizumab showed an opposite heavy chain (HC) and light chain (LC) usage, which recognizes several overlapping amino acid residues on PD-1. We compared HLX10 to Nivolumab and Pembrolizumab and it showed similar or better bioactivity in vitro and in vivo, providing a rationale for clinical evaluation in cancer immunotherapy.	[Issafras, Hassan; Lin, Peihua; Li, Ou; Wang, Yanling; Mao, Yi-Ting; Jiang, Weidong] Hengenix Inc, Fremont, CA 94538 USA; [Fan, Shilong; Li, Min] Tsinghua Univ, Natl Prot Sci Facil, Beijing, Peoples R China; [Tseng, Chi-Ling; Cheng, Yunchih; Huang, Yun-Ju; Tu, Chih-Hsiang; Hsiao, Ya-Chin; Chen, Yen-Hsiao; Ho, Chien-Hsin] HanchorBio Inc Ltd, Taipei, Taiwan; [Xiao, Lisa; Ji, Zhenyu; Zhang, Eric; Yang, Shumin; Jiang, Weidong] Shanghai Henlius Biotech Inc, Shanghai, Peoples R China; [Chen, Sandra] Anwita Biosci, San Carlos, CA USA; [Liu, Eugene] Taipei Med Univ, Taipei, Taiwan	Tsinghua University; Taipei Medical University	Issafras, H (corresponding author), Hengenix Inc, Fremont, CA 94538 USA.; Fan, SL (corresponding author), Tsinghua Univ, Natl Prot Sci Facil, Beijing, Peoples R China.	hissafras@gmail.com; fanshilong@mail.tsinghua.edu.cn			Shanghai Henlius Biotech, Inc.	Shanghai Henlius Biotech, Inc.	The authors received funding in the form of salary for this work from Shanghai Henlius Biotech, Inc. Hassan Issafras, Chi-Ling Tseng, Yunchih Cheng, Peihua Lin, Lisa Xiao, Yun-Ju Huang, Chih-Hsiang Tu, Ya-Chin Hsiao, Yen-Hsiao Chen, Chien-Hsin Ho, Ou Li, Yanling Wang, Sandra Chen, Zhenyu Ji, Eric Zhang, Yi-Ting Mao, Eugen Liu, Shumin Yang and Weidong Jiang were employees of Shanghai Henlius Biotech, Inc., P. R. China and its US subsidiary Hengenix Inc. Fremont, CA, US. Shilong Fan and Min Li received funding from Shanghai Henlius Biotech, Inc. but were not salaried employees. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study. The role of the authors as articulated in the 'author contributions' section.	Ai LY, 2020, ADV EXP MED BIOL, V1248, P33, DOI 10.1007/978-981-15-3266-5_3; Arasanz H, 2017, ONCOTARGET, V8, P51936, DOI 10.18632/oncotarget.17232; Assessment Report, 2015, EMACHMP766882015, P24; Brown ME, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229206; Chen Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01088; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; Curran MA, 2018, CANCER J, V24, P2, DOI 10.1097/PPO.0000000000000298; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Gong J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0316-z; Horita S, 2016, SCI REP-UK, V6, DOI 10.1038/srep35297; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lee WS, 2020, EXP MOL MED, V52, P1475, DOI 10.1038/s12276-020-00500-y; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Na ZK, 2017, CELL RES, V27, P147, DOI 10.1038/cr.2016.77; Patsoukis N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd2712; Patsoukis N, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0845-0; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Tam SH, 2017, ANTIBODIES, V6, DOI 10.3390/antib6030012; Tan SG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14369; Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559; Yi M, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01045-x; Yi M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0974-6; Yu JW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206223; Zak KM, 2017, STRUCTURE, V25, P1163, DOI 10.1016/j.str.2017.06.011; Zak KM, 2015, STRUCTURE, V23, P2341, DOI 10.1016/j.str.2015.09.010	26	3	3	4	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2021	16	12							e0257972	10.1371/journal.pone.0257972	http://dx.doi.org/10.1371/journal.pone.0257972			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ9AO	34972111	Green Published, gold			2023-01-03	WOS:000773555700007
J	Shrestha, S; Chapagain, RH; Purakayastha, DR; Basnet, S; Wadhwa, N; Strand, TA; Basnet, S				Shrestha, Suchita; Chapagain, Ram Hari; Purakayastha, Debjani Ram; Basnet, Srijana; Wadhwa, Nitya; Strand, Tor A.; Basnet, Sudha			Assessment of hospitalization costs and its determinants in infants with clinical severe infection at a public tertiary hospital in Nepal	PLOS ONE			English	Article							CHILDREN; SEPSIS	Sepsis, an important and preventable cause of death in the newborn, is associated with high out of pocket hospitalization costs for the parents/guardians. The government of Nepal's Free Newborn Care (FNC) service that covers hospitalization costs has set a maximum limit of Nepalese rupees (NPR) 8000 i.e. USD 73.5, the basis of which is unclear. We aimed to estimate the costs of treatment in neonates and young infants fulfilling clinical criteria for sepsis, defined as clinical severe infection (CSI) to identify determinants of increased cost. This study assessed costs for treatment of 206 infants 3-59 days old, enrolled in a clinical trial, and admitted to the Kanti Children's Hospital in Nepal through June 2017 to December 2018. Total costs were derived as the sum of direct costs for bed charges, investigations, and medicines and indirect costs calculated by using work time loss of parents. We estimated treatment costs for CSI, the proportion exceeding NPR 8000 and performed multivariable linear regression to identify determinants of high cost. Of the 206 infants, 138 (67%) were neonates (3-28 days). The median (IQR) direct costs for treatment of CSI in neonates and young infants (29-59 days) were USD 111.7 (69.8-155.5) and 65.17 (43.4-98.5) respectively. The direct costs exceeded NPR 8000 (USD 73.5) in 69% of neonates with CSI. Age < 29 days, moderate malnutrition, presence of any sign of critical illness and documented treatment failure were found to be important determinants of high costs for treatment of CSI. According to this study, the average treatment cost for a newborn with CSI in a public tertiary level hospital is substantial. The maximum limit offered for free newborn care in public hospitals needs to be revised for better acceptance and successful implementation of the FNC service to avert catastrophic health expenditures in developing countries like Nepal.	[Shrestha, Suchita] Tribhuvan Univ, Inst Med, Dept Pediat, Child Hlth Res Project, Kathmandu, Nepal; [Chapagain, Ram Hari] Kanti Childrens Hosp, Med Dept, Kathmandu, Nepal; [Purakayastha, Debjani Ram; Wadhwa, Nitya] Translat Hlth Sci & Technol Inst, Pediat Biol Ctr, Faridabad, Haryana, India; [Basnet, Srijana; Basnet, Sudha] Tribhuvan Univ, Inst Med, Dept Pediat, Kathmandu, Nepal; [Strand, Tor A.; Basnet, Sudha] Univ Bergen, Ctr Intervent Sci Maternal & Child Hlth, Ctr Int Hlth, Bergen, Norway; [Strand, Tor A.] Innlandet Hosp Trust, Dept Res, Lillehammer, Norway; [Shrestha, Suchita] Patan Acad Hlth Sci, Oxford Univ Clin Res Unit, Kathmandu, Nepal	Tribhuvan University; Institute of Medicine (IoM) - Nepal; Department of Biotechnology (DBT) India; Translational Health Science & Technology Institute (THSTI); Tribhuvan University; Institute of Medicine (IoM) - Nepal; University of Bergen; Innlandet Hospital Trust	Basnet, S (corresponding author), Tribhuvan Univ, Inst Med, Dept Pediat, Kathmandu, Nepal.; Basnet, S (corresponding author), Univ Bergen, Ctr Intervent Sci Maternal & Child Hlth, Ctr Int Hlth, Bergen, Norway.	sudhacbasnet@gmail.com	Strand, Tor/D-9836-2016	Strand, Tor/0000-0002-4038-151X; Ram Purakayastha, Debjani/0000-0003-0120-7612; Basnet, Sudha/0000-0001-8433-2499	Centre for Intervention Science in Maternal and Child Health (CISMAC) - Research Council of Norway through its Centres of Excellence scheme [223269]; University of Bergen (UiB), Norway	Centre for Intervention Science in Maternal and Child Health (CISMAC) - Research Council of Norway through its Centres of Excellence scheme; University of Bergen (UiB), Norway	The work described in the manuscript was supported by a writing grant awarded by the Centre for Intervention Science in Maternal and Child Health (CISMAC; project number 223269), which is funded by the Research Council of Norway through its Centres of Excellence scheme and the University of Bergen (UiB), Norway. Authors SS and RHC were direct recipients of the writing grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Basnet S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122052; Bhuiyan MU, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.010412; Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17; Chapagain R H, 2015, J Nepal Health Res Counc, V13, P205; Child Health Division, 2017, NIS NAW SISH UP KAR; Dang DA, 2010, J HEALTH POPUL NUTR, V28, P436; Fell DB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18371-1; Garg Pankaj, 2005, Indian Journal of Pediatrics, V72, P27, DOI 10.1007/BF02760575; Ghimire M, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0736-x; Government of Nepal Ministry of Labor Employment and Social security., 2018, PUBL NOT MIN WAG 207; Jo C, 2014, CLIN MOL HEPATOL, V20, P327, DOI 10.3350/cmh.2014.20.4.327; Koopmanschap MA, 1996, PHARMACOECONOMICS, V10, P460, DOI 10.2165/00019053-199610050-00003; Madsen HO, 2009, TROP MED INT HEALTH, V14, P1315, DOI 10.1111/j.1365-3156.2009.02374.x; Ministry of Health and Population, 2017, ANN REPORT; Ministry of Health Nepal; New ERA; ICF, 2017, NEP DEM HLTH SURV 20; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Purakayastha DR, 2017, INDIAN J PEDIATR, V84, P902, DOI 10.1007/s12098-017-2420-3; Neira RAQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195873; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Scrimshaw N S, 1968, Monogr Ser World Health Organ, V57, P3; Shane AL, 2017, LANCET, V390, P1770, DOI 10.1016/S0140-6736(17)31002-4; Sharma S., 2020, Journal of Nepal Paediatric Society, V40, P41, DOI 10.3126/jnps.v40i1.28600; Shrestha G., 2018, J NEPAL HLTH RES COU, V16, P1, DOI [10.33314/jnhrc.v16i1.1007, DOI 10.33314/JNHRC.V16I1.1007]; Shrestha Gambhir, 2018, J Nepal Health Res Counc, V16, P340; Stephens BE, 2009, PEDIATR CLIN N AM, V56, P631, DOI 10.1016/j.pcl.2009.03.005; Stoll BJ, 2004, JAMA-J AM MED ASSOC, V292, P2357, DOI 10.1001/jama.292.19.2357; Sunny AK, 2020, MATERN CHILD HLTH J, V24, DOI 10.1007/s10995-020-02881-y; The United Nations Children's Fund, 2015, MAT NEWB HLTH DISP N; The World Bank, 2018, OFF EXCH RAT LCU US; The World Bank, 2019, OUT OF POCK EXP; Tshefu A, 2015, LANCET, V385, P1767, DOI 10.1016/S0140-6736(14)62284-4; United Nations Inter-agency Group for Child Mortality Estimation [UN IGME], 2019, LEVELS TRENDS CHILD; Walson JL, 2018, CURR OPIN INFECT DIS, V31, P231, DOI 10.1097/QCO.0000000000000448; Williams DJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1019; World Bank, 2019, CURR HLTH EXP; World Bank, 2020, INFL CONS PRIC ANN; World Health Organization, 2003, INTEGRATED MANAGEMEN; World Health Organization, 2019, FACT SHEET NEWB RED; World Health Organization, 2014, INTEGRATED MANAGEMEN; Zea-Vera A, 2015, J TROP PEDIATRICS, V61, P1, DOI 10.1093/tropej/fmu079	40	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2021	16	11							e0260127	10.1371/journal.pone.0260127	http://dx.doi.org/10.1371/journal.pone.0260127			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU5IH	34843530	Green Published, gold			2023-01-03	WOS:000752076100046
J	Marshall, J; Ross, S; Buchanan, P; Gavine, A				Marshall, Joyce; Ross, Sam; Buchanan, Phyll; Gavine, Anna			Providing effective evidence based support for breastfeeding women in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							NIPPLE PAIN; MILK; PERCEPTIONS; CHILDHOOD; MOTHERS; IMPACT		[Marshall, Joyce] Univ Huddersfield, Div Maternal Hlth, Huddersfield, W Yorkshire, England; [Ross, Sam] Univ Glasgow, Sch Med Dent & Nursing, Glasgow, Lanark, Scotland; [Ross, Sam] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland; [Buchanan, Phyll] Breastfeeding Network, Paisley, Renfrew, Scotland; [Gavine, Anna] Univ Dundee, Sch Hlth Sci, Dundee, Scotland	University of Huddersfield; University of Glasgow; University of Dundee	Marshall, J (corresponding author), Univ Huddersfield, Div Maternal Hlth, Huddersfield, W Yorkshire, England.	j.marshall@hud.ac.uk		Buchanan, Phyllis/0000-0002-1436-4396				Abdelhakim AM, 2019, EUR J CONTRACEP REPR, V24, P327, DOI 10.1080/13625187.2019.1665175; American College of Obstetricians and Gynaecologists, 2020, COV 19 VACC CONS OBS; Amir LH, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1628; Amir LH, 2014, BREASTFEED MED, V9, P239, DOI 10.1089/bfm.2014.9984; Amir LH, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002351; Amir LH, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-62; [Anonymous], 2014, DOMP RISKS CARD SID; [Anonymous], DRUGS LACTATION DATA, P2021; [Anonymous], 2017, EN BREASTF MOTH BAB; Baby Friendly UNICEF, BREASTF RES; Bowatte G, 2015, ACTA PAEDIATR, V104, P85, DOI 10.1111/apa.13151; Breastfeeding Network, 2019, DRUGS FACTSH; Brockway M, 2017, J HUM LACT, V33, P486, DOI 10.1177/0890334417707957; Brown A, 2021, MATERN CHILD NUTR, V17, DOI 10.1111/mcn.13088; Buck ML, 2014, BREASTFEED MED, V9, P56, DOI 10.1089/bfm.2013.0106; Centers for Disease Control and Prevention, CAR BREASTF PEOPL IN, P2021; Chang YS, 2020, MATERN CHILD NUTR, V16, DOI 10.1111/mcn.12865; Crepinsek MA, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007239.pub4; Cryan JF, 2012, NAT REV NEUROSCI, V13, P701, DOI 10.1038/nrn3346; De Bortoli J, 2016, DIABETIC MED, V33, P17, DOI 10.1111/dme.12846; Dennis CL, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007366.pub2; Frank Nicole M, 2019, BMC Pediatr, V19, P339, DOI 10.1186/s12887-019-1693-2; Furuta M, 2016, MATERN CHILD NUTR, V12, P808, DOI 10.1111/mcn.12176; Galipeau R, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12607; Galipeau R, 2017, BREASTFEED MED, V12, P210, DOI 10.1089/bfm.2016.0183; Gatti L, 2008, J NURS SCHOLARSHIP, V40, P355, DOI 10.1111/j.1547-5069.2008.00234.x; Gavine A, MATERN CHILD NUTR; Gila-Diaz A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061307; Harrison S, 2021, YOU YOUR BABY NATL S; Hobbs AJ, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0876-1; Horta BL, 2015, ACTA PAEDIATR, V104, P30, DOI 10.1111/apa.13133; Horta BL., 2013, SHORT TERM EFFECTS B, V49; Hospital Infant Feeding Network, 2019, DONT SAY STOP LOOK I; Ito S, 2018, J CLIN PHARMACOL, V58, pS151, DOI 10.1002/jcph.1113; Jahanfar S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005458.pub3; Jones W, BREASTFEEDING MED, V2nd, DOI [10.4324/ 9781315098739, DOI 10.4324/9781315098739]; Kam RL, 2021, BREASTFEED MED, V16, P594, DOI 10.1089/bfm.2021.0032; Kearney L, 2018, WHICH WEAK OPIOIDS C; Kearney L, 2020, UKDILAS GEN PRINCIPL; Kent JC, 2015, INT J ENV RES PUB HE, V12, P12247, DOI 10.3390/ijerph121012247; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003517.pub2; Lackey KA, 2020, MATERN CHILD NUTR, V16, DOI 10.1111/mcn.13032; Lucassen PLBJ, 2001, ARCH DIS CHILD, V84, P398, DOI 10.1136/adc.84.5.398; Marshall JL, 2007, SOC SCI MED, V65, P2147, DOI 10.1016/j.socscimed.2007.06.015; Mathew JL, 2004, POSTGRAD MED J, V80, P196, DOI 10.1136/pgmj.2003.011973; McAndrew F., 2012, INFANT FEEDING SURVE; McClellan HL, 2012, J HUM LACT, V28, P511, DOI 10.1177/0890334412444464; McFadden A, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001141.pub5; Medicines and Healthcare products Regulatory Agency, DRUG SAFETY UPDATE20, V6, pS1; Moore ER, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub4; Munblit D, 2020, JAMA PEDIATR, V174, P599, DOI 10.1001/jamapediatrics.2020.0153; National Institute for Health and Care Excellence, 2017, BREASTF PROBL; National Institute for Health and Care Excellence, MAST BREAST ABSC CLI, P2021; National Institute for health and care excellence, 2015, GASTR REFL DIS CHILD; National Institute for Health and Care Excellence, COWS MILK ALL CHILD, P2021; National Institute for Health and Care Excellence, 2020, GORD CHILDR SHOULD A; National Institute for Health and Clinical Excellence, 2011, FOOD ALL CHILDR YOUN; O'Reilly D, 2020, EUR J PEDIATR, V179, P1963, DOI 10.1007/s00431-020-03837-8; Odeniyi AO, 2020, MATERN CHILD NUTR, V16, DOI 10.1111/mcn.12970; Peek RJ, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3533; Pinheiro E, 2015, ARCH WOMEN MENT HLTH, V18, P139, DOI 10.1007/s00737-015-0499-y; Piwoz EG, 2015, FOOD NUTR BULL, V36, P373, DOI 10.1177/0379572115602174; Prior E, 2012, AM J CLIN NUTR, V95, P1113, DOI 10.3945/ajcn.111.030254; Rayfield S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009144; Renfrew MJ, 2020, MIDWIFERY, V88, DOI 10.1016/j.midw.2020.102759; Royal College of General Practitioners, 2021, PERINATAL MENTAL HLT; Royal College of Obstetricians and Gynaecologists, 2012, GREEN TOP GUIDELINE, V2nd; Save the Children, 2018, STUFF; Schmied V, 2011, BIRTH-ISS PERINAT C, V38, P49, DOI 10.1111/j.1523-536X.2010.00446.x; Scime NV, 2022, J MATERN-FETAL NEO M, V35, P1148, DOI 10.1080/14767058.2020.1743664; Stewart CJ, 2018, NATURE, V562, P583, DOI 10.1038/s41586-018-0617-x; Sumilo D, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-31; The Faculty of Sexual and Reproductive Healthcare, 2019, UK MED EL CRIT CONTR; UK Health Security Agency, 2021, COVID 19 INF; UK Medicines Information, MED LACT SPEC ADV SE; UNICEF, 2015, BEST START; United Nations Children's Fund (UNICEF), 2019, INF YOUNG CHILD FEED; Uvnas-Moberg K, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01529; Vandenplas Y, 2007, ARCH DIS CHILD, V92, P902, DOI 10.1136/adc.2006.110999; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; Webb AN, 2013, INT J PEDIATR OTORHI, V77, P635, DOI 10.1016/j.ijporl.2013.03.008; World Health Organization, 2001, OPT DUR EXCL BREASTF; World Health Organization, 1981, INT COD MARK BREAST; World Health Organization, 2000, MAST CAUS MAN; Zeevenhooven J, 2017, PEDIATR GASTROENTERO, V20, P1, DOI 10.5223/pghn.2017.20.1.1	85	1	1	2	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 1	2021	375								e065927	10.1136/bmj-2021-065927	http://dx.doi.org/10.1136/bmj-2021-065927			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT0CM	34725097	Green Submitted			2023-01-03	WOS:000715541800007
J	Blommer, J; Fischer, MC; Olszewski, AR; Katzenberger, RJ; Ganetzky, B; Wassarman, DA				Blommer, Joseph; Fischer, Megan C.; Olszewski, Athena R.; Katzenberger, Rebeccah J.; Ganetzky, Barry; Wassarman, David A.			Ketogenic diet reduces early mortality following traumatic brain injury in Drosophila via the PPAR gamma ortholog Eip75B	PLOS ONE			English	Article							NF-KAPPA-B; TISSUE LOSS; JUVENILE; MODEL; AGE	Traumatic brain injury (TBI) is a common neurological disorder whose outcomes vary widely depending on a variety of environmental factors, including diet. Using a Drosophila melanogaster TBI model that reproduces key aspects of TBI in humans, we previously found that the diet consumed immediately following a primary brain injury has a substantial effect on the incidence of mortality within 24 h (early mortality). Flies that receive equivalent primary injuries have a higher incidence of early mortality when fed high-carbohydrate diets versus water. Here, we report that flies fed high-fat ketogenic diet (KD) following TBI exhibited early mortality that was equivalent to that of flies fed water and that flies protected from early mortality by KD continued to show survival benefits weeks later. KD also has beneficial effects in mammalian TBI models, indicating that the mechanism of action of KD is evolutionarily conserved. To probe the mechanism, we examined the effect of KD in flies mutant for Eip75B, an ortholog of the transcription factor PPAR gamma (peroxisome proliferator-activated receptor gamma) that contributes to the mechanism of action of KD and has neuroprotective effects in mammalian TBI models. We found that the incidence of early mortality of Eip75B mutant flies was higher when they were fed KD than when they were fed water following TBI. These data indicate that Eip75B/PPAR gamma is necessary for the beneficial effects of KD following TBI. In summary, this work provides the first evidence that KD activates PPAR gamma to reduce deleterious outcomes of TBI and it demonstrates the utility of the fly TBI model for dissecting molecular pathways that contribute to heterogeneity in TBI outcomes.	[Blommer, Joseph; Fischer, Megan C.; Olszewski, Athena R.; Katzenberger, Rebeccah J.; Wassarman, David A.] Univ Wisconsin, Dept Med Genet, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Ganetzky, Barry] Univ Wisconsin, Coll Agr & Life Sci, Dept Genet, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Wassarman, DA (corresponding author), Univ Wisconsin, Dept Med Genet, Sch Med & Publ Hlth, Madison, WI 53706 USA.	dwassarman@wisc.edu			National Institute of Neurological Disorders and Stroke of the National Institutes of Health [RF1NS114359]; Sophomore Research Fellowship; Hilldale Research Fellowship from UW-Madison; UW-Madison Genetics Department Summer Fellowship	National Institute of Neurological Disorders and Stroke of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Sophomore Research Fellowship; Hilldale Research Fellowship from UW-Madison; UW-Madison Genetics Department Summer Fellowship	Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (grant number RF1NS114359) awarded to DAW. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. JB was supported by a Sophomore Research Fellowship and a Hilldale Research Fellowship from UW-Madison. MCF was supported by a UW-Madison Genetics Department Summer Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Bridgham JT, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000497; Caglayan B, 2019, MOL BIOL REP, V46, P241, DOI 10.1007/s11033-018-4465-4; Cai W, 2018, PROG NEUROBIOL, V163, P27, DOI 10.1016/j.pneurobio.2017.10.002; Celotto AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025823; Chen XR, 2017, J NEUROINFLAMM, V14, DOI [10.1186/s12974-017-0917-3, 10.1186/s12974-018-1151-3]; Cortes D, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536-020-00114-y; Deng YB, 2020, GENES DIS, V7, P253, DOI 10.1016/j.gendis.2019.05.002; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Ganesan S, 2011, CURR TOP MICROBIOL, V349, P25, DOI 10.1007/82_2010_107; Greco T, 2013, J CHILD NEUROL, V28, P983, DOI 10.1177/0883073813487594; Han SK, 2016, ONCOTARGET, V7, P56147, DOI 10.18632/oncotarget.11269; Hill CS, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00401; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Jensen NJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228767; Joardar A, 2015, HUM MOL GENET, V24, P1741, DOI 10.1093/hmg/ddu587; Johnson WD, 2017, LANCET NEUROL, V16, P949, DOI 10.1016/S1474-4422(17)30362-9; Katzenberger RJ, 2016, G3-GENES GENOM GENET, V6, P4151, DOI 10.1534/g3.116.036194; Katzenberger RJ, 2015, JOVE-J VIS EXP, DOI 10.3791/52905; Katzenberger RJ, 2015, ELIFE, V4, DOI 10.7554/eLife.04790; Katzenberger RJ, 2013, P NATL ACAD SCI USA, V110, pE4152, DOI 10.1073/pnas.1316895110; Knowles S, 2018, EPILEPSY RES, V147, P71, DOI 10.1016/j.eplepsyres.2018.09.009; Lee DC, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01140; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Mackay TFC, 2012, NATURE, V482, P173, DOI 10.1038/nature10811; McDougall A, 2018, BRAIN INJURY, V32, P416, DOI 10.1080/02699052.2018.1429025; McKenna MC, 2015, NEUROCHEM RES, V40, P2527, DOI 10.1007/s11064-015-1600-7; Morris AAM, 2005, J INHERIT METAB DIS, V28, P109, DOI 10.1007/s10545-005-5518-0; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Ratliff WA, 2020, BRAIN RES, V1746, DOI 10.1016/j.brainres.2020.147019; Ratliff WA, 2020, J NEUROTRAUM, V37, P1910, DOI 10.1089/neu.2020.7005; Salberg S, 2019, BEHAV BRAIN RES, V376, DOI 10.1016/j.bbr.2019.112225; Salim A, 2009, AM SURGEON, V75, P25; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Shao XF, 2020, INT IMMUNOPHARMACOL, V79, DOI 10.1016/j.intimp.2019.106175; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Swanson LC, 2020, GENETICS, V216, P1117, DOI 10.1534/genetics.120.303776; Swanson LC, 2020, G3-GENES GENOM GENET, V10, P3109, DOI 10.1534/g3.120.401377; Tao L, 2018, BRAIN RES BULL, V140, P154, DOI 10.1016/j.brainresbull.2018.04.008; Thapa K, 2021, J MOL NEUROSCI, V71, P1725, DOI 10.1007/s12031-021-01841-7; Thau-Zuchman O, 2021, THERANOSTICS, V11, P346, DOI 10.7150/thno.48995; van Alphen B, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abc2999; Varga T, 2011, BBA-MOL BASIS DIS, V1812, P1007, DOI 10.1016/j.bbadis.2011.02.014; Wagner AK, 2014, J SPINAL CORD MED, V37, P493, DOI 10.1179/2045772314Y.0000000248; Wahli W, 2012, TRENDS ENDOCRIN MET, V23, P351, DOI 10.1016/j.tem.2012.05.001; White H, 2011, CRIT CARE, V15, DOI 10.1186/cc10020; Yang HJ, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00585; Zhang FC, 2018, WORLD NEUROSURG, V120, pE1193, DOI 10.1016/j.wneu.2018.09.037; Zipper L, 2020, ELIFE, V9, DOI 10.7554/eLife.55795	50	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2021	16	10							e0258873	10.1371/journal.pone.0258873	http://dx.doi.org/10.1371/journal.pone.0258873			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8IO	34699541	Green Published, gold			2023-01-03	WOS:000755029000013
J	Saksornchai, K; Jaruthien, T; Nantavithya, C; Shotelersuk, K; Rojpornpradit, P				Saksornchai, Kitwadee; Jaruthien, Thitiporn; Nantavithya, Chonnipa; Shotelersuk, Kanjana; Rojpornpradit, Prayuth			Long-term results of hypofractionation with concomitant boost in patients with early breast cancer: A prospective study	PLOS ONE			English	Article							20-YEAR FOLLOW-UP; SIMULTANEOUS INTEGRATED BOOST; MODULATED RADIATION-THERAPY; PHASE-I-II; CONSERVING SURGERY; RANDOMIZED-TRIAL; RADIOTHERAPY HYPOFRACTIONATION; CONSERVATIVE TREATMENT; UK STANDARDIZATION; TOTAL MASTECTOMY	Aim To report the long-term local control and survival of patients with early breast cancer who had hypofractionated whole breast irradiation with concomitant boost (Hypo-CB). Methods and materials Between October 2009 and June 2010, 73 patients with early breast cancer (T1-3N0-1M0) who underwent breast conserving surgery were enrolled into the study. Thirty-six of these participants received 50 Gy of conventional irradiation in 25 fractions over 5 weeks to the whole breast with a sequential boost to the tumor bed with 10-16 Gy in 5-8 fractions (Conv-SEQ). The other 37 participants received a hypofractionated dose of 43.2 Gy in 16 fractions with an additional daily concomitant boost (CB) of 0.6 Gy over 3 weeks (Hypo-CB). Results At a median follow-up time of 123 months, ipsilateral local recurrence (ILR) was found in 3 participants, 1 of whom was in the hypofractionated group. All 3 ILR were true local recurrence (TR). There were no significant differences in the 10-year disease free survival (DFS) and 10-year overall survival rates (OS) between the conventional and hypofractionated groups (93.9% vs. 94.4%, p = 0.96 and 91.9% vs. 91.6%, p = 0.792, respectively). Conclusion This study showed that the effectiveness, DFS and OS were comparable between hypofractionated whole breast irradiation with a CB and the conventional irradiation with a sequential boost.	[Saksornchai, Kitwadee; Jaruthien, Thitiporn; Nantavithya, Chonnipa; Shotelersuk, Kanjana] Chulalongkorn Univ, Fac Med, Div Therapeut Radiol & Oncol, Bangkok, Thailand; [Jaruthien, Thitiporn; Nantavithya, Chonnipa; Rojpornpradit, Prayuth] King Chulalongkorn Mem Hosp, Dept Radiol, Div Therapeut Radiol & Oncol, Thai Red Cross Soc, Bangkok, Thailand	Chulalongkorn University; Chulalongkorn University; Thai Red Cross Society	Saksornchai, K (corresponding author), Chulalongkorn Univ, Fac Med, Div Therapeut Radiol & Oncol, Bangkok, Thailand.	kitwadee.s@chula.ac.th	Saksornchai, Kitwadee/AAX-2919-2021	Saksornchai, Kitwadee/0000-0002-5461-8661	Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand	Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand	We would like to acknowledge the support of the Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.	Arriagada R, 2003, ANN ONCOL, V14, P1617, DOI 10.1093/annonc/mdg452; Bantema-Joppe EJ, 2012, INT J RADIAT ONCOL, V83, pE471, DOI 10.1016/j.ijrobp.2012.01.050; Bartelink H, 2007, J CLIN ONCOL, V25, P3259, DOI 10.1200/JCO.2007.11.4991; Bartelink H, 2015, LANCET ONCOL, V16, P47, DOI 10.1016/S1470-2045(14)71156-8; Bentzen SM, 2008, LANCET, V371, P1098, DOI 10.1016/S0140-6736(08)60348-7; Bentzen SM, 2008, LANCET ONCOL, V9, P331, DOI [10.1016/S1470-2045(08)60348-7, 10.1016/S1470-2045(08)70077-9]; Blichert-Toft M, 2008, ACTA ONCOL, V47, P672, DOI 10.1080/02841860801971439; Brunt AM, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.02750; Cante D, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0518-7; Chadha M, 2012, CLIN BREAST CANCER, V12, P57, DOI 10.1016/j.clbc.2011.09.002; Chatterjee S, 2019, CLIN ONCOL-UK, V31, P266, DOI 10.1016/j.clon.2018.12.004; ClinicalTrials.gov, 2000, ID NCT00287391 HIGH; Coles C, 2006, CLIN ONCOL-UK, V18, P587, DOI 10.1016/j.clon.2006.07.010; Corvo R, 2010, ANTICANCER RES, V30, P4749; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Dellas K, 2014, STRAHLENTHER ONKOL, V190, P646, DOI 10.1007/s00066-014-0658-5; Donovan E, 2007, RADIOTHER ONCOL, V82, P254, DOI 10.1016/j.radonc.2006.12.008; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Formenti SC, 2007, J CLIN ONCOL, V25, P2236, DOI 10.1200/JCO.2006.09.1041; Freedman GM, 2012, INT J RADIAT ONCOL, V84, P888, DOI 10.1016/j.ijrobp.2012.01.091; Graham P, 2010, RADIOTHER ONCOL, V96, pS145; Graham P., 2007, AUSTRALAS RADIOL, V51, pA85; Haviland JS, 2013, LANCET ONCOL, V14, P1086, DOI 10.1016/S1470-2045(13)70386-3; Hopwood P, 2010, LANCET ONCOL, V11, P231, DOI 10.1016/S1470-2045(09)70382-1; Kindts I, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011987.pub2; Krug D, 2021, STRAHLENTHER ONKOL, V197, P48, DOI 10.1007/s00066-020-01689-7; Litiere S, 2012, LANCET ONCOL, V13, P412, DOI 10.1016/S1470-2045(12)70042-6; Morganti AG, 2009, RADIOTHER ONCOL, V90, P86, DOI 10.1016/j.radonc.2008.10.017; National Comprehensive Cancer Network, 2006, BREAST CANC VER 1 20; Polgar C, 2002, STRAHLENTHER ONKOL, V178, P615, DOI 10.1007/s00066-002-1053-1; Romestaing P, 1997, J CLIN ONCOL, V15, P963, DOI 10.1200/JCO.1997.15.3.963; Saksornchai Kitwadee, 2012, Journal of the Medical Association of Thailand, V95, P229; Simone NL, 2012, BREAST CANCER RES TR, V132, P197, DOI 10.1007/s10549-011-1867-6; Teissier E., 1998, BREAST CANCER RES TR, V50, P287; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; Veronesi U, 2002, NEW ENGL J MED, V347, P1227, DOI 10.1056/NEJMoa020989; Whelan TJ, 2010, NEW ENGL J MED, V362, P513, DOI 10.1056/NEJMoa0906260; Yarnold J, 2005, RADIOTHER ONCOL, V75, P9, DOI 10.1016/j.radonc.2005.01.005	39	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2021	16	10							e0258186	10.1371/journal.pone.0258186	http://dx.doi.org/10.1371/journal.pone.0258186			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV0SF	34618862	Green Published, gold			2023-01-03	WOS:000752443000046
J	Salerno, S; Sun, YM; Morris, EL; He, XW; Li, YJ; Pan, ZY; Han, PS; Kang, J; Sjoding, MW; Li, Y				Salerno, Stephen; Sun, Yuming; Morris, Emily L.; He, Xinwei; Li, Yajing; Pan, Ziyang; Han, Peisong; Kang, Jian; Sjoding, Michael W.; Li, Yi			Comprehensive evaluation of COVID-19 patient short- and long-term outcomes: Disparities in healthcare utilization and post-hospitalization outcomes	PLOS ONE			English	Article							UNITED-STATES; MORTALITY; DISEASE; MULTICENTER	Background Understanding risk factors for short- and long-term COVID-19 outcomes have implications for current guidelines and practice. We study whether early identified risk factors for COVID-19 persist one year later and through varying disease progression trajectories. Methods This was a retrospective study of 6,731 COVID-19 patients presenting to Michigan Medicine between March 10, 2020 and March 10, 2021. We describe disease progression trajectories from diagnosis to potential hospital admission, discharge, readmission, or death. Outcomes pertained to all patients: rate of medical encounters, hospitalization-free survival, and overall survival, and hospitalized patients: discharge versus in-hospital death and readmission. Risk factors included patient age, sex, race, body mass index, and 29 comorbidity conditions. Results Younger, non-Black patients utilized healthcare resources at higher rates, while older, male, and Black patients had higher rates of hospitalization and mortality. Diabetes with complications, coagulopathy, fluid and electrolyte disorders, and blood loss anemia were risk factors for these outcomes. Diabetes with complications, coagulopathy, fluid and electrolyte disorders, and blood loss were associated with lower discharge and higher inpatient mortality rates. Conclusions This study found differences in healthcare utilization and adverse COVID-19 outcomes, as well as differing risk factors for short- and long-term outcomes throughout disease progression. These findings may inform providers in emergency departments or critical care settings of treatment priorities, empower healthcare stakeholders with effective disease management strategies, and aid health policy makers in optimizing allocations of medical resources.	[Salerno, Stephen; Sun, Yuming; Morris, Emily L.; He, Xinwei; Li, Yajing; Pan, Ziyang; Han, Peisong; Kang, Jian; Li, Yi] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Sjoding, Michael W.] Univ Michigan, Div Pulm & Crit Care Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Li, Y (corresponding author), Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.	yili@umich.edu		Salerno, Stephen/0000-0003-2763-0494; Pan, Ziyang/0000-0003-1600-5597	University of Michigan Precision Health Initiative; National Institutes of Health -National Cancer Institute [R01CA249096]	University of Michigan Precision Health Initiative; National Institutes of Health -National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	YL is supported by the University of Michigan Precision Health Initiative (https://precisionhealth.umich.edu/) and National Institutes of Health -National Cancer Institute (https://www.cancer.gov/) grant R01CA249096. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adapa Sreedhar, 2020, J Clin Med Res, V12, P276, DOI 10.14740/jocmr4160; Alcendor DJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082442; Alfano G, 2021, CLIN EXP NEPHROL, V25, P401, DOI 10.1007/s10157-020-01996-4; Alqahtani JS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233147; [Anonymous], COR MICH DAT; Baron DM, 2020, ANAESTHESIA, V75, P1105, DOI 10.1111/anae.15095; Baron DM, 2020, CURR OPIN ANESTHESIO, V33, P234, DOI 10.1097/ACO.0000000000000824; Bequette B.W., 2020, COVIDNET BRING DATA, V140; Besler MS, 2020, AM J EMERG MED, V38, DOI 10.1016/j.ajem.2020.05.100; Bhatla A, 2020, HEART RHYTHM, V17, P1439, DOI 10.1016/j.hrthm.2020.06.016; Bilal U., 2020, EARLY EVIDENCE DISPA; Cavaliere K, 2020, GASTROINTEST ENDOSC, V92, P454, DOI 10.1016/j.gie.2020.04.028; Centers for Disease Control and Prevention, 2020, EV US UPD LIST UND M; Chen CYC, 2022, J FAM ISSUES, V43, P719, DOI 10.1177/0192513X21994153; Chunara R, 2021, J AM MED INFORM ASSN, V28, P33, DOI 10.1093/jamia/ocaa217; Coxe S, 2009, J PERS ASSESS, V91, P121, DOI 10.1080/00223890802634175; Crabb BT, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.17703; DataDirect, 2021, PREC HLTH AN PLATF; Daugherty AM, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113266; De Carvalho H, 2021, INTERN EMERG MED, V16, P1945, DOI 10.1007/s11739-021-02632-z; Dietz W, 2020, OBESITY, V28, P1005, DOI 10.1002/oby.22818; Drefahl S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18926-3; Ebinger JE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236240; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Estiri H, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00383-x; Fan BE, 2020, AM J HEMATOL, V95, pE158, DOI 10.1002/ajh.25823; Farooqi F, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5030112; Carrillo-Vega MF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238905; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fragasso G, 2013, INT J CARDIOL, V163, P320, DOI 10.1016/j.ijcard.2012.09.123; Gausman J, 2020, J WOMENS HEALTH, V29, P465, DOI 10.1089/jwh.2020.8472; Goel A, 2022, DISASTER MED PUBLIC, V16, P1889, DOI 10.1017/dmp.2021.85; Gu T, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25197; Habib MB, 2020, IDCASES, V21, DOI 10.1016/j.idcr.2020.e00859; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Hussain A, 2020, OBES RES CLIN PRACT, V14, P295, DOI 10.1016/j.orcp.2020.07.002; Jin J, 2021, NAT MED, V27, P264, DOI 10.1038/s41591-020-01191-8; Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198; Karmakar M, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.36462; Karpman M., 2020, COVID 19 PANDEMIC IS, V500; Khalangot M, 2020, AM J PHYSIOL-ENDOC M, V319, pE196, DOI 10.1152/ajpendo.00288.2020; Khan MMA, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.020503; Khatana SAM, 2020, J GEN INTERN MED, V35, P2431, DOI 10.1007/s11606-020-05916-w; Khoshdel-Rad N., 2021, OUTBREAK CHRONIC REN; Kim L, 2021, CLIN INFECT DIS, V72, P206, DOI DOI 10.1093/cid/ciaa1012; Klang E, 2020, OBESITY, V28, P1595, DOI 10.1002/oby.22913; Kontis V, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1112-0; Ladha KS, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008990; Lieberman-Cribbin W, 2020, AM J PREV MED, V59, P326, DOI 10.1016/j.amepre.2020.06.005; Ma KL, 2020, COVID 19 MYOCARDITIS; Madhavan S, 2021, J AM MED INFORM ASSN, V28, P393, DOI 10.1093/jamia/ocaa287; Martini A, 2020, ENCOUNTERING EXTREMISM, P1; Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621; Mikami T, 2021, J GEN INTERN MED, V36, P17, DOI 10.1007/s11606-020-05983-z; Mitrani RD, 2020, HEART RHYTHM, V17, P1984, DOI 10.1016/j.hrthm.2020.06.026; Mogaji E., 2020, RES AGENDA WORKING P, V2020, P57, DOI [10.2139/ssrn.3564702, DOI 10.2139/SSRN.3564702]; Montenovo L., 2020, W27132 NAT BUR EC RE, DOI [10.3386/w27132, DOI 10.3386/W27132]; Moreno-Perez O, 2020, INT J INFECT DIS, V100, P449, DOI 10.1016/j.ijid.2020.09.033; Moser DK, 2009, J CARD FAIL, V15, P763, DOI 10.1016/j.cardfail.2009.05.003; Nadkarni GN, 2020, J AM COLL CARDIOL, V76, P1815, DOI 10.1016/j.jacc.2020.08.041; Office of the Governor of Michigan, 2020, EX ORD 2020 04 COVID; Oster AM, 2020, MMWR-MORBID MORTAL W, V69, P1127, DOI 10.15585/mmwr.mm6933e2; Oulhaj A., 2020, COMPETING RISK IN HO; Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262; Patel AP, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01227-y; Pranata R, 2020, INT J TUBERC LUNG D, V24, P838, DOI 10.5588/ijtld.20.0278; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rastad H, 2020, DIABETOL METAB SYNDR, V12, DOI 10.1186/s13098-020-00565-9; Ravi K, 2020, LANCET, V396, P22, DOI 10.1016/S0140-6736(20)31423-9; Raza A, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.8429; Rentsch CT, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003379; Rod JE, 2020, REV SAUDE PUBL, V54, DOI 10.11606/s1518-8787.2020054002481; Rogers TN, 2020, WORLD MED HEALTH POL, V12, P311, DOI 10.1002/wmh3.358; Rosenthal N, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.29058; Salerno S, 2021, J INTERN MED, V289, P726, DOI 10.1111/joim.13213; Salvatore M, 2021, J CLIN MED, V10, DOI [10.1101/2020.06.29.20141564, 10.3390/jcm10071351]; Santeusanio AD, 2020, CLIN TRANSPLANT, V34, DOI 10.1111/ctr.14055; Shi M, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23415; Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950; Simard M, 2018, MED CARE, V56, P441, DOI 10.1097/MLR.0000000000000905; Spector-Bagdady K, 2020, CLIN INFECT DIS, V71, P2187, DOI 10.1093/cid/ciaa560; Ssentongo P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238215; Taquet M, 2021, LANCET PSYCHIAT, V8, P130, DOI 10.1016/S2215-0366(20)30462-4; Tartof SY, 2020, ANN INTERN MED, V173, P773, DOI 10.7326/M20-3742; Therneau TM., 2000, MODELING SURVIVAL DA, V39; Thompson NR, 2015, MED CARE, V53, P374, DOI 10.1097/MLR.0000000000000326; Townsend M.J., 2020, OUTCOMES COVID 19 DI; Trindade AJ, 2021, J INTERN MED, V289, P887, DOI 10.1111/joim.13232; Unwin HJT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19652-6; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5; Venkatesan P, 2020, LANCET RESP MED, V8, pE95, DOI 10.1016/S2213-2600(20)30461-6; Vlaar APJ, 2019, TRANSFUSION, V59, P2465, DOI 10.1111/trf.15311; Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000; West CP, 2020, MAYO CLIN PROC, V95, P1127, DOI 10.1016/j.mayocp.2020.04.004; Wiley Z, 2022, J RACIAL ETHN HEALTH, V9, P117, DOI 10.1007/s40615-020-00934-0; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Woolf SH, 2021, JAMA-J AM MED ASSOC, V325, P123, DOI 10.1001/jama.2020.24865; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu F, 2020, J THORAC DIS, V12, P1811, DOI 10.21037/jtd-20-1914; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Yousaf Z, 2020, AM J PHYSIOL-ENDOC M, V318, pE882, DOI 10.1152/ajpendo.00178.2020; Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618; Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859	106	2	2	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2021	16	10							e0258278	10.1371/journal.pone.0258278	http://dx.doi.org/10.1371/journal.pone.0258278			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YQ9DX	34614008	Green Published, gold, Green Submitted			2023-01-03	WOS:000749604400061
J	Lobo, EH; Johnson, T; Frolich, A; Kensing, F; Rasmussen, LJ; Hosking, SM; Page, AT; Livingston, PM; Islam, SMS; Grundy, J; Abdelrazek, M				Lobo, Elton H.; Johnson, Tara; Frolich, Anne; Kensing, Finn; Rasmussen, Lene J.; Hosking, Sarah M.; Page, Amy T.; Livingston, Patricia M.; Islam, Sheikh Mohammed Shariful; Grundy, John; Abdelrazek, Mohamed			Utilization of social media communities for caregiver information support in stroke recovery: An analysis of content and interactions	PLOS ONE			English	Article							HEALTH INFORMATION; FAMILY CAREGIVERS; EDUCATION; SEEKING; NEEDS; EXPERIENCES; SURVIVORS	Background Caregivers often use the internet to access information related to stroke care to improve preparedness, thereby reducing uncertainty and enhancing the quality of care. Method Social media communities used by caregivers of people affected by stroke were identified using popular keywords searched for using Google. Communities were filtered based on their ability to provide support to caregivers. Data from the included communities were extracted and analysed to determine the content and level of interaction. Results There was a significant rise in the use of social media by caregivers of people affected by stroke. The most popular social media communities were charitable and governmental organizations with the highest user interaction-this was for topics related to stroke prevention, signs and symptoms, and caregiver self-care delivered through video-based resources. Conclusion Findings show the ability of social media to support stroke caregiver needs and practices that should be considered to increase their interaction and support.	[Lobo, Elton H.; Abdelrazek, Mohamed] Deakin Univ, Sch Informat Technol, Geelong, Vic, Australia; [Lobo, Elton H.; Johnson, Tara; Frolich, Anne] Univ Copenhagen, Dept Publ Hlth, Copenhagen, Denmark; [Johnson, Tara; Hosking, Sarah M.; Livingston, Patricia M.] Deakin Univ, Fac Hlth, Geelong, Vic, Australia; [Frolich, Anne] Slagelse Hosp, Innovat & Res Ctr Multimorbid, Slagelse, Region Zealand, Denmark; [Kensing, Finn] Univ Copenhagen, Dept Comp Sci, Copenhagen, Denmark; [Rasmussen, Lene J.] Univ Copenhagen, Dept Cellular & Mol Med, Copenhagen, Denmark; [Rasmussen, Lene J.] Univ Copenhagen, Ctr Hlth Aging, Copenhagen, Denmark; [Page, Amy T.] Alfred Hlth, Pharm Dept, Melbourne, Vic, Australia; [Page, Amy T.] Monash Univ, Ctr Med Use & Safety, Melbourne, Vic, Australia; [Islam, Sheikh Mohammed Shariful] Deakin Univ, Inst Phys Act & Nutr IPAN, Geelong, Vic, Australia; [Grundy, John] Monash Univ, Fac Informat Technol, Melbourne, Vic, Australia	Deakin University; University of Copenhagen; Deakin University; University of Copenhagen; University of Copenhagen; University of Copenhagen; Monash University; Deakin University; Monash University	Lobo, EH (corresponding author), Deakin Univ, Sch Informat Technol, Geelong, Vic, Australia.; Lobo, EH (corresponding author), Univ Copenhagen, Dept Publ Hlth, Copenhagen, Denmark.	elobo@deakin.edu.au	Islam, Mohammed Shariful/B-1219-2011; Grundy, John/I-6681-2012; Page, Amy/F-9424-2013	Islam, Mohammed Shariful/0000-0001-7926-9368; Grundy, John/0000-0003-4928-7076; Lobo, Elton/0000-0003-0096-6318; Rasmussen, Lene Juel/0000-0001-6864-963X; Page, Amy/0000-0002-2084-8469; Abdelrazek, Mohamed/0000-0003-3812-9785	School of Information Technology, Deakin University; Department of Public Health, University of Copenhagen; ARC Laureate Fellowship [FL190100035]; Alfred Deakin Postdoctoral Research Fellowship	School of Information Technology, Deakin University; Department of Public Health, University of Copenhagen; ARC Laureate Fellowship(Australian Research Council); Alfred Deakin Postdoctoral Research Fellowship	This study was supported through doctoral scholarships from the School of Information Technology, Deakin University, and the Department of Public Health, University of Copenhagen. Further, Prof John Grundy is supported by ARC Laureate Fellowship FL190100035, and Dr. Sarah Hosking is supported by an Alfred Deakin Postdoctoral Research Fellowship.	Ang SY, 2013, PROC SINGAP HEALTHC, V22, P166, DOI 10.1177/201010581302200303; Bansler JP., 2018, COMPUT SUPPORTED COO, V27, P1181, DOI [10.1007/s10606-018-9309-1, DOI 10.1007/S10606-018, DOI 10.1007/S10606-018-9309-1]; Chu Joanna Tw, 2017, Interact J Med Res, V6, pe24, DOI 10.2196/ijmr.7000; Creasy KR, 2013, REHABIL NURS, V38, P88, DOI 10.1002/rnj.69; Crocco AG, 2002, JAMA-J AM MED ASSOC, V287, P2869, DOI 10.1001/jama.287.21.2869; Danzl MM, 2016, J RURAL HEALTH, V32, P13, DOI 10.1111/jrh.12124; Deyhoul N, 2020, AGING CLIN EXP RES, V32, P1343, DOI 10.1007/s40520-019-01321-4; Dutta-Bergman M, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.3.e21; Ferguson LA, 2012, JNP-J NURSE PRACT, V8, pE17, DOI 10.1016/j.nurpra.2012.07.025; Kumar R., 2016, ADV PRACTICE NURS, V1, P2; Li YB, 2018, TECHNOL FORECAST SOC, V126, P28, DOI 10.1016/j.techfore.2016.07.021; Lobo EH, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.647249; Luhnen J, 2018, Z EVIDENZ FORTBILD Q, V137, P77, DOI 10.1016/j.zefq.2018.08.002; Lutz BJ, 2017, GERONTOLOGIST, V57, P880, DOI 10.1093/geront/gnw135; Cabrera-Maqueda JM, 2018, STROKE, V49, pE25, DOI 10.1161/STROKEAHA.117.020068; McCurley JL, 2019, NEUROCRIT CARE, V30, P581, DOI 10.1007/s12028-018-0641-6; Mores G, 2018, CAN J NEUROL SCI, V45, P660, DOI 10.1017/cjn.2018.335; Naqvi IA, 2021, JMIR FORM RES, V5, DOI 10.2196/25123; Neuhauser L, 2009, AM J PUBLIC HEALTH, V99, P2188, DOI 10.2105/AJPH.2008.155648; Paulovich B., 2015, VISIBLE LANG, V49, P144; Pian WJ, 2020, INFORM PROCESS MANAG, V57, DOI 10.1016/j.ipm.2019.102077; Pierce Linda L, 2004, Rehabil Nurs, V29, P14; Scantlebury A, 2017, INT J MED INFORM, V103, P103, DOI 10.1016/j.ijmedinf.2017.04.018; Schoonenboom J, 2017, KOLNER Z SOZIOL SOZ, V69, P107, DOI 10.1007/s11577-017-0454-1; Smith F, 2017, ACTION RES-LONDON, V15, P310, DOI 10.1177/1476750316646832; Smith SD, 2008, TOP STROKE REHABIL, V15, P593, DOI 10.1310/tsr1506-593; Swire-Thompson B, 2020, ANNU REV PUBL HEALTH, V41, P433, DOI 10.1146/annurev-publhealth-040119-094127; Tan SSL, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.5729; Thomas J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-45; Tsai PC, 2015, PATIENT PREFER ADHER, V9, P449, DOI 10.2147/PPA.S77713; Tseung V, 2021, DISABIL REHABIL, V43, P1145, DOI 10.1080/09638288.2019.1652704; Tuong W, 2014, J BEHAV MED, V37, P218, DOI 10.1007/s10865-012-9480-7; van Beusekom MM, 2016, INT J CLIN PHARM-NET, V38, P1372, DOI 10.1007/s11096-016-0376-4; Wu C.-M., 2009, LEARNING BE FAMILY C; Cuan-Baltazar JY, 2020, JMIR PUBLIC HLTH SUR, V6, P176, DOI 10.2196/18444; Zhao YH, 2017, HEALTH INFO LIBR J, V34, P268, DOI 10.1111/hir.12192; Zhou LN, 2018, ELECTRON COMMER R A, V27, P139, DOI 10.1016/j.elerap.2017.12.003	37	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2022	17	1							e0262919	10.1371/journal.pone.0262919	http://dx.doi.org/10.1371/journal.pone.0262919			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3D9IN	35081150	Green Published, gold			2023-01-03	WOS:000829607600042
J	Mulder, M; Nijland, RHM; Vloothuis, JDM; van den Berg, M; Crotty, M; Kwakkel, G; van Wegen, EEH				Mulder, Marijn; Nijland, Rinske H. M.; Vloothuis, Judith D. M.; van den Berg, Maayken; Crotty, Maria; Kwakkel, Gert; van Wegen, Erwin E. H.			Comparing two identically protocolized, multicentre, randomized controlled trials on caregiver-mediated exercises poststroke: Any differences across countries?	PLOS ONE			English	Article							ACUTE STROKE; REHABILITATION; RECOVERY; IMPACT; SCALE; DISCHARGE; SELECTION; VALIDITY	Background The evidence for rehabilitation interventions poststroke lack sufficient robustness. However, variation in treatment effects across countries have been given little attention. Objective To compare two identically protocolized trials conducted in different western countries in order to identify factors that may have caused variation in secondary trial outcomes. Methods Comparative study based on individual patient data (N = 129) from two randomized controlled trials, conducted in hospitals and rehabilitation facilities in the Netherlands (N = 66) and Australia (N = 63). Patients with stroke and their caregivers were randomly allocated to an 8-week caregiver-mediated exercises intervention (N = 63; 31 Australian and 32 Dutch) or to a control group (N = 66; 32 Australian and 34 Dutch). Patient characteristics, compliance, usual care and process measures were compared across countries. We examined if study setting significantly moderated the trial outcomes: Hospital Anxiety and Depression Scale, Fatigue Severity Scale and General Self-Efficacy Scale, measured at 8- and 12 weeks follow-up. In addition, we explored if factors that were significantly different across countries caused variation in these trial outcomes. Results Most patients suffered an ischemic stroke, were in the subacute phase and participated with their partner. Dutch patients were younger (P= 0.005) and had a lower functional status (P = 0.001). Australian patients were recruited earlier poststroke (P<0.001), spent less time in exercise therapy (P<0.001) and had a shorter length of stay (P<0.001). The level of contamination was higher (P= 0.040) among Dutch controls. No effect modification was observed and trial outcomes did not change after controlling for cross-country differences. Conclusions The present study highlighted important clinical differences across countries whilst using an identical study protocol. The observed differences could result in a different potential for recovery and variation in treatment effects across trials. We argue that we can proceed faster to evaluating interventions within international pragmatic trials.	[Mulder, Marijn; Kwakkel, Gert; van Wegen, Erwin E. H.] Amsterdam UMC, VU Univ Med Ctr, Dept Rehabil Med, Amsterdam Movement Sci, Amsterdam, Netherlands; [Mulder, Marijn; Nijland, Rinske H. M.; Vloothuis, Judith D. M.; Kwakkel, Gert] Rehabil Res Ctr Reade, Amsterdam, Netherlands; [van den Berg, Maayken] Flinders Univ S Australia, Dept Rehabil Aged & Extended Care, Adelaide, SA, Australia; [Kwakkel, Gert; van Wegen, Erwin E. H.] Amsterdam Neurosci, Amsterdam, Netherlands; [Kwakkel, Gert] Northwestern Univ, Dept Phys Therapy & Human Movement Sci, Chicago, IL USA	University of Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Flinders University South Australia; Vrije Universiteit Amsterdam; Northwestern University	Nijland, RHM (corresponding author), Rehabil Res Ctr Reade, Amsterdam, Netherlands.	r.nijland@reade.nl						AHO K, 1980, B WORLD HEALTH ORGAN, V58, P113; Bernhardt J, 2016, INT J STROKE, V11, P454, DOI 10.1177/1747493016643851; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; DEHAAN R, 1995, STROKE, V26, P2027, DOI 10.1161/01.STR.26.11.2027; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; Dutrieux RD, 2016, J REHABIL MED, V48, P14, DOI 10.2340/16501977-2045; Fahey M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0185402; Gagnier JJ, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-106; Gamerman V, 2019, HEALTH SERV OUTCOME, V19, P23, DOI 10.1007/s10742-018-0192-5; Grant C, 2014, ARCH PHYS MED REHAB, V95, P74, DOI 10.1016/j.apmr.2013.08.014; Hakkennes SJ, 2011, ARCH PHYS MED REHAB, V92, P2057, DOI 10.1016/j.apmr.2011.07.189; Ivers NM, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-120; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; Labberton AS, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4713-x; Langhorne P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub4; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lohse KR, 2018, ARCH PHYS MED REHAB, V99, P1424, DOI 10.1016/j.apmr.2017.12.024; Lohse KR, 2014, STROKE, V45, P2053, DOI 10.1161/STROKEAHA.114.004695; Luengo-Fernandez R, 2020, EUR STROKE J, V5, P17, DOI 10.1177/2396987319883160; Lugo-Palacios DG, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030426; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Magill N, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-018-0646-z; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Outpatient Service Trialists, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.cd002925, 10.1002/14651858.CD002925, DOI 10.1002/14651858.CD002925]; Rajsic S, 2019, EUR J HEALTH ECON, V20, P107, DOI 10.1007/s10198-018-0984-0; Schwarzer R., 1995, MEASURES HLTH PSYCHO, P35, DOI DOI 10.1037/T00393-000; Stinear CM, 2020, LANCET NEUROL, V19, P348, DOI 10.1016/S1474-4422(19)30415-6; Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1503/cmaj.090523, 10.1016/j.jclinepi.2008.12.011]; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Twisk J., 2013, APPL LONGITUDINAL DA, V2, DOI [10.1017/CBO9781139342834, DOI 10.1017/CBO9781139342834]; Twisk J.W.R., 2016, INLEIDING TOEGEPASTE, V4th; Valko PO, 2008, SLEEP, V31, P1601, DOI 10.1093/sleep/31.11.1601; van den Berg M, 2016, STROKE, V47, P1885, DOI 10.1161/STROKEAHA.116.013431; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Vloothuis J, 2018, PHYSIOTHER RES INT, V23, DOI 10.1002/pri.1719; Vloothuis J, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0440-z; Vloothuis JDM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214241; Vloothuis JDM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011058.pub2; Walker MF, 2017, INT J STROKE, V12, P472, DOI 10.1177/1747493017711815; Winstein C, 2019, STROKE, V50, P1831, DOI 10.1161/STROKEAHA.118.023603; Winstein C, 2018, INT J STROKE, V13, P112, DOI 10.1177/1747493017743061; Yasmeen Israt, 2020, Arch Rehabil Res Clin Transl, V2, P100053, DOI 10.1016/j.arrct.2020.100053	45	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2022	17	1							e0263013	10.1371/journal.pone.0263013	http://dx.doi.org/10.1371/journal.pone.0263013			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	1B8ZK	35077507	Green Published, gold			2023-01-03	WOS:000792720400056
J	Berger, JS; Kornblith, LZ; Gong, MN; Reynolds, HR; Cushman, M; Cheng, Y; McVerry, BJ; Kim, KS; Lopes, RD; Atassi, B; Berry, S; Bochicchio, G; Antunes, MD; Farkouh, ME; Greenstein, Y; Hade, EM; Hudock, K; Hyzy, R; Khatri, P; Kindzelski, A; Kirwan, BA; Kreuziger, LB; Lawler, PR; Leifer, E; Moreno, JLS; Lopez-Sendon, J; Luther, JF; Maia, LN; Quigley, J; Sherwin, R; Wahid, L; Wilson, J; Hochman, JS; Neal, MD				Berger, Jeffrey S.; Kornblith, Lucy Z.; Gong, Michelle N.; Reynolds, Harmony R.; Cushman, Mary; Cheng, Yu; McVerry, Bryan J.; Kim, Keri S.; Lopes, Renato D.; Atassi, Bassel; Berry, Scott; Bochicchio, Grant; Antunes, Murillo de Oliveira; Farkouh, Michael E.; Greenstein, Yonatan; Hade, Erinn M.; Hudock, Kristin; Hyzy, Robert; Khatri, Pooja; Kindzelski, Andrei; Kirwan, Bridget-Anne; Kreuziger, Lisa Baumann; Lawler, Patrick R.; Leifer, Eric; Moreno, Jose Lopez-Sendon; Lopez-Sendon, Jose; Luther, James F.; Maia, Lilia Nigro; Quigley, John; Sherwin, Robert; Wahid, Lana; Wilson, Jennifer; Hochman, Judith S.; Neal, Matthew D.		ACTIV-4a Investigators	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19 A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								IMPORTANCE Platelets represent a potential therapeutic target for improved clinical outcomes in patients with COVID-19. OBJECTIVE To evaluate the benefits and risks of adding a P2Y12 inhibitor to anticoagulant therapy among non-critically ill patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS An open-label, bayesian, adaptive randomized clinical trial including 562 non-critically ill patients hospitalized for COVID-19 was conducted between February 2021 and June 2021 at 60 hospitals in Brazil, Italy, Spain, and the US. The date of final 90-day follow-up was September 15, 2021. INTERVENTIONS Patients were randomized to a therapeutic dose of heparin plus a P2Y12 inhibitor (n = 293) or a therapeutic dose of heparin only (usual care) (n = 269) in a 1:1 ratio for 14 days or until hospital discharge, whichever was sooner. Ticagrelor was the preferred P2Y12 inhibitor. MAIN OUTCOMES AND MEASURES The composite primary outcome was organ support-free days evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and, for those who survived to hospital discharge, the number of days free of respiratory or cardiovascular organ support up to day 21 of the index hospitalization (range, -1 to 21 days; higher scores indicate less organ support and better outcomes). The primary safety outcome was major bleeding by 28 days as defined by the International Society on Thrombosis and Hemostasis. RESULTS Enrollment of non-critically ill patients was discontinued when the prespecified criterion for futility was met. All 562 patients who were randomized (mean age, 523 [SD, 13.5] years; 41.5% women) completed the trial and 87% received a therapeutic dose of heparin by the end of study day 1. In the P2Y12 inhibitor group, ticagrelor was used in 63% of patients and clopidogrel in 37%. The median number of organ support-free days was 21 days (IQR, 20-21days) among patients in the P2Y12 inhibitor group and was 21 days (IQR, 21-21 days) in the usual care group (adjusted odds ratio, 0.83 [95% credible interval, 0.55-1.25]; posterior probability of futility [defined as an odds ratio <1.2], 96%). Major bleeding occurred in 6 patients (2.0%) in the P2Y12 inhibitor group and in 2 patients (0.7%) in the usual care group (adjusted odds ratio, 3.31 [95% CI, 0.64-17.2]; P = .15). CONCLUSIONS AND RELEVANCE Among non-critically ill patients hospitalized for COVID-19, the use of a P2Y12 inhibitor in addition to a therapeutic dose of heparin, compared with a therapeutic dose of heparin only, did not result in an increased odds of improvement in organ support-free days within 21days during hospitalization.	[Berger, Jeffrey S.; Reynolds, Harmony R.; Hade, Erinn M.; Hochman, Judith S.] NYU Grossman Sch Med, 530 First Ave,Skirball 9R, New York, NY 10016 USA; [Kornblith, Lucy Z.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Gong, Michelle N.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Cushman, Mary] Univ Vermont, Coll Med, Burlington, VT USA; [Cheng, Yu; McVerry, Bryan J.; Luther, James F.; Neal, Matthew D.] Univ Pittsburgh, Pittsburgh, PA USA; [Kim, Keri S.; Quigley, John] Univ Illinois, Chicago, IL USA; [Lopes, Renato D.] Duke Univ, Med Ctr, Durham, NC USA; [Atassi, Bassel] OSF Little Co Mary Med Ctr, Evergreen Pk, IL USA; [Berry, Scott] Berry Consultants LLC, Austin, TX USA; [Bochicchio, Grant] Washington Univ, Sch Med, St Louis, MO USA; [Antunes, Murillo de Oliveira] Hosp Univ Sao Francisco Assis, Sao Paulo, Brazil; [Farkouh, Michael E.; Lawler, Patrick R.] Peter Munk Cardiac Ctr, Toronto, ON, Canada; [Greenstein, Yonatan] Rutgers State Univ, New Jersey Med Sch, Newark, NJ USA; [Hudock, Kristin; Khatri, Pooja] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; [Hyzy, Robert] Univ Michigan, Ann Arbor, MI USA; [Kindzelski, Andrei; Leifer, Eric] NHLBI, Bldg 10, Bethesda, MD 20892 USA; [Kirwan, Bridget-Anne] Socar Res SA, Nyon, Switzerland; [Kreuziger, Lisa Baumann] Vers Blood Res Inst, Milwaukee, WI USA; [Moreno, Jose Lopez-Sendon] Hosp Univ Ramon Y Cajal, Madrid, Spain; [Lopez-Sendon, Jose] Hosp Univ La Paz, Madrid, Spain; [Maia, Lilia Nigro] Fundacao Fac Reg Med Sao Jose Rio Do Preto, Sao Jose Do Rio Preto, Brazil; [Sherwin, Robert] Wayne State Univ, Detroit, MI USA; [Wahid, Lana] Duke Univ Hosp, Durham, NC USA; [Wilson, Jennifer] Stanford Univ, Med Ctr, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Yeshiva University; Albert Einstein College of Medicine; University of Vermont; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Duke University; Washington University (WUSTL); University of Toronto; Peter Munk Cardiac Centre; Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; University of Cincinnati; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Hospital Universitario Ramon y Cajal; Hospital Universitario La Paz; Wayne State University; Duke University; Stanford University	Berger, JS (corresponding author), NYU Grossman Sch Med, 530 First Ave,Skirball 9R, New York, NY 10016 USA.	jeffrey.berger@nyulangone.org	Vallurupalli, Srikanth/H-9413-2019; Neal, Matthew/GMW-5601-2022	Vallurupalli, Srikanth/0000-0002-2404-1152; Neal, Matthew/0000-0001-8931-6236; Jimenez, Jose Victor/0000-0002-9209-0327; Wahid, Lana/0000-0002-2160-3287; Morin, Haley/0000-0003-1967-7890; Kim, Keri S./0000-0002-8480-4801; Gonzalez Juanatey, Jose Ramon/0000-0001-9681-3388	National Institutes of Health [1OT2HL156812-01];  [OTA-20-011]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 	This research was funded by agreement 1OT2HL156812-01 with the National Institutes of Health. The ACTIV-4a platform was sponsored by the National Heart, Lung, and Blood Institute and administered through an other transactions authority (OTA-20-011).	Abdulnour REE, 2018, AM J RESP CRIT CARE, V197, P1575, DOI 10.1164/rccm.201712-2530OC; Barnes GD, 2020, HEMATOL-AM SOC HEMAT, P642, DOI 10.1182/hematology.2020000151; Barrett T, 2021, CIRCULATION, V144, DOI 10.1111/jth.15534; Barrett TJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abh2434; Barrett TJ, 2020, CIRC RES, V127, P945, DOI 10.1161/CIRCRESAHA.120.317803; Bilaloglu S, 2020, JAMA-J AM MED ASSOC, V324, P799, DOI 10.1001/jama.2020.13372; Challen R, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n579; Hottz ED, 2020, BLOOD, V136, P1330, DOI 10.1182/blood.2020007252; Kamran H, 2021, JAMA-J AM MED ASSOC, V325, P1545, DOI 10.1001/jama.2021.0716; Koupenova M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09607-x; Lancellotti P, 2019, JAMA CARDIOL, V4, P596, DOI 10.1001/jamacardio.2019.1189; Lawler PR, 2021, NEW ENGL J MED, V385, P790, DOI 10.1056/NEJMoa2105911; Lowenstein CJ, 2020, CIRCULATION, V142, P1609, DOI 10.1161/CIRCULATIONAHA.120.050354; Manne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214; Newman JD, 2018, J AM COLL CARDIOL, V72, P1856, DOI 10.1016/j.jacc.2018.07.071; Nguyen NT, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0417; Rapkiewicz AV, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100434; RECOVERY Collaborative Group, 2022, Lancet, V399, P143, DOI 10.1016/S0140-6736(21)01825-0; Rodriguez F, 2021, NEW ENGL J MED, V384, P452, DOI 10.1056/NEJMra1607714; Taus F, 2020, ARTERIOSCL THROM VAS, V40, P2975, DOI 10.1161/ATVBAHA.120.315175; Thomas MR, 2015, THROMB HAEMOSTASIS, V114, P490, DOI 10.1160/TH14-12-1068	21	36	37	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2022	327	3					227	236		10.1001/jama.2021.23605	http://dx.doi.org/10.1001/jama.2021.23605			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV9PQ	35040887	Green Published, Bronze			2023-01-03	WOS:000753055100017
J	Nguyen, JL; Benigno, M; Malhotra, D; Khan, F; Angulo, FJ; Hammond, J; Swerdlow, DL; Reimbaeva, M; Emir, B; McLaughlin, JM				Nguyen, Jennifer L.; Benigno, Michael; Malhotra, Deepa; Khan, Farid; Angulo, Frederick J.; Hammond, Jennifer; Swerdlow, David L.; Reimbaeva, Maya; Emir, Birol; McLaughlin, John M.			Pandemic-related declines in hospitalization for non-COVID-19-related illness in the United States from January through July 2020	PLOS ONE			English	Article							COVID-19; ADMISSIONS; TRENDS; IMPACT	Background The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has substantially impacted healthcare utilization worldwide. The objective of this retrospective analysis of a large hospital discharge database was to compare all-cause and cause-specific hospitalizations during the first six months of the pandemic in the United States with the same months in the previous four years. Methods Data were collected from all hospitals in the Premier Healthcare Database (PHD) and PHD Special Release reporting hospitalizations from January through July for each year from 2016 through 2020. Hospitalization trends were analyzed stratified by age group, major diagnostic categories (MDCs), and geographic region. Results The analysis included 286 hospitals from all 9 US Census divisions. The number of allcause hospitalizations per month was relatively stable from 2016 through 2019 and then fell by 21% (57,281 fewer hospitalizations) between March and April 2020, particularly in hospitalizations for non-respiratory illnesses. From April onward there was a rise in the number of monthly hospitalizations per month. Hospitalizations per month, nationally and in each Census division, decreased for 20 of 25 MDCs between March and April 2020. There was also a decrease in hospitalizations per month for all age groups between March and April 2020 with the greatest decreases in hospitalizations observed for patients 50-64 and >= 65 years of age. Conclusions Rates of hospitalization declined substantially during the first months of the COVID-19 pandemic, suggesting delayed routine, elective, and emergency care in the United States. These lapses in care for illnesses not related to COVID-19 may lead to increases in morbidity and mortality for other conditions. Thus, in the current stage of the pandemic, clinicians and public-health officials should work, not only to prevent SARS-CoV-2 transmission, but also to ensure that care for non-COVID-19 conditions is not delayed.	[Nguyen, Jennifer L.; Benigno, Michael; Malhotra, Deepa] Pfizer Inc, Real World Evidence Ctr Excellence, New York, NY 10017 USA; [Nguyen, Jennifer L.; Khan, Farid; Angulo, Frederick J.; Swerdlow, David L.; McLaughlin, John M.] Pfizer Inc, Pfizer Vaccines, Med Dev & Sci Clin Affairs, Collegeville, PA 19426 USA; [Hammond, Jennifer] Pfizer Inc, Clin Dev Internal Med & Hosp, Pfizer Global Prod Dev, Collegeville, PA USA; [Reimbaeva, Maya] Pfizer Inc, Global Biometr & Data Management, Pfizer Global Prod Dev, Groton, CT 06340 USA; [Emir, Birol] Pfizer Inc, Pfizer Global Prod Dev, Global Biometr & Data Management, New York, NY USA	Pfizer; Pfizer; Pfizer; Pfizer; Pfizer	Nguyen, JL (corresponding author), Pfizer Inc, Real World Evidence Ctr Excellence, New York, NY 10017 USA.; Nguyen, JL (corresponding author), Pfizer Inc, Pfizer Vaccines, Med Dev & Sci Clin Affairs, Collegeville, PA 19426 USA.	Jennifer.Nguyen2@pfizer.com	Nguyen, Jennifer/GVS-4347-2022		Pfizer Inc.	Pfizer Inc.(Pfizer)	This work and the article processing charges were sponsored by Pfizer Inc. The funder provided support in the form of salaries for authors F.A, M.B, B.E, J.H, F.K, D.M, J.M, J.L.N, M.R, and D.L.S, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Argenziano MG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1996; Birkmeyer JD, 2020, HEALTH AFFAIR, V39, P2010, DOI 10.1377/hlthaff.2020.00980; Center for Systems Science and Engineering at Johns Hopkins University, COVID 19 DASHB 2020; Centers for Disease Control and Prevention, FRAM HEALTHC SYST PR; Centers for Disease Control and Prevention, CDC COVID DATA TRACK, DOI [10.2196/1939932788148, DOI 10.2196/1939932788148]; Centers for Disease Control and Prevention, EST DIS BURD COVID 1; Centers for Disease Control and Prevention, ICD 10 CM OFF COD RE; Centers for Medicare and Medicaid Services, ICD 10 CM PCS MS DRG; Centers for Medicare and Medicaid Services, 2020, ICD 10 MS DRGS VERS; Cowling BJ, 2020, J INFECT DIS, V221, P1749, DOI 10.1093/infdis/jiaa123; Cox C., 2020, HAVE HEALTHCARE UTIL; Czeisler ME, 2020, MMWR-MORBID MORTAL W, V69, P1250, DOI 10.15585/mmwr.mm6936a4; de Pablo GS, 2020, J AFFECT DISORDERS, V275, P48, DOI 10.1016/j.jad.2020.06.022; De Rosa S, 2020, EUR HEART J, V41, P2083, DOI 10.1093/eurheartj/ehaa409; Ettman CK, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.19686; Gallaway MS, 2020, MMWR-MORBID MORTAL W, V69, P1460, DOI 10.15585/mmwr.mm6940e3; Hartnett KP, 2020, MMWR-MORBID MORTAL W, V69, P699, DOI 10.15585/mmwr.mm6923e1; Hutchins HJ, 2020, MMWR-MORBID MORTAL W, V69, P1584, DOI 10.15585/mmwr.mm6943e4; Jewell JS, 2020, JMIR FORM RES, V4, DOI 10.2196/22043; Kadri SS, 2020, JAMA-J AM MED ASSOC, V324, P2553, DOI 10.1001/jama.2020.20323; Kim HS, 2020, ACAD EMERG MED, V27, P910, DOI 10.1111/acem.14099; Lai PH, 2020, JAMA CARDIOL, V5, P1154, DOI 10.1001/jamacardio.2020.2488; Mafham MM, 2020, LANCET, V396, P381, DOI 10.1016/S0140-6736(20)31356-8; Moreland A, 2020, MMWR-MORBID MORTAL W, V69, P1198, DOI 10.15585/mmwr.mm6935a2; Olsen SJ, 2020, MMWR-MORBID MORTAL W, V69, P1305, DOI 10.15585/mmwr.mm6937a6; Oseran AS, 2020, AM J MANAG CARE, V26, P327, DOI 10.37765/ajmc.2020.43837; Oster AM, 2020, MMWR-MORBID MORTAL W, V69, P1127, DOI 10.15585/mmwr.mm6933e2; Pollard MS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.22942; Premier Applied Sciences PI, 2020, PREM HEALTHC DAT COV; Prevention CfDCa, CDC COVID DAT TRACK; Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2; Tenforde MW, 2020, MMWR-MORBID MORTAL W, V69, P993, DOI 10.15585/mmwr.mm6930e1externalicon; Thompson CN, 2020, MMWR-MORBID MORTAL W, V69, P1725, DOI 10.15585/mmwr.mm6946a2; Trump DJ., 2020, WHITE HOUSE PRO 0313; United Van Lines, 2020, ANN 2020 UN LIN NAT; US Census Bureau, CENS REG DIV US 2010; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013	37	9	9	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2022	17	1							e0262347	10.1371/journal.pone.0262347	http://dx.doi.org/10.1371/journal.pone.0262347			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2J6SK	34990489	Green Published, gold			2023-01-03	WOS:000815783800029
J	Melcher, A; Harrington, K; Vile, R				Melcher, Alan; Harrington, Kevin; Vile, Richard			Oncolytic virotherapy as immunotherapy	SCIENCE			English	Editorial Material							DELIVERY		[Melcher, Alan; Harrington, Kevin] Inst Canc Res, London, England; [Vile, Richard] Mayo Clin, Rochester, MN USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Mayo Clinic	Melcher, A (corresponding author), Inst Canc Res, London, England.	alan.melcher@icr.ac.uk; kevin.harrington@icr.ac.uk; vile.richard@mayo.edu						Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Breitbach CJ, 2011, NATURE, V477, P99, DOI 10.1038/nature10358; Chesney J, 2018, J CLIN ONCOL, V36, P1658, DOI 10.1200/JCO.2017.73.7379; Cloughesy TF, 2020, JAMA ONCOL, V6, P1939, DOI 10.1001/jamaoncol.2020.3161; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Fares J, 2021, LANCET ONCOL, V22, P1103, DOI 10.1016/S1470-2045(21)00245-X; Filley AC, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00106; Friedman GK, 2021, NEW ENGL J MED, V384, P1613, DOI 10.1056/NEJMoa2024947; Garcia-Carbonero R, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0277-7; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Moehler M, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1615817; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Samson A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7577	14	11	11	3	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	2021	374	6573					1325	1326		10.1126/science.abk3436	http://dx.doi.org/10.1126/science.abk3436			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XM1JK	34882456	Green Accepted			2023-01-03	WOS:000728591700027
J	Vera, M; Cheak, BB; Chmelickova, H; Bavanandan, S; Goh, BL; Halim, AGA; Garcia, I; Gajdos, M; Valente, RA; De los Rios, T; Atiye, S; Stauss-Grabo, M; Galli, E				Vera, Manel; Cheak, Bee Boon; Chmelickova, Hana; Bavanandan, Sunita; Goh, Bak Leong; Halim, Abdul Gafor Abdul; Garcia, Isabel; Gajdos, Martin; Valente, Rafael Alonso; De los Rios, Tatiana; Atiye, Saynab; Stauss-Grabo, Manuela; Galli, Emilio			Current clinical practice in adapted automated peritoneal dialysis (aAPD)-A prospective, non-interventional study	PLOS ONE			English	Article							SODIUM REMOVAL; FILL VOLUME; AREA	Adapted automated peritoneal dialysis (aAPD), comprising a sequence of dwells with different durations and fill volumes, has been shown to enhance both ultrafiltration and solute clearance compared to standard peritoneal dialysis with constant time and volume dwells. The aim of this non-interventional study was to describe the different prescription patterns used in aAPD in clinical practice and to observe outcomes characterizing volume status, dialysis efficiency, and residual renal function over 1 year. Prevalent and incident, adult aAPD patients were recruited during routine clinic visits, and aAPD prescription, volume status, residual renal function and laboratory data were documented at baseline and every quarter thereafter for 1 year. Treatments were prescribed according to the nephrologist's medical judgement in accordance with each center's clinical routine. Of 180 recruited patients, 160 were analyzed. 27 different aAPD prescription patterns were identified. 79 patients (49.4%) received 2 small, short dwells followed by 3 long, large dwells. During follow-up, volume status changed only marginally, with visit mean values ranging between 1.59 (95% confidence interval: 1.19; 1.99) and 1.97 (1.33; 2.61) L. Urine output and creatinine clearance decreased significantly, accompanied by reductions in ultrafiltration and Kt/V. 25 patients (15.6%) received a renal transplant and 15 (9.4%) were changed to hemodialysis. Options for individualization offered by aAPD are actually used in practice for optimized treatment. Changes observed in renal function and dialysis efficiency measures reflect the natural course of chronic kidney disease. No safety events were observed during the study period.	[Vera, Manel] Hosp Clin Barcelona, Nephrol, Barcelona, Spain; [Cheak, Bee Boon] Hosp Selayang, Dept Nephrol, Batu Caves, Selangor, Malaysia; [Chmelickova, Hana] Hosp Treb, Nephrol, Trebic, Czech Republic; [Bavanandan, Sunita] Hosp Kuala Lumpur, Nephrol, Kuala Lumpur, Malaysia; [Goh, Bak Leong] Hosp Serdang, Dept Nephrol, Batu Caves, Selangor, Malaysia; [Goh, Bak Leong] Hosp Serdang, Clin Res Ctr, Batu Caves, Selangor, Malaysia; [Halim, Abdul Gafor Abdul] Univ Kebangsaan Malaysia, Kuala Lumpur, Malaysia; [Garcia, Isabel] Hosp Univ Girona Josep Trueta, Nephrol, Girona, Spain; [Gajdos, Martin] NC Ctr Sokolov, Nephrol, Sokolov, Czech Republic; [Valente, Rafael Alonso] Univ Santiago, Nephrol, Complejo Hosp, Santiago De Compostela, Spain; [De los Rios, Tatiana; Atiye, Saynab; Stauss-Grabo, Manuela] Fresenius Med Care, Global Med Off, Bad Homburg, Germany; [Galli, Emilio] ASST Bergamo Ovest, Nefrol & Dialisi, Treviglio, Italy	University of Barcelona; Hospital Clinic de Barcelona; Universiti Kebangsaan Malaysia; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela	De los Rios, T (corresponding author), Fresenius Med Care, Global Med Off, Bad Homburg, Germany.	tatiana.de-los-rios@fmc-ag.com		GOH, BAK LEONG/0000-0002-4644-7743; VERA, MANEL/0000-0001-9937-7235	Fresenius Medical Care	Fresenius Medical Care	The study has been funded by Fresenius Medical Care. The funder was involved in the design, analysis, decision to publish and preparation of the manuscript.	[Anonymous], 2001, Am J Kidney Dis, V37, pS65; Aragó Sorrosal Sergi, 2014, Enferm Nefrol, V17, P202; Chagnac A, 2002, J AM SOC NEPHROL, V13, P2554, DOI 10.1097/01.ASN.0000026492.83560.81; Durand P Y, 1994, Adv Perit Dial, V10, P63; Durand PY, 2000, PERITON DIALYSIS INT, V20, pS83; Fischbach M, 1994, Adv Perit Dial, V10, P307; Fischbach M, 1996, Perit Dial Int, V16 Suppl 1, pS557; Fischbach M, 2001, J AM SOC NEPHROL, V12, P1524, DOI 10.1681/ASN.V1271524; Fischbach M, 2017, PEDIATR NEPHROL, V32, P419, DOI 10.1007/s00467-016-3378-5; Fischbach M, 2016, KIDNEY INT, V89, P761, DOI 10.1016/j.kint.2015.12.032; Fischbach Michel, 2014, Adv Perit Dial, V30, P94; Fischbach M, 2011, PERITON DIALYSIS INT, V31, P450, DOI 10.3747/pdi.2010.00146; Galli Emilio G, 2011, Adv Perit Dial, V27, P90; Keane DF, 2017, BIOMED PHYS ENG EXPR, V3, DOI 10.1088/2057-1976/aa6f45; KESHAVIAH P, 1994, J AM SOC NEPHROL, V4, P1820; LITTLE RJA, 1995, J AM STAT ASSOC, V90, P1112, DOI 10.2307/2291350; National Kidney Foundation, 2006, CLIN PRACTICE GUIDEL; O'Lone EL, 2014, NEPHROL DIAL TRANSPL, V29, P1430, DOI 10.1093/ndt/gfu049; Trinh E, 2018, CLIN J AM SOC NEPHRO, V13, P1732, DOI 10.2215/CJN.02570218; Van Biesen W, 2019, CLIN J AM SOC NEPHRO, V14, P882, DOI 10.2215/CJN.11590918; van Biesen W, 2013, NEPHROL DIAL TRANSPL, V28, P2620, DOI 10.1093/ndt/gft296; Vrtovsnik F, 2021, CLIN KIDNEY J, V14, P570, DOI 10.1093/ckj/sfz175; Wabel P, 2008, NEPHROL DIAL TRANSPL, V23, P2965, DOI 10.1093/ndt/gfn228; Wieskotten S, 2008, PHYSIOL MEAS, V29, P639, DOI 10.1088/0967-3334/29/5/009; Zaloszyc A, 2017, NEPHROL THER, V13, P30, DOI 10.1016/j.nephro.2016.07.444	25	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2021	16	12							e0258440	10.1371/journal.pone.0258440	http://dx.doi.org/10.1371/journal.pone.0258440			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY8LQ	34882678	Green Published, Green Submitted, gold			2023-01-03	WOS:000755037200003
J	Kalinsky, K; Barlow, WE; Gralow, JR; Meric-Bernstam, F; Albain, KS; Hayes, DF; Lin, NU; Perez, EA; Goldstein, LJ; Chia, SKL; Dhesy-Thind, S; Rastogi, P; Alba, E; Delaloge, S; Martin, M; Kelly, CM; Ruiz-Borrego, M; Gil-Gil, M; Arce-Salinas, CH; Brain, EGC; Lee, ES; Pierga, JY; Bermejo, B; Ramos-Vazquez, M; Jung, KH; Ferrero, JM; Schott, AF; Shak, S; Sharma, P; Lew, DL; Miao, JL; Tripathy, D; Pusztai, L; Hortobagyi, GN				Kalinsky, Kevin; Barlow, William E.; Gralow, Julie R.; Meric-Bernstam, Funda; Albain, Kathy S.; Hayes, Daniel F.; Lin, Nancy U.; Perez, Edith A.; Goldstein, Lori J.; Chia, Stephen K. L.; Dhesy-Thind, Sukhbinder; Rastogi, Priya; Alba, Emilio; Delaloge, Suzette; Martin, Miguel; Kelly, Catherine M.; Ruiz-Borrego, Manuel; Gil-Gil, Miguel; Arce-Salinas, Claudia H.; Brain, Etienne G. C.; Lee, Eun-Sook; Pierga, Jean-Yves; Bermejo, Begona; Ramos-Vazquez, Manuel; Jung, Kyung-Hae; Ferrero, Jean-Marc; Schott, Anne F.; Shak, Steven; Sharma, Priyanka; Lew, Danika L.; Miao, Jieling; Tripathy, Debasish; Pusztai, Lajos; Hortobagyi, Gabriel N.			21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADJUVANT SYSTEMIC THERAPY; POSTMENOPAUSAL PATIENTS; RECURRENCE SCORE; AMERICAN SOCIETY; GUIDE DECISIONS; ONCOTYPE DX; WOMEN; TAMOXIFEN; BIOMARKERS; SURVIVAL	BACKGROUND The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary lymph-node-negative breast cancer. In women with positive lymph-node disease, the role of the recurrence score with respect to predicting a benefit of adjuvant chemotherapy is unclear. METHODS In a prospective trial, we randomly assigned women with hormone-receptor-positive, HER2-negative breast cancer, one to three positive axillary lymph nodes, and a recurrence score of 25 or lower (scores range from 0 to 100, with higher scores indicating a worse prognosis) to endocrine therapy only or to chemotherapy plus endocrine (chemoendocrine) therapy. The primary objective was to determine the effect of chemotherapy on invasive disease-free survival and whether the effect was influenced by the recurrence score. Secondary end points included distant relapse-free survival. RESULTS A total of 5083 women (33.2% premenopausal and 66.8% postmenopausal) underwent randomization, and 5018 participated in the trial. At the prespecified third interim analysis, the chemotherapy benefit with respect to increasing invasive disease-free survival differed according to menopausal status (P = 0.008 for the comparison of chemotherapy benefit in premenopausal and postmenopausal participants), and separate prespecified analyses were conducted. Among postmenopausal women, invasive disease-free survival at 5 years was 91.9% in the endocrine-only group and 91.3% in the chemoendocrine group, with no chemotherapy benefit (hazard ratio for invasive disease recurrence, new primary cancer [breast cancer or another type], or death, 1.02; 95% confidence interval [CI], 0.82 to 1.26; P = 0.89). Among premenopausal women, invasive disease-free survival at 5 years was 89.0% with endocrine-only therapy and 93.9% with chemoendocrine therapy (hazard ratio, 0.60; 95% CI, 0.43 to 0.83; P = 0.002), with a similar increase in distant relapse-free survival (hazard ratio, 0.58; 95% CI, 0.39 to 0.87; P = 0.009). The relative chemotherapy benefit did not increase as the recurrence score increased. CONCLUSIONS Among premenopausal women with one to three positive lymph nodes and a recurrence score of 25 or lower, those who received chemoendocrine therapy had longer invasive disease-free survival and distant relapse-free survival than those who received endocrine-only therapy, whereas postmenopausal women with similar characteristics did not benefit from adjuvant chemotherapy.	[Kalinsky, Kevin] Emory Univ, Winship Canc Inst, 1365 Clifton Rd, Atlanta, GA 30322 USA; [Barlow, William E.; Lew, Danika L.; Miao, Jieling] Southwest Oncol Grp, Stat & Data Management Ctr, Seattle, WA USA; [Gralow, Julie R.] Univ Washington, Sch Med, Seattle Canc Care Alliance, Seattle, WA USA; [Meric-Bernstam, Funda; Tripathy, Debasish; Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Albain, Kathy S.] Loyola Univ Chicago, Maywood, IL USA; [Hayes, Daniel F.; Schott, Anne F.] Univ Michigan, Ann Arbor, MI 48109 USA; [Lin, Nancy U.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Perez, Edith A.] Mayo Clin, Jacksonville, FL 32224 USA; [Goldstein, Lori J.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Rastogi, Priya] Univ Pittsburgh, Pittsburgh, PA USA; [Chia, Stephen K. L.] BC Canc Vancouver Canc Ctr, Vancouver, BC, Canada; [Dhesy-Thind, Sukhbinder] Hamilton Hlth Sci, Juravinski Canc Ctr, Hamilton, ON, Canada; [Alba, Emilio] UGCI Med Oncol Hosp Virgen de la Victoria, Inst Invest Biomed Malaga, Malaga, Spain; [Martin, Miguel] Univ Complutense, Ctr Invest Biomed Red Canc, Inst Invest Sanitaria Gregorio Maranon, Inst Salud Carlos III, Madrid, Spain; [Ruiz-Borrego, Manuel] Hosp Univ Virgen del Rocio, Seville, Spain; [Gil-Gil, Miguel] Inst Catala Oncol, Barcelona, Spain; [Bermejo, Begona] Hosp Clin Univ Valencia, Hosp Clin Comunidad Valenciana, Biomed Res Inst Invest, Valencia, Spain; [Ramos-Vazquez, Manuel] Ctr Oncol Galicia, La Coruna, Spain; [Delaloge, Suzette] Inst Gustave Roussy, Paris, France; [Pierga, Jean-Yves] Inst Curie, Paris, France; [Brain, Etienne G. C.] Inst Curie, Ctr Rene Huguenin, St Cloud, France; [Ferrero, Jean-Marc] Ctr Antoine Lacassagne, Nice, France; [Kelly, Catherine M.] Mater Misericordiae Univ Hosp, Dublin, Ireland; [Arce-Salinas, Claudia H.] Inst Nacl Cancerol Mexico, Mexico City, DF, Mexico; [Lee, Eun-Sook] Natl Canc Ctr Korea, Goyang Si, South Korea; [Jung, Kyung-Hae] Univ Ulsan, Coll Med, Asa Med Ctr, Seoul, South Korea; [Shak, Steven] Exact Sci, Redwood City, CA USA; [Sharma, Priyanka] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA; [Pusztai, Lajos] Yale Univ, New Haven, CT USA	Emory University; Southwest Oncology Group; Seattle Cancer Care Alliance; University of Washington; University of Washington Seattle; University of Texas System; UTMD Anderson Cancer Center; Loyola University Chicago; University of Michigan System; University of Michigan; Harvard University; Dana-Farber Cancer Institute; Mayo Clinic; Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; McMaster University; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Complutense University of Madrid; Instituto de Salud Carlos III; Virgen del Rocio University Hospital; Catalan Institute of Oncology; UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Rene Huguenin Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Centre Antoine Lacassagne; Mater Misericordiae University Hospital; University College Dublin; Instituto Nacional de Cancerologia (INCAN); National Cancer Center - Korea (NCC); University of Ulsan; University of Kansas; University of Kansas Medical Center; Yale University	Kalinsky, K (corresponding author), Emory Univ, Winship Canc Inst, 1365 Clifton Rd, Atlanta, GA 30322 USA.	kevin.michael.kalinsky@emory.edu		Kelly, Professor Catherine M./0000-0001-8355-6714	National Cancer Institute [U10CA180888, U10CA180819, U10CA180820, U10CA180821, U10CA180868, U10CA180863, UG1CA2333247, UG1CA233329, UG1CA233160, UG1CA233180, UG1CA239767, UG1CA233337, P30CA015704, P30CA006927]; Susan G. Komen for the Cure Research Program; Hope Foundation for Cancer Research; Breast Cancer Research Foundation; Genomic Health	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G. Komen for the Cure Research Program; Hope Foundation for Cancer Research; Breast Cancer Research Foundation; Genomic Health	Supported by grants from the National Cancer Institute (U10CA180888, U10CA180819, U10CA180820, U10CA180821, U10CA180868, U10CA180863, UG1CA2333247, UG1CA233329, UG1CA233160, UG1CA233180, UG1CA239767, UG1CA233337, P30CA015704, and P30CA006927) and by the Susan G. Komen for the Cure Research Program, the Hope Foundation for Cancer Research, the Breast Cancer Research Foundation, and Genomic Health.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Albain KS, 2009, LANCET, V374, P2055, DOI 10.1016/S0140-6736(09)61523-3; Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6; Buus R, 2021, J CLIN ONCOL, V39, P126, DOI 10.1200/JCO.20.00853; Cardoso F, 2016, NEW ENGL J MED, V375, P717, DOI 10.1056/NEJMoa1602253; Cuzick J, 2007, LANCET, V369, P1711; Dowsett M, 2010, J CLIN ONCOL, V28, P1829, DOI 10.1200/JCO.2009.24.4798; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Harris LN, 2016, J CLIN ONCOL, V34, P1134, DOI 10.1200/JCO.2015.65.2289; Howlader N, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju055; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Ibraheem AF, 2019, CANCER-AM CANCER SOC, V125, P213, DOI 10.1002/cncr.31818; Krop I, 2017, J CLIN ONCOL, V35, P2838, DOI 10.1200/JCO.2017.74.0472; Nitz U, 2017, BREAST CANCER RES TR, V165, P573, DOI 10.1007/s10549-017-4358-6; Pagani O, 2020, J CLIN ONCOL, V38, P1293, DOI 10.1200/JCO.18.01967; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Piccart M, 2021, LANCET ONCOL, V22, P476, DOI 10.1016/S1470-2045(21)00007-3; Poorvu PD, 2020, J CLIN ONCOL, V38, P725, DOI 10.1200/JCO.19.01959; Roberts MC, 2017, BREAST CANCER RES TR, V163, P303, DOI 10.1007/s10549-017-4162-3; Sparano JA, 2018, NEW ENGL J MED, V379, P111, DOI 10.1056/NEJMoa1804710; Sparano JA, 2019, NEW ENGL J MED, V380, P2395, DOI 10.1056/NEJMoa1904819; Stemmer SM, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0033-7; Swain SM, 2010, NEW ENGL J MED, V362, P2053, DOI 10.1056/NEJMoa0909638; Weiser R, 2021, BREAST CANCER RES TR, V185, P667, DOI 10.1007/s10549-020-05971-1; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	28	110	111	9	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 16	2021	385	25					2336	2347		10.1056/NEJMoa2108873	http://dx.doi.org/10.1056/NEJMoa2108873		DEC 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE4WZ	34914339	Bronze, Green Accepted			2023-01-03	WOS:000724451400001
J	Evans, E; Swanson, MB; Mohr, N; Boulos, N; Vaughan-Sarrazin, M; Chan, PS; Girotra, S				Evans, Erin; Swanson, Morgan B.; Mohr, Nicholas; Boulos, Nassar; Vaughan-Sarrazin, Mary; Chan, Paul S.; Girotra, Saket		Amer Heart Assoc Get Guidelines-Re	Epinephrine before defibrillation in patients with shockable in-hospital cardiac arrest: propensity matched analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EUROPEAN RESUSCITATION COUNCIL; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; CARDIOPULMONARY-RESUSCITATION; TRACHEAL INTUBATION; STROKE FOUNDATION; SURVIVAL; GUIDELINES; STATEMENT; CANADA	OBJECTIVE To determine the use of epinephrine (adrenaline) before defibrillation for treatment of in-hospital cardiac arrest due to a ventricular arrhythmia and examine its association with patient survival. DESIGN Propensity matched analysis. SETTING 2000-18 data from 497 hospitals participating in the American Heart Association's Get With The Guidelines-Resuscitation registry. PARTICIPANTS Adults aged 18 and older with an index in-hospital cardiac arrest due to an initial shockable rhythm treated with defibrillation. INTERVENTIONS Administration of epinephrine before first defibrillation. MAIN OUTCOME MEASURES Survival to discharge; favorable neurological survival, defined as survival to discharge with none, mild, or moderate neurological disability measured using cerebral performance category scores; and survival after acute resuscitation (that is, return of spontaneous circulation for >20 minutes). A time dependent, propensity matched analysis was performed to adjust for confounding due to indication and evaluate the independent association of epinephrine before defibrillation with study outcomes. RESULTS Among 34 820 patients with an initial shockable rhythm, 9630 (27.6%) were treated with epinephrine before defibrillation, contrary to current guidelines. In comparison with participants treated with defibrillation first, participants receiving epinephrine first were less likely to have a history of myocardial infarction or heart failure, but more likely to have renal failure, sepsis, pneumonia, and receive mechanical ventilation before in-hospital cardiac arrest (P<0.0001 for all). Treatment with epinephrine before defibrillation was strongly associated with delayed defibrillation (median 3 minutes v 0 minutes). In propensity matched analysis (9011 matched pairs), epinephrine before defibrillation was associated with lower odds of survival to discharge (25.2% v 29.9%; adjusted odds ratio 0.81, 95% confidence interval 0.74 to 0.88; P<0.001), favorable neurological survival (18.6% v 21.4%; 0.85, 0.76 to 0.92; P<0.001), and survival after acute resuscitation (64.4% v 69.4%; 0.76, 0.70 to 0.83; P<0.001). The above findings were consistent in a range of sensitivity analyses, including matching according to defibrillation time. CONCLUSIONS Contrary to current guidelines that prioritize immediate defibrillation for in-hospital cardiac arrest due to a shockable rhythm, more than one in four patients are treated with epinephrine before defibrillation, which is associated with worse survival.	[Evans, Erin; Swanson, Morgan B.; Mohr, Nicholas] Univ Iowa, Carver Coll Med, Dept Internal Med, Dept Emergency Med, Iowa City, IA USA; [Swanson, Morgan B.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; [Boulos, Nassar] Univ Iowa, Carver Coll Med, Dept Internal Med, Div Pulm & Crit Care, Iowa City, IA USA; [Vaughan-Sarrazin, Mary] Univ Iowa, Carver Coll Med, Dept Internal Med, Div Gen Internal Med, Iowa City, IA USA; [Vaughan-Sarrazin, Mary; Girotra, Saket] Iowa City Vet Affairs Med Ctr, Ctr Access Delivery Res & Evaluat, Iowa City, IA 52246 USA; [Chan, Paul S.] Univ Missouri, St Lukes Mid Amer Heart & Vasc Inst, Kansas City, MO 64110 USA; [Girotra, Saket] Univ Iowa, Dept Internal Med, Carver Coll Med, Div Cardiovasc Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City; University of Iowa	Girotra, S (corresponding author), Iowa City Vet Affairs Med Ctr, Ctr Access Delivery Res & Evaluat, Iowa City, IA 52246 USA.; Girotra, S (corresponding author), Univ Iowa, Dept Internal Med, Carver Coll Med, Div Cardiovasc Med, Iowa City, IA 52242 USA.	saket-girotra@uiowa.edu	; Mohr, Nicholas/N-1112-2017	Vaughan Sarrazin, Mary/0000-0001-8717-1061; Girotra, Saket/0000-0002-4784-4513; Mohr, Nicholas/0000-0003-0497-5828	Eunice Kennedy Shriver National Institute of Child Health and Human Development [F30HD100074]; National Institutes of Health [R01HL123980, R56HL158803]; American Heart Association	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association)	No external funding was used for the conduct of this study. MBS is additionally supported by a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (F30HD100074) . PSC has received funding support from the National Institutes of Health (R01HL123980) and the American Heart Association. SG has received funding from the National Institutes of Health (R56HL158803) and the American Heart Association for editorial work. The content is solely the responsibility of the authors and does not necessarily reflect the views of the National Institutes of Health, the US Department of Health and Human Services, or the Department of Veterans Affairs. The Get With The Guidelines programs are provided by the American Heart Association. IQVIA serves as the data collection (through their Patient Management Tool) and coordination center for the American Heart Association/American Stroke Association Get With The Guidelines programs. The University of Pennsylvania serves as the data analytic center and has an agreement to prepare the data for research purposes. None of the funding partners had a role in the study design, data analysis, or manuscript preparation and revision, and the decision to submit the manuscript for publication.	Andersen LW, 2017, JAMA-J AM MED ASSOC, V317, P494, DOI 10.1001/jama.2016.20165; Andersen LW, 2016, JAMA-J AM MED ASSOC, V316, P1786, DOI 10.1001/jama.2016.14486; Andersen LW, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1577; Angelos MG, 2008, RESUSCITATION, V77, P101, DOI 10.1016/j.resuscitation.2007.10.017; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Aves T, 2020, CRIT CARE MED, V48, P225, DOI 10.1097/CCM.0000000000004130; Chan PS, 2008, NEW ENGL J MED, V358, P9, DOI 10.1056/NEJMoa0706467; Chan PS, 2013, J AM COLL CARDIOL, V62, P601, DOI 10.1016/j.jacc.2013.05.051; Chan PS, 2009, JAMA-J AM MED ASSOC, V302, P1195, DOI 10.1001/jama.2009.1340; Cummins RO, 1997, CIRCULATION, V95, P2213, DOI 10.1161/01.CIR.95.8.2213; Donnino MW, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3028; Girotra S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10403; Girotra S, 2012, NEW ENGL J MED, V367, P1912, DOI 10.1056/NEJMoa1109148; Holmberg MJ, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.119.005580; Honarmand K, 2018, RESUSCITATION, V129, P76, DOI 10.1016/j.resuscitation.2018.06.005; Huan L, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017502; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; Jacobs IG, 2011, RESUSCITATION, V82, P1138, DOI 10.1016/j.resuscitation.2011.06.029; JENNETT B, 1975, LANCET, V1, P480; Joseph L, 2017, JAMA CARDIOL, V2, P976, DOI 10.1001/jamacardio.2017.2403; Khera R, 2016, CIRCULATION, V134, P2105, DOI 10.1161/CIRCULATIONAHA.116.025459; Morales-Cane I, 2016, REV LAT-AM ENFERM, V24, DOI 10.1590/1518-8345.1317.2821; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Olasveengen TM, 2009, JAMA-J AM MED ASSOC, V302, P2222, DOI 10.1001/jama.2009.1729; OTTO CW, 1981, CRIT CARE MED, V9, P321, DOI 10.1097/00003246-198104000-00008; Panchal AR, 2020, CIRCULATION, V142, pS366, DOI 10.1161/CIR.0000000000000916; Patel KK, 2018, CIRCULATION, V137, P2041, DOI 10.1161/CIRCULATIONAHA.117.030488; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Perkins GD, 2018, NEW ENGL J MED, V379, P711, DOI 10.1056/NEJMoa1806842; Ristagno G, 2007, CRIT CARE MED, V35, P2145, DOI 10.1097/01.CCM.0000280427.76175.D2; Shao H, 2017, CHINESE MED J-PEKING, V130, P2112, DOI 10.4103/0366-6999.213429; Soar J, 2015, RESUSCITATION, V95, P100, DOI 10.1016/j.resuscitation.2015.07.016; TANG WC, 1995, CIRCULATION, V92, P3089, DOI 10.1161/01.CIR.92.10.3089; Vincent R, 2003, HEART, V89, P673, DOI 10.1136/heart.89.6.673; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X	35	0	0	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 10	2021	375								e066534	10.1136/bmj-2021-066534	http://dx.doi.org/10.1136/bmj-2021-066534			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE5JT	34759038	Green Published, hybrid			2023-01-03	WOS:000723424500004
J	Cheng, JX; Cui, JB; Yu, WW; Kang, H; Tian, YM; Jiang, XL				Cheng, Jingxia; Cui, Jinbo; Yu, Wenwen; Kang, Hua; Tian, Yongming; Jiang, Xiaolian			Factors influencing nurses' behavioral intention toward caring for COVID-19 patients on mechanical ventilation: A cross-sectional study	PLOS ONE			English	Article							NEW-YORK-CITY; COMPASSION FATIGUE; CARE; WILLINGNESS; PERCEPTIONS; EXPERIENCE; OUTBREAK; OUTCOMES; STRESS; WORK	Objectives To investigate nurses' behavioral intention toward caring for COVID-19 patients on mechanical ventilation, as well as the factors affecting their intention. Background COVID-19 patients undergoing mechanical ventilation have many care needs and pose more challenges for nurses, which might adversely affect nurses' intention toward caring behavior. Methods A cross-sectional study was conducted by using simple random sampling to recruit 598 nurses from five tertiary hospitals in Sichuan Province, China. The participants responded to an online questionnaire that included questions on demographic characteristics; the Attitude, Subjective Norms, and Behavioral Intention of Nurses toward Mechanically Ventilated Patients (ASIMP) questionnaire; the Nursing Professional Identity Scale (NPIS); and the Compassion Fatigue-Short Scale (CF-Short Scale). ANOVA, Spearman correlation analysis, and multiple linear regression were performed to analyze the data. Results The mean total behavioral intention score was 179.46 ( 14.83) out of a total score of 189.00, which represented a high level of intention toward caring for patients on mechanical ventilation. Multiple linear regression revealed that subjective norms (beta = 0.390, P<0.001), perceived behavioral control (beta = 0.149, P<0.001), professional identity (beta = 0.101, P = 0.009), and compassion fatigue (beta = 0.088 P = 0.024) were significant predictors of nurses' behavioral intention. Conclusions Most nurses have a positive behavioral intention to care for COVID-19 patients undergoing mechanical ventilation. The findings in this study provide some insight for developing effective and tailored strategies to promote nurses' behavioral intention toward caring for ventilated patients under the pandemic situation.	[Cheng, Jingxia; Cui, Jinbo; Yu, Wenwen; Jiang, Xiaolian] Sichuan Univ, West China Hosp, West China Sch Nursing, Chengdu, Sichuan, Peoples R China; [Kang, Hua] Chengdu Univ Tradit Chinese Med, Coll Nursing, Chengdu, Sichuan, Peoples R China; [Tian, Yongming] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China	Sichuan University; Chengdu University of Traditional Chinese Medicine; Sichuan University	Jiang, XL (corresponding author), Sichuan Univ, West China Hosp, West China Sch Nursing, Chengdu, Sichuan, Peoples R China.	jiangxiaolianhl@163.com						Ajzen I, 2002, J APPL SOC PSYCHOL, V32, P665, DOI 10.1111/j.1559-1816.2002.tb00236.x; Ajzen I., 2006, CONSTRUCTING THEORY; Anderson H, 2020, J CLIN NURS, V29, P1195, DOI 10.1111/jocn.15155; [Anonymous], 2020, LANCET, V395, P922, DOI 10.1016/S0140-6736(20)30644-9; Bai XL, 2019, J CLIN NURS, V28, P2101, DOI 10.1111/jocn.14791; Cao XY, 2016, J NURS MANAGE, V24, pE77, DOI 10.1111/jonm.12292; Chow M., 2005, IDENTIFICATION FACTO; Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2; Damery S, 2010, J MED ETHICS, V36, P12, DOI 10.1136/jme.2009.032821; Dosil M, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.606121; Drury V, 2014, J NURS MANAGE, V22, P519, DOI 10.1111/jonm.12168; Ferencz-Kaddari M, 2016, PSYCHOL REP, V118, P691, DOI 10.1177/0033294116647691; Fernandez-Castillo RJ, 2021, NURS CRIT CARE, V26, P397, DOI 10.1111/nicc.12589; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hu Y., 2017, NURS RES, V5; Inocian EP, 2021, J CLIN NURS, DOI 10.1111/jocn.15937; Joanne Elliot Zoe, 2018, Nurs Stand, V32, P41, DOI 10.7748/ns.2018.e10710; Kang H., 2006, STUDY BEHAV INTENTIO; Keim-Malpass Jessica, 2021, Int J Nurs Stud Adv, V3, P100019, DOI 10.1016/j.ijnsa.2021.100019; Kim Cho-Ja, 2006, Taehan Kanho Hakhoe Chi, V36, P596; Kim JS, 2016, NURS HEALTH SCI, V18, P299, DOI 10.1111/nhs.12269; Kinnear B, 2021, J HOSP MED, V16, P44, DOI [10.12788/jhm.3540, 10.12788/jhm.3540|10.12788/jhm.3540]; Lang KLR, 2021, AM J BIOETHICS, V21, P84, DOI 10.1080/15265161.2020.1850914; Langendyk V, 2015, ACAD MED, V90, P732, DOI 10.1097/ACM.0000000000000714; Lee JY, 2020, NURS HEALTH SCI, V22, P82, DOI 10.1111/nhs.12652; Li ZY, 2021, NURS OUTLOOK, V69, P389, DOI 10.1016/j.outlook.2020.09.006; Lou B., 2012, STRUCTURE MACH COMP; Lu W, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112936; Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1201; Oh N, 2017, ASIAN NURS RES, V11, P230, DOI 10.1016/j.anr.2017.08.005; Orru G, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18010337; Pesiridis T, 2021, AIMS PUBLIC HEALTH, V8, P456, DOI 10.3934/publichealth.2021035; Raso R, 2021, J NURS ADMIN, V51, P257, DOI 10.1097/NNA.0000000000001010; Rezaee N, 2020, J MED ETHICS HIST ME, V13; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Schunemann HJ, 2020, ANN INTERN MED, V173, P204, DOI 10.7326/M20-2306; Serin EK, 2021, PERSPECT PSYCHIATR C, V57, P371, DOI 10.1111/ppc.12607; Nia HS, 2021, J CLIN NURS, V30, P1684, DOI 10.1111/jocn.15723; Sheeran P., 2002, EUROPEAN REV SOCIAL, V12, P1, DOI [10.1080/14792772143000003, DOI 10.1080/14792772143000003]; Sheng QQ, 2020, J NURS MANAGE, V28, P1662, DOI 10.1111/jonm.13122; Sun NN, 2020, AM J INFECT CONTROL, V48, P592, DOI 10.1016/j.ajic.2020.03.018; Via-Clavero G, 2019, J ADV NURS, V75, P2036, DOI 10.1111/jan.14046; WHO, 2021, WHO COR DIS COVID 19; WHO, 2020, WHO DIR GEN OP REM M; Wu CC, 2012, INT J HUM RESOUR MAN, V23, P2698, DOI 10.1080/09585192.2011.637056; Xie WQ, 2021, J CLIN NURS, V30, P615, DOI 10.1111/jocn.15565; Zakeri MA, 2021, NURS OPEN, V8, P354, DOI 10.1002/nop2.636; Zhao H., 2010, CHIN NURS MANAG, V10, P49	48	5	5	5	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2021	16	11							e0259658	10.1371/journal.pone.0259658	http://dx.doi.org/10.1371/journal.pone.0259658			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY7XS	34739532	Green Published, gold			2023-01-03	WOS:000755000800047
J	Shah, H; Madni, A; Rahim, MA; Jan, N; Khan, A; Khan, S; Jabar, A; Ali, A				Shah, Hassan; Madni, Asadullah; Rahim, Muhammad Abdur; Jan, Nasrullah; Khan, Arshad; Khan, Safiullah; Jabar, Abdul; Ali, Ahsan			Fabrication, in vitro and ex vivo evaluation of proliposomes and liposomal derived gel for enhanced solubility and permeability of diacerein	PLOS ONE			English	Article							IMPROVED ORAL BIOAVAILABILITY; DELIVERY; FORMULATION; PHARMACOKINETICS; NANOPARTICLES; DISSOLUTION; TOXICITY; PERMEATION; ABSORPTION	The present study is associated with the development of proliposomes and liposomal derived gel for enhanced solubility and permeability of diacerein. Proliposomes were developed by thin film hydration method and converted into the liposomal derived gel using carbopol-934 as a gelling agent. Formulations with varied lecithin to cholesterol ratios were investigated to obtain the optimal size, entrapment efficiency, and enhanced in vitro dissolution. Dynamic light scattering analysis revealed the particle size and zeta potential in the range of 385.1 +/- 2.45-762.8 +/- 2.05 nm and -22.4 +/- 0.55-31.2 +/- 0.96mV respectively. Fourier transform infrared (FTIR) spectroscopic analysis depicted the physicochemical compatibility, powdered x-ray diffraction (PXRD) analysis predicted the crystalline nature of pure drug and its transition into amorphous form within formulation. The differential scanning calorimetry (DSC) demonstrated the thermal stability of the formulation. The in vitro drug release study using dialysis membrane displayed the enhanced dissolution of diacerein due to the presence of hydrophilic carrier (Maltodextrin) followed by sustained drug release due to the presence of lipid mixture (lecithin and cholesterol). Ex vivo permeation studies depicted 3.50 +/- 0.27 and 3.21 +/- 0.22 folds enhanced flux of liposomal gels as compared to control. The acute oral toxicity study showed safety and biocompatibility of the system as no histopathological changes in vital organs were observed. These results suggests that proliposomes and liposomal derived gel are promising candidates for the solubility and permeability enhancement of diacerein in the management of osteoarthritis.	[Shah, Hassan; Madni, Asadullah; Rahim, Muhammad Abdur; Jan, Nasrullah; Khan, Arshad; Khan, Safiullah; Ali, Ahsan] Islamia Univ Bahawalpur, Fac Pharm, Dept Pharmaceut, Bahawalpur, Punjab, Pakistan; [Jabar, Abdul] Univ Sargodha, Coll Pharm, Sargodha, Punjab, Pakistan	Islamia University of Bahawalpur; University of Sargodha	Madni, A (corresponding author), Islamia Univ Bahawalpur, Fac Pharm, Dept Pharmaceut, Bahawalpur, Punjab, Pakistan.	asadpharmacist@hotmail.com	Jan, Nasrullah/GPP-6186-2022	Jan, Nasrullah/0000-0002-1279-2397; Madni, Prof. Dr. M. Asadullah/0000-0002-0388-9867				Aggarwal AK, 2011, DRUG DEV IND PHARM, V37, P1181, DOI 10.3109/03639045.2011.563782; ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1068, P133, DOI 10.1016/0005-2736(91)90201-I; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; Barkat K, 2018, ADV POLYM TECH, V37, P1806, DOI 10.1002/adv.21840; Bobbala SKR, 2012, J LIPOSOME RES, V22, P285, DOI 10.3109/08982104.2012.697067; Bozzuto G, 2015, INT J NANOMED, V10, P975, DOI 10.2147/IJN.S68861; Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1; El-Laithy HM, 2015, INT J PHARMACEUT, V490, P146, DOI 10.1016/j.ijpharm.2015.05.039; Elsayed I, 2014, INT J NANOMED, V9, P2943, DOI 10.2147/IJN.S63395; Glavas-Dodov M, 2002, INT J PHARM, V242, P381, DOI 10.1016/S0378-5173(02)00221-1; GRIT M, 1993, CHEM PHYS LIPIDS, V64, P3, DOI 10.1016/0009-3084(93)90053-6; Gupta V, 2008, INDIAN J PHARM SCI, V70, P768, DOI 10.4103/0250-474X.49119; Gurrapu A, 2012, ADV POWDER TECHNOL, V23, P583, DOI 10.1016/j.apt.2011.06.005; Hiremath PS, 2009, INT J PHARMACEUT, V380, P96, DOI 10.1016/j.ijpharm.2009.07.008; Jain A, 2014, NANOMED-NANOTECHNOL, V10, P1031, DOI 10.1016/j.nano.2014.01.008; Jain S., 2014, ADV PHARMACOL, DOI [10.3390/pharmaceutics6020298, DOI 10.3390/PHARMACEUTICS6020298]; Janga KY, 2012, EUR J PHARM BIOPHARM, V80, P347, DOI 10.1016/j.ejpb.2011.10.010; Jeon D, 2019, EUR J PHARM BIOPHARM, V141, P139, DOI 10.1016/j.ejpb.2019.05.025; Kantarci G, 2005, DRUG DEVELOP RES, V65, P17, DOI 10.1002/ddr.20003; Khan MI, 2016, EUR J PHARM SCI, V95, P88, DOI 10.1016/j.ejps.2016.09.002; Khan MM, 2019, DRUG DELIV, V26, P765, DOI 10.1080/10717544.2019.1642420; Khan S., 2021, J DRUG DELIV SCI TEC; Kim C, 2002, J COSMET SCI, V53, P363; Madni A, 2018, AAPS PHARMSCITECH, V19, P1544, DOI 10.1208/s12249-018-0967-6; Mahmood MA, 2019, INT J NANOMED, V14, P10035, DOI 10.2147/IJN.S232350; Nekkanti V, 2016, AAPS PHARMSCITECH, V17, P851, DOI 10.1208/s12249-015-0388-8; Nekkanti V, 2015, DRUG DEV IND PHARM, V41, P2077, DOI 10.3109/03639045.2015.1075026; Nicolas P, 1998, CLIN PHARMACOKINET, V35, P347, DOI 10.2165/00003088-199835050-00002; Ning MY, 2005, CHEM PHARM BULL, V53, P620, DOI 10.1248/cpb.53.620; Pattni BS, 2015, CHEM REV, V115, P10938, DOI 10.1021/acs.chemrev.5b00046; PAYNE NI, 1986, J PHARM SCI, V75, P325, DOI 10.1002/jps.2600750402; Prabu PC, 2013, PHYTOTHER RES, V27, P1169, DOI 10.1002/ptr.4854; Rajalakshmi S, 2018, ARTIF CELL NANOMED B, V46, pS209, DOI 10.1080/21691401.2017.1417865; Silva MGB, 2011, J ETHNOPHARMACOL, V136, P341, DOI 10.1016/j.jep.2011.04.070; Staniforth J., 1988, PHARMACEUTICS, P610; Udeh NE, 2018, AM J RES MED SCI, V3, P7; Velpula A, 2013, DRUG DEV IND PHARM, V39, P1895, DOI 10.3109/03639045.2012.670641; Wang W, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00635-0; Xu HT, 2009, J CONTROL RELEASE, V140, P61, DOI 10.1016/j.jconrel.2009.07.014	39	2	2	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2021	16	10							e0258141	10.1371/journal.pone.0258141	http://dx.doi.org/10.1371/journal.pone.0258141			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7WQ	34665836	Green Published, gold			2023-01-03	WOS:000755683100005
J	Ouspenskaia, T; Law, T; Clauser, KR; Klaeger, S; Sarkizova, S; Aguet, F; Li, B; Christian, E; Knisbacher, BA; Le, PM; Hartigan, CR; Keshishian, H; Apffel, A; Oliveira, G; Zhang, WD; Chen, S; Chow, YT; Ji, Z; Jungreis, I; Shukla, SA; Justesen, S; Bachireddy, P; Kellis, M; Getz, G; Hacohen, N; Keskin, DB; Carr, SA; Wu, CJ; Regev, A				Ouspenskaia, Tamara; Law, Travis; Clauser, Karl R.; Klaeger, Susan; Sarkizova, Siranush; Aguet, Francois; Li, Bo; Christian, Elena; Knisbacher, Binyamin A.; Le, Phuong M.; Hartigan, Christina R.; Keshishian, Hasmik; Apffel, Annie; Oliveira, Giacomo; Zhang, Wandi; Chen, Sarah; Chow, Yuen Ting; Ji, Zhe; Jungreis, Irwin; Shukla, Sachet A.; Justesen, Sune; Bachireddy, Pavan; Kellis, Manolis; Getz, Gad; Hacohen, Nir; Keskin, Derin B.; Carr, Steven A.; Wu, Catherine J.; Regev, Aviv			Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer	NATURE BIOTECHNOLOGY			English	Article							RIBOSOME PROFILING REVEALS; LONG NONCODING RNAS; TRANSLATION; IDENTIFICATION; PEPTIDOMES; EXPRESSION; PREDICTION; MUTATIONS; LANDSCAPE; ANTIGENS	Tumor-associated epitopes presented on MHC-I that can activate the immune system against cancer cells are typically identified from annotated protein-coding regions of the genome, but whether peptides originating from novel or unannotated open reading frames (nuORFs) can contribute to antitumor immune responses remains unclear. Here we show that peptides originating from nuORFs detected by ribosome profiling of malignant and healthy samples can be displayed on MHC-I of cancer cells, acting as additional sources of cancer antigens. We constructed a high-confidence database of translated nuORFs across tissues (nuORFdb) and used it to detect 3,555 translated nuORFs from MHC-I immunopeptidome mass spectrometry analysis, including peptides that result from somatic mutations in nuORFs of cancer samples as well as tumor-specific nuORFs translated in melanoma, chronic lymphocytic leukemia and glioblastoma. NuORFs are an unexplored pool of MHC-I-presented, tumor-specific peptides with potential as immunotherapy targets.	[Ouspenskaia, Tamara; Law, Travis; Clauser, Karl R.; Klaeger, Susan; Sarkizova, Siranush; Aguet, Francois; Knisbacher, Binyamin A.; Hartigan, Christina R.; Keshishian, Hasmik; Apffel, Annie; Jungreis, Irwin; Shukla, Sachet A.; Kellis, Manolis; Getz, Gad; Hacohen, Nir; Keskin, Derin B.; Carr, Steven A.; Wu, Catherine J.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Sarkizova, Siranush] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA; [Li, Bo; Regev, Aviv] Broad Inst Harvard & MIT, Klarman Cell Observ, Cambridge, MA 02142 USA; [Li, Bo] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Li, Bo; Keskin, Derin B.; Wu, Catherine J.] Harvard Med Sch, Boston, MA 02115 USA; [Christian, Elena; Chow, Yuen Ting] Harvard Univ, Cambridge, MA 02138 USA; [Le, Phuong M.; Oliveira, Giacomo; Zhang, Wandi; Shukla, Sachet A.; Bachireddy, Pavan; Keskin, Derin B.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Chen, Sarah] Phillips Acad, Andover, MA USA; [Ji, Zhe] Northwestern Univ, Feinberg Sch Med, Dept Pharmacol, Chicago, IL 60611 USA; [Ji, Zhe] Northwestern Univ, McCormick Sch Engn, Dept Biomed Engn, Evanston, IL USA; [Jungreis, Irwin; Kellis, Manolis] MIT Comp Sci & Artificial Intelligence Lab, Cambridge, MA USA; [Justesen, Sune] Immunitrack, Copenhagen, Denmark; [Hacohen, Nir] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA; [Keskin, Derin B.; Wu, Catherine J.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Keskin, Derin B.] Dana Farber Canc Inst, Translat Immunogen Lab, Boston, MA 02115 USA; [Regev, Aviv] MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02142 USA; [Ouspenskaia, Tamara] Flagship Labs 69, Cambridge, MA USA; [Regev, Aviv] Genentech Inc, San Francisco, CA 94080 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard University; Dana-Farber Cancer Institute; Northwestern University; Feinberg School of Medicine; Northwestern University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Roche Holding; Genentech	Wu, CJ (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Regev, A (corresponding author), Broad Inst Harvard & MIT, Klarman Cell Observ, Cambridge, MA 02142 USA.; Wu, CJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Wu, CJ (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Wu, CJ (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.; Regev, A (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02142 USA.; Regev, A (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.	cwu@partners.org; aviv.regev@broadinstitute.org	Law, Travis/E-6792-2017; Li, Bo/AAS-8773-2021; Ji, Zhe/U-8320-2018	Law, Travis/0000-0002-7399-3299; Li, Bo/0000-0003-0668-1620; Aguet, Francois/0000-0001-9414-300X; Chow, Yuen Ting/0000-0002-9483-7324; Knisbacher, Binyamin/0000-0002-4962-9956; Christian, Elena/0000-0002-5593-0155; Klaeger, Susan/0000-0002-0074-5163; Ji, Zhe/0000-0002-1809-8099	Klarman Cell Observatory; HHMI; NIH [NCI-1R01CA155010-02, NHLBI-5R01HL103532-03, NIH/NCI R21 CA216772-01A1, NCI-SPORE-2P50CA101942-11A1, NHGRI T32HG002295, NIH/NCI T32CA207021, NCI R50CA211482, NHGRI U41HG007234, R01 HG004037]; NCI Clinical Proteomic Tumor Analysis Consortium grant [NIH/NCI U24-CA210986, NIH/NCI U01 CA214125, NIH/NCI U24CA210979]; G. Harold and Leila Y. Mathers Foundation; Koch Institute for Integrative Cancer Research at MIT; Dana-Farber/Harvard Cancer Center; Parker Institute for Cancer Immunotherapy; long-term EMBO fellowship [ALTF 14-2018]; Amy Strelzer Manasevit Grant; American Society of Hematology Scholar Award; American-Italian Cancer Foundation	Klarman Cell Observatory; HHMI(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Clinical Proteomic Tumor Analysis Consortium grant; G. Harold and Leila Y. Mathers Foundation; Koch Institute for Integrative Cancer Research at MIT; Dana-Farber/Harvard Cancer Center; Parker Institute for Cancer Immunotherapy; long-term EMBO fellowship(European Molecular Biology Organization (EMBO)); Amy Strelzer Manasevit Grant; American Society of Hematology Scholar Award; American-Italian Cancer Foundation	We thank K. Gosik and R. Herbst for their help with the statistical analysis. We thank D. Fu for her help with the nonmetric multidimensional scaling analysis. We thank E. Hodis and J. Kwon for providing cultured primary melanocytes. We thank K.L. Ligon for providing the GBM cell line. We thank L. Gaffney for help with figure preparation. Work was supported by the Klarman Cell Observatory and HHMI (A.R.), NIH grant nos. NCI-1R01CA155010-02 (to C.J.W.), NHLBI-5R01HL103532-03 (to C.J.W.), NIH/NCI R21 CA216772-01A1 (to D.B.K.), NCI-SPORE-2P50CA101942-11A1 (to D.B.K), NHGRI T32HG002295 and NIH/NCI T32CA207021 (to S.S.), NCI R50CA211482 (to S.A.S.), NHGRI U41HG007234 and R01 HG004037 (to I.J.), NCI Clinical Proteomic Tumor Analysis Consortium grant nos. NIH/NCI U24-CA210986 and NIH/NCI U01 CA214125 (to S.A.C.) and NIH/NCI U24CA210979 (to D.R. Mani and G. Getz). This work was supported in part by The G. Harold and Leila Y. Mathers Foundation and the Bridge Project, a partnership between the Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center. C.J.W. is a scholar of the Leukemia and Lymphoma Society, and is supported in part by the Parker Institute for Cancer Immunotherapy. S.K. is a Cancer Research Institute/Hearst Foundation fellow. T.O. is a Leukemia and Lymphoma Society Fellow. B.A.K. is supported by a long-term EMBO fellowship (ALTF 14-2018). P.B. is supported by an Amy Strelzer Manasevit Grant and an American Society of Hematology Scholar Award. G.O. is supported by a postdoctoral fellowship sponsored by the American-Italian Cancer Foundation.	Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Bassani-Sternberg M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13404; Blair JD, 2017, CELL REP, V21, P2005, DOI 10.1016/j.celrep.2017.10.095; Blum A, 2018, CELL, V173, P530, DOI 10.1016/j.cell.2018.03.059; Campbell PJ, 2020, NATURE, V578, P82, DOI 10.1038/s41586-020-1969-6; Chen J, 2020, SCIENCE, V367, P1140, DOI 10.1126/science.aay0262; Chew GL, 2013, DEVELOPMENT, V140, P2828, DOI 10.1242/dev.098343; Chong CE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14968-9; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Erhard F, 2018, NAT METHODS, V15, P363, DOI 10.1038/nmeth.4631; Rodriguez AE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048485; Faridi P, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar3947; Ferreira PG, 2014, GENOME RES, V24, P212, DOI 10.1101/gr.152132.112; Fields AP, 2015, MOL CELL, V60, P816, DOI 10.1016/j.molcel.2015.11.013; Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955; Georgiadis P, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4117-4; Gonzalez C, 2014, J NEUROSCI, V34, P10924, DOI 10.1523/JNEUROSCI.0084-14.2014; Harndahl M, 2009, J BIOMOL SCREEN, V14, P173, DOI 10.1177/1087057108329453; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Hu Z, 2018, NAT REV IMMUNOL, V18, P168, DOI 10.1038/nri.2017.131; Hutter C, 2018, CELL, V173, P283, DOI 10.1016/j.cell.2018.03.042; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Ji Z, 2015, ELIFE, V4, DOI 10.7554/eLife.08890; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Laumont CM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau5516; Laumont CM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10238; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liepe J, 2016, SCIENCE, V354, P354, DOI 10.1126/science.aaf4384; Malone B, 2017, NUCLEIC ACIDS RES, V45, P2960, DOI 10.1093/nar/gkw1350; Martinez TF, 2020, NAT CHEM BIOL, V16, P458, DOI 10.1038/s41589-019-0425-0; Mylonas R, 2018, MOL CELL PROTEOMICS, V17, P2347, DOI 10.1074/mcp.RA118.000877; Nesvizhskii AI, 2014, NAT METHODS, V11, P1114, DOI [10.1038/nmeth.3144, 10.1038/NMETH.3144]; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Freitas MRP, 2013, ONCOTARGET, V4, P636, DOI 10.18632/oncotarget.950; Puente XS, 2015, NATURE, V526, P519, DOI 10.1038/nature14666; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Raj A, 2016, ELIFE, V5, DOI 10.7554/eLife.13328; Rajasagi M, 2014, BLOOD, V124, P453, DOI 10.1182/blood-2014-04-567933; Robbins PF, 1997, J IMMUNOL, V159, P303; Rolfs Z, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw1622; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9; Shraibman B, 2019, MOL CELL PROTEOMICS, V18, P1255, DOI 10.1074/mcp.RA119.001524; Su R, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0737-1; Van den Eynde B, 1999, J EXP MED, V190, P1793, DOI 10.1084/jem.190.12.1793; Wang RF, 1998, J IMMUNOL, V161, P3596; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093	52	29	29	2	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2022	40	2					209	+		10.1038/s41587-021-01021-3	http://dx.doi.org/10.1038/s41587-021-01021-3		OCT 2021	29	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZB2EM	34663921				2023-01-03	WOS:000708367800002
J	Wang, XQ; Tokheim, C; Gu, SS; Wang, BB; Tang, Q; Li, YH; Traugh, N; Zeng, ZX; Zhang, Y; Li, ZY; Zhang, BN; Fu, JX; Xiao, TF; Li, W; Meyer, CA; Chu, J; Jiang, P; Cejas, P; Lim, K; Long, H; Brown, M; Liu, XS				Wang, Xiaoqing; Tokheim, Collin; Gu, Shengqing Stan; Wang, Binbin; Tang, Qin; Li, Yihao; Traugh, Nicole; Zeng, Zexian; Zhang, Yi; Li, Ziyi; Zhang, Boning; Fu, Jingxin; Xiao, Tengfei; Li, Wei; Meyer, Clifford A.; Chu, Jun; Jiang, Peng; Cejas, Paloma; Lim, Klothilda; Long, Henry; Brown, Myles; Liu, X. Shirley			In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target	CELL			English	Article							HUMAN INTERFERON-GAMMA; REGULATES C-JUN; TUMOR-SUPPRESSOR; CHECKPOINT BLOCKADE; NEGATIVE REGULATOR; READ ALIGNMENT; C/EBP-ALPHA; IFN-GAMMA; B7 FAMILY; MHC-I	Despite remarkable clinical efficacy of immune checkpoint blockade (ICB) in cancer treatment, ICB benefits for triple-negative breast cancer (TNBC) remain limited. Through pooled in vivo CRISPR knockout (KO) screens in syngeneic TNBC mouse models, we found that deletion of the E3 ubiquitin ligase Cop1 in cancer cells decreases secretion of macrophage-associated chemokines, reduces tumor macrophage infiltration, enhances anti-tumor immunity, and strengthens ICB response, Transcriptomics, epigenomics, and proteomics analyses revealed that Cop1 functions through proteasomal degradation of the C/ebp delta protein. The Cop1 substrate Trib2 functions as a scaffold linking Cop1 and C/ebp delta, which leads to polyubiquitination of C/ebp delta. In addition, deletion of the E3 ubiquitin ligase Cop1 in cancer cells stabilizes C/ebp delta to suppress expression of macrophage chemoattractant genes. Our integrated approach implicates Cop1 as a target for improving cancer immunotherapy efficacy in TNBC by regulating chemokine secretion and macrophage infiltration in the tumor microenvironment.	[Wang, Xiaoqing; Gu, Shengqing Stan; Tang, Qin; Li, Yihao; Zhang, Boning; Fu, Jingxin; Xiao, Tengfei; Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Wang, Xiaoqing; Tokheim, Collin; Gu, Shengqing Stan; Wang, Binbin; Tang, Qin; Traugh, Nicole; Zeng, Zexian; Zhang, Yi; Li, Ziyi; Zhang, Boning; Fu, Jingxin; Xiao, Tengfei; Li, Wei; Meyer, Clifford A.; Chu, Jun; Jiang, Peng; Liu, X. Shirley] Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02215 USA; [Wang, Xiaoqing; Tokheim, Collin; Gu, Shengqing Stan; Wang, Binbin; Zeng, Zexian; Zhang, Yi; Zhang, Boning; Xiao, Tengfei; Li, Wei; Meyer, Clifford A.; Jiang, Peng; Liu, X. Shirley] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA; [Wang, Xiaoqing; Tokheim, Collin; Gu, Shengqing Stan; Tang, Qin; Li, Yihao; Zeng, Zexian; Zhang, Yi; Zhang, Boning; Xiao, Tengfei; Li, Wei; Meyer, Clifford A.; Jiang, Peng; Cejas, Paloma; Lim, Klothilda; Long, Henry; Brown, Myles; Liu, X. Shirley] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA; [Chu, Jun] Anhui Univ Chinese Med, Minist Educ, Key Lab Xinan Med, Hefei 230038, Anhui, Peoples R China; [Wang, Xiaoqing] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Cardiol, Shanghai 200233, Peoples R China; [Wang, Binbin; Jiang, Peng] NCI, Ctr Canc Res, Bethesda, MD 20892 USA; [Tang, Qin] Salk Inst Biol Studies, San Diego, CA 92037 USA; [Traugh, Nicole] Tufts Univ, Grad Sch Biomed Sci, Boston, MA 02111 USA; [Xiao, Tengfei] GV20 Oncotherapy, Shanghai 201203, Peoples R China; [Li, Wei] Childrens Natl Hosp, Med Genet Res Ctr, Washington, DC 20010 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Anhui University of Chinese Medicine; Shanghai Jiao Tong University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Salk Institute; Tufts University; Children's National Health System	Brown, M (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; Liu, XS (corresponding author), Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02215 USA.; Liu, XS (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA.; Brown, M; Liu, XS (corresponding author), Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.	myles_brown@dfci.harvard.edu; xsliu@ds.dfci.harvard.edu	Wang, Binbin/AAH-7215-2019	Wang, Binbin/0000-0003-2885-6428; Liu, Xiaole/0000-0003-4736-7339; Gu, Shengqing/0000-0002-4200-0864; Zhang, Yi/0000-0002-7453-6188; Traugh, Nicole/0000-0002-1194-8177; Li, Yihao/0000-0003-1900-8099; Tokheim, Collin/0000-0003-1395-5378	Breast Cancer Research Foundation [BCRF-20-100, BCRF-20-019]; NIH [R01CA234018]; Damon Runyon Cancer Research Foundation [DRQ-04-20]; Sara Elizabeth O'Brien Trust; Dana-Farber Cancer Institute	Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation; Sara Elizabeth O'Brien Trust; Dana-Farber Cancer Institute	The authors would like to thank Jin Zhao and Jingyu Peng for assistance and discussions. This study was supported by the Breast Cancer Research Foundation (BCRF-20-100 to X.S.L. and BCRF-20-019 to M.B.), NIH grants R01CA234018 (to X.S.L. and M.B.), Damon Runyon Cancer Research Foundation DRQ-04-20 (to C.T.), the Sara Elizabeth O'Brien Trust (to S.S.G.), and the Dana-Farber Cancer Institute.	Alshaker HA, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-33; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Bateman A, 2006, NUCLEIC ACIDS RES, V34, pD1, DOI 10.1093/nar/gkj150; Beatty GL, 2000, J IMMUNOL, V165, P5502, DOI 10.4049/jimmunol.165.10.5502; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Benci JL, 2019, CELL, V178, P933, DOI 10.1016/j.cell.2019.07.019; Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Cassetta L, 2019, CANCER CELL, V35, P588, DOI 10.1016/j.ccell.2019.02.009; Cassetta L, 2018, NAT REV DRUG DISCOV, V17, P887, DOI 10.1038/nrd.2018.169; Chen CH, 2018, BIOINFORMATICS, V34, P4095, DOI 10.1093/bioinformatics/bty450; Chen MX, 2018, CLIN BREAST CANCER, V18, pE1205, DOI 10.1016/j.clbc.2018.05.006; Codina A, 2019, CELL SYST, V8, P136, DOI 10.1016/j.cels.2019.01.004; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; de Sena Brandine Guilherme, 2019, F1000Res, V8, P1874, DOI 10.12688/f1000research.21142.1; Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128; Dersh D, 2021, IMMUNITY, V54, P116, DOI 10.1016/j.immuni.2020.11.002; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Doench JG, 2014, NAT BIOTECHNOL, V32, P1262, DOI 10.1038/nbt.3026; Dong HD, 1999, NAT MED, V5, P1365; Dornan D, 2004, CANCER RES, V64, P7226, DOI 10.1158/0008-5472.CAN-04-2601; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eyers PA, 2017, TRENDS CELL BIOL, V27, P284, DOI 10.1016/j.tcb.2016.11.002; Fallahpour Saber, 2017, CMAJ Open, V5, pE734, DOI 10.9778/cmajo.20170030; Fei T, 2017, P NATL ACAD SCI USA, V114, pE5207, DOI 10.1073/pnas.1617467114; Finotello F, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0638-6; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; Gechijian LN, 2018, NAT CHEM BIOL, V14, P405, DOI 10.1038/s41589-018-0010-y; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Gouw M, 2018, NUCLEIC ACIDS RES, V46, pD428, DOI 10.1093/nar/gkx1077; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Groner AC, 2016, CANCER CELL, V29, P846, DOI 10.1016/j.ccell.2016.04.012; Gschwandtner M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02759; Gu SS, 2021, CANCER DISCOV, V11, P1524, DOI 10.1158/2159-8290.CD-20-0812; Halle S, 2017, TRENDS IMMUNOL, V38, P432, DOI 10.1016/j.it.2017.04.002; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ishizuka JJ, 2019, NATURE, V565, P43, DOI 10.1038/s41586-018-0768-9; Jacquelot N, 2019, CELL RES, V29, P846, DOI 10.1038/s41422-019-0224-x; Jamieson SA, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aau0597; Janic A, 2018, NAT MED, V24, P947, DOI 10.1038/s41591-018-0043-5; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Kim K, 2014, P NATL ACAD SCI USA, V111, P11774, DOI 10.1073/pnas.1410626111; Ko CY, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-014-0110-2; Landskron G, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/149185; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lawson KA, 2020, NATURE, V586, P120, DOI 10.1038/s41586-020-2746-2; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li L, 2018, THORAC CANCER, V9, P775, DOI 10.1111/1759-7714.12643; Li SJ, 2019, NUCLEIC ACIDS RES, V47, pW206, DOI 10.1093/nar/gkz332; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Li W, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0843-6; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lim SY, 2016, ONCOTARGET, V7, P28697, DOI 10.18632/oncotarget.7376; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mandal R, 2019, SCIENCE, V364, P485, DOI 10.1126/science.aau0447; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Marine JC, 2012, NAT REV CANCER, V12, P455, DOI 10.1038/nrc3271; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Meszaros B, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9982; MEYSKENS FL, 1990, J NATL CANCER I, V82, P1071, DOI 10.1093/jnci/82.12.1071-a; MEYSKENS FL, 1995, J NATL CANCER I, V87, P1710, DOI 10.1093/jnci/87.22.1710; Mezzadra R, 2017, NATURE, V549, P106, DOI 10.1038/nature23669; Miao ZH, 2003, CANCER RES, V63, P4527; Migliorini D, 2011, J CLIN INVEST, V121, P1329, DOI 10.1172/JCI45784; Minn AJ, 2015, TRENDS IMMUNOL, V36, P725, DOI 10.1016/j.it.2015.09.007; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Motz GT, 2013, IMMUNITY, V39, P61, DOI 10.1016/j.immuni.2013.07.005; Murphy JM, 2015, STRUCTURE, V23, P2111, DOI 10.1016/j.str.2015.08.017; Nakamae I, 2017, BLOOD ADV, V1, P1682, DOI 10.1182/bloodadvances.2017007054; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Ndoja A, 2020, CELL, V182, P1156, DOI 10.1016/j.cell.2020.07.011; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nielsen SR, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9624760; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Nusinow DP, 2020, CELL, V180, P387, DOI 10.1016/j.cell.2019.12.023; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Pearlman R, 2017, JAMA ONCOL, V3, P464, DOI 10.1001/jamaoncol.2016.5194; Peranzoni E, 2018, P NATL ACAD SCI USA, V115, pE4041, DOI 10.1073/pnas.1720948115; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qin Q, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1934-6; Qin Q, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1274-4; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Racle J, 2017, ELIFE, V6, DOI 10.7554/eLife.26476; Ramilowski JA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8866; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sagiv-Barfi I, 2015, P NATL ACAD SCI USA, V112, pE966, DOI 10.1073/pnas.1500712112; Satoh T, 2013, NATURE, V495, P524, DOI 10.1038/nature11930; Savio MG, 2008, ONCOGENE, V27, P2401, DOI 10.1038/sj.onc.1210892; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Seo HS, 2003, NATURE, V423, P995, DOI 10.1038/nature01696; Singh AA, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201800115; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Sun HY, 2014, ACS CHEM BIOL, V9, P994, DOI 10.1021/cb400889a; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tisato V, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0500-5; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Vitari AC, 2011, NATURE, V474, P403, DOI 10.1038/nature10005; Wachter F, 2017, ONCOGENE, V36, P2184, DOI 10.1038/onc.2016.361; Waks AG, 2019, JAMA-J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323; Walens A, 2019, ELIFE, V8, DOI 10.7554/eLife.43653; Wang BB, 2019, NAT PROTOC, V14, P756, DOI 10.1038/s41596-018-0113-7; Wang CF, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02116-x; Wang DZ, 2017, CANCER RES, V77, P3655, DOI 10.1158/0008-5472.CAN-16-3199; Wehde BL, 2018, CELL REP, V25, P2192, DOI 10.1016/j.celrep.2018.10.063; Wei WY, 2011, J CLIN INVEST, V121, P1263, DOI 10.1172/JCI57080; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Wong WC, 2011, BIOINFORMATICS, V27, P2147, DOI 10.1093/bioinformatics/btr357; Xiao TF, 2018, P NATL ACAD SCI USA, V115, P7869, DOI 10.1073/pnas.1722617115; Xu H, 2015, GENOME RES, V25, P1147, DOI 10.1101/gr.191452.115; Xu W., 2021, BIORXIV, DOI [10.1101/2021.04.15.439923, DOI 10.1101/2021.04.15.439923]; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang J, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002636; Zhang XY, 2019, NAT CHEM BIOL, V15, P737, DOI 10.1038/s41589-019-0279-5; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao JK, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0629-4; Zheng RB, 2019, NUCLEIC ACIDS RES, V47, pD729, DOI 10.1093/nar/gky1094	131	20	21	26	103	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 14	2021	184	21					5357	+		10.1016/j.cell.2021.09.006	http://dx.doi.org/10.1016/j.cell.2021.09.006		OCT 2021	40	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ8MO	34582788	Green Accepted, Bronze, Green Submitted			2023-01-03	WOS:000714065000015
J	Johnstone, J; Meade, M; Lauzier, F; Marshall, J; Duan, E; Dionne, J; Arabi, YM; Heels-Ansdell, D; Thabane, L; Lamarche, D; Surette, M; Zytaruk, N; Mehta, S; Dodek, P; McIntyre, L; English, S; Rochwerg, B; Karachi, T; Henderson, W; Wood, G; Ovakim, D; Herridge, M; Granton, J; Wilcox, ME; Goffi, A; Stelfox, HT; Niven, D; Muscedere, J; Lamontagne, F; D'Aragon, F; St-Arnaud, C; Ball, I; Nagpal, D; Girard, M; Aslanian, P; Charbonney, E; Williamson, D; Sligl, W; Friedrich, J; Adhikari, NK; Marquis, F; Archambault, P; Khwaja, K; Kristof, A; Kutsogiannis, J; Zarychanski, R; Paunovic, B; Reeve, B; Lellouche, F; Hosek, P; Tsang, J; Binnie, A; Trop, S; Loubani, O; Hall, R; Cirone, R; Reynolds, S; Lysecki, P; Golan, E; Cartin-Ceba, R; Taylor, R; Cook, D				Johnstone, Jennie; Meade, Maureen; Lauzier, Francois; Marshall, John; Duan, Erick; Dionne, Joanna; Arabi, Yaseen M.; Heels-Ansdell, Diane; Thabane, Lehana; Lamarche, Daphnee; Surette, Michael; Zytaruk, Nicole; Mehta, Sangeeta; Dodek, Peter; McIntyre, Lauralyn; English, Shane; Rochwerg, Bram; Karachi, Tim; Henderson, William; Wood, Gordon; Ovakim, Daniel; Herridge, Margaret; Granton, John; Wilcox, M. Elizabeth; Goffi, Alberto; Stelfox, Henry T.; Niven, Daniel; Muscedere, John; Lamontagne, Francois; D'Aragon, Frederick; St-Arnaud, Charles; Ball, Ian; Nagpal, Dave; Girard, Martin; Aslanian, Pierre; Charbonney, Emmanuel; Williamson, David; Sligl, Wendy; Friedrich, Jan; Adhikari, Neill K.; Marquis, Francois; Archambault, Patrick; Khwaja, Kosar; Kristof, Arnold; Kutsogiannis, James; Zarychanski, Ryan; Paunovic, Bojan; Reeve, Brenda; Lellouche, Francois; Hosek, Paul; Tsang, Jennifer; Binnie, Alexandra; Trop, Sebastien; Loubani, Osama; Hall, Richard; Cirone, Robert; Reynolds, Steve; Lysecki, Paul; Golan, Eyal; Cartin-Ceba, Rodrigo; Taylor, Robert; Cook, Deborah		Prevention Severe Pneumonia Endotr; Canadian Critical Care Trials Grp	Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLOSTRIDIUM-DIFFICILE INFECTION; ANTIBIOTIC-ASSOCIATED DIARRHEA; PREVENTION; MICROBIOME; GUIDELINES; INPATIENTS; DYSBIOSIS; SOCIETY; SEPSIS; ADULTS	Question Does the probiotic Lactobacillus rhamnosus GG prevent ventilator-associated pneumonia (VAP) among critically ill patients? Findings In this randomized trial involving 2650 patients, no significant difference in VAP incidence was found among patients treated with probiotics compared with placebo (21.9% vs 21.3%, respectively; hazard ratio 1.03; 95% CI 0.87-1.22). Meaning These findings do not support the use of Lactobacillus rhamnosus GG for prevention of ventilator-associated pneumonia in critically ill patients requiring mechanical ventilation. Importance Growing interest in microbial dysbiosis during critical illness has raised questions about the therapeutic potential of microbiome modification with probiotics. Prior randomized trials in this population suggest that probiotics reduce infection, particularly ventilator-associated pneumonia (VAP), although probiotic-associated infections have also been reported. Objective To evaluate the effect of Lactobacillus rhamnosus GG on preventing VAP, additional infections, and other clinically important outcomes in the intensive care unit (ICU). Design, Setting, and Participants Randomized placebo-controlled trial in 44 ICUs in Canada, the United States, and Saudi Arabia enrolling adults predicted to require mechanical ventilation for at least 72 hours. A total of 2653 patients were enrolled from October 2013 to March 2019 (final follow-up, October 2020). Interventions Enteral L rhamnosus GG (1 x 10(10) colony-forming units) (n = 1321) or placebo (n = 1332) twice daily in the ICU. Main Outcomes and Measures The primary outcome was VAP determined by duplicate blinded central adjudication. Secondary outcomes were other ICU-acquired infections including Clostridioides difficile infection, diarrhea, antimicrobial use, ICU and hospital length of stay, and mortality. Results Among 2653 randomized patients (mean age, 59.8 years [SD], 16.5 years), 2650 (99.9%) completed the trial (mean age, 59.8 years [SD], 16.5 years; 1063 women [40.1%.] with a mean Acute Physiology and Chronic Health Evaluation II score of 22.0 (SD, 7.8) and received the study product for a median of 9 days (IQR, 5-15 days). VAP developed among 289 of 1318 patients (21.9%) receiving probiotics vs 284 of 1332 controls (21.3%; hazard ratio [HR], 1.03 (95% CI, 0.87-1.22; P = .73, absolute difference, 0.6%, 95% CI, -2.5% to 3.7%). None of the 20 prespecified secondary outcomes, including other ICU-acquired infections, diarrhea, antimicrobial use, mortality, or length of stay showed a significant difference. Fifteen patients (1.1%) receiving probiotics vs 1 (0.1%) in the control group experienced the adverse event of L rhamnosus in a sterile site or the sole or predominant organism in a nonsterile site (odds ratio, 14.02; 95% CI, 1.79-109.58; P < .001). Conclusions and Relevance Among critically ill patients requiring mechanical ventilation, administration of the probiotic L rhamnosus GG compared with placebo, resulted in no significant difference in the development of ventilator-associated pneumonia. These findings do not support the use of L rhamnosus GG in critically ill patients. This clinical trial assessed whether Lactobacillus rhamnosus GG compared with placebo reduces ventilator-associated pneumonia and other clinically important outcomes for a broad range of critically ill patients.	[Johnstone, Jennie; Marshall, John; Mehta, Sangeeta; Herridge, Margaret; Granton, John; Wilcox, M. Elizabeth; Goffi, Alberto; Friedrich, Jan; Adhikari, Neill K.; Binnie, Alexandra; Cirone, Robert; Golan, Eyal] Univ Toronto, Toronto, ON, Canada; [Meade, Maureen; Duan, Erick; Dionne, Joanna; Heels-Ansdell, Diane; Thabane, Lehana; Lamarche, Daphnee; Surette, Michael; Zytaruk, Nicole; Rochwerg, Bram; Karachi, Tim; Reeve, Brenda; Hosek, Paul; Tsang, Jennifer; Lysecki, Paul; Cook, Deborah] McMaster Univ, Hamilton, ON, Canada; [Lauzier, Francois; Archambault, Patrick; Lellouche, Francois] Univ Laval, Quebec City, PQ, Canada; [Arabi, Yaseen M.] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia; [Dodek, Peter; Henderson, William; Reynolds, Steve] Univ British Columbia, Vancouver, BC, Canada; [McIntyre, Lauralyn; English, Shane] Univ Ottawa, Ottawa, ON, Canada; [Wood, Gordon; Ovakim, Daniel] Univ Victoria, Victoria, BC, Canada; [Stelfox, Henry T.; Niven, Daniel] Univ Calgary, Calgary, AB, Canada; [Muscedere, John] Queens Univ, Kingston, ON, Canada; [Lamontagne, Francois; D'Aragon, Frederick; St-Arnaud, Charles] Univ Sherbrooke, Sherbrooke, PQ, Canada; [Ball, Ian; Nagpal, Dave] Western Univ, London, ON, Canada; [Girard, Martin; Aslanian, Pierre; Charbonney, Emmanuel; Williamson, David; Marquis, Francois; Trop, Sebastien] Univ Montreal, Montreal, PQ, Canada; [Sligl, Wendy; Kutsogiannis, James] Univ Alberta, Edmonton, AB, Canada; [Khwaja, Kosar; Kristof, Arnold] McGill Univ, Montreal, PQ, Canada; [Zarychanski, Ryan; Paunovic, Bojan] Univ Manitoba, Winnipeg, MB, Canada; [Loubani, Osama; Hall, Richard] Dalhousie Univ, Halifax, NS, Canada; [Cartin-Ceba, Rodrigo] Mayo Clin, Rochester, MN USA; [Taylor, Robert] Mercy Hosp, St Louis, MO USA	University of Toronto; McMaster University; Laval University; King Saud Bin Abdulaziz University for Health Sciences; University of British Columbia; University of Ottawa; University of Victoria; University of Calgary; Queens University - Canada; University of Sherbrooke; Western University (University of Western Ontario); Universite de Montreal; University of Alberta; McGill University; University of Manitoba; Dalhousie University; Mayo Clinic; Saint Johns Mercy Medical Center	Cook, D (corresponding author), St Josephs Healthcare, Methods Ctr, 50 Charlton Ave E,Room H327, Hamilton, ON L9H 4A6, Canada.	debcook@mcmaster.ca	Girard, Martin/AFU-8351-2022; Ball, Ian/GRR-4073-2022; Zarychanski, Ryan/AAB-6369-2022	Girard, Martin/0000-0003-2420-0106; Binnie, Alexandra/0000-0003-2969-8177; Herridge, Margaret/0000-0002-2903-1631; Lamontagne, Francois/0000-0002-0360-3427; Goffi, Alberto/0000-0002-9658-3903				Allen SJ, 2013, LANCET, V382, P1249, DOI 10.1016/S0140-6736(13)61218-0; Bafeta A, 2018, ANN INTERN MED, V169, P240, DOI 10.7326/M18-0343; Bassetti M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2780-3; Batra P, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00487-8; Branch-Elliman W, 2015, AM J RESP CRIT CARE, V192, P57, DOI 10.1164/rccm.201412-2316OC; Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; Cook DJ, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1495-x; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Goldenberg JZ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006095.pub3; Grossman RF, 2000, CHEST, V117, p177S, DOI 10.1378/chest.117.4_suppl_2.177S; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Hempel Susanne, 2011, Evid Rep Technol Assess (Full Rep), P1; Hempel S, 2012, JAMA-J AM MED ASSOC, V307, P1959, DOI 10.1001/jama.2012.3507; Heyland D, 2013, NEW ENGL J MED, V368, P1489, DOI 10.1056/NEJMoa1212722; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Johnston BC, 2018, INFECT CONT HOSP EP, V39, P771, DOI 10.1017/ice.2018.84; Johnstone J, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025228; Johnstone Jennie, 2015, Pilot Feasibility Stud, V1, P19; Kitsios GD, 2017, J CRIT CARE, V38, P84, DOI 10.1016/j.jcrc.2016.09.029; Lamarche D., 2014, CRIT CAR CAN FOR OCT; Lamarche D, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0950-5; Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203; Li GW, 2017, INT J EPIDEMIOL, V46, P746, DOI 10.1093/ije/dyw320; Manzanares W, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1434-y; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; McDonald D, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00199-16; Morrow LE, 2010, AM J RESP CRIT CARE, V182, P1058, DOI 10.1164/rccm.200912-1853OC; Panigrahi P, 2017, NATURE, V548, P407, DOI 10.1038/nature23480; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Petrof EO, 2012, CRIT CARE MED, V40, P3290, DOI 10.1097/CCM.0b013e318260cc33; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; Relman DA, 2015, JAMA-J AM MED ASSOC, V314, P1127, DOI 10.1001/jama.2015.10700; Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051; Salminen MK, 2004, CLIN INFECT DIS, V38, P62, DOI 10.1086/380455; Schandelmaier S, 2020, CAN MED ASSOC J, V192, pE901, DOI 10.1503/cmaj.200077; Thibault R, 2013, CRIT CARE, V17, DOI 10.1186/cc12832; Yelin I, 2019, NAT MED, V25, P1728, DOI 10.1038/s41591-019-0626-9; Yi SH, 2016, AM J INFECT CONTROL, V44, P548, DOI 10.1016/j.ajic.2015.12.001	39	34	37	5	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	2021	326	11					1024	1033		10.1001/jama.2021.13355	http://dx.doi.org/10.1001/jama.2021.13355			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ4IM	34546300	Bronze, Green Published			2023-01-03	WOS:000702170600016
J	Zhang, L; Wu, YB; Dai, YK; Liu, Q; Ren, YJ; Xu, SJ; Pan, HG; Chen, WJ; Li, RL; Hu, L				Zhang, Ling; Wu, Yun-bo; Dai, Yun-kai; Liu, Qi; Ren, Yu-jie; Xu, Shi-jie; Pan, Huai-geng; Chen, Wei-jing; Li, Ru-liu; Hu, Ling			Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis	PLOS ONE			English	Article							INFLAMMATORY BOWEL DISEASES; TRADITIONAL CHINESE MEDICINE; POPULATION-BASED COHORT; PRACTICE GUIDELINES; RISK; MANAGEMENT; ASSOCIATION; MESALAZINE; TRIALS; CELLS	Background Ulcerative colitis (UC) is a chronic inflammatory disease with an increasing incidence in the world. Qingre-Chushi therapies (QC) can alleviate clinical symptoms. Therefore, a network meta-analysis was conducted to systematically evaluate the efficacy and safety of QC in the treatment of active UC patients. Methods 7 databases were screened and relevant randomized controlled trials were selected. The tools of Cochrane Handbook and the GRADE system were conducted to assess the quality of outcomes. Pooled risk ratio or standard mean difference was calculated with 95% credible interval for outcomes measurement using the random-effects model. The surface under the cumulative ranking curve (SUCRA) was performed to rank the treatments. The larger SUCRA scores, the more effective interventions. Results A total of 3560 articles were identified and 21 studies including 1829 participants were included for further analysis. Totally, 9 therapies regimens were compared: oral mesalazine, mesalazine enema, mesalazine suppository, oral mesalazine + mesalazine enema, oral QC, oral QC + oral mesalazine, QC enema, oral QC + QC enema, and oral mesalazine + QC enema. Based on the SUCRA plot, oral QC + oral mesalazine was the best treatment in inducing clinical response; oral QC + QC enema had the best efficacy in the improvement of Mayo scores and alleviating abdominal pain; oral mesalazine + mesalazine enema was the optimal therapy in the endoscopic improvement and reducing diarrhea; QC enema + oral mesalazine was the best option in preventing bloody stool. Conclusion This study confirmed the efficacy and safety of QC in treating active UC and suggested that the combination of oral medications with topical can achieve more benefits.	[Zhang, Ling; Wu, Yun-bo; Dai, Yun-kai; Liu, Qi; Ren, Yu-jie; Chen, Wei-jing; Li, Ru-liu; Hu, Ling] Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Zhang, Ling; Wu, Yun-bo; Dai, Yun-kai; Liu, Qi; Ren, Yu-jie; Xu, Shi-jie; Pan, Huai-geng; Chen, Wei-jing; Li, Ru-liu; Hu, Ling] Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Guangzhou, Guangdong, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine	Hu, L (corresponding author), Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China.; Hu, L (corresponding author), Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Guangzhou, Guangdong, Peoples R China.	drhuling@163.com	hu, ling/GWC-1104-2022		National Natural Science Foundation of China [81774238, 81373563, 30772689]; Guangzhou University of Chinese Medicine [62, 5, 6, 70, 64]; innovation team to foster scientific research projects of Guangzhou University of Chinese Medicine [2016KYTD07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou University of Chinese Medicine; innovation team to foster scientific research projects of Guangzhou University of Chinese Medicine	This work was supported by National Natural Science Foundation of China (No. 81774238, 81373563 and 30772689), construction of Chinese first-class discipline research of key project of Guangzhou University of Chinese Medicine ([2020] No. 62, [2019] No. 5 and [2018] No. 6), construction of Chinese first-class discipline of Guangzhou University of Chinese Medicine (2017, No. 70), construction of high-level university of Guangzhou University of Chinese Medicine (2016, No. 64), innovation team to foster scientific research projects of Guangzhou University of Chinese Medicine (No. 2016KYTD07). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abegunde AT, 2016, WORLD J GASTROENTERO, V22, P6296, DOI 10.3748/wjg.v22.i27.6296; Ades AE, 2006, PHARMACOECONOMICS, V24, P1, DOI 10.2165/00019053-200624010-00001; Ananthakrishnan AN, 2012, ANN INTERN MED, V156, P350, DOI 10.7326/0003-4819-156-5-201203060-00007; Ardesjo B, 2008, INFLAMM BOWEL DIS, V14, P652, DOI 10.1002/ibd.20370; Bao J., 2015, CLIN J CHINESE MED, V7, P1; Bressler B, 2015, GASTROENTEROLOGY, V148, P1035, DOI 10.1053/j.gastro.2015.03.001; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Chen G, 2016, ONCOTARGET, V7, P61643, DOI 10.18632/oncotarget.11426; Chen PD, 2015, J ETHNOPHARMACOL, V162, P207, DOI 10.1016/j.jep.2014.12.039; Dai YC, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006651; Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767; Dignass A, 2012, J CROHNS COLITIS, V6, P991, DOI 10.1016/j.crohns.2012.09.002; Ding S., 2019, CLIN OBSERVATION COL; Du J, 2019, ARXIV; Fan M., 2020, HUBEI J TCM, V42, P39; Fan YL, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018512; [冯卓 Feng Zhuo], 2018, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V24, P149; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Gionchetti P, 1998, DIS COLON RECTUM, V41, P93, DOI 10.1007/BF02236902; Gong Y, 2012, J ETHNOPHARMACOL, V141, P592, DOI 10.1016/j.jep.2011.08.057; Guo L., 2020, CHINA MODERN MED, V27, P26; Harbord M, 2017, J CROHNS COLITIS, V11, P1512, DOI 10.1093/ecco-jcc/jjx105; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jia ZJ, 2020, WORLD J TRAD CHINESE, V6, P74, DOI 10.4103/wjtcm.wjtcm_1_20; Johansson MEV, 2014, GUT, V63, P281, DOI 10.1136/gutjnl-2012-303207; Ke F, 2012, SAUDI J GASTROENTERO, V18, P3, DOI 10.4103/1319-3767.91726; Kornbluth A, 2010, AM J GASTROENTEROL, V105, P501, DOI 10.1038/ajg.2009.727; Li J., 2020, CLIN J TRADITIONAL C, V32, P767; Li Y, 2021, PHYTOMEDICINE, V80, DOI 10.1016/j.phymed.2020.153372; Liu L, 2011, CLIN STUDY SHAOYAO Q; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; Moller FT, 2015, AM J GASTROENTEROL, V110, P564, DOI 10.1038/ajg.2015.50; Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001; Peyrin-Biroulet L, 2015, AM J GASTROENTEROL, V110, P1324, DOI 10.1038/ajg.2015.233; Porter CK, 2008, GASTROENTEROLOGY, V135, P781, DOI 10.1053/j.gastro.2008.05.081; Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630; Qin L., 2017, CLIN OBSERVATION QUF; Sahami S, 2016, AM J GASTROENTEROL, V111, P163, DOI 10.1038/ajg.2015.301; Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016; Savovic J, 2018, AM J EPIDEMIOL, V187, P1113, DOI 10.1093/aje/kwx344; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647; Shan L., 2020, CLIN EFFICACY QINGKU; Shaw SY, 2010, AM J GASTROENTEROL, V105, P2687, DOI 10.1038/ajg.2010.398; Tabibian A, 2015, DIGEST DIS SCI, V60, P1366, DOI 10.1007/s10620-014-3471-1; Tong Zhan-Qi, 2011, Zhongguo Zhong Xi Yi Jie He Za Zhi, V31, P172; Tonin FS, 2017, PHARM PRACT-GRANADA, V15, DOI [10.18549/PharmPract.2017.01.943, 10.18549/pharmpract.2017.01.943]; Ungaro R, 2017, LANCET, V389, P1756, DOI 10.1016/S0140-6736(16)32126-2; Wang C., 2019, CJGMCM, V34, P63; Wang P, 2014, NBER WORKING PAPER; Wang T, 2020, ARXIV201201950; Wu C., 2019, ELASTIC UNCONS UNPUB; Yadav S, 2015, MAYO CLIN PROC, V90, P738, DOI 10.1016/j.mayocp.2015.03.024; Yang S., 2014, SHAANXI J TRADITIONA, V35, P1121; Yao L., 2018, ARXIV PREPRINT ARXIV; Yuan H, 2020, EUR J INTEGR MED, V36, DOI 10.1016/j.eujim.2020.101119; Yuan ZW, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01354; Zhang C, 2013, CLIN REV ALLERG IMMU, V44, P274, DOI 10.1007/s12016-012-8328-9; Zhang X., 2019, P NETW DISTR SYST SE; Zhang X, 2018, FUJIAN J TCM, V49, P10; Zhao YX, 2020, PHYTOMEDICINE, V68, DOI 10.1016/j.phymed.2020.153182; Zhong C., 2020, J GUANGZHOU U TCM, V37, P226	62	0	0	7	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2021	16	9							e0257599	10.1371/journal.pone.0257599	http://dx.doi.org/10.1371/journal.pone.0257599			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG6BN	34543327	Green Published, gold			2023-01-03	WOS:000707078200057
J	Mukai, RG; Matsumoto, HG; Akiyama, HG				Mukai, Ryo G.; Matsumoto, Hidetaka G.; Akiyama, Hideo G.			Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration	PLOS ONE			English	Article							DISEASE; SAFETY; RANIBIZUMAB; MORTALITY	PurposeTo analyze the risk factors associated with emerging intraocular inflammation (IOI) after intravitreal brolucizumab injection (IVBr) to treat age-related macular degeneration (AMD). MethodsThis study included 93 eyes of 90 patients. The incidence of emerging IOI was analyzed. The patients were classified into IOI or non-IOI groups, and background clinical characteristics in each group were compared. ResultsIOI occurred in 14 eyes of 14 cases (16%; five women, nine men [5:9]; IOI group) after IVBr; contrastingly, no IOI occurred in 76 patients (10 women, 66 men [10:66]; non-IOI group). The mean ages in IOI and non-IOI groups were 79.4 +/- 8.1 and 73.8 +/- 8.9 years old, respectively, and the average age in the IOI group was significantly higher than that in the non-IOI group (P = 0.0425). In addition, the percentages of females in the IOI and non-IOI groups were 43% and 13%, respectively, and IOI occurred predominantly in females (odds ratio: 4.95, P = 0.0076). Moreover, the prevalence of diabetes in the IOI and non-IOI groups was 64% and 32%, respectively, with a significant difference (odds ratio: 3.90, P = 0.0196). In contrast, the prevalence of hypertension in the IOI and non-IOI groups was 36% and 57%, respectively, with no significant difference (P = 0.15). ConclusionThe comparison of clinical profiles of IOI or non-IOI cases in IVBr treatment for AMD suggests that the risk factors for IOI are old age, female sex, and history of diabetes; however, IOI with vasculitis or vascular occlusion in this cohort does not seem to cause severe visual impairment. Further studies are required to investigate potential risk factors for IOI.	[Mukai, Ryo G.; Matsumoto, Hidetaka G.; Akiyama, Hideo G.] Gunma Univ, Dept Ophthalmol, Grad Sch Med, Maebashi, Gunma, Japan	Gunma University	Mukai, RG (corresponding author), Gunma Univ, Dept Ophthalmol, Grad Sch Med, Maebashi, Gunma, Japan.	rmukai@gunma-u.ac.jp		Matsumoto, Hidetaka/0000-0003-2311-0280; Mukai, Ryo/0000-0003-1796-9232				Beovu&TRADE;(brolucizumab), POSTMARKETING DAT; Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522; Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]; Enriquez AB, 2021, JAMA OPHTHALMOL, V139, P441, DOI 10.1001/jamaophthalmol.2020.7085; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680; Iyer Prashanth G, 2020, Am J Ophthalmol Case Rep, V20, P100989, DOI 10.1016/j.ajoc.2020.100989; Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687; JANKA HU, 1985, HORM METAB RES, V15, P15; Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046; Krentz AJ, 2009, J VASC RES, V46, P515, DOI 10.1159/000226220; Kubo M, 2003, STROKE, V34, P2349, DOI 10.1161/01.STR.0000090348.52943.A2; Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422; Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045; Maruko I, 2021, GRAEF ARCH CLIN EXP, V259, P2857, DOI 10.1007/s00417-021-05136-w; Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7; Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011; Noma H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073427; Ogura Yuichiro, 2016, Nippon Ganka Gakkai Zasshi, V120, P87; Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a; Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Sauerborn M, 2010, TRENDS PHARMACOL SCI, V31, P53, DOI 10.1016/j.tips.2009.11.001; Sharma A, 2021, EYE, V35, P1292, DOI 10.1038/s41433-020-01227-w; Spinelli FR, 2013, CLIN EXP RHEUMATOL, V31, P954; STOUT RW, 1979, DIABETOLOGIA, V16, P141, DOI 10.1007/BF01219790; Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006; Uemura A, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100954; Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022; Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863; Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1; Zarbin MA, 2018, ASIA-PAC J OPHTHALMO, V7, P63, DOI 10.22608/APO.2017495	32	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	12							e0259879	10.1371/journal.pone.0259879	http://dx.doi.org/10.1371/journal.pone.0259879			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM1MC	34871313	gold, Green Published			2023-01-03	WOS:000728598900004
J	Kentish-Barnes, N; Chevret, S; Valade, S; Jaber, S; Kerhuel, L; Guisset, O; Martin, M; Mazaud, A; Papazian, L; Argaud, L; Demoule, A; Schnell, D; Lebas, E; Ethuin, F; Hammad, E; Merceron, S; Audibert, J; Blayau, C; Delannoy, PY; Lautrette, A; Lesieur, O; Renault, A; Reuter, D; Terzi, N; Philippon-Jouve, B; Fiancette, M; Ramakers, M; Rigaud, JP; Souppart, V; Asehnoune, K; Champigneulle, B; Goldgran-Toledano, D; Dubost, JL; Bollaert, PE; Chouquer, R; Pochard, F; Cariou, A; Azoulay, E				Kentish-Barnes, Nancy; Chevret, Sylvie; Valade, Sandrine; Jaber, Samir; Kerhuel, Lionel; Guisset, Olivier; Martin, Maelle; Mazaud, Amelie; Papazian, Laurent; Argaud, Laurent; Demoule, Alexandre; Schnell, David; Lebas, Eddy; Ethuin, Frederic; Hammad, Emmanuelle; Merceron, Sybille; Audibert, Juliette; Blayau, Clarisse; Delannoy, Pierre-Yves; Lautrette, Alexandre; Lesieur, Olivier; Renault, Anne; Reuter, Danielle; Terzi, Nicolas; Philippon-Jouve, Benedicte; Fiancette, Maud; Ramakers, Michel; Rigaud, Jean-Philippe; Souppart, Virginie; Asehnoune, Karim; Champigneulle, Benoit; Goldgran-Toledano, Dany; Dubost, Jean-Louis; Bollaert, Pierre-Edouard; Chouquer, Renaud; Pochard, Frederic; Cariou, Alain; Azoulay, Elie			A three-step support strategy for relatives of patients dying in the intensive care unit: a cluster randomised trial	LANCET			English	Article							OF-LIFE CARE; BEREAVED FAMILY-MEMBERS; PALLIATIVE CARE; COMPLICATED GRIEF; COMMUNICATION; DEATH; QUALITY; SYMPTOMS; OUTCOMES; INTERVENTION	Background In relatives of patients dying in intensive care units (ICUs), inadequate team support can increase the prevalence of prolonged grief and other psychological harm. We aimed to evaluate whether a proactive communication and support intervention would improve relatives' outcomes. Methods We undertook a prospective, multicentre, cluster randomised controlled trial in 34 ICUs in France, to compare standard care with a physician-driven, nurse-aided, three-step support strategy for families throughout the dying process, following a decision to withdraw or withhold life support. Inclusion criteria were relatives of patients older than 18 years with an ICU length of stay 2 days or longer. Participating ICUs were randomly assigned (1:1 ratio) into an intervention cluster and a control cluster. The randomisation scheme was generated centrally by a statistician not otherwise involved in the study, using permutation blocks of non-released size. In the intervention group, three meetings were held with relatives: a family conference to prepare the relatives for the imminent death, an ICU-room visit to provide active support, and a meeting after the patient's death to offer condolences and closure. ICUs randomly assigned to the control group applied their best standard of care in terms of support and communication with relatives of dying patients. The primary endpoint was the proportion of relatives with prolonged grief (measured with PG-13, score >= 30) 6 months after the death. Analysis was by intention to treat, with the bereaved relatives as the unit of observation. The study is registered with ClinicalTrials.gov, NCT02955992. Findings Between Feb 23, 2017, and Oct 8, 2019, we enrolled 484 relatives of ICU patients to the intervention group and 391 to the control group. 379 (78%) relatives in the intervention group and 309 (79%) in the control group completed the 6-month interview to measure the primary endpoint. The intervention significantly reduced the number of relatives with prolonged grief symptoms (66 [21%] vs 57 [15%]; p=0.035) and the median PG-13 score was significantly lower in the intervention group than in the control group (19 [IQR 14-26] vs 21 [15-29], mean difference 2.5, 95% CI 1.04-3.95). Interpretation Among relatives of patients dying in the ICU, a physician-driven, nurse-aided, three-step support strategy significantly reduced prolonged grief symptoms. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.	[Kentish-Barnes, Nancy; Valade, Sandrine; Kerhuel, Lionel; Souppart, Virginie; Pochard, Frederic; Azoulay, Elie] St Louis Hosp, AP HP Nord, Med Intens Care, Famirea Res Grp, Paris, France; [Chevret, Sylvie; Azoulay, Elie] Paris Univ, St Louis Hosp, AP HP, UMR 1153,ECSTRRA Team,INSERM,Dept Biostat & Med I, Paris, France; [Valade, Sandrine; Cariou, Alain] Cochin Hosp, AP HP Ctr, Med Intens Care, Paris, France; [Cariou, Alain] Paris Univ, Paris, France; [Jaber, Samir] St Eloi Univ Hosp, Dept Anesthesia & Crit Care Med, Montpellier, France; [Jaber, Samir] Univ Montpellier, INSERM, CNRS, PhyMedExp, Montpellier, France; [Guisset, Olivier] St Andre Univ Hosp, Med Intens Care, Bordeaux, France; [Martin, Maelle] Hotel Dieu Univ Hosp, Med Intens Care, Nantes, France; [Mazaud, Amelie] Hosp Civils Lyon, Edouard Herriot Univ Hosp, Surg Intens Care, Lyon, France; [Papazian, Laurent] Hop Nord Marseille, AP HM, Med Intens Care, Marseille, France; [Papazian, Laurent] Aix Marseille Univ, Fac Sci Med & Paramed, Ctr Etud & Rech Sur, Serv Sante & Qualite Vie EA 3279, Marseille, France; [Argaud, Laurent] Hosp Civils Lyon, Edouard Herriot Hosp, Med Intens Care, Lyon, France; [Argaud, Laurent] Univ Lyon, Lyon, France; [Demoule, Alexandre] Sorbonne Univ, La Pitie Salpetriere Univ Hosp, AP HP, Med Intens Care Unit, Paris, France; [Demoule, Alexandre] Sorbonne Univ, INSERM, UMRS11S8, Neurophysiol Resp Expt & Clin, Paris, France; [Schnell, David] Angouleme Hosp, Med & Surg Intens Care, Angouleme, France; [Lebas, Eddy] Bretagne Atlantique Hosp, Med & Surg Intens Care, Vannes, France; [Ethuin, Frederic] Cote Nacre Univ Hosp, Surg Intens Care, Caen, France; [Hammad, Emmanuelle] Hosp Nord, AP HM, Anaesthesia & Intens Care, Marseille, France; [Merceron, Sybille] Andre Mignot Hosp, Med Intens Care, Le Chesnay, France; [Audibert, Juliette] Louis Pasteur Hosp, Med & Surg Intens Care, Chartres, Eure & Loir, France; [Blayau, Clarisse] Sorbonne Univ, Tenon Hosp, AP HP, Med Intens Care, Paris, France; [Delannoy, Pierre-Yves] Chatilliez Hosp, Med & Surg Intens Care, Tourcoing, France; [Lautrette, Alexandre] Gabriel Montpied Univ Hosp, Med Intens Care, Clermont Ferrand, France; [Lesieur, Olivier] La Rochelle Hosp, Med & Surg Intens Care, La Rochelle, France; [Renault, Anne] Cavale Blanche Univ Hosp, Med Intens Care, Brest, France; [Reuter, Danielle] Sud Francilien Hosp, Med & Surg Intens Care, Evry, France; [Terzi, Nicolas] Grenoble Alpes Univ Hosp, Med Intens Care, Grenoble, France; [Philippon-Jouve, Benedicte] Roanne Hosp, Med & Surg Intens Care, Roanne, France; [Fiancette, Maud] Les Oudairies Hosp, Med & Surg Intens Care, La Roche Sur Yon, France; [Ramakers, Michel] St Lo Hosp, Med & Surg Intens Care, St Lo, France; [Rigaud, Jean-Philippe] Dieppe Hosp, Med & Surg Intens Care, Paris, France; [Asehnoune, Karim] Hotel Dieu Univ Hosp, Dept Anesthesia & Crit Care, Nantes, France; [Champigneulle, Benoit] Hop Europeen Georges Pompidou, AP HP Ctr, Dept Aaesthesia & Crit Care, Paris, France; [Goldgran-Toledano, Dany] Montfermeil Hosp, Med & Surg Intens Care, Montfermeil, France; [Dubost, Jean-Louis] Rene Dubos Hosp, Med & Surg Intens Care, Pontoise, France; [Bollaert, Pierre-Edouard] Univ Hosp Cent, Med Intens Care, Nancy, France; [Chouquer, Renaud] Annecy Hosp, Med & Surg Intens Care, Annecy, France; [Pochard, Frederic] Fernand Widal Hosp, AP HP Nord, DMU Neurosdences, Dept Psychiat & Med Addictol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU Bordeaux; Nantes Universite; CHU de Nantes; CHU Lyon; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU de Caen NORMANDIE; Universite de Caen Normandie; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre Hospitalier de Versailles; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Clermont Ferrand; CHU Brest; Centre Hospitalier Sud Francilien; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHD Vendee; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Rene Dubos, Pontoise; Centre Hospitalier Annecy Genevois; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Kentish-Barnes, N (corresponding author), Hop St Louis, Med ICU, F-75010 Paris, France.	nancy.kentish@aphp.fr	Carmen, Team3/Y-7384-2019	Carmen, Team3/0000-0002-3614-0924; Lab, Carmen/0000-0002-5935-3236	French Ministry of Health	French Ministry of Health	French Ministry of Health	Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Carson SS, 2016, JAMA-J AM MED ASSOC, V316, P51, DOI 10.1001/jama.2016.8474; Curtis JR, 2016, AM J RESP CRIT CARE, V193, P154, DOI 10.1164/rccm.201505-0900OC; Curtis JR, 2013, JAMA-J AM MED ASSOC, V310, P2271, DOI 10.1001/jama.2013.282081; Curtis JR, 2011, AM J RESP CRIT CARE, V183, P348, DOI 10.1164/rccm.201006-1004OC; Curtis JR, 2010, LANCET, V376, P1347, DOI 10.1016/S0140-6736(10)60143-2; Curtis JR, 2005, AM J RESP CRIT CARE, V171, P844, DOI 10.1164/rccm.200409-1267OC; Curtis JR, 2002, J PAIN SYMPTOM MANAG, V24, P17, DOI 10.1016/S0885-3924(02)00419-0; Davidson JE, 2017, CRIT CARE MED, V45, P103, DOI 10.1097/CCM.0000000000002169; Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8; Kentish-Barnes N, 2018, TRIALS, V19, DOI 10.1186/s13063-018-3084-7; Kentish-Barnes N, 2017, INTENS CARE MED, V43, P473, DOI 10.1007/s00134-016-4669-9; Kentish-Barnes N, 2016, INTENS CARE MED, V42, P995, DOI 10.1007/s00134-016-4260-4; Kentish-Barnes N, 2015, CRIT CARE MED, V43, P1839, DOI 10.1097/CCM.0000000000001092; Kentish-Barnes N, 2015, EUR RESPIR J, V45, P1341, DOI 10.1183/09031936.00160014; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; Little P, 2015, BRIT J GEN PRACT, V65, pE351, DOI 10.3399/bjgp15X685237; Meakin R, 2002, FAM PRACT, V19, P257, DOI 10.1093/fampra/19.3.257; Nelson JE, 2006, QUAL SAF HEALTH CARE, V15, P264, DOI 10.1136/qshc.2005.017707; Nelson JE, 2012, J PALLIAT MED, V15, P168, DOI 10.1089/jpm.2011.9599; Nelson JE, 2010, CRIT CARE MED, V38, P808, DOI 10.1097/CCM.0b013e3181c5887c; Otani H, 2017, J PAIN SYMPTOM MANAG, V54, P273, DOI 10.1016/j.jpainsymman.2017.07.010; Pochard F, 2005, J CRIT CARE, V20, P90, DOI 10.1016/j.jcrc.2004.11.004; Prigerson HG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000121; Selph RB, 2008, J GEN INTERN MED, V23, P1311, DOI 10.1007/s11606-008-0643-8; Shear MK, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0406-z; TILDEN VP, 1995, ARCH INTERN MED, V155, P633, DOI 10.1001/archinte.155.6.633; White DB, 2018, NEW ENGL J MED, V378, P2365, DOI 10.1056/NEJMoa1802637; Wilson JP., 2004, ASSESSING PSYCHOL TR	30	9	9	14	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB	2022	399	10325					656	664		10.1016/S0140-6736(21)02176-0	http://dx.doi.org/10.1016/S0140-6736(21)02176-0		FEB 2022	9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY1RO	35065008	Green Submitted			2023-01-03	WOS:000754571600023
J	Cassone, G; Dolci, G; Besutti, G; Braglia, L; Pavone, P; Corsini, R; Sampaolesi, F; Iotti, V; Teopompi, E; Massari, M; Fontana, M; Ghidoni, G; Matei, A; Croci, S; Negri, EA; Costantini, M; Facciolongo, N; Salvarani, C				Cassone, Giulia; Dolci, Giovanni; Besutti, Giulia; Braglia, Luca; Pavone, Paolo; Corsini, Romina; Sampaolesi, Fabio; Iotti, Valentina; Teopompi, Elisabetta; Massari, Marco; Fontana, Matteo; Ghidoni, Giulia; Matei, Anaflorina; Croci, Stefania; Negri, Emanuele Alberto; Costantini, Massimo; Facciolongo, Nicola; Salvarani, Carlo			Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis	PLOS ONE			English	Article								Objective The aim of this retrospective observational study is to analyse clinical, serological and radiological predictors of outcome in patients with COVID-19 pneumonia treated with tocilizumab, providing clinical guidance to its use in real-life. Method This is a retrospective, monocentric observational cohort study. All consecutive patients hospitalized between February the 11th and April 14th 2020 for severe COVID-19 pneumonia at Reggio Emilia AUSL and treated with tocilizumab were enrolled. The patient's clinical status was recorded every day using the WHO ordinal scale for clinical improvement. Response to treatment was defined as an improvement of one point (from the status at the beginning of tocilizumab treatment) during the follow-up on this scale. Bivariate association of main patients' characteristics with outcomes was explored by descriptive statistics and Fisher or Kruskal Wallis tests (respectively for qualitative or quantitative variables). Each clinically significant predictor was checked by a loglikelihood ratio test (in univariate logistic models for each of the considered outcomes) against the null model. Results A total of 173 patients were included. Only hypertension, the use of angiotensin-converting enzyme inhibitors, PaO2/FiO(2), respiratory rate and C-reactive protein were selected for the multivariate analysis. In the multivariable model, none of them was significantly associated with response. Conclusions Evaluating a large number of clinical variables, our study did not find new predictors of outcome in COVID19 patients treated with tocilizumab. Further studies are needed to investigate the use of tocilizumab in COVID-19 and to better identify clinical phenotypes which could benefit from this treatment.	[Cassone, Giulia; Salvarani, Carlo] IRCCS Arcispedale Santa Maria Nuova, Azienda Unita Sanitaria Locale IRCCS Reggio Emili, Rheumatol Unit, Reggio Emilia, Italy; [Cassone, Giulia; Besutti, Giulia] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy; [Dolci, Giovanni] Univ Modena & Reggio Emilia, Infect Dis Unit, Modena, Italy; [Besutti, Giulia; Iotti, Valentina] Azienda USL IRCCS Reggio Emilia, Radiol Unit, Dept Imaging & Lab Med, Reggio Emilia, Italy; [Braglia, Luca; Costantini, Massimo] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy; [Pavone, Paolo; Corsini, Romina; Sampaolesi, Fabio; Massari, Marco] Azienda USL IRCCS Reggio Emilia, Infect Dis Unit, Reggio Emilia, Italy; [Teopompi, Elisabetta] Azienda USL IRCCS Reggio Emilia, Osped Civile Guastalla, SOC Internist Multidisciplinare, Reggio Emilia, Italy; [Fontana, Matteo; Ghidoni, Giulia; Facciolongo, Nicola] Azienda USL IRCCS Reggio Emilia, Pneumol Unit, Reggio Emilia, Italy; [Matei, Anaflorina] Azienda USL IRCCS Reggio Emilia, Dept Anesthesia & Intens Care, Reggio Emilia, Italy; [Croci, Stefania] Azienda USL IRCCS Reggio Emilia, Clin Immunol Allergy & Adv Biotechnol Unit, Reggio Emilia, Italy; [Negri, Emanuele Alberto] Azienda USL IRCCS Reggio Emilia, High Intens Unit, Reggio Emilia, Italy; [Salvarani, Carlo] Univ Modena & Reggio Emilia, Rheumatol Unit, Modena, Italy	IRCCS Arcispedale S. Maria Nuova; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia	Dolci, G (corresponding author), Univ Modena & Reggio Emilia, Infect Dis Unit, Modena, Italy.	giodolci@hotmail.it	Fontana, Matteo/AAU-4692-2021; Braglia, Luca/AAL-7565-2021	Fontana, Matteo/0000-0001-8758-8449; Dolci, Giovanni/0000-0001-9948-652X; Braglia, Luca/0000-0001-8225-2938				Besutti G, 2020, EUR RADIOL, V30, P6818, DOI 10.1007/s00330-020-07050-x; Cassone G, 2020, CLIN EXP RHEUMATOL, V38, P1215; Colombi D, 2020, RADIOLOGY, V296, pE86, DOI 10.1148/radiol.2020201433; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI [10.1056/NEJMoa2100433, 10.1056/NEJMc2108482]; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Horby PW, 2021, MEDRXIV, DOI [10.1101/2021.02.11.21249258, DOI 10.1101/2021.02.11.21249258]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; National Society of Infectious Diseases' (SIMIT), GUID MAN COVID 19 IN; Patoulias D, 2020, CURR HYPERTENS REP, V22, DOI 10.1007/s11906-020-01101-w; Piccirillo MC, 2020, CONTEMP CLIN TRIALS, V98, DOI 10.1016/j.cct.2020.106165; Richier Q, 2021, REV MED INTERNE, V42, P73, DOI 10.1016/j.revmed.2020.11.016; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237; Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954	18	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2022	17	1							e0262908	10.1371/journal.pone.0262908	http://dx.doi.org/10.1371/journal.pone.0262908			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3D9IN	35081151	Green Published, gold			2023-01-03	WOS:000829607600041
J	Elmahi, OKO; Musa, RAE; Shareef, AAH; Omer, MEA; Elmahi, MAM; Altamih, RAA; Mohamed, RIH; Alsadig, TFM				Elmahi, Osman Kamal Osman; Musa, Reem Abdalla Elsiddig; Shareef, Ahd Alaaeldin Hussain; Omer, Mohammed Eltahier Abdalla; Elmahi, Mugahid Awad Mohamed; Altamih, Randa Ahmed Abdalrheem; Mohamed, Rayan Ibrahim Hamid; Alsadig, Tagwa Faisal Mohamed			Perception and practice of self-medication with antibiotics among medical students in Sudanese universities: A cross-sectional study	PLOS ONE			English	Article							ANTIMICROBIAL RESISTANCE; PRESCRIPTION; PREVALENCE; KNOWLEDGE	Introduction The benefits of antibiotics are under threat by self-medication, which culminated in economic burdening of developing countries, treatment failures, the emergence of antibiotic-resistant strains of bacteria and an increased probability of exposure and infection of the general population by antibiotic-resistant bacterial strains. Objectives This study aimed to evaluate the knowledge and attitude of medical students in Sudan towards the use of antibiotics, the prevalence of self-medication with antibiotics among medical students in Sudan and to identify risk factors which promote self-medication with antibiotics. Materials and methods This was a cross-sectional, descriptive and institution-based study, between November 2020 and May 2021. 1,110 medical students were selected by multistage cluster sampling. Logistic regression was used to identify risk factors of self-medication with antibiotics among the study participants. Results The median knowledge score was 7 out of a maximum of 10 (IQR: 5-8). A moderately positive attitude was observed among the participants (Median: 7/10; IQR: 6-8). Knowledge and attitude scores were significantly associated with academic year and monthly allowance (p < 0.05). 675 (60.8%) self-medicated with antibiotics within the previous 12 months, mostly from community pharmacies (321/675; 47.5%). Antibiotics were most commonly used to treat respiratory tract infections (38.1%) and cough (30.4%). Chi-square analysis demonstrated that self-medication with antibiotics was significantly associated with gender, year of study and monthly income. Conclusions Undergraduate medical students had moderate knowledge and attitude towards antibiotic use and antibiotic resistance, and an alarmingly high prevalence of self-medication with antibiotics. This highlights the urgent need for tighter legislation regarding the sales of antibiotics in community pharmacies by the state and federal health ministries.	[Elmahi, Osman Kamal Osman] Ibn Sina Univ, Fac Med, Khartoum, Sudan; [Musa, Reem Abdalla Elsiddig] Univ Bahkt Alruda, Fac Med & Hlth Sci, Ed Dueim, Sudan; [Shareef, Ahd Alaaeldin Hussain; Omer, Mohammed Eltahier Abdalla] Univ Gadarif, Fac Med & Hlth Sci, Gadarif, Sudan; [Elmahi, Mugahid Awad Mohamed] Univ Gezira, Fac Med, Wad Madani, Sudan; [Altamih, Randa Ahmed Abdalrheem; Mohamed, Rayan Ibrahim Hamid] Univ Khartoum, Fac Med, Khartoum, Sudan; [Alsadig, Tagwa Faisal Mohamed] Alzaiem Alazhari Univ, Fac Med, Dept Community Med, Khartoum, Sudan	University of Khartoum	Elmahi, OKO (corresponding author), Ibn Sina Univ, Fac Med, Khartoum, Sudan.	osman19091995@gmail.com	Altamih, Randa/AFY-8626-2022	Altamih, Randa/0000-0002-8708-7588; Elmahi, Osman/0000-0002-8672-3255				Abdulraheem IS, 2016, BRIT J PHARM RES, V11, DOI 10.9734/BJPR/2016/25268; Abduzaimovic Amila, 2016, Mater Sociomed, V28, P416, DOI 10.5455/msm.2016.28.416-419; Ahmad A, 2015, J RES PHARM PRACT, V4, P37, DOI 10.4103/2279-042X.150057; Ajayi I, 2014, SELF MEDICATION PRAC; Al Rasheed A, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3916874; Alhomoud F, 2017, INT J INFECT DIS, V57, P3, DOI 10.1016/j.ijid.2017.01.014; Alrasheedy AA, 2020, EXPERT REV ANTI-INFE, V18, P87, DOI 10.1080/14787210.2020.1705156; Aslam A, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9020097; Assar A, 2020, ENVIRON SCI POLLUT R, V27, P21292, DOI 10.1007/s11356-020-08534-5; Ateshim Y, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7020-x; Auta A, 2012, N AM J MED SCI, V4, P24, DOI 10.4103/1947-2714.92899; Awad AI, 2007, ANN PHARMACOTHER, V41, P1249, DOI 10.1345/aph.1K068; Awad AI, 2006, EUR J CLIN PHARMACOL, V62, P317, DOI 10.1007/s00228-006-0107-1; Ayukekbong JA, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-017-0208-x; Bavestrello L, 2002, REV MED CHILE, V130, P1265; Belachew G., 2011, J APPL PHARM SCI, V1, P183; Beytur A, 2015, JUNDISHAPUR J MICROB, V8, DOI 10.5812/jjm.13792; Chacko CT., 2020, INT J RES REV, V7, P122; Chalker J, 2001, B WORLD HEALTH ORGAN, V79, P313; Chokshi A, 2019, J GLOB INFECT DIS, V11, P36, DOI 10.4103/jgid.jgid_110_18; Dyar OJ, 2018, ANTIBIOTICS-BASEL, V7, DOI 10.3390/antibiotics7010010; Ehigiator O., 2013, EUR J GEN DENT, V2, P54, DOI [10.4103/2278-9626.106813, DOI 10.4103/2278-9626.106813]; Ekambi GAE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212875; Elhada AH, 2014, WORLD J PHARM RES, V3, P678; Elmahi OKO., 2020, INT J TROP DIS HLTH, V41, P17, DOI DOI 10.9734/IJTDH/2020/V41I430267; Escourrou B., 2010, REV PRATICIEN, V60, P34; Flanigan J, 2012, J MED ETHICS, V38, P579, DOI 10.1136/medethics-2011-100240; Gajdacs M, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9020041; Gelayee DA, 2017, J PHARMACEUTICS, V2017, DOI 10.1155/2017/8680714; Hogberg LD, 2014, LANCET INFECT DIS, V14, P1179, DOI 10.1016/S1473-3099(14)70987-9; Horumpende PG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206623; Hughes CM, 2001, DRUG SAFETY, V24, P1027, DOI 10.2165/00002018-200124140-00002; Jairoun A, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6878-y; Jakupi A, 2019, PHARM PRACT-GRANADA, V17, DOI [10.18549/pharmpract.2019.3.1540, 10.18549/PharmPract.2019.3.1540]; Kabi Thapa, 2017, Nepal Journal of Biotechnology, V5, P14, DOI 10.3126/njb.v5i1.18865; Kamati M, 2019, J RES PHARM PRACT, V8, P220, DOI 10.4103/jrpp.JRPP_19_121; Kotwani A, 2012, J CLIN PHARM THER, V37, P308, DOI 10.1111/j.1365-2710.2011.01293.x; Le Grand A, 1999, HEALTH POLICY PLANN, V14, P89, DOI 10.1093/heapol/14.2.89; Loyola Filho Antônio I. de, 2004, Cad. Saúde Pública, V20, P1661, DOI 10.1590/S0102-311X2004000600025; Lv B, 2014, TROP MED INT HEALTH, V19, P769, DOI 10.1111/tmi.12322; Morgan DJ, 2011, LANCET INFECT DIS, V11, P692, DOI 10.1016/S1473-3099(11)70054-8; Ngigi CK., 2016, IMP J INTERDISCIP RE, V2, P4415; Ocan M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2109-3; Okedo-Alex I, 2019, MALAWI MED J, V31, P133, DOI 10.4314/mmj.v31i2.5; Osemene KP, 2012, TROP J PHARM RES, V11, P683, DOI 10.4314/tjpr.v11i4.21; Sakeena MHF, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3107-8; Santa-Ana-Tellez Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075550; Shehnaz SI, 2014, J ADOLESCENT HEALTH, V55, P467, DOI 10.1016/j.jadohealth.2014.07.001; Spellberg B, 2008, CLIN INFECT DIS, V46, P155, DOI 10.1086/524891; Sridhar Sathvik B, 2018, Int J Appl Basic Med Res, V8, P3, DOI 10.4103/ijabmr.IJABMR_46_17; Torres NF, 2019, PUBLIC HEALTH, V168, P92, DOI 10.1016/j.puhe.2018.11.018; Torres NF, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-041323; Torres NF, 2019, ANTIMICROB RESIST IN, V8, DOI 10.1186/s13756-019-0618-z; WHO, GLOB STRAT CONT ANT; WHO, 2019, ASS NONPR IN US ANT; WHO,Fact sheet N194, 2002, ANTIMICROBIAL RESIST; Williams DN, 2016, J ROY COLL PHYS EDIN, V46, P150, DOI 10.4997/JRCPE.2016.302; Wise R, 2002, J ANTIMICROB CHEMOTH, V49, P585, DOI 10.1093/jac/49.4.585; World Health Organization, 2008, The global burden of disease: 2004 update; World Health Organization, 2015, Worldwide country situation analysis: response to antimicrobial resistance; World Health Organization, 2015, GLOB ACT PLAN ANT RE; World Health Organization, 2009, COMM BAS SURV ANT US; Yadav S., 2015, INT J PHARM CHEM ANA, V2, P139; Zapata-Cachafeiro M, 2019, J ANTIMICROB CHEMOTH, V74, P511, DOI 10.1093/jac/dky440; Zdziarski Przemyslaw, 2003, Acta Microbiologica Polonica, V52, P5; Zhu X, 2016, PUBLIC HEALTH, V130, P78, DOI 10.1016/j.puhe.2015.04.005	66	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2022	17	1							e0263067	10.1371/journal.pone.0263067	http://dx.doi.org/10.1371/journal.pone.0263067			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3D9IN	35081149	gold, Green Submitted, Green Published			2023-01-03	WOS:000829607600053
J	Panyajai, P; Chueahongthong, F; Viriyaadhammaa, N; Nirachonkul, W; Tima, S; Chiampanichayakul, S; Anuchapreeda, S; Okonogi, S				Panyajai, Pawaret; Chueahongthong, Fah; Viriyaadhammaa, Natsima; Nirachonkul, Wariya; Tima, Singkome; Chiampanichayakul, Sawitree; Anuchapreeda, Songyot; Okonogi, Siriporn			Anticancer activity of Zingiber ottensii essential oil and its nanoformulations	PLOS ONE			English	Article							CHEMICAL-COMPOSITION; POLYMERIC MICELLES; OFFICINALIS L.; YIELD; ANTIOXIDANT; STABILITY; CURCUMIN; DELIVERY; LEAVES	Zingiber ottensii, is widely used in Asian traditional remedies for the treatment of many diseases. The present study explores anticancer activity of Z. ottensii essential oil (ZOEO) and its nanoformulations. ZOEO obtained from hydrodistillation of Z. ottensii fresh rhizomes was analysis using gas chromatography mass spectroscopy. Zerumbone (25.21%) was the major compound of ZOEO followed by sabinene (23.35%) and terpene-4-ol (15.97%). Four types of ZOEO loaded nanoformulations; nanoemulsion, microemulsion, nanoemulgels, and microemulgel, were developed. The average droplet size of the nanoemulsion and microemulsion was significantly smaller than that of the nanoemulgel and microemulgel. Comparison with other essential oils of plants of the same family on anticancer activity against A549, MCF-7, HeLa, and K562, ZOEO showed the highest cytotoxicity with IC50 of 43.37 +/- 6.69, 9.77 +/- 1.61, 23.25 +/- 7.73, and 60.49 +/- 9.41 mu g/mL, respectively. Investigation using flow cytometry showed that ZOEO significantly increased the sub-G1 populations (cell death) in cell cycle analysis and induced cell apoptosis by apoptotic analysis. The developed nanoformulations significantly enhanced cytotoxicity of ZOEO, particularly against MCF-7 with the IC50 of 3.08 +/- 2.58, 0.74 +/- 0.45, 2.31 +/- 0.91, and 6.45 +/- 5.84 mu g/mL, respectively. Among the four nanoformulations developed in the present study, nanoemulsion and microemulsion were superior to nanoemulgel and microemulgel in delivering ZOEO into cancer cells.	[Panyajai, Pawaret; Chueahongthong, Fah; Viriyaadhammaa, Natsima; Nirachonkul, Wariya; Tima, Singkome; Chiampanichayakul, Sawitree; Anuchapreeda, Songyot] Chiang Mai Univ, Fac Associated Med Sci, Dept Med Technol, Chiang Mai, Thailand; [Tima, Singkome; Chiampanichayakul, Sawitree; Anuchapreeda, Songyot] Chiang Mai Univ, Fac Associated Med Sci, Canc Res Unit Associated Med Sci AMS CRU, Chiang Mai, Thailand; [Tima, Singkome; Chiampanichayakul, Sawitree; Anuchapreeda, Songyot; Okonogi, Siriporn] Chiang Mai Univ, Res Ctr Pharmaceut Nanotechnol, Chiang Mai, Thailand; [Okonogi, Siriporn] Chiang Mai Univ, Fac Pharm, Dept Pharmaceut Sci, Chiang Mai, Thailand	Chiang Mai University; Chiang Mai University; Chiang Mai University; Chiang Mai University	Anuchapreeda, S (corresponding author), Chiang Mai Univ, Fac Associated Med Sci, Dept Med Technol, Chiang Mai, Thailand.; Anuchapreeda, S (corresponding author), Chiang Mai Univ, Fac Associated Med Sci, Canc Res Unit Associated Med Sci AMS CRU, Chiang Mai, Thailand.; Anuchapreeda, S; Okonogi, S (corresponding author), Chiang Mai Univ, Res Ctr Pharmaceut Nanotechnol, Chiang Mai, Thailand.; Okonogi, S (corresponding author), Chiang Mai Univ, Fac Pharm, Dept Pharmaceut Sci, Chiang Mai, Thailand.	sanuchapreeda@gmail.com; okng2000@gmail.com	Chueahongthong, Fah/HHM-7757-2022	Tima, Singkome/0000-0002-3072-3715	Agricultural Research Development Agency [GSCMU(HRD6405069)/08/2564]; National Research Council of Thailand [NRCT-16845, NRCT-71738]; Thailand Research Fund [RSA6280034]	Agricultural Research Development Agency; National Research Council of Thailand(National Research Council of Thailand (NRCT)); Thailand Research Fund(Thailand Research Fund (TRF))	The authors received the funds as follows. 1. The Agricultural Research Development Agency, grant number GSCMU(HRD6405069)/08/2564. 2. The National Research Council of Thailand, grant number NRCT-16845 and number NRCT-71738. 3. The Thailand Research Fund, grant number RSA6280034. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alambra J. R., 2012, AACL Bioflux, V5, P13; Anantaworasakul P, 2017, J MICROENCAPSUL, V34, P73, DOI 10.1080/02652048.2017.1284277; Ashara KC., 2014, CHEMINFORM, V45, DOI [10.1002/chin.201434272, DOI 10.1002/CHIN.201434272]; Aung Mu Mu, 2019, Bulletin of the National Museum of Nature and Science Series B-Botany, V45, P1; Baldin VP, 2019, J ETHNOPHARMACOL, V244, DOI 10.1016/j.jep.2019.112095; Cao B., 2020, WORLD CANC REP CANC; Carrasco FR, 2009, J PHARM PHARMACOL, V61, P961, DOI [10.1211/jpp/61.07.0017, 10.1211/jpp.61.07.0017]; Chaiyana W, 2017, AAPS PHARMSCITECH, V18, P1332, DOI 10.1208/s12249-016-0603-2; Chen IN, 2008, PLANT FOOD HUM NUTR, V63, P15, DOI 10.1007/s11130-007-0063-7; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; Djouahri A, 2015, IND CROP PROD, V63, P138, DOI 10.1016/j.indcrop.2014.10.018; Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566; Firoozi M, 2020, J FOOD PROCESS ENG, V43, DOI 10.1111/jfpe.13434; Formisano C, 2015, IND CROP PROD, V63, P256, DOI 10.1016/j.indcrop.2014.09.042; Gazim ZC, 2010, MOLECULES, V15, P5509, DOI 10.3390/molecules15085509; Govindarajan M, 2016, PARASITOL RES, V115, P1807, DOI 10.1007/s00436-016-4920-x; Huong L.T., 2016, BIOSCI DISCOV, V7, P93; Jeevanandam J, 2016, BIOCHIMIE, V128, P99, DOI 10.1016/j.biochi.2016.07.008; Kale S., 2017, SYST REV PHARM, V8, P39, DOI [10.5530/srp.2017.1.8, DOI 10.5530/SRP.2017.1.8]; Khammaneejan O., 2020, RSU INT RES C, V1, P404; Liber Z, 2011, CHEM BIODIVERS, V8, P1978, DOI 10.1002/cbdv.201100039; Lima Daniel Augusto Nunes De, 2020, Asian Pac J Cancer Prev, V21, P2141, DOI 10.31557/APJCP.2020.21.7.2141; Marliani L., 2018, RES J CHEM ENVIRON, V22, P54; Mostafa N. M., 2018, Journal of Applied Pharmaceutical Science, V8, P34, DOI 10.7324/JAPS.2018.8906; Naksuriya O, 2016, AAPS J, V18, P777, DOI 10.1208/s12248-015-9863-0; Naksuriya O, 2015, EUR J PHARM BIOPHARM, V94, P501, DOI 10.1016/j.ejpb.2015.06.010; Okonogi S, 2012, DRUG DISCOV THER, V6, P249, DOI 10.5582/ddt.2012.v6.5.249; Okonogi S, 2011, AFR J MICROBIOL RES, V5, P2847; Patel RP, 2016, IND CROP PROD, V87, P210, DOI 10.1016/j.indcrop.2016.04.001; Rajeswary M, 2018, ENVIRON SCI POLLUT R, V25, P10307, DOI 10.1007/s11356-017-9093-3; Ruttanapattanakul J, 2021, PLANTS-BASEL, V10, DOI 10.3390/plants10071419; Sadeghi H, 2015, IND CROP PROD, V67, P221, DOI 10.1016/j.indcrop.2015.01.021; Saeio K., 2007, SCI PHARM, V75, P147, DOI 10.3797/scipharm.2007.75.147; Santos P A S R, 2016, ScientificWorldJournal, V2016, P9273078, DOI 10.1155/2016/9273078; Singh M, 2013, IND CROP PROD, V42, P37, DOI 10.1016/j.indcrop.2012.04.054; Sirat H. M., 1994, Journal of Essential Oil Research, V6, P635; Sirousmehr A., 2014, Advances in Environmental Biology, V8, P1322; Sri Nurestri A. M., 2005, Malaysian Journal of Science, V24, P49; Theanphong O, 2016, THAI J BOT, V8, P127; Thubthimthed S, 2005, ACTA HORTIC, P107, DOI 10.17660/ActaHortic.2005.675.14; Vidic D, 2010, CHEM BIODIVERS, V7, P1208, DOI 10.1002/cbdv.200900126; Viriyaadhammaa N, 2020, MOLECULES, V25, DOI 10.3390/molecules25225476	42	4	4	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2022	17	1							e0262335	10.1371/journal.pone.0262335	http://dx.doi.org/10.1371/journal.pone.0262335			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ4EH	35073347	gold, Green Published			2023-01-03	WOS:000773223800028
J	Kurata, K; Shimada, K; Takamatsu, H				Kurata, Kosaku; Shimada, Kazuki; Takamatsu, Hiroshi			Application of the Taguchi method to explore a robust condition of tumor-treating field treatment	PLOS ONE			English	Article							APPLIED ELECTRIC-FIELDS; DIELECTRIC-PROPERTIES; CELLS; MEMBRANES; ELECTROROTATION; GLIOBLASTOMA; DISRUPTION	Tumor-treating fields have potential as minimally invasive cancer treatment. This study aimed to explore the optimum tumor-treating field conditions that minimize unpredicted variations in therapeutic outcomes resulting from differences in cell size and electrical properties. The electric field concentration that induces a dielectrophoretic force near the division plane of a mitotic cell was calculated by finite element analysis for 144 cases, based on different combinations of six noise factors associated with cells and four controllable factors including frequency, as determined by the Taguchi method. Changing the frequency from 200 to 400 kHz strongly increased robustness in producing a dielectrophoretic force, irrespective of noise factors. However, this frequency change reduced the force magnitude, which can be increased by simply applying a higher voltage. Based on additional simulations that considered this trade-off effect, a frequency of 300 kHz is recommended for a robust TTF treatment with allowable variations. The dielectrophoretic force was almost independent of the angle of applied electric field deviated from the most effective direction by +/- 20 degrees. Furthermore, increased robustness was observed for extracellular fluid with higher conductivity and permittivity. The Taguchi method was useful for identifying robust tumor-treating field therapy conditions from a considerably small number of replicated simulations.	[Kurata, Kosaku; Takamatsu, Hiroshi] Kyushu Univ, Dept Mech Engn, Fukuoka, Japan; [Shimada, Kazuki] Kyushu Univ, Grad Sch Engn, Fukuoka, Japan	Kyushu University; Kyushu University	Kurata, K (corresponding author), Kyushu Univ, Dept Mech Engn, Fukuoka, Japan.	kurata@mech.kyushu-u.ac.jp		Kurata, Kosaku/0000-0002-3261-5363	JSPS KAKENHI [18H03520]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by JSPS KAKENHI Grant Number 18H03520. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelraof M, 2019, CARBOHYD POLYM, V211, P75, DOI 10.1016/j.carbpol.2019.01.095; ARNOLD WM, 1987, BIOCHIM BIOPHYS ACTA, V905, P454, DOI 10.1016/0005-2736(87)90475-5; Bomzon Z, 2015, IEEE ENG MED BIO, P6888, DOI 10.1109/EMBC.2015.7319976; Ermolina I, 2001, IEEE T DIELECT EL IN, V8, P253, DOI 10.1109/94.919948; Fisher R. A., 1963, Statistical tables for biological, agricultural and medical research.; Garakani SS, 2020, INT J BIOL MACROMOL, V143, P533, DOI 10.1016/j.ijbiomac.2019.12.040; GASCOYNE PRC, 1993, BIOCHIM BIOPHYS ACTA, V1149, P119, DOI 10.1016/0005-2736(93)90032-U; Gera N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125269; Giladi M, 2015, SCI REP-UK, V5, DOI 10.1038/srep18046; Giladi M, 2014, PANCREATOLOGY, V14, P54, DOI 10.1016/j.pan.2013.11.009; Gowrishankar TR, 2006, BIOELECTROCHEMISTRY, V68, P181, DOI [10.1016/j.bioelechem.2005.07.002, DOI 10.1016/J.BI0ELECHEM.2005.07.002]; Harris C. M., 1983, ELECTROANAL CHEM INT, V156, P15; HOLZEL R, 1992, BIOCHIM BIOPHYS ACTA, V1104, P195, DOI 10.1016/0005-2736(92)90150-K; HU X, 1990, BIOCHIM BIOPHYS ACTA, V1021, P191, DOI 10.1016/0005-2736(90)90033-K; Jones T. B., 2005, ELECTROMECHANICS PAR; Jones TB, 2003, IEEE ENG MED BIOL, V22, P33, DOI 10.1109/MEMB.2003.1304999; Joshi RP, 2004, IEEE T PLASMA SCI, V32, P1677, DOI 10.1109/TPS.2004.830971; Kaushik A, 2020, INT J MED ROBOT COMP, V16, DOI 10.1002/rcs.2102; Kirson ED, 2004, CANCER RES, V64, P3288, DOI 10.1158/0008-5472.CAN-04-0083; Kirson ED, 2007, P NATL ACAD SCI USA, V104, P10152, DOI 10.1073/pnas.0702916104; Ko C, 2018, INT J NUMER METH BIO, V34, DOI 10.1002/cnm.2967; Korshoej AR, 2019, PHYS MED BIOL, V64, DOI 10.1088/1361-6560/aafe54; Korshoej AR, 2018, 2018 40 ANN INT C IE; Korshoej AR, 2019, ESTIMATION TTFIELDS; Kotnik T, 1997, BIOELECTROCH BIOENER, V43, P285, DOI 10.1016/S0302-4598(97)00023-8; Kotnik T, 2006, BIOPHYS J, V90, P480, DOI 10.1529/biophysj.105.070771; Kotnik T, 2000, IEEE T BIO-MED ENG, V47, P1074, DOI 10.1109/10.855935; Li X, 2020, IEEE T BIO-MED ENG, V67, P2594, DOI 10.1109/TBME.2020.2965883; Mun EJ, 2018, CLIN CANCER RES, V24, P266, DOI 10.1158/1078-0432.CCR-17-1117; Nortemann K, 1997, J PHYS CHEM A, V101, P6864, DOI 10.1021/jp971623a; Ogunlade O, 2015, MED PHYS, V42, P170, DOI 10.1118/1.4903277; Sathitkowitchai W, 2018, 3 BIOTECH, V8, DOI 10.1007/s13205-018-1433-6; Savari M, 2015, PROTEIN EXPRES PURIF, V114, P128, DOI 10.1016/j.pep.2015.06.006; Schneiderman RS., 2013, J CLIN ONCOL, V31, pe22134, DOI [10.1200/jco.2013.31.15_suppl.e22134, DOI 10.1200/JCO.2013.31.15_SUPPL.E22134]; Sedighian H, 2018, ANAL BIOCHEM, V548, P69, DOI 10.1016/j.ab.2018.02.017; Shie AJ, 2019, BIOMED ENG ONLINE, V18, DOI 10.1186/s12938-019-0696-4; Soni VS, 2019, CANCER IMAGING, V19, DOI 10.1186/s40644-019-0259-8; Stewart DA, 2005, IEEE T BIO-MED ENG, V52, P1643, DOI 10.1109/TBME.2005.856030; Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718; Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669; Stupp R, 2012, EUR J CANCER, V48, P2192, DOI 10.1016/j.ejca.2012.04.011; Sui JB, 2020, MED ENG PHYS, V78, P64, DOI 10.1016/j.medengphy.2020.01.007; Sullivan W, 2019, MOL BIOL CELL, V30, P1635, DOI 10.1091/mbc.E19-02-0100; SUNDERMAN FW, 1949, AM J CLIN PATHOL, V19, P659; SUNDERMAN FW, 1945, AM J CLIN PATHOL, V15, P219; Taguchi G., 2005, TAGUCHIS QUALITY ENG; Tiwari PK, 2009, JPN J APPL PHYS, V48, DOI 10.1143/JJAP.48.087001; Wang YF, 2019, ONCOLOGIST, V24, pE1426, DOI 10.1634/theoncologist.2017-0603; Wenger Cornelia, 2018, IEEE Rev Biomed Eng, V11, P195, DOI 10.1109/RBME.2017.2765282; Wenger C, 2015, IEEE ENG MED BIO, P6892, DOI 10.1109/EMBC.2015.7319977; Ye H., 2012, Progress In Electromagnetics Research B, V39, P141, DOI 10.2528/PIERB11122705; Ye H, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-12	52	0	0	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0262133	10.1371/journal.pone.0262133	http://dx.doi.org/10.1371/journal.pone.0262133			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061762	gold, Green Published			2023-01-03	WOS:000791072800104
J	Kim, MY; Han, JW; Dang, QL; Kim, JC; Kim, H; Choi, GJ				Kim, Min Young; Han, Jae Woo; Quang Le Dang; Kim, Jin-Cheol; Kim, Hun; Choi, Gyung Ja			Characterization of Alternaria porri causing onion purple blotch and its antifungal compound magnolol identified from Caryodaphnopsis baviensis	PLOS ONE			English	Article							ANTIMICROBIAL ACTIVITY; FR. KEISSLER; INFECTION; BIOCONTROL; NEOLIGNANS; RESISTANCE; PRODUCTS; MANCOZEB; BOTRYTIS; LEAVES	Alternaria porri (Ellis) Clf. causes purple blotch disease on Allium plants which results in the reduction of crop yields and quality. In this study, to efficiently find natural antifungal compounds against A. porri, we optimized the culture condition for the spore production of A. porri and the disease development condition for an in vivo antifungal assay. From tested plant materials, the methanol extracts derived from ten plant species belonging to the families Cupressaceae, Fabaceae, Dipterocarpaceae, Apocynaceae, Lauraceae, and Melastomataceae were selected as potent antifungal agents against A. porri. In particular, the methanol extract of Caryodaphnopsis baviensis (Lec.) A.-Shaw completely inhibited the growth of A. porri at a concentration of 111 mu g/ml. Based on chromatographic and spectroscopic analyses, a neolignan compound magnolol was identified as the antifungal compound of the C. baviensis methanol extract. Magnolol showed a significant inhibitory activity against the spore germination and mycelial growth of A. porri with IC50 values of 4.5 and 5.4 fag/ml, respectively. Furthermore, when magnolol was sprayed onto onion plants at a concentration of 500 mu g/ml, it showed more than an 80% disease control efficacy for the purple blotch diseases. In terms of the antifungal mechanism of magnolol, we explored the in vitro inhibitory activity on individual oxidative phosphorylation complexes I-V, and the results showed that magnolol acts as multiple inhibitors of complexes I-V. Taken together, our results provide new insight into the potential of magnolol as an active ingredient with antifungal inhibitory action to control purple blotch on onions.	[Kim, Min Young; Han, Jae Woo; Kim, Hun; Choi, Gyung Ja] Korea Res Inst Chem Technol, Ctr Ecofriendly New Mat, Daejeon, South Korea; [Kim, Min Young; Kim, Jin-Cheol] Chonnam Natl Univ, Dept Agr & Biol Chem, Gwangju, South Korea; [Quang Le Dang] Vietnam Inst Ind Chem, Res & Dev Ctr Bioact Cpds, Hanoi, Vietnam; [Kim, Hun; Choi, Gyung Ja] Univ Sci & Technol, Dept Med Chem & Pharmacol, Daejeon, South Korea	Korea Research Institute of Chemical Technology (KRICT); Chonnam National University; University of Science & Technology (UST)	Kim, H; Choi, GJ (corresponding author), Korea Res Inst Chem Technol, Ctr Ecofriendly New Mat, Daejeon, South Korea.; Kim, H; Choi, GJ (corresponding author), Univ Sci & Technol, Dept Med Chem & Pharmacol, Daejeon, South Korea.	hunkim@krict.re.kr; kjchoi@krict.re.kr	Le Dang, Quang/HJA-4857-2022	Le Dang, Quang/0000-0001-7203-8081; Kim, Hun/0000-0001-6727-4469	Cooperative Research Program for Agriculture Science and Technology Development [PJ01481604]; Rural Development Administration, Republic of Korea; National Research Foundation of Korea (NRF) - Korean government (MSIT) [2019R1A2C1008103]	Cooperative Research Program for Agriculture Science and Technology Development(Rural Development Administration (RDA), Republic of Korea); Rural Development Administration, Republic of Korea(Rural Development Administration (RDA), Republic of Korea); National Research Foundation of Korea (NRF) - Korean government (MSIT)(National Research Foundation of KoreaMinistry of Science & ICT (MSIT), Republic of Korea)	This study was carried out with the support of the Cooperative Research Program for Agriculture Science and Technology Development (Project no. PJ01481604), the Rural Development Administration, Republic of Korea and the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (Project no. 2019R1A2C1008103). For this study, funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Hafez SII, 2015, EUR J PHYCOL, V50, P239, DOI 10.1080/09670262.2015.1028105; Akiyama K, 2009, BIOSCI BIOTECH BIOCH, V73, P129, DOI 10.1271/bbb.80536; Anh NH, 1997, PHYTOCHEMISTRY, V46, P569, DOI 10.1016/S0031-9422(97)00209-4; AVELING TAS, 1994, CAN J BOT, V72, P1164, DOI 10.1139/b94-142; Bang KH, 2000, ARCH PHARM RES, V23, P46, DOI 10.1007/BF02976465; Campos VAC, 2014, PEST MANAG SCI, V70, P1815, DOI 10.1002/ps.3722; Castro JC, 2017, IND CROP PROD, V97, P101, DOI 10.1016/j.indcrop.2016.12.007; Chen YH, 2019, MOLECULES, V24, DOI 10.3390/molecules24112140; Choi NH, 2009, J APPL MICROBIOL, V106, P2057, DOI 10.1111/j.1365-2672.2009.04175.x; Cui XM, 2021, POSTHARVEST BIOL TEC, V180, DOI 10.1016/j.postharvbio.2021.111596; Espinel-Ingroff A, 2011, ANTIMICROB AGENTS CH, V55, P5150, DOI 10.1128/AAC.00686-11; Gisi U, 2000, CROP PROT, V19, P863, DOI 10.1016/S0261-2194(00)00114-9; Gullino ML, 2010, PLANT DIS, V94, P1076, DOI 10.1094/PDIS-94-9-1076; GUPTA R B L, 1988, Phytophylactica, V20, P21; Hahn Matthias, 2014, Journal of Chemical Biology, V7, P133, DOI 10.1007/s12154-014-0113-1; Han JW, 2020, MYCOBIOLOGY, V48, P326, DOI 10.1080/12298093.2020.1766648; HATTORI M, 1986, CHEM PHARM BULL, V34, P158; Ho KY, 2001, PHYTOTHER RES, V15, P139, DOI 10.1002/ptr.736; Horiuchi M, 2002, J NAT PROD, V65, P1204, DOI 10.1021/np020072z; Islam M., 2020, American Journal of Plant Sciences, V11, P1847, DOI 10.4236/ajps.2020.1111132; Jiang DM, 2021, J SCI FOOD AGR, V101, P3071, DOI 10.1002/jsfa.10901; Kim B, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32956-4; Knight SC, 1997, ANNU REV PHYTOPATHOL, V35, P349, DOI 10.1146/annurev.phyto.35.1.349; Li N, 2007, REGUL TOXICOL PHARM, V49, P154, DOI 10.1016/j.yrtph.2007.06.005; Ngo LH., 2021, ASIAN J PHARM CLIN R, V14, P62; Ngo MT, 2019, J AGR FOOD CHEM, V67, P7706, DOI 10.1021/acs.jafc.9b02236; Perina FJ, 2015, PEST MANAG SCI, V71, P1371, DOI 10.1002/ps.3933; Prakasam V., 2012, Journal of Agricultural Science (Toronto), V4, P266; Runkle J, 2017, ENVIRON INT, V99, P29, DOI 10.1016/j.envint.2016.11.006; Sarrica A, 2018, PLANTA MED, V84, P1151, DOI 10.1055/a-0642-1966; Schwartz H.F., 2007, COMPENDIUM ONION GAR; SHAHIN EA, 1979, PHYTOPATHOLOGY, V69, P618, DOI 10.1094/Phyto-69-618; Slusarenko AJ, 2008, EUR J PLANT PATHOL, V121, P313, DOI 10.1007/s10658-007-9232-7; Suheri H, 2000, PLANT PATHOL, V49, P375, DOI 10.1046/j.1365-3059.2000.00458.x; Sun LM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184003; Teponno RB, 2016, NAT PROD REP, V33, P1044, DOI 10.1039/c6np00021e; Ngo MT, 2021, PEST MANAG SCI, V77, P1864, DOI 10.1002/ps.6211; VANDERWERFF H, 1985, SYST BOT, V10, P166, DOI 10.2307/2418342; Wang LQ, 2020, TOXINS, V12, DOI 10.3390/toxins12100665; Wightwick A, 2010, FUNGICIDES, P273; YAHARA S, 1991, CHEM PHARM BULL, V39, P2024, DOI 10.1248/cpb.39.2024; Yan FJ, 2015, J SCI FOOD AGR, V95, P1469, DOI 10.1002/jsfa.6845	42	0	0	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2022	17	1							e0262836	10.1371/journal.pone.0262836	http://dx.doi.org/10.1371/journal.pone.0262836			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3B4UH	35051224	Green Published, gold			2023-01-03	WOS:000827937300066
J	Li, T; Li, J; Yuan, LY; Wu, JZ; Jiang, CC; Daniels, J; Mehta, RL; Wang, MC; Yeung, OC; Jackson, T; Melody, T; Jin, SW; Yao, YG; Wu, JM; Chen, JP; Smith, FG; Lian, QQ				Li, Ting; Li, Jun; Yuan, Liyong; Wu, Jinze; Jiang, Chenchen; Daniels, Jane; Mehta, Rajnikant Laxmishanker; Wang, Mingcang; Yeung, Joyce; Jackson, Thomas; Melody, Teresa; Jin, Shengwei; Yao, Yinguang; Wu, Jimin; Chen, Junping; Smith, Fang Gao; Lian, Qingquan		RAGA Study Investigators	Effect of Regional vs General Anesthesia on Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery The RAGA Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY-PATIENTS; CONSENSUS; OUTCOMES; MODE	IMPORTANCE In adults undergoing hip fracture surgery, regional anesthesia may reduce postoperative delirium, but there is uncertainty about its effectiveness. OBJECTIVE To investigate, in older adults undergoing surgical repair for hip fracture, the effects of regional anesthesia on the incidence of postoperative delirium compared with general anesthesia. DESIGN, SETTING, AND PARTICIPANTS A randomized, allocation-concealed, open-label, multicenter clinical trial of 950 patients, aged 65 years and older, with or without preexisting dementia, and a fragility hip fracture requiring surgical repair from 9 university teaching hospitals in Southeastern China. Participants were enrolled between October 2014 and September 2018; 30-day follow-up ended November 2018. INTERVENTIONS Patients were randomized to receive either regional anesthesia (spinal, epidural, or both techniques combined with no sedation; n = 476) or general anesthesia (intravenous, inhalational, or combined anesthetic agents; n = 474). MAIN OUTCOMES AND MEASURES Primary outcome was incidence of delirium during the first 7 postoperative days. Secondary outcomes analyzed in this article include delirium severity, duration, and subtype; postoperative pain score; length of hospitalization; 30-day all-cause mortality; and complications. RESULTS Among 950 randomized patients (mean age, 76.5 years; 247 [26.8%] male). 941 were evaluable for the primary outcome (6 canceled surgery and 3 withdrew consent). Postoperative delirium occurred in 29 (6.2%) in the regional anesthesia group vs 24 (5.1%) in the general anesthesia group (unadjusted risk difference [RD], 1.1%; 95% Cl. -1.7% to 3.8%; P = .48; unadjusted relative risk [RR], 1.2 [95% CI, 0.7 to 2.0]; P = .57]). Mean severity score of delirium was 23.0 vs 24.1, respectively (unadjusted difference. -1.1; 95% Cl. -4.6 to 3.1). A single delirium episode occurred in 16 (3.4%) vs 10 (2.1%) (unadjusted RD, 1.1%; 95% CI, -1.7% to 3.9%; RR, 1.6 [95% CI, 0.7 to 3.5]). Hypoactive subtype in 11(37.9%) vs 5 (20.8%) (RD, 11.5; 95% CI, -11.0% to 35.7%; RR, 2.2 [95% CI, 0.8 to 6.3]). Median worst pain score was 0 (IQR, 0 to 20) vs 0 (IQR, 0 to 10) (difference 0; 95% CI, 0 to 0). Median length of hospitalization was 7 days (IQR, 5 to 10) vs 7 days (IQR, 6 to 10) (difference 0; 95% CI, 0 to 0). Death occurred in 8 (1.7%) vs 4 (0.9%) (unadjusted RD, -0.8%; 95% Cl, -2.2% to 0.7%; RR, 2.0 [95% CI, 0.6 to 6.5]). Adverse events were reported in 106 episodes in the regional anesthesia group and 102 in the general anesthesia group; the most frequently reported adverse events were nausea and vomiting (47 [44.3%] vs 34 [33.3%]) and postoperative hypotension (13 [12.3%] vs 10 [9.8%]). CONCLUSIONS AND RELEVANCE In patients aged 65 years and older undergoing hip fracture surgery, regional anesthesia without sedation did not significantly reduce the incidence of postoperative delirium compared with general anesthesia.	[Li, Ting; Li, Jun; Jin, Shengwei; Smith, Fang Gao; Lian, Qingquan] Wenzhou Med Univ, Dept Anesthesiol & Perioperat Med, Affiliated Hosp 2, 1111 Wenzhou Ave, Wenzhou 325038, Zhejiang, Peoples R China; [Li, Ting; Li, Jun; Jiang, Chenchen; Jin, Shengwei; Smith, Fang Gao; Lian, Qingquan] Wenzhou Med Univ, Yuying Childrens Hosp, 1111 Wenzhou Ave, Wenzhou 325038, Zhejiang, Peoples R China; [Li, Ting; Jiang, Chenchen] Wenzhou Med Univ, Clin Res Unit, Affiliated Hosp 2, Wenzhou, Zhejiang, Peoples R China; [Yuan, Liyong] Ningbo 6 Hosp, Dept Anesthesiol & Perioperat Med, Ningbo, Zhejiang, Peoples R China; [Wu, Jinze] Wenzhou Med Univ, Prov Wenzhou Hosp Zhejiang 1, Dept Anesthesiol & Perioperat Med, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; [Daniels, Jane] Univ Nottingham, Nottingham Clin Trials Unit, Nottingham, England; [Mehta, Rajnikant Laxmishanker] Univ Birmingham, Birmingham Clin Trials Unit, Birmingham, W Midlands, England; [Wang, Mingcang] Taizhou Hosp Zhejiang Prov, Dept Anesthesiol & Perioperat Med, Taizhou, Zhejiang, Peoples R China; [Yeung, Joyce] Univ Warwick, Warwick Clin Trials Unit, Warwick, England; [Yeung, Joyce; Melody, Teresa; Smith, Fang Gao] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Jackson, Thomas; Smith, Fang Gao] Univ Birmingham, Inst Inflammat & Ageing, Birmingham, W Midlands, England; [Yao, Yinguang] Lishui Cent Hosp, Lishui Municipal Peoples Hosp, Dept Anesthesia & Crit Care, Lishui, Zhejiang, Peoples R China; [Yao, Yinguang] Wenzhou Med Coll, Affiliated Hosp 5, Lishui, Zhejiang, Peoples R China; [Wu, Jimin] Lishui City Peoples Hosp, Dept Anesthesia & Crit Care, Lishui, Zhejiang, Peoples R China; [Chen, Junping] Univ Chinese Acad Sci, Hwa Mei Hosp, Dept Anesthesia & Crit Care, Ningbo 2 Hosp, Ningbo, Zhejiang, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; University of Nottingham; University of Birmingham; University of Warwick; University of Birmingham; University of Birmingham; Wenzhou Medical University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Lian, QQ (corresponding author), Wenzhou Med Univ, Dept Anesthesiol & Perioperat Med, Affiliated Hosp 2, 1111 Wenzhou Ave, Wenzhou 325038, Zhejiang, Peoples R China.; Lian, QQ (corresponding author), Wenzhou Med Univ, Yuying Childrens Hosp, 1111 Wenzhou Ave, Wenzhou 325038, Zhejiang, Peoples R China.; Smith, FG (corresponding author), Univ Birmingham, Res Labs, Inst Inflammat Arid Ageing, Birmingham Acute Care Res Ctr, Birmingham B15 2WB, W Midlands, England.	f.gaosmith@bham.ac.uk; lqq13889@163.com	; Smith, Fang G/H-8451-2018	Melody, Teresa/0000-0002-4424-8310; Yeung, Joyce/0000-0003-2950-4758; Smith, Fang G/0000-0002-8095-0609	Recruitment Program of Global Experts, China; Zhejiang Province Basic PublicWelfare Research Project [LGF21H250004]; Zhejiang Health and Family Planning Commission Programme [2014PYA015]; NIHR Senior Investigator Award; Health Commission of Zhejiang Province; Zhejiang Provincial Department of Science and Technology; Second Affiliated Hospital of Wenzhou Medical University; Yuying Children's Hospital of Wenzhou Medical University	Recruitment Program of Global Experts, China; Zhejiang Province Basic PublicWelfare Research Project; Zhejiang Health and Family Planning Commission Programme; NIHR Senior Investigator Award; Health Commission of Zhejiang Province; Zhejiang Provincial Department of Science and Technology; Second Affiliated Hospital of Wenzhou Medical University; Yuying Children's Hospital of Wenzhou Medical University	This trial was funded by Recruitment Program of Global Experts, China; Zhejiang Province Basic PublicWelfare Research Project (LGF21H250004); Zhejiang Health and Family Planning Commission Programme 2014PYA015); an NIHR Senior Investigator Award; the Health Commission of Zhejiang Province; Zhejiang Provincial Department of Science and Technology; and sponsored by the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University.	Aldecoa C, 2017, EUR J ANAESTH, V34, P192, DOI 10.1097/EJA.0000000000000594; Chan MTV, 2013, J NEUROSURG ANESTH, V25, P33, DOI 10.1097/ANA.0b013e3182712fba; Chuan A, 2020, ANAESTHESIA, V75, P63, DOI 10.1111/anae.14840; Coburn M, 2018, BRIT J ANAESTH, V120, P127, DOI 10.1016/j.bja.2017.11.015; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gao F, 2005, CRIT CARE, V9, pR764, DOI 10.1186/cc3909; Griffiths R, 2021, ANAESTHESIA, V76, P225, DOI 10.1111/anae.15291; Griffiths R, 2012, ANAESTHESIA, V67, P85, DOI 10.1111/j.1365-2044.2011.06957.x; Guay J, 2016, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000521.PUB3; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Huang MC, 2009, COMPR PSYCHIAT, V50, P81, DOI 10.1016/j.comppsych.2008.05.011; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Li T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016937; Marcantonio ER, 2001, J AM GERIATR SOC, V49, P516, DOI 10.1046/j.1532-5415.2001.49108.x; Metcalfe D, 2019, BONE JOINT J, V101B, P1015, DOI 10.1302/0301-620X.101B8.BJJ-2019-0173.R1; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; National Institute for Health and Care Excellence, 2011, HIP FRACTURE MANAGEM; Neuman MD, 2021, NEW ENGL J MED, V385, P2025, DOI 10.1056/NEJMoa2113514; O'Donnell CM, 2018, BRIT J ANAESTH, V120, P37, DOI 10.1016/j.bja.2017.09.002; Official Home of UK Legislation, MED HUM US CLIN TRIA; Parker MJ, 2015, INJURY, V46, P1562, DOI 10.1016/j.injury.2015.05.004; Patel V, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020757; Ravi B, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0111; Scottish Intercollegiate Guidelines Network, 2009, MAN HIP FRACT OLD PE; Sepulveda Esteban, 2017, Alzheimers Dement (Amst), V7, P1, DOI 10.1016/j.dadm.2016.11.002; Shelton C, 2020, BJA EDUC, V20, P142, DOI 10.1016/j.bjae.2020.02.003; Steiner LA, 2011, EUR J ANAESTH, V28, P628, DOI 10.1097/EJA.0b013e328349b7f5; Tan G., 2011, MED J PEKING UNION M, V2, P319, DOI [10.3969/j.issn.1674-9081.2011.04.008, DOI 10.3969/J.ISSN.1674-9081.2011.04.008]; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; [王彬 Wang Bin], 2013, [临床麻醉学杂志, Journal of Clinical Anesthestology], V29, P785; Wang YY, 2020, JAMA INTERN MED, V180, P17, DOI 10.1001/jamainternmed.2019.4446; Wang Z., 1989, SHANGHAI ARCH PSYCHI, V7, P108; Weinstein SM, 2018, BRIT J ANAESTH, V120, P999, DOI 10.1016/j.bja.2017.12.046; White SM, 2018, ANAESTHESIA, V73, P863, DOI 10.1111/anae.14225; White SM, 2014, ANAESTHESIA, V69, P224, DOI 10.1111/anae.12542; Woo J, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0160-7; Wu J, 2021, INT J GERIATR PSYCH, V36, P3, DOI 10.1002/gps.5408; Yang YJ, 2017, AGING CLIN EXP RES, V29, P115, DOI 10.1007/s40520-016-0541-6; Zhang CG, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003180; Zou Y, 1998, Int Psychogeriatr, V10, P303, DOI 10.1017/S1041610298005390	40	38	39	10	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	2022	327	1					50	58		10.1001/jama.2021.22647	http://dx.doi.org/10.1001/jama.2021.22647		DEC 2021	9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF7YT	34928310	Green Published			2023-01-03	WOS:000734928000004
J	Walji, S; McIsaac, W; Moineddin, R; Kalia, S; Levy, M; Tu, K; Bell, CM				Walji, Sakina; McIsaac, Warren; Moineddin, Rahim; Kalia, Sumeet; Levy, Michelle; Tu, Karen; Bell, Chaim M.			Predicting hospital readmission risk: A prospective observational study to compare primary care providers' assessments with the LACE readmission risk index	PLOS ONE			English	Article							30-DAY READMISSION; FOLLOW-UP; DEATH	Purpose This study aims to determine if the primary care provider (PCP) assessment of readmission risk is comparable to the validated LACE tool at predicting readmission to hospital. Methods A prospective observational study of recently discharged adult patients clustered by PCPs in the primary care setting. Physician readmission risk assessment was determined via a questionnaire after the PCP reviewed the hospital discharge summary. LACE scores were calculated using administrative data and the discharge summary. The sensitivity and specificity of the physician assessment and the LACE tool in predicting readmission risk, agreement between the 2 assessments and the area under receiver operating characteristic (AUROC) curves were calculated. Results 217 patient readmission encounters were included in this study from September 2017 till June 2018. The rate of readmission within 30 days was 14.7%, and 217 discharge summaries were used for analysis. The weighted kappa coefficient was 0.41 (95% CI: 0.30-0.51) demonstrating a moderate level of agreement. Sensitivity of physician assessment was 0.31 (95% CI: 0.22-0.40) and specificity was 0.80 (95% CI: 0.77-0.83). The sensitivity of the LACE assessment was 0.42 (95% CI: 0.25-0.59) and specificity was 0.79 (95% CI: 0.73-0.85). The AUROC for the LACE readmission risk was 0.65 (95% C.I. 0.55-0.76) demonstrating modest predictive power and was 0.57 (95% C.I. 0.46-0.68) for physician assessment, demonstrating low predictive power. Conclusion The LACE index shows moderate discriminatory power in identifying high-risk patients for readmission when compared to the PCP's assessment. If this score can be provided to the PCP, it may help identify patients who requires more intensive follow-up after discharge.	[Walji, Sakina; McIsaac, Warren; Levy, Michelle; Bell, Chaim M.] Mt Sinai Hosp, Ray Wolfe Dept Family Med, Toronto, ON, Canada; [Walji, Sakina; McIsaac, Warren; Moineddin, Rahim; Kalia, Sumeet; Tu, Karen] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Moineddin, Rahim] ICES, Primary Care & Hlth Syst Res Program, Toronto, ON, Canada; [Kalia, Sumeet] Univ Toronto Practice Based Res Network UTOPIAN, Toronto, ON, Canada; [Kalia, Sumeet; Tu, Karen] North York Gen Hosp, N York, ON, Canada; [Tu, Karen] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Bell, Chaim M.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Bell, Chaim M.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; North York General Hospital; University of Toronto; University of Toronto; University of Toronto	Walji, S (corresponding author), Mt Sinai Hosp, Ray Wolfe Dept Family Med, Toronto, ON, Canada.; Walji, S (corresponding author), Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.	sakina.walji@sinaihealth.ca			University of Toronto	University of Toronto(University of Toronto)	This study received grant funding from the University of Toronto's UTOPIAN Ideas to Proposal program. The funder provided support to cover the cost of conducting the study but did not have any additional role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	Allaudeen N, 2011, J GEN INTERN MED, V26, P771, DOI 10.1007/s11606-011-1663-3; ALTMAN DG, 1994, BRIT MED J, V309, P188, DOI 10.1136/bmj.309.6948.188; Amarasingham R, 2010, MED CARE, V48, P981, DOI 10.1097/MLR.0b013e3181ef60d9; ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; [Anonymous], 2007, MPA COMMITTEE REPORT; Baker GR., 2011, ENHANCING CONTINUUM; Bashir Babar, 2016, Hosp Pract (1995), V44, P123, DOI 10.1080/21548331.2016.1210472; Brooke BS, 2014, JAMA SURG, V149, P821, DOI 10.1001/jamasurg.2014.157; Canadian Institute for Health Information, 2012, ALL CAUS READM AC CA; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Conroy S, 2012, AGE AGEING, V41, P702, DOI 10.1093/ageing/afs154; Cotter PE, 2012, AGE AGEING, V41, P784, DOI 10.1093/ageing/afs073; Damery S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016921; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Donze J, 2013, JAMA INTERN MED, V173, P632, DOI 10.1001/jamainternmed.2013.3023; Epstein AM, 2009, NEW ENGL J MED, V360, P1457, DOI 10.1056/NEJMe0901006; Gruneir Andrea, 2011, Open Med, V5, pe104; Ham C, 2010, AVOIDING HOSP ADMISS; Health Quality Ontario, 2014, PRIM CAR QUAL IMPR P; Hosmer DWJ., 2013, APPL LOGISITC REGRES, V3rd; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Lee KK, 2016, MED CARE, V54, P365, DOI 10.1097/MLR.0000000000000492; Miller WD, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2833-3; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117; Viera AJ, 2005, FAM MED, V37, P360; Yazdan-Ashoori P, 2016, AM HEART J, V179, P51, DOI 10.1016/j.ahj.2016.06.007	27	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2021	16	12							e0260943	10.1371/journal.pone.0260943	http://dx.doi.org/10.1371/journal.pone.0260943			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY5KW	34910740	Green Published, gold			2023-01-03	WOS:000754828900031
J	Berman, L; Kavalier, M; Gelana, B; Tesfaw, G; Siraj, D; Shirley, D; Yilma, D				Berman, Leigh; Kavalier, Meredith; Gelana, Beshea; Tesfaw, Getnet; Siraj, Dawd; Shirley, Daniel; Yilma, Daniel			Utilizing the SEIPS model to guide hand hygiene interventions at a tertiary hospital in Ethiopia	PLOS ONE			English	Article							PATIENT SAFETY; INFECTION; STRATEGY; NURSES	We aimed to apply the Systems Engineering Initiative for Patient Safety (SEIPS) model to increase effectiveness and sustainability of the World Health Organization's (WHOs) hand hygiene (HH) guidelines within healthcare systems. Our cross-sectional, mixed-methods study took place at Jimma University Medical Center (JUMC), a tertiary care hospital in Jimma, Ethiopia, between November 2018 and August 2020 and consisted of three phases: baseline assessment, intervention, and follow-up assessment. We conducted questionnaires addressing HH knowledge and attitudes, interviews to identify HH barriers and facilitators within the SEIPS framework, and observations at the WHO's 5 moments of HH amongst healthcare workers (HCWs) at JUMC. We then implemented HH interventions based on WHO guidelines and results from our baseline assessment. Follow-up HH observations were conducted months later during the Covid-19 pandemic. 250 HCWs completed questionnaires with an average knowledge score of 61.4% and attitude scores indicating agreement that HH promotes patient safety. Interview participants cited multiple barriers to HH including shortages and location of HH materials, inadequate training, minimal Infection Prevention Control team presence, and high workload. We found an overall baseline HH compliance rate of 9.4% and a follow-up compliance rate of 72.1%. Drastically higher follow-up compared to baseline compliance rates were likely impacted by our HH interventions and Covid-1 9. HCWs showed motivation for patient safety despite low HH knowledge. Utilizing the SEIPS model helped identify institution-specific barriers that informed targeted interventions beyond WHO guidelines aimed at increasing effectiveness and sustainability of HH efforts.	[Berman, Leigh] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Kavalier, Meredith; Siraj, Dawd; Shirley, Daniel] Univ Wisconsin, Dept Med, Div Infect Dis, Sch Med & Publ Hlth, Madison, WI USA; [Gelana, Beshea] Jimma Univ, Dept Hlth Policy & Management, Jimma, Ethiopia; [Tesfaw, Getnet] Jimma Univ, Sch Med Lab Sci, Jimma, Ethiopia; [Yilma, Daniel] Jimma Univ, Dept Internal Med, Jimma, Ethiopia; [Yilma, Daniel] Jimma Univ, Clin Trial Unit, Jimma, Ethiopia	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Jimma University; Jimma University; Jimma University; Jimma University	Berman, L (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA.	lrberman@wisc.edu	Shirley, Daniel/GLT-7316-2022; Yilma, Daniel/AAJ-2072-2021	Yilma, Daniel/0000-0001-6058-2696; Deressa, Beshea/0000-0003-0457-846X	Jimma University Medical Center; Jimma University Clinical Trial Unit; University of Wisconsin School of Medicine and Public Health Shapiro Summer Research Program; University of Wisconsin-Madison Global Health Institute	Jimma University Medical Center; Jimma University Clinical Trial Unit; University of Wisconsin School of Medicine and Public Health Shapiro Summer Research Program; University of Wisconsin-Madison Global Health Institute	This project is supported by Jimma University Medical Center (DY), the Jimma University Clinical Trial Unit (DY), and the University of Wisconsin School of Medicine and Public Health Shapiro Summer Research Program (LB, summerresearch.med.wisc.edu). This project was also partially funded through a Faculty and Staff Travel Award from the University of Wisconsin-Madison Global Health Institute (DSh). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allegranzi B, 2007, INFECT CONT HOSP EP, V28, P1323, DOI 10.1086/521656; Allegranzi B, 2013, LANCET INFECT DIS, V13, P843, DOI 10.1016/S1473-3099(13)70163-4; Allegranzi B, 2011, LANCET, V377, P228, DOI 10.1016/S0140-6736(10)61458-4; Ataiyero Y, 2019, AM J INFECT CONTROL, V47, P565, DOI 10.1016/j.ajic.2018.09.014; Awoke N, 2018, NURS RES PRACT, V2018, DOI 10.1155/2018/2654947; Baubie K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026193; Berman L., 2021, OPEN SCI FRAMEWORK R; Carayon P, 2006, QUAL SAF HEALTH CARE, V15, pI50, DOI 10.1136/qshc.2005.015842; Doronina O, 2017, J NURS SCHOLARSHIP, V49, P143, DOI 10.1111/jnu.12274; Gould DJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005186.pub4; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Holmen IC, 2017, AM J INFECT CONTROL, V45, P855, DOI 10.1016/j.ajic.2017.04.006; Huis A, 2013, INT J NURS STUD, V50, P464, DOI 10.1016/j.ijnurstu.2012.08.004; Institute for Healthcare Improvement, 2006, HOW TO GUID IMPR HAN; Kenzie M., 2019, INT J INFECT CONTROL, V15, DOI [10.3396/ijic.v15i3.18912, DOI 10.3396/IJIC.V15I3.18912]; Kolola T, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-017-0268-y; Loftus MJ, 2019, INT J INFECT DIS, V86, P25, DOI 10.1016/j.ijid.2019.06.002; Luangasanatip N, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3728; Muller SA, 2020, ANTIMICROB RESIST IN, V9, DOI 10.1186/s13756-020-00723-8; Pfafflin F, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-016-0165-9; Pincock T, 2012, AM J INFECT CONTROL, V40, pS18, DOI 10.1016/j.ajic.2012.02.008; Pittet D, 2004, J HOSP INFECT, V58, P1, DOI 10.1016/j.jhin.2004.06.002; Salmon S, 2015, J HOSP INFECT, V91, P95, DOI 10.1016/j.jhin.2015.04.011; Scheithauer S, 2017, J HOSP INFECT, V97, P11, DOI 10.1016/j.jhin.2017.02.013; Schmitz K, 2014, ANTIMICROB RESIST IN, V3, DOI 10.1186/2047-2994-3-8; Uneke CJ, 2014, BRAZ J INFECT DIS, V18, P21, DOI 10.1016/j.bjid.2013.04.006; Vermeil T, 2019, J HOSP INFECT, V101, P383, DOI 10.1016/j.jhin.2018.09.003; WHO, 2011, WHO LIB CAT PUBL DAT; Wong SC, 2020, J HOSP INFECT, V105, P779, DOI 10.1016/j.jhin.2020.05.016; World Health Organization, 2009, WHO GUID HAND HYG HL; Zhang S, 2019, INT J NURS PRACT, V25, DOI 10.1111/ijn.12720	31	0	0	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2021	16	10							e0258662	10.1371/journal.pone.0258662	http://dx.doi.org/10.1371/journal.pone.0258662			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ6CS	34710135	Green Published, gold			2023-01-03	WOS:000755563200028
J	Koopmans, SJ; van Beusekom, HMM; van der Staay, FJ; Binnendijk, G; Hulst, M; Mroz, Z; Ackermans, MT; Benthem, L				Koopmans, Sietse J.; van Beusekom, Heleen M. M.; van der Staay, F. Josef; Binnendijk, Gisabeth; Hulst, Marcel; Mroz, Zlaw; Ackermans, Mariette T.; Benthem, Lambertus			Beneficial effects of a plant-fish oil, slow carbohydrate diet on cardio-metabolic health exceed the correcting effects of metformin-pioglitazone in diabetic pigs fed a fast-food diet	PLOS ONE			English	Article							TRADITIONAL MEDITERRANEAN DIET; LIFE-STYLE INTERVENTION; INSULIN-RESISTANCE; INTESTINAL-MUCOSA; TYPE-2; ATHEROSCLEROSIS; PREVENTION; EXPRESSION; MELLITUS; GLUCOSE	Background Lifestyle influences endocrine, metabolic and cardiovascular homeostasis. This study investigated the impact of diet and oral anti-diabetic medication on cardio-metabolic health in human-sized diabetic pigs. Methods After a growing pre-phase from similar to 30 to similar to 69 kg during which domestic pigs were fed either a low fat, low sucrose diet (group A) or a fast food-type diet elevated in lard (15%) and sucrose (40%) (group B), the pigs were subdivided in 5 groups (n = 7-8 pigs per group). Group 1, normal pigs from group A on a low fat, low sugar (L) pig diet and group 2, normal pigs from group B on a high lard (25%), sucrose-fructose (40%), cholesterol (1%) fast food-type (F) diet. Diabetes (D) was induced in group B pigs by streptozotocin and group 3 received the F diet (DF), group 4 received the F diet with Anti-diabetic medication metformin (2 g.day(-1) )pioglitazone (40 mg.day(-1)) (DFA) and group 5 switched to a Plant-Fish oil (25%), Slowly digestible starch (40%) diet (DPFS). The F and PFS diets were identical for fat, carbohydrate and protein content but only differed in fat and carbohydrate composition. The 5 pig groups were followed up for 7 weeks until reaching similar to 120 kg. Results In normal pigs, the F diet predisposed to several abnormalities related to metabolic syndrome. Diabetes amplified the inflammatory and cardiometabolic abnormalities of the F but both oral FA medication and the PFS diet partially corrected these abnormalities (mean +/- SEM) as follows: Fasting plasma TNF-alpha (pg.ml(-1)) and NEFA (mmol.l(-1)) concentrations were high (p<0.02) in DF (193 +/- 55 and 0.79 +/- 0.16), intermediate in DFA (136 +/- 40 and 0.57 +/- 012) and low in DPFS pigs (107 +/- 31 and 0.48 +/- 0.19). Meal intolerance (response over fasting) for glucose and triglycerides (area under the curve, mmol.h(-1)) and for lactate (3-h postprandial, mmol.l(-1)) was high (p<0.03) in DF (489 +/- 131, 8.6 +/- 4.8 and 2.2 +/- 0.6), intermediate in DFA (276 +/- 145, 1.4 +/- 1.1 and 1.6 +/- 0.4) and low in DPFS (184 +/- 62, 0.7 +/- 1.8 and 0.1 +/- 0.1). Insulin-mediated glucose disposal (mg.kg(-1).min(-1)) showed a numerical trend (p = NS): low in DF (6.9 +/- 2.2), intermediate in DFA (8.2 +/- 1.3) and high in DPFS pigs (10.4 +/- 2.7). Liver weight (g. kg(-1) body weight) and liver triglyceride concentration (g.kg(-1) liver) were high (p<0.001) in DF (23.8 +/- 2.0 and 69 +/- 14), intermediate in DFA (21.1 +/- 2.0 and 49 +/- 15) and low in DPFS pigs (16.4 +/- 0.7 and 13 +/- 2.0). Aorta fatty streaks were high (p<0.01) in DF (16.4 +/- 5.7%), intermediate in DFA (7.4 +/- 4.5%) and low in DPFS pigs (0.05 +/- 0.02%). Conclusion This translational study using pigs with induced type 2 diabetes provides evidence that a change in nutritional life style from fast food to a plant-fish oil, slowly digestible starch diet can be more effective than sole anti-diabetic medication.	[Koopmans, Sietse J.; Binnendijk, Gisabeth; Hulst, Marcel] Wageningen Univ & Res, Wageningen Livestock Res, Wageningen, Netherlands; [van Beusekom, Heleen M. M.] Erasmus MC, Expt Cardiol, Rotterdam, Netherlands; [van der Staay, F. Josef] Univ Utrecht, Fac Vet, Dept Farm Anim Hlth, Utrecht, Netherlands; [Hulst, Marcel] Wageningen Biovet Res, Lelystad, Netherlands; [Mroz, Zlaw] Univ Life Sci, Dept Anim Sci & Bioecon, Lublin, Poland; [Ackermans, Mariette T.] Amsterdam UMC, Clin Chem, Endocrine Lab, Location AMC, Amsterdam, Netherlands; [Benthem, Lambertus] Inorbit Therapeut AB, Gothenburg, Sweden	Wageningen University & Research; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Wageningen University & Research; University of Amsterdam	Koopmans, SJ (corresponding author), Wageningen Univ & Res, Wageningen Livestock Res, Wageningen, Netherlands.	sietsejan.koopmans@wur.nl		van der Staay, F. Josef/0000-0002-8704-3366				ADER M, 1985, DIABETES, V34, P1092, DOI 10.2337/diabetes.34.11.1092; Aroda VR, 2017, DIABETOLOGIA, V60, P1601, DOI 10.1007/s00125-017-4361-9; Billingsley HE, 2018, NUTR DIABETES, V8, DOI 10.1038/s41387-018-0025-1; Camargo A, 2014, GENES NUTR, V9, DOI 10.1007/s12263-014-0409-3; CASTELLO A, 1995, BIOCHEM J, V309, P271, DOI 10.1042/bj3090271; Roldan CC, 2019, CLIN INVEST ARTERIOS, V31, P210, DOI 10.1016/j.arteri.2019.03.005; Centraal Veevoeder Bureau, 2011, CVB TABL PIGS; Cotton JW., 1998, ANAL WITHIN SUBJECTS; da Silva CS, 2014, ANIMAL, V8, P1402, DOI 10.1017/S1751731114001116; de Groot J, 2005, IMMUNOLOGY, V115, P495, DOI 10.1111/j.1365-2567.2005.02184.x; DeFronzo RA, 2019, DIABETES VASC DIS RE, V16, P133, DOI 10.1177/1479164118825376; Derosa G, 2007, CORE EVID, V2, P189; Dixon JL, 1999, ARTERIOSCL THROM VAS, V19, P2981, DOI 10.1161/01.ATV.19.12.2981; DPP Res Grp, 2002, DIABETES CARE, V25, P2165; Dyer J, 2002, AM J PHYSIOL-GASTR L, V282, pG241, DOI 10.1152/ajpgi.00310.2001; Dziegiel N, 2018, POSTEP HIG MED DOSW, V72, P1032, DOI 10.5604/01.3001.0012.7815; EGGSTEIN M, 1966, KLIN WOCHENSCHR, V44, P262, DOI 10.1007/BF01747716; Ellulu MS, 2015, INFLAMMOPHARMACOLOGY, V23, P79, DOI 10.1007/s10787-015-0228-1; Esposito K, 2017, ENDOCRINE, V56, P27, DOI 10.1007/s12020-016-1018-2; Funtikova AN, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0107-z; Gerrity RG, 2001, DIABETES, V50, P1654, DOI 10.2337/diabetes.50.7.1654; Golay A, 2008, INT J OBESITY, V32, P61, DOI 10.1038/sj.ijo.0803695; Jenkins AJ, 2018, CURR OPIN LIPIDOL, V29, P346, DOI 10.1097/MOL.0000000000000532; Karamanos B, 2002, EUR J CLIN NUTR, V56, P983, DOI 10.1038/sj.ejcn.1601413; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kinaan M, 2015, MED PRIN PRACT, V24, P401, DOI 10.1159/000381643; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Ko KD, 2017, J OBES METAB SYNDR, V26, P102, DOI 10.7570/jomes.2017.26.2.102; Koopmans SJ, 2006, HORM METAB RES, V38, P607, DOI 10.1055/s-2006-951306; Koopmans SJ, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-64; Koopmans SJ, 2006, METABOLISM, V55, P960, DOI 10.1016/j.metabol.2006.03.004; Koopmans SJ, 2015, EUR J PHARMACOL, V759, P231, DOI 10.1016/j.ejphar.2015.03.044; KOOPMANS SJ, 1992, BIOCHIM BIOPHYS ACTA, V1115, P230, DOI 10.1016/0304-4165(92)90059-4; Large V, 1999, DIABETES, V48, P1251, DOI 10.2337/diabetes.48.6.1251; Libby P, 2007, AM J CARDIOL, V99, p27B, DOI 10.1016/j.amjcard.2006.11.004; Maggio ABR, 2008, J PEDIATR-US, V152, P489, DOI 10.1016/j.jpeds.2007.10.042; NAKAMURA T, 1994, ATHEROSCLEROSIS, V107, P239, DOI 10.1016/0021-9150(94)90025-6; Niewold TA, 2005, VET IMMUNOL IMMUNOP, V105, P317, DOI 10.1016/j.vetimm.2005.02.010; Niewold TA, 2007, MOL IMMUNOL, V44, P1316, DOI 10.1016/j.molimm.2006.05.013; Ochi E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050552; Orchard TJ, 2005, ANN INTERN MED, V142, P611, DOI 10.7326/0003-4819-142-8-200504190-00009; Payne RW., 2017, REFERENCE MANUAL; Roura E, 2016, NUTR RES REV, V29, P60, DOI 10.1017/S0954422416000020; Sacks HS, 2011, DIABETES CARE, V34, P730, DOI 10.2337/dc10-2083; Salas-Salvado J, 2016, J NUTR, V146, p920S, DOI 10.3945/jn.115.218487; Schmidt S, 2005, CZECH J FOOD SCI, V23, P93, DOI 10.17221/3377-CJFS; Sorop O, 2016, AM J PHYSIOL-HEART C, V311, pH1339, DOI 10.1152/ajpheart.00458.2015; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; Suzuki M, 2002, CLIN EXP PHARMACOL P, V29, P269, DOI 10.1046/j.1440-1681.2002.03644.x; te Pas MFW, 2018, COMPARATIVE MED, V68, P286, DOI 10.30802/AALAS-CM-17-000099; te Pas MFW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073087; Trichopoulou A, 1997, NUTR REV, V55, P383, DOI 10.1111/j.1753-4887.1997.tb01578.x; Trichopoulou A, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-112; Tuberoso CIG, 2007, FOOD CHEM, V103, P1494, DOI 10.1016/j.foodchem.2006.08.014; Turk JR, 2003, J APPL PHYSIOL, V95, P1301, DOI 10.1152/japplphysiol.00342.2003; Wang HH, 2004, CARDIOVASC RES, V61, P169, DOI 10.1016/j.cardiores.2003.11.002; Winer B. J., 1971, STAT PRINCIPLES EXPT, V2; Wing R, 2013, NEW ENGL J MED, V369, P145, DOI 10.1056/NEJMoa1212914; WING RR, 1994, DIABETES CARE, V17, P30, DOI 10.2337/diacare.17.1.30; Yubero-Serrano EM, 2015, AM J CLIN NUTR, V102, P1509, DOI 10.3945/ajcn.115.111286; Yuen A, 2010, AUST NZ J PUBL HEAL, V34, P172, DOI 10.1111/j.1753-6405.2010.00503.x; Zhao WP, 2009, J IMMUNOL, V183, P2729, DOI 10.4049/jimmunol.0804341	62	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2021	16	10							e0257299	10.1371/journal.pone.0257299	http://dx.doi.org/10.1371/journal.pone.0257299			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YN0PH	34669714	Green Published, gold			2023-01-03	WOS:000746969100008
J	Sugiura, M; Ishibashi, R; Abe, T; Nouchi, R; Honda, A; Sato, S; Muramoto, T; Imamura, F; Sarker, MNI				Sugiura, Motoaki; Ishibashi, Ryo; Abe, Tsuneyuki; Nouchi, Rui; Honda, Akio; Sato, Shosuke; Muramoto, Toshiaki; Imamura, Fumihiko; Sarker, Md Nazirul Islam			Self-help and mutual assistance in the aftermath of a tsunami: How individual factors contribute to resolving difficulties	PLOS ONE			English	Article							SOCIAL VULNERABILITY; POSTTRAUMATIC GROWTH; DISASTER; EXPERIENCE	Self-aid and mutual assistance among victims are critical for resolving difficulties in the immediate aftermath of a disaster, but individual facilitative factors for such resolution processes are poorly understood. To identify such individual factors in the background (i.e., disaster damage and demographic) and personality domains considering different types of difficulty and resolution, we analyzed survey data collected in the 3-year aftermath of the 2011 Great East Japan Earthquake and Tsunami. We first identified major types of difficulty using a cluster analysis of 18 difficulty domains and then explored individual factors that facilitated six types of resolution (self-help, request for help, help from family, help from an acquaintance, help through cooperation, and public assistance) of these difficulty types. We identified general life difficulties and medico-psychological difficulties as two broad types of difficulty; disaster damage contributed to both types, while some personality factors (e.g., neuroticism) exacerbated the latter. Disaster damage hampered self-resolution and forced a reliance on resolution through cooperation or public assistance. On the other hand, some demographic factors, such as being young and living in a three-generation household, facilitated resolution thorough the family. Several personality factors facilitated different types of resolution, primarily of general life difficulties; the problem-solving factor facilitated self-resolution, altruism, or stubbornness resolutions through requests, leadership resolution through acquaintance, and emotion-regulation resolution through public assistance. Our findings are the first to demonstrate the involvement of different individual, particularly personality, factors in survival in the complex social dynamics of this disaster stage. They may contribute to disaster risk mitigation, allowing sophisticated risk evaluation and community resilience building.	[Sugiura, Motoaki; Sato, Shosuke; Muramoto, Toshiaki; Imamura, Fumihiko] Tohoku Univ, Int Res Inst Disaster Sci, Sendai, Miyagi, Japan; [Sugiura, Motoaki; Ishibashi, Ryo; Nouchi, Rui] Tohoku Univ, Inst Dev Aging & Canc, Sendai, Miyagi, Japan; [Sugiura, Motoaki; Ishibashi, Ryo; Nouchi, Rui] Tohoku Univ, Smart Aging Res Ctr, Sendai, Miyagi, Japan; [Abe, Tsuneyuki] Tohoku Univ, Grad Sch Arts & Letters, Sendai, Miyagi, Japan; [Honda, Akio] Shizuoka Inst Sci & Technol, Fac Informat, Fukuroi, Japan	Tohoku University; Tohoku University; Tohoku University; Tohoku University	Sugiura, M (corresponding author), Tohoku Univ, Int Res Inst Disaster Sci, Sendai, Miyagi, Japan.; Sugiura, M (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Sendai, Miyagi, Japan.; Sugiura, M (corresponding author), Tohoku Univ, Smart Aging Res Ctr, Sendai, Miyagi, Japan.	sugiura@tohoku.ac.jp	Nouchi, Rui/GQH-1608-2022; Abe, Tsuneyuki/ABD-9727-2020	Abe, Tsuneyuki/0000-0001-9694-357X; Honda, Akio/0000-0002-5399-4016; Sugiura, Motoaki/0000-0001-5412-0380; Nouchi, Rui/0000-0002-2078-9518	International Research Institute of Disaster Science, Tohoku University [H24-A-5, H25-A-4]; Topic-Setting Program to Advance Cutting-Edge Humanities and Social Sciences Research [H24-A-5, H25-A-4]; Japan Society for the Promotion of Science [17H06219]	International Research Institute of Disaster Science, Tohoku University; Topic-Setting Program to Advance Cutting-Edge Humanities and Social Sciences Research; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	M.S. was supported by Special Project Researches (http://irides.tohoku.ac.jp/topics_ project/index.html) (H24-A-5 and H25-A-4 to MS) from International Research Institute of Disaster Science, Tohoku University, and Topic-Setting Program to Advance Cutting-Edge Humanities and Social Sciences Research and KAKENHI 17H06219 from Japan Society for the Promotion of Science (https://www.jsps.go.jp/english/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramson DM, 2010, DISASTER MED PUBLIC, V4, pS46, DOI 10.1001/dmp.2010.14; Alexander D., 2016, HLTH EMERGENCIES DIS, V4, P215, DOI [10.18869/nrip.hdq.1.4.215, DOI 10.18869/NRIP.HDQ.1.4.215]; [Anonymous], 2015, AUST J EMERG MANAG, V30, P9; Aota R., 2012, JAP SOC INNOV J, V2, P1, DOI [10.12668/jsij.2.1, DOI 10.12668/JSIJ.2.1]; Armstrong RA, 2014, OPHTHAL PHYSL OPT, V34, P502, DOI 10.1111/opo.12131; Assheuer T, 2013, ERDKUNDE, V67, P21, DOI 10.3112/erdkunde.2013.01.03; BOWLER RM, 1994, J TRAUMA STRESS, V7, P601, DOI 10.1007/BF02103010; Brodie M, 2006, AM J PUBLIC HEALTH, V96, P1402, DOI 10.2105/AJPH.2005.084475; Chandra YA., 2020, HLTH EMERGENCY DISAS, V7, P9, DOI [10.24298/hedn.2018-0010, DOI 10.24298/HEDN.2018-0010]; Chatterjee M, 2010, MITIG ADAPT STRAT GL, V15, P337, DOI 10.1007/s11027-010-9221-6; Cutter SL, 2003, SOC SCI QUART, V84, P242, DOI 10.1111/1540-6237.8402002; Galea S, 2005, EPIDEMIOL REV, V27, P78, DOI 10.1093/epirev/mxi003; Gall M, 2015, INT J DISAST RISK RE, V12, P255, DOI 10.1016/j.ijdrr.2015.01.010; Goldmann E, 2014, ANNU REV PUBL HEALTH, V35, P169, DOI 10.1146/annurev-publhealth-032013-182435; Gosling SD, 2003, J RES PERS, V37, P504, DOI 10.1016/S0092-6566(03)00046-1; Horigome Y., 2015, J POLICY STUDIES B P, V17, P21; Ishibashi R, 2019, GEOSCIENCES, V9, DOI 10.3390/geosciences9090366; Islam MS, 2005, PREHOSPITAL DISASTER, V20, P423, DOI 10.1017/S1049023X00003034; Kawano T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009711; Mishra S, 2009, J PAC RIM PSYCHOL, V3, P11, DOI 10.1375/prp.3.1.11; Mustafa D, 2011, DISASTERS, V35, P62, DOI 10.1111/j.1467-7717.2010.01193.x; Norris FH, 2002, PSYCHIATRY, V65, P207, DOI 10.1521/psyc.65.3.207.20173; Oshio A., 2012, JAPANESE J PERSONALI, V21, P40, DOI [DOI 10.2132/PERSONALITY.21.40, https://doi.org/10.2132/personality.21.40]; Rodriguez H., 2006, DISASTER PREVENTION, V15, P163, DOI [10.1108/09653560610654310, DOI 10.1108/09653560610654310]; Rufat S, 2015, INT J DISAST RISK RE, V14, P470, DOI 10.1016/j.ijdrr.2015.09.013; Sattler DN, 2000, J APPL SOC PSYCHOL, V30, P1396, DOI 10.1111/j.1559-1816.2000.tb02527.x; SIMS JH, 1972, SCIENCE, V176, P1386, DOI 10.1126/science.176.4042.1386; Staples SL, 1996, AM PSYCHOL, V51, P143, DOI 10.1037/0003-066X.51.2.143; Sugiura M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228875; Sugiura M, 2019, GEOSCIENCES, V9, DOI 10.3390/geosciences9080326; Sugiura M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130349; Tabachnick BG., 2007, MULTIPLE REGRESSION, V7th, P99; Tatsuki S., 2004, J SOCIAL SAFETY SCI, V6, P2004, DOI [10.11314/jisss.6.251, DOI 10.11314/JISSS.6.251]; Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1002/jts.2490090305; Tomasello M, 2013, ANNU REV PSYCHOL, V64, P231, DOI 10.1146/annurev-psych-113011-143812; Ungar M, 2012, SOCIAL ECOLOGY OF RESILIENCE: A HANDBOOK OF THEORY AND PRACTICE, P1, DOI 10.1007/978-1-4614-0586-3; Zoellner T, 2006, CLIN PSYCHOL REV, V26, P626, DOI 10.1016/j.cpr.2006.01.008	37	1	1	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2021	16	10							e0258325	10.1371/journal.pone.0258325	http://dx.doi.org/10.1371/journal.pone.0258325			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YV0SF	34618878	Green Published, gold			2023-01-03	WOS:000752443000061
J	Irungu, BN; Koech, LC; Ondicho, JM; Keter, LK				Irungu, Beatrice Njeri; Koech, Lilian C.; Ondicho, Joyce M.; Keter, Lucia K.			Quality assessment of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya	PLOS ONE			English	Article							PROPHYLAXIS; TABLETS	Introduction Quality of medicines in both developed and developing countries is sometimes compromised due to infiltration of counterfeit, substandard or degraded medicines into the markets. It is a public health concern as poor quality medicines endanger public health where patients are exposed to chemical toxins and/or sub-therapeutic doses. This could lead to reduced treatment efficacy and promote development of drug resistance. Co-trimoxazole, a fixed dose combination of sulfamethoxazole and trimethoprim, is a broad spectrum for bacterial diseases and is also used as a prophylaxis for opportunistic infections in HIV infected individuals. This study evaluated quality of selected co-trimoxazole suspension brands marketed in Nairobi County, Kenya. Methods A total of 106 samples were collected, categorized into 15 brands and evaluated for active pharmaceutical ingredient content (API) and pH following United States Pharmacopeia. Assay for API was conducted using High Performance Liquid Chromatography. Results were compared with pharmacopeia references. Visual examination of labels and confirmation of retention status of the brands with Pharmacy and Poisons Board retention register was carried out. Results The samples were primarily of local origin (86.7%). On October 23, 2019, retention status of six of the fifteen brands documented were no longer listed in the Pharmacy and Poisons Board retention register. Of the 106 samples tested 70.6% and 86.8% were compliant with United States Pharmacopeia (USP) specifications for pH and API respectively while 84.0% adhered to packaging and labelling requirements. Conclusion This study has demonstrated that majority of co-trimoxazole suspensions tested were compliant with USP requirements. Additionally, it has provided evidence of poor quality co-trimoxazole medicines that could compromise treatment of infectious diseases in children. This emphasizes the need for regular quality assurance tests to ensure only quality medicines are in the market.	[Irungu, Beatrice Njeri; Koech, Lilian C.; Ondicho, Joyce M.; Keter, Lucia K.] Ctr Tradit Med & Drug Res, Kenya Med Res Inst, Nairobi, Kenya	Kenya Medical Research Institute	Irungu, BN (corresponding author), Ctr Tradit Med & Drug Res, Kenya Med Res Inst, Nairobi, Kenya.	Blrungu@kemri.org		/0000-0002-9966-0572	Wellcome Trust; Health Research Capacity Strengthening Postdoctoral Grant [080883/E/06/D]	Wellcome Trust(Wellcome TrustEuropean Commission); Health Research Capacity Strengthening Postdoctoral Grant	BNI thanks Wellcome Trust; Health Research Capacity Strengthening Postdoctoral Grant for the funding (080883/E/06/D). https://wellcome.org/grant-funding/schemes The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abuga K, 2013, E CENTRAL AFRICAN J; Abuye H, 2020, INFECT DRUG RESIST, V13, P691, DOI 10.2147/IDR.S234684; Amin AA, 2005, J CLIN PHARM THER, V30, P559, DOI 10.1111/j.1365-2710.2005.00685.x; [Anonymous], 2017, USP 40 NF 35, V35, P4061; Atemnkeng MA, 2007, TROP MED INT HEALTH, V12, P68, DOI 10.1111/j.1365-3156.2006.01769.x; Bourke CD, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav0537; Chikowe I, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0637-z; Daniels B, 2019, LANCET GLOB HEALTH, V7, pE1717, DOI 10.1016/S2214-109X(19)30422-X; Evans C, 2017, LANCET GLOB HEALTH, V5, pE468, DOI 10.1016/S2214-109X(17)30147-X; Ewen M, 2018, HLTH ACTION INT, V4, P1; Fadeyi I, 2015, AM J TROP MED HYG, V92, P87, DOI 10.4269/ajtmh.14-0539; Frimpong G, 2018, J TROP MED-US, V2018, DOI 10.1155/2018/1494957; Goldberg E, 2012, CLIN MICROBIOL INFEC, V18, P8, DOI 10.1111/j.1469-0691.2011.03613.x; Hadi U, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-203; Hetzel MW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096810; Jiang JJ, 2019, EMERG MICROBES INFEC, V8, P367, DOI 10.1080/22221751.2019.1588078; Johnston A, 2014, BRIT J CLIN PHARMACO, V78, P218, DOI 10.1111/bcp.12298; Kaale E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165785; Kenya National Bureau of Statistics, 2019, KEN POP HOUS CENS RE; Khuluza F, 2014, MALAWI MED J, V26, P38; Koech LC, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7091278; Lawal MG, 2019, ASIAN J PHARM RES DE, V7, P6; Minyeto D, 2014, INVITRO COMP EVALUAT; Morgan, 1970, KENYA PROJECTS ORG, P1; Mostafa SA, 2018, J STAT THEORY PRACT, V12, P290, DOI 10.1080/15598608.2017.1353456; Nassiri R., 2019, PHARM DRUG ACTION ST, V2019, P1; Ndwigah S, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2482-3; Opuni KFM, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-3045-y; Organization WH, 2018, WHO REP SURV ANT CON; Orwa J, 2008, QUALITY SOME PHARM P, V2008; Petersen A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184165; Pharmacy and Poisons Board, 2010, REG DRUGS GUID SUBM, P1; Rahman MS, 2019, AM J TROP MED HYG, V101, P1018, DOI 10.4269/ajtmh.19-0247; Sanada T, 2020, FORENSIC SCI INT, V307, DOI 10.1016/j.forsciint.2020.110143; Schiavetti B, 2018, AM J TROP MED HYG, V98, P894, DOI 10.4269/ajtmh.17-0732; Shankar P.R., 2017, J CHITWAN MED COLL, V6, P68, DOI [10.3126/jcmc.v6i4.16721, DOI 10.3126/JCMC.V6I4.16721]; Simonetti R., 2016, MAKING MED AFRICA PO, P25; Thoithi GN, 2008, E CENTRAL AFRICAN J, V11; Wafula Francis, 2017, Drugs Real World Outcomes, V4, P53, DOI 10.1007/s40801-016-0100-7; WHO,, 2015, WHO GUID IMPL WHO CE; World Bank, 2018, KEN EC UPD POL OPT A, DOI 10.1596/29676; World Bank Group, 2006, DEC MEET DRAFT REP K; World Health Organization, 2002, WHO TECHN REP SER, V902, P120; Yoshida N, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-13	44	0	0	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2021	16	9							e0257625	10.1371/journal.pone.0257625	http://dx.doi.org/10.1371/journal.pone.0257625			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YS4WS	34551002	gold, Green Published			2023-01-03	WOS:000750679800032
J	Zampieri, FG; Machado, FR; Biondi, RS; Freitas, FGR; Veiga, VC; Figueiredo, RC; Lovato, WJ; Amendola, CP; Assuncao, MSC; Serpa-Neto, A; Paranhos, JLR; Andrade, J; Godoy, MMG; Romano, E; Dal Pizzol, F; Silva, EB; Silva, MML; Machado, MCV; Malbouisson, LMS; Manoel, ALO; Thompson, MM; Figueiredo, LM; Soares, RM; Miranda, TA; de Lima, LM; Santucci,, EV; Correa, TD; Azevedo, LCP; Kellum, JA; Damiani, LP; Silva, NB; Cavalcanti, AB				Zampieri, Fernando G.; Machado, Flavia R.; Biondi, Rodrigo S.; Freitas, Flavio G. R.; Veiga, Viviane C.; Figueiredo, Rodrigo C.; Lovato, Wilson J.; Amendola, Cristina P.; Assuncao, Murillo S. C.; Serpa-Neto, Ary; Paranhos, Jorge L. R.; Andrade, Jose; Godoy, Michele M. G.; Romano, Edson; Dal Pizzol, Felipe; Silva, Emerson B.; Silva, Miqueias M. L.; Machado, Miriam C. V.; Malbouisson, Luiz Marcelo S.; Manoel, Airton L. O.; Thompson, Marlus M.; Figueiredo, Lanese M.; Soares, Rafael M.; Miranda, Tamiris A.; de Lima, Lucas M.; Santucci, Eliana V.; Correa, Thiago D.; Azevedo, Luciano C. P.; Kellum, John A.; Damiani, Lucas P.; Silva, Nilton B.; Cavalcanti, Alexandre B.		BaSICS Investigators BRICNet Memb	Effect of Slower vs Faster Intravenous Fluid Bolus Rates on Mortality in Critically Ill Patients The BaSICS Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE; INFUSION; SALINE; RESUSCITATION	IMPORTANCE Slower intravenous fluid infusion rates could reduce the formation of tissue edema and organ dysfunction in critically ill patients; however, there are no data to support different infusion rates during fluid challenges for important outcomes such as mortality. OBJECTIVE To determine the effect of a slower infusion rate vs control infusion rate on 90-day survival in patients in the intensive care unit (ICU). DESIGN, SETTING, AND PARTICIPANTS Unblinded randomized factorial clinical trial in 75 ICUs in Brazil, involving 11 052 patients requiring at least 1 fluid challenge and with 1 risk factor for worse outcomes were randomized from May 29, 2017, to March 2, 2020. Follow-up was concluded on October 29, 2020. Patients were randomized to 2 different infusion rates (reported in this article) and 2 different fluid types (balanced fluids or saline, reported separately). INTERVENTIONS Patients were randomized to receive fluid challenges at 2 different infusion rates; 5538 to the slower rate (333 mL/h) and 5514 to the control group (999 mL/h). Patients were also randomized to receive balanced solution or 0.9% saline using a factorial design. MAIN OUTCOMES AND MEASURES The primary end pointwas 90-day survival. RESULTS Of all randomized patients, 10 520 (95.2%) were analyzed (mean age, 61.1 years [SD, 17.0 years]; 44.2% were women) after excluding duplicates and consent withdrawals. Patients assigned to the slower rate received a mean of 1162mL on the first day vs 1252 mL for the control group. By day 90, 1406 of 5276 patients (26.6%) in the slower rate group had died vs 1414 of 5244 (27.0%) in the control group (adjusted hazard ratio, 1.03; 95% CI, 0.96-1.11; P = .46). There was no significant interaction between fluid type and infusion rate (P = .98). CONCLUSIONS AND RELEVANCE Among patients in the intensive care unit requiring fluid challenges, infusing at a slower rate compared with a faster rate did not reduce 90-day mortality. These findings do not support the use of a slower infusion rate.	[Zampieri, Fernando G.; Soares, Rafael M.; Miranda, Tamiris A.; Damiani, Lucas P.; Silva, Nilton B.] HCor Res Inst, Rua Abilio Soares 250,12th Floor, Sao Paulo, Brazil; [Zampieri, Fernando G.; Machado, Flavia R.; Biondi, Rodrigo S.; Freitas, Flavio G. R.; Veiga, Viviane C.; Serpa-Neto, Ary; Dal Pizzol, Felipe; Correa, Thiago D.; Azevedo, Luciano C. P.; Cavalcanti, Alexandre B.] Brazilian Res Intens Care Network BRICNet, Sao Paulo, Brazil; [Machado, Flavia R.] Univ Fed Sao Paulo UNIFESP, Dept Anesthesiol Pain & Intens Care, Sao Paulo, Brazil; [Biondi, Rodrigo S.] Inst Cardiol Distrito Fed, Brasilia, DF, Brazil; [Freitas, Flavio G. R.] Hosp SEPACO, Sao Paulo, Brazil; [Veiga, Viviane C.] BPA Beneficencia Portuguesa Sao Paulo, Sao Paulo, Brazil; [Figueiredo, Rodrigo C.] Ctr Univ Espirito Santo UNESC, Hosp Maternidade Sao Jose, Colatina, Brazil; [Lovato, Wilson J.] Univ Sao Paulo, Hosp Clin, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil; [Amendola, Cristina P.] Hosp Canc Barretos, Fundacao Pio 12, Barretos, Brazil; [Assuncao, Murillo S. C.; Serpa-Neto, Ary; Correa, Thiago D.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil; [Paranhos, Jorge L. R.] Santa Casa Misericordia Sao Joao Rei, Sao Joao Dei Rei, Brazil; [Andrade, Jose] Hosp Geral Vitoria Conquista, Vitoria, ES, Brazil; [Godoy, Michele M. G.] Univ Fed Pernambuco, Hosp Clin, Recife, PE, Brazil; [Romano, Edson] HCor, Sao Paulo, Brazil; [Dal Pizzol, Felipe] Hosp Sao Jose, Criciuma, SC, Brazil; [Silva, Emerson B.] Hosp Geral Caxias Sul, Caxias Do Sul, RS, Brazil; [Silva, Miqueias M. L.] Hosp SAMUR, Vitoria, Brazil; [Machado, Miriam C. V.] Ctr Hospitar UNIMED, Joinville, Brazil; [Malbouisson, Luiz Marcelo S.] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil; [Manoel, Airton L. O.] Hosp Paulistano, Sao Paulo, Brazil; [Thompson, Marlus M.] Hosp Evangel Cachoeiro Itapemirim, Cachoeiro Do Itapemirim, Brazil; [Figueiredo, Lanese M.] Hosp Distrital Doutor Evandro Ayres Moura, Fortaleza, Ceara, Brazil; [Azevedo, Luciano C. P.] Hosp Sirio Libanes, Sao Paulo, Brazil; [Kellum, John A.] Univ Pittsburgh, Dept Crit Care Med, Ctr Crit Care Nephrol, Pittsburgh, PA USA; [Silva, Nilton B.] Fed Univ Hlth Sci, Sch Med, Porto Alegre, RS, Brazil	Hospital do Coracao - HCor; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Hospital de Cancer de Barretos; Hospital Israelita Albert Einstein; Universidade Federal de Pernambuco; Hospital do Coracao - HCor; Universidade Federal do Rio Grande do Sul; Universidade de Sao Paulo; Hospital Sirio Libanes; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Cavalcanti, AB (corresponding author), HCor Res Inst, Rua Abilio Soares 250,12th Floor, Sao Paulo, Brazil.	abiasi@hcor.com.br	Ravetti, Cecilia Gómez/ABD-7540-2021; Kellum, John A/HCH-2944-2022; Garces, Thiago Santos/M-2623-2018; Taniguchi, Leandro Utino/L-6471-2015; Boschi, Emerson/AHA-5269-2022; Roepke, Roberta Muriel Longo/AAN-6414-2020; Soares, Rafael/GSN-9271-2022; Serpa Neto, Ary/D-1927-2012; Azevedo, Luciano CP/H-2652-2012; Biondi, Rodrigo/H-5212-2016	Ravetti, Cecilia Gómez/0000-0002-6349-3063; Kellum, John A/0000-0003-1995-2653; Garces, Thiago Santos/0000-0002-1670-725X; Taniguchi, Leandro Utino/0000-0003-4384-0408; Boschi, Emerson/0000-0002-0273-4759; Roepke, Roberta Muriel Longo/0000-0003-2214-5166; Serpa Neto, Ary/0000-0003-1520-9387; Azevedo, Luciano CP/0000-0001-6759-3910; Rea-Neto, Alvaro/0000-0001-5524-0907; Biondi, Rodrigo/0000-0002-9242-6062	Brazilian Ministry of Health through the Programa de Desenvolvimento Institucional do Sistema Unico de Saude	Brazilian Ministry of Health through the Programa de Desenvolvimento Institucional do Sistema Unico de Saude	This trial was supported by the Brazilian Ministry of Health through the Programa de Desenvolvimento Institucional do Sistema Unico de Saude. Fluids and logistics were supplied by Baxter Hospitalar.	Cecconi M, 2015, INTENS CARE MED, V41, P1529, DOI 10.1007/s00134-015-3850-x; Damiani Lucas Petri, 2020, Rev. bras. ter. intensiva, V32, P493, DOI [10.5935/0103-507x.20200081, 10.5935/0103-507X.20200081]; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hahn RG, 2016, ACTA ANAESTH SCAND, V60, P569, DOI 10.1111/aas.12686; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Henderson AC, 2012, RESP PHYSIOL NEUROBI, V180, P331, DOI 10.1016/j.resp.2011.12.013; Hernandez G, 2019, JAMA-J AM MED ASSOC, V321, P654, DOI 10.1001/jama.2019.0071; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krzych LJ, 2018, CARDIOL J, V25, P254, DOI 10.5603/CJ.a2017.0054; Maitland K, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-68; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Garcia MIM, 2015, INTENS CARE MED, V41, P1247, DOI 10.1007/s00134-015-3898-7; MUIR AL, 1975, J APPL PHYSIOL, V38, P786, DOI 10.1152/jappl.1975.38.5.786; Robertson HT, 2004, J APPL PHYSIOL, V97, P697, DOI 10.1152/japplphysiol.00108.2004; Tatara T, 2007, BRIT J ANAESTH, V99, P212, DOI 10.1093/bja/aem165; Ukor IF, 2017, J CRIT CARE, V41, P254, DOI 10.1016/j.jcrc.2017.05.036; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Zampieri FG, 2021, JAMA-J AM MED ASSOC, V326, P818, DOI 10.1001/jama.2021.11684; Zampieri FG, 2017, CRIT CARE RESUSC, V19, P175	21	20	21	1	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	2021	326	9					830	838		10.1001/jama.2021.11444	http://dx.doi.org/10.1001/jama.2021.11444		AUG 2021	9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ7LK	34547081	Green Published, Bronze			2023-01-03	WOS:000684941800003
J	Bosquet, A; Affo, C; Plaisance, L; Poenou, G; Mortier, E; Mahe, I				Bosquet, Antoine; Affo, Comlan; Plaisance, Ludovic; Poenou, Geraldine; Mortier, Emmanuel; Mahe, Isabelle			Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists	PLOS ONE			English	Article							CHLOROQUINE	Introduction During the first wave of the coronavirus-disease 2019 (covid-19) pandemic in early 2020, hydroxychloroquine (HCQ) was widely prescribed in light of in vitro activity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Our objective was to evaluate in early 2020 the rate of French hospitalists declaring having prescribed HCQ to treat covid-19 patients outside any therapeutic trial, compare the reasons and the determinants for having prescribed HCQ or not. Material and methods A national inquiry submitted by email from May 7 to 25, 2020, to a sample of French hospitalists: doctors managing patients hospitalized for covid-19 in a French department of internal medicine or infectious diseases and identified in the directories of French hospitals or as a member of the French Infectious Diseases Society (SPILF). Primary outcome was the percentage of hospitalists declaring having prescribed HCQ to covid-19 patients. Secondary outcomes were reasons and determinants of HCQ prescription. Results Among 400 (22.8%) responding hospitalists, 45.3% (95% CI, 40.4 to 50.1%) declared having prescribed HCQ to covid-19 patients. Two main profiles were discerned: HCQ prescribers who did not raise its efficacy as a motive, and non-prescribers who based their decision on evidence-based medicine. Multivariate analysis retained the following prescription determinants (adjusted odds ratio; 95% confidence interval): a departmental procedure for HCQ prescription (8.25; 4.79 to 14.20), having prescribed other treatments outside a therapeutic trial (3.21; 1.81 to 5.71), prior HCQ prescription (2.75; 1.5 to 5.03) and HCQ prescribed within the framework of a therapeutic trial (0.56; 0.33 to 0.95). Conclusion Almost half of the hospitalists prescribed HCQ. The physician's personality (questioning or not evidence-based-medicine principles in the context of the pandemic) and departmental therapeutic procedures were the main factors influencing HCQ prescription. Establishment of "therapeutic" procedures represents a potential means to improve the quality of therapeutic decision-making during a pandemic.	[Bosquet, Antoine; Affo, Comlan; Plaisance, Ludovic; Poenou, Geraldine; Mahe, Isabelle] Univ Paris, Hop Louis Mourier, AP HP, DMU ESPRIT,Serv Med Interne, Colombes, France; [Mortier, Emmanuel] Hop Louis Mourier, AP HP, DMU ESPRIT, Policlin, Colombes, France; [Mahe, Isabelle] INSERM, UMR S1140, Innovat Therapies Haemostasis Paris, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bosquet, A (corresponding author), Univ Paris, Hop Louis Mourier, AP HP, DMU ESPRIT,Serv Med Interne, Colombes, France.	antoine.bosquet@aphp.fr		BOSQUET, Antoine/0000-0001-7282-6512				Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1895, DOI 10.1001/jama.2020.4984; [Anonymous], 2020, CMAJ CAN MED ASS J J, DOI DOI 10.1503/CMAJ.200438; [Anonymous], [No title captured]; [Anonymous], 2020, BMJ; [Anonymous], IS FRANC PRES FUEL H; Aquino YSJ, 2020, J MED ETHICS, V46, P574, DOI 10.1136/medethics-2020-106306; Attanasi M, 2020, RESPIRATION, V99, P667, DOI 10.1159/000509007; Axfors C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22446-z; Baicus C, 2020, J EVAL CLIN PRACT, V26, P1579, DOI 10.1111/jep.13484; Belayneh A, 2020, RES REP TROP MED, V11, P61, DOI 10.2147/RRTM.S269936; Bull-Otterson L, 2020, MMWR-MORBID MORTAL W, V69, P1210, DOI 10.15585/mmwr.mm6935a4; Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03; Dagens A, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1936; Davari M, 2018, ETHIOP J HEALTH SCI, V28, P795, DOI 10.4314/ejhs.v28i6.15; Davey P, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003543.pub2, 10.1002/14651858.CD003543.pub4, 10.1002/14651858.CD003543.pub3]; Fiolet T, 2021, CLIN MICROBIOL INFEC, V27, P19, DOI 10.1016/j.cmi.2020.08.022; Harrigan JJ, 2020, J GEN INTERN MED, V35, P2826, DOI 10.1007/s11606-020-05938-4; HCSP, 2020, SARS COV2 THER REC; Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496; Horby P, 2020, NEW ENGL J MED, DOI [10.1101/2020.06.22.20137273:24, DOI 10.1056/NEJMOA2021436, 10.1101/2020.06.22.20137273, 10.1101/2020.06.22.20137273v1, DOI 10.1101/2020.07.15.20151852]; Janda A, 2020, Z RHEUMATOL, V79, P710, DOI 10.1007/s00393-020-00854-8; Kahn SR, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008201.pub3; Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742; Kim AHJ, 2020, ANN INTERN MED, V172, P819, DOI 10.7326/M20-1223; Ledford H, 2020, NATURE, V580, P573, DOI 10.1038/d41586-020-01165-3; Liu M, 2020, JAMA INTERN MED, V180, P1116, DOI 10.1001/jamainternmed.2020.1764; Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4; Mehta B, 2020, JCR-J CLIN RHEUMATOL, V26, P224, DOI 10.1097/RHU.0000000000001539; Michaud K, 2020, ACR OPEN RHEUMATOL, V2, P335, DOI 10.1002/acr2.11148; Roques P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050268; Sattui SE, 2020, EXPERT REV CLIN IMMU, V16, P659, DOI 10.1080/1744666X.2020.1792778; Schumock GT, 2004, ANN PHARMACOTHER, V38, P557, DOI 10.1345/aph.1D390; Shehab N, 2020, JAMA INTERN MED, V180, P1384, DOI 10.1001/jamainternmed.2020.2594; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; Vaduganathan M, 2020, JAMA-J AM MED ASSOC, V323, P2524, DOI 10.1001/jama.2020.9184; WHO, 2021, ENDING NEGLECT ATTAI; WHO, MAN ETH ISS INF DIS; Yu B, 2020, SCI CHINA LIFE SCI, V63, P1515, DOI 10.1007/s11427-020-1732-2	38	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2022	17	1							e0261843	10.1371/journal.pone.0261843	http://dx.doi.org/10.1371/journal.pone.0261843			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	0Z4TQ	35061735	Green Published, gold			2023-01-03	WOS:000791072800068
J	O'Brien, MP; Forleo-Neto, E; Sarkar, N; Isa, F; Hou, PJ; Chan, KC; Musser, BJ; Bar, KJ; Barnabas, RV; Barouch, DH; Cohen, MS; Hurt, CB; Burwen, DR; Marovich, MA; Brown, ER; Heirman, I; Davis, JD; Turner, KC; Ramesh, D; Mahmood, A; Hooper, AT; Hamilton, JD; Kim, Y; Purcell, LA; Baum, A; Kyratsous, CA; Krainson, J; Perez-Perez, R; Mohseni, R; Kowal, B; DiCioccio, AT; Geba, GP; Stahl, N; Lipsich, L; Braunstein, N; Herman, G; Yancopoulos, GD; Weinreich, DM				O'Brien, Meagan P.; Forleo-Neto, Eduardo; Sarkar, Neena; Isa, Flonza; Hou, Peijie; Chan, Kuo-Chen; Musser, Bret J.; Bar, Katharine J.; Barnabas, Ruanne, V; Barouch, Dan H.; Cohen, Myron S.; Hurt, Christopher B.; Burwen, Dale R.; Marovich, Mary A.; Brown, Elizabeth R.; Heirman, Ingeborg; Davis, John D.; Turner, Kenneth C.; Ramesh, Divya; Mahmood, Adnan; Hooper, Andrea T.; Hamilton, Jennifer D.; Kim, Yunji; Purcell, Lisa A.; Baum, Alina; Kyratsous, Christos A.; Krainson, James; Perez-Perez, Richard; Mohseni, Rizwana; Kowal, Bari; DiCioccio, A. Thomas; Geba, Gregory P.; Stahl, Neil; Lipsich, Leah; Braunstein, Ned; Herman, Gary; Yancopoulos, George D.; Weinreich, David M.		COVID-19 Phase 3 Prevention Trial	Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								IMPORTANCE Easy-to-administer anti-SARS-CoV-2 treatments may be used to prevent progression from asymptomatic infection to symptomatic disease and to reduce viral carriage. OBJECTIVE To evaluate the effect of combination subcutaneous casirivimab and imdevimab on progression from early asymptomatic SARS-CoV-2 infection to symptomatic COVID-19. DESIGN, SETTING, AND PARTICIPANTS Randomized, double-blind, placebo-controlled, phase 3 trial of close household contacts of a SARS-CoV-2-infected index case at 112 sites in the US, Romania, and Moldova enrolled July 13, 2020-January 28, 2021; follow-up ended March 11, 2021. Asymptomatic individuals (aged >= 12 years) were eligible if identified within 96 hours of index case positive test collection. Results from 314 individuals positive on SARS-CoV-2 reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) testing are reported. INTERVENTIONS Individuals were randomized 1:1 to receive 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each; n = 158), or placebo (n = 156). MAIN OUTCOMES AND MEASURES The primary end point was the proportion of seronegative participants who developed symptomatic COVID-19 during the 28-day efficacy assessment period. The key secondary efficacy end points were the number of weeks of symptomatic SARS-CoV-2 infection and the number of weeks of high viral load (>4 log(10) copies/mL). RESULTS Among 314 randomized participants (mean age, 41.0 years; 51.6% women), 310 (99.7%) completed the efficacy assessment period; 204 were asymptomatic and seronegative at baseline and included in the primary efficacy analysis. Subcutaneous casirivimab and imdevimab, 1200 mg, significantly prevented progression to symptomatic disease (29/100 [29.0%] vs 44/104 [42.3%] with placebo; odds ratio, 0.54 [95% CI, 0.30-0.97]; P = .04; absolute risk difference, -13.3% [95% CI, -26.3% to -0.3%]). Casirivimab and imdevimab reduced the number of symptomatic weeks per 1000 participants (895.7 weeks vs 1637.4 weeks with placebo; P = .03), an approximately 5.6-day reduction in symptom duration per symptomatic participant. Treatment with casirivimab and imdevimab also reduced the number of high viral load weeks per 1000 participants (489.8 weeks vs 811.9 weeks with placebo; P = .001). The proportion of participants receiving casirivimab and imdevimab who had 1 or more treatment-emergent adverse event was 33.5% vs 48.1% for placebo, including events related (25.8% vs 39.7%) or not related (11.0% vs 16.0%) to COVID-19. CONCLUSIONS AND RELEVANCE Among asymptomatic SARS-CoV-2 RT-qPCR-positive individuals living with an infected household contact, treatment with subcutaneous casirivimab and imdevimab antibody combination vs placebo significantly reduced the incidence of symptomatic COVID-19 over 28 days.	[O'Brien, Meagan P.; Forleo-Neto, Eduardo; Sarkar, Neena; Isa, Flonza; Hou, Peijie; Chan, Kuo-Chen; Musser, Bret J.; Heirman, Ingeborg; Davis, John D.; Turner, Kenneth C.; Ramesh, Divya; Mahmood, Adnan; Hooper, Andrea T.; Hamilton, Jennifer D.; Kim, Yunji; Purcell, Lisa A.; Baum, Alina; Kyratsous, Christos A.; Kowal, Bari; DiCioccio, A. Thomas; Geba, Gregory P.; Stahl, Neil; Lipsich, Leah; Braunstein, Ned; Herman, Gary; Yancopoulos, George D.; Weinreich, David M.] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA; [Bar, Katharine J.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Bar, Katharine J.] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; [Barnabas, Ruanne, V] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Barnabas, Ruanne, V] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA; [Barnabas, Ruanne, V] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Barnabas, Ruanne, V; Brown, Elizabeth R.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA; [Barouch, Dan H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA; [Cohen, Myron S.; Hurt, Christopher B.] Univ N Carolina, Inst Global Hlth & Infect Dis, Chapel Hill, NC 27515 USA; [Burwen, Dale R.; Marovich, Mary A.] NIAID, NIH, Rockville, MD USA; [Brown, Elizabeth R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Krainson, James] Clin Trials Florida LLC, Miami, FL USA; [Perez-Perez, Richard] Med Res Westchester, Miami, FL USA; [Mohseni, Rizwana] Catalina Res Inst LLC, Montclair, CA USA	Regeneron; University of Pennsylvania; University of Pennsylvania; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle	O'Brien, MP (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	meagan.obrien@regeneron.com	Narayanan, Shivakumar/AGO-6664-2022; Streinu-Cercel, Adrian/M-5835-2017	Narayanan, Shivakumar/0000-0003-3440-0259; Streinu-Cercel, Adrian/0000-0001-6382-5067; Hooper, Andrea/0000-0003-1131-1229; Huaman, Moises/0000-0002-6839-5809; OBrien, Meagan/0000-0003-4476-8057; Stankiewicz Karita, Helen C./0000-0002-9458-286X; Andrews, Jason/0000-0002-5967-251X	Regeneron Pharmaceuticals Inc; F. Hoffmann-La Roche Ltd.; NIAID, NIH;  [UM1AI068619];  [UM1AI148684]	Regeneron Pharmaceuticals Inc(Regeneron); F. Hoffmann-La Roche Ltd.(Hoffmann-La Roche); NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ; 	This study was supported by Regeneron Pharmaceuticals Inc and F. Hoffmann-La Roche Ltd. This trial was conducted jointly with the NIAID, NIH. The CoVPN is supported by cooperative agreement awards from the NIAID, NIH. The work on this study was supported by awards UM1AI068619 and UM1AI148684.	Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Boutron I., 2020, COCHRANE DB SYST REV, pCD013769, DOI [10.1002/14651858.CD013769, DOI 10.1002/14651858.CD013769]; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Buitrago-Garcia D, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003346; Centers for Disease Control and Prevention, CLIN QUEST COVID 19; Centers for Disease Control and Prevention, COVID 19 PEOPL CERT; Copin R, 2021, CELL, V184, P3949, DOI 10.1016/j.cell.2021.06.002; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1101/2021.02.14.21251704, 10.1016/j.cell.2021.04.006]; GISAID, HCOV19 VAR; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Higdon MM, PREPRINT, V2021, DOI [10.1101/2021.09.17.21263549, DOI 10.1101/2021.09.17.21263549]; Kreuzberger N, 2021, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD013825.pub2, 10.1002/14651858.CD013825]; Magesh S, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.34147; O'Brien MP, 2021, NEW ENGL J MED, V385, P1184, DOI 10.1056/NEJMoa2109682; Portal-Celhay C., 2021, 31 EUR C CLIN MICR I; U.S. Food and Drug Administration, FACT SHEET HLTH CAR; US Food and Drug Administration, 2021, LETT AUTH EM US REGE; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; WHO, COR COVID 19 DASHB; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053	22	33	35	2	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2022	327	5					432	441		10.1001/jama.2021.24939	http://dx.doi.org/10.1001/jama.2021.24939		JAN 2022	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV9QB	35029629	Bronze, Green Published			2023-01-03	WOS:000742417400004
J	Xu, ZY; Neuber, S; Nazari-Shafti, T; Liu, ZH; Dong, FQ; Stamm, C				Xu, Zhiyi; Neuber, Sebastian; Nazari-Shafti, Timo; Liu, Zihou; Dong, Fengquan; Stamm, Christof			Impact of procedural variability and study design quality on the efficacy of cell-based therapies for heart failure - a meta-analysis	PLOS ONE			English	Article							AUTOLOGOUS BONE-MARROW; MESENCHYMAL STEM-CELLS; ACUTE MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR FUNCTION; NONISCHEMIC DILATED CARDIOMYOPATHY; RANDOMIZED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; MONONUCLEAR-CELLS; DOUBLE-BLIND; ISCHEMIC CARDIOMYOPATHY	Background Cell-based therapy has long been considered a promising strategy for the treatment of heart failure (HF). However, its effectiveness in the clinical setting is now doubted. Because previous meta-analyses provided conflicting results, we sought to review all available data focusing on cell type and trial design. Methods and findings The electronic databases PubMed, Cochrane library, ClinicalTrials.gov, and EudraCT were searched for randomized controlled trials (RCTs) utilizing cell therapy for HF patients from January 1, 2000 to December 31, 2020. Forty-three RCTs with 2855 participants were identified. The quality of the reported study design was assessed by evaluating the risk-of-bias (ROB). Primary outcomes were defined as mortality rate and left ventricular ejection fraction (LVEF) change from baseline. Secondary outcomes included both heart function data and clinical symptoms/events. Between-study heterogeneity was assessed using the I2 index. Subgroup analysis was performed based on HF type, cell source, cell origin, cell type, cell processing, type of surgical intervention, cell delivery routes, cell dose, and follow-up duration. Only 10 of the 43 studies had a low ROB for all method- and outcome parameters. A higher ROB was associated with a greater increase in LVEF. Overall, there was no impact on mortality for up to 12 months follow-up, and a clinically irrelevant average LVEF increase by LVEF (2.4%, 95% CI = 0.75- 4.05, p = 0.004). Freshly isolated, primary cells tended to produce better outcomes than cultured cell products, but there was no clear impact of the cell source tissue, bone marrow cell phenotype or cell chricdose (raw or normalized for CD34+ cells). A meaningful increase in LVEF was only observed when cell therapy was combined with myocardial revascularization. Conclusions The published results suggest a small increase in LVEF following cell therapy for heart failure, but publication bias and methodologic shortcomings need to be taken into account. Given that cardiac cell therapy has now been pursued for 20 years without real progress, further efforts should not be made.	[Xu, Zhiyi; Neuber, Sebastian; Nazari-Shafti, Timo; Liu, Zihou; Stamm, Christof] Charite Univ Med Berlin, Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany; [Neuber, Sebastian; Nazari-Shafti, Timo; Stamm, Christof] German Heart Ctr Berlin, Dept Cardiothorac & Vasc Surg, Berlin, Germany; [Neuber, Sebastian; Nazari-Shafti, Timo; Stamm, Christof] German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany; [Nazari-Shafti, Timo] Univ Med Berlin, Berlin Inst Hlth Charite, Berlin, Germany; [Dong, Fengquan] Shenzhen Univ Gen Hosp, Dept Cardiol, Shenzhen, Guangdong, Peoples R China; [Stamm, Christof] Helmholtz Zentrum Geesthacht, Inst Akt Polymere, Teltow, Germany	Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin; German Centre for Cardiovascular Research; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz-Zentrum Geesthacht - Zentrum fur Material- und Kustenforschung	Stamm, C (corresponding author), Charite Univ Med Berlin, Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany.; Stamm, C (corresponding author), German Heart Ctr Berlin, Dept Cardiothorac & Vasc Surg, Berlin, Germany.; Stamm, C (corresponding author), German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany.; Stamm, C (corresponding author), Helmholtz Zentrum Geesthacht, Inst Akt Polymere, Teltow, Germany.	stamm@dhzb.de		Neuber, Sebastian/0000-0003-1833-8440; Stamm, Christof/0000-0003-3035-2106				Abdel-Latif A, 2007, ARCH INTERN MED, V167, P989, DOI 10.1001/archinte.167.10.989; Ang KL, 2008, NAT CLIN PRACT CARD, V5, P663, DOI 10.1038/ncpcardio1321; Assmus B, 2013, JAMA-J AM MED ASSOC, V309, P1622, DOI 10.1001/jama.2013.3527; Bai YY, 2010, AGEING RES REV, V9, P418, DOI 10.1016/j.arr.2010.05.001; Bartel RL, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt117; Bartolucci J, 2017, CIRC RES, V121, P1192, DOI 10.1161/CIRCRESAHA.117.310712; Bartunek J, 2017, EUR HEART J, V38, P648, DOI 10.1093/eurheartj/ehw543; Bartunek J, 2013, J AM COLL CARDIOL, V61, P2329, DOI 10.1016/j.jacc.2013.02.071; BELLESISLES M, 1993, EUR J HISTOCHEM, V37, P375; Boquest AC, 2005, MOL BIOL CELL, V16, P1131, DOI 10.1091/mbc.E04-10-0949; Bourin P, 2013, CYTOTHERAPY, V15, P641, DOI 10.1016/j.jcyt.2013.02.006; Breathett K, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.115.002962; Brickwedel J, 2014, INTERACT CARDIOV TH, V18, P61, DOI 10.1093/icvts/ivt434; Burns PB, 2011, PLAST RECONSTR SURG, V128, P305, DOI 10.1097/PRS.0b013e318219c171; Cambria E, 2016, TRANSFUS MED HEMOTH, V43, P275, DOI 10.1159/000448179; Cheng K, 2013, HEART LUNG CIRC, V22, P887, DOI 10.1016/j.hlc.2013.04.112; Cheng K, 2010, CIRC RES, V106, P1570, DOI 10.1161/CIRCRESAHA.109.212589; Choudhury T, 2017, EUR J HEART FAIL, V19, P138, DOI 10.1002/ejhf.676; Clifford DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037373; Clifford DM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006536.pub3; de Jong R, 2014, CIRC-CARDIOVASC INTE, V7, P156, DOI 10.1161/CIRCINTERVENTIONS.113.001009; Dib N, 2009, JACC-CARDIOVASC INTE, V2, P9, DOI 10.1016/j.jcin.2008.11.003; Duckers HJ, 2011, EUROINTERVENTION, V6, P805, DOI 10.4244/EIJV6I7A139; Eding JEC, 2015, CIRC RES, V116, P80, DOI 10.1161/CIRCRESAHA.116.304872; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fijany A, 2019, MOL BIOL REP, V46, P1459, DOI 10.1007/s11033-018-4516-x; Fisher SA, 2018, HEART, V104, P8, DOI 10.1136/heartjnl-2017-311684; Fisher SA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007888.pub3; Fisher SA, 2015, CIRC RES, V116, P1361, DOI 10.1161/CIRCRESAHA.116.304386; Flower A, 2016, BEHAV MODIF, V40, P396, DOI 10.1177/0145445515616105; Foley T., 2012, EUR CARDIOL REV, V8, P108, DOI [10.15420/ecr.2012.8.2.108, DOI 10.15420/ECR.2012.8.2.108]; Frljak S, 2018, STEM CELL TRANSL MED, V7, P168, DOI 10.1002/sctm.17-0197; Goff ZD, 2017, JAMA INTERN MED, V177, P1387, DOI 10.1001/jamainternmed.2017.2988; Golpanian S, 2016, STEM CELL TRANSL MED, V5, P186, DOI 10.5966/sctm.2015-0101; Grayburn PA, 2014, CIRC-CARDIOVASC IMAG, V7, P220, DOI 10.1161/CIRCIMAGING.114.001675; Heldman AW, 2014, JAMA-J AM MED ASSOC, V311, P62, DOI 10.1001/jama.2013.282909; Hendrikx M, 2006, CIRCULATION, V114, pI101, DOI 10.1161/CIRCULATIONAHA.105.000505; Henry TD, 2017, CATHETER CARDIO INTE, V89, P169, DOI 10.1002/ccd.26601; Henry TD, 2014, CIRC RES, V115, P730, DOI 10.1161/CIRCRESAHA.115.304554; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hong KU, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096725; Hou DM, 2005, CIRCULATION, V112, pI150, DOI 10.1161/CIRCULATIONAHA.104.526749; Hristov M, 2006, J CELL MOL MED, V10, P727, DOI 10.1111/j.1582-4934.2006.tb00432.x; Hu SS, 2011, J AM COLL CARDIOL, V57, P2409, DOI 10.1016/j.jacc.2011.01.037; Jeevanantham V, 2012, CIRCULATION, V126, P551, DOI 10.1161/CIRCULATIONAHA.111.086074; Jiang TM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.215; Julian Higgins, 2019, COCHRANE HDB SYSTEMA, V2nd; Kanelidis AJ, 2017, CIRC RES, V120, P1139, DOI 10.1161/CIRCRESAHA.116.309819; Kresnik PK, 2016, TRANSFUSION, V56, P1792, DOI 10.1111/trf.13646; Laitinen A, 2016, CYTOTHERAPY, V18, P423, DOI 10.1016/j.jcyt.2015.11.014; Lancet Editors, 2014, LANCET, V383, P1279, DOI 10.1016/S0140-6736(14)60608-5; Lee SH, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0415-z; Lezaic L, 2015, J CARD FAIL, V21, P145, DOI 10.1016/j.cardfail.2014.11.005; Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111850; Lin YH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134770; Liu B, 2014, INT J CARDIOL, V177, P764, DOI 10.1016/j.ijcard.2014.11.005; Makkar RR, 2020, EUR HEART J, V41, P3451, DOI 10.1093/eurheartj/ehaa541; Martino H, 2015, EUR HEART J, V36, P2898, DOI 10.1093/eurheartj/ehv477; Mathiasen AB, 2015, EUR HEART J, V36, P1744, DOI 10.1093/eurheartj/ehv136; Maureira P, 2012, CLIN NUCL MED, V37, P738, DOI 10.1097/RLU.0b013e318251e38a; Menasche P, 2008, CIRCULATION, V117, P1189, DOI 10.1161/CIRCULATIONAHA.107.734103; Moustgaard H, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6802; Moye L, 2014, CIRC RES, V115, P484, DOI 10.1161/CIRCRESAHA.114.304767; Nasseri BA, 2014, EUR HEART J, V35, P1263, DOI 10.1093/eurheartj/ehu007; Nazari-Shafti TZ, 2019, EUR HEART J, V40, P953, DOI 10.1093/eurheartj/ehz106; Neumann FJ, 2019, EUR HEART J, V40, P87, DOI 10.1093/eurheartj/ehy394; Noiseux N, 2016, J THORAC CARDIOV SUR, V152, P1582, DOI 10.1016/j.jtcvs.2016.07.067; Nowbar AN, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2688; Patel AN, 2016, LANCET, V387, P2412, DOI 10.1016/S0140-6736(16)30137-4; Patel AN, 2015, STEM CELL TRANSL MED, V4, P1021, DOI 10.5966/sctm.2015-0070; Patel AN, 2005, J THORAC CARDIOV SUR, V130, P1631, DOI 10.1016/j.jtcvs.2005.07.056; Patila T, 2014, J HEART LUNG TRANSPL, V33, P567, DOI 10.1016/j.healun.2014.02.009; Perin EC, 2015, CIRC RES, V117, P576, DOI 10.1161/CIRCRESAHA.115.306332; Perin EC, 2014, AM HEART J, V168, P88, DOI 10.1016/j.ahj.2014.03.022; Perin EC, 2012, JAMA-J AM MED ASSOC, V307, P1717, DOI 10.1001/jama.2012.418; Perin EC, 2012, AM HEART J, V163, P415, DOI 10.1016/j.ahj.2011.11.020; Perin EC, 2011, AM HEART J, V161, P1078, DOI 10.1016/j.ahj.2011.01.028; Pham P, 2016, PROG STEM CELL, V3, P87, DOI [10.15419/psc.v3i02.123, DOI 10.15419/PSC.V3I02.123]; Poglajen G, 2014, CIRC-CARDIOVASC INTE, V7, P552, DOI 10.1161/CIRCINTERVENTIONS.114.001436; Pokushalov E, 2010, J CARDIOVASC TRANSL, V3, P160, DOI 10.1007/s12265-009-9123-8; Povsic TJ, 2011, AM HEART J, V162, P654, DOI 10.1016/j.ahj.2011.07.020; Qi Z, 2018, J CLIN ULTRASOUND, V46, P512, DOI 10.1002/jcu.22609; Redaelli MB, 2018, J CRIT CARE, V48, P414, DOI 10.1016/j.jcrc.2018.09.031; Saltaji H, 2018, BMC MED RES METHODOL, V18, DOI [10.1186/S12874-018-0491-0, 10.1186/s12874-018-0491-0]; Sant'Anna RT, 2014, REV BRAS CIR CARDIOV, V29, P437, DOI 10.5935/1678-9741.20140091; Santoso T, 2014, J CARDIOVASC TRANSL, V7, P545, DOI 10.1007/s12265-014-9580-6; Savarese Gianluigi, 2017, Card Fail Rev, V3, P7, DOI 10.15420/cfr.2016:25:2; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Seth S, 2006, J AM COLL CARDIOL, V48, P2350, DOI 10.1016/j.jacc.2006.07.057; Seth S, 2010, J AM COLL CARDIOL, V55, P1643, DOI 10.1016/j.jacc.2009.11.070; Shahdadfar A, 2005, STEM CELLS, V23, P1357, DOI 10.1634/stemcells.2005-0094; Steinhoff G, 2017, EBIOMEDICINE, V22, P208, DOI 10.1016/j.ebiom.2017.07.022; Sunagawa G, 2017, EXPERT REV CARDIOVAS, V15, P377, DOI 10.1080/14779072.2017.1313114; Tardif JC, 2011, EUR HEART J, V32, P2507, DOI 10.1093/eurheartj/ehr311; Tossios P, 2008, EUR HEART J, V29, P1911, DOI 10.1093/eurheartj/ehn218; van der Spoel TIG, 2011, CARDIOVASC RES, V91, P649, DOI 10.1093/cvr/cvr113; Velazquez EJ, 2016, NEW ENGL J MED, V374, P1511, DOI 10.1056/NEJMoa1602001; Vrtovec B, 2011, J CARD FAIL, V17, P272, DOI 10.1016/j.cardfail.2010.11.007; Wang HS, 2015, CARDIOLOGY, V130, P27, DOI 10.1159/000369381; Wang Z, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-016-0450-9; Wolfien M, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102862; Xiao WT, 2017, INT HEART J, V58, P238, DOI 10.1536/ihj.16-328; Xu Jia-Ying, 2016, Chronic Dis Transl Med, V2, P92, DOI 10.1016/j.cdtm.2016.09.006; Yang YHK, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0876-3; Yasuhara S, 2010, ARTIF ORGANS, V34, P594, DOI 10.1111/j.1525-1594.2009.00980.x; Zein H, 2015, EXTRACT DATA GRAPHS, DOI [10.13140/RG.2.2. 17070.72002, DOI 10.13140/RG.2.2.17070.72002]; Zhao Q, 2008, ANN THORAC SURG, V86, P1833, DOI 10.1016/j.athoracsur.2008.08.068; Zhao XF, 2015, GENET MOL RES, V14, P3010, DOI 10.4238/2015.April.10.11; Zimmet H, 2012, EUR J HEART FAIL, V14, P91, DOI 10.1093/eurjhf/hfr148; Zwetsloot PP, 2016, CIRC RES, V118, P1223, DOI 10.1161/CIRCRESAHA.115.307676	110	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2022	17	1							e0261462	10.1371/journal.pone.0261462	http://dx.doi.org/10.1371/journal.pone.0261462			34	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZO8DB	34986181	Green Published, gold			2023-01-03	WOS:000765956200011
J	Anane-Fenin, B; Agbeno, EK; Osarfo, J; Anning, DAO; Boateng, AS; Ken-Amoah, S; Amanfo, AO; Derkyi-Kwarteng, L; Mouhajer, M; Amoo, SA; Ashong, J; Jeffery, E				Anane-Fenin, Betty; Agbeno, Evans Kofi; Osarfo, Joseph; Anning, Douglas Aninng Opoku; Boateng, Abigail Serwaa; Ken-Amoah, Sebastian; Amanfo, Anthony Ofori; Derkyi-Kwarteng, Leonard; Mouhajer, Mohammed; Amoo, Sarah Ama; Ashong, Joycelyn; Jeffery, Ernestina			A ten-year review of indications and outcomes of obstetric admissions to an intensive care unit in a low-resource country	PLOS ONE			English	Review							MATERNAL MORTALITY; PREGNANCY; AGE	Introduction Obstetric intensive care unit admission (ICU) suggests severe morbidity. However, there is no available data on the subject in Ghana. This retrospective review was conducted to determine the indications for obstetric ICU admission, their outcomes and factors influencing these outcomes to aid continuous quality improvement in obstetric care. Methods This was a retrospective review conducted in a tertiary hospital in Ghana. Data on participant characteristics including age and whether participant was intubated were collected from patient records for all obstetric ICU admissions from 1(st) January 2010 to 31(st) December 2019. Descriptive statistics were presented as frequencies, proportions and charts. Hazard ratios were generated for relations between obstetric ICU admission outcome and participant characteristics. A p-value <0.05 was deemed statistically significant. Results There were 443 obstetric ICU admissions over the review period making up 25.7% of all ICU admissions. The commonest indications for obstetric ICU admissions were hypertensive disorders of pregnancy (70.4%, n = 312/443), hemorrhage (14.4%, n = 64/443) and sepsis (9.3%, n = 41/443). The case fatality rates for hypertension, hemorrhage, and sepsis were 17.6%, 37.5%, and 63.4% respectively. The obstetric ICU mortality rate was 26% (115/443) over the review period. Age >= 25 years and a need for mechanical ventilation carried increased mortality risks following ICU admission while surgery in the index pregnancy was associated with a reduced risk of death. Conclusion Hypertension, haemorrhage and sepsis are the leading indications for obstetric ICU admissions. Thus, preeclampsia screening and prevention, as well as intensifying antenatal education on the danger signs of pregnancy can minimize obstetric complications. The establishment of an obstetric HDU in CCTH and the strengthening of communication between specialists and the healthcare providers in the lower facilities, are also essential for improved pregnancy outcomes. Further studies are needed to better appreciate the wider issues underlying obstetric ICU admission outcomes. Plain language summary This was a review of the reasons for admitting severely-ill pregnant women and women who had delivered within the past 42 days to the intensive care unit (ICU), the admission outcomes and risk factors associated with ICU mortality in a tertiary hospital in a low-resource country. High blood pressure and its complications, bleeding and severe infections were observed as the three most significant reasons for ICU admissions in decreasing order of significance. Pre-existing medical conditions and those arising as a result of, or aggravated by pregnancy; obstructed labour and post-operative monitoring were the other reasons for ICU admission over the study period. Overall, 26% of the admitted patients died at the ICU and maternal age of at least 25 years and the need for intubation were identified as risk factors for ICU deaths. Attention must be paid to high blood pressure during pregnancy.	[Anane-Fenin, Betty; Boateng, Abigail Serwaa; Ashong, Joycelyn] Cape Coast Teaching Hosp, Dept Obstet & Gynaecol, Cape Coast, Ghana; [Agbeno, Evans Kofi; Ken-Amoah, Sebastian; Amanfo, Anthony Ofori; Mouhajer, Mohammed] Univ Cape Coast, Dept Obstet & Gynaecol, Sch Med Sci, Cape Coast, Ghana; [Osarfo, Joseph] Univ Hlth & Allied Sci, Sch Med, Dept Community Med, Ho, Ghana; [Anning, Douglas Aninng Opoku] Kwame Nkrumah Univ Sci & Technol, Sch Publ Hlth, Kumasi, Ghana; [Derkyi-Kwarteng, Leonard] Univ Cape Coast, Dept Pathol, Sch Med Sci, Cape Coast, Ghana; [Amoo, Sarah Ama; Jeffery, Ernestina] Cape Coast Teaching Hosp, Intens Care Unit, Cape Coast, Ghana	University of Cape Coast; Kwame Nkrumah University Science & Technology; University of Cape Coast	Anane-Fenin, B (corresponding author), Cape Coast Teaching Hosp, Dept Obstet & Gynaecol, Cape Coast, Ghana.	oparebea81@gmail.com	Opoku, Douglas Aninng/CAF-0150-2022	Opoku, Douglas Aninng/0000-0003-2321-387X; Anane-Fenin, Betty/0000-0003-3020-2159; Ken-Amoah, Sebastian/0000-0001-8293-6862				Abiodun J., 2015, GLOB SCHOLAST RES J, V1; Adelaiye SM., 2016, TROP J OBSTET GYNAEC, V33, P44; Adeniran AS, 2015, MALAWI MED J, V27, P16, DOI 10.4314/mmj.v27i1.5; Adu-Bonsaffoh K, 2013, INT J GYNECOL OBSTET, V123, P110, DOI 10.1016/j.ijgo.2013.05.017; Ahinkorah BO, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9030272; Asseffa NA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213240; Awoyesuku PA., 2020, J ADV MED MED RES, V32, P103; Bahadur BR., 2018, INT J REPROD CONTRAC, V7, P2909, DOI [10.18203/2320-1770.ijrcog20182905, DOI 10.18203/2320-1770.IJRCOG20182905]; Bas EK, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919922; Boafor TK, 2021, AFR J REPROD HEALTH, V25, P56, DOI 10.29063/ajrh2021/v25i1.7; Bosu W K, 2012, Ghana Med J, V46, P69; Cavazos-Rehg PA, 2015, MATERN CHILD HLTH J, V19, P1202, DOI 10.1007/s10995-014-1624-7; Chawla Sushil, 2013, Med J Armed Forces India, V69, P134, DOI 10.1016/j.mjafi.2012.08.033; Crozier TM, 2011, AUST NZ J OBSTET GYN, V51, P233, DOI 10.1111/j.1479-828X.2011.01303.x; de-Graft Aikins Ama, 2007, Ghana Med J, V41, P154; Duley L, 2009, SEMIN PERINATOL, V33, P130, DOI 10.1053/j.semperi.2009.02.010; El-Abd H., 2011, CRIT CARE, V15, pP513, DOI [10.1186/cc9933, DOI 10.1186/CC9933]; Endeshaw Gezehagn, 2015, Int Sch Res Notices, V2015, P208043, DOI 10.1155/2015/208043; Filippi V, 2016, REPROD MATERNAL NEWB, V2; Ghosh G, 2014, ETHNIC DIS, V24, P283; Githae F., 2011, E AFR MED J, V88, P356; Jain Shruti, 2016, Indian J Public Health, V60, P159, DOI 10.4103/0019-557X.184575; Kumari N., 2016, IOSR J DENT MED SCI, V15, P55, DOI [10.9790/0853-1512085557, DOI 10.9790/0853-1512085557]; Maiden MJ, 2020, BJOG-INT J OBSTET GY, V127, P1558, DOI 10.1111/1471-0528.16285; Marshall JC, 2017, J CRIT CARE, V37, P270, DOI 10.1016/j.jcrc.2016.07.015; Mjahed K, 2006, J Obstet Gynaecol, V26, P418, DOI 10.1080/01443610600720188; Motiang M, 2017, SOUTH AFR J CRIT CAR, V33, P12, DOI 10.7196/SAJCC.2017.v33i1.279; Murthy S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116949; Ntuli TS, 2015, SOUTH AFR J CRIT CAR, V31, P8, DOI 10.7196/SAJCC.164; Okafor UV, 2004, INT J OBSTET ANESTH, V13, P164, DOI 10.1016/j.ijoa.2004.04.002; Pollock W, 2010, INTENS CARE MED, V36, P1465, DOI 10.1007/s00134-010-1951-0; Poon LCY, 2010, J HUM HYPERTENS, V24, P104, DOI 10.1038/jhh.2009.45; Prin M, 2019, INT J OBSTET ANESTH, V39, P99, DOI 10.1016/j.ijoa.2019.03.004; Ramlakhan KP, 2021, BMC WOMENS HEALTH, V21, DOI 10.1186/s12905-021-01396-0; Rudakemwa A, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-03882-7; Sauer MV, 2015, FERTIL STERIL, V103, P1136, DOI 10.1016/j.fertnstert.2015.03.004; Siaw-Frimpong M, 2021, J CRIT CARE, V61, P76, DOI 10.1016/j.jcrc.2020.10.009; Sodhi K., 2018, J OBSTET ANAESTHESIA, V8, P73, DOI [10.4103/joacc.JOACC_57_17, DOI 10.4103/J0ACC.J0ACC_57_17]; WHO, 2012, EV QUAL CAR SEV PREG; Witteveen T, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1370-0; World Health Organization, 2012, EARL MARR AD YOUNG P; World Health Organization, 2019, MAT DEATHS DECL SLOW; Yi Hye Yeon, 2018, Obstet Gynecol Sci, V61, P209, DOI 10.5468/ogs.2018.61.2.209; Zieleskiewicz L, 2016, ANAESTH CRIT CARE PA, V35, pS51, DOI 10.1016/j.accpm.2016.06.005; Zwart JJ, 2010, INTENS CARE MED, V36, P256, DOI 10.1007/s00134-009-1707-x	45	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2021	16	12							e0261974	10.1371/journal.pone.0261974	http://dx.doi.org/10.1371/journal.pone.0261974			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ9AO	34972184	gold, Green Published			2023-01-03	WOS:000773555700078
J	Rahman, M; Tariqujjaman, M; Mahfuz, M; Ahmed, T; Sarma, H				Rahman, Mahfuzur; Tariqujjaman, Md; Mahfuz, Mustafa; Ahmed, Tahmeed; Sarma, Haribondhu			Caregiver perceived barriers to the use of micronutrient powder for children aged 6-59 months in Bangladesh	PLOS ONE			English	Article							NUTRITION; PREDICTORS; PROGRAMS; COVERAGE	Background The effectiveness of micronutrient powder (MNP) on the health outcome of children is yet to be proved. Although studies identified the barriers to the use of MNP the underlying factors related to the barriers to the use of MNP are still unexplored. We examined the underlying factors associated with the barriers reported by the caregivers of the children aged 6-59 months in Bangladesh. Methods We analyzed pooled data of 3, 634 caregiver-child dyads extracted from eight cross-sectional surveys. The surveys were conducted as part of an evaluation of the Maternal, Infant and Young Children Nutrition programme (phase 2) in Bangladesh. We performed univariate analysis to find the barriers reported by the caregivers of the children. We identified the underlying factors related to the reported barriers by performing multiple logistic regression analysis. Results The mostly reported barrier was perceived lack of need for MNP among the caregivers of the children (39.9%), followed by lack of awareness of the product (21.7%) and cost of the product (18.1%). Caregivers of older children (adjusted odds ratio (aOR): 1.69; 95% CI: 1.43, 2.00) and caregivers who maintained good infant and young child feeding practices (aOR: 1.32; 95% CI: 1.12, 1.57) perceived more lack of need for MNP. Caregivers of the female children (aOR: 0.79; 95% CI: 0.63, 0.98) were less likely to report that their children disliked MNP compared to the caregivers of the male children. Conclusion Programmes intended to effectively promote MNP among the caregivers of children aged 6-59 months should carefully consider the factors that could underlie the barriers to the use of MNP.	[Rahman, Mahfuzur; Tariqujjaman, Md; Mahfuz, Mustafa; Ahmed, Tahmeed] Icddr B, Nutr & Clin Serv Div, Dhaka, Bangladesh; [Sarma, Haribondhu] Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, Australia	International Centre for Diarrhoeal Disease Research (ICDDR); Australian National University	Rahman, M (corresponding author), Icddr B, Nutr & Clin Serv Div, Dhaka, Bangladesh.	mahfuzur.rahman@icddrb.org	Mahfuz, Mustafa/H-5923-2017	Mahfuz, Mustafa/0000-0002-4090-785X; Sarma, Haribondhu/0000-0003-1553-8498; Rahman, Mahfuzur/0000-0002-3117-9846	Children's Investment Fund Foundation (CIFF), UK	Children's Investment Fund Foundation (CIFF), UK	Research for this article was founded by the Children's Investment Fund Foundation (CIFF), UK. The views, opinions, assumptions, or any other information set out in this article are solely those of the authors and should not be attributed to CIFF or any person connected with CIFF.	Ahmed S, 2021, PUBLIC HEALTH NUTR, V24, pS59, DOI 10.1017/S1368980020003602; Aparco Juan Pablo, 2017, Rev. perú. med. exp. salud publica, V34, P590, DOI 10.17843/rpmesp.2017.344.3164; Bahl K., 2013, NUTR BETTER TOMORROW, V110; Burchi F, 2010, ECON HUM BIOL, V8, P331, DOI 10.1016/j.ehb.2010.05.010; De-Regil LM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008959.pub2; Dewey Kathryn G., 2003, Food and Nutrition Bulletin, V24, P5; Global Alliance for Improved Nutrition, HOM FORT BANGL; Gross GJ, 2001, PUBLIC HEALTH NURS, V18, P157, DOI 10.1046/j.1525-1446.2001.00157.x; Guevarra E., 2014, Field Exchange - Emergency Nutrition Network ENN, P60; Jefferds MED, 2015, MATERN CHILD NUTR, V11, P77, DOI 10.1111/mcn.12214; Kim SB, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0147745, 10.1371/journal.pone.0164800]; Kodish S, 2015, FOOD NUTR BULL, V36, P138, DOI 10.1177/0379572115586784; Kodish S, 2011, FOOD NUTR BULL, V32, P292, DOI 10.1177/156482651103200315; Leyvraz M, 2017, J NUTR, V147, p995S, DOI 10.3945/jn.116.245407; McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401; Mirkovic KR, 2016, PUBLIC HEALTH NUTR, V19, P1768, DOI 10.1017/S1368980015003572; National Institute of Population Research and Training (NIPORT) Mitra and Associates and ICF International, 2016, BANGL DEM HLTH SURV; Olney DK, 2012, J NUTR, V142, p178S, DOI 10.3945/jn.110.137182; Sarma H, 2021, PUBLIC HEALTH NUTR, V24, pS7, DOI 10.1017/S1368980019004415; Sarma H, 2021, PUBLIC HEALTH NUTR, V24, pS37, DOI 10.1017/S1368980020000439; Sarma H, 2021, PUBLIC HEALTH NUTR, V24, pS48, DOI 10.1017/S1368980020000038; Sarma H, 2021, PUBLIC HEALTH NUTR, V24, pS23, DOI 10.1017/S1368980019003768; Sarma H, 2016, FOOD NUTR BULL, V37, P340, DOI 10.1177/0379572116645916; Tanner J., 1990, FETUS MAN PHYS GROWT; World Health Organization, 2001, GUID PRINC COMPL FEE; World Health Organization, 2005, GUID PRINC FEED NONB; World Health Organization, 2001, IR DEF ASS PREV CONT	27	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2021	16	12							e0260773	10.1371/journal.pone.0260773	http://dx.doi.org/10.1371/journal.pone.0260773			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW0CT	34855857	gold, Green Published			2023-01-03	WOS:000735299000117
J	Leyenaar, JK; Freyleue, SD; Bordogna, A; Wong, C; Penwill, N; Bode, R				Leyenaar, JoAnna K.; Freyleue, Seneca D.; Bordogna, Amy; Wong, Christopher; Penwill, Nicole; Bode, Ryan			Frequency and Duration of Boarding for Pediatric Mental Health Conditions at Acute Care Hospitals in the US	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This study estimates the frequency and duration of boarding for pediatric mental health conditions at US acute care hospitals and describes hospital resources available to support youths during boarding.	[Leyenaar, JoAnna K.] Dartmouth Coll, Geisel Sch Med, Dept Pediat, Hanover, NH 03755 USA; [Freyleue, Seneca D.; Bordogna, Amy; Wong, Christopher] Dartmouth Coll, Dartmouth Inst Hlth Policy & Clin Practice, Geisel Sch Med, Hanover, NS USA; [Penwill, Nicole] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Bode, Ryan] Nationwide Childrens Hosp, Hosp Med, Sect Pediat, Columbus, OH USA	Dartmouth College; University of California System; University of California San Francisco; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Leyenaar, JK (corresponding author), Dartmouth Hitchcock Med Ctr, Dartmouth Inst, 1 Med Ctr Dr,Williamson Bldg, Lebanon, NH 03756 USA.; Leyenaar, JK (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Pediat, 1 Med Ctr Dr,Williamson Bldg, Lebanon, NH 03756 USA.	joanna.k.leyenaar@hitchcock.org		Bordogna, Amy/0000-0002-0742-5816; Leyenaar, JoAnna/0000-0002-0555-0154; Wong, Christopher/0000-0001-8626-6704				[Anonymous], 2013, Jt Comm Perspect, V33, P3; Beatty PC, 2007, PUBLIC OPIN QUART, V71, P287, DOI 10.1093/poq/nfm006; Lo CB, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-1536; McEnany FB, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1174; R Core Team, 2021, R LANG ENV STAT COMP; Simon TD, 2013, ACAD PEDIATR, V13, pS54, DOI 10.1016/j.acap.2013.04.006	6	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	2021	326	22					2326	+		10.1001/jama.2021.18377	http://dx.doi.org/10.1001/jama.2021.18377		NOV 2021	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ5NW	34792533	Bronze, Green Published			2023-01-03	WOS:000720517500002
J	Teitelbaum, I				Teitelbaum, Isaac			Peritoneal Dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE KIDNEY INJURY; QUALITY-OF-LIFE; CARDIAC-SURGERY; HIGH-VOLUME; CATHETER; HEMODIALYSIS; SURVIVAL; OUTCOMES; ACCESS; TRANSPLANTATION	Peritoneal Dialysis An estimated 3.8 million people worldwide have end-stage kidney disease and require some form of dialysis to survive. Peritoneal dialysis is used in approximately 11% of patients undergoing dialysis. This review discusses the pragmatic aspects of caring for such patients.	[Teitelbaum, Isaac] Univ Colorado, Sch Med, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Teitelbaum, I (corresponding author), Univ Colorado, Sch Med, Aurora, CO 80045 USA.	isaac.teitelbaum@cuanschutz.edu						Aithal GP, 2021, GUT, V70, P9, DOI 10.1136/gutjnl-2020-321790; Almeida CP, 2014, PERITON DIALYSIS INT, V34, P544, DOI 10.3747/pdi.2013.00092; Back C, 2017, SCAND CARDIOVASC J, V51, P334, DOI 10.1080/14017431.2017.1384565; Badve SV, 2008, KIDNEY INT, V73, P480, DOI 10.1038/sj.ki.5002705; Bieber S, 2019, ADV CHRONIC KIDNEY D, V26, P23, DOI 10.1053/j.ackd.2018.09.002; Bieber SD, 2014, AM J KIDNEY DIS, V63, P1027, DOI 10.1053/j.ajkd.2013.11.025; Blake P.G., 2015, HDB DIALYSIS, V5th ed., P392; Boudville N, 2012, J AM SOC NEPHROL, V23, P1398, DOI 10.1681/ASN.2011121135; Brown EA, 2003, J AM SOC NEPHROL, V14, P2948, DOI 10.1097/01.ASN.0000092146.67909.E2; Brown EA, 2020, J AM SOC NEPHROL, V31, P1928, DOI 10.1681/ASN.2020050729; Brown EA, 2017, PERITON DIALYSIS INT, V37, P362, DOI 10.3747/pdi.2017.00018; Brown PA, 2008, NEPHROL DIAL TRANSPL, V23, P2299, DOI 10.1093/ndt/gfn003; CHARYTAN C, 1992, PERITON DIALYSIS INT, V12, P227; Chaudhry RI, 2019, PERITON DIALYSIS INT, V39, P315, DOI 10.3747/pdi.2018.00148; Chionh CY, 2013, CLIN J AM SOC NEPHRO, V8, P1649, DOI 10.2215/CJN.01540213; Cho Y, 2021, AM J KIDNEY DIS, V77, P315, DOI 10.1053/j.ajkd.2020.05.032; Cho Y, 2017, SEMIN NEPHROL, V37, P66, DOI 10.1016/j.semnephrol.2016.10.008; Choy A.S.-M., 2015, HONG KONG J NEPHROL, V17, P28, DOI [10.1016/j.hkjn.2015.08.001, DOI 10.1016/J.HKJN.2015.08.001]; Crabtree JH, 2006, PERITON DIALYSIS INT, V26, P677; Crabtree JH, 2019, PERITON DIALYSIS INT, V39, P414, DOI 10.3747/pdi.2018.00232; Crabtree JH, 2009, AM J SURG, V198, P135, DOI 10.1016/j.amjsurg.2008.10.019; Cullis B, 2021, PERITON DIALYSIS INT, V41, P15, DOI 10.1177/0896860820970834; Cullis B, 2020, PERITON DIALYSIS INT, V40, P438, DOI 10.1177/0896860820931662; Davenport A., 2019, CRITICAL CARE NEPHRO, V3rd, P800; Davies SJ, 2011, SEMIN NEPHROL, V31, P172, DOI 10.1016/j.semnephrol.2011.01.006; de Wit GA, 2001, PERITON DIALYSIS INT, V21, P306; Di Paolo N, 2000, PERITON DIALYSIS INT, V20, pS5; El Shamy O, 2020, J AM SOC NEPHROL, V31, P1680, DOI 10.1681/ASN.2020050599; Elhassan E, 2011, PERITON DIALYSIS INT, V31, P558, DOI 10.3747/pdi.2010.00160; Executive Office of the President, 2019, FED REG, V84, P33817; Finkelstein F, 2005, J AM SOC NEPHROL, V16, P546, DOI 10.1681/ASN.2004090793; Finkelstein FO, 2014, PERITON DIALYSIS INT, V34, P478, DOI 10.3747/pdi.2014.00041; Gabriel DP, 2008, KIDNEY INT, V73, pS87, DOI 10.1038/sj.ki.5002608; Ghaffari A, 2013, PERITON DIALYSIS INT, V33, P611, DOI 10.3747/pdi.2013.00017; Goffin E, 2008, SEMIN DIALYSIS, V21, P258, DOI 10.1111/j.1525-139X.2008.00425.x; Golper TA, 1996, AM J KIDNEY DIS, V28, P428, DOI 10.1016/S0272-6386(96)90502-8; Goodlad C, 2020, KIDNEY INT, V97, P1253, DOI 10.1016/j.kint.2020.01.044; GULANIKAR AC, 1991, NEPHROL DIAL TRANSPL, V6, P215, DOI 10.1093/ndt/6.3.215; HAJARIZADEH H, 1995, AM J SURG, V170, P223, DOI 10.1016/S0002-9610(99)80291-8; Heaf JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090119; Jin HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166181; Karopadi AN, 2013, NEPHROL DIAL TRANSPL, V28, P2553, DOI 10.1093/ndt/gft214; Kim JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139033; Koch M, 2012, NEPHROL DIAL TRANSPL, V27, P375, DOI 10.1093/ndt/gfr262; Krezalek MA, 2016, SURGERY, V160, P924, DOI 10.1016/j.surg.2016.06.005; Kumar VA, 2012, PERITON DIALYSIS INT, V32, P137, DOI 10.3747/pdi.2010.00263; Lee MB, 2016, CURR OPIN NEPHROL HY, V25, P602, DOI 10.1097/MNH.0000000000000274; Li PKT, 2017, NAT REV NEPHROL, V13, P90, DOI 10.1038/nrneph.2016.181; Li PKT, 2016, PERITON DIALYSIS INT, V36, P481, DOI 10.3747/pdi.2016.00078; Lievense H, 2012, NEPHROL DIAL TRANSPL, V27, P3631, DOI 10.1093/ndt/gfs131; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Lobbedez T, 2008, NEPHROL DIAL TRANSPL, V23, P3290, DOI 10.1093/ndt/gfn213; Mari G, 2017, SURG INNOV, V24, P397, DOI 10.1177/1553350617708723; McCormick BB, 2007, J AM SOC NEPHROL, V18, P3023, DOI 10.1681/ASN.2007070796; Mehrotra R, 1997, PERITON DIALYSIS INT, V17, P426; Mehrotra R, 2016, J AM SOC NEPHROL, V27, P3238, DOI 10.1681/ASN.2016010112; Mehrotra R, 2011, ARCH INTERN MED, V171, P110, DOI 10.1001/archinternmed.2010.352; Mehrotra R, 2009, KIDNEY INT, V76, P97, DOI 10.1038/ki.2009.94; Michels WM, 2011, PERITON DIALYSIS INT, V31, P138, DOI 10.3747/pdi.2010.00063; Michels WM, 2009, CLIN J AM SOC NEPHRO, V4, P943, DOI 10.2215/CJN.04440908; Moncrief J W, 1993, ASAIO J, V39, P62, DOI 10.1097/00002480-199301000-00014; Muthucumarana K, 2016, KIDNEY INT REP, V1, P65, DOI 10.1016/j.ekir.2016.05.003; Namachivayam SP, 2019, PEDIATR CRIT CARE ME, V20, P158, DOI 10.1097/PCC.0000000000001793; Paniagua R, 2004, PERITON DIALYSIS INT, V24, P156; Perl J, 2020, AM J KIDNEY DIS, V76, P42, DOI 10.1053/j.ajkd.2019.09.016; Piraino B, 2011, PERITON DIALYSIS INT, V31, P614, DOI 10.3747/pdi.2011.00057; Purnell TS, 2013, AM J KIDNEY DIS, V62, P953, DOI 10.1053/j.ajkd.2013.03.022; Rabindranath KS, 2007, NEPHROL DIAL TRANSPL, V22, P2991, DOI 10.1093/ndt/gfm515; Rocklin MA, 2001, SEMIN DIALYSIS, V14, P37, DOI 10.1046/j.1525-139x.2001.00012.x; Ryu JH, 2015, YONSEI MED J, V56, P666, DOI 10.3349/ymj.2015.56.3.666; Saiprasertkit N, 2018, PERITON DIALYSIS INT, V38, P44, DOI 10.3747/pdi.2017.00134; Santos CR, 2012, PERITON DIALYSIS INT, V32, P273, DOI 10.3747/pdi.2009.00239; Shah H, 2006, PERITON DIALYSIS INT, V26, P684; Song Y, 2012, NEPHROL DIAL TRANSPL, V27, P1639, DOI 10.1093/ndt/gfr504; Sourial MY, 2020, AM J KIDNEY DIS, V76, P401, DOI 10.1053/j.ajkd.2020.06.001; Szeto CC, 2017, PERITON DIALYSIS INT, V37, P141, DOI 10.3747/pdi.2016.00120; Szeto CC, 2014, CLIN J AM SOC NEPHRO, V9, P779, DOI 10.2215/CJN.06620613; Teitelbaum I, 2018, CLIN J AM SOC NEPHRO, V13, P483, DOI 10.2215/CJN.10770917; Teitelbaum I, 2012, PERITON DIALYSIS INT, V32, P131, DOI 10.3747/pdi.2011.00199; TWARDOWSKI ZJ, 1983, KIDNEY INT, V23, P64, DOI 10.1038/ki.1983.12; TZAMALOUKAS AH, 1973, ARCH SURG-CHICAGO, V106, P639; de Luijtgaarden MWM, 2016, NEPHROL DIAL TRANSPL, V31, P120, DOI 10.1093/ndt/gfv295; Wilkie ME, 1997, PERITON DIALYSIS INT, V17, P84; Yohanna S, 2015, CLIN J AM SOC NEPHRO, V10, P1380, DOI 10.2215/CJN.05410514; Zazzeroni L, 2017, KIDNEY BLOOD PRESS R, V42, P717, DOI 10.1159/000484115	85	11	11	4	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2021	385	19					1786	1795		10.1056/NEJMra2100152	http://dx.doi.org/10.1056/NEJMra2100152			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR0CF	34731538				2023-01-03	WOS:000714176800012
J	Kebede, AA; Taye, BT; Wondie, KY; Tiguh, AE; Eriku, GA; Mihret, MS				Kebede, Azmeraw Ambachew; Taye, Birhan Tsegaw; Wondie, Kindu Yinges; Tiguh, Agumas Eskezia; Eriku, Getachew Azeze; Mihret, Muhabaw Shumye			Healthcare provider's adherence to immediate postpartum care guidelines in Gondar province hospitals, northwest Ethiopia: A multicenter study	PLOS ONE			English	Article							EDUCATION	Background The immediate postpartum period is the most critical time for both the mother and the newborn. However, it is the most neglected part of the maternal continuum of care, and evidence in this regard was scarce in Ethiopia. Therefore, this study aimed to assess the healthcare provider's adherence to immediate postpartum care guidelines and associated factors in hospitals of Gondar province. Methods A multicenter observational cross-sectional study was conducted among 406 healthcare providers from 15th November 2020 to 10th March 2021. Data were collected through face-to-face interviews and direct observation using a structured questionnaire and standardized checklist respectively. Data was entered into EPI INFO 7.1.2 and analyzed by SPSS version 25. Both bivariable and multivariable logistic regression analyses were carried out. The level of significance was declared based on the adjusted odds ratio (AOR) with a 95% confidence interval (CI) at a p-value of <= 0.05. Results Overall, 42.4% (95% CI: 37.5, 47.2) of healthcare providers had complete adherence to immediate postpartum care guidelines. Having birth assistant (AOR = 1.87; 95% CI: 1.10, 9.67), being married (AOR = 1.59; 95% CI: 1.15, 3.31), availability of postpartum care guidelines at the maternity ward (AOR = 2.39; 95% CI: 1.44, 3.98), received basic emergency obstetric and newborn care (BEmONC) training (AOR = 2.1; 95% CI: 1.2, 3.6), monthly income of >= 10001 Ethiopian birr (AOR = 3.55; 95% CI: 1.30, 9.67), and work experience of >= 6 years (AOR = 0.15; 95% CI: 0.06, 0.38) were significantly associated with healthcare providers adherence to immediate postpartum care guidelines. Conclusion This study indicated that health worker's adherence to immediate postpartum care guidelines was low. Hiring adequate health workers, availing postpartum guidelines at the maternity ward, improving the salary and education opportunities for healthcare workers of healthcare workers, and provision of BEmONC training will have a great role in improving healthcare provider's adherence to immediate postpartum care guidelines.	[Kebede, Azmeraw Ambachew; Wondie, Kindu Yinges; Tiguh, Agumas Eskezia; Mihret, Muhabaw Shumye] Univ Gondar, Coll Med & Hlth Sci, Sch Midwifery, Dept Clin Midwifery, Gondar, Ethiopia; [Taye, Birhan Tsegaw] Debre Berhan Univ, Coll Med & Hlth Sci, Dept Clin Midwifery, Debre Berhan, Ethiopia; [Eriku, Getachew Azeze] Univ Gondar, Coll Med & Hlth Sci, Dept Physiotherapy, Gondar, Ethiopia	University of Gondar; University of Gondar	Kebede, AA (corresponding author), Univ Gondar, Coll Med & Hlth Sci, Sch Midwifery, Dept Clin Midwifery, Gondar, Ethiopia.	azmuzwagholic@gmail.com	Wondie, Kindu Yinges/AFM-6063-2022; Kebede, Azmeraw Ambachew/ABE-1909-2021; Taye, Birhan Tsegaw/AAX-6617-2021	Wondie, Kindu Yinges/0000-0002-2769-0385; Kebede, Azmeraw Ambachew/0000-0003-0831-8470; Taye, Birhan Tsegaw/0000-0003-2174-3797; Mihret, Muhabaw/0000-0002-4595-5578				[Anonymous], 2018, AM COLL OBSTET GYNEC, V131, P35; [Anonymous], 2017, TRENDS MATERNAL MORT; [Anonymous], 2017, WHOMCA1710; [Anonymous], 2012, STATE ETHIOPIANS MID; [Anonymous], 2016, IMPORTANT NEW PARTNE; [Anonymous], 2011, ETHIOPIA DEMOGRAPHIC, P452; [Anonymous], 2013, WHO RECOMMENDATIONS; Arba A, 2020, INT J PEDIAT, V2020, DOI 10.1155/2020/3647309; Benova L, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002943; Beraki GG, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-019-2694-8; Bordignon M, 2019, REV LAT-AM ENFERM, V27, DOI 10.1590/1518-8345.3280.3219; Centeral statical agency of Ethiopia and ICF, 2016, ETH DEM HLTH SURV; Central Statistical Agency, 2001, ETH DHS 2000, P1; Central Statistical Agency ORC Macro, 2006, HEAL SAN FR, P446; Dlamini BR., 2017, J AIDS CLIN RES, V8; Figueiredo KMS, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0817-x; Filby A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153391; Gavine A, 2019, MIDWIFERY, V78, P104, DOI 10.1016/j.midw.2019.08.007; Haftu Abera, 2018, BMC Res Notes, V11, P872, DOI 10.1186/s13104-018-3987-0; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Langlois EV, 2015, B WORLD HEALTH ORGAN, V93, P259, DOI 10.2471/BLT.14.140996; Lu Y, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011388; Mannava P, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0117-9; Matthews Mathai, 2010, DEP MAK PREGNACY SAF; Nove A, 2021, LANCET GLOB HEALTH, V9, pE24, DOI 10.1016/S2214-109X(20)30397-1; Odonkor ST, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/1614968; Otolorin E, 2015, INT J GYNECOL OBSTET, V130, pS46, DOI 10.1016/j.ijgo.2015.03.007; Sandall J, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004667.pub5, 10.1002/14651858.CD004667.pub3]; Tasneem S., 2018, The Open Public Health Journal, V11, P17, DOI 10.2174/1874944501811010017; Trends in Maternal Mortality Estimates by WHO UNICEF World Bank Group and the UN Population Division, 2019, UNICEF DAT MON SIT C; UN Inter-agency Group for Child Mortality, 2020, LEVELS TRENDS CHILD; Yigzaw T, 2016, INT J WOMENS HEALTH, V8, P181, DOI 10.2147/IJWH.S105046	32	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2021	16	10							e0259263	10.1371/journal.pone.0259263	http://dx.doi.org/10.1371/journal.pone.0259263			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ6CS	34710191	Green Published, gold			2023-01-03	WOS:000755563200087
J	Rossin, S; Barbieri, E; Cantarutti, A; Martinolli, F; Giaquinto, C; Da Dalt, L; Dona, D				Rossin, Sara; Barbieri, Elisa; Cantarutti, Anna; Martinolli, Francesco; Giaquinto, Carlo; Da Dalt, Liviana; Dona, Daniele			Multistep antimicrobial stewardship intervention on antibiotic prescriptions and treatment duration in children with pneumonia	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; GUIDELINES	Introduction The Italian antimicrobial prescription rate is one of the highest in Europe, and antibiotic resistance has become a serious problem with high costs and severe consequences, including prolonged illnesses, the increased period of hospitalization and mortality. Inadequate antibiotic prescriptions have been frequently reported, especially for lower respiratory tract infections (LRTI); many patients receive antibiotics for viral pneumonia or bronchiolitis or broad-spectrum antibiotics for not complicated community-acquired pneumonia. For this reason, healthcare organizations need to implement strategies to raise physicians' awareness about this kind of drug and their overall effect on the population. The implementation of antibiotic stewardship programs and the use of Clinical Pathways (CPs) are excellent solutions because they have proven to be effective tools at diagnostic and therapeutic levels. Aims This study evaluates the impact of CPs implementation in a Pediatric Emergency Department (PED), analyzing antibiotic prescriptions before and after the publication in 2015 and 2019. The CP developed in 2019 represents an update of the previous one with the introduction of serum procalcitonin. The study aims to evaluate the antibiotic prescriptions in patients with community-acquired pneumonia (CAP) before and after both CPs (2015 and 2019). Methods The periods analyzed are seven semesters (one before CP-2015 called PRE period, five post CP-2015 called POST 1-5 and 1 post CP-2019 called POSTE). The patients have been split into two groups: (i) children admitted to the Pediatric Acute Care Unit (INPATIENTS), and (ii) patients evaluated in the PED and sent back home (OUTPATIENTS). We have analyzed all descriptive diagnosis of CAP (the assessment of episodes with a descriptive diagnosis were conducted independently by two pediatricians) and CAP with ICD9 classification. All antibiotic prescriptions for pediatric patients with CAP were analyzed. Results A drastic reduction of broad-spectrum antibiotics prescription for inpatients has been noticed; from 100.0% in the PRE-period to 66.7% in POST1, and up to 38.5% in POST6. Simultaneously, an increase in amoxicillin use from 33.3% in the PRE-period to 76.1% in POST1 (p-value 0.078 and 0.018) has been seen. The outpatients' group's broad-spectrum antibiotics prescriptions decreased from 54.6% PRE to 17.4% in POST6. Both for outpatients and inpatients, there was a decrease of macrolides. The inpatient group's antibiotic therapy duration decreased from 13.5 days (PRE-period) to 7.0 days in the POST6. Antibiotic therapy duration in the outpatient group decreased from 9.0 days (PRE) to 7.0 days (POST1), maintaining the same value in subsequent periods. Overlapping results were seen in the ICD9 group for both inpatients and outpatients. Conclusions This study shows that CPs are effective tools for an antibiotic stewardship program. Indeed, broad-spectrum antibiotics usage has dropped and amoxicillin prescriptions have increased after implementing the CAP CP-2015 and the 2019 update.	[Rossin, Sara; Martinolli, Francesco; Da Dalt, Liviana] Univ Padua, Pediat Emergency Dept, Dept Woman & Child Hlth, Padua, Italy; [Barbieri, Elisa; Giaquinto, Carlo; Dona, Daniele] Univ Padua, Dept Woman & Child Hlth, Div Pediat Infect Dis, Padua, Italy; [Cantarutti, Anna] Univ Milano Bicocca, Natl Ctr Healthcare Res & Pharmacoepidemiol, Dept Stat & Quantitat Methods, Milan, Italy; [Cantarutti, Anna] Univ Milano Bicocca, Dept Stat & Quantitat Methods, Unit Biostat Epidemiol & Publ Hlth, Milan, Italy	University of Padua; University of Padua; University of Milano-Bicocca; University of Milano-Bicocca	Rossin, S (corresponding author), Univ Padua, Pediat Emergency Dept, Dept Woman & Child Hlth, Padua, Italy.	sara.rossin1988@gmail.com	Barbieri, Elisa/W-7086-2019; Barbieri, Elisa/GQH-7032-2022	Barbieri, Elisa/0000-0003-0850-8784; GIAQUINTO, CARLO/0000-0001-9365-0413				Ambroggio L, 2013, PEDIATRICS, V131, pE1623, DOI 10.1542/peds.2012-2635; Baer G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068419; Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI [10.1093/cid/cir531, 10.1093/cid/cir625]; Cardinale F, 2013, EARLY HUM DEV, V89, pS49, DOI 10.1016/j.earlhumdev.2013.07.023; Charani E, 2011, CLIN INFECT DIS, V53, P651, DOI 10.1093/cid/cir445; Christ-Crain M, 2004, LANCET, V363, P600, DOI 10.1016/S0140-6736(04)15591-8; Clavenna A, 2011, ARCH DIS CHILD, V96, P590, DOI 10.1136/adc.2010.183541; Di Pietro P, 2017, ITAL J PEDIATR, V43, DOI 10.1186/s13052-017-0432-2; Don M, 2010, ACTA PAEDIATR, V99, P1602, DOI 10.1111/j.1651-2227.2010.01924.x; Dona D, 2020, ANTIMICROB RESIST IN, V9, DOI 10.1186/s13756-019-0659-3; Dona D, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9060490; Dona D, 2018, PEDIATR INFECT DIS J, V37, P901, DOI [10.1097/INF.0000000000001976, 10.1097/inf.0000000000001976]; Dona D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193581; Esposito S, 2011, RESP MED, V105, P1939, DOI 10.1016/j.rmed.2011.09.003; Frei CR, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-188; Gotta V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185197; Hakenbeck R, 2012, FUTURE MICROBIOL, V7, P395, DOI [10.2217/FMB.12.2, 10.2217/fmb.12.2]; Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598; Hawley S, 2019, CLIN EPIDEMIOL, V11, P197, DOI 10.2147/CLEP.S176723; Jenkins TC, 2013, AM J MED, V126, P327, DOI 10.1016/j.amjmed.2012.10.027; Liu Wei., SIMULATION BASED POW; Marrie TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/jama.283.6.749; Mewes JC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214222; Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769; Samore MH, 2005, JAMA-J AM MED ASSOC, V294, P2305, DOI 10.1001/jama.294.18.2305; Schuetz P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007498.pub3; Smith J, 2012, PEDIATRICS, V129, pE1326, DOI 10.1542/peds.2011-2412; South M, 2003, MED J AUSTRALIA, V178, P207, DOI 10.5694/j.1326-5377.2003.tb05163.x; Stein RT, 2007, PEDIATR PULM, V42, P1095, DOI 10.1002/ppul.20652; Stockmann C, 2018, J PEDIAT INF DIS SOC, V7, P46, DOI 10.1093/jpids/piw091	30	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2021	16	10							e0257993	10.1371/journal.pone.0257993	http://dx.doi.org/10.1371/journal.pone.0257993			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ7EW	34705849	gold, Green Published			2023-01-03	WOS:000755636500011
J	Van Dyk, K; Ganz, PA				Van Dyk, Kathleen; Ganz, Patricia A.			Cancer-Related Cognitive Impairment in Patients With a History of Breast Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SURVIVORS	This JAMA Insights Clinical Update discusses cancer-related cognitive impairment, including risks, management recommendations, and cognitive and behavioral treatments.	[Van Dyk, Kathleen] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Psychiat & Biobehav Sci, Semel Inst, Los Angeles, CA 90024 USA; [Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Fielding Sch Publ Hlth, Los Angeles, CA 90024 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Ganz, PA (corresponding author), UCLA, Jonsson Comprehens Canc Ctr, 650 Charles Young Dr S,Room A2-125 CHS, Los Angeles, CA 90095 USA.	pganz@mednet.ucla.edu		Ganz, Patricia/0000-0002-1841-4143	NCI NIH HHS [R35 CA197289] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernstein LJ, 2017, NEUROSCI BIOBEHAV R, V83, P417, DOI 10.1016/j.neubiorev.2017.10.028; Buchanan ND, 2015, AM J PREV MED, V49, pS498, DOI 10.1016/j.amepre.2015.08.013; Fernandes HA, 2019, SUPPORT CARE CANCER, V27, P3253, DOI 10.1007/s00520-019-04866-2; Hurria A, 2007, CANCER INVEST, V25, P373, DOI 10.1080/07357900701506672; Janelsins MC, 2018, J CLIN ONCOL, V36, P3231, DOI 10.1200/JCO.2018.78.6624; Janelsins MC, 2017, J CLIN ONCOL, V35, P506, DOI 10.1200/JCO.2016.68.5826; Lange M, 2019, ANN ONCOL, V30, P1925, DOI 10.1093/annonc/mdz410; Ruddy KJ, 2019, JAMA-J AM MED ASSOC, V321, P1716, DOI 10.1001/jama.2019.3927; Wagner LI, 2020, J CLIN ONCOL, V38, P1875, DOI 10.1200/JCO.19.01866; Wefel JS, 2015, CA-CANCER J CLIN, V65, P123, DOI 10.3322/caac.21258	10	3	3	3	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2021	326	17					1736	1737		10.1001/jama.2021.13309	http://dx.doi.org/10.1001/jama.2021.13309		OCT 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW8DB	34652424	Bronze			2023-01-03	WOS:000707427100001
J	Bennardi, M; Diviani, N; Stussi, G; Saletti, P; Gamondi, C; Cinesi, I; Rubinelli, S				Bennardi, Marco; Diviani, Nicola; Stuessi, Georg; Saletti, Piercarlo; Gamondi, Claudia; Cinesi, Ivan; Rubinelli, Sara			A qualitative exploration of interactional and organizational determinants of collaboration in cancer palliative care settings: Family members', health care professionals' and key informants' perspectives	PLOS ONE			English	Article							IMPLEMENTATION; BARRIERS; NURSES	As life expectancy has increased, a growing number of people experience conditions, including cancers, that carry complex health and social needs. Palliative care services have the potential to address these needs but face significant obstacles. One major obstacle is suboptimal interprofessional collaboration. This study's goal was an in-depth exploration of interactional and organizational barriers and supports of collaboration in palliative care in Switzerland. We sought the perspectives of health care professionals, patients' family members and leaders and experts in oncology/palliative care delivery (key informants) through interviews and focus groups with fifty HPs and key informants and ten patients' family members. Qualitative analyses of interviews and focus groups used framework analysis. We identified three major themes of interaction: personal characteristics, communication, and connectedness with other health care professionals; and three major organizational themes: service characteristics, standardized communication and processes, and service coordination and promotion. Based on our findings, we recommend that health care professionals consider strategies to increase their collaboration and communication skills and opportunities to interact. We advocate the implementation of methods for coordinating services, standardization of consultation/referral procedures and communication between health care professionals, and the promotion of underutilized services to foster successful, sustainable collaboration.	[Bennardi, Marco; Diviani, Nicola; Rubinelli, Sara] Swiss Parapleg Res, Person Ctr Healthcare & Hlth Commun, Nottwil, Canton Of Lucer, Switzerland; [Bennardi, Marco; Diviani, Nicola; Rubinelli, Sara] Univ Lucerne, Dept Hlth Sci & Med, Luzern, Canton Of Lucer, Switzerland; [Stuessi, Georg] Osped San Giovanni Bellinzona, Oncol Inst Southern Switzerland, Hematol, Bellinzona, Canton Of Ticin, Switzerland; [Saletti, Piercarlo] Clin Luganese Moncucco, Lugano, Canton Of Ticin, Switzerland; [Gamondi, Claudia] Osped San Giovanni Bellinzona, Oncol Inst Southern Switzerland, Palliat Care, Bellinzona, Canton Of Ticin, Switzerland; [Cinesi, Ivan] Palliat TI Assoc Cure Palliat Ticino, Cadenazzo, Canton Of Ticin, Switzerland	Swiss Paraplegic Research; University of Lucerne; Institute of Oncology Research (IOR); Regional Hospital of Bellinzona & Valleys, San Giovanni; Institute of Oncology Research (IOR); Regional Hospital of Bellinzona & Valleys, San Giovanni	Bennardi, M (corresponding author), Swiss Parapleg Res, Person Ctr Healthcare & Hlth Commun, Nottwil, Canton Of Lucer, Switzerland.; Bennardi, M (corresponding author), Univ Lucerne, Dept Hlth Sci & Med, Luzern, Canton Of Lucer, Switzerland.	marco.bennardi@gmail.com	Bennardi, Marco/ABC-4493-2020	Bennardi, Marco/0000-0001-8934-5416	Swiss Cancer League [KFS-4163-02-2017]	Swiss Cancer League	Funding for this research was awarded to SR, ND, CG, GS, and PS under a grant, which was financed by the Swiss Cancer League (Grant number KFS-4163-02-2017). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beernaert K, 2014, PALLIATIVE MED, V28, P480, DOI 10.1177/0269216314522318; Bennardi M, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00556-7; Cabello Charlotte C, 2002, Outcomes Manag, V6, P67; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; D'Amour D., 2004, INTERDISCIPLINARY ED, P63; Dumanovsky T, 2016, J PALLIAT MED, V19, P8, DOI 10.1089/jpm.2015.0351; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Gidwani R, 2017, J PALLIAT MED, V20, P395, DOI 10.1089/jpm.2016.0399; Glare PA, 2013, J NATL COMPR CANC NE, V11, pS3; Grant R., 1995, INTERDISCIPLINARY CO; Groot MM, 2005, PALLIATIVE MED, V19, P111, DOI 10.1191/0269216305pm937oa; Gum LF, 2012, J INTERPROF CARE, V26, P21, DOI 10.3109/13561820.2011.636157; Hui D, 2016, NAT REV CLIN ONCOL, V13, P159, DOI 10.1038/nrclinonc.2015.201; Kontis V, 2017, LANCET, V389, P1323, DOI 10.1016/S0140-6736(16)32381-9; Kvale SaB Svend, 2009, INTERVIEWS LEARNING, V2nd; McDarby M, 2019, AM J HOSP PALLIAT ME, V36, P191, DOI 10.1177/1049909118793635; McMillan E., 2002, TACKLING IND COMPLEX, P123; Mishler E.G., 1991, RES INTERVIEWING; Morley L, 2017, J MED IMAGING RADIAT, V48, P207, DOI 10.1016/j.jmir.2017.02.071; Newhouse RP, 2010, NURS OUTLOOK, V58, P309, DOI 10.1016/j.outlook.2010.09.001; Ritchie, 2003, QUALITATIVE RES PRAC, DOI DOI 10.4135/9781452230108; Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI [DOI 10.4324/9780203413081_CHAPTER_9, 10.4324/9780203413081_chapter_9]; San Martin-Rodriguez Leticia, 2005, J Interprof Care, V19 Suppl 1, P132; Schenker Y, 2014, J ONCOL PRACT, V10, pE37, DOI 10.1200/JOP.2013.001130; Spencer L, 2003, QUALITATIVE RES PRAC, P199; Taskin N., INTERDISCIPLINARY CO; WHO W-H-O, 2015, WORLD REP AG HLTH; Zhang Z, 2014, AM J HOSP PALLIAT ME, V31, P338, DOI 10.1177/1049909113484168	28	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2021	16	10							e0256965	10.1371/journal.pone.0256965	http://dx.doi.org/10.1371/journal.pone.0256965			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ9DX	34613982	gold, Green Published			2023-01-03	WOS:000749604400014
J	Chouairi, F; Mullan, CW; Ravindra, N; Clark, KAA; Jaffe, EM; Bhinder, J; Fuery, M; Guha, A; Ahmad, T; Desai, NR				Chouairi, Fouad; Mullan, Clancy W.; Ravindra, Neal; Clark, Katherine A. A.; Jaffe, Edward M.; Bhinder, Jasjit; Fuery, Michael; Guha, Avirup; Ahmad, Tariq; Desai, Nihar R.			Brief report: Cannabis and opioid use disorder among heart failure admissions, 2008-2018	PLOS ONE			English	Article							READMISSION; PREVALENCE; MARIJUANA	Background In the United States, both cannabis use disorder (CUD) and opioid use disorder (OUD) have increased in prevalence. The prevalence, demographics, and costs of CUD and OUD are not well known in heart failure (HF) admissions. This study aimed to use a national database to examine the prevalence, demographics, and costs associated with CUD and OUD in HF. Methods This study used the National Inpatient Sample from 2008 to 2018 to identify all primary HF admissions with and without the co-diagnosis of OUD or CUD using International Classification for Diagnosis, diagnosis codes. Demographics, costs, and trends were examined. Results Between 2008 and 2018, we identified 11,692,995 admissions for HF of which 84,796 (0.8%) had a co-diagnosis of CUD only, and 67,137 (0.6%) had a co-diagnosis of OUD only. The proportion of HF admissions with CUD significantly increased from 0.3% in 2008 to 1.3% in 2018 (p < 0.001). The proportion of HF admissions with OUD significantly increased from 0.2% in 2008 to 1.1% in 2018 (p < 0.001). Patients admitted with HF and either CUD or OUD were younger, more likely to be Black, and from lower socioeconomic backgrounds (p < 0.001, all). HF admissions with OUD or CUD had higher median costs compared to HF admissions without associated substance abuse diagnoses ($8,611 vs. $8,337 for CUD HF and $10,019 vs. $8,337 for OUD HF, p < 0.001 for both). Conclusions Among discharge records for HF, CUD and OUD are increasing in prevalence, significantly affect underserved populations and are associated with higher costs of stay. Future research is essential to better delineate the cause of these increased costs and create interventions, particularly in underserved populations.	[Chouairi, Fouad] Duke Univ, Med Ctr, Dept Internal Med, Durham, NC 27710 USA; [Mullan, Clancy W.] Yale Sch Med, Div Cardiac Surg, New Haven, CT USA; [Ravindra, Neal; Clark, Katherine A. A.; Bhinder, Jasjit; Fuery, Michael; Ahmad, Tariq; Desai, Nihar R.] Yale Sch Med, Dept Internal Med, Div Cardiovasc Med, New Haven, CT 06510 USA; [Ravindra, Neal] Stanford Univ, Dept Comp Sci, Palo Alto, CA 94304 USA; [Jaffe, Edward M.] George Washington Univ, Dept Anesthesiol & Crit Care Med, Washington, DC USA; [Guha, Avirup] Case Western Reserve Univ, Cleveland, OH 44106 USA	Duke University; Yale University; Yale University; Stanford University; George Washington University; Case Western Reserve University	Chouairi, F (corresponding author), Duke Univ, Med Ctr, Dept Internal Med, Durham, NC 27710 USA.; Desai, NR (corresponding author), Yale Sch Med, Dept Internal Med, Div Cardiovasc Med, New Haven, CT 06510 USA.	Fouad.chouairi@yale.edu; Nihar.desai@yale.edu	; Ahamed, Tariq/E-8985-2016; Guha, Avirup/P-5929-2016	Ravindra, Neal/0000-0001-5558-3758; Clark, Katherine A.A./0000-0003-0797-9875; Ahamed, Tariq/0000-0002-4525-0738; Jaffe, Edward/0000-0002-1300-484X; Guha, Avirup/0000-0003-0253-1174				Akintoye E, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006955; Alinejad S, 2015, EXCLI J, V14, P577, DOI 10.17179/excli2015-553; Bonz A, 2003, J CARDIOVASC PHARM, V41, P657, DOI 10.1097/00005344-200304000-00020; Chang HY, 2018, BMC MED, V16, DOI [10.1186/S12916-018-1058-y, 10.1186/s12916-018-1058-y]; Compton WM, 2019, DRUG ALCOHOL DEPEN, V204, DOI 10.1016/j.drugalcdep.2019.05.008; Dispennette Rachel, 2014, Consult Pharm, V29, P158, DOI 10.4140/TCP.n.2014.158; Grant BF, 2016, JAMA PSYCHIAT, V73, P39, DOI 10.1001/jamapsychiatry.2015.2132; Gupta T, 2016, AM J THER, V23, pE350, DOI 10.1097/MJT.0000000000000190; Hasin DS, 2015, JAMA PSYCHIAT, V72, P1235, DOI 10.1001/jamapsychiatry.2015.1858; Healthcare Cost and Utilization Project (HCUP), 2019, OVERVEIW NATL NATION; Kadri AN, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012969; Kalla A, 2018, J CARDIOVASC MED, V19, P480, DOI 10.2459/JCM.0000000000000681; Labor Do, INFLATION CONSUMER S; Latif Z, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061925; Lesyuk W, 2018, BMC CARDIOVASC DISOR, V18, DOI 10.1186/s12872-018-0815-3; MANCINI DM, 1994, J AM COLL CARDIOL, V24, P972, DOI 10.1016/0735-1097(94)90858-3; Nishimura M, 2020, AM J MED, V133, P207, DOI 10.1016/j.amjmed.2019.07.017; Oldenburg O, 2007, EUR J HEART FAIL, V9, P251, DOI 10.1016/j.ejheart.2006.08.003; Pacher P, 2018, NAT REV CARDIOL, V15, P151, DOI 10.1038/nrcardio.2017.130; Smith MW, 2015, COMMUNITY MENT HLT J, V51, P190, DOI 10.1007/s10597-014-9784-x; van Draanen Jenna, 2020, Drug Alcohol Depend, V214, P108127, DOI 10.1016/j.drugalcdep.2020.108127; Van Ryswyk E, 2016, CHEST, V150, P934, DOI 10.1016/j.chest.2016.05.022; Zhu H, 2020, DRUG ALCOHOL DEPEN, V213, DOI 10.1016/j.drugalcdep.2020.108113	23	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2021	16	9							e0255514	10.1371/journal.pone.0255514	http://dx.doi.org/10.1371/journal.pone.0255514			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YI5QV	34591847	Green Published, gold			2023-01-03	WOS:000743903000005
J	Cheah, KL; Norhayati, MN; Yaacob, LH; Rahman, RA				Cheah, Kae Ling; Norhayati, Mohd Noor; Yaacob, Lili Husniati; Rahman, Razlina Abdul			Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis	PLOS ONE			English	Review							INDIAN GINSENG; KOREAN ADULTS; DOUBLE-BLIND; DURATION; RISK; ACTIGRAPHY; QUALITY; MEDICINE; HEALTH; POLYSOMNOGRAPHY	Objective To determine the effect of Ashwagandha extract on sleep. Methods A comprehensive search was conducted in CENTRAL, MEDLINE, SCOPUS, Google Scholars, World Health Organization Trials Portal, ClinicalTrials.gov, Clinical Trial Registry of India, and AYUSH Research Portal for all appropriate trials. Randomized controlled trials that examined the effect of Ashwagandha extract versus placebo on sleep in human participants 18 years old and above were considered. Two authors independently read all trials and independently extracted all relevant data. The primary outcomes were sleep quantity and sleep quality. The secondary outcomes were mental alertness on rising, anxiety level, and quality of life. Results A total of five randomized controlled trials containing 400 participants were analyzed. Ashwagandha extract exhibited a small but significant effect on overall sleep (Standardized Mean Difference -0.59; 95% Confidence Interval -0.75 to -0.42; I-2 = 62%). The effects on sleep were more prominent in the subgroup of adults diagnosed with insomnia, treatment dosage >= 600 mg/day, and treatment duration >= 8 weeks. Ashwagandha extract was also found to improve mental alertness on rising and anxiety level, but no significant effect on quality of life. No serious side effects were reported. Conclusion Ashwagandha extract appears to has a beneficial effect in improving sleep in adults. However, data on the serious adverse effects of Ashwagandha extract are limited, and more safety data would be needed to assess whether it would be safe for long-term use.	[Cheah, Kae Ling; Norhayati, Mohd Noor; Yaacob, Lili Husniati; Rahman, Razlina Abdul] Univ Sains Malaysia, Sch Med Sci, Dept Family Med, Kota Baharu, Kelantan, Malaysia	Universiti Sains Malaysia	Yaacob, LH (corresponding author), Univ Sains Malaysia, Sch Med Sci, Dept Family Med, Kota Baharu, Kelantan, Malaysia.	husniati@usm.my	Rahman, Razlina Abdul/P-2575-2015; Norhayati, Mohd Noor/E-3868-2012	Rahman, Razlina Abdul/0000-0003-2593-1832; Norhayati, Mohd Noor/0000-0002-6372-1476; Cheah, Kae Ling/0000-0003-3474-2814				Abedon B., 2008, JANA, V11; Altevogt BM, 2006, SLEEP DISORDERS SLEE; Bacaro V, 2020, OBES RES CLIN PRACT, V14, P301, DOI 10.1016/j.orcp.2020.03.004; Baek Y, 2020, SLEEP MED, V70, P60, DOI 10.1016/j.sleep.2020.02.006; Bhattarai JP, 2010, PHYTOTHER RES, V24, P1147, DOI 10.1002/ptr.3088; Bonilla Diego A, 2021, J Funct Morphol Kinesiol, V6, DOI 10.3390/jfmk6010020; Boulos MI, 2019, LANCET RESP MED, V7, P533, DOI 10.1016/S2213-2600(19)30057-8; Cao YT, 2016, NUTRITION, V32, P970, DOI 10.1016/j.nut.2016.02.012; Rodriguez JC, 2015, MED CLIN N AM, V99, P431, DOI 10.1016/j.mcna.2014.11.013; Chandrasekhar K, 2012, Indian J Psychol Med, V34, P255, DOI 10.4103/0253-7176.106022; Chaput JP, 2018, NAT SCI SLEEP, V10, P421, DOI 10.2147/NSS.S163071; Chimanchod PI., 2020, JAIMS, V5, P123; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Cunnington D, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5819; Deshpande A, 2020, SLEEP MED, V72, P28, DOI 10.1016/j.sleep.2020.03.012; Deshpande A, 2018, MEDICINE, V97, DOI [10.1097/md.0000000000011299, 10.1097/MD.0000000000011299]; Durg S, 2018, PHYTOMEDICINE, V50, P247, DOI 10.1016/j.phymed.2017.11.011; Fekedulegn D, 2020, ANN WORK EXPOS HEAL, V64, P350, DOI 10.1093/annweh/wxaa007; Ford ES, 2015, SLEEP, V38, P829, DOI 10.5665/sleep.4684; Frass M, 2012, OCHSNER J, V12, P45; Guo XF, 2013, SLEEP MED, V14, P324, DOI 10.1016/j.sleep.2012.12.001; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hillman D, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy083; Hirshkowitz M, 2004, MED CLIN N AM, V88, P551, DOI 10.1016/j.mcna.2004.01.001; Hirshkowitz M, 2015, SLEEP HEALTH, V1, P40, DOI 10.1016/j.sleh.2014.12.010; Hrehova L, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14084; Itani O, 2017, SLEEP MED, V32, P246, DOI 10.1016/j.sleep.2016.08.006; Kaushik MK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172508; Kelgane SB, 2020, CUREUS, V12, DOI 10.7759/cureus.7083; Khurshid KA., 2015, REV CHANGES DSM 5 SL; Langade D, 2021, J ETHNOPHARMACOL, V264, DOI 10.1016/j.jep.2020.113276; Langade D, 2019, CUREUS, V11, DOI 10.7759/cureus.5797; Levenson JC, 2015, CHEST, V147, P1179, DOI 10.1378/chest.14-1617; Li WZ, 2016, INT J CARDIOL, V223, P870, DOI 10.1016/j.ijcard.2016.08.302; Lopresti AL, 2021, J HERB MED, V28, DOI 10.1016/j.hermed.2021.100434; Manzar Md Dilshad, 2015, Oman Med J, V30, P193, DOI 10.5001/omj.2015.41; Marino M, 2013, SLEEP, V36, P1747, DOI 10.5665/sleep.3142; Mendonca F, 2019, IEEE ACCESS, V7, P24527, DOI 10.1109/ACCESS.2019.2900345; Miner B, 2017, SLEEP MED CLIN, V12, P31, DOI 10.1016/j.jsmc.2016.10.008; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Mollayeva T, 2016, SLEEP MED REV, V25, P52, DOI 10.1016/j.smrv.2015.01.009; Morin CM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.26; Mukherjee PK, 2021, J ETHNOPHARMACOL, V264, DOI 10.1016/j.jep.2020.113157; Ng QX, 2020, PHYTOTHER RES, V34, P583, DOI 10.1002/ptr.6552; Nussbaumer-Streit B, 2020, J CLIN EPIDEMIOL, V118, P42, DOI 10.1016/j.jclinepi.2019.10.011; Ohayon M, 2017, SLEEP HEALTH, V3, P6, DOI 10.1016/j.sleh.2016.11.006; Pratte MA, 2014, J ALTERN COMPLEM MED, V20, P901, DOI 10.1089/acm.2014.0177; Raut Ashwinikumar A, 2012, J Ayurveda Integr Med, V3, P111, DOI 10.4103/0975-9476.100168; Ruchi Tiwari, 2014, Journal of Biological Sciences, V14, P77; Sadeh A, 2011, SLEEP MED REV, V15, P259, DOI 10.1016/j.smrv.2010.10.001; Salahuddin M, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0637-5; Salve J, 2019, CUREUS, V11, DOI 10.7759/cureus.6466; Schupp M., 2003, BJA CEPD REV, V3, P69, DOI [10.1093/bjacepd/mkg069, DOI 10.1093/BJACEPD/MKG069]; Sengupta P, 2018, REPROD BIOMED ONLINE, V36, P311, DOI 10.1016/j.rbmo.2017.11.007; Shan ZL, 2015, DIABETES CARE, V38, P529, DOI 10.2337/dc14-2073; Sharma U. K., 2015, Environment Conservation Journal, V16, P159; Shin D, 2018, SLEEP MED, V52, P103, DOI 10.1016/j.sleep.2018.08.008; Singh P, 2015, BIOTECHNOL GENET ENG, V31, P1, DOI 10.1080/02648725.2015.1020467; Smith MT, 2018, J CLIN SLEEP MED, V14, P1209, DOI 10.5664/jcsm.7228; Srivastava A, 2018, J GINSENG RES, V42, P158, DOI 10.1016/j.jgr.2017.01.014; Suzuki K, 2017, J GEN FAM MED, V18, P61, DOI 10.1002/jgf2.27; Tetali SD, 2021, J ETHNOPHARMACOL, V267, DOI 10.1016/j.jep.2020.113469; van de Water ATM, 2011, J SLEEP RES, V20, P183, DOI 10.1111/j.1365-2869.2009.00814.x; Varghese NE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72612-4; Vyazovskiy VV, 2014, NEUROSCIENTIST, V20, P203, DOI 10.1177/1073858413518152; Wang DM, 2016, INT J CARDIOL, V219, P231, DOI 10.1016/j.ijcard.2016.06.027; Wang QJ, 2012, HYPERTENS RES, V35, P1012, DOI 10.1038/hr.2012.91; Xi B, 2014, SLEEP MED REV, V18, P293, DOI 10.1016/j.smrv.2013.06.001	68	2	2	4	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2021	16	9							e0257843	10.1371/journal.pone.0257843	http://dx.doi.org/10.1371/journal.pone.0257843			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY2YF	34559859	gold, Green Published			2023-01-03	WOS:000754657900047
J	Rana, MA; Mahmood, R; Ali, S				Rana, Muhammad Ajmal; Mahmood, Rashid; Ali, Sajid			Soil urease inhibition by various plant extracts	PLOS ONE			English	Article							EFFICIENCY; PROTEINS; ASSAY	Urea is the most popular and widely used nitrogenous fertilizer. High soil urease activity rapidly hydrolyses applied urea to ammonia which contributes to soil nitrogen (N) losses and reduces N use efficiency of crop plants. The ammonia losses can be minimized by the inhibition of soil urease activity which has been explored using various potential chemical inhibitors. However, the soil urease activity inhibition potential of plant extracts is rarely explored to date. In the present study, extracts of 35 plant materials were taken and evaluated against jack bean urease. Eleven extracts, showing >50% jack bean urease inhibition, were selected and further investigated in 13 soils collected from various districts of Punjab, Pakistan. Interestingly, except Capsicum annum, Melia azedarach, Citrus reticulata and Quercus infectoria, the plant extracts showed urease inhibition activities in soils, the extent of which was lower as compared to that observed in jack bean urease though. Maximum urea hydrolysis inhibition (70%) was noted with Vachellia nilotica which was 40% more than that of hydroquinone (50%) followed by that of Eucalyptus camaldulensis (24%). The extracts of V. nilotica and E. camaldulensis were coated on urea and applied to soil in the next step. At 21(st) day, 239% and 116% more urea-N was recovered from soil treated with V. nilotica and E. camaldulensis extracts coated urea, respectively, as compared to uncoated urea. Conclusively, these results indicated that the coating of V. nilotica and E. camaldulensis extracts on urea prills prolonged urea persistence in soil owing to minimum urea hydrolysis, probably, the extracts of V. nilotica and E. camaldulensis showed their urease inhibition potential. The results of this study provide a base line for the identification of new soil urease inhibitor compounds from plant materials in future.	[Rana, Muhammad Ajmal; Ali, Sajid] Univ Punjab, Dept Agron, Lahore, Pakistan; [Mahmood, Rashid] Univ Punjab, Dept Soil Sci, Lahore, Pakistan	University of Punjab; University of Punjab	Mahmood, R (corresponding author), Univ Punjab, Dept Soil Sci, Lahore, Pakistan.	rashid.iags@pu.edu.pk			Higher Education Commission of Pakistan	Higher Education Commission of Pakistan(Higher Education Commission of Pakistan)	M. Ajmal Rana received funding for his Ph.D. from Higher Education Commission of Pakistan (www.hec.gov.pk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas HMK, 2020, NAT PROD COMMUN, V15, DOI 10.1177/1934578X20920983; Allende-Montalban R, 2021, AGRICULTURE-BASEL, V11, DOI 10.3390/agriculture11070684; Amin M, 2013, MOLECULES, V18, P2135, DOI 10.3390/molecules18022135; Amtul Z, 2002, CURR MED CHEM, V9, P1323, DOI 10.2174/0929867023369853; Del-Castillo-Alonso MA, 2016, J AGR FOOD CHEM, V64, P8722, DOI 10.1021/acs.jafc.6b03272; Azizian H, 2020, CHEMISTRYSELECT, V5, P4580, DOI 10.1002/slct.202000578; Breuillin-Sessoms F, 2017, SOIL BIOL BIOCHEM, V111, P143, DOI 10.1016/j.soilbio.2017.04.007; Callahan BP, 2005, J AM CHEM SOC, V127, P10828, DOI 10.1021/ja0525399; Cambui CA, 2009, PHYSIOL PLANTARUM, V136, P86, DOI 10.1111/j.1399-3054.2009.01217.x; Cantarella H, 2018, J ADV RES, V13, P19, DOI 10.1016/j.jare.2018.05.008; Carlini CR, 2016, TOXICON, V110, P90, DOI 10.1016/j.toxicon.2015.11.020; Chung H, 2020, SCI TOTAL ENVIRON, V740, DOI 10.1016/j.scitotenv.2020.140194; Crowell AMJ, 2013, ANAL CHIM ACTA, V796, P48, DOI 10.1016/j.aca.2013.08.005; DOUGLAS L A, 1970, Soil Science Society of America Proceedings, V34, P859; Gee GW, 1986, METHODS SOIL ANAL PA, V1, P404; Heffer P., 2017, P 85 IFA ANN C MARR, P22; Jha P, 2014, COMMUN SOIL SCI PLAN, V45, P713, DOI 10.1080/00103624.2013.874023; KANDELER E, 1988, BIOL FERT SOILS, V6, P68, DOI 10.1007/BF00257924; Kataria R, 2019, CURR PHARM BIOTECHNO, V20, P410, DOI 10.2174/1389201020666190409110948; Kiss S, 2002, IMPROVING EFFICIENCY OF UREA FERTILIZERS BY INHIBITION OF SOIL UREASE ACTIVITY, P1; Li WY, 2019, GEODERMA, V354, DOI 10.1016/j.geoderma.2019.07.035; Liu X, 2019, BIORESOURCE TECHNOL, V290, DOI 10.1016/j.biortech.2019.121767; Mahernia S, 2015, IRAN J PHARM RES, V14, P943; Marschner P, 2012, MARSCHNER'S MINERAL NUTRITION OF HIGHER PLANTS, 3RD EDITION, P1; Mathialagan R, 2017, PROCEDIA ENGINEER, V184, P449, DOI 10.1016/j.proeng.2017.04.116; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; Modolo LV, 2018, J ADV RES, V13, P29, DOI 10.1016/j.jare.2018.04.001; Modolo LV, 2015, J ADV RES, V6, P35, DOI 10.1016/j.jare.2014.09.001; Nabati F, 2012, DARU, V20, DOI 10.1186/2008-2231-20-72; NELSON DW, 1983, COMMUN SOIL SCI PLAN, V14, P1051, DOI 10.1080/00103628309367431; Nhung HTN, 2019, BIORESEARCH COMMUN, V5, P606; Park SH, 2021, ANIM BIOSCI, V34, P2023, DOI 10.5713/ab.21.0046; Rhoades J. D., 1982, Methods of soil analysis. Part 2. Chemical and microbiological properties, P149; Ryu HW, 2017, FOOD CONTROL, V73, P916, DOI 10.1016/j.foodcont.2016.10.017; Francisco SS, 2011, J SCI FOOD AGR, V91, P1569, DOI 10.1002/jsfa.4349; Sigurdarson JJ, 2018, REV ENVIRON SCI BIO, V17, P241, DOI 10.1007/s11157-018-9466-1; Sirko A, 2000, ACTA BIOCHIM POL, V47, P1189, DOI 10.18388/abp.2000_3972; Smith AP, 2020, AGR FOREST METEOROL, V287, DOI 10.1016/j.agrformet.2020.107952; Sunderlage B, 2018, SOIL SCI SOC AM J, V82, P253, DOI 10.2136/sssaj2017.05.0151; Swab RM, 2015, ECOGRAPHY, V38, P221, DOI 10.1111/ecog.00585; Verma N, 2015, J APPL RES MED AROMA, V2, P105, DOI 10.1016/j.jarmap.2015.09.002; Warncke D., 1998, POTASSIUM OTHER BASI, P31	42	6	6	3	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	10							e0258568	10.1371/journal.pone.0258568	http://dx.doi.org/10.1371/journal.pone.0258568			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9YI	34648559	Green Published, gold			2023-01-03	WOS:000729172300058
